<SEC-DOCUMENT>0000927066-25-000012.txt : 20250213
<SEC-HEADER>0000927066-25-000012.hdr.sgml : 20250213
<ACCEPTANCE-DATETIME>20250213172547
ACCESSION NUMBER:		0000927066-25-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		140
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250213
DATE AS OF CHANGE:		20250213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DAVITA INC.
		CENTRAL INDEX KEY:			0000927066
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				510354549
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14106
		FILM NUMBER:		25621766

	BUSINESS ADDRESS:	
		STREET 1:		2000 16TH STREET
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202
		BUSINESS PHONE:		310-536-2668

	MAIL ADDRESS:	
		STREET 1:		2000 16TH STREET
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAVITA HEALTHCARE PARTNERS INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAVITA INC
		DATE OF NAME CHANGE:	20001005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TOTAL RENAL CARE HOLDINGS INC
		DATE OF NAME CHANGE:	19950524
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dva-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:47070f41-4839-4fd6-beb4-023e08dfe312,g:db2e526f-c810-4a70-bbc2-9b01e625d97f,d:f6ba8dc5b26140f49e5fc4e21f5168f4-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dva="http://www.davita.com/20241231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dva-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-30">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-32">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-34">0000927066</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-267">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-268">5,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-269">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-270">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-271">450,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-272">80,536</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-273">88,824</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-137" decimals="INF" name="dva:NumberOfConcentrationRiskCustomers" format="ixt:fixed-zero" scale="0" id="f-698">No</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-699">10</ix:nonFraction><ix:nonNumeric contextRef="c-135" name="dva:AccountsReceivablePeriodOutstanding" format="ixt-sec:durwordsen" id="f-700">six months</ix:nonNumeric><ix:nonNumeric contextRef="c-136" name="dva:AccountsReceivablePeriodOutstanding" format="ixt-sec:durwordsen" id="f-701">six months</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-863">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-864">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-865">no</ix:nonFraction><ix:nonNumeric contextRef="c-205" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="f-1089">2036-12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-206" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="f-1090">2029-12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-207" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="f-1091">2044-12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-208" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="f-1092">2026-12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-209" name="us-gaap:TaxCreditCarryforwardExpirationDate" id="f-1093">2025-12-31</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1094">21.00</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1095">21.00</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1096">21.00</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1097">3.40</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1098">2.60</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1099">3.80</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1100">1.10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1101">1.10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1102">1.60</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="f-1103">0.70</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="f-1104">1.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="f-1105">1.10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1106">0.30</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1107">0.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1108">2.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-1109">0.50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-1110">1.10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-1111">1.10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1112">0.10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1113">0.80</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1114">1.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1115">1.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1116">1.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1117">1.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1118">0.30</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1119">1.90</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1120">1.10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1121">4.70</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1122">5.60</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1123">6.00</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1124">18.30</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1125">18.70</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1126">20.50</ix:nonFraction><ix:nonNumeric contextRef="c-298" name="us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1334">http://fasb.org/us-gaap/2024#InterestAndDebtExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-301" name="us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1341">http://fasb.org/us-gaap/2024#IncomeTaxExpenseBenefit</ix:nonNumeric><ix:nonNumeric contextRef="c-309" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="f-1364">Base + 1.75%</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" format="ixt:num-dot-decimal" scale="3" id="f-1365">1,533,635</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" format="ixt:num-dot-decimal" scale="3" id="f-1366">1,828,245</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1367">1,000,000</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-269" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1368">3.75</ix:nonFraction><ix:nonNumeric contextRef="c-270" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1369">6/30/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-270" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1370">12/31/2025</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312024" format="ixt:num-dot-decimal" scale="3" id="f-1371">500,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1372">500,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1373">1,000,000</ix:nonFraction><ix:nonNumeric contextRef="c-272" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1374">6/30/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-272" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1375">12/31/2025</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312024" format="ixt:num-dot-decimal" scale="3" id="f-1376">250,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1377">750,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1378">1,000,000</ix:nonFraction><ix:nonNumeric contextRef="c-274" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1379">6/30/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-274" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1380">12/31/2025</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312024" format="ixt:num-dot-decimal" scale="3" id="f-1381">250,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1382">750,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1383">500,000</ix:nonFraction><ix:nonNumeric contextRef="c-276" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1384">6/30/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-276" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1385">12/31/2026</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1386">500,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1387">250,000</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-277" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1388">4.50</ix:nonFraction><ix:nonNumeric contextRef="c-278" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1389">12/31/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-278" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1390">12/31/2025</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1391">250,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1392">750,000</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-279" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1393">4.00</ix:nonFraction><ix:nonNumeric contextRef="c-280" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1394">12/31/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-280" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1395">12/31/2026</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312025" format="ixt:num-dot-decimal" scale="3" id="f-1396">250,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1397">500,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1398">1,750,000</ix:nonFraction><ix:nonNumeric contextRef="c-282" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1399">12/31/2025</ix:nonNumeric><ix:nonNumeric contextRef="c-282" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1400">12/31/2027</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312026" format="ixt:num-dot-decimal" scale="3" id="f-1401">750,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1402">1,000,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1403">750,000</ix:nonFraction><ix:nonNumeric contextRef="c-284" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1404">12/31/2025</ix:nonNumeric><ix:nonNumeric contextRef="c-284" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1405">12/31/2027</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312026" format="ixt:num-dot-decimal" scale="3" id="f-1406">250,000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1407">500,000</ix:nonFraction><ix:nonNumeric contextRef="c-7" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1413">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1414">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="f-1481">http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="f-1482">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1488">689,130</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1489">692,834</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1490">679,815</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-234" decimals="INF" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1491">4.58</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-235" decimals="INF" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1492">4.58</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-320" decimals="INF" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1493">4.51</ix:nonFraction><ix:nonNumeric contextRef="c-313" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" format="ixt-sec:duryear" id="f-1509">1</ix:nonNumeric><ix:nonNumeric contextRef="c-314" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" format="ixt-sec:duryear" id="f-1510">2</ix:nonNumeric><ix:nonNumeric contextRef="c-313" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" format="ixt-sec:duryear" id="f-1511">3</ix:nonNumeric><ix:nonNumeric contextRef="c-314" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" format="ixt-sec:duryear" id="f-1512">4</ix:nonNumeric><ix:nonNumeric contextRef="c-337" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-1623">0</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="c-356" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1624">50.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-356" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1625">60.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1626">60.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1627">70.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-358" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1628">70.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-358" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1629">80.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-359" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1630">100.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-359" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1631">110.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-360" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1632">110.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-360" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1633">120.00</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-361" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-1634">100</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-1635">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-1636">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:fixed-zero" scale="0" id="f-1637">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:fixed-zero" scale="0" id="f-1638">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:fixed-zero" scale="0" id="f-1639">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-1640">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-1641">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" name="dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" format="ixt:num-dot-decimal" scale="3" id="f-1686">329,302</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-1687">2,904</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="f-1861">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="f-1862">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="f-1863">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="f-1864">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="f-1865">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1866">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1867">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1868">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="f-1869">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="f-1870">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="f-1871">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dva-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="clinic"><xbrli:measure>dva:clinic</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>dva:state</xbrli:measure></xbrli:unit><xbrli:unit id="patient"><xbrli:measure>dva:patient</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>dva:country</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="entity"><xbrli:measure>dva:entity</xbrli:measure></xbrli:unit><xbrli:unit id="segments"><xbrli:measure>dva:Segments</xbrli:measure></xbrli:unit><xbrli:unit id="clinic2"><xbrli:measure>dva:Clinic</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:IKCVBCArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:IKCVBCArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">dva:TransplantSoftwareReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">dva:TransplantSoftwareReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:IndefiniteLifeNetOperatingLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">dva:TaxYear2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-13</xbrli:startDate><xbrli:endDate>2024-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-13</xbrli:startDate><xbrli:endDate>2024-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:ChangeHealthcareTemporaryFundingAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:ChangeHealthcareTemporaryFundingAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1AndRevolverMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:BaseRateLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:BaseRateLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:BaseRateLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dva:A1MonthSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:SOFRLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:BaseRateLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-07</xbrli:startDate><xbrli:endDate>2024-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-13</xbrli:startDate><xbrli:endDate>2024-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-13</xbrli:startDate><xbrli:endDate>2024-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-13</xbrli:startDate><xbrli:endDate>2024-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-13</xbrli:startDate><xbrli:endDate>2024-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:NewCreditAgreementAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:ChangeHealthcareTemporaryFundingAssistanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.50EffectiveDecember312025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.50EffectiveDecember312025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.00EffectiveDecember312025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.00EffectiveDecember312025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.50EffectiveDecember312025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.00EffectiveDecember312025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1AndRevolverMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">dva:A2017USAttorneyColoradoInvestigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-22</xbrli:startDate><xbrli:endDate>2019-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:CommitmentsToProvideOperatingCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-13</xbrli:startDate><xbrli:endDate>2025-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dva:DaVitaCarePte.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dva:DaVitaCarePte.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dva:GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis">dva:NonCashGainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dva:DaVitaCarePte.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dva:GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis">dva:ForeignCurrencyGainLossTranslationAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dva:DaVitaCarePte.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dva:GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis">dva:NonCashGainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-19</xbrli:startDate><xbrli:endDate>2019-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.138%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"/><td style="width:22.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:484.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"/><td style="width:22.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:484.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">1-14106</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><img src="dva-20241231_g1.gif" alt="davitalogorgbfa76.gif" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">DAVITA INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:244.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:16.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:244.75pt"/><td style="width:1.0pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">51-0354549</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.50pt"><tr><td style="width:1.0pt"/><td style="width:39.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:19.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:30.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">2000 16th Street</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Denver,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">80202</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Telephone number (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">720</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">631-2100</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:159.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:30.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:115.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:6.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:190.00pt"/><td style="width:1.0pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading symbol(s):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">DVA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"><tr><td style="width:1.0pt"/><td style="width:85.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:10.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:127.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-24">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its final report.     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2024, the aggregate market value of the registrant's common stock outstanding held by non-affiliates based upon the closing price on the New York Stock Exchange was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" scale="9" id="f-28">11.8</ix:nonFraction> billion.</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of January&#160;31, 2025, the number of shares of the registrant&#8217;s common stock outstanding was approximately <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="dei:EntityCommonStockSharesOutstanding" scale="6" id="f-29">80.0</ix:nonFraction> million shares.</span></div><div style="margin-top:3pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Documents incorporated by reference</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s proxy statement for its 2025 annual meeting of stockholders are incorporated by reference in Part III of this Form 10-K.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_13">Business</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_55">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_55">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_145">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_145">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_148">Cybersecurity</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_148">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_151">Properties</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_151">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_154">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_154">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_157">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_157">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_163">Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_163">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_166">Reserved</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_166">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_169">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_169">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_217">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_217">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_220">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_220">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_223">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_223">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_226">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_226">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_229">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_229">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_232">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_232">80</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_238">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_238">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_241">Executive Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_241">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_244">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_244">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_247">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_247">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_250">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_250">82</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_256">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_256">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_259">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_259">83</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_400">Exhibit Index</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_400">1 of 4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_403">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_403">S-1</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_13"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Business</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC). The SEC also maintains a website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_16"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of DaVita Inc.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, we have been a leader in clinical quality and innovation for 25 years. We care for patients at every stage and setting along their kidney health journey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from earlier diagnosis and prevention through supporting the transplant process. This includes ensuring they are supported at home, in our dialysis centers, in the hospital and/or skilled nursing facilities. In our unwavering pursuit of a healthier tomorrow, we strive to reimagine what high quality care looks like: more preventative, better integrated, improved outcomes at the lowest total cost, and personalized at scale to deliver a better tomorrow regardless of location, insurance status or other factors. Our caring culture fuels our continuous drive toward achieving our mission to be the provider, partner and employer of choice.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defining chronic kidney disease </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are five stages of chronic kidney disease (CKD). These stages are generally based on how well the kidneys work to filter waste and extra fluid out of the blood&#8211;with higher stages of CKD corresponding to progressing levels of kidney disease. Stage 1 CKD is the closest to healthy kidney function. Stage 5 CKD indicates that a patient has severe kidney damage.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patient diagnosed with Stage 5 CKD has kidneys that have lost nearly all functionality or have failed. If an individual's kidneys fail, the person is then diagnosed with end stage renal disease (ESRD), also known as end stage kidney disease (ESKD). Because kidney function is essential for survival and the loss of kidney function is normally irreversible, ESKD patients require continued dialysis treatments or a kidney transplant to sustain life. Dialysis is the removal of toxins, fluids and salt from the blood of patients by artificial means. Patients suffering from ESKD generally require regular life-sustaining dialysis therapy for the rest of their lives or until they receive a kidney transplant. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The treatment goal for CKD patients prior to Stage 5 is to manage and slow the progression of the disease to preserve kidney functionality. Because kidney failure is typically caused by one or more comorbidities such as Type I and Type II diabetes, hypertension, polycystic kidney disease, long-term autoimmune attack on the kidneys or prolonged urinary tract obstruction, slowing the progression generally involves working with nephrologists and dieticians to help control blood pressure, monitor blood glucose and maintain healthy diet and exercise routines, among other things. If the kidney disease continues to progress, the goal is to support efforts for kidney transplantation where available and medically appropriate, and in the event transplantation is not possible, to work with the patient and his or her nephrologist to safely transition the patient to the dialysis treatment and modality of their choice.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our businesses</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading dialysis provider in the United States. Our U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, ESKD, in the United States, and is our largest line of business. Our robust platform to deliver kidney care services also includes established nephrology and payor relationships. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December&#160;31, 2024, our international operations provided dialysis and administrative services to a total of 509 outpatient dialysis centers located in 13 countries outside of the U.S., serving approximately 80,300 patients.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our U.S. integrated kidney care (IKC) business provided integrated care and disease management services to 70,400 patients in risk-based integrated care arrangements and to an additional 11,600 patients in other integrated care arrangements across the United States as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also maintain a few other ancillary services and investments outside of our U.S. dialysis, U.S. IKC, or international operations, which we refer to as our U.S. other ancillary services. We refer to our U.S. integrated kidney care business, U.S. other ancillary services and international operations as, collectively, our "ancillary services." We also have a separate corporate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative support function that supports our U.S. dialysis business and these ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each of our businesses are described in greater detail in the sections that follow.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our care model</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient-centric care model leverages our platform of kidney care services to maximize patient choice in both models and modalities of care. We believe that the flexibility we offer coupled with a focus on comprehensive kidney care supports our commitments to help improve equitable clinical outcomes and quality of life for our patients. According to the most recently published data, for the ten most recently reported years, we have continued as an industry leader in the Centers for Medicare &amp; Medicaid Services&#8217; (CMS) Quality Incentive Program (QIP), which promotes high quality services in outpatient dialysis facilities treating patients with ESKD. In addition, according to the most recently published data, for the nine most recently reported years, we have also continued as an industry leader under CMS&#8217; Five-Star Quality Rating System (Star Rating), which rates eligible dialysis centers based on the quality of outcomes to help patients, their families, and caregivers make more informed decisions about where patients receive care. Following a pause in refreshed Star Ratings in October 2020 and October 2021 due to the COVID-19 pandemic, CMS reset the baseline with the October 2023 Star Rating release to reflect current performance and provide clinical differentiation through newly defined cutoff values. Under the new baseline, the lowest scoring 10% of facilities receive one star, the next 20% receive two stars, the next 40% receive three stars, the next 20% receive four stars and the highest 10% of facilities receive five stars in the baseline period for each subsequent evaluation period.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical outcomes are driven by our experienced and knowledgeable caregivers. We employ registered nurses, licensed practical or vocational nurses, patient care technicians, social workers, registered dietitians, biomedical technicians and other administrative and support teammates who strive to achieve superior clinical outcomes at our dialysis facilities. In addition to our teammates at our dialysis facilities, as of December&#160;31, 2024, our domestic Chief Medical Officer leads a team of 23 nephrologists in our physician leadership team as part of our domestic Office of the Chief Medical Officer (OCMO). Our international Chief Medical Officer leads a team of 11 nephrologists in our physician leadership team as part of our international OCMO as of December&#160;31, 2024. Our OCMO teammates represent a variety of academic, clinical practice, and clinical research backgrounds. We also have a Physician Council that serves as an advisory body to senior management, which was composed of 10 physicians with extensive experience in clinical practice and five Group Medical Directors as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value-based care arrangements continue to impact the kidney health space. These arrangements are fostering a much larger degree of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> between nephrologists and other providers, including transplant programs, resulting in a more complete understanding of each patient&#8217;s clinical needs. We believe this more complete understanding allows for better care coordination and earlier intervention, which we believe ultimately leads to improved clinical outcomes, lower overall costs and improved patient experiences. Our IKC business provides comprehensive care management for complex CKD patients nationwide, with payment models that include a variety of structures to advance and encourage integrated and value-based care. Among other arrangements, our IKC business has percent-of-premium arrangements in several Medicare Advantage ESRD Chronic Special Needs Plans and is an active participant in CMMI&#8217;s Comprehensive Kidney Care Contracting (CKCC) model that seeks to manage the care of late stage CKD and ESKD patients to delay the progression of kidney disease, promote home dialysis when appropriate, and incentivize transplants. Our IKC business also utilizes other value-based payment methodologies in its care coordination and disease management contracts, which include two-sided shared savings/shared losses and outcomes-based pay-for-performance compensation arrangements.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_19"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. dialysis business</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis business is a leading provider of kidney dialysis services for patients suffering from ESKD. As of December&#160;31, 2024, we provided dialysis, administrative and related laboratory services in the U.S. through a network of 2,657 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 200,800 patients. We also have contracts to provide hospital inpatient dialysis services in approximately 760 hospitals throughout the U.S. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the most recent 2024 annual data report from the United States Renal Data System (USRDS), there were over 554,000 ESKD dialysis patients in the U.S. in 2022. The underlying ESKD dialysis patient population grew at an approximate compound annual rate of 3.3% from 2012 to 2022 and 3.4% from 2017 to 2022 as compared to a decline in annual growth of 0.4% from 2021 to 2022. Despite this near term slowdown, which, among other things, included impacts from the COVID-19 pandemic on mortality rates amongst the ESKD dialysis patient population, the rate of growth has been relatively consistent over time. In general, a number of factors may impact ESKD growth rates, including, among others, mortality rates for dialysis patients or CKD patients, the growth and aging of the U.S. population, limitations on immigration in the U.S., transplant rates, incidence rates for diseases that cause kidney failure such as diabetes and hypertension, growth rates of minority populations with higher than average incidence rates of ESKD or other changes in demand for dialysis treatments over time, including for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">example, as a result of the development and application of certain innovative technologies, drugs or other treatments. Certain of these factors, in particular mortality rates for dialysis or CKD patients, have been impacted by the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment options for ESKD</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment options for ESKD are dialysis and kidney transplantation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis options</span></div><div style="margin-top:9pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hemodialysis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hemodialysis is the most common form of ESKD treatment. The hemodialysis machine uses a filter, called a dialyzer, to remove toxins, fluids and salt from the patient&#8217;s blood. The dialysis process occurs across a semi-permeable membrane that divides the dialyzer into two distinct chambers. While blood is circulated through one chamber, a pre-mixed fluid is circulated through the other chamber. The toxins, salt and excess fluids from the blood cross the membrane into the fluid, allowing cleansed blood to return back into the patient&#8217;s body. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hemodialysis is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, in a skilled nursing facility or at the patient's home. Our freestanding outpatient dialysis centers are staffed with members of our care team and store the supplies necessary for treatment. Treatments are usually performed three times per week.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospital inpatient hemodialysis services are required for patients with acute kidney failure primarily resulting from acute medical illness or trauma, patients in early stages of ESKD and ESKD patients who require hospitalization for other reasons. Hospital inpatient hemodialysis is generally performed at the patient&#8217;s bedside or in a dedicated treatment room in the hospital, as needed.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some ESKD patients may perform hemodialysis with the help of a care partner in their home or residence through the use of a hemodialysis machine designed specifically for home therapy that is portable, smaller and easier to use. This is referred to as home hemodialysis (HHD). Patients receive training, support and monitoring from registered nurses, usually in our outpatient dialysis centers, in connection with their HHD treatment. HHD is typically performed with greater frequency than dialysis treatments performed in outpatient dialysis centers and on varying schedules.</span></div><div style="margin-top:9pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Peritoneal dialysis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peritoneal dialysis uses the patient&#8217;s peritoneal or abdominal cavity to eliminate fluid and toxins and is typically performed at home. The most common methods of peritoneal dialysis are continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD). Because it does not involve going to an outpatient dialysis center three times a week for treatment, peritoneal dialysis is generally an alternative to hemodialysis for patients who are healthier, more independent and desire more flexibility in their lifestyle. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAPD introduces dialysis solution into the patient&#8217;s peritoneal cavity through a surgically placed catheter. Toxins in the blood continuously cross the peritoneal membrane into the dialysis solution. After several hours, the patient drains the used dialysis solution and replaces it with fresh solution. This procedure is usually repeated four times per day.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CCPD is performed in a manner similar to CAPD, but uses a mechanical device to cycle dialysis solution through the patient&#8217;s peritoneal cavity while the patient is sleeping or at rest.</span></div><div style="margin-top:9pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Kidney transplantation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kidney transplantation, when successful, is considered the most desirable form of therapeutic intervention. However, in light of the shortage of suitable donors, side effects of immunosuppressive pharmaceuticals given to transplant recipients and dangers associated with transplant surgery, some patient populations have generally limited the use of this treatment option. In accordance with an executive order signed in July 2019 (the 2019 Executive Order), the U.S. Department of Health and Human Services (HHS) developed policies addressing, among other things, the goal of making more kidneys available for transplant. CMS, through CMMI, also subsequently released the framework for certain proposed and existing voluntary and mandatory payment models, including ESRD Treatment Choices Model (ETC) model, which would adjust payment incentives to encourage kidney transplants. For more information about these payment models, please see the discussion below under the heading "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Integrated Kidney Care, Medicare and Medicaid program reforms and Other Healthcare Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:9pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hemodiafiltration</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hemodiafiltration (HDF) is a form of augmented hemodialysis that includes a component of convection to remove additional molecules from the blood. Like hemodialysis, HDF can be performed at certain freestanding outpatient dialysis </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">centers and may also be performed in hospital in-patient centers. HDF usage varies by country, and the efficacy of this modality is still being assessed in the U.S.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_22"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. dialysis services we provide</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outpatient hemodialysis services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of services we provide to patients are outpatient hemodialysis treatments. As a condition of our enrollment in Medicare for the provision of dialysis services, we contract with a nephrologist or a group of associated nephrologists to provide medical director services at each of our dialysis centers. In addition, other nephrologists may apply for practice privileges to treat their patients at our centers. Each center has an administrator, often a registered nurse, who supervises the day-to-day operations of the center and its staff. The staff of each center typically consists of registered nurses, licensed practical or vocational nurses, patient care technicians, a social worker, a registered dietician, biomedical technician support and other administrative and support personnel.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall number of patients to whom we provided services in the U.S. in 2024 was relatively flat compared to 2023, primarily due to growth in new admits partially offset by elevated mortality rates, which continue to be elevated relative to our pre-COVID-19 mortality rates.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital inpatient hemodialysis services</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we have contracts to provide hospital inpatient dialysis services to patients in approximately 760 hospitals throughout the U.S. We render these services based on a contracted per-treatment fee that is individually negotiated with each hospital. When a hospital requests our services, we typically administer the dialysis treatment at the patient&#8217;s bedside or in a dedicated treatment room in the hospital, as needed. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home-based dialysis services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home-based dialysis services includes HHD and peritoneal dialysis. Many of our outpatient dialysis centers offer certain support services for dialysis patients who prefer and are able to perform either HHD or peritoneal dialysis in their homes. Home-based hemodialysis support services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance. Registered nurses train patients and their families or other caregivers to perform either HHD or peritoneal dialysis. The 2019 Executive Order and related HHS guidance described above also included a stated goal of increasing the relative number of new ESKD patients that receive dialysis at home.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the most recent annual data report from the USRDS, in 2022 approximately 14% of ESKD dialysis patients in the U.S. utilized home-based dialysis.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatments and revenues by modality:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph summarizes our U.S. dialysis treatments by modality and U.S. dialysis patient service revenues by modality for the year ended December&#160;31, 2024.</span></div><div style="margin-top:6pt;text-indent:27pt"><img src="dva-20241231_g2.jpg" alt="2782" style="height:175px;margin-bottom:5pt;vertical-align:text-bottom;width:625px"/></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESKD laboratory services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a separately licensed and highly automated clinical laboratory that specializes in ESKD patient testing. This specialized laboratory provides routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESKD patients. The vast majority of these tests are performed for our ESKD patients throughout the U.S. These tests are performed for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a variety of reasons, including to monitor a patient&#8217;s ESKD condition, including the adequacy of dialysis, as well as other medical conditions of the patient. Our laboratory utilizes information systems that provide information to certain members of the dialysis centers&#8217; staff and medical directors regarding critical outcome indicators.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate or provide management and administrative services pursuant to management and administrative services agreements to 52 outpatient dialysis centers located in the U.S. in which we either own a noncontrolling interest or which are wholly-owned by third parties. Management fees are established by contract and are recognized as earned typically based on a percentage of revenues or cash collections generated by the outpatient dialysis centers.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_25"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of revenue&#8212;concentrations and risks</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis revenues represent approximately 88% of our consolidated revenues for the year ended December&#160;31, 2024. Our U.S. dialysis revenues are derived primarily from our core business of providing dialysis services and related laboratory services and, to a lesser extent, the administration of pharmaceuticals and management fees generated from providing management and administrative services to certain outpatient dialysis centers, as discussed above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sources of our U.S. dialysis revenues are principally from government-based programs, including Medicare and Medicare Advantage plans, Medicaid and managed Medicaid plans, other government-based programs including our agreement with the Veterans Administration, and commercial insurance plans. The following table summarizes our U.S. dialysis revenues by payor source for U.S. dialysis patient service revenues for the year ended December&#160;31, 2024:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.064%"><tr><td style="width:1.0%"/><td style="width:72.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.891%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and managed Medicaid plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government-based programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total government-based programs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial (including hospital dialysis services)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare revenue</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare fee for service</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 1972, the federal government has provided healthcare coverage for qualified ESRD patients under the Medicare ESRD program regardless of age or financial circumstances. ESRD is the first and only disease state eligible for Medicare coverage both for dialysis and dialysis-related services and for all benefits available under the Medicare program. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government dialysis related payment rates in the U.S. are principally determined by federal Medicare and state Medicaid policy. For patients with Medicare coverage, all ESRD payments for dialysis treatments are made under a single bundled payment rate that provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment that are related to the dialysis treatment, including certain pharmaceuticals, such as erythropoiesis-stimulating agents (ESAs), calcimimetics, vitamin D analogs, oral-only renal phosphate binders and iron supplements, irrespective of the level of pharmaceuticals administered to the patient or additional services performed. Most lab services are also included in the bundled payment. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Medicare reimbursement limits the allowable charge per treatment, it provides industry participants with a relatively predictable and recurring revenue stream for dialysis services provided to patients without commercial insurance. For the year ended December&#160;31, 2024, approximately 89% of our total U.S. dialysis patients were covered under some form of government-based program, with approximately 74% of our total U.S. dialysis patients covered under Medicare and Medicare Advantage plans. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this bundled payment rate system, known as the ESRD Prospective Payment System (PPS), the payments to a dialysis facility may be reduced by as much as 2% based on the facility&#8217;s performance in specified quality measures set annually by CMS through its QIP. CMS established QIP through the Medicare Improvements for Patients and Providers Act of 2008 to promote high quality services in outpatient dialysis facilities treating patients with ESRD. QIP associates a portion of Medicare reimbursement directly with a facility&#8217;s performance on quality of care measures. Reductions in Medicare reimbursement result when a facility&#8217;s overall score on applicable measures does not meet established standards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty about future payment rates remains a material risk to our business, as well as the potential implementation of or changes in coverage determinations or other rules or regulations by CMS or Medicare Administrative Contractors that may impact reimbursement. An important provision in the Medicare ESRD statute is an annual adjustment, or market basket update, to the ESRD PPS base rate. Absent action by Congress, the ESRD PPS base rate is updated annually by an inflation adjustment based on historical data and forecasts that may create a lag between these adjustments and actual inflationary increase. As a result, an inflation adjustment may not always cover the actual inflationary increase experienced. Due in part to continued higher than expected inflation rates, the annual update for the 2024 ESRD PPS base rate did not accurately forecast the cost increase experienced by providers. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, CMS issued a final rule to update the Medicare ESRD PPS payment rate and policies for calendar year 2025. Among other things, the final rule updated both the ESRD and Acute Kidney Injury (AKI) dialysis payment rate for renal dialysis services furnished by ESRD facilities, extended payment for dialysis in a home setting for AKI, and outlined requirements for the ESRD QIP. CMS estimates that the overall impact of the rule will increase ESRD facilities' average reimbursement by a productivity-adjusted market basket increase of 2.2%. On January 1, 2025, phosphate binders, a drug class taken orally by many ESKD patients to reduce absorption of dietary phosphate, were incorporated into the ESRD PPS bundled payment rate. Phosphate binders are not considered accounted for in the ESRD PPS base rate at this time and will be reimbursed through a Transitional Drug Add-on Payment Adjustment (TDAPA). The TDAPA period is expected to continue for a period of at least two years.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Budget Control Act of 2011 (BCA) and subsequent activity in Congress, a $1.2 trillion sequester (across-the-board spending cuts) in discretionary programs took effect in 2013 reducing Medicare payments (currently by 2%), which was subsequently extended into fiscal year 2032. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most ESRD patients receiving dialysis services become eligible for primary Medicare coverage at various times, depending on their age or disability status, as well as whether they are covered by a commercial insurance plan. Generally, for a patient not covered by a commercial insurance plan, Medicare can become the primary payor for qualified ESRD patients receiving dialysis services either immediately or after a three-month waiting period. In most cases, for a patient covered by a commercial insurance plan, Medicare will either become the primary payor after 33 months, which includes the three-month waiting period, or earlier if the patient&#8217;s commercial insurance plan coverage terminates or if the patient chooses Medicare over the commercial plan. When Medicare becomes the primary payor, the payment rates we receive for that patient shift from the commercial insurance plan rates to Medicare payment rates, which are on average significantly lower than commercial insurance rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare pays 80% of the amount set by the Medicare system for each covered dialysis treatment. The patient is responsible for the remaining 20%. In many cases, a secondary payor, such as Medicare supplemental insurance, a state Medicaid program or a commercial health plan, covers all or part of these balances. If a patient does not have secondary insurance coverage, we are generally unsuccessful in our efforts to collect from the patient the remaining 20% portion of the ESRD composite rate that Medicare does not pay. In those instances, however, we are able to recover some portion of this unpaid patient balance from Medicare through an established cost reporting process by identifying these Medicare bad debts on each center&#8217;s Medicare cost report. For additional detail on the associated risks, see the risk factor in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state legislation or regulations..." </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Advantage revenue</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage (MA, managed Medicare or Medicare Part C) plans are offered by private health insurers who contract with CMS to provide their members with Medicare Part A, Part B and/or Part D benefits. These MA plans include health maintenance organizations, preferred provider organizations, private fee-for-service (FFS) organizations, special needs plans (SNPs) or Medicare medical savings account plans. Since January 1, 2021, under the 21st Century Cures Act (the Cures Act) Medicare-eligible beneficiaries with ESRD can choose coverage under an MA plan. MA plans usually provide reimbursement to us at a negotiated rate that is generally higher than Medicare FFS rates. CMS releases an annual MA notice that includes, among other things, a MA payment rate for MA plans and updates certain policies associated with risk adjustments. We continue to monitor MA notices, regulatory updates and guidance, as well as enforcement for impact on our business. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid revenue</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid programs are state-administered programs partially funded by the federal government. These programs are intended to provide health coverage for patients whose income and assets fall below state-defined levels and who are otherwise uninsured. These programs also serve as supplemental insurance programs for co-insurance payments due from Medicaid-eligible patients with primary coverage under the Medicare program. Some Medicaid programs also pay for additional services, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including some oral medications that are not covered by Medicare. We are enrolled in the Medicaid programs in the states in which we conduct our business.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial revenue</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, if a patient has commercial insurance, then that commercial insurance plan is generally responsible for payment of dialysis services for up to the first 33 months before that patient becomes eligible to elect to have Medicare as their primary payor for dialysis services. Although commercial payment rates vary, average commercial payment rates negotiated with commercial payors are generally significantly higher than Medicare rates. The payments we receive from commercial payors generate nearly all of our profits and all of our non-hospital dialysis profits come from commercial payors. Payment methods from commercial payors can include a single per treatment rate, referred to as bundled rates, or in other cases separate payments for dialysis treatments and pharmaceuticals, if used as part of the treatment, referred to as FFS rates. Commercial payment rates are the result of negotiations between us and commercial payors or third party administrators. Our commercial contracts sometimes contain annual price escalator provisions. We are comprehensively contracted, and the vast majority of patients insured through commercial health plans are covered by one of our commercial contracts, though we also receive payments for a limited set of commercial patients that are covered by a health plan that considers us out-of-network. While our out-of-network payment rates are on average higher than in-network commercial contract payment rates, we have made efforts to be contracted with the majority of commercial payors offering health plans.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 27% of our U.S. dialysis patient service revenues and approximately 11% of our U.S. dialysis patients are associated with non-hospital commercial payors for the year ended December&#160;31, 2024. Non-hospital commercial patients as a percentage of our total U.S. dialysis patients for 2024 increased slightly compared to 2023. Less than 1% of our U.S. dialysis revenues are due directly from patients. No single commercial payor accounted for more than 10% of total U.S. dialysis revenues for the year ended December&#160;31, 2024. See Note 2 to the consolidated financial statements included in this report for disclosure on our concentration related to our commercial payors on a total consolidated revenue basis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the number of our patients under commercial plans and the rates under these commercial plans are subject to change based on a number of factors. For additional detail on these factors and other risks associated with our commercial revenue, see the risk factors in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings "</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;" "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state legislation or regulations...;" "If the number or percentage of patients with higher-paying commercial insurance declines...;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">" </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"External conditions, including those related to general economic, marketplace and global health conditions..."</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_28"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician relationships</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint venture partners</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and operate certain of our dialysis centers through entities that are structured as joint ventures. We generally hold controlling interests in these joint ventures, with nephrologists, hospitals, management services organizations, and/or other healthcare providers holding minority equity interests. These joint ventures are typically formed as limited liability companies. For the year ended December&#160;31, 2024, revenues from joint ventures in which we have a controlling interest represented approximately 30% of our U.S. dialysis revenues. We expect to continue to enter into new U.S. dialysis-related joint ventures in the ordinary course of business.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Community physicians</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ESKD patient generally seeks treatment or support for their home treatment at an outpatient dialysis center near their home where their treating nephrologist has practice privileges. Our relationships with local nephrologists and our ability to provide quality dialysis services and to meet the needs of their patients are key factors in the success of our dialysis operations. Nearly 5,300 nephrologists currently refer patients to our outpatient dialysis centers.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical directors</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participation in the Medicare ESRD program requires that dialysis services at an outpatient dialysis center be under the general supervision of a medical director.&#160;Per these requirements, this individual is usually a board certified nephrologist. We engage physicians or groups of physicians to serve as medical directors for each of our outpatient dialysis centers. At some outpatient dialysis centers, we also separately contract with one or more other physicians or groups to serve as assistant or associate medical directors over other modalities such as home dialysis. We have over 900 individual physicians and physician groups under contract to provide medical director services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical directors for our dialysis centers enter into written contracts with us that specify their duties and fix their compensation. These agreements range in duration, but generally are for periods of ten years. The compensation of our medical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors is the result of arm&#8217;s length negotiations, consistent with fair market value, and generally depends upon an analysis of various factors such as the physician&#8217;s duties, responsibilities, professional qualifications and experience, as well as the time and effort required to provide such services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical director contracts and joint venture operating agreements generally include covenants not to compete or own interests in dialysis centers operated by other providers within a defined geographic area for various time periods, as applicable. These non-compete agreements do not restrict or limit the physicians from practicing medicine or prohibit the physicians from referring patients to any outpatient dialysis center, including dialysis centers operated by other providers. </span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_31"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Location of our U.S. dialysis centers</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operated 2,657 outpatient dialysis centers in the U.S. as of December&#160;31, 2024 and 2,605 of these centers are consolidated in our financial statements. Of the remaining 52 nonconsolidated U.S. outpatient dialysis centers, we own noncontrolling interests in 49 centers and provide management and administrative services to three centers that are wholly-owned by third parties. The locations of the 2,605 U.S. outpatient dialysis centers consolidated in our financial statements at December&#160;31, 2024, were as follows:</span></div><div style="margin-top:9pt;text-indent:27pt"><img src="dva-20241231_g3.jpg" alt="DVA Location of US Dialysis Centers Map 2024 v2.jpg" style="height:422px;margin-bottom:5pt;vertical-align:text-bottom;width:648px"/></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ancillary services, including our international operations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our ancillary services relate primarily to our core business of providing kidney care services. As of December&#160;31, 2024, these consisted primarily of our U.S. integrated kidney care (IKC) business, certain U.S. other ancillary businesses (including our clinical research programs, transplant software business, and venture investment group), and our international operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made and continue to make investments in building our integrated care capabilities, including the operation of certain strategic business initiatives that are intended to integrate and coordinate care among healthcare participants across the renal care continuum from CKD to ESKD to kidney transplant. Through improved technology and data sharing, as well as an increasing focus on value-based contracting and care, these initiatives seek to bring together physicians, nurses, dieticians, pharmacists, hospitals, dialysis clinics, transplant centers, payors and other specialists with a view towards improving clinical outcomes for our patients and reducing the overall cost of comprehensive kidney care. Certain of our ancillary services are described below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Integrated Kidney Care</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Integrated Kidney Care.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;DaVita Integrated Kidney Care (DaVita IKC), provides advanced integrated care management services to health plans and government programs for members/beneficiaries diagnosed with ESKD and CKD. Through a combination of health monitoring, clinical coordination, innovative interventions, predictive analytics, medical claims analysis and information technology, we endeavor to assist our health plan and government program customers and patients in obtaining superior renal healthcare and improved clinical outcomes, as well as helping to reduce overall medical costs. Integrated kidney care management revenues from commercial and Medicare Advantage insurers can be based upon either an established contract fee recognized as earned for services provided over the contract period, or related to the operation of risk-based and value-based care programs, including shared savings, pay-for-performance, and capitation contracts. DaVita IKC also contracts with payors to support MA ESKD chronic condition special needs plans (C-SNPs) to provide ESKD patients full service healthcare and integrated care management services. DaVita IKC currently participates in both the involuntary and certain voluntary payment models administered by CMMI. As described below under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Government regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CMMI Payment Models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", we have invested resources, and expect to continue to invest substantial resources in these models as part of our overall plan to grow our integrated kidney care business and value-based care initiatives. See Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Company's consolidated financial statements for more information on how the Company accounts for its integrated care arrangements.</span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing, and has entered into, various forms of technology-based, administrative, financial and other collaboration and incentive arrangements with physician partners and other providers in support of our innovative care model, developing and expanding IKC programs and arrangements.</span></div><div style="margin-top:9pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Other Ancillary services</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;DaVita Clinical Research (DCR) is a provider-based specialty clinical research organization with a wide spectrum of services for clinical drug research and device development. DCR uses its extensive real-world healthcare expertise to assist in the design, recruitment and completion of retrospective and prospective studies. Revenues are based upon study generated fees, as determined by contract with drug companies and other sponsors, and are recognized as earned according to the contract terms.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Transplant software business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;DaVita's transplant software business, MedSleuth, works with transplant centers across the U.S. to provide greater connectivity among transplant candidates, transplant centers, physicians and care teams to help improve the experience and outcomes for kidney and liver transplant patients. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Venture group. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita Venture Group (DVG) focuses on innovative products, solutions and businesses that improve care for patients with kidney disease and related conditions. DVG identifies companies and products for acquisitions, strategic partnerships, and venture investment opportunities. DVG&#8217;s focus includes innovation in digital health, pharmaceuticals, medical devices, and care delivery models. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our ancillary services, see Part II Item 7, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International dialysis operations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operated, managed or administered 509 outpatient dialysis centers located in 13 countries outside of the U.S. serving approximately 80,300 patients as of December&#160;31, 2024. Our international dialysis operations have continued to grow steadily and expand as a result of acquiring and developing outpatient dialysis centers in various strategic markets. Our international operations are included in our ancillary services. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the international outpatient dialysis centers we operate or provide administrative services to were located as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"/><td style="width:67.237%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ecuador</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our international business, see Part II Item 7, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate administrative support</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate administrative support consists primarily of labor, benefits and long-term incentive compensation costs, as well as professional fees for departments which provide support to more than one of our different operating lines of business. These expenses are included in our consolidated general and administrative expenses.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government regulation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a complex regulatory environment with an extensive and evolving set of federal, state, local and international governmental laws, regulations and other requirements. These laws, regulations and other requirements are promulgated and overseen by a number of different legislative, regulatory, administrative and quasi-regulatory bodies, each of which may have varying interpretations, judgments or related guidance. As such, we utilize considerable resources on an ongoing basis to monitor, assess and respond to applicable legislative, regulatory and administrative requirements, but there is no guarantee that we will be successful in our efforts to adhere to all of these requirements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our personnel, representatives, third party vendors or operations are alleged to have violated these or other laws, regulations or requirements, we could experience material harm to our reputation and stock price, and it could impact our relationships and/or contracts related to our business, among other things. If any of our personnel, representatives, third party vendors or operations are found to violate these or other laws, regulations or requirements, we could suffer additional severe consequences that could have a material adverse effect on our business, results of operations, financial condition and cash flows. Additional discussion on certain of these laws, regulations and other requirements is set forth below in this section.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is and we expect that our industry will continue to be subject to extensive and complex federal, state, local and international laws, regulations and other requirements, the scope and effect of which are difficult to predict. We are also currently subject to various legal proceedings, such as lawsuits, investigations, audits and inquiries by various government and regulatory agencies, as described in Note 15 to the consolidated financial statements, and our operations and activities could be reviewed or challenged by regulatory authorities at any time in the future. In addition, each of the laws, regulations and other requirements, including interpretations thereof, that govern our business may continue to change over time, and there is no assurance that we will be able to accurately predict the nature, timing or extent of such changes or the impact of such changes on the markets in which we conduct business or on the other participants that operate in those markets. For additional detail on risks related to each of the foregoing, as well as the consequences of any violation of applicable laws, regulations or other requirements, see the discussion in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "We are, and may in the future be, a party to various lawsuits, demands, claims, qui tam suits, governmental investigations and audits and other legal matters..."</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensure and Certification</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our dialysis centers are certified by CMS, as required for the receipt of Medicare payments. Certain of our payor contracts also condition payment on Medicare certification. In some states, our outpatient dialysis centers also are required to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secure additional state licenses and permits. Governmental authorities, primarily state departments of health, periodically inspect our centers to determine if we satisfy applicable federal and state standards and requirements, including the conditions for coverage in the Medicare ESRD program.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced some delays in obtaining Medicare certifications from CMS, though changes by CMS in the prioritizing of dialysis providers as well as legislation allowing private entities to perform initial dialysis facility surveys for certification has helped to decrease or limit certain delays.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the Provider Enrollment Rule, CMS has authority to revoke provider enrollment and to impose a Medicare reapplication bar where a prospective provider's Medicare enrollment application is denied because the provider submitted incomplete, false, or misleading information for providers who are terminated from the Medicare program. CMS may also deny enrollment to providers who have affiliations with other providers that CMS has determined pose undue risk of fraud, waste or abuse. If we fail to comply with these and other applicable requirements on our licensure and certification programs, particularly in light of increased penalties that include a 10-year bar to Medicare re-enrollment, under certain circumstances it could have a material adverse impact on our business, results of operations, financial condition, cash flows and reputation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to certification by CMS, our dialysis centers are also certified by each state Medicaid program, are licensed in those states that require licensing for dialysis clinics, and are required to obtain licenses, permits and certificates, including for such areas as biomedical waste. Failure to obtain the correct certifications, permits and certificates as well as a failure to adhere to the requirements thereunder, may result in penalties, fines, and the loss of the right to operate, any of which could have a material adverse impact on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Anti-Kickback Statute</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or kind, to induce or reward either the referral of an individual for, or the purchase, or order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal criminal penalties for the violation of the federal Anti-Kickback Statute include imprisonment, fines and exclusion of the provider from future participation in the federal healthcare programs, including Medicare and Medicaid. Violations of the federal Anti-Kickback Statute are punishable by imprisonment for up to ten years and statutory fines of up to $100,000 or both. Larger criminal fines can be imposed under the provisions of the U.S. Sentencing Guidelines and the Alternate Fines Statute. Individuals and entities convicted of violating the federal Anti-Kickback Statute are subject to mandatory exclusion from participation in Medicare, Medicaid and other federal healthcare programs for a minimum of five years. Civil penalties for violation of this law include statutory amounts of up to $100,000 (adjusted for inflation) in monetary penalties per violation, assessments of up to three times the total payments between the parties to the arrangement, and permissive exclusion from participation in the federal healthcare programs or suspension from future participation in Medicare and Medicaid. The Patient Protection and Affordable Care Act and the Health Care Reconciliation Act of 2010, as amended (collectively, the ACA), amended the federal Anti-Kickback Statute to clarify that the defendant may not need to have actual knowledge of the federal Anti-Kickback Statute or have the specific intent to violate it and to provide that any claims for items or services resulting from a violation of the federal Anti-Kickback Statute are considered false or fraudulent for purposes of the False Claims Act (FCA) and can result in treble damages and other penalties under the FCA.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute includes statutory exceptions and regulatory safe harbors that protect certain arrangements. Business transactions and arrangements that are structured fully within an applicable safe harbor do not violate the federal Anti-Kickback Statute. When an arrangement is not structured fully within a safe harbor, the arrangement must be evaluated on a case-by-case basis in light of the parties&#8217; intent and the arrangement&#8217;s potential for abuse, and may be subject to greater scrutiny by enforcement agencies. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business operations, DaVita and its ancillary businesses and subsidiaries enter into numerous arrangements with physicians and other potential referral sources, that potentially implicate the Anti-Kickback Statute. Examples of such arrangements include, among other things, medical director agreements, joint ventures, leases and subleases with entities in which physicians, hospitals or medical groups hold ownership interests, consulting agreements, hospital services agreements, discharge planning services agreements, acute dialysis services agreements, value-based care arrangements, employment and coverage agreements, and incentive performance arrangements. In addition, some referring physicians may own DaVita Inc. common stock. Furthermore, our dialysis centers and subsidiaries sometimes enter into certain rebate, pricing, or other contracts to acquire certain discounted items and services that may be reimbursed by a federal healthcare program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreements and other arrangements can still be appropriate under the federal Anti-Kickback Statute even if they fail to meet all parameters of a relevant safe harbor provision; and we endeavor to structure our arrangements within applicable safe harbors, although some arrangements are not structured fully within a safe harbor. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or previous business transactions or arrangements, including but not limited to those described above, were found to violate the federal Anti-Kickback Statute, we, among other things, could face criminal, civil or administrative sanctions, including possible exclusion from participation in Medicare, Medicaid and other state and federal healthcare programs. </span></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stark Law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stark Law is a strict liability civil law that prohibits a physician who has a financial relationship, or who has an immediate family member who has a financial relationship, with entities providing Designated Health Services (DHS), from referring Medicare and Medicaid patients to such entities for the furnishing of DHS, unless an exception applies. The types of financial arrangements between a physician and a DHS entity that trigger the self-referral prohibitions of the Stark Law are broad and include direct and indirect ownership and investment interests and compensation arrangements. The Stark Law also prohibits the DHS entity receiving a prohibited referral from presenting, or causing to be presented, a claim or billing for the services arising out of the prohibited referral. If the Stark Law is implicated, the financial relationship must fully satisfy a Stark Law exception. If an exception to the Stark Law is not satisfied, then the parties to the arrangement could be subject to sanctions. Sanctions for violation of the Stark Law include denial of payment for claims for services provided in violation of the prohibition, refunds of amounts collected in violation of the prohibition, a civil penalty of up to $15,000 (adjusted for inflation) for each service arising out of the prohibited referral, a statutory civil penalty of up to $100,000 (adjusted for inflation) against parties that enter into a scheme to circumvent the Stark Law prohibition, civil assessment of up to three times the amount claimed, and potential exclusion from the federal healthcare programs, including Medicare and Medicaid. Furthermore, Stark Law violations and failure to return overpayments timely can form the basis for FCA liability as discussed below. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definition of DHS under the Stark Law excludes services paid under a composite rate, even if some of the components bundled in the composite rate are DHS. Although the ESRD bundled payment system is no longer titled a composite rate, we believe that the former composite rate payment system and the current bundled system are both composite systems excluded from the Stark Law. Since most services furnished to Medicare beneficiaries provided in our dialysis centers are reimbursed through a bundled rate, we believe that the services performed in our facilities generally are not DHS. Certain separately billable drugs (drugs furnished to an ESRD patient that are not for the treatment of ESRD that CMS allows our centers to bill for using the so-called AY modifier) may be considered DHS. However, we have implemented certain billing controls designed to limit DHS being billed out of our dialysis clinics. Likewise, the definition of inpatient hospital services, for purposes of the Stark Law, also excludes inpatient dialysis performed in hospitals that are not certified to provide ESRD services. Consequently, we believe that our arrangements with such hospitals for the provision of dialysis services to hospital inpatients should not trigger the Stark Law referral prohibition.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although prescription drugs are DHS, there is an exception in the Stark Law for calcimimetics, ESAs and other specifically enumerated dialysis drugs when furnished in or by an ESRD facility such that the arrangement for the furnishing of the drugs does not violate the Stark Law. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business operations, DaVita and its ancillary businesses and subsidiaries have many different types of financial arrangements with referring physicians that potentially implicate the Stark Law, including, but not limited to, medical director agreements, joint ventures, leases and subleases with entities in which physicians, hospitals or medical groups hold ownership interests, consulting agreements, hospital services agreements, discharge planning services agreements, acute dialysis services agreements, value-based care arrangements, employment agreements and incentive performance arrangements. In addition, some referring physicians may own our common stock in reliance on the Stark Law exception for investment interests in large publicly traded companies. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our interpretation of the applicability of the Stark Law to our operations is incorrect, the controls we have implemented fail, an arrangement is entered into outside of our processes, or we were to fail to satisfy an applicable exception to the Stark Law, we could be found to be in violation of the Stark Law and required to change our practices, face civil penalties, pay substantial fines, return certain payments received from Medicare and beneficiaries or otherwise experience a material adverse effect.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, it might be necessary to restructure existing compensation agreements with our medical directors and to repurchase or to request the sale of ownership interests in subsidiaries and partnerships held by referring physicians or, alternatively, to refuse to accept referrals for DHS from these physicians, or take other actions to modify our operations. Any finding by CMS or other regulatory or enforcement authorities that we have violated the Stark Law or related penalties and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restructuring or other required actions could have a material adverse effect on our business, results of operations, financial condition, cash flows, stock price and reputation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">False Claims Act</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal FCA is a means of policing false claims, false bills or false requests for payment in the healthcare delivery system. In part, the FCA authorizes the imposition of up to three times the government&#8217;s damages and civil penalties, plus up to approximately $28,000 per claim, on any person who, among other acts:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Knowingly presents or causes to be presented to the federal government, a false or fraudulent claim for payment or approval;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Knowingly makes, uses, or causes to be made or used, a false record or statement material to an obligation to pay the government, or knowingly conceals or knowingly and improperly, avoids or decreases an obligation to pay or transmit money or property to the federal government; or</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conspires to commit the above acts.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FCA imposes severe penalties for the knowing and improper retention of overpayments collected from government payors. Under these provisions, a provider is required to refund overpayments within 60 days of obtaining knowledge of the overpayment. A provider is deemed to have knowledge of the overpayment if it has actual knowledge, or if it acts with reckless disregard or deliberate ignorance of the overpayment. An overpayment impermissibly retained could subject us to liability under the FCA, exclusion from government healthcare programs, and penalties under the federal Civil Monetary Penalty statute. As a result of these provisions, our procedures for identifying and processing overpayments may be subject to greater scrutiny.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government has used the FCA to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs, including coding errors, billing for services not rendered, the submission of false cost reports, billing for services at a higher payment rate than appropriate, billing under a comprehensive code as well as under one or more component codes included in the comprehensive code and billing for care that is not considered medically necessary. The ACA provides that claims tainted by a violation of the federal Anti-Kickback Statute are false for purposes of the FCA. Some courts have held that filing claims or failing to refund amounts collected in violation of the Stark Law can form the basis for liability under the FCA. In addition to the provisions of the FCA, which provide for civil enforcement, the federal government can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fraud and abuse under state law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State fraud and abuse laws related to anti-kickback, physician self-referral, beneficiary inducement and false claims often mirror those requirements of the applicable federal laws, or, in some instances contain additional or different requirements. If we were found to violate these state laws and regulations, we, among other things, could face criminal, civil or administrative sanctions, including loss of licensure or possible exclusion from Medicaid and other state and federal healthcare programs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these fraud waste and abuse laws, some states in which we operate dialysis centers have laws prohibiting physicians from holding financial interests in various types of medical facilities to which they refer patients. Some of these laws could potentially be interpreted broadly as prohibiting physicians who hold shares of our publicly traded stock or are physician owners from referring patients to our dialysis centers if the centers use our laboratory subsidiary to perform laboratory services for their patients or do not otherwise satisfy an exception to the law. States also have laws similar to or stricter than the federal Anti-Kickback Statute that may affect our ability to receive referrals from physicians with whom we have financial relationships, such as our medical directors and value-based care partners, or with other referral sources, including hospitals. Some state anti-kickback laws also include civil and criminal penalties. Some of these laws include exemptions that may be applicable to our medical directors, value-based care partners and other physician and referral source relationships or for financial interests limited to shares of publicly traded stock. Some, however, may include no explicit exemption for certain types of agreements and/or relationships entered into with referral sources such as physicians and hospitals. If these laws are interpreted to apply to referring sources with whom we contract for items or services, including medical directors, value-based care partners, and hospitals, to referring physicians or hospitals with whom we hold joint ownership interests, or to referring entities or individuals who hold interests in DaVita Inc. limited solely to our publicly traded stock, and for which no applicable exception exists, we may be required to terminate or restructure our relationships with or refuse referrals from these referring </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entities or individuals and could be subject to criminal, civil and administrative sanctions, refund requirements and exclusions from participation in government healthcare programs, including Medicare and Medicaid. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Practice of Medicine and Fee-Splitting</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are states in which we operate that have laws that prohibit business entities not owned by health care providers, such as our Company and our subsidiaries, from practicing medicine, employing physicians and other licensed health care providers providing certain clinical services or exercising control over medical or clinical decisions by physicians and potentially other types of licensed health care providers (known collectively as the corporate practice of medicine). These states may also prohibit entities from engaging in certain financial arrangements, such as fee-splitting, with physicians and potentially other types of licensed health care providers. Violations of the corporate practice of medicine, fee-splitting and related laws vary by state and may result in physicians and potentially other types of licensed health care providers being subject to disciplinary action, as well as to forfeiture of revenues from payors for services rendered. Violations may also bring both civil and, in more extreme cases, criminal liability for engaging in medical practice without a license and violating the corporate practice of medicine, fee-splitting and related laws. Some of the relevant laws, regulations, and agency interpretations in states with corporate practice of medicine restrictions have been subject to limited judicial and regulatory interpretation. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Monetary Penalties Statute</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Civil Monetary Penalties Statute, 42 U.S.C. &#167; 1320a-7a, authorizes the imposition of civil money penalties, assessments, and exclusion against an individual or entity based on a variety of prohibited conduct, including, but not limited to:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payors that the individual or entity knows or should know are for an item or service that was not provided as claimed or is false or fraudulent; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Offering remuneration to a federal healthcare program beneficiary that the individual or entity knows or should know is likely to influence the beneficiary to order or receive healthcare items or services from a particular provider;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arranging contracts with an entity or individual excluded from participation in the federal healthcare programs;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Violating the federal Anti-Kickback Statute;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim for payment for items and services furnished under a federal healthcare program;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Making, using, or causing to be made any false statement, omission, or misrepresentation of a material fact in any application, bid, or contract to participate or enroll as a provider of services or a supplier under a federal healthcare program; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failing to report and return an overpayment owed to the federal government.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial civil monetary penalties may be imposed under the federal Civil Monetary Penalty Statute and vary, depending on the underlying violation. In addition, an assessment of not more than three times the total amount claimed for each item or service may also apply, and a violator may be subject to exclusion from participation in federal and state healthcare programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Corrupt Practices Act</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the provisions of the Foreign Corrupt Practices Act (FCPA) in the United States and similar laws in other countries, which generally prohibit companies and those acting on their behalf from making improper payments to foreign government officials and others for the purpose of obtaining or retaining business. A violation of the FCPA or other similar laws by us and/or our agents or representatives could result in, among other things, the imposition of fines and penalties, changes to our business practices, the termination of or other adverse impacts under our debt arrangements and contracts or debarment from bidding on contracts, and/or harm to our reputation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and Security</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 and its implementing privacy and security regulations, as amended by the federal Health Information Technology for Economic and Clinical Health Act (HITECH Act) (collectively referred to as HIPAA), require us to provide certain protections to patients and their health information. The HIPAA privacy and security regulations extensively regulate the use and disclosure of PHI and require covered entities, which include </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">healthcare providers, to implement and maintain administrative, physical and technical safeguards to protect the security of such information. Additional security requirements apply to electronic PHI. These regulations also provide patients with substantive rights with respect to their health information.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA privacy and security regulations also require us to enter into written agreements with certain contractors, known as business associates, to whom we disclose PHI. Covered entities may be subject to penalties for, among other activities, failing to enter into a business associate agreement where required by law or as a result of a business associate violating HIPAA if the business associate is found to be an agent of the covered entity and acting within the scope of the agency. Business associates are also directly subject to liability under the HIPAA privacy and security regulations. In instances where we act as a business associate to a covered entity, there is the potential for additional liability beyond our status as a covered entity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covered entities must report breaches of unsecured PHI to affected individuals without unreasonable delay but not to exceed 60 days of discovery of the breach by a covered entity or its agents. Notification must also be made to the HHS and, for breaches of unsecured PHI involving more than 500 residents of a state or jurisdiction, to the media. All non-permitted uses or disclosures of unsecured PHI are presumed to be breaches unless the covered entity or business associate establishes that there is a low probability the information has been compromised. Various state laws and regulations may also require us to notify affected individuals, and U.S. state attorneys general, or other regulators or law enforcement, in the event of a data breach involving individually identifiable information without regard to whether there is a low probability of the information being compromised.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penalties for impermissible use or disclosure of PHI were increased by the HITECH Act by imposing tiered penalties of more than $50,000 per violation and up to $1.5&#160;million per year for identical violations. In addition, HIPAA provides for criminal penalties of up to $250,000 and ten years in prison, with the severest penalties for obtaining and disclosing PHI with the intent to sell, transfer or use such information for commercial advantage, personal gain or malicious harm. Further, state attorneys general may bring civil actions seeking either injunction or damages in response to violations of the HIPAA privacy and security regulations that threaten the privacy of state residents.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection of PHI, healthcare companies must meet privacy and security requirements applicable to other categories of personal information. Companies may process consumer information in conjunction with website and corporate operations. They may also handle employee information, including Social Security Numbers, payroll information, and other categories of sensitive information, to further their employment practices. In processing this additional information, companies must comply with the applicable privacy and security requirements of comprehensive privacy and data protection laws, consumer protection laws, labor and employment laws, and its publicly-available notices. In addition, federal and state laws governing the use of artificial intelligence and machine learning technologies are evolving. As the regulation of these technologies matures, we may face additional compliance costs and legal risk to our operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, the requirements of applicable privacy and data protection laws and regulations, and any related implementation guidance from and enforcement postures of local country regulators, may present varying implementation and compliance considerations for our local country operations. These include the European Union General Data Protection Regulation (GDPR), the United Kingdom General Data Protection Regulation (UK GDPR), and other non-GDPR laws, such as the Brazilian Lei Geral de Prote&#231;&#227;o de Dados (LGPD), the Saudi Arabia Personal Data Protection Law and the Data Security Law of the People's Republic of China (DSL), among others. This variation presents compliance costs and legal risks to our international operations. When providing services or using personal data, we must ensure compliance with the applicable legislation and local legal requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR imposes a comprehensive data protection regime with the potential for regulatory fines as well as data breach litigation by impacted data subjects. Under the GDPR, regulatory penalties may be passed by data protection authorities for up to the greater of 4% of worldwide turnover or &#8364;20 million. The UK GDPR carries similar compliance and operational costs, and carries similar fines of up to the greater of &#163;17.5 million or 4% of global turnover. In non-GDPR countries, the cost of non-compliance varies but can also be just as significant as those under the GDPR. For example, the maximum fine for non-compliance with the LGPD is 50 million Brazilian real (approximately $8 million) or 2% of the company&#8217;s annual revenue, while the maximum fine for non-compliance with the DSL is RMB 50 million (approximately $7 million) or 5% of the previous year's turnover. In addition to fines, data protection authorities in non-GDPR countries may also impose criminal sanctions as well as other penalties, such as orders to cease processing personal data, orders to delete personal data, or warnings and reprimands.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy and data protection laws are also evolving nationally, providing for enhanced state privacy rights that are broader than the current federal privacy rights, and may add additional compliance costs and legal risks to our U.S. operations. For example, the California Consumer Privacy Act of 2018 (CCPA), which was significantly amended by the California Privacy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights Act (CPRA), the Colorado Privacy Act, as well as multiple other states, afford consumers expanded privacy protections. These provide for civil penalties for violations, and the CCPA and CPRA provide for a private right of action for data breaches. Additionally, several privacy bills have been proposed both at the federal and state level that may result in additional legal requirements that impact our business. On a related front, states continue to enact laws focusing on consumer health data that are similar to other comprehensive data laws, but impose more stringent consent requirements (e.g., opt-in consent for certain types of processing) for consumer health data. These laws carry statutory damages and in some cases allow for a private right of action. These state data protection laws (both the comprehensive laws and the health-focused laws) will likely result in broader increased regulatory scrutiny in applicable states of businesses' privacy and security practices, could lead to a further rise in data protection litigation, and will require additional compliance investment and potential business process changes. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the breach reporting requirements under HIPAA, companies are subject to state breach notification laws. Each state enforces a law requiring companies to provide notice of a breach of certain categories of sensitive personal information, e.g. Social Security Number, financial account information, or username and password. A company impacted by a breach must notify affected individuals, attorney&#8217;s general or other agencies within a certain time frame. If a company does not provide timely notice with the required content, it may be subject to civil penalties brought by attorneys general or affected individuals. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies must also safeguard personal information in accordance with federal and state data security laws and requirements. These requirements are akin to the HIPAA requirements to safeguard PHI, described above. The FTC, for example, requires companies to implement reasonable data security measures relative to its operations and the volume and complexity of the information it processes. Also, various state data security laws require companies to safeguard data with technical security controls and underlying policies and processes. Due to the constant changes in the data security space, companies must continuously review and update data security practices to seek to mitigate any potential operational or legal liabilities stemming from data security risks. For additional details on the risks of compliance with applicable privacy and security laws, regulations and standards, see the discussion in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and information security laws are complex..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our assessment of our cybersecurity risks, see the discussion in Part I Item 1C. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Integrated Kidney Care, Medicare and Medicaid program reforms and Other Healthcare Regulations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework of the healthcare marketplace continues to evolve as a result of executive, legislative, regulatory and administrative developments and judicial proceedings. These changes shape the landscape for our current dialysis business as well as for emerging comprehensive and integrated kidney care programs. The following discussion describes certain of these changes in further detail.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CMMI Payment Models:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As described above, CMS has launched payment models through CMMI to evaluate the effects of creating payment incentives for the greater use of home-based dialysis and kidney transplants for those already on dialysis, improve quality of care for kidney patients and reduce expenditures. The first of these, the ETC mandatory payment model, launched in approximately 30% of dialysis clinics across the country on January 1, 2021. CMS subsequently issued several clarifying rules and continues to evaluate the model. CMS has also implemented two voluntary kidney care payment models, Kidney Care First (KCF) and Comprehensive Kidney Care Contracting (CKCC), with the stated goal of helping healthcare providers reduce the cost and improve the quality of care for patients with late-stage chronic kidney disease and ESRD. CMS has stated these payment models are aimed to prevent or delay the need for dialysis and encourage kidney transplantation. As described above, we have invested substantial resources, and expect to continue to invest substantial resources in these models as part of our overall plan to grow our integrated kidney care business and value-based care initiatives.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional details on the risks related to integrated kidney care and Medicare and Medicaid program reforms, see the discussion in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives...;" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "If we are unable to compete successfully..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform, ACA and Related Regulatory and Legal Developments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The ACA regulatory framework of the healthcare marketplace continues to evolve as a result of executive, legislative, regulatory and administrative developments and judicial proceedings. For example, the expanded access to healthcare developed under the ACA has been both positively and negatively impacted over time by subsequent legal, regulatory and judicial action. In 2021 and 2022, respectively, the American Rescue Plan and Inflation Reduction Act of 2022 included several provisions designed to expand health coverage, including the expansion and extension of premium tax credits that assist consumers who purchase health insurance on marketplaces developed under the ACA and temporarily offering incentives to expand Medicaid coverage for states that have not yet done so. Our revenue and operating income levels are highly sensitive to the percentage of our patients with higher-paying commercial health insurance and any legislative, regulatory or other changes that decrease the accessibility and availability, including the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">duration, of commercial insurance, such as the potential expiration at the end of 2025 of the premium tax credits described above, is likely to have a material adverse impact on our business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the political environment may increase the likelihood of legislative or regulatory changes that would impact us, such as changes to the healthcare regulatory landscape. Examples of such potential changes also could include, among other things, legislative, regulatory, or executive development, including those that may impact the availability of certain premium tax credits under the ACA exchanges or may impact the eligibility age for Medicare beneficiaries. Some of these or other changes could in turn impact the percentage of our patients with higher-paying commercial health insurance, impact the scope or terms of coverage under commercial health plans and/or increase our expenses, among other things. The timing of legislative, regulatory or executive action related to these potential initiatives, if any, remains uncertain, particularly in light of the current economic and political environment, and as such, considerable uncertainty exists surrounding the continued development of the ACA and related regulations, programs and models, as well as similar healthcare reform measures and/or other potential changes at the federal and/or state level to laws, regulations and other requirements that govern our business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Century Cures Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above under the heading "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Advantage revenue,"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Cures Act broadened patient access to certain enhanced benefits offered by MA plans. This change in benefit eligibility has increased the percentage of our patients on MA plans as compared to Medicare Part B plans. In addition, the Cures Act also includes provisions related to data interoperability, information blocking and patient access. For details on the risks associated with these provisions of the Cures Act, see the risk factors in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Our business is subject to a complex set of governmental laws, regulations and other requirements...;" "If the number or percentage of patients with higher-paying commercial insurance declines...;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Plan Price Transparency Rules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In addition, recent price transparency regulations require most group health plans, and health insurance issuers in the group and individual markets, to make certain pricing and patient responsibility information publicly available. On July 1, 2022, most group health plans and issuers of group or individual health insurance were required to begin publishing machine-readable files that include negotiated rates for all covered items and services with all providers and out-of-network allowed amounts. For plan years that begin on or after January 1, 2023, most group health plans, and health insurance issuers in the group and individual markets, must provide enrollees with out-of-pocket cost and underlying provider negotiated rate information in a consumer-friendly format for an initial list of 500 designated services (which do not include dialysis). A plan or issuer may choose to include more than these 500 services, and for plan years that begin on or after January 1, 2024, most group health plans, and health insurance issuers in the group and individual markets, must provide enrollees with this information for all covered items and services. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned pricing transparency rules, the government has also implemented certain additional pricing transparency requirements that apply to certain types of providers, including DaVita. Under the No Surprises Act, which went into effect January 1, 2022, certain providers, including DaVita, are required to develop and disclose a "Good Faith Estimate" (GFE) that details the expected charges for furnishing certain items or services, although the government is currently only enforcing portions of this requirement with respect to uninsured or self-pay patients. The GFE is currently required to include specific information regarding the service provided and diagnostic codes, among other things, and is subject to formatting requirements, notice requirements, availability and dispute resolution procedures; in the future, GFEs will be required to include additional information, including co-provider service estimates. Similar to the aforementioned pricing transparency rules, the impact of the GFE requirements on DaVita remains uncertain at this time, in part due to ongoing rulemaking around the No Surprises Act as well as the delayed effective date of certain provisions of the GFE framework, uncertainty around operational timeframes, potential penalties and patient reaction, among other things. For additional details about the risks associated with these requirements, see the discussion in the risk factor in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If the number or percentage of patients with higher-paying commercial insurance declines...</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other regulations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis and related lab services operations are subject to various state hazardous waste and non-hazardous medical waste disposal laws at both the state and federal level. In addition, OSHA regulations require employers to provide workers who are occupationally subject to blood or other potentially infectious materials with prescribed protections. These regulatory requirements apply to all healthcare facilities, including dialysis centers, and require employers to make a determination as to which employees may be exposed to blood or other potentially infectious materials and to have in effect a written exposure control plan. In addition, employers are required to provide or employ hepatitis B vaccinations, personal protective equipment and other safety devices, infection control training, post-exposure evaluation and follow-up, waste disposal techniques and procedures and work practice controls. Employers are also required to comply with various record-keeping requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain states in which we do business have certificate of need programs regulating the establishment or expansion of healthcare facilities, including dialysis centers. Furthermore, given the evolving nature of our business, agencies, including but not limited to the Food and Drug Administration, FTC, and HHS's Office of Civil Rights, will continue to introduce and/or enforce existing laws and regulations that we may need to comply with. For additional information of the risks to our business associated with the impact of these and other laws and regulations, see the risk factors in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Our business is subject to a complex set of governmental laws, regulations, and other requirements..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Changes in federal and state legislation or regulations..."</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State laws and initiatives</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several state-based policy initiatives to limit payments to dialysis providers or impose other burdensome operational requirements, which, if passed, could have a material adverse impact on our business, results of operation, financial condition and cash flows. For example, in October 2019, a California bill (AB 290) was signed into law that limits the amount of reimbursement paid to certain providers for services provided to patients with commercial insurance who receive charitable premium assistance (reimbursement cap). The implementation of AB 290 has been stayed pending resolution of legal challenges. The trial court has issued a decision relating to these challenges to AB 290, which is currently on appeal. In addition, California passed into law California Senate Bill No. 525 (SB 525), which raises minimum wage for many California healthcare workers and went into effect in October 2024. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion on the risks associated with the evolving payment and regulatory landscape for kidney care, see the discussion in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," including the discussion under the headings,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Our business is subject to a complex set of governmental laws, regulations and other requirements..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Changes in federal and state legislation or regulations..."</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate compliance program</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has designed and implemented a corporate compliance program as part of our commitment to comply fully with applicable criminal, civil and administrative laws and regulations and to maintain the high standards of conduct we expect from all of our teammates, physician partners, and certain other third parties. We continuously review this program and work to enhance and evolve it as appropriate. The primary purposes of the program include:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assessing and identifying health care regulatory risks for existing and new businesses;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Training and educating our teammates, physician partners, and certain other third parties to promote awareness of legal and regulatory requirements, a culture of compliance, and the necessity of complying with all applicable laws, regulations and requirements;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing and implementing compliance policies and procedures and creating controls to support compliance with applicable laws, regulations and requirements and our policies and procedures;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Auditing and monitoring the activities of our operating units and business support functions to identify and mitigate risks and potential instances of noncompliance in a timely manner; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ensuring that we promptly take steps to resolve any instances of noncompliance and address areas of weakness or potential noncompliance.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a code of conduct that each of our teammates, members of our Board of Directors (Board), physician partners, and certain other third parties must follow, and we have an anonymous compliance hotline for teammates, physician partners, patients and other third parties to report potential instances of noncompliance that is managed by a third party. Our Chief Compliance Officer administers the compliance program. The Chief Compliance Officer reports directly to our Chief Executive Officer (CEO) and the Chair of the Compliance and Quality Committee of our Board.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could be subject to penalties or other consequences if the OIG or a similar regulatory authority determines that we failed to comply with applicable laws, regulations or requirements, including, among other things substantial monetary penalties and exclusion from participation in federal healthcare programs that could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dialysis industry remains highly competitive, with many new and emerging entrants entering the kidney healthcare business space. In our U.S. dialysis business, we continue to face intense competition from large and medium-sized providers, among others, which compete directly with us for limited acquisition targets, for individual patients who may choose </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to dialyze with us and to engage physicians qualified to provide required medical director services. In addition to these large and medium sized dialysis providers with substantial financial resources and other established participants in the dialysis space, we also compete with new dialysis providers, individual nephrologists and former medical directors or physicians that have opened their own dialysis units or facilities. Moreover, as we continue our international dialysis expansion into various international markets, we face competition from large and medium-sized providers, among others, for acquisition targets as well as physician relationships. We also experience competitive pressures from other dialysis and healthcare providers in recruiting and retaining qualified skilled clinical personnel as well as in connection with negotiating contracts with commercial healthcare payors and inpatient dialysis service agreements with hospitals. Acquisitions, developing new outpatient dialysis centers, patient retention and referrals, and referral source relationships, in which such sources understand us to be the clinical and operational leaders in the market are significant components of our growth strategy and our business could be adversely affected if we are not able to continue to make dialysis acquisitions on reasonable and acceptable terms, continue to develop new outpatient dialysis centers, maintain our referral sources' trust in our capabilities or if we experience significant patient attrition or lack of new patient growth relative to our competitors. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest competitor, Fresenius Medical Care (FMC), manufactures a full line of dialysis supplies and equipment in addition to owning and operating outpatient dialysis centers worldwide. This may, among other things, give FMC cost advantages over us because of its ability to manufacture its own products. Additionally, FMC is one of our largest suppliers of dialysis products and equipment. Our agreement with FMC typically requires us to purchase a certain amount of dialysis equipment, parts and supplies from FMC based upon a number of factors, including the operating requirements of our centers, the number of centers we acquire, and growth of our existing centers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our efforts to grow across the full continuum of kidney care from CKD care to dialysis treatment to transplant facilitation, we also face competition outside dialysis. In the integrated care market, we face competition from other dialysis providers who, similar to DaVita, may be seeking to expand arrangements with payors, physicians and hospitals. We also face competition from non-traditional providers and others in this space, who have made a number of announcements, initiatives and capital raises in areas along the full continuum of kidney care from CKD to dialysis to transplant. These business entities, certain of which command considerable resources and capital, increasingly compete with us in the integrated kidney care market, and they may also focus their efforts on the development of more traditional dialysis competition or the commencement of other new business activities or the development of innovative technologies, drugs or other treatments that could impact the rate of growth of the kidney care patient population or otherwise be transformative to the industry. For additional discussion on these developments and associated risks, see the risk factors in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully..</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..."</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are primarily self-insured with respect to professional and general liability, workers' compensation and automobile risks, and a portion of our employment liability practice risks, through wholly-owned captive insurance companies.&#160;We are also predominantly self-insured with respect to employee medical and other health benefits. We also maintain insurance, excess coverage, or reinsurance for property and general liability, professional liability, directors&#8217; and officers&#8217; liability, workers' compensation, cybersecurity and other coverage in amounts and on terms deemed appropriate by management, based on our actual claims experience and expectations for future claims. Future claims could, however, exceed our applicable insurance coverage. Physicians practicing at our dialysis centers are required to maintain their own malpractice insurance, and our medical directors are required to maintain coverage for their individual private medical practices. Our liability policies cover our medical directors for the performance of their duties as medical directors at our outpatient dialysis centers.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human capital management</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At DaVita, we are guided by our Mission&#8212;to be the provider, partner and employer of choice&#8212;and our Core Values&#8212;Service Excellence, Integrity, Team, Continuous Improvement, Accountability, Fulfillment and Fun&#8212;which are reinforced at all levels of the organization. Our teammates share a common passion for equitably improving patients' lives and are the cornerstone for the health of DaVita.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to be a community first and a company second, and affectionately call ourselves a Village. To be a healthy Village, we need to attract, develop and retain top talent that reflect the communities we serve. To do so, we have implemented strategies that support our mission to be the employer of choice, such as: </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Designing programs and processes to cultivate a talent pipeline that can allow us to hire ahead of needs;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Providing development and professional growth opportunities; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Offering a robust and competitive total rewards program. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that this intentional investment of time and resources fosters a special community of teammates that, in turn, leads to better care for our patients and the communities we serve.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we employed approximately 76,000 teammates, including our international teammates, with approximately 75% of our teammates located within the U.S.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oversight &amp; Management</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board provides oversight on human capital matters, receiving regular updates from our Chief People Officer about People Services&#8217; activities, strategies and initiatives, and through the Board&#8217;s annual work with our CEO on management development and succession planning. Among other things, our Board and/or its committees also receive reports related to pay equity, risks and trends related to labor and human capital management issues and other issues generally pertaining to our teammates. The Board, in conjunction with its committees, also oversees the Company's activities, policies and programs related to corporate environmental and social responsibility, including considering the impact of such activities, policies and programs on the Company, teammates, patients and communities, among others.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reports and recommendations to the Board and its committees are part of our broader People Services leadership and oversight framework, which includes guidance from various stakeholders across the business and benefits from the broad participation of senior leadership.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Connection &amp; Belonging</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in our teammates is anchored by our commitment to building a team of high performing teammates that reflect the communities we serve. We take a collaborative, leader-led approach, with everyone from our front-line patient care technicians and nurses to our divisional vice presidents, our CEO, and our Board playing a role in implementing our strategy. It truly does take a Village to bring our vision to life.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help achieve this vision, we empower all leaders and teammates to cultivate connection and belonging in their centers and on their teams. We offer a suite of training to ensure our leaders are well-versed in how to cultivate belonging on their teams, reduce bias in hiring and talent reviews, and more. Leaders may also go deeper into more complex topics to understand how to create trust and safety, respect and value others and provide fair and consistent support. Finally, the fundamentals of creating a culture of belonging are integrated into new teammate onboarding to ensure all teammates understand their role in bringing our vision to life.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years, our efforts to build culture have focused primarily on ensuring that we are creating a welcoming, open environment where all teammates, patients, physicians and care partners belong. Based on our most recent internal engagement surveys, 84% of our U.S. teammates indicated that they feel a sense of belonging within the DaVita community. We also celebrate a Week of Belonging each year, engaging teammates globally with activities and education designed to further create a sense of belonging.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, DaVita in the U.S. was composed of 78% women and 58% people of color. As of December&#160;31, 2024, in the U.S. 73% of our managers and 62% of our directors are women and that leaders with profit and loss responsibility are 52% women and 27% people of color. Our Board is composed of 40% women and 20% people of color. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Pipeline and Career Development</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Helping teammates and leaders grow and increase their earning potential are important tenets of our Employer of Choice strategy. We have a robust set of career development offerings to support teammates in reaching their professional ambitions. We have invested in an end-to-end career development pipeline that includes programs and initiatives that provide financial, educational and social support to our clinical and operations personnel to help achieve their higher education and leadership goals. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DaVita Ladders program &#8211; which currently includes Clinical Ladders for our clinical teammates &#8211; is designed to unlock clarity, competitive pay and transparent career journeys to systematically create more effective teammates and leaders. Through Clinical Ladders, the Village offers clinical teammates and leaders:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clarity around role expectations;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A shared language to describe and understand career progression across the business units and regions;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">More structured talent mobility efforts to empower teammates to explore alternative career pathways based on interest, competency, and skill;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A tool to support all aspects of the talent lifecycle through selection practices, professional development review (PDR) discussions, and succession planning, among other things;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Standardization in how we execute performance and talent conversations that are aligned to factors for role success; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market informed pay structure, pay design and guidance to consistently execute our pay for performance philosophy.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to make resources available to teammates at each step of a possible career path to enable teammates to increase their earnings potential. For example, our Bridge to Your Dreams program supports high performing teammates pursuing an associate's degree in nursing with financial assistance, resources and role placement support to become a DaVita nurse. We currently have 2,400 teammates going through the program and on the way to becoming registered nurses. We also offer programs that help develop high potential nurses, clinical coordinators and clinic nurse managers into operational managers, along with programs that prepare and coach operational managers for regional operations director roles. These are just some of the many other career development opportunities we have in place for our teammates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are proud of the work we have done in this area. In 2024 approximately 58% of our managers in the U.S. were promoted from within. We will continue to lean into our teammates' growth and help them achieve their career objectives.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Rewards Program</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards philosophy and practices are designed to be competitive in the local market and reward strong team and individual performance. We believe merit-driven pay encourages teammates to do their best work, including in caring for our patients, and we strive to link pay to performance so we can continue to incentivize the provision of extraordinary care to our patients and grow our Village.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To attract, retain and grow our teammates, we have a holistic approach to total rewards that includes financial, physical and emotional support. Highlights include, among other things:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare benefits including a menu of plan designs and health savings accounts.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Free health programs in support of the most prevalent health conditions affecting our teammates, including hypertension, diabetes prevention/maintenance, musculoskeletal issues and weight loss/management. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial wellness elements including 401(k) match, employee stock purchase plan (ESPP), a deferred compensation plan, financial planning support and access to free banking services. Additionally, DailyPay is a service that provides teammates with financial flexibility by allowing them to access earned but unpaid wages before payday.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Family support programs to our teammates and their families that include family care programs for back-up child and elder care, family planning support for fertility, adoption and surrogacy, parental support for children&#8217;s educational and special needs and parental leave programs. We also offer a number of scholarships for teammates' children and grandchildren.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Teammate Assistance Program that offers counseling sessions to all teammates and their household members, along with critical incident support for work related trauma, on both a personal and group level, with access to ten free sessions annually for each household member.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Free access to Headspace, an application for digital meditation and mindfulness, and referrals/consultations on everyday issues such as dependent care, auto repair, pet care and home improvement.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vitality Points, a voluntary wellness incentive program that encourages teammates and their spouses/domestic partners to engage with their provider to manage their overall health. In addition, it allows participating teammates and spouses/domestic partners to earn credits toward their medical premium for getting a biometric screening with a primary care provider.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Short &amp; Long term disability for full time teammates and Life/AD&amp;D coverage at both the basic and supplemental levels. Our voluntary Whole Life plan also includes long-term care coverage.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our DaVita Village Network, which provides financial support to eligible teammates experiencing a specific tragedy or hardship and helps cover additional costs that insurance does not fully cover.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pay Equity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At DaVita, we are committed to equal pay for equal work; meaning, teammates in the same position, performing at the same level, and in similar geographies, are paid equitably relative to one another, regardless of their gender, race or ethnicity. We believe that equitable pay is a critical component of establishing a work environment where all teammates are valued and feel like they belong. Equitable pay is essential to our ability to attract, motivate and retain the top talent that reflect the communities we serve who are at the center of our current and future success.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teammate Health and Safety </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to promoting a safe and compliant environment for our teammates, particularly in our clinical settings. Our safety programs are designed to proactively identify, prevent and mitigate risk in these settings, prioritizing the health, safety and well-being of both our teammates and patients. We routinely assess facilities to closely monitor adherence to established security and safety standards. We have an electronic audit system that includes monthly OSHA and infection control audits, and survey preparedness and biomedical audits are performed every six months. The audits are tracked for timely completion and correction of issues found in the audit. In the spirit of our safety culture, we also have an electronic system for capturing adverse clinical events. These events are tracked and trended to identify opportunity to improve our teammate trainings and enhance our clinical safety systems. Our teammates complete mandatory annual compliance trainings focused on key areas, reflecting our dedication to ensuring the health and safety of our teammates and patients. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about certain risks associated with our human capital management, see the risk factors in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is labor intensive and if our labor costs continue to rise...;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"External conditions, including those related to general economic, marketplace and global health conditions..."</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws. Please read the cautionary notice regarding forward-looking statements in Item 7 of Part II of this Annual Report on Form 10-K under the heading "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations." These forward-looking statements involve risks and uncertainties, including those discussed below, which could have a material adverse effect on our business, cash flows, financial condition, results of operations and/or reputation. The risks and uncertainties discussed below are not the only ones facing our business. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial could also have a material adverse effect on our business, cash flows, financial condition, results of operations and/or reputation.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks and uncertainties that could adversely affect our business, cash flows, financial condition and/or results of operations, and these adverse impacts may be material. This summary is qualified in its entirety by reference to the more detailed descriptions of the risks and uncertainties included in this Item 1A. below and you should read this summary together with those more detailed descriptions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These principal risk and uncertainties relate to, among other things: </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to the Operation of our Business</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_64">external conditions, including those related to general economic, marketplace and global health conditions, including, among other things, conditions that may impact treatment volumes or the rate of growth of our ESKD patient population;</a></span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_67">the complex set of governmental laws, regulations and other requirements that impact us, including potential changes thereto</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_70">changes in federal and state legislation or regulations;</a></span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_73">the various lawsuits, demands, claims, </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_73">qui tam</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_73"> suits, governmental investigations and audits and other legal matters that we may be subject to from time to time</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_76">the number or percentage of patients with higher-paying commercial insurance, the average rates that commercial payors pay us, any restrictions in plan designs or other contractual terms, including, without limitation, the scope and duration of coverage and in-network benefits</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_79">our ability to successfully implement our strategy with respect to integrated kidney care, value-based care and home-based dialysis</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_85">changes in the structure of and payment rates under government-based programs</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_88">increases in labor costs, including, without limitation, due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; currently pending or future governmental laws, rules, regulations or initiatives; our ability to attract and retain key leadership talent or employees; or union organizing activities or other legislative or other changes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_91">our ability to comply with complex privacy and information security laws that impact us and/or our ability to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_94">our ability to establish and maintain supplier and service provider relationships that meet our needs at cost-effective prices or at prices that allow for adequate reimbursement as applicable, our ability to access new technology or superior products in a cost-effective manner and our increasing reliance on third party service providers</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_97">changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_100">our ability to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and physicians willing to serve as medical directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_103">our U.S. integrated kidney care, U.S. other ancillary services and our international operations and our ability to expand within markets or to new markets, or invest in new products or services</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_106">political, economic, legal, operational and other risks as we expand our operations and offer our services in markets outside of the U.S., and utilizing third-party suppliers and service providers operating outside of the U.S.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_109">our ability to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems, and our ability to adhere to federal and state data sharing and access requirements and regulations</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_112">our acquisitions, mergers, joint ventures, noncontrolling interest investments or dispositions</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_115">if our joint ventures were found to violate the law;</a></span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_118">our goals and disclosures related to environmental, social and governance (ESG) matters</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_121">our ability to appropriately estimate the amount of dialysis revenues and related refund liabilities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Risks</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_127">our current or future level of indebtedness, including, without limitation, our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_130">changes in tax laws, regulations and interpretations or challenges to our tax positions</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_133">the effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_136">liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_139">our ability to successfully maintain an effective internal control over financial reporting</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_142">provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law that may deter changes of control or make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Operation of our Business</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_64"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">External conditions, including those related to general economic, marketplace and global health conditions, have impacted and will continue to impact our business and cost structure in a variety of ways, and these and other uncontrollable events may in the future impact the rate of growth of our patient population and our ability to grow the business. There can be no assurance that we will be able to successfully execute cost savings or other initiatives in a manner that will offset the impact of these conditions, which could result in a material adverse impact on us.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to be impacted by external conditions, including those related to general economic, marketplace and global health conditions, many of which are interrelated, including, among other things, inflation, interest rate volatility, labor market conditions, wage pressure, supply chain challenges, increased mortality rates of our patients and other ESKD and CKD patients, and the potential application of innovative technologies, drugs or other treatments. Certain of these impacts could be further intensified by concurrent global events such as the ongoing conflicts between Russia and Ukraine and in Israel, Gaza and the surrounding areas, severe weather events and other natural disasters, such as Hurricane Helene, Hurricane Milton and the recent wildfires in California, and the impact of policies implemented by the new administration in the United States. These global events continue to drive sociopolitical and economic uncertainty across the globe and may further impact supply chain challenges and macroeconomic conditions and trade relationships, among other things. The ultimate impact of these and other conditions on our business over time depends on future developments that are highly uncertain and difficult to predict. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience a negative impact on revenue and treatment volume due to, among other things, elevated mortality rates of our patients in comparison to the periods prior to the COVID-19 pandemic and the associated impact on our patient census. Treatment volumes during the year have been and we expect may continue to be adversely impacted by higher than expected missed treatment rates, which during the second half of 2024 were driven primarily by severe weather events. In addition, new-to-dialysis admission rates, treatment volumes, future revenues and non-acquired growth, among other things, could continue to be negatively impacted over time to the extent that the ESKD and CKD populations experience sustained elevated mortality levels, including, among other things, due to the availability and use of vaccines, treatments and therapies. As described below in the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", certain other events beyond our control could also impact the rate of growth of our ESKD patient population. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any decrease in growth rates for the ESKD or CKD patient population, higher mortality rates for dialysis patients or other reductions in demand for dialysis treatments, if sustained or significant, could have a material adverse effect on our business, results of operations, financial condition and cash flows. Any such impact would be magnified to the extent it also resulted in a lower number of patients with commercial insurance or a lower percentage of patients under commercial insurance relative to government-based programs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing global economic conditions and political and regulatory developments, such as general labor, supply chain and inflationary pressures have also increased, and will likely continue to increase, our expenses, including among other things, staffing, labor and supply costs. Our business is labor intensive and our financial and operating results have been and continue to be sensitive to variations in labor-related costs and productivity. We have historically faced and expect to continue to face difficulties in hiring and retaining caregivers due in part to a nationwide shortage of clinical personnel, which may be exacerbated with more limitations on immigration in the United States. We expect certain of these increased staffing and labor costs to continue, due to, among other factors, the continuation of a challenging labor market. The cumulative impact of these increased costs could be material. In addition, potential staffing shortages or other potential developments or disruptions related to our teammates, if material, could ultimately lead to the unplanned closures of certain centers or adversely impact clinical operations, or may otherwise have a material adverse impact on our ability to provide dialysis services or the cost of providing those services, among other things. Our industry has also experienced increased union organizing activities. For example, union petitions have been filed in nine of our clinics in California and eight of these are in different stages of the voting process and have been subject to legal challenges. For further discussion of the risks related to rising labor costs and union organizing activities, see the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is labor intensive..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the pandemic on our patient population combined with cost inflation trends and the failure of government reimbursement rates to keep pace with these cost trends have put pressure on our existing cost structure, and we expect that certain of those increased costs will persist as inflationary and supply chain pressures and challenging labor market conditions continue. Prolonged geopolitical or global economic volatility, uncertainty, trade disputes, labor supply shortages and other challenging labor market conditions could have an adverse impact on our growth and ability to execute on our other strategic initiatives and a material adverse impact on our labor costs, among other things. Prolonged strain on global supply chains, including as a result of trade disputes, geopolitical instability, fluctuations in foreign currency exchange rates or regulatory requirements may result in equipment and clinical supply shortages, disruptions, delays or associated price increases that could impact our ability to provide dialysis services or the cost of providing those services, among other things. Moreover, to the extent that monetary policies, tariffs, or other factors impacting structural costs over the long term have contributed to or may in the future contribute to inflationary pressures, this may in turn continue to increase our labor and supply costs at a rate that outpaces the Medicare or any other rate increases we may receive. In our value-based care and other programs where we assume financial accountability for total patient cost, an increase in our underlying staffing and labor expenses could have an impact on total cost of care. This increase may in turn impact the profitability of those programs relative to their respective funding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invested in and implemented cost savings initiatives designed to help mitigate these cost and volume pressures. These included, among other things, identified cost savings related to the achievement of general and administrative cost efficiencies through ongoing initiatives, including, among others, those that increase our use of third party service providers to perform certain activities. These opportunities and investments also included, among others, initiatives relating to clinic optimization, capacity utilization improvement and procurement opportunities, as well as investment in revenue cycle management. We incurred charges in connection with the continued implementation of these initiatives. There can be no assurance that we will be able to continue to successfully execute these initiatives or that they will achieve expectations or succeed in helping offset the impact of these challenging conditions. Any failure on our part to adjust our business and operations in this manner, to adjust to other marketplace developments or dynamics or to appropriately implement these initiatives in accordance with applicable legal, regulatory or compliance requirements could adversely impact our ability to provide dialysis services or the cost of providing those services, among other things, and ultimately could have a material adverse effect on our business, reputation, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deterioration in economic conditions, whether driven by macroeconomic conditions, global events, domestic political or governmental volatility or other events beyond our control, including the aforementioned inflationary and labor market pressures, changes in domestic policies, volatility and uncertainty, as well as potential volatility in the global trade markets or interest rates, could have a material adverse effect on our business, results of operations, financial condition and cash flows. Among other things, the potential decline in federal and state tax revenues that may result from a deterioration in economic conditions or political initiatives targeted at reducing government spending may create additional pressures to government sponsored programs. Any potential period of extended or increased job losses in the U.S. as a result of adverse economic conditions, including economic deterioration or changes in immigration regulations, could ultimately result in a smaller percentage of our patients being covered by an employer group health plan and a larger percentage being covered by lower-paying government insurance programs or being uninsured. In addition, the potential expiration at the end of 2025 of premium </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax credits available for patients who purchase health insurance on marketplaces developed under the ACA for may similarly lead to a smaller percentage of patients being covered by a commercial insurance plan. In the event a material reduction in the share of our patients covered by commercial insurance plans occurs, it would have a material adverse impact on our business, results of operations, financial condition and cash flows. The extent of these effects will depend upon, among other things, the extent and duration of any increased unemployment levels for our patient population, any economic deterioration or potential recession; and patients&#8217; ability to retain existing insurance and their individual choices with respect to their coverage, all of which are highly uncertain and difficult to predict. Declining economic conditions or political or other pressures that drive increased focus on healthcare costs may lead employers to select more restrictive commercial plans with lower reimbursement rates. To the extent that payors are negatively impacted by a decline in the economy, we may experience further pressure on commercial rates, a slowdown in collections and a reduction in the amounts we expect to collect. For additional information on risks regarding the potential impact of decreases to the percentage or number of our patients with commercial insurance, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If general economic conditions or labor market conditions deteriorate or remain uncertain for an extended period of time, we may experience negative impacts on reimbursement rates or the availability of insurance coverage for our patients, which may in turn materially and unfavorably impact our revenues and financial results. These impacts could lead us to incur future charges to recognize impairment in the carrying amount of our goodwill and other intangible assets, which could have a material adverse effect on our business, results of operations and financial condition. As of December&#160;31, 2024, we had approximately $7 billion of goodwill recorded on our consolidated balance sheet. We account for impairments of goodwill in accordance with the provisions of applicable accounting guidance, and record impairment charges when and to the extent a reporting unit's carrying amount is determined to exceed its estimated fair value. We use a variety of factors to assess changes in the financial condition, future prospects and other circumstances concerning our businesses and to estimate their fair value when applicable. These assessments and the related valuations can involve significant uncertainties and require significant judgment on various matters. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned impacts may also drive an increased need for additional liquidity funded by accessing existing credit facilities, raising new debt in the capital markets, or other sources, and we may seek to refinance existing debt, which may be more difficult or costly in an uncertain or declining economic environment. For additional information regarding the risks related to our indebtedness, see the discussion in the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The level of our current and future debt...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of these economic conditions or developments, as well as other consequences of these conditions or developments, some of which are beyond our control and none of which we can reasonably predict, could have a material adverse effect on our patients, teammates, physician partners, suppliers, business, results of operations, financial condition and/or cash flows or materially harm our reputation. In addition, these conditions or developments each may heighten many of the other risks and uncertainties discussed herein.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements, could have a material adverse effect on our business, results of operations, financial condition and cash flows, could materially harm our stock price, and in some circumstances, could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a complex regulatory environment with an extensive and evolving set of federal, state and local governmental laws, regulations and other requirements that apply to us. These laws, regulations and other requirements are promulgated and overseen by a number of different legislative, regulatory, administrative, and quasi-regulatory bodies, each of which may have varying interpretations, judgments or related guidance. As such, we utilize considerable resources on an ongoing basis to monitor, assess and respond to applicable legislative, regulatory and administrative requirements, but there is no guarantee that we will be successful in our efforts to adhere to all of these requirements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws, regulations and other requirements that apply to or impact our business include, but are not limited to:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare and Medicaid coverage and reimbursement statutes, and other federal coverage and reimbursement statutes, rules and regulations (including, but not limited to, manual provisions, local coverage determinations, national coverage determinations, payment schedules and agency guidance); </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare and Medicaid provider requirements, including, but not limited to, requirements associated with providing and updating certain information about the Medicare or Medicaid entity, as applicable, and its direct and indirect affiliates; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Section 1115A of the Social Security Act, which, among other things, authorizes the Center for Medicare and Medicaid Innovation (CMMI) to test certain innovation models;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal and state fraud waste and abuse laws;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the 21st Century Cures Act (the Cures Act);</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Veteran Administration and other Federal Acquisition Regulations;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">executive orders and other presidential memoranda;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act (FCPA), the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Public Law 107-56 (Patriot Act), Executive Order No. 13224 on Terrorist Financing, effective September 24, 2001, and similar laws and regulations; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">antitrust and competition laws and regulations;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations related to the corporate practice of medicine;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations regarding the collection, use and disclosure of patient health information (e.g., Health Insurance Portability and Accountability Act of 1996 (HIPAA)); </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the No Surprises Act and related laws and regulations associated with transparency, interoperability, and access to data and information;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations regarding the storage, handling, shipment, disposal and/or dispensing of pharmaceuticals and blood products and other biological and/or patient related materials; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws, regulations or other guidance across jurisdictions that require enhanced disclosures and due diligence surrounding the impacts of our Company and value chain on, and the financial risks and opportunities for our Company from, environmental, social and governance (ESG) or other similar sustainability or corporate responsibility matters, as well as enhanced policies, processes and controls designed to appropriately monitor and track such information and enhanced actions to address our Company's impact on these matters; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">individualized state laws and regulations associated with the operation of our business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our personnel, representatives, third party vendors, or operations are alleged to have violated these or other laws, regulations or requirements, we could experience material harm to our reputation and stock price, and it could impact our relationships and/or contracts related to our business, among other things. If any of our personnel, representatives, third party vendors or operations are found to violate these or other laws, regulations or requirements, we could suffer additional severe consequences that could have a material adverse effect on our business, results of operations, financial condition and cash flows, including, among others:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of required certifications or suspension or exclusion from or termination of our participation in government programs (including, without limitation, Medicare, Medicaid and CMMI demonstration programs); </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refunds of amounts received in violation of law or applicable payment program requirements dating back to the applicable statute of limitation periods; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of licenses required to operate healthcare facilities or administer pharmaceuticals in the states in which we operate; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reductions in payment rates or coverage for dialysis and ancillary services and pharmaceuticals; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Criminal or civil liability, fines, damages or monetary penalties; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposition of corporate integrity agreements, corrective action plans or consent agreements; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations, or audits by governmental agencies and/or state law claims for monetary damages by patients who believe their protected health information (PHI) has been used, disclosed or not properly safeguarded in violation of federal or state patient privacy laws, including, among others, HIPAA and the Privacy Act of 1974; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations, or audits by government agencies related to healthcare laws and regulations inclusive of fraud and abuse laws, interoperability and related data sharing and access requirements and regulations;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandated changes to our practices or procedures that significantly increase operating expenses that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our billing and business practices which could lead to potential fines, among other things;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Termination of various relationships and/or contracts related to our business, such as joint venture arrangements, medical director agreements, hospital services and skilled nursing home agreements, real estate leases, value-based care arrangements, clinical incentive programs, payor contracts, debt agreements and consulting or participating provider agreements with physicians, among others; and </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Harm to our reputation, which could negatively impact our business relationships and stock price, our ability to attract and retain patients, physicians and teammates, our ability to obtain financing and our access to new business opportunities, among other things.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future penalties, sanctions or other consequences could be more severe in certain circumstances if the OIG or a similar regulatory authority determines that we knowingly or repeatedly failed to comply with laws, regulations or requirements that apply to our business. Additionally, the healthcare sector, including the dialysis industry, is regularly subject to negative publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding the U.S. healthcare system, among other things. Negative publicity, regardless of merit, regarding the dialysis industry generally, the U.S. healthcare system or DaVita in particular may adversely affect us. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 15 to the consolidated financial statements included in this report for further details regarding certain pending legal proceedings and regulatory matters to which we are or may be subject from time to time, any of which may include allegations of violations of applicable laws, regulations and requirements.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in federal and state legislation or regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the laws, regulations and other requirements that govern our business may continue to change over time, and there is no assurance that we will be able to accurately predict the nature, timing or extent of such changes or the impact of such changes on the markets in which we conduct business or on the other participants that operate in those markets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, the regulatory framework of the healthcare marketplace continues to evolve as a result of executive orders, presidential memoranda, legislative, regulatory and administrative developments and judicial proceedings. These changes shape the landscape for our current dialysis and ancillary businesses as well as for emerging comprehensive and integrated kidney care markets. For example, as described below, we have made substantial investments in and dedicated resources to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our integrated care business, value-based care initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and home-based dialysis business to address regulatory developments that include innovative payment models, and there are risks to those investments, or additional investments may be required, in the event the regulatory environment changes and we do not adequately adapt to such changes. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, access to healthcare has been both positively and negatively impacted over time by legal, regulatory and judicial action and changes to the political environment may increase the likelihood, scale and velocity of regulatory or legislative changes that would impact us. If access to healthcare is significantly altered or if other reforms limiting access to healthcare are enacted in the future, such changes could impact our business in a number of ways, some of which may be material. Considerable uncertainty exists surrounding the continued development of the healthcare regulatory and legislative environment including pilot programs and models, as well as similar healthcare reform measures and/or other changes or extensions to laws, regulations and other requirements at the federal and/or state level that govern our business. The regulatory environment may also be impacted by recent legal decisions at all levels of the federal judicial system that could have a material impact on our business. For example, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper Bright Enterprises v. Raimondo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Supreme Court decision in June 2024 may impact current and prospective regulatory policies, including those promulgated by CMS and other agencies with significant oversight of the healthcare industry, and subject those policies to increased litigation and judicial scrutiny. Any resulting changes in regulation or enforcement may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predict. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the continuously evolving healthcare regulatory landscape may also have the potential to generate opportunities with relative ease of entry for certain different and/or non-traditional providers and we may be competing with them for patients in an asymmetrical environment with respect to reimbursement rates, data and/or regulatory requirements or obligations given our status as an ESRD service provider and relative scale. For example, CMS may consider opening for comment its established Medicare ESRD conditions for coverage. In the event that this process results in reductions or other changes in minimum health and safety standards for the provision of dialysis services, it may change the marketplace in which we operate. If we are unable to successfully adapt to these marketplace developments in a timely and compliant manner, we may experience a material adverse reduction in our overall number of patients, among other things. For additional detail on our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evolving competitive environment, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" Broader changes to the regulatory landscape may also impact our business. For example, on May 7, 2024, the Federal Trade Commission (FTC) published in the federal register a final rule that would generally ban all post-employment non-compete clauses with employees and prohibit employers from enforcing existing non-compete clauses in contracts with workers, with limited exceptions. On August 20, 2024, a federal court issued an injunction against the rule, preventing the FTC from enforcing it nationwide. As result, the FTC cannot implement or enforce its rule against any employer without violating the nationwide ban. The FTC has appealed this decision. Even though the rule has been enjoined, many state legislatures continue to introduce legislation that seeks to place similar limitations on restrictive covenants. While few of these states have passed legislation that has directly affected our business, it is possible that new legislation could be introduced in the future. We are continuing to assess the potential impact of the rule as well as Congressional and state legislative efforts on our business. Such efforts, if successful, could have an adverse impact on, among other things, our agreements with teammates, our arrangements with medical directors, or the terms of our existing agreements with physicians. Any failure on our part to adequately adjust to any state regulations or future federal or state regulations and the potential impact thereof could have a material adverse effect on our business, results of operations, financial condition, cash flows, and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we cannot predict the short- or long-term effects of any legislative or regulatory changes, future market changes could result in, among other things, more restrictive commercial plans with lower reimbursement rates or higher deductibles and co-payments that patients may not be able to pay. Because our revenue and operating income levels are highly sensitive to the percentage and number of our patients with higher-paying commercial health insurance, any legislative, regulatory or other changes that decrease the accessibility and availability, including the duration, of commercial insurance is likely to have a material adverse impact on our business. For additional information on the impact of economic conditions or legislative or regulatory changes on the coverage and rates for our services and the percentage or number of our patients with commercial insurance, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have also been several state initiatives to limit payments to dialysis providers, impose other burdensome operational requirements or prescribe wage levels. Depending on the extent of the limitations, burdens or prescriptions of such initiatives, the passage of such initiatives into law could have a material adverse impact on our business, results of operation, financial condition and cash flow. For example, California Senate Bill No. 525 (SB 525), which raised the minimum wage for many California healthcare workers, went into effect in October 2024. We may continue to face other proposed regulations or legislation or ballot initiatives in various states in future years, which, if passed, could have a material adverse impact on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, there have </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> been rule making and legislative efforts at both the federal and state level regarding the use of charitable premium assistance for ESRD patients. For example, as described in Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" certain provisions of California bill (AB 290), including the amount of reimbursement paid to certain providers for services provided to patients with commercial insurance who receive charitable premium assistance (reimbursement cap), could have negative consequences on our business if implemented in its proposed form. Depending on what provisions are implemented, organizations that provide charitable premium assistance may choose to withdraw from California, which would have an adverse impact on the ability of patients to afford Medicare premiums and Medicare supplemental and commercial coverage. We expect that such an adverse impact will in turn adversely impact our business, results of operations, financial condition and cash flows. In the past, bills similar to AB 290 have been introduced in other states, but none has become law. If these or similar bills are introduced and implemented in other jurisdictions, and organizations that provide charitable premium assistance in those jurisdictions are similarly impacted, it could in the aggregate have a material adverse impact on our business, results of operations, financial condition and cash flows. For additional information on risks associated with charitable premium assistance for ESRD patients and the potential impact of decreases to the percentage or number of our patients with commercial insurance, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If the number or percentage of patients with higher-paying commercial insurance declines..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, legislation, regulations, regulatory guidance, ballot initiatives and any similar initiatives could result in a reduction in the percentage of our patients with commercial insurance; limit the scope or nature of coverage through the healthcare exchanges established by the ACA or other health insurance programs or otherwise reduce reimbursement rates for our services from commercial and/or government payors; restrict or prohibit the ability of patients with access to alternative coverage from selecting a marketplace plan on or off exchange; limit the amount of revenue that a dialysis provider can retain for caring for patients with commercial insurance; impose burdensome operational requirements; affect payments made to providers for services provided to patients who receive charitable premium assistance and/or otherwise restrict or prohibit the use of charitable premium assistance; or reduce the standards for network adequacy or require disclosure of certain pricing and patient responsibility information. In turn, these potential impacts could cause us to incur substantial costs to oppose any such proposed requirements or measures, impact our dialysis center development plans, and if passed and/or implemented, could materially reduce our revenues and increase our operating and other costs, adversely impact dialysis centers across the U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making certain centers economically unviable, lead to the closure of certain centers, restrict the ability of dialysis patients to obtain and maintain optimal insurance coverage and reduce the number of patients that select commercial insurance plans or Medicare Advantage (MA) plans for their dialysis care, among other things. For additional details regarding insurance coverage for dialysis services, see the discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If the number or percentage of patients with higher-paying commercial insurance declines..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare legislative and regulatory environment is dynamic and evolving, and any such proposed or issued laws, requirements, rules and guidance could impact our business, including as may be described above, and any failure on our part to adequately adjust to any resulting marketplace developments or regulatory compliance requirements, may, among other things, erode our patient base or reimbursement rates and could otherwise have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the information above describes statutory and regulatory provisions, it is qualified in its entirety by reference to the particular statutory and regulatory provisions that are referenced. For additional information related to the laws, rules and other regulations described above, see Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are, and may in the future be, a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> suits, governmental investigations and audits and other legal matters, any of which could result in, among other things, substantial financial penalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or awards against us, mandated refunds, substantial payments made by us, required changes to our business practices, exclusion from future participation in Medicare, Medicaid and other healthcare programs and possible criminal penalties, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and may in the future be, subject to investigations and audits by governmental agencies, private civil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators and other lawsuits, demands, claims, legal proceedings and/or other actions alleging our failure to comply with a rule, regulation, law or practice of medicine. We are, and can be in the future, subject to audits from the government concerning the billing for our patients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, following the conclusion of any audit, the government were to require us to refund amounts and/or modify our business practices, and such amounts or changes are significant, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. The healthcare industry is highly visible and politically charged, and any allegation against us, our personnel, representatives, third party vendors, or operations in such matters or matters that involve patients suffering adverse health outcomes, may, among other things harm our reputation, stock price, and it could impact our relationships and/or contracts related to our business, among other things. Each of these impacts may be material. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Responding to subpoenas, investigations and other lawsuits, claims and legal proceedings, as well as defending ourselves in such matters, will continue to require management's attention and cause us to incur significant legal expense. Negative developments, findings or terms and conditions that we might agree to accept as part of a negotiated resolution of pending or future legal or regulatory matters, or have been forced upon us, could result in, among other things, harm to our reputation, substantial financial penalties or awards against us, substantial payments made by us, required changes to our business practices, impacts on our various relationships and/or contracts related to our business, exclusion from future participation in Medicare, Medicaid and other healthcare programs and, in certain cases, criminal penalties, any of which could have a material adverse effect on us. It is possible that criminal proceedings may be initiated against us and/or individuals in our business in connection with governmental investigations. Other than as may be described in Note 15 to the consolidated financial statements included in this report, we cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which we are or may be subject from time to time, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price. See Note 15 to the consolidated financial statements included in this report for further details regarding these and other legal proceedings and regulatory matters.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines, if the average rates that commercial payors pay us decline, if commercial plans subject patients to restriction in plan designs, or if we are unable to maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our U.S. dialysis patient service revenues are generated from patients who have commercial payors as their primary payor. The majority of these patients have insurance policies that pay us on terms and at rates that are generally significantly higher than Medicare rates. As such our revenue and net income levels are sensitive to the number of our patients with higher-paying commercial insurance coverage and the percentage of our patients under higher-paying commercial plans relative to government-based programs. The payments we receive from commercial payors generate nearly all of our profit and all of our nonacute dialysis profits come from commercial payors. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When traditional or original Medicare (Medicare) becomes the primary payor for a patient, the payment rate we receive for that patient decreases from the employer group health plan or commercial plan rate to the lower Medicare payment rate. There are a number of factors that could drive a decline in the number or percentage of our patients covered under commercial insurance plans, including, among other things, improved mortality, changes in the patient's or a family member's employment status, reduced availability of commercial health plans or reduced coverage by such plans through the ACA exchanges or otherwise due to changes to the laws, marketplace, healthcare regulatory system or otherwise. For example, certain premium tax credits available to patients who purchase health insurance on marketplaces developed under the ACA are scheduled to expire at the end of 2025 unless extended or made permanent by legislative action. The potential expiration of these tax credits may significantly reduce the affordability of commercial insurance plans, leading to fewer patients covered by such plans. This may, in turn, result in more patients shifting to Medicare or other government-based program, further decreasing the percentage of patients covered under commercial insurance plans. Commercial payors could also cease paying in the primary position after providing 30 months of coverage resulting in potentially material reductions in payment as the patient moves to Medicare primary. Declining macroeconomic conditions could also negatively impact the percentage of our patients covered under commercial insurance plans. To the extent there are job losses in the U.S., we could experience a decrease in the number of patients covered under commercial plans and/or an increase in uninsured and underinsured patients independent of whether general economic conditions improve. If we experience higher numbers of uninsured or underinsured patients, it also would result in an increase in uncollectible accounts.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our arrangements and negotiations with payors also impact the number or percentage of patients with higher-paying commercial insurance. We continuously are in the process of negotiating existing and potential new agreements with commercial payors who aggressively negotiate terms with us, and we can make no assurances about the ultimate results of these negotiations or the timing of any potential rate changes resulting from these negotiations. A material portion of both our commercial revenue and MA revenue is concentrated with a limited number of commercial payors, and any changes impacting our highest paying commercial payors or our relationships with these payors will have a disproportionate impact on us. Sometimes many significant agreements are being renegotiated at the same time. We believe payor consolidations have significantly increased the negotiating leverage of commercial payors, and ongoing consolidations may continue to increase this leverage in the future. In addition, our agreements and rates with commercial payors may be impacted by new business activities of these commercial payors as well as steps that these commercial payors have taken and may continue to take to control the cost of and/or the eligibility for access to the services that we provide, including, without limitation, relative to products on and off the healthcare exchanges. These efforts could impact the number of our patients who are eligible to enroll in commercial insurance plans, and remain on the plans, including plans offered through healthcare exchanges. We continue to experience downward pressure on some of our rates with commercial payors as a result of these and other general conditions in the market, including, among other things, as employers seek to shift to less expensive options for medical services or as commercial payors dedicate increased focus on dialysis services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our negotiations with commercial payors may relate to commercial fee-for-service contracts and value-based care (VBC) contracts in which we share risk with commercial payors or other structures that allow the parties to share in cost savings upon the achievement of certain outcomes, as well as contracts to provide dialysis services to MA patients. If we fail to maintain contracts with payors and other healthcare providers with competitive or favorable terms, either with respect to commercial plans, commercial VBC contracts, MA plans or otherwise, including, without limitation, with respect to reimbursement rates, scope and duration of coverage and in-network benefits, contract term or termination rights, or if we fail to accurately estimate the price for and manage our medical costs in an effective manner, whether due to inflationary pressures or otherwise, such that the profitability of our commercial or other value-based products is negatively impacted, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. The ultimate result of our negotiations with payors cannot be predicted as they occur in a highly competitive environment and are influenced by changes to payment rates set by CMS and other marketplace dynamics such as those previously discussed. Among other things, these negotiations may result in termination or non-renewals of existing agreements, decreases in contracted rates, and reduction in the number of our patients that are covered by commercial plans, and we may not be able to enter into new agreements on competitive terms or at all. In the event that our ongoing negotiations with commercial payors result in overall rate reductions in excess of overall rate increases, the cumulative effect could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, to the extent that these negotiations result in a reduction in the number of our patients covered by plans with commercial payors, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain payors have been attempting to design and implement plans that restrict or limit coverage for treatment needed by ESRD patients in the commercial market. Among other things, these restrictive plan designs seek to limit the duration and/or the breadth of ESRD benefits, limit in-network providers, set arbitrary provider reimbursement rates, or otherwise restrict access to care, all of which may result in a decrease in the number of patients covered by commercial insurance or the reimbursement rate for ESRD services, among other things. Payors have also disputed the scope and duration of ESRD benefit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coverage under their plans, and, among other things, have required patients to seek Medicare coverage for ESRD treatments. On June 21, 2022, the U.S. Supreme Court issued a decision in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc., et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a case evaluating the current language of the Medicare Secondary Payor Act (MSPA), deciding that a group health plan that limits the benefits for outpatient dialysis, but does so uniformly for all plan participants, does not violate the terms of the MSPA because the plan treats all patients uniformly, regardless of whether a participant has ESRD and regardless of whether the participant is eligible for Medicare. We cannot reasonably estimate the ultimate impact of the U.S. Supreme Court&#8217;s decision at this time, as there is significant uncertainty as to, among other things, whether and to what extent payors, including, among others employer group health plans, may seek to design and implement plans to restrict access to ESRD in light of the decision; the results of proposed and pending legislative responses to the decision; how courts will interpret other anti-discriminatory provisions of the MSPA that may apply; whether there could be other potential negative impacts of the decision and any resultant plan behavior on our commercial or government mix or the number of our patients covered by commercial insurance; and the timing of each of these items. If more commercial or employer group health plans seek to implement or utilize plan designs that discourage or prevent ESRD patients from retaining their commercial coverage, during upcoming open enrollment periods or otherwise, it may lead to a decrease in the number of patients with commercial plans, the duration of benefits for patients under commercial plans and/or a decrease in the payment rates we receive, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some commercial payors are pursuing or have incorporated policies into their provider manuals limiting or refusing to accept charitable premium assistance from non-profit organizations, such as the American Kidney Fund (AKF), which may impact the number of patients who are able to afford commercial plans. Paying for coverage is a significant financial burden for many patients, and ESRD disproportionately affects the low-income population. Charitable premium assistance supports continuity of coverage and access to care for patients, many of whom are unable to continue working full-time as a result of their severe health condition. Many patients with commercial and government insurance also rely on financial assistance from charitable organizations, such as the AKF. Certain payors have challenged our patients' and other providers' patients' ability to utilize assistance from charitable organizations for the payment of premiums, including, without limitation, through litigation and other legal proceedings. The use of charitable premium assistance for ESRD patients has also faced challenges and inquiries from legislators, regulators and other governmental authorities, including California AB 290 as described in the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state legislation or regulations...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", and this may continue. In addition, CMS or another regulatory agency or legislative authority may issue a new rule or guidance that challenges or restricts charitable premium assistance. If any of these challenges to kidney patients' use of premium assistance is successful or restrictions are imposed on the use of financial assistance from such charitable organizations or if organizations providing such assistance are no longer available such that kidney patients are unable to obtain, or continue to receive or receive for a limited duration, such financial assistance, it may restrict the ability of dialysis patients to obtain and maintain optimal insurance coverage and could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, if our assumptions about how kidney patients will respond to any change in financial assistance from charitable organizations are incorrect, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our negotiations and relationships with payors may also be impacted by legislative or regulatory developments and associated legal rulings. For example, the final rules for the Cures Act, which are described in detail in Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">broadened ESRD patient access to certain enhanced benefits offered by MA plans. While these rules increased our MA plan enrollment for ESRD benefits in their first year, the potential ultimate impact of this change in benefit eligibility remains subject to change as market participants continue to adjust to this regulatory environment, including such changes as, for example, the overall increases in MA plan enrollment for ESRD benefits or the removal of objective time and distance standards for network adequacy for outpatient dialysis centers. In addition, the ultimate impact of the price transparency regulations and "Good Faith Estimate" (GFE) requirements described in Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation," </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remains uncertain at this time, in part due to ongoing rulemaking around the No Surprises Act as well as the delayed effective date of certain provisions of the GFE framework, and uncertainty around operational timeframes, potential penalties and patient reaction, among other things. While the ultimate impact of these requirements and the aforementioned price transparency rules remains uncertain, any changes by group health plans, health insurance issuers in the group and individual markets, or consumer choices resulting from these requirements could have a material adverse impact on our business, results of operations, and financial condition, and could materially harm our reputation. For additional details regarding these regulations and potential legislative or regulatory changes, the specific risks we face in connection with these regulations, and any decrease in payments we receive for services due to, for example, fewer patients being covered under commercial plans or an increase of patients covered under more restrictive commercial plans, or plans with lower reimbursement rates, see the discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Changes in federal and state legislation or regulations...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted, the foregoing dynamics of our arrangements and negotiations with commercial payors each may have an impact on, among other things, our ability to enter into and maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits as well as the number or percentage of our patients with higher-paying commercial insurance. If, as a result of these or other dynamics, we experience a decline in the average rates that commercial payors pay us or a reduction in the number of patients with ESRD coverage under higher-paying commercial plans either in total or relative to the number of patients under government-based programs that pay at lower rates or an increase in the number of patients that are uninsured or underinsured, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">it could result in a loss of our investments and have a material adverse effect on our growth strategy, could adversely impact our business, results of operations, financial condition and cash flows, and could materially harm our reputation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our integrated kidney care business manages patients and coordinates their care through value-based care arrangements with commercial payors and through government programs. We have continued to grow this portion of our business both with commercial payors, including as MA has expanded, and with government programs as CMS and CMMI implement new payment models focused on comprehensive and integrated kidney care. A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s part of our growth strategy, we have invested and expect to continue to invest substantial resources in the further development of our integrated care business and value-based care initiatives. There can be no assurances that we will be able to successfully implement our strategies with respect to integrated kidney care and value-based care in a complex, evolving and highly competitive and regulated environment, including, among other things, executing on initiatives to reduce the overall cost of care for our IKC patients; maintaining our existing business; recovering our investments; entering into agreements with payors, physicians, third party vendors and others on competitive terms, as appropriate, that prove actuarially sound; structuring these agreements and arrangements to comply with evolving rules and regulations, including, among other things, rules </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations related to fraud and abuse and the use of protected health information. Implementing our expanded integrated kidney care strategies and value-based care initiatives at scale also increases certain execution and compliance risks associated with developing our operational, IT, billing and telehealth systems, including our ability to accurately capture relevant patient care data, among other things. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional details on risks associated with information systems and new technology generally, see the risk factor under the heading </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging entrants are pursuing opportunities to participate in the CMMI payment models as well as broader risk arrangements with other payors, and with increasing investment and funding, these emerging entrants may adopt strategies that increase our costs to participate in these payment models and/or adversely impact our ability to enter into competitive arrangements with payors, physicians and hospitals. In addition, they may have the ability to operate without regard to regulations to which we comply. For additional detail on our evolving competitive environment, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are unable to compete successfully..." </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these or other of our integrated kidney care and value-based care initiatives are unsuccessful, it could result in a loss of our investments and have a material adverse effect on our growth strategy, could adversely impact our business, results of operations, financial condition and cash flows, and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future legislative or regulatory action related to, among other things, existing or future integrated kidney care initiatives, including among others, CMMI payment models, and/or full capitation demonstration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for ESRD may impact our ability to provide a competitive and successful integrated care program at scale. There can be no assurances that any other legislation or regulation that aligns with our strategy and investments will be extended, passed into law or enacted. Additionally, the ultimate terms and conditions of any potential legislative or regulatory action impacting integrated kidney care, full capitation demonstrations or the existing CMMI payment models remain unclear. For example, the CKCC program is a 5-year demonstration that launched in 2022. CMMI continues to monitor the performance of these and other kidney care payment models, and there is no assurance that this program will be extended or modified in the future and, among other things, our costs of care could exceed our associated reimbursement rates under such legislation or regulation. Irrespective of whether such laws are passed or regulations enacted, there can be no assurances that we will be able to successfully execute on the required strategic initiatives that would allow us to maintain a competitive and successful integrated care program on a broad scale, and in the desired time frame. Any failure on our part to adequately implement strategic initiatives, including to adjust to any marketplace developments resulting from executive, legislative, regulatory or administrative changes, could have a material adverse impact on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home-based dialysis services, which include home hemodialysis and peritoneal dialysis (PD), represented approximately 19% of our U.S. dialysis patient service revenues for the year ended December&#160;31, 2024, and have increasingly become an important part of our overall strategy. In addition, home-based dialysis recently has been the subject of increased legislative, regulatory, political and industry focus. For example, in connection with the 2019 Executive Order, HHS set out specific goals related to home dialysis and CMMI&#8217;s ESRD Treatment Choices (ETC) mandatory payment model and voluntary payment models included new incentives to encourage dialysis at home. CMS subsequently finalized changes to the ETC model and other regulations to encourage dialysis facilities and healthcare providers to seek to decrease disparities in health outcomes across racial and socioeconomic status in rates of home dialysis and kidney transplants among ESRD patients. CMS also regulates home dialysis under the ESRD Prospective Payment System (PPS) rule. Under this, CMS recently finalized a proposal to allow payment for acute kidney injury (AKI) renal dialysis services furnished to beneficiaries in their home and the agency will permit ESRD facilities to bill Medicare for the home and self-dialysis training add-on payment adjustment for beneficiaries with AKI. We are a leader in home-based dialysis and have made investments in processes and infrastructure to continue to grow this modality. There are, however, risks associated with this growth, including, among other things, financial, legal, regulatory and operational risks related to our ability to design and develop infrastructure and to plan for capacity in a modality that is part of an evolving marketplace. For example, there is a limited number of available suppliers for certain critical home-based dialysis supplies, including key products provided by a supplier that was impacted by a severe weather event in 2024. As described further in the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If certain of our suppliers and service providers&#8230;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," any disruptions involving such supplies could materially impact our operations and require significant resources or operational changes in response.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to associated risks related to our ability to successfully manage related operational initiatives, find, train and retain appropriate staff, contract with payors for appropriate reimbursement, and maintain processes to adhere to the complex regulatory and legal requirements, including without limitation those associated with billing Medicare. For additional detail on risks associated with operating in a highly regulated environment, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the above risks, certain risks inherent to home-based dialysis will increase as we expand our home-based dialysis offerings, including risks related to managing transitions between in-center and home-based dialysis, billing and telehealth systems, among others. For additional detail on risks associated with information systems and new technology generally, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An increased focus on home-based dialysis is also indicative of the generally evolving market for kidney care. This developing market may create additional opportunities for competition with relative ease of entry, and if we are unable to successfully adapt to these or other marketplace developments, which, among other things, may include regulatory changes with respect to conditions of coverage, in a timely and compliant manner, we may experience a material adverse impact on our growth in home-based dialysis or a reduction in our overall number of patients, among other things. For additional detail on the competitive landscape in kidney care, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are unable to compete successfully..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in the structure of and payment rates under the Medicare ESRD or Medicare Advantage programs or changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our dialysis revenues are generated from patients who have Medicare or MA as their primary payor. For patients with Medicare coverage, payments for dialysis treatments are currently made under a single bundled payment rate which provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment that are related to the treatment of dialysis, subject to certain adjustments. Most lab services are also included in the bundled payment. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESRD PPS, bundled payments to a dialysis facility may be reduced by as much as 2% based on the facility's performance in specified quality measures set annually by CMS through the ESRD Quality Incentive Program, which was established by the Medicare Improvements for Patients and Providers Act of 2008. The bundled payment rate is also adjusted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for certain patient characteristics, a geographic usage index, a wage index and certain other factors. In addition, the ESRD PPS is subject to rebasing, which can have a positive financial effect, or a negative one if the government fails to rebase in a manner that adequately addresses the costs borne by dialysis facilities. Similarly, as new drugs, services or labs are added to the ESRD bundle, CMS' failure to adequately calculate or fund the costs associated with the drugs, services or labs could have a material adverse effect on our business, results of operations, financial condition and cash flows. In certain instances, new injectable, intravenous or oral products may be reimbursed separately from the bundled payment for a defined period of time through a transitional drug add-on payment adjustment (TDAPA). For a discussion of certain risks associated with this transitional pricing process, see the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current bundled payment system presents certain operating, clinical and financial risks, which include, without limitation:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that our reimbursement rates are reduced by CMS or are otherwise inadequate. CMS publishes a final rule for the ESRD PPS each year and uncertainty about future payment rates remains a material risk to our business.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that CMS, on its own or through its contracted Medicare Administrative Contractors (MACs) or otherwise, implements Local Coverage Determinations (LCDs) or implements payment provisions, policy or regulatory mandates, including changes to the existing or future PPS, that limit our ability to either be paid for covered dialysis services or bill for treatments or other drugs and services or other rules that may impact reimbursement. Such payment rules and regulations and coverage determinations or related decisions could have an adverse impact on our operations and revenue. There is also risk that commercial insurers could seek to incorporate the requirements or limitations associated with such LCDs or CMS guidance into their contracted terms with dialysis providers, which could have an adverse impact on our revenue. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that a MAC, or multiple MACs, change their interpretations of existing regulations, manual provisions and/or guidance, or seek to implement or enforce new interpretations that are inconsistent with how we have interpreted existing regulations, manual provisions and/or guidance.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that CMS implements data and related reporting requirements that result in decreased reimbursement and/or increased technology and operational costs and/or creates brand risk.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that increases in our operating costs will outpace the Medicare rate increases we receive. We expect operating costs to continue to increase due to inflationary factors, such as increases in labor and supply costs, including, without limitation, increases in maintenance costs and capital expenditures to improve, renovate and maintain our facilities, equipment and information technology to meet changing regulatory requirements and business needs, regardless of whether there is a compensating inflation-based increase in Medicare payment rates or in payments under the bundled payment rate system. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of continued federal budget sequestration cuts or other disruptions in federal government operations and funding. As a result of the Budget Control Act of 2011, the Bipartisan Budget Act (BBA) and subsequent legislation, an annual reduction (currently 2%) to Medicare payments took effect on April 1, 2013, and has been extended into 2032. These across-the-board spending cuts have affected and will continue to adversely affect our business, results of operations, financial condition and cash flows. Any extended disruption in federal government operations and funding, including an extended government shutdown, U.S. government debt default and/or failure of the U.S. government to enact annual appropriations could have a material adverse effect on our business, results of operations, financial condition and cash flows. Additionally, disruptions in federal government operations may delay or negatively impact regulatory approvals and guidance that are important to our operations, and create uncertainty about the pace of upcoming regulatory developments.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that failure to adequately develop and maintain our clinical or other operational systems or failure of our clinical or operational systems to operate effectively could have a material adverse effect on our business, results of operations, financial condition and cash flows. For example, in connection with claims for which at least part of the government's payments to us is based on clinical performance or patient outcomes or co-morbidities, if our clinical systems fail to accurately capture the data we report to CMS or we otherwise have data integrity issues with respect to the reported information, we might be over-reimbursed by the government, which could, among other things, subject us to liability exclusion from participation in federal healthcare programs and penalties under the federal Civil Monetary Penalty statute, and could adversely impact our reputation. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we also contract with commercial payors that administer MA plans to provide their members with Medicare Part A, Part B and/or Part D benefits. Our MA business presents similar operating, clinical and financial risks as those related to the bundled payment system, which include, without limitation: </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that reimbursement rates for the MA program are reduced by CMS or are otherwise inadequate and that payors, therefore, reduce our rates and/or fund us less for services rendered. CMS publishes a final rule for MA program rates each year and uncertainty about future payment rates remains a material risk to our business, particularly as our MA enrollment increases. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of ensuring that we remain compliant with applicable MA requirements, inclusive of MA marketing and education requirements and restrictions, as well as our contractual terms with associated plans, as our initiatives associated with MA (including chronic condition special needs and dual eligible special needs plans) continue to evolve and progress. Failure to do so could resolve in termination of agreements with plans as well as enforcement by state and federal agencies for violation of insurance, consumer protection and fraud and abuse laws and regulations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above risks under the current Medicare ESRD and MA programs, changing legislation and other regulatory and executive developments have led and may continue to lead to the emergence of new models of care and other initiatives in both the government and private sector that, among other things, may impact the structure of, and payment rates under, the Medicare ESRD and MA programs. Moreover, the number of our patients with primary Medicare coverage may be subject to change, particularly with the effectiveness of the Cures Act, which allows Medicare-eligible individuals with ESRD to enroll in MA managed care plans. For additional details regarding the risks we face for failing to adhere to our Medicare, MA and Medicaid regulatory compliance obligations or failing to adequately implement strategic initiatives to adjust to marketplace developments, see the risk factors above under the headings "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Changes in federal and state legislation or regulations..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, increased political pressures to reduce government spending, including potential cuts to Medicare funding, may create additional risks to payment rates and the structure of the Medicare ESRD and MA programs. For additional information on the impact of potential reduced government spending, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"External conditions, including those related to general economic, marketplace and global health conditions..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary coverage for a significant number of our patients also comes from state Medicaid programs partially funded by the federal government and we have patients covered by other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs (VA). As state governments and other governmental organizations face increasing financial hardship and budgetary pressure, including as a result of the COVID-19 pandemic or changes in the political environment, we may in turn face reductions in payment rates, delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs. For example, certain state Medicaid programs and the VA have recently considered, proposed or implemented payment rate reductions, such as the VA's proposed adoption of Medicare's bundled PPS pricing methodology for any veterans receiving treatment from non-VA providers under a national contracting initiative. Since we are a non-VA provider, these reimbursements are tied to a percentage of Medicare reimbursement, and we have exposure to any dialysis reimbursement changes made by CMS. In addition, in 2019 and subsequently renewed, we entered into a Nationwide Dialysis Services contract with the VA that includes five separate one-year renewal periods throughout the term of the contract. The term structure is similar to our prior five-year agreement with the VA, and is consistent with VA practice for similar provider agreements. With this contract award, the VA has agreed to keep our percentage of Medicare reimbursement consistent with that under our prior agreement with the VA during the term of the contract. As with that prior agreement, this agreement provides the VA with the right to terminate the agreements without cause on short notice, among other things. The current contract expires at the end of September 2025. Should the VA renegotiate, not renew or cancel these agreements for any reason, we may cease accepting patients under this program and may be forced to close centers or experience lower reimbursement rates, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs are increasingly adopting Medicare-like bundled payment systems, but sometimes these payment systems are poorly defined and are implemented without any claims processing infrastructure, or patient or facility adjusters. If these payment systems are implemented without any adjusters and claims processing infrastructure, Medicaid payments will be substantially reduced and the costs to submit such claims may increase, which will have a negative impact on our business, results of operations, financial condition and cash flows. In addition, some state Medicaid program eligibility requirements mandate that citizen enrollees in such programs provide documented proof of citizenship. If our patients cannot meet these proof of citizenship documentation requirements, they may be denied coverage under these programs, resulting in decreased patient volumes and revenue. These Medicaid payment and enrollment changes, along with similar changes to other non-Medicare government programs, could reduce the rates paid by these programs for dialysis and related services, delay the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receipt of payment for services provided and further limit eligibility for coverage which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business is labor intensive and if our labor costs continue to rise, including due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; or currently pending or future governmental laws, rules, regulations or initiatives impose additional requirements or limitations on our operations or profitability; or, if we are unable to attract and retain employees or key leadership positions; or if union organizing activities or legislative or other changes result in significant increases in our operating costs or decreases in productivity, we may experience disruptions in our business operations and increases in operating expenses, among other things, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face increasing labor costs generally, and in particular, we continue to face increased labor costs and difficulties in hiring skilled clinical personnel, including nurses, due to a nationwide shortage of such personnel that has been exacerbated by current macroeconomic conditions and developments in the labor market. As referenced above, the current labor market is challenging and continues to experience volatility, uncertainty and labor supply shortages, particularly in healthcare. Our business is labor intensive, and our financial and operating results have been and continue to be sensitive to variations in labor-related costs, productivity and the number of pending or potential claims against us related to labor and employment practices. We have incurred and expect to continue to incur increased labor costs, including through elevated compensation levels to our teammates, the ultimate extent of which will depend on current macroeconomic conditions and ancillary impacts on the labor market, among other things. For additional discussion of the risks facing us related to the current labor environment, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"External conditions, including those related to general economic, marketplace and global health conditions..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, to the extent that general inflationary pressures continue or further increase, this may in turn increase our labor and supply costs at a rate that outpaces the Medicare or any other rate increases we may receive. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete for nurses with hospitals and other healthcare providers. The ongoing nursing shortage may limit our ability to expand our operations. Furthermore, changes in certification requirements can impact our ability to maintain sufficient staff levels, including to the extent our teammates are not able to meet new requirements, among other things. In addition, if we experience a higher than normal turnover rate for our skilled clinical personnel, our operations and treatment growth may be negatively impacted, which could adversely affect our business, results of operations, financial condition and cash flows. For example, in 2024, we again had significant teammate turnover, particularly amongst teammates in their first year, which led to increased training costs, among other things. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face competition in attracting and retaining talent for key leadership positions that are responsible for developing and executing the Company's business strategy and operational initiatives. Increased competition for top leadership talent in our industry and general marketplace conditions, including recent negative publicity and events surrounding the healthcare industry, could also impact our ability to attract and retain qualified leaders. If we are unable to attract and retain qualified individuals, including with respect to our leadership team, we may experience disruptions in our business operations, including, without limitation, our ability to achieve strategic goals, which could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Political or other efforts at the national or local level could result in actions or proposals that increase the likelihood of success of union organizing activities at our facilities and ongoing union organizing activities at our facilities could continue or increase for other reasons. Our industry has also experienced increased union organizing activities. For example, union petitions have been filed in nine of our clinics in California and eight of these petitions are in different stages of the voting process and have been subject to legal challenges. We also have experienced a week-long attempted union-related work stoppage in these eight clinics, which concluded without impacting our ability to provide patient care. Regardless of the outcome of the ongoing elections, other teammates at other clinics may file similar petitions in the future, and these petitions, if filed, may lead to additional elections. If a significant portion of our teammates were to become unionized, we could experience, among other things, potential additional work stoppages or other business disruptions; adverse impacts to our financial results due to the costs of bargaining or implementing a grievance procedure and processing grievances; decreases in our operational flexibility and efficiency; or negative impacts on our employee culture. In addition, we are and may continue to be subject to targeted corporate campaigns by union organizers in response to which we have been and expect to continue to be required to expend substantial resources, both time and financial. Any of these events or circumstances, including our responses to such events or circumstances, could have a material adverse effect on our employee relations, treatment growth, productivity, business, results of operations, financial condition, cash flows and reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches or suffer losses to our data and information technology assets, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with numerous federal and state laws and regulations in both the U.S. and the foreign jurisdictions in which we operate governing the collection, dissemination, access, use, security and privacy of PHI. In the U.S., these regulations include, without limitation, HIPAA and its implementing privacy, security, and related regulations, as amended by the federal Health Information Technology for Economic and Clinical Health Act (HITECH) and collectively referred to as HIPAA. We are also required to report known breaches of PHI and other certain personal information consistent with applicable breach reporting requirements set forth in applicable laws and regulations. From time to time, we may be subject to both federal and state inquiries or audits related to HIPAA, HITECH and other state privacy laws associated with complaints, desk audits, and data breaches. Requirements under HIPAA also continue to evolve. Globally, these regulations include, but are not limited to, European Union (EU) General Data Protection Regulation (GDPR), the United Kingdom GDPR, the EU Artificial Intelligence Act, the EU Data Act and the EU Health Data Space Regulation. If we fail to comply with applicable privacy and security laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information, including PHI, or financial information or payroll data on our behalf or with respect to the use of certain third-party digital advertising technologies, or if we fail to properly maintain the integrity of our data, protect our proprietary rights, or defend against cybersecurity attacks, it could materially harm our reputation and/or have a material adverse effect on our business, results of operations, financial condition and cash flows. These risks may be intensified to the extent that the laws change or to the extent that we increase our use of third-party service providers that utilize sensitive personal information, including PHI, on our behalf.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data protection laws are evolving globally, and may continue to add additional compliance costs and legal risks to our international operations. For more details on certain international data protection laws and regulations affecting our business, see Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Government Regulation."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The costs of compliance with, and other burdens imposed by these international data protection laws and regulations and other new laws, regulations and policies implementing these regulations may impact our international operations and may limit the ways in which we can provide services and operate, use or otherwise process personal data collected while providing services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy and data protection laws and regulations are also evolving nationally and in the states. At the federal level, this includes proposed updates to the HIPAA Security Rule, which, if enacted as proposed, could impose potentially significant compliance training costs on our operations. At the state level, legislatures around the country continue to enact state privacy laws that are broader than the current federal privacy laws, which may add additional compliance costs and legal risks to our U.S. operations. The costs of compliance with, and the burdens imposed by, these and other new federal and state laws, regulations or policies may impact our operations and/or limit the ways in which we can provide services or use personal data collected while providing services. If we fail to comply with the requirements of these and other new laws, regulations or policies, we could be subject to damage awards in private litigation or penalties that, in some cases, would have a material adverse impact on our business, results of operations, financial condition and cash flows. For more details on the privacy and other regulations affecting our business, see Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, laws governing the commercialization and use of artificial intelligence and machine learning technologies are evolving and as the regulation of these technologies matures, it may add additional compliance costs and legal risk to our operations. Scrutiny over cybersecurity standards in the health sector is also increasing, and ongoing developments in this area may cause us to invest additional resources in technology, personnel and programmatic cybersecurity controls as the cybersecurity risks we face continue to evolve.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the increasing use of the Internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including, among others, foreign state agents. Our business and operations rely on the secure and continuous processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks, including sensitive personal information, such as PHI, social security numbers, and/or credit card information of our patients, teammates, physicians, business partners and others. Our business and operations also rely on certain critical IT vendors that support such processing, transmission and storage (which have become more relevant and important given the information security issues and risks that are intensified through remote work arrangements). For example, as previously reported, due to a cybersecurity breach that affected Change Healthcare (CHC), a subsidiary of UnitedHealth Group (United) that serves as an intermediary for processing the vast majority of our payment claims for domestic commercial and government payors, we temporarily suspended all claims processing activity with CHC (CHC Outage), primarily during a period of time during the first and second quarters of 2024, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which impacted our cash flows. We have since resumed claims submissions and billing processes through CHC&#8217;s information technology systems and as of the date of this filing, through a combination of CHC's platform and certain alternate billing processes, we are current on our primary claims submissions. However, the CHC Outage, and the resultant delay in claims submissions, led to a decrease in our collections and an increase in our days sales outstanding, among other things, which increase has since subsided, but we do continue to see delays in, and issues with, collections with some payors. CHC has publicly reported online and in notices to affected individuals that it identified protected health information (PHI), or personally identifiable information (PII), from users of the CHC systems, and CHC has been conducting investigations and data forensics. CHC informed the Company that a small number of patients had certain PHI exposed as a result of this breach and CHC is taking responsibility for notifying these patients. The ultimate impact of the CHC Outage remains subject to future developments and risks that are difficult to predict. These risks may include, among other things, a recurrence of system outages or service suspensions or the risk that our information technology systems or our proprietary information and sensitive or confidential data, including PHI or PII, may have been compromised through the CHC Outage, any of which may have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review, monitor and implement multiple layers of security measures through technology, processes and our people. We utilize security technologies designed to protect and maintain the integrity of our information systems and data, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses and other malicious code; coordinated attacks by a variety of actors, including, among others, activist entities or state sponsored cyberattacks; emerging cybersecurity risks; cyber risk related to connected devices; misplaced or lost data; programming and/or human errors; or other similar events that could impact the security, reliability and availability of our systems and the availability, authenticity, integrity and/or confidentiality of personal information stored on those systems. Internal or external parties have attempted to, and will continue to attempt to, circumvent our security systems, and we have in the past, and expect that we will in the future, defend against, experience, and respond to attacks on our network including, without limitation, reconnaissance probes, denial of service attempts, malicious software attacks including ransomware or other attacks intended to render our internal operating systems or data unavailable, and phishing attacks or business email compromise. Cybersecurity requires ongoing investment and diligence against evolving threats. For example, healthcare companies, including our Company and certain of our third-party service providers, strategic partners, consultants or contractors, are increasingly incorporating self-learning or "artificial intelligence" features into information technology capabilities. The use of this rapidly evolving technology may intensify the cybersecurity and reputational risks we face given its novel and untested nature, particularly to the extent such technology involves the use of PHI or PII. Emerging and advanced security threats, including, without limitation, coordinated attacks, require additional layers of security which may disrupt or impact efficiency of operations. As with any security program, there always exists the risk that employees will violate our policies despite our compliance efforts or that certain attacks may be beyond the ability of our security and other systems to detect. There can be no assurance that investments, diligence and/or our internal controls will be sufficient to prevent or timely discover an attack.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any security breach involving the misappropriation, loss or other unauthorized disclosure or use of confidential information, including, among others, PHI, financial data, competitively sensitive information, or other proprietary data, whether by us or a third party, could have a material adverse effect on our business, results of operations, financial condition, and cash flows and materially harm our reputation. We may be required to expend significant additional resources to modify our protective measures, to investigate and remediate vulnerabilities or other exposures, or to make required notifications. The occurrence of any of these events could, among other things, result in interruptions, delays, the loss or corruption of data, cessations in the availability of systems and liability under privacy and security laws, all of which could have a material adverse effect on our business, results of operations, financial condition and cash flows, or materially harm our reputation and trigger regulatory actions and private party litigation. If we are unable to protect the physical and electronic security and privacy of our databases and transactions, we could be subject to potential liability and regulatory action, our reputation and relationships with our patients, physicians, vendors and other business partners would be harmed, and our business, results of operations, financial condition and cash flows could be materially and adversely affected. Failure to adequately protect and maintain the integrity of our information systems (including our networks) and data, or to defend against cybersecurity attacks, could subject us to monetary fines, civil suits, civil penalties or criminal sanctions and requirements to disclose the breach publicly, could subject our legal representatives or senior management to liability and/or a temporary suspension during which they cannot exercise managerial duties, and could further result in a material adverse effect on our business, results of operations, financial condition and cash flows or harm our reputation. As malicious cyber activity escalates, including activity that originates outside of the U.S., and as we continue with certain remote work arrangements and a broadened technology footprint, the risks we face relating to transmission of data and our use of service providers outside of our network, as well as the storing or processing of data within our network, have intensified. There have been increased international, federal and state and other privacy, data protection and security enforcement efforts and we expect this trend to continue. While we plan to maintain cyber liability insurance, there can be no assurance that we will successfully be able to obtain such insurance on terms and conditions that are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">favorable to us or at all. Additionally, any cyber liability insurance may not cover us for all types of losses or harms and may not be sufficient to protect us against the amount of all losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our assessment of our cybersecurity risks, see discussion in Part I Item 1C. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If certain of our suppliers and service providers do not meet our needs, if there are material price increases on supplies, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation. We are also subject to the risk associated with our increased reliance on third party service providers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have significant suppliers and service providers, with a substantial portion of our total vendor spend concentrated with a limited number of third party suppliers and service providers. These third party suppliers and service providers include, without limitation, service providers performing certain key functions for us such as claims processing, financial accounting, and information technology functions, and suppliers of pharmaceuticals or clinical products that may be the primary source of products critical to the services we provide, or to which we have committed obligations to make purchases, sometimes at particular prices. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on these third-party suppliers and service providers to provide the products or services we require, and this reliance subjects us to risks arising from the loss of control over these services, changes in pricing that may affect our operating results, and potentially, termination of provisions of these services by our providers. There can be no assurance that third party suppliers and service providers will provide, or will continue to provide, the services or products that we require, or that substitute services or products, or alternate suppliers or service providers, can be identified or transitioned to on a timely or cost-effective basis or at all. In certain cases, there may be a limited number of viable alternate suppliers or service providers that have the capacity or capability to offer these supplies or services. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our significant suppliers and service providers do not meet our needs for the products and services they supply, including, without limitation, in the event of supply chain disruptions due to global events, geopolitical instability, trade disputes, natural disasters or severe weather events, product recalls, logistical challenges, fluctuations in foreign currency exchange rates, varying regulatory requirements or other shortages or disputes, and we are not able to find adequate alternative sources for these products or services on a timely or cost-effective basis; if we experience material price increases from these suppliers or otherwise in connection with our actions to secure needed products that we are unable to mitigate; if some of the drugs that we purchase from our suppliers are not reimbursed or not adequately reimbursed by commercial or government payors; or if we are unable to secure products, including pharmaceuticals at competitive rates and within the desired time frame; it could require us to make significant operational changes, could negatively impact our ability to effectively provide the services we offer or negatively impact our ability to effectively execute certain important corporate functions, and could otherwise have a material adverse impact on our business, results of operations, financial condition and cash flows and materially harm our reputation. In addition, the technology related to the products critical to the services we provide is subject to new developments that may result in superior products, and if we are unable to incorporate these superior products into our business or otherwise find adequate alternatives on a cost-effective and timely basis, it could impact our ability to compete effectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced service disruptions relating to key business functions and supply chain shortages with respect to certain of our equipment and clinical supplies, including critical clinical and other supplies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in September 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one of our suppliers notified us that a severe weather event caused extensive damage to its manufacturing plant. The damage required the supplier to close the facility and halt production of certain clinical products it supplies to us and other health care providers, including saline and peritoneal dialysate. As a result of this disruption, we worked with the supplier, other suppliers, and federal and state governmental agencies to identify alternate sources for these supplies and implemented certain operational measures that were developed to maintain continuity of care for our patients. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These operational measures, including securing alternate supply and temporarily holding new starts for PD home-based dialysis resulted in increased expense and slowed growth of our home-based dialysis business in 2024 and the early portion of 2025. In general, while we have made certain operational changes in response to the foregoing, there can be no assurance that a future shortage or disruption would not require additional resources or further operational changes in the future and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we are continuing to assess the balance of efficiency and resilience in evaluating the risk of future supply chain shortages or service disruptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Separately, current macroeconomic conditions also have resulted in global supply chain challenges and have materially impacted global supply chain reliability, as described in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"External conditions, including those related to general economic, marketplace and global health conditions..."</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices could have a material adverse effect on our business, results of operations, financial condition, and cash flows and negatively impact our ability to care for patients.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare bundles certain pharmaceuticals into the ESRD PPS payment rate at industry average doses and prices. Variations above the industry average may be subject to partial reimbursement through the PPS outlier reimbursement policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to industry averages, which can be caused by, among other things, changes in physician prescribing practices, including in response to the introduction of new drugs, treatments or technologies, changes in best and/or accepted clinical practice, changes on the reliance of artificial intelligence to support clinical practices, changes in private or governmental payment criteria regarding pharmaceuticals and/or devices, or the introduction of administration policies may negatively impact our ability to obtain sufficient reimbursement levels for the care we provide, which could have a material adverse effect on our business, results of operations, financial condition and cash flows. Physician practice patterns, including their independent determinations as to appropriate pharmaceuticals and dosing, are subject to change, including, for example, as a result of changes in labeling of pharmaceuticals or the introduction of new pharmaceuticals. Additionally, commercial payors have increasingly examined their administration policies for pharmaceuticals and, in some cases, have modified those policies. If such policy and practice trends or other changes to private and governmental payment criteria make it more difficult to preserve our margins per treatment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. Further, increased utilization of certain pharmaceuticals whose costs are included in a bundled reimbursement rate, or decreases in reimbursement for pharmaceuticals whose costs are not included in a bundled reimbursement rate, could also have a material adverse effect on our business, results of operation, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulations and processes impacting reimbursement for pharmaceuticals and/or devices and any changes thereto could similarly affect our operating results. Among other things, as new kidney care drugs, treatments or technologies are introduced over time, we expect that the use of transitional payment adjustments to incorporate certain of these new drugs, treatments or technologies as defined by the CMS policy into the bundled Medicare Part B ESRD payment may lead to fluctuations in associated levels of operating income and risk that the reimbursement levels of such drugs, treatments or technologies may not adequately cover our cost to obtain the drug or other associated costs. Drivers of these risks include, among other things, the risk that CMS may not provide adequate funding in the Medicare Part B ESRD payment in the transitional or post-transitional period or such items are not covered by transitional add on pricing, in which case there may be less clarity on the reimbursement, either of which may in turn materially adversely impact our business, results of operations, financial condition and cash flows. For example, under current CMS regulation, certain oral-only drugs were paid separately under Medicare Part D until January 1, 2025, at which time they were incorporated in the ESRD bundled payment. In recent rulemaking, CMS has finalized a policy to increase TDAPA amounts for oral phosphate binders, based on 100% of Average Sales Price, increased by a fixed amount of $36.41 for certain incremental costs. We cannot predict, at this time, whether CMS' TDAPA amounts for oral phosphate binders will adequately account for the inclusion of these oral medications and the additional costs associated with dialysis providers having to supply such drugs. We have developed operational and clinical processes designed to provide the drug as may be required under the applicable regulations and as may be prescribed by physicians and have also worked to contract with manufacturers of drug(s) to establish terms and access to the product, as well as payors, as applicable, for reimbursement and/or administration of the drug. If the government or other payors implement other new requirements or protocols for patients to receive the drug and include pricing in the bundle, we could experience significant fluctuations in our associated levels of operating income and could be subject to material financial, operational and/or legal risk if we are not adequately reimbursed for the cost of the drug, if we are unable to implement effective and appropriate operational measures to distribute or bill for the drug, if we fail to implement appropriate storage and diversion controls or if we cannot obtain competitive pricing for the drug. The aggregate impact of these risks could have a material adverse effect on our business, results of operation, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar operating and clinical rigor and appropriate processes will be needed for other potential new drugs, treatments or technologies that are approved and come onto the market, as well as for drugs, treatments or technologies that we contract to receive from different suppliers. Any failure to successfully contract with manufacturers for competitive pricing, failure to successfully contract with the government or other payors for appropriate reimbursement, or failure to prepare, develop and implement processes that provide for appropriate availability and use in our clinics in compliance with applicable laws, including those related to controlled substances, could have a material adverse impact on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to increased inquiries or audits from a variety of governmental bodies or claims by third parties related to pharmaceuticals, which would require management's attention and could result in significant legal expense. Any negative findings could result in, among other things, substantial financial penalties or repayment obligations, the imposition of certain obligations on and changes to our practices and procedures as well as the attendant financial burden on us to comply with the obligations, or exclusion from future participation in the Medicare and Medicaid programs, and could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation. For additional details, see </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and developing and maintaining relationships with physicians and hospitals, it could materially adversely affect our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive and continuously evolving environment across the spectrum of kidney care, and operating in this market requires us to successfully execute on strategic initiatives which, among other things, build or retain our patient population through acquisition or referrals, or that develop and maintain our relationships with physicians and hospitals in both the dialysis and pre-dialysis space. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for relationships with certain referral sources, including nephrologists and hospitals, in existing and expanding geographies or areas is intense, and we continue to face intense competition from large and medium-sized providers, among others, which compete directly with us for physicians qualified to serve as medical directors, for limited acquisition targets and for individual patients. In addition to these large and medium-sized competitors with substantial financial resources and other established participants in the dialysis space, we also compete with individual nephrologists who have opened their own dialysis units or facilities. Our largest competitor, Fresenius Medical Care (FMC), manufactures a full line of dialysis supplies and equipment in addition to owning and operating dialysis centers. This may, among other things, give FMC cost advantages over us because of its ability to manufacture its own products. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously compete for maintaining or developing relationships with physicians that can serve as medical directors at our centers. Physicians, including medical directors, choose where they refer their patients, and neither of our current or former medical directors have an obligation to refer their patients to our centers. Certain physicians prefer to have their patients treated at dialysis centers where they or other members of their practice supervise the overall care provided as medical director of the center. As a result, referral sources for many of our centers include the physician or physician group providing medical director services to the center. Moreover, because Medicare regulations require medical directors for each of our Medicare certified dialysis centers, our ability to operate our centers depends in part on our ability to secure medical director agreements with a sufficient number of nephrologists. Our medical director agreements range in duration, but generally are for periods of ten years, and at any given time a large number of them could be up for renewal at the same time. Medical directors have no obligation to extend their agreements with us and, under certain circumstances, our former medical directors may choose to provide medical director services for competing providers or establish their own dialysis centers in competition with ours. If we are unable to contract with nephrologists to provide medical director services, then we may be unable to satisfy the federal Medicare requirements associated with medical directors and to operate our centers. The aging of the nephrologist population and opportunities presented by our competitors or other hospitals and other healthcare providers may negatively impact a medical director's decision to enter into or extend his or her agreement with us and potential declines in the overall number of nephrologists may negatively impact our ability to enter into medical director agreements in the future. In addition, if the terms of any existing agreement are found to violate applicable laws, there can be no assurances that we would be successful in restructuring the relationship, which would lead to the early termination of the agreement. If we are unable to obtain qualified medical directors to provide supervision of the operations and care provided at our dialysis centers, it could affect not only our ability to operate the center but also the degree to which other physicians to feel confident in referring patients to our dialysis centers. If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to law, rule or regulation, new competition, a perceived decrease in the quality of service levels at our centers or other reasons, it would have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we continue to expand our offerings across the kidney care continuum, our ability to enter into and maintain integrated kidney care relationships with payors, physicians and other providers may have an impact on our ability to participate in integrated kidney care. This environment is highly competitive and has been evolving. For example, there have been a number of announcements, initiatives and capital raises by non-traditional kidney care providers and others, which relate to entry into the dialysis and pre-dialysis space, the development of innovative technologies, or the commencement of new business activities that could be transformative to the industry. Some of these emerging entrants have considerable financial resources. Although these and other potential competitors may face operational or financial challenges, the evolving nature of the dialysis and pre-dialysis marketplaces have presented some opportunities for relative ease of entry for these and other potential competitors. As a result, we may compete with these smaller or non-traditional providers or others in an asymmetrical environment with respect to data and regulatory requirements that we face as an ESRD service provider, thereby negatively impacting our ability to effectively compete. These and other factors have continued to drive change in the dialysis and pre-dialysis space, and if we are unable to successfully adapt to these dynamics, it could have a material adverse impact on our business, results of operations, financial condition and cash flows. As an example, emerging entrants are pursuing opportunities to participate in the CMMI payment models or otherwise establish value-based care programs, and increasing investment in and availability of funding to emerging entrants in the dialysis and pre-dialysis marketplace that may not be as cautious in adhering </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to applicable laws and regulations and/or may not be subject to the same regulatory restrictions as the Company, could adversely impact our ability to enter into competitive arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the aforementioned competitive pressures and related risks may be impacted by a continued decline in the rate of growth of the ESRD patient population, higher mortality rates for dialysis patients or other reductions in demand for dialysis treatments, whether due to population growth trends, the development and application of innovative technologies or otherwise. As described in Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," the recent 2024 annual data report from the United States Renal Data System (USRDS) the decline in annual growth rate of ESKD dialysis patient population was 0.4% from 2021 to 2022, representing a slowdown from longer term growth. Despite this near term slowdown presented in the report, which, among other things, included impacts from the COVID-19 pandemic on mortality rates amongst the ESKD dialysis patient population, the rate of growth has been relatively consistent over time.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of factors may impact ESKD growth rates, including, among others, mortality rates for dialysis patients or CKD patients, the growth and aging of the U.S. population, limitation on immigration into the United States, transplant rates, incidence rates for diseases that cause kidney failure such as diabetes and hypertension, growth rates of minority populations with higher than average incidence rates of ESKD or other changes in demand for dialysis treatments over time, including for example, as a result of the development and application of certain innovative technologies, drugs or other treatments such as the glucagon-like peptide 1 (GLP-1) receptor agonist, SGLT2 inhibitors, and other classes of drugs or new classes of drugs or other treatments that may, among other things, slow the progression of CKD. Any decrease in growth rates for the ESRD patient population, higher mortality rates for dialysis patients, increase in the availability to kidneys or replacement kidneys for transplant, or other reductions in demand for dialysis treatments, if sustained or significant, could have a material adverse effect on our business, results of operations, financial condition and cash flows. Any such impact would be magnified to the extent it also resulted in a lower number of patients with commercial insurance or a lower percentage of patients under commercial insurance relative to government-based programs. While we have continued efforts to seek growth opportunities, such as by expanding our business into various international markets, we face ongoing competition from large and medium-sized providers, among others, for acquisition targets in those markets. Providers may reduce pricing in an attempt to capture more volume in the face of declining ESRD patient growth. Any failure on our part to appropriately adjust our business and operations in light of these complicated marketplace dynamics could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively compete in the markets in which we operate, including by implementing our growth strategy, effectively adjusting our business and operations in light of evolving marketplace dynamics, building or retaining our patient population, maintaining and developing relationships with nephrologists and hospitals, particularly medical director relationships, or making acquisitions at the desired pace or at all; if we are not able to continue to maintain the expected or desired level of non-acquired growth; or if we experience significant patient attrition either as a result of new business activities in the dialysis or pre-dialysis space by our existing competitors, other market participants, new entrants, new technology or other forms of competition, or as a result of reductions in demand for dialysis treatments, including, without limitation, due to increased mortality rates for dialysis patients resulting from COVID-19 or otherwise, reduced prevalence of ESRD, the development of innovative technologies, drugs or other treatments or an increase in the number of kidney transplants, including xenotransplants, it could materially adversely affect our business, results of operations, financial condition and cash flows.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_103"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The U.S. integrated kidney care, U.S. other ancillary services and international operations that we operate or invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one or more of these activities is unsuccessful, our business, results of operations, financial condition and cash flows may be negatively impacted and we may have to write off our investment and incur other exit costs.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. integrated kidney care and U.S. other ancillary services are subject to many of the same risks, regulations and laws, as described in the risk factors related to our dialysis business set forth in this Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," and are also subject to additional risks, regulations and laws specific to the nature of the particular strategic initiative. We have added, and expect to continue to add additional service offerings to our business and pursue additional strategic initiatives in the future as circumstances warrant, which could include healthcare products or services not directly related to dialysis. Many of these initiatives require or would require investments of both management and financial resources and can generate significant losses for a substantial period of time and may not become profitable in the expected timeframe or at all. There can be no assurance that any such strategic initiative will ultimately be successful. Any significant change in market conditions or business performance, including, without limitation, as a result of the political, legislative or regulatory environment, may impact the performance or economic viability of any of these strategic initiatives. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our U.S. integrated kidney care, U.S. other ancillary services or international operations are unsuccessful, it may have a negative impact on our business, results of operations, financial condition and cash flows, and if we determine to exit that line of business we may incur significant termination costs. For discussion of risks and potential impacts specific to our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">integrated kidney care business and related growth strategy, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur material write-offs or impairments of our investments, including, without limitation, goodwill or other assets, in one or more of our U.S. integrated kidney care, U.S. other ancillary services or international operations. In that regard, we have taken, and may in the future take, impairment and restructuring charges in addition to those described above related to our U.S. integrated kidney care, U.S. other ancillary services and international operations.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_106"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expansion of our operations to and offering our services in markets outside of the U.S., and utilizing third-party suppliers and service providers operating outside of the U.S., subjects us to political, economic, legal, operational and other risks that could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to expand our operations by offering our services and entering new lines of business in certain markets outside of the U.S., and we have increased our utilization of third-party suppliers and service providers operating outside of the U.S., which increases our exposure to the inherent risks of doing business in international markets. Depending on the market, these risks include those relating to:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the local economic environment including, among other things, labor cost increases and other general inflationary pressures;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political instability, armed conflicts or terrorism;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public health crises, such as pandemics or epidemics;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">social changes;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property legal protections and remedies;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade regulations;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">procedures and actions affecting approval, production, pricing, reimbursement and marketing of products and services;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency and applicable exchange rates;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional U.S. and foreign taxes;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">export controls;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">antitrust and competition laws and regulations;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of reliable legal systems which may affect our ability to enforce contractual rights;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local laws or regulations, or interpretation or enforcement thereof;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially longer ramp-up times for starting up new operations and for payment and collection cycles;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial and operational, and information technology systems integration;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to comply with U.S. laws, such as the FCPA, or local laws that prohibit us, our partners, or our partners' or our agents or intermediaries from making improper payments to foreign officials or any third party for the purpose of obtaining or retaining business; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws, regulations or other guidance that require enhanced disclosures and due diligence surrounding the impacts of our Company and value chain on, and the financial risks and opportunities for our Company from, ESG or other similar sustainability or corporate responsibility matters, as well as enhanced policies, processes and controls designed to appropriately monitor and track such information and enhanced actions to address our Company's impact on these matters; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data and privacy restrictions, among other things.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issues relating to the failure to comply with applicable non-U.S. laws, requirements or restrictions may also impact our domestic business and/or raise scrutiny on our domestic practices.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some factors that will be critical to the success of our international business and operations will be different than those affecting our domestic business and operations. For example, conducting international operations requires us to devote significant management resources to implement our controls and systems in new markets, to comply with local laws and regulations, including to fulfill financial reporting and records retention requirements among other things, and to overcome the numerous new challenges inherent in managing international operations, including, without limitation, challenges based on differing languages and cultures, challenges related to establishing clinical operations in differing regulatory and compliance environments, and challenges related to the timely hiring, integration and retention of a sufficient number of skilled personnel to carry out operations in an environment with which we are not familiar.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expansion of our international operations through acquisitions or through organic growth could increase these risks. Additionally, while we may invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, including to start up or acquire new operations, we may not be able to operate them profitably on the anticipated timeline, or at all.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems, or failure to adhere to federal and state data sharing and access requirements and regulations could materially adversely affect our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends significantly on effective information systems. Our information systems require an ongoing commitment of significant resources to maintain, upgrade and enhance existing systems and develop or contract for new systems in order to keep pace with continuing changes in information processing technology, emerging cybersecurity risks and threats, evolving industry, legal and regulatory standards and requirements, new models of care, and other changes in our business, among other things. For example, the provisions related to data interoperability, information blocking, and patient access in the Cures Act and No Surprises Act include, among other things, changes to the Office of the National Coordinator for Health Information Technology&#8217;s (ONC's) Health IT Certification Program and requirements that CMS-regulated payors make relevant claims/care data and provider directory information available through standardized patient access and provider directory application programming interfaces (APIs) that connect to provider electronic health records. We have made and expect to continue to make significant investments in updating and integrating our clinical IT systems and continuing to build our data interoperability capabilities. Any failure to adequately comply with these and other provisions related to data interoperability, information blocking, and patient access may, among other things, result in fines and sanctions, adversely impact our Medicare business, our ability to scale our integrated care business and our ability to compete with certain smaller and/or non-traditional providers taking advantage of an asymmetrical environment with respect to data and/or regulatory requirements given our status as an ESRD service provider; or otherwise have a material adverse effect on our business, financial condition, results of operations and cash flows. Rulemaking in these areas is ongoing, and there can be no assurances that the implementation of planned enhancements to our systems, such as our implementation of these data interoperability provisions or our other ongoing efforts to upgrade and better integrate our clinical systems, will be successful once the regulatory environment settles or that we will ultimately realize anticipated benefits from investments in new or existing information systems. In addition, we may from time to time obtain significant portions of our systems-related support, technology or other services from third parties, which may make our operations vulnerable if such third parties fail to perform adequately.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to successfully implement, operate and maintain effective and efficient information systems with adequate technological capabilities, deficiencies or defects in the systems and related technology, or our failure to efficiently and effectively implement ongoing system upgrades or consolidate our information systems to eliminate redundant or obsolete applications, could result in increased legal and compliance risks and competitive disadvantages, among other things, which could have a material adverse effect on our business, financial condition, results of operations and reputation. For additional information on the risks we face in a highly competitive market, see the risk factor under the heading, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are unable to compete successfully..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the information we rely upon to run our business was found to be inaccurate or unreliable or if we or third parties on which we rely fail to adequately maintain information systems and data integrity effectively, whether due to software deficiencies, human coding or implementation error or otherwise, we could experience difficulty meeting clinical outcome goals, face regulatory problems, including sanctions and penalties, incur increases in operating expenses or suffer other adverse consequences, any of which could be material. Moreover, failure to adequately protect and maintain the integrity of our information systems (including our networks) and data, or information systems and data hosted by third parties upon which we rely, could subject us to severe consequences as described in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Privacy and information security laws are complex..."</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our billing systems, among others, are critical to our billing operations. This includes our systems for our dialysis clinics as well as our systems for our hospital services and our ancillary businesses, including our international business. If there are defects in our billing systems, or billing systems or services of third parties upon which we rely, we may experience difficulties in our ability to successfully bill and collect for services rendered, including, without limitation, a delay in collections, a reduction in the amounts collected, increased risk of retractions from and refunds to commercial and government payors, an increase in our provision for uncollectible accounts receivable and noncompliance with reimbursement laws and related requirements, any or all of which could materially adversely affect our results of operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the clinical environment, a failure of our clinical systems, or the systems of our third-party service providers, to operate effectively could have a material adverse effect on our business, the clinical care provided to patients, results of operations, financial condition and cash flows. For example, in connection with claims for which at least part of the government's payments to us is based on clinical performance or patient outcomes or co-morbidities, if relevant clinical systems fail to accurately capture the data we report to CMS or we otherwise have data integrity issues with respect to the reported information, this could impact our payments from government payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we expect the highly competitive environment in which we operate to become increasingly more competitive as the market evolves and new technologies are introduced. This dynamic environment requires continuous investment in new technologies and clinical applications. Machine learning and artificial intelligence are increasingly driving innovations in technology, and parts of our operations may employ new technology and analytics, including artificial intelligence. If these rapidly evolving technologies or applications fail to operate as anticipated or do not perform as specified, including due to potential design defects and defects in the development of algorithms or other technologies, human error or otherwise, our clinical operations, business and reputation may be harmed. If we are unable to successfully maintain, enhance or operate our information systems, including through the implementation of such technologies or applications in our clinical operations and laboratory, or if we are unable to successfully implement adequate governance structures to manage these new technologies, we may be, among other things, unable to efficiently adapt to evolving laws and requirements, unable to remain competitive with others who successfully implement and advance this technology, subject to increased risk under existing laws, regulations and requirements that apply to our business, and our patients' safety may be adversely impacted, any of which could have a material adverse impact on our business, results of operations and financial condition and could materially harm our reputation. For additional detail, see the discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_112"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may engage in acquisitions, mergers, joint ventures, noncontrolling interest investments, or dispositions, which may materially affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business, and, under certain circumstances, could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes growth through acquisitions of dialysis centers and other businesses, as well as through entry into joint ventures. We may engage in acquisitions, mergers, joint ventures or dispositions or expand into new business lines or models, which may affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business. See the discussion under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Off-balance sheet arrangements and aggregate contractual obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" in Part II Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to identify suitable acquisition or joint venture targets or merger partners or buyers for dispositions or that, if identified, we will be able to agree to acceptable terms or on the desired timetable. There can also be no assurance that we will be successful in completing any acquisitions, joint ventures, mergers or dispositions that we announce, executing new business lines or models or integrating any acquired business into our overall operations. There is no guarantee that we will be able to operate acquired businesses successfully as stand-alone businesses, or that any such acquired business will operate profitably or will not otherwise have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation. In addition, acquisition, merger or joint venture activity conducted as part of our overall growth strategy is subject to antitrust and competition laws, and antitrust regulators can investigate future (or pending) and consummated transactions. These laws could impact our ability to pursue these transactions or our ability to consummate them on a timely basis; could require us to devote additional resources to potential transactions; and under certain circumstances, could result in mandated divestitures, among other things. If a proposed transaction or series of transactions is subject to challenge under antitrust or competition laws, we may incur substantial legal costs, management&#8217;s attention and resources may be diverted, and if we are found to have violated these or other related laws, regulations or requirements, we could suffer severe consequences that could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation and stock price. For additional detail, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Further, we cannot be certain that key talented individuals at the business being acquired will continue to work for us after the acquisition or that they will be able to continue to successfully manage or have adequate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources to successfully operate any acquired business. In addition, certain of our acquired dialysis centers and facilities have been in service for many years, which may result in a higher level of maintenance costs. Further, our facilities, equipment and information technology may need to be improved or renovated to maintain or increase operational efficiency, compete for patients and medical directors, or meet changing regulatory requirements. Increases in maintenance costs and/or capital expenditures could have, under certain circumstances, a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Businesses we acquire may have unknown or contingent liabilities or liabilities that are in excess of the amounts that we originally estimated, and may have other issues, including, without limitation, those related to internal control over financial reporting or issues that could affect our ability to comply with healthcare laws and regulations and other laws applicable to our expanded business, which could harm our reputation. As a result, we cannot make any assurances that the acquisitions we consummate will be successful. Although we generally seek indemnification from the sellers of businesses we acquire for matters that are not properly disclosed to us, we are not always successful. In addition, even in cases where we are able to obtain indemnification, we may discover liabilities greater than the contractual limits, the amounts held in escrow for our benefit (if any), or the financial resources of the indemnifying party. In the event that we are responsible for liabilities substantially in excess of any amounts recovered through rights to indemnification or alternative remedies that might be available to us, or any applicable insurance, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of the equity purchase agreement for the DaVita Medical Group (DMG) sale (the DMG sale agreement), we agreed to certain indemnification obligations, including claims for taxes or for which we provided the buyer with a special indemnity. As a result, we may become obligated to make payments to the buyer relating to our previous ownership and operation of the DMG business. Any such post-closing liabilities and required payments under the DMG sale agreement, or otherwise, or in connection with any other past or future disposition of material assets or businesses could individually or in the aggregate have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, joint ventures or noncontrolling interest investments inherently involve a lesser degree of control over business operations, thereby potentially increasing the financial, legal, operational and/or compliance risks associated with the joint venture or noncontrolling interest investment. In addition, we may be dependent on joint venture partners, controlling shareholders or management who may have business interests, strategies or goals that are inconsistent with ours. Business decisions or other actions or omissions of the joint venture partner, controlling shareholders or management may require us to make capital contributions or necessitate other payments, result in litigation or regulatory action against us, result in reputational harm to us or adversely affect the value of our investment or partnership, among other things. In addition, we have potential obligations to purchase the interests held by third parties in many of our joint ventures as a result of put provisions that are exercisable at the third party's discretion within specified time periods, pursuant to the applicable agreement. If these put provisions were exercised, we would be required to purchase the third party owner's equity interest, generally at the appraised market value. There can be no assurances that these joint ventures and/or noncontrolling interest investments ultimately will be successful.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_115"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we owned a controlling interest in numerous dialysis-related joint ventures, which represented approximately 30% of our U.S. dialysis revenues for the year ended December&#160;31, 2024. In addition, we also owned noncontrolling equity investments in several other dialysis-related joint ventures. We expect to continue to increase the number of our joint ventures. Many of our joint ventures with physicians or physician groups also have certain physician owners providing medical director services to centers we own and operate. Because our relationships with physicians are governed by the federal and state anti-kickback statutes, we have sought to structure our joint venture arrangements to satisfy as many federal safe harbor requirements as we believe are commercially reasonable. Our joint venture arrangements do not satisfy all of the elements of any safe harbor under the federal Anti-Kickback Statute, however, and therefore are susceptible to government scrutiny. Additionally, our joint ventures and minority investments inherently involve a lesser degree of control over business operations, thereby potentially increasing the financial, legal, operational and/or compliance risks associated with the joint venture or minority investment. If our joint ventures are found to violate applicable laws or regulations, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation. For additional information on these risks, see the risk factors under the headings "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may engage in acquisitions, mergers, joint ventures, noncontrolling interest investments, or dispositions..."</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our goals and disclosures related to ESG matters expose us to numerous risks, including without limitation risks to our reputation and stock price.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a longstanding program relating to environmental, social and governance (ESG) issues and have engaged with key stakeholders to develop ESG focus areas and to set ESG-related goals, many of which are aspirational. We have set and disclosed these focus areas, goals and related objectives as part of our continued commitment to ESG matters, but our goals and objectives reflect our current plans and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives present numerous operational, reputational, financial, legal and other risks, certain of which are outside of our control, and could have, under certain circumstances, a material adverse impact on us, including on our reputation and stock price. Examples of such risks include, among others: the availability and cost of low- or non-carbon-based energy sources and technologies for us and our vendors, evolving regulatory requirements affecting ESG standards, frameworks and disclosures, including evolving standards for measuring and reporting on related metrics, the availability of suppliers that can meet our standards, our ability to recruit, develop and retain strong talent in our labor markets, and our ability to grow our home based dialysis business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices do not meet investor or other stakeholder expectations and standards, then our reputation, our ability to attract or retain employees and our attractiveness as an investment, business partner or acquirer could be negatively impacted. In addition, if there are new regulations or orders that proscribe the ability to focus on ESG programs, then there would be a risk if we continued to pursue these goals. In addition, our failure or perceived failure to adequately pursue or fulfill our goals and objectives or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to other risks, which under certain circumstances could be material. If we are not able to adequately recognize and respond to the rapid and ongoing developments and governmental and social expectations relating to ESG matters, this failure could result in missed corporate opportunities, additional regulatory, social or other scrutiny of us, the imposition of unexpected costs, or damage to our reputation with governments, patients, teammates, third parties and the communities in which we operate, which in turn could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common stock to decline.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_121"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">There are significant risks associated with estimating the amount of dialysis revenues and related refund liabilities that we recognize, and if our estimates of revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenues recognition or have a material adverse effect on our business,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are significant risks associated with estimating the amount of U.S. dialysis patient service revenues and related refund liabilities that we recognize in a reporting period. The billing and collection process is complex due to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues, such as ensuring appropriate documentation. Determining applicable primary and secondary coverage for approximately 200,800 U.S. patients at any point in time, together with the changes in patient coverage that occur each month, requires complex, resource-intensive processes. Errors in determining the correct coordination of benefits may result in refunds to payors. Revenues associated with Medicare and Medicaid programs are also subject to estimating risk related to the amounts not paid by the primary government payor that will ultimately be collectible from other government programs paying secondary coverage, the patient's commercial health plan secondary coverage or the patient. Collections, refunds and payor retractions typically continue to occur for up to three years and longer after services are provided. We generally expect our range of U.S. dialysis patient service revenues estimating risk to be within 1% of revenues. If our estimates of U.S. dialysis patient service revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenues recognition and have a material adverse impact on our business, results of operations, financial condition and cash flows.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_124"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_127"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The level of our current and future debt could have an adverse impact on our business, and our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants depends on many factors beyond our control.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a substantial amount of indebtedness outstanding and we may incur substantial additional indebtedness in the future, including indebtedness incurred to finance repurchases of our common stock pursuant to our share repurchase authorization discussed under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" in Part II Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 12 to the consolidated financial statements included in this report, we are party to a senior secured credit agreement (as amended, the Credit Agreement), which consists of an up to $1.5 billion secured revolving line of credit, a secured term loan A-1 facility and a secured term loan B-1 facility. Our long-term indebtedness also includes $5.250 billion aggregate principal amount of senior notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior secured credit facilities bear, and other indebtedness we may incur in the future may bear, interest at a variable rate. As a result, at any given time interest rates on the senior secured credit facilities and any other variable rate debt could be higher or lower than current levels. If interest rates increase, our debt service obligations on our variable rate indebtedness will increase even though the amount borrowed remains the same, and therefore net income and associated cash flows, including cash available for servicing our indebtedness, will correspondingly decrease.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable interest rates payable under our senior secured credit facilities have historically been linked to LIBOR as the benchmark for establishing such rates. The LIBOR rate used in our senior secured credit facilities ceased to be available starting June 30, 2023. Prior to that date, we transitioned all the debt from our senior secured credit facilities from LIBOR to Secured Overnight Financing Rate (SOFR). SOFR is a broad measure of the cost of borrowing cash overnight collateralized by U.S. Treasury securities. The SOFR rate may not perform in a manner similar to LIBOR and may result in interest rates that are higher or lower than those that would have resulted had LIBOR remained in effect, which could impact our cost of capital.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make payments on our indebtedness, to fund planned capital expenditures and expansion efforts, including, without limitation, any strategic acquisitions or investments we may make in the future, to repurchase our stock at the levels intended or announced and to meet our other liquidity needs such as for working capital or capital expenditures, will depend on our ability to generate cash. This depends not only on the success of our business but is also subject to economic, financial, competitive, regulatory and other factors that are beyond our control. We cannot provide assurances that our business will generate sufficient cash flows from operations in the future or that future borrowings will be available to us in amounts sufficient to enable us to service our indebtedness or to fund our working capital and other liquidity needs, including those described above. If we are unable to generate sufficient funds to service our outstanding indebtedness or to meet our working capital or other liquidity needs, including those described above, we would be required to refinance, restructure, or otherwise amend some or all of such indebtedness, sell assets, change or reduce our intended or announced uses or strategy for capital deployment, including, without limitation, for stock repurchases, reduce capital expenditures, planned expansions or other strategic initiatives, or raise additional cash through the sale of our equity or equity-related securities. We cannot make any assurances that any such refinancing, restructurings, amendments, sales of assets, or issuances of equity or equity-related securities can be accomplished or, if accomplished, will be on favorable terms or would raise sufficient funds to meet these obligations or our other liquidity needs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may continue to incur indebtedness in the future, and the amount of that additional indebtedness may be substantial. Although the Credit Agreement includes covenants that could limit our indebtedness, we currently have, and expect to continue to have, the ability to incur substantial additional debt. The risks described in this risk factor could intensify as new debt is added to current debt levels or if we incur any new debt obligations that subject us to restrictive covenants that limit our financial and operational flexibility. Any breach or failure to comply with any of these covenants could result in a default under our indebtedness. Other risks related to our ability to generate sufficient cash to service our indebtedness and for other intended purposes, include, for example:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we operate;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expose us to interest rate volatility that could adversely affect our business, results of operations, financial condition and cash flows, and our ability to service our indebtedness;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">place us at a competitive disadvantage compared to our competitors that have less debt; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to borrow additional funds, or to refinance existing debt on favorable terms when otherwise available or at all.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to pay any of our indebtedness when due or any other default under our credit facilities or our other indebtedness could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could trigger cross default or cross acceleration provisions in our other debt instruments, thereby permitting the holders of that other indebtedness to demand immediate repayment or cease to make future extensions of credit, and, in the case of secured indebtedness, to take possession of and sell the collateral securing such indebtedness to satisfy our obligations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The borrowings under our senior secured credit facilities and senior indentures are guaranteed by certain of our domestic subsidiaries, and borrowings under our senior secured credit facilities are secured by substantially all of our and certain of our domestic subsidiaries' assets. Such guarantees and the fact that we have pledged such assets may make it more difficult and expensive for us to make, or under certain circumstances could effectively prevent us from making, additional secured and unsecured borrowings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to tax laws and regulations of the U.S. federal, state and local governments as well as various foreign jurisdictions. We compute our income tax provision based on enacted tax rates in the jurisdictions in which we operate. As the tax rates vary among jurisdictions, a change in earnings attributable to the various jurisdictions in which we operate could result in a change in our overall tax provision.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws or regulations may be proposed or enacted that could adversely affect our overall tax liability. There can be no assurance that changes in tax laws or regulations, both within the domestic and foreign jurisdictions in which we operate, will not materially and adversely affect our effective tax rate, tax payments, results of operations, financial condition and cash flows. Similarly, changes in tax laws and regulations that impact our patients, business partners and counterparties or the economy may also impact our results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, tax laws and regulations are complex and subject to varying interpretations, and any significant failure to comply with applicable tax laws and regulations in all relevant jurisdictions could give rise to material penalties and liabilities. We are regularly subject to audits by various tax authorities. It is possible that the final determination of any such tax audits and any related litigation could be materially different from our historical income tax provisions and accruals. Any changes in enacted tax laws, rules or regulatory or judicial interpretations; any adverse development or outcome in connection with tax audits in any jurisdiction; or any change in the pronouncements relating to accounting for income taxes could materially and adversely impact our effective tax rate, tax payments, results of operations, financial condition and cash flows.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_133"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our operations, including our clinical laboratory, dialysis centers and other facilities, as well as the operations of our third party suppliers and service providers, may be adversely impacted by the effects of natural or other disasters, political instability, public health crises such as global pandemics or epidemics, or adverse weather events such as hurricanes, earthquakes, fires or flooding. Each of these effects and risks may be further intensified by the potential impact of climate change on a global scale. In addition, these risks are particularly heightened for our patients in part because individuals with chronic illness may be more susceptible to the adverse effects of epidemics or other public health crises and also because any natural or other disaster, political instability or adverse weather event that disrupts or limits the operation of any of our centers or other facilities or services may delay or otherwise impact the critical services we provide to dialysis patients. Further, any such event or other occurrence that results in a failure of the fitness of our clinical laboratory, dialysis centers and related operations and/or other facilities or the operations of our third party suppliers and service providers or otherwise adversely impacts the safety of our teammates or patients at any of those locations could lead us to face adverse consequences, including, without limitation, the potential loss of data, including PHI or PII, compliance or regulatory investigations, any of which could materially impact our business, results of operations and financial condition, and could materially harm our reputation. For example, our clinical laboratory is located in Florida, a state that has in the past experienced and may in the future experience hurricanes. Natural or other disasters or adverse weather events could significantly damage or destroy our facilities, disrupt operations, increase our costs to maintain operations and require substantial expenditures and recovery time to fully resume operations. In addition, if the frequency, intensity and widening potential geographic scope of natural or other disasters or adverse weather events increase or a number of laws or regulations adopted in response to such changes, we may face increased costs associated with operating our clinics, as well as potential interruptions to and changes in our clinical and business operations, including, without limitation, with respect to increasing costs for energy, supplies of water, or pharmaceuticals or other supplies necessary to the operations or our clinics. For additional information regarding the risks to our supply chain and third party service providers, see the discussion in the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If certain of our suppliers and service providers&#8230;"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our presence in markets outside the U.S. may increase our exposure to these and similar risks related to natural disasters, public health crises, political instability, adverse weather or other catastrophic events outside our control. For additional information regarding the risks related to our international business, see the discussion in the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expansion of our operations to and offering our services in markets outside of the U.S....</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of these factors, as well as other consequences of these events, none of which we can currently predict, could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage that could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and how we manage our business may subject us, as well as our officers and directors to whom we owe certain defense and indemnity obligations, to litigation and liability. Our business, profitability and growth prospects could suffer if we face negative publicity or we pay damages or defense costs in connection with a claim that is outside the scope or limits of coverage of any applicable insurance coverage, including, without limitation, claims related to adverse patient events, cybersecurity incidents, contractual disputes, antitrust and competition laws and regulations, professional and general liability and directors' and officers' duties. In addition, we have received notices of claims from commercial payors and other third parties, as well as subpoenas and civil investigative demands from the federal government, related to our business practices, including, without limitation, our historical billing practices and the historical billing practices of acquired businesses. Although the ultimate outcome of these claims cannot be predicted, an adverse result with respect to one or more of these claims could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation. We maintain insurance coverage for those risks we deem are appropriate to insure against and make determinations about whether to self-insure as to other risks or layers of coverage. However, a successful claim, including, without limitation, a professional liability, malpractice or negligence claim or a claim related to antitrust and competition laws or a cybersecurity incident, which is in excess of any applicable insurance coverage, that is outside the scope or limits of any applicable insurance coverage, or that is subject to our self-insurance retentions, could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our costs of insurance and claims increase, then our earnings could decline. Market rates for insurance premiums and deductibles have been steadily increasing. Our business, results of operations, financial condition and cash flows could be materially and adversely affected by any of the following:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the collapse or insolvency of our insurance carriers;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further increases in premiums and deductibles;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in the number of liability claims against us or the cost of settling or trying cases related to those claims; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining insurance with exclusions for things such as communicable diseases; or</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to obtain one or more types of insurance on acceptable terms, if at all.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_139"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The integration of acquisitions and addition of new business lines into our internal control over financial reporting has required and will continue to require significant time and resources from our management and other personnel and has increased, and is expected to continue to increase, our compliance costs. Failure to maintain an effective internal control environment could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price. In addition, we could be required to restate our financial results in the event of a significant failure of our internal control over financial reporting or in the event of inappropriate application of accounting principles.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_142"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law may deter changes of control and may make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our organizational documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in our management, or limit the ability of our stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting our stockholders from acting by written consent, advance notice requirements for director nominations and stockholder proposals and granting our Board of Directors the authority to issue preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our outstanding employee stock-based compensation awards include a provision accelerating the vesting of the awards in the event of a change of control under certain circumstances. These and any other change of control provisions may affect the price an acquirer would be willing to pay for our Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, prohibits us from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions described above may discourage, delay or prevent an acquisition of our Company at a price that our stockholders may find attractive. These provisions could also make it more difficult for our stockholders to elect directors and take other corporate actions and could limit the price that investors might be willing to pay for shares of our common stock.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_145"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_148"></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-35" continuedAt="f-35-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1C.&#160;&#160;&#160;&#160;Cybersecurity</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the increasing use of the Internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including, among others, foreign state agents. Our business and operations rely on the secure and continuous processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks, including, but not limited to, sensitive personal information, such as PHI, social security numbers, and/or credit card information of our patients, teammates, physicians, business partners and others. Our business and operations also rely on certain critical IT vendors that support such processing, transmission and storage (which have become more relevant and important given the information security issues and risks that are intensified through our increased use of remote work arrangements).</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-36" continuedAt="f-36-1" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage risks to our Company, including information and security risks, our Board oversees our enterprise-wide approach to risk management with a fundamental belief that the key components of risk management are:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identifying potential risks that we face;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assessing the likelihood and potential impact of the risks;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adopting strategies and controls designed to manage the risks;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reporting on a regular basis regarding the assessment and management of the risks; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Monitoring these potential risks on a regular basis; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluating whether there are new potential risks to assess.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Enterprise Risk Management (ERM) process, the Company evaluates risks to the enterprise on short, intermediate and long-term bases. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-37" escape="true">The ERM Committee, a group comprised of members of senior management, meet on a regular basis to oversee the performance of these risk management functions.</ix:nonNumeric> We assess risks using a probability-magnitude lens, with shorter and intermediate term risks generally given greater weight. We prioritize mitigating activities on shorter and intermediate term risks, but also use risk analyses and oversight to proactively incorporate mitigating activities into our long-term strategy. The ERM process reflects a Company-wide effort designed to identify, assess, manage, report and monitor enterprise risks and risk areas. This effort includes the Company's Enterprise Risk Services (Internal Audit), Sarbanes-Oxley (SOX), Compliance Audit, legal and IT security teams, among others. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-38">The identification and evaluation of cybersecurity threats and risks is integrated into this ERM process.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ERM process is incorporated into our disclosure controls and procedures. Representatives of each of our ERM, Internal Audit, legal and compliance teams sit on the Company&#8217;s management Disclosure Committee, which is responsible for, among other things, the design and establishment of disclosure controls and procedures to help ensure the timeliness, accuracy and completeness of corporate disclosure. Our IT security and privacy teams, who are responsible for assessing cybersecurity threats and risks, in turn maintain policies and procedures designed to ensure appropriate escalation of cybersecurity incidents to meet external disclosure requirements. Our Chief Information Officer (CIO) and Chief Information Security Officer (CISO) regularly meet and coordinate with our Chief Privacy Officer (CPO). Each of the CIO, CISO and CPO also advise members of the Disclosure Committee, including our Chief Legal and Public Affairs Officer (CLO), on disclosure matters on an as-needed basis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to assessing privacy, data and cybersecurity risks, the Company adopts a hybrid approach that primarily aligns with the National Institute of Standards and Technology (NIST) Cybersecurity Framework, including the guidance set </span></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-36-1"><ix:continuation id="f-35-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forth in the NIST HIPAA Security Rule Cybersecurity Guide, while also evaluating against certain elements of the ISO 27001 and 27005 standards that management believes provide additional levels of guidance or structure. We regularly evaluate the Company&#8217;s cybersecurity and privacy processes and procedures, both through regular audits by our Internal Audit and IT security teams, as well as regular retention of outside advisors under direction of our IT security team. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-39">Among other things, the IT security team oversees an external third party review at least every two years that evaluates the readiness of the entire Company against the NIST Cybersecurity Framework and provides an assessment that measures Capability Maturity Model Integration levels</ix:nonNumeric>. Additionally, our CISO engages in regular consultations, typically monthly, with third-party cybersecurity advisors. Among other things, these sessions provide the Company with a broader review of the external cybersecurity environment, helping us to stay current on emerging or developing security approaches and risks. Among other initiatives, our CISO and the Company&#8217;s IT security team actively participate in industry conferences and maintain memberships to resources such as the Health Information Sharing and Analysis Center (Health-ISAC), a trusted community of critical infrastructure owners and operators within the Health Care and Public Health sector which, among other things, allows the Company to monitor email updates and alerts coordinated with the U.S. Department of Homeland Security&#8217;s Cybersecurity and Infrastructure Security Agency. In order to maintain awareness of privacy, data and cybersecurity risks, the Company incorporates these topics into its annual compliance training materials that are mandatory for all teammates and new hires, and among other things cover HIPAA privacy and security requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and have established processes involving our IT security, privacy and legal teams that assess potential cybersecurity risks associated with our retention and use of third-party service providers. These policies and procedures are generally aligned with the NIST Cybersecurity Framework. Prior to retaining or renewing a third-party vendor, the Company policy requires a risk assessment of such potential new vendor or new engagement through a collaborative process among the Company&#8217;s IT security, privacy, insurance and legal teams, among others. Potential vendor engagements also are reviewed to assess a range of other considerations and contractual terms and conditions, including, among other things, a potential vendor&#8217;s liability insurance limits, scope and coverage of cyber insurance and privacy data protections. Our IT SOX team also conducts annual SOX reviews for those vendors that are considered in scope for SOX controls. All finalized vendor engagements are considered by Internal Audit as part of our ordinary course risk assessment and audit planning.</span></div></ix:continuation></ix:continuation><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="f-40" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity Risks and the Impact on our Company</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the continuously evolving series of laws and regulations related to cybersecurity, data protection and privacy that are applicable to our business, as well as the associated risks from cybersecurity threats, we have expended significant resources in order to protect our information systems and data. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-41">We regularly review, monitor and implement multiple layers of security measures through technology, processes and our people. We utilize security technologies designed to protect and maintain the integrity of our information systems and data, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses and other malicious code; coordinated attacks by a variety of actors, including, among others, activist entities or state sponsored cyberattacks; emerging cybersecurity risks; cyber risk related to connected devices; misplaced or lost data; programming and/or human errors; or other similar events that could impact the security, reliability and availability of our systems. Internal or external parties have attempted to, and will continue to attempt to, circumvent our security systems, and we have in the past, and expect that we will in the future, defend against, experience, and respond to attacks on our network including, without limitation, reconnaissance probes, denial of service attempts, malicious software attacks including ransomware or other attacks intended to render our internal operating systems or data unavailable, and phishing attacks or business email compromise.</ix:nonNumeric> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-42">While we have experienced cybersecurity incidents in the past, to date none have had a material impact on our business, results of operations, financial condition and cash flows.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity requires ongoing investment and diligence against evolving threats and in the context of new or developing technologies. For further information regarding the risks we face from cybersecurity threats and how our business strategy, results of operations, and financial condition could be materially affected by such risks, see Part I Item IA. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and information security laws are complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8230;".</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governance</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-43" continuedAt="f-43-1" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board Oversight</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its oversight responsibilities, the Audit Committee monitors privacy, data and cybersecurity as specific risk areas. The Audit Committee also works with the Compliance and Quality Committee to oversee enterprise risks with healthcare and anti-corruption requirements, and those requirements include certain privacy, data and cybersecurity aspects. Both Mr. Schechter, a member of the Audit Committee, and Ms. Schoppert, a member of the Audit Committee, hold a CERT Certificate in Cybersecurity Oversight. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-46" continuedAt="f-46-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-45" continuedAt="f-45-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-44" continuedAt="f-44-1">The Audit Committee engages in regular discussions with management on privacy, data, and </ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-43-1"><ix:continuation id="f-46-1"><ix:continuation id="f-45-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-44-1">cybersecurity risk exposures, receiving quarterly reports from the ERM team and the CIO. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-false" id="f-47">On a periodic basis, the full Board of Directors also receives these reports from the ERM team and the CIO. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-48" escape="true">The CPO and/or CLO periodically reports to the Audit Committee about the Company&#8217;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.</ix:nonNumeric></ix:nonNumeric></ix:continuation></span></div></ix:continuation></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, the Company&#8217;s privacy team actively develops and implements policies designed to comply with the requirements of privacy laws in the countries where the Company operates. Working with Internal Audit and the CIO, the privacy team assesses the nature and potential severity of privacy risks within DaVita and guides the organization in taking steps to help mitigate such risks. The Audit Committee also oversees the Company's negotiation of any cybersecurity insurance. Currently, the Company maintains a cybersecurity risk insurance policy providing coverage for certain cybersecurity breaches among other specified risks.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-49" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, our IT security team, in consultation with our privacy team, is primarily responsible for frontline assessments and management of day-to-day risks from cybersecurity threats, including the monitoring and detection of cybersecurity incidents and the execution of DaVita's cybersecurity and privacy incident response plans, as needed. Pursuant to the plan, the teams are responsible for assessing and classifying cybersecurity incidents and coordinating the response to such incidents, including managing both internal and external reporting obligations and remediation efforts. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-50" escape="true">Our key personnel responsible for privacy and cybersecurity expertise include our CIO, CISO and CPO. Their qualifications include expertise in international privacy laws, compliance, global IT strategy, and security responsibilities, helping to ensure a comprehensive approach to risk management. Our CISO has more than two decades of experience in information technology risk and compliance and holds a Certified Chief Information Security Officer certification from EC-Council, a Certified Information Security Manager certification from ISACA and a certification from the Massachusetts Institute of Technology on AI management in healthcare. Our CPO is a Certified Information Privacy Professional and a Certified Compliance and Ethics Professional, and has more than two decades of experience in creating and implementing privacy and data protection programs that enable multinational organizations to respect and protect personal data and execute mission critical business strategies.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IT security team also operates a 24x7 security operations center through a managed service provider. This dedicated center, alongside active monitoring of the dark web for DaVita-related data, and our use of both internal and external tools, is designed to ensure proactive detection, prevention and remediation of cybersecurity incidents. We inform and develop this integrated approach through our ongoing internal and external evaluations and risk assessments of our IT security program as described above.</span></div></ix:nonNumeric><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_151"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Properties</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Denver, Colorado, consisting of one owned office building and one leased office building. We lease space for our international headquarters located in the United Kingdom. Our laboratory is based in Florida where we operate our lab services out of one leased building. We also lease other administrative offices in the U.S. and worldwide.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of our U.S. and international outpatient dialysis centers are leased. We believe that if we were unable to renew a lease of a dialysis center or administrative office, we could find alternative space at competitive market rates and relocate our operations to such new location without material disruption to our business. See Note 13 to the consolidated financial statements included in this report for information regarding our leases and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Location of our U.S. dialysis centers"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the locations of our U.S. dialysis centers.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_154"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Part I Item&#160;3&#160;is incorporated herein by reference to the information set forth under the caption "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 15 to the consolidated financial statements included in this report.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_157"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_163"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of </span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the New York Stock Exchange under the symbol DVA. The closing price of our common stock on January&#160;31, 2025 was $176.20 per share. According to Computershare, our registrar and transfer agent, as of January&#160;31, 2025, there were 6,265 holders of record of our common stock. This figure does not include the indeterminate number of beneficial holders whose shares are held of record by brokerage firms and clearing agencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial public offering was in 1994, and we have not declared or paid cash dividends to holders of our common stock since going public. We have no current plans to pay cash dividends and there are certain limitations on our ability to pay dividends under the terms of our senior secured credit facilities. See "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and capital resources"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the notes to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchases</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our repurchases of our common stock during 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:30.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total number<br/>of shares<br/>purchased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">paid per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total number of shares purchased as part of publicly announced plans or programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate dollar value<br/>of shares that may yet be purchased under the plans or programs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars and shares in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 - March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1 - June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1 - September 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,298,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,934,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.06&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes commissions and the 1% excise tax imposed by the Inflation Reduction Act of 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we are authorized to make share repurchases pursuant to a September 5, 2024 Board authorized repurchase plan of $2.0 billion. This authorization allows us to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;13, 2025, we have a total of $1.811 billion, excluding excise taxes, available under the current repurchase authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, we remain subject to share repurchase limitations, including under the terms of our senior secured credit facilities.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_166"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reserved</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_172"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contains statements that are forward-looking statements within the meaning of the federal securities laws and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. These forward-looking statements could include, among other things, statements about our balance sheet and liquidity, our expenses, revenues, billings and collections, patient census, availability or cost of supplies, including without limitation the impact of any reduction in clinical and other supplies due to any disruptions experienced by third party vendors, including with respect to our ability to provide home dialysis services, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, the effects on us and our operations of any interruptions in key functions performed by our third party service providers or suppliers, current macroeconomic, marketplace and labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our future operations, financial condition and prospects, capital allocation plans, expenses, cost saving initiatives, other strategic initiatives, use of contract labor, government and commercial payment rates, expectations related to value-based care (VBC), integrated kidney care (IKC), Medicare Advantage (MA) plan enrollment and our international operations, expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs, or other treatments on the dialysis industry, and expectations regarding our stock repurchase program. All statements in this report, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this report. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">external conditions, including those related to general economic, marketplace and global health conditions, including without limitation, the impact of global events and political or governmental volatility; the impact of the domestic political environment and related developments on the current healthcare marketplace, our patients and on our business; the continuing impact of the COVID-19 pandemic on our financial condition and the chronic kidney disease (CKD) population and our patient population; supply chain challenges and disruptions, including without limitation with respect to certain key services, critical clinical supplies and equipment we obtain from third parties, and including any impacts on our supply chain as a result of natural disasters; the potential impact of new or potential entrants in the dialysis and pre-dialysis marketplace and potential impact of innovative technologies, drugs, or other treatments on our patients and industry; elevated teammate turnover or labor costs; the impact of continued increased competition from dialysis providers and others; and our ability to respond to challenging U.S. and global economic and marketplace conditions, including, among other things, our ability to successfully identify cost saving opportunities;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; a reduction in the number or percentage of our patients under commercial plans, including, without limitation, as a result of continuing legislative efforts to restrict or prohibit the use and/or availability of charitable premium assistance, or as a result of payors implementing restrictive plan designs; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">risks arising from potential changes in or new laws, regulations or requirements applicable to us, including, without limitation, those related to healthcare, privacy, antitrust matters, and acquisition, merger, joint venture or similar transactions and/or labor matters, and potential impacts of changes in interpretation or enforcement thereof or related litigation impacting, among other things, coverage or reimbursement rates for our services or the number of patients enrolled in or that select higher-paying commercial plans, and the risk that we make incorrect assumptions about how our patients will respond to any such developments; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to successfully implement our strategies with respect to IKC and VBC initiatives and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the MA benchmark structure;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our reliance on significant suppliers, service providers and other third party vendors to provide key support to our business operations and enable our provision of services to patients, including, among others, suppliers of certain pharmaceuticals, administrative or other services or critical clinical products; and risks resulting from a closure, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">reduction or other disruption in the services or products provided to us by such suppliers, service providers and third party vendors;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party, including, among other things, any such non-compliance or breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">legal and compliance risks, such as compliance with complex, and at times, evolving government regulations and requirements, and with additional laws that may apply to our operations as we expand geographically or enter into new lines of business;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to attract, retain and motivate teammates, including key leadership personnel, and our ability to manage potential disruptions to our business and operations, including potential work stoppages, operating cost increases or productivity decreases whether due to union organizing activities, legislative or other changes, demand for labor, volatility and uncertainty in the labor market, the current challenging and highly competitive labor market conditions, including due to the ongoing nationwide shortage of skilled clinical personnel, or other reasons;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to oral phosphate binders, among other things; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives that, among other things, may erode our patient base and impact reimbursement rates;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures or other strategic transactions on terms favorable to us or at all; and our ability to continue to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the variability of our cash flows, including, without limitation, any extended billing or collections cycles including, without limitation, due to defects or operational issues in our billing systems or in the billing systems or services of third parties on which we rely; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the effects on us or others of natural or other disasters, public health crises or severe adverse weather events such as hurricanes, earthquakes, fires or flooding;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">factors that may impact our ability to repurchase stock under our stock repurchase program and the timing of any such stock repurchases, as well as any use by us of a considerable amount of available funds to repurchase stock; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our goals and disclosures related to environmental, social and governance (ESG) matters, including, among other things, evolving regulatory requirements affecting ESG standards, measurements and reporting requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the other risk factors, trends and uncertainties set forth in Part I Item 1A. of this Annual Report on Form 10-K, and the other risks and uncertainties discussed in any subsequent reports that we file or furnish with the Securities and Exchange Commission (SEC) from time to time.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following should be read in conjunction with our consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company overview</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal business is to provide dialysis and related lab services to patients in the United States, which we refer to as our U.S. dialysis business. We also operate our U.S. integrated kidney care (IKC) business, our U.S. other ancillary services, and our international operations, which we collectively refer to as our ancillary services, as well as our corporate administrative support functions. Our U.S. dialysis business is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD) or end stage kidney disease (ESKD).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operational and financial highlights for 2024 include, among other things:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. dialysis revenue growth of 4.2% from an increase in average patient services revenue per treatment of $13.88;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue growth of 16.2% in our other ancillary businesses, primarily in our international operations; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating income of $2,090 million and adjusted operating income of $1,981 million;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating cash flows of $2,022 million and free cash flows of $1,162 million; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">repurchase of 9,832,705 shares of our common stock for aggregate consideration of $1,389 million, and a 9.3% reduction in our outstanding share count year-over-year;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entered into an amendment to our senior secured credit agreement which extended the maturity date of a portion of our Term Loan B-1 in the aggregate principal amount of $1,640 million. We further amended the senior secured credit agreement to incur an incremental Term Loan A-1 tranche in the aggregate principal amount of $1,100 million and issued an aggregate principal amount of $1,000 million of 6.875% senior notes due 2032. A portion of the proceeds of these transactions was used to repay the Term Loan B-1 maturing in 2026 of approximately $950 million; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we purchased an additional $2,500 million notional amount of forward interest rate caps to shield our exposure to significant interest rate increases through 2027; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">leverage ratio, as a multiple of Consolidated EBITDA, each as defined by our credit agreement, remained within our target range of 3.0x to 3.5x throughout 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional highlights include:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a net increase in consolidated patient growth of 12.4%, with flat patient growth in U.S. dialysis and 62.6% international patient growth as of December&#160;31, 2024; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a net decrease of 18 U.S. dialysis centers as we continued to improve center capacity utilization, as well as a net increase of 142 international dialysis centers from acquisitions; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued patient growth in IKC to </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patients in risk-based integrated care arrangements and an additional 11,600 patients in other integrated care arrangements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, we expect relatively flat year-over-year treatment volumes due to a number of factors. These include, among other things, elevated mortality levels relative to pre-pandemic levels; the continued impact of missed treatment rates, which in recent years have been impacted by increased hospitalizations and the prevalence of severe weather events; and the impact of the supply disruption affecting our home dialysis supplies. We expect operating income growth resulting from revenue per treatment improvements, primarily driven by rate increases, the net impact of our continued improvements in our billing and collections process, mix improvement and the incorporation of oral phosphate binder reimbursement into the bundle, as described below. We expect an increase in costs per treatment due to the oral phosphate binders and inflationary increases in labor and other costs, partially offset by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a decline in center closure costs. In 2025, we also expect operating growth in our international business as we continue our expansion in international markets and we expect results in our 2025 integrated kidney care business to be consistent with 2024. We expect a continued increase in debt expense in 2025 due in part to the financing transactions announced in 2024 and the expiration of our 2019 interest cap agreements in 2024 as described below. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, considerable uncertainty remains surrounding the continued implementation and development of the various governmental laws, regulations and other requirements that may impact our business, including the extent to the which such developments impact the behavior of other health care market participants such as payors, employers, charitable organizations and government agencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion below includes analysis of our financial condition and results of operations for the years ended December&#160;31, 2024 compared to December&#160;31, 2023. Our Annual Report on Form 10-K for the year ended December&#160;31, 2023, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">includes a discussion and analysis of our financial condition and results of operations for the year ended December&#160;31, 2022, in its Part II Item 7, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to the "Notes" in the discussion below refer to the notes to the Company's consolidated financial statements included in this Annual Report on Form 10-K at Part IV Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" as referred from Part II Item 8, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements and Supplementary Data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_178"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Economic, Marketplace and Global Health Conditions; Legal and Regulatory Developments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above and described below, developments in general economic, marketplace and global health conditions have directly and indirectly impacted the Company and in the future could have a material adverse impact on our patients, teammates, physician partners, suppliers, business, operations, reputation, financial condition, results of operations, share price, cash flows and/or liquidity. Many of these external factors and conditions are interrelated, including, among other things, inflation, interest rate volatility, and other economic conditions, labor market conditions, wage pressure, the increased mortality rates of our patients and other ESKD or CKD patients, supply chain challenges and the potential impact and application of innovative technologies, drugs or other treatments. Certain of these impacts could be further intensified by concurrent global events, which have continued to drive sociopolitical, geopolitical and economic uncertainty; severe weather events and other natural disasters, which have impacted national supply chain challenges; the impact of new policies implemented by the new administration in the United States, which have affected certain government sponsored programs, among other things. For additional discussion of general economic, marketplace and global health conditions that could impact our business, see Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and Part I Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operational and Financial Impacts</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a full year basis, we experienced a negative impact on revenue and treatment volume due to, among other things, continued elevated mortality rates of our patients in comparison to the periods prior to the COVID-19 pandemic and the associated impact on our patient census, missed treatments driven by severe weather events and the impact of a temporary pause in home dialysis starts that resulted from the closure of one of our supplier's facilities. Treatment volumes during the year were also adversely impacted by continued elevated missed treatment rates, which during 2024 were driven primarily by severe weather events. New-to-dialysis admission rates, treatment volumes, future revenues and non-acquired growth, among other things, could continue to be negatively impacted over time to the extent that the ESKD and CKD populations experience sustained elevated mortality levels. These mortality levels could be influenced by, among other things, the availability and use of vaccines, treatments and therapies. As described in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" the magnitude of these cumulative impacts could have a material adverse impact on our results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing global economic conditions and political and regulatory developments, such as general labor, supply chain and inflationary pressures have increased, and will likely continue to increase, our expenses, including, among others, staffing, labor and supply costs. We have also experienced service disruptions relating to key business functions and supply chain shortages with respect to certain of our equipment and clinical supplies, including critical clinical and other supplies. Certain of these disruptions related to external conditions, such as the aforementioned severe weather event that impacted our supply chain for key products as well as the cybersecurity incident at Change Healthcare (CHC) that impacted our billing operations. As described in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If certain of our supplier and service providers&#8230;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", any disruption involving such suppliers could materially impact our operations and require significant resources or operational changes in response. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect certain of these increased staffing and labor costs to continue into 2025, due to, among other factors, the continuation of inflationary conditions and a challenging healthcare labor market. The cumulative impact of these increased costs could be material. During 2024, our industry also continued to experience increased union organizing activities. For example, union petitions have been filed in nine of our clinics in California and eight of these petitions are in different stages of the voting process and have been subject to legal challenges. For additional details on the risks related to rising labor costs and union organizing activities, see the discussion in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is labor intensive..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"External conditions, including those related to general economic, marketplace and global health conditions..."</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal and Regulatory Developments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Federal Trade Commission (FTC) published in the federal register a final rule that would generally ban all post-employment personal service non-compete clauses with employees and prohibit employers from enforcing existing non-compete clauses in contracts with workers, with limited exceptions. Even though the rule has been enjoined, many state legislatures continue to introduce legislation that seeks to place limitations on restrictive covenants with workers. For additional details on federal and state regulations or future federal or state regulations and the potential impact on our business, see the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discussion in Part I Item 1. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Dialysis Business"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state legislation and regulations..."</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change Healthcare</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above and previously reported, due to a cybersecurity breach that affected CHC, a subsidiary of UnitedHealth Group Incorporated (United) that serves as an intermediary for processing the vast majority of our payment claims for domestic commercial and government payors, we temporarily suspended all claims processing activity with CHC (CHC Outage), primarily during a period of time during the first and second quarters of 2024, which impacted our cash flows. We have since resumed claims submissions and billing processes through CHC&#8217;s information technology systems and as of the date of this filing, through a combination of CHC's platform and certain alternate billing processes, we are current on our primary claims submissions. However, the CHC Outage, and the resultant delay in claims submissions, led to an increase in our days sales outstanding (DSO), among other things. That DSO increase has subsided, but we do continue to see delays in, and issues with, collections with some payors. For additional details on the CHC Outage and a discussion of the risks associated with outages, disruptions or incidents at third parties on which we rely, see the discussion in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and information security laws are complex&#8230;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the aforementioned recent developments and general economic, marketplace and global health conditions will continue to impact the Company in the future. Their ultimate impact depends on future developments that are highly uncertain and difficult to predict.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated results of operations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenues, operating income (loss) and adjusted operating income (loss) by line of business. See the discussion of our results for each line of business following this table. When multiple drivers are identified in the following discussion of results, they are listed in order of magnitude: </span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"/><td style="width:46.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.555%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.555%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted operating income (loss):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of adjusted operating income (loss) by reportable segment, see the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of non-GAAP measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" section below. </span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_184"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. dialysis business</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our U.S. dialysis business is a leading provider of kidney dialysis services, operating 2,657 outpatient dialysis centers serving approximately 200,800 patients, and contracted to provide hospital inpatient dialysis services in approximately 760 hospitals. We estimate that we have approximately a 36% share of the U.S. dialysis market based upon the number of patients we serve.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 88% of our 2024 consolidated revenues were derived directly from our U.S. dialysis business. The principal drivers of our U.S. dialysis revenues include&#160;&#160;&#160;&#160;:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our number of treatments, which is primarily a function of the number of chronic patients requiring approximately three in-center treatments per week as well as, to a lesser extent, the number of treatments for home-based dialysis and hospital inpatient dialysis; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our average dialysis patient service revenue per treatment, including the mix of patients with commercial plans and government programs as primary payor.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our U.S. dialysis business, our home-based dialysis and hospital inpatient dialysis services are operationally integrated with our outpatient dialysis centers and related laboratory services. Our outpatient, home-based and hospital inpatient dialysis services comprise approximately 75%, 19% and 6% of our U.S. dialysis revenues, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., government dialysis-related payment rates are principally determined by federal Medicare and state Medicaid policy. For 2024, approximately 67% of our total U.S. dialysis patient service revenues were generated from government-based programs for services to approximately 89% of our total U.S. patients. These government-based programs are principally Medicare and MA, Medicaid and managed Medicaid plans, and other government plans, representing approximately 56%, 8% and 3% of our U.S. dialysis patient service revenues, respectively. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Centers for Medicare &amp; Medicaid Services (CMS) issued a final rule to update the Medicare ESRD Prospective Payment System payment rate and policies for calendar year 2024. CMS has finalized ESRD facilities' average reimbursement by a productivity-adjusted market basket increase of 2.2% in 2025. In addition, from time-to-time CMS identifies drugs to be added to the ESRD PPS bundled payment. On January 1, 2025, phosphate binders, a drug class taken orally by many ESKD patients to reduce absorption of dietary phosphate, were incorporated into the ESRD PPS bundle. Phosphate binders are not considered accounted for in the ESRD PPS base rate at this time and will be reimbursed through a Transitional Drug Add-on Payment Adjustment (TDAPA). The TDAPA period is expected to continue for a period of at least two years. Currently, phosphate binders are offered in both generic and branded forms and are produced by multiple manufacturers. During this TDAPA period, our operating results could be materially impacted by certain factors, including physician prescribing patterns, the terms of supplier and other vendor contracts, the mix of branded and generic forms of the drug used by our patients, whether the drug enters into the ESRD PPS and becomes part of its bundled payment following TDAPA and, if so, at what rate and how payors will treat reimbursement of the drug at the conclusion of the TDAPA period.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialysis payment rates from commercial payors vary and a major portion of our commercial rates are set at contracted amounts with payors and are subject to intense negotiation pressure. On average, dialysis-related payment rates from contracted commercial payors are significantly higher than Medicare, Medicaid and other government program payment rates, and therefore the percentage of commercial patients in relation to total patients represents a significant driver of our total average dialysis patient service revenue per treatment. Commercial payors (including hospital dialysis services) represent approximately 33% of U.S. dialysis patient service revenues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of government reimbursement, the Medicare ESRD bundled payment system, MA and commercial reimbursement, see Part I Item 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">."Business"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. dialysis business &#8211; Sources of revenue-concentrations and risks."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For a discussion of operational, clinical and financial risks and uncertainties that we face in connection with the Medicare ESRD bundled payment system, see the risk factor in Part I Item 1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of operational, clinical and financial risks and uncertainties that we face in connection with commercial payors, see the risk factor in Part I Item 1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Risk Factors"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines, if the average rates that commercial payors pay us declines...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will continue to experience increases in our operating costs in 2025 that may outpace any net Medicare, commercial or other rate increases that we may receive, which could significantly impact our operating results.&#160;In particular, we expect to continue experiencing increases in operating costs that are subject to inflation, such as labor and supply costs, including increases in maintenance costs, regardless of whether there is a compensating inflation-based increase in Medicare, commercial or other payor payment rates. In addition, we expect to continue to incur capital expenditures and associated depreciation and amortization costs to improve, renovate and maintain our facilities, equipment and information technology to meet evolving regulatory requirements and otherwise.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis patient care costs are those costs directly associated with operating and supporting our dialysis centers, home-based dialysis programs and hospital inpatient dialysis programs, and consist principally of labor, benefits, pharmaceuticals, medical supplies and other operating costs of the dialysis centers. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal drivers of our U.S. dialysis patient care costs include:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical hours per treatment, labor rates and benefit costs;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendor pricing and utilization levels of pharmaceuticals;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business infrastructure costs, which include the operating costs of our dialysis centers; and </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical supply costs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other cost categories that can present significant variability include insurance costs and professional fees. In addition, proposed ballot initiatives or referendums, legislation, regulations or policy changes could cause us to incur substantial costs to prepare for, or implement changes required. Any such changes could result in, among other things, increases in our labor costs or limitations on the amount of revenue that we can retain. For additional information on risks associated with potential and proposed ballot initiatives, referendums, legislation, regulations or policy changes, see the risk factor in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state healthcare legislation or regulations...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our average clinical hours per treatment decreased in 2024 compared to 2023 primarily due to a decrease in turnover as described below. We are always striving for improved productivity levels, however, changes in factors such as federal and state </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">policies or regulatory billing requirements can lead to increased labor costs as can increases in turnover. In 2024, the demand for skilled clinical personnel continued, exacerbated by the nationwide shortage of these resources. In 2024 and 2023, we experienced increases in our clinical labor wage rates, which includes contract labor, of approximately 3.8% and 1.3%, respectively. We expect to continue to see higher clinical labor rates in 2025 due to labor market conditions, including changes in local minimum wage laws, and the continued competition for skilled clinical personnel. In 2024, our overall clinical teammate turnover decreased from 2023, but remains elevated from historical pre-COVID levels. We also continue to experience increases in the infrastructure and operating costs of our dialysis centers and general increases in utilities and repairs and maintenance. In 2024, we continued to implement certain cost control initiatives to help manage our overall operating costs, including labor productivity, and we expect to continue these initiatives in 2025.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis general and administrative expenses represented 10.3% and 10.1% of our U.S. dialysis revenues in 2024 and 2023, respectively. Increases in general and administrative expenses over the last several years were primarily related to strengthening our dialysis business and related compliance and operational processes, responding to certain legal and compliance matters and professional fees. We expect that these levels of general and administrative expenses will be impacted by continued investment in developing our capabilities and executing on our strategic priorities, among other things.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. dialysis results of operations</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment volume:&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:42.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis treatments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,046,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,910,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average treatments per day</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Normalized non-acquired treatment growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers</span></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Normalized non-acquired treatment growth reflects year over year growth in treatment volume, adjusted to exclude acquisitions and other similar transactions, and further adjusted to normalize for the number and mix of treatment days in a given period versus the prior period.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis operating revenues and expenses are directly driven by treatment volume. The increase in our U.S. dialysis treatments in 2024 was primarily driven by additional treatment days and increased treatments from acquired treatment growth partially offset by an increase in missed treatments.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues:&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:42.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions, except per treatment data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average patient service revenue per treatment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis average patient service revenue per treatment increased primarily driven by the increase in average reimbursement rates from normal annual rate increases including Medicare rate increases, revenue cycle improvements, favorable changes in mix, and an increase in hospital inpatient dialysis rates.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses and charges:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:42.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions, except per treatment data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on changes in ownership interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses and charges</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs per treatment</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.12&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.78&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charges impacting operating income</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Closure costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the third quarter of 2022, we began a strategic review of our outpatient clinic capacity requirements and utilization, which had been significantly impacted by declines in our patient census due to the COVID-19 pandemic. This review continued through 2023, with impacts continuing into 2024, and has resulted in higher than normal charges for center capacity closures over the last several quarters. These capacity closure costs include net losses on assets retired, lease termination costs, asset impairments and accelerated depreciation and amortization.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, U.S. dialysis center closure costs were approximately $72.4&#160;million, which impacted our patient care costs by $30.8&#160;million, our general and administrative expenses by $25.6&#160;million and our depreciation and amortization expense by $16.0&#160;million. By comparison, during the year ended December&#160;31, 2023, U.S. dialysis center closures were approximately $99.1&#160;million, which impacted our patient care costs by $28.0&#160;million, our general and administrative expenses by $20.6&#160;million and our depreciation and amortization expense by $50.5&#160;million.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the upcoming fiscal year, we expect a decrease in our center closure costs as we expect future closures to return to pre-COVID levels.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Severance costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the fourth quarter of 2022, we committed to a plan to increase efficiencies and cost savings in certain general and administrative support functions. As a result of this plan, we recognized expenses related to termination and other benefit commitments in our U.S. dialysis business of $26.7 million during the twelve months ended December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient care costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis patient care costs are those costs directly associated with operating and supporting our dialysis centers and consist principally of compensation expenses including labor and benefits, pharmaceuticals, medical supplies and other operating costs of the dialysis centers. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis patient care costs per treatment increased primarily due to increased compensation expenses, including increased wage rates, as well as increases in health benefit expense and medical supply costs. Other drivers of this change include increases in utilities expense driven by lower expense in 2023 related to our virtual power purchase arrangements, insurance costs and routine repairs and maintenance. These increases were partially offset by decreases in contributions to charitable organizations, other direct operating expenses associated with our dialysis centers, contract wages and a gain on settlement received in the fourth quarter of 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis general and administrative expenses increased primarily due to increases in compensation expense, including increased wage rates and headcount, as well as IT-related costs and advocacy costs, including a refund received in 2023 related to 2022 advocacy costs. Other drivers of this change include increased professional fees, center closure costs, as described above, and health benefit expense. These increases were partially offset by decreases in severance costs, as described above, and contributions to our charitable foundation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense is directly impacted by the number of our dialysis centers and the information technology that we develop and acquire as well as changes in useful lives of assets. U.S. dialysis depreciation and amortization expense decreased in 2024 primarily due to decreased accelerated depreciation related to center closures, as described above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investment income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis equity investment income decreased due to the consolidation of a previously nonconsolidated dialysis partnership in the first quarter of 2024, partially offset by increased profitability at certain nonconsolidated dialysis partnerships.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on changes in ownership interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the first quarter of 2024, we acquired a controlling interest in a previously nonconsolidated dialysis partnership for which we recognized a non-cash gain of $35.1 million on our prior investment upon consolidation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating income and adjusted operating income</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:46.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of adjusted operating income by reportable segment, see the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of non-GAAP measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" section below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis operating income for 2024 compared to 2023 was positively impacted by a gain on a change in business ownership interest and severance costs, as described above. U.S. dialysis operating income and adjusted operating income increased compared to 2023 primarily due to an increase in our average patient service revenue per treatment and dialysis treatments, as described above, as well as decreases in charitable contributions, center closure costs, as described above, other direct operating expenses associated with our dialysis centers, contract wages and a gain on settlement, as described above. These increases in operating income and adjusted operating income were partially offset by increases in compensation expenses, as described above, as well as increases in health benefit expense, IT-related costs, medical supply costs, advocacy costs and utilities expense, as described above. Operating income and adjusted operating income were also negatively impacted by increased insurance costs, routine repairs and maintenance and professional fees.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_187"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other - Ancillary services</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other operations include ancillary services that are primarily aligned with our core business of providing dialysis services to our network of patients. As of December&#160;31, 2024, these consisted primarily of our U.S. IKC business, certain U.S. other ancillary businesses (including our clinical research programs, transplant software business, and venture investment group), and our international operations. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These ancillary services, including our international operations, generated revenues of approximately $1.510 billion in 2024, representing approximately 12% of our consolidated revenues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, DaVita IKC provided integrated care and disease management services to approximately 70,400 patients in risk-based integrated care arrangements and to an additional 11,600 patients in other integrated care arrangements. We also expect to add additional service offerings to our business and pursue additional strategic initiatives in the future as circumstances warrant, which could include, among other things, healthcare services not related to kidney disease.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the risks related to IKC and our ancillary services, see the discussion in the risk factors in Part I Item 1A. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The U.S. integrated kidney care, U.S. other ancillary services and international operations that we operate or invest in now or in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..." and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..." </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our international dialysis business owned or operated 509 outpatient dialysis centers located in 13 countries outside of the U.S. For 2024, total revenues generated from our international operations were approximately 8% of our consolidated revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ancillary services results of operations</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"/><td style="width:45.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. IKC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. other ancillary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating (loss) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. IKC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. other ancillary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating (loss) income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. IKC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. other ancillary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjusted operating income (loss):</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The reported operating income and adjusted operating income for the years ended December&#160;31, 2024 and December&#160;31, 2023, includes foreign currency gains (losses) embedded in equity method income recognized from our APAC joint venture, which was consolidated in the fourth quarter of 2024, of approximately $0.6 million and $(1.6) million, respectively.</span></div><div style="margin-top:3pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of adjusted operating (loss) income by reportable segment, see the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of non-GAAP measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" section below. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IKC revenues were impacted by decreased revenues from our special needs plans and the divestiture of our physician services business, partially offset by a net increase in shared savings. Our U.S. other ancillary services revenues were impacted by increased revenues from our transplant software business, offset by decreased revenues in our clinical research programs. Our international revenues increased due to acquired and non-acquired treatment growth and average reimbursement rate increases in certain countries, partially offset by charges for balances deemed uncollectible.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Items impacting operating income</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IKC adjustment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in IKC revenues for 2024, as described above, was impacted by the lifting of certain revenue recognition constraints for some of our value-based care contracts with health plans in 2023, which allowed us to recognize approximately $55 million in incremental shared savings revenues during 2023 compared to what we would have recognized under previous years' constraints.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we launched our IKC VBC business, the COVID-19 pandemic and its distorting effects on medical utilization have subsided, our VBC contracts have continued to mature, we have begun to receive more timely and granular data from our health plan partners and we have gained more experience making total medical cost estimates for this population. These changes and refinements have helped to mitigate or alleviate a number of the information and measurement limitations that constrained our revenue recognition in the past, allowing us to recognize a greater share of expected shared savings revenues for our VBC plans sooner than we had in previous periods. As a result, we recognized a majority of the VBC shared savings revenues we expected to earn for 2023 in 2023, while in previous years a substantial majority of the shared savings earned for a VBC plan year were recognized in a subsequent year.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year 2023 therefore included a general shift in the timing of our revenue recognition for shared savings under our VBC contracts with health plans, as it included a majority of shared savings revenues earned for both 2022 and 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Severance and other costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the fourth quarter of 2022, similar to U.S. dialysis, we committed to a plan to increase efficiencies and cost savings in certain general and administrative support functions and other overhead costs. As a result of this plan, we recognized expenses related to termination and other benefit commitments in our IKC business of $0.5 million during the year ended December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill impairment charge and related items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the fourth quarter of 2023, we recognized a goodwill impairment charge of $26.1 million in our transplant software business. We also recognized a gain of $7.7 million due to a reduction in the estimated value of earn-out obligations from our original acquisition of this business. This impairment charge and related gain resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on changes in ownership interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the fourth quarter of 2024, we acquired a controlling interest in the previously nonconsolidated partnership known as the Company's APAC joint venture, for which we recognized a non-cash gain of $74.3 million on our prior investment upon consolidation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating income (loss) and adjusted operating income (loss):</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IKC operating loss for 2024 compared to 2023 was impacted by the IKC adjustment, as described above. Our IKC operating loss and adjusted operating loss decreased primarily due to a net increase in shared savings, decreased medical costs for our special needs plans and the divestiture of our physician services business. These increases were partially offset by decreased revenues from our special needs plans and continued investments in our integrated care support functions. Our U.S. other ancillary services operating loss for 2024 compared to 2023 was impacted by a goodwill impairment charge and related gain, as described above. Our U.S. other ancillary services operating loss and adjusted operating loss was impacted by decreased revenues in our clinical research programs and increased expenses in our transplant software business, partially offset by increased revenues from our transplant software business. Our international operating income was impacted by a gain on a change in business ownership interests, as described above. International operating income and adjusted operating income were impacted by increased revenues, as described above, partially offset by increases in operating and deal costs from acquisition-related growth.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_190"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate administrative support</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate administrative support consists primarily of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">labor, benefits and long-term incentive compensation expense, as well as professional fees, for departments which provide support to more than one of our various operating lines of business. Corporate administrative support expenses are included in general and administrative expenses on our consolidated income statement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accruals for legal matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During 2023, we recorded a charge of $40 million for a legal matter within corporate administrative support.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate administrative support expenses decreased $50 million due to the absence in 2024 of the legal charge described above, and decreased long-term incentive compensation costs, partially offset by increased compensation expenses in 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate-level charges</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt prepayment, extinguishment and modification costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average effective interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate attributable to DaVita Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents our overall weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, premium and deferred financing charges.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of our effective income tax rate attributable to DaVita Inc., see the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of non-GAAP measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" section below. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt expense</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt expense increased primarily due to an increase in overall weighted average effective interest rate principally related to the expiration of our 2019 interest rate cap agreements on June 30, 2024, which had lower rates than our currently effective interest rate caps, as well as an increase in our our long-term debt balance related to the issuance of 6.875% senior notes due 2032 and incremental borrowing on our Term Loan A-1, partially offset by the repayment of the non-extended Term Loan B-1. See Note 12 to the consolidated financial statements for further information on the components of our debt and changes in them since 2023.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt extinguishment and modification costs</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt prepayment, extinguishment and modification costs were $20 million in 2024 composed of fees incurred in connection with the additional incremental borrowing on our Term Loan A-1 (Incremental Term Loan A-1), the extension of the maturity date of a portion of our Term Loan B-1 from August 2026 to May 2031 (Extended Term Loan B-1), and deferred financing costs and original issue discount written off for the extinguishment of the non-extended Term Loan B-1. Comparatively, debt extinguishment and modification costs were $8 million in 2023 related to the refinancing of our prior Term Loan A and prior revolving line of credit. These costs were composed of deferred financing costs written off for the portion of this debt considered extinguished and reborrowed and fees incurred as part of this debt refinancing. See Note 12 to the condensed consolidated financial statements for further information on the Incremental Term Loan A-1, Extended Term Loan B-1 and the components of our debt.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other loss consists primarily of interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses. Other loss increased primarily due to equity investment losses on our investment in Mozarc Medical Holding LLC (Mozarc), including the $14 million gain recognized in 2023 on the non-cash assets contributed to Mozarc, partially offset by decreased losses recognized on other investments, decreased losses on foreign currency transactions and an increase in interest income.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate and effective income tax rate attributable to DaVita Inc. decreased in 2024 primarily due to the tax impact of non-taxable non-cash gains related to previously nonconsolidated businesses and a decrease in nondeductible executive compensation. This benefit was partially offset by additional expense recognized in 2024 for finalized tax returns and a decrease in benefits recognized for uncertain tax positions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in income attributable to noncontrolling interests was due to an increase in earnings at certain U.S. dialysis partnerships.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_196"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> U.S. dialysis accounts receivable</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis accounts receivable balances at December&#160;31, 2024 and December&#160;31, 2023 were $1.615 billion and $1.632 billion, respectively, representing approximately 52 days and 54 days of revenue (DSO), respectively. The decrease in DSO was primarily due to continued collections improvements.&#160;Our DSO calculation is based on the most recent quarter&#8217;s average revenues per day. There were no significant changes during 2024 from 2023 in the carrying amount of accounts receivable outstanding over one year old or in the amounts pending approval from third-party payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, our U.S. dialysis accounts receivable balances that are more than six months old represented approximately 23% and 19% of our U.S. dialysis accounts receivable balances outstanding, respectively. Substantially all revenue realized for patient services is received from government and commercial payors, as discussed above. Less than 1% of our revenues in both periods were classified as patient pay.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts pending approval from third-party payors associated with Medicare bad debt claims as of December&#160;31, 2024 and 2023, other than the standard monthly billing, were approximately $107 million, and are classified within other receivables. A significant portion of our Medicare bad debt claims are typically paid to us before the Medicare fiscal intermediary audits the claims but are subject to subsequent adjustment based upon the actual results of those audits. Such audits typically occur one to four years after the claims are filed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our major sources and uses of cash, cash equivalents and restricted cash:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:53.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash items in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other working capital changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maintenance capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of self-developed properties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(771)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt proceeds (payments), net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and debt related financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock award exercises and other share issuances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,386)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares repurchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,832,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Maintenance capital expenditures represent capital expenditures to maintain the productive capacity of the business and include those made for investments in information technology, dialysis center renovations, capital asset replacements, and any other capital expenditures that are not development or acquisition expenditures.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Development capital expenditures principally represent capital expenditures (other than acquisition expenditures) made to expand the productive capacity of the business and include those for new U.S. and international dialysis center developments, dialysis center expansions and relocations, and new or expanded contracted hospital operations.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of our free cash flow, see the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of Non-GAAP measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" section below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated cash flows</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated cash flows from operating activities for 2024 and 2023 were $2,022 million and $2,059 million, respectively. The decrease in cash flows was primarily driven by increases in taxes and interest paid combined with changes in other working capital items partially offset by improved operating results. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used for investing activities in 2024 was flat compared to 2023. An increase in acquisitions due to our international growth was largely offset by decreases in equity investments driven by our investment in Mozarc in 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities decreased $353 million in 2024 compared to 2023. Significant sources of cash during the period included the extension of the maturity date from August 2026 to May 2031 for a portion of our Term Loan B-1 (the Extended Term Loan B-1 transaction) in the aggregate principal amount of approximately $1,640 million, (such portion referred to as the Extended Term Loan B-1), the incurrence of an incremental Term Loan A-1 tranche in the aggregate principal amount of $1,100 million (such portion referred to as the Incremental Term Loan A-1), the issuance of 6.875% senior notes due 2032 in the amount of $1,000 million (the 6.875% Senior Notes) and Change Healthcare temporary funding assistance of $93 million, net, pursuant to the CHC Funding Arrangement during the year ended December&#160;31, 2024. Significant uses of cash during that same period included debt prepayments on Term Loan B-1 in the aggregate amount of approximately $2,590 million as part of the Extended Term Loan B-1, Incremental Term Loan A-1 and 6.875% Senior Notes transactions, and regularly scheduled principal payments under our senior secured credit facilities totaling approximately $75 million on our Term Loan A-1, $14 million on Term Loan B-1 and $4 million on Extended Term Loan B-1, as well as additional required payments under other debt arrangements. Additionally, we recognized financing cash outflows of $36 million in deferred financing costs and discount related to the Fourth and Sixth Amendments to the Senior Secured Credit Agreement and 6.875% Senior Notes transactions, as well as $15 million in cap premium fees for our 2024 forward interest rate cap agreements. During the year ended December&#160;31, 2024 we also used cash to repurchase 9,832,705 shares of our common stock.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By comparison, 2023 significant uses of cash included the pay-off of the remaining principal balance outstanding on our prior Term Loan A and prior revolving line of credit in the amount of $1,444 million and $150 million, respectively. Other uses of cash included regularly scheduled and other principal payments under our senior secured credit facilities totaling approximately $54 million on our prior Term Loan A, $16 million on our new Term Loan A-1, $57 million on Term Loan B-1, additional net repayments of $15 million on our revolving line of credit, as well as additional required payments under other debt arrangements. Additionally, we recognized financing cash outflows of $30 million in deferred financing costs related to the Amendments to the Senior Secured Credit Agreement and $40 million in cap premium fees for our 2023 forward interest cap agreements. Significant sources of cash during the period included the refinancing of the Term Loan A and revolving line of credit with a secured Term Loan A-1 facility in the aggregate principal amount of $1,250 million. During the year ended December 31, 2023 we also used cash to repurchase 2,903,832 shares of our common stock.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis center capacity and growth</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are typically able to increase our capacity by extending hours at our existing dialysis centers, expanding our existing dialysis centers, relocating our dialysis centers, developing new dialysis centers and by acquiring dialysis centers. The development of a typical new outpatient dialysis center generally requires approximately $2 million for leasehold improvements and other capital expenditures. Based on our experience, a new outpatient dialysis center typically opens within a year after the property lease is signed, normally achieves operating profitability in the second year after Medicare certification, and normally reaches maturity within three to five years. Acquiring an existing outpatient dialysis center requires a substantially greater initial investment, but profitability and cash flows are generally accelerated and more predictable. To a limited extent, we enter into agreements to provide management and administrative services to outpatient dialysis centers in which we own a noncontrolling interest or which are wholly-owned by third parties in return for management fees.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the growth in our dialysis operations by number of dialysis centers owned or operated:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of centers operated at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired centers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed centers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-owned managed or administered centers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sold and closed centers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed centers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of centers operated at end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents the change in the number of dialysis centers which we manage or provide administrative services to but in which we own a noncontrolling equity interest or which are wholly-owned by third parties. For our international business, 2024 activity includes a reduction in managed centers, and an increase in acquired centers, from the consolidation of our APAC joint venture on November 1, 2024.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents dialysis centers that were sold and/or closed for which the majority of patients were not retained.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents dialysis centers that were closed for which the majority of patients were retained and transferred to one of our other existing outpatient dialysis centers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchases</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchases during the years ended December&#160;31, 2024 and 2023:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.152%"><tr><td style="width:1.0%"/><td style="width:40.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions and shares in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#8217; equity.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes commissions and the excise tax described above</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2024, we have repurchased 778,746 shares of our common stock for $125 million at an average price paid of $158.48 per share through February&#160;13, 2025, including repurchases from Berkshire Hathaway Inc. (Berkshire) pursuant to our previously disclosed share repurchase agreement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See further discussion of our share repurchase activity, authorizations and information on our share repurchase agreement with Berkshire in Note 18 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available liquidity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our cash balance was $795 million and we held approximately $51 million in short-term investments. At that time we also had undrawn capacity on the revolving line of credit under our senior credit facilities of $1.5 billion. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were none as of December&#160;31, 2024. As of December&#160;31, 2024 we separately had approximately $161 million in letters of credit outstanding under a separate bilateral secured letter of credit facility.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 to the consolidated financial statements for components of our long-term debt and their interest rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash flows from operations and other sources of liquidity, including from amounts available under our senior secured credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months. From time to time, depending on market conditions, our capital requirements and the availability of financing, among other things, we may seek to refinance our existing debt and may incur additional indebtedness. Our primary recurrent sources of liquidity are cash from operations and cash from borrowings, which are subject to general, economic, financial, competitive, regulatory and other factors that are beyond our control, as described in Part I Item 1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Risk Factors"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The level of our current and future debt...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_202"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliations of non-GAAP measures</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide reconciliations of adjusted operating income (loss) to operating income (loss) as presented on a U.S. generally accepted accounting principles (GAAP) basis for our U.S. dialysis reportable segment as well as for our U.S. IKC business, our U.S. other ancillary services, our international business, and for our total ancillary services which combines them and is disclosed as our other segments category, in addition to our corporate administrative support.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a comment letter from the Securities and Exchange Commission Staff, beginning in the second quarter of 2024, we have updated the presentation of our non-GAAP measures to no longer exclude center closure costs for all periods presented. To facilitate comparisons, the non-GAAP measures presented for prior periods have also been conformed to the presentation of non-GAAP measures for the current period.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These non-GAAP or "adjusted" measures are presented because management believes these measures are useful adjuncts to, but not alternatives for, our GAAP results. Specifically, management uses adjusted operating income (loss) to compare and evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe this non-GAAP measure is also useful to investors and analysts in evaluating our performance over time and relative to competitors, as well as in analyzing the underlying trends in our business. We also believe this presentation enhances a user's understanding of our normal operating income by excluding certain items which we do not believe are indicative of our ordinary results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our effective income tax rate on income attributable to DaVita Inc. excludes noncontrolling owners' income, which primarily relates to non-tax paying entities. We believe this adjusted effective income tax rate is useful to management, investors and analysts in evaluating our performance and establishing expectations for income taxes incurred on our ordinary results attributable to DaVita Inc.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our free cash flow represents net cash provided by operating activities less distributions to noncontrolling interests, development capital expenditures, and maintenance capital expenditures; plus contributions from noncontrolling interests and proceeds from the sale of self-developed properties. Management uses this measure to assess our ability to fund acquisitions and meet our debt service obligations and we believe this measure is equally useful to investors and analysts as an adjunct to cash flows from operating activities and other measures under GAAP.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to bear in mind that these non-GAAP "adjusted" measures are not measures of financial performance under GAAP and should not be considered in isolation from, nor as substitutes for, their most comparable GAAP measures.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2024</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. <br/>dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Corporate <br/>administration</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. IKC</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on changes in ownership</span></div><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. <br/>dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Corporate <br/>administration</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. IKC</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IKC adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earn-out revaluation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents non-cash gains recognized on the acquisitions of controlling financial interests in previously nonconsolidated partnerships in 2024. See additional discussion above under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gain on changes in ownership interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" within "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">U.S. dialysis results of operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">"Ancillary services results of operation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for the $35 million and $74 million, respectively. These gains were to mark our prior investments in these businesses to fair value before consolidation and to recognize related foreign currency gains from translation adjustments previously deferred in accumulated other comprehensive loss. Gains on changes in business ownership interests do not represent a normal and recurring requirement of operating our business or generating revenues and may obscure analysis of underlying trends and financial performance.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In connection with the conclusion of a comment letter from the Securities and Exchange Commission Staff in July 2024, beginning in the second quarter 2024, we have updated the presentation of our non-GAAP measures to no longer exclude center closure costs for all periods presented. To facilitate comparisons, the non-GAAP measures presented for prior periods also have been conformed to the presentation of the non-GAAP measures for the current period.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes severance and other termination costs related to a prior strategic restructuring initiative and associated transition of certain general and administrative support functions to a third party. See additional discussion above under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Severance costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" within "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">U.S. dialysis results of operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Severance and other costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" within "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Ancillary services results of operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">".</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents an amount that was accrued for costs prior to agreement on a third-party settlement for the matter further described in Note 15 to our consolidated financial statements under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">". We have excluded this charge, which had been previously disclosed, from our non-GAAP metrics because, among other things, we do not believe it is indicative of our ordinary results of operations. In this instance, among the factors considered were that the claim relates to prior ancillary operations or activities that we sold or closed (or otherwise ceased) prior to June 2020, and the charge is significant and may obscure analysis of underlying trends and financial performance of our current business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Our fiscal year 2023 results included a majority of shared savings revenues earned for both 2022 and 2023 as a result of a general shift in the timing of recognition for shared savings under our VBC contracts with health plans due to the lifting of certain revenue recognition constraints in 2023. This amount represents the effect of shared savings revenues recognized in 2023 incremental to what we would have recognized in 2023 under prior year constraints. We have excluded this benefit to operating income because it is both unusual to our business and significant in size, and may obscure analysis of underlying trends and financial performance. See additional discussion above under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">IKC adjustment"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Ancillary services results of operations"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents a goodwill impairment charge, and related gain from a reduction in earn-out obligation values, for our transplant software business. See additional discussion above under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goodwill impairment charge and related items"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Ancillary services results of operations"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. This charge and this gain are excluded from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations, are inherently unpredictable and, in the case of impairments, are non-cash amounts, the exclusion of which facilitates comparison of historical, current, and forecasted financial results.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Noncontrolling owners&#8217; income primarily attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate on income attributable to DaVita Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net cash provided by operating activities to free cash flow:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maintenance capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of self-developed properties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-balance sheet arrangements and aggregate contractual obligations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the debt obligations and operating lease liabilities reflected on our balance sheet, we have commitments associated with letters of credit as well as certain working capital funding obligations associated with our equity investments in nonconsolidated dialysis ventures that we manage and some we manage that are wholly-owned by third parties.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have potential obligations to purchase the noncontrolling interests held by third parties in many of our majority-owned dialysis partnerships and other nonconsolidated entities. These obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods as outlined in each specific put provision. For additional information see Notes 16 and 23 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of these cash contractual obligations and commitments as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:50.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026-2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028-2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt and leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payments on credit facilities and senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases, including imputed interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership interests subject to put provisions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On-balance sheet:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Off-balance sheet:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-owned and minority owned put provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">See Note 12 to the consolidated financial statements for components of our long-term debt and related interest rates. </span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">See Note 13 to the consolidated financial statements for components of our leases and related interest rates. </span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents amounts for which we are contractually committed, should the outside partner exercise its put option.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 we had outstanding letters of credit in the aggregate amount of approximately $161 million under a separate bilateral secured letter of credit facility.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 we have outstanding purchase agreements with various suppliers to purchase set amounts of dialysis equipment, parts, pharmaceuticals, and supplies. If we fail to meet the minimum purchase commitments under these contracts during any year, we are required to pay the difference to the supplier. For additional information see Note 16 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that we manage and in which we own a noncontrolling equity interest or which are wholly-owned by third parties. For additional information see Note 16 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we expect our 2025 capital expenditures to be consistent with our 2024 capital expenditures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have approximately $39 million of existing long-term income tax liabilities for unrecognized tax benefits, including interest and penalties, which are excluded from the table above as reasonably reliable estimates of their timing cannot be made.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, we entered into four separate purchase agreements with Fresenius Medical Care AG and its affiliates to acquire their dialysis service operations in Chile, Ecuador, Colombia and Brazil. The Chile, Ecuador and Colombia transactions closed during 2024. The Brazil transaction is expected to close mid-year 2025 and remains subject to customary closing conditions and regulatory approval. The expected cash payment for this remaining transaction is approximately $100 million, subject to certain customary adjustments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Note 15 to the consolidated financial statements included in this report is incorporated by reference in response to this item.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_211"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies, estimates and judgments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements and accompanying notes are prepared in accordance with United States generally accepted accounting principles. These accounting principles require us to make estimates, judgments and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions (redeemable equity interests). All significant estimates, judgments and assumptions are developed based on the best information available to us at the time made and are regularly reviewed and updated when necessary. Actual results will generally differ from these estimates, and such differences may be material. Changes in estimates are reflected in our financial statements in the period of change based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Certain accounting estimates, including those concerning revenue recognition and accounts receivable, fair value estimates for goodwill and noncontrolling interests, accounting for income taxes, and loss contingencies are considered to be critical to evaluating and understanding our financial results because they involve inherently uncertain matters and their application requires the most difficult and complex judgments and estimates. For additional information, see Part IV Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules" &#8211; Note 1 &#8211; "Organization and summary of significant accounting policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" as referred from Part II Item 8, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements and Supplementary Data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition and accounts receivable for our U.S. dialysis patient services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There are significant estimating risks associated with the amount of U.S. dialysis patient service revenue that we recognize in a given reporting period. Payment rates are often subject to significant uncertainties related to wide variations in the coverage terms of the commercial healthcare plans under which we receive payments. In addition, ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage, and other payor issues complicate the billing and collection process. The measurement and recognition of revenue requires the use of estimates of the amounts that will ultimately be realized considering, among other items, retroactive adjustments that may be associated with regulatory reviews, audits, billing reviews and other matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with Medicare and Medicaid programs are recognized based on (a)&#160;the payment rates that are established by statute or regulation for the portion of the payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b)&#160;for the portion not paid by the primary government payor, the estimated amounts that will ultimately be collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient. Our dialysis-related reimbursements from Medicare are subject to certain variations under Medicare&#8217;s single bundled payment rate system whereby our reimbursements can be adjusted for certain patient characteristics and other variable factors. Our revenue recognition depends upon our ability to effectively capture, document and bill for Medicare&#8217;s base payment rate and these other factors. In addition, as a result of the potential range of variations that can occur in our dialysis-related reimbursements from Medicare under the single bundled payment rate system, our revenue recognition is subject to a greater degree of estimating risk.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial healthcare plans, including contracted managed-care payors, are billed at our usual and customary rates; however, revenue is recognized based on estimated net realizable revenue for the services provided. Net realizable revenue is estimated based on contractual terms for the patients covered under commercial healthcare plans with which we have formal agreements, non-contracted commercial healthcare plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in our billing and collection processes that can result in denied claims for payments, the estimated timing of collections, changes in our expectations of the amounts that we expect to collect and regulatory compliance matters. Determining applicable primary and secondary coverage for our approximately 200,800 U.S. dialysis patients at any given point in time, together with the changes in patient coverages that occur each month, requires complex, resource-intensive processes. Collections, refunds and payor retractions typically continue to occur for up to three years or longer after services are provided.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expect the range of our U.S. dialysis revenue estimating risk to be within 1% of revenue, which can represent as much as approximately 5% of our U.S. dialysis business&#8217;s operating income and adjusted operating income. Changes in estimates are reflected in the then-current financial statements based on on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Changes in revenue estimates for prior periods are separately disclosed and reported if material to the current reporting period and longer term trend analyses, and have not been significant.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for laboratory services, which are integrally related to our dialysis services, are recognized in the period services are provided at the estimated net realizable amounts to be received.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain fair value estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair value measurements and estimates affect, or potentially affect, a variety of elements in the Company's financial statements. Two of the elements most significantly impacted by fair value estimates are the Company's goodwill impairment assessments and remeasurements of its noncontrolling interests subject to put provisions balance.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but is assessed for impairment at least annually, or when changes in circumstances warrant. An impairment charge is recorded when and to the extent a reporting unit's carrying amount is determined to exceed its estimated fair value. Changes in circumstance that may trigger a goodwill impairment assessment for one of our business units can include, among others, changes in the legal environment, addressable market, business strategy, development or business plans, reimbursement structure or rates, operating performance, future prospects, relationships with partners, interest rates and/or market value indications for the subject business. We use a variety of factors to assess changes in the financial condition, future prospects and other circumstances for businesses subject to goodwill impairment assessment. However, these assessments and the related valuations can involve significant uncertainties and require significant judgment on various matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to remeasure its noncontrolling interests subject to put provisions to estimated fair value each reporting period. These estimates also require substantive judgment on meaningful uncertainties concerning this significant balance. See Notes 16 and 23 to the consolidated financial statements for a summary of the Company's approach to these valuations, the variables and uncertainties involved, and the sensitivity of these valuations to changes in a primary aggregate valuation metric.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management&#8217;s best assessment of estimated current and future taxes to be paid. We are subject to income taxes in the United States and numerous state and foreign jurisdictions, and changes in tax laws or regulations may be proposed or enacted that could adversely affect our overall tax liability. The actual impact of any such laws or regulations could be materially different from our current estimates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments and estimates are required in determining our consolidated income tax expense. Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, results of recent operations, and assumptions about the amount of future federal, state, and foreign pre-tax operating income adjusted for items that do not have tax consequences. The assumptions about future taxable income require significant judgments and are consistent with the plans and estimates we use to manage the underlying businesses. To the extent that recovery is not likely, a valuation allowance is established. The allowance is regularly reviewed and updated for changes in circumstances that would cause a change in judgment about the realizability of the related deferred tax assets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss contingencies.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 15 to the consolidated financial statements, we operate in a highly regulated industry and are party to various lawsuits, claims, qui tam suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from our obligation to self-report suspected violations of law), contract disputes and other legal proceedings.&#160;Assessments of such matters can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. We record accruals for loss contingencies on such matters to the extent that we determine an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. See Note 15 to the consolidated financial statements included in this report for further discussion.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_214"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant new accounting standards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 to the consolidated financial statements included in this report for information regarding certain recent financial accounting standards that have been issued by the Financial Accounting Standards Board (FASB).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_217"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk is the potential loss arising from adverse changes in market rates and prices, such as foreign currency exchange rates, interest rates and other relevant market rate or price changes. In the ordinary course of business, the Company is exposed to various market risks, including changes in foreign currency exchange and interest rates, and the Company regularly evaluates the exposure to such changes. The Company addresses its exposure to market risks, principally the market risks associated with changes in interest rates, through a controlled program of risk management that includes, from time to time, the use of derivative financial instruments such as interest rate cap agreements. The Company does not hold or issue derivative financial instruments for trading purposes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest rate sensitivity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash flows from operations and other sources of liquidity, including from amounts available under our current credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months. Our primary recurrent sources of liquidity are cash from operations and cash from borrowings.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One means of assessing exposure to debt-related interest rate changes is a duration-based analysis that measures the potential loss in net income resulting from a hypothetical increase in interest rates of 100 basis points across all variable rate maturities (referred to as a parallel shift in the yield curve). Under this model, with all else held constant, it is estimated that such an increase would have reduced net income by approximately $4.2 million, $4.8 million, and $21.4 million, net of tax and the effect of our interest rate caps, for the years ended December&#160;31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of our debt and interest rate cap agreements, see Note 12 to our consolidated financial statements at Part IV Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules" &#8211; Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as referred from Part II Item 8, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements and Supplementary Data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange rate sensitivity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our business is predominantly conducted in the U.S., we have developing operations in 13 other countries as well. For financial reporting purposes, the U.S. dollar is our reporting currency. However, the functional currencies of our operating businesses in other countries are typically those of the countries in which they operate. Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which our international operations are conducted affect our results of operations and financial position as reported in our consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have consolidated the balance sheets of our non-U.S. dollar denominated operations into U.S. dollars at the exchange rates prevailing at the balance sheet dates and have translated their revenues and expenses at average exchange rates during each period.&#160;Additionally, our individual subsidiaries are exposed to transactional risks mainly resulting from intercompany transactions between and among subsidiaries with different functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the invoicing or obligation currencies and the currency in which their local operations are conducted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our exposure to foreign exchange risk through the judgment of our international and corporate management teams.&#160;Our international operations constitute approximately 14% of our consolidated assets and approximately 8% of our consolidated revenues for the year ended December&#160;31, 2024, with no single country constituting more than 4% of consolidated assets.&#160;In addition, our unrealized foreign currency translation (losses) gains were approximately 9.9%, 5.5%, and 2.2% of our consolidated operating income for the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the relatively small size of our international operations, management does not consider our exposure to foreign exchange risk to be significant to the consolidated enterprise.&#160;As such, through December&#160;31, 2024, we have not engaged in transactions to hedge the exposure of our international transactions or net investments to foreign currency risk.&#160;</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_220"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Index to Financial Statements and Index to Financial Statement Schedules included at Part IV Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules."</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_223"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has established and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits pursuant to the Securities Exchange Act of 1934 (Exchange Act) as amended is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO) as appropriate to allow for timely decisions regarding required disclosures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO and CFO, of the effectiveness of the design and operation of the Company's disclosure controls and procedures in accordance with the Exchange Act requirements as of December&#160;31, 2024. Based upon that evaluation, the CEO and CFO concluded that the Company's disclosure controls and procedures were effective as required by the Exchange Act as of such date for our Exchange Act reports, including this report. Management recognizes that these controls and procedures can provide only reasonable assurance of desired outcomes, and that estimates and judgments are still inherent in the process of maintaining effective controls and procedures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in the Company's internal control over financial reporting that was identified during the evaluation that occurred during the fourth fiscal quarter of 2024 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_229"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-51"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-52"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-53"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-54">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarter ended December&#160;31, 2024.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_232"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_238"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to disclose any amendments or waivers to the Code of Ethics applicable to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions, on our website located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2002, we adopted a Corporate Governance Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and to all of our financial accounting and legal professionals who are directly or indirectly involved in the preparation, reporting and fair presentation of our financial statements and Exchange Act reports. The Code of Ethics is posted on our website, located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also maintain a Corporate Code of Conduct that applies to all of our employees, officers and directors, which is posted on our website.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Corporate Governance Guidelines all Board Committees including the Audit Committee, Nominating and Governance Committee and the Compensation Committee, which are composed solely of independent directors as defined within the listing standards of the New York Stock Exchange, have written charters that outline the committee&#8217;s purpose, goals, membership requirements and responsibilities. These charters are regularly reviewed and updated as necessary by our Board of Directors. All Board Committee charters as well as the Corporate Governance Guidelines are posted on our website located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other information required to be disclosed by this item will appear in, and is incorporated by reference from, the sections entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposal 1 Election of Directors"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Management"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2025 annual stockholder meeting.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_241"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will appear in, and is incorporated by reference from, the sections entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pay Ratio Disclosure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation of Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Interlocks and Insider Participation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" included in our definitive proxy statement relating to our 2025 annual stockholder meeting. The information required by Item&#160;407(e)(5) of Regulation S-K will appear in and is incorporated by reference from the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Report"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2025 annual stockholder meeting; however, this information shall not be deemed to be filed.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_244"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about our common stock that may be issued upon the exercise of stock-settled stock appreciation rights, restricted stock units, performance stock units and other rights under all of our existing equity compensation plans as of December&#160;31, 2024, which consist of our DaVita Inc. 2020 Incentive Award Plan, DaVita Healthcare Partners Inc. 2011 Incentive Award Plan and our DaVita Inc. Employee Stock Purchase Plan. The material terms of these plans are described in Note 17 to the consolidated financial statements.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan category (shares in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">shares&#160;to&#160;be issued upon&#160;exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of outstanding options, warrants and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price of outstanding options, warrants and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares remaining<br/>available&#160;for future issuance under&#160;equity<br/>compensation plans&#160;(excluding securities reflected&#160;in<br/>column&#160;(a))</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total of shares reflected in columns (a) and (c)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(c)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(d)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not requiring shareholder approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.02&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes 673 shares of common stock reserved for issuance in connection with performance share units at the maximum number of shares issuable thereunder.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;This weighted average excludes full value awards such as restricted stock units and performance share units.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information required to be disclosed by Item&#160;12 will appear in, and is incorporated by reference from, the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Management"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2025 annual stockholder meeting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_247"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will appear in, and is incorporated by reference from, the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships and Related Transactions"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2025 annual stockholder meeting.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_250"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will appear in, and is incorporated by reference from, the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposal 2 Ratification of the Appointment of our Independent Registered Public Accounting Firm"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2025 annual stockholder meeting. Our independent registered public accounting firm is <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-55">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-56">Seattle, WA, USA</ix:nonNumeric> PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-57">185</ix:nonNumeric>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_256"></div><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits, Financial Statement Schedules</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Documents filed as part of this Report:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1)&#160;Index to Financial Statements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:87.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_262">Management&#8217;s Report on Internal Control Over Financial Reporting</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_262">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_265">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_265">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_268">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_268">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_271">Consolidated Statements of Income for the years ended December&#160;31, 2024, 2023, and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_271">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_274">Consolidated Statements of Comprehensive Income for the years ended December&#160;31, 2024, 2023, and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_274">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_277">Consolidated Balance Sheets as of December&#160;31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_277">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_283">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2024, 2023, and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_283">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_286">Consolidated Statements of Equity for the years ended December&#160;31, 2024, 2023, and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_286">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_289">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_289">11</a></span></div></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(2)&#160;Exhibits</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth in the Exhibit Index that precedes the signature pages of this Annual Report on Form 10-K.</span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_259"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining an adequate system of internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and which includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the last fiscal year, the Company conducted an evaluation, under the oversight of the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company&#8217;s internal control over financial reporting. This evaluation was completed based on the criteria established in the report titled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our evaluation under the COSO framework, we have concluded that the Company&#8217;s internal control over financial reporting was effective as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s independent registered public accounting firm, KPMG LLP, has issued an attestation report on the Company&#8217;s internal control over financial reporting, which report is included in this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita Inc.:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of DaVita Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of income, comprehensive income, cash flows, and equity for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 13, 2025 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. dialysis patient service revenue recognition</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 2 to the consolidated financial statements, the Company recognized $11,366 million in U.S. dialysis patient service revenue for the year ended December 31, 2024. There are uncertainties associated with estimating U.S. dialysis patient service revenue, which generally take several years to resolve. As these estimates are refined over time, both positive and negative adjustments are recognized in the current period.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the recognition of the transaction price the Company expects to collect as a result of satisfying its performance obligations related to U.S. dialysis patient service revenue as a critical audit matter because it involves estimation that requires complex auditor judgment. The key assumptions and inputs used to estimate the transaction price relate to ongoing insurance coverage changes, differing interpretations of contract coverage, determination of applicable primary and secondary coverage, coordination of benefits, and varying patient characteristics impacting Medicare reimbursements. Changes to the key assumptions and inputs used in the application of the methodology may have a significant effect on the Company&#8217;s determination of the estimate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s U.S. dialysis patient service revenue recognition process, including controls related to the application of the methodology used to estimate the transaction price, and the key assumptions and inputs. We evaluated the Company&#8217;s key assumptions and inputs to estimate the transaction price the Company expects to collect as a result of satisfying its performance obligation by comparing key assumptions to historical collection experience, trends of refunds and payor payment adjustments, delays in the Company&#8217;s billing and collection process and regulatory compliance matters. Additionally, we compared U.S. dialysis patient service revenue related to the transaction price estimates recognized in prior periods to actual cash collections related to performance obligations satisfied in prior periods to analyze the Company&#8217;s ability to estimate the transaction price the Company expects to collect as a result of satisfying its performance obligations. We developed an estimate of U.S. dialysis patient service revenue recorded by the Company for the year ended December 31, 2024.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of legal proceedings and regulatory matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 15 to the consolidated financial statements, the Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, qui tam suits, governmental investigations, audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violation of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent an unfavorable outcome is probable, and the amount of the loss can be reasonably estimated.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of legal proceedings and regulatory matters as a critical audit matter. Due to the nature of the legal proceedings and regulatory matters, a high degree of subjectivity was required in evaluating the completeness of the Company&#8217;s population of legal proceedings and regulatory matters. Additionally, complex auditor judgment was required in evaluating the Company&#8217;s probability of outcome assessment, and related disclosures.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s legal proceedings and regulatory matters process. This includes controls over the Company&#8217;s determination of the completeness of the population of legal proceedings and regulatory matters, as well as controls over the Company&#8217;s probability of outcome assessment, and related disclosures. We tested existing legal proceedings and regulatory matters by reading certain written correspondence received from outside parties as well as reading certain written responses provided to outside parties. We read letters received directly from the Company&#8217;s external and internal legal counsel that described certain legal proceedings and regulatory matters. We involved forensic professionals with specialized skills and knowledge who inspected the Company&#8217;s compliance case log. Additionally, we assessed the completeness of the population of legal proceedings and regulatory matters and related disclosures by 1) inquiring of certain key executives and directors and 2) evaluating information received through procedures described above and through publicly available information about the Company, its competitors, and the industry.</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-bottom:10pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2000. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seattle, Washington</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;13, 2025</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_268"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita Inc.:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reportin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited DaVita Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of income, comprehensive income, cash flows, and equity for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements), and our report dated February 13, 2025 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seattle, Washington</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;13, 2025</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_271"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis patient service revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" format="ixt:num-dot-decimal" scale="3" id="f-58">12,260,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" format="ixt:num-dot-decimal" scale="3" id="f-59">11,574,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" format="ixt:num-dot-decimal" scale="3" id="f-60">11,176,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-61">555,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-62">565,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-63">433,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-64">12,815,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-65">12,140,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-66">11,609,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="f-67">8,598,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="f-68">8,319,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="f-69">8,209,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-70">1,538,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-71">1,473,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-72">1,355,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-73">723,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-74">745,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-75">732,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-76">26,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-77">27,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-78">26,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-80">26,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on changes in ownership interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-82">109,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-85">10,725,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-86">10,537,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-87">10,270,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-88">2,090,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-89">1,602,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-90">1,339,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-91">470,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-92">398,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-93">357,019</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt prepayment, extinguishment and modification costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:DebtPrepaymentExtinguishmentAndModificationCosts" format="ixt:num-dot-decimal" scale="3" id="f-94">19,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:DebtPrepaymentExtinguishmentAndModificationCosts" format="ixt:num-dot-decimal" scale="3" id="f-95">7,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:DebtPrepaymentExtinguishmentAndModificationCosts" format="ixt:fixed-zero" scale="3" id="f-96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-97">69,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-98">19,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-99">15,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-100">1,530,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-101">1,177,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-102">966,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-103">279,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-104">220,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-105">198,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-106">1,250,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-107">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-108">768,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="f-109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="f-110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-111">13,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-112">1,250,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-113">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-114">781,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-115">314,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-116">265,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-117">221,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">936,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-121">11.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-122">7.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-123">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-124">11.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-125">7.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-126">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income from continuing operations</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-127">10.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-128">7.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-129">5.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-130">10.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-131">7.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-132">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares for earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-133">84,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-134">90,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-135">92,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-136">87,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-137">93,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-138">95,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-139">936,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-140">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-141">546,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-144">13,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">936,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-147">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_274"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars in thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-148">1,250,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">781,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on interest rate cap agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-151">7,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-152">6,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-153">108,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of net realized gains into net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-154">43,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-155">77,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-156">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on defined benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-157">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains on foreign currency translation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-160">207,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-161">87,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-162">29,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of net realized gains into net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-163">14,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:fixed-zero" scale="3" id="f-164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:fixed-zero" scale="3" id="f-165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-166">258,712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-167">17,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-168">70,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-169">992,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-170">974,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-171">851,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-172">314,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-173">265,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-174">221,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-175">677,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-176">708,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-177">630,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_277"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-178">794,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-179">380,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-180">84,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-181">84,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-182">51,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-183">11,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-184">2,146,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-185">1,986,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-186">134,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-187">143,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-188">383,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-189">422,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-190">122,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-191">102,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-192">27,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-193">6,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-194">3,746,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-195">3,137,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-196">2,940,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-197">3,073,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-198">2,393,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-199">2,501,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net of accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-200">197,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-201">203,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-202">336,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-203">545,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-204">33,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-205">47,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-206">261,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-207">271,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-208">7,375,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-209">7,112,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-210">17,285,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-211">16,893,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-212">547,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-213">514,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-214">934,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-215">828,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-216">800,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-217">752,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-218">410,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-219">394,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-220">270,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-221">123,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-222">10,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-223">28,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-224">2,973,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-225">2,642,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-226">2,209,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-227">2,330,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-228">9,175,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-229">8,268,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-230">169,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-231">183,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-232">665,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-233">726,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-234">15,193,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-235">14,150,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-236">1,695,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-237">1,499,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-238">0.001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-239">5,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-240">none</ix:nonFraction> issued)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#cceeff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#cceeff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-243">0.001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-244">450,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-245">90,369</ix:nonFraction> and 80,536 shares</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;issued and outstanding at December&#160;31, 2024, respectively, and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-246">88,824</ix:nonFraction> shares issued</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and outstanding at December&#160;31, 2023)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-247">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-248">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-249">286,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-250">509,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-251">1,534,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-252">598,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock (<ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-253">9,833</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="3" id="f-254">zero</ix:nonFraction> shares, respectively)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="f-255">1,389,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:fixed-zero" scale="3" id="f-256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-257">310,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-258">52,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DaVita Inc. shareholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-259">121,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-260">1,056,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests not subject to put provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-261">274,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-262">187,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-263">395,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-264">1,244,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-265">17,285,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-266">16,893,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_283"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-274">1,250,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-275">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-276">781,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="f-277">723,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="f-278">745,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="f-279">732,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-281">26,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:DebtRefinancingCharges" format="ixt:num-dot-decimal" scale="3" id="f-283">12,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:DebtRefinancingCharges" format="ixt:num-dot-decimal" scale="3" id="f-284">7,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:DebtRefinancingCharges" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-286">102,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-287">112,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-288">95,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-289">57,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-290">39,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-291">75,669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investment loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="dva:AdjustmentIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-292">115,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="dva:AdjustmentIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-293">64,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="dva:AdjustmentIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-294">8,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on changes in ownership interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="3" id="f-295">109,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="3" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-cash losses and (gains), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-298">13,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-299">8,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-300">21,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-301">29,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-302">172,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-303">148,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-304">17,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-305">32,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-306">757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-307">36,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-308">43,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-309">27,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-310">67,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-311">5,792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-312">50,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-313">1,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-314">26,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-315">87,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-316">14,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-317">56,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-318">34,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-319">46,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-320">27,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-321">89,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-322">44,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-323">1,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-324">24,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-325">6,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-326">8,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-327">15,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-328">2,022,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-329">2,059,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-330">1,564,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-331">555,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-332">567,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-333">603,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-334">246,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-335">26,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-336">57,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from asset and business sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-337">25,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-338">30,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-339">117,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of debt investments held-to-maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-340">15,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-341">37,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-342">129,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of other debt and equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:PaymentsToAcquireOtherDebtAndEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-343">9,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:PaymentsToAcquireOtherDebtAndEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-344">9,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:PaymentsToAcquireOtherDebtAndEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-345">3,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from debt investments held-to-maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-346">22,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-347">99,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-348">71,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of other debt and equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-349">4,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-350">10,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-351">3,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-352">5,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-353">276,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-354">31,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="f-355">6,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="f-356">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="f-357">3,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="3" id="f-360">782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-361">771,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-362">771,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-363">630,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-364">6,624,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-365">2,468,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-366">2,393,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments on long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-367">5,515,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-368">3,020,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-369">2,404,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred and debt related financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:DebtFinancingAndDebtRedemptionCosts" format="ixt:num-dot-decimal" scale="3" id="f-370">50,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:DebtFinancingAndDebtRedemptionCosts" format="ixt:num-dot-decimal" scale="3" id="f-371">69,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:DebtFinancingAndDebtRedemptionCosts" scale="3" id="f-372">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-373">1,385,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-374">272,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-375">802,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-376">337,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-377">280,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-378">267,946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock under employee stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:NetProceedsFromIssuanceOfStockToEmployees" format="ixt:num-dot-decimal" scale="3" id="f-379">20,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:NetProceedsFromIssuanceOfStockToEmployees" format="ixt:num-dot-decimal" scale="3" id="f-380">16,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:NetProceedsFromIssuanceOfStockToEmployees" format="ixt:num-dot-decimal" scale="3" id="f-381">18,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of tax withholdings on net share settlements of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-382">134,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-383">65,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-384">55,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-385">14,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-386">14,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-387">14,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of additional noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="f-388">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-389">50,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-390">3,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-391">53,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-392">12,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-393">20,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-394">816,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-395">1,170,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-396">1,121,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-397">18,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-398">8,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-399">29,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-400">415,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-401">125,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-402">215,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-403">464,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-404">338,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-405">554,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-406">879,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-407">464,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-408">338,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_286"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands)</span></div><div><span><br/></span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.759%"><tr><td style="width:1.0%"/><td style="width:19.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.216%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling<br/>interests<br/>subject to put<br/>provisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">DaVita Inc. Shareholders' Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling interests not<br/>subject to<br/>put provisions</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-409">1,434,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-410">97,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-411">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-412">540,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-413">354,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-416">139,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-417">755,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-418">180,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="f-419">151,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-420">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-421">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-422">69,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-423">70,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-424">70,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-425">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="f-426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-427">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-428">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock award plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-429">932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-430">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-431">55,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-432">55,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-settled stock-based<br/>&#160;compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-433">95,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-434">95,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in noncontrolling<br/>&#160;interest from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-435">176,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-436">90,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-437">10,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dva:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="f-438">3,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="dva:TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-439">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-440">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-441">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-442">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Partial purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="dva:TemporaryEquityDecreasePurchaseOfInterests" format="ixt:num-dot-decimal" scale="3" id="f-443">11,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-444">6,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-445">6,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-446">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-447">62,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-448">62,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-449">62,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:TemporaryEquityOtherChanges" scale="3" id="f-450">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" scale="3" id="f-452">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-453">8,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-454">787,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-455">787,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-456">8,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="f-457">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-458">47,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-459">740,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-460">8,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-461">787,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-463">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-464">90,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-465">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-466">606,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-467">174,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-470">69,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-471">712,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-472">163,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="f-473">176,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-474">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-475">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-476">88,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-477">17,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-478">17,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-479">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-481">18,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-482">18,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock award plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-483">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-484">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-485">65,014</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-486">65,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-settled stock-based<br/>&#160;compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-487">109,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-488">109,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in noncontrolling<br/>&#160;interest from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-489">184,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-490">96,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-491">12,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="dva:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="f-492">1,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-493">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-494">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-495">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-496">30,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Partial purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="dva:TemporaryEquityDecreasePurchaseOfInterests" format="ixt:num-dot-decimal" scale="3" id="f-497">5,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-498">5,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-499">5,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-500">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-501">149,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-502">149,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-503">149,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-504">2,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-505">285,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-506">285,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-507">2,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="f-508">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-509">17,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-510">267,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-511">2,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-512">285,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-514">1,499,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-515">88,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-516">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-517">509,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-518">598,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-521">52,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-522">1,056,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-523">187,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY - continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.743%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.743%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.049%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling<br/>interests<br/>subject to put<br/>provisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">DaVita Inc. Shareholders' Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling interests not<br/>subject to<br/>put provisions</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-524">1,499,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-525">88,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-526">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-527">509,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-528">598,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-531">52,084</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-532">1,056,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-533">187,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="f-534">214,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-535">936,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-536">936,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-537">99,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-538">258,712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-539">258,712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-540">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-55" xsi:nil="true" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="f-541"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-542">20,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-543">20,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock award plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-544">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-545">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-546">134,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-547">134,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-settled stock-based<br/>&#160;compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-548">99,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-549">99,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in noncontrolling<br/>&#160;interest from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-550">226,389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-551">110,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-552">11,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="dva:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="f-553">2,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-554">38,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-555">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-556">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-557">95,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Partial purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="dva:TemporaryEquityDecreasePurchaseOfInterests" format="ixt:num-dot-decimal" scale="3" id="f-558">49,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-559">3,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-560">3,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-561">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-562">206,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-563">206,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-564">206,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-565">9,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-566">1,389,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-567">1,389,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-568">1,695,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-569">90,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-570">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-571">286,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-572">1,534,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-573">9,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-574">1,389,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-575">310,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-576">121,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-577">274,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_289"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_292"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-578" continuedAt="f-578-1" escape="true">Organization and summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="f-578-1" continuedAt="f-578-2"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are composed of its dialysis and related lab services to patients in the United States (its U.S. dialysis business), its U.S. integrated kidney care (IKC) business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support functions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s largest line of business is its U.S. dialysis business, which operates kidney dialysis centers in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease or end stage kidney disease (ESRD or ESKD). As of December&#160;31, 2024, the Company operated or provided administrative services through a network of <ix:nonFraction unitRef="clinic" contextRef="c-66" decimals="INF" name="dva:NumberOfSites" format="ixt:num-dot-decimal" scale="0" id="f-579">2,657</ix:nonFraction> U.S. outpatient dialysis centers in <ix:nonFraction unitRef="state" contextRef="c-66" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="f-580">46</ix:nonFraction> states and the District of Columbia, serving a total of approximately <ix:nonFraction unitRef="patient" contextRef="c-67" decimals="0" name="dva:NumberOfCustomers" format="ixt:num-dot-decimal" scale="0" id="f-581">200,800</ix:nonFraction> patients. In addition, as of December&#160;31, 2024, the Company operated or provided administrative services to a total of <ix:nonFraction unitRef="clinic" contextRef="c-68" decimals="INF" name="dva:NumberOfSites" scale="0" id="f-582">509</ix:nonFraction> outpatient dialysis centers serving approximately <ix:nonFraction unitRef="patient" contextRef="c-69" decimals="0" name="dva:NumberOfCustomers" format="ixt:num-dot-decimal" scale="0" id="f-583">80,300</ix:nonFraction> patients located in <ix:nonFraction unitRef="country" contextRef="c-68" decimals="INF" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="f-584">13</ix:nonFraction> countries outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-585" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#8217;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#8217;s international subsidiaries from their functional currencies into the Company&#8217;s reporting currency (the U.S. dollar, or USD).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-586" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, certain fair value estimates, accounting for income taxes and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock" id="f-587" continuedAt="f-587-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis patient service revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized based on the Company&#8217;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's revenues are paid from government programs, principally Medicare, Medicare Advantage and Medicaid. Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-587-1" continuedAt="f-587-2"><ix:continuation id="f-578-2" continuedAt="f-578-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., <ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" scale="-2" id="f-588">80</ix:nonFraction>% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare&#8217;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#8217;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#8217;s base payment rate as well as these other variable factors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues earned under government programs are subject to significant estimating risk, as they can be subject to adjustment as a result of examination by government agencies or contractors, differing interpretations of applicable regulations by different Medicare contractors or regulatory authorities, differing opinions regarding a patient's diagnosis or the medical necessity of patient services, or retroactive applications or interpretations of governmental requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to government programs, the Company also earns revenues that are paid by commercial health plans. Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#8217;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#8217;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#8217;s usual and customary rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, there are significant risks associated with estimating dialysis patient service revenue, whether paid from governmental or commercial sources, many of which take several years to resolve. These estimates are subject to examinations by or differing interpretations among government contractors or agencies or other regulatory authorities, retroactive application of interpretations, commercial insurance coverage changes, geographic coverage differences, differing interpretations of commercial contract coverage and other payor- and patient-specific issues, including determination of applicable primary and secondary coverage, changes in patient insurance coverage and coordination of benefits. As the Company's revenue estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-578-3" continuedAt="f-578-4"><ix:continuation id="f-587-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="dva:OtherNonoperatingIncomeExpensePolicyTextBlock" id="f-589" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (loss) income, net</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-590" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-591" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash and equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-592" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in debt and equity securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#8217;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-593" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-594" continuedAt="f-594-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes expenditures to purchase property and equipment, improvements thereon, leasehold improvements, and qualifying software costs, as well as costs to replace, extend the life of or improve the functionality of existing capital assets, where such purchases and costs have an expected benefit period of more than one year. All other expenditures related to capital assets are expensed as incurred (i.e., as repairs and maintenance expense).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-578-4" continuedAt="f-578-5"><ix:continuation id="f-594-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-595" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-596" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortizable intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="f-597" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-578-5" continuedAt="f-578-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-598" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method and other investments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-599" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates multiple reporting units. The Company's annual impairment assessment is performed in the third quarter for its U.S. dialysis reporting unit and at various points throughout the year for its other reporting units. In addition to these annual impairment assessments, the Company performs impairment assessments at intervening periods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when a reporting unit is considered at risk of significant goodwill impairment.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing these assessments, the Company may first assess goodwill for impairment qualitatively as determined appropriate. If goodwill is more likely than not impaired, the Company is required to perform a quantitative assessment. When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm, which consider both discounted cash flow estimates for the subject business and observed market multiples for similar businesses, or recent good-faith offer prices received for the subject business that would be acceptable to the Company. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value after taking into account the effect of deferred taxes arising from the impairment. See Note 9 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dva:InsuranceAndSelfInsurancePolicyTextBlock" id="f-600" continuedAt="f-600-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-insurance</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-600-1">The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#8217; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-601" continuedAt="f-601-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-578-6" continuedAt="f-578-7"><ix:continuation id="f-601-1" continuedAt="f-601-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-602" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation to be settled in shares is recorded to the Company&#8217;s shareholders&#8217; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-603" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="f-604" continuedAt="f-604-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests represent third-party equity interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2024, third parties held direct or indirect noncontrolling equity interests in <ix:nonFraction unitRef="entity" contextRef="c-6" decimals="INF" name="dva:NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" scale="0" id="f-605">728</ix:nonFraction> consolidated legal entities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-606" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-607" continuedAt="f-607-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New accounting standards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards recently adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-607-1"><ix:continuation id="f-578-7"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment&#8217;s performance. The amendments in this ASU became effective for the Company beginning January 1, 2024. See Note 24 for further discussion of the Company's reportable segments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards not yet adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company intends to adopt this ASU for the fiscal year ended December 31, 2025 and is still assessing the effect this guidance may have on its consolidated financial statement disclosures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which requires disaggregated disclosure of income statement expenses, including purchases of inventory, employee compensation, depreciation, and amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this ASU are effective for fiscal years beginning after December 15, 2026. The amendments in this ASU may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_295"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-608" continuedAt="f-608-1" escape="true">Revenue recognition and accounts receivable</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-609" escape="true"><ix:continuation id="f-608-1" continuedAt="f-608-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues by segment and primary payor source were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-610">6,374,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-611">6,374,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-612">863,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-613">863,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-614">343,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-615">717,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-616">1,061,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-617">3,783,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-618">248,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-619">4,031,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-620">463,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-621">463,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:OtherIncome" scale="3" id="f-622">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:OtherIncome" scale="3" id="f-623">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-624">21,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-625">21,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-626">24,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-627">58,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-628">83,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" sign="-" name="dva:EliminationsOfIntersegmentRevenues" format="ixt:num-dot-decimal" scale="3" id="f-629">71,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" sign="-" name="dva:EliminationsOfIntersegmentRevenues" format="ixt:num-dot-decimal" scale="3" id="f-630">13,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" sign="-" name="dva:EliminationsOfIntersegmentRevenues" format="ixt:num-dot-decimal" scale="3" id="f-631">85,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="dva:TotalRevenueNetOfIntersegmentRevenue" format="ixt:num-dot-decimal" scale="3" id="f-632">11,318,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="dva:TotalRevenueNetOfIntersegmentRevenue" format="ixt:num-dot-decimal" scale="3" id="f-633">1,496,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:TotalRevenueNetOfIntersegmentRevenue" format="ixt:num-dot-decimal" scale="3" id="f-634">12,815,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-635">6,100,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-636">6,100,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-637">833,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-638">833,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-639">354,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-640">500,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-641">854,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-642">3,623,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-643">251,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-644">3,874,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-645">460,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-646">460,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-647">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-648">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-649">32,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-650">32,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-651">25,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-652">52,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-653">78,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" sign="-" name="dva:EliminationsOfIntersegmentRevenues" format="ixt:num-dot-decimal" scale="3" id="f-654">88,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" sign="-" name="dva:EliminationsOfIntersegmentRevenues" format="ixt:num-dot-decimal" scale="3" id="f-655">7,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="dva:EliminationsOfIntersegmentRevenues" format="ixt:num-dot-decimal" scale="3" id="f-656">96,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="dva:TotalRevenueNetOfIntersegmentRevenue" format="ixt:num-dot-decimal" scale="3" id="f-657">10,848,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="dva:TotalRevenueNetOfIntersegmentRevenue" format="ixt:num-dot-decimal" scale="3" id="f-658">1,291,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:TotalRevenueNetOfIntersegmentRevenue" format="ixt:num-dot-decimal" scale="3" id="f-659">12,140,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-660">6,041,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-661">6,041,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-662">759,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-663">759,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-664">336,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-665">464,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-666">801,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-667">3,437,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-668">223,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-669">3,660,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-670">345,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-671">345,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-672">1,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-673">1,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-674">22,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-675">22,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-676">24,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-677">44,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-678">68,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" sign="-" name="dva:EliminationsOfIntersegmentRevenues" format="ixt:num-dot-decimal" scale="3" id="f-679">87,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="dva:EliminationsOfIntersegmentRevenues" format="ixt:num-dot-decimal" scale="3" id="f-680">4,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" sign="-" name="dva:EliminationsOfIntersegmentRevenues" format="ixt:num-dot-decimal" scale="3" id="f-681">91,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="dva:TotalRevenueNetOfIntersegmentRevenue" format="ixt:num-dot-decimal" scale="3" id="f-682">10,512,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="dva:TotalRevenueNetOfIntersegmentRevenue" format="ixt:num-dot-decimal" scale="3" id="f-683">1,097,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:TotalRevenueNetOfIntersegmentRevenue" format="ixt:num-dot-decimal" scale="3" id="f-684">11,609,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-608-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. IKC business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its IKC business, the Company recognized revenues for performance obligations satisfied in previous years of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="3" id="f-685">116,336</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="3" id="f-686">94,361</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="3" id="f-687">34,600</ix:nonFraction> during the years ended December&#160;31, 2024, 2023 and 2022, respectively. The delay in recognition of these amounts resulted predominantly from measurement limitations and recognition constraints on both the Company's VBC contracts with health plans, many of which are complex and relatively new arrangements, as well as its government Comprehensive Kidney Care Contracting (CKCC) program. The Company's revenue recognition for its government CKCC program also remains heavily constrained for plan year 2024. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Other revenues"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Company's accounting for these value-based care arrangements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="INF" name="dva:NumberOfConcentrationRiskCustomers" format="ixt:fixed-zero" scale="0" id="f-688">No</ix:nonFraction> single commercial payor accounted for more than <ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-689">10</ix:nonFraction>% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively.&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-690">833,464</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-691">817,045</ix:nonFraction> as of December&#160;31, 2024 and 2023, respectively. Approximately <ix:nonFraction unitRef="number" contextRef="c-133" decimals="INF" name="dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue" scale="-2" id="f-692">23</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-134" decimals="INF" name="dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue" scale="-2" id="f-693">19</ix:nonFraction>% of the Company&#8217;s U.S. dialysis accounts receivable balances as of December&#160;31, 2024 and 2023, respectively, were more than <ix:nonNumeric contextRef="c-135" name="dva:AccountsReceivablePeriodOutstanding" format="ixt-sec:durwordsen" id="f-694"><ix:nonNumeric contextRef="c-136" name="dva:AccountsReceivablePeriodOutstanding" format="ixt-sec:durwordsen" id="f-695">six months</ix:nonNumeric></ix:nonNumeric> old. There were <ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="f-696">no</ix:nonFraction> significant balances over <ix:nonNumeric contextRef="c-133" name="us-gaap:AccountsReceivableNoncurrentThresholdPeriodPastDue" format="ixt-sec:durwordsen" id="f-697">one year</ix:nonNumeric> old at December&#160;31, 2024. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_301"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-702" continuedAt="f-702-1" escape="true">Earnings&#160;per share</ix:nonNumeric></span></div><ix:continuation id="f-702-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-703" escape="true"><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-704" escape="true"><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-705">936,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-706">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-707">546,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-710">13,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-711">936,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-712">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-713">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-714">84,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-715">90,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-716">92,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed incremental from stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-717">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-718">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-719">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-720">87,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-721">93,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-722">95,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-723">11.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-724">7.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-725">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-728">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-729">11.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-730">7.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-731">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-732">10.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-733">7.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-734">5.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-737">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-738">10.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-739">7.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-740">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock-settled awards excluded from calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-741">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-742">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-743">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_304"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-744" continuedAt="f-744-1" escape="true">Short-term and long-term investments</ix:nonNumeric></span></div><ix:continuation id="f-744-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-745" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit and other time deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-746">44,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-748">44,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-749">22,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-750">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-751">22,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in mutual funds and common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="f-752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-753">40,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-754">40,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="f-755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-756">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-757">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-758">44,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-759">40,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-760">84,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-761">22,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-762">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-763">59,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-764">44,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-765">6,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-766">51,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-767">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-768">4,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-769">11,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-771">33,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-772">33,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-773">14,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-774">32,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-775">47,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-776">44,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-777">40,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-778">84,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-779">22,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-780">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-781">59,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-782" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. Typically, the Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2024 and 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#8217;s non-qualified deferred compensation plans.</span></div></ix:nonNumeric></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_307"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="f-783" continuedAt="f-783-1" escape="true">Other receivables</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="dva:ScheduleOfOtherReceivablesTableTextBlock" id="f-784" escape="true"><ix:continuation id="f-783-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"><tr><td style="width:1.0%"/><td style="width:56.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare bad debt claims</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-785">107,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-786">107,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IKC risk-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-787">143,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-788">127,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier rebates and non-trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-789">132,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-790">187,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-791">383,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-792">422,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_310"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-793" continuedAt="f-793-1" escape="true">Property and equipment</ix:nonNumeric></span></div><ix:continuation id="f-793-1" continuedAt="f-793-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-794" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.467%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="f-795">50,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="f-796">35,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-797">428,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-798">436,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-799">4,180,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-800">4,058,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and information systems, including internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-801">4,410,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-802">4,125,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New center and capital asset projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-803">133,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-804">177,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-805">9,203,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-806">8,833,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-807">6,262,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-808">5,759,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-809">2,940,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-810">3,073,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, <ix:nonNumeric contextRef="c-152" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-811">25</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-153" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-812">40</ix:nonNumeric> years; leasehold improvements, the shorter of <ix:nonNumeric contextRef="c-154" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-813">ten years</ix:nonNumeric> or the expected lease term; and equipment and information systems, including internally developed software, principally <ix:nonNumeric contextRef="c-155" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-814">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-156" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-815">15</ix:nonNumeric> years. Depreciation expense on property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-816">716,396</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-817">736,474</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-818">721,133</ix:nonFraction> for 2024, 2023 and 2022, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-793-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="f-819">7,978</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="f-820">9,178</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="f-821">12,677</ix:nonFraction> for 2024, 2023 and 2022, respectively.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_313"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-822" continuedAt="f-822-1" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="f-822-1" continuedAt="f-822-2"><ix:nonNumeric contextRef="c-1" name="dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" id="f-823" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"><tr><td style="width:1.0%"/><td style="width:59.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.768%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.282%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-824">146,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-825">153,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedNoncompeteAgreementsGross" format="ixt:num-dot-decimal" scale="3" id="f-826">22,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedNoncompeteAgreementsGross" format="ixt:num-dot-decimal" scale="3" id="f-827">31,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-828">61,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-829">56,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-830">229,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-831">241,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-832">13,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-833">23,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-834">18,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-835">14,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-836">197,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-837">203,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompetition agreements are generally amortized over <ix:nonNumeric contextRef="c-161" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:durwordsen" id="f-838">four years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-162" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-839">10</ix:nonNumeric> years and customer relationships are principally amortized over <ix:nonNumeric contextRef="c-163" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-840">10</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-164" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-841">20</ix:nonNumeric> years. The weighted average renewal or extension period of customer relationships was <ix:nonNumeric contextRef="c-165" name="us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" format="ixt-sec:durwordsen" id="f-842">three years</ix:nonNumeric> and <ix:nonNumeric contextRef="c-166" name="us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" format="ixt-sec:durwordsen" id="f-843">two years</ix:nonNumeric> as of December&#160;31, 2024 and 2023, respectively. Amortization expense from amortizable intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-844">7,464</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-845">8,969</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-846">11,469</ix:nonFraction> for 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-847">no</ix:nonFraction> impairment charges on any intangible assets other than goodwill. See Note 9 for further information regarding goodwill.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-848" continuedAt="f-848-1" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2024 were as follows:&#160;</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><ix:continuation id="f-848-1"><ix:continuation id="f-822-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"/><td style="width:37.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.029%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncompetition<br/>agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Customer relationships and other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-849">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-850">4,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-851">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-852">4,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-853">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-854">3,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-855">956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-856">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="f-857">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-858">3,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-859">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-860">23,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-861">8,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-862">43,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:27pt"><span><br/></span></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_319"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="f-866" continuedAt="f-866-1" escape="true">Equity method and other investments</ix:nonNumeric></span></div><ix:continuation id="f-866-1" continuedAt="f-866-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsTextBlock" id="f-867" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"/><td style="width:56.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.612%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mozarc Medical Holding LLC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-868">215,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-869">324,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:fixed-zero" scale="3" id="f-870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-871">98,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity method partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-872">99,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-873">107,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost method and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-874">21,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-875">14,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-876">336,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-877">545,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, 2023 and 2022, the Company recognized equity investment income of $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-878">26,189</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-879">27,864</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-880">26,520</ix:nonFraction>, respectively, from its equity method investments in nonconsolidated dialysis partnerships.&#160;The Company also recognized equity investment losses from other equity method investments of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" sign="-" name="dva:IncomeLossFromOtherEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-881">112,696</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" sign="-" name="dva:IncomeLossFromOtherEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-882">59,508</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" sign="-" name="dva:IncomeLossFromOtherEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-883">4,703</ix:nonFraction> in other loss, net during 2024, 2023 </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-866-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective <ix:nonNumeric contextRef="c-181" name="dva:BusinessAgreementEffectiveClosingDate" format="ixt:date-monthname-day-year-en" id="f-884">April&#160;1, 2023</ix:nonNumeric>, the Company formed a new, independent kidney care-focused medical device company (Mozarc Medical Holding LLC, or Mozarc) with Medtronic, Inc. (Medtronic). The Company holds a <ix:nonFraction unitRef="number" contextRef="c-182" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-885">50</ix:nonFraction>% voting equity interest in Mozarc and Medtronic holds the other <ix:nonFraction unitRef="number" contextRef="c-182" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-886">50</ix:nonFraction>% voting equity interest. The Company does not maintain a controlling financial interest in Mozarc and accounts for this investment on the equity method, with equity method income or loss recognized in other loss, net, on a one-month lag.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investment in Mozarc was recorded at a cumulative measured cost of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="3" id="f-887">370,740</ix:nonFraction>, which includes the value of contingent consideration payable to Medtronic of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="dva:FairValuePayableOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-888">86,200</ix:nonFraction>. As of December&#160;31, 2024, the book value of the Company's contingent consideration payable to Medtronic approximates its estimated fair value, which is based on level 3 inputs.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also holds a <ix:nonFraction unitRef="number" contextRef="c-169" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-889">75</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">voting and economic interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV) and an unrelated noncontrolling investor holds the other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-169" decimals="2" name="dva:OwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-890">25</ix:nonFraction>% voting and economic interest in the joint venture. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to November 1, 2024, the Company did not control or consolidate the APAC JV as a result of substantive participating rights retained by the unrelated investor over certain key operating decisions for the joint venture. Effective November 1, 2024, the third-party rights that blocked the Company's ultimate unilateral operating control of this business were removed, resulting in the Company's consolidation of this business. See Note 20 for further information.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other equity method investments include <ix:nonFraction unitRef="number" contextRef="c-184" decimals="INF" name="dva:NumberOfPartnerships" scale="0" id="f-891">17</ix:nonFraction> legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. dialysis partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, and are often subject to blocking rights on certain key operating decisions held by outside investors, but mostly range from <ix:nonFraction unitRef="number" contextRef="c-185" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-892">30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-186" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-893">65</ix:nonFraction>%. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-894"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-895">no</ix:nonFraction></ix:nonFraction> significant investment impairments or other valuation adjustments for the years ended December 31, 2024 and 2023. For the year ended December&#160;31, 2022, the Company recognized impairments and other valuation adjustments on the Company's adjusted cost method and other investments of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="f-896">20,154</ix:nonFraction> in other loss, net.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_325"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillDisclosureTextBlock" id="f-897" continuedAt="f-897-1" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-897-1" continuedAt="f-897-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-898" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill by reportable segment were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:40.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary<br/>services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-899">6,416,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-900">659,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-901">7,076,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="f-902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-903">25,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-904">25,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-906">26,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-907">26,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="f-908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-909">36,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-910">36,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-911">6,416,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-912">695,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-913">7,112,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-914">102,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-915">246,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-916">349,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="f-917">1,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="f-918">1,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="f-919">3,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="f-920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-921">83,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-922">83,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-923">6,517,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-924">857,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-925">7,375,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="f-926">6,517,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="f-927">999,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="f-928">7,517,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-930">141,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-931">141,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-932">6,517,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-933">857,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-934">7,375,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company&#8217;s operating segments described in Note 24 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-897-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied a similar aggregation to the dialysis centers within each of its international reporting units. For the Company&#8217;s other operating segments, discrete business components below the operating segment level constitute individual reporting units.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed various annual impairment assessments during the year ended December&#160;31, 2024, with no impairment indicated. <ix:nonFraction unitRef="segments" contextRef="c-193" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt:fixed-zero" scale="0" id="f-935">None</ix:nonFraction>&#160;of the Company&#8217;s reporting units were considered at risk of significant goodwill impairment as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company performed its annual impairment assessment of its transplant software reporting unit and recognized a goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-936">26,083</ix:nonFraction> in that reporting unit, or $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:GoodwillImpairmentLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-937">19,575</ix:nonFraction> net of tax. This charge resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate. After this impairment charge, the transplant software reporting unit had a goodwill balance of $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-938">14,424</ix:nonFraction> remaining.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_328"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="f-939" continuedAt="f-939-1" escape="true">Other liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherLiabilitiesTableTextBlock" id="f-940" escape="true"><ix:continuation id="f-939-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"><tr><td style="width:1.0%"/><td style="width:51.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.759%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor refunds and retractions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:PayorRefundsAndRetractions" format="ixt:num-dot-decimal" scale="3" id="f-941">484,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:PayorRefundsAndRetractions" format="ixt:num-dot-decimal" scale="3" id="f-942">448,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance and self-insurance accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="f-943">83,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="f-944">74,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-945">60,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-946">35,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-947">59,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-948">47,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-949">247,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-950">222,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-951">934,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-952">828,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_331"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-953" continuedAt="f-953-1" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="f-953-1" continuedAt="f-953-2"><ix:continuation id="f-601-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-954" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes from continuing operations consisted of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:37.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-955">1,374,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-956">1,100,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-957">926,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-958">155,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-959">76,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-960">39,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-961">1,530,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-962">1,177,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-963">966,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-953-2" continuedAt="f-953-3"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-964" continuedAt="f-964-1" escape="true">Income tax expense for continuing operations consisted of the following:</ix:nonNumeric></span></div><ix:continuation id="f-964-1"><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"/><td style="width:46.460%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-965">253,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-966">200,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-967">201,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-968">52,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-969">38,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-970">55,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-971">31,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-972">21,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-973">16,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-974">337,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-975">259,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-976">273,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-977">47,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-978">40,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-979">66,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-980">2,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-981">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-982">12,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-983">7,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-984">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-985">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-986">57,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-987">39,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-988">75,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-989">279,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-990">220,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-991">198,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-992" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company&#8217;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"/><td style="width:46.460%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-993">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-994">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-995">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-996">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-997">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-998">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-999">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1000">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1001">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="f-1002">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="f-1003">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="f-1004">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Political advocacy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1005">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1006">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1007">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-1008">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-1009">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-1010">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in international valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1011">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1012">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1013">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1014">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1015">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1016">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1017">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1018">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1019">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests primarily<br/>&#160;attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1020">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1021">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1022">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1023">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1024">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1025">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-953-3" continuedAt="f-953-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1026" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:60.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:DeferredTaxAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1027">37,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:DeferredTaxAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1028">23,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1029">74,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1030">81,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1031">508,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1032">533,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1033">161,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1034">183,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1035">4,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:fixed-zero" scale="3" id="f-1036">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1037">54,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1038">52,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1039">840,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1040">873,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1041">107,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1042">113,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1043">732,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1044">760,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1045">757,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1046">731,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1047">63,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1048">127,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:DeferredTaxLiabilitiesOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1049">464,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:DeferredTaxLiabilitiesOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1050">486,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestments" format="ixt:fixed-zero" scale="3" id="f-1051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1052">19,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1053">66,035</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1054">87,918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1055">1,352,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1056">1,452,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1057">619,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1058">691,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1059">665,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1060">726,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other long-term assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1061">46,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1062">34,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 25.75pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1063">619,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1064">691,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the Company had federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1065">44,248</ix:nonFraction> that expire through 2036, although a substantial amount expire by 2029. The Company also had state net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1066">555,691</ix:nonFraction>, some of which have an indefinite life, while a substantial amount expire by 2044. Additionally, the Company had international net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1067">410,313</ix:nonFraction>, some of which will begin to expire in 2026, though the majority have an indefinite life. The Company has a state capital loss carryover of $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-1068">9,653</ix:nonFraction>, the majority of which will expire in 2025. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. A valuation allowance is recorded to account for the unrealizable balances in the table above. The net decrease of $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-1069">5,285</ix:nonFraction> in the valuation allowance is primarily due to unutilized state capital losses that expired in the current year.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains indefinitely reinvested in several of the foreign jurisdictions in which it operates as of December&#160;31, 2024. As a result of the passage of the Tax Cuts and Jobs Act (2017 Tax Act), the Company does not expect any significant taxes to be incurred if such earnings were remitted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized tax benefits</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1070" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"/><td style="width:61.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1071">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1072">63,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1073">3,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1074">4,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1075">1,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1076">7,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to lapse of applicable statute</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="3" id="f-1077">8,309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="3" id="f-1078">5,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="f-1079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="3" id="f-1080">7,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1081">41,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1082">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-953-4"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company&#8217;s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1083">41,484</ix:nonFraction>. Of this balance, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1084">27,336</ix:nonFraction> would impact the Company&#8217;s effective tax rate if recognized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. We recognized a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="f-1085">679</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="f-1086">138</ix:nonFraction> related to interest and penalties net of federal tax benefit within tax expense in 2024 and 2023, respectively. At December&#160;31, 2024 and December 31, 2023, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="3" id="f-1087">5,846</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="3" id="f-1088">6,525</ix:nonFraction>, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are under examination in various state, local and foreign tax jurisdictions. In 2022, the Company was able to reach a settlement with the IRS for tax years 2014-2015. Subsequent to the settlement, the Company filed a 2014 refund claim with respect to a contested issue that was included in the IRS examination. During 2023 the IRS denied the refund claim and the Company has until September 2025 to appeal. Except for the 2014 refund claim, the Company is no longer subject to U.S. federal examinations prior to 2021.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_337"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LongTermDebtTextBlock" id="f-1127" continuedAt="f-1127-1" escape="true">Long-term debt</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-1128" continuedAt="f-1128-1" escape="true"><ix:continuation id="f-1127-1" continuedAt="f-1127-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt comprised the following:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:39.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan A-1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1129">2,259,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1130">1,234,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-212" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1131"><ix:nonNumeric contextRef="c-213" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1132"><ix:nonNumeric contextRef="c-213" name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" format="ixt:date-month-day-year" id="f-1133">4/28/2028</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Base +1.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1134">2,256,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan B-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:fixed-zero" scale="3" id="f-1135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1136">2,603,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="f-1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Extended Term Loan B-1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1138">1,636,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-217" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1139">5/9/2031</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-218" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="f-1140">SOFR + 2.00%</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1141">1,638,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:fixed-zero" scale="3" id="f-1142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:fixed-zero" scale="3" id="f-1143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-221" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1144">4/28/2028</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Base +1.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" format="ixt:fixed-zero" scale="3" id="f-1145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1146">2,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1147">2,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-224" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1148">6/1/2030</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1149">4.625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1150">2,533,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75% Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1151">1,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1152">1,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-227" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1153">2/15/2031</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-227" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1154">3.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1155">1,301,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.875% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1156">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-229" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1157"><ix:nonNumeric contextRef="c-230" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1158">9/1/2032</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1159">6.875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1160">1,007,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisition obligations and other notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="dva:AcquisitionObligationsAndOtherNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-1161">56,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="dva:AcquisitionObligationsAndOtherNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-1162">102,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-233" name="us-gaap:DebtInstrumentMaturityDateDescription" id="f-1163">2025-2038</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="f-1164">5.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="dva:AcquisitionObligationsAndOtherNotesPayableFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1165">56,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1166">216,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1167">255,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-236" name="us-gaap:DebtInstrumentMaturityDateDescription" id="f-1168">2025-2039</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">CHC temporary funding assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="dva:CHCTemporaryFundingAssistance" format="ixt:num-dot-decimal" scale="3" id="f-1169">92,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-238" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" format="ixt:fixed-zero" scale="-2" id="f-1170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="dva:CHCTemporaryFundingAssistanceFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1171">92,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total debt principal outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1172">9,511,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1173">8,445,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Discount, premium and deferred financing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:DiscountPremiumAndDeferredFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-1174">64,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:DiscountPremiumAndDeferredFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-1175">54,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="f-1176">9,446,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="f-1177">8,391,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1178">270,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1179">123,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-1180">9,175,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-1181">8,268,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the Company's senior secured credit facilities, fair value estimates are based on bid and ask quotes, a level 2 input. For the Company's senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. For the CHC temporary funding assistance, the carrying value presented here approximates the estimated fair value based on the short-term nature of settlement.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company's senior secured credit facilities bear interest at Term SOFR, plus an interest rate margin, with certain portions also subject to a credit spread adjustment (CSA). Term SOFR plus CSA is referred to as "Base" in the table above. The Term Loan A-1 and revolving line of credit bear a CSA of <ix:nonFraction unitRef="number" contextRef="c-239" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1182">0.10</ix:nonFraction>%.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2024.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Change Healthcare (CHC) temporary funding assistance, as described below, is interest-free and amounts provided under this program are subject to repayment at a future date to be mutually agreed to by the parties. The balance is included in the Company's current portion of long-term debt as of December&#160;31, 2024.</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1127-2" continuedAt="f-1127-3"><ix:continuation id="f-1128-1"><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2024, the carrying amount of the Company's senior secured credit facilities has been reduced by a discount of $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1183">8,084</ix:nonFraction> and deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1184">28,879</ix:nonFraction>, and the carrying amount of the Company's senior notes has been reduced by deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1185">37,612</ix:nonFraction> and increased by a debt premium of $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="3" id="f-1186">10,239</ix:nonFraction>. As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1187">2,487</ix:nonFraction> and deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1188">32,498</ix:nonFraction>, and the carrying amounts of the Company's senior notes was reduced by deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1189">31,491</ix:nonFraction> and increased by a debt premium of $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="3" id="f-1190">12,129</ix:nonFraction>.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1191" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of long-term debt at December&#160;31, 2024 were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"><tr><td style="width:1.0%"/><td style="width:58.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1192">270,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1193">174,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1194">202,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2028</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1195">1,922,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2029</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1196">39,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1197">6,900,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-244" name="us-gaap:DebtInstrumentIssuanceDate1" format="ixt:date-monthname-day-year-en" id="f-1198">May&#160;9, 2024</ix:nonNumeric> (the Fourth Amendment Effective Date), the Company entered into the Fourth Amendment (the Fourth Amendment) to its senior secured credit agreement dated as of August 12, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the Credit Agreement). The Fourth Amendment modified the Credit Agreement to, among other things, extend the maturity date for a portion of its Term Loan B-1 in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="dva:SecuredDebtExtendedMaturity" format="ixt:num-dot-decimal" scale="3" id="f-1199">911,598</ix:nonFraction> and extend an additional incremental principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" format="ixt:num-dot-decimal" scale="3" id="f-1200"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1201">728,653</ix:nonFraction></ix:nonFraction> (together, referred to as the Extended Term Loan B-1). The Company used the incremental proceeds from the Extended Term Loan B-1 to prepay a proportionate amount of the principal balance still outstanding on its Term Loan B-1.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Extended Term Loan B-1 bears interest at the Company&#8217;s option, based on (i) the Base Rate (as defined below) plus the Applicable Margin (as defined below), or (ii) the forward-looking term rate based on the secured overnight financing rate that is published by CME Group Benchmark Administration Limited (Term SOFR) plus the Applicable Margin. The "Base Rate" is defined as the highest of (i) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus <ix:nonFraction unitRef="number" contextRef="c-247" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1202">0.50</ix:nonFraction>%, (ii) the <ix:nonNumeric contextRef="c-248" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="f-1203">prime commercial lending rate</ix:nonNumeric> of Wells Fargo as established from time to time and (iii) Term SOFR for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="c-249" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1204">1.00</ix:nonFraction>%; provided that if Term SOFR or the Base Rate is less than <ix:nonFraction unitRef="number" contextRef="c-250" decimals="2" name="dva:DebtInstrumentVariableRate" scale="-2" id="f-1205">0.00</ix:nonFraction>% such rate shall be deemed to be <ix:nonFraction unitRef="number" contextRef="c-250" decimals="2" name="dva:DebtInstrumentVariableRate" scale="-2" id="f-1206">0.00</ix:nonFraction>% for purposes of the Credit Agreement. The "Applicable Margin" for the Extended Term Loan B-1 is <ix:nonFraction unitRef="number" contextRef="c-251" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1207">2.00</ix:nonFraction>% in the case of Term SOFR loans, and <ix:nonFraction unitRef="number" contextRef="c-252" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1208">1.00</ix:nonFraction>% in the case of Base Rate loans. <ix:nonNumeric contextRef="c-244" name="us-gaap:DebtInstrumentPaymentTerms" id="f-1209">The Extended Term Loan B-1 requires <ix:nonNumeric contextRef="c-244" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" id="f-1210">quarterly</ix:nonNumeric> principal payments beginning on <ix:nonNumeric contextRef="c-244" name="us-gaap:DebtInstrumentMaturityDateRangeStart1" format="ixt:date-monthname-day-year-en" id="f-1211"><ix:nonNumeric contextRef="c-244" name="us-gaap:DebtInstrumentDateOfFirstRequiredPayment1" format="ixt:date-monthname-day-year-en" id="f-1212">December&#160;31, 2024</ix:nonNumeric></ix:nonNumeric> of <ix:nonFraction unitRef="number" contextRef="c-253" decimals="4" name="dva:DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding" scale="-2" id="f-1213">0.25</ix:nonFraction>% of the aggregate principal amount of the Extended Term Loan B-1 outstanding on the Fourth Amendment Effective Date, with the balance due on <ix:nonNumeric contextRef="c-244" name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" format="ixt:date-monthname-day-year-en" id="f-1214"><ix:nonNumeric contextRef="c-244" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="f-1215">May&#160;9, 2031</ix:nonNumeric></ix:nonNumeric>.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Fourth Amendment transaction described above, the Company recognized debt prepayment, extinguishment and modification costs of $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="dva:DebtPrepaymentExtinguishmentAndModificationCosts" format="ixt:num-dot-decimal" scale="3" id="f-1216">9,732</ix:nonFraction> in the second quarter of 2024 composed partially of fees incurred for this transaction and partially of deferred financing costs and original issue discount written off for the portion of debt considered extinguished and reborrowed as a result of the Fourth Amendment. For the portion of the debt that was considered extinguished and reborrowed, the Company recognized constructive financing cash outflows and financing cash inflows on the statement of cash flows of $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="dva:ConstructiveFinancingCashOutflow" format="ixt:num-dot-decimal" scale="3" id="f-1217">6,302</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="dva:ConstructiveFinancingCashInflow" format="ixt:num-dot-decimal" scale="3" id="f-1218">728,653</ix:nonFraction> for the Extended Term Loan B-1, respectively, and constructive financing cash outflows of $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="dva:ConstructiveFinancingCashOutflow" format="ixt:num-dot-decimal" scale="3" id="f-1219">722,351</ix:nonFraction> for the prepayment of a portion of Term Loan B-1, even though no funds were actually paid or received. Another $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="dva:OtherSignificantNoncashFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="f-1220">13,282</ix:nonFraction> of the debt considered extinguished related to the Extended Term Loan B-1 represented a non-cash financing activity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-213" name="us-gaap:DebtInstrumentIssuanceDate1" format="ixt:date-monthname-day-year-en" id="f-1221">August&#160;13, 2024</ix:nonNumeric>, the Company entered into the Sixth Amendment (the Sixth Amendment) to the Credit Agreement. The Sixth Amendment modified the Credit Agreement to extend an additional incremental principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1222">1,100,000</ix:nonFraction> on its Term Loan A-1 (together with the existing Term Loan A-1 balance, referred to as the Increased Term Loan A-1). <ix:nonNumeric contextRef="c-255" name="us-gaap:DebtInstrumentDescription" id="f-1223">The Sixth Amendment also incorporated the provisions of the Fifth Amendment to the Credit Agreement, dated as of <ix:nonNumeric contextRef="c-255" name="us-gaap:DebtInstrumentIssuanceDate1" format="ixt:date-monthname-day-year-en" id="f-1224">August&#160;7, 2024</ix:nonNumeric>, which removed a cap on the amount of incremental term "A" loans the Company can incur under the Credit Agreement.</ix:nonNumeric> The Company used a portion of the net proceeds from this transaction along with the net proceeds from the issuance of 6.875% Senior Notes due 2032, described below, to prepay the remainder of the balance outstanding on its Term Loan B-1 maturing 2026 in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1225">949,819</ix:nonFraction>, the balance outstanding on its revolving line of credit and related accrued interest and fees. The remaining borrowings added cash to the balance sheet for general corporate purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Increased Term Loan A-1 bears interest at Term SOFR, plus a CSA of <ix:nonFraction unitRef="number" contextRef="c-257" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1226">0.10</ix:nonFraction>% and an interest rate margin which is subject to adjustment depending upon the Company's leverage ratio under the Credit Agreement, and which can range from </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1127-3" continuedAt="f-1127-4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-258" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1227">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-259" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1228">2.25</ix:nonFraction>%, provided that this adjusted rate shall never be less than <ix:nonFraction unitRef="number" contextRef="c-260" decimals="2" name="dva:DebtInstrumentVariableRate" scale="-2" id="f-1229">0.00</ix:nonFraction>%. <ix:nonNumeric contextRef="c-213" name="us-gaap:DebtInstrumentPaymentTerms" id="f-1230">The Increased Term Loan A-1 requires amortizing <ix:nonNumeric contextRef="c-213" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" id="f-1231">quarterly</ix:nonNumeric> principal payments that began on <ix:nonNumeric contextRef="c-213" name="us-gaap:DebtInstrumentMaturityDateRangeStart1" format="ixt:date-monthname-day-year-en" id="f-1232"><ix:nonNumeric contextRef="c-213" name="us-gaap:DebtInstrumentDateOfFirstRequiredPayment1" format="ixt:date-monthname-day-year-en" id="f-1233">September&#160;30, 2024</ix:nonNumeric></ix:nonNumeric> of $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="dva:DebtInstrumentQuarterlyPaymentThroughJune302027" format="ixt:num-dot-decimal" scale="3" id="f-1234">29,728</ix:nonFraction> per quarter through June&#160;30, 2027, and $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="dva:DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028" format="ixt:num-dot-decimal" scale="3" id="f-1235">44,591</ix:nonFraction> per quarter from September&#160;30, 2027 through March&#160;31, 2028, with the balance due on <ix:nonNumeric contextRef="c-212" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="f-1236"><ix:nonNumeric contextRef="c-213" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="f-1237"><ix:nonNumeric contextRef="c-213" name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" format="ixt:date-monthname-day-year-en" id="f-1238">April&#160;28, 2028</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Sixth Amendment transaction described above, the Company recognized debt prepayment, extinguishment and modification costs of $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="dva:DebtPrepaymentExtinguishmentAndModificationCosts" format="ixt:num-dot-decimal" scale="3" id="f-1239">10,081</ix:nonFraction> in the third quarter of 2024 composed partially of fees incurred for this transaction and partially of deferred financing costs and original issue discount written off for the extinguishment of the Term Loan B-1. Additionally, $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="dva:OtherSignificantNoncashFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="f-1240">861,282</ix:nonFraction> of the debt considered extinguished and reborrowed related to the Increased Term Loan A-1 represented a non-cash financing activity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company&#8217;s domestic subsidiaries' assets and rank senior to all unsecured indebtedness. Borrowings under the Term Loan A-1, Extended Term Loan B-1 and revolving line of credit rank equal in priority for that security and related subsidiary guarantees. The Credit Agreement contains certain customary affirmative and negative covenants such as various restrictions or limitations on permitted amounts of investments (including acquisitions), share repurchases, payment of dividends, and redemptions and incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company&#8217;s leverage ratio calculated in accordance with the Credit Agreement is below <ix:nonFraction unitRef="number" contextRef="c-263" decimals="2" name="dva:LeverageRatioCovenant" scale="0" id="f-1241">4.00</ix:nonFraction>:1.00. In addition, the Credit Agreement requires compliance with a maximum leverage ratio covenant, tested quarterly, of <ix:nonFraction unitRef="number" contextRef="c-263" decimals="2" name="dva:LeverageRatioCovenantThroughJun302026" scale="0" id="f-1242">5.00</ix:nonFraction>:1.00 through June&#160;30, 2026 and <ix:nonFraction unitRef="number" contextRef="c-263" decimals="3" name="dva:LeverageRatioCovenantAfterJun302026" scale="0" id="f-1243">4.50</ix:nonFraction>:1.00 thereafter (subject to an increase to <ix:nonFraction unitRef="number" contextRef="c-263" decimals="3" name="dva:LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition" scale="0" id="f-1244">5.00</ix:nonFraction>:1.00 during the four fiscal quarters following a material acquisition).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the prepayments described above, during 2024, the Company made regularly scheduled and other principal payments under its senior secured credit facilities totaling $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="3" id="f-1245">75,080</ix:nonFraction> on Term Loan A-1, $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="3" id="f-1246">13,716</ix:nonFraction> on Term Loan B-1 and $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="3" id="f-1247">4,101</ix:nonFraction> on Extended Term Loan B-1.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had undrawn capacity on the revolving line of credit under its senior secured credit facilities of $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1248">1,500,000</ix:nonFraction>. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="f-1249">none</ix:nonFraction> as of December&#160;31, 2024. The Company also had letters of credit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1250">161,496</ix:nonFraction> outstanding under a separate bilateral secured letter of credit facility as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2019 interest rate cap agreements expired on <ix:nonNumeric contextRef="c-266" name="us-gaap:DerivativeMaturityDates" format="ixt:date-monthname-day-year-en" id="f-1251">June&#160;30, 2024</ix:nonNumeric> and a portion of the Company's 2023 cap agreements became effective on or prior to <ix:nonNumeric contextRef="c-266" name="us-gaap:DerivativeMaturityDates" format="ixt:date-monthname-day-year-en" id="f-1252">June&#160;30, 2024</ix:nonNumeric>. As of December&#160;31, 2024, the effective portion of the Company's 2023 interest rate cap agreements had the economic effect of capping the Company's maximum exposure to SOFR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Extended Term Loan B-1 and a portion of Term Loan A-1. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="dva:SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" format="ixt:num-dot-decimal" scale="3" id="f-1253">395,445</ix:nonFraction> outstanding principal balance of Term Loan A-1 is subject to SOFR-based interest rate volatility. These cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. The original premiums paid for the caps are amortized to debt expense utilizing the effective interest rate method over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit risk-contingent features.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;13, 2024, the Company issued $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1254">1,000,000</ix:nonFraction> aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1255">6.875</ix:nonFraction>% senior notes due 2032 (the <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1256">6.875</ix:nonFraction>% Senior Notes) in a private offering pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended. <ix:nonNumeric contextRef="c-229" name="us-gaap:DebtInstrumentPaymentTerms" id="f-1257">The <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1258">6.875</ix:nonFraction>% Senior Notes pay interest on March 1 and September 1 of each year beginning <ix:nonNumeric contextRef="c-229" name="us-gaap:DebtInstrumentDateOfFirstRequiredPayment1" format="ixt:date-monthname-day-year-en" id="f-1259">March&#160;1, 2025</ix:nonNumeric> and mature on September&#160;1, 2032</ix:nonNumeric>. The <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1260">6.875</ix:nonFraction>% Senior Notes are unsecured senior obligations and rank equally in right of payment with the Company's existing and future unsecured senior indebtedness. The <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1261">6.875</ix:nonFraction>% Senior Notes are guaranteed by each of the Company&#8217;s domestic subsidiaries that guarantee its senior secured credit facilities. <ix:nonNumeric contextRef="c-229" name="us-gaap:DebtInstrumentRedemptionDescription" id="f-1262">The Company may redeem up to 40% of the aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1263">6.875</ix:nonFraction>% Senior Notes at any time prior to September&#160;1, 2027 at <ix:nonFraction unitRef="number" contextRef="c-229" decimals="INF" name="dva:DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027" scale="-2" id="f-1264">106.875</ix:nonFraction>% of the aggregate principal amount from the proceeds of one or more equity offerings, plus accrued and unpaid interest.</ix:nonNumeric> On and after September&#160;1, 2027, the Company may at its option redeem the <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1265">6.875</ix:nonFraction>% Senior Notes, in whole or from time to time in part, at certain redemption prices specified in the indenture governing these notes plus accrued and unpaid interest. If the Company experiences certain change of control events, the Company must offer to repurchase all of the <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1266">6.875</ix:nonFraction>% Senior Notes (unless otherwise redeemed) at a price equal to <ix:nonFraction unitRef="number" contextRef="c-229" decimals="INF" name="dva:DebtInstrumentRedemptionPriceIfChangeOfControl" scale="-2" id="f-1267">101</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest. The <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1268">6.875</ix:nonFraction>% Senior Notes contain restrictive covenants that limit the ability of the Company and the subsidiary guarantors of the <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1269">6.875</ix:nonFraction>% Senior Notes to, among other things and subject to certain exceptions and qualifications, create certain liens, enter into certain sale/leaseback transactions, or merge with or into, or convey, transfer or lease all or substantially all of their assets. The <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1270">6.875</ix:nonFraction>% Senior Notes and related subsidiary guarantees do not have any registration or similar rights and are not expected to be registered for exchange on public markets. As of December&#160;31, 2024, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="3" id="f-1271">11,421</ix:nonFraction> in fees and other </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1127-4" continuedAt="f-1127-5"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">professional expenses associated with this transaction that were capitalized and will amortize over the term of the <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1272">6.875</ix:nonFraction>% Senior Notes.</span></div><div style="margin-top:9pt;text-indent:27.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's outstanding senior notes, including the <ix:nonFraction unitRef="number" contextRef="c-229" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1273">6.875</ix:nonFraction>% Senior Notes (collectively, the Senior Notes), are unsecured obligations, rank equally in right of payment with the Company&#8217;s existing and future unsecured senior indebtedness and require semi-annual interest payments. The Company may redeem some or all of the Senior Notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in the indenture governing each series of Senior Notes. Interest rates on the Senior Notes are fixed by their terms.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change Healthcare</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;1, 2024, Change Healthcare (CHC), a subsidiary of UnitedHealth Group, launched a temporary assistance funding program (CHC Funding) to help bridge the gap in short-term cash flow needs for providers impacted by the disruption of CHC's services. Under the program, CHC provides funding to providers for amounts that would otherwise have been received (with certain limitations), but for the disruption in processing electronic claims as a result of the outage. Amounts provided under this program are subject to repayment at a future date to be mutually agreed to by CHC and the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHC has restored claims submission functionality and the Company has resumed claims submissions and billing processes through CHC&#8217;s information technology systems. Through a combination of CHC's platform and certain alternate billing processes, the Company is current on its primary claims submissions, but does continue to see delays in collections with some payors. As of December&#160;31, 2024, the remaining CHC Funding amount outstanding was $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="dva:CHCTemporaryFundingAssistance" format="ixt:num-dot-decimal" scale="3" id="f-1274">92,777</ix:nonFraction>. Subsequent to December&#160;31, 2024, the Company made a payment for a portion of the CHC Funding amount, leaving a remaining balance outstanding of $<ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="dva:CHCTemporaryFundingAssistance" format="ixt:num-dot-decimal" scale="3" id="f-1275">70,000</ix:nonFraction> as of February&#160;13, 2025.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024 the Company entered into several forward interest rate cap agreements, described below, that have the economic effect of capping the Company's exposure to SOFR variable interest rate changes on specific portions of the Company's floating rate debt (2024 cap agreements). These 2024 cap agreements are designated as cash flow hedges and, as a result, changes in their fair values will be reported in other comprehensive income. These 2024 cap agreements do not contain credit-risk contingent features, and become effective and expire as described in the table below.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-1276" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s interest rate cap agreements outstanding as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount effective<br/>through December 31 unless noted</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year cap agreements executed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial notional amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SOFR maximum rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate effective date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1277">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1278">3.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-270" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1279">6/30/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-270" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1280">12/31/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1281">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1282">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-272" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1283">6/30/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-272" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1284">12/31/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1285">750,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1286">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-274" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1287">6/30/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-274" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1288">12/31/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1289">750,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1290">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-276" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1291">6/30/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-276" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1292">12/31/2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1293">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1294">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-277" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1295">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-278" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1296">12/31/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-278" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1297">12/31/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1298">250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1299">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-279" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1300">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-280" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1301">12/31/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-280" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1302">12/31/2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1303">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1304">1,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-282" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1305">12/31/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-282" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1306">12/31/2027</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1307">1,000,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1308">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-284" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1309">12/31/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-284" name="us-gaap:DerivativeMaturityDates" format="ixt:date-month-day-year" id="f-1310">12/31/2027</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1311">500,000</ix:nonFraction></span></td></tr><tr><td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional coverage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1312">3,500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1313">3,500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1314">3,500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1315">1,500,000</ix:nonFraction></span></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average strike rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-289" decimals="INF" name="us-gaap:DerivativeAverageFixedInterestRate" scale="-2" id="f-1316">4.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-290" decimals="INF" name="us-gaap:DerivativeAverageFixedInterestRate" scale="-2" id="f-1317">4.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="INF" name="us-gaap:DerivativeAverageFixedInterestRate" scale="-2" id="f-1318">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="INF" name="us-gaap:DerivativeAverageFixedInterestRate" scale="-2" id="f-1319">4.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective January&#160;1, 2025, the maximum rate of <ix:nonFraction unitRef="number" contextRef="c-271" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1320">4.00</ix:nonFraction>% decreased to <ix:nonFraction unitRef="number" contextRef="c-293" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1321">3.75</ix:nonFraction>% for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective January&#160;1, 2025, the maximum rate of <ix:nonFraction unitRef="number" contextRef="c-273" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1322">4.75</ix:nonFraction>% decreased to <ix:nonFraction unitRef="number" contextRef="c-294" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1323">4.00</ix:nonFraction>% for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective January&#160;1, 2025, the maximum rate of <ix:nonFraction unitRef="number" contextRef="c-275" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1324">5.00</ix:nonFraction>% decreased to <ix:nonFraction unitRef="number" contextRef="c-295" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1325">4.50</ix:nonFraction>% for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective December&#160;31, 2026, the maximum rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-281" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1326">4.50</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-296" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1327">4.75</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective December&#160;31, 2026, the maximum rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-283" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1328">4.00</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increases to <ix:nonFraction unitRef="number" contextRef="c-297" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="f-1329">4.25</ix:nonFraction>% for these interest rate caps.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1127-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-1330" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of the Company&#8217;s interest rate cap agreements for the years ended December&#160;31, 2024, 2023 and 2022:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.536%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location in Consolidated Statements of Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification from accumulated other comprehensive income into net income</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1331">9,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1332">9,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1333">144,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1334">Debt expense</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1335">58,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1336">103,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1337">11,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1338">2,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1339">2,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1340">36,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1341">Related income tax</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1342">14,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1343">25,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1344">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1345">7,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1346">6,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1347">108,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1348">43,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1349">77,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1350">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's interest rate cap agreements, which are classified in other long-term assets on its consolidated balance sheet, were $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="f-1351">30,062</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="f-1352">79,805</ix:nonFraction> for the years ended December&#160;31, 2024 and December&#160;31, 2023, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for further details on amounts recorded and reclassified from accumulated other comprehensive (loss) income and recorded as debt expense (offset) related to the Company&#8217;s interest rate cap agreements for the year ended December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the variable rate cap from the Company's 2023 interest rate cap agreements, the Company&#8217;s weighted average effective interest rate on its senior secured credit facilities at the end of December&#160;31, 2024 was <ix:nonFraction unitRef="number" contextRef="c-240" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="f-1353">6.91</ix:nonFraction>%, based on the current margins in effect for its senior secured credit facilities as of December&#160;31, 2024, as detailed in the table above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was <ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="f-1354">5.07</ix:nonFraction>% for the year ended December&#160;31, 2024 and <ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="f-1355">5.68</ix:nonFraction>% as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company&#8217;s interest rates were fixed and economically fixed on approximately <ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-1356">59</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="dva:LongTermDebtPercentageBearingEconomicallyFixedInterestRate" scale="-2" id="f-1357">96</ix:nonFraction>% of its total debt, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt expense</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt expense consisted of interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1358">435,203</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1359">373,951</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1360">339,247</ix:nonFraction> and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs, costs for the undrawn portion of the revolving line of credit and the amortization of interest rate cap agreements of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1361">35,266</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1362">24,600</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1363">17,772</ix:nonFraction> for 2024, 2023 and 2022, respectively. These interest expense amounts are net of capitalized interest.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_343"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dva:LeasesDisclosureTextBlock" id="f-1408" continuedAt="f-1408-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-1408-1" continuedAt="f-1408-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which range in terms from <ix:nonNumeric contextRef="c-311" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-1409">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-312" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1410">15</ix:nonNumeric> years and which contain renewal options of <ix:nonNumeric contextRef="c-311" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1411">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-312" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="f-1412">10</ix:nonNumeric> years at the fair rental value at the time of renewal. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases. See Note 1 for further information on how the Company accounts for leases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and December&#160;31, 2023, assets recorded under <span style="-sec-ix-hidden:f-1413"><span style="-sec-ix-hidden:f-1414">finance leases</span></span> were $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1415">309,363</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1416">322,844</ix:nonFraction>, respectively, and accumulated amortization associated with finance leases was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:FinanceLeaseAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1417">139,071</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:FinanceLeaseAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1418">122,286</ix:nonFraction>, respectively, included in property and equipment, net, on the Company's consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain markets, the Company acquires and develops dialysis centers. Upon completion, the Company sells the center to a third party and leases the space back with the intent of operating the center on a long-term basis. Both the sale and leaseback terms are generally market terms. Substantially all of the lease terms are consistent with the Company's other operating leases with the majority of the leases under non-cancellable operating leases ranging in terms from <ix:nonNumeric contextRef="c-313" name="us-gaap:SaleLeasebackTransactionLeaseTerm" format="ixt-sec:duryear" id="f-1419">10</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-314" name="us-gaap:SaleLeasebackTransactionLeaseTerm" format="ixt-sec:duryear" id="f-1420">15</ix:nonNumeric> years and containing renewal options of <ix:nonNumeric contextRef="c-315" name="dva:SaleLeasebackTransactionRenewalLeaseTerm" format="ixt-sec:durwordsen" id="f-1421">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-316" name="dva:SaleLeasebackTransactionRenewalLeaseTerm" format="ixt-sec:duryear" id="f-1422">15</ix:nonNumeric> years at the fair rental value at the time of renewal.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1408-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1423" continuedAt="f-1423-1" escape="true"><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1424">557,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1425">556,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1426">552,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1427">131,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1428">135,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1429">127,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1430">28,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1431">26,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1432">27,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1433">10,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1434">11,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1435">12,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1436">728,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1437">731,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1438">719,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><ix:continuation id="f-1423-1" continuedAt="f-1423-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"><ix:continuation id="f-1423-2">Includes short-term lease expense and sublease income, which are immaterial.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="dva:LeaseOtherInformationTableTextBlockTableTextBlock" id="f-1439" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease term and discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1440">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1441">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1442">8.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1443">7.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1444">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1445">9.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1446">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1447">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1448">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sale leasebacks, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1449">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1450">3,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1451">28,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the <br/>&#160;measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1452">719,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1453">708,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1454">696,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="f-1455">18,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="f-1456">19,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="f-1457">20,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-1458">29,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-1459">26,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-1460">24,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease assets obtained in exchange<br/>&#160;for new or modified operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1461">286,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1462">269,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1463">278,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dva:ScheduleOfMinimumLeasePaymentsTextBlock" id="f-1464" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2024 are as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:52.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1465">508,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1466">36,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1467">517,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1468">38,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1469">453,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1470">37,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1471">385,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1472">33,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1473">310,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1474">24,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1475">863,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1476">82,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1477">3,038,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1478">253,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less portion representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1479">418,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1480">37,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1481"><span style="-sec-ix-hidden:f-1482">Present value of lease liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1483">2,620,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1484">216,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense under all operating leases for 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1485">689,130</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1486">692,834</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1487">679,815</ix:nonFraction>, respectively. Rent expense is recorded on a straight-line basis over the term of the lease, including leases that contain fixed escalation clauses or include abatement provisions. Leasehold improvement incentives reduce the carrying value of right-of-use assets and are amortized to rent expense over the term of the lease. Finance lease obligations are included in long-term debt. See Note 12 for further details on long-term debt.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_349"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1494" continuedAt="f-1494-1" escape="true">Employee benefit plans</ix:nonNumeric></span></div><ix:continuation id="f-1494-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) retirement savings plan for substantially all of its U.S. employees which has been established pursuant to applicable provisions of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company maintains a 401(k) matching program under which the Company matches <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1495">50</ix:nonFraction>% of the employee's contribution up to <ix:nonFraction unitRef="number" contextRef="c-314" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1496">6</ix:nonFraction>% of the employee's salary, subject to certain limitations. The matching contributions are subject to certain eligibility and vesting conditions. For the years ended December&#160;31, 2024, 2023 and 2022, the Company accrued matching contributions totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="3" id="f-1497">79,006</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="3" id="f-1498">73,725</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="3" id="f-1499">70,084</ix:nonFraction>, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains a voluntary compensation deferral plan, the Deferred Compensation Plan. The Deferred Compensation Plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to <ix:nonFraction unitRef="number" contextRef="c-321" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-1500">50</ix:nonFraction>% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2024, 2023 and 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="f-1501">2,521</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="f-1502">2,695</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="f-1503">3,573</ix:nonFraction>, respectively. Deferred amounts are generally paid out in cash at the participant&#8217;s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2024, 2023 and 2022 the Company distributed $<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" format="ixt:num-dot-decimal" scale="3" id="f-1504">4,511</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" format="ixt:num-dot-decimal" scale="3" id="f-1505">3,899</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" format="ixt:num-dot-decimal" scale="3" id="f-1506">3,731</ix:nonFraction>, respectively, to participants from its deferred compensation plans. Participants are credited with their proportional amount of annual earnings from the plans. The assets of these plans are held in rabbi trusts subject to the claims of the Company&#8217;s general creditors in the event of its bankruptcy. As of December&#160;31, 2024 and 2023, the total fair value of assets held in these plans' trusts was $<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="f-1507">39,527</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="f-1508">36,936</ix:nonFraction>, respectively. The assets of these plans are recorded at fair value with changes in fair value recorded in other loss, net. See Note 4 for further details. Any fair value changes to the corresponding liability balance are recorded as compensation expense.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_355"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LossContingencyDisclosures" id="f-1513" continuedAt="f-1513-1" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-1513-1" continuedAt="f-1513-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to, or has the potential to be a party to, various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. Excluding amounts stated below, as of December&#160;31, 2024 and December&#160;31, 2023, the Company&#8217;s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company&#8217;s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney&#8217;s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company&#8217;s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter included an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a Civil Investigative Demand (CID) pursuant to the False Claims Act from the U.S. Attorney's Office relating to this investigation. On May 6, 2024, the Company finalized and executed a settlement agreement with the government and the relator in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matter that included a settlement amount of $<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="3" id="f-1514">34,487</ix:nonFraction> for this matter. On May 7, 2024, the government notified the U.S. District Court, District of Colorado of its decision to intervene for purposes of settlement in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Kogod v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The government and the relator agreed to voluntarily dismiss all substantive claims in the matter, and, on July 18, 2024, the District Court dismissed all claims except for the relator&#8217;s statutory claim for expenses, attorney&#8217;s fees, and costs. On December 10, 2024, the parties signed an agreement to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1513-2" continuedAt="f-1513-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resolve the remaining claim for relator&#8217;s statutory claim for expenses, attorney&#8217;s fees, and costs for an immaterial amount. On December 20, 2024, the parties filed a stipulation of dismissal with the District Court on the remaining claim and the District Court ordered the relator&#8217;s claim withdrawn.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney&#8217;s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney&#8217;s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company&#8217;s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired <ix:nonNumeric contextRef="c-328" name="dva:CorporateIntegrityAgreementExpirationDate" format="ixt:date-monthname-day-year-en" id="f-1515">October 22, 2019</ix:nonNumeric>. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney&#8217;s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Bayne v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company&#8217;s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients&#8217; decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 District of Columbia Office of Attorney General Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company&#8217;s communications with the AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Federal Trade Commission Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2024, the Company received from the Federal Trade Commission (FTC) two CIDs in connection with an industry investigation under Section 5 of the Federal Trade Commission Act regarding the acquisition of medical director services and provision of dialysis services. The CIDs cover the period from January 1, 2016 to the present and generally seek information relating to restrictive covenants, such as non-competes, with physicians. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies. Negative findings or terms and conditions that the Company might agree to accept could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company&#8217;s reputation, required changes to the Company&#8217;s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company&#8217;s </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1513-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company. On October 27, 2024, the plaintiffs filed a Third Amended Complaint, seeking to bring an action on behalf of certain groups of individuals employed by the Company between March 2008 and January 2021, to which the Company responded on December 20, 2024. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 15, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company&#8217;s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management&#8217;s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company&#8217;s business, results of operations, financial condition, cash flows or reputation.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_358"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsDisclosureTextBlock" id="f-1516" continuedAt="f-1516-1" escape="true">Noncontrolling interests subject to put provisions and other commitments</ix:nonNumeric></span></div><ix:continuation id="f-1516-1" continuedAt="f-1516-2"><ix:continuation id="f-604-1"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests subject to put provisions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#8217; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#8217;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#8217; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#8217; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain consolidated dialysis partnerships are originally contractually scheduled to dissolve after terms ranging from <ix:nonNumeric contextRef="c-313" name="dva:DissolutionTermOfJointVentures" format="ixt-sec:durwordsen" id="f-1517">ten years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-314" name="dva:DissolutionTermOfJointVentures" format="ixt-sec:duryear" id="f-1518">50</ix:nonNumeric> years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1516-2"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with various suppliers to purchase established amounts of dialysis equipment, parts, pharmaceuticals and supplies. As of December&#160;31, 2024, the remaining minimum purchase commitments under these arrangements were approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1519">559,952</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="3" id="f-1520">547,079</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="3" id="f-1521">547,031</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInFourthYear" format="ixt:num-dot-decimal" scale="3" id="f-1522">564,134</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInFifthYear" format="ixt:num-dot-decimal" scale="3" id="f-1523">414,491</ix:nonFraction> for the years 2025, 2026, 2027, 2028 and 2029, respectively. If the Company fails to meet the minimum purchase commitments under these contracts during any year, it is required to pay the difference to the supplier.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately $<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="f-1524">7,131</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the letters of credit disclosed in Note 12 to these consolidated financial statements, and the arrangements as described above, the Company has <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:OffBalanceSheetFinancingArrangements" format="ixt:fixed-zero" scale="3" id="f-1525">no</ix:nonFraction> off balance sheet financing arrangements as of December&#160;31, 2024.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_361"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1526" continuedAt="f-1526-1" escape="true">Stock-based compensation</ix:nonNumeric></span></div><ix:continuation id="f-1526-1" continuedAt="f-1526-2"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation consists primarily of stock-settled stock appreciation rights, restricted stock units and performance stock units. Stock-based compensation, which is primarily general and administrative in nature, is attributed to the Company&#8217;s U.S. dialysis business, its corporate administrative support, and its ancillary services. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization and summary of significant accounting policies" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on how the Company measures and recognizes stock-based compensation expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term incentive compensation plans</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DaVita Inc. 2020 Incentive Award Plan (the 2020 Plan) is the Company&#8217;s current omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2020 Plan provides for the grant of stock appreciation rights, nonqualified stock options, incentive stock options, restricted stock units, restricted stock, performance stock awards, dividend equivalents, stock payments, deferred stock unit awards, deferred stock awards and performance cash awards. The 2020 Plan mandates a maximum award term of <ix:nonNumeric contextRef="c-330" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-1527">10</ix:nonNumeric> years for stock appreciation rights and stock options and stipulates that awards of these types be granted with a base or exercise price per share of not less than the fair market value of the Company's common stock on the date of grant. Shares available under the 2020 Plan are stated on a full value share basis. The 2020 Plan therefore provides that shares available for issuance under the plan are reduced by <ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" format="ixt-sec:numwordsen" scale="0" id="f-1528">one</ix:nonFraction> share available for every <ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="dva:StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" format="ixt-sec:numwordsen" scale="0" id="f-1529">four</ix:nonFraction> shares underlying stock appreciation rights and stock options, and are reduced by <ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" format="ixt-sec:numwordsen" scale="0" id="f-1530">one</ix:nonFraction> share available for every <ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="dva:StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" format="ixt-sec:numwordsen" scale="0" id="f-1531">one</ix:nonFraction> share underlying stock-based awards other than stock appreciation rights and stock options. At December&#160;31, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-332" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="f-1532">4,969</ix:nonFraction> shares available for future grants under the 2020 Plan. The Company&#8217;s stock awards granted under the 2020 Plan generally vest over <ix:nonNumeric contextRef="c-333" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-1533">36</ix:nonNumeric> months to <ix:nonNumeric contextRef="c-330" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-1534">48</ix:nonNumeric> months from the date of grant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1526-2" continuedAt="f-1526-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-1535" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company&#8217;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:37.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock appreciation rights</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1536">3,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-334" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1537">67.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1538">3,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-336" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="3" id="f-1539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-336" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="f-1540"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1541">827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Added by performance factor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-337" decimals="-3" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" scale="3" id="f-1542">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-336" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-1543">3,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-336" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1544">63.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1545">628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-336" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-1546">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-336" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1547">75.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1548">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-338" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-1549">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-338" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1550">108.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-336" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1551">1.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-339" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1552">3,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-337" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-1553">1.96</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-338" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="f-1554">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-338" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1555">102.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-336" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1556">1.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-339" decimals="INF" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" format="ixt:fixed-zero" scale="0" id="f-1557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of grants:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-336" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="f-1558"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-337" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1559">142.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-340" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="f-1560"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-341" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1561">77.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-342" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1562">35.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-343" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1563">107.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-1564" escape="true"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"/><td style="width:28.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.438%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards Outstanding</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards exercisable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of SSARs base prices</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.01&#8211;$80.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-344" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1565">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-344" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1566">75.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-344" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1567">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-344" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1568">75.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01&#8211;$110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-345" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1569">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-345" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1570">108.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-345" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1571">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-345" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1572">108.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110.01&#8211;$120.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-346" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1573">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-346" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1574">110.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-346" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:fixed-zero" scale="3" id="f-1575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-346" xsi:nil="true" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="f-1576"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1577">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1578">108.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1579">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1580">102.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the aggregate intrinsic value of stock-based awards exercised was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1581">323,681</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1582">168,500</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1583">149,442</ix:nonFraction>, respectively. At December&#160;31, 2024, the aggregate intrinsic value of stock-based awards outstanding was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1584">490,209</ix:nonFraction> and the aggregate intrinsic value of stock awards exercisable was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1585">3,394</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of stock-based compensation awards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant, except for portions of the Company&#8217;s performance stock unit awards for which a Monte Carlo simulation was used to estimate the grant-date fair value. The following assumptions were used in estimating these values and determining the related stock-based compensation expense attributable to the current period:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term of the awards:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company&#8217;s historical exercise and post-vesting termination patterns.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatilities expected by peer companies in near industries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1526-3"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No SSAR awards were granted during the years ended December&#160;31, 2024 or 2023. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1586" continuedAt="f-1586-1" escape="true">A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted during the year end December&#160;31, 2022 were as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1586-1"><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.181%"><tr><td style="width:1.0%"/><td style="width:67.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-347" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1587">4.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-347" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1588">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-347" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-347" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1590">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="INF" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" scale="3" id="f-1591">25</ix:nonFraction> of the Company&#8217;s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of <ix:nonFraction unitRef="number" contextRef="c-349" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-1592">100</ix:nonFraction>% of its fair market value on the first day of the purchase right period or <ix:nonFraction unitRef="number" contextRef="c-350" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-1593">85</ix:nonFraction>% of its fair market value on the last day of the purchase right period. Purchase right periods begin on January&#160;1 and July&#160;1, and end on December&#160;31. Contributions used to purchase the Company&#8217;s common stock under this plan for the 2024, 2023 and 2022 purchase periods were $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-3" name="dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" format="ixt:num-dot-decimal" scale="3" id="f-1594">20,441</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" format="ixt:num-dot-decimal" scale="3" id="f-1595">18,213</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-3" name="dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" format="ixt:num-dot-decimal" scale="3" id="f-1596">18,061</ix:nonFraction>, respectively. Shares purchased pursuant to the plan&#8217;s 2024, 2023 and 2022 purchase periods were <ix:nonFraction unitRef="shares" contextRef="c-348" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-1597">184</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-354" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-1598">231</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-355" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-1599">285</ix:nonFraction>, respectively. At December&#160;31, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-351" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="f-1600">5,286</ix:nonFraction> shares remaining available for future grants under this plan.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of participants&#8217; purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2024, 2023 and 2022, respectively: expected volatility of <ix:nonFraction unitRef="number" contextRef="c-348" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1601">32.6</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-354" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1602">41.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-355" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1603">31.7</ix:nonFraction>%; risk-free interest rates of <ix:nonFraction unitRef="number" contextRef="c-348" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1604">4.8</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-354" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1605">4.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-355" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1606">1.3</ix:nonFraction>%; and <ix:nonFraction unitRef="usd" contextRef="c-348" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-1607">no</ix:nonFraction> dividends. Using these assumptions, the weighted average estimated per share fair value of each purchase right was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-348" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1608">31.78</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-354" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1609">25.25</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1610">26.50</ix:nonFraction> for 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense and proceeds</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1611">102,788</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1612">112,375</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1613">95,427</ix:nonFraction> in stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock purchase plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2024, 2023 and 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1614">16,398</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1615">16,536</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1616">14,723</ix:nonFraction>, respectively. As of December&#160;31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1617">146,350</ix:nonFraction> of total estimated but unrecognized stock-based compensation expense under the Company&#8217;s equity compensation plans. The Company expects to recognize this expense over a weighted average remaining period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1618">1.2</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1619">27,531</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1620">25,629</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1621">24,805</ix:nonFraction>, respectively, in actual tax benefits upon the exercise or vesting of stock awards. Since the Company issues stock-settled stock appreciation rights rather than stock options, there were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-1622">no</ix:nonFraction> cash proceeds from stock option exercises.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_367"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:TreasuryStockTextBlock" id="f-1642" continuedAt="f-1642-1" escape="true">Shareholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="f-1642-1" continuedAt="f-1642-2"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchases</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="f-1643" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:38.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open market repurchases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-362" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1644">9,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-363" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1645">2,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-364" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1646">8,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1647">1,389,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1648">285,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1649">787,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-362" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1650">140.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-363" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1651">97.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-364" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1652">97.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#8217; equity.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes commissions and the excise tax described above.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company repurchased <ix:nonFraction unitRef="shares" contextRef="c-365" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-1653">779</ix:nonFraction> shares of its common stock for $<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1654">124,665</ix:nonFraction> at an average price paid of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-365" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1655">158.48</ix:nonFraction> per share subsequent to December&#160;31, 2024 through February&#160;13, 2025, inclusive of the shares repurchased from Berkshire Inc. as discussed below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company is authorized to make share repurchases pursuant to a September 5, 2024 Board authorized repurchase plan of $<ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="3" id="f-1656">2,000,000</ix:nonFraction>. This authorization allows the Company to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, trading plans pursuant to Rule 10b5-1 or Rule 10b-18, or any combination of the foregoing, depending upon market conditions and other considerations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;13, 2025, the Company has a total of $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="3" id="f-1657">1,811,069</ix:nonFraction>, excluding excise taxes, available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.</span></div><ix:nonNumeric contextRef="c-368" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-1658" continuedAt="f-1658-1" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Berkshire share repurchase agreement</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-368" name="us-gaap:RepurchaseAgreementDate" format="ixt:date-monthname-day-year-en" id="f-1659">April&#160;30, 2024</ix:nonNumeric>, the Company entered into an agreement (the share repurchase agreement) with Berkshire Hathaway Inc. on behalf of itself and its affiliates (collectively, Berkshire). Under the share repurchase agreement, at any time <ix:nonNumeric contextRef="c-368" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="f-1660">Berkshire beneficially owns at least 45.0%</ix:nonNumeric> of the issued and outstanding common stock of the Company in the aggregate, the Company will repurchase from Berkshire, and Berkshire will sell to the Company, on a quarterly basis, a number of shares of common stock sufficient to return Berkshire&#8217;s aggregate beneficial ownership to 45.0% of the Company's issued and outstanding common stock. The per share price the Company will pay Berkshire for any such share repurchase will be the volume-weighted average price per share paid by the Company for any shares of common stock repurchased by the Company from public stockholders pursuant to the Company&#8217;s share repurchase program during the applicable repurchase period.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, repurchases of common stock by the Company from Berkshire will occur on the date that is <ix:nonNumeric contextRef="c-368" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement" id="f-1661">two business days prior to the date of the Company&#8217;s regular quarterly or annual investor call to publicly report earnings</ix:nonNumeric>; however, if at any time the Company determines that <ix:nonNumeric contextRef="c-368" name="dva:RelatedPartyTransactionDescriptionOfTransaction1" id="f-1662">Berkshire beneficially owns or will beneficially own shares of common stock representing more than 49.5% of the issued and outstanding common stock in the aggregate, such determination will trigger immediate share repurchases under this agreement.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-369" name="dva:RelatedPartyTransactionDescriptionOfTransaction2" id="f-1663">As of December&#160;31, 2024, Berkshire beneficially owned less than 45.0% of the issued and outstanding common stock of the Company and, as a result, no repurchase obligation existed at such date.</ix:nonNumeric> <ix:nonNumeric contextRef="c-370" name="dva:RelatedPartyTransactionDescriptionOfTransaction2" id="f-1664">Subsequent to December&#160;31, 2024, through February&#160;13, 2025, the Company's open market share repurchases caused Berkshire to beneficially own greater then 45.0%. As such, on February 11, 2025 the Company repurchased 203 shares of common stock from Berkshire for $32,001 at an average price paid of $156.01 per share.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Berkshire standstill agreement</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Berkshire remains subject to a standstill agreement with the Company, as amended and restated as of February 9, 2022 (the standstill agreement). The standstill agreement currently restricts Berkshire&#8217;s actions with respect to acquiring additional </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1642-2"><ix:continuation id="f-1658-1" continuedAt="f-1658-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of the Company&#8217;s common stock, and for any matter presented to Company stockholders, the standstill agreement requires Berkshire to vote any shares it beneficially holds in excess of 40% of the then-outstanding voting stock of the Company in accordance with the recommendation of the Board of Directors of the Company (Board). The standstill agreement also restricts Berkshire from taking certain actions, including, among other things, actions relating to stockholder proposals and actions seeking to control or influence the Board, management or policies of the Company. The standstill agreement provisions vary depending on Berkshire&#8217;s ownership levels and in the event of certain specified leadership changes at Berkshire.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1658-2">The standstill agreement may be terminated by Berkshire at any time it ceases to beneficially own more than 15% of the Company's then-outstanding common stock, and terminates automatically if the Company enters into or publicly announces a plan to enter into a definitive agreement concerning a transaction involving all or a controlling portion of the Company's equity securities or all, or substantially all, of the Company's assets.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charter documents&#160;&amp; Delaware law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice for director nominations and stockholder proposals and granting the Company's Board of Directors the authority to issue up to <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-1665">5,000</ix:nonFraction> shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, prohibits the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of <ix:nonNumeric contextRef="c-1" name="dva:PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" format="ixt-sec:durwordsen" id="f-1666">three years</ix:nonNumeric> following the date on which that stockholder became an interested stockholder. The provisions described above may discourage, delay or prevent an acquisition of the Company at a price that stockholders may find attractive.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries</span></div><ix:nonNumeric contextRef="c-1" name="dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" id="f-1667" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries on the Company&#8217;s consolidated equity were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:52.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1668">936,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1669">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1670">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in paid-in capital for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-1671">3,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-1672">5,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-1673">6,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-1674">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-1675">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-1676">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1677">2,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1678">7,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1679">5,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc. net of transfers in <br/>&#160;noncontrolling interests</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-1680">933,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-1681">699,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-1682">554,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired additional ownership interests in several existing majority-owned partnerships for $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-1683">53,958</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-1684">12,555</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-1685">20,775</ix:nonFraction> in 2024, 2023 and 2022, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_373"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="f-1688" continuedAt="f-1688-1" escape="true">Accumulated other comprehensive loss</ix:nonNumeric></span></div><ix:continuation id="f-1688-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1689" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and credits to other comprehensive (loss) income have been as follows:&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"/><td style="width:40.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">cap agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined benefit plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other<br/>comprehensive<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1690">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-1691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1692">138,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1693">139,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1694">144,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1696">30,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1697">114,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1698">36,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="3" id="f-1699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="3" id="f-1700">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1701">35,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1702">108,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1704">29,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1705">78,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1706">11,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1709">11,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1710">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="f-1711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="f-1712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1713">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1714">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1717">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1718">98,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-1719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1720">167,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1721">69,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1722">9,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1724">89,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1725">98,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1726">2,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="3" id="f-1727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1728">1,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1729">3,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1730">6,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1732">87,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1733">94,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1734">103,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1737">103,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1738">25,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="f-1739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="f-1740">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1741">25,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1742">77,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1745">77,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1746">27,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-1747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1748">79,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1749">52,084</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1750">9,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="3" id="f-1751">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1752">207,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1753">198,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1754">2,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="3" id="f-1755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="3" id="f-1756">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1757">2,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1758">7,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="f-1759">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1760">207,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1761">200,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1762">58,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1763">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1764">15,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1765">73,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1766">14,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="f-1767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="3" id="f-1768">765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1769">15,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1770">43,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1772">14,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1773">58,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1774">8,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-1775">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1776">302,285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1777">310,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-1778" escape="true">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income.</ix:nonNumeric> See Note 12 for further details.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_376"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="f-1779" continuedAt="f-1779-1" escape="true">Acquisitions and divestitures</ix:nonNumeric></span></div><ix:continuation id="f-1779-1" continuedAt="f-1779-2"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of DaVita Care Pte. Ltd.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective <ix:nonNumeric contextRef="c-400" name="us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1" format="ixt:date-monthname-day-year-en" id="f-1780">November&#160;1, 2024</ix:nonNumeric>, the Company acquired control of <ix:nonNumeric contextRef="c-400" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" id="f-1781">DaVita Care Pte. Ltd.</ix:nonNumeric> (DVC), previously referred to as the Company's APAC joint venture, through a change in control rights for no cash consideration. See Note 8 for more information.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, the Company recognized a non-cash gain of $<ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="3" id="f-1782">59,067</ix:nonFraction> on its previously held equity interests in the acquiree and realized a related foreign currency gain of $<ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="3" id="f-1783">15,252</ix:nonFraction> from foreign currency translation adjustments on this investment which were previously classified in accumulated other comprehensive loss. The Company estimated the fair value of its previously held equity interests of $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-1784">114,744</ix:nonFraction> using appraisals developed with an independent third party valuation firm.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in this transaction and recognized at the acquisition date at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in this transaction:</span></div><div style="margin-top:9pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.894%"><tr><td style="width:1.0%"/><td style="width:76.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1785">34,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1786">44,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1787">22,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-1788">37,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1789">15,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1790">127,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1791">54,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1792">112,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1793">114,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other international and routine acquisitions</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" id="f-1794" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, 2023 and 2022, the Company acquired other dialysis and related businesses for consideration paid in cash. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of these other international and routine transactions in 2024, the Company acquired a controlling interest in a previously nonconsolidated U.S. dialysis partnership for which it recognized a non-cash gain of $<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="3" id="f-1795">35,147</ix:nonFraction> on its prior investment upon consolidation. The Company estimated the fair value of its previously held equity interest in this business using appraisals developed with independent third party valuation firms.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aggregate consideration &#8211; DVC and all other acquisitions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate consideration for both the DaVita Care Pte. Ltd. acquisition and all other international and routine acquisitions described above has been as follows:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"/><td style="width:54.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-1796">329,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-1797">27,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-1798">59,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent purchase price and liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-1799">50,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-1800">19,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-1801">19,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-1802">182,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:fixed-zero" scale="3" id="f-1803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:fixed-zero" scale="3" id="f-1804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1805">561,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1806">47,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1807">78,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-411" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1808">12</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-412" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" format="ixt:fixed-zero" id="f-1809">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-413" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1810">5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; International</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-414" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1811">198</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-415" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1812">12</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-416" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1813">11</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase price allocations &#8212; DVC and all other acquisitions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company&#8217;s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1779-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2024 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-1814" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"/><td style="width:52.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1815">83,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1816">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1817">1,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1818">249,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1819">6,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1820">6,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1821">94,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1822">4,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1823">7,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use lease assets and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-1824">97,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="f-1825">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-1826">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1827">22,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1828">15,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1829">19,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1830">349,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1831">25,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1832">49,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1833">201,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1834">6,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1835">6,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1836">133,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="3" id="f-1837">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="3" id="f-1838">867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1839">561,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1840">47,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1841">78,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" id="f-1842" escape="true">The amount of goodwill related to these acquisitions recognized or adjusted in 2024, 2023 and 2022 that is deductible for local tax purposes was $<ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="f-1843">54,810</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="f-1844">17,836</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="f-1845">49,047</ix:nonFraction>, respectively.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro forma financial information (unaudited)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="f-1846" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions in 2024 and 2023 had been consummated as of the beginning of 2023, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:62.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1847">13,073,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1848">12,625,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1849">952,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1850">732,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="f-1851">11.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="f-1852">8.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="f-1853">10.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="f-1854">7.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_382"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-1855" continuedAt="f-1855-1" escape="true">Discontinued operations previously held for sale</ix:nonNumeric></span></div><ix:continuation id="f-1855-1"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DaVita Medical Group (DMG)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-417" name="dva:BusinessSaleEffectiveDateOfSale" format="ixt:date-monthname-day-year-en" id="f-1856">June&#160;19, 2019</ix:nonNumeric>, the Company completed the sale of its prior DMG business to Optum, a subsidiary of UnitedHealth Group Inc. At close, the Company's ultimate net proceeds from this sale remained subject to resolution of certain post-closing adjustments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shortly after December 31, 2022, Optum made an additional purchase price payment of $<ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="dva:GainOnDispositionOfBusinessAdditionalPurchasePricePayment" format="ixt:num-dot-decimal" scale="3" id="f-1857">13,452</ix:nonFraction> to the Company after resolution of one such post-closing matter, which represented a contingent gain to the Company for the fourth quarter of 2022. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1858"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1859"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1860">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> DMG operating, financing or investing cash flows for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity purchase agreement, the Company also has certain continuing indemnification obligations that could require payments to the buyer relating to the Company's previous ownership and operation of the DMG business. Potential payments under these provisions, if any, remain subject to continuing uncertainties and the amounts of such payments could be significant to the Company.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_388"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-1872" continuedAt="f-1872-1" escape="true">Variable interest entities</ix:nonNumeric></span></div><ix:continuation id="f-1872-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-1873" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, non-U.S. subsidiaries that are structurally dependent on subordinated debt, or other legal entities subject to nominee ownership arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#8217;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#8217;s economic performance, the obligation to absorb the entity&#8217;s expected losses, or the right to receive the entity&#8217;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#8217;s losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the VIEs described above, these consolidated financial statements include total assets of $<ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1874">577,585</ix:nonFraction> and total liabilities and noncontrolling interests to third parties of $<ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1875">249,900</ix:nonFraction> at December&#160;31, 2024. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also sponsors certain non-qualified deferred compensation plans whose trusts qualify as VIEs and the Company consolidates these plans as their primary beneficiary.&#160;The assets of these plans are recorded in short-term or long-term investments with related liabilities recorded in accrued compensation and benefits and other long-term liabilities.&#160;See Notes 4 and 14 for disclosures concerning the assets of these consolidated non-qualified deferred compensation plans.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_391"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-1876" continuedAt="f-1876-1" escape="true">Fair values of financial instruments</ix:nonNumeric></span></div><ix:continuation id="f-1876-1" continuedAt="f-1876-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the FASB.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1876-2" continuedAt="f-1876-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-1877" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1878">40,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1879">40,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-425" xsi:nil="true" name="us-gaap:EquitySecuritiesFvNi" id="f-1880"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-426" xsi:nil="true" name="us-gaap:EquitySecuritiesFvNi" id="f-1881"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1882">30,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-428" xsi:nil="true" name="us-gaap:DerivativeAssets" id="f-1883"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1884">30,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-430" xsi:nil="true" name="us-gaap:DerivativeAssets" id="f-1885"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1886">13,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-424" xsi:nil="true" name="us-gaap:BusinessCombinationContingentConsiderationLiability" id="f-1887"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-425" xsi:nil="true" name="us-gaap:BusinessCombinationContingentConsiderationLiability" id="f-1888"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1889">13,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1890">1,695,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-424" xsi:nil="true" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" id="f-1891"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-425" xsi:nil="true" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" id="f-1892"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1893">1,695,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1894">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1895">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-433" xsi:nil="true" name="us-gaap:EquitySecuritiesFvNi" id="f-1896"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-434" xsi:nil="true" name="us-gaap:EquitySecuritiesFvNi" id="f-1897"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1898">79,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-436" xsi:nil="true" name="us-gaap:DerivativeAssets" id="f-1899"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1900">79,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-438" xsi:nil="true" name="us-gaap:DerivativeAssets" id="f-1901"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1902">23,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-432" xsi:nil="true" name="us-gaap:BusinessCombinationContingentConsiderationLiability" id="f-1903"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-433" xsi:nil="true" name="us-gaap:BusinessCombinationContingentConsiderationLiability" id="f-1904"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1905">23,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1906">1,499,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-432" xsi:nil="true" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" id="f-1907"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-433" xsi:nil="true" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" id="f-1908"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1909">1,499,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 4 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 12 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had contingent earn-out obligations associated with business acquisitions that could result in the Company paying the former owners a total of up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1910">24,580</ix:nonFraction> if certain performance targets or quality margins are met over the next <ix:nonNumeric contextRef="c-439" name="dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" format="ixt-sec:durwordsen" id="f-1911">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="c-440" name="dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" format="ixt-sec:durwordsen" id="f-1912">five years</ix:nonNumeric>. The estimated fair value measurements of these contingent earn-out obligations are primarily based on unobservable inputs, including projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and key performance indicators. The estimated fair value of these contingent earn-out obligations is remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of December&#160;31, 2024, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" format="ixt:num-dot-decimal" scale="3" id="f-1913">225,000</ix:nonFraction>. See Note 16 for a discussion of the Company&#8217;s methodology for estimating the fair values of noncontrolling interests subject to put obligations and the reconciliation of changes on the consolidated statements of equity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair value estimates for its senior secured credit facilities are based upon quoted bid and ask prices for these instruments, a level 2 input. For the Company's senior notes, fair value estimates are based on level 1 market inputs. See Note 12 for further discussion of the Company's debt. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1876-3"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in the consolidated financial statements at December&#160;31, 2024 and 2023 at their approximate fair values due to the short-term nature of their settlements.</span></div></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_394"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1914" continuedAt="f-1914-1" escape="true">Segment reporting</ix:nonNumeric></span></div><ix:continuation id="f-1914-1" continuedAt="f-1914-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating divisions are composed of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support functions. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a summary description of the Company's businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company&#8217;s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company&#8217;s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its operations in each foreign sovereign jurisdiction, and, until its reconsolidation in the fourth quarter of 2024, the Company's equity method investment in its Asia Pacific joint venture (APAC JV). The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to assess the financial performance of and allocate resources among the Company's operating segments. For internal management reporting, segment operations include direct segment operating expenses but generally exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive compensation expenses of certain departments which provide support to more than one of the Company&#8217;s various operating lines of business. The chief operating decision maker uses segment operating margin to assess segment profitability and resource allocation. The chief operating decision maker does not review total assets by segment to make decisions regarding resources; therefore, the total assets by segment disclosure has not been included.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-1915" escape="true"><ix:continuation id="f-1914-2" continuedAt="f-1914-3"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of segment revenues, segment operating margin, and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1916">11,294,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1917">10,823,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1918">10,488,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1919">71,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1920">88,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1921">87,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1922">11,366,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1923">10,911,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1924">10,575,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1925">24,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1926">25,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1927">24,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="3" id="f-1928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-3" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="3" id="f-1929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-3" sign="-" name="us-gaap:OtherIncome" scale="3" id="f-1930">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1931">11,390,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1932">10,936,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1933">10,599,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1934">965,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1935">751,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1936">688,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external sources</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1937">530,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1938">539,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1939">408,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1940">13,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1941">7,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1942">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1943">1,510,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1944">1,299,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1945">1,101,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1946">12,901,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1947">12,236,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1948">11,701,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1949">85,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1950">96,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1951">91,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1952">12,815,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1953">12,140,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1954">11,609,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant segment expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="f-1955">7,497,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="f-1956">7,394,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="f-1957">7,334,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1958">1,173,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1959">1,102,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1960">1,037,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1961">661,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1962">695,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1963">690,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-1964">63,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-1965">29,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-1966">28,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis segment expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1967">9,269,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1968">9,162,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1969">9,034,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1970">1,427,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1971">1,307,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1972">1,197,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1973">2,121,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1974">1,774,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1975">1,565,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1976">82,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1977">8,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1978">96,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1979">2,203,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1980">1,765,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1981">1,468,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:SegmentReportingInformationCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1982">113,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:SegmentReportingInformationCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1983">163,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:SegmentReportingInformationCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1984">129,669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1985">2,090,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1986">1,602,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1987">1,339,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-1988">470,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-1989">398,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-1990">357,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt prepayment, extinguishment and modification costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:DebtPrepaymentExtinguishmentAndModificationCosts" format="ixt:num-dot-decimal" scale="3" id="f-1991">19,813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:DebtPrepaymentExtinguishmentAndModificationCosts" format="ixt:num-dot-decimal" scale="3" id="f-1992">7,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:DebtPrepaymentExtinguishmentAndModificationCosts" format="ixt:fixed-zero" scale="3" id="f-1993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1994">69,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1995">19,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1996">15,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1997">1,530,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1998">1,177,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1999">966,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other segment items for our U.S. dialysis segment include equity income from nonconsolidated joint ventures and a gain on changes in ownership interest.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating margin (loss) for Other - Ancillary services includes equity investment loss of $<ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-2000">1,701</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-2001">2,103</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-2002">1,898</ix:nonFraction> in 2024, 2023 and 2022, respectively.</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1914-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="f-2003" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:48.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2004">661,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2005">695,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2006">690,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2007">62,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2008">49,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2009">41,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2010">723,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2011">745,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2012">732,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" id="f-2013" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for property and equipment by reportable segment were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:48.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-2014">469,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-2015">501,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-2016">533,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-2017">85,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-2018">66,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-2019">69,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-2020">555,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-2021">567,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-2022">603,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dva:NetPropertyAndEquipmentInternationalOperationsTextBlock" id="f-2023" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's international operations include approximately $<ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-2024">317,488</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-2025">240,742</ix:nonFraction> in 2024 and 2023, respectively, of net property and equipment.</span></div></ix:nonNumeric></ix:continuation><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_397"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="f-2026" continuedAt="f-2026-1" escape="true">Supplemental cash flow information</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="f-2027" escape="true"><ix:continuation id="f-2026-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides supplemental cash flow information:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"/><td style="width:49.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-2028">387,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-2029">268,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-2030">344,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-2031">423,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-2032">387,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-2033">350,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets under financing lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-2034">11,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-2035">13,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-2036">1,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_400"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.950%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312517362136/d496893dex101.htm">2.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., Collaborative Care Holdings, LLC, and solely with respect to Section 9.3 and Section 9.18 thereto, UnitedHealth Group Incorporated.(2)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312518280459/d621366dex101.htm">2.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 dated as of September 20, 2018, to that certain Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., a Delaware corporation, Collaborative Care Holdings, LLC, a Delaware limited liability company and a wholly owned subsidiary of Optum, Inc., and solely with respect to Section 9.3 and Section 9.18 thereto, UnitedHealth Group Incorporated, a Delaware corporation.(14)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312518350364/d658923dex101.htm">2.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment to Equity Purchase Agreement by and between DaVita Inc., a Delaware corporation, and Collaborative Care Holdings, LLC, a Delaware limited liability company, dated as of December 11, 2018, amending that certain Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., Collaborative Care Holdings, LLC, and, solely with respect to Section&#160;9.3 and Section 9.18 thereto, UnitedHealth Group Incorporated (as previously amended).(9)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000152/ex31-dvaamendedandrestated.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation of DaVita Inc.(1)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706622000160/ex31-amendedandrestatedbyl.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Bylaws for DaVita Inc. adopted on September 5, 2024.(23)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706620000125/exhibit41-indenture692.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture for the 4.625% Senior Notes due 2030, dated as of June 9, 2020, by and among DaVita Inc., the subsidiary guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as Trustee.(13)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706620000125/exhibit41-indenture692.htm">4.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 4.625% Senior Notes due 2030 and related Guarantee (included in Exhibit 4.1).(13)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706620000177/ex41-indentureaugust20.htm">4.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture for the 3.750% Senior Notes due 2031, dated August 11, 2020, by and among DaVita Inc., the subsidiary guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as Trustee.(11)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706620000177/ex41-indentureaugust20.htm">4.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 3.750% Senior Notes due 2031 and related Guarantee (included in Exhibit 4.3).(11)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000120677424000784/dva4366031-ex41.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture for 6.785% Senior Notes due 2032, dated as of August 13, 2024, by and among DaVita Inc., the subsidiary guarantors party thereto and the Bank of New York Mellon Trust Company, N.A., as Trustee.(26)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000120677424000784/dva4366031-ex41.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 6.875% Senior Notes due 2032 and related Guarantee (included in Exhibit 4.5).(26)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706620000014/dva-123119ex45.htm">4.7</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Securities.(20)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706619000137/ex1012019creditagreement.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement, dated August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, Credit Agricole Corporate and Investment Bank, JPMorgan Chase Bank, N.A. and MUFG Bank Ltd., as co-syndication agents, Bank of America, N.A., Barclays Bank PLC, Credit Suisse Loan Funding LLC, Goldman Sachs Bank USA, Morgan Stanley Senior Funding, Inc. and Suntrust Bank, as co-documentation agents, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(16)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706620000014/dva-123119ex103.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment, dated as of February 13, 2020, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(20)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000104/ex104-secondamendmenttocre.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment, dated as of April 3, 2023, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(25)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000096/ex101-thirdamendmenttocred.htm">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Amendment, dated as of April 28, 2023, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(24)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 1 of 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.950%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706624000093/ex101-fourthamendmentexfor.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth Amendment, dated as of May 9, 2024, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(28)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex106-fifthamendmenttocred.htm">10.6</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fifth Amendment, dated as of August 7, 2024, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000120677424000784/dva4366031-ex101.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sixth Amendment, dated as of August 13, 2024, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender (including a conformed copy of the Credit Agreement, reflecting all amendments through the Sixth Amendment, attached as Annex A thereto).(26)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706622000002/ex991standstillagreementdt.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Standstill Agreement, dated February 9, 2022, by and between DaVita inc. and Berkshire Hathaway Inc.(27)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706624000083/ex101-brksharerepurchaseag.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Repurchase Agreement, dated as of April 30, 2024, by and between DaVita Inc. and Berkshire Hathaway Inc.(29)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312519123788/d726706dex101.htm">10.10</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, dated as of April 29, 2019, by and between Javier J. Rodriguez and DaVita Inc.(10)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706619000202/dva-def14a.htm#sE0D95A9952875B7195329C9BDDFC0BDC">10.11</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Appreciation Rights Agreement, effective November 4, 2019, by and between Javier J. Rodriguez and DaVita Inc.(19)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000156459017002409/dva-ex1013_1293.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective February 21, 2017, by and between DaVita Inc. and Joel Ackerman.(6)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000162828017004680/dva-33117ex102.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective April 27, 2016, by and between DaVita HealthCare Partners Inc. and Kathleen A. Waters.(4)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706620000014/dva-123119ex1021.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective April 29, 2015, by and between DaVita HealthCare Partners Inc. and Michael Staffieri.(20)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000120677424000897/dva4379221-ex101.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000120677424000897/dva4379221-ex101.htm">0.15</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective September 15, 2024, by and between DaVita Inc. and David Maughan.(31)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312506257237/dex101.htm">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnity Agreement.(8)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312505041002/dex1028.htm">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnity Agreement.(5)*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000156459017002409/dva-ex1016_1294.htm">10.18</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Deferred Compensation Plan.(6)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000104746916013062/a2228594zdef14a.htm#du73201_stockholder_proposals_for_2017_annual_meeting">10.19</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Employee Stock Purchase Plan.(18)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706621000166/dva-93021ex101x2021davitai.htm">10.20</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Severance Plan for Directors and Above.(3)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000011/ex1014-nonxemployeedirecto.htm">10.21</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Non-Employee Director Compensation Policy.(15)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312514163315/d701196ddef14a.htm#toc701196_76">10.22</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated DaVita Inc. 2011 Incentive Award Plan.(7)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706619000202/dva-def14a.htm#s443F0CA95E025906867096037A067CF7">10.23</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to the Amended and Restated DaVita Inc. 2011 Incentive Award Plan.(19)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706620000064/dva-123119xdef14a.htm">10.24</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. 2020 Incentive Award Plan.(21)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d27.htm">10.25</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 2 of 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.950%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.038%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312520221812/d905943dex99d31.htm">10.26</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement (DaVita Inc. 2020 Incentive Award Plan).(22)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312520221812/d905943dex99d32.htm">10.27</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance-Based Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(22)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000119312520221812/d905943dex99d33.htm">10.28</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(22)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000104/ex101-formssarawardagreeme.htm">10.29</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement (DaVita Inc. 2020 Incentive Award Plan).(25)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000104/ex102-formpsuawardagreemen.htm">10.30</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance-Based Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(25)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000104/ex103-formrsuawardagreemen.htm">10.31</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(25)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706624000090/ex101-2024formpsuawardagre.htm">10.32</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance-Based Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(30)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706624000090/ex102-2024formrsuawardagre.htm">10.33</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(30)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706624000090/ex103-2024formssarawardagr.htm">10.34</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement (DaVita Inc. 2020 Incentive Award Plan).(30)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex191-dvainsidertradingpol.htm">19.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Insider Trading Policy.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123124ex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">List of our subsidiaries.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123124ex231.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of KPMG LLP, independent registered public accounting firm.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if6ba8dc5b26140f49e5fc4e21f5168f4_403">24.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Powers of Attorney with respect to DaVita Inc. (Included on Page S-1).</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123124ex31110xk.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Executive Officer, dated February&#160;13, 2025, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123124ex31210xk.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Financial Officer, dated February&#160;13, 2025, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123124ex32110xk.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Executive Officer, dated February&#160;13, 2025, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123124ex32210xk.htm">32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Financial Officer, dated February&#160;13, 2025, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706624000013/a971davitadodd-frankcompen.htm">97.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Dodd-Frank Policy on Recoupment of Incentive Compensation.(12)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 3 of 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.950%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.735%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"/><td style="width:5.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in this filing.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or executive compensation plan or arrangement.</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on June 8, 2023 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on December 6, 2017 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on October 28, 2021 as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on May 2, 2017 as an exhibit to the Company&#8217;s Quarterly Report on 10-Q for the quarter ended March 31, 2017.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on March 3, 2005 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2004.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on February 24, 2017 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on April 28, 2014 as an appendix to the Company's Definitive Proxy Statement on Schedule 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on December 20, 2006 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on December 17, 2018 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on April 29, 2019 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 11, 2020 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on February 14, 2024 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on June 9, 2020 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on September 24, 2018 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on February 22, 2023 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 14, 2019 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on July 22, 2019 as an exhibit to the Company&#8217;s Tender Offer Statement on Schedule TO-I. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 10, 2016 as an appendix to the Company's Proxy Statement on DEF 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on December 6, 2019 as an appendix to the Company's Proxy Statement on DEF 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on February 21, 2020 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on April 27, 2020 as an appendix to the Company's Proxy Statement on DEF 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 17, 2020 as an exhibit to the Company&#8217;s Tender Offer Statement on Schedule TO-I.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on September 5, 2024 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 1, 2023 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 8, 2023 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 14, 2024 as an exhibit to the Company&#8217;s Current Report on Form 8-K. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on February 9, 2022 as an exhibit to the Company&#8217;s Current Report on Form 8-K. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 13, 2024 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 1, 2024 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 2, 2024 as an exhibit to the Company&#8217;s Quarterly Report on 10-Q for the quarter ended March 31, 2024.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on September 13, 2024 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 4 of 4</span></div></div></div><div id="if6ba8dc5b26140f49e5fc4e21f5168f4_403"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, we have duly caused this Annual Report on Form 10-K to be signed on our behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado, on February&#160;13, 2025.</span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.807%"><tr><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.552%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DAVITA INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Javier J. Rodriguez<br/>Chief Executive Officer</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL MEN BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Javier J. Rodriguez, Joel Ackerman, and Kathleen Waters, and each of them his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Javier J. Rodriguez</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OEL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CKERMAN</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joel Ackerman</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERRY</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher M. Berry </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RWAY</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pamela M. Arway</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HARLES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> G. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERG</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles G. Berg</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARBARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESOER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbara J. Desoer</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OLLAR</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">REGORY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OORE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory J. Moore</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ULLIN</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dennis W. Pullin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DAM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CHECHTER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam H. Schechter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENDY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CHOPPERT</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy L. Schoppert</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HYLLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R. Y</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phyllis R. Yale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>ex106-fifthamendmenttocred.htm
<DESCRIPTION>EX-10.6
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8cdfa47783e54c08b9867ad353235252_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.6</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FIFTH AMENDMENT dated as of August 7, 2024 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), to the Credit Agreement (as defined below) among DaVita Inc., as Borrower (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the other Loan Parties party hereto, each Lender party hereto and Wells Fargo Bank, National Association, as Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.  &#160;&#160;&#160;&#160;The Borrower, the Lenders party thereto from time to time, the other parties thereto and Wells Fargo Bank, National Association, as Administrative Agent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Collateral Agent and Swingline Lender, are party to that certain Credit Agreement dated as of August 12, 2019 (as amended, supplemented or otherwise modified from time to time prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;The Borrower desires to amend the Credit Agreement on the terms set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Section 11.1 of the Credit Agreement provides that the Credit Agreement may be amended with the consent of the Required Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">D.&#160;&#160;&#160;&#160;Subject to certain conditions, the Required Lenders are willing to agree to such amendments.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AGREEMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower, the Lenders party hereto and the Administrative Agent hereby agree as follows&#58;</font></div><div id="i8cdfa47783e54c08b9867ad353235252_4"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.45pt"><br><br>Amendment</font></div><div id="i8cdfa47783e54c08b9867ad353235252_7"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 1.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.85pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Capitalized terms used herein (including in the recitals hereto) and not otherwise defined herein shall have the meanings assigned to such terms in the Credit Agreement.  The rules of construction specified in Section&#160;1.3 of the Credit Agreement also apply to this Amendment.</font></div><div id="i8cdfa47783e54c08b9867ad353235252_10"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 1.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.85pt;text-decoration:underline">Amendment of Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective as of the Fifth Amendment Effective Date, Section 2.24(b)(i) of the Credit Agreement is amended to remove the proviso set forth below&#58;</font></div><div id="i8cdfa47783e54c08b9867ad353235252_13"></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 1.03.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:0.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the aggregate principal amount of all Incremental Term A Loans shall not exceed (A) $750,000,000 plus (B) an amount equal to the excess, if any, of (x) the amount of Tranche A-1 Term Loans outstanding on the Third Amendment Effective Date less (y) the amount of  Tranche A-1 Term Loans outstanding on the applicable Increase Effective Date&#59;&#8221;</font></div><div id="i8cdfa47783e54c08b9867ad353235252_16"></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 1.04.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.85pt;text-decoration:underline">Amendment Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment shall become effective on the date (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Fifth Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that the Administrative Agent shall have received executed signature pages hereto from Lenders constituting the Required Lenders, the Borrower and each other Loan Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i8cdfa47783e54c08b9867ad353235252_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Execution Version</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.79pt"><br><br>Miscellaneous</font></div><div id="i8cdfa47783e54c08b9867ad353235252_22"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 2.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.85pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div id="i8cdfa47783e54c08b9867ad353235252_25"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">To induce the other parties hereto to enter into this Amendment, each Loan Party represents and warrants to each of the Lenders, and the Administrative Agent that, as of the Fifth Amendment Effective Date and after giving effect to the transactions and amendments to occur on the Fifth Amendment Effective Date, this Amendment has been duly authorized, executed and delivered by each Loan Party and constitutes, and the Credit Agreement, as amended hereby on the Fifth Amendment Effective Date, will constitute, its legal, valid and binding obligation, enforceable against each of the Loan Parties in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors&#8217; rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.</font></div><div id="i8cdfa47783e54c08b9867ad353235252_28"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The representations and warranties of each Loan Party set forth in the Loan Documents are, after giving effect to this Amendment on such date, true and correct in all material respects (except that any representation and warranty that is qualified as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; shall be true and correct in all respects) on and as of the Fifth Amendment Effective Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and warranties were true and correct in all material respects as of such earlier date).</font></div><div id="i8cdfa47783e54c08b9867ad353235252_31"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">After giving effect to this Amendment and the transactions contemplated hereby on the Fifth Amendment Effective Date, no Default or Event of Default has occurred and is continuing on the Fifth Amendment Effective Date.</font></div><div id="i8cdfa47783e54c08b9867ad353235252_34"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 2.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.85pt;text-decoration:underline">Effect of Amendment&#59; Reaffirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  (a)  This Amendment is not intended to and shall not constitute a novation of the Credit Agreement or any of the other Loan Documents.  Except as expressly set forth herein, this Amendment (i) shall not by implication or otherwise limit, impair, constitute a waiver of, or otherwise affect the rights and remedies of, the Lenders, the Issuing Lenders or the Agents under the Credit Agreement or any other Loan Document, and (ii) shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document. Except as expressly set forth herein, each and every term, condition, obligation, covenant and agreement contained in the Credit Agreement or any other Loan Document is hereby ratified and re-affirmed in all respects and shall continue in full force and effect.  Each Loan Party hereby expressly acknowledges the terms of this Amendment and (except as expressly set forth herein) reaffirms, as of the date hereof, (i) the covenants and agreements contained in each Loan Document to which such Loan Party is a party, including, in each case, such covenants and agreements as in effect immediately after giving effect to this Amendment and the transactions contemplated hereby and (ii) such Loan Party&#8217;s guarantee of the Obligations under the Guarantee in Section 10.1 of the Credit Agreement, as applicable, and such Loan Party&#8217;s prior grant and the validity of Liens and security interests on the Collateral to secure the Secured Obligations pursuant to the Security Documents and confirms that all such Liens and security interests continue in full force and effect to secure the Secured Obligations under the Loan Documents after giving effect to this Amendment.  Without limiting the generality of the foregoing, the Security Documents and all of the Collateral described therein do and shall continue to secure the payment of all Secured Obligations of the Loan Parties under the Loan Documents, as amended by, and after giving effect to, this Amendment. Each Loan Party hereby consents to this Amendment and confirms that all obligations of the Loan Parties under the Loan Documents to which the Loan Parties are a party shall continue to apply to the Credit Agreement, including on and after the Fifth Amendment Effective Date, as amended hereby.  Nothing herein shall be deemed to establish a precedent for purposes of interpreting the provisions of the Credit Agreement or entitle any Loan Party to a consent to, or a waiver, amendment, modification or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document in similar or different circumstances.  This Amendment shall apply to and be effective only with respect to the provisions of the Credit Agreement and the other Loan Documents specifically referred to herein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt"> On and after the Fifth Amendment Effective Date each reference in the Credit Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221;, &#8220;herein&#8221; or words of like import, and each reference to the Credit Agreement, &#8220;thereunder&#8221;, &#8220;thereof&#8221;, &#8220;therein&#8221; or words of like import in any other Loan Document, shall be deemed a reference to the Credit Agreement, as amended hereby on the Fifth Amendment Effective Date.  This Amendment shall constitute a &#8220;Loan Document&#8221; for all purposes of the Credit Agreement and the other Loan Documents.</font></div><div id="i8cdfa47783e54c08b9867ad353235252_40"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 2.03.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:0.85pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.  THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK (INCLUDING, WITHOUT LIMITATION, SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW, BUT OTHERWISE WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES THEREOF)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The jurisdiction and waiver of right to trial by jury provisions in Section 11.12 of the Credit Agreement are incorporated herein by reference mutatis mutandis.</font></div><div id="i8cdfa47783e54c08b9867ad353235252_43"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 2.04.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.85pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument.  Any signature to this Amendment may be delivered by facsimile, .pdf, electronic mail or any electronic signature complying with the U.S. federal ESIGN Act of 2000 or the New York Electronic Signature and Records Act or other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes to the fullest extent permitted by applicable law.  The Administrative Agent may require that any such documents and signatures delivered by facsimile, .pdf or other electronic means be confirmed by a manually signed original thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the failure to request or deliver the same shall not limit the effectiveness of any document or signature delivered by facsimile, .pdf or other electronic means.</font></div><div id="i8cdfa47783e54c08b9867ad353235252_46"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 2.05.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.85pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The headings of this Amendment are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.</font></div><div style="padding-left:0.9pt;padding-right:0.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature pages follow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i8cdfa47783e54c08b9867ad353235252_49"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their officers as of the date first above written.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DAVITA INC.</font></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Nicolas K. Eliason</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nicolas K. Eliason</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Group Vice President, Capital Markets &#38; Investor Relations</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;DVA &#8211; Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GUARANTORS&#58;</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DIALYSIS HOLDINGS, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DVA OF NEW YORK, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DVA HEALTHCARE OF MASSACHUSETTS, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DVA HEALTHCARE RENAL CARE, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DVA RENAL HEALTHCARE, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ISD I HOLDING COMPANY, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ISD II HOLDING COMPANY, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ISD RENAL, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PHYSICIANS DIALYSIS ACQUISITIONS, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RENAL LIFE LINK, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RENAL TREATMENT CENTERS, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RENAL TREATMENT CENTERS &#8211; CALIFORNIA, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RENAL TREATMENT CENTERS &#8211; ILLINOIS, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RENAL TREATMENT CENTERS &#8211; MID-ATLANTIC, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RENAL TREATMENT CENTERS &#8211; NORTHEAST, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RENAL TREATMENT CENTERS &#8211; WEST, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TOTAL RENAL CARE, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TOTAL RENAL LABORATORIES, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TRC WEST, INC.</font></div><div style="padding-left:207.35pt;text-indent:-27.35pt"><font><br></font></div><div style="padding-left:207.35pt;text-indent:-27.35pt"><font><br></font></div><div style="padding-left:207.35pt;text-indent:-27.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Patrick J. McKinnon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patrick J. McKinnon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="padding-left:207.35pt;text-indent:-27.35pt"><font><br></font></div><div style="padding-left:207.35pt;text-indent:-27.35pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RENAL TREATMENT CENTERS - SOUTHEAST, LP</font></div><div style="padding-left:216pt;text-indent:72pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;Renal Treatment Centers, Inc.,</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;its general partner</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Patrick J. McKinnon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patrick J. McKinnon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;DVA &#8211; Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TOTAL RENAL CARE TEXAS LIMITED PARTNERSHIP</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; Total Renal Care, Inc., its general partner</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Patrick J. McKinnon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patrick J. McKinnon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">VILLAGEHEALTH DM, LLC</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; Total Renal Care, Inc., its managing member</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Patrick J. McKinnon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patrick J. McKinnon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="padding-left:180pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;DVA &#8211; Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">KNICKERBOCKER DIALYSIS, INC.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DAVITA OF NEW YORK, INC.</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt;text-indent:-0.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Luann D. Regensburg</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Luann D. Regensburg</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vice President and Treasurer</font></td></tr></table></div><div style="padding-left:180pt;text-indent:-0.35pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LIBERTY RC, INC.</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt;text-indent:-0.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Pierce</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Caroline Pierce</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President</font></td></tr></table></div><div style="padding-left:180pt;text-indent:-0.35pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;DVA &#8211; Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent</font></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Darin Mullis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Darin Mullis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Director</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;DVA &#8211; Signature Page to Fifth Amendment&#93;</font></div></div></div><div id="i8cdfa47783e54c08b9867ad353235252_52"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;margin-top:12pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;LENDER NAME&#93;, As a Lender</font></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:216pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If second signature is necessary&#58;</font></div><div style="margin-bottom:24pt;margin-top:12pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:24pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Amendment is also executed by the following lenders (signature pages omitted from filing)&#58;</font></div><div style="margin-bottom:24pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.519%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bank of America, N.A.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bank of Cyprus Public Company Ltd</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bank of Nova Scotia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Banner Bank</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cr&#233;dit Agricole Corporate and Investment Bank</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DNB Capital, LLC</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">First Horizon Bank</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goldman Sachs Bank USA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HSBC Bank USA, N.A.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JPMorgan Chase N.A.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">M&#38;T Bank</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MUFG Bank, Ltd</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regions Bank</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Santander Bank, N.A.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">State Bank of India, California</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sumitomo Mitsui Banking Corporation</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TD Bank, N.A.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Huntington National Bank</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Trust Bank N.A.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Trustmark National Bank</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wells Fargo Bank, National Association</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;DVA &#8211; Signature Page to Fifth Amendment&#93;</font></div></div></div><div id="i8cdfa47783e54c08b9867ad353235252_549755814278"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;margin-top:12pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CAPITAL ONE NATIONAL ASSOCIATION, as a Tranche A-1 Term Lender, Revolving A-1 Lender and Incremental Revolving A-1 Lender</font></td></tr><tr style="height:17pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Esha Shah</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Esha Shah</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duly Authorized Signatory</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;DVA &#8211; Signature Page to Fifth Amendment&#93;</font></div></div></div><div id="i8cdfa47783e54c08b9867ad353235252_549755814451"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;margin-top:12pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">UBS AG New York (Eleven Madison Avenue) Branch, as a Revolving A-1 Lender and Alternative Currency  Revolving A-1 Lender</font></td></tr><tr style="height:17pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Vipul Dhadda</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vipul Dhadda</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Director</font></td></tr></table></div><div style="margin-bottom:24pt;margin-top:12pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Cassandra Droogan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cassandra Droogan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;DVA &#8211; Signature Page to Fifth Amendment&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>ex191-dvainsidertradingpol.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i821a725b6e0b4c8a867d543a895cbb82_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 19.1</font></div></div><div style="text-align:justify"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:230px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt">PURPOSE</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To provide guidelines to directors, executive officers and teammates (including temporary and provisional teammates and independent contractors) (collectively &#8220;teammates&#8221;) of DaVita Inc. (the &#8220;Company&#8221;) or any of its subsidiaries regarding transactions involving Company Securities (as defined below) or securities of third parties (&#8220;Third-Party Securities&#8221;).  It is the Company&#8217;s policy that Insiders (as defined below) must comply with applicable securities laws and regulations at all times.  Under no circumstances may any Insider trade in any Company Securities or Third-Party Securities while in possession of Material Non-Public Information (as defined below) regarding the Company or such other entity obtained as a result of his or her service with the Company.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt">APPLICABILITY</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Insider Trading Policy (this &#8220;Policy&#8221;) applies to all transactions in the Company&#8217;s securities (&#8220;Company Securities&#8221;), including, without limitation, common stock, options for common stock, stock-settled stock appreciation rights, restricted stock units and any other securities the Company may issue from time to time, such as preferred stock, warrants and debt, as well as to derivative securities relating to the Company&#8217;s stock or other securities, whether or not issued by the Company, such as exchange-traded options, and to Third-Party Securities.  </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy applies to&#58; (i) all members of the Company&#8217;s Board of Directors, (ii) all executive officers of the Company, and (iii) all teammates of the Company or any of its subsidiaries who receive or have access to Material Non-Public Information regarding the Company or Third-Party Securities and any person who receives Material Non-Public Information from any Insider (sometimes referred to as &#8220;you&#8221; or a &#8220;Person&#8221;).  This Policy is meant to apply globally, inside and outside the U.S. alike, and applies to citizens of countries other than the U.S.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy also applies to family members who reside with you, including, without limitation, a child (even while temporarily away at college), stepchild, parent, stepparent, spouse, sibling and in-law, anyone else who lives in your household, and any family members who do not live in your household but whose transactions in Company Securities or Third-Party Securities are directed by you or subject to your influence or control, such as parents or children who consult with you before they trade in Company Securities or Third-Party Securities (each a &#8220;Related Person&#8221; and collectively, &#8220;Related Persons&#8221;).  This Policy also applies to any entities you influence or control, including, without limitation, any corporations, partnerships, trusts or investment clubs (collectively referred to as &#8220;Controlled Entities&#8221;).</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Transactions by Related Persons and Controlled Entities should be treated for purposes of this Policy and applicable securities laws and regulations as if they were for your own account. </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You are reminded that the Company&#8217;s Code of Conduct and any confidentiality agreement with the Company prohibit disclosure of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> confidential information to third parties other than in accordance with the Company&#8217;s policies, whether or not such information would be deemed &#8220;material&#8221; under insider trading rules.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt">DEFINITIONS OF INSIDER, MATERIAL NON-PUBLIC INFORMATION AND TRADING DAY</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Insider.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Any Person who possesses Material Non-Public Information (as defined below) is considered an &#8220;Insider&#8221; as to that information for so long as that information is not publicly known.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Insiders&#8221; include members of the Company&#8217;s Board of Directors, all executive officers of the Company and all teammates of the Company and its subsidiaries who are in possession of or have access to Material Non-Public Information, as well as such person&#8217;s Related Persons and Controlled Entities.  </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Any teammate can be a temporary Insider from time to time, and would at those times be subject to the restrictions described in this Policy.  </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Material Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The materiality of information depends on the facts and circumstances of the situation, and while there is no bright-line standard for assessing materiality, materiality is often evaluated by enforcement authorities with the benefit of hindsight.  Based on the general principles established by the courts, information is considered material if&#58;</font></div><div style="margin-bottom:6pt;padding-left:56.65pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision regarding the purchase or sale of Company Securities or Third-Party Securities&#59;</font></div><div style="margin-bottom:6pt;padding-left:56.65pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">it would be viewed by a reasonable investor as significantly altering the total mix of information available publicly about the Company or applicable third party&#59; or</font></div><div style="margin-bottom:6pt;padding-left:56.65pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">it is reasonably certain to have a substantial effect on the market price of Company Securities or Third-Party Securities.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-Public Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Information that has not been disclosed to the public is generally considered to be non-public information.  To establish that information has been disclosed, it may be necessary to demonstrate that the information has been widely disseminated and fully absorbed by the investing public.  </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Generally speaking, information should not be considered widely disseminated and fully absorbed by the marketplace until after the first full Trading Day (as defined below) after the information is released.  For example, if the Company were to make an announcement after market close on a Monday, you should not trade until Wednesday.  In certain circumstances, the Company may determine that a longer period is required with respect to the release of certain information.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Material Non-Public Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Information that is both &#8220;Material&#8221; and &#8220;Non-Public&#8221; as described above is considered &#8220;Material Non-Public Information.&#8221;  Material Non-Public Information can be positive or negative and is information that has not been previously disclosed to the general public and is otherwise not available to the general public.  </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Materiality depends on the specific circumstances of each situation. While there are no universal thresholds for materiality, the following are some examples of the types of information that may be regarded as material and should be reviewed carefully&#58;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Financial results&#59;</font></div><div style="padding-left:54pt;padding-right:-36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Projections of future earnings or losses&#59;</font></div><div style="padding-left:54pt;padding-right:-36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Guidance or changes in guidance to be provided publicly regarding earnings, revenues or other financial performance&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Quarterly or annual earnings, revenues or other financial performance significantly different than analysts&#8217; consensus&#59;  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Changes in the structure and payment rates under the Medicare or Medicaid programs or set forth in contracts with major private payors&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Significant litigation exposure due to actual or threatened litigation or the initiation of or a major development in an investigation by a regulatory body or significant litigation&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Gain or loss of a substantial customer or supplier, or entry into or the termination of a significant agreement&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Major changes in senior management, corporate strategy or operations&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A change in auditor or notification that the auditor&#8217;s reports may no longer be relied upon&#59; </font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Stock splits&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">New equity or debt offerings or other significant financing activity&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Impending bankruptcy or financial liquidity problems&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Changes in dividend policy&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">New product or services announcements of a significant nature&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Significant pricing changes&#59;</font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">News of a pending or proposed merger or acquisition, or disposition of a subsidiary&#59; </font></div><div style="padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A significant cybersecurity incident, such as a data breach, or any other significant disruption in the Company&#8217;s operations or loss, potential loss, breach or unauthorized access of its property or assets, whether at its facilities or through its information technology infrastructure&#59; and </font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Other favorable or unfavorable business developments.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The events listed above are only examples&#59; many other types of information may be considered &#8220;material&#8221; depending on the circumstances.  The materiality of particular information is subject to reassessment on a regular basis.  When doubt exists as to whether information is material, you should assume the information is material.  Teammates are reminded that no Insider (other than the Company&#8217;s CEO, CFO and Head of Investor Relations, or their designee), without consulting with the Company&#8217;s legal counsel in advance, may comment on stock price movement or rumors concerning corporate developments that are of possible significance to the investing public.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Trading Day.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Any day on which the New York Stock Exchange is open for trading.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt">POLICY</font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Trading on Material Non-Public Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as otherwise specified in Section 5.4, an Insider may not engage in any transaction involving a purchase or sale or other disposition (including gifts) of Company Securities or Third-Party Securities, as applicable, including any offer to purchase or offer to sell, during any blackout period or any other period beginning with the date and time that he or she comes into possession of Material Non-Public Information concerning the Company or the Third-Party Securities obtained as a result of his or her service with the Company, as applicable, and ending after the first full Trading Day following public disclosure of that information, or when such Material Non-Public Information is no longer material.  During a blackout period or a period in which an Insider possesses Material Non-Public Information regarding the Company, these restrictions generally also apply to elections under Benefit Plans and the ESPP (each as defined below), and to the timing of stock option and SSAR (as defined below) exercises.  More details on these restrictions are provided below in Section 5.4.</font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, the Company may engage in transactions in Company Securities. The Company will not trade in Company Securities in violation of applicable securities laws or stock exchange listing standards.</font></div><div style="margin-bottom:6pt;padding-left:43.2pt;padding-right:-9pt;text-align:justify;text-indent:-25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.7pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tipping&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  An Insider may not disclose Material Non-Public Information (also known as &#8220;tipping&#8221;) to any other person (including Related Persons, co-workers, customers, suppliers or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:43.2pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">friends) where the information may be used by such person to profit by trading in the securities of companies to which the information relates.  &#8220;Tipping&#8221; is always prohibited.</font></div><div style="margin-bottom:6pt;padding-left:43.2pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the course of performing your duties with the Company, you may have access to Material Non-Public Information regarding other companies, such as, for example, companies with which the Company does business or is considering significant transaction(s).  You should not disclose any Material Non-Public Information regarding the Company or such other companies, nor make recommendations or express opinions about trading in Company Securities or Third-Party Securities on the basis of Material Non-Public Information about the Company or such other company to anyone where the information may be used by the recipient to profit by trading in Company Securities or Third-Party Securities to which the information relates.  </font></div><div style="margin-bottom:6pt;padding-left:43.2pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To prevent tipping, do not discuss Material Non-Public Information where it may be overheard, such as in restaurants, elevators, restrooms, and other public places.  Remember that cellular phone conversations are often overheard and that voice mail and e-mail messages may be retrieved by persons other than their intended recipients.  </font></div><div style="margin-bottom:6pt;padding-left:43.2pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even if you are not in possession of Material Non-Public Information, you should not recommend to any other person that they buy or sell Company Securities or Third-Party Securities.  Your recommendation could be unfairly attributed to the Company and may be misleading if you do not have all relevant information.  </font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Transactions in Company Securities through Benefit Plans and the Employee Stock Purchase Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Policy also applies to certain elections you may make under the Company&#8217;s Retirement Savings Plan, the Deferred Compensation Plan and other similar benefit plans that may be available from time to time (&#8220;Benefit Plans&#8221;) and the Company&#8217;s employee stock purchase plan (the &#8220;ESPP&#8221;).  Regular and matching contributions to a Company stock fund or other investments in Company Securities under a Benefit Plan pursuant to an election you made while you were not subject to a blackout period (as described in Section 5.1 below) or in possession of Material Non-Public Information regarding the Company are permitted during a blackout period or while you are in possession of Material Non-Public Information.  However, while you are subject to a blackout period or in possession of Material Non-Public Information regarding the Company, you may not make a new election under a Benefit Plan or the ESPP to the extent that election would involve a Company stock fund or Company Securities.  This Policy does not apply to (x) enrollment in any of the Benefit Plans while you are subject to a blackout period or in possession of Material Non-Public Information so long as such enrollment decision and any related elections do not involve a Company stock fund or Company Securities or (y) purchases by the Benefit Plan trustee of Company Securities in the Company&#8217;s Benefit Plan resulting from periodic contributions of money to the plan pursuant to your payroll deduction, dividend reinvestments within the Benefit Plan or distributions of cash or Company Securities out of the Benefit Plan by reason of death, disability, retirement or termination of employment.  In addition, the purchase of shares under the ESPP pursuant to an election you made while you were not subject to a blackout period or in possession of Material Non-Public Information regarding the Company is permitted during a blackout period, but not the subsequent sale or certain other dispositions of any such shares during such blackout period.</font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Share Withholding for Taxes or to Pay Exercise Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Any election to satisfy tax or exercise price obligations arising in connection with equity awards held by you other than through the use of share withholding must be approved by the Chief Legal Officer of the Company or the Chief Legal Officer&#8217;s designee.  For the avoidance of doubt, such approval will not be granted if you are (i) subject to a Company Blackout Period (as hereinafter defined) or any other blackout period described in Section 5.1 below, or (ii) if you are subject to a pre-clearance requirement imposed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hereunder by the Chief Legal Officer and, as determined in the Chief Legal Officer&#8217;s sole discretion, are in possession of Material Non-Public Information regarding the Company.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt">COMPANY PROCEDURES </font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Trading Window</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company strongly recommends that all teammates with access to the Company&#8217;s internal financial statements refrain from transactions involving the purchase or sale or other dispositions of Company Securities outside of the Trading Window.  The &#8220;Trading Window&#8221; begins when the New York Stock Exchange closes on the first full Trading Day after the Company&#8217;s announcement of financial results for the prior fiscal quarter or year and ends at 11&#58;59 p.m. U.S. Mountain Time on the 15th calendar day prior to the current fiscal quarter or year end.</font></div><div style="margin-bottom:6pt;padding-left:40.5pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although the Company endeavors to monitor when teammates might have access to Material Non-Public Information and communicate timely guidance to teammates to refrain from purchases or sales or other dispositions of Company Securities, it is ultimately your responsibility to understand and comply with this Policy regardless of whether you receive such guidance. Even during the Trading Window, any person possessing Material Non-Public Information concerning the Company should not engage in any transactions in Company Securities until at least one full Trading Day following the public disclosure of such information, or when such Material Non-Public Information is no longer material.  Trading in Company Securities during the Trading Window is not a &#8220;safe harbor,&#8221; and all members of the Board of Directors, executive officers and teammates should use good judgment at all times.</font></div><div style="margin-bottom:6pt;padding-left:40.5pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has established regular blackout periods and may establish event-driven blackout periods for Insiders and other teammates. The U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) also prohibits Insiders from trading and other dispositions of securities during certain periods.  This Policy refers to Company Blackout Periods, Off-Cycle Blackout Periods and SEC Blackout Periods (each as defined below) as &#8220;blackout periods.&#8221;</font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Quarterly Earnings Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Members of the Board of Directors, all executive officers, certain members of senior management, certain teammates from the Finance, Accounting and Legal departments and other teammates, as identified from time to time as having access to the Company&#8217;s financial results, are prohibited from trading in or other dispositions of Company Securities during the period beginning at 12&#58;00 a.m. U.S. Mountain Time on the 14th calendar day before the end of any fiscal quarter or year and continuing through close of the New York Stock Exchange on the first full Trading Day after the Company&#8217;s release of financial results for the quarter or year (the &#8220;Company Blackout Period&#8221;).  The Company endeavors to provide advance notice of the beginning and end of each Company Blackout Period&#59; however, you are responsible for being aware of each Company Blackout Period applicable to you.  You should also plan for the possibility that the Chief Legal Officer may institute an Off-Cycle Blackout Period (as discussed in Section 5.3) at any time and upon limited notice, if any.</font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Off-Cycle Blackout or Pre-clearance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  From time to time the Chief Legal Officer may determine that members of the Board of Directors, executive officers, and certain teammates of the Company or any of its subsidiaries must either suspend any trading or other dispositions of Company Securities or obtain pre-clearance (as discussed in Section 6.4) before engaging in such activities because of material or potentially material developments known to such individuals and not disclosed yet to the public.  If such a blackout (an &#8220;Off-Cycle Blackout Period&#8221;) is declared or if pre-clearance is deemed applicable, the Company will endeavor to advise those individuals to whom it applies&#59; however, such individuals must exercise appropriate judgment in connection with any trade in Company Securities or Third-Party Securities and are ultimately responsible for any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">violations of this Policy or applicable securities laws even if they have not been notified of such Off-Cycle Blackout Period or pre-clearance requirement.</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Exceptions to Quarterly Earnings Blackout Period and Off-Cycle Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  There are certain limited exceptions to the Company Blackout Period and Off-Cycle Blackout Periods.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt;text-decoration:underline">Gifts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  A bona fide gift of Company Securities is generally only permitted when you are not in a blackout period and under circumstances where transactions in Company Securities are not prohibited under this Policy.  The Chief Legal Officer, however, upon your written request during a Company Blackout Period will evaluate (or during any other blackout period, will re-evaluate) whether you are not in possession of Material Non-Public Information regarding the Company and therefore should be authorized to make the gift.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt;text-decoration:underline">Expiring Stock-Settled Stock Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unexercised stock-settled stock appreciation rights (&#8220;SSARs&#8221;) that will expire during a blackout period may be exercised on the last Trading Day prior to the expiration of the award, if the SSARs are &#8220;in the money.&#8221; Any shares acquired through the exercise of SSARs must be held by the SSAR grant holder until after the applicable blackout period has ended.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt;text-decoration:underline">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Policy does not apply to the vesting of restricted stock units (&#8220;RSUs&#8221;) and other full-value awards, such as performance awards and restricted stock (collectively, &#8220;Full-Value Awards&#8221;), that occurs during a blackout period.  Any shares acquired pursuant to vesting of RSUs or other Full-Value Awards during a blackout period must be held until after the applicable blackout period has ended. </font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt;text-decoration:underline">Expiring Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unexercised stock options that will expire during a blackout period may be exercised on the last Trading Day prior to the expiration of the option if the options are &#8220;in the money.&#8221;  Any shares acquired through the exercise of an option must be held until after the applicable blackout period has ended. </font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt;text-decoration:underline">Benefit Plans and Employee Stock Purchase Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Regular and matching contributions to the Company stock fund in a Benefit Plan pursuant to the election you made while you were not subject to a blackout period or in possession of Material Non-Public Information regarding the Company are permitted during a blackout period.  In addition, the purchase of shares under the ESPP pursuant to an election you made while you were not subject to a blackout period or in possession of Material Non-Public Information regarding the Company is permitted during the blackout period, but not the subsequent sale or certain other dispositions of any such shares during such blackout period.  Restrictions on your activities under Benefit Plans and the ESPP are described in Section 4.3 above.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.59pt;text-decoration:underline">10b5-1 Trading Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Automatic trading pursuant to a written program established prior to the applicable blackout period and in accordance with the conditions described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is permitted during a blackout period.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt;text-decoration:underline">Share Withholding to Cover Taxes or Exercise Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For the avoidance of doubt, this Policy does not apply to the withholding of shares to satisfy tax withholding requirements upon (i) vesting of any Full-Value Awards or (ii) exercise of any expiring SSARs or stock options in accordance with this Policy.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt">ADDITIONAL INFORMATION FOR DIRECTORS AND EXECUTIVE OFFICERS</font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Section 16 of the Securities Exchange Act of 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Members of the Company&#8217;s Board of Directors and officers of the Company (as defined in Section 16 (&#8220;Section 16&#8221;) of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;)) are referred to collectively as &#8220;Section 16 Persons&#8221; and individually as a &#8220;Section 16 Person&#8221; in this Policy and are subject to the requirements of Section 16.  Section 16 Persons are required to report their holdings and transactions in Company Securities.  Section 16 Persons must report their beneficial ownership of the Company&#8217;s stock or derivative securities to the SEC on Form 3 within ten days of becoming a Section 16 Person and on Form 4 within two business days of any transaction that changes their ownership. The Company offers assistance with these reporting requirements, and Section 16 Persons must instruct their brokers to report transaction details to specific Company officials within two hours of the transaction. In addition, Section 16 Persons should take care not to violate the prohibition on short-swing trading (Section 16(b) of the Exchange Act) and the restrictions on sales by control persons (Rule&#160;144 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)).</font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Transactions in Company Benefit Plans and Section 16 Reporting Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Executive Officers subject to Section 16 may also have reporting obligations for certain transactions in the Company&#8217;s stock fund included in the Benefit Plans. For example, such transactions may include&#58;  (a) an election to increase or decrease the amount or percentage of your periodic contributions that will be allocated to the Company stock fund, (b) an election to make an intra-plan transfer of an existing account balance into or out of the Company stock fund, (c) an election to borrow money against your Benefit Plan account if the loan will result in the liquidation of some or all of your Company stock fund balance, and (d) your election to prepay a Benefit Plan loan if the prepayment will result in a change in your Company stock fund balance.  Any of these transactions, and potentially others, may be reportable on a Form 4 within two business days of the execution date.  </font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Transfers of funds in and out of a Company stock fund or a cash-out of assets in a Company stock fund may be subject to short-swing liability if there has been an opposite-way fund transfer or cash-out within six months of the initial transaction.  The second, non-exempt plan transaction is matchable against any other non-exempt transactions that you may have made in the equity securities of the Company within six months whether under the plan, on the open market or otherwise, resulting in short-swing liability.</font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Participants in Benefit Plans subject to Section 16 reporting will not be permitted to process fund transfers, loans and in-service withdrawals through the employee benefit plan automated systems.  Like other transactions, Insiders who wish to effect a transaction through a Benefit Plan must obtain written clearance from the Chief Legal Officer prior to execution of such Discretionary Transaction.  </font></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">SEC Blackout Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  SEC rules prohibit Section 16 Persons from trading in Company equity securities during an &#8220;SEC Blackout Period,&#8221; which is any period of three or more consecutive days during which at least 50% of the participants or beneficiaries in an &#8220;individual account&#8221; retirement plan of the Company or its subsidiaries are unable to purchase, sell, or otherwise acquire or transfer an interest in the equity of the Company held in such plan due to a temporary suspension by the Company or a fiduciary.  &#8220;Individual account&#8221; plans include, without limitation, defined contribution plans such as broad-based tax-qualified 401(k) plans and profit sharing plans, stock bonus plans, and certain nonqualified deferred compensation arrangements.  There are limited exceptions to this rule, and Section 16 Persons should consult with the Company&#8217;s Chief Legal Officer prior to attempting a stock transaction during the above-described SEC Blackout Period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:39.6pt;padding-right:-9pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Pre-Clearance Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In addition to the pre-clearance requirements under Section 5.3, the Company has determined that neither Section 16 Persons nor their Related Persons may acquire or dispose of Company Securities without first obtaining pre-clearance from the Chief Legal Officer of the Company or the Chief Legal Officer&#8217;s designee, which may be either the Chief Executive Officer or the Chief Financial Officer of the Company.  The Chief Legal Officer may not acquire or dispose Company Securities without first obtaining the pre-clearance of either the Chief Executive Officer or the Chief Financial Officer of the Company.  The Chief Executive Officer, in addition to obtaining clearance from the Chief Legal Officer (or the Chief Financial Officer, when acting as the Chief Legal Officer&#8217;s designee), shall notify the Chair of the Board (or, if the Chief Executive Officer serves as the Chair of the Board, the lead independent director) and the Chair of the Compensation Committee of any planned transaction as soon as reasonably practicable prior to such transaction.  In all instances, clearance may be verbal and followed by a written confirmation. If you become aware of Material Non-Public Information regarding the Company before the transaction is executed, the pre-clearance is void and the transaction must not be completed.  If the transaction is not executed within five business days (or such other shorter period as the Chief Legal Officer determines to be appropriate under the circumstances ) of receipt of pre-clearance, a new pre-clearance request must be submitted to the Chief Legal Officer.  The person to whom a pre-clearance request is submitted is under no obligation to approve the request, and may determine not to permit the transaction.  If a person seeks pre-clearance and permission to engage in a transaction is denied, they must refrain from initiating any transaction involving Company Securities, and should not disclose the restriction to any other person.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt">ADDITIONAL PROHIBITED TRANSACTIONS, RESTRICTIONS AND GUIDANCE</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company generally considers it improper and inappropriate for any directors, executive officers and teammates of the Company and&#47;or its subsidiaries to engage in short-term or speculative transactions in Company Securities or in other transactions in Company Securities that may lead to inadvertent violations of the insider trading laws.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Short Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  A short sale involves a sale of securities that are not then owned by the seller, including a &#8220;sale against the box&#8221; (a sale with delayed delivery).  Short sales of Company Securities, among other things, evidence an expectation on the part of the seller that the securities will decline in value, and therefore may reduce the seller&#8217;s incentive to improve the Company&#8217;s performance.  For these reasons, short sales of Company Securities are prohibited by this Policy.  In addition, Section 16(c) of the Exchange Act prohibits directors and executive officers from engaging in short sales.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Publicly Traded Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  A transaction in options is, in effect, a bet on the short-term movement of the Company&#8217;s stock.  Transactions in options may focus the director&#8217;s, executive officer&#8217;s or other teammate&#8217;s attention on short-term performance at the expense of the Company&#8217;s long-term objectives.  Accordingly, transactions in puts, calls or other derivative securities with respect to the Company on an exchange or in any other organized market are prohibited by this Policy. </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Hedging Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Certain forms of hedging or monetization transactions, such as zero-cost dollars and forward sale contracts, allow a director, executive officer or other teammate to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock.  These transactions allow the director, executive officer or other teammate to continue to own the covered securities, but without the full risks and rewards of ownership.  When that occurs, the director, executive officer or other teammate&#8217;s interests may no longer be aligned with those of the Company&#8217;s other stockholders.  In addition, such transactions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">are complex and require a careful analysis of many aspects of the securities laws, including filing and disclosure laws.  For these reasons, hedging or monetization transactions involving Company Securities for the purpose or with the effect as described above are prohibited by this Policy.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Pledges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because this type of sale may occur at a time when the pledger is aware of Material Non-Public Information regarding the Company or otherwise is not permitted to trade in Company Securities, all members of the Company&#8217;s Board of Directors and all teammates at Vice President levels and above are prohibited, and all other teammates are strongly discouraged, from pledging Company Securities as collateral for a loan. </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Margin Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Securities held in a margin account may be sold by the broker without the customer&#8217;s consent if the customer fails to meet a margin call.  Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of Material Non-Public Information regarding the Company or otherwise is not permitted to trade in Company Securities, all members of the Company&#8217;s Board of Directors and all teammates at Vice President levels and above are prohibited, and all other teammates are strongly discouraged, from holding Company Securities in a margin account.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:39.6pt;padding-right:-9.35pt;text-align:justify;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.1pt;text-decoration:underline">Standing Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Certain kinds of standing orders can create heightened risks for insider trading violations. Accordingly, you should inform your broker about any applicable blackout periods and cancel any standing orders at the start of any blackout period applicable to you.  The Company may, but shall not be required to, instruct its stock plan administrator to cancel any outstanding standing orders at the start of any blackout period.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt">POST-TERMINATION TRANSACTIONS</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If you are aware of Material Non-Public Information when you terminate employment with or services to the Company or one of its subsidiaries, you may not trade in Company Securities or Third-Party Securities, as applicable, until that information has become public or is no longer material.  In all other respects, the procedures set in this Policy will cease to apply to your transactions in Company Securities upon the expiration of any blackout period that is applicable to your transactions at the time of your termination of employment or services.  Please note, however, that for directors and executive officers of the Company, certain other securities laws requirements may continue to apply to you for a period of time post-termination, such as the short-swing profit rule and the need to comply with Rule 144 promulgated under the Securities Act with respect to sales of Company Securities.</font></div><div style="margin-bottom:6pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">CONSEQUENCES OF VIOLATIONS</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The purchase or sale or other dispositions of securities while aware of Material Non-Public Information, or the disclosure of Material Non-Public Information to others who then trade in Company Securities or Third-Party Securities, is prohibited by federal and state laws.  Each person is individually responsible for complying with the securities laws applicable to their region and this Policy, regardless of whether we have prohibited trading by that person or any other Insiders.  The responsibility of determining whether an Insider possesses Material Non-Public Information rests with the Insider, and pre-clearance of a transaction does not constitute legal advice and does not in any way insulate an Insider from liability under the securities laws.</font></div><div style="margin-bottom:6pt;padding-left:49.5pt;padding-right:-9pt;text-align:justify;text-indent:-30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.1pt;text-decoration:underline">Liability for Insider Trading</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Insiders may be subject to both civil and criminal liabilities and sanctions, including up to $5,000,000 in criminal fines, up to 20 years in jail and civil penalties up to three times the illegal profit gained or loss avoided for engaging in transactions in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:49.5pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">securities at a time when they have knowledge of Material Non-Public Information regarding those securities.</font></div><div style="margin-bottom:6pt;padding-left:49.5pt;padding-right:-9pt;text-align:justify;text-indent:-30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.1pt;text-decoration:underline">Liability for Tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Insiders may be liable for improper transactions by any person (commonly referred to as a &#8220;tippee&#8221;) to whom they have disclosed Material Non-Public Information, or to whom they have made recommendations or expressed opinions on the basis of such information about trading securities.  The SEC has imposed large penalties even when the disclosing person did not profit from the trading.  The SEC, the stock exchanges and the National Association of Securities Dealers, Inc. use sophisticated electronic surveillance techniques to uncover insider trading.</font></div><div style="margin-bottom:6pt;padding-left:49.5pt;padding-right:-9pt;text-align:justify;text-indent:-30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.1pt;text-decoration:underline">Sanctions for Violations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Any person who violates this Policy may be subject to sanctions, up to and including termination of employment, whether or not such failure to comply results in a violation of law.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Appropriate judgment should be exercised in connection with securities trading.  The guidelines in this Policy should not be a substitute for any applicable laws and regulations which may apply in the jurisdictions where you work or do business.</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:4.25pt"> INTERPRETATION</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Legal Officer has the authority to interpret and enforce this Policy, and to grant certain exceptions to this Policy to the extent any such exceptions are consistent with the general purposes of this Policy and applicable laws. Any suspected or known violation of this Policy should be reported immediately to the Chief Legal Officer.  All questions about this Policy should be directed in the first instance to the Chief Legal Officer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i821a725b6e0b4c8a867d543a895cbb82_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.32pt;padding-right:4.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">APPENDIX A</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;padding-right:-9.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RULE 10B5-1 TRADING PLANS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to Rule 10b5-1 of the Exchange Act (&#8220;Rule 10b5-1&#8221;), members of the Board of Directors, officers and teammates of the Company may establish written programs which permit&#58; (a) automatic trading of Company Securities through a third-party broker or (b) trading of Company Securities by an independent person (e.g., an investment banker or broker) who is not aware of Material Non-Public Information regarding the Company or subject to a blackout period at the time of a trade.  Once a program is implemented that complies with Rule 10b5-1, trades pursuant to such program will not be subject to certain of the limitations and restrictions set forth in other sections of this Policy, as  trading pursuant to a program may occur even at a time outside of the Company&#8217;s Trading Window, during a blackout period or when the person on whose behalf such trade is made is in possession of Material Non-Public Information.  Each program must be reviewed and approved by the Company&#8217;s Chief Legal Officer prior to establishment.  If the Chief Legal Officer desires to establish a trading program, the program must be submitted for review to the Chief Financial Officer for review and approval of the program prior to establishment. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The establishment or termination of programs pursuant to this Policy and all trades made pursuant thereto may be disclosed to the public through a press release, by placement on the Company&#8217;s website or through other means, and&#47;or as may be required by SEC disclosure rules, including pursuant to the quarterly reporting requirements of Rule 10b5-1.  The Company will not have any liability to any Program Eligible Person (defined below) in connection with the establishment or use of a program, including any Company disclosure with respect thereto or any cancellation of transactions and&#47;or suspension of a program as discussed below, or otherwise. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:29.59pt;text-decoration:underline">Trading Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Trading plans established in compliance with this Policy (each a &#8220;Program&#8221;) must comply with the requirements set forth in Rule 10b5-1 and are limited to the following two types&#58; </font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">A written Program which permits automatic trading of the Company&#8217;s stock through a third-party broker (an &#8220;Automatic Trading Program&#8221;) established by a member of the Board of Directors, officer, or teammate of the Company (a &#8220;Program Eligible Person&#8221;) at a time when the Program Eligible Person is not subject to a blackout period or aware of any Material Non-Public Information regarding the Company.  The Automatic Trading Program document must specify the number of shares to be purchased or sold, and the prices at which and the dates on which the planned transactions will be executed.  Alternatively, the Automatic Trading Program may establish an objective formula for any or all of these criteria (e.g., the number of shares could be specified as a percentage of the holdings of the Program Eligible Person)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;padding-right:-9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">A Program where transactions in the Company&#8217;s stock are initiated by the trustee of a so-called &#8220;blind&#8221; trust, provided the Program is established by a Program Eligible Person at a time when the Program Eligible Person is not subject to a blackout period or aware of any Material Non-Public Information regarding the Company.  A &#8220;blind&#8221; trust is a trust established by a Program Eligible Person.  The investment and disposition decisions must be made by an independent trustee without the Program Eligible Person&#8217;s involvement or knowledge.  The trustee should be a recognized financial institution possessing trust powers.  Under this type of Program, the Program Eligible Person cannot exert any influence over, or even communicate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:58.5pt;padding-right:-9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with, the trustee regarding specific investments.  If the trustee becomes aware of Material Non-Public Information regarding the Company, whether from the Program Eligible Person or otherwise, the trustee may not engage in a purchase or sale of the Company&#8217;s stock on behalf of such Program Eligible Person through a Program.</font></div><div style="margin-bottom:12pt;padding-right:-9pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.43pt;text-decoration:underline">Additional Program Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  All Programs will also be subject to the following restrictions&#58;</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">The Program Eligible Person cannot engage in any separate transaction (e.g., a hedging transaction) which directly or indirectly alters or offsets an authorized transaction made under a Program.</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Any Program Eligible Person preparing a Program must allow for the cancellation of a transaction and&#47;or suspension of the Program upon notice and request by the Company to the extent the Program or any proposed trade&#58; (a) fails to comply with applicable law (e.g., exceeding the number of shares which the Program Eligible Person may sell under Rule 144 promulgated under the Securities Act, in a rolling three month period), or (b) would create material adverse consequences for the Company (e.g., because it would prevent the Company from being able to enter into or would lead to a violation of a lock-up agreement on the Company officers).</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">No Program may be established at a time when the Program Eligible Person is aware of any Material Non-Public Information regarding the Company or subject to a blackout period in effect at the time of establishment.  For Section 16 Persons, the first transaction under the Program cannot occur earlier than the later to occur of (i) 90 calendar days following the establishment of the Program, or (ii) two business days following the filing of the Form 10-Q or Form 10-K for the fiscal quarter in which the Program was established, up to a maximum of 120 days after the date of establishment.  For all other Program Eligible Persons, unless an exception is requested and authorized by the Chief Legal Officer when the Program is established, the first transaction under the Program cannot occur sooner than 30 calendar days following the establishment of the Program. </font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Programs must include a representation that, on the date of establishment, the Program Eligible Person entering into the Program&#58; (i) is not aware of any Material Non-Public Information regarding the Company&#59; and (ii) is establishing the Program in good faith.</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Once a Program is established, it cannot be modified, changed or deviated from except&#58; (i) with approval of the Chief Legal Officer (or in the event the Program Eligible Person is the Chief Legal Officer, the Chief Financial Officer) and (ii) at a time when the Program Eligible Person is permitted to trade in the Company&#8217;s stock under this Policy (i.e., when the Program Eligible Person is not blocked from trading because of any applicable blackout period and when the Program Eligible Person is not otherwise aware of any Material Non-Public Information regarding the Company). Any Program that is modified must meet all requirements of a newly established Program, as if established on the date of modification.</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.59pt">The approval of the Company&#8217;s Chief Legal Officer must be obtained before a Program may be terminated.</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Single-trade plans (i.e., Programs that have only one trading event) are limited to one such Program during any consecutive twelve-month trading period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">All Programs must be entered into in good faith and not as part of a plan or scheme to evade the prohibitions of the securities laws, including, without limitation, Rule 10b5-1, and all Program Eligible Persons who have entered into a Program must act in good faith with respect to such Program for its duration.  The Company may immediately terminate or require termination of a Program if it determines that the Program Eligible Person entered into such Program or has acted with respect to such Program either&#58; (i) not in good faith, or (ii) as part of a plan or scheme to evade the prohibitions of the securities laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>dva-123124ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8a8a05af750a497a9e98efd6539e679e_1"></div><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1 </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF THE COMPANY </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December&#160;31, 2024&#160;</font></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aberdeen Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adair Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Afton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ahern Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alenes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alomie Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alterra Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Fork Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Medical Insurance, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amery Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arbela Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcadia Gardens Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arrowhead Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Artesia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashdow Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Astro, Hobby, West Mt. Renal Care Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atchison Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atlantic Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austin Dialysis Centers, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bainbridge Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Banfort Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bannack Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bannon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barnell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bastrop Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayshore Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bear Creek Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beck Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bedell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bellevue Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beverly Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beverly Hills Dialysis Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Birch Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bladon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blanco Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bliss Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bogachiel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bohama Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrego Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bothwell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Botkins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bottle Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bowan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brache Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Braddock Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Braden Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branbur Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bretton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bridges Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brimfield Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brook Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brookstone Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brownsville Kidney Center, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brownwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruno Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buckhorn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buford Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bullards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bullock Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burrill Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Butano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cadiz Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cagles Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Campton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canney Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canyon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canyon Springs Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Dialysis Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carlton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Virgin Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carroll County Dialysis Facility Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carroll County Dialysis Facility, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cascades Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caverns Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cedar Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centennial LV, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Carolina Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Georgia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Iowa Dialysis Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Kentucky Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chadron Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Challis Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changsha Baijun Medical Investment Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Channel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chantry Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cheraw Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chipeta Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chouteau Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Churchill Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cinco Rios Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clark Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claymount Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clayton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinica Central do Bonfim S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinton Township Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clyfee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coast Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Columbus-RNA-DaVita, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commerce Township Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conconully Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conecuh Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continental Dialysis Centers, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coral Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Couer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Court Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cowell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craville Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crossings Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crowder Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystals Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cuivre Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Culbert Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curecanti Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curlew Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dallas-Fort Worth Nephrology, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Damon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daroga Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita - Riverside II, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita - Riverside, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita - West, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita &#38; Dignity Health Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita (UK) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita (UK) Trading Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita APAC Holding B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Brasil Participa&#231;&#245;es e Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Care (Saudi Arabia)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Care Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Chile Holding SpA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita China Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Cia Ltda</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ecuador</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Dakota Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Deutschland AG</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita EL Paso East, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Forge Holding, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Germany GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Kidney Care Contracting, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Natal Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Nephron Care Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita of New York, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Rien Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Alvorada Ltda</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Ananindeua Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Asa Sul Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Bel&#233;m Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Boa Vista Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Bueno Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Campo Grande Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia de Araraquara Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Fonte Nova Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Franca Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Guarulhos Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Jo&#227;o Pessoa Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Lagoa Nova Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Marco Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Pacini Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Pantanal Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Santos Dumont Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Serra Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Sumar&#233; Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Taubat&#233; Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Vila Aricanduva Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os Nefrologia Madalena Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Singapore Holding Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Sp. z o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Sud-Niedersachsen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Tratamento Renal Participa&#231;&#245;es Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita UK Holding Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita UTR Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Value-Based Enterprise, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita VillageHealth, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dawson Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DC Healthcare International, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deowee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis of Des Moines, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis of Northern Illinois, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis Specialists of Dallas, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dierks Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dighton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dolores Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dome Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Doves Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Downriver Centers, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dresher Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dunes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dunkins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Durango Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DV Care Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DV Care Netherlands C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare - Southwest Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Maryland, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Massachusetts, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of New London, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Norwich, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Tuscaloosa, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare Renal Care, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Holdings Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Laboratory Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA of New York, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Renal Healthcare, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dworsher Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East End Dialysis Center, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East Ft. Lauderdale, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East Houston Kidney Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eavers Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ebrea Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edisto Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elandon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eldrist Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elgin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elk Grove Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elkhorn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empire State DC, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endicott Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Etowah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eufaula Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EURODIAL - Centro de Nefrologia e Dialise de Leiria S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fairfield Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Falcon, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanthorp Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Way Assurance, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ferne Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fields Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Star Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fjords Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flamingo Park Kidney Center, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forester Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freehold Artificial Kidney Center, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fremont Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontier Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fullerton Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ganchis Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ganois Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gansett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Garden State Renal, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Garner Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Garrett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gate Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gaviota Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GDC International, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gebhard Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genesis KC Development, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geyser Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilwards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glassland Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glosser Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Golden Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goldendale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goliad Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gordina Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gouache Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gramleer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grand Home Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Great Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater Las Vegas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater Los Angeles Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Green Country Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Green Desert Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Griffin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Groten Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hallowell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harmony Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harris Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hart Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Havenwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hawn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hazelton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hegan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helmer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hewett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heyburn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hilgards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hochatown Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holdrege Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holten Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Kidney Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Honey Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Honeyman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Houston Kidney Center&#47;Total Renal Care Integrated Service Network Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humboldt Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hummer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hunan Baijun Hightech Medical Investment Management Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hunter Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Huntington Artificial Kidney Center, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Huntington Park Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hyattsville Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hyde Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDC - International Dialysis Centers, Lda</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indian River Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Central California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Georgia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Great Plains, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Illinois And Indiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Lake Erie, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Michigan, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Mid-Atlantic, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Minnesota, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Missouri, Arkansas And Western Tennessee, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Nevada, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of New Jersey And Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Northern California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Pennsylvania And Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of South Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of South Texas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Southern California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Texas And Oklahoma, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of The Pacific Northwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Virginia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of West Texas And New Mexico, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iroquois Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Brandon, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Buffalo Grove, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Corpus Christi, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD I Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD II Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Kendallville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Las Vegas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Lees Summit, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Renal, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Spring Valley, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Summit Renal Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jabine Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacinto Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jenness Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jericho Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joshua Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kadden Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamiah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kasaskia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kavett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kearn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenai Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kidney HOME Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kidney Life, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimball Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kingston Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kinter Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knickerbocker Dialysis, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krapell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lakeshore Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Landing Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Landor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lantell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lassen Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lathrop Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latrobe Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasburg Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leawood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lees Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liberty RC, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lighthouse Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Park Dialysis Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincolnton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Little Rock Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livingston Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Llano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lofield Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Logoley Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lone Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long Beach Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lord Baltimore Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lory Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loup Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lourdes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lyndale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madigan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madison Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Magney Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Magnolia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Magoffin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Makonee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mammoth Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maple Grove Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marseille Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marysville Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mashero Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mason-Dixon Dialysis Facilities, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mazonia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSleuth, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Memorial Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mendocino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meramec Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meridian Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mermet Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merrik Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Middlesex Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milltown Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minam Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minneopa Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monad Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moraine Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mountain West Dialysis Services, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mulgee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Alzey GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Aurich GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Bad Aibling GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Bad D&#252;ben GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Dillenburg GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Dinkelsb&#252;hl GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Dormagen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Duisburg GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Elsterland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Emden GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Falkensee GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Geilenkirchen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Iserlohn GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita M&#246;nchengladbach GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Neuss GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Niederrhein GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Nierenzentrum Aachen Alsdorf GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Nierenzentrum Berlin-Britz GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Nierenzentrum Hamm-Ahlen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Prenzlau-Pasewalk GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Rhein-Ruhr GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Viersen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myrtle Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nansen Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Trail Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natomas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Navarro Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCA - Mid-Atlantic, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCA-National, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCA-SoCal, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neff Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neoporte Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nephrology Care Alliance, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Bay Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicona Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norte Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noster Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oasis Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ogano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio River Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Okanogan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olive Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orange Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordust Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orion Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osage Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owens Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owyhee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palmetto Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palomar Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panther Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient Pathways, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peaks Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pearl Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pendster Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percha Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pershing Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfeiffer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharis Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Choice Dialysis Of Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Choice Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Dialysis Acquisitions, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Dialysis of Lancaster, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Dialysis Ventures, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Management, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pible Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pike Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pinewoods Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pinson Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pittsburgh Dialysis Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Piute Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placid Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plaine Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plattaz Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platte Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise - Benfica, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise - Cascais, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise - Sacavem, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pobello Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poinsett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pokagon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portola Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prineville Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pruneau Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pyramid Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ramsey Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rancho Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ravalli Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rayburn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Red Willow Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redcliff Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refuge Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Beaumont, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Carrollton, L.P.L.L.L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Flower Mound, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Fort Dodge, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Frisco, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Hamilton, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Lewisville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Morristown, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Mountain Home, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Newton, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of North Denton, L.L.L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Port Arthur, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Sewell, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Succasunna, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of the Hills, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Tyler, L.P.L.L.L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of West Beaumont, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Westwood, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Clinic of Houston, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Life Link, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - California, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Illinois, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Mid-Atlantic, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Northeast, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Southeast, LP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - West, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Ventures Management, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RenalServ LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rend Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renwick Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rhodes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rickwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riddle Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ringwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rio Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">River Valley Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RNA - DaVita Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rollins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roose Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rophets Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roushe Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routt Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rusk Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rutland Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RV Academy, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saddleback Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sahara Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAKDC-DaVita Dialysis Partners, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Marcos Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sands Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santa Fe Springs Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santiam Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sapelo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seabay Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secour Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensiba Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shadow Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shawano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shayano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelling Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sherman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shetek Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shining Star Dialysis, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shoals Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shone Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Siena Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simeon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skagit Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sloss Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soledad Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Somerville Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Central Florida Dialysis Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Fork Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Shore Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southcrest Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern Hills Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southlake Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southwest Atlanta Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sparks Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sprague Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Springpond Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Star Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stevenson Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stewart Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stines Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Storrie Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sugarloaf Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sula Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun City Dialysis Center, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunapee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunset Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Talimena Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tannor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targhee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarley Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taum Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taylor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenack Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee Valley Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terbole Participa&#231;&#245;es Societ&#225;rias Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Woodlands Dialysis Center, LP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tolland Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tortugas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Care Of North Carolina, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Care Texas Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Care, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Laboratories, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Research, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toulouse Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Townsend Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transmountain Dialysis, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC - Indiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC - Petersburg, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC EL Paso Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC of New York, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC West, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC-Georgetown Regional Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">District Of Columbia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tross Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tugman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumalo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunnel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tustin Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Twain Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyler Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ubonsie Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unicoi Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">University Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upper Valley Dialysis, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USC-DaVita Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valley Springs Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Central Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Chicago and Indiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Connecticut, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of District of Columbia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of El Paso, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Georgia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Great Plains, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Illinois, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Louisville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Michigan, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Minnesota, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Nevada, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of New England, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of New Jersey and Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of New York Metro, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Northern Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Pacific Northwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Southern California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Southern Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Southern Texas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Texas And Oklahoma, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of The South, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Virginia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Western Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Wisconsin, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vancile Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vancleer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vanell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Victory Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vilander Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VillageHealth DM, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Villanueva Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vively Health, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vogel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waddell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wahconah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wakoni Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walker Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wallips Dialysis LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walteria Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washburne Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Watkins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wauseon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayside Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weldon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wesley Chapel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Elk Grove Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Sacramento Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weston Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Whitney Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wilder Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Willowbrook Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Winster Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Woodcrest Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wyandotte Central Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yargol Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yucaipa Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zara Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zellier Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:65.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zephyrhills Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zillmar Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>dva-123124ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i1232d89a363f4e45a0ae53fe12c78c15_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:63pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Exhibit 23.1</font></div><div style="margin-bottom:20pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements (Nos. 333-240022, 333-239191, 333-213119, 333-190434, 333-169467, 333-158220, 333-144097, 333-86550, and 333-30736) on Form S-8 and the registration statement (No. 333-182572) on Form S-4 of our reports dated February 13, 2025, with respect to the consolidated financial statements of DaVita Inc. and subsidiaries and the effectiveness of internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seattle, Washington</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;13, 2025</font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:63pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>dva-123124ex31110xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie6f8708cde1c4957a0bb3bd9b0249796_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Javier J. Rodriguez, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of DaVita Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.00pt"><tr><td style="width:1.0pt"></td><td style="width:277.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Javier J. Rodriguez</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;13, 2025</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>dva-123124ex31210xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2c4e5c6d603c403f9f38b2b23611cb82_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joel Ackerman, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of DaVita Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.75pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Joel Ackerman</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joel Ackerman</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;13, 2025</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>dva-123124ex32110xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie4108686aa2e426e981957944bd293d0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of DaVita Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Javier J. Rodriguez, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.75pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Javier J. Rodriguez</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</font></div></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>dva-123124ex32210xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie10117e723c94245b20d47b35a57a052_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of DaVita Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Joel Ackerman, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.75pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Joel Ackerman</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joel Ackerman</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;13, 2025</font></div></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>dva-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:47070f41-4839-4fd6-beb4-023e08dfe312,g:db2e526f-c810-4a70-bbc2-9b01e625d97f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dva="http://www.davita.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.davita.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.davita.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.davita.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>9952151 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME_1" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1">
        <link:definition>9952151 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952153 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFEQUITY" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY">
        <link:definition>9952156 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.davita.com/role/RevenueRecognition">
        <link:definition>9952158 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.davita.com/role/EarningsPerShare">
        <link:definition>9952159 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shorttermandlongterminvestments" roleURI="http://www.davita.com/role/Shorttermandlongterminvestments">
        <link:definition>9952160 - Disclosure - Short-term and long-term investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherReceivablesOtherReceivables" roleURI="http://www.davita.com/role/OtherReceivablesOtherReceivables">
        <link:definition>9952161 - Disclosure - Other Receivables Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.davita.com/role/PropertyandEquipment">
        <link:definition>9952162 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibles" roleURI="http://www.davita.com/role/Intangibles">
        <link:definition>9952163 - Disclosure - Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestments" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestments">
        <link:definition>9952164 - Disclosure - Equity Method and Other Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.davita.com/role/Goodwill">
        <link:definition>9952165 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilities" roleURI="http://www.davita.com/role/OtherLiabilities">
        <link:definition>9952166 - Disclosure - Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.davita.com/role/IncomeTaxes">
        <link:definition>9952167 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.davita.com/role/LongTermDebt">
        <link:definition>9952168 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.davita.com/role/Leases">
        <link:definition>9952169 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.davita.com/role/EmployeeBenefitPlans">
        <link:definition>9952170 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.davita.com/role/Contingencies">
        <link:definition>9952171 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments" roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments">
        <link:definition>9952172 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensation" roleURI="http://www.davita.com/role/Stockbasedcompensation">
        <link:definition>9952173 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockholdersequity" roleURI="http://www.davita.com/role/Stockholdersequity">
        <link:definition>9952174 - Disclosure - Stockholder's equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncome" roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome">
        <link:definition>9952175 - Disclosure - Accumulated Other Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.davita.com/role/AcquisitionsandDivestitures">
        <link:definition>9952176 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HeldforSaleandDiscontinuedOperations" roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperations">
        <link:definition>9952177 - Disclosure - Held for Sale and Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://www.davita.com/role/VariableInterestEntities">
        <link:definition>9952178 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstruments" roleURI="http://www.davita.com/role/FairValuesofFinancialInstruments">
        <link:definition>9952179 - Disclosure - Fair Values of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.davita.com/role/SegmentReporting">
        <link:definition>9952180 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.davita.com/role/SupplementalCashFlowInformation">
        <link:definition>9952181 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables" roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables">
        <link:definition>9955512 - Disclosure - Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.davita.com/role/EarningsPerShareTables">
        <link:definition>9955513 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermandlongterminvesmtentsTables" roleURI="http://www.davita.com/role/ShorttermandlongterminvesmtentsTables">
        <link:definition>9955514 - Disclosure - Short-term and long-term invesmtents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherReceivablesTables" roleURI="http://www.davita.com/role/OtherReceivablesTables">
        <link:definition>9955515 - Disclosure - Other Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.davita.com/role/PropertyandEquipmentTables">
        <link:definition>9955516 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesTables" roleURI="http://www.davita.com/role/IntangiblesTables">
        <link:definition>9955517 - Disclosure - Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables">
        <link:definition>9955518 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.davita.com/role/GoodwillTables">
        <link:definition>9955519 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesTables" roleURI="http://www.davita.com/role/OtherLiabilitiesTables">
        <link:definition>9955520 - Disclosure - Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.davita.com/role/IncomeTaxesTables">
        <link:definition>9955521 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.davita.com/role/LongTermDebtTables">
        <link:definition>9955522 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.davita.com/role/LeasesTables">
        <link:definition>9955523 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationandShareholdersEquityTables" roleURI="http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables">
        <link:definition>9955524 - Disclosure - Stock-based compensation and Shareholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityTables" roleURI="http://www.davita.com/role/StockholdersequityTables">
        <link:definition>9955525 - Disclosure - Stockholder's equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncomeTables" roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables">
        <link:definition>9955526 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresTables" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresTables">
        <link:definition>9955527 - Disclosure - Acquisitions and Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstrumentsTables" roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsTables">
        <link:definition>9955528 - Disclosure - Fair Values of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.davita.com/role/SegmentReportingTables">
        <link:definition>9955529 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.davita.com/role/SupplementalCashFlowInformationTables">
        <link:definition>9955530 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9955531 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails">
        <link:definition>9955532 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails">
        <link:definition>9955533 - Disclosure - Revenue Recognition and Accounts Receivable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails">
        <link:definition>9955534 - Disclosure - Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermandlongterminvestmentsDetails" roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails">
        <link:definition>9955535 - Disclosure - Short-term and long-term investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherReceivablesDetails" roleURI="http://www.davita.com/role/OtherReceivablesDetails">
        <link:definition>9955536 - Disclosure - Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.davita.com/role/PropertyandEquipmentDetails">
        <link:definition>9955537 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetails" roleURI="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails">
        <link:definition>9955538 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails">
        <link:definition>9955539 - Disclosure - Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails">
        <link:definition>9955540 - Disclosure - Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesAdditionalInformationDetails" roleURI="http://www.davita.com/role/IntangiblesAdditionalInformationDetails">
        <link:definition>9955541 - Disclosure - Intangibles - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails">
        <link:definition>9955542 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestmentsAdditionalInformationDetails" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails">
        <link:definition>9955543 - Disclosure - Equity Method and Other Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" roleURI="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails">
        <link:definition>9955544 - Disclosure - Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" roleURI="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails">
        <link:definition>9955545 - Disclosure - Goodwill - Schedule of Reporting Units Goodwill Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAdditionalInformationDetails" roleURI="http://www.davita.com/role/GoodwillAdditionalInformationDetails">
        <link:definition>9955546 - Disclosure - Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesDetails" roleURI="http://www.davita.com/role/OtherLiabilitiesDetails">
        <link:definition>9955547 - Disclosure - Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" roleURI="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails">
        <link:definition>9955548 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseDetails" roleURI="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails">
        <link:definition>9955549 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" roleURI="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails">
        <link:definition>9955550 - Disclosure - Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails">
        <link:definition>9955551 - Disclosure - Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails" roleURI="http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails">
        <link:definition>9955552 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9955553 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofLongTermDebtDetails" roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails">
        <link:definition>9955554 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduledMaturitiesofLongtermDebtDetails" roleURI="http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails">
        <link:definition>9955555 - Disclosure - Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDerivativeInstrumentsDetails" roleURI="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails">
        <link:definition>9955556 - Disclosure - Long-Term Debt - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" roleURI="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails">
        <link:definition>9955557 - Disclosure - Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalinformationDetail" roleURI="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail">
        <link:definition>9955558 - Disclosure - Long-Term Debt - Additional information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseExpenseComponentsDetails" roleURI="http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails">
        <link:definition>9955559 - Disclosure - Leases Lease Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesOtherInformationDetails" roleURI="http://www.davita.com/role/LeasesLeasesOtherInformationDetails">
        <link:definition>9955560 - Disclosure - Leases Leases Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" roleURI="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails">
        <link:definition>9955561 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.davita.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9955562 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>9955563 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.davita.com/role/ContingenciesDetails">
        <link:definition>9955564 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails">
        <link:definition>9955565 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails">
        <link:definition>9955566 - Disclosure - Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails">
        <link:definition>9955567 - Disclosure - Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Range of Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails">
        <link:definition>9955568 - Disclosure - Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails">
        <link:definition>9955569 - Disclosure - Long-term Incentive Compensation and Shareholders&#8217; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockRepurchasesTenderOfferDetails" roleURI="http://www.davita.com/role/StockRepurchasesTenderOfferDetails">
        <link:definition>9955570 - Disclosure - Stock Repurchases Tender Offer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" roleURI="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails">
        <link:definition>9955571 - Disclosure - Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityDetails" roleURI="http://www.davita.com/role/ShareholdersequityDetails">
        <link:definition>9955572 - Disclosure - Shareholder's equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.davita.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9955573 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>9955574 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsComponentsofRoutineAcquisitionsDetails" roleURI="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails">
        <link:definition>9955575 - Disclosure - Acquisitions - Components of Routine Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsacquiredandliabilitiesassumedDetails" roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails">
        <link:definition>9955576 - Disclosure - Acquisitions - Assets acquired and liabilities assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" roleURI="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails">
        <link:definition>9955577 - Disclosure - Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails">
        <link:definition>9955578 - Disclosure - Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails">
        <link:definition>9955579 - Disclosure - Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresAdditionalInformationDetails" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails">
        <link:definition>9955580 - Disclosure - Acquisitions and Divestitures - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails">
        <link:definition>9955581 - Disclosure - Held for Sale and Discontinued Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesAdditionalInformationDetails" roleURI="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails">
        <link:definition>9955582 - Disclosure - Variable Interest Entities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9955583 - Disclosure - Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstrumentsDetails" roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails">
        <link:definition>9955584 - Disclosure - Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails">
        <link:definition>9955585 - Disclosure - Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails">
        <link:definition>9955586 - Disclosure - Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails">
        <link:definition>9955587 - Disclosure - Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofAssetsbySegmentDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails">
        <link:definition>9955588 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>9955589 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.davita.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>9955590 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dva_AuditorAbstract" abstract="true" name="AuditorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" abstract="false" name="RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_PatientCareCosts" abstract="false" name="PatientCareCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DebtPrepaymentExtinguishmentAndModificationCosts" abstract="false" name="DebtPrepaymentExtinguishmentAndModificationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DebtRefinancingCharges" abstract="false" name="DebtRefinancingCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_AdjustmentIncomeLossFromEquityMethodInvestments" abstract="false" name="AdjustmentIncomeLossFromEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_PaymentsToAcquireOtherDebtAndEquityInvestments" abstract="false" name="PaymentsToAcquireOtherDebtAndEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DebtFinancingAndDebtRedemptionCosts" abstract="false" name="DebtFinancingAndDebtRedemptionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NetProceedsFromIssuanceOfStockToEmployees" abstract="false" name="NetProceedsFromIssuanceOfStockToEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" abstract="true" name="TemporaryEquityRedeemableNoncontrollingInterestsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" abstract="false" name="TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" abstract="false" name="TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" abstract="false" name="TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" abstract="false" name="TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TemporaryEquityDecreasePurchaseOfInterests" abstract="false" name="TemporaryEquityDecreasePurchaseOfInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NoncontrollingInterestIncreaseFromContributions" abstract="false" name="NoncontrollingInterestIncreaseFromContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" abstract="false" name="NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" abstract="false" name="NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" abstract="false" name="NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_LeasesDisclosureTextBlock" abstract="false" name="LeasesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" abstract="false" name="NetPropertyAndEquipmentInternationalOperationsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" abstract="false" name="RevenueRecognitionAndAccountsReceivablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_OtherNonoperatingIncomeExpensePolicyTextBlock" abstract="false" name="OtherNonoperatingIncomeExpensePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_InsuranceAndSelfInsurancePolicyTextBlock" abstract="false" name="InsuranceAndSelfInsurancePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_ScheduleOfOtherReceivablesTableTextBlock" abstract="false" name="ScheduleOfOtherReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_LeaseOtherInformationTableTextBlockTableTextBlock" abstract="false" name="LeaseOtherInformationTableTextBlockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_ScheduleOfMinimumLeasePaymentsTextBlock" abstract="false" name="ScheduleOfMinimumLeasePaymentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" abstract="false" name="NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" abstract="false" name="ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" abstract="false" name="ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_InternationalOperationsMember" abstract="true" name="InternationalOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_NumberOfSites" abstract="false" name="NumberOfSites" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_NumberOfCustomers" abstract="false" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" abstract="false" name="MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" abstract="false" name="NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_SegmentRevenuebyMajorPayorAbstract" abstract="true" name="SegmentRevenuebyMajorPayorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_USDialysisAndRelatedLabServicesMember" abstract="true" name="USDialysisAndRelatedLabServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_MedicareandMedicareAdvantageMember" abstract="true" name="MedicareandMedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_MedicaidandManagedMedicaidMember" abstract="true" name="MedicaidandManagedMedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_OtherGovernmentPayorsMember" abstract="true" name="OtherGovernmentPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_CommercialPayorsMember" abstract="true" name="CommercialPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_OtherSourcesofRevenueMember" abstract="true" name="OtherSourcesofRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_EliminationsOfIntersegmentRevenues" abstract="false" name="EliminationsOfIntersegmentRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TotalRevenueNetOfIntersegmentRevenue" abstract="false" name="TotalRevenueNetOfIntersegmentRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" abstract="false" name="PercentageOfAccountsReceivableSixMonthsOrMorePastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dva_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_NumberOfConcentrationRiskCustomers" abstract="false" name="NumberOfConcentrationRiskCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_AccountsReceivablePeriodOutstanding" abstract="false" name="AccountsReceivablePeriodOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" abstract="true" name="CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_MutualFundsAndCommonStockMember" abstract="true" name="MutualFundsAndCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_SupplierRebatesAndOtherNonTradeReceivablesMember" abstract="true" name="SupplierRebatesAndOtherNonTradeReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_IKCVBCArrangementsMember" abstract="true" name="IKCVBCArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ExpectedAmortizationExpenseTable" abstract="true" name="ExpectedAmortizationExpenseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_ExpectedAmortizationExpenseLineItems" abstract="true" name="ExpectedAmortizationExpenseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_AgreementWithMedtronicMember" abstract="true" name="AgreementWithMedtronicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_DeconsolidatedNoncontrollingEntityMember" abstract="true" name="DeconsolidatedNoncontrollingEntityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_OwnershipPercentageByNoncontrollingOwners" abstract="false" name="OwnershipPercentageByNoncontrollingOwners" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_BusinessAgreementEffectiveClosingDate" abstract="false" name="BusinessAgreementEffectiveClosingDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_FairValuePayableOfContingentConsideration" abstract="false" name="FairValuePayableOfContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" abstract="true" name="EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_ParentCompanyAndRestrictedSubsidiariesMember" abstract="true" name="ParentCompanyAndRestrictedSubsidiariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_IncomeLossFromOtherEquityMethodInvestments" abstract="false" name="IncomeLossFromOtherEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NumberOfPartnerships" abstract="false" name="NumberOfPartnerships" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_TransplantSoftwareReportingUnitMember" abstract="true" name="TransplantSoftwareReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_OtherReportingUnitsMember" abstract="true" name="OtherReportingUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_PayorRefundsAndRetractions" abstract="false" name="PayorRefundsAndRetractions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" abstract="false" name="EffectiveIncomeTaxReconciliationInvestmentImpairment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dva_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_DeferredTaxLiabilitiesMember" abstract="true" name="DeferredTaxLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_DeferredTaxAssetsReceivables" abstract="false" name="DeferredTaxAssetsReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DeferredTaxLiabilitiesOperatingLeaseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TaxYear2029Member" abstract="true" name="TaxYear2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_IndefiniteLifeNetOperatingLossesMember" abstract="true" name="IndefiniteLifeNetOperatingLossesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_TermLoanA1AndRevolverMember" abstract="true" name="TermLoanA1AndRevolverMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TermLoanA1Member" abstract="true" name="TermLoanA1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_IncreasedTermLoanA1Member" abstract="true" name="IncreasedTermLoanA1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TermLoanB1Member" abstract="true" name="TermLoanB1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_ExtendedTermLoanB1Member" abstract="true" name="ExtendedTermLoanB1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" abstract="true" name="SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" abstract="true" name="SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember" abstract="true" name="SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_FinanceLeaseMember" abstract="true" name="FinanceLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_ChangeHealthcareTemporaryFundingAssistanceMember" abstract="true" name="ChangeHealthcareTemporaryFundingAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_A1MonthSOFRMember" abstract="true" name="A1MonthSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_LoansTypeAxis" abstract="true" name="LoansTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_LoansTypeDomain" abstract="true" name="LoansTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_BaseRateLoansMember" abstract="true" name="BaseRateLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_SOFRLoansMember" abstract="true" name="SOFRLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_AcquisitionObligationsAndOtherNotesPayable" abstract="false" name="AcquisitionObligationsAndOtherNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_AcquisitionObligationsAndOtherNotesPayableFairValue" abstract="false" name="AcquisitionObligationsAndOtherNotesPayableFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DiscountPremiumAndDeferredFinanceCosts" abstract="false" name="DiscountPremiumAndDeferredFinanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_CHCTemporaryFundingAssistance" abstract="false" name="CHCTemporaryFundingAssistance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_CHCTemporaryFundingAssistanceFairValue" abstract="false" name="CHCTemporaryFundingAssistanceFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" abstract="false" name="SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ConstructiveFinancingCashOutflow" abstract="false" name="ConstructiveFinancingCashOutflow" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ConstructiveFinancingCashInflow" abstract="false" name="ConstructiveFinancingCashInflow" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_OtherSignificantNoncashFinancingActivity" abstract="false" name="OtherSignificantNoncashFinancingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_SecuredDebtExtendedMaturity" abstract="false" name="SecuredDebtExtendedMaturity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding" abstract="false" name="DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_DebtInstrumentQuarterlyPaymentThroughJune302027" abstract="false" name="DebtInstrumentQuarterlyPaymentThroughJune302027" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028" abstract="false" name="DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027" abstract="false" name="DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_DebtInstrumentRedemptionPriceIfChangeOfControl" abstract="false" name="DebtInstrumentRedemptionPriceIfChangeOfControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_DebtInstrumentVariableRate" abstract="false" name="DebtInstrumentVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" abstract="true" name="A2019InterestRateCapAgreementsEffectiveJune302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" abstract="true" name="A2023InterestRateCapAgreements3.75EffectiveJune302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" abstract="true" name="A2023InterestRateCapAgreements4.00EffectiveJune302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" abstract="true" name="A2023InterestRateCapAgreements4.75EffectiveJune302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" abstract="true" name="A2023InterestRateCapAgreements5.00EffectiveJune302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" abstract="true" name="A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" abstract="true" name="A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member" abstract="true" name="A2024InterestRateCapAgreements4.50EffectiveDecember312025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member" abstract="true" name="A2024InterestRateCapAgreements4.00EffectiveDecember312025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TotalNotionalAmountEffectiveThroughDecember312024Member" abstract="true" name="TotalNotionalAmountEffectiveThroughDecember312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TotalNotionalAmountEffectiveThroughDecember312025Member" abstract="true" name="TotalNotionalAmountEffectiveThroughDecember312025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TotalNotionalAmountEffectiveThroughDecember312026Member" abstract="true" name="TotalNotionalAmountEffectiveThroughDecember312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TotalNotionalAmountEffectiveThroughDecember312027Member" abstract="true" name="TotalNotionalAmountEffectiveThroughDecember312027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_NotionalAmountAmortizableByDecember312024" abstract="false" name="NotionalAmountAmortizableByDecember312024" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NotionalAmountAmortizableByDecember312025" abstract="false" name="NotionalAmountAmortizableByDecember312025" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NotionalAmountAmortizableByDecember312026" abstract="false" name="NotionalAmountAmortizableByDecember312026" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NotionalAmountAmortizableByMaturityDate" abstract="false" name="NotionalAmountAmortizableByMaturityDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_IncomeTaxRelatedToCashFlowHedgesMember" abstract="true" name="IncomeTaxRelatedToCashFlowHedgesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_NewCreditAgreementAmendedMember" abstract="true" name="NewCreditAgreementAmendedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" abstract="false" name="LongTermDebtPercentageBearingEconomicallyFixedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dva_LeverageRatioCovenant" abstract="false" name="LeverageRatioCovenant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_LeverageRatioCovenantThroughJun302026" abstract="false" name="LeverageRatioCovenantThroughJun302026" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_LeverageRatioCovenantAfterJun302026" abstract="false" name="LeverageRatioCovenantAfterJun302026" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition" abstract="false" name="LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_LesseeLeaseDescriptionLineItemsAbstract" abstract="true" name="LesseeLeaseDescriptionLineItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_LeasesOtherInformationAbstract" abstract="true" name="LeasesOtherInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" abstract="false" name="NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_LeasesDisclosureTable" abstract="true" name="LeasesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_OperatingLeaseMember" abstract="true" name="OperatingLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_LeasesDisclosureLineItems" abstract="true" name="LeasesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_FinanceLeaseAccumulatedDepreciation" abstract="false" name="FinanceLeaseAccumulatedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_SaleLeasebackTransactionRenewalLeaseTerm" abstract="false" name="SaleLeasebackTransactionRenewalLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_AllTrustsMember" abstract="true" name="AllTrustsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" abstract="false" name="VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" abstract="false" name="VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_A2017USAttorneyColoradoInvestigationMember" abstract="true" name="A2017USAttorneyColoradoInvestigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_CorporateIntegrityAgreementExpirationDate" abstract="false" name="CorporateIntegrityAgreementExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_CommitmentsAndContingenciesDisclosureTable" abstract="true" name="CommitmentsAndContingenciesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_CommitmentsToProvideOperatingCapitalMember" abstract="true" name="CommitmentsToProvideOperatingCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_CommitmentsAndContingenciesDisclosureLineItems" abstract="true" name="CommitmentsAndContingenciesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_DissolutionTermOfJointVentures" abstract="false" name="DissolutionTermOfJointVentures" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_OffBalanceSheetFinancingArrangements" abstract="false" name="OffBalanceSheetFinancingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_StockUnitMember" abstract="true" name="StockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_RangeOneMember" abstract="true" name="RangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_RangeTwoMember" abstract="true" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_RangeThreeMember" abstract="true" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_RangeFourMember" abstract="true" name="RangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_RangeFiveMember" abstract="true" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_StockSettledStockAppreciationRightsMember" abstract="true" name="StockSettledStockAppreciationRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_StockIncentivePlanTwentyTwentyMember" abstract="true" name="StockIncentivePlanTwentyTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" abstract="false" name="StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" abstract="false" name="StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" abstract="false" name="StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" abstract="false" name="StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" abstract="false" name="EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" abstract="false" name="EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_OpenMarketPurchasesMember" abstract="true" name="OpenMarketPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" abstract="true" name="ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" abstract="false" name="NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" abstract="false" name="TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_CharterdocumentsandDelawarelawAbstract" abstract="true" name="CharterdocumentsandDelawarelawAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" abstract="false" name="PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_RelatedPartyTransactionDescriptionOfTransaction1" abstract="false" name="RelatedPartyTransactionDescriptionOfTransaction1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_RelatedPartyTransactionDescriptionOfTransaction2" abstract="false" name="RelatedPartyTransactionDescriptionOfTransaction2" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_DaVitaCarePte.Ltd.Member" abstract="true" name="DaVitaCarePte.Ltd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ForeignDialysisCentersMember" abstract="true" name="ForeignDialysisCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis" abstract="true" name="GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain" abstract="true" name="GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_NonCashGainMember" abstract="true" name="NonCashGainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_OtherCompaniesMember" abstract="true" name="OtherCompaniesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" abstract="true" name="EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_ForeignCurrencyGainLossTranslationAdjustmentsMember" abstract="true" name="ForeignCurrencyGainLossTranslationAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" abstract="false" name="BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_DaVitaMedicalGroupMember" abstract="true" name="DaVitaMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_BusinessSaleEffectiveDateOfSale" abstract="false" name="BusinessSaleEffectiveDateOfSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" abstract="false" name="GainOnDispositionOfBusinessAdditionalPurchasePricePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" abstract="false" name="PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_USDialysisAndRelatedLabServicesWithIntersegmentMember" abstract="true" name="USDialysisAndRelatedLabServicesWithIntersegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_OtherOperatingSegmentsWithIntersegmentMember" abstract="true" name="OtherOperatingSegmentsWithIntersegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ExternalSourcesMember" abstract="true" name="ExternalSourcesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_SegmentReportingInformationCorporateExpenses" abstract="false" name="SegmentReportingInformationCorporateExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_CashPaidDuringPeriodForAbstract" abstract="true" name="CashPaidDuringPeriodForAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>dva-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:47070f41-4839-4fd6-beb4-023e08dfe312,g:db2e526f-c810-4a70-bbc2-9b01e625d97f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_de327cfe-5623-4230-a9c7-d3a2016632cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_40d000a4-4a42-4152-b31a-fdc7bfb73a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_de327cfe-5623-4230-a9c7-d3a2016632cf" xlink:to="loc_us-gaap_Revenues_40d000a4-4a42-4152-b31a-fdc7bfb73a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f578fb8e-e089-406f-b2b4-5caf9ad88fed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_de327cfe-5623-4230-a9c7-d3a2016632cf" xlink:to="loc_us-gaap_CostsAndExpenses_f578fb8e-e089-406f-b2b4-5caf9ad88fed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0e0b4b3b-5996-4ed6-8bbd-0e7b264014ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5f49b83e-cca9-4bb2-a26f-d889ca66dff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_0e0b4b3b-5996-4ed6-8bbd-0e7b264014ae" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5f49b83e-cca9-4bb2-a26f-d889ca66dff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e1c4423e-d39f-49ca-a6c9-13665c9eed4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_0e0b4b3b-5996-4ed6-8bbd-0e7b264014ae" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e1c4423e-d39f-49ca-a6c9-13665c9eed4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8e84f80c-926b-4f47-8dc3-5b4f6db4c1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_31d46bab-f6be-4499-bf0a-e9b9811634f2" xlink:href="dva-20241231.xsd#dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_8e84f80c-926b-4f47-8dc3-5b4f6db4c1d2" xlink:to="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_31d46bab-f6be-4499-bf0a-e9b9811634f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_3ec28c99-6309-4c23-a434-0b6fafccc096" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_8e84f80c-926b-4f47-8dc3-5b4f6db4c1d2" xlink:to="loc_us-gaap_OtherIncome_3ec28c99-6309-4c23-a434-0b6fafccc096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_461bdd9c-cacb-4497-9821-c95c3020c7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3aa06fdd-055b-48de-89e3-a0af358ccc80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_461bdd9c-cacb-4497-9821-c95c3020c7a6" xlink:to="loc_us-gaap_ProfitLoss_3aa06fdd-055b-48de-89e3-a0af358ccc80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b1920102-da2e-4a3d-bbe7-205bace4c14c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_461bdd9c-cacb-4497-9821-c95c3020c7a6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b1920102-da2e-4a3d-bbe7-205bace4c14c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8e082b78-689a-4fc5-8a0f-1752e4ccc3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c38a125d-ddf7-402e-9eb2-770b9ec5e453" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8e082b78-689a-4fc5-8a0f-1752e4ccc3a1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c38a125d-ddf7-402e-9eb2-770b9ec5e453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6457f474-a804-4e00-a9e5-49f0907027fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8e082b78-689a-4fc5-8a0f-1752e4ccc3a1" xlink:to="loc_us-gaap_DepreciationAndAmortization_6457f474-a804-4e00-a9e5-49f0907027fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_c6b0562f-0198-4076-a1f4-07b70d2ea904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8e082b78-689a-4fc5-8a0f-1752e4ccc3a1" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_c6b0562f-0198-4076-a1f4-07b70d2ea904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_01399f3d-704f-4f5d-a610-37af2eb31eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8e082b78-689a-4fc5-8a0f-1752e4ccc3a1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_01399f3d-704f-4f5d-a610-37af2eb31eae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1497a98c-0df1-492e-9cb7-61d029991378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8e082b78-689a-4fc5-8a0f-1752e4ccc3a1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1497a98c-0df1-492e-9cb7-61d029991378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts_c0e8dd37-c413-4bf7-8cde-e6c8eab5eb35" xlink:href="dva-20241231.xsd#dva_PatientCareCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8e082b78-689a-4fc5-8a0f-1752e4ccc3a1" xlink:to="loc_dva_PatientCareCosts_c0e8dd37-c413-4bf7-8cde-e6c8eab5eb35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a23d87c1-9f80-47b3-a352-89eff8c2a14d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51c9ee7c-6fd6-4c50-9afd-2381413705ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a23d87c1-9f80-47b3-a352-89eff8c2a14d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51c9ee7c-6fd6-4c50-9afd-2381413705ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a2aada3f-8126-4ef3-8a81-1dff3f433c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a23d87c1-9f80-47b3-a352-89eff8c2a14d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a2aada3f-8126-4ef3-8a81-1dff3f433c0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbf34cfd-e0d1-4428-9ddd-2273207aaba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cc27c9aa-44bc-4589-a475-a13346364a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbf34cfd-e0d1-4428-9ddd-2273207aaba1" xlink:to="loc_us-gaap_OperatingIncomeLoss_cc27c9aa-44bc-4589-a475-a13346364a75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_75f04db9-fffa-4a66-a4e0-2ddfbc2766e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbf34cfd-e0d1-4428-9ddd-2273207aaba1" xlink:to="loc_us-gaap_InterestAndDebtExpense_75f04db9-fffa-4a66-a4e0-2ddfbc2766e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7c318100-292d-42a3-8570-7519f08df5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbf34cfd-e0d1-4428-9ddd-2273207aaba1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7c318100-292d-42a3-8570-7519f08df5ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_e4670dbc-00a1-4905-a1a3-926bf98295b1" xlink:href="dva-20241231.xsd#dva_DebtPrepaymentExtinguishmentAndModificationCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbf34cfd-e0d1-4428-9ddd-2273207aaba1" xlink:to="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_e4670dbc-00a1-4905-a1a3-926bf98295b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME_1"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_54572600-7ca8-4a4f-91e3-7b8a61993e66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_c7731b47-bb08-496e-b320-1887c75522e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_54572600-7ca8-4a4f-91e3-7b8a61993e66" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_c7731b47-bb08-496e-b320-1887c75522e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_94eccedc-d00c-4630-b0dd-09f50d4fd266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_54572600-7ca8-4a4f-91e3-7b8a61993e66" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_94eccedc-d00c-4630-b0dd-09f50d4fd266" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_07847d74-60dd-4dd0-b87a-48262455d16f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2db2b0d0-9719-4701-a94e-5280b1ec7c25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_07847d74-60dd-4dd0-b87a-48262455d16f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2db2b0d0-9719-4701-a94e-5280b1ec7c25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2a2209ee-8350-499a-a481-ba9cea80e2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_07847d74-60dd-4dd0-b87a-48262455d16f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2a2209ee-8350-499a-a481-ba9cea80e2f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_54e6ee92-9b0f-4cd8-ad33-4548bf251fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_fe1a36c7-3431-4c6a-8f6b-0c6bc5b483d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_54e6ee92-9b0f-4cd8-ad33-4548bf251fa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_fe1a36c7-3431-4c6a-8f6b-0c6bc5b483d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_e4a5c4c4-2e1b-40c9-be52-73892967b45f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_54e6ee92-9b0f-4cd8-ad33-4548bf251fa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_e4a5c4c4-2e1b-40c9-be52-73892967b45f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_153d9049-2001-4881-a925-ae0a15b5ad9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_54e6ee92-9b0f-4cd8-ad33-4548bf251fa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_153d9049-2001-4881-a925-ae0a15b5ad9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_1fad1fe0-0344-4520-9a75-47c39ec9f2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_54e6ee92-9b0f-4cd8-ad33-4548bf251fa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_1fad1fe0-0344-4520-9a75-47c39ec9f2e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_7ebee5f3-6bd5-48dc-b897-43f1ef4cb1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_54e6ee92-9b0f-4cd8-ad33-4548bf251fa5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_7ebee5f3-6bd5-48dc-b897-43f1ef4cb1f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e7d64290-669e-48f6-9365-a77bc10cecd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_70d05f44-2ee2-4de1-8ba9-fd9b9e8790b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e7d64290-669e-48f6-9365-a77bc10cecd6" xlink:to="loc_us-gaap_ProfitLoss_70d05f44-2ee2-4de1-8ba9-fd9b9e8790b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66a6885c-c150-4374-a7d2-9b71778ba4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e7d64290-669e-48f6-9365-a77bc10cecd6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66a6885c-c150-4374-a7d2-9b71778ba4a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daee3829-7b94-4305-b214-791d394bab91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7ad87782-ffcb-4e45-8ac7-96d1338965ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daee3829-7b94-4305-b214-791d394bab91" xlink:to="loc_us-gaap_StockholdersEquity_7ad87782-ffcb-4e45-8ac7-96d1338965ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b737079c-e097-44a6-bc45-6a0a5b38da44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daee3829-7b94-4305-b214-791d394bab91" xlink:to="loc_us-gaap_MinorityInterest_b737079c-e097-44a6-bc45-6a0a5b38da44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2fbad718-5491-44ba-b1d2-de976aa0b0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f7af2681-fc2b-44bc-b21b-67f929219869" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2fbad718-5491-44ba-b1d2-de976aa0b0f9" xlink:to="loc_us-gaap_TreasuryStockValue_f7af2681-fc2b-44bc-b21b-67f929219869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_aa4cd5ef-7d7e-4c43-b54c-f9e2541fecd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2fbad718-5491-44ba-b1d2-de976aa0b0f9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_aa4cd5ef-7d7e-4c43-b54c-f9e2541fecd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0538cfe6-6cd9-4cba-bbe6-527f62adc943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2fbad718-5491-44ba-b1d2-de976aa0b0f9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0538cfe6-6cd9-4cba-bbe6-527f62adc943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b7c7b4a5-30de-4af6-9345-a013c5a767a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2fbad718-5491-44ba-b1d2-de976aa0b0f9" xlink:to="loc_us-gaap_CommonStockValue_b7c7b4a5-30de-4af6-9345-a013c5a767a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7008daa0-9f0f-452b-8a90-2f39f41a5e12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2fbad718-5491-44ba-b1d2-de976aa0b0f9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7008daa0-9f0f-452b-8a90-2f39f41a5e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_06c9af79-d872-421f-9867-ed006ddf4a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2fbad718-5491-44ba-b1d2-de976aa0b0f9" xlink:to="loc_us-gaap_PreferredStockValue_06c9af79-d872-421f-9867-ed006ddf4a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f4e77c87-7e4e-49fa-b89c-7840fbec0ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_15caab2e-5b04-4181-a836-a5a15859337a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f4e77c87-7e4e-49fa-b89c-7840fbec0ea1" xlink:to="loc_us-gaap_AssetsCurrent_15caab2e-5b04-4181-a836-a5a15859337a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e133809b-5bcb-488b-bc64-d5844981d8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f4e77c87-7e4e-49fa-b89c-7840fbec0ea1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e133809b-5bcb-488b-bc64-d5844981d8d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa835a96-c25d-416c-a259-4194b4cf7960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f4e77c87-7e4e-49fa-b89c-7840fbec0ea1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa835a96-c25d-416c-a259-4194b4cf7960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a2759851-9204-4943-a015-922484ada3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f4e77c87-7e4e-49fa-b89c-7840fbec0ea1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a2759851-9204-4943-a015-922484ada3b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_13ea39a6-c9d4-426f-b10d-59c885ad3314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f4e77c87-7e4e-49fa-b89c-7840fbec0ea1" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_13ea39a6-c9d4-426f-b10d-59c885ad3314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_fda59522-9c61-4078-ba11-aebcc876f0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f4e77c87-7e4e-49fa-b89c-7840fbec0ea1" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_fda59522-9c61-4078-ba11-aebcc876f0ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3f615f60-4408-4df1-a984-a0eb9b8fd84f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f4e77c87-7e4e-49fa-b89c-7840fbec0ea1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3f615f60-4408-4df1-a984-a0eb9b8fd84f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1c0fb23e-452e-4fe0-8f50-c91adcf45b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f4e77c87-7e4e-49fa-b89c-7840fbec0ea1" xlink:to="loc_us-gaap_Goodwill_1c0fb23e-452e-4fe0-8f50-c91adcf45b0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed34c898-6d79-4560-a1e5-5b5bba9bb689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d3a53c78-e764-44a1-9fd7-7579444b6bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed34c898-6d79-4560-a1e5-5b5bba9bb689" xlink:to="loc_us-gaap_Liabilities_d3a53c78-e764-44a1-9fd7-7579444b6bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_d8beccc4-f1f1-4f6c-9ce0-868dc5c029c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed34c898-6d79-4560-a1e5-5b5bba9bb689" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_d8beccc4-f1f1-4f6c-9ce0-868dc5c029c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8619ee0c-eca0-4fa3-ae26-e437095fd601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed34c898-6d79-4560-a1e5-5b5bba9bb689" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8619ee0c-eca0-4fa3-ae26-e437095fd601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d10a0120-2014-44b4-bb3e-adfeee8c9546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_224a67f3-11c1-47de-820f-26d893a40cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d10a0120-2014-44b4-bb3e-adfeee8c9546" xlink:to="loc_us-gaap_AccountsPayableCurrent_224a67f3-11c1-47de-820f-26d893a40cf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4dfa795a-76f4-48ad-9295-c0a68c920043" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d10a0120-2014-44b4-bb3e-adfeee8c9546" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4dfa795a-76f4-48ad-9295-c0a68c920043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_db24f91f-f66a-4f01-a794-f1492f1e951f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d10a0120-2014-44b4-bb3e-adfeee8c9546" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_db24f91f-f66a-4f01-a794-f1492f1e951f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6370ab26-019e-4323-be6c-5fe65b256b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d10a0120-2014-44b4-bb3e-adfeee8c9546" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6370ab26-019e-4323-be6c-5fe65b256b25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_d16733b0-c454-47c1-b14c-b2c1f60876c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d10a0120-2014-44b4-bb3e-adfeee8c9546" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_d16733b0-c454-47c1-b14c-b2c1f60876c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_22006eeb-da39-48b4-9560-0abbff2d093d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d10a0120-2014-44b4-bb3e-adfeee8c9546" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_22006eeb-da39-48b4-9560-0abbff2d093d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a59a9bef-3b29-49f4-a5dc-929e9a95f783" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9c5a7f9a-7879-4f2c-8842-bf8a3e642737" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a59a9bef-3b29-49f4-a5dc-929e9a95f783" xlink:to="loc_us-gaap_LiabilitiesCurrent_9c5a7f9a-7879-4f2c-8842-bf8a3e642737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c38987bc-9858-4d63-8cbe-827db43a2df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a59a9bef-3b29-49f4-a5dc-929e9a95f783" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c38987bc-9858-4d63-8cbe-827db43a2df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c213d550-9afd-4069-8341-01c8b7ce1047" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a59a9bef-3b29-49f4-a5dc-929e9a95f783" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c213d550-9afd-4069-8341-01c8b7ce1047" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7139b732-d870-473e-8a4f-051d175d9cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a59a9bef-3b29-49f4-a5dc-929e9a95f783" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7139b732-d870-473e-8a4f-051d175d9cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5949a87c-e8d4-49e5-a27a-ae9ea8a4f077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a59a9bef-3b29-49f4-a5dc-929e9a95f783" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5949a87c-e8d4-49e5-a27a-ae9ea8a4f077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2875936a-4654-4b78-a252-75a8e4b17941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5359076e-9de4-4fc5-b6b1-e4c383614e74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2875936a-4654-4b78-a252-75a8e4b17941" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5359076e-9de4-4fc5-b6b1-e4c383614e74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_640892c7-5c24-4e02-a327-22a609d68941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2875936a-4654-4b78-a252-75a8e4b17941" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_640892c7-5c24-4e02-a327-22a609d68941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_54e8026d-8ed3-4ac1-af60-579e4ed94124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2875936a-4654-4b78-a252-75a8e4b17941" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_54e8026d-8ed3-4ac1-af60-579e4ed94124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_12df3b13-a36f-4063-9e45-2ff83ab63e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2875936a-4654-4b78-a252-75a8e4b17941" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_12df3b13-a36f-4063-9e45-2ff83ab63e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6a618e2b-941a-4885-8b77-7de01b334bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2875936a-4654-4b78-a252-75a8e4b17941" xlink:to="loc_us-gaap_InventoryNet_6a618e2b-941a-4885-8b77-7de01b334bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_6b1f6c63-27af-486b-b2e4-682745d6feac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2875936a-4654-4b78-a252-75a8e4b17941" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_6b1f6c63-27af-486b-b2e4-682745d6feac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_affccea9-bf30-47ad-a000-e307781041a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2875936a-4654-4b78-a252-75a8e4b17941" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_affccea9-bf30-47ad-a000-e307781041a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_60c53527-a855-4105-88df-08eaff852dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2875936a-4654-4b78-a252-75a8e4b17941" xlink:to="loc_us-gaap_IncomeTaxesReceivable_60c53527-a855-4105-88df-08eaff852dde" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6f04738f-b3ac-4683-96e8-735b5dec670a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_ShareBasedCompensation_6f04738f-b3ac-4683-96e8-735b5dec670a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_20ee53a7-08b5-451a-a05e-fc419821765b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_20ee53a7-08b5-451a-a05e-fc419821765b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_e2243fde-dead-404f-ae8d-c0017a722914" xlink:href="dva-20241231.xsd#dva_AdjustmentIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_e2243fde-dead-404f-ae8d-c0017a722914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9d24ffa8-6b97-42e2-ba79-e6f0316e2ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_ProfitLoss_9d24ffa8-6b97-42e2-ba79-e6f0316e2ca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_207de31b-68c8-4073-84c6-21fedd4e246f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_207de31b-68c8-4073-84c6-21fedd4e246f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtRefinancingCharges_d616d2fd-0a7f-4a65-a44b-6e2430d23b26" xlink:href="dva-20241231.xsd#dva_DebtRefinancingCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_dva_DebtRefinancingCharges_d616d2fd-0a7f-4a65-a44b-6e2430d23b26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1c8f4f1b-d92a-490c-b041-88b32cd5d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1c8f4f1b-d92a-490c-b041-88b32cd5d1d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f4e2f503-18c4-4f1b-b4a1-f7a37dcf80fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f4e2f503-18c4-4f1b-b4a1-f7a37dcf80fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_db369b82-c8f7-429e-a6c9-99b4039177b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_db369b82-c8f7-429e-a6c9-99b4039177b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6372e050-49b0-4fed-a9ca-3eb0a8a99147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6372e050-49b0-4fed-a9ca-3eb0a8a99147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5effa2d8-841e-43b0-9d80-7a8401b46dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5effa2d8-841e-43b0-9d80-7a8401b46dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_949dd22d-5899-4f0c-bef5-d16de9dbe7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_949dd22d-5899-4f0c-bef5-d16de9dbe7c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f1beb242-b7dd-47d7-80ca-750b215067f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f1beb242-b7dd-47d7-80ca-750b215067f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_beaadafb-d27a-4c43-b476-a3c70a82ee35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_beaadafb-d27a-4c43-b476-a3c70a82ee35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_052f0b78-2243-4ea0-9e49-42872a7f00ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_052f0b78-2243-4ea0-9e49-42872a7f00ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_2d5abc2d-8e54-47e8-b269-9b9a08ea0415" xlink:href="dva-20241231.xsd#dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_2d5abc2d-8e54-47e8-b269-9b9a08ea0415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d93e2474-8d52-47cd-a8d1-36267ee36c56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d93e2474-8d52-47cd-a8d1-36267ee36c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_73f8d189-8dc0-452a-8b5e-a04421917be4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12cb289e-9d2e-4071-9230-9011ced83c42" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_73f8d189-8dc0-452a-8b5e-a04421917be4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dee483a5-c293-4eb2-a85d-929ae7ede982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b7d7ccc-31da-47d5-a3a9-a9e4d8fb0c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dee483a5-c293-4eb2-a85d-929ae7ede982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b7d7ccc-31da-47d5-a3a9-a9e4d8fb0c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4e08b895-c072-4ba9-bf37-5bfe4fa59eca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dee483a5-c293-4eb2-a85d-929ae7ede982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4e08b895-c072-4ba9-bf37-5bfe4fa59eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71399346-ec83-4b98-a8cb-877787ec224b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dee483a5-c293-4eb2-a85d-929ae7ede982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71399346-ec83-4b98-a8cb-877787ec224b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7957bd58-e0fc-4df2-b589-e8bacece00ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dee483a5-c293-4eb2-a85d-929ae7ede982" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7957bd58-e0fc-4df2-b589-e8bacece00ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_1e0843e7-7785-47f7-91fe-54155d7e3b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_1e0843e7-7785-47f7-91fe-54155d7e3b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_687c1518-4b82-4981-ad38-14877ce15214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_687c1518-4b82-4981-ad38-14877ce15214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_7796f9e1-ecc1-4e35-b9f8-aa02378358e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_7796f9e1-ecc1-4e35-b9f8-aa02378358e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtFinancingAndDebtRedemptionCosts_456421cd-b217-471d-bbe9-dfc3efa0c67d" xlink:href="dva-20241231.xsd#dva_DebtFinancingAndDebtRedemptionCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_dva_DebtFinancingAndDebtRedemptionCosts_456421cd-b217-471d-bbe9-dfc3efa0c67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_b78ebc16-3df3-4698-bf12-10f82fdcd56c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_b78ebc16-3df3-4698-bf12-10f82fdcd56c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_76c18f74-482c-4587-b371-2832d00ceaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_76c18f74-482c-4587-b371-2832d00ceaa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_accb7df1-51c1-469b-9585-a9a6738d2e91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_accb7df1-51c1-469b-9585-a9a6738d2e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4c8d96df-ad0d-41d6-ab4b-f92735f80c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4c8d96df-ad0d-41d6-ab4b-f92735f80c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_1eab7de2-569d-4401-bdd8-fcec51f9cf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_1eab7de2-569d-4401-bdd8-fcec51f9cf2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetProceedsFromIssuanceOfStockToEmployees_f0914a26-9d9e-4ec8-b6e9-1f2af9d1e5a0" xlink:href="dva-20241231.xsd#dva_NetProceedsFromIssuanceOfStockToEmployees"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3bbc608-76e4-4870-935e-ffa422177b96" xlink:to="loc_dva_NetProceedsFromIssuanceOfStockToEmployees_f0914a26-9d9e-4ec8-b6e9-1f2af9d1e5a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_841879c3-d5f5-4414-868d-2386bd07dada" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_841879c3-d5f5-4414-868d-2386bd07dada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d038451a-d28b-40bc-99f5-7b021944a14d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d038451a-d28b-40bc-99f5-7b021944a14d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_78722c5e-e4ef-489b-b3f9-df3040647a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_78722c5e-e4ef-489b-b3f9-df3040647a2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_67d50ee4-1ce1-41b9-892c-65b883bca402" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_67d50ee4-1ce1-41b9-892c-65b883bca402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_7b1dc8ff-5b49-4f4b-a253-ef61c29b9811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_7b1dc8ff-5b49-4f4b-a253-ef61c29b9811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_ee6f1b8d-f05f-488b-ad0d-c06cf9ed1542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_ee6f1b8d-f05f-488b-ad0d-c06cf9ed1542" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_630a1738-0a89-4f8f-b1f1-5313b7287b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_630a1738-0a89-4f8f-b1f1-5313b7287b5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_5bd52666-0713-41cd-831e-a68ed93af4b1" xlink:href="dva-20241231.xsd#dva_PaymentsToAcquireOtherDebtAndEquityInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_5bd52666-0713-41cd-831e-a68ed93af4b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_33b37f26-523d-4b42-82e9-d02e66e2ef7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_33b37f26-523d-4b42-82e9-d02e66e2ef7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_dbdc5e3a-a3f4-41a3-b16c-cf5b3ba37368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8413333-df81-4ef5-9c81-2f8a24de4608" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_dbdc5e3a-a3f4-41a3-b16c-cf5b3ba37368" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_81505e7d-f931-41de-8234-5edf8df3f47b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1ae97683-0e8e-4337-a2b0-9638e36b43a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_81505e7d-f931-41de-8234-5edf8df3f47b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1ae97683-0e8e-4337-a2b0-9638e36b43a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_9a0e85a7-c4db-4996-94f7-42cb635051ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_81505e7d-f931-41de-8234-5edf8df3f47b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_9a0e85a7-c4db-4996-94f7-42cb635051ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_87051701-9256-4d52-98df-2e1fda03d936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_793c70f1-e4cc-4641-9ec1-ad17dfbb34ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_87051701-9256-4d52-98df-2e1fda03d936" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_793c70f1-e4cc-4641-9ec1-ad17dfbb34ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_2dbdf3e7-9f77-447b-aa1d-51e1268f2e72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_87051701-9256-4d52-98df-2e1fda03d936" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_2dbdf3e7-9f77-447b-aa1d-51e1268f2e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1705e596-69ce-400d-b41c-2136c95fa14c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_b766832b-401e-4a4c-bcc3-ed84d06d2576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1705e596-69ce-400d-b41c-2136c95fa14c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_b766832b-401e-4a4c-bcc3-ed84d06d2576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e926981a-7791-4607-b27b-e9b6e5ced4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1705e596-69ce-400d-b41c-2136c95fa14c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e926981a-7791-4607-b27b-e9b6e5ced4ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ShorttermandlongterminvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_614e3c3a-3217-4743-9285-1bafa79f8d38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_1463c167-b480-46ea-a757-ab1ce5b119f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_614e3c3a-3217-4743-9285-1bafa79f8d38" xlink:to="loc_us-gaap_HeldToMaturitySecurities_1463c167-b480-46ea-a757-ab1ce5b119f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_682db9dc-7ce8-4a21-ab42-b26c7f4670f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_614e3c3a-3217-4743-9285-1bafa79f8d38" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_682db9dc-7ce8-4a21-ab42-b26c7f4670f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d5f2ce2d-ea6a-4fa0-86d7-4f231c7f4214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_791661a3-da8b-4692-bb79-bb09ef22aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_d5f2ce2d-ea6a-4fa0-86d7-4f231c7f4214" xlink:to="loc_us-gaap_Land_791661a3-da8b-4692-bb79-bb09ef22aa28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_c10846b4-99a2-4eed-a058-6c7472950795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_d5f2ce2d-ea6a-4fa0-86d7-4f231c7f4214" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_c10846b4-99a2-4eed-a058-6c7472950795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_d06a98a1-4450-40ae-b7c6-3c88aa3da5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_d5f2ce2d-ea6a-4fa0-86d7-4f231c7f4214" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_d06a98a1-4450-40ae-b7c6-3c88aa3da5c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_725c81ec-e7f7-4a2c-b4cf-e8e44a504da5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_d5f2ce2d-ea6a-4fa0-86d7-4f231c7f4214" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_725c81ec-e7f7-4a2c-b4cf-e8e44a504da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_23da77c7-c78e-4a1b-a604-58d9708530c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_d5f2ce2d-ea6a-4fa0-86d7-4f231c7f4214" xlink:to="loc_us-gaap_ConstructionInProgressGross_23da77c7-c78e-4a1b-a604-58d9708530c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_eb01d85f-aeff-409e-915f-5366ba1185e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_75482ec6-520f-4b9f-826f-a3436496b2da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_eb01d85f-aeff-409e-915f-5366ba1185e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_75482ec6-520f-4b9f-826f-a3436496b2da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6558dd0a-a723-4f3c-a835-f1f8d57f6c28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_eb01d85f-aeff-409e-915f-5366ba1185e0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6558dd0a-a723-4f3c-a835-f1f8d57f6c28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2756d3be-caf7-4d1a-acbb-8740799a1b81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_86f59567-77a2-4493-9571-1eae84fcfaae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2756d3be-caf7-4d1a-acbb-8740799a1b81" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_86f59567-77a2-4493-9571-1eae84fcfaae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_00402391-b5fa-4d61-a0fd-22cd6c659cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2756d3be-caf7-4d1a-acbb-8740799a1b81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_00402391-b5fa-4d61-a0fd-22cd6c659cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f97b7cb7-366c-4e0d-939b-369d10c3ef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_102e2225-0d30-40bc-b07c-340923207c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f97b7cb7-366c-4e0d-939b-369d10c3ef4d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_102e2225-0d30-40bc-b07c-340923207c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_0b39edb7-8733-4386-a365-220875bf321c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f97b7cb7-366c-4e0d-939b-369d10c3ef4d" xlink:to="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_0b39edb7-8733-4386-a365-220875bf321c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1b449edd-c2cb-4986-8c59-96b3c00ba274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f97b7cb7-366c-4e0d-939b-369d10c3ef4d" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1b449edd-c2cb-4986-8c59-96b3c00ba274" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6f50160-4f5e-48ea-9dd6-437677756888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3a27cda4-7500-425d-97ed-624cf2b4cd48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6f50160-4f5e-48ea-9dd6-437677756888" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3a27cda4-7500-425d-97ed-624cf2b4cd48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ef13867e-1742-4396-ae2d-91cea223b8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6f50160-4f5e-48ea-9dd6-437677756888" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ef13867e-1742-4396-ae2d-91cea223b8c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5618530e-5410-46de-a955-3cacee26c2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6f50160-4f5e-48ea-9dd6-437677756888" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5618530e-5410-46de-a955-3cacee26c2c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e8a5761c-e3b2-472a-8a4c-56945fea5be5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6f50160-4f5e-48ea-9dd6-437677756888" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e8a5761c-e3b2-472a-8a4c-56945fea5be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d13c1772-45b4-4e15-8c45-184a50eecd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6f50160-4f5e-48ea-9dd6-437677756888" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d13c1772-45b4-4e15-8c45-184a50eecd6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_75f776d0-de7d-4214-833b-3cf2e43d25c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6f50160-4f5e-48ea-9dd6-437677756888" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_75f776d0-de7d-4214-833b-3cf2e43d25c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#OtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_49d13233-6086-4da8-aded-7b8bcb5e7bec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PayorRefundsAndRetractions_3667939d-d0bb-4bef-a457-d96b63bb3c3f" xlink:href="dva-20241231.xsd#dva_PayorRefundsAndRetractions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_49d13233-6086-4da8-aded-7b8bcb5e7bec" xlink:to="loc_dva_PayorRefundsAndRetractions_3667939d-d0bb-4bef-a457-d96b63bb3c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_7d0ade4b-baf3-490c-910e-ac1387fce894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_49d13233-6086-4da8-aded-7b8bcb5e7bec" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_7d0ade4b-baf3-490c-910e-ac1387fce894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_ce984a3b-2639-48bc-988d-1fe4599d4758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_49d13233-6086-4da8-aded-7b8bcb5e7bec" xlink:to="loc_us-gaap_InterestPayableCurrent_ce984a3b-2639-48bc-988d-1fe4599d4758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_8b0865ec-edc8-41cd-85aa-5a51e362d33b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_49d13233-6086-4da8-aded-7b8bcb5e7bec" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_8b0865ec-edc8-41cd-85aa-5a51e362d33b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_28675a5d-3628-4312-8e32-995648cc11fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_49d13233-6086-4da8-aded-7b8bcb5e7bec" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_28675a5d-3628-4312-8e32-995648cc11fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d1726ec3-39d4-40bd-b9d7-e54096b6aeab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0d0bdfe5-4074-469a-b33c-4add0fa78516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d1726ec3-39d4-40bd-b9d7-e54096b6aeab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0d0bdfe5-4074-469a-b33c-4add0fa78516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8976cb0e-e646-47ec-a603-8e9083686de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d1726ec3-39d4-40bd-b9d7-e54096b6aeab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8976cb0e-e646-47ec-a603-8e9083686de2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3dd79230-7b22-4fe7-92e8-6d82fc1cc654" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_87fe0d7a-a5f7-4258-972a-a5a3062e3531" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3dd79230-7b22-4fe7-92e8-6d82fc1cc654" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_87fe0d7a-a5f7-4258-972a-a5a3062e3531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_fd550228-6091-4720-83e2-23d914b1cf94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3dd79230-7b22-4fe7-92e8-6d82fc1cc654" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_fd550228-6091-4720-83e2-23d914b1cf94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b908de9e-dc56-4ed3-a756-98ccb8c04afd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3dd79230-7b22-4fe7-92e8-6d82fc1cc654" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b908de9e-dc56-4ed3-a756-98ccb8c04afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_83821083-4c60-4ec5-8b5e-80bccec0eaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0bfa8a9e-0489-4b8b-928a-80fec73f901e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_83821083-4c60-4ec5-8b5e-80bccec0eaf6" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0bfa8a9e-0489-4b8b-928a-80fec73f901e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_83842cf9-9e2e-4a10-bc3a-8735a31114d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_83821083-4c60-4ec5-8b5e-80bccec0eaf6" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_83842cf9-9e2e-4a10-bc3a-8735a31114d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_19be250f-4ebd-4fcf-936c-b28c3a52c031" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_83821083-4c60-4ec5-8b5e-80bccec0eaf6" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_19be250f-4ebd-4fcf-936c-b28c3a52c031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c79facda-ac0a-4af3-a366-01c049d05a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9fd5d298-4b77-4d0a-9c7a-76ba7bfba065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c79facda-ac0a-4af3-a366-01c049d05a6e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9fd5d298-4b77-4d0a-9c7a-76ba7bfba065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_5a7fd8de-bd2d-4df0-85e5-c854cb242734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c79facda-ac0a-4af3-a366-01c049d05a6e" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_5a7fd8de-bd2d-4df0-85e5-c854cb242734" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_85389dc8-9587-484c-adc1-b49111392a58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_85389dc8-9587-484c-adc1-b49111392a58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8672068b-d814-483c-accd-b75e437e5731" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8672068b-d814-483c-accd-b75e437e5731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_cbec946a-791e-41f0-8361-74855e795029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_cbec946a-791e-41f0-8361-74855e795029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0360832f-3606-4f06-a3ed-45265068ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0360832f-3606-4f06-a3ed-45265068ff59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_5bccf2d7-8515-40c3-b6c0-fda2b02ce2d7" xlink:href="dva-20241231.xsd#dva_EffectiveIncomeTaxReconciliationInvestmentImpairment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_5bccf2d7-8515-40c3-b6c0-fda2b02ce2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ec8b44ac-e6ec-4dcf-a6f9-6f1666877676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ec8b44ac-e6ec-4dcf-a6f9-6f1666877676" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8679a296-6da9-4bb2-b06a-8b33b80e32f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8679a296-6da9-4bb2-b06a-8b33b80e32f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_123089b3-54af-42d5-a339-a000fcb184d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_123089b3-54af-42d5-a339-a000fcb184d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_86cecdff-4af8-4b0e-8706-8c9e4617217f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_86cecdff-4af8-4b0e-8706-8c9e4617217f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_2976573c-32b9-464d-9ba1-01a916f2321c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0810c23c-ae67-4c3c-9433-b2d504938774" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_2976573c-32b9-464d-9ba1-01a916f2321c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_82e569c6-6e10-41b4-bb85-f35dbb9fc432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c92a2aa6-cfc7-435e-8362-9c0be87169aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_82e569c6-6e10-41b4-bb85-f35dbb9fc432" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c92a2aa6-cfc7-435e-8362-9c0be87169aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cee7f373-095b-4b1e-bf0a-5f77a5d75934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_82e569c6-6e10-41b4-bb85-f35dbb9fc432" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cee7f373-095b-4b1e-bf0a-5f77a5d75934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_ba5893d8-5410-49ab-80e6-15b72f39a067" xlink:href="dva-20241231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_82e569c6-6e10-41b4-bb85-f35dbb9fc432" xlink:to="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_ba5893d8-5410-49ab-80e6-15b72f39a067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_7689b005-eb55-4567-b92c-1356f78cd2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_82e569c6-6e10-41b4-bb85-f35dbb9fc432" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_7689b005-eb55-4567-b92c-1356f78cd2b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_62cd0184-bc6c-46ed-9555-f17737ff57f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_82e569c6-6e10-41b4-bb85-f35dbb9fc432" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_62cd0184-bc6c-46ed-9555-f17737ff57f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a4fe6fac-7239-4971-9cfa-270dc7a14e26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables_243fec54-9af8-4463-ba20-463fc4462427" xlink:href="dva-20241231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a4fe6fac-7239-4971-9cfa-270dc7a14e26" xlink:to="loc_dva_DeferredTaxAssetsReceivables_243fec54-9af8-4463-ba20-463fc4462427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_54917413-9125-42bc-9897-0d6243fa0d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a4fe6fac-7239-4971-9cfa-270dc7a14e26" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_54917413-9125-42bc-9897-0d6243fa0d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_c30f2259-3718-474f-81d9-0ba608325754" xlink:href="dva-20241231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a4fe6fac-7239-4971-9cfa-270dc7a14e26" xlink:to="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_c30f2259-3718-474f-81d9-0ba608325754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_951a4622-f6d8-4c25-987d-be07dad66bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a4fe6fac-7239-4971-9cfa-270dc7a14e26" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_951a4622-f6d8-4c25-987d-be07dad66bb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_23ccffe9-3ff4-48cd-8517-dc4a7b6e1a57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a4fe6fac-7239-4971-9cfa-270dc7a14e26" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_23ccffe9-3ff4-48cd-8517-dc4a7b6e1a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_6942387f-9f43-49c5-8f2d-13262d296b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a4fe6fac-7239-4971-9cfa-270dc7a14e26" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_6942387f-9f43-49c5-8f2d-13262d296b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_d7a1851b-57c6-4016-ab0e-99541263ea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_025d16a3-7bbb-47fa-aec4-51daa163b1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_d7a1851b-57c6-4016-ab0e-99541263ea1a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_025d16a3-7bbb-47fa-aec4-51daa163b1d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b1c84adf-2044-4f1d-9e81-3a4c56334ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_d7a1851b-57c6-4016-ab0e-99541263ea1a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b1c84adf-2044-4f1d-9e81-3a4c56334ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1b1f68d1-268c-4404-b8b8-b05202e0d8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6dc6e63f-5b90-4974-9613-680075104507" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1b1f68d1-268c-4404-b8b8-b05202e0d8eb" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6dc6e63f-5b90-4974-9613-680075104507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_333fcff0-632b-4e46-b528-bc6758fb80ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1b1f68d1-268c-4404-b8b8-b05202e0d8eb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_333fcff0-632b-4e46-b528-bc6758fb80ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_7f3809b8-e938-4c41-87b4-aa927dddda40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9eea1c01-9673-4311-85ed-f16a9055afdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_7f3809b8-e938-4c41-87b4-aa927dddda40" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9eea1c01-9673-4311-85ed-f16a9055afdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountPremiumAndDeferredFinanceCosts_f205a430-ba95-4d10-9089-7ef9a609736f" xlink:href="dva-20241231.xsd#dva_DiscountPremiumAndDeferredFinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_7f3809b8-e938-4c41-87b4-aa927dddda40" xlink:to="loc_dva_DiscountPremiumAndDeferredFinanceCosts_f205a430-ba95-4d10-9089-7ef9a609736f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0a66b80-d659-4cfe-a974-9b03b807d303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a1f54c47-0198-45c1-8774-918802d81d26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0a66b80-d659-4cfe-a974-9b03b807d303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a1f54c47-0198-45c1-8774-918802d81d26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c001316d-cfe5-405f-9656-3e29a4b61167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0a66b80-d659-4cfe-a974-9b03b807d303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c001316d-cfe5-405f-9656-3e29a4b61167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b93303cb-41e0-49d6-81e2-05bd7b2ff2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0a66b80-d659-4cfe-a974-9b03b807d303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b93303cb-41e0-49d6-81e2-05bd7b2ff2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09070b15-6001-4937-bb9d-42ed677a6272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0a66b80-d659-4cfe-a974-9b03b807d303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09070b15-6001-4937-bb9d-42ed677a6272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f3e37ab6-798c-48fa-a706-c2609fb9f451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0a66b80-d659-4cfe-a974-9b03b807d303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f3e37ab6-798c-48fa-a706-c2609fb9f451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3dc2ac99-0727-401b-9999-b5f1da2d0f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0a66b80-d659-4cfe-a974-9b03b807d303" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3dc2ac99-0727-401b-9999-b5f1da2d0f29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a039bde7-1b3e-48f5-8aee-e18afdf99983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_38ca6920-4290-41fa-8e08-48b2ee09d607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a039bde7-1b3e-48f5-8aee-e18afdf99983" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_38ca6920-4290-41fa-8e08-48b2ee09d607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f7b388f6-9c19-4e37-a2f5-d1e8dfb39e21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a039bde7-1b3e-48f5-8aee-e18afdf99983" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f7b388f6-9c19-4e37-a2f5-d1e8dfb39e21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0caae4d9-2f24-4379-83d4-0ed54366263a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a039bde7-1b3e-48f5-8aee-e18afdf99983" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0caae4d9-2f24-4379-83d4-0ed54366263a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7ce41b21-55ba-4c34-8348-7f38fc371241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a039bde7-1b3e-48f5-8aee-e18afdf99983" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7ce41b21-55ba-4c34-8348-7f38fc371241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c33609dc-56f5-4410-a2a3-936c43272091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a039bde7-1b3e-48f5-8aee-e18afdf99983" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c33609dc-56f5-4410-a2a3-936c43272091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f7b452b0-ff2b-4c15-ad62-277752bfc049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a039bde7-1b3e-48f5-8aee-e18afdf99983" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f7b452b0-ff2b-4c15-ad62-277752bfc049" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_c40632d2-996b-4b2e-beb4-6b35e714c788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_6ae2ab24-a8a9-469b-9a56-d8d6729e6517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_c40632d2-996b-4b2e-beb4-6b35e714c788" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_6ae2ab24-a8a9-469b-9a56-d8d6729e6517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_b23fd338-167e-4b75-82f3-ca943a8bdd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_c40632d2-996b-4b2e-beb4-6b35e714c788" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_b23fd338-167e-4b75-82f3-ca943a8bdd1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_dc880ddc-ec3a-4472-9101-dcf96c316d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_1e7335ee-6c56-42e8-9610-1ecd1f139f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_dc880ddc-ec3a-4472-9101-dcf96c316d27" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_1e7335ee-6c56-42e8-9610-1ecd1f139f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_76e01aa4-9e12-4a35-89db-b89e85b8409c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_dc880ddc-ec3a-4472-9101-dcf96c316d27" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_76e01aa4-9e12-4a35-89db-b89e85b8409c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsAssetsacquiredandliabilitiesassumedDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f53c1007-c04b-45c5-ab31-627bbc7fa05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_f06bb352-3a2a-4e34-9623-6c47a39415ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f53c1007-c04b-45c5-ab31-627bbc7fa05f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_f06bb352-3a2a-4e34-9623-6c47a39415ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7d7d3163-1b40-4b24-94bc-2780b31b9ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f53c1007-c04b-45c5-ab31-627bbc7fa05f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7d7d3163-1b40-4b24-94bc-2780b31b9ab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad8e67a1-4b7b-45cf-ae86-c78ab0b30ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f53c1007-c04b-45c5-ab31-627bbc7fa05f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad8e67a1-4b7b-45cf-ae86-c78ab0b30ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_19007409-08a7-4ca8-a7bf-1e22480b38ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f53c1007-c04b-45c5-ab31-627bbc7fa05f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_19007409-08a7-4ca8-a7bf-1e22480b38ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9e4a7444-7d6b-41bf-9fb4-91fabd188360" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f53c1007-c04b-45c5-ab31-627bbc7fa05f" xlink:to="loc_us-gaap_Goodwill_9e4a7444-7d6b-41bf-9fb4-91fabd188360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3a28cb80-f278-4be8-9fc0-4f0a35157469" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f53c1007-c04b-45c5-ab31-627bbc7fa05f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3a28cb80-f278-4be8-9fc0-4f0a35157469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_58a8d85c-9777-4371-abd8-87af504829a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f53c1007-c04b-45c5-ab31-627bbc7fa05f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_58a8d85c-9777-4371-abd8-87af504829a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_46de0c6f-037b-40c2-ad57-9ba3a15a1602" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f53c1007-c04b-45c5-ab31-627bbc7fa05f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_46de0c6f-037b-40c2-ad57-9ba3a15a1602" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>dva-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:47070f41-4839-4fd6-beb4-023e08dfe312,g:db2e526f-c810-4a70-bbc2-9b01e625d97f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_37deeedf-fc69-4ba0-8e84-0b0810ca2118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7cbe968e-c751-4d5c-a610-e903130e0971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_37deeedf-fc69-4ba0-8e84-0b0810ca2118" xlink:to="loc_us-gaap_StatementTable_7cbe968e-c751-4d5c-a610-e903130e0971" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_841623e3-4009-4a68-b550-08270153af44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7cbe968e-c751-4d5c-a610-e903130e0971" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_841623e3-4009-4a68-b550-08270153af44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_841623e3-4009-4a68-b550-08270153af44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_841623e3-4009-4a68-b550-08270153af44" xlink:to="loc_us-gaap_EquityComponentDomain_841623e3-4009-4a68-b550-08270153af44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_841623e3-4009-4a68-b550-08270153af44" xlink:to="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_bd828bee-dfd2-4507-80ee-1cbe62e1740e" xlink:href="dva-20241231.xsd#dva_TemporaryEquityRedeemableNoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:to="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_bd828bee-dfd2-4507-80ee-1cbe62e1740e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:to="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86e70892-aeb7-4c1f-a909-964928964143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_CommonStockMember_86e70892-aeb7-4c1f-a909-964928964143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dcb40e22-7650-4c9c-85eb-6a36c0a6e707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dcb40e22-7650-4c9c-85eb-6a36c0a6e707" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_286ab489-3dd3-44aa-b051-99de5443af09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_RetainedEarningsMember_286ab489-3dd3-44aa-b051-99de5443af09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_3d678014-fc5a-4d0b-bb1d-38af3552fead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_TreasuryStockCommonMember_3d678014-fc5a-4d0b-bb1d-38af3552fead" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db7bf65c-8864-462d-82e3-db9ce5a9ea80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db7bf65c-8864-462d-82e3-db9ce5a9ea80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_931dab9c-2042-4669-a681-915a243527fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_931dab9c-2042-4669-a681-915a243527fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_37deeedf-fc69-4ba0-8e84-0b0810ca2118" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9c2adab8-1ec9-44e0-a3cf-913d83be7edd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9c2adab8-1ec9-44e0-a3cf-913d83be7edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b7a30137-aa69-4319-a14d-12ad15f1f999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b7a30137-aa69-4319-a14d-12ad15f1f999" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fc158b71-1e1d-4172-9886-09f0493410ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fc158b71-1e1d-4172-9886-09f0493410ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_0b1558ce-806f-498c-9a8d-0e0c5d3cffd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_0b1558ce-806f-498c-9a8d-0e0c5d3cffd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_1e28a025-9bc4-450a-9d4e-93b7930b345e" xlink:href="dva-20241231.xsd#dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_1e28a025-9bc4-450a-9d4e-93b7930b345e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_b4b8af51-be34-4f44-8e6e-5d9efaa2e306" xlink:href="dva-20241231.xsd#dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_b4b8af51-be34-4f44-8e6e-5d9efaa2e306" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_460e53d9-3850-433c-b935-4dcdeeb86b85" xlink:href="dva-20241231.xsd#dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_460e53d9-3850-433c-b935-4dcdeeb86b85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_2535f9ec-e74a-4bd5-b663-569a8c311285" xlink:href="dva-20241231.xsd#dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_2535f9ec-e74a-4bd5-b663-569a8c311285" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_a152a989-d742-4bfd-80b4-5a9dde365c60" xlink:href="dva-20241231.xsd#dva_TemporaryEquityDecreasePurchaseOfInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_a152a989-d742-4bfd-80b4-5a9dde365c60" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_339fc744-07b1-4b39-a0ed-f8bd9173622b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_339fc744-07b1-4b39-a0ed-f8bd9173622b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_26c4a566-d2c6-4994-a766-81638e014ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_26c4a566-d2c6-4994-a766-81638e014ce7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_db691754-b165-4794-a6f9-78e0613b84d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_b95365b2-fa67-46fd-8b93-c2bdbb02aea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_b95365b2-fa67-46fd-8b93-c2bdbb02aea3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8e6563f6-e332-4683-90eb-43c623eb90cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_b95365b2-fa67-46fd-8b93-c2bdbb02aea3" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8e6563f6-e332-4683-90eb-43c623eb90cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2fc52e58-959e-4de1-ae56-83c495c1cd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_b95365b2-fa67-46fd-8b93-c2bdbb02aea3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2fc52e58-959e-4de1-ae56-83c495c1cd1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2a3a6e3c-95f2-49dd-99c6-de076fc5911b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2a3a6e3c-95f2-49dd-99c6-de076fc5911b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_923727d6-cfee-4a42-8343-4be5f5714b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_923727d6-cfee-4a42-8343-4be5f5714b8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_899675d5-4c08-4e0c-8ae2-893a92a97ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_899675d5-4c08-4e0c-8ae2-893a92a97ce5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4e0c2ab1-3a0e-43da-8b62-540a512f86e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4e0c2ab1-3a0e-43da-8b62-540a512f86e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a8452fb-d7eb-4287-a369-f9196fa8476f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a8452fb-d7eb-4287-a369-f9196fa8476f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_495476b1-ad7b-4377-88d3-491c4d6b0077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_495476b1-ad7b-4377-88d3-491c4d6b0077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseFromContributions_ea456045-3c99-4d80-afc6-986b801b33aa" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestIncreaseFromContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_dva_NoncontrollingInterestIncreaseFromContributions_ea456045-3c99-4d80-afc6-986b801b33aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_8f5fb32e-54ee-4e36-9b08-4338bbeb42bc" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_8f5fb32e-54ee-4e36-9b08-4338bbeb42bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_dd00d159-8c19-4801-adea-71f005f7fc72" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_dd00d159-8c19-4801-adea-71f005f7fc72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_0a7fba1e-f351-435f-9752-8763b568c3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_0a7fba1e-f351-435f-9752-8763b568c3c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_e8c43e6b-8e9b-4548-8af4-ad1057bda0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_e8c43e6b-8e9b-4548-8af4-ad1057bda0a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_0c3f88a2-46d7-45cc-85b8-403336ddb90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_0c3f88a2-46d7-45cc-85b8-403336ddb90c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_38689cff-51ab-474f-8c5c-fd26da61dc22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_38689cff-51ab-474f-8c5c-fd26da61dc22" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_ee7ce09f-09f7-4c5c-9df8-9406636df02a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_ee7ce09f-09f7-4c5c-9df8-9406636df02a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_f67f094c-bee2-4a97-9c36-7dd17b516464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_f67f094c-bee2-4a97-9c36-7dd17b516464" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_a28834ee-c775-4ca7-96c4-9e65a480d99a" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_a28834ee-c775-4ca7-96c4-9e65a480d99a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5ea2230-0741-40bd-9b13-f407c59f0b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9652c167-2cf7-4ff7-889f-91a9461baa0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:href="dva-20241231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_142144c9-2dfa-473c-8834-e69a75676dc4" xlink:href="dva-20241231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_142144c9-2dfa-473c-8834-e69a75676dc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4bab9a8c-fdc2-453e-b3f3-92796deaf933" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_142144c9-2dfa-473c-8834-e69a75676dc4" xlink:to="loc_srt_StatementGeographicalAxis_4bab9a8c-fdc2-453e-b3f3-92796deaf933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4bab9a8c-fdc2-453e-b3f3-92796deaf933_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4bab9a8c-fdc2-453e-b3f3-92796deaf933" xlink:to="loc_srt_SegmentGeographicalDomain_4bab9a8c-fdc2-453e-b3f3-92796deaf933_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d924b5d2-8576-44ee-87ed-440dba501f11" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4bab9a8c-fdc2-453e-b3f3-92796deaf933" xlink:to="loc_srt_SegmentGeographicalDomain_d924b5d2-8576-44ee-87ed-440dba501f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_eb55836d-e3f7-4715-9473-b62bbab23307" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d924b5d2-8576-44ee-87ed-440dba501f11" xlink:to="loc_country_US_eb55836d-e3f7-4715-9473-b62bbab23307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InternationalOperationsMember_9b017c8e-888d-4737-b5c6-2e8180ead9b2" xlink:href="dva-20241231.xsd#dva_InternationalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d924b5d2-8576-44ee-87ed-440dba501f11" xlink:to="loc_dva_InternationalOperationsMember_9b017c8e-888d-4737-b5c6-2e8180ead9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfSites_73696e92-a2f8-4102-920f-7910341ca8f9" xlink:href="dva-20241231.xsd#dva_NumberOfSites"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_dva_NumberOfSites_73696e92-a2f8-4102-920f-7910341ca8f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_9af725dd-ae6c-4950-a722-977b5ceb0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_9af725dd-ae6c-4950-a722-977b5ceb0e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfCustomers_7664178b-b3ff-4f94-a885-f2db6eb37df4" xlink:href="dva-20241231.xsd#dva_NumberOfCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_dva_NumberOfCustomers_7664178b-b3ff-4f94-a885-f2db6eb37df4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_865300b5-fe46-4c44-8992-f0137ae8b6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_865300b5-fe46-4c44-8992-f0137ae8b6c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_959e1b68-f12d-4cd8-80aa-729791c0868d" xlink:href="dva-20241231.xsd#dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_959e1b68-f12d-4cd8-80aa-729791c0868d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_560cd326-19f7-4dc2-9115-fc98db498657" xlink:href="dva-20241231.xsd#dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_560cd326-19f7-4dc2-9115-fc98db498657" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b60c5b1f-ebf2-4bef-88ca-5b85fc5b0d12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b60c5b1f-ebf2-4bef-88ca-5b85fc5b0d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b60c5b1f-ebf2-4bef-88ca-5b85fc5b0d12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b60c5b1f-ebf2-4bef-88ca-5b85fc5b0d12" xlink:to="loc_us-gaap_SegmentDomain_b60c5b1f-ebf2-4bef-88ca-5b85fc5b0d12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f83c5685-adc8-4f9b-b72f-6a3a9ff2a4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b60c5b1f-ebf2-4bef-88ca-5b85fc5b0d12" xlink:to="loc_us-gaap_SegmentDomain_f83c5685-adc8-4f9b-b72f-6a3a9ff2a4d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_7fb77c8b-22e4-44da-b47e-1693dc5fe62a" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f83c5685-adc8-4f9b-b72f-6a3a9ff2a4d7" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_7fb77c8b-22e4-44da-b47e-1693dc5fe62a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_680d075b-a569-458d-83b1-b36018859b27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f83c5685-adc8-4f9b-b72f-6a3a9ff2a4d7" xlink:to="loc_us-gaap_AllOtherSegmentsMember_680d075b-a569-458d-83b1-b36018859b27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_0f85939d-c5a6-4498-994e-50bbe4079f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_0f85939d-c5a6-4498-994e-50bbe4079f63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_0f85939d-c5a6-4498-994e-50bbe4079f63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_0f85939d-c5a6-4498-994e-50bbe4079f63" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_0f85939d-c5a6-4498-994e-50bbe4079f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_0f85939d-c5a6-4498-994e-50bbe4079f63" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareandMedicareAdvantageMember_ad53b975-e17e-4b11-9b4c-feda8decfdd2" xlink:href="dva-20241231.xsd#dva_MedicareandMedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_MedicareandMedicareAdvantageMember_ad53b975-e17e-4b11-9b4c-feda8decfdd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicaidandManagedMedicaidMember_3752a4d7-ee53-438a-a683-4c9fcecd75cf" xlink:href="dva-20241231.xsd#dva_MedicaidandManagedMedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_MedicaidandManagedMedicaidMember_3752a4d7-ee53-438a-a683-4c9fcecd75cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherGovernmentPayorsMember_107d9f2a-c62e-4890-af75-f51621ea8d03" xlink:href="dva-20241231.xsd#dva_OtherGovernmentPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_OtherGovernmentPayorsMember_107d9f2a-c62e-4890-af75-f51621ea8d03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommercialPayorsMember_2b82e993-2659-4238-8bd1-b60748406e02" xlink:href="dva-20241231.xsd#dva_CommercialPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_CommercialPayorsMember_2b82e993-2659-4238-8bd1-b60748406e02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSourcesofRevenueMember_66d7de0a-779d-4d2e-947f-bf2d15081036" xlink:href="dva-20241231.xsd#dva_OtherSourcesofRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_OtherSourcesofRevenueMember_66d7de0a-779d-4d2e-947f-bf2d15081036" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ed48f823-7f07-4199-920f-6b1a2500df41" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:to="loc_srt_ConsolidationItemsAxis_ed48f823-7f07-4199-920f-6b1a2500df41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ed48f823-7f07-4199-920f-6b1a2500df41_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_ed48f823-7f07-4199-920f-6b1a2500df41" xlink:to="loc_srt_ConsolidationItemsDomain_ed48f823-7f07-4199-920f-6b1a2500df41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a769ca97-9408-432a-b3fb-6a34018c8985" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_ed48f823-7f07-4199-920f-6b1a2500df41" xlink:to="loc_srt_ConsolidationItemsDomain_a769ca97-9408-432a-b3fb-6a34018c8985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_b0b11cef-fc0b-44a2-8dbb-80fed85eaf33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a769ca97-9408-432a-b3fb-6a34018c8985" xlink:to="loc_us-gaap_IntersegmentEliminationMember_b0b11cef-fc0b-44a2-8dbb-80fed85eaf33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9513b50d-1539-4fe7-a552-3905b360a46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9513b50d-1539-4fe7-a552-3905b360a46f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9513b50d-1539-4fe7-a552-3905b360a46f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9513b50d-1539-4fe7-a552-3905b360a46f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9513b50d-1539-4fe7-a552-3905b360a46f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fb9942f-f113-4435-a93a-61707455fd84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9513b50d-1539-4fe7-a552-3905b360a46f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fb9942f-f113-4435-a93a-61707455fd84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_30bfe635-31f1-4aa0-bdd6-c18cbed627b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fb9942f-f113-4435-a93a-61707455fd84" xlink:to="loc_us-gaap_AccountsReceivableMember_30bfe635-31f1-4aa0-bdd6-c18cbed627b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ffb37eaf-fb73-468c-b333-57fe2d60b0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ffb37eaf-fb73-468c-b333-57fe2d60b0fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_cf23db2f-964c-482d-bb78-458001d6f37f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_us-gaap_OtherIncome_cf23db2f-964c-482d-bb78-458001d6f37f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EliminationsOfIntersegmentRevenues_34ad80b6-8a93-4195-8be3-390872f2e87e" xlink:href="dva-20241231.xsd#dva_EliminationsOfIntersegmentRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_dva_EliminationsOfIntersegmentRevenues_34ad80b6-8a93-4195-8be3-390872f2e87e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalRevenueNetOfIntersegmentRevenue_0f3eb05d-7ffa-4d06-a053-ca07179d9d19" xlink:href="dva-20241231.xsd#dva_TotalRevenueNetOfIntersegmentRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_dva_TotalRevenueNetOfIntersegmentRevenue_0f3eb05d-7ffa-4d06-a053-ca07179d9d19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_e2801288-5a56-404e-ae7b-d8778d65892f" xlink:href="dva-20241231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_e2801288-5a56-404e-ae7b-d8778d65892f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_85c966da-5299-4b4d-9c53-6730b4e3375f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_85c966da-5299-4b4d-9c53-6730b4e3375f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_85c966da-5299-4b4d-9c53-6730b4e3375f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_85c966da-5299-4b4d-9c53-6730b4e3375f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_85c966da-5299-4b4d-9c53-6730b4e3375f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4b303a54-4f2e-4e39-a4b9-15d0932acddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_85c966da-5299-4b4d-9c53-6730b4e3375f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4b303a54-4f2e-4e39-a4b9-15d0932acddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4fe713e4-49c4-42a6-a92d-a41034f63219" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4b303a54-4f2e-4e39-a4b9-15d0932acddc" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4fe713e4-49c4-42a6-a92d-a41034f63219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77e5db50-d6dd-484d-a095-0c169a3f3afc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77e5db50-d6dd-484d-a095-0c169a3f3afc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77e5db50-d6dd-484d-a095-0c169a3f3afc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77e5db50-d6dd-484d-a095-0c169a3f3afc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77e5db50-d6dd-484d-a095-0c169a3f3afc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9694fa71-5e44-48a8-abc8-78f79363127e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77e5db50-d6dd-484d-a095-0c169a3f3afc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9694fa71-5e44-48a8-abc8-78f79363127e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d6f11678-9187-44ba-ba88-2bb293cd5fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9694fa71-5e44-48a8-abc8-78f79363127e" xlink:to="loc_us-gaap_AccountsReceivableMember_d6f11678-9187-44ba-ba88-2bb293cd5fc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2e346460-cb24-4546-b6ef-8ca952e5214e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2e346460-cb24-4546-b6ef-8ca952e5214e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2e346460-cb24-4546-b6ef-8ca952e5214e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2e346460-cb24-4546-b6ef-8ca952e5214e" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2e346460-cb24-4546-b6ef-8ca952e5214e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_77d7bced-9737-4c3a-9319-a017fd07e891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2e346460-cb24-4546-b6ef-8ca952e5214e" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_77d7bced-9737-4c3a-9319-a017fd07e891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_1b5ddd54-4ac5-4279-bad4-601ae7c14cd0" xlink:href="dva-20241231.xsd#dva_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_77d7bced-9737-4c3a-9319-a017fd07e891" xlink:to="loc_dva_MedicareMember_1b5ddd54-4ac5-4279-bad4-601ae7c14cd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_1bcedd30-5841-4212-9587-dc16141223b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_77d7bced-9737-4c3a-9319-a017fd07e891" xlink:to="loc_us-gaap_ThirdPartyPayorMember_1bcedd30-5841-4212-9587-dc16141223b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfConcentrationRiskCustomers_6c375855-16c4-483b-afb5-25cc0b6dd6a1" xlink:href="dva-20241231.xsd#dva_NumberOfConcentrationRiskCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_dva_NumberOfConcentrationRiskCustomers_6c375855-16c4-483b-afb5-25cc0b6dd6a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_aec3a3d6-5d77-4156-b602-a429d8be5e18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_aec3a3d6-5d77-4156-b602-a429d8be5e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_42efe63d-e23f-43ce-bb0f-bae7886c0848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_42efe63d-e23f-43ce-bb0f-bae7886c0848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_4d15a11d-7bfd-4329-bc05-563297b53a26" xlink:href="dva-20241231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_4d15a11d-7bfd-4329-bc05-563297b53a26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AccountsReceivablePeriodOutstanding_49639b2f-9e20-425f-8286-67e9a3badd26" xlink:href="dva-20241231.xsd#dva_AccountsReceivablePeriodOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_dva_AccountsReceivablePeriodOutstanding_49639b2f-9e20-425f-8286-67e9a3badd26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_573218e6-03b8-43c5-87d9-b1203b942e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_573218e6-03b8-43c5-87d9-b1203b942e8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_258974f8-dbf3-4f64-a4a7-c05a7e65fb89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_258974f8-dbf3-4f64-a4a7-c05a7e65fb89" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ShorttermandlongterminvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_8572186f-337d-4d4a-b8ce-68e236adf3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_8572186f-337d-4d4a-b8ce-68e236adf3a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_2bbdb0b1-a074-4d8f-b591-ff9912b8711e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_8572186f-337d-4d4a-b8ce-68e236adf3a2" xlink:to="loc_us-gaap_InvestmentTypeAxis_2bbdb0b1-a074-4d8f-b591-ff9912b8711e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2bbdb0b1-a074-4d8f-b591-ff9912b8711e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_2bbdb0b1-a074-4d8f-b591-ff9912b8711e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2bbdb0b1-a074-4d8f-b591-ff9912b8711e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_2bbdb0b1-a074-4d8f-b591-ff9912b8711e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_4055847d-23f8-4982-8cf8-0ef10666227c" xlink:href="dva-20241231.xsd#dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:to="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_4055847d-23f8-4982-8cf8-0ef10666227c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MutualFundsAndCommonStockMember_d0a2cf7c-f60f-41dd-881a-8dea15739ebd" xlink:href="dva-20241231.xsd#dva_MutualFundsAndCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:to="loc_dva_MutualFundsAndCommonStockMember_d0a2cf7c-f60f-41dd-881a-8dea15739ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1bbbc694-4c8b-4e55-8221-e612a7f7a343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1bbbc694-4c8b-4e55-8221-e612a7f7a343" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_6fcf9ed4-4386-45d5-ade1-ea2bd70b774c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_6fcf9ed4-4386-45d5-ade1-ea2bd70b774c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_74342330-d51e-4ecf-8e95-a1cd17ba8b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_HeldToMaturitySecurities_74342330-d51e-4ecf-8e95-a1cd17ba8b8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0b2d6124-c6ff-45b6-8ab3-bceef0f8d4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0b2d6124-c6ff-45b6-8ab3-bceef0f8d4fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_0fcf3f3b-6045-471a-9c04-1ea2a3f83291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_MarketableSecurities_0fcf3f3b-6045-471a-9c04-1ea2a3f83291" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_4f2027ed-c389-4e58-ba4b-dd6f539c1ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_4f2027ed-c389-4e58-ba4b-dd6f539c1ad1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_03aa9a6b-aca5-43aa-a2b5-42094184e66d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_03aa9a6b-aca5-43aa-a2b5-42094184e66d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_87a72d1b-5183-4be2-a86d-ece9b09b9ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_87a72d1b-5183-4be2-a86d-ece9b09b9ed1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0642a445-caf4-4f90-a1fe-0e189af0ba50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0642a445-caf4-4f90-a1fe-0e189af0ba50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5d6ff3bc-4123-4a12-a091-fe1b05be9147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5d6ff3bc-4123-4a12-a091-fe1b05be9147" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_07332c9f-33d2-41d4-8fc4-bacbfe70726a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_07332c9f-33d2-41d4-8fc4-bacbfe70726a" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#OtherReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ca2a3b7e-1579-497d-8851-2fdfaf16bab1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_07e92c3d-b1c2-441f-a303-29d5bafe2d54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ca2a3b7e-1579-497d-8851-2fdfaf16bab1" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_07e92c3d-b1c2-441f-a303-29d5bafe2d54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c295f1ae-2e00-4959-9f20-d1d878086ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_07e92c3d-b1c2-441f-a303-29d5bafe2d54" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c295f1ae-2e00-4959-9f20-d1d878086ca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_c295f1ae-2e00-4959-9f20-d1d878086ca0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c295f1ae-2e00-4959-9f20-d1d878086ca0" xlink:to="loc_us-gaap_ReceivableTypeDomain_c295f1ae-2e00-4959-9f20-d1d878086ca0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c295f1ae-2e00-4959-9f20-d1d878086ca0" xlink:to="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_a1814962-970c-4e9f-a0a9-c6fa4f071bb7" xlink:href="dva-20241231.xsd#dva_SupplierRebatesAndOtherNonTradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:to="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_a1814962-970c-4e9f-a0a9-c6fa4f071bb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_8cd11c67-a135-4b05-a4e0-d24ec6a52d1b" xlink:href="dva-20241231.xsd#dva_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:to="loc_dva_MedicareMember_8cd11c67-a135-4b05-a4e0-d24ec6a52d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IKCVBCArrangementsMember_05cabfd4-2966-4c7a-8acc-727adaceb39c" xlink:href="dva-20241231.xsd#dva_IKCVBCArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:to="loc_dva_IKCVBCArrangementsMember_05cabfd4-2966-4c7a-8acc-727adaceb39c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_40f171bd-b24a-4355-85e0-510e5c3289fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ca2a3b7e-1579-497d-8851-2fdfaf16bab1" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_40f171bd-b24a-4355-85e0-510e5c3289fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d9c4806c-d4bb-44e2-80e9-dcf9f1a2b15e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d9c4806c-d4bb-44e2-80e9-dcf9f1a2b15e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25aa514d-3380-4bb9-b331-ab03bbaccc50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d9c4806c-d4bb-44e2-80e9-dcf9f1a2b15e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25aa514d-3380-4bb9-b331-ab03bbaccc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_25aa514d-3380-4bb9-b331-ab03bbaccc50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25aa514d-3380-4bb9-b331-ab03bbaccc50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_25aa514d-3380-4bb9-b331-ab03bbaccc50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25aa514d-3380-4bb9-b331-ab03bbaccc50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_1d125dbf-e03b-4224-bbc3-44b27367b4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:to="loc_us-gaap_BuildingMember_1d125dbf-e03b-4224-bbc3-44b27367b4ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d732f6f8-ff9b-42e9-9b9f-1f32e1262d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d732f6f8-ff9b-42e9-9b9f-1f32e1262d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_9c304557-f378-44a7-9cea-bb0bea1ab7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_9c304557-f378-44a7-9cea-bb0bea1ab7b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03037ed8-d5f3-4486-8732-1127979177d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d9c4806c-d4bb-44e2-80e9-dcf9f1a2b15e" xlink:to="loc_srt_RangeAxis_03037ed8-d5f3-4486-8732-1127979177d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03037ed8-d5f3-4486-8732-1127979177d2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_03037ed8-d5f3-4486-8732-1127979177d2" xlink:to="loc_srt_RangeMember_03037ed8-d5f3-4486-8732-1127979177d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7664d67-8118-4442-8f21-c3e6932bfb02" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_03037ed8-d5f3-4486-8732-1127979177d2" xlink:to="loc_srt_RangeMember_b7664d67-8118-4442-8f21-c3e6932bfb02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b5db783a-3c77-41a1-8ee9-c69b5e893dee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7664d67-8118-4442-8f21-c3e6932bfb02" xlink:to="loc_srt_MinimumMember_b5db783a-3c77-41a1-8ee9-c69b5e893dee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38bafed4-c59e-4f91-a559-851a12c23372" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7664d67-8118-4442-8f21-c3e6932bfb02" xlink:to="loc_srt_MaximumMember_38bafed4-c59e-4f91-a559-851a12c23372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_92797b50-56ba-41dd-8df7-da403137b3de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_92797b50-56ba-41dd-8df7-da403137b3de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7e932bb7-a14d-4509-af8b-5e2038044c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7e932bb7-a14d-4509-af8b-5e2038044c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_68c4caa6-1fcc-47f8-a060-850af1d7cdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:to="loc_us-gaap_InterestCostsCapitalized_68c4caa6-1fcc-47f8-a060-850af1d7cdcb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7200e3c5-feef-4104-95b3-09553c511f27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7200e3c5-feef-4104-95b3-09553c511f27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_269ae2ae-a076-4330-b437-2a1d36d38b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7200e3c5-feef-4104-95b3-09553c511f27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_269ae2ae-a076-4330-b437-2a1d36d38b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_269ae2ae-a076-4330-b437-2a1d36d38b51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_269ae2ae-a076-4330-b437-2a1d36d38b51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_269ae2ae-a076-4330-b437-2a1d36d38b51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d204a59-d56a-4dd8-900d-fa6ac99f20af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_269ae2ae-a076-4330-b437-2a1d36d38b51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d204a59-d56a-4dd8-900d-fa6ac99f20af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_02d533a9-a629-4fce-8160-64558b3f9c83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d204a59-d56a-4dd8-900d-fa6ac99f20af" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_02d533a9-a629-4fce-8160-64558b3f9c83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_11d23083-9aa4-4094-a39f-892e4fd609e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d204a59-d56a-4dd8-900d-fa6ac99f20af" xlink:to="loc_us-gaap_ServiceAgreementsMember_11d23083-9aa4-4094-a39f-892e4fd609e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_54e703d4-4aac-4422-a3f3-7d5339925496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_54e703d4-4aac-4422-a3f3-7d5339925496" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_51dadc78-4396-477e-ba8b-181e73e7fb16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_51dadc78-4396-477e-ba8b-181e73e7fb16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b65248fe-10d8-4a5d-82ff-1defeb394170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b65248fe-10d8-4a5d-82ff-1defeb394170" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_35bcb8c6-c072-46bc-9ec8-486e9c7dd562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_35bcb8c6-c072-46bc-9ec8-486e9c7dd562" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6303ee29-6082-4ef5-8413-de5f960298ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6303ee29-6082-4ef5-8413-de5f960298ad" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:href="dva-20241231.xsd#dva_ExpectedAmortizationExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseTable_3003eba5-6777-43d2-abaf-838fdeb444cc" xlink:href="dva-20241231.xsd#dva_ExpectedAmortizationExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_dva_ExpectedAmortizationExpenseTable_3003eba5-6777-43d2-abaf-838fdeb444cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eca66858-dcca-4ef0-959f-b8e6cc75f581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_ExpectedAmortizationExpenseTable_3003eba5-6777-43d2-abaf-838fdeb444cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eca66858-dcca-4ef0-959f-b8e6cc75f581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eca66858-dcca-4ef0-959f-b8e6cc75f581_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eca66858-dcca-4ef0-959f-b8e6cc75f581" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eca66858-dcca-4ef0-959f-b8e6cc75f581_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5f46d7-5340-426b-af16-ee339dc7e14e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eca66858-dcca-4ef0-959f-b8e6cc75f581" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5f46d7-5340-426b-af16-ee339dc7e14e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_da84ff52-0e66-415c-aa07-f1ec968b47b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5f46d7-5340-426b-af16-ee339dc7e14e" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_da84ff52-0e66-415c-aa07-f1ec968b47b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_0467bd89-e28d-44c1-a35f-5b06c6559859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5f46d7-5340-426b-af16-ee339dc7e14e" xlink:to="loc_us-gaap_ServiceAgreementsMember_0467bd89-e28d-44c1-a35f-5b06c6559859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5f4f0143-2bb2-4e01-8b9f-8f57c95f2fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5f4f0143-2bb2-4e01-8b9f-8f57c95f2fe3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c3536884-d248-4ef2-a2d3-8f2dc39b10a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c3536884-d248-4ef2-a2d3-8f2dc39b10a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b7c27a09-62a6-4f74-a2e5-a5117c32dcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b7c27a09-62a6-4f74-a2e5-a5117c32dcaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7885dcba-600b-4f78-a55e-49bbf39f496d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7885dcba-600b-4f78-a55e-49bbf39f496d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_26d013f0-bd06-40f5-a047-8262784c4734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_26d013f0-bd06-40f5-a047-8262784c4734" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fc7cec40-7e27-4a6b-9139-026acdb2a804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fc7cec40-7e27-4a6b-9139-026acdb2a804" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5dc9b169-b844-4ce6-939c-0824daf8516a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5dc9b169-b844-4ce6-939c-0824daf8516a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IntangiblesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a554e95-a3df-4cb5-b49a-32c32a34619b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a554e95-a3df-4cb5-b49a-32c32a34619b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a6225069-f11b-4a08-88e1-50cd4e2e05f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a554e95-a3df-4cb5-b49a-32c32a34619b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a6225069-f11b-4a08-88e1-50cd4e2e05f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6225069-f11b-4a08-88e1-50cd4e2e05f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a6225069-f11b-4a08-88e1-50cd4e2e05f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6225069-f11b-4a08-88e1-50cd4e2e05f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_595994ed-0276-49c4-b11c-5bbb8b53e95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a6225069-f11b-4a08-88e1-50cd4e2e05f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_595994ed-0276-49c4-b11c-5bbb8b53e95f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_d3efcbfa-9b11-46e4-ab75-3d3d236aedd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_595994ed-0276-49c4-b11c-5bbb8b53e95f" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_d3efcbfa-9b11-46e4-ab75-3d3d236aedd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3a3a63ce-ae2b-4640-9300-8445d7e96416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_595994ed-0276-49c4-b11c-5bbb8b53e95f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3a3a63ce-ae2b-4640-9300-8445d7e96416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7d0bfbf-40a8-4c1f-9ec7-03b5eaafc721" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a554e95-a3df-4cb5-b49a-32c32a34619b" xlink:to="loc_srt_RangeAxis_a7d0bfbf-40a8-4c1f-9ec7-03b5eaafc721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7d0bfbf-40a8-4c1f-9ec7-03b5eaafc721_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a7d0bfbf-40a8-4c1f-9ec7-03b5eaafc721" xlink:to="loc_srt_RangeMember_a7d0bfbf-40a8-4c1f-9ec7-03b5eaafc721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bfcd9fab-c79b-460c-b763-97fca803bf87" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a7d0bfbf-40a8-4c1f-9ec7-03b5eaafc721" xlink:to="loc_srt_RangeMember_bfcd9fab-c79b-460c-b763-97fca803bf87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4375966d-4bc6-407f-813d-98d3a7486981" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bfcd9fab-c79b-460c-b763-97fca803bf87" xlink:to="loc_srt_MinimumMember_4375966d-4bc6-407f-813d-98d3a7486981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a079233d-c34e-48db-a20b-3dcd87cabb3f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bfcd9fab-c79b-460c-b763-97fca803bf87" xlink:to="loc_srt_MaximumMember_a079233d-c34e-48db-a20b-3dcd87cabb3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7ad466fc-4ba7-4618-b6f3-ab7c79652f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7ad466fc-4ba7-4618-b6f3-ab7c79652f8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_323f7766-508f-4bf4-94f2-3ad2fd641e96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_323f7766-508f-4bf4-94f2-3ad2fd641e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3a7ceeca-fe9b-4fbc-b1f5-30b875458992" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3a7ceeca-fe9b-4fbc-b1f5-30b875458992" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_23851cae-afed-422a-b5ae-57f32327cd34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_23851cae-afed-422a-b5ae-57f32327cd34" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_0d8e37d2-feb1-467f-aff2-6989118dbf33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_0d8e37d2-feb1-467f-aff2-6989118dbf33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_0d8e37d2-feb1-467f-aff2-6989118dbf33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_0d8e37d2-feb1-467f-aff2-6989118dbf33" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_0d8e37d2-feb1-467f-aff2-6989118dbf33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_b607a82e-9e87-4eb1-a5ab-aca5d7f05917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_0d8e37d2-feb1-467f-aff2-6989118dbf33" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_b607a82e-9e87-4eb1-a5ab-aca5d7f05917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestMember_5e573d8a-9d4e-45ac-b4ee-0135033b6a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOwnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_b607a82e-9e87-4eb1-a5ab-aca5d7f05917" xlink:to="loc_us-gaap_OtherOwnershipInterestMember_5e573d8a-9d4e-45ac-b4ee-0135033b6a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ba8ec781-77b8-42a1-aaf8-c89dc4b2e831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:to="loc_us-gaap_InvestmentTypeAxis_ba8ec781-77b8-42a1-aaf8-c89dc4b2e831" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ba8ec781-77b8-42a1-aaf8-c89dc4b2e831_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_ba8ec781-77b8-42a1-aaf8-c89dc4b2e831" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ba8ec781-77b8-42a1-aaf8-c89dc4b2e831_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_33cb793a-65a6-47d9-9f70-fca92cb44d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_ba8ec781-77b8-42a1-aaf8-c89dc4b2e831" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_33cb793a-65a6-47d9-9f70-fca92cb44d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d251f4ad-2839-4831-b4a7-0fa530761fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_33cb793a-65a6-47d9-9f70-fca92cb44d6c" xlink:to="loc_us-gaap_EquitySecuritiesMember_d251f4ad-2839-4831-b4a7-0fa530761fbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ef8c6863-62fa-4331-af96-e8970a9d9254" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:to="loc_srt_OwnershipAxis_ef8c6863-62fa-4331-af96-e8970a9d9254" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ef8c6863-62fa-4331-af96-e8970a9d9254_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_ef8c6863-62fa-4331-af96-e8970a9d9254" xlink:to="loc_srt_OwnershipDomain_ef8c6863-62fa-4331-af96-e8970a9d9254_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c6415dff-bff6-428b-b6bc-f50bd6e4140d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_ef8c6863-62fa-4331-af96-e8970a9d9254" xlink:to="loc_srt_OwnershipDomain_c6415dff-bff6-428b-b6bc-f50bd6e4140d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember_e1d1f5f7-8bb2-4c22-9144-261f1c949f29" xlink:href="dva-20241231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_c6415dff-bff6-428b-b6bc-f50bd6e4140d" xlink:to="loc_dva_AgreementWithMedtronicMember_e1d1f5f7-8bb2-4c22-9144-261f1c949f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember_150423a3-c67b-4d07-9203-c770701f04fe" xlink:href="dva-20241231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_c6415dff-bff6-428b-b6bc-f50bd6e4140d" xlink:to="loc_dva_DeconsolidatedNoncontrollingEntityMember_150423a3-c67b-4d07-9203-c770701f04fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_24cdbfb4-b71a-4bdb-b69b-16f9f06b51d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:to="loc_us-gaap_OtherCommitmentsAxis_24cdbfb4-b71a-4bdb-b69b-16f9f06b51d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_24cdbfb4-b71a-4bdb-b69b-16f9f06b51d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_24cdbfb4-b71a-4bdb-b69b-16f9f06b51d6" xlink:to="loc_us-gaap_OtherCommitmentsDomain_24cdbfb4-b71a-4bdb-b69b-16f9f06b51d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_daf47d62-e69d-4fee-a5a6-b9e7e54ff2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_24cdbfb4-b71a-4bdb-b69b-16f9f06b51d6" xlink:to="loc_us-gaap_OtherCommitmentsDomain_daf47d62-e69d-4fee-a5a6-b9e7e54ff2e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember_21fe63ca-3c8c-44b6-a3e7-f88d9e39d5fb" xlink:href="dva-20241231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_daf47d62-e69d-4fee-a5a6-b9e7e54ff2e5" xlink:to="loc_dva_AgreementWithMedtronicMember_21fe63ca-3c8c-44b6-a3e7-f88d9e39d5fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ebf5c366-3fb7-49e0-8d85-08dd2d4b3155" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ebf5c366-3fb7-49e0-8d85-08dd2d4b3155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_49802091-181b-44ec-ab6c-da680d46f1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_49802091-181b-44ec-ab6c-da680d46f1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_2470af1f-e381-451c-8b22-79b1c07039e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_2470af1f-e381-451c-8b22-79b1c07039e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OwnershipPercentageByNoncontrollingOwners_0a53338e-d44e-464b-961c-0bec2801ec86" xlink:href="dva-20241231.xsd#dva_OwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_dva_OwnershipPercentageByNoncontrollingOwners_0a53338e-d44e-464b-961c-0bec2801ec86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAgreementEffectiveClosingDate_030e66b4-539e-4790-b053-70b3d8a44000" xlink:href="dva-20241231.xsd#dva_BusinessAgreementEffectiveClosingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_dva_BusinessAgreementEffectiveClosingDate_030e66b4-539e-4790-b053-70b3d8a44000" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FairValuePayableOfContingentConsideration_d86e8575-301e-4266-87e8-56789243101a" xlink:href="dva-20241231.xsd#dva_FairValuePayableOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_dva_FairValuePayableOfContingentConsideration_d86e8575-301e-4266-87e8-56789243101a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_682ae03b-4124-41d1-800e-d7a96134d80c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_682ae03b-4124-41d1-800e-d7a96134d80c" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#EquityMethodandOtherInvestmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4e3f1cae-967e-418a-8fbe-7fd0354a71d7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4e3f1cae-967e-418a-8fbe-7fd0354a71d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4e3f1cae-967e-418a-8fbe-7fd0354a71d7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4e3f1cae-967e-418a-8fbe-7fd0354a71d7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4e3f1cae-967e-418a-8fbe-7fd0354a71d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_06e00b48-4695-47b9-898e-c91de29ade4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4e3f1cae-967e-418a-8fbe-7fd0354a71d7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_06e00b48-4695-47b9-898e-c91de29ade4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_7821ae68-2d94-4d69-a167-c0c2a181ecf4" xlink:href="dva-20241231.xsd#dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_06e00b48-4695-47b9-898e-c91de29ade4a" xlink:to="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_7821ae68-2d94-4d69-a167-c0c2a181ecf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_08ef2969-898b-4844-b2df-4a68b35d3988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_08ef2969-898b-4844-b2df-4a68b35d3988" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_08ef2969-898b-4844-b2df-4a68b35d3988_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08ef2969-898b-4844-b2df-4a68b35d3988" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_08ef2969-898b-4844-b2df-4a68b35d3988_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c65e48be-9574-46e7-a8bb-2d944c3edbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08ef2969-898b-4844-b2df-4a68b35d3988" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c65e48be-9574-46e7-a8bb-2d944c3edbd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1da2e15e-9343-43e9-afc2-ef27241565ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c65e48be-9574-46e7-a8bb-2d944c3edbd3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1da2e15e-9343-43e9-afc2-ef27241565ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1dfad46d-1d8c-4431-a976-3beeb1f69ba5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:to="loc_srt_RangeAxis_1dfad46d-1d8c-4431-a976-3beeb1f69ba5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1dfad46d-1d8c-4431-a976-3beeb1f69ba5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1dfad46d-1d8c-4431-a976-3beeb1f69ba5" xlink:to="loc_srt_RangeMember_1dfad46d-1d8c-4431-a976-3beeb1f69ba5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_080dddbd-1873-497e-aa34-96c5bfbbe206" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1dfad46d-1d8c-4431-a976-3beeb1f69ba5" xlink:to="loc_srt_RangeMember_080dddbd-1873-497e-aa34-96c5bfbbe206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9398b870-2ced-4545-86b6-f1c7919d0e10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_080dddbd-1873-497e-aa34-96c5bfbbe206" xlink:to="loc_srt_MinimumMember_9398b870-2ced-4545-86b6-f1c7919d0e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60b8074d-52ad-485e-be06-a60470b83231" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_080dddbd-1873-497e-aa34-96c5bfbbe206" xlink:to="loc_srt_MaximumMember_60b8074d-52ad-485e-be06-a60470b83231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_2026df7c-c081-4ba2-9d0e-d4560c263eb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:to="loc_srt_OwnershipAxis_2026df7c-c081-4ba2-9d0e-d4560c263eb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2026df7c-c081-4ba2-9d0e-d4560c263eb8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_2026df7c-c081-4ba2-9d0e-d4560c263eb8" xlink:to="loc_srt_OwnershipDomain_2026df7c-c081-4ba2-9d0e-d4560c263eb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_eba945e4-30ac-4ae7-a91d-8dd07f1760c3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_2026df7c-c081-4ba2-9d0e-d4560c263eb8" xlink:to="loc_srt_OwnershipDomain_eba945e4-30ac-4ae7-a91d-8dd07f1760c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_80c49a6b-a03a-4347-bb59-3737cea05ec9" xlink:href="dva-20241231.xsd#dva_ParentCompanyAndRestrictedSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_eba945e4-30ac-4ae7-a91d-8dd07f1760c3" xlink:to="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_80c49a6b-a03a-4347-bb59-3737cea05ec9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1a05eb5b-755c-4e66-ad2c-49dd4f449037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1a05eb5b-755c-4e66-ad2c-49dd4f449037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_23e2ee2e-d569-418c-a4a5-c0563989d3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_23e2ee2e-d569-418c-a4a5-c0563989d3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeLossFromOtherEquityMethodInvestments_2e1524fe-63f3-4938-b40a-11b9ef7675c9" xlink:href="dva-20241231.xsd#dva_IncomeLossFromOtherEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_dva_IncomeLossFromOtherEquityMethodInvestments_2e1524fe-63f3-4938-b40a-11b9ef7675c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfPartnerships_4941fd17-f3bc-4fb7-8314-f6f4565c5b55" xlink:href="dva-20241231.xsd#dva_NumberOfPartnerships"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_dva_NumberOfPartnerships_4941fd17-f3bc-4fb7-8314-f6f4565c5b55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6ed67a10-13e2-4196-b12f-c3703c53d835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6ed67a10-13e2-4196-b12f-c3703c53d835" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6c3197fa-3532-438b-a357-b4d9d5b580b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6c3197fa-3532-438b-a357-b4d9d5b580b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_280b3a74-720f-4e06-9e01-76fec8224b73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c3197fa-3532-438b-a357-b4d9d5b580b3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_280b3a74-720f-4e06-9e01-76fec8224b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_280b3a74-720f-4e06-9e01-76fec8224b73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_280b3a74-720f-4e06-9e01-76fec8224b73" xlink:to="loc_us-gaap_SegmentDomain_280b3a74-720f-4e06-9e01-76fec8224b73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1318ec87-ac1c-4d34-97be-e1e534ca823d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_280b3a74-720f-4e06-9e01-76fec8224b73" xlink:to="loc_us-gaap_SegmentDomain_1318ec87-ac1c-4d34-97be-e1e534ca823d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_fc73e268-af88-4d77-b3f6-759a5fa23bd9" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1318ec87-ac1c-4d34-97be-e1e534ca823d" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_fc73e268-af88-4d77-b3f6-759a5fa23bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a6c21bd3-7193-41f9-a42a-dc0cad949858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1318ec87-ac1c-4d34-97be-e1e534ca823d" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a6c21bd3-7193-41f9-a42a-dc0cad949858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_6f335e1a-3792-4539-bd5d-7f01ddd3f902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c3197fa-3532-438b-a357-b4d9d5b580b3" xlink:to="loc_us-gaap_ReportingUnitAxis_6f335e1a-3792-4539-bd5d-7f01ddd3f902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_6f335e1a-3792-4539-bd5d-7f01ddd3f902_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_6f335e1a-3792-4539-bd5d-7f01ddd3f902" xlink:to="loc_us-gaap_ReportingUnitDomain_6f335e1a-3792-4539-bd5d-7f01ddd3f902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_fc951aab-dbb5-44ba-92f8-2ab7e2b21d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_6f335e1a-3792-4539-bd5d-7f01ddd3f902" xlink:to="loc_us-gaap_ReportingUnitDomain_fc951aab-dbb5-44ba-92f8-2ab7e2b21d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember_b4abb70b-28db-488b-bdc3-ba3d8017f1dc" xlink:href="dva-20241231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_fc951aab-dbb5-44ba-92f8-2ab7e2b21d4f" xlink:to="loc_dva_TransplantSoftwareReportingUnitMember_b4abb70b-28db-488b-bdc3-ba3d8017f1dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:to="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fa6ae642-2ca2-448b-99ae-57c783868ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_Goodwill_fa6ae642-2ca2-448b-99ae-57c783868ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1961b684-02a8-4cca-a8b8-8fcec213f002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_1961b684-02a8-4cca-a8b8-8fcec213f002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_3248a4ca-fdd0-4199-bdac-ddf123cc6722" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_3248a4ca-fdd0-4199-bdac-ddf123cc6722" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_738fd0b6-ad5f-4610-b142-e5446ff31d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_738fd0b6-ad5f-4610-b142-e5446ff31d4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_41b71c4b-0db2-47e6-a29c-336276e44d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_41b71c4b-0db2-47e6-a29c-336276e44d8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6cefc040-dcf0-4363-8d0c-efc23e4115af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_458f88b6-ae3a-4890-81d6-ec1f3380bb87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:to="loc_us-gaap_GoodwillGross_458f88b6-ae3a-4890-81d6-ec1f3380bb87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_53e8998e-ac53-4004-98ed-24e66ae04e24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_53e8998e-ac53-4004-98ed-24e66ae04e24" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5fbfca08-e232-4eca-8f15-14ffdb18f134" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5fbfca08-e232-4eca-8f15-14ffdb18f134" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2e4c429e-d1e9-4953-98e6-1d8761f02dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5fbfca08-e232-4eca-8f15-14ffdb18f134" xlink:to="loc_us-gaap_ReportingUnitAxis_2e4c429e-d1e9-4953-98e6-1d8761f02dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_2e4c429e-d1e9-4953-98e6-1d8761f02dfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_2e4c429e-d1e9-4953-98e6-1d8761f02dfa" xlink:to="loc_us-gaap_ReportingUnitDomain_2e4c429e-d1e9-4953-98e6-1d8761f02dfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_e1e1dda6-8a77-4c28-9ce5-900de8e9fb93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_2e4c429e-d1e9-4953-98e6-1d8761f02dfa" xlink:to="loc_us-gaap_ReportingUnitDomain_e1e1dda6-8a77-4c28-9ce5-900de8e9fb93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember_b619165a-1949-4642-8e83-c66670a9dc6e" xlink:href="dva-20241231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_e1e1dda6-8a77-4c28-9ce5-900de8e9fb93" xlink:to="loc_dva_TransplantSoftwareReportingUnitMember_b619165a-1949-4642-8e83-c66670a9dc6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_182b704a-1bf0-41ab-98b8-f77b29f33c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5fbfca08-e232-4eca-8f15-14ffdb18f134" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_182b704a-1bf0-41ab-98b8-f77b29f33c3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_182b704a-1bf0-41ab-98b8-f77b29f33c3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_182b704a-1bf0-41ab-98b8-f77b29f33c3a" xlink:to="loc_us-gaap_SegmentDomain_182b704a-1bf0-41ab-98b8-f77b29f33c3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eb5a9c97-b095-4572-b52d-50871c7ceee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_182b704a-1bf0-41ab-98b8-f77b29f33c3a" xlink:to="loc_us-gaap_SegmentDomain_eb5a9c97-b095-4572-b52d-50871c7ceee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember_57ad7ab3-9196-4eff-95d9-97196e5f691b" xlink:href="dva-20241231.xsd#dva_OtherReportingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eb5a9c97-b095-4572-b52d-50871c7ceee6" xlink:to="loc_dva_OtherReportingUnitsMember_57ad7ab3-9196-4eff-95d9-97196e5f691b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0f31fcb6-d9b9-46bd-a007-db6e06fbdd29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:to="loc_us-gaap_Goodwill_0f31fcb6-d9b9-46bd-a007-db6e06fbdd29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax_b58da91c-e4cc-4916-a33e-bf0d7cfdf1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:to="loc_us-gaap_GoodwillImpairmentLossNetOfTax_b58da91c-e4cc-4916-a33e-bf0d7cfdf1a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6c127f7f-071a-4095-8f6e-2e7328fd479c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6c127f7f-071a-4095-8f6e-2e7328fd479c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_72f3e09a-9805-42bb-990a-484d279d70f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:to="loc_us-gaap_NumberOfOperatingSegments_72f3e09a-9805-42bb-990a-484d279d70f7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#GoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_681dca0f-30fc-43af-9593-8b73abd5e2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_4265a44f-2f6a-4118-a2d4-98bcb1122426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_681dca0f-30fc-43af-9593-8b73abd5e2f8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_4265a44f-2f6a-4118-a2d4-98bcb1122426" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_55d78fb2-43f0-4c3e-80e4-7d7134795bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_4265a44f-2f6a-4118-a2d4-98bcb1122426" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_55d78fb2-43f0-4c3e-80e4-7d7134795bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_55d78fb2-43f0-4c3e-80e4-7d7134795bd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_55d78fb2-43f0-4c3e-80e4-7d7134795bd8" xlink:to="loc_us-gaap_SegmentDomain_55d78fb2-43f0-4c3e-80e4-7d7134795bd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4c297e65-021a-4346-91a0-3d943b2e5968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_55d78fb2-43f0-4c3e-80e4-7d7134795bd8" xlink:to="loc_us-gaap_SegmentDomain_4c297e65-021a-4346-91a0-3d943b2e5968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember_59e469fa-99eb-46a3-8120-2e5df51a4e3f" xlink:href="dva-20241231.xsd#dva_OtherReportingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4c297e65-021a-4346-91a0-3d943b2e5968" xlink:to="loc_dva_OtherReportingUnitsMember_59e469fa-99eb-46a3-8120-2e5df51a4e3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ab0bfe5a-19d7-4206-a297-ea255d215a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_681dca0f-30fc-43af-9593-8b73abd5e2f8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ab0bfe5a-19d7-4206-a297-ea255d215a25" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:href="dva-20241231.xsd#dva_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_76494627-f88c-4ab3-aa6f-bbbcbb45c401" xlink:href="dva-20241231.xsd#dva_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_dva_IncomeTaxesTable_76494627-f88c-4ab3-aa6f-bbbcbb45c401" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d83e0f0d-69bd-4013-a9bb-afbc7204449c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_76494627-f88c-4ab3-aa6f-bbbcbb45c401" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d83e0f0d-69bd-4013-a9bb-afbc7204449c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d83e0f0d-69bd-4013-a9bb-afbc7204449c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d83e0f0d-69bd-4013-a9bb-afbc7204449c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d83e0f0d-69bd-4013-a9bb-afbc7204449c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e8c3f3d7-828f-458a-836f-7bcdd2e2bcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d83e0f0d-69bd-4013-a9bb-afbc7204449c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e8c3f3d7-828f-458a-836f-7bcdd2e2bcd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesMember_a1bed24d-6f25-4249-bc8a-7db54ccad76d" xlink:href="dva-20241231.xsd#dva_DeferredTaxLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e8c3f3d7-828f-458a-836f-7bcdd2e2bcd6" xlink:to="loc_dva_DeferredTaxLiabilitiesMember_a1bed24d-6f25-4249-bc8a-7db54ccad76d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_fb7043fb-90c3-40c1-81bc-a085dbc60854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e8c3f3d7-828f-458a-836f-7bcdd2e2bcd6" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_fb7043fb-90c3-40c1-81bc-a085dbc60854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables_ceb4e772-f064-41ae-b2b2-357418639542" xlink:href="dva-20241231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_dva_DeferredTaxAssetsReceivables_ceb4e772-f064-41ae-b2b2-357418639542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2bc87cd9-aafa-4e31-8350-bafdd476b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2bc87cd9-aafa-4e31-8350-bafdd476b7fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_b74c59d2-3e45-4df3-8903-677d72838fc5" xlink:href="dva-20241231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_b74c59d2-3e45-4df3-8903-677d72838fc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1e91978d-e760-4d28-b88f-18a490b7cd43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1e91978d-e760-4d28-b88f-18a490b7cd43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_7a4bb0d4-135f-487f-90f6-316e239de791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_7a4bb0d4-135f-487f-90f6-316e239de791" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_6df9650e-d740-4e7c-bcee-cab0fa8b1f38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_6df9650e-d740-4e7c-bcee-cab0fa8b1f38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_13f895b7-bb68-444f-b63b-93c985278ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_13f895b7-bb68-444f-b63b-93c985278ddd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_07d1b0eb-8343-469f-923b-8eeb4495fa67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_07d1b0eb-8343-469f-923b-8eeb4495fa67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_238bf500-8b02-45a9-a9ea-3a0ed1853be9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_238bf500-8b02-45a9-a9ea-3a0ed1853be9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_38827de0-32fe-4850-986d-56d14ebf04dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_38827de0-32fe-4850-986d-56d14ebf04dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8d5f1046-f7df-49f4-a2dc-92e37d34b95a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8d5f1046-f7df-49f4-a2dc-92e37d34b95a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_a0f1dfae-81d1-4095-a015-3459f1051fa0" xlink:href="dva-20241231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_a0f1dfae-81d1-4095-a015-3459f1051fa0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_22173adf-13ac-4805-a173-5f80b9d486b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_22173adf-13ac-4805-a173-5f80b9d486b8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_e45e6dee-7880-44f7-9d96-033222043bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_e45e6dee-7880-44f7-9d96-033222043bef" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d6bc8b7a-a7a0-4fea-9c4a-5f98c889c13b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d6bc8b7a-a7a0-4fea-9c4a-5f98c889c13b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4000a0af-21b4-478c-9f08-c0b65205c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4000a0af-21b4-478c-9f08-c0b65205c06e" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:href="dva-20241231.xsd#dva_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:href="dva-20241231.xsd#dva_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b87a6a4d-cc28-46d0-813b-8a412fdf1c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b87a6a4d-cc28-46d0-813b-8a412fdf1c8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b87a6a4d-cc28-46d0-813b-8a412fdf1c8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b87a6a4d-cc28-46d0-813b-8a412fdf1c8d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b87a6a4d-cc28-46d0-813b-8a412fdf1c8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b87a6a4d-cc28-46d0-813b-8a412fdf1c8d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c229316c-dd89-4e1d-bdc1-ca391f937b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:to="loc_us-gaap_DomesticCountryMember_c229316c-dd89-4e1d-bdc1-ca391f937b97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9bde2d7a-9e38-40c8-b537-d2edfe579145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9bde2d7a-9e38-40c8-b537-d2edfe579145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_38831b06-0bd5-4b85-b2da-2e311df59302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:to="loc_us-gaap_ForeignCountryMember_38831b06-0bd5-4b85-b2da-2e311df59302" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_16385460-cddb-4d8a-98e0-3728510250d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_TaxPeriodAxis_16385460-cddb-4d8a-98e0-3728510250d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_16385460-cddb-4d8a-98e0-3728510250d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_16385460-cddb-4d8a-98e0-3728510250d5" xlink:to="loc_us-gaap_TaxPeriodDomain_16385460-cddb-4d8a-98e0-3728510250d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_efc33810-30fc-4586-81a4-07068e172c10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_16385460-cddb-4d8a-98e0-3728510250d5" xlink:to="loc_us-gaap_TaxPeriodDomain_efc33810-30fc-4586-81a4-07068e172c10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TaxYear2029Member_f48a3467-64da-4bfe-9cf4-33e913873f10" xlink:href="dva-20241231.xsd#dva_TaxYear2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_efc33810-30fc-4586-81a4-07068e172c10" xlink:to="loc_dva_TaxYear2029Member_f48a3467-64da-4bfe-9cf4-33e913873f10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_08d33853-b366-49e7-aaa9-dba4553772cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_08d33853-b366-49e7-aaa9-dba4553772cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_08d33853-b366-49e7-aaa9-dba4553772cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_08d33853-b366-49e7-aaa9-dba4553772cf" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_08d33853-b366-49e7-aaa9-dba4553772cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c8dccf78-4299-4af5-89dd-1341ee624396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_08d33853-b366-49e7-aaa9-dba4553772cf" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c8dccf78-4299-4af5-89dd-1341ee624396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_711e733f-3251-484e-9bee-3094cd329838" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_c8dccf78-4299-4af5-89dd-1341ee624396" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_711e733f-3251-484e-9bee-3094cd329838" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_96808d07-4a67-4ca1-bfda-dbac0d523c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_96808d07-4a67-4ca1-bfda-dbac0d523c91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_96808d07-4a67-4ca1-bfda-dbac0d523c91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_96808d07-4a67-4ca1-bfda-dbac0d523c91" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_96808d07-4a67-4ca1-bfda-dbac0d523c91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_c3bdbcc4-5708-4978-b559-8a21a6260626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_96808d07-4a67-4ca1-bfda-dbac0d523c91" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_c3bdbcc4-5708-4978-b559-8a21a6260626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IndefiniteLifeNetOperatingLossesMember_04c7ab3b-04e7-4791-9115-04dfe82a1c8d" xlink:href="dva-20241231.xsd#dva_IndefiniteLifeNetOperatingLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_c3bdbcc4-5708-4978-b559-8a21a6260626" xlink:to="loc_dva_IndefiniteLifeNetOperatingLossesMember_04c7ab3b-04e7-4791-9115-04dfe82a1c8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_93db957e-f1e2-4e89-bf52-982d8b748392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_93db957e-f1e2-4e89-bf52-982d8b748392" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_93db957e-f1e2-4e89-bf52-982d8b748392_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_93db957e-f1e2-4e89-bf52-982d8b748392" xlink:to="loc_us-gaap_EquityComponentDomain_93db957e-f1e2-4e89-bf52-982d8b748392_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af982986-84dc-4a68-b7ed-8a2981cfc4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_93db957e-f1e2-4e89-bf52-982d8b748392" xlink:to="loc_us-gaap_EquityComponentDomain_af982986-84dc-4a68-b7ed-8a2981cfc4d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8fe6bdc2-0454-4d05-a672-59a5980245fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_af982986-84dc-4a68-b7ed-8a2981cfc4d6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8fe6bdc2-0454-4d05-a672-59a5980245fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3c5e22f1-6a7d-4923-ae6d-d253b9ddd527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3c5e22f1-6a7d-4923-ae6d-d253b9ddd527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_98dcfa60-4027-4b58-a178-9b9afd018280" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_98dcfa60-4027-4b58-a178-9b9afd018280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_631adfcb-f8a7-4835-b3d2-ace9b6575e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_631adfcb-f8a7-4835-b3d2-ace9b6575e7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_3f535c00-baaf-4431-b845-319f33860a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_3f535c00-baaf-4431-b845-319f33860a5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9494a878-42ab-4077-bdd5-413e525af452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9494a878-42ab-4077-bdd5-413e525af452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_55279972-c9b5-4a03-87ff-585c946b731f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_55279972-c9b5-4a03-87ff-585c946b731f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_80c21e5b-48d0-4284-891d-a01fcee625e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_80c21e5b-48d0-4284-891d-a01fcee625e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7ea35fc4-811f-4a79-9d98-6b952e8b6f14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7ea35fc4-811f-4a79-9d98-6b952e8b6f14" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1ab73b48-e5cd-4e30-b285-4a452faabf89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1ab73b48-e5cd-4e30-b285-4a452faabf89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_095a05c5-9c47-411c-88b0-ce9af0099446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_095a05c5-9c47-411c-88b0-ce9af0099446" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_597d1cf6-05af-4757-a1ac-79088b38607b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_597d1cf6-05af-4757-a1ac-79088b38607b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_597d1cf6-05af-4757-a1ac-79088b38607b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_597d1cf6-05af-4757-a1ac-79088b38607b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_597d1cf6-05af-4757-a1ac-79088b38607b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_597d1cf6-05af-4757-a1ac-79088b38607b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1AndRevolverMember_6038268d-049b-4588-a026-6ea1125867a1" xlink:href="dva-20241231.xsd#dva_TermLoanA1AndRevolverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_TermLoanA1AndRevolverMember_6038268d-049b-4588-a026-6ea1125867a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member_f042d8a2-c9d4-45b1-b3f0-5a868042c965" xlink:href="dva-20241231.xsd#dva_TermLoanA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_TermLoanA1Member_f042d8a2-c9d4-45b1-b3f0-5a868042c965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreasedTermLoanA1Member_7b8f5727-a2cf-4aa6-b24d-0f23175e491c" xlink:href="dva-20241231.xsd#dva_IncreasedTermLoanA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_IncreasedTermLoanA1Member_7b8f5727-a2cf-4aa6-b24d-0f23175e491c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_9d39c6ee-9609-4599-a8bf-a311799ac059" xlink:href="dva-20241231.xsd#dva_TermLoanB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_TermLoanB1Member_9d39c6ee-9609-4599-a8bf-a311799ac059" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExtendedTermLoanB1Member_f866f0a7-72ef-49e3-8209-928ab6657fc2" xlink:href="dva-20241231.xsd#dva_ExtendedTermLoanB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_ExtendedTermLoanB1Member_f866f0a7-72ef-49e3-8209-928ab6657fc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_2f41e429-097d-4d4c-8410-d387b6e1407c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_us-gaap_SeniorNotesMember_2f41e429-097d-4d4c-8410-d387b6e1407c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_79b35210-0ac9-4a29-ab82-12d9ead7a0d7" xlink:href="dva-20241231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_79b35210-0ac9-4a29-ab82-12d9ead7a0d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fb137ab5-bee3-44e5-bfd6-69e3dcc8ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_CreditFacilityAxis_fb137ab5-bee3-44e5-bfd6-69e3dcc8ca4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fb137ab5-bee3-44e5-bfd6-69e3dcc8ca4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_fb137ab5-bee3-44e5-bfd6-69e3dcc8ca4a" xlink:to="loc_us-gaap_CreditFacilityDomain_fb137ab5-bee3-44e5-bfd6-69e3dcc8ca4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_13a227ba-310e-4371-93b3-766a6e93ea89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_fb137ab5-bee3-44e5-bfd6-69e3dcc8ca4a" xlink:to="loc_us-gaap_CreditFacilityDomain_13a227ba-310e-4371-93b3-766a6e93ea89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_415c15ad-93b4-44f8-b722-a786fdfa9303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_13a227ba-310e-4371-93b3-766a6e93ea89" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_415c15ad-93b4-44f8-b722-a786fdfa9303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_68c9b7e5-f2bc-44ab-b91e-edb194507a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_DebtInstrumentAxis_68c9b7e5-f2bc-44ab-b91e-edb194507a48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_68c9b7e5-f2bc-44ab-b91e-edb194507a48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_68c9b7e5-f2bc-44ab-b91e-edb194507a48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_68c9b7e5-f2bc-44ab-b91e-edb194507a48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_68c9b7e5-f2bc-44ab-b91e-edb194507a48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_b2716297-eee4-4b25-873e-6ebf228d1f1d" xlink:href="dva-20241231.xsd#dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_b2716297-eee4-4b25-873e-6ebf228d1f1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_2662ddf8-a088-42ec-9f2f-6f674915ed06" xlink:href="dva-20241231.xsd#dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_2662ddf8-a088-42ec-9f2f-6f674915ed06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember_730c1162-7249-4354-8a99-bebae1b6abc4" xlink:href="dva-20241231.xsd#dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember_730c1162-7249-4354-8a99-bebae1b6abc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_cf8ec62e-f450-40f6-8325-ca6186f916ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_cf8ec62e-f450-40f6-8325-ca6186f916ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_08730d21-a2fb-4890-90fa-b47645e9210b" xlink:href="dva-20241231.xsd#dva_FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_FinanceLeaseMember_08730d21-a2fb-4890-90fa-b47645e9210b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ChangeHealthcareTemporaryFundingAssistanceMember_1acd54c1-43dc-4e52-b2f5-1c76fec8532d" xlink:href="dva-20241231.xsd#dva_ChangeHealthcareTemporaryFundingAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_ChangeHealthcareTemporaryFundingAssistanceMember_1acd54c1-43dc-4e52-b2f5-1c76fec8532d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b626c697-5f4d-4d8d-9761-d48056e0b2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_VariableRateAxis_b626c697-5f4d-4d8d-9761-d48056e0b2d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b626c697-5f4d-4d8d-9761-d48056e0b2d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_b626c697-5f4d-4d8d-9761-d48056e0b2d1" xlink:to="loc_us-gaap_VariableRateDomain_b626c697-5f4d-4d8d-9761-d48056e0b2d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_b626c697-5f4d-4d8d-9761-d48056e0b2d1" xlink:to="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_57b8f581-c571-468d-8620-f5b26932c2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_57b8f581-c571-468d-8620-f5b26932c2b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember_b4a944d4-452a-432b-9f31-b0e200d9c515" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_us-gaap_AdjustableRateLoansMember_b4a944d4-452a-432b-9f31-b0e200d9c515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_0d9e92d9-9cf2-4a3d-bf42-b7ecd68d8ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_0d9e92d9-9cf2-4a3d-bf42-b7ecd68d8ec9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A1MonthSOFRMember_17048c94-0d11-42cf-9f90-0eeb23a53b26" xlink:href="dva-20241231.xsd#dva_A1MonthSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_dva_A1MonthSOFRMember_17048c94-0d11-42cf-9f90-0eeb23a53b26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_f6f09fb9-a118-43b2-bb11-14e2d1e4a538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_us-gaap_PrimeRateMember_f6f09fb9-a118-43b2-bb11-14e2d1e4a538" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_33cfc6c0-e017-4315-b536-b8b7b2a7cc51" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_srt_RangeAxis_33cfc6c0-e017-4315-b536-b8b7b2a7cc51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33cfc6c0-e017-4315-b536-b8b7b2a7cc51_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_33cfc6c0-e017-4315-b536-b8b7b2a7cc51" xlink:to="loc_srt_RangeMember_33cfc6c0-e017-4315-b536-b8b7b2a7cc51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_49a78ae7-325c-4b9f-b9b9-5414954d8d82" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_33cfc6c0-e017-4315-b536-b8b7b2a7cc51" xlink:to="loc_srt_RangeMember_49a78ae7-325c-4b9f-b9b9-5414954d8d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37afa4d5-a214-4e4d-9acc-7da04481e76f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49a78ae7-325c-4b9f-b9b9-5414954d8d82" xlink:to="loc_srt_MinimumMember_37afa4d5-a214-4e4d-9acc-7da04481e76f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_277beacd-b647-41f7-8975-4cabdcc9b34f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49a78ae7-325c-4b9f-b9b9-5414954d8d82" xlink:to="loc_srt_MaximumMember_277beacd-b647-41f7-8975-4cabdcc9b34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeAxis_381c229a-e355-4325-a5b9-17639de98cba" xlink:href="dva-20241231.xsd#dva_LoansTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_dva_LoansTypeAxis_381c229a-e355-4325-a5b9-17639de98cba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeDomain_381c229a-e355-4325-a5b9-17639de98cba_default" xlink:href="dva-20241231.xsd#dva_LoansTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dva_LoansTypeAxis_381c229a-e355-4325-a5b9-17639de98cba" xlink:to="loc_dva_LoansTypeDomain_381c229a-e355-4325-a5b9-17639de98cba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeDomain_42f83a2f-365a-483a-b674-973a7c166e55" xlink:href="dva-20241231.xsd#dva_LoansTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dva_LoansTypeAxis_381c229a-e355-4325-a5b9-17639de98cba" xlink:to="loc_dva_LoansTypeDomain_42f83a2f-365a-483a-b674-973a7c166e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BaseRateLoansMember_5ecc5a01-c00d-4e00-b2ca-6874855c3d06" xlink:href="dva-20241231.xsd#dva_BaseRateLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LoansTypeDomain_42f83a2f-365a-483a-b674-973a7c166e55" xlink:to="loc_dva_BaseRateLoansMember_5ecc5a01-c00d-4e00-b2ca-6874855c3d06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SOFRLoansMember_a5cca77c-5888-416d-9b67-646ff89ff1ea" xlink:href="dva-20241231.xsd#dva_SOFRLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LoansTypeDomain_42f83a2f-365a-483a-b674-973a7c166e55" xlink:to="loc_dva_SOFRLoansMember_a5cca77c-5888-416d-9b67-646ff89ff1ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e1c75750-7efb-4467-b815-bff33d953520" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e1c75750-7efb-4467-b815-bff33d953520" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e1c75750-7efb-4467-b815-bff33d953520_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e1c75750-7efb-4467-b815-bff33d953520" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e1c75750-7efb-4467-b815-bff33d953520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_29f9c553-8530-4a87-a740-59fff9a69d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e1c75750-7efb-4467-b815-bff33d953520" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_29f9c553-8530-4a87-a740-59fff9a69d5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b1c68891-c454-44f3-96ce-022c0db30f06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_29f9c553-8530-4a87-a740-59fff9a69d5b" xlink:to="loc_us-gaap_SubsequentEventMember_b1c68891-c454-44f3-96ce-022c0db30f06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_56009a38-07e6-4bb1-bd50-9f2d89e3e459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_56009a38-07e6-4bb1-bd50-9f2d89e3e459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_87c8fac5-f2c8-475e-bac4-9a1f661879a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_56009a38-07e6-4bb1-bd50-9f2d89e3e459" xlink:to="loc_us-gaap_SecuredDebt_87c8fac5-f2c8-475e-bac4-9a1f661879a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableAbstract_f51fcf66-6897-4729-a199-f382f5f74a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_NotesPayableAbstract_f51fcf66-6897-4729-a199-f382f5f74a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_5817cc20-fbc9-4460-9011-051c7b5b68df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NotesPayableAbstract_f51fcf66-6897-4729-a199-f382f5f74a34" xlink:to="loc_us-gaap_SeniorNotes_5817cc20-fbc9-4460-9011-051c7b5b68df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_222de770-728b-4de4-92e7-a83994317377" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_222de770-728b-4de4-92e7-a83994317377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_a6b2dd11-9c9e-41bf-9e4c-1bcdf55a3263" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_a6b2dd11-9c9e-41bf-9e4c-1bcdf55a3263" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_32fb4d3d-9471-45fa-b9ca-9036a71a9465" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_32fb4d3d-9471-45fa-b9ca-9036a71a9465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_11da17cd-bc89-4a00-ae44-75802da2163b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_DebtInstrumentFairValue_11da17cd-bc89-4a00-ae44-75802da2163b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayable_fba8d0bb-2d89-4de1-8c15-a0ad79c67140" xlink:href="dva-20241231.xsd#dva_AcquisitionObligationsAndOtherNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayable_fba8d0bb-2d89-4de1-8c15-a0ad79c67140" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_0e6b55f1-25d0-4150-9fd8-471392be0228" xlink:href="dva-20241231.xsd#dva_AcquisitionObligationsAndOtherNotesPayableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_0e6b55f1-25d0-4150-9fd8-471392be0228" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_b906f214-df0c-42aa-a05a-acdece890e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_FinanceLeaseLiability_b906f214-df0c-42aa-a05a-acdece890e56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_1a4b38cc-785a-40ca-b6cb-38288c0de31b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_1a4b38cc-785a-40ca-b6cb-38288c0de31b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_8cfbc2ac-290a-48aa-914d-51845925d4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_8cfbc2ac-290a-48aa-914d-51845925d4e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_38e46ff6-b3a0-4952-ab6c-8c16ab98afe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_38e46ff6-b3a0-4952-ab6c-8c16ab98afe8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_782570d5-cae3-44ff-99a6-a5d3304bd41c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_782570d5-cae3-44ff-99a6-a5d3304bd41c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountPremiumAndDeferredFinanceCosts_c29c9853-af29-4793-821f-0c09c140719e" xlink:href="dva-20241231.xsd#dva_DiscountPremiumAndDeferredFinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_dva_DiscountPremiumAndDeferredFinanceCosts_c29c9853-af29-4793-821f-0c09c140719e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c6d69431-4fe9-4865-813e-662c99100a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c6d69431-4fe9-4865-813e-662c99100a68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e4d4bd94-20e9-4a9a-932e-d343cc3d7688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e4d4bd94-20e9-4a9a-932e-d343cc3d7688" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b44c8cd5-ddf4-468c-a09e-32247ab272d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b44c8cd5-ddf4-468c-a09e-32247ab272d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6f872606-9f09-4fbc-bc3b-d4184b0f98cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6f872606-9f09-4fbc-bc3b-d4184b0f98cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_ff84ce9d-bd8c-471c-89b8-3fea770e27c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:to="loc_us-gaap_DeferredOfferingCosts_ff84ce9d-bd8c-471c-89b8-3fea770e27c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_9a3be0e8-403d-4572-bc7c-46ff9486bbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_9a3be0e8-403d-4572-bc7c-46ff9486bbb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CHCTemporaryFundingAssistance_85756fe4-2264-45d2-8a60-b65df7fe37eb" xlink:href="dva-20241231.xsd#dva_CHCTemporaryFundingAssistance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_CHCTemporaryFundingAssistance_85756fe4-2264-45d2-8a60-b65df7fe37eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_9be31d3b-21e4-4d76-b836-f19c26263cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_9be31d3b-21e4-4d76-b836-f19c26263cd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CHCTemporaryFundingAssistanceFairValue_beb65dc8-ee7e-4f7d-8e16-4ad7d69f2709" xlink:href="dva-20241231.xsd#dva_CHCTemporaryFundingAssistanceFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_CHCTemporaryFundingAssistanceFairValue_beb65dc8-ee7e-4f7d-8e16-4ad7d69f2709" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6dba3143-c7a6-41a2-8422-b951cc8dbc96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6dba3143-c7a6-41a2-8422-b951cc8dbc96" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_2df82ee0-ae1a-4013-a86a-dd4705e33978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_2df82ee0-ae1a-4013-a86a-dd4705e33978" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_f7dce8f1-a0b6-49bb-bc2a-9d03446e27c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_f7dce8f1-a0b6-49bb-bc2a-9d03446e27c0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_fd0652b1-19b6-4ea6-860d-b0e840a66e5b" xlink:href="dva-20241231.xsd#dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_fd0652b1-19b6-4ea6-860d-b0e840a66e5b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConstructiveFinancingCashOutflow_36ab1d99-df41-4aa7-9f7e-b18571165fc9" xlink:href="dva-20241231.xsd#dva_ConstructiveFinancingCashOutflow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_ConstructiveFinancingCashOutflow_36ab1d99-df41-4aa7-9f7e-b18571165fc9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConstructiveFinancingCashInflow_801e69e7-c3ef-4736-a0ec-ec6f86b4c89a" xlink:href="dva-20241231.xsd#dva_ConstructiveFinancingCashInflow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_ConstructiveFinancingCashInflow_801e69e7-c3ef-4736-a0ec-ec6f86b4c89a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_7888cd95-fe48-42d1-9616-d725b9240013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_7888cd95-fe48-42d1-9616-d725b9240013" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_b2ec483a-b1f6-4a9f-aeb8-77cedb94336f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_RepaymentsOfDebt_b2ec483a-b1f6-4a9f-aeb8-77cedb94336f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescription_3644b829-4d43-4b26-8893-48d544ffc2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentDescription_3644b829-4d43-4b26-8893-48d544ffc2d0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_e1e5cabd-13ad-4a07-a007-256b3ba9dcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_e1e5cabd-13ad-4a07-a007-256b3ba9dcb7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_241321d6-5250-46dd-88f4-cd432c76db7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_241321d6-5250-46dd-88f4-cd432c76db7c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSignificantNoncashFinancingActivity_b7713bc3-6a77-4360-90e4-2246d4c49a04" xlink:href="dva-20241231.xsd#dva_OtherSignificantNoncashFinancingActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_OtherSignificantNoncashFinancingActivity_b7713bc3-6a77-4360-90e4-2246d4c49a04" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_145e7bd2-288f-4316-b26c-f2360b0ea564" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_145e7bd2-288f-4316-b26c-f2360b0ea564" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_d843fe08-89b6-48d3-ba4a-5371ef221da8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_d843fe08-89b6-48d3-ba4a-5371ef221da8" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtExtendedMaturity_ef8a827c-3496-4fdd-8ba7-493a69e4fce1" xlink:href="dva-20241231.xsd#dva_SecuredDebtExtendedMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_SecuredDebtExtendedMaturity_ef8a827c-3496-4fdd-8ba7-493a69e4fce1" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_14c1a5f1-f6a7-4e0f-ac21-d5e0b814b423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_14c1a5f1-f6a7-4e0f-ac21-d5e0b814b423" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding_2a5e54f8-bfb4-4450-950d-84f6e0ad22a6" xlink:href="dva-20241231.xsd#dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding_2a5e54f8-bfb4-4450-950d-84f6e0ad22a6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_739770f8-392c-4fab-8703-5d4f0928678e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_739770f8-392c-4fab-8703-5d4f0928678e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_93dd69b2-da59-460e-93df-4c4223ffa0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_93dd69b2-da59-460e-93df-4c4223ffa0b6" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentThroughJune302027_2d01df39-1abe-4e99-8204-f09360856422" xlink:href="dva-20241231.xsd#dva_DebtInstrumentQuarterlyPaymentThroughJune302027"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentThroughJune302027_2d01df39-1abe-4e99-8204-f09360856422" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028_b22944bc-b78c-4acb-955b-eab0e5bb8377" xlink:href="dva-20241231.xsd#dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028_b22944bc-b78c-4acb-955b-eab0e5bb8377" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_fd27b4ea-e84c-4288-bd8e-c274e721d46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_fd27b4ea-e84c-4288-bd8e-c274e721d46d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1e4a576f-643f-44c1-accf-e552855e601c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1e4a576f-643f-44c1-accf-e552855e601c" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e67cca5b-5e5b-4304-b06e-3eaa2038d3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e67cca5b-5e5b-4304-b06e-3eaa2038d3cc" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_58a707d7-9756-4860-b516-1d06e75e6235" xlink:href="dva-20241231.xsd#dva_DebtPrepaymentExtinguishmentAndModificationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_58a707d7-9756-4860-b516-1d06e75e6235" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027_0e436bac-fae6-4e85-bcb2-966776f7e22d" xlink:href="dva-20241231.xsd#dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027_0e436bac-fae6-4e85-bcb2-966776f7e22d" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentRedemptionPriceIfChangeOfControl_61a54915-4624-4787-bba0-e94833d16e1d" xlink:href="dva-20241231.xsd#dva_DebtInstrumentRedemptionPriceIfChangeOfControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentRedemptionPriceIfChangeOfControl_61a54915-4624-4787-bba0-e94833d16e1d" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_3f5c4223-f7bf-4122-a02a-0a21892726cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_3f5c4223-f7bf-4122-a02a-0a21892726cd" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentVariableRate_bf1d8f28-9c93-4fa4-9794-f12d96a18e95" xlink:href="dva-20241231.xsd#dva_DebtInstrumentVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentVariableRate_bf1d8f28-9c93-4fa4-9794-f12d96a18e95" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b389ee4d-7db9-4c11-a7ca-cd36fcbe122c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b389ee4d-7db9-4c11-a7ca-cd36fcbe122c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b389ee4d-7db9-4c11-a7ca-cd36fcbe122c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b389ee4d-7db9-4c11-a7ca-cd36fcbe122c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b389ee4d-7db9-4c11-a7ca-cd36fcbe122c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b389ee4d-7db9-4c11-a7ca-cd36fcbe122c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_213a0abf-5b07-4e1d-9b1b-628126e28310" xlink:href="dva-20241231.xsd#dva_A2019InterestRateCapAgreementsEffectiveJune302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_213a0abf-5b07-4e1d-9b1b-628126e28310" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_d4e2dc1f-7eb1-4f6d-b28c-9182c1cc6b02" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_d4e2dc1f-7eb1-4f6d-b28c-9182c1cc6b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_44b19f50-4511-42c3-82c4-b955b64bd09b" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_44b19f50-4511-42c3-82c4-b955b64bd09b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_67a4d822-5ce4-4d3e-b08d-6ddfaad283f5" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_67a4d822-5ce4-4d3e-b08d-6ddfaad283f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_e777b5a7-fa18-4c67-b85a-6eb3d8516243" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_e777b5a7-fa18-4c67-b85a-6eb3d8516243" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_c8bdf5c6-b89f-4b2c-8651-be0582cf8f18" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_c8bdf5c6-b89f-4b2c-8651-be0582cf8f18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_950b75b8-edc3-4d68-954b-7cba04d3ee1f" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_950b75b8-edc3-4d68-954b-7cba04d3ee1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member_261b20ff-5dfb-4209-8b41-ad0e205b22d1" xlink:href="dva-20241231.xsd#dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member_261b20ff-5dfb-4209-8b41-ad0e205b22d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member_6719b64b-d088-41bb-8a2f-766ba7723b99" xlink:href="dva-20241231.xsd#dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member_6719b64b-d088-41bb-8a2f-766ba7723b99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312024Member_3e7554f7-fd42-4ae8-958f-ad1b001f2e89" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_TotalNotionalAmountEffectiveThroughDecember312024Member_3e7554f7-fd42-4ae8-958f-ad1b001f2e89" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312025Member_b62c3a82-58e2-4a35-acb4-799b5c7d6340" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_TotalNotionalAmountEffectiveThroughDecember312025Member_b62c3a82-58e2-4a35-acb4-799b5c7d6340" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312026Member_6469db10-8c0a-4255-b972-38c1c61ba6bc" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_TotalNotionalAmountEffectiveThroughDecember312026Member_6469db10-8c0a-4255-b972-38c1c61ba6bc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312027Member_e3bca083-eeaa-4f4a-a699-2f605c1a6568" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_TotalNotionalAmountEffectiveThroughDecember312027Member_e3bca083-eeaa-4f4a-a699-2f605c1a6568" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b84f29fd-635b-4e94-b569-f0c440752f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_DebtInstrumentAxis_b84f29fd-635b-4e94-b569-f0c440752f3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b84f29fd-635b-4e94-b569-f0c440752f3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b84f29fd-635b-4e94-b569-f0c440752f3e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b84f29fd-635b-4e94-b569-f0c440752f3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e920e97f-aa6e-4674-b023-43752aaec838" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b84f29fd-635b-4e94-b569-f0c440752f3e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e920e97f-aa6e-4674-b023-43752aaec838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember_c3530995-5552-4a37-9a91-748291d5683b" xlink:href="dva-20241231.xsd#dva_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e920e97f-aa6e-4674-b023-43752aaec838" xlink:to="loc_dva_TermLoanFacilityMember_c3530995-5552-4a37-9a91-748291d5683b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_401f9c2d-23ec-4a49-ac7a-9fa0f4a98277" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_srt_RangeAxis_401f9c2d-23ec-4a49-ac7a-9fa0f4a98277" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_401f9c2d-23ec-4a49-ac7a-9fa0f4a98277_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_401f9c2d-23ec-4a49-ac7a-9fa0f4a98277" xlink:to="loc_srt_RangeMember_401f9c2d-23ec-4a49-ac7a-9fa0f4a98277_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0353f2e-afc3-4762-91ee-543681d0c4df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_401f9c2d-23ec-4a49-ac7a-9fa0f4a98277" xlink:to="loc_srt_RangeMember_c0353f2e-afc3-4762-91ee-543681d0c4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c0cab4d-f868-4b95-8831-d0889d609b1c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c0353f2e-afc3-4762-91ee-543681d0c4df" xlink:to="loc_srt_MaximumMember_5c0cab4d-f868-4b95-8831-d0889d609b1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_76174bbf-e7c6-400c-b410-c6cb121774e4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c0353f2e-afc3-4762-91ee-543681d0c4df" xlink:to="loc_srt_WeightedAverageMember_76174bbf-e7c6-400c-b410-c6cb121774e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d583f251-b1b6-46a6-9d45-c3c314908b45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d583f251-b1b6-46a6-9d45-c3c314908b45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d583f251-b1b6-46a6-9d45-c3c314908b45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d583f251-b1b6-46a6-9d45-c3c314908b45" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d583f251-b1b6-46a6-9d45-c3c314908b45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_15077b86-a502-4e4e-ac12-d87ad732087a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d583f251-b1b6-46a6-9d45-c3c314908b45" xlink:to="loc_us-gaap_HedgingRelationshipDomain_15077b86-a502-4e4e-ac12-d87ad732087a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_4709fa65-d295-41eb-a9a1-c4d562b1c212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_15077b86-a502-4e4e-ac12-d87ad732087a" xlink:to="loc_us-gaap_CashFlowHedgingMember_4709fa65-d295-41eb-a9a1-c4d562b1c212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bf78dfb5-1428-4dd5-86a6-5078a52caf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bf78dfb5-1428-4dd5-86a6-5078a52caf9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bf78dfb5-1428-4dd5-86a6-5078a52caf9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf78dfb5-1428-4dd5-86a6-5078a52caf9a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bf78dfb5-1428-4dd5-86a6-5078a52caf9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cae8c2e0-595f-4632-87be-c22217084c89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf78dfb5-1428-4dd5-86a6-5078a52caf9a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cae8c2e0-595f-4632-87be-c22217084c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_d918231b-a673-4ede-93b4-85351cf4bf98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cae8c2e0-595f-4632-87be-c22217084c89" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_d918231b-a673-4ede-93b4-85351cf4bf98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d391d6a1-cae3-4475-ae0f-37084d61adf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d391d6a1-cae3-4475-ae0f-37084d61adf7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d391d6a1-cae3-4475-ae0f-37084d61adf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d391d6a1-cae3-4475-ae0f-37084d61adf7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d391d6a1-cae3-4475-ae0f-37084d61adf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_69191d05-1302-404f-830b-2cd22aab1569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d391d6a1-cae3-4475-ae0f-37084d61adf7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_69191d05-1302-404f-830b-2cd22aab1569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_beb60c3a-07ca-4eec-afcc-1afd3a08397a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_69191d05-1302-404f-830b-2cd22aab1569" xlink:to="loc_us-gaap_SubsequentEventMember_beb60c3a-07ca-4eec-afcc-1afd3a08397a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_0238f121-7f3a-48af-9bfb-88536c72d31e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_0238f121-7f3a-48af-9bfb-88536c72d31e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageFixedInterestRate_0bc2b956-8c08-4aa4-993a-6ecfff3266f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAverageFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeAverageFixedInterestRate_0bc2b956-8c08-4aa4-993a-6ecfff3266f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInceptionDates_bdf389fd-9f78-4535-89b2-9b3d9f48fe90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInceptionDates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeInceptionDates_bdf389fd-9f78-4535-89b2-9b3d9f48fe90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMaturityDates_633a61df-6b35-447f-8743-073d0b81e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeMaturityDates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeMaturityDates_633a61df-6b35-447f-8743-073d0b81e9ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312024_98c174dd-03e5-4f51-9237-8dbea31ecd1c" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByDecember312024"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312024_98c174dd-03e5-4f51-9237-8dbea31ecd1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312025_5aef4d95-3a2d-482d-a76c-22c5f2fc537e" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByDecember312025"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312025_5aef4d95-3a2d-482d-a76c-22c5f2fc537e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312026_da3c6606-80b1-4a4a-89b6-fd5f6e489f03" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByDecember312026"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312026_da3c6606-80b1-4a4a-89b6-fd5f6e489f03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByMaturityDate_ce0eb906-de21-4a40-946f-4147737606c4" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_dva_NotionalAmountAmortizableByMaturityDate_ce0eb906-de21-4a40-946f-4147737606c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_e3d6bed0-0a1e-49bd-9c87-a32b60e05486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_e3d6bed0-0a1e-49bd-9c87-a32b60e05486" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d3aa8536-2678-42ba-afea-0b5164eb8d15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d3aa8536-2678-42ba-afea-0b5164eb8d15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_26ec4009-9555-4fd1-9748-9f4558141e24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d3aa8536-2678-42ba-afea-0b5164eb8d15" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_26ec4009-9555-4fd1-9748-9f4558141e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_26ec4009-9555-4fd1-9748-9f4558141e24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_26ec4009-9555-4fd1-9748-9f4558141e24" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_26ec4009-9555-4fd1-9748-9f4558141e24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_71183c37-0295-4411-99a2-68dd152f15ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_26ec4009-9555-4fd1-9748-9f4558141e24" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_71183c37-0295-4411-99a2-68dd152f15ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_6d36da74-871c-4876-8977-9493c93588e9" xlink:href="dva-20241231.xsd#dva_IncomeTaxRelatedToCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71183c37-0295-4411-99a2-68dd152f15ee" xlink:to="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_6d36da74-871c-4876-8977-9493c93588e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_c3f3f86d-1b3d-4c93-bcec-1e81e3978285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71183c37-0295-4411-99a2-68dd152f15ee" xlink:to="loc_us-gaap_InterestRateCapMember_c3f3f86d-1b3d-4c93-bcec-1e81e3978285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8641868d-18f4-4ce2-9cbf-1bac66b33455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d3aa8536-2678-42ba-afea-0b5164eb8d15" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8641868d-18f4-4ce2-9cbf-1bac66b33455" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8641868d-18f4-4ce2-9cbf-1bac66b33455_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8641868d-18f4-4ce2-9cbf-1bac66b33455" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8641868d-18f4-4ce2-9cbf-1bac66b33455_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_633047b6-33a7-42ca-82fd-a50447338272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8641868d-18f4-4ce2-9cbf-1bac66b33455" xlink:to="loc_us-gaap_HedgingRelationshipDomain_633047b6-33a7-42ca-82fd-a50447338272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_7fe2e060-dab9-4ae3-b1b8-73ad73efdc34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_633047b6-33a7-42ca-82fd-a50447338272" xlink:to="loc_us-gaap_CashFlowHedgingMember_7fe2e060-dab9-4ae3-b1b8-73ad73efdc34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_062600b8-aaea-4e10-8111-30ccc47c674b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_062600b8-aaea-4e10-8111-30ccc47c674b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_743f3bac-5583-44b3-b972-b296fc5ed1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_743f3bac-5583-44b3-b972-b296fc5ed1f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e5815168-4703-44fc-b3d8-f5fb58da76f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:to="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e5815168-4703-44fc-b3d8-f5fb58da76f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_345789c9-ce1f-4457-b6a7-e16c69510f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_adb552ea-5d12-4991-87c0-50740389722b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_345789c9-ce1f-4457-b6a7-e16c69510f40" xlink:to="loc_us-gaap_DerivativeTable_adb552ea-5d12-4991-87c0-50740389722b" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_41705b1f-2b84-4614-8de5-2a99e6727fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_adb552ea-5d12-4991-87c0-50740389722b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_41705b1f-2b84-4614-8de5-2a99e6727fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_41705b1f-2b84-4614-8de5-2a99e6727fb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_41705b1f-2b84-4614-8de5-2a99e6727fb1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_41705b1f-2b84-4614-8de5-2a99e6727fb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7e7d47b6-00bd-47cc-9c3f-16ffb6d80b39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_41705b1f-2b84-4614-8de5-2a99e6727fb1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7e7d47b6-00bd-47cc-9c3f-16ffb6d80b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_404efe40-9846-4527-9389-3c7bdaa91470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7e7d47b6-00bd-47cc-9c3f-16ffb6d80b39" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_404efe40-9846-4527-9389-3c7bdaa91470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d1eab3c1-7cb5-4ae7-95af-05786997c151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_adb552ea-5d12-4991-87c0-50740389722b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d1eab3c1-7cb5-4ae7-95af-05786997c151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d1eab3c1-7cb5-4ae7-95af-05786997c151_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d7a8893c-f712-464a-8d95-b898d5c58a96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_c4a9d815-5095-4d7c-96d2-c07d2418bb76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateCapMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c8bd1b5e-c7e0-4f93-bcb3-34701403ddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_345789c9-ce1f-4457-b6a7-e16c69510f40" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c8bd1b5e-c7e0-4f93-bcb3-34701403ddc9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtAdditionalinformationDetail"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_04f6b42c-2f9b-485c-82d3-4c5d3dbfd3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_04f6b42c-2f9b-485c-82d3-4c5d3dbfd3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_04f6b42c-2f9b-485c-82d3-4c5d3dbfd3ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_04f6b42c-2f9b-485c-82d3-4c5d3dbfd3ec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_04f6b42c-2f9b-485c-82d3-4c5d3dbfd3ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_04f6b42c-2f9b-485c-82d3-4c5d3dbfd3ec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member_243e9509-f302-4b60-8b54-1936d6764ae6" xlink:href="dva-20241231.xsd#dva_TermLoanA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_TermLoanA1Member_243e9509-f302-4b60-8b54-1936d6764ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_8c77f013-cb25-4f69-8257-5c967cd3aaa8" xlink:href="dva-20241231.xsd#dva_TermLoanB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_TermLoanB1Member_8c77f013-cb25-4f69-8257-5c967cd3aaa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_52c267ae-a4f5-4d14-b552-914fa8faa42f" xlink:href="dva-20241231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_52c267ae-a4f5-4d14-b552-914fa8faa42f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NewCreditAgreementAmendedMember_ac876af1-1756-4c24-a08b-e64ef6bfdd6b" xlink:href="dva-20241231.xsd#dva_NewCreditAgreementAmendedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_NewCreditAgreementAmendedMember_ac876af1-1756-4c24-a08b-e64ef6bfdd6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1AndRevolverMember_367a22a3-a67d-4fab-8d7e-3d9f2166dfde" xlink:href="dva-20241231.xsd#dva_TermLoanA1AndRevolverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_TermLoanA1AndRevolverMember_367a22a3-a67d-4fab-8d7e-3d9f2166dfde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d5236d39-fce2-4832-b9a5-1c92966e0a89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_CreditFacilityAxis_d5236d39-fce2-4832-b9a5-1c92966e0a89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d5236d39-fce2-4832-b9a5-1c92966e0a89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_d5236d39-fce2-4832-b9a5-1c92966e0a89" xlink:to="loc_us-gaap_CreditFacilityDomain_d5236d39-fce2-4832-b9a5-1c92966e0a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2599b073-c87d-4d11-9dc2-b23dc06ec939" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_d5236d39-fce2-4832-b9a5-1c92966e0a89" xlink:to="loc_us-gaap_CreditFacilityDomain_2599b073-c87d-4d11-9dc2-b23dc06ec939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_1e63e57e-d81b-44c2-a9d9-344e27453e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2599b073-c87d-4d11-9dc2-b23dc06ec939" xlink:to="loc_us-gaap_LetterOfCreditMember_1e63e57e-d81b-44c2-a9d9-344e27453e1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_540630af-7bd0-4541-9035-1a53339104bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_srt_RangeAxis_540630af-7bd0-4541-9035-1a53339104bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_540630af-7bd0-4541-9035-1a53339104bb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_540630af-7bd0-4541-9035-1a53339104bb" xlink:to="loc_srt_RangeMember_540630af-7bd0-4541-9035-1a53339104bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_170b5c51-157f-4e96-a061-d606e2b7b933" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_540630af-7bd0-4541-9035-1a53339104bb" xlink:to="loc_srt_RangeMember_170b5c51-157f-4e96-a061-d606e2b7b933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8672135c-d05a-48ed-b189-480ec45e7726" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_170b5c51-157f-4e96-a061-d606e2b7b933" xlink:to="loc_srt_MinimumMember_8672135c-d05a-48ed-b189-480ec45e7726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb800573-c7aa-476b-b862-b05bd70dd7b0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_170b5c51-157f-4e96-a061-d606e2b7b933" xlink:to="loc_srt_MaximumMember_bb800573-c7aa-476b-b862-b05bd70dd7b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a1f35101-4c60-475c-a172-9b9e9317a491" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_DebtInstrumentAxis_a1f35101-4c60-475c-a172-9b9e9317a491" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a1f35101-4c60-475c-a172-9b9e9317a491_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a1f35101-4c60-475c-a172-9b9e9317a491" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a1f35101-4c60-475c-a172-9b9e9317a491_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06af9c4d-f900-4a1b-9c00-64c0b842687e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a1f35101-4c60-475c-a172-9b9e9317a491" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06af9c4d-f900-4a1b-9c00-64c0b842687e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_096ecc34-6fad-4697-9d07-65c26cf909d8" xlink:href="dva-20241231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06af9c4d-f900-4a1b-9c00-64c0b842687e" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_096ecc34-6fad-4697-9d07-65c26cf909d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember_d07447b5-19c1-4c9a-89cc-84c792536887" xlink:href="dva-20241231.xsd#dva_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06af9c4d-f900-4a1b-9c00-64c0b842687e" xlink:to="loc_dva_TermLoanFacilityMember_d07447b5-19c1-4c9a-89cc-84c792536887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_985babd1-c9c2-4d0f-842b-d35e538672b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_VariableRateAxis_985babd1-c9c2-4d0f-842b-d35e538672b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_985babd1-c9c2-4d0f-842b-d35e538672b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_985babd1-c9c2-4d0f-842b-d35e538672b7" xlink:to="loc_us-gaap_VariableRateDomain_985babd1-c9c2-4d0f-842b-d35e538672b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_985babd1-c9c2-4d0f-842b-d35e538672b7" xlink:to="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1655d63b-44a6-4ac5-808c-4faebac1db59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1655d63b-44a6-4ac5-808c-4faebac1db59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember_a52e43cc-4fbe-49ab-a432-19e19397f049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:to="loc_us-gaap_AdjustableRateLoansMember_a52e43cc-4fbe-49ab-a432-19e19397f049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_5e405608-f614-4003-9e30-f34cb0464dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:to="loc_us-gaap_PrimeRateMember_5e405608-f614-4003-9e30-f34cb0464dc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7481af1b-210b-4b4b-b34b-1aea0149c225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7481af1b-210b-4b4b-b34b-1aea0149c225" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7481af1b-210b-4b4b-b34b-1aea0149c225_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7481af1b-210b-4b4b-b34b-1aea0149c225" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7481af1b-210b-4b4b-b34b-1aea0149c225_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0523a2a-2d64-4ae3-80a2-12987fb659a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7481af1b-210b-4b4b-b34b-1aea0149c225" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0523a2a-2d64-4ae3-80a2-12987fb659a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8f37485a-4521-4ccb-9689-754069df2e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c0523a2a-2d64-4ae3-80a2-12987fb659a7" xlink:to="loc_us-gaap_SubsequentEventMember_8f37485a-4521-4ccb-9689-754069df2e2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeAxis_4169efb6-ab89-461f-8cad-89ba1f2b3bbd" xlink:href="dva-20241231.xsd#dva_LoansTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_dva_LoansTypeAxis_4169efb6-ab89-461f-8cad-89ba1f2b3bbd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeDomain_4169efb6-ab89-461f-8cad-89ba1f2b3bbd_default" xlink:href="dva-20241231.xsd#dva_LoansTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dva_LoansTypeAxis_4169efb6-ab89-461f-8cad-89ba1f2b3bbd" xlink:to="loc_dva_LoansTypeDomain_4169efb6-ab89-461f-8cad-89ba1f2b3bbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeDomain_ba931977-9bc3-409c-b091-9db78a8ed844" xlink:href="dva-20241231.xsd#dva_LoansTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dva_LoansTypeAxis_4169efb6-ab89-461f-8cad-89ba1f2b3bbd" xlink:to="loc_dva_LoansTypeDomain_ba931977-9bc3-409c-b091-9db78a8ed844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BaseRateLoansMember_529af6a8-fef9-4daa-af31-b25057f4a4be" xlink:href="dva-20241231.xsd#dva_BaseRateLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LoansTypeDomain_ba931977-9bc3-409c-b091-9db78a8ed844" xlink:to="loc_dva_BaseRateLoansMember_529af6a8-fef9-4daa-af31-b25057f4a4be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_88aa8105-df1a-4c8c-8a48-21dd56667b40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_88aa8105-df1a-4c8c-8a48-21dd56667b40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_7d47829e-2677-4ea7-b736-21994e79c584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_7d47829e-2677-4ea7-b736-21994e79c584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_07c2f2bb-353f-4b0b-810a-6d762a11b3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_InterestExpenseDebt_07c2f2bb-353f-4b0b-810a-6d762a11b3d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_cefd370e-ecfc-4399-a0ae-d4be9091b478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_cefd370e-ecfc-4399-a0ae-d4be9091b478" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_eeeeff0a-0285-421d-b8c3-4ee26247499a" xlink:href="dva-20241231.xsd#dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_eeeeff0a-0285-421d-b8c3-4ee26247499a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenant_5024b1fd-d04d-49a7-a85c-f266325743f4" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LeverageRatioCovenant_5024b1fd-d04d-49a7-a85c-f266325743f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantThroughJun302026_8f3033a2-6cb4-47cf-a275-d6e04e1763af" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenantThroughJun302026"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LeverageRatioCovenantThroughJun302026_8f3033a2-6cb4-47cf-a275-d6e04e1763af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantAfterJun302026_b45fedc2-c1c9-4eaf-baa4-df6d2cfc0a39" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenantAfterJun302026"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LeverageRatioCovenantAfterJun302026_b45fedc2-c1c9-4eaf-baa4-df6d2cfc0a39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition_77ff314b-5d4c-4c0b-8920-41bf091b55e4" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition_77ff314b-5d4c-4c0b-8920-41bf091b55e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9056b490-ab53-490a-802e-020308d60122" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9056b490-ab53-490a-802e-020308d60122" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LeasesLeasesOtherInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a8d4888b-8e67-4aa0-b779-866cfcf0e203" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d166df54-512c-47ba-b12b-c7bc9f749835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a8d4888b-8e67-4aa0-b779-866cfcf0e203" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d166df54-512c-47ba-b12b-c7bc9f749835" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fac1256b-6a2e-4d16-a11f-cf2d68b06a61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d166df54-512c-47ba-b12b-c7bc9f749835" xlink:to="loc_us-gaap_DebtInstrumentAxis_fac1256b-6a2e-4d16-a11f-cf2d68b06a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fac1256b-6a2e-4d16-a11f-cf2d68b06a61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fac1256b-6a2e-4d16-a11f-cf2d68b06a61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fac1256b-6a2e-4d16-a11f-cf2d68b06a61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bb7fc9cb-4410-4b54-9947-19c5442bc51c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fac1256b-6a2e-4d16-a11f-cf2d68b06a61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bb7fc9cb-4410-4b54-9947-19c5442bc51c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_173f06f5-83d0-41c2-9ad5-a47c3f0bbdeb" xlink:href="dva-20241231.xsd#dva_FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bb7fc9cb-4410-4b54-9947-19c5442bc51c" xlink:to="loc_dva_FinanceLeaseMember_173f06f5-83d0-41c2-9ad5-a47c3f0bbdeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a8d4888b-8e67-4aa0-b779-866cfcf0e203" xlink:to="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1bed511f-8d7c-454b-a740-cef601b09ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1bed511f-8d7c-454b-a740-cef601b09ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b45128ef-d78e-4fc7-b38f-075d9817c842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b45128ef-d78e-4fc7-b38f-075d9817c842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d2ac926c-5f6b-4531-b335-ca053df58252" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d2ac926c-5f6b-4531-b335-ca053df58252" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3223d82c-3316-4089-8c89-cd03c6b9276c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3223d82c-3316-4089-8c89-cd03c6b9276c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:href="dva-20241231.xsd#dva_LeasesOtherInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a8d4888b-8e67-4aa0-b779-866cfcf0e203" xlink:to="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_88d73c38-5d8c-4926-aeca-821c4665fd97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_88d73c38-5d8c-4926-aeca-821c4665fd97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_35696480-2087-45a8-a9ea-d95fcaae5faf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:to="loc_us-gaap_OperatingLeasePayments_35696480-2087-45a8-a9ea-d95fcaae5faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_fbf76914-6364-45aa-ace9-1a285d91a21e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_fbf76914-6364-45aa-ace9-1a285d91a21e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_dba230bc-e8eb-4953-8cbe-7d53fd467791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_dba230bc-e8eb-4953-8cbe-7d53fd467791" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_edd4b316-2859-44ba-ac81-78975fa2a6e2" xlink:href="dva-20241231.xsd#dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:to="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_edd4b316-2859-44ba-ac81-78975fa2a6e2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:href="dva-20241231.xsd#dva_LeasesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:href="dva-20241231.xsd#dva_LeasesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c75d050a-1552-461e-8ef0-3b60cb105433" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:to="loc_srt_RangeAxis_c75d050a-1552-461e-8ef0-3b60cb105433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c75d050a-1552-461e-8ef0-3b60cb105433_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c75d050a-1552-461e-8ef0-3b60cb105433" xlink:to="loc_srt_RangeMember_c75d050a-1552-461e-8ef0-3b60cb105433_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32151ec0-ffd9-481a-aae5-01e1f91a025f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c75d050a-1552-461e-8ef0-3b60cb105433" xlink:to="loc_srt_RangeMember_32151ec0-ffd9-481a-aae5-01e1f91a025f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a2538fd9-16cd-4a60-ad09-734e4c96472f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32151ec0-ffd9-481a-aae5-01e1f91a025f" xlink:to="loc_srt_MinimumMember_a2538fd9-16cd-4a60-ad09-734e4c96472f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ba99e281-f59d-44d9-8298-4285cba36a8d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32151ec0-ffd9-481a-aae5-01e1f91a025f" xlink:to="loc_srt_MaximumMember_ba99e281-f59d-44d9-8298-4285cba36a8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_4a42092f-0af9-4ddf-9e9e-743d31b8a386" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:to="loc_us-gaap_LeaseContractualTermAxis_4a42092f-0af9-4ddf-9e9e-743d31b8a386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_4a42092f-0af9-4ddf-9e9e-743d31b8a386_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_4a42092f-0af9-4ddf-9e9e-743d31b8a386" xlink:to="loc_us-gaap_LeaseContractualTermDomain_4a42092f-0af9-4ddf-9e9e-743d31b8a386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_986f97b6-7c1e-4065-8924-2c0a4896978e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_4a42092f-0af9-4ddf-9e9e-743d31b8a386" xlink:to="loc_us-gaap_LeaseContractualTermDomain_986f97b6-7c1e-4065-8924-2c0a4896978e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OperatingLeaseMember_f225adb4-226c-4a97-9095-8229e610e634" xlink:href="dva-20241231.xsd#dva_OperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_986f97b6-7c1e-4065-8924-2c0a4896978e" xlink:to="loc_dva_OperatingLeaseMember_f225adb4-226c-4a97-9095-8229e610e634" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_90e479b1-a864-4629-8d3f-0af68c23850c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:to="loc_us-gaap_DebtInstrumentAxis_90e479b1-a864-4629-8d3f-0af68c23850c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90e479b1-a864-4629-8d3f-0af68c23850c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_90e479b1-a864-4629-8d3f-0af68c23850c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90e479b1-a864-4629-8d3f-0af68c23850c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f1a07c9c-0dce-45cb-91f9-d3eaa39c15d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_90e479b1-a864-4629-8d3f-0af68c23850c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f1a07c9c-0dce-45cb-91f9-d3eaa39c15d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_4341869d-c438-4ddd-8251-631dcd500d2c" xlink:href="dva-20241231.xsd#dva_FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f1a07c9c-0dce-45cb-91f9-d3eaa39c15d6" xlink:to="loc_dva_FinanceLeaseMember_4341869d-c438-4ddd-8251-631dcd500d2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7d87b3d4-4672-45fc-a9c9-d5a0fd477ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7d87b3d4-4672-45fc-a9c9-d5a0fd477ed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d3705514-c62e-49ac-883d-8551517a8712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d3705514-c62e-49ac-883d-8551517a8712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c0bc784c-7b23-443a-9934-9ecfdae8461e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c0bc784c-7b23-443a-9934-9ecfdae8461e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6eeae28b-6fe2-4aa9-9cf9-06d9fc3d9d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6eeae28b-6fe2-4aa9-9cf9-06d9fc3d9d94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseAccumulatedDepreciation_2aacd2e7-827d-4b1e-8970-50414b208c67" xlink:href="dva-20241231.xsd#dva_FinanceLeaseAccumulatedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_dva_FinanceLeaseAccumulatedDepreciation_2aacd2e7-827d-4b1e-8970-50414b208c67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0101b16d-76c3-4613-8497-0dc005078440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_OperatingLeaseCost_0101b16d-76c3-4613-8497-0dc005078440" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionLeaseTerm_be9b322e-e95e-4b03-8ba7-56e700a27673" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_SaleLeasebackTransactionLeaseTerm_be9b322e-e95e-4b03-8ba7-56e700a27673" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SaleLeasebackTransactionRenewalLeaseTerm_c8a744eb-5e8e-4dbc-ba2a-83f761f6a90c" xlink:href="dva-20241231.xsd#dva_SaleLeasebackTransactionRenewalLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_dva_SaleLeasebackTransactionRenewalLeaseTerm_c8a744eb-5e8e-4dbc-ba2a-83f761f6a90c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0ac38d68-3c26-43fc-b43c-63c392606f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0ac38d68-3c26-43fc-b43c-63c392606f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0ac38d68-3c26-43fc-b43c-63c392606f8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0ac38d68-3c26-43fc-b43c-63c392606f8a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0ac38d68-3c26-43fc-b43c-63c392606f8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3c4a8ff3-3813-4a81-9377-d8f4f14bf51a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0ac38d68-3c26-43fc-b43c-63c392606f8a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3c4a8ff3-3813-4a81-9377-d8f4f14bf51a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_7488a58f-cdae-48fc-8d9f-56b4500e62c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3c4a8ff3-3813-4a81-9377-d8f4f14bf51a" xlink:to="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_7488a58f-cdae-48fc-8d9f-56b4500e62c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ba8c264b-be14-4146-9ef7-6e1ae38384cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ba8c264b-be14-4146-9ef7-6e1ae38384cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ba8c264b-be14-4146-9ef7-6e1ae38384cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ba8c264b-be14-4146-9ef7-6e1ae38384cd" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ba8c264b-be14-4146-9ef7-6e1ae38384cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_359ad0ef-9674-403e-a7a4-14fd2083290f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ba8c264b-be14-4146-9ef7-6e1ae38384cd" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_359ad0ef-9674-403e-a7a4-14fd2083290f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AllTrustsMember_2e0cbb04-b179-490c-b612-be635d8d9747" xlink:href="dva-20241231.xsd#dva_AllTrustsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_359ad0ef-9674-403e-a7a4-14fd2083290f" xlink:to="loc_dva_AllTrustsMember_2e0cbb04-b179-490c-b612-be635d8d9747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05b158bb-ddc4-4e1b-845e-9969df86ca37" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:to="loc_srt_RangeAxis_05b158bb-ddc4-4e1b-845e-9969df86ca37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05b158bb-ddc4-4e1b-845e-9969df86ca37_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_05b158bb-ddc4-4e1b-845e-9969df86ca37" xlink:to="loc_srt_RangeMember_05b158bb-ddc4-4e1b-845e-9969df86ca37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92e41b11-e8d9-4288-ab4b-1d813a6e4b88" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_05b158bb-ddc4-4e1b-845e-9969df86ca37" xlink:to="loc_srt_RangeMember_92e41b11-e8d9-4288-ab4b-1d813a6e4b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c8c0c94c-767f-45c8-b4f3-9e17a426286f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92e41b11-e8d9-4288-ab4b-1d813a6e4b88" xlink:to="loc_srt_MinimumMember_c8c0c94c-767f-45c8-b4f3-9e17a426286f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_462a3dc2-e5b6-4965-b645-c21d8a34ca16" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92e41b11-e8d9-4288-ab4b-1d813a6e4b88" xlink:to="loc_srt_MaximumMember_462a3dc2-e5b6-4965-b645-c21d8a34ca16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_1fda8e78-c77d-4114-88c8-addb72f69c25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_1fda8e78-c77d-4114-88c8-addb72f69c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_2caa2556-e053-42fe-9297-5191f5d9bddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_2caa2556-e053-42fe-9297-5191f5d9bddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_d2f90a13-bba5-4de9-b461-39b3342c4a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_d2f90a13-bba5-4de9-b461-39b3342c4a6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_bab4edc0-ebf3-4f41-ac85-763b075e20ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_bab4edc0-ebf3-4f41-ac85-763b075e20ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_6478d50b-ad27-47e4-8c51-8ee6b01d334a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_6478d50b-ad27-47e4-8c51-8ee6b01d334a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_8e82429b-fde3-442c-9b7e-f29204c14271" xlink:href="dva-20241231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_8e82429b-fde3-442c-9b7e-f29204c14271" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_ab4c0a46-b96a-4893-8141-952ae142c201" xlink:href="dva-20241231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_ab4c0a46-b96a-4893-8141-952ae142c201" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_fb6ad53a-80c9-4f84-a734-7649215640a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_fb6ad53a-80c9-4f84-a734-7649215640a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_edb5252a-5df1-4b63-9ac7-54940cd2de42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_edb5252a-5df1-4b63-9ac7-54940cd2de42" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c8ce7bb2-473d-4458-817c-5a0a3f1c2027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_c8ce7bb2-473d-4458-817c-5a0a3f1c2027" xlink:to="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_83f14f60-0fe8-4603-a10d-897c7a1f761c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_83f14f60-0fe8-4603-a10d-897c7a1f761c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_83f14f60-0fe8-4603-a10d-897c7a1f761c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_83f14f60-0fe8-4603-a10d-897c7a1f761c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_83f14f60-0fe8-4603-a10d-897c7a1f761c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_965b236a-8099-4eb5-9604-6da73160a964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_83f14f60-0fe8-4603-a10d-897c7a1f761c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_965b236a-8099-4eb5-9604-6da73160a964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7ac0a79e-6af3-42ef-a45d-295a836a3495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7ac0a79e-6af3-42ef-a45d-295a836a3495" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7ac0a79e-6af3-42ef-a45d-295a836a3495_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7ac0a79e-6af3-42ef-a45d-295a836a3495" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7ac0a79e-6af3-42ef-a45d-295a836a3495_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19881e87-33a1-4e50-b9c2-8ec51f06fc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7ac0a79e-6af3-42ef-a45d-295a836a3495" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19881e87-33a1-4e50-b9c2-8ec51f06fc8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d119c8e6-64b7-4006-a600-6d1eacbaa88e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_srt_LitigationCaseAxis_d119c8e6-64b7-4006-a600-6d1eacbaa88e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d119c8e6-64b7-4006-a600-6d1eacbaa88e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d119c8e6-64b7-4006-a600-6d1eacbaa88e" xlink:to="loc_srt_LitigationCaseTypeDomain_d119c8e6-64b7-4006-a600-6d1eacbaa88e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a7520c48-5757-4db2-a0b9-cf6099ff212b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d119c8e6-64b7-4006-a600-6d1eacbaa88e" xlink:to="loc_srt_LitigationCaseTypeDomain_a7520c48-5757-4db2-a0b9-cf6099ff212b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_31f91f98-72bf-4de9-b7d2-00e97b2cd824" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_us-gaap_LitigationStatusAxis_31f91f98-72bf-4de9-b7d2-00e97b2cd824" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_31f91f98-72bf-4de9-b7d2-00e97b2cd824_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_31f91f98-72bf-4de9-b7d2-00e97b2cd824" xlink:to="loc_us-gaap_LitigationStatusDomain_31f91f98-72bf-4de9-b7d2-00e97b2cd824_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7a558ef6-8d5e-4283-8c23-e114b87c70c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_31f91f98-72bf-4de9-b7d2-00e97b2cd824" xlink:to="loc_us-gaap_LitigationStatusDomain_7a558ef6-8d5e-4283-8c23-e114b87c70c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebe8343-839c-4c0b-8e65-17955207d919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebe8343-839c-4c0b-8e65-17955207d919" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6ebe8343-839c-4c0b-8e65-17955207d919_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebe8343-839c-4c0b-8e65-17955207d919" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6ebe8343-839c-4c0b-8e65-17955207d919_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_3dc62db0-9afc-40f5-b171-bc2e0e50a08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebe8343-839c-4c0b-8e65-17955207d919" xlink:to="loc_us-gaap_LossContingencyNatureDomain_3dc62db0-9afc-40f5-b171-bc2e0e50a08d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2017USAttorneyColoradoInvestigationMember_4d31c128-c073-4c34-8353-aa5d9225de60" xlink:href="dva-20241231.xsd#dva_A2017USAttorneyColoradoInvestigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_3dc62db0-9afc-40f5-b171-bc2e0e50a08d" xlink:to="loc_dva_A2017USAttorneyColoradoInvestigationMember_4d31c128-c073-4c34-8353-aa5d9225de60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c7976e0-8fb6-460b-bd4d-0cab975213cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_srt_RangeAxis_7c7976e0-8fb6-460b-bd4d-0cab975213cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c7976e0-8fb6-460b-bd4d-0cab975213cf_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7c7976e0-8fb6-460b-bd4d-0cab975213cf" xlink:to="loc_srt_RangeMember_7c7976e0-8fb6-460b-bd4d-0cab975213cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2e189b5d-7b5d-4175-9d68-1f3f10279df3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7c7976e0-8fb6-460b-bd4d-0cab975213cf" xlink:to="loc_srt_RangeMember_2e189b5d-7b5d-4175-9d68-1f3f10279df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CorporateIntegrityAgreementExpirationDate_5b35ea45-5914-41a7-a030-f77d44733f64" xlink:href="dva-20241231.xsd#dva_CorporateIntegrityAgreementExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c8ce7bb2-473d-4458-817c-5a0a3f1c2027" xlink:to="loc_dva_CorporateIntegrityAgreementExpirationDate_5b35ea45-5914-41a7-a030-f77d44733f64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_03a3cd6c-8c85-4ad2-9470-eaad155c4238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c8ce7bb2-473d-4458-817c-5a0a3f1c2027" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_03a3cd6c-8c85-4ad2-9470-eaad155c4238" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:href="dva-20241231.xsd#dva_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureTable_40fd7a83-b1ad-4aa9-9f6e-ee3705b990d6" xlink:href="dva-20241231.xsd#dva_CommitmentsAndContingenciesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_dva_CommitmentsAndContingenciesDisclosureTable_40fd7a83-b1ad-4aa9-9f6e-ee3705b990d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_a8fce990-6ab9-467a-bbd9-5a138041ad4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_40fd7a83-b1ad-4aa9-9f6e-ee3705b990d6" xlink:to="loc_us-gaap_OtherCommitmentsAxis_a8fce990-6ab9-467a-bbd9-5a138041ad4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_a8fce990-6ab9-467a-bbd9-5a138041ad4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_a8fce990-6ab9-467a-bbd9-5a138041ad4d" xlink:to="loc_us-gaap_OtherCommitmentsDomain_a8fce990-6ab9-467a-bbd9-5a138041ad4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_c4f0ff55-b1ab-4d8e-946c-8a22bcba6780" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_a8fce990-6ab9-467a-bbd9-5a138041ad4d" xlink:to="loc_us-gaap_OtherCommitmentsDomain_c4f0ff55-b1ab-4d8e-946c-8a22bcba6780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsToProvideOperatingCapitalMember_14de79b2-1a0d-424c-b6ef-1ddd5eb4dcee" xlink:href="dva-20241231.xsd#dva_CommitmentsToProvideOperatingCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_c4f0ff55-b1ab-4d8e-946c-8a22bcba6780" xlink:to="loc_dva_CommitmentsToProvideOperatingCapitalMember_14de79b2-1a0d-424c-b6ef-1ddd5eb4dcee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3cfe7fcb-67e8-4826-92ca-5a889f8e0dc2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_40fd7a83-b1ad-4aa9-9f6e-ee3705b990d6" xlink:to="loc_srt_RangeAxis_3cfe7fcb-67e8-4826-92ca-5a889f8e0dc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3cfe7fcb-67e8-4826-92ca-5a889f8e0dc2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3cfe7fcb-67e8-4826-92ca-5a889f8e0dc2" xlink:to="loc_srt_RangeMember_3cfe7fcb-67e8-4826-92ca-5a889f8e0dc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_730d4a28-1db8-442d-8301-7d37fef13755" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3cfe7fcb-67e8-4826-92ca-5a889f8e0dc2" xlink:to="loc_srt_RangeMember_730d4a28-1db8-442d-8301-7d37fef13755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d427e536-c8e3-4c9d-bee6-508a634bcc40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_730d4a28-1db8-442d-8301-7d37fef13755" xlink:to="loc_srt_MinimumMember_d427e536-c8e3-4c9d-bee6-508a634bcc40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af363ddb-949c-4b9f-8ab6-f4cb2100844c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_730d4a28-1db8-442d-8301-7d37fef13755" xlink:to="loc_srt_MaximumMember_af363ddb-949c-4b9f-8ab6-f4cb2100844c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DissolutionTermOfJointVentures_f17d0275-d555-42ee-890c-c0c2027c4a77" xlink:href="dva-20241231.xsd#dva_DissolutionTermOfJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_dva_DissolutionTermOfJointVentures_f17d0275-d555-42ee-890c-c0c2027c4a77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_5c261fbc-2990-44a1-8ef3-0e7e1766e3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_5c261fbc-2990-44a1-8ef3-0e7e1766e3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_6f07e293-151a-4cb0-bf65-054e6a1c7f44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_6f07e293-151a-4cb0-bf65-054e6a1c7f44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_c71d0db5-aad6-4de1-ba45-e48148dddc34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_c71d0db5-aad6-4de1-ba45-e48148dddc34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_7a5bd231-50a2-4fd5-936e-26d9c0571819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_7a5bd231-50a2-4fd5-936e-26d9c0571819" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_10ebaf58-978c-441b-8dae-91d10beb3225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_10ebaf58-978c-441b-8dae-91d10beb3225" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_c98e3869-6b7b-451a-8461-b9ccad1b84db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_OtherCommitment_c98e3869-6b7b-451a-8461-b9ccad1b84db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OffBalanceSheetFinancingArrangements_1e8e88b3-e15b-47b0-a68e-813a4814747b" xlink:href="dva-20241231.xsd#dva_OffBalanceSheetFinancingArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_dva_OffBalanceSheetFinancingArrangements_1e8e88b3-e15b-47b0-a68e-813a4814747b" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_599e7b08-c7c6-40a2-a921-8d11fd83e25c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_599e7b08-c7c6-40a2-a921-8d11fd83e25c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_88e4bca8-1f58-4428-8e52-d94ddd0b6b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_599e7b08-c7c6-40a2-a921-8d11fd83e25c" xlink:to="loc_us-gaap_AwardTypeAxis_88e4bca8-1f58-4428-8e52-d94ddd0b6b9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88e4bca8-1f58-4428-8e52-d94ddd0b6b9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_88e4bca8-1f58-4428-8e52-d94ddd0b6b9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88e4bca8-1f58-4428-8e52-d94ddd0b6b9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e43a334-2cc7-42c6-b786-0f30f75886d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_88e4bca8-1f58-4428-8e52-d94ddd0b6b9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e43a334-2cc7-42c6-b786-0f30f75886d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_09f8cef1-4512-4a8c-9f2f-ae8a50e51e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e43a334-2cc7-42c6-b786-0f30f75886d8" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_09f8cef1-4512-4a8c-9f2f-ae8a50e51e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember_28ce9426-01b6-4fd5-ba12-b64488735f40" xlink:href="dva-20241231.xsd#dva_StockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e43a334-2cc7-42c6-b786-0f30f75886d8" xlink:to="loc_dva_StockUnitMember_28ce9426-01b6-4fd5-ba12-b64488735f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f53b99ac-b4cb-4f64-a1a4-3ea256405694" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f53b99ac-b4cb-4f64-a1a4-3ea256405694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_da005f06-80f3-457b-8ce7-d1737fbe5235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_da005f06-80f3-457b-8ce7-d1737fbe5235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bce2969d-8a96-474d-8101-16819c53d7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bce2969d-8a96-474d-8101-16819c53d7ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d7a12a57-e953-434a-8eee-082ab4b22fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d7a12a57-e953-434a-8eee-082ab4b22fb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70802258-e40b-4cd5-9a02-61ec3a071a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_588dbb1e-3402-4ab5-b3a9-6e36adfc3db5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_588dbb1e-3402-4ab5-b3a9-6e36adfc3db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f961adc9-7746-4e29-9cf7-53be0c6cf3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f961adc9-7746-4e29-9cf7-53be0c6cf3c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d36065fb-ea5e-429a-bfdf-93e813ffe243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d36065fb-ea5e-429a-bfdf-93e813ffe243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43f7f4f8-9645-4a07-8907-15119482e17a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43f7f4f8-9645-4a07-8907-15119482e17a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6f9c4a16-e95b-4bf9-b897-49a5af02a27e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6f9c4a16-e95b-4bf9-b897-49a5af02a27e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_33c2d815-854c-41b4-8688-746407667fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_33c2d815-854c-41b4-8688-746407667fe2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d8a90cf7-3cf4-4ce9-936c-5afe95797ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7be6c675-3070-4bf1-bb5a-1956bb0cd875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7be6c675-3070-4bf1-bb5a-1956bb0cd875" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_67d97623-58c9-4cff-9314-eeca098ac13c" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_67d97623-58c9-4cff-9314-eeca098ac13c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ddf119da-d02b-4a6d-aca4-b78b25f71df4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_67d97623-58c9-4cff-9314-eeca098ac13c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ddf119da-d02b-4a6d-aca4-b78b25f71df4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7c8908f-6118-468c-ae67-12b749ce058b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_67d97623-58c9-4cff-9314-eeca098ac13c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7c8908f-6118-468c-ae67-12b749ce058b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2b341b67-7455-40d8-9789-970b3aedad01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2b341b67-7455-40d8-9789-970b3aedad01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cc5c686c-cac2-44af-b2c2-765334008542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cc5c686c-cac2-44af-b2c2-765334008542" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_b35775b9-e522-432a-8515-b226b0a4783b" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_b35775b9-e522-432a-8515-b226b0a4783b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bbe22068-ab59-4f99-b277-d1ac9695f4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bbe22068-ab59-4f99-b277-d1ac9695f4b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b90a1945-738a-4890-9694-95fdcb3642f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b90a1945-738a-4890-9694-95fdcb3642f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d55127d7-f32b-42e0-a3cd-14997fbe8a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_0b07d6af-de98-41a6-aac9-ffe9458e5bc3" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_0b07d6af-de98-41a6-aac9-ffe9458e5bc3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b29f5d42-e9f1-4a7d-b318-28ec06e2744f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b29f5d42-e9f1-4a7d-b318-28ec06e2744f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_9c5608d8-a351-4381-817f-c941dd7818f7" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_9c5608d8-a351-4381-817f-c941dd7818f7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1dd124de-26d0-42f9-ae53-283b792bb2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_9c5608d8-a351-4381-817f-c941dd7818f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1dd124de-26d0-42f9-ae53-283b792bb2e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_e17aa97c-9d46-41d5-9f45-b0974b4641ad" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_9c5608d8-a351-4381-817f-c941dd7818f7" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_e17aa97c-9d46-41d5-9f45-b0974b4641ad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_3d0af312-faa9-4c7f-a49f-1eb2366cd24f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_3d0af312-faa9-4c7f-a49f-1eb2366cd24f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6c08dbfc-b003-449d-a002-0b103f8be7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_3d0af312-faa9-4c7f-a49f-1eb2366cd24f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6c08dbfc-b003-449d-a002-0b103f8be7ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6c08dbfc-b003-449d-a002-0b103f8be7ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6c08dbfc-b003-449d-a002-0b103f8be7ae" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6c08dbfc-b003-449d-a002-0b103f8be7ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6c08dbfc-b003-449d-a002-0b103f8be7ae" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeOneMember_6c01ea12-b40a-4ddb-b09c-c39b31af24a5" xlink:href="dva-20241231.xsd#dva_RangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeOneMember_6c01ea12-b40a-4ddb-b09c-c39b31af24a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeTwoMember_46cd1ea8-349a-4df0-a765-5d5fcdfac7c4" xlink:href="dva-20241231.xsd#dva_RangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeTwoMember_46cd1ea8-349a-4df0-a765-5d5fcdfac7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeThreeMember_f1e8436e-8957-4683-91aa-9103bd7fc953" xlink:href="dva-20241231.xsd#dva_RangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeThreeMember_f1e8436e-8957-4683-91aa-9103bd7fc953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFourMember_27fd7bde-f4bb-4350-876c-61337e87bf50" xlink:href="dva-20241231.xsd#dva_RangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeFourMember_27fd7bde-f4bb-4350-876c-61337e87bf50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFiveMember_0d2434c1-53e0-4d5d-8768-c40cf709ab83" xlink:href="dva-20241231.xsd#dva_RangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeFiveMember_0d2434c1-53e0-4d5d-8768-c40cf709ab83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_95861fa3-23ee-4efa-8ebf-32febc5d047a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_95861fa3-23ee-4efa-8ebf-32febc5d047a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_a1698224-f327-48f0-892a-695f590591a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_a1698224-f327-48f0-892a-695f590591a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_82f0b1f2-16eb-4071-a2d7-3496003d274a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_82f0b1f2-16eb-4071-a2d7-3496003d274a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_83f0f047-af8c-4045-8e13-154cfdff6dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_83f0f047-af8c-4045-8e13-154cfdff6dd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_78e08ef4-b6d2-43ed-83b0-b652ab13f373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_78e08ef4-b6d2-43ed-83b0-b652ab13f373" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_7d29a8cf-a8e5-4604-ab53-f3ce5ffbbb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_7d29a8cf-a8e5-4604-ab53-f3ce5ffbbb7e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83abb995-683c-463c-8471-46a687fdfd97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83abb995-683c-463c-8471-46a687fdfd97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_873aa22e-60ab-4cc1-adf7-efff96001657" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83abb995-683c-463c-8471-46a687fdfd97" xlink:to="loc_us-gaap_AwardTypeAxis_873aa22e-60ab-4cc1-adf7-efff96001657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_873aa22e-60ab-4cc1-adf7-efff96001657_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_873aa22e-60ab-4cc1-adf7-efff96001657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_873aa22e-60ab-4cc1-adf7-efff96001657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8fa5ef8-a438-43a5-8f22-a50beebab9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_873aa22e-60ab-4cc1-adf7-efff96001657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8fa5ef8-a438-43a5-8f22-a50beebab9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember_d9d9c9c6-1215-4b47-b966-87dc17fc5c3d" xlink:href="dva-20241231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8fa5ef8-a438-43a5-8f22-a50beebab9a3" xlink:to="loc_dva_StockSettledStockAppreciationRightsMember_d9d9c9c6-1215-4b47-b966-87dc17fc5c3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7762d74e-bf7c-4241-b2ce-d8a1b98b175c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7762d74e-bf7c-4241-b2ce-d8a1b98b175c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_58d9ce49-3f4f-4e84-bc39-e458a97d926f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_58d9ce49-3f4f-4e84-bc39-e458a97d926f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24820d2f-7164-4a8d-a0ca-dbb18dd88707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24820d2f-7164-4a8d-a0ca-dbb18dd88707" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1bc07e19-b1a6-4c06-85cf-6cb351101806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1bc07e19-b1a6-4c06-85cf-6cb351101806" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1614a3b1-bd0e-44e5-ae83-296a595c71fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:to="loc_us-gaap_PlanNameAxis_1614a3b1-bd0e-44e5-ae83-296a595c71fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1614a3b1-bd0e-44e5-ae83-296a595c71fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1614a3b1-bd0e-44e5-ae83-296a595c71fd" xlink:to="loc_us-gaap_PlanNameDomain_1614a3b1-bd0e-44e5-ae83-296a595c71fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cbc0facb-44ec-4545-93c0-adad66989492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1614a3b1-bd0e-44e5-ae83-296a595c71fd" xlink:to="loc_us-gaap_PlanNameDomain_cbc0facb-44ec-4545-93c0-adad66989492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyTwentyMember_87a9942e-2c29-425a-aae3-ec403fb84d63" xlink:href="dva-20241231.xsd#dva_StockIncentivePlanTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cbc0facb-44ec-4545-93c0-adad66989492" xlink:to="loc_dva_StockIncentivePlanTwentyTwentyMember_87a9942e-2c29-425a-aae3-ec403fb84d63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98962af0-bec4-4104-b6c7-cbcf16fac54f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:to="loc_srt_RangeAxis_98962af0-bec4-4104-b6c7-cbcf16fac54f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98962af0-bec4-4104-b6c7-cbcf16fac54f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_98962af0-bec4-4104-b6c7-cbcf16fac54f" xlink:to="loc_srt_RangeMember_98962af0-bec4-4104-b6c7-cbcf16fac54f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86ce1851-30bf-4c89-9b5c-56cd1b626bcd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_98962af0-bec4-4104-b6c7-cbcf16fac54f" xlink:to="loc_srt_RangeMember_86ce1851-30bf-4c89-9b5c-56cd1b626bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d78f92ca-1b69-455d-bd26-85950fe3799b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86ce1851-30bf-4c89-9b5c-56cd1b626bcd" xlink:to="loc_srt_MinimumMember_d78f92ca-1b69-455d-bd26-85950fe3799b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_157fe9ae-a816-437d-9ef9-faf2e2816c06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86ce1851-30bf-4c89-9b5c-56cd1b626bcd" xlink:to="loc_srt_MaximumMember_157fe9ae-a816-437d-9ef9-faf2e2816c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_289831cc-18b5-4c52-a0ff-cda1b16a59c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:to="loc_us-gaap_AwardTypeAxis_289831cc-18b5-4c52-a0ff-cda1b16a59c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_289831cc-18b5-4c52-a0ff-cda1b16a59c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_289831cc-18b5-4c52-a0ff-cda1b16a59c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_289831cc-18b5-4c52-a0ff-cda1b16a59c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df703902-372c-49e7-b263-513f341782ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_289831cc-18b5-4c52-a0ff-cda1b16a59c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df703902-372c-49e7-b263-513f341782ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember_e5ea723b-597a-4d81-8aac-cd15eaab4303" xlink:href="dva-20241231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df703902-372c-49e7-b263-513f341782ad" xlink:to="loc_dva_EmployeeStockPurchasePlanMember_e5ea723b-597a-4d81-8aac-cd15eaab4303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e0f7396a-9d3e-4a86-ae35-14830a11b63f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e0f7396a-9d3e-4a86-ae35-14830a11b63f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_0f5a8b55-e414-4d88-a3ef-ad5da3bbb38c" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_0f5a8b55-e414-4d88-a3ef-ad5da3bbb38c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_d9ccb183-5424-4982-885e-e4edbf4e7e41" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_d9ccb183-5424-4982-885e-e4edbf4e7e41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_e1753b94-f4b3-42a4-a40c-043952854ba2" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_e1753b94-f4b3-42a4-a40c-043952854ba2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_0483252b-e082-4d17-973e-ca678b43ab28" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_0483252b-e082-4d17-973e-ca678b43ab28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8f6d514f-205f-41f3-8a95-11384d722da6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8f6d514f-205f-41f3-8a95-11384d722da6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1de2098d-3214-4392-b73e-e43e9353935f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1de2098d-3214-4392-b73e-e43e9353935f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98033df2-0dbf-4eaf-9aaf-3e4ec95ff568" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98033df2-0dbf-4eaf-9aaf-3e4ec95ff568" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4859786b-e22d-4b7c-996e-bbc6884216ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4859786b-e22d-4b7c-996e-bbc6884216ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7aa38d1a-a52a-476b-a68b-53682753b779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7aa38d1a-a52a-476b-a68b-53682753b779" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_026173b2-98b7-4b17-bf54-4af755fab293" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_026173b2-98b7-4b17-bf54-4af755fab293" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_03647a7e-f1e2-4de8-b5d1-f1ea9f00e89c" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_03647a7e-f1e2-4de8-b5d1-f1ea9f00e89c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1513f7b6-ed9f-4e16-8dfb-4e6f62d89aae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1513f7b6-ed9f-4e16-8dfb-4e6f62d89aae" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_f6404f1c-422a-4e0e-9e08-cc220d142b82" xlink:href="dva-20241231.xsd#dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_f6404f1c-422a-4e0e-9e08-cc220d142b82" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8499bbdb-428e-4731-a3a0-53810b54173a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8499bbdb-428e-4731-a3a0-53810b54173a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a7ebaa7f-61b3-4ed7-ad2f-8cfddcd1ae3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a7ebaa7f-61b3-4ed7-ad2f-8cfddcd1ae3c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_281bf54e-14fe-4156-93d7-70d11ed839cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_281bf54e-14fe-4156-93d7-70d11ed839cd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_0140d503-ec27-45d0-b077-7ef0f0244115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_0140d503-ec27-45d0-b077-7ef0f0244115" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9aaf9966-d086-4f1c-bf25-5975e09bf059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9aaf9966-d086-4f1c-bf25-5975e09bf059" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0384c5cb-f372-4bd4-b183-0f7a178d4cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensation_0384c5cb-f372-4bd4-b183-0f7a178d4cd6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_98824fbd-11c7-4573-ae6d-a6324d0f7e22" xlink:href="dva-20241231.xsd#dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_98824fbd-11c7-4573-ae6d-a6324d0f7e22" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c8e90491-11d0-4652-a7ca-6cdbe0cb1610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c8e90491-11d0-4652-a7ca-6cdbe0cb1610" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36ce4713-04f4-44aa-ad3f-ee3653fdaf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36ce4713-04f4-44aa-ad3f-ee3653fdaf6d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_efa544d6-eec9-444b-833f-755f5b9d926a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_efa544d6-eec9-444b-833f-755f5b9d926a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f2e99b95-84cd-4d68-9982-2d0f381f81f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f2e99b95-84cd-4d68-9982-2d0f381f81f9" xlink:type="arc" order="24"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#StockRepurchasesTenderOfferDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_aea80217-66e9-4f7e-a21c-2def0989391d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_aea80217-66e9-4f7e-a21c-2def0989391d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_6e85351c-c7b2-43cf-b0b3-94548558bfed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_aea80217-66e9-4f7e-a21c-2def0989391d" xlink:to="loc_srt_ShareRepurchaseProgramAxis_6e85351c-c7b2-43cf-b0b3-94548558bfed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_6e85351c-c7b2-43cf-b0b3-94548558bfed_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_6e85351c-c7b2-43cf-b0b3-94548558bfed" xlink:to="loc_srt_ShareRepurchaseProgramDomain_6e85351c-c7b2-43cf-b0b3-94548558bfed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_afeb6c58-3e4f-4a68-aae4-e44c0336a810" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_6e85351c-c7b2-43cf-b0b3-94548558bfed" xlink:to="loc_srt_ShareRepurchaseProgramDomain_afeb6c58-3e4f-4a68-aae4-e44c0336a810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_369f8db6-845c-4002-bbcd-011e79434a16" xlink:href="dva-20241231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_afeb6c58-3e4f-4a68-aae4-e44c0336a810" xlink:to="loc_dva_OpenMarketPurchasesMember_369f8db6-845c-4002-bbcd-011e79434a16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_34ade406-1c63-42cb-9314-e14a2ce455e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_34ade406-1c63-42cb-9314-e14a2ce455e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_980486a1-074d-4d6e-be9c-84b1faa0efed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_980486a1-074d-4d6e-be9c-84b1faa0efed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1575fb9c-8ecf-49aa-8d89-09de033e9c95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1575fb9c-8ecf-49aa-8d89-09de033e9c95" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_e503be50-dd9e-4ff3-99fa-d0ec02f9a1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_fd59372b-8d95-4a5a-9206-7ab2b9147d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_e503be50-dd9e-4ff3-99fa-d0ec02f9a1f0" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_fd59372b-8d95-4a5a-9206-7ab2b9147d67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4fa9ad78-0fda-44d2-9179-20f7e21f4fda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_fd59372b-8d95-4a5a-9206-7ab2b9147d67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4fa9ad78-0fda-44d2-9179-20f7e21f4fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4fa9ad78-0fda-44d2-9179-20f7e21f4fda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4fa9ad78-0fda-44d2-9179-20f7e21f4fda" xlink:to="loc_us-gaap_EquityComponentDomain_4fa9ad78-0fda-44d2-9179-20f7e21f4fda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0c445553-55ba-478b-bdfe-3c145e5117a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4fa9ad78-0fda-44d2-9179-20f7e21f4fda" xlink:to="loc_us-gaap_EquityComponentDomain_0c445553-55ba-478b-bdfe-3c145e5117a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_aaa6ae70-53fe-4ba9-a688-3b79c355ae76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0c445553-55ba-478b-bdfe-3c145e5117a6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_aaa6ae70-53fe-4ba9-a688-3b79c355ae76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_554d8f73-7796-4fda-8b76-a173fde1e31f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_e503be50-dd9e-4ff3-99fa-d0ec02f9a1f0" xlink:to="loc_us-gaap_NetIncomeLoss_554d8f73-7796-4fda-8b76-a173fde1e31f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_e503be50-dd9e-4ff3-99fa-d0ec02f9a1f0" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8121538c-1caa-4ee0-9d0d-fed3c7541f13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8121538c-1caa-4ee0-9d0d-fed3c7541f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_95521c81-da34-474e-a63e-c925b2703266" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_95521c81-da34-474e-a63e-c925b2703266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_413a3ae4-28ea-4f6c-a95a-5e8e05ac029c" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_413a3ae4-28ea-4f6c-a95a-5e8e05ac029c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_05d32ed9-2046-4e4f-979d-dbaa5372a2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_05d32ed9-2046-4e4f-979d-dbaa5372a2b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_c17452ad-5e93-4918-896a-7f64d8168100" xlink:href="dva-20241231.xsd#dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_c17452ad-5e93-4918-896a-7f64d8168100" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ShareholdersequityDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d43f34c3-74df-4630-b804-d2585598bd04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d43f34c3-74df-4630-b804-d2585598bd04" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_860aa391-9ac2-4c8b-b36b-e02420f30e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_860aa391-9ac2-4c8b-b36b-e02420f30e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_860aa391-9ac2-4c8b-b36b-e02420f30e56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_860aa391-9ac2-4c8b-b36b-e02420f30e56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_860aa391-9ac2-4c8b-b36b-e02420f30e56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_24d0cf25-e37f-4c4f-a980-3bbde6f57f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_860aa391-9ac2-4c8b-b36b-e02420f30e56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_24d0cf25-e37f-4c4f-a980-3bbde6f57f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0317027c-e429-46dc-92ff-8a5418a81229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_24d0cf25-e37f-4c4f-a980-3bbde6f57f43" xlink:to="loc_us-gaap_SubsequentEventMember_0317027c-e429-46dc-92ff-8a5418a81229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6d2629e6-63ca-49ba-b0ee-aaf8f8dd6878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6d2629e6-63ca-49ba-b0ee-aaf8f8dd6878" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d2629e6-63ca-49ba-b0ee-aaf8f8dd6878_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d2629e6-63ca-49ba-b0ee-aaf8f8dd6878" xlink:to="loc_us-gaap_EquityComponentDomain_6d2629e6-63ca-49ba-b0ee-aaf8f8dd6878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d89d57f9-bf5d-42b4-8742-9b710259b070" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d2629e6-63ca-49ba-b0ee-aaf8f8dd6878" xlink:to="loc_us-gaap_EquityComponentDomain_d89d57f9-bf5d-42b4-8742-9b710259b070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_ee5b69cf-3632-4060-a56d-ec4f246e5fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d89d57f9-bf5d-42b4-8742-9b710259b070" xlink:to="loc_us-gaap_TreasuryStockCommonMember_ee5b69cf-3632-4060-a56d-ec4f246e5fc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_38194b18-2473-49cc-935f-81e9be7e8e23" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:to="loc_srt_ShareRepurchaseProgramAxis_38194b18-2473-49cc-935f-81e9be7e8e23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_38194b18-2473-49cc-935f-81e9be7e8e23_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_38194b18-2473-49cc-935f-81e9be7e8e23" xlink:to="loc_srt_ShareRepurchaseProgramDomain_38194b18-2473-49cc-935f-81e9be7e8e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_3acb2669-c7f1-46ec-86bd-d02e32c1e9af" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_38194b18-2473-49cc-935f-81e9be7e8e23" xlink:to="loc_srt_ShareRepurchaseProgramDomain_3acb2669-c7f1-46ec-86bd-d02e32c1e9af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_c569ee89-6fe6-4211-85e6-49fe33e495b8" xlink:href="dva-20241231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_3acb2669-c7f1-46ec-86bd-d02e32c1e9af" xlink:to="loc_dva_OpenMarketPurchasesMember_c569ee89-6fe6-4211-85e6-49fe33e495b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d43f34c3-74df-4630-b804-d2585598bd04" xlink:to="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_5262f657-66c7-4338-a172-486934541160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_5262f657-66c7-4338-a172-486934541160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_79df363d-c791-422d-86b0-a3a18ba4fc24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_79df363d-c791-422d-86b0-a3a18ba4fc24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7d8daa02-88ea-455f-95a7-f00f64dbf822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7d8daa02-88ea-455f-95a7-f00f64dbf822" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_a6f32774-4e24-4ce6-b347-b606a20d4920" xlink:href="dva-20241231.xsd#dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_a6f32774-4e24-4ce6-b347-b606a20d4920" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_965bcd89-6ce2-45cd-b4c7-a8a109963ac0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_965bcd89-6ce2-45cd-b4c7-a8a109963ac0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_2bff7cb2-deb2-413e-ae63-913bfaa2379b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_2bff7cb2-deb2-413e-ae63-913bfaa2379b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_19496c31-d56b-41c7-a0c4-30ca6c5c985c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_19496c31-d56b-41c7-a0c4-30ca6c5c985c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:href="dva-20241231.xsd#dva_CharterdocumentsandDelawarelawAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d43f34c3-74df-4630-b804-d2585598bd04" xlink:to="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a55ee545-fc57-48ac-b864-c94c4edcea72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a55ee545-fc57-48ac-b864-c94c4edcea72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_53bfe59a-5a8c-4ad9-903d-17c458b4716f" xlink:href="dva-20241231.xsd#dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:to="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_53bfe59a-5a8c-4ad9-903d-17c458b4716f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_912b6ede-de1c-4255-b8af-eba2c14d0abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_912b6ede-de1c-4255-b8af-eba2c14d0abb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_25c2273d-7608-42f6-89ea-7b3f26fdb5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_25c2273d-7608-42f6-89ea-7b3f26fdb5ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f20b4194-a740-422f-90e4-e5cd0fc05ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_25c2273d-7608-42f6-89ea-7b3f26fdb5ab" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f20b4194-a740-422f-90e4-e5cd0fc05ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f20b4194-a740-422f-90e4-e5cd0fc05ebd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f20b4194-a740-422f-90e4-e5cd0fc05ebd" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f20b4194-a740-422f-90e4-e5cd0fc05ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c74bb65b-c34c-4b95-b697-28d103d4c26e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f20b4194-a740-422f-90e4-e5cd0fc05ebd" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c74bb65b-c34c-4b95-b697-28d103d4c26e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_238a7e03-fd46-4580-85b5-20545b5a8d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c74bb65b-c34c-4b95-b697-28d103d4c26e" xlink:to="loc_us-gaap_PrincipalOwnerMember_238a7e03-fd46-4580-85b5-20545b5a8d89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bbe5f78e-2f51-44f4-a7ed-0b5287f284e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_25c2273d-7608-42f6-89ea-7b3f26fdb5ab" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bbe5f78e-2f51-44f4-a7ed-0b5287f284e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bbe5f78e-2f51-44f4-a7ed-0b5287f284e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bbe5f78e-2f51-44f4-a7ed-0b5287f284e2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bbe5f78e-2f51-44f4-a7ed-0b5287f284e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fed3befe-2057-4007-a5b2-57b074365f59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bbe5f78e-2f51-44f4-a7ed-0b5287f284e2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fed3befe-2057-4007-a5b2-57b074365f59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_08bb1cf4-5c60-4a50-8ff4-39b406b84218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fed3befe-2057-4007-a5b2-57b074365f59" xlink:to="loc_us-gaap_SubsequentEventMember_08bb1cf4-5c60-4a50-8ff4-39b406b84218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_16b1c24b-c687-45a9-82be-10eb52e292f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_16b1c24b-c687-45a9-82be-10eb52e292f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_c721e6d0-17f7-4ac6-af51-0daf9f12256d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_c721e6d0-17f7-4ac6-af51-0daf9f12256d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_f9669a30-9bc5-443b-a9b2-4bcc9a8c34a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RelatedPartyTransactionDescriptionOfTransaction1_02410e05-df17-49ca-a41b-5c8fac90f3dd" xlink:href="dva-20241231.xsd#dva_RelatedPartyTransactionDescriptionOfTransaction1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_dva_RelatedPartyTransactionDescriptionOfTransaction1_02410e05-df17-49ca-a41b-5c8fac90f3dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RelatedPartyTransactionDescriptionOfTransaction2_5ba2be2f-61f6-47fd-9841-8b75abd13ef0" xlink:href="dva-20241231.xsd#dva_RelatedPartyTransactionDescriptionOfTransaction2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_dva_RelatedPartyTransactionDescriptionOfTransaction2_5ba2be2f-61f6-47fd-9841-8b75abd13ef0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementDate_9e57b561-afe2-4076-90cf-68fdd2288b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepurchaseAgreementDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_us-gaap_RepurchaseAgreementDate_9e57b561-afe2-4076-90cf-68fdd2288b91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_19289a0c-b502-416b-a21f-21e0b5060ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_19289a0c-b502-416b-a21f-21e0b5060ee4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9de2cbca-cfbe-48f4-8ba3-14fdca4f5a50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9de2cbca-cfbe-48f4-8ba3-14fdca4f5a50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ccb9797-c4a8-4a38-bde4-297ff4d4e4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9de2cbca-cfbe-48f4-8ba3-14fdca4f5a50" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ccb9797-c4a8-4a38-bde4-297ff4d4e4f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ccb9797-c4a8-4a38-bde4-297ff4d4e4f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ccb9797-c4a8-4a38-bde4-297ff4d4e4f2" xlink:to="loc_us-gaap_EquityComponentDomain_5ccb9797-c4a8-4a38-bde4-297ff4d4e4f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ccb9797-c4a8-4a38-bde4-297ff4d4e4f2" xlink:to="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_04d7c127-6747-4894-a773-9c7750195b04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_04d7c127-6747-4894-a773-9c7750195b04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_51e9dc38-69de-4f76-b772-b670dcfc52be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_51e9dc38-69de-4f76-b772-b670dcfc52be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8bf49747-c853-42e4-9f26-de6984e536e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8bf49747-c853-42e4-9f26-de6984e536e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f3d92b89-60bd-4533-b032-75ab7e40ac4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f3d92b89-60bd-4533-b032-75ab7e40ac4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7c0fe23d-395e-43ee-ab65-9e7575a240a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7c0fe23d-395e-43ee-ab65-9e7575a240a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_701c1ce2-41ea-46a5-89c0-9380a89b09e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_701c1ce2-41ea-46a5-89c0-9380a89b09e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_4839a00e-7e8b-41ad-9515-d899d659b0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_4839a00e-7e8b-41ad-9515-d899d659b0ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_8f5559ba-9d55-42a5-a629-005f57831790" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_8f5559ba-9d55-42a5-a629-005f57831790" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_10f85615-933f-4f0c-b133-93fa01da9e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_10f85615-933f-4f0c-b133-93fa01da9e8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_0633c24f-2b8a-490b-9574-c7c8146eebfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_0633c24f-2b8a-490b-9574-c7c8146eebfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_517508d1-7b2c-4459-812f-65e5fc6e21f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_517508d1-7b2c-4459-812f-65e5fc6e21f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5922aa50-9e39-47f0-b3ad-c3ea9ba70e02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsComponentsofRoutineAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3e16a36f-850d-41ac-8f49-98662091d311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3e16a36f-850d-41ac-8f49-98662091d311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e16a36f-850d-41ac-8f49-98662091d311_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3e16a36f-850d-41ac-8f49-98662091d311" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e16a36f-850d-41ac-8f49-98662091d311_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e350c7b0-54c6-4d29-b4bd-2904c58dc4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3e16a36f-850d-41ac-8f49-98662091d311" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e350c7b0-54c6-4d29-b4bd-2904c58dc4f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_d6d84631-57a0-4f9f-ba7d-3e9dbea65b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e350c7b0-54c6-4d29-b4bd-2904c58dc4f5" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_d6d84631-57a0-4f9f-ba7d-3e9dbea65b6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaCarePte.Ltd.Member_a7673f15-becb-453c-8c94-380438bfbf80" xlink:href="dva-20241231.xsd#dva_DaVitaCarePte.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e350c7b0-54c6-4d29-b4bd-2904c58dc4f5" xlink:to="loc_dva_DaVitaCarePte.Ltd.Member_a7673f15-becb-453c-8c94-380438bfbf80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d25681a7-a48b-42d8-aa9b-e7bdc6d3766c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d25681a7-a48b-42d8-aa9b-e7bdc6d3766c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d25681a7-a48b-42d8-aa9b-e7bdc6d3766c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d25681a7-a48b-42d8-aa9b-e7bdc6d3766c" xlink:to="loc_us-gaap_SegmentDomain_d25681a7-a48b-42d8-aa9b-e7bdc6d3766c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_64e8364b-9e11-4f15-9cd1-cdd6adc9c394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d25681a7-a48b-42d8-aa9b-e7bdc6d3766c" xlink:to="loc_us-gaap_SegmentDomain_64e8364b-9e11-4f15-9cd1-cdd6adc9c394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_527ccf51-cb25-46b9-bef9-b286ad08c33c" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_64e8364b-9e11-4f15-9cd1-cdd6adc9c394" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_527ccf51-cb25-46b9-bef9-b286ad08c33c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignDialysisCentersMember_c617d727-73ad-4532-87b2-8256310fccb1" xlink:href="dva-20241231.xsd#dva_ForeignDialysisCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_64e8364b-9e11-4f15-9cd1-cdd6adc9c394" xlink:to="loc_dva_ForeignDialysisCentersMember_c617d727-73ad-4532-87b2-8256310fccb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_4df1334d-4abc-47ea-8b06-55fd3fefe683" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_4df1334d-4abc-47ea-8b06-55fd3fefe683" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_4df1334d-4abc-47ea-8b06-55fd3fefe683_default" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_4df1334d-4abc-47ea-8b06-55fd3fefe683" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_4df1334d-4abc-47ea-8b06-55fd3fefe683_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_26760f34-62cd-4518-b112-70ce15c05f1d" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_4df1334d-4abc-47ea-8b06-55fd3fefe683" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_26760f34-62cd-4518-b112-70ce15c05f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NonCashGainMember_5a46cfff-d787-465f-9956-75a0973d8805" xlink:href="dva-20241231.xsd#dva_NonCashGainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_26760f34-62cd-4518-b112-70ce15c05f1d" xlink:to="loc_dva_NonCashGainMember_5a46cfff-d787-465f-9956-75a0973d8805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be228cc9-e20f-43c8-8dca-a3ccfc76d409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be228cc9-e20f-43c8-8dca-a3ccfc76d409" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6fc4fab9-1214-4bb8-bd0b-76dbb198aeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6fc4fab9-1214-4bb8-bd0b-76dbb198aeb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_70eeefb6-e78f-4d82-9a6b-8858d708f269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_70eeefb6-e78f-4d82-9a6b-8858d708f269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92e46038-a818-4b6d-876e-895bd61b819e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92e46038-a818-4b6d-876e-895bd61b819e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_5338e20a-5ea2-43af-bb70-e543806037b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_5338e20a-5ea2-43af-bb70-e543806037b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_67aaa26a-7c46-4554-9fdf-946deecd3849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_67aaa26a-7c46-4554-9fdf-946deecd3849" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsAssetsacquiredandliabilitiesassumedDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c6d72b7e-9544-4323-b88c-2392f4cc59a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c6d72b7e-9544-4323-b88c-2392f4cc59a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d4d1a14d-44ae-4721-93ec-8f70ed813ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c6d72b7e-9544-4323-b88c-2392f4cc59a2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d4d1a14d-44ae-4721-93ec-8f70ed813ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4d1a14d-44ae-4721-93ec-8f70ed813ec7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4d1a14d-44ae-4721-93ec-8f70ed813ec7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4d1a14d-44ae-4721-93ec-8f70ed813ec7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9ceed66-935e-4c96-8359-022065658391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4d1a14d-44ae-4721-93ec-8f70ed813ec7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9ceed66-935e-4c96-8359-022065658391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_847e4449-2250-4cee-a860-965321c899c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9ceed66-935e-4c96-8359-022065658391" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_847e4449-2250-4cee-a860-965321c899c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaCarePte.Ltd.Member_a2f09e55-feaf-4a55-9892-d139f895d205" xlink:href="dva-20241231.xsd#dva_DaVitaCarePte.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9ceed66-935e-4c96-8359-022065658391" xlink:to="loc_dva_DaVitaCarePte.Ltd.Member_a2f09e55-feaf-4a55-9892-d139f895d205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f21e309-099d-4ae9-984c-26650fc216d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f21e309-099d-4ae9-984c-26650fc216d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_743d0b2c-cf7c-4d94-b024-23c825a34902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_743d0b2c-cf7c-4d94-b024-23c825a34902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a3fb70cd-0adc-45db-904a-868b8d09d1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a3fb70cd-0adc-45db-904a-868b8d09d1aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e269b553-746b-486f-9934-cb3b8bd00020" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e269b553-746b-486f-9934-cb3b8bd00020" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d170a986-d24c-4c57-98d9-df55d528d0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d170a986-d24c-4c57-98d9-df55d528d0cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2d60d880-3a4b-4eaf-a79b-2cf9d9ac45d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_Goodwill_2d60d880-3a4b-4eaf-a79b-2cf9d9ac45d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c20e5cc1-b26c-475b-affd-53b7307c39d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c20e5cc1-b26c-475b-affd-53b7307c39d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_3135f6a2-fe1a-450b-93bc-a40546646d17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_3135f6a2-fe1a-450b-93bc-a40546646d17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0948164f-8f64-4f36-9c71-f44c3a937f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0948164f-8f64-4f36-9c71-f44c3a937f9f" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9eaad074-9f97-4bee-8864-2da8f2e287f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0507a69d-8a28-48a3-8665-6a4182a88462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9eaad074-9f97-4bee-8864-2da8f2e287f0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0507a69d-8a28-48a3-8665-6a4182a88462" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8bdaa82f-67a9-4f40-a625-428291a47064" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0507a69d-8a28-48a3-8665-6a4182a88462" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8bdaa82f-67a9-4f40-a625-428291a47064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdaa82f-67a9-4f40-a625-428291a47064_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8bdaa82f-67a9-4f40-a625-428291a47064" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bdaa82f-67a9-4f40-a625-428291a47064_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_185facb0-ceac-45ff-9191-e80379bf603b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8bdaa82f-67a9-4f40-a625-428291a47064" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_185facb0-ceac-45ff-9191-e80379bf603b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_228ee6fb-54e2-4a7f-acf8-34d2bea7eb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_185facb0-ceac-45ff-9191-e80379bf603b" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_228ee6fb-54e2-4a7f-acf8-34d2bea7eb0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ab010b6e-4774-49a6-816e-0c7d77060d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9eaad074-9f97-4bee-8864-2da8f2e287f0" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ab010b6e-4774-49a6-816e-0c7d77060d72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0729ac92-32e1-4186-8192-2a0ea30bea53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93abae29-f459-4822-b2a0-c34feb14c7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0729ac92-32e1-4186-8192-2a0ea30bea53" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93abae29-f459-4822-b2a0-c34feb14c7f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c7a2008b-c400-41b3-8a9d-eabef0046100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93abae29-f459-4822-b2a0-c34feb14c7f0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c7a2008b-c400-41b3-8a9d-eabef0046100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7a2008b-c400-41b3-8a9d-eabef0046100_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c7a2008b-c400-41b3-8a9d-eabef0046100" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7a2008b-c400-41b3-8a9d-eabef0046100_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b1a8a1-1992-4c0a-b536-7e2e8294479a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c7a2008b-c400-41b3-8a9d-eabef0046100" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b1a8a1-1992-4c0a-b536-7e2e8294479a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_55145292-8708-4eaf-9bbd-4ba8650ed9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b1a8a1-1992-4c0a-b536-7e2e8294479a" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_55145292-8708-4eaf-9bbd-4ba8650ed9dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsandDivestituresAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5df98de6-1e13-4469-9e4b-a56c4b27959e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5df98de6-1e13-4469-9e4b-a56c4b27959e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5df98de6-1e13-4469-9e4b-a56c4b27959e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5df98de6-1e13-4469-9e4b-a56c4b27959e" xlink:to="loc_us-gaap_RelatedPartyDomain_5df98de6-1e13-4469-9e4b-a56c4b27959e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ee4daf3b-40e0-47fd-a245-3b9f4aca4fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5df98de6-1e13-4469-9e4b-a56c4b27959e" xlink:to="loc_us-gaap_RelatedPartyDomain_ee4daf3b-40e0-47fd-a245-3b9f4aca4fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherCompaniesMember_4ffbe986-c55d-403c-9d62-bff7aff185f3" xlink:href="dva-20241231.xsd#dva_OtherCompaniesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ee4daf3b-40e0-47fd-a245-3b9f4aca4fbf" xlink:to="loc_dva_OtherCompaniesMember_4ffbe986-c55d-403c-9d62-bff7aff185f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_61de872e-f254-4bbc-80a9-539ce5d11837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_61de872e-f254-4bbc-80a9-539ce5d11837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_61de872e-f254-4bbc-80a9-539ce5d11837_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_61de872e-f254-4bbc-80a9-539ce5d11837" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_61de872e-f254-4bbc-80a9-539ce5d11837_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_40e28772-6fcc-4456-95ca-8c55328461cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_61de872e-f254-4bbc-80a9-539ce5d11837" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_40e28772-6fcc-4456-95ca-8c55328461cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_55c7abf1-53c7-4ba3-ab45-baac485a4e6a" xlink:href="dva-20241231.xsd#dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_40e28772-6fcc-4456-95ca-8c55328461cb" xlink:to="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_55c7abf1-53c7-4ba3-ab45-baac485a4e6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1b3272f9-2a0d-473d-a6f7-9bc46c2f4b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1b3272f9-2a0d-473d-a6f7-9bc46c2f4b90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1b3272f9-2a0d-473d-a6f7-9bc46c2f4b90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1b3272f9-2a0d-473d-a6f7-9bc46c2f4b90" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1b3272f9-2a0d-473d-a6f7-9bc46c2f4b90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46c1ea59-f236-4468-bb7d-640a3b7fa65d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1b3272f9-2a0d-473d-a6f7-9bc46c2f4b90" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46c1ea59-f236-4468-bb7d-640a3b7fa65d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_f7d48305-ec44-4314-a790-ee14d7cc2e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46c1ea59-f236-4468-bb7d-640a3b7fa65d" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_f7d48305-ec44-4314-a790-ee14d7cc2e1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaCarePte.Ltd.Member_e02993a2-d0f7-4650-a114-2ee4e2b70164" xlink:href="dva-20241231.xsd#dva_DaVitaCarePte.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46c1ea59-f236-4468-bb7d-640a3b7fa65d" xlink:to="loc_dva_DaVitaCarePte.Ltd.Member_e02993a2-d0f7-4650-a114-2ee4e2b70164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_782179af-8874-4430-ba6f-6bc54aa4a4ef" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_782179af-8874-4430-ba6f-6bc54aa4a4ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_782179af-8874-4430-ba6f-6bc54aa4a4ef_default" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_782179af-8874-4430-ba6f-6bc54aa4a4ef" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_782179af-8874-4430-ba6f-6bc54aa4a4ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_146c5744-6b9b-43f5-b8d1-f5328ee1a71a" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_782179af-8874-4430-ba6f-6bc54aa4a4ef" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_146c5744-6b9b-43f5-b8d1-f5328ee1a71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember_7f6b1d31-7963-49a2-9189-7301ad8d844e" xlink:href="dva-20241231.xsd#dva_ForeignCurrencyGainLossTranslationAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_146c5744-6b9b-43f5-b8d1-f5328ee1a71a" xlink:to="loc_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember_7f6b1d31-7963-49a2-9189-7301ad8d844e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0f6b936-77f3-46a9-9af6-808c7ab0e9b2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_srt_RangeAxis_b0f6b936-77f3-46a9-9af6-808c7ab0e9b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0f6b936-77f3-46a9-9af6-808c7ab0e9b2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b0f6b936-77f3-46a9-9af6-808c7ab0e9b2" xlink:to="loc_srt_RangeMember_b0f6b936-77f3-46a9-9af6-808c7ab0e9b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff2c2f93-38ea-4e69-b451-bbf8b4361885" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b0f6b936-77f3-46a9-9af6-808c7ab0e9b2" xlink:to="loc_srt_RangeMember_ff2c2f93-38ea-4e69-b451-bbf8b4361885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2fa39d97-ce4d-4152-8dd5-75279618dc86" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ff2c2f93-38ea-4e69-b451-bbf8b4361885" xlink:to="loc_srt_MinimumMember_2fa39d97-ce4d-4152-8dd5-75279618dc86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1247fd40-bf6b-4d4b-aed4-9aff7f5242d6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ff2c2f93-38ea-4e69-b451-bbf8b4361885" xlink:to="loc_srt_MaximumMember_1247fd40-bf6b-4d4b-aed4-9aff7f5242d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aa277501-d833-4a98-8bae-03de40a18ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aa277501-d833-4a98-8bae-03de40a18ce1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_dc8dcd7d-0a74-4fed-af1a-013c4461c501" xlink:href="dva-20241231.xsd#dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_dc8dcd7d-0a74-4fed-af1a-013c4461c501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_a36360d4-738b-4d39-a3ca-d6fe73f42719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_a36360d4-738b-4d39-a3ca-d6fe73f42719" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_a25aa0d6-5f77-4e03-8701-8d8f3e50bc42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_a25aa0d6-5f77-4e03-8701-8d8f3e50bc42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_e45cf259-b4f5-4350-be26-86e865bf220d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_e45cf259-b4f5-4350-be26-86e865bf220d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2241be05-b35e-4695-9345-fbcf3740ec78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2241be05-b35e-4695-9345-fbcf3740ec78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5e02d048-fd5e-48ef-8673-9396e1c86245" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2241be05-b35e-4695-9345-fbcf3740ec78" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5e02d048-fd5e-48ef-8673-9396e1c86245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5e02d048-fd5e-48ef-8673-9396e1c86245_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5e02d048-fd5e-48ef-8673-9396e1c86245" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5e02d048-fd5e-48ef-8673-9396e1c86245_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6dd67cce-b453-4aa9-80eb-0959d16f7c80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5e02d048-fd5e-48ef-8673-9396e1c86245" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6dd67cce-b453-4aa9-80eb-0959d16f7c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_638c8304-a630-46da-bcb4-afe1df11a00a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6dd67cce-b453-4aa9-80eb-0959d16f7c80" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_638c8304-a630-46da-bcb4-afe1df11a00a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_62293597-7311-4da1-8534-7c04b3a9ffdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2241be05-b35e-4695-9345-fbcf3740ec78" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_62293597-7311-4da1-8534-7c04b3a9ffdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_62293597-7311-4da1-8534-7c04b3a9ffdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_62293597-7311-4da1-8534-7c04b3a9ffdf" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_62293597-7311-4da1-8534-7c04b3a9ffdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4df9a4f-fcb0-495a-8505-642c8635679d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_62293597-7311-4da1-8534-7c04b3a9ffdf" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4df9a4f-fcb0-495a-8505-642c8635679d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_fb130baf-141a-4454-a3e1-99bf52c59975" xlink:href="dva-20241231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4df9a4f-fcb0-495a-8505-642c8635679d" xlink:to="loc_dva_DaVitaMedicalGroupMember_fb130baf-141a-4454-a3e1-99bf52c59975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_ba7eb5f1-fdbd-462c-8bed-ee601807aea4" xlink:href="dva-20241231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_ba7eb5f1-fdbd-462c-8bed-ee601807aea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_162ddbae-c845-4747-ac3d-abe9e5a43da8" xlink:href="dva-20241231.xsd#dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_162ddbae-c845-4747-ac3d-abe9e5a43da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_4c39bd55-ee90-4360-9a2e-60475b8f6086" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_4c39bd55-ee90-4360-9a2e-60475b8f6086" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_23a8353c-90fe-476a-b125-f2102822c7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_23a8353c-90fe-476a-b125-f2102822c7a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_4ea87dfc-bca2-4f99-b29e-82a319171383" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_4ea87dfc-bca2-4f99-b29e-82a319171383" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#VariableInterestEntitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_64fafa83-1575-4061-bb0a-56ac6ab8463e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46dac269-fd13-4c28-9b75-8f8a37fe1ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_64fafa83-1575-4061-bb0a-56ac6ab8463e" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46dac269-fd13-4c28-9b75-8f8a37fe1ff0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6f733aa7-da72-4b93-bcc0-521588f61435" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46dac269-fd13-4c28-9b75-8f8a37fe1ff0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6f733aa7-da72-4b93-bcc0-521588f61435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6f733aa7-da72-4b93-bcc0-521588f61435_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6f733aa7-da72-4b93-bcc0-521588f61435" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6f733aa7-da72-4b93-bcc0-521588f61435_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8597657f-2eb9-45ca-8e95-682ffc1f7498" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6f733aa7-da72-4b93-bcc0-521588f61435" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8597657f-2eb9-45ca-8e95-682ffc1f7498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_525d09a9-0d93-4d60-a2fb-ca5d998c773e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8597657f-2eb9-45ca-8e95-682ffc1f7498" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_525d09a9-0d93-4d60-a2fb-ca5d998c773e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f3cb7d54-0383-4299-b7b5-76ea3ee140b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_64fafa83-1575-4061-bb0a-56ac6ab8463e" xlink:to="loc_us-gaap_Assets_f3cb7d54-0383-4299-b7b5-76ea3ee140b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_52a88fe3-751c-42bd-911c-01e66e1e09b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_64fafa83-1575-4061-bb0a-56ac6ab8463e" xlink:to="loc_us-gaap_Liabilities_52a88fe3-751c-42bd-911c-01e66e1e09b2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_793b4240-8c5b-494c-b8db-adbace8c4657" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_793b4240-8c5b-494c-b8db-adbace8c4657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_793b4240-8c5b-494c-b8db-adbace8c4657_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_793b4240-8c5b-494c-b8db-adbace8c4657" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_793b4240-8c5b-494c-b8db-adbace8c4657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_88a9a8af-db5d-40db-81d9-b6a2f3d65416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_793b4240-8c5b-494c-b8db-adbace8c4657" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_88a9a8af-db5d-40db-81d9-b6a2f3d65416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9a0ef7c9-c5a9-4780-87ef-6086471cbbda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_88a9a8af-db5d-40db-81d9-b6a2f3d65416" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9a0ef7c9-c5a9-4780-87ef-6086471cbbda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e192fac-30f3-4a4c-9eb3-b018beb79665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e192fac-30f3-4a4c-9eb3-b018beb79665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e192fac-30f3-4a4c-9eb3-b018beb79665_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e192fac-30f3-4a4c-9eb3-b018beb79665" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e192fac-30f3-4a4c-9eb3-b018beb79665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e192fac-30f3-4a4c-9eb3-b018beb79665" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7d8c0d80-425a-438c-9d35-02a88c787da4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7d8c0d80-425a-438c-9d35-02a88c787da4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_50a276ea-db33-4ed9-bdef-bd4427fbe4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_50a276ea-db33-4ed9-bdef-bd4427fbe4dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_77ed7bfa-42bc-47bc-a61f-0e317da4307c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_77ed7bfa-42bc-47bc-a61f-0e317da4307c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_433895eb-c762-43db-bf0a-3d11420b0479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_433895eb-c762-43db-bf0a-3d11420b0479" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_433895eb-c762-43db-bf0a-3d11420b0479_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_433895eb-c762-43db-bf0a-3d11420b0479" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_433895eb-c762-43db-bf0a-3d11420b0479_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d059efb9-6375-4074-b4ab-7f36e9ac59a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_433895eb-c762-43db-bf0a-3d11420b0479" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d059efb9-6375-4074-b4ab-7f36e9ac59a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_1084bd11-cd19-4cab-ba53-6a620a323dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d059efb9-6375-4074-b4ab-7f36e9ac59a7" xlink:to="loc_us-gaap_InterestRateCapMember_1084bd11-cd19-4cab-ba53-6a620a323dc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d2b8716e-e2ef-43fe-8539-eb4db51bf94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d2b8716e-e2ef-43fe-8539-eb4db51bf94d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_5043df74-a917-4c4e-8f76-12177f30c294" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d2b8716e-e2ef-43fe-8539-eb4db51bf94d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_5043df74-a917-4c4e-8f76-12177f30c294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_96858fe6-abe0-49a1-8f3f-e638e874722b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d2b8716e-e2ef-43fe-8539-eb4db51bf94d" xlink:to="loc_us-gaap_DerivativeAssets_96858fe6-abe0-49a1-8f3f-e638e874722b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c29dcae5-12b0-4a5f-9103-f4d9454a4f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c29dcae5-12b0-4a5f-9103-f4d9454a4f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_90b89f43-45df-4f73-a1b2-18ee2a8a1344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c29dcae5-12b0-4a5f-9103-f4d9454a4f9e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_90b89f43-45df-4f73-a1b2-18ee2a8a1344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_9c897b5d-a785-4657-bbc9-e8a6bb5ea37c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:to="loc_us-gaap_TemporaryEquityAbstract_9c897b5d-a785-4657-bbc9-e8a6bb5ea37c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_980efabc-b370-49e8-a619-8c3529f0255d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityAbstract_9c897b5d-a785-4657-bbc9-e8a6bb5ea37c" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_980efabc-b370-49e8-a619-8c3529f0255d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c7f816c8-fc3d-41b6-9fd5-f3df3bd3fdf8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:to="loc_srt_ConsolidationItemsAxis_c7f816c8-fc3d-41b6-9fd5-f3df3bd3fdf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c7f816c8-fc3d-41b6-9fd5-f3df3bd3fdf8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_c7f816c8-fc3d-41b6-9fd5-f3df3bd3fdf8" xlink:to="loc_srt_ConsolidationItemsDomain_c7f816c8-fc3d-41b6-9fd5-f3df3bd3fdf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_33498bad-483c-45cc-9dbe-5a1726b46447" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_c7f816c8-fc3d-41b6-9fd5-f3df3bd3fdf8" xlink:to="loc_srt_ConsolidationItemsDomain_33498bad-483c-45cc-9dbe-5a1726b46447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4bec5b50-4145-449a-8eda-ab9f59c953db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_33498bad-483c-45cc-9dbe-5a1726b46447" xlink:to="loc_us-gaap_OperatingSegmentsMember_4bec5b50-4145-449a-8eda-ab9f59c953db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_68baecb0-713d-4694-ba31-eed03db04cea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_33498bad-483c-45cc-9dbe-5a1726b46447" xlink:to="loc_us-gaap_IntersegmentEliminationMember_68baecb0-713d-4694-ba31-eed03db04cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7bab60c8-88e6-4cb7-bfea-de7cdc108a01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7bab60c8-88e6-4cb7-bfea-de7cdc108a01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7bab60c8-88e6-4cb7-bfea-de7cdc108a01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7bab60c8-88e6-4cb7-bfea-de7cdc108a01" xlink:to="loc_us-gaap_SegmentDomain_7bab60c8-88e6-4cb7-bfea-de7cdc108a01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7bab60c8-88e6-4cb7-bfea-de7cdc108a01" xlink:to="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_d9900676-13bc-494a-8370-d992839ec507" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_d9900676-13bc-494a-8370-d992839ec507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_98002beb-74c6-4922-9146-bd6e5bf8a457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:to="loc_us-gaap_AllOtherSegmentsMember_98002beb-74c6-4922-9146-bd6e5bf8a457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember_54569fb9-79fe-4f19-9609-4b0f6a1151a9" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesWithIntersegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:to="loc_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember_54569fb9-79fe-4f19-9609-4b0f6a1151a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherOperatingSegmentsWithIntersegmentMember_f8dde8be-2d14-4b62-9e06-d7ee9f7ff68c" xlink:href="dva-20241231.xsd#dva_OtherOperatingSegmentsWithIntersegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:to="loc_dva_OtherOperatingSegmentsWithIntersegmentMember_f8dde8be-2d14-4b62-9e06-d7ee9f7ff68c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_27e3fddb-11e4-4bab-8c36-39603b1492bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_27e3fddb-11e4-4bab-8c36-39603b1492bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_27e3fddb-11e4-4bab-8c36-39603b1492bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_27e3fddb-11e4-4bab-8c36-39603b1492bc" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_27e3fddb-11e4-4bab-8c36-39603b1492bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_e5862e4d-5644-4aac-b0e1-e9dc9c63fbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_27e3fddb-11e4-4bab-8c36-39603b1492bc" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_e5862e4d-5644-4aac-b0e1-e9dc9c63fbc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExternalSourcesMember_5609a41b-cd9f-49fa-a6e1-cf2842829092" xlink:href="dva-20241231.xsd#dva_ExternalSourcesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_e5862e4d-5644-4aac-b0e1-e9dc9c63fbc4" xlink:to="loc_dva_ExternalSourcesMember_5609a41b-cd9f-49fa-a6e1-cf2842829092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersubsegmentEliminationsMember_2cd43cbd-6cee-4403-81b0-1f87e416662a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersubsegmentEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_e5862e4d-5644-4aac-b0e1-e9dc9c63fbc4" xlink:to="loc_us-gaap_IntersubsegmentEliminationsMember_2cd43cbd-6cee-4403-81b0-1f87e416662a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3d726f07-9be1-481b-b759-ed3055fe999e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3d726f07-9be1-481b-b759-ed3055fe999e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_b9fd8cb5-11e1-44d7-b8f5-10f7bb19d1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_OtherIncome_b9fd8cb5-11e1-44d7-b8f5-10f7bb19d1f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0a528013-3b02-4f60-b0ac-496bff1dca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_Revenues_0a528013-3b02-4f60-b0ac-496bff1dca6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_59a00326-9c6e-4f70-97c3-18aa05a75da3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_OperatingIncomeLoss_59a00326-9c6e-4f70-97c3-18aa05a75da3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentReportingInformationCorporateExpenses_07e951d1-0ce2-46c4-9912-217cba816c72" xlink:href="dva-20241231.xsd#dva_SegmentReportingInformationCorporateExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_dva_SegmentReportingInformationCorporateExpenses_07e951d1-0ce2-46c4-9912-217cba816c72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_76f459aa-41f4-45a1-a55c-023083fca8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_InterestAndDebtExpense_76f459aa-41f4-45a1-a55c-023083fca8d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_6d8c6ef4-ce69-4a5b-bc95-bba02460f9ac" xlink:href="dva-20241231.xsd#dva_DebtPrepaymentExtinguishmentAndModificationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_6d8c6ef4-ce69-4a5b-bc95-bba02460f9ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9fd2fd0e-f780-4164-a32d-ffadafd8f533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9fd2fd0e-f780-4164-a32d-ffadafd8f533" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8b79d81-75f2-4efe-90c0-518dd7ea2b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8b79d81-75f2-4efe-90c0-518dd7ea2b3b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1072cf80-473e-4e1b-b151-62f1d5ad5f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1072cf80-473e-4e1b-b151-62f1d5ad5f33" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3d62d197-7e2e-4315-bdf1-a42a7417fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1072cf80-473e-4e1b-b151-62f1d5ad5f33" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3d62d197-7e2e-4315-bdf1-a42a7417fe31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts_fe363fd1-ad1c-45a4-9e89-a275644819fa" xlink:href="dva-20241231.xsd#dva_PatientCareCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_dva_PatientCareCosts_fe363fd1-ad1c-45a4-9e89-a275644819fa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_125d1ba5-60d4-4164-ae2b-11604a992dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_125d1ba5-60d4-4164-ae2b-11604a992dc6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_967b88f7-ffb6-4843-a7b2-5ab87bb72346" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_967b88f7-ffb6-4843-a7b2-5ab87bb72346" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9b097fc1-290b-4774-a706-6a8aeab9f93e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_CostsAndExpenses_9b097fc1-290b-4774-a706-6a8aeab9f93e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b44a1b59-5a95-4970-b093-ffa84e319915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_DepreciationAndAmortization_b44a1b59-5a95-4970-b093-ffa84e319915" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c667cbb7-355f-411e-a1c7-cc03399d1896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e65ca44-3191-4e2f-ad98-6e00e3bfc5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c667cbb7-355f-411e-a1c7-cc03399d1896" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e65ca44-3191-4e2f-ad98-6e00e3bfc5f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f17e121a-7aaf-402a-a15c-3ae743d2b0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e65ca44-3191-4e2f-ad98-6e00e3bfc5f9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f17e121a-7aaf-402a-a15c-3ae743d2b0f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f17e121a-7aaf-402a-a15c-3ae743d2b0f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f17e121a-7aaf-402a-a15c-3ae743d2b0f2" xlink:to="loc_us-gaap_SegmentDomain_f17e121a-7aaf-402a-a15c-3ae743d2b0f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2dc08ade-c372-4273-80d7-3697272a74e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f17e121a-7aaf-402a-a15c-3ae743d2b0f2" xlink:to="loc_us-gaap_SegmentDomain_2dc08ade-c372-4273-80d7-3697272a74e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_39bc5cb3-e627-46f9-b5d7-3a26dca59cb3" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2dc08ade-c372-4273-80d7-3697272a74e9" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_39bc5cb3-e627-46f9-b5d7-3a26dca59cb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a5bebc7c-039a-4ba3-bb79-a0645218e86d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2dc08ade-c372-4273-80d7-3697272a74e9" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a5bebc7c-039a-4ba3-bb79-a0645218e86d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d12b045c-df3c-457e-988b-3154524d8268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c667cbb7-355f-411e-a1c7-cc03399d1896" xlink:to="loc_us-gaap_DepreciationAndAmortization_d12b045c-df3c-457e-988b-3154524d8268" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d7500c7e-5d83-49a4-89dd-a64d414b756e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f26d0467-3ccb-4d2f-826c-f0c98c561b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d7500c7e-5d83-49a4-89dd-a64d414b756e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f26d0467-3ccb-4d2f-826c-f0c98c561b47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2f725a03-cce7-42c3-b77b-1822f6621daa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f26d0467-3ccb-4d2f-826c-f0c98c561b47" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2f725a03-cce7-42c3-b77b-1822f6621daa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2f725a03-cce7-42c3-b77b-1822f6621daa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2f725a03-cce7-42c3-b77b-1822f6621daa" xlink:to="loc_us-gaap_SegmentDomain_2f725a03-cce7-42c3-b77b-1822f6621daa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bbe67b1b-ed59-416f-8932-647860f7a610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2f725a03-cce7-42c3-b77b-1822f6621daa" xlink:to="loc_us-gaap_SegmentDomain_bbe67b1b-ed59-416f-8932-647860f7a610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_9ad93985-e9dc-453b-a2c0-05f68bd70fb7" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bbe67b1b-ed59-416f-8932-647860f7a610" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_9ad93985-e9dc-453b-a2c0-05f68bd70fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_d7ef469e-8361-469d-b7d4-2e8639783b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bbe67b1b-ed59-416f-8932-647860f7a610" xlink:to="loc_us-gaap_AllOtherSegmentsMember_d7ef469e-8361-469d-b7d4-2e8639783b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_93146b4e-4e42-4f71-bb3a-5fba7291241c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d7500c7e-5d83-49a4-89dd-a64d414b756e" xlink:to="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_93146b4e-4e42-4f71-bb3a-5fba7291241c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingSummaryofAssetsbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9dc21de6-7c34-4c1a-aa96-3eb02d1f019e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_83a060e4-d8dc-48de-973e-6cae332e2fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9dc21de6-7c34-4c1a-aa96-3eb02d1f019e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_83a060e4-d8dc-48de-973e-6cae332e2fa7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8e2cbdf1-ff24-4f6c-ae5f-334a9f97dad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_83a060e4-d8dc-48de-973e-6cae332e2fa7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8e2cbdf1-ff24-4f6c-ae5f-334a9f97dad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8e2cbdf1-ff24-4f6c-ae5f-334a9f97dad5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8e2cbdf1-ff24-4f6c-ae5f-334a9f97dad5" xlink:to="loc_us-gaap_SegmentDomain_8e2cbdf1-ff24-4f6c-ae5f-334a9f97dad5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_228a49cf-d67d-433c-b7d3-ec2678f7cdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8e2cbdf1-ff24-4f6c-ae5f-334a9f97dad5" xlink:to="loc_us-gaap_SegmentDomain_228a49cf-d67d-433c-b7d3-ec2678f7cdbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_66e1895c-3099-4319-92ce-7d7aec33eb6f" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_228a49cf-d67d-433c-b7d3-ec2678f7cdbd" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_66e1895c-3099-4319-92ce-7d7aec33eb6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_fa4c8966-b613-4e35-8643-b94fd6013f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_228a49cf-d67d-433c-b7d3-ec2678f7cdbd" xlink:to="loc_us-gaap_AllOtherSegmentsMember_fa4c8966-b613-4e35-8643-b94fd6013f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e5729f65-ec2c-47c9-80b5-f9a540c71bb7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_83a060e4-d8dc-48de-973e-6cae332e2fa7" xlink:to="loc_srt_StatementGeographicalAxis_e5729f65-ec2c-47c9-80b5-f9a540c71bb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e5729f65-ec2c-47c9-80b5-f9a540c71bb7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e5729f65-ec2c-47c9-80b5-f9a540c71bb7" xlink:to="loc_srt_SegmentGeographicalDomain_e5729f65-ec2c-47c9-80b5-f9a540c71bb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_df56b135-d5bc-4e14-9b81-5b83b387871a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e5729f65-ec2c-47c9-80b5-f9a540c71bb7" xlink:to="loc_srt_SegmentGeographicalDomain_df56b135-d5bc-4e14-9b81-5b83b387871a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_d5426520-c7d2-4731-99e2-74b1868b5ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_df56b135-d5bc-4e14-9b81-5b83b387871a" xlink:to="loc_us-gaap_NonUsMember_d5426520-c7d2-4731-99e2-74b1868b5ce3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9dc21de6-7c34-4c1a-aa96-3eb02d1f019e" xlink:to="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_75526cee-b6f1-4e41-95f7-e170d6eea168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:to="loc_us-gaap_Assets_75526cee-b6f1-4e41-95f7-e170d6eea168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7c811a85-13eb-4e5f-9919-bb62435919cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7c811a85-13eb-4e5f-9919-bb62435919cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e7a02409-a251-4f1a-bed2-91545cb0d17b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e7a02409-a251-4f1a-bed2-91545cb0d17b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bd6b69d2-3c9f-479c-aa14-ac4eef80267b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7440bbab-148e-4760-b9bf-5b43da7060b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd6b69d2-3c9f-479c-aa14-ac4eef80267b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7440bbab-148e-4760-b9bf-5b43da7060b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_de8552f1-bc71-4315-b1b2-cd28cb9697f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7440bbab-148e-4760-b9bf-5b43da7060b7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_de8552f1-bc71-4315-b1b2-cd28cb9697f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_de8552f1-bc71-4315-b1b2-cd28cb9697f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_de8552f1-bc71-4315-b1b2-cd28cb9697f2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_de8552f1-bc71-4315-b1b2-cd28cb9697f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00d8452b-aa14-4a7f-a921-cd211ac293e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_de8552f1-bc71-4315-b1b2-cd28cb9697f2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00d8452b-aa14-4a7f-a921-cd211ac293e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_3feca224-d083-45fe-b626-bcf878c4070c" xlink:href="dva-20241231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00d8452b-aa14-4a7f-a921-cd211ac293e8" xlink:to="loc_dva_DaVitaMedicalGroupMember_3feca224-d083-45fe-b626-bcf878c4070c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_d6d4c099-22fb-4c56-8573-d1f9e94e8e66" xlink:href="dva-20241231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd6b69d2-3c9f-479c-aa14-ac4eef80267b" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_d6d4c099-22fb-4c56-8573-d1f9e94e8e66" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="101"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="34"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>dva-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:47070f41-4839-4fd6-beb4-023e08dfe312,g:db2e526f-c810-4a70-bbc2-9b01e625d97f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_29bcd6fc-6901-479f-adbf-5ab8947aa46a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Distributions to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Distributions to Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:to="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_6a2fd5ef-9d3f-4c00-a38d-ccc602338468_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage of employees' base salary to be maintained into deferral account</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_036f97c0-279e-40cb-a602-9848b80091d2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_76295912-5dca-45d3-9a79-2cf795d69d97_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Berkshire Share Repurchase Agreement</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_945514b4-5393-4f63-b61f-79f2a4d3e158_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_7ea1ca95-d04a-4d9e-a3bc-25d3defb4754_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Carrying amount of long-term debt, net of unamortized discounts, premiums and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_3478286e-15d0-42d1-8202-f9cbd3d6caf5_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeThreeMember_ef825a26-0add-4de1-96c0-663fe58b31a0_terseLabel_en-US" xlink:label="lab_dva_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$70.01&#8211;$80.00</link:label>
    <link:label id="lab_dva_RangeThreeMember_label_en-US" xlink:label="lab_dva_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Three [Member]</link:label>
    <link:label id="lab_dva_RangeThreeMember_documentation_en-US" xlink:label="lab_dva_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeThreeMember" xlink:href="dva-20241231.xsd#dva_RangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeThreeMember" xlink:to="lab_dva_RangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_624013b9-f7fe-49ff-8602-ddbb07a8ba6b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8b5c064f-db00-46f0-ad08-da0867f7e501_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Less: Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EliminationsOfIntersegmentRevenues_c1767ea4-4f7e-4a84-9b0f-c407e2f07ccb_terseLabel_en-US" xlink:label="lab_dva_EliminationsOfIntersegmentRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eliminations of intersegment revenues</link:label>
    <link:label id="lab_dva_EliminationsOfIntersegmentRevenues_label_en-US" xlink:label="lab_dva_EliminationsOfIntersegmentRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eliminations of intersegment revenues</link:label>
    <link:label id="lab_dva_EliminationsOfIntersegmentRevenues_documentation_en-US" xlink:label="lab_dva_EliminationsOfIntersegmentRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eliminations of intersegment revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EliminationsOfIntersegmentRevenues" xlink:href="dva-20241231.xsd#dva_EliminationsOfIntersegmentRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EliminationsOfIntersegmentRevenues" xlink:to="lab_dva_EliminationsOfIntersegmentRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementDate_ac4ab024-0a54-4537-b5d3-25d1df29a653_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase Agreement, Date</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementDate_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreement, Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepurchaseAgreementDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementDate" xlink:to="lab_us-gaap_RepurchaseAgreementDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_c157c583-c395-4fe7-9865-62c6f8a35c53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AccountsReceivablePeriodOutstanding_c6bcd6ed-6d70-4e0d-81b3-939f85951d63_terseLabel_en-US" xlink:label="lab_dva_AccountsReceivablePeriodOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable Period Outstanding</link:label>
    <link:label id="lab_dva_AccountsReceivablePeriodOutstanding_label_en-US" xlink:label="lab_dva_AccountsReceivablePeriodOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable Period Outstanding</link:label>
    <link:label id="lab_dva_AccountsReceivablePeriodOutstanding_documentation_en-US" xlink:label="lab_dva_AccountsReceivablePeriodOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patient accounts receivable months outstanding to be reserved per company policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AccountsReceivablePeriodOutstanding" xlink:href="dva-20241231.xsd#dva_AccountsReceivablePeriodOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AccountsReceivablePeriodOutstanding" xlink:to="lab_dva_AccountsReceivablePeriodOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ae98c0bf-7f57-4894-9573-0457a9b6c865_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_722a8ae7-67ba-414a-b206-e8d1839c746c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_f96142bb-6efe-467f-815d-179195585993_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_0f990f5e-bc69-49ea-9c7a-8da84ae9409b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0f6ba5c1-c977-40a6-a982-53ed11da7d4e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_7a6c6f11-7b2d-4fdc-83d6-ff1e608df4f8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_164ebf82-f723-4174-b11c-b1bc774e9c3c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ab9b581d-eab9-479e-9316-d31a51f562c7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_412edf58-981d-4ccc-9d81-c7a412c2c86c_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_a9e8f20a-a691-4194-b34c-71ee9cda830c_terseLabel_en-US" xlink:label="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient service net revenues and accounts receivable</link:label>
    <link:label id="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_label_en-US" xlink:label="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition And Accounts Receivable Policy [Text Block]</link:label>
    <link:label id="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_documentation_en-US" xlink:label="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognition and accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:href="dva-20241231.xsd#dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:to="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_d31e90f1-50d6-4904-afa6-19d219839f0e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_6aa2d1e1-0604-4769-9e5b-88fd75d4ba38_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurements</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6a105a4e-ad89-4372-88a2-9676b0aace93_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8ca9c540-c276-4c23-8d1d-a3a84deb85c3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_a54c5f1e-c90e-4870-a228-fad8c398e8d3_terseLabel_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Increase Due To Acquisitions And Divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Increase Due To Acquisitions And Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20241231.xsd#dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_02bad43e-80f6-4951-a1e1-b2daec7c81ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4d687e8a-34c8-4786-9619-a71a7fbf42e4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3bf51afb-9356-4d07-ad6f-dab400fa3269_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_bfbfb5f4-5819-4194-bde6-5a6cc9723d37_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0e2cac68-98b0-471d-a4bb-0368f79388f1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_41a9d45d-7c74-4793-99a3-f1a34aea6b4c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e30eb3ba-6137-4e96-9eb9-f2602f77ce48_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0a11e763-aee2-44db-95ac-7691cf0ef468_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_f6ef464f-9958-481a-afd8-fadd63d9c7e1_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncreasedTermLoanA1Member_9847ce94-1605-4229-bdae-fca2385c0e71_terseLabel_en-US" xlink:label="lab_dva_IncreasedTermLoanA1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increased Term Loan A-1</link:label>
    <link:label id="lab_dva_IncreasedTermLoanA1Member_label_en-US" xlink:label="lab_dva_IncreasedTermLoanA1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increased Term Loan A-1 [Member]</link:label>
    <link:label id="lab_dva_IncreasedTermLoanA1Member_documentation_en-US" xlink:label="lab_dva_IncreasedTermLoanA1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increased Term Loan A-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreasedTermLoanA1Member" xlink:href="dva-20241231.xsd#dva_IncreasedTermLoanA1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncreasedTermLoanA1Member" xlink:to="lab_dva_IncreasedTermLoanA1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_8029421e-e33a-4b79-bbc2-dd0b933c1b0a_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of other information related to acquired intangibles and goodwill</link:label>
    <link:label id="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of other information related to acquisitions [Table Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of other information related to acquisitions, including weighted-average estimated useful lives of intangible assets acquired, and goodwill deductible for tax purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:href="dva-20241231.xsd#dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:to="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicareMember_d0387a0d-7031-4a22-9cf2-5ce6957a2268_terseLabel_en-US" xlink:label="lab_dva_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare bad debt claims</link:label>
    <link:label id="lab_dva_MedicareMember_label_en-US" xlink:label="lab_dva_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_dva_MedicareMember_documentation_en-US" xlink:label="lab_dva_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare governmental agency.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember" xlink:href="dva-20241231.xsd#dva_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicareMember" xlink:to="lab_dva_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_c92d66cf-9049-4b73-901e-0ecbcfb32b43_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_c6e0209a-b01b-4828-9a58-4115c97c57d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_51908af1-42e9-4525-b635-d16cb23d67e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_b87a197c-6ec3-45d9-bed9-ce6c46ceda8a_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Second Year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d0b9e3f1-3af3-481a-97bc-51ab0c5c11a1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5179f9af-c85a-45ed-86d3-accaabd23cd9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_efb4e1fc-e306-4f77-b729-b627238d2098_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_906b813a-d7a4-456a-bee1-3a860a59ec26_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DaVitaCarePte.Ltd.Member_08bacf75-ab69-4016-b3e6-d5b2a34d31fa_terseLabel_en-US" xlink:label="lab_dva_DaVitaCarePte.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DaVita Care Pte. Ltd.</link:label>
    <link:label id="lab_dva_DaVitaCarePte.Ltd.Member_label_en-US" xlink:label="lab_dva_DaVitaCarePte.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DaVita Care Pte. Ltd. [Member]</link:label>
    <link:label id="lab_dva_DaVitaCarePte.Ltd.Member_documentation_en-US" xlink:label="lab_dva_DaVitaCarePte.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DaVita Care Pte. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaCarePte.Ltd.Member" xlink:href="dva-20241231.xsd#dva_DaVitaCarePte.Ltd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DaVitaCarePte.Ltd.Member" xlink:to="lab_dva_DaVitaCarePte.Ltd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_360b017b-5e1b-4911-922a-502fe664b2a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e3f15e9b-98f7-4c98-9400-0259f1202e36_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_a14e2d0f-c575-49ce-b21a-0648d72ba78f_verboseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Leases term and discount rate</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4f0183e3-93a8-4dab-aa22-4b50efd3b353_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_fdda5639-daaf-4411-b008-71e4718e510f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4e4fa2b3-0723-4688-b871-7ccdefa4f1e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable Type</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4d586f44-938d-46db-935b-e32829ddd86c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f8c3562c-c6cb-484a-aef0-8541ccc93372_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_369a852d-0219-41fc-9dc0-dcc40f82cbe1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027_cffaf0b6-8c66-4b72-a86c-6f546fc7488f_terseLabel_en-US" xlink:label="lab_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage Any time Prior to September 1, 2027</link:label>
    <link:label id="lab_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027_label_en-US" xlink:label="lab_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage Any time Prior to September 1, 2027</link:label>
    <link:label id="lab_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027_documentation_en-US" xlink:label="lab_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage Any time Prior to September 1, 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027" xlink:href="dva-20241231.xsd#dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027" xlink:to="lab_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_da1898a8-db42-48fa-8b55-897831b8c5fd_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1bb05ba4-4fd6-4083-b5f0-3b634ea58b3b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e4c00055-5da9-46dc-9cb1-182b22686d40_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3bcdead5-78e7-4566-90f0-472303beea55_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2c908671-2069-4ce9-8620-21426f72f291_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_7e6dadb5-4624-4549-8786-1f3da2ebb15e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from accumulated other comprehensive income (losses) into net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicareandMedicareAdvantageMember_b67f0a67-e709-434f-a033-f010308c869a_terseLabel_en-US" xlink:label="lab_dva_MedicareandMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare and Medicare Advantage</link:label>
    <link:label id="lab_dva_MedicareandMedicareAdvantageMember_label_en-US" xlink:label="lab_dva_MedicareandMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare and Medicare Advantage [Member]</link:label>
    <link:label id="lab_dva_MedicareandMedicareAdvantageMember_documentation_en-US" xlink:label="lab_dva_MedicareandMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare and Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareandMedicareAdvantageMember" xlink:href="dva-20241231.xsd#dva_MedicareandMedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicareandMedicareAdvantageMember" xlink:to="lab_dva_MedicareandMedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOwnershipInterestMember_ca12b739-852b-4f80-a0d4-80c8426ba80c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOwnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other equity method partnerships</link:label>
    <link:label id="lab_us-gaap_OtherOwnershipInterestMember_label_en-US" xlink:label="lab_us-gaap_OtherOwnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Ownership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOwnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOwnershipInterestMember" xlink:to="lab_us-gaap_OtherOwnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0f72c9bb-9ace-4469-a87f-07c7b9471ac4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_a24133b3-c7d7-425e-9a9e-5c60f1117e22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of net realized gains into net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_38cf05f3-d940-4510-983b-5a69c7ed1f80_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_7b67b208-cfc0-447c-b5b5-4dd9c6e8e3a1_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of states where dialysis centers are located</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_59185ae9-2df3-4957-9893-398abf34d741_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition_406fbc95-9695-41c4-aa91-7e4958ae6466_terseLabel_en-US" xlink:label="lab_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant after Jun 30, 2026 - Subject to Increase during four fiscal quarters following a material acquisition</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition_label_en-US" xlink:label="lab_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant after Jun 30, 2026 - Subject to Increase during four fiscal quarters following a material acquisition</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition_documentation_en-US" xlink:label="lab_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant after Jun 30, 2026 - Subject to Increase during four fiscal quarters following a material acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition" xlink:to="lab_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseFromContributions_41d24397-1e32-4125-acfa-c00eb69eaae0_terseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseFromContributions_label_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest Increase From Contributions</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseFromContributions_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest increase from contributions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseFromContributions" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestIncreaseFromContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestIncreaseFromContributions" xlink:to="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ba844aa4-7ffa-43d0-8300-c6904c9170ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfafbf95-ab86-44b7-8fa7-3ed75f3a1aba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_705453db-8a90-4229-82e6-0e4ca333e4cc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive stock-settled awards excluded from calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_1a234aae-ac79-462c-ad14-d9408523ea5d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of debt investments held-to-maturity</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1f0b2dd5-7c48-435a-b1f8-50abf4504d01_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less portion representing interest, financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_883cfc40-7e8b-406e-9ed6-dfe89ed312d5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_62370c53-5018-4658-ac43-c098099d48d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts and Financing Receivables [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Financing Receivables [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ConstructiveFinancingCashOutflow_2de32c9a-25f5-4ac7-a864-a20527c01237_terseLabel_en-US" xlink:label="lab_dva_ConstructiveFinancingCashOutflow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Constructive Financing Cash Outflow</link:label>
    <link:label id="lab_dva_ConstructiveFinancingCashOutflow_label_en-US" xlink:label="lab_dva_ConstructiveFinancingCashOutflow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Constructive Financing Cash Outflow</link:label>
    <link:label id="lab_dva_ConstructiveFinancingCashOutflow_documentation_en-US" xlink:label="lab_dva_ConstructiveFinancingCashOutflow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Constructive Financing Cash Outflow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConstructiveFinancingCashOutflow" xlink:href="dva-20241231.xsd#dva_ConstructiveFinancingCashOutflow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ConstructiveFinancingCashOutflow" xlink:to="lab_dva_ConstructiveFinancingCashOutflow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_026894cd-9433-4df6-bea1-f506f7eb3de8_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_37ec7965-a742-45a5-ac98-86170511deb3_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_f86e069e-7e7e-47a2-b9b0-40ad67018e9a_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities_2dc7519f-0b21-4c00-8f49-9647d5953dbd_terseLabel_en-US" xlink:label="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="dva-20241231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4c0bd0d4-14eb-446d-99f8-72a36a53109a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1427f20c-cb75-47d8-8d78-9f6f38191ef6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_7e7700ee-e566-44d5-8295-801cf16bb187_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeOneMember_0ba5a020-4fb0-406b-bbcb-335ec45ccd70_terseLabel_en-US" xlink:label="lab_dva_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range One [Member]</link:label>
    <link:label id="lab_dva_RangeOneMember_label_en-US" xlink:label="lab_dva_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range One [Member]</link:label>
    <link:label id="lab_dva_RangeOneMember_documentation_en-US" xlink:label="lab_dva_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeOneMember" xlink:href="dva-20241231.xsd#dva_RangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeOneMember" xlink:to="lab_dva_RangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherCompaniesMember_efdffbac-ca2a-4076-9ef3-9e07e38d5d7f_terseLabel_en-US" xlink:label="lab_dva_OtherCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other companies</link:label>
    <link:label id="lab_dva_OtherCompaniesMember_label_en-US" xlink:label="lab_dva_OtherCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Companies [Member]</link:label>
    <link:label id="lab_dva_OtherCompaniesMember_documentation_en-US" xlink:label="lab_dva_OtherCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherCompaniesMember" xlink:href="dva-20241231.xsd#dva_OtherCompaniesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherCompaniesMember" xlink:to="lab_dva_OtherCompaniesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_90cac48f-d714-42be-897d-c10802caf4c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_672c6d84-6a25-44d7-a696-3e084deb33b5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_85c4120d-3898-42d0-ada4-c2c8d6e8e696_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_4cbdc278-8095-4289-bb89-1e2e75ad589e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_dac35838-a140-4f4d-a3b5-3b31433a0980_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeconsolidatedNoncontrollingEntityMember_dce5a2b6-a6a6-4e8b-a8be-daee92d18b29_terseLabel_en-US" xlink:label="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">APAC joint venture</link:label>
    <link:label id="lab_dva_DeconsolidatedNoncontrollingEntityMember_label_en-US" xlink:label="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidated Noncontrolling Entity [Member]</link:label>
    <link:label id="lab_dva_DeconsolidatedNoncontrollingEntityMember_documentation_en-US" xlink:label="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deconsolidated Noncontrolling Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember" xlink:href="dva-20241231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeconsolidatedNoncontrollingEntityMember" xlink:to="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_583aeef0-4a06-4494-a061-40c256b8f3a1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_193557ce-3223-4d5f-b869-e9c54c436914_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_081fe581-2f2a-41de-995f-e3bd6e88976b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_456c3bf3-4d99-42a5-91bb-2feec241f63a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Range of Exercise Prices</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_198124f4-831c-4947-bf96-4376939986b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency and other adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4edfee80-1275-4ce3-a3b6-9656c471c2db_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net income attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_87b942c4-1278-43c1-9e8a-904e401bdcda_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember_1e804884-d880-4bc0-87f1-ed66e361784e_terseLabel_en-US" xlink:label="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company and Restricted Subsidiaries</link:label>
    <link:label id="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember_label_en-US" xlink:label="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent Company And Restricted Subsidiaries [Member]</link:label>
    <link:label id="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember_documentation_en-US" xlink:label="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Parent company and restricted subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:href="dva-20241231.xsd#dva_ParentCompanyAndRestrictedSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:to="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8194a4f2-3bbc-432c-9b1e-65e16b3fbdae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_36f2c1e8-60b8-4f86-a3fe-1cb3cfe437ba_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_fcd8f0ff-83b2-49fd-abdf-e4dc05f01b5c_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_71e2cc68-7f84-423f-aa22-46be445c9c28_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7c3b3843-33b7-4c45-9520-1629f012b0e9_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_f993b6e7-0177-41ba-9a0f-5f022f6d4e72_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_ffc8fbac-d159-4d1a-b9e1-8e086769e93b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests not subject to put provisions</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_80d3cdf0-0343-4f42-85e6-b5f4b7b82993_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_ae7975bd-40b3-46b6-a356-9e3efee2437f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dda9470a-4727-4b41-8e9b-243ecd628718_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa1ddb0-5183-472e-8547-da0ac474f8f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_InternationalOperationsMember_9d97897e-f5ff-4e45-96bb-295c8c46573f_terseLabel_en-US" xlink:label="lab_dva_InternationalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International Operations</link:label>
    <link:label id="lab_dva_InternationalOperationsMember_label_en-US" xlink:label="lab_dva_InternationalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">International Operations [Member]</link:label>
    <link:label id="lab_dva_InternationalOperationsMember_documentation_en-US" xlink:label="lab_dva_InternationalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">International operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InternationalOperationsMember" xlink:href="dva-20241231.xsd#dva_InternationalOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_InternationalOperationsMember" xlink:to="lab_dva_InternationalOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_09e80727-a3a2-4255-96ec-e919de7bbf45_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_bf6a7442-2ed6-42ed-a1ac-28393bbf36d3_terseLabel_en-US" xlink:label="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible executive compensation</link:label>
    <link:label id="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_label_en-US" xlink:label="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Investment Impairment</link:label>
    <link:label id="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_documentation_en-US" xlink:label="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Investment Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:href="dva-20241231.xsd#dva_EffectiveIncomeTaxReconciliationInvestmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:to="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_257df4d4-b22e-463e-b25d-e979f8347e94_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_7dc7da18-931c-4365-b602-f6a6219017b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease cost:</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentRedemptionPriceIfChangeOfControl_9fd9d988-24b7-40f2-afda-9f6d3ebec3db_terseLabel_en-US" xlink:label="lab_dva_DebtInstrumentRedemptionPriceIfChangeOfControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, if change of control</link:label>
    <link:label id="lab_dva_DebtInstrumentRedemptionPriceIfChangeOfControl_label_en-US" xlink:label="lab_dva_DebtInstrumentRedemptionPriceIfChangeOfControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, if change of control</link:label>
    <link:label id="lab_dva_DebtInstrumentRedemptionPriceIfChangeOfControl_documentation_en-US" xlink:label="lab_dva_DebtInstrumentRedemptionPriceIfChangeOfControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, if change of control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentRedemptionPriceIfChangeOfControl" xlink:href="dva-20241231.xsd#dva_DebtInstrumentRedemptionPriceIfChangeOfControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentRedemptionPriceIfChangeOfControl" xlink:to="lab_dva_DebtInstrumentRedemptionPriceIfChangeOfControl" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_aa037756-ce89-4991-afc2-923300e7d76e_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual&#160;life</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c1b7b7f0-bb39-47ec-99f7-4bfb06fb1bbe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_20750055-e941-43c3-935a-ff19a5ecf127_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchases summary table</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b5cb3223-4ff7-4b78-bc8e-e39e3926db36_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross, total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60ea7c68-b14c-4372-8379-5ed54e1bd7da_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised/ Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_c3130f28-da46-4938-8d79-245f78f2eb91_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_30893294-f4d0-414f-b01c-b18dc45fcd3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_880c1ae9-ae58-4e46-8042-adf18a0cd689_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3e2b78dd-0e95-4bbf-83f7-66414689b7ae_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reductions related to lapse of applicable statute</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e3f6ee32-83ea-44b1-afcd-f5abf82ae00b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_017f6c28-7852-4f1c-a243-d290b675fa56_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_add2b814-003e-4509-87ce-343142c8c9d9_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_bebec669-020d-475a-8a36-75096d4a8f32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_51cfb719-6b6a-40fa-bb83-de91d84bd405_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Description of Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Description of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_2a83c42c-7b43-490d-acf9-e2df8e7422c6_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock_10bfd9b8-6eb4-4cab-a716-8287453a0542_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Minimum Lease Payments</link:label>
    <link:label id="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Minimum Lease Payments [Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of minimum lease payments under non-cancelable operating leases and capital leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:href="dva-20241231.xsd#dva_ScheduleOfMinimumLeasePaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:to="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_678dd4e8-70bb-4734-84e7-7b944a839178_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total DaVita Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_a0a69c69-e8d3-4abb-998b-a2d027cdb6f4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_88026937-5276-4f0e-82c9-05810ef5f9ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_35899fb4-a934-4334-aec3-03dfa71e74e0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_a09c991d-ef8d-4578-ab4e-20301e99f711_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_0e594cc5-db81-4e96-9e87-d144ea4a0177_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New center and capital asset projects in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_b27f8035-1a75-4b96-88da-947eaefc7c09_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d7caa954-1fea-42ef-a8e4-ad13743cb69f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_558cc50d-6ddf-440c-93a0-c1736da6decc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Carrying Value of Goodwill by Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_dade9d36-6255-4f19-a352-55ab94a3f620_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ForeignDialysisCentersMember_748963f8-58eb-4eec-8c8c-49dc7f2e28bd_terseLabel_en-US" xlink:label="lab_dva_ForeignDialysisCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Dialysis Centers</link:label>
    <link:label id="lab_dva_ForeignDialysisCentersMember_label_en-US" xlink:label="lab_dva_ForeignDialysisCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Dialysis Centers [Member]</link:label>
    <link:label id="lab_dva_ForeignDialysisCentersMember_documentation_en-US" xlink:label="lab_dva_ForeignDialysisCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign dialysis and other medical businesses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignDialysisCentersMember" xlink:href="dva-20241231.xsd#dva_ForeignDialysisCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ForeignDialysisCentersMember" xlink:to="lab_dva_ForeignDialysisCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_038e5049-7f9a-4885-a286-57046fff05b2_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_4cddb3d9-132f-4897-9b8c-a3de80a9e509_terseLabel_en-US" xlink:label="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Interest Rate Cap Agreements Effective June 30, 2020</link:label>
    <link:label id="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_label_en-US" xlink:label="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Interest Rate Cap Agreements Effective June 30, 2020 [Member]</link:label>
    <link:label id="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_documentation_en-US" xlink:label="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Interest Rate Cap Agreements Effective June 30, 2020.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:href="dva-20241231.xsd#dva_A2019InterestRateCapAgreementsEffectiveJune302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:to="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentThroughJune302027_dfc9cca5-df0d-454f-8ff1-4ec1bc324340_terseLabel_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentThroughJune302027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Quarterly Payment Through June 30, 2027</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentThroughJune302027_label_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentThroughJune302027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Quarterly Payment Through June 30, 2027</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentThroughJune302027_documentation_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentThroughJune302027" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Quarterly Payment Through June 30, 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentThroughJune302027" xlink:href="dva-20241231.xsd#dva_DebtInstrumentQuarterlyPaymentThroughJune302027"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentQuarterlyPaymentThroughJune302027" xlink:to="lab_dva_DebtInstrumentQuarterlyPaymentThroughJune302027" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_1a523c79-2cba-4a4e-9d76-b0d82910e9db_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of other debt and equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCapMember_efcdb9eb-188f-498c-87f9-923e2364aa82_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Cap</link:label>
    <link:label id="lab_us-gaap_InterestRateCapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Cap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateCapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCapMember" xlink:to="lab_us-gaap_InterestRateCapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_e4c96358-e90d-40a4-b702-a66115fc1dbf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (losses) gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_51f26cf1-2e5d-4417-8069-96eb4c3c8a00_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e6312c9d-7b3a-464c-9598-17ed1769e753_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ac6cda8d-8543-4a54-a195-da87b95937f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumed incremental shares from stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_3863f32f-837c-413b-a74b-c71871031085_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_e5d90b69-e699-41ec-93f3-5f341f2e9ccf_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted cost method and other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInceptionDates_f25da4ba-7650-443a-bb29-fee099cfd844_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInceptionDates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, effective date</link:label>
    <link:label id="lab_us-gaap_DerivativeInceptionDates_label_en-US" xlink:label="lab_us-gaap_DerivativeInceptionDates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Inception Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInceptionDates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInceptionDates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInceptionDates" xlink:to="lab_us-gaap_DerivativeInceptionDates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e823c0ef-d5c9-45f8-b20e-c67075078049_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d59cde16-1386-438d-be7e-1e767bed6cc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill deductible for tax purposes associated with acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_51a219a8-a22b-4930-bef6-33c5c631e21c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6ba47581-6196-4d11-9d6d-7311f3afafe8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_cb27ab95-d278-445f-8459-d23bd832b10c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_1ed975e1-b647-451e-8d78-d16eefbf4b05_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_40b52ad6-01f3-41e1-a0be-23a448ccffc1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0cde7f60-e7f3-4d92-b9ab-d05e5fff3f1d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7b930454-74df-40f2-9b7b-33b7fea3952c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1ad0f1d9-cb7c-411b-817a-643a951cef85_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_039c2b26-8f0b-4137-a207-d4347fd43864_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_e405ded8-b71d-49c3-984e-a66deb25f726_terseLabel_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_label_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_documentation_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election Effective date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:href="dva-20241231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:to="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember_8c333f69-1400-4cb5-821d-12aa36d7401d_terseLabel_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U S Dialysis And Related Lab Services with Intersegment</link:label>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember_label_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U S Dialysis And Related Lab Services with Intersegment [Member]</link:label>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember_documentation_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U S Dialysis And Related Lab Services with Intersegment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesWithIntersegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember" xlink:to="lab_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAverageFixedInterestRate_3da55160-7e28-4ae3-982e-46dc04bf098d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAverageFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Average Fixed Interest Rate</link:label>
    <link:label id="lab_us-gaap_DerivativeAverageFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeAverageFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Average Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAverageFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAverageFixedInterestRate" xlink:to="lab_us-gaap_DerivativeAverageFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4b33c7bb-6d3d-4ef6-a58c-02ae6477dd51_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bb0abf01-8705-4bc3-b7b3-538eb268759f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_6a198af4-15e9-4b9e-a16c-ea0994bedfb8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_c2a9e293-f947-4e63-b9be-d6b470c806c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_451fbaf2-02ad-492b-8451-484f8b349619_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scheduled Amortization Charges from Intangible Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_f03eaba1-326c-4fd3-b575-ae3a8a4d7113_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a4f7a00f-96b8-4681-b2a8-264e056bc21e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_e1266f8b-1aa0-43e9-9385-dddd40679d9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_57460133-8f40-4c41-9f2a-89efb7e87ce7_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_c50a647c-1a1a-4322-a6d6-1efcf86a6b70_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IKCVBCArrangementsMember_906c7a09-dc34-4976-ad8c-3ae6a38303ca_terseLabel_en-US" xlink:label="lab_dva_IKCVBCArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IKC VBC arrangements</link:label>
    <link:label id="lab_dva_IKCVBCArrangementsMember_label_en-US" xlink:label="lab_dva_IKCVBCArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IKC VBC arrangements [Member]</link:label>
    <link:label id="lab_dva_IKCVBCArrangementsMember_documentation_en-US" xlink:label="lab_dva_IKCVBCArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IKC VBC arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IKCVBCArrangementsMember" xlink:href="dva-20241231.xsd#dva_IKCVBCArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IKCVBCArrangementsMember" xlink:to="lab_dva_IKCVBCArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_77450fa3-c3a9-4b4d-a3e9-60118cda69a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_5776117d-b9f6-429d-be73-fa6cce312abf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c8471ffa-9349-4a8a-a1e7-125d88b2bfbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Weighted Average Valuation Inputs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_85c232d7-6938-42c1-ad52-8a8a85318632_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_998c434a-0ccb-4862-9f08-1a44bc46624b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_bd3416db-b9be-4f00-8dfe-63360d01e353_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_64ec3788-238d-4369-ab74-afd6d9af577e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88deee99-7897-4fc3-a9a8-2ed83151523c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherOperatingSegmentsWithIntersegmentMember_bf1e273e-6062-44e4-85c5-048043f8124b_terseLabel_en-US" xlink:label="lab_dva_OtherOperatingSegmentsWithIntersegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Operating Segments with Intersegment</link:label>
    <link:label id="lab_dva_OtherOperatingSegmentsWithIntersegmentMember_label_en-US" xlink:label="lab_dva_OtherOperatingSegmentsWithIntersegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Segments with Intersegment [Member]</link:label>
    <link:label id="lab_dva_OtherOperatingSegmentsWithIntersegmentMember_documentation_en-US" xlink:label="lab_dva_OtherOperatingSegmentsWithIntersegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Segments with Intersegment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherOperatingSegmentsWithIntersegmentMember" xlink:href="dva-20241231.xsd#dva_OtherOperatingSegmentsWithIntersegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherOperatingSegmentsWithIntersegmentMember" xlink:to="lab_dva_OtherOperatingSegmentsWithIntersegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_2d830a8c-b7f3-4779-b3aa-b198cb47ffd6_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Added by performance factor (in shares)</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_91c9e523-5fdd-4997-8c4e-f663e5310ce7_terseLabel_en-US" xlink:label="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Expenditures for Property and Equipment by Segment</link:label>
    <link:label id="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_label_en-US" xlink:label="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Capital Expenditures For Property And Equipment From Segment To Consolidated Table [Text Block]</link:label>
    <link:label id="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_documentation_en-US" xlink:label="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of capital expenditures for property and equipment from segment to consolidated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:href="dva-20241231.xsd#dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:to="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_eae69d50-b4a2-4aff-9e09-8fc9d339473b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Previously Held Equity Interests</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f7678b96-d81a-4c7f-91b3-e141b1e69df7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_7ec211a4-4ebe-43ca-be79-d8e327f034db_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9007cb21-7973-4778-a531-ab6aacdee57d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_ef73c217-634c-41b2-b6d4-3577220e9bdc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_12d4fac3-3d02-40cb-a5ea-8908cb29450a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_1f7bc282-e47d-473d-a1c5-5da2968ae261_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanA1AndRevolverMember_4f3ea19d-7673-459c-b913-8ac3a5f80ef7_terseLabel_en-US" xlink:label="lab_dva_TermLoanA1AndRevolverMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan A-1 and Revolver</link:label>
    <link:label id="lab_dva_TermLoanA1AndRevolverMember_label_en-US" xlink:label="lab_dva_TermLoanA1AndRevolverMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A-1 and Revolver [Member]</link:label>
    <link:label id="lab_dva_TermLoanA1AndRevolverMember_documentation_en-US" xlink:label="lab_dva_TermLoanA1AndRevolverMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan A-1 and Revolver</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1AndRevolverMember" xlink:href="dva-20241231.xsd#dva_TermLoanA1AndRevolverMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanA1AndRevolverMember" xlink:to="lab_dva_TermLoanA1AndRevolverMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanA1Member_6cbe08cc-622f-4410-8757-e5c85aec8d30_terseLabel_en-US" xlink:label="lab_dva_TermLoanA1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan A-1</link:label>
    <link:label id="lab_dva_TermLoanA1Member_label_en-US" xlink:label="lab_dva_TermLoanA1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A-1 [Member]</link:label>
    <link:label id="lab_dva_TermLoanA1Member_documentation_en-US" xlink:label="lab_dva_TermLoanA1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan A-1 Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member" xlink:href="dva-20241231.xsd#dva_TermLoanA1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanA1Member" xlink:to="lab_dva_TermLoanA1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_7b20472b-b195-412a-923e-b4222245f498_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, long-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_e41c0bd9-afc6-44fa-9a93-a43a399b58c6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of ordinary dividends, common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_502af604-4819-43dd-8de5-45ebe8e23998_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_1e151c27-650c-40ca-8b4e-2811f68b36df_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Cumulative measured cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_73a05542-afe6-4221-8b75-691fd5ab5dea_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_beb7bb12-c7d5-467e-b75a-b78c4300150f_terseLabel_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_label_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_documentation_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization consolidation and presentation of financial statements disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:href="dva-20241231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_43aec01a-7f62-4820-8265-40c2347422c3_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_932a6f85-e7e0-4d2a-b005-e4c0d2986e6e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0c0c8160-53e3-4533-bece-c2950a53eb9a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net income</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_39e1b49b-7553-44ee-9d16-1a5e0c1dda00_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted net income per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_bc88aa78-9efe-49dd-a492-9a16b9bd84f0_terseLabel_en-US" xlink:label="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earn-out consideration payment period</link:label>
    <link:label id="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_label_en-US" xlink:label="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Contingent Consideration Revenue Earnout Period</link:label>
    <link:label id="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_documentation_en-US" xlink:label="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition contingent consideration revenue earn-out period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:href="dva-20241231.xsd#dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:to="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExtendedTermLoanB1Member_4dc6b09f-610e-4db1-9e5d-e5304b267aeb_terseLabel_en-US" xlink:label="lab_dva_ExtendedTermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended Term Loan B-1</link:label>
    <link:label id="lab_dva_ExtendedTermLoanB1Member_label_en-US" xlink:label="lab_dva_ExtendedTermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extended Term Loan B-1 [Member]</link:label>
    <link:label id="lab_dva_ExtendedTermLoanB1Member_documentation_en-US" xlink:label="lab_dva_ExtendedTermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extended Term Loan B-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExtendedTermLoanB1Member" xlink:href="dva-20241231.xsd#dva_ExtendedTermLoanB1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExtendedTermLoanB1Member" xlink:to="lab_dva_ExtendedTermLoanB1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_b918a83a-cc58-4a28-8773-35f740bb4b64_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a3e6177c-3e72-4b1e-83e6-30765c317edf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_3ba09f83-b5fa-4e22-92cd-08a21c08a66f_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current income tax</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_6194e9c2-32d4-4186-a1fb-04a273cf4bdf_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherSourcesofRevenueMember_12fd4d6f-ed6d-4ec7-8cc6-a9f15946126d_terseLabel_en-US" xlink:label="lab_dva_OtherSourcesofRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dva_OtherSourcesofRevenueMember_label_en-US" xlink:label="lab_dva_OtherSourcesofRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sources of Revenue [Member]</link:label>
    <link:label id="lab_dva_OtherSourcesofRevenueMember_documentation_en-US" xlink:label="lab_dva_OtherSourcesofRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other sources of revenue (management fees and revenue from the Company's ancillary services and strategic initiatives).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSourcesofRevenueMember" xlink:href="dva-20241231.xsd#dva_OtherSourcesofRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherSourcesofRevenueMember" xlink:to="lab_dva_OtherSourcesofRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_7f1939f5-2522-4a94-9040-b39980489dcb_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortizable intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_97849801-d51a-4474-963e-9a03ef59773e_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_fff97075-9c7d-475b-a266-08801db43722_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution, percent of employees' gross wages</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3e239ec8-4942-44b6-9f24-68101b3c2e35_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LoansTypeDomain_319b8d9b-919c-4dfa-9694-1f16c5e19473_terseLabel_en-US" xlink:label="lab_dva_LoansTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans Type [Domain]</link:label>
    <link:label id="lab_dva_LoansTypeDomain_label_en-US" xlink:label="lab_dva_LoansTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Type [Domain]</link:label>
    <link:label id="lab_dva_LoansTypeDomain_documentation_en-US" xlink:label="lab_dva_LoansTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeDomain" xlink:href="dva-20241231.xsd#dva_LoansTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LoansTypeDomain" xlink:to="lab_dva_LoansTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_14351ea8-6401-4456-96a9-f83d28022481_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_88c2ade3-7a6a-4540-86e8-ad494e457b3c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_abd9c679-2b9c-47f0-8e34-e2aaa41f1a0a_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_fb062985-5d1c-4bd3-ba55-3541ae1c620a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_154fb430-fa2a-4472-8bbd-3b65d95577d3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_73db23b4-ffd2-4ec5-959c-d9b830edcd3e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e92b8452-2a5e-4784-a487-5074b31d8fff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_3c7c810a-0149-4d44-ad10-cd1669004501_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate cap agreements</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_3727af10-9be4-46a4-8ec6-b76ec4bf34b9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross_afd680de-8140-4a24-a99f-dbde1bb18b4d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncompetition agreements</link:label>
    <link:label id="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Noncompete Agreements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:to="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d9ae0a68-c4f3-4c95-b177-de7bed987510_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_2a8e6e7d-6abc-43c3-82df-626bbbad5703_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_29a000d0-a908-42a3-9733-e3f37dceadf5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e6657b7e-557e-41d3-abdd-0abad083e117_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ConstructiveFinancingCashInflow_d52acc18-ebb2-4442-9c7a-69fa46395740_terseLabel_en-US" xlink:label="lab_dva_ConstructiveFinancingCashInflow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Constructive Financing Cash Inflow</link:label>
    <link:label id="lab_dva_ConstructiveFinancingCashInflow_label_en-US" xlink:label="lab_dva_ConstructiveFinancingCashInflow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Constructive Financing Cash Inflow</link:label>
    <link:label id="lab_dva_ConstructiveFinancingCashInflow_documentation_en-US" xlink:label="lab_dva_ConstructiveFinancingCashInflow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Constructive Financing Cash Inflow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConstructiveFinancingCashInflow" xlink:href="dva-20241231.xsd#dva_ConstructiveFinancingCashInflow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ConstructiveFinancingCashInflow" xlink:to="lab_dva_ConstructiveFinancingCashInflow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_fdc52b2b-e93c-452a-9e5a-b0e047393c87_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7296ad71-30b1-469c-8331-e27cfd4f18d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_26f682e0-b8bc-4988-8ca0-6174cc9f7054_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_99fb31cf-137f-4bc5-8f6f-0d23efa16f05_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_d413b017-3cc0-4444-bad8-a775798c4523_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investments and other investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockSettledStockAppreciationRightsMember_fffe2238-502e-447c-8a8c-4edeebeac6df_terseLabel_en-US" xlink:label="lab_dva_StockSettledStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-settled Stock Appreciation Rights</link:label>
    <link:label id="lab_dva_StockSettledStockAppreciationRightsMember_label_en-US" xlink:label="lab_dva_StockSettledStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-Settled Stock Appreciation Rights [Member]</link:label>
    <link:label id="lab_dva_StockSettledStockAppreciationRightsMember_documentation_en-US" xlink:label="lab_dva_StockSettledStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-Settled Stock Appreciation Rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember" xlink:href="dva-20241231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockSettledStockAppreciationRightsMember" xlink:to="lab_dva_StockSettledStockAppreciationRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_b99f6274-1ffd-4766-9483-f9b1c7bf7b23_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_14d04941-1ca2-4a9a-8790-fb3b0ee40721_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TransplantSoftwareReportingUnitMember_5e9bb8f0-712f-4eaf-befc-d88535b9eb69_terseLabel_en-US" xlink:label="lab_dva_TransplantSoftwareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transplant Software Reporting Unit</link:label>
    <link:label id="lab_dva_TransplantSoftwareReportingUnitMember_label_en-US" xlink:label="lab_dva_TransplantSoftwareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transplant Software Reporting Unit [Member]</link:label>
    <link:label id="lab_dva_TransplantSoftwareReportingUnitMember_documentation_en-US" xlink:label="lab_dva_TransplantSoftwareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transplant Software Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember" xlink:href="dva-20241231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TransplantSoftwareReportingUnitMember" xlink:to="lab_dva_TransplantSoftwareReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_4b85915c-287c-4afe-883d-3a26b4d9cf29_terseLabel_en-US" xlink:label="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on disposition of business, additional purchase price payment</link:label>
    <link:label id="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_label_en-US" xlink:label="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on disposition of business, additional purchase price payment</link:label>
    <link:label id="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_documentation_en-US" xlink:label="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on disposition of business, additional purchase price payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:href="dva-20241231.xsd#dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:to="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_8d9e2842-75b2-4774-ab30-5775f5c9c1c7_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_59a2fedf-009b-4dd2-9089-4d92a60d72ba_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2eb389af-e43e-4ba3-bcd8-ae84d2219df5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f6db91da-7436-4197-b690-e7f915241d3b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_e8ce3dd5-c00b-4472-bc25-d894125c7202_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7d8df624-f53d-4b43-9ce9-5910483dcea3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_e22705dc-5ebb-4401-bdd9-b8706833b002_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments Consolidation Items</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e64edace-425e-450a-a0cb-e41c7c11f385_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_7c36ccf6-44c2-4e27-9332-24324115cac5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CHCTemporaryFundingAssistance_29e071e9-9006-463a-9183-35694d8c32cf_terseLabel_en-US" xlink:label="lab_dva_CHCTemporaryFundingAssistance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHC Temporary Funding Assistance</link:label>
    <link:label id="lab_dva_CHCTemporaryFundingAssistance_label_en-US" xlink:label="lab_dva_CHCTemporaryFundingAssistance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHC Temporary Funding Assistance</link:label>
    <link:label id="lab_dva_CHCTemporaryFundingAssistance_documentation_en-US" xlink:label="lab_dva_CHCTemporaryFundingAssistance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CHC Temporary Funding Assistance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CHCTemporaryFundingAssistance" xlink:href="dva-20241231.xsd#dva_CHCTemporaryFundingAssistance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CHCTemporaryFundingAssistance" xlink:to="lab_dva_CHCTemporaryFundingAssistance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d097b9fc-5599-4562-b5d4-ede213966746_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9c9e0a9a-1469-4884-8475-a38c06022271_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_11c2ffa4-fcba-424c-88b4-fca0a5e34fab_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurements</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4f925ee0-ff4b-4240-b309-cb36a19c6aaf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eb52a090-58c5-401a-af9a-c89b9c8c9906_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1f3b935e-0082-4e05-a4b9-d4148616faab_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment income from equity method investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_3d4926d3-58ee-4bfd-bc45-a436c2f4c69c_negatedTerseLabel_en-US" xlink:label="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Decrease Due To Acquisitions and Divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Decrease Due To Acquisitions and Divestitures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20241231.xsd#dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_b522785b-6c42-4062-bd6e-516908a1aade_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Asset Categories</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_90cc463e-2c34-4e01-93a1-db1d92afe194_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_97f53b50-b5d0-49c4-b8ca-5af812ad01f7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_52f3826d-e670-441d-9779-410f00d38ab0_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_c05ea4ed-da2f-4bb3-90a6-d56023fc5400_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeFiveMember_a585c0f3-e64e-4ccc-95bb-36b0abf79915_terseLabel_en-US" xlink:label="lab_dva_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$110.01&#8211;$120.00</link:label>
    <link:label id="lab_dva_RangeFiveMember_label_en-US" xlink:label="lab_dva_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Five [Member]</link:label>
    <link:label id="lab_dva_RangeFiveMember_documentation_en-US" xlink:label="lab_dva_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFiveMember" xlink:href="dva-20241231.xsd#dva_RangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeFiveMember" xlink:to="lab_dva_RangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7818f324-1cf5-4173-9b9e-687b73716fb8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureLineItems_64066a12-802b-45ee-ad84-e15f4b18100d_terseLabel_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureLineItems_label_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureLineItems_documentation_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:href="dva-20241231.xsd#dva_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_05f76a8e-1138-496c-8371-c86b490eced7_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeMaturityDates_b8d70dac-4be0-4a0c-a39c-e1085bc8cc49_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeMaturityDates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative, contractual maturity date</link:label>
    <link:label id="lab_us-gaap_DerivativeMaturityDates_label_en-US" xlink:label="lab_us-gaap_DerivativeMaturityDates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Contract End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMaturityDates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeMaturityDates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeMaturityDates" xlink:to="lab_us-gaap_DerivativeMaturityDates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dbac17e2-7748-4ce3-8ca1-36bd918b2bd9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in international valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06c4e702-4843-438c-9a70-77b31fe91a26_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5dc6b2a6-7a9b-4cca-b0ac-a312766212e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of year (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b8feb8b9-8e28-4978-bb5c-c054bc8beace_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeTaxesLineItems_683bdb7a-425d-4c6e-81a4-ab421b9a84c5_terseLabel_en-US" xlink:label="lab_dva_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_dva_IncomeTaxesLineItems_label_en-US" xlink:label="lab_dva_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_dva_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_dva_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems" xlink:href="dva-20241231.xsd#dva_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeTaxesLineItems" xlink:to="lab_dva_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2e9794c7-e048-4057-8df1-433a2baa5d43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_4fb5a12f-b42f-4e48-9b15-3833f23f8415_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ef9b9f0-3ff7-4604-ae87-d00d5a74aaea_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f46163fc-8f4d-4b3d-8cd4-ac06a60102e5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtRefinancingCharges_fa214fb2-8aa9-4a0b-9131-7cea1e28c63d_terseLabel_en-US" xlink:label="lab_dva_DebtRefinancingCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_dva_DebtRefinancingCharges_label_en-US" xlink:label="lab_dva_DebtRefinancingCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Refinancing Charges</link:label>
    <link:label id="lab_dva_DebtRefinancingCharges_documentation_en-US" xlink:label="lab_dva_DebtRefinancingCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt prepayment refinancing redemption charges related to debt modification of long-term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtRefinancingCharges" xlink:href="dva-20241231.xsd#dva_DebtRefinancingCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtRefinancingCharges" xlink:to="lab_dva_DebtRefinancingCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f799271b-f19c-4e68-a04f-eb306034c3a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_29da059c-cf78-4ab7-a3fa-619b0014d4d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Credit Facilities:</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract" xlink:to="lab_us-gaap_DebtInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_9519d647-7f94-4030-8501-450ab0ff15df_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_9db77cbe-621d-4f5f-8075-6d206246e856_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommercialPayorsMember_be89507b-9089-4d62-8eef-0a47d866274d_terseLabel_en-US" xlink:label="lab_dva_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Payors</link:label>
    <link:label id="lab_dva_CommercialPayorsMember_label_en-US" xlink:label="lab_dva_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Payors [Member]</link:label>
    <link:label id="lab_dva_CommercialPayorsMember_documentation_en-US" xlink:label="lab_dva_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Payors in healthcare industry.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommercialPayorsMember" xlink:href="dva-20241231.xsd#dva_CommercialPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommercialPayorsMember" xlink:to="lab_dva_CommercialPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_6eda3778-8303-48c1-8b8b-3d7f1b639a1a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IndefiniteLifeNetOperatingLossesMember_e66451c4-e5c4-4720-a24b-6c27e522a578_terseLabel_en-US" xlink:label="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite Life Net Operating Losses</link:label>
    <link:label id="lab_dva_IndefiniteLifeNetOperatingLossesMember_label_en-US" xlink:label="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Life Net Operating Losses [Member]</link:label>
    <link:label id="lab_dva_IndefiniteLifeNetOperatingLossesMember_documentation_en-US" xlink:label="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite Life Net Operating Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IndefiniteLifeNetOperatingLossesMember" xlink:href="dva-20241231.xsd#dva_IndefiniteLifeNetOperatingLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IndefiniteLifeNetOperatingLossesMember" xlink:to="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_255d8f56-cc0a-4f65-9f1c-2f50969b6b40_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_313635c1-8b5f-45e7-ba47-7a3c677bd837_terseLabel_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third-Party Payor</link:label>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_label_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third-Party Payor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThirdPartyPayorMember" xlink:to="lab_us-gaap_ThirdPartyPayorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_194a02be-55a4-43d7-9d49-49e19f09e539_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6c4c1c68-e5bc-4bf5-a715-14d7813a4f07_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_16155723-bc35-431f-8c35-142961e34842_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_d901735d-8daa-4486-b6fc-759238009e52_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_df3a00b1-b73c-46b4-88fb-f869e1c3941a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_11b5d68d-b0e6-4561-9c11-21009c97703d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5f507bb5-c1b5-435b-b108-fe65807e23fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value of grants (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_a5e21772-2e71-4d29-9e38-08f8cfea75a0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract" xlink:to="lab_us-gaap_LesseeDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfPartnerships_ce03f383-301d-4d20-8516-bd8c11a08ef9_terseLabel_en-US" xlink:label="lab_dva_NumberOfPartnerships" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of equity method investments</link:label>
    <link:label id="lab_dva_NumberOfPartnerships_label_en-US" xlink:label="lab_dva_NumberOfPartnerships" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Partnerships</link:label>
    <link:label id="lab_dva_NumberOfPartnerships_documentation_en-US" xlink:label="lab_dva_NumberOfPartnerships" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Partnerships that are included in the Equity Investments category.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfPartnerships" xlink:href="dva-20241231.xsd#dva_NumberOfPartnerships"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfPartnerships" xlink:to="lab_dva_NumberOfPartnerships" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_1e7c2b57-388f-4179-9976-d1eaf7a23b5a_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_37213a02-feb0-4a20-bf1c-aa6589b19f5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_9338afd3-e6bd-4d49-89fd-71038708b0df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_16fcb5db-be16-4f29-8a10-7dc5a8d7d8a7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_1fdc8f6f-db93-4e07-911b-d7614b509cdf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fc2da59e-2ded-441f-863f-df70b07e15ae_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_049ea687-533d-4320-8864-a57d87c778a7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceAgreementsMember_00fdd41d-3185-4fa8-9530-420a8b92942a_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships and other</link:label>
    <link:label id="lab_us-gaap_ServiceAgreementsMember_label_en-US" xlink:label="lab_us-gaap_ServiceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceAgreementsMember" xlink:to="lab_us-gaap_ServiceAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_f793725b-8c68-448d-96c2-37eca2943561_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests Subject to Put Provisions and Other Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_e332d707-8a16-4db7-93d8-c14f27e42577_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_4208afb2-67bb-4083-b6b0-83c8b45df053_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Routine Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Noncash or Part Noncash Acquisitions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:to="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58b23634-d2cb-4b7c-92fc-be234da20a22_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_a5fb8e02-8a47-41d2-93a9-59c22181e50f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cbe6a017-4817-403b-8dbf-1de46e0e127d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_14834f11-6fcb-4500-9277-2121e2e656ff_terseLabel_en-US" xlink:label="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Term Debt Percentage Bearing Economically Fixed Interest Rate</link:label>
    <link:label id="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_label_en-US" xlink:label="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Debt Percentage Bearing Economically Fixed Interest Rate</link:label>
    <link:label id="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_documentation_en-US" xlink:label="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long Term Debt Percentage Bearing Economically Fixed Interest Rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:href="dva-20241231.xsd#dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:to="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_78011893-4562-4583-bc23-b74a7dbb1966_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity investment income, net</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_a30a50fe-2d5b-41ec-b960-c06c927b0c07_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_a291b323-36cf-402f-aaa8-b6af300a8ac3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Net Minimum Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_FinanceLeaseAccumulatedDepreciation_4625597e-28d3-47b9-959b-13bd87812e9c_terseLabel_en-US" xlink:label="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease Accumulated Depreciation</link:label>
    <link:label id="lab_dva_FinanceLeaseAccumulatedDepreciation_label_en-US" xlink:label="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease Accumulated Depreciation</link:label>
    <link:label id="lab_dva_FinanceLeaseAccumulatedDepreciation_documentation_en-US" xlink:label="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease Accumulated Depreciation, contra asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseAccumulatedDepreciation" xlink:href="dva-20241231.xsd#dva_FinanceLeaseAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_FinanceLeaseAccumulatedDepreciation" xlink:to="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OperatingLeaseMember_5f1e447d-babc-448a-8f77-ff2f921d64f1_terseLabel_en-US" xlink:label="lab_dva_OperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease</link:label>
    <link:label id="lab_dva_OperatingLeaseMember_label_en-US" xlink:label="lab_dva_OperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease [Member]</link:label>
    <link:label id="lab_dva_OperatingLeaseMember_documentation_en-US" xlink:label="lab_dva_OperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OperatingLeaseMember" xlink:href="dva-20241231.xsd#dva_OperatingLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OperatingLeaseMember" xlink:to="lab_dva_OperatingLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesMember_91fa4382-25ec-4a93-a891-2294ba61001c_terseLabel_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. dialysis</link:label>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesMember_label_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U S Dialysis And Related Lab Services [Member]</link:label>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesMember_documentation_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US dialysis &#8203;and &#8203;related &#8203;lab&#8203; services&#8203;.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_USDialysisAndRelatedLabServicesMember" xlink:to="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_cf5682c3-7e5f-4972-b546-cf83b6dd0f90_terseLabel_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_label_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:to="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_12834cdd-713c-49b8-a0fa-4c3e4d9b7121_terseLabel_en-US" xlink:label="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dialysis patient service revenues</link:label>
    <link:label id="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_label_en-US" xlink:label="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts</link:label>
    <link:label id="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_documentation_en-US" xlink:label="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:href="dva-20241231.xsd#dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:to="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_e47cb1d3-5c71-43f6-a0fd-f67cc5ad30c6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information footnote:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information, Operating Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_b066c087-5de7-4216-bc29-1f1bc9bbbf0b_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net income from discontinued operations per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9c8bee72-870b-4ac2-ab18-c5bef68fd3ea_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b202f72c-ff34-471c-a69c-3713c2aee011_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0b862e88-9424-4a6e-a742-e5c02340bf96_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member_84fcd5b0-64a8-44b2-ba19-4c881c06d908_terseLabel_en-US" xlink:label="lab_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Interest Rate Cap Agreements 4.50% Effective December 31 2025</link:label>
    <link:label id="lab_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member_label_en-US" xlink:label="lab_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Interest Rate Cap Agreements 4.50% Effective December 31 2025 [Member]</link:label>
    <link:label id="lab_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member_documentation_en-US" xlink:label="lab_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Interest Rate Cap Agreements 4.50% Effective December 31 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member" xlink:href="dva-20241231.xsd#dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member" xlink:to="lab_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract_e16508b5-dfd6-43de-89c8-f37f048fc4b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, footnotes to the table</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:to="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2752d7c6-a2ee-4029-81ca-8ee3fe000058_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_c983fd97-847c-48aa-bf71-e4ec39584afd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OwnershipPercentageByNoncontrollingOwners_c22cca8b-243e-4851-b872-aa2005cc3ddb_terseLabel_en-US" xlink:label="lab_dva_OwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current economic interest in the APAC JV, Owned by Other Noncontrolling Investors</link:label>
    <link:label id="lab_dva_OwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_dva_OwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Percentage By Noncontrolling Owners</link:label>
    <link:label id="lab_dva_OwnershipPercentageByNoncontrollingOwners_documentation_en-US" xlink:label="lab_dva_OwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ownership Percentage By Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OwnershipPercentageByNoncontrollingOwners" xlink:href="dva-20241231.xsd#dva_OwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OwnershipPercentageByNoncontrollingOwners" xlink:to="lab_dva_OwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94c9a312-2fec-4285-aaff-a5ad4e0ec470_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_5978da7c-de5a-4152-ad86-4e4a863a398b_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investments in partnerships</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7c90229c-a9d5-4fc7-bf20-15c918774105_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock purchase price as percentage of fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotes_36f20b9c-a141-490f-bcb5-d4cb165035dc_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_label_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_42702e08-9a30-47be-8136-8de26408643f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_918de7b2-b334-414f-af08-1beca83cc3b8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6d801efc-ac1b-4ebc-9206-cab378cf15b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2d66b4f9-b2d2-4a89-8f93-04f450b6080b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Asset Categories</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_737b9e7a-da01-42a4-918a-a3a604773054_terseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_e4c84fef-725d-41d5-b676-19b19be1f17d_verboseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of noncontrolling interest</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase Due To Acquisitions and Divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_2fbc3b5b-6e0d-402d-bc17-e6efdca5a5ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b42daf02-e0f1-46c1-b85e-0fec9504670f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_6681a39b-3b5e-4668-a250-49dafc17e8f6_terseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_97288bcb-f1d7-4ddc-98b6-01a7599ba864_verboseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of noncontrolling interest</link:label>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e74a0de3-750a-44dd-b17e-5fc9143e7007_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_8c565dc6-4895-4b90-9b95-130f5359f3ce_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, weighted average interest rate, at point in time</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_151b7d59-6b13-476b-be2c-d60a41996142_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ac257f5b-a1e6-4a07-9925-12d5d5af836e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_aea73e47-e59a-4ff0-9eaa-924e149c587d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4337ffc7-0ba4-4813-8fcb-046efd843ca6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7b90c40e-e804-42ea-9a43-6fd715226d31_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_b27fe338-e2d6-4fbe-9a5d-6af1df307771_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based awards, fair value assumptions, expected dividend</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_991d8a74-dbba-4834-ad98-e4e781086a7f_terseLabel_en-US" xlink:label="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation</link:label>
    <link:label id="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_label_en-US" xlink:label="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation</link:label>
    <link:label id="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_documentation_en-US" xlink:label="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law limitation. The Company is subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period three years following the date on which that stockholder became an interested stockholder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:href="dva-20241231.xsd#dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:to="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_279fce2e-dcc4-4f3c-9e00-bd7391daa05e_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_6fca1a66-9ad0-4099-a478-59fbde825c84_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Effective Date of Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Effective Date of Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bf6aee6c-b944-428e-8b60-0477686b7e03_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Incentive Compensation and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_b4ca4730-b36c-4943-ae85-9633ad386843_terseLabel_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partner Type of Partners' Capital Account, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_label_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partner Type of Partners' Capital Account, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:to="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_e4f5a092-bfd5-4be1-8402-44ed954d2b45_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_79d9ff5f-81cf-4a45-98aa-4c1291b60dfe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments Consolidation Items</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_370a411b-f6fa-4d92-bec1-3fc75f671adb_terseLabel_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f221fb8-f8b9-4629-8f8c-3d4a295629c7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-settled stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_470bd44a-c876-4302-88e4-3fa9e107c8b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_1cad6301-e467-4e21-b767-2120b381d309_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_b1faa6dc-b5b6-4373-863d-ffa084e860a3_terseLabel_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition obligations and other notes payable, fair value</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_label_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition Obligations And Other Notes Payable, Fair Value</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_documentation_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquisition Obligations And Other Notes Payable, Fair Value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:href="dva-20241231.xsd#dva_AcquisitionObligationsAndOtherNotesPayableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:to="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_ac8c5665-d24e-44d3-a3c4-4ec0ccc06d49_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_860dccc9-d6b8-411b-94cc-48dcde1e6ef4_negatedLabel_en-US" xlink:label="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_label_en-US" xlink:label="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Other Current Receivables And Other Current Assets</link:label>
    <link:label id="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net change during the reporting period in other current receivables and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:href="dva-20241231.xsd#dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:to="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_a1ad1fb6-5e4e-47b0-b61d-c20ebf4c0be7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9e9b5606-2d73-4489-b0fc-1cb6729426b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ba06e3c6-9b24-4643-82ca-a722e0b64467_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_187fd65d-bddd-45df-afa4-8bf0d24b6c71_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_9531efb4-51c8-4962-8d46-f72a83ed5d63_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4f86028e-6045-4b45-a48f-fe43399767d4_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_0f96811d-17d3-429f-91a6-95dad7919226_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2105d178-d226-48ae-9b0a-c8acbc68f6d9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ef21c407-c353-4d3e-9de8-e89c63660274_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_85a38e8b-f515-49b4-a8f6-411de2011add_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityDecreasePurchaseOfInterests_aa03ebf2-fa17-4671-88c0-f60ddc40f6f1_negatedTerseLabel_en-US" xlink:label="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Partial purchases</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasePurchaseOfInterests_label_en-US" xlink:label="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Decrease Purchase Of Interests</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasePurchaseOfInterests_documentation_en-US" xlink:label="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Decrease Purchase Of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:href="dva-20241231.xsd#dva_TemporaryEquityDecreasePurchaseOfInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:to="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_028f4b29-ca8d-432c-8967-cb4c5c57222d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of countries in which dialysis centers located</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1ea72b81-0596-4f9b-9881-3ff1bbba3dd6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent earn-out obligations for acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_6f813e3b-bbd6-4e98-bef4-40cc288d5eb1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TotalRevenueNetOfIntersegmentRevenue_5d7a281f-9e76-48e5-bc92-303170d71df6_terseLabel_en-US" xlink:label="lab_dva_TotalRevenueNetOfIntersegmentRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue net of intersegment revenue</link:label>
    <link:label id="lab_dva_TotalRevenueNetOfIntersegmentRevenue_label_en-US" xlink:label="lab_dva_TotalRevenueNetOfIntersegmentRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total revenue net of intersegment revenue</link:label>
    <link:label id="lab_dva_TotalRevenueNetOfIntersegmentRevenue_documentation_en-US" xlink:label="lab_dva_TotalRevenueNetOfIntersegmentRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total revenue net of intersegment revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalRevenueNetOfIntersegmentRevenue" xlink:href="dva-20241231.xsd#dva_TotalRevenueNetOfIntersegmentRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TotalRevenueNetOfIntersegmentRevenue" xlink:to="lab_dva_TotalRevenueNetOfIntersegmentRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_7f0ba1ec-619c-4d69-b039-1b7fbcb881f1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c5d22192-bbe2-4491-9721-9d18968311ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c8a74342-2b0e-4e28-8fbb-dff04b3904c8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A1MonthSOFRMember_7ec6dd03-7811-4b71-a851-a84022a900a6_terseLabel_en-US" xlink:label="lab_dva_A1MonthSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1-Month SOFR</link:label>
    <link:label id="lab_dva_A1MonthSOFRMember_label_en-US" xlink:label="lab_dva_A1MonthSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1-Month SOFR [Member]</link:label>
    <link:label id="lab_dva_A1MonthSOFRMember_documentation_en-US" xlink:label="lab_dva_A1MonthSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1-Month SOFR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A1MonthSOFRMember" xlink:href="dva-20241231.xsd#dva_A1MonthSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A1MonthSOFRMember" xlink:to="lab_dva_A1MonthSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c99e0d08-03ff-4381-8ca1-4cae184eed71_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ff081d9c-16fe-408a-b9cd-4c3567bd181b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_466c1a26-9539-4b70-986d-d6941efc5c7a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LoansTypeAxis_0df8e8ea-1d4e-4b53-b5d3-fe5b124a0f6f_terseLabel_en-US" xlink:label="lab_dva_LoansTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans Type [Axis]</link:label>
    <link:label id="lab_dva_LoansTypeAxis_label_en-US" xlink:label="lab_dva_LoansTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Type [Axis]</link:label>
    <link:label id="lab_dva_LoansTypeAxis_documentation_en-US" xlink:label="lab_dva_LoansTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeAxis" xlink:href="dva-20241231.xsd#dva_LoansTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LoansTypeAxis" xlink:to="lab_dva_LoansTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4b1a1522-7543-4700-b63b-12a20e5f47d9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3069c351-284c-43ee-825e-88428f7be8e1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4a5eaa92-15ee-4147-a7f5-6b9ffb757ab7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_86bd1af4-f36d-4b4a-bd13-65b5fb806148_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_1bd0b6e3-1e24-4949-86b4-b2605fdbd876_terseLabel_en-US" xlink:label="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions used to purchase shares, employee-related current liabilities</link:label>
    <link:label id="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_label_en-US" xlink:label="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares</link:label>
    <link:label id="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_documentation_en-US" xlink:label="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:href="dva-20241231.xsd#dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:to="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_a859d068-726a-4342-bd91-be706dc6c0bf_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_cfbf900e-b7f1-47e3-b0d6-e4221a582168_terseLabel_en-US" xlink:label="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests subject to put provisions</link:label>
    <link:label id="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_label_en-US" xlink:label="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Redeemable Noncontrolling Interests [Member]</link:label>
    <link:label id="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_documentation_en-US" xlink:label="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interests Temporary Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:href="dva-20241231.xsd#dva_TemporaryEquityRedeemableNoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:to="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9d2d7d55-b3ea-4655-abcb-29591bc2c8da_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_9fc90d45-4912-4ae0-8c73-18a691df11f4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ebef188d-1014-442b-b4b5-4d741c80c67c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f447ec58-35ff-4aef-a647-2289b66372da_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6b330c90-d752-411a-b9bd-e589be5e8166_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_832eb505-968c-4e59-a0f4-16033ae0a438_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d6a7e7e8-b382-4940-b9dc-8cb24d900aae_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_ade65819-68c9-4376-b16f-43c60dba527d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessAgreementEffectiveClosingDate_dcee4fd0-1b0b-4026-9d59-9d499a9eb65e_terseLabel_en-US" xlink:label="lab_dva_BusinessAgreementEffectiveClosingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Agreement Effective Closing Date</link:label>
    <link:label id="lab_dva_BusinessAgreementEffectiveClosingDate_label_en-US" xlink:label="lab_dva_BusinessAgreementEffectiveClosingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Agreement Effective Closing Date</link:label>
    <link:label id="lab_dva_BusinessAgreementEffectiveClosingDate_documentation_en-US" xlink:label="lab_dva_BusinessAgreementEffectiveClosingDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Agreement Effective Closing Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAgreementEffectiveClosingDate" xlink:href="dva-20241231.xsd#dva_BusinessAgreementEffectiveClosingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessAgreementEffectiveClosingDate" xlink:to="lab_dva_BusinessAgreementEffectiveClosingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c9a2a7d9-9b6e-4de0-828a-6c9f11bbcf86_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_3395c1ea-e7de-42d9-a952-4cb22d3e8b0f_terseLabel_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_label_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_documentation_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:to="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_4eaf7128-2dfc-4184-816e-4e6d71eff471_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock_518a9620-0111-4a9b-9d85-58f29a4a092d_terseLabel_en-US" xlink:label="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Other Information</link:label>
    <link:label id="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock_label_en-US" xlink:label="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Other Information Table Text Block [Table Text Block]</link:label>
    <link:label id="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock_documentation_en-US" xlink:label="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Other Information in tabular disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:href="dva-20241231.xsd#dva_LeaseOtherInformationTableTextBlockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:to="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_ab65e6d8-1e01-4eae-8fcf-27c66198417a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_f8f5263e-b0e8-4b12-b146-0f8979439b99_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Noncurrent, Threshold Period Past Due</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Noncurrent, Threshold Period Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_ddfe0d93-8f1b-4f70-90de-31d5bca24809_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and Information Systems</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b3659065-33ce-4089-a216-33a85c7abb13_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of leased assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_4e05bf52-a5a1-418c-b2d8-c3a3c4564539_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AuditorAbstract_770d6def-96a2-440d-b11c-895eb68bc2dd_terseLabel_en-US" xlink:label="lab_dva_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor [Abstract]</link:label>
    <link:label id="lab_dva_AuditorAbstract_label_en-US" xlink:label="lab_dva_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor [Abstract]</link:label>
    <link:label id="lab_dva_AuditorAbstract_documentation_en-US" xlink:label="lab_dva_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AuditorAbstract" xlink:href="dva-20241231.xsd#dva_AuditorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AuditorAbstract" xlink:to="lab_dva_AuditorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d606974-12b7-4dc6-b507-9d7767ab1e9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanFacilityMember_df06f19f-59f4-4a3e-b380-0c56bd313885_terseLabel_en-US" xlink:label="lab_dva_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_dva_TermLoanFacilityMember_label_en-US" xlink:label="lab_dva_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_dva_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_dva_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember" xlink:href="dva-20241231.xsd#dva_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanFacilityMember" xlink:to="lab_dva_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_00e61632-5ecf-4e22-99c9-80ace8709c1b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_953f57c3-de42-40eb-b5f2-52e4956c6b8e_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition obligations and other notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_4e6962c2-665a-451d-a2ea-320f9e1f16a6_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_2c758025-3e0d-489b-8e4d-9da598c266a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net income from discontinued operations per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_23ebb6c6-e25a-466c-a5a9-0154089dbecd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_39ac1cf1-90c0-4bfd-83d5-9582c1b6771e_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_ee38bc84-65f6-49c0-ba1e-f253d2d2b73a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_ef02aa88-5126-4f45-9983-0ad0dca113fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_926f7e1c-23ff-4528-88ec-a5f3a3d682a2_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_21a0d6ef-a962-468e-8e12-fbc5babc4a6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Related income tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_57056ea8-4171-4544-aa4e-56d1252826ed_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_996e4644-9d51-4553-b40c-0a96da520d70_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_bb7bcdcb-8b65-485d-bc84-55169be8efa3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, and equipment useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d07f5cf0-935a-4cd4-863f-2d8a74875704_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_7052c0b4-dcfc-4ae0-b34b-41c0c9abb0fc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1721d043-7537-45d3-b9f6-c800cf2a02c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_68aea70d-5587-4974-8854-f5051a82e610_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_28c51a68-b268-4fe5-b221-ce87815be6a3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PatientCareCosts_13548b92-c43b-401e-b9ca-5c1117d7c92d_terseLabel_en-US" xlink:label="lab_dva_PatientCareCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient care costs</link:label>
    <link:label id="lab_dva_PatientCareCosts_label_en-US" xlink:label="lab_dva_PatientCareCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patient Care Costs</link:label>
    <link:label id="lab_dva_PatientCareCosts_documentation_en-US" xlink:label="lab_dva_PatientCareCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts" xlink:href="dva-20241231.xsd#dva_PatientCareCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PatientCareCosts" xlink:to="lab_dva_PatientCareCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_79d23b78-3aee-4242-8705-4a12c5a2fd63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherSignificantNoncashFinancingActivity_a656f6d6-474b-49bb-b063-179190b3e3a0_terseLabel_en-US" xlink:label="lab_dva_OtherSignificantNoncashFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Significant Noncash Financing Activity</link:label>
    <link:label id="lab_dva_OtherSignificantNoncashFinancingActivity_label_en-US" xlink:label="lab_dva_OtherSignificantNoncashFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Significant Noncash Financing Activity</link:label>
    <link:label id="lab_dva_OtherSignificantNoncashFinancingActivity_documentation_en-US" xlink:label="lab_dva_OtherSignificantNoncashFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Significant Noncash Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSignificantNoncashFinancingActivity" xlink:href="dva-20241231.xsd#dva_OtherSignificantNoncashFinancingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherSignificantNoncashFinancingActivity" xlink:to="lab_dva_OtherSignificantNoncashFinancingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_a7ad1e46-80d4-49d3-97bd-ae002b20b615_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and information systems, including internally developed software</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_8e471632-5a80-40f6-b714-e50904128634_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares for earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c414f042-c531-49c3-b006-a689719fcb58_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Assets, Total</link:label>
    <link:label id="lab_us-gaap_Assets_ba80a9c2-9aca-4f9f-9466-fd822fb7ffeb_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SegmentReportingInformationCorporateExpenses_7ae04080-b323-4953-90f0-5776348449fb_negatedLabel_en-US" xlink:label="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Corporate administrative support</link:label>
    <link:label id="lab_dva_SegmentReportingInformationCorporateExpenses_label_en-US" xlink:label="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information Corporate Expenses</link:label>
    <link:label id="lab_dva_SegmentReportingInformationCorporateExpenses_documentation_en-US" xlink:label="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of general and administrative support costs, such as labor, benefits and stock-based compensation costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentReportingInformationCorporateExpenses" xlink:href="dva-20241231.xsd#dva_SegmentReportingInformationCorporateExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SegmentReportingInformationCorporateExpenses" xlink:to="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_b11b9133-bfe5-425e-8a68-7cf92160fb2d_terseLabel_en-US" xlink:label="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments In Nonconsolidated Dialysis Partnerships</link:label>
    <link:label id="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_label_en-US" xlink:label="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments In Nonconsolidated Dialysis Partnerships [Member]</link:label>
    <link:label id="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_documentation_en-US" xlink:label="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments In Nonconsolidated Dialysis Partnerships.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:href="dva-20241231.xsd#dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:to="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_be609859-c1a1-4cb6-8d3e-f6809c3dd168_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3e481d59-ea5e-4b44-b8be-99d32f215303_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_daa268c4-be56-46a9-b5f8-0f4faf9149f9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_88301726-ea08-440d-a0dd-d02e5d551236_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholder's equity</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxLiabilitiesMember_00d8cef4-503f-44aa-9206-4af758b13397_terseLabel_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesMember_label_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities [Member]</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesMember_documentation_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesMember" xlink:href="dva-20241231.xsd#dva_DeferredTaxLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxLiabilitiesMember" xlink:to="lab_dva_DeferredTaxLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfOtherReceivablesTableTextBlock_2bffb5d6-5725-4a65-9ad0-c189d67600fb_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Receivables</link:label>
    <link:label id="lab_dva_ScheduleOfOtherReceivablesTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Other Receivables [Table Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfOtherReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of claims held for amounts due to an entity. Examples include non-trade receivables and Medicare bad debt claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:href="dva-20241231.xsd#dva_ScheduleOfOtherReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:to="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2718116c-6632-47a5-864f-e74068c5f485_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NonCashGainMember_ca6ff1db-67a8-413d-ac53-4c728a264864_terseLabel_en-US" xlink:label="lab_dva_NonCashGainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Cash Gain</link:label>
    <link:label id="lab_dva_NonCashGainMember_label_en-US" xlink:label="lab_dva_NonCashGainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Gain [Member]</link:label>
    <link:label id="lab_dva_NonCashGainMember_documentation_en-US" xlink:label="lab_dva_NonCashGainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NonCashGainMember" xlink:href="dva-20241231.xsd#dva_NonCashGainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NonCashGainMember" xlink:to="lab_dva_NonCashGainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_076112e4-ff91-4945-bff3-e661c96a36d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between U.S. Federal Income Tax Rate and Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_141767fc-9bee-4398-973b-ce421cd8cb42_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_70623239-99ea-45a6-9b0f-48f04b04aded_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance and self-insurance accruals</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_1bc299b5-5597-4f8d-9dc3-d4b988655ef7_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_131a3bb5-449d-4cc3-a646-e83c16017faa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments_2a065f86-f6bb-4d8b-a516-8b0c19032544_negatedLabel_en-US" xlink:label="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity investment loss, net</link:label>
    <link:label id="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment Income Loss From Equity Method Investments</link:label>
    <link:label id="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments_documentation_en-US" xlink:label="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the entity's proportionate share for the period of the undistributed net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:href="dva-20241231.xsd#dva_AdjustmentIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:to="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_a854a9cf-f228-447f-b705-18252ede1c6b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DaVitaMedicalGroupMember_9bc34d5e-705f-4396-b433-8be6e5714ba5_verboseLabel_en-US" xlink:label="lab_dva_DaVitaMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">DMG - discontinued operations</link:label>
    <link:label id="lab_dva_DaVitaMedicalGroupMember_label_en-US" xlink:label="lab_dva_DaVitaMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Da Vita Medical Group [Member]</link:label>
    <link:label id="lab_dva_DaVitaMedicalGroupMember_documentation_en-US" xlink:label="lab_dva_DaVitaMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DaVita medical group.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember" xlink:href="dva-20241231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DaVitaMedicalGroupMember" xlink:to="lab_dva_DaVitaMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e5673712-b77a-425f-bb22-bb6a51ee99f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Purchase Cost Allocations for Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_491818d9-7b2e-4224-a0e2-8e1f30a9a247_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member_16d21b00-940a-4c0e-a455-139e1bc4cead_terseLabel_en-US" xlink:label="lab_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Interest Rate Cap Agreements 4.00% Effective December 31 2025</link:label>
    <link:label id="lab_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member_label_en-US" xlink:label="lab_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Interest Rate Cap Agreements 4.00% Effective December 31 2025 [Member]</link:label>
    <link:label id="lab_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member_documentation_en-US" xlink:label="lab_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Interest Rate Cap Agreements 4.00% Effective December 31 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member" xlink:href="dva-20241231.xsd#dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member" xlink:to="lab_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_e342018e-429a-4aaa-92a6-24b453be5760_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9ddc1fb1-4704-47f9-bb57-1c7d8bc75420_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_53668c69-6c8b-4822-9d57-ad36405b87a4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_011ea08b-b8a8-416e-bad5-996e5b924a68_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Patient service revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7ee0e737-5f7b-41d5-8e97-5e55e1f370ae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dialysis patient service revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_51e5e671-526a-4f9b-a67c-231ce67a3079_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Depreciation and Amortization Expense by Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPaymentTerms_33d2b7ab-29f3-4f78-afad-d571e63a9ce0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Payment Terms</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPaymentTerms_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPaymentTerms" xlink:to="lab_us-gaap_DebtInstrumentPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9e09e00c-29fa-4a19-906a-48258e0c9fc6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da7adfee-04b2-499c-94ce-f6041f265aa7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_cb2dd795-4551-4595-8372-e63730e63cd9_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_1baf4e5c-0fa0-4c5f-ad8f-4d64485df61d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests not subject to put provisions</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_03eb1884-ebff-4aef-a956-0fb3da7f1266_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e5204faa-18ae-445d-8b40-06f577834174_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_22dfc352-baff-4947-a55d-668a56f627fa_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_6d946210-8ee3-4bb5-ac6a-6a93370009e2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_fe998416-d166-4866-9329-d8c64be49b85_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses on foreign currency translation.</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_c71d7a71-30f3-43d1-93c2-4f089c2fd246_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c4008d10-44b9-4282-ab79-cf997466a246_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_4f0f73b4-9937-4a05-8fde-bd0b724dc0a1_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Other Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityOtherChanges" xlink:to="lab_us-gaap_TemporaryEquityOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeverageRatioCovenantAfterJun302026_d97649d2-19c6-4c34-b127-96d88f853caa_terseLabel_en-US" xlink:label="lab_dva_LeverageRatioCovenantAfterJun302026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant after Jun 30, 2026</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantAfterJun302026_label_en-US" xlink:label="lab_dva_LeverageRatioCovenantAfterJun302026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant after Jun 30, 2026</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantAfterJun302026_documentation_en-US" xlink:label="lab_dva_LeverageRatioCovenantAfterJun302026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant after Jun 30, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantAfterJun302026" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenantAfterJun302026"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeverageRatioCovenantAfterJun302026" xlink:to="lab_dva_LeverageRatioCovenantAfterJun302026" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_a3a9baad-e463-47ba-a32a-a93c52908c9b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-qualified deferred compensation plan, contributions</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorSecuredCreditFacilitiesMember_9e500dc1-cabd-43f2-9be9-c6b24f372843_terseLabel_en-US" xlink:label="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_dva_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_dva_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior secured credit facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember" xlink:href="dva-20241231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6099fb2c-6ff6-4908-9676-6cbed6993f94_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2ab61c53-dfa3-45e2-b6bc-bd187cc2b992_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of stock awards exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4845c7b1-c514-4ef6-a66a-951f5d0151df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_8eedfea8-aca7-4250-aa88-be4c03fe3896_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_eb5b6cdc-b583-4915-8627-0c0044fdc3b0_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_d4c2aa7d-79b9-4c77-89f9-40d118fd3e45_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Five</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_b838187e-5067-4621-9a67-d9de6eac3d88_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in debt and equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_dd2f029f-ba31-40dd-9bc8-6627c6272736_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-cash losses and (gains), net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_7c4f1dee-4f90-4382-82b1-0a2e7baee44c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma basic net income per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_fcdfa2d6-07ec-481f-a095-b6f29b47ac94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of noncontrolling interests primarily attributable to non-tax paying entities</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_781d2a4b-1446-4e8a-96be-1986cfd0f7ca_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_5c5ded44-82af-4432-b9a7-2f0dfcc9efaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeverageRatioCovenantThroughJun302026_3ad38a31-4f89-4e4e-970f-dfe1d1eccfe2_terseLabel_en-US" xlink:label="lab_dva_LeverageRatioCovenantThroughJun302026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant Through Jun 30, 2026</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantThroughJun302026_label_en-US" xlink:label="lab_dva_LeverageRatioCovenantThroughJun302026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant Through Jun 30, 2026</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantThroughJun302026_documentation_en-US" xlink:label="lab_dva_LeverageRatioCovenantThroughJun302026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant Through Jun 30, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantThroughJun302026" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenantThroughJun302026"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeverageRatioCovenantThroughJun302026" xlink:to="lab_dva_LeverageRatioCovenantThroughJun302026" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_FinanceLeaseMember_80dade38-be96-4359-a19b-acb169386568_terseLabel_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease obligations</link:label>
    <link:label id="lab_dva_FinanceLeaseMember_dc913a85-cb96-4fc4-ab0d-dc11bcd0428f_verboseLabel_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease</link:label>
    <link:label id="lab_dva_FinanceLeaseMember_label_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease [Member]</link:label>
    <link:label id="lab_dva_FinanceLeaseMember_documentation_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember" xlink:href="dva-20241231.xsd#dva_FinanceLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_FinanceLeaseMember" xlink:to="lab_dva_FinanceLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_2c8e4f1c-dfa3-4ef7-8315-a4c76a8d1d0b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_276b6331-717c-410b-8a78-b586582db1ad_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ee1388b6-013a-43ff-ad52-ea38a598fb1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net income from continuing operations per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_d05d15f1-00c8-4a5d-aa7e-3d1c43823f1c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_1cca9c24-d44c-4ba7-b033-a54cc747f148_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt investments held-to-maturity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_ae8a24d5-e87f-4a45-9d67-83493c3f4750_terseLabel_en-US" xlink:label="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_label_en-US" xlink:label="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income Expense Policy [Text Block]</link:label>
    <link:label id="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_documentation_en-US" xlink:label="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other nonoperating income (expense), policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:href="dva-20241231.xsd#dva_OtherNonoperatingIncomeExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:to="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ddb06517-4d13-4d67-94f6-5ee3d6046381_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9e12675a-2d62-47cf-b937-46bf1618f746_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5bbafb7e-0108-454d-989e-af9e19334ee7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Political advocacy costs</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_c50e285d-3493-46ab-9158-a179261f6e05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_00812aad-b29c-42d8-8a89-60564b015b22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of net realized gains into net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CorporateIntegrityAgreementExpirationDate_9db42d40-c08d-4747-9918-a68a84593f25_terseLabel_en-US" xlink:label="lab_dva_CorporateIntegrityAgreementExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Integrity Agreement Expiration Date</link:label>
    <link:label id="lab_dva_CorporateIntegrityAgreementExpirationDate_label_en-US" xlink:label="lab_dva_CorporateIntegrityAgreementExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Integrity Agreement Expiration Date</link:label>
    <link:label id="lab_dva_CorporateIntegrityAgreementExpirationDate_documentation_en-US" xlink:label="lab_dva_CorporateIntegrityAgreementExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Integrity Agreement Expiration Date, in CCYY-MM-DD format.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CorporateIntegrityAgreementExpirationDate" xlink:href="dva-20241231.xsd#dva_CorporateIntegrityAgreementExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CorporateIntegrityAgreementExpirationDate" xlink:to="lab_dva_CorporateIntegrityAgreementExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_9a6a458e-01d9-4ddc-9840-fd94994d4c6a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_c6b5f14b-dee7-4c24-838a-1302b1837daf_terseLabel_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_label_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_documentation_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:href="dva-20241231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:to="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0278f572-e975-4ce0-9107-665655b235b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a529aeca-d65b-443e-8efc-4d3798c199d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance of AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_086ca3e0-8ce6-4634-9764-9a89a82e52a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance of AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtFinancingAndDebtRedemptionCosts_273283dd-f23e-47b4-9316-32b767eb6bc2_negatedTerseLabel_en-US" xlink:label="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred and debt related financing costs</link:label>
    <link:label id="lab_dva_DebtFinancingAndDebtRedemptionCosts_label_en-US" xlink:label="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Financing And Debt Redemption Costs</link:label>
    <link:label id="lab_dva_DebtFinancingAndDebtRedemptionCosts_documentation_en-US" xlink:label="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Financing And Debt Redemption Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtFinancingAndDebtRedemptionCosts" xlink:href="dva-20241231.xsd#dva_DebtFinancingAndDebtRedemptionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtFinancingAndDebtRedemptionCosts" xlink:to="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_c4123c47-ff92-4bf6-87c4-c1e5e1f6df7e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3a3a641e-e6f1-4fe7-8dd8-3088f4a21af5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_99681bc4-3a95-4d86-bff8-5dfa8f7c6607_terseLabel_en-US" xlink:label="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes 4.625% due 2030</link:label>
    <link:label id="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_label_en-US" xlink:label="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Six Two Five Percent Due Twenty Thirty [Member]</link:label>
    <link:label id="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_documentation_en-US" xlink:label="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Six Two Five Percent Due Twenty Thirty.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:href="dva-20241231.xsd#dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:to="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_96cfe432-ee14-454c-9fb6-a0e6fdca0707_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_fbe5c335-ee21-4288-8955-3e1c4be26158_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived licenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_efe43c2a-f611-4835-9646-4d3aee2001c8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30e483cf-d8dc-4f84-9e83-2bd07cf55a47_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52d4ef0f-75bd-4d2d-bbe3-e8a73cf907ab_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_42549756-a797-4808-8616-60f4a603432a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5054fcdd-eab0-43c5-996d-c6d0360e7ab4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_febd5227-67f8-4d66-a91e-00d5744dfd62_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of businesses acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3f8a32ce-08e5-481f-9bf0-2410dae96b74_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_97c7e37a-4e8f-43fd-8bdc-dbc75fb84592_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_59611cb9-4579-49d3-a154-e22162d95663_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_863df188-25f7-49d3-a923-d1ae46a126c9_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_81707ae4-a7b7-49e2-a447-2237627b95d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_ee77c8a8-5edd-40ec-a9f7-afa8742a4b53_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPensionPlansDefinedBenefitMember_4d21b3f5-2304-4c31-bbee-b532c8278e9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Plan</link:label>
    <link:label id="lab_us-gaap_OtherPensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8cc76fdf-1332-49e3-89c9-889303895ee9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_99d71cc5-87cf-475f-9dbc-9e92ee91d975_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Expenditure, Addition to Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_label_en-US" xlink:label="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment, Expenditure, Addition to Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:to="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_b630a41d-62d1-4634-bb1e-95925e3f5a32_terseLabel_en-US" xlink:label="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</link:label>
    <link:label id="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_label_en-US" xlink:label="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</link:label>
    <link:label id="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_documentation_en-US" xlink:label="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:href="dva-20241231.xsd#dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:to="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_33c141ca-a93b-499d-877f-8a058a620a11_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Expense Components</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_43590eec-5120-4d69-8c00-fb58fd4a981e_terseLabel_en-US" xlink:label="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier rebates and non-trade receivables</link:label>
    <link:label id="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_label_en-US" xlink:label="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Rebates And Other Non Trade Receivables [Member]</link:label>
    <link:label id="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_documentation_en-US" xlink:label="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Rebates And Other Non Trade Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:href="dva-20241231.xsd#dva_SupplierRebatesAndOtherNonTradeReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:to="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_d3675701-3a02-48d5-9f7e-94fa98d60d10_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ce1c3e4f-8b91-4e05-9efa-e7f7d462fea0_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3349e4c6-2741-4f65-b752-71854af7d721_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SegmentRevenuebyMajorPayorAbstract_2752e6a0-2971-44d9-bc54-07b0dc8b9d6b_terseLabel_en-US" xlink:label="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Revenue by Major Payor [Abstract]</link:label>
    <link:label id="lab_dva_SegmentRevenuebyMajorPayorAbstract_label_en-US" xlink:label="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Revenue by Major Payor [Abstract]</link:label>
    <link:label id="lab_dva_SegmentRevenuebyMajorPayorAbstract_documentation_en-US" xlink:label="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Revenue by Major Payor [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentRevenuebyMajorPayorAbstract" xlink:href="dva-20241231.xsd#dva_SegmentRevenuebyMajorPayorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SegmentRevenuebyMajorPayorAbstract" xlink:to="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_8fcc2da7-5bb2-4f3c-b6d3-35f468c41d95_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_f7f1ef0c-ce41-4ad9-a180-a3b1c494bb21_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fd4e9ac9-8ff5-425c-8712-672a41596175_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_089e5a69-2ca3-4901-b3c0-5db4497ca784_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_69d489c9-36ac-4e9f-b148-0c39ab11613f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_85ff6b30-65fd-4d44-a2c9-c6f38606252b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State capital loss carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_38435515-66de-47ad-ac8b-eb8d36d834f7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_75b8c286-2df0-48d2-8f03-0da7f42ddfb1_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests subject to put provisions</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_84748933-a26a-4ed5-bf58-cc339e1c4413_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_adc1a858-0111-41af-a361-5c850b5b4539_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SecuredDebtExtendedMaturity_fd3a69a1-20ca-4075-a345-614f42d2deec_terseLabel_en-US" xlink:label="lab_dva_SecuredDebtExtendedMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt, Extended Maturity</link:label>
    <link:label id="lab_dva_SecuredDebtExtendedMaturity_label_en-US" xlink:label="lab_dva_SecuredDebtExtendedMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt, Extended Maturity</link:label>
    <link:label id="lab_dva_SecuredDebtExtendedMaturity_documentation_en-US" xlink:label="lab_dva_SecuredDebtExtendedMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Debt, Extended Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtExtendedMaturity" xlink:href="dva-20241231.xsd#dva_SecuredDebtExtendedMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SecuredDebtExtendedMaturity" xlink:to="lab_dva_SecuredDebtExtendedMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_128f1734-ba28-4e89-aed7-f2747c76bf9c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ee96df17-1b92-44e3-9b19-b6aaa476e332_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MutualFundsAndCommonStockMember_2e138b92-f419-4cf7-9c65-b405e1ae8ad5_terseLabel_en-US" xlink:label="lab_dva_MutualFundsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in mutual funds and common stock</link:label>
    <link:label id="lab_dva_MutualFundsAndCommonStockMember_label_en-US" xlink:label="lab_dva_MutualFundsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Funds And Common Stock [Member]</link:label>
    <link:label id="lab_dva_MutualFundsAndCommonStockMember_documentation_en-US" xlink:label="lab_dva_MutualFundsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mutual Funds And Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MutualFundsAndCommonStockMember" xlink:href="dva-20241231.xsd#dva_MutualFundsAndCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MutualFundsAndCommonStockMember" xlink:to="lab_dva_MutualFundsAndCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardExpirationDate_5d286d05-ed3b-44d7-8351-e147dedfdf88_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State capital loss carryforward, expiration date</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardExpirationDate_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5a9a1a2a-b577-4002-a8e4-b59315447b0f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OpenMarketPurchasesMember_b3378b65-9a94-48b1-a7f5-0f7a07b092f7_terseLabel_en-US" xlink:label="lab_dva_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Market Purchases</link:label>
    <link:label id="lab_dva_OpenMarketPurchasesMember_label_en-US" xlink:label="lab_dva_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Market Purchases [Member]</link:label>
    <link:label id="lab_dva_OpenMarketPurchasesMember_documentation_en-US" xlink:label="lab_dva_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Open Market Purchases Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember" xlink:href="dva-20241231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OpenMarketPurchasesMember" xlink:to="lab_dva_OpenMarketPurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_4bdd3600-624d-4411-a035-cb23bb7a2726_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_582b47e9-5c8a-46e0-a4cc-38d5a2abde3d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2e61a9e3-e9a5-4408-b4da-4f20a62ba277_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_52763adf-f7a4-4df1-8731-43d95672e40f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4562334d-5deb-4a5f-a3ef-4086e438a050_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_83a4c6e4-ca0d-43fa-8fe7-e389c4919a24_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rent Expense, Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_62de4dbc-8d92-4329-8d14-ab886c245cc7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a79f666a-bc6e-47ad-90d7-024bf7047306_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_70bb9d37-03b0-4f28-ad52-c60bd91fdba3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_4049a3d4-ca09-49bf-abc8-4efb525d4c77_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_1430ecd2-4b16-4e78-a8cd-8af253d89f12_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_bd53be4c-efa1-4e54-a4b1-79a2405edf2f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partial purchases</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_424838df-a5ea-42ce-9b23-5b44d778be6a_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchase of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_eec67091-6b18-4aab-88e9-3a9ad3af4383_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtPrepaymentExtinguishmentAndModificationCosts_ff0015ae-5410-4fe1-8a00-488288d7bb59_negatedTerseLabel_en-US" xlink:label="lab_dva_DebtPrepaymentExtinguishmentAndModificationCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt prepayment, extinguishment and modification costs</link:label>
    <link:label id="lab_dva_DebtPrepaymentExtinguishmentAndModificationCosts_68e8063c-aa0e-4c57-8554-43719378c017_terseLabel_en-US" xlink:label="lab_dva_DebtPrepaymentExtinguishmentAndModificationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt prepayment, extinguishment and modification costs</link:label>
    <link:label id="lab_dva_DebtPrepaymentExtinguishmentAndModificationCosts_label_en-US" xlink:label="lab_dva_DebtPrepaymentExtinguishmentAndModificationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment, Extinguishment And Modification Costs</link:label>
    <link:label id="lab_dva_DebtPrepaymentExtinguishmentAndModificationCosts_documentation_en-US" xlink:label="lab_dva_DebtPrepaymentExtinguishmentAndModificationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment, Extinguishment And Modification Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts" xlink:href="dva-20241231.xsd#dva_DebtPrepaymentExtinguishmentAndModificationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts" xlink:to="lab_dva_DebtPrepaymentExtinguishmentAndModificationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_914a07d0-7e93-4675-969a-54b14f9e9f5c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_d66e0102-5b2a-4413-ad82-f18bdef6bf24_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, significant impairments and other valuation adjustments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Other-than-Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c7e6ca5b-967e-42ed-8c02-b80c3d5158b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_84ce119a-8e41-4f74-a8ab-12e4f4966e7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebt_d89d3063-12ec-4d44-9ea3-aaec7a66933d_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_label_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt" xlink:to="lab_us-gaap_SecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_6eae0895-9a52-4a42-9192-b9a43f3b7ac6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_811bf1dd-511d-44d3-b0ad-69e5f7bd9d8d_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_bd26b636-6ea1-41b3-b465-372d1edbc30f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_2f05babe-71b2-49c5-9d8e-0aacb2bdbb74_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cff1d96d-c19e-4058-8736-7cfd64c95de9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_46d3dc56-c9c2-4866-a668-8f1e5275d28d_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Receivables</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8bea3a0c-fb33-4362-89d2-db283f06dc0a_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_91b49bad-f9cb-4b68-997c-0ec975a64273_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_d211c865-4b23-4839-8edd-7e3f81bd57f4_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests subject to put provisions</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_e5bd3c3e-fbde-4540-a65a-409b907c532f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_a6dad80a-57b2-403d-9e47-403f504d8664_terseLabel_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_label_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_documentation_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization consolidation and presentation of financial statements disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:href="dva-20241231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_9c29ac8c-eae0-4093-8dbd-92da51aebbb7_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intersegment Elimination</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9bcfeccd-07a1-40d2-aff8-dbf7ef84c90a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember_cebd2cab-84cd-4fe5-b272-2900bac90238_terseLabel_en-US" xlink:label="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Related To Cash Flow Hedges</link:label>
    <link:label id="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember_label_en-US" xlink:label="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Related To Cash Flow Hedges [Member]</link:label>
    <link:label id="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember_documentation_en-US" xlink:label="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Related To Cash Flow Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:href="dva-20241231.xsd#dva_IncomeTaxRelatedToCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:to="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_74d12bb1-ef4c-4cb8-999e-34cb8ab94a07_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b34afc5e-586d-47a3-8808-2c93738dd941_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_df8478af-7968-49e6-ba62-2f89f4643b19_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum payments due under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAbstract_2640b466-25b2-423a-af79-799b019f3c98_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchases</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAbstract_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAbstract" xlink:to="lab_us-gaap_TreasuryStockValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_27d004d9-623f-471a-a9d6-8485de4ede95_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_bca6916e-ac63-4802-b5af-088fa38ad348_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_005e6f8b-e4bd-4bd3-b1f8-2aa08a1e95f7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_8f9475a8-aefe-4f78-a4c4-d33660ddb440_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_198ebac1-a43e-40ea-8480-f4af6f2326ec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma net income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_4d224024-6a5b-4d9a-9128-95a86e79d13e_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_7c83168f-0f2f-4f2f-8fba-5f158ed4c5e2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amounts of interest rate agreements</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_837ba362-76ab-4adb-84e0-e5fa21257e9f_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_d0401c1b-6dd7-4a4b-b895-09a7e1330936_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses and charges</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_4f693637-d5ee-4ec1-81e8-9fb68bd5bb62_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b1921f77-b3ea-49be-a2b8-10e02db41d64_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_feabf3b2-6acf-463c-95f7-249987062ec4_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5d68f2fb-cd68-42ba-afaf-0b45e39fbe6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of stock awards outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_9eebdb1a-03b0-4af8-b799-0a9918918c9f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_89dd86f0-b857-4c39-845a-3b6d213363d0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net income attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b1cf4997-0240-465c-a10c-321e19ed009f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_2532781d-b431-4088-992d-756f88c4c65b_terseLabel_en-US" xlink:label="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terminated Remaining Prior Share Repurchases Authorized, Amount</link:label>
    <link:label id="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_label_en-US" xlink:label="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Terminated Remaining Prior Share Repurchases Authorized, Amount</link:label>
    <link:label id="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_documentation_en-US" xlink:label="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Terminated Remaining Prior Share Repurchases Authorized, Amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:href="dva-20241231.xsd#dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:to="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_83e78e9b-122c-448d-ae3f-c3a69f0c5a1b_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a7192292-c218-41c7-b611-681de43355fe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d66b939e-632f-49e9-bd51-e4017c2fa77d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in valuation allowance related to changes in the estimated tax benefit</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_83eadef2-e0b8-460b-b696-e9e39fa3ee0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on changes in ownership interests</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_bb05a323-3469-4416-b1e2-ff2019d7164d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_d0513a8b-584b-4012-929b-89c2217a7627_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SOFRLoansMember_7009eebd-a88e-42a0-901e-1e8bb7ac5931_terseLabel_en-US" xlink:label="lab_dva_SOFRLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOFR Loans</link:label>
    <link:label id="lab_dva_SOFRLoansMember_label_en-US" xlink:label="lab_dva_SOFRLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOFR Loans [Member]</link:label>
    <link:label id="lab_dva_SOFRLoansMember_documentation_en-US" xlink:label="lab_dva_SOFRLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SOFR Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SOFRLoansMember" xlink:href="dva-20241231.xsd#dva_SOFRLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SOFRLoansMember" xlink:to="lab_dva_SOFRLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_4c878b28-4fe1-4454-b896-beb12748e908_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_17f265ef-4e1b-4f58-9245-d2dca3aeafec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock purchase shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_859301a7-20ca-402d-bcf0-1bf5ad4e1aea_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for employee stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_f357976c-7456-495f-b331-ec32fb01d5ad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_6635f8c3-2624-4467-9378-3d7a0c33f217_terseLabel_en-US" xlink:label="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated tax benefits recorded for stock-based compensation</link:label>
    <link:label id="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense</link:label>
    <link:label id="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_documentation_en-US" xlink:label="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation estimated tax benefit from compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:href="dva-20241231.xsd#dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:to="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6ba51ec-c87e-4916-b31e-c3c0df731ca3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash of continuing operations at beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c32d9fb2-b6bc-4052-94a3-ab51b33b9636_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash of continuing operations at end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_6b569ab3-9d32-4d1f-aa9c-8a2b7fd88659_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_e9eabd5e-cd3c-45e7-9413-c483c7068b2d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_c82b430b-151d-4934-b291-fdb2305135c4_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_bab58f4b-b4ae-4d8a-ba01-c3cef18be13b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains on interest rate cap agreements:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5fb036c3-c386-416f-9356-fa040372c532_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_f00eaf98-fe2d-4c87-8531-23705515fa65_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetProceedsFromIssuanceOfStockToEmployees_f45d8db3-2ca1-4103-b6a1-d29552eb2d4e_terseLabel_en-US" xlink:label="lab_dva_NetProceedsFromIssuanceOfStockToEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock under employee stock plans</link:label>
    <link:label id="lab_dva_NetProceedsFromIssuanceOfStockToEmployees_label_en-US" xlink:label="lab_dva_NetProceedsFromIssuanceOfStockToEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Issuance Of Stock To Employees</link:label>
    <link:label id="lab_dva_NetProceedsFromIssuanceOfStockToEmployees_documentation_en-US" xlink:label="lab_dva_NetProceedsFromIssuanceOfStockToEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Proceeds From Issuance Of Stock To Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetProceedsFromIssuanceOfStockToEmployees" xlink:href="dva-20241231.xsd#dva_NetProceedsFromIssuanceOfStockToEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetProceedsFromIssuanceOfStockToEmployees" xlink:to="lab_dva_NetProceedsFromIssuanceOfStockToEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_f0d67a0b-06f8-4835-81da-945cacf165f5_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_680b21d2-ffb9-4078-bd51-2373c9c7d320_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value estimates</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanB1Member_cc4729d3-5b8a-4e2e-8bc2-77f037e2e301_terseLabel_en-US" xlink:label="lab_dva_TermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan B-1</link:label>
    <link:label id="lab_dva_TermLoanB1Member_label_en-US" xlink:label="lab_dva_TermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan B-1 [Member]</link:label>
    <link:label id="lab_dva_TermLoanB1Member_documentation_en-US" xlink:label="lab_dva_TermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan B-1 member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member" xlink:href="dva-20241231.xsd#dva_TermLoanB1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanB1Member" xlink:to="lab_dva_TermLoanB1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_20e892e8-f1f1-416f-a182-522cfae0a137_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_aead6be3-bb66-4508-8e13-7723ed62ed85_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_e561b16a-abda-42ae-ba79-76cbf58ef2c3_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt totals:</link:label>
    <link:label id="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_caf1ce7d-514b-4bf5-bbd1-8ad5ef6443ca_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_379b93b5-3c16-406c-a12b-ad146676acc1_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Weighted-Average Period before Renewal or Extension</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Asset, Weighted-Average Period before Renewal or Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a53a080c-b572-4902-babb-00a6179999b9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_bf4a4001-f63e-4ebb-bb18-7cde279954df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_d56e870b-5df5-49eb-98ba-6296d06a89aa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation plan, distributions</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Distribution Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_6aedd63b-453e-4549-9246-789b4c78d96c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_fa43cb0f-bcee-4d3d-a63a-9713e20ddb94_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_6ce5450f-3ca2-409d-a122-ff4b214c7d8a_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee entitlement for purchase of the Company's common stock during each calendar year</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Maximum Share Value Authorized For Purchase</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum share value authorized for purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312024_1d48cab9-ec48-45e3-a18a-f6bd12f4beee_terseLabel_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By December 31, 2024</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312024_label_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By December 31, 2024</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312024_documentation_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312024" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312024" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByDecember312024"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NotionalAmountAmortizableByDecember312024" xlink:to="lab_dva_NotionalAmountAmortizableByDecember312024" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312026_1d1a6959-b444-42d9-ab6e-210bec615462_terseLabel_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By December 31, 2026</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312026_label_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By December 31, 2026</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312026_documentation_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By December 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312026" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByDecember312026"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NotionalAmountAmortizableByDecember312026" xlink:to="lab_dva_NotionalAmountAmortizableByDecember312026" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312025_d9e57ad9-947b-48f4-baa0-38bf81eda5b9_terseLabel_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By December 31, 2025</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312025_label_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By December 31, 2025</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312025_documentation_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312025" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By December 31, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312025" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByDecember312025"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NotionalAmountAmortizableByDecember312025" xlink:to="lab_dva_NotionalAmountAmortizableByDecember312025" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_508390b6-d378-4d76-8dd3-0a38698574ec_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e3300986-b413-4a0a-8b9c-d614def52985_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9bdc8167-04bf-45c0-9e61-50a8b51ff44d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">SOFR Plus Interest Rate Margin</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_d0b76897-724b-4e18-9909-47a1cf4a8647_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1_4514ea53-a577-4dee-89e3-671283be8273_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date Range, End</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date Range, End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c232eab5-fadf-4687-ab1c-a72dbee9f42f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d46a904e-f0e6-40d0-aa82-141a9d31744f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_0bc5e74a-8b34-49ff-9871-2aaec7f53464_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember_5a59e73e-073b-4827-9d37-995a78110a28_terseLabel_en-US" xlink:label="lab_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes 6.875% due 2032</link:label>
    <link:label id="lab_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember_label_en-US" xlink:label="lab_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Thirty Two [Member]</link:label>
    <link:label id="lab_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember_documentation_en-US" xlink:label="lab_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Thirty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember" xlink:href="dva-20241231.xsd#dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember" xlink:to="lab_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockIncentivePlanTwentyTwentyMember_584197ee-f52d-4894-80f4-7d068405281f_terseLabel_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive 2020 Plan</link:label>
    <link:label id="lab_dva_StockIncentivePlanTwentyTwentyMember_label_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan Twenty Twenty [Member]</link:label>
    <link:label id="lab_dva_StockIncentivePlanTwentyTwentyMember_documentation_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan Twenty Twenty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyTwentyMember" xlink:href="dva-20241231.xsd#dva_StockIncentivePlanTwentyTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockIncentivePlanTwentyTwentyMember" xlink:to="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OffBalanceSheetFinancingArrangements_ec639aff-c70d-46d8-98a3-01ab2e7215ed_terseLabel_en-US" xlink:label="lab_dva_OffBalanceSheetFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Off -Balance Sheet Financing Arrangements</link:label>
    <link:label id="lab_dva_OffBalanceSheetFinancingArrangements_label_en-US" xlink:label="lab_dva_OffBalanceSheetFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Off -Balance Sheet Financing Arrangements</link:label>
    <link:label id="lab_dva_OffBalanceSheetFinancingArrangements_documentation_en-US" xlink:label="lab_dva_OffBalanceSheetFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Off -Balance Sheet Financing Arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OffBalanceSheetFinancingArrangements" xlink:href="dva-20241231.xsd#dva_OffBalanceSheetFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OffBalanceSheetFinancingArrangements" xlink:to="lab_dva_OffBalanceSheetFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_77e2c59a-71eb-40fc-bc04-8112d5d90552_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AllTrustsMember_d683cd40-6cce-442b-9954-7fa9a49caddf_terseLabel_en-US" xlink:label="lab_dva_AllTrustsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rabbi trusts</link:label>
    <link:label id="lab_dva_AllTrustsMember_label_en-US" xlink:label="lab_dva_AllTrustsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trusts [Member]</link:label>
    <link:label id="lab_dva_AllTrustsMember_documentation_en-US" xlink:label="lab_dva_AllTrustsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All trusts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AllTrustsMember" xlink:href="dva-20241231.xsd#dva_AllTrustsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AllTrustsMember" xlink:to="lab_dva_AllTrustsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_72fe8842-1661-4d8a-b7e8-3236dbf292f2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other potential commitments to provide operating capital to nonconsolidated dialysis centers</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_96511fab-210f-4e3f-817d-f18d146403fa_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_708edfaf-53ad-4771-ac02-7693af0570eb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2798c3fe-ba7b-487b-86af-9aeec41601e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_64d4a6a8-66f8-4b88-98c2-7cf2557d1915_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity on revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_3683d432-15fd-42b6-a0ca-f9fd00224e36_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312027Member_071af437-1aad-4248-a0a5-d6e1163be0d1_terseLabel_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2027</link:label>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312027Member_label_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2027 [Member]</link:label>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312027Member_documentation_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312027Member" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TotalNotionalAmountEffectiveThroughDecember312027Member" xlink:to="lab_dva_TotalNotionalAmountEffectiveThroughDecember312027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_113c767e-6d33-4a00-a399-89590ca80625_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockUnitMember_314db7ae-0168-4a36-934a-7b0419720e9e_terseLabel_en-US" xlink:label="lab_dva_StockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_dva_StockUnitMember_label_en-US" xlink:label="lab_dva_StockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Unit [Member]</link:label>
    <link:label id="lab_dva_StockUnitMember_documentation_en-US" xlink:label="lab_dva_StockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Unit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember" xlink:href="dva-20241231.xsd#dva_StockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockUnitMember" xlink:to="lab_dva_StockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ed4bc8e2-3721-49d8-baad-b773fc282958_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_c4be4443-e7b8-43cc-9cd1-92c5727a34b4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_682d7db9-b2d4-44af-a42c-a735e97c8687_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_480121dd-8690-420c-9a1a-a4018deaed7f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_556f9559-cfc5-4d07-865d-b40fb442a7d7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_55b46610-961c-4d13-9c0d-5c0b876a96a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate cap agreements</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_2ee1f3f1-4ce1-425d-b31c-c4f71b4a63f6_terseLabel_en-US" xlink:label="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt Outstanding Principal Balance Subject To SOFR</link:label>
    <link:label id="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_label_en-US" xlink:label="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt Outstanding Principal Balance Subject To SOFR</link:label>
    <link:label id="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_documentation_en-US" xlink:label="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Debt Outstanding Principal Balance Subject To SOFR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:href="dva-20241231.xsd#dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:to="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_3ecaa4be-0017-44b7-98c3-98195650c7c7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f5c3f05e-8066-4dad-b461-09ec8e14f96b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_dbd10642-d442-43bb-b4c9-b25373640c6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_e5a4b31b-5f57-4d7c-bb88-08ea87e6d73a_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filer</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_ea42f68b-f104-4dfa-983b-e5f64f5a0e8a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_be65d847-d406-4dbd-9e4f-d6c78258d43b_terseLabel_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_label_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_documentation_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:to="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_c673ab91-3686-4db2-aa64-4e43741bdf1e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_25a12b3a-65ed-44d4-b31f-a93de0993c38_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_110ab92f-f59e-4977-8db2-dbf21a020b50_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5cec15b2-1cd2-4a36-9ca0-1673d1bcbc08_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_25159edd-ff40-4634-8e75-d009a353eb6b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro Forma Summary of Results of Operations</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxAssetsReceivables_b32c7dbf-9fca-478a-b8a0-47054a518a88_terseLabel_en-US" xlink:label="lab_dva_DeferredTaxAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsReceivables_label_en-US" xlink:label="lab_dva_DeferredTaxAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Receivables</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsReceivables_documentation_en-US" xlink:label="lab_dva_DeferredTaxAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets, receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables" xlink:href="dva-20241231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxAssetsReceivables" xlink:to="lab_dva_DeferredTaxAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3fc67140-4aa8-4dc5-8010-0cab5ad69179_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_386d575b-9193-43d0-a8c4-1c4875e1981a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7c5df322-dc15-4d20-922f-5e123b6d017e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_a4b3e198-43a4-49d7-9a21-b17520b52a1d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting Equity Interest by the Company</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_1b392506-9105-44de-ab07-a6b5d52f5c32_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage by the Company</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_3309e1de-bb43-407f-b169-1c1e3f25d78d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets under financing lease obligations</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_13c697db-9faa-4b2e-894b-93c0737bdda5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of assets held in trust</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExternalSourcesMember_d829d16a-ee73-4d3d-9bba-0310cb2bc816_terseLabel_en-US" xlink:label="lab_dva_ExternalSourcesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External Sources</link:label>
    <link:label id="lab_dva_ExternalSourcesMember_label_en-US" xlink:label="lab_dva_ExternalSourcesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">External Sources [Member]</link:label>
    <link:label id="lab_dva_ExternalSourcesMember_documentation_en-US" xlink:label="lab_dva_ExternalSourcesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">External sources.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExternalSourcesMember" xlink:href="dva-20241231.xsd#dva_ExternalSourcesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExternalSourcesMember" xlink:to="lab_dva_ExternalSourcesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionLeaseTerm_e6f8616d-4360-40a0-aec0-6c1c228e5edd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Lease Term</link:label>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionLeaseTerm_label_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:to="lab_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_07ed82ce-7ced-41c4-b8cb-472a65a5aef3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_0d201a4c-4d41-4cdc-8add-df2ac6a94f08_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution, percent of match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescription_1959f697-4682-4bca-8608-24b87d47efeb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescription_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescription" xlink:to="lab_us-gaap_DebtInstrumentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_2e11601a-4ea8-4c20-bb8c-335f1c4756c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_87ed26ff-a07f-4fa7-a28f-a00fa9a3d3fb_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_a26e6f66-6ce8-4d34-a148-22d3f91cb771_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfCustomers_e1e23796-b9d1-4062-bda2-bb430d59223d_verboseLabel_en-US" xlink:label="lab_dva_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of patients served</link:label>
    <link:label id="lab_dva_NumberOfCustomers_label_en-US" xlink:label="lab_dva_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Customers</link:label>
    <link:label id="lab_dva_NumberOfCustomers_documentation_en-US" xlink:label="lab_dva_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfCustomers" xlink:href="dva-20241231.xsd#dva_NumberOfCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfCustomers" xlink:to="lab_dva_NumberOfCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b0845ce5-ab8a-4108-9116-93f1f4d122cd_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock acquired, average cost per share</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_78553cd9-e87a-48f6-8846-f81f069df2d9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method and other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_0f069d22-03d4-4117-865f-be67e7d9992e_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_6bb4b5c7-ff0a-40e2-a331-efe644478159_verboseLabel_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_label_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:href="dva-20241231.xsd#dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:to="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_58fe489e-f360-4061-95e0-fc7792ba9302_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_44e6c8f4-0f3d-48e2-a0a1-02574068fb04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of exercise prices, lower range (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestItemsAbstract_b65e3eee-3c7a-4a4f-a719-81022a61c396_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in noncontrolling interest from:</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_023d1300-d149-4a77-b482-df685958f320_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised/ Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NewCreditAgreementAmendedMember_38fda10e-f390-4d04-911a-4cbf42808f3d_terseLabel_en-US" xlink:label="lab_dva_NewCreditAgreementAmendedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Credit Agreement - Amended</link:label>
    <link:label id="lab_dva_NewCreditAgreementAmendedMember_label_en-US" xlink:label="lab_dva_NewCreditAgreementAmendedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Credit Agreement - Amended [Member]</link:label>
    <link:label id="lab_dva_NewCreditAgreementAmendedMember_documentation_en-US" xlink:label="lab_dva_NewCreditAgreementAmendedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Credit Agreement - Amended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NewCreditAgreementAmendedMember" xlink:href="dva-20241231.xsd#dva_NewCreditAgreementAmendedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NewCreditAgreementAmendedMember" xlink:to="lab_dva_NewCreditAgreementAmendedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_6943f2a2-446f-440b-a185-2af655e37df1_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ea19d93f-4831-4159-8664-b25037297653_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b70ee698-a07f-4264-aae8-778a63dd75e5_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived licenses</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_422eef72-66f8-40a3-9dd7-c7c2332b6653_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense from amortizable intangible assets, other than lease agreements</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_FairValuePayableOfContingentConsideration_0d7485a4-15f5-4292-a068-44e4887611a8_terseLabel_en-US" xlink:label="lab_dva_FairValuePayableOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of Contingent Consideration payable to Medtronic</link:label>
    <link:label id="lab_dva_FairValuePayableOfContingentConsideration_label_en-US" xlink:label="lab_dva_FairValuePayableOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Payable Of Contingent Consideration</link:label>
    <link:label id="lab_dva_FairValuePayableOfContingentConsideration_documentation_en-US" xlink:label="lab_dva_FairValuePayableOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Payable Of Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FairValuePayableOfContingentConsideration" xlink:href="dva-20241231.xsd#dva_FairValuePayableOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_FairValuePayableOfContingentConsideration" xlink:to="lab_dva_FairValuePayableOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_ac3e484a-d081-4c56-8b8f-3571459113fb_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_229342f9-e7d7-4e00-a775-2a6d9478cca4_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary equity</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3ab96252-28c6-4d1f-b5c5-dc219ddaee82_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_d598cfc6-119d-40bc-8e4b-9049d439e024_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_a56a715d-914e-4d34-b99d-1311670a757a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9b86480b-53e2-4989-9f09-aa62b5b8518b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3dd7c232-e6eb-42a2-a925-6d441555d277_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less portion representing interest, operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DissolutionTermOfJointVentures_e2178951-ba8e-4e6a-92b7-783b3e247eea_terseLabel_en-US" xlink:label="lab_dva_DissolutionTermOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scheduled dissolution term of joint ventures</link:label>
    <link:label id="lab_dva_DissolutionTermOfJointVentures_label_en-US" xlink:label="lab_dva_DissolutionTermOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dissolution Term Of Joint Ventures</link:label>
    <link:label id="lab_dva_DissolutionTermOfJointVentures_documentation_en-US" xlink:label="lab_dva_DissolutionTermOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dissolution term of joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DissolutionTermOfJointVentures" xlink:href="dva-20241231.xsd#dva_DissolutionTermOfJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DissolutionTermOfJointVentures" xlink:to="lab_dva_DissolutionTermOfJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11b4991a-3276-4d60-a26f-cb128e31ea64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5c8f4e5b-4e13-4178-9274-311f97e8df5a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_220acb9a-59e6-44c4-b4c6-5095ff3a8e9d_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Related income tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_8bae504e-4b68-427e-a52a-3e641c7dfcb4_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, short-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1327ec3d-9b61-457d-8156-ae95d2905bd8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock award payment plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_ec9be786-2cb2-4ab7-b62d-f9ecdf07f61e_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Held-for-sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Held-for-Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentIssuanceDate1_004eb7a7-36c9-4709-ace1-ad4cda464792_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIssuanceDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Effective Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIssuanceDate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIssuanceDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Issuance Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIssuanceDate1" xlink:to="lab_us-gaap_DebtInstrumentIssuanceDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ace78686-00e4-4ec8-ad69-c3ff02e1ec0d_totalLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized (losses) gains net</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b6c823f9-f376-4750-b767-aab5f3ff6d49_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8d580138-ce63-4f08-85b6-d67ccb8132c7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_6501b778-cb54-4d04-90e2-fcf7b19e6b7d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_cb4d3fa8-5368-46df-9633-2fde240bd588_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_c8857808-80a3-4ff4-b65e-c4852d281e62_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_f6b4221d-0e48-481a-ad49-e237211590de_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual&#160;life</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Other than Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_baaa5a2f-39fd-4e0f-a7d6-f563050de082_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4ddf2d3b-75b0-4bf3-8761-4f672a6878e7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_12f78d87-bee2-419b-8b43-c9508d1d307e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d21089fd-74be-49d5-9c73-a4baea07922a_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2974ea9c-e51d-46b0-b2e2-16c06673e0ad_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_18218500-e7ef-44b7-9d6d-f140431cb2d8_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series of individually immaterial business acquisitions</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9e6c9292-5921-44c1-b3e5-9c9aa615403b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLossNetOfTax_2361a192-d843-46c9-ba3a-4967aaac260d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss, Net of Tax</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:to="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_17757185-a4bf-4c17-b8d4-f063f2158b4d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments that were considered at risk of significant goodwill impairment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_26c351b1-8c61-4380-ae52-7094d78fcbd7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e17032e9-438f-4416-bb03-5f63add96ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_0d0636c5-78e9-4389-8a93-8174fbb90711_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_fdff9e17-881c-4238-a147-b83ecc183856_terseLabel_en-US" xlink:label="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Property and Equipment International Operations</link:label>
    <link:label id="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_label_en-US" xlink:label="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Property and Equipment International Operations [Text Block]</link:label>
    <link:label id="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_documentation_en-US" xlink:label="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Property and Equipment International Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:href="dva-20241231.xsd#dva_NetPropertyAndEquipmentInternationalOperationsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:to="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_dd7e9a36-91f4-47e3-970e-98d32b8d5f8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_f47d1710-3a68-4140-9b98-044beb6bb404_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_bf25112b-3f12-4114-9108-1f1729abbafe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_2bfb2e67-e448-4a64-a380-39e4675e8a78_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_b99790ab-771b-478a-9afe-6dd4272bb111_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_a1d86d5e-2337-4baf-92d2-9053920b72ca_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Third Year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableAbstract_025d0869-2e7e-4977-8ac6-7b3a29e21c5c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes:</link:label>
    <link:label id="lab_us-gaap_NotesPayableAbstract_label_en-US" xlink:label="lab_us-gaap_NotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableAbstract" xlink:to="lab_us-gaap_NotesPayableAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_1a2d3763-d292-48f1-ad5a-c4ab91774e21_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e6450e6e-a936-43a0-9033-e52d2f0a4d9c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_9de9ad20-9ed3-427e-bfa3-b6265c1d8d84_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reductions related to settlements with taxing authorities</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NotionalAmountAmortizableByMaturityDate_57698cff-8bc8-4931-8264-08ceee03e058_terseLabel_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By Maturity Date</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByMaturityDate_label_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By Maturity Date</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByMaturityDate_documentation_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByMaturityDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notional Amount Amortizable By Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByMaturityDate" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NotionalAmountAmortizableByMaturityDate" xlink:to="lab_dva_NotionalAmountAmortizableByMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4ea2bb8e-e8b2-484a-9c32-7a5b89513bd9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of Interest Rate Swap and Cap Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_b21547e1-8578-4453-a458-887e05b9f012_terseLabel_en-US" xlink:label="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</link:label>
    <link:label id="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_label_en-US" xlink:label="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</link:label>
    <link:label id="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_documentation_en-US" xlink:label="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:href="dva-20241231.xsd#dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:to="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_7d7b7a4d-78ac-4a68-9423-9da07a898dae_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_24ee8c0a-ce19-4502-81d3-a4beb02519e3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_6a2c95db-1804-4025-8b5f-83eba551fdae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CHCTemporaryFundingAssistanceFairValue_efd3b1ae-fbdd-4e1c-a142-bdcf0c0d8dab_terseLabel_en-US" xlink:label="lab_dva_CHCTemporaryFundingAssistanceFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHC Temporary Funding Assistance, Fair Value</link:label>
    <link:label id="lab_dva_CHCTemporaryFundingAssistanceFairValue_label_en-US" xlink:label="lab_dva_CHCTemporaryFundingAssistanceFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHC Temporary Funding Assistance, Fair Value</link:label>
    <link:label id="lab_dva_CHCTemporaryFundingAssistanceFairValue_documentation_en-US" xlink:label="lab_dva_CHCTemporaryFundingAssistanceFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CHC Temporary Funding Assistance, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CHCTemporaryFundingAssistanceFairValue" xlink:href="dva-20241231.xsd#dva_CHCTemporaryFundingAssistanceFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CHCTemporaryFundingAssistanceFairValue" xlink:to="lab_dva_CHCTemporaryFundingAssistanceFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_c1c7a3f2-1c5e-4d15-90c4-0701b2d67928_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa92d1a7-d6ee-47fc-b67b-ba528552fed4_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0d8155a2-3fab-49c2-b4cf-8dc396315984_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_42da4943-6fda-4052-a3f1-e4faab74cbb8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_baceee1e-ac11-491a-bb4c-c2089ee63f0a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f35c6154-91e0-4202-b619-b8bfe1816dad_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74d6add8-80cb-48bd-aa56-a2b5476bcacd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_eb24f0b3-d3d8-43c9-a41e-cbda7ff9cbb9_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term and long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_81b67f0a-4246-4f6a-a578-ac2ad417442a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8ffd9670-b6d4-4a55-96f3-276b951f912f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8d37b12a-cd11-4afb-a097-ee02ac510dd9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ba95e0b4-32d4-4648-9b2e-c876b25fc832_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a0202044-1c65-4984-8521-4c5bf0f756d8_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fcbcac1b-1efd-4433-9867-520f74fbd4ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scheduled Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_ef5403d1-e873-489d-833c-c813d8017dc8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2336e859-664f-4f93-8845-2f4d7a2acf00_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_119c591b-bb23-49d8-b7d3-d2c06fab5c4c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Date of First Required Payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Date of First Required Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:to="lab_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_bdacdcdf-15e5-4cf4-9893-ef6f34a40f17_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent purchase price and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_517b72af-ce17-4ce1-8e0e-e29227e7b854_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_18c72ea7-fff8-4aaa-9ec0-b4226c350851_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_39af2197-ce31-4696-b187-d347d5d213e3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_23ebd2ce-3994-41a1-ad67-fd853b66966b_terseLabel_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_label_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_documentation_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:to="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_daa2aa8c-46c3-4f55-92f1-2b9698a8dd7d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_49948f38-11c6-45d6-854b-922b91e06ab3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_6e1c46a5-bf15-4749-88c7-3090ca9b02df_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from accumulated other comprehensive income into net income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_c8200166-4a24-4e3e-9aeb-5bce5b4bf414_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_16a4503a-a0b0-4d45-bfe6-23a309f7fb01_negatedLabel_en-US" xlink:label="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Distributions</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_label_en-US" xlink:label="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:href="dva-20241231.xsd#dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:to="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5f4dc18f-fa12-46e0-ac1d-a22e690ed7eb_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase cost recognized</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a8a1c8cc-0e65-4b80-b4bd-8bfbaba80783_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9f0ebd51-286c-4d7c-9567-6c8cf508f4ee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersubsegmentEliminationsMember_30fe6573-f73c-4bf5-b3e1-5f27214dfc84_terseLabel_en-US" xlink:label="lab_us-gaap_IntersubsegmentEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intersubsegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersubsegmentEliminationsMember_label_en-US" xlink:label="lab_us-gaap_IntersubsegmentEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intersubsegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersubsegmentEliminationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersubsegmentEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersubsegmentEliminationsMember" xlink:to="lab_us-gaap_IntersubsegmentEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_8c865055-98a5-410c-91b9-320112264122_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap and cap agreements</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_32bba357-34d2-414a-8e0f-ddf966a2a891_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_38b8b10e-28ab-4fa8-b637-a3bc6cc492b1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureTable_9b89525d-7d17-4930-a7f9-22bd38fe2498_terseLabel_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureTable_label_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureTable_documentation_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureTable" xlink:href="dva-20241231.xsd#dva_CommitmentsAndContingenciesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable" xlink:to="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RelatedPartyTransactionDescriptionOfTransaction1_abb6cc1e-103e-4ebb-ac71-5d7f5ce3de76_terseLabel_en-US" xlink:label="lab_dva_RelatedPartyTransactionDescriptionOfTransaction1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Description of Transaction 1</link:label>
    <link:label id="lab_dva_RelatedPartyTransactionDescriptionOfTransaction1_label_en-US" xlink:label="lab_dva_RelatedPartyTransactionDescriptionOfTransaction1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Description of Transaction 1</link:label>
    <link:label id="lab_dva_RelatedPartyTransactionDescriptionOfTransaction1_documentation_en-US" xlink:label="lab_dva_RelatedPartyTransactionDescriptionOfTransaction1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Description of Transaction 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RelatedPartyTransactionDescriptionOfTransaction1" xlink:href="dva-20241231.xsd#dva_RelatedPartyTransactionDescriptionOfTransaction1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RelatedPartyTransactionDescriptionOfTransaction1" xlink:to="lab_dva_RelatedPartyTransactionDescriptionOfTransaction1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RelatedPartyTransactionDescriptionOfTransaction2_15124773-de56-4c63-bc94-fc10732de03d_terseLabel_en-US" xlink:label="lab_dva_RelatedPartyTransactionDescriptionOfTransaction2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Description of Transaction 2</link:label>
    <link:label id="lab_dva_RelatedPartyTransactionDescriptionOfTransaction2_label_en-US" xlink:label="lab_dva_RelatedPartyTransactionDescriptionOfTransaction2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Description of Transaction 2</link:label>
    <link:label id="lab_dva_RelatedPartyTransactionDescriptionOfTransaction2_documentation_en-US" xlink:label="lab_dva_RelatedPartyTransactionDescriptionOfTransaction2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Description of Transaction 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RelatedPartyTransactionDescriptionOfTransaction2" xlink:href="dva-20241231.xsd#dva_RelatedPartyTransactionDescriptionOfTransaction2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RelatedPartyTransactionDescriptionOfTransaction2" xlink:to="lab_dva_RelatedPartyTransactionDescriptionOfTransaction2" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AgreementWithMedtronicMember_bf74897c-7a1b-4053-ad35-90268d80300e_terseLabel_en-US" xlink:label="lab_dva_AgreementWithMedtronicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mozarc Medical Holding LLC</link:label>
    <link:label id="lab_dva_AgreementWithMedtronicMember_label_en-US" xlink:label="lab_dva_AgreementWithMedtronicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement with Medtronic [Member]</link:label>
    <link:label id="lab_dva_AgreementWithMedtronicMember_documentation_en-US" xlink:label="lab_dva_AgreementWithMedtronicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (NewCo).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember" xlink:href="dva-20241231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AgreementWithMedtronicMember" xlink:to="lab_dva_AgreementWithMedtronicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfConcentrationRiskCustomers_b8246eb9-127b-403f-90fd-b802cb68a28c_terseLabel_en-US" xlink:label="lab_dva_NumberOfConcentrationRiskCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of concentration risk customers</link:label>
    <link:label id="lab_dva_NumberOfConcentrationRiskCustomers_label_en-US" xlink:label="lab_dva_NumberOfConcentrationRiskCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Concentration Risk Customers</link:label>
    <link:label id="lab_dva_NumberOfConcentrationRiskCustomers_documentation_en-US" xlink:label="lab_dva_NumberOfConcentrationRiskCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Concentration Risk Customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfConcentrationRiskCustomers" xlink:href="dva-20241231.xsd#dva_NumberOfConcentrationRiskCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfConcentrationRiskCustomers" xlink:to="lab_dva_NumberOfConcentrationRiskCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_82b1a0aa-813f-4f4b-9f03-09492ea4a8d8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_5174b13e-8fa6-4897-b767-e04f260ef3f7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_ac20a757-e0f6-4c68-b18b-23d8fd3cfbe5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma total revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DiscountPremiumAndDeferredFinanceCosts_703170d5-39da-4807-a6c2-b6e85207d16c_negatedLabel_en-US" xlink:label="lab_dva_DiscountPremiumAndDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Discount, premium and deferred financing costs</link:label>
    <link:label id="lab_dva_DiscountPremiumAndDeferredFinanceCosts_label_en-US" xlink:label="lab_dva_DiscountPremiumAndDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount, Premium and Deferred Finance Costs</link:label>
    <link:label id="lab_dva_DiscountPremiumAndDeferredFinanceCosts_documentation_en-US" xlink:label="lab_dva_DiscountPremiumAndDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discount, premium and deferred financing costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountPremiumAndDeferredFinanceCosts" xlink:href="dva-20241231.xsd#dva_DiscountPremiumAndDeferredFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DiscountPremiumAndDeferredFinanceCosts" xlink:to="lab_dva_DiscountPremiumAndDeferredFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_f8ebe321-f7c6-49ee-809c-c0da13b42fa7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_8e16edda-05bc-4776-ac6b-9b90f701954b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_72085039-9acf-4e6d-82eb-16628fa9450a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e8771bbe-1bed-40ab-8dde-a3b93d840d27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_effe7980-2cc8-402c-b004-226857cfcd96_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributions from equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_8114cb13-1df6-496d-9a09-5ae72c170051_negatedLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_label_en-US" xlink:label="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests Reclassifications And Expirations Of Put Obligations</link:label>
    <link:label id="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests Reclassifications And Expirations Of Put Obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:to="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_04736e8f-30d7-47cb-bc11-98b1ed6c47c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets and Liabilities Arising from Temporary Differences</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeFourMember_dcd0f275-344e-4956-8c1c-17589d149c0c_terseLabel_en-US" xlink:label="lab_dva_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$100.01&#8211;$110.00</link:label>
    <link:label id="lab_dva_RangeFourMember_label_en-US" xlink:label="lab_dva_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Four [Member]</link:label>
    <link:label id="lab_dva_RangeFourMember_documentation_en-US" xlink:label="lab_dva_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range Four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFourMember" xlink:href="dva-20241231.xsd#dva_RangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeFourMember" xlink:to="lab_dva_RangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_80458ca7-4390-4028-88b3-230842eff858_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_477b1a0f-6639-4b93-a6dc-e9715d07ecce_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_601d8597-d5de-4a21-83f9-c5603c9d5175_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_185c4406-5934-4e78-9c6c-121352dcf693_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_dfdeed2f-1bb7-46c9-89ca-d56f46904043_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_5d351b5d-507e-4f56-abf3-de44309180ae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6c4cdce1-4391-45ab-a83b-3cd224c83ad7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_fde7ccef-d2af-4ef6-ba41-b3af4cc6865e_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_1920d057-ee26-4b3a-a1e7-27adcd39f60e_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExpectedAmortizationExpenseLineItems_c79f51d1-e8b1-4378-983c-1622b645e473_terseLabel_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Amortization Expense [Line Items]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseLineItems_label_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Amortization Expense [Line Items]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseLineItems_documentation_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Amortization Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseLineItems" xlink:href="dva-20241231.xsd#dva_ExpectedAmortizationExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems" xlink:to="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_e53f9a65-1176-43c0-8234-23cb43695f2d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_6bbb0fc0-fad3-4254-b322-6748ec902f34_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_299dfb8e-58a3-46b8-853b-8ba40cc5708d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_00ed6178-0ab6-47bf-a180-99f243cfe5b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other loss, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_ed65bcaf-53e0-4016-850d-66243ba66d37_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_271786f7-a8c2-46f6-b7bb-06b7698a08b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_73d7d9d9-d83b-449b-8f38-3127715a146d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net of accumulated amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d936d5ee-4635-4a76-93c9-f0948c9bd2b9_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_39019b08-53c0-456c-a26e-e69586dd0903_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeTaxesTable_7198ae46-61e5-42de-bb6f-1457261a82c4_terseLabel_en-US" xlink:label="lab_dva_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_dva_IncomeTaxesTable_label_en-US" xlink:label="lab_dva_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_dva_IncomeTaxesTable_documentation_en-US" xlink:label="lab_dva_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable" xlink:href="dva-20241231.xsd#dva_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeTaxesTable" xlink:to="lab_dva_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_3e8876c0-de9e-40b6-af91-375abf5a5bea_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_128a580b-6b94-4a13-8e47-96f92ffd8d86_negatedTerseLabel_en-US" xlink:label="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of other debt and equity investments</link:label>
    <link:label id="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_label_en-US" xlink:label="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Other Debt And Equity Investments</link:label>
    <link:label id="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_documentation_en-US" xlink:label="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Other Debt And Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:href="dva-20241231.xsd#dva_PaymentsToAcquireOtherDebtAndEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:to="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3e4a3689-045f-4962-b489-7a2573329fbb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_185c91f2-ae26-43e0-9eab-7955fdc97aa0_terseLabel_en-US" xlink:label="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Accounts Receivable Six Months Or More Past Due</link:label>
    <link:label id="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_label_en-US" xlink:label="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Accounts Receivable Six Months Or More Past Due</link:label>
    <link:label id="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_documentation_en-US" xlink:label="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Accounts Receivable , 6 months or More Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:href="dva-20241231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:to="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BaseRateLoansMember_4038afef-674e-4b1c-adc1-3fe239b855fb_terseLabel_en-US" xlink:label="lab_dva_BaseRateLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate Loans</link:label>
    <link:label id="lab_dva_BaseRateLoansMember_label_en-US" xlink:label="lab_dva_BaseRateLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate Loans [Member]</link:label>
    <link:label id="lab_dva_BaseRateLoansMember_documentation_en-US" xlink:label="lab_dva_BaseRateLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Base Rate Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BaseRateLoansMember" xlink:href="dva-20241231.xsd#dva_BaseRateLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BaseRateLoansMember" xlink:to="lab_dva_BaseRateLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98cc0b95-c203-4e94-a491-b6a6cbe24e35_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_2e05b3dd-5f6a-4bba-859e-cc41538f43a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_91f8537c-3b10-43c4-a4da-1c4b7d54b6d7_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other - Ancillary services</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_386054e4-8cb4-4863-b043-7c3d26748b15_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from asset and business sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4d92fc39-9910-41f3-97d9-b0a051cdab63_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_eec1e043-5025-4a06-aed6-b428c70cdc0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_11611188-e795-4dbc-af40-7479f74cd053_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma diluted net income per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_2486525c-f9b4-4c3e-a003-dc805dd833c0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_aa704b2e-9191-443c-9865-8642e831e32b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionDescription_97aac831-a070-47b9-bf9b-977162e941d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionDescription_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionDescription" xlink:to="lab_us-gaap_DebtInstrumentRedemptionDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_842a2298-bd66-4ca0-9fb9-23dbd2e78280_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_343331d6-f4f7-4bc1-a56c-48378099063b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_cabc761b-16c6-4804-9ef5-970f4c65a582_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_115bcc9c-783c-4e40-9e22-6f3dec739cb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8d0cb227-b001-4192-822a-2741242293c1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2017USAttorneyColoradoInvestigationMember_f4b96f9c-3f8e-4b6d-8c3d-f6471e9c0b35_terseLabel_en-US" xlink:label="lab_dva_A2017USAttorneyColoradoInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 U S Attorney Colorado Investigation</link:label>
    <link:label id="lab_dva_A2017USAttorneyColoradoInvestigationMember_label_en-US" xlink:label="lab_dva_A2017USAttorneyColoradoInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 U S Attorney Colorado Investigation [Member]</link:label>
    <link:label id="lab_dva_A2017USAttorneyColoradoInvestigationMember_documentation_en-US" xlink:label="lab_dva_A2017USAttorneyColoradoInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 U S Attorney Colorado Investigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2017USAttorneyColoradoInvestigationMember" xlink:href="dva-20241231.xsd#dva_A2017USAttorneyColoradoInvestigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2017USAttorneyColoradoInvestigationMember" xlink:to="lab_dva_A2017USAttorneyColoradoInvestigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentVariableRate_22665c31-73cf-4828-ab52-49af890715a5_terseLabel_en-US" xlink:label="lab_dva_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Rate</link:label>
    <link:label id="lab_dva_DebtInstrumentVariableRate_label_en-US" xlink:label="lab_dva_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Rate</link:label>
    <link:label id="lab_dva_DebtInstrumentVariableRate_documentation_en-US" xlink:label="lab_dva_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentVariableRate" xlink:href="dva-20241231.xsd#dva_DebtInstrumentVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentVariableRate" xlink:to="lab_dva_DebtInstrumentVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_dfa1e030-2ed2-4b3f-80b1-e5a7130a39f4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3310c795-a7e5-4133-8482-5a742bd09d48_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicaidandManagedMedicaidMember_eed7c235-e7c7-4d68-b9de-100d74d78486_terseLabel_en-US" xlink:label="lab_dva_MedicaidandManagedMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicaid and Managed Medicaid</link:label>
    <link:label id="lab_dva_MedicaidandManagedMedicaidMember_label_en-US" xlink:label="lab_dva_MedicaidandManagedMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicaid and Managed Medicaid [Member]</link:label>
    <link:label id="lab_dva_MedicaidandManagedMedicaidMember_documentation_en-US" xlink:label="lab_dva_MedicaidandManagedMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicaid and Managed Medicaid Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicaidandManagedMedicaidMember" xlink:href="dva-20241231.xsd#dva_MedicaidandManagedMedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicaidandManagedMedicaidMember" xlink:to="lab_dva_MedicaidandManagedMedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_b576b2c9-2538-4332-b039-49d3b21adadd_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_dbc7f344-2722-408f-a8eb-f008225c0eca_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1_7867bcbf-ff72-47bc-8b25-84145c34ad8c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date Range, Start</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date Range, Start</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_22f88c82-a22a-4d95-ad4f-0d36692cf409_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_30b4a2e4-892b-4a5a-aa3d-8acf81334f50_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock award plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_a6cb9596-02a4-450e-90af-14978536d877_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_44421b33-6419-4e2f-ad0e-62d6863520ff_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherGovernmentPayorsMember_bf5179e7-0143-4ff0-bfc0-53d4a9888d10_terseLabel_en-US" xlink:label="lab_dva_OtherGovernmentPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Government Payors</link:label>
    <link:label id="lab_dva_OtherGovernmentPayorsMember_label_en-US" xlink:label="lab_dva_OtherGovernmentPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Government Payors [Member]</link:label>
    <link:label id="lab_dva_OtherGovernmentPayorsMember_documentation_en-US" xlink:label="lab_dva_OtherGovernmentPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other government payors in healthcare industry.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherGovernmentPayorsMember" xlink:href="dva-20241231.xsd#dva_OtherGovernmentPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherGovernmentPayorsMember" xlink:to="lab_dva_OtherGovernmentPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f723abbf-58b8-4273-a1f1-603396f04531_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_9ddcf850-9323-4543-9215-b814f1ec0bfa_terseLabel_en-US" xlink:label="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net effect of transfers from to noncontrolling interests on stock holders equity disclosure</link:label>
    <link:label id="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_label_en-US" xlink:label="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Effect Of Transfers From To Noncontrolling Interests On Stock Holders Equity Disclosure [Text Block]</link:label>
    <link:label id="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_documentation_en-US" xlink:label="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:href="dva-20241231.xsd#dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:to="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock_fe5073e4-61a2-443a-896b-fa23265cb0d7_terseLabel_en-US" xlink:label="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Self insurance</link:label>
    <link:label id="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock_label_en-US" xlink:label="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance And Self Insurance Policy [Text Block]</link:label>
    <link:label id="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock_documentation_en-US" xlink:label="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance and self insurance policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:href="dva-20241231.xsd#dva_InsuranceAndSelfInsurancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:to="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2dd2c548-af53-4886-8124-b95ea9e2525d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_e4aa0c44-d433-4d81-9861-87914a88188f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312026Member_b2455286-83ec-441d-9384-ffa87b2df95f_terseLabel_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2026</link:label>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312026Member_label_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2026 [Member]</link:label>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312026Member_documentation_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312026Member" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TotalNotionalAmountEffectiveThroughDecember312026Member" xlink:to="lab_dva_TotalNotionalAmountEffectiveThroughDecember312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_08f7ae27-19d5-4752-9a16-1021cb0c55f0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_675b2f6e-e3ba-4a2f-a5c4-bb8c18b38342_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_0a08fa5c-7842-4854-acc4-d0a6e3a3ba5c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfSites_d4531d9e-03b2-4e72-ae60-aef6d93e6fd6_terseLabel_en-US" xlink:label="lab_dva_NumberOfSites" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of dialysis centers that the company operated or provided administrative services</link:label>
    <link:label id="lab_dva_NumberOfSites_label_en-US" xlink:label="lab_dva_NumberOfSites" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Sites</link:label>
    <link:label id="lab_dva_NumberOfSites_documentation_en-US" xlink:label="lab_dva_NumberOfSites" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of sites.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfSites" xlink:href="dva-20241231.xsd#dva_NumberOfSites"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfSites" xlink:to="lab_dva_NumberOfSites" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_36d5d83b-ebf9-4e1e-8bcc-3ba1aaaad1b9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeverageRatioCovenant_7efe3be7-e832-4e2c-a552-eaf97cd5adf8_terseLabel_en-US" xlink:label="lab_dva_LeverageRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant</link:label>
    <link:label id="lab_dva_LeverageRatioCovenant_label_en-US" xlink:label="lab_dva_LeverageRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant</link:label>
    <link:label id="lab_dva_LeverageRatioCovenant_documentation_en-US" xlink:label="lab_dva_LeverageRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leverage Ratio Covenant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenant" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeverageRatioCovenant" xlink:to="lab_dva_LeverageRatioCovenant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_46baf28a-c2ad-423d-bcf1-4896644b1474_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b039ad3b-28f3-458b-894c-70a3c7c2d58e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_4acd1bd4-e443-4cef-b577-5f50f25cfee1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_682dd2dc-4c8a-4f72-963c-45f36b7bcc53_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships and other</link:label>
    <link:label id="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_cc7625c8-7e39-4722-ace5-5f777ac222d6_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EmployeeStockPurchasePlanMember_9e24f6a0-2ea4-42e8-baea-564be154bf47_terseLabel_en-US" xlink:label="lab_dva_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_dva_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_dva_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dva_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_dva_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember" xlink:href="dva-20241231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EmployeeStockPurchasePlanMember" xlink:to="lab_dva_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_0371dceb-1022-47ba-83f5-b2451ded0d67_terseLabel_en-US" xlink:label="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Targets or Quality Margins</link:label>
    <link:label id="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_label_en-US" xlink:label="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E B I T D A Operating Income Performance Targets Or Quality Margins [Member]</link:label>
    <link:label id="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_documentation_en-US" xlink:label="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EBITDA operating income performance targets or quality margins.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:href="dva-20241231.xsd#dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:to="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_61515103-7c14-44c7-bbfa-1b76747cfd42_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1d0cb0cb-08d0-470d-8eeb-b97fd3dee035_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_90a7ec47-e847-48cc-b1f0-686d75790887_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_ecd99d79-be18-44ae-aa0d-b04af1040caa_terseLabel_en-US" xlink:label="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit and other time deposits</link:label>
    <link:label id="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_label_en-US" xlink:label="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates Of Deposit Commercial Paper And Money Market Funds [Member]</link:label>
    <link:label id="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_documentation_en-US" xlink:label="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certificates of deposit, commercial paper, and money market funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:href="dva-20241231.xsd#dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:to="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_c09bd9de-26fb-4653-914b-dabe3df22842_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Holdings [Line Items]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0d0a2e37-c380-4c12-8318-2a48e779c099_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_48d3b9d0-794b-4bc6-a0a1-90a6d38a6a13_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_17af38d8-51dd-4b21-bed7-f6f6dd2872a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_0aab396d-282e-4a25-9a7d-f556dfec1bca_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_9980a34b-4114-480b-8044-16ffa1b7ba47_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_ec72441b-47ef-4013-931a-271b470deb47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, maturity date, description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_fdefd7c5-97ba-4d26-b954-6f3d5c55a991_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest, net</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9068f916-f1f4-4a70-a4df-cd06b7af70a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted&#160;prices&#160;in active&#160;markets&#160;for identical assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_62b6ba24-6acc-47d5-a8c7-33f2cce85327_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_deccafff-c7ad-43c0-b104-53a0bc8c3ba8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_509aa229-1113-4a99-83e4-a8c26902ffa8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_add36382-224d-4981-866a-5695881f2e2e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Terms and Manner of Settlement</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Terms and Manner of Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="lab_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_066af3e7-c165-4dd6-accb-bad1ac5f3e6a_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_ab94cf9b-2036-43f3-be2f-6f49f0266eca_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0ae7b71b-e674-4884-8836-bb0e8fb1c492_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_65483c1b-c986-49c5-bd64-6b2799a0257f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ff088742-bd5f-42e9-bff9-c0700b213bcf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_a2a4b830-3494-4641-a863-d4a5a62bf4ea_totalLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesDisclosureTable_ea40dcf6-8a5e-4be2-8391-8422df0c5e42_terseLabel_en-US" xlink:label="lab_dva_LeasesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases Disclosure [Table]</link:label>
    <link:label id="lab_dva_LeasesDisclosureTable_label_en-US" xlink:label="lab_dva_LeasesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases Disclosure [Table]</link:label>
    <link:label id="lab_dva_LeasesDisclosureTable_documentation_en-US" xlink:label="lab_dva_LeasesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTable" xlink:href="dva-20241231.xsd#dva_LeasesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesDisclosureTable" xlink:to="lab_dva_LeasesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6ba6aec1-8f5c-4c08-90fe-c7690408ee24_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value of grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_61ad1f95-2d94-473d-9a70-4b7ef71ed298_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_382f67ac-8e84-4b41-8a2e-532b759cac7c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_4e94415b-ad98-4d70-95e3-be3e9f718e46_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_606833fe-7213-4cd4-a751-f9a46bea3ed6_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3432c57c-bbf5-4ab4-ade1-4d8843aeb18b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e45d7d66-3d44-4ffa-9d69-a61e03b3adc9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_db021b9a-1ae5-4f03-ae36-c4388b725111_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_9dd8b5c2-d5e7-4ea0-84e5-2ce839886a59_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_6accd1b1-1f68-405c-ab57-7eca65c93d52_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued non-income tax liabilities</link:label>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_5de56f72-3785-4e2e-956b-e00be868c158_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term Investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:to="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_54b70dfb-d451-4b4f-848b-05403053363a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_d042818b-d11e-4fb9-9bc6-24e12f8d70cd_terseLabel_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_label_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_documentation_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:to="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b490803e-ce46-4ead-bac6-f91629fa6446_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_12312201-74cb-4262-b3d2-9b40ceb4a5f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cf663f19-1edb-49dc-9ebd-6ba9d7e3a0d4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c372455b-e63f-4c2a-88d9-e1ee67e8e446_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312025Member_9893572e-97ac-40a5-8d5c-f54e1b8c3cab_terseLabel_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2025</link:label>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312025Member_label_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2025 [Member]</link:label>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312025Member_documentation_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312025Member" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TotalNotionalAmountEffectiveThroughDecember312025Member" xlink:to="lab_dva_TotalNotionalAmountEffectiveThroughDecember312025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_013a2514-55c9-4e4f-a12f-a085faba75f3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding_b240afa1-020f-421e-8e27-c0535d6de1d9_terseLabel_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Quarterly Payment, % of Beginning Balance Outstanding</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding_label_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Quarterly Payment, % of Beginning Balance Outstanding</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding_documentation_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Quarterly Payment, % of Beginning Balance Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding" xlink:href="dva-20241231.xsd#dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding" xlink:to="lab_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_eddfdd40-5c42-482f-90f5-76623828ba78_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8ea51b11-a0ad-4f9d-ac32-21efd3daf0c8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_6a87b2ef-0aca-42c5-aba9-78561549268d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ChangeHealthcareTemporaryFundingAssistanceMember_cb7042ea-045a-4adc-aa07-a2366119d67a_terseLabel_en-US" xlink:label="lab_dva_ChangeHealthcareTemporaryFundingAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change Healthcare Temporary Funding Assistance</link:label>
    <link:label id="lab_dva_ChangeHealthcareTemporaryFundingAssistanceMember_label_en-US" xlink:label="lab_dva_ChangeHealthcareTemporaryFundingAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change Healthcare Temporary Funding Assistance [Member]</link:label>
    <link:label id="lab_dva_ChangeHealthcareTemporaryFundingAssistanceMember_documentation_en-US" xlink:label="lab_dva_ChangeHealthcareTemporaryFundingAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change Healthcare Temporary Funding Assistance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ChangeHealthcareTemporaryFundingAssistanceMember" xlink:href="dva-20241231.xsd#dva_ChangeHealthcareTemporaryFundingAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ChangeHealthcareTemporaryFundingAssistanceMember" xlink:to="lab_dva_ChangeHealthcareTemporaryFundingAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_68210f40-2300-4204-8e2e-fe196f996c82_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a539af83-d598-40cc-ad2a-a8aea01c4e96_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense on property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_0597adf8-5b8c-420b-be27-96fde6a5415a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d285926f-5e1f-4bf9-99ee-a60e9dd42829_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_42fbab79-a4a6-4a99-802f-ecfe9334805b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8b4cb589-30ab-467e-9882-3477ae23ce2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant&#160;other observable&#160;inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e6591ea9-ba6b-43e1-8c56-58b0adf22c50_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fd3b6dac-d210-4880-9d31-d91c10158e70_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_450b4bfb-efc0-47cd-88da-5143f0eeaf07_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1bc5c241-1b9d-4c33-839e-53a883ebefeb_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_298ce19b-fc0d-4567-9251-835cc0765a09_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0ccd4785-ee41-4680-9f4e-f83c20173d19_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_24ad8eb8-519c-45d4-ad42-cc6c50c83d79_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_96eaf367-3142-4bfe-ab58-ee8cff0ed34c_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_06881949-aba9-4214-9791-988f433e95a6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_811c2382-2c12-40c6-81d7-741d926e0b60_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TaxYear2029Member_86ff993f-f622-481e-b991-fed65a39ca83_terseLabel_en-US" xlink:label="lab_dva_TaxYear2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2029</link:label>
    <link:label id="lab_dva_TaxYear2029Member_label_en-US" xlink:label="lab_dva_TaxYear2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2029 [Member]</link:label>
    <link:label id="lab_dva_TaxYear2029Member_documentation_en-US" xlink:label="lab_dva_TaxYear2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TaxYear2029Member" xlink:href="dva-20241231.xsd#dva_TaxYear2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TaxYear2029Member" xlink:to="lab_dva_TaxYear2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_79dc9a5a-86b9-42c1-970a-d9f6940cd4e5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt, interest rate at a point in time.</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessSaleEffectiveDateOfSale_e92453cd-b375-4be2-94a3-d8cc8a552039_terseLabel_en-US" xlink:label="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Sale, Effective Date Of Sale</link:label>
    <link:label id="lab_dva_BusinessSaleEffectiveDateOfSale_label_en-US" xlink:label="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Sale, Effective Date Of Sale</link:label>
    <link:label id="lab_dva_BusinessSaleEffectiveDateOfSale_documentation_en-US" xlink:label="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Sale, Effective Date Of Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale" xlink:href="dva-20241231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessSaleEffectiveDateOfSale" xlink:to="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_d2a873dd-921a-4e04-b6e7-9812d5124171_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2d7032e2-8cab-4082-ae62-8fa02f674b66_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_0f289197-038b-44e9-97f6-c320cce34fa8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3cece996-1c51-4650-9831-01d3348a0a58_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_50cd79c7-a59c-40b8-8ee8-ffa3da70bb5c_terseLabel_en-US" xlink:label="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</link:label>
    <link:label id="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_label_en-US" xlink:label="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</link:label>
    <link:label id="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_documentation_en-US" xlink:label="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:href="dva-20241231.xsd#dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:to="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7b0525f4-41cc-4cc3-a4e2-0a364c7a8097_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_587d05d2-c85d-497c-ad80-71e45c70f861_terseLabel_en-US" xlink:label="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Recognized on its Previously Held Equity Interest in Acquiree [Domain]</link:label>
    <link:label id="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_label_en-US" xlink:label="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Recognized on its Previously Held Equity Interest in Acquiree [Domain]</link:label>
    <link:label id="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_documentation_en-US" xlink:label="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Recognized on its Previously Held Equity Interest in Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain" xlink:to="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d7308314-5854-4fb2-a8ef-326f6773d336_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_28ada5d0-0fb1-40b5-b2f8-6ec4a4b250e4_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_cacc6237-355a-4a1f-8db5-da232d88d471_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_cb9a3f45-92d6-4b42-a81d-1e3a2bf8a5b3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_adb51339-d1e3-461c-abec-d3fbf7f311fb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net income</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_fbede641-97f7-49b4-88ec-5e01f418f578_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Basic net income per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_3621e6ec-9c35-46d8-95fd-64e0b1e7fb31_terseLabel_en-US" xlink:label="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes 3.75% due 2031</link:label>
    <link:label id="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_label_en-US" xlink:label="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Seven Five Percent Due Twenty Thirty One [Member]</link:label>
    <link:label id="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_documentation_en-US" xlink:label="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Seven Five Percent Due Twenty Thirty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:href="dva-20241231.xsd#dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:to="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_6626c21e-f890-42c0-a8e2-1a3d6378500b_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_5aa207c2-c1de-445a-9b4f-53feceec84cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_87f60dda-d9b8-4e77-9b76-061c804449fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, expiration date</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ea46e275-b188-4d67-899a-121dbbab0063_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terms of award (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_e488cbba-c399-4433-b165-531a5528e529_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in partnerships</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_0731c2d0-8f10-4428-964d-93d151364fbd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_bf27a572-1f46-4929-9630-d1c8a32a7c7d_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_d59cf54d-297f-4976-949e-2f3304ecf19a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d22afcc5-0949-4a19-b22b-5fdcbb1b97f3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b528353f-b886-43d4-b793-0027f112239f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_39a00aae-6a75-4bfd-8c3a-b2055dd1ebc9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_b41b062c-ee66-43d0-b4fb-53fe2dadda4b_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_63e04572-ea0e-40f0-acdb-e11eadef0efa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5ee32ac6-8750-4956-826e-ee77c08ceb16_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74c99beb-7ec8-4419-b8d9-fd74d735e0a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_0d6e6d84-6c00-48db-92d2-4c9aece256b8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains on defined benefit plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312024Member_1a73a90c-bf7f-4dcc-b672-1be620b89934_terseLabel_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2024</link:label>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312024Member_label_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2024 [Member]</link:label>
    <link:label id="lab_dva_TotalNotionalAmountEffectiveThroughDecember312024Member_documentation_en-US" xlink:label="lab_dva_TotalNotionalAmountEffectiveThroughDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Notional Amount Effective Through December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312024Member" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TotalNotionalAmountEffectiveThroughDecember312024Member" xlink:to="lab_dva_TotalNotionalAmountEffectiveThroughDecember312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherReportingUnitsMember_460d6e96-0f1c-4d1a-bca0-74298dfcfb73_terseLabel_en-US" xlink:label="lab_dva_OtherReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other reporting units</link:label>
    <link:label id="lab_dva_OtherReportingUnitsMember_label_en-US" xlink:label="lab_dva_OtherReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Reporting Units [Member]</link:label>
    <link:label id="lab_dva_OtherReportingUnitsMember_documentation_en-US" xlink:label="lab_dva_OtherReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Reporting Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember" xlink:href="dva-20241231.xsd#dva_OtherReportingUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherReportingUnitsMember" xlink:to="lab_dva_OtherReportingUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_39cd2e93-aa65-4b07-a62e-66764578724b_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets other than Goodwill</link:label>
    <link:label id="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Finite And Indefinite Intangible Assets Table [Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Finite And Indefinite Intangible Assets Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:href="dva-20241231.xsd#dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:to="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_bf6ca039-4324-4a06-b961-3ba8feaa3d26_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt expense</link:label>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_label_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense" xlink:to="lab_us-gaap_InterestAndDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_6d80823a-7d1a-46b1-a93a-7bec3d74ab5d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_3e94d4c5-6aac-421f-9b19-196b5ba33c80_terseLabel_en-US" xlink:label="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Recognized on its Previously Held Equity Interest in Acquiree [Axis]</link:label>
    <link:label id="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_label_en-US" xlink:label="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Recognized on its Previously Held Equity Interest in Acquiree [Axis]</link:label>
    <link:label id="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_documentation_en-US" xlink:label="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Recognized on its Previously Held Equity Interest in Acquiree</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis" xlink:to="lab_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayable_ca107995-3497-4b46-943b-bf0adc3dcf94_terseLabel_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition obligations and other notes payable</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayable_label_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition Obligations And Other Notes Payable</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayable_documentation_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This represents deferred purchase price obligations associated with acquisitions as well as other notes payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:href="dva-20241231.xsd#dva_AcquisitionObligationsAndOtherNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:to="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_27db4652-cf10-4b25-8b5d-53fe38855115_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_553e20f3-7ca1-4cfe-86b4-38c401d9de71_terseLabel_en-US" xlink:label="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_label_en-US" xlink:label="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_documentation_en-US" xlink:label="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:href="dva-20241231.xsd#dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:to="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PayorRefundsAndRetractions_c1c98abe-9047-4550-8ae3-4e4196cd4fd3_terseLabel_en-US" xlink:label="lab_dva_PayorRefundsAndRetractions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payor refunds and retractions</link:label>
    <link:label id="lab_dva_PayorRefundsAndRetractions_label_en-US" xlink:label="lab_dva_PayorRefundsAndRetractions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor Refunds And Retractions</link:label>
    <link:label id="lab_dva_PayorRefundsAndRetractions_documentation_en-US" xlink:label="lab_dva_PayorRefundsAndRetractions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payor Refunds And Retractions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PayorRefundsAndRetractions" xlink:href="dva-20241231.xsd#dva_PayorRefundsAndRetractions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PayorRefundsAndRetractions" xlink:to="lab_dva_PayorRefundsAndRetractions" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesOtherInformationAbstract_8db4ae76-125d-441f-9a0e-3f3c70d6f19a_terseLabel_en-US" xlink:label="lab_dva_LeasesOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases Other Information [Abstract]</link:label>
    <link:label id="lab_dva_LeasesOtherInformationAbstract_label_en-US" xlink:label="lab_dva_LeasesOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases Other Information [Abstract]</link:label>
    <link:label id="lab_dva_LeasesOtherInformationAbstract_documentation_en-US" xlink:label="lab_dva_LeasesOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases Other Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesOtherInformationAbstract" xlink:href="dva-20241231.xsd#dva_LeasesOtherInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesOtherInformationAbstract" xlink:to="lab_dva_LeasesOtherInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7552b27a-4eb0-46aa-9cde-90b4e39b8f7a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_94aa418a-ef98-4404-b86d-b4d9f2f08384_terseLabel_en-US" xlink:label="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of legal entities that third parties held noncontrolling equity interests</link:label>
    <link:label id="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_label_en-US" xlink:label="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Entities That Third Parties Held Non Controlling Equity Interests</link:label>
    <link:label id="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_documentation_en-US" xlink:label="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of entities that third parties held non controlling equity interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:href="dva-20241231.xsd#dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:to="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_198f0cbf-a046-4e74-bc55-7c47915b0d07_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_31cc1196-c80c-46a9-8693-177cfbaf17d9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_37d32f46-3f45-49eb-b9a9-106455bc3868_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of stock awards exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesDisclosureLineItems_681aec8b-ca33-4089-a26a-a78fcfa8c015_terseLabel_en-US" xlink:label="lab_dva_LeasesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_LeasesDisclosureLineItems_label_en-US" xlink:label="lab_dva_LeasesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_LeasesDisclosureLineItems_documentation_en-US" xlink:label="lab_dva_LeasesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureLineItems" xlink:href="dva-20241231.xsd#dva_LeasesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesDisclosureLineItems" xlink:to="lab_dva_LeasesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_5df50ec3-ab14-4efe-b169-52a681b4ed52_terseLabel_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partner Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_label_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partner Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract_45b28ead-a903-43c6-8f96-e9dcce35827e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt disclosure</link:label>
    <link:label id="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:to="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7a105ffb-85bf-49b4-b2dd-8a3c056d55cd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held for Sale and Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f6037045-9e72-41d9-af7d-e59228f95b30_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028_6a619087-39e8-4009-9b7e-86009a494612_terseLabel_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Quarterly Payment From September 30, 2027 Through March 31, 2028</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028_label_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Quarterly Payment From September 30, 2027 Through March 31, 2028</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028_documentation_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Quarterly Payment From September 30, 2027 Through March 31, 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028" xlink:href="dva-20241231.xsd#dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028" xlink:to="lab_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_621493be-4051-4f64-b9ab-95707aee6a8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax expense (benefit), income tax penalties and interest expense, net of federal tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7f2d6dac-cef2-45c2-91ca-f5b3e03a5ce3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_261fe63d-a89f-4d7a-a687-0c219843f59d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a87d0453-86dc-48e8-ab3e-4b7b2db02117_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_ba406ec9-214a-4f95-af26-e8ca4353f838_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_909bfa0b-c668-4639-a970-7f1941597cd8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on changes in ownership interests</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_162819fb-f870-49f3-9f12-59aef93438b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on changes in ownership interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_dac504df-9d7c-4be9-83ae-4bdf4119f660_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember_9d0f71fc-d9a6-40af-be7a-6827d25f6938_terseLabel_en-US" xlink:label="lab_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Gain (Loss) Translation Adjustments</link:label>
    <link:label id="lab_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember_label_en-US" xlink:label="lab_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Gain (Loss) Translation Adjustments [Member]</link:label>
    <link:label id="lab_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember_documentation_en-US" xlink:label="lab_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Gain (Loss) Translation Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember" xlink:href="dva-20241231.xsd#dva_ForeignCurrencyGainLossTranslationAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember" xlink:to="lab_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_ec377496-3f3c-4876-aa69-8f84aac1d93c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExpectedAmortizationExpenseTable_76db12c5-070c-4803-8661-abcd208caed5_terseLabel_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Amortization Expense [Table]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseTable_label_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Amortization Expense [Table]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseTable_documentation_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Amortization Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseTable" xlink:href="dva-20241231.xsd#dva_ExpectedAmortizationExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExpectedAmortizationExpenseTable" xlink:to="lab_dva_ExpectedAmortizationExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_bbce1a82-a914-4c30-a6ce-54ab37c6c577_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_c2bb5b34-23a6-426f-aff7-2084e23aba4e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_290c17e5-4f22-45cb-b167-d26c0db46386_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_81d3f520-ede6-4301-9079-bb6369e5aeac_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_744fbbfc-9db1-40da-b685-2d1871b875b2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of treasury stock acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ee0919ef-f1bb-45c7-8a03-1f47475fee3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4a66e47f-8cb0-4a01-a83d-0e1a7f88fb17_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0748d9f7-f05e-4a2b-809e-d08aac33542b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b5399715-eba0-4dc7-bf11-bcbc44177daf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustableRateLoansMember_23b946e0-8053-4842-b900-99792bbc80b5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustableRateLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted Rate</link:label>
    <link:label id="lab_us-gaap_AdjustableRateLoansMember_label_en-US" xlink:label="lab_us-gaap_AdjustableRateLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustable Rate Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustableRateLoansMember" xlink:to="lab_us-gaap_AdjustableRateLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_d59f5c1f-b176-427e-a8d7-f2b804142b7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of additional noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60cc7a2f-f038-45d6-ad0a-078710f6d95f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments due under operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_2a1ad4cf-5c93-4e53-8c44-0c896001eb70_terseLabel_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Berkshire</link:label>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_label_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrincipalOwnerMember" xlink:to="lab_us-gaap_PrincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8e009706-1b9c-410f-af36-9a9d6dc5335e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a1dc3e0-369c-4361-87e6-d543b032f398_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_42249c82-6ef4-41d0-a1f2-9d719d18e423_negatedTerseLabel_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_label_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Assets</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_documentation_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:href="dva-20241231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:to="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CharterdocumentsandDelawarelawAbstract_b5c905e0-bd62-4316-837c-c56199d823fe_terseLabel_en-US" xlink:label="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charter documents and Delaware law:</link:label>
    <link:label id="lab_dva_CharterdocumentsandDelawarelawAbstract_label_en-US" xlink:label="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charter documents and Delaware law [Abstract]</link:label>
    <link:label id="lab_dva_CharterdocumentsandDelawarelawAbstract_documentation_en-US" xlink:label="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charter documents and Delaware law [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CharterdocumentsandDelawarelawAbstract" xlink:href="dva-20241231.xsd#dva_CharterdocumentsandDelawarelawAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract" xlink:to="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommitmentsToProvideOperatingCapitalMember_c581dcfa-0b08-4289-8bca-371e793fc729_terseLabel_en-US" xlink:label="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments to Provide Operating Capital</link:label>
    <link:label id="lab_dva_CommitmentsToProvideOperatingCapitalMember_label_en-US" xlink:label="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments To Provide Operating Capital [Member]</link:label>
    <link:label id="lab_dva_CommitmentsToProvideOperatingCapitalMember_documentation_en-US" xlink:label="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments to provide operating capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsToProvideOperatingCapitalMember" xlink:href="dva-20241231.xsd#dva_CommitmentsToProvideOperatingCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommitmentsToProvideOperatingCapitalMember" xlink:to="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dfa9eaa8-2b11-4225-adb5-211e5bf25b2b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f0cc834d-3a8c-4c60-a8c1-7855bf72a0d0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeLossFromOtherEquityMethodInvestments_5bf4c0bc-dd97-4538-b9fc-125e9206a5e1_terseLabel_en-US" xlink:label="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investment income (loss) from other equity method investments</link:label>
    <link:label id="lab_dva_IncomeLossFromOtherEquityMethodInvestments_label_en-US" xlink:label="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss From Other Equity Method Investments</link:label>
    <link:label id="lab_dva_IncomeLossFromOtherEquityMethodInvestments_documentation_en-US" xlink:label="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Loss From Other Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:href="dva-20241231.xsd#dva_IncomeLossFromOtherEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:to="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_52249710-f6bc-4511-843f-81f4b07a3c06_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeTwoMember_7317bb0c-cc1e-4daf-93e8-6d63a4400b07_terseLabel_en-US" xlink:label="lab_dva_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label id="lab_dva_RangeTwoMember_label_en-US" xlink:label="lab_dva_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label id="lab_dva_RangeTwoMember_documentation_en-US" xlink:label="lab_dva_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeTwoMember" xlink:href="dva-20241231.xsd#dva_RangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeTwoMember" xlink:to="lab_dva_RangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6ff643fb-f185-4246-bca1-e9cdab70669d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesDisclosureTextBlock_cb89be4f-edd5-4810-a7e5-4f94a309041f_terseLabel_en-US" xlink:label="lab_dva_LeasesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases Disclosure</link:label>
    <link:label id="lab_dva_LeasesDisclosureTextBlock_label_en-US" xlink:label="lab_dva_LeasesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases Disclosure [Text Block]</link:label>
    <link:label id="lab_dva_LeasesDisclosureTextBlock_documentation_en-US" xlink:label="lab_dva_LeasesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases complete footnote disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTextBlock" xlink:href="dva-20241231.xsd#dva_LeasesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesDisclosureTextBlock" xlink:to="lab_dva_LeasesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_dde854d4-5f81-48a7-9d8e-e6a2b3bdf36c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_b0893834-cddf-47e4-a54d-859aa560b4f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d6bb73bd-4d49-43e5-926d-8f4e9c895e85_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_eec07ea1-a7d0-4738-aef4-447b6500892f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SaleLeasebackTransactionRenewalLeaseTerm_f2420ce3-1387-47b0-834a-14ba9a05ebde_terseLabel_en-US" xlink:label="lab_dva_SaleLeasebackTransactionRenewalLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Renewal Lease Term</link:label>
    <link:label id="lab_dva_SaleLeasebackTransactionRenewalLeaseTerm_label_en-US" xlink:label="lab_dva_SaleLeasebackTransactionRenewalLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Renewal Lease Term</link:label>
    <link:label id="lab_dva_SaleLeasebackTransactionRenewalLeaseTerm_documentation_en-US" xlink:label="lab_dva_SaleLeasebackTransactionRenewalLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Renewal Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SaleLeasebackTransactionRenewalLeaseTerm" xlink:href="dva-20241231.xsd#dva_SaleLeasebackTransactionRenewalLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SaleLeasebackTransactionRenewalLeaseTerm" xlink:to="lab_dva_SaleLeasebackTransactionRenewalLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_1c1033b0-89fe-425f-b9e1-6ed2b694ea6f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discounts, Premiums and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1aa33308-3374-41ff-9c2a-0813b6df21ec_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting Equity Interest in Mozarc, Owned by Medtronic</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_4fbb515f-fc99-4c78-8276-775ccd3010d6_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_639d905c-1d1f-49cc-a2b2-6f17e80ba1bf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions from noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Contributions from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_8c76f1f6-f6e1-480f-bc9c-25bf9097b953_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of exercise prices, upper range (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_daf98b70-baae-4914-99d6-f4fb8d1d86ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bc66178-444a-4a6f-bb68-31c6116e15d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_4e8ac50e-579f-4359-986a-c3637d405cc2_terseLabel_en-US" xlink:label="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Operating Lease Assets Obtained In Exchange For Lease Liabilities</link:label>
    <link:label id="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_label_en-US" xlink:label="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Operating Lease Assets Obtained In Exchange For Lease Liabilities</link:label>
    <link:label id="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_documentation_en-US" xlink:label="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Operating Lease Assets Obtained In Exchange For New or Modified Lease Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:href="dva-20241231.xsd#dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:to="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CashPaidDuringPeriodForAbstract_663ba0b3-fbbc-44c1-b015-e78c25406de1_terseLabel_en-US" xlink:label="lab_dva_CashPaidDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid:</link:label>
    <link:label id="lab_dva_CashPaidDuringPeriodForAbstract_label_en-US" xlink:label="lab_dva_CashPaidDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid During Period For [Abstract]</link:label>
    <link:label id="lab_dva_CashPaidDuringPeriodForAbstract_documentation_en-US" xlink:label="lab_dva_CashPaidDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash paid during period for.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CashPaidDuringPeriodForAbstract" xlink:href="dva-20241231.xsd#dva_CashPaidDuringPeriodForAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CashPaidDuringPeriodForAbstract" xlink:to="lab_dva_CashPaidDuringPeriodForAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_69784be3-740c-4368-b8ae-c09b3e5e0663_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LesseeLeaseDescriptionLineItemsAbstract_40727263-c7a1-459b-bc62-d8324740b953_terseLabel_en-US" xlink:label="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_LesseeLeaseDescriptionLineItemsAbstract_label_en-US" xlink:label="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_LesseeLeaseDescriptionLineItemsAbstract_documentation_en-US" xlink:label="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items] [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:href="dva-20241231.xsd#dva_LesseeLeaseDescriptionLineItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:to="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_3f99bc31-5f66-4856-acd8-2eb313bf2430_totalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ac7ea0fe-860a-4e2c-8f38-8b6ec6fe4ec6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_65e8a3aa-a435-49db-a5d0-bef40d6e1e47_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>dva-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:47070f41-4839-4fd6-beb4-023e08dfe312,g:db2e526f-c810-4a70-bbc2-9b01e625d97f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.davita.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dva-20241231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_06284126-1a0f-42eb-8a7f-89d4da840d63" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_DocumentType_06284126-1a0f-42eb-8a7f-89d4da840d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_8d8af035-ef3c-4805-942a-a6db93839eb5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_DocumentAnnualReport_8d8af035-ef3c-4805-942a-a6db93839eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ab24ab96-5aad-441d-8d79-5d2d27fdfbd9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_DocumentPeriodEndDate_ab24ab96-5aad-441d-8d79-5d2d27fdfbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6a5aa88f-ead4-4452-b89b-247a08968dc0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_CurrentFiscalYearEndDate_6a5aa88f-ead4-4452-b89b-247a08968dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_912a6969-dd32-4227-8c3c-bd8e81e414ed" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_DocumentTransitionReport_912a6969-dd32-4227-8c3c-bd8e81e414ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d1eae4d6-d440-4acf-88ac-34570519f904" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityFileNumber_d1eae4d6-d440-4acf-88ac-34570519f904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_de7cbd8e-57c4-446f-b4fc-d39330b31d4e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityRegistrantName_de7cbd8e-57c4-446f-b4fc-d39330b31d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cc6d1714-02a9-4dd9-a8dd-fd465303001b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cc6d1714-02a9-4dd9-a8dd-fd465303001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_56fa7b3d-0f4b-437c-a60d-a5fe022a133f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityTaxIdentificationNumber_56fa7b3d-0f4b-437c-a60d-a5fe022a133f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4c53a68e-fbf7-4cbe-8a43-e2798a3ab403" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityAddressAddressLine1_4c53a68e-fbf7-4cbe-8a43-e2798a3ab403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_baac2d0c-ff9d-4123-86ec-394215904d66" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityAddressCityOrTown_baac2d0c-ff9d-4123-86ec-394215904d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_01c36f9d-8807-403d-a153-2856280a3543" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityAddressStateOrProvince_01c36f9d-8807-403d-a153-2856280a3543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b2b8face-cadf-45a0-909a-d7665633808d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityAddressPostalZipCode_b2b8face-cadf-45a0-909a-d7665633808d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_69ed18c8-963e-4ad6-b0f8-c421b868a89b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_CityAreaCode_69ed18c8-963e-4ad6-b0f8-c421b868a89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_88631df6-942f-48c2-9789-b18cde8d66c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_LocalPhoneNumber_88631df6-942f-48c2-9789-b18cde8d66c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1de7ab0c-74aa-44c8-936e-c15f3bada119" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_Security12bTitle_1de7ab0c-74aa-44c8-936e-c15f3bada119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3672d763-3a47-4c4f-a0af-c5a60a0e56bd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_TradingSymbol_3672d763-3a47-4c4f-a0af-c5a60a0e56bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d01fea7a-1b1c-40ae-b02d-0522a645b3d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_SecurityExchangeName_d01fea7a-1b1c-40ae-b02d-0522a645b3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_654e80e2-e117-40cf-bac2-9f8dfcbe0fe6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_654e80e2-e117-40cf-bac2-9f8dfcbe0fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_82341b85-3ab2-45f5-99e0-e5ed6c3e5fed" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityVoluntaryFilers_82341b85-3ab2-45f5-99e0-e5ed6c3e5fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ecad9b6d-4d09-4a00-81db-88b3ea555436" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityCurrentReportingStatus_ecad9b6d-4d09-4a00-81db-88b3ea555436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a00790fb-e0f2-475c-b8c7-e781943594e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityInteractiveDataCurrent_a00790fb-e0f2-475c-b8c7-e781943594e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bb37f0fd-40bb-46c5-9fe8-222e7f72645e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityFilerCategory_bb37f0fd-40bb-46c5-9fe8-222e7f72645e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7f0b0bb7-3874-4886-b0e4-def6144a4698" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntitySmallBusiness_7f0b0bb7-3874-4886-b0e4-def6144a4698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ad2c24cf-99f1-4370-b6e8-487bfcdb5d33" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityEmergingGrowthCompany_ad2c24cf-99f1-4370-b6e8-487bfcdb5d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_a41d17c7-a7d6-4278-a374-5f756c2d4b54" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_IcfrAuditorAttestationFlag_a41d17c7-a7d6-4278-a374-5f756c2d4b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_84302183-1195-45eb-8d15-905461bab43f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityShellCompany_84302183-1195-45eb-8d15-905461bab43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_8d8cef1f-2cc8-431f-95d7-019764087f9d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityPublicFloat_8d8cef1f-2cc8-431f-95d7-019764087f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_403596bc-a773-4e25-8123-5b51059233f2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_403596bc-a773-4e25-8123-5b51059233f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e992960e-6ed0-46e6-b384-7ec0dad3a017" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_AmendmentFlag_e992960e-6ed0-46e6-b384-7ec0dad3a017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_ef4131d5-4832-43eb-a614-99a443805f27" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_ef4131d5-4832-43eb-a614-99a443805f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4eb0857e-d8e7-43e1-b7d5-34bd65b6de2e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_DocumentFiscalYearFocus_4eb0857e-d8e7-43e1-b7d5-34bd65b6de2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a836eadf-55f0-4907-9b9f-1104b54425a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a836eadf-55f0-4907-9b9f-1104b54425a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f6231b2b-5b16-4435-962a-00f98d8dc27a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ec72092-772c-456e-bfe6-b5365c635d01" xlink:to="loc_dei_EntityCentralIndexKey_f6231b2b-5b16-4435-962a-00f98d8dc27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AuditInformation" xlink:type="simple" xlink:href="dva-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_AuditorAbstract_465a8ebe-b8e7-41cf-9747-cb0d41b2cfb8" xlink:href="dva-20241231.xsd#dva_AuditorAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_f4a7c25f-6b06-4e30-95f4-1c585c85b49e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_AuditorAbstract_465a8ebe-b8e7-41cf-9747-cb0d41b2cfb8" xlink:to="loc_dei_AuditorName_f4a7c25f-6b06-4e30-95f4-1c585c85b49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_cc9d0d3b-692e-4347-8a76-8e066f0fef44" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_AuditorAbstract_465a8ebe-b8e7-41cf-9747-cb0d41b2cfb8" xlink:to="loc_dei_AuditorLocation_cc9d0d3b-692e-4347-8a76-8e066f0fef44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_b4f5739d-c741-4bd3-90d8-030627e0c8bd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_AuditorAbstract_465a8ebe-b8e7-41cf-9747-cb0d41b2cfb8" xlink:to="loc_dei_AuditorFirmId_b4f5739d-c741-4bd3-90d8-030627e0c8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_c4ac2266-e0ae-4a6d-be92-c88c759f23e4" xlink:href="dva-20241231.xsd#dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_c4ac2266-e0ae-4a6d-be92-c88c759f23e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_efaa0995-8f71-4a84-a877-fe3c8b109da7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_OtherIncome_efaa0995-8f71-4a84-a877-fe3c8b109da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e17b0476-ca00-491c-8000-7bd0edd4f95c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_Revenues_e17b0476-ca00-491c-8000-7bd0edd4f95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_a59d5190-ac27-4270-993c-b578f4f9ba52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_a59d5190-ac27-4270-993c-b578f4f9ba52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts_257482b2-b59f-4af1-bb9b-143735b10898" xlink:href="dva-20241231.xsd#dva_PatientCareCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a59d5190-ac27-4270-993c-b578f4f9ba52" xlink:to="loc_dva_PatientCareCosts_257482b2-b59f-4af1-bb9b-143735b10898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fab09c71-f15e-4c5e-8764-b6ba22339aba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a59d5190-ac27-4270-993c-b578f4f9ba52" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fab09c71-f15e-4c5e-8764-b6ba22339aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_237d2987-6308-432b-b998-fac0912cec94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a59d5190-ac27-4270-993c-b578f4f9ba52" xlink:to="loc_us-gaap_DepreciationAndAmortization_237d2987-6308-432b-b998-fac0912cec94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0079b1ad-818c-4a9a-9fa7-64b10913dfed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a59d5190-ac27-4270-993c-b578f4f9ba52" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0079b1ad-818c-4a9a-9fa7-64b10913dfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_13d267a2-ec02-4153-81c9-ca7b975875d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a59d5190-ac27-4270-993c-b578f4f9ba52" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_13d267a2-ec02-4153-81c9-ca7b975875d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_7a16729d-795e-46f2-b6a3-a1820f4c6aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a59d5190-ac27-4270-993c-b578f4f9ba52" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_7a16729d-795e-46f2-b6a3-a1820f4c6aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_14c15b2e-5288-4cf3-bab4-108a8d9a698b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a59d5190-ac27-4270-993c-b578f4f9ba52" xlink:to="loc_us-gaap_CostsAndExpenses_14c15b2e-5288-4cf3-bab4-108a8d9a698b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_53bc26dc-42fa-4c7d-a65e-b6d07ecc508a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_OperatingIncomeLoss_53bc26dc-42fa-4c7d-a65e-b6d07ecc508a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_f0337727-3f5e-406b-97f1-83ad58d8b8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_InterestAndDebtExpense_f0337727-3f5e-406b-97f1-83ad58d8b8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_ebd96b45-50fa-4b83-aa19-7a2d2763ce0a" xlink:href="dva-20241231.xsd#dva_DebtPrepaymentExtinguishmentAndModificationCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_ebd96b45-50fa-4b83-aa19-7a2d2763ce0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_151191cb-e5b4-41fc-ae14-7ab54c5c186a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_151191cb-e5b4-41fc-ae14-7ab54c5c186a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ce2116c2-dd43-4171-a0b3-0f5a806df6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ce2116c2-dd43-4171-a0b3-0f5a806df6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6539fffa-b416-4147-8673-cdf06a865dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6539fffa-b416-4147-8673-cdf06a865dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0f2a65c0-83b9-4dc6-b136-9ff1098b8953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0f2a65c0-83b9-4dc6-b136-9ff1098b8953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a1bf7d01-0b2c-4d1e-81b9-47382fee14d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a1bf7d01-0b2c-4d1e-81b9-47382fee14d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ed20551b-0239-4691-86fd-7d8310fa89b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_ProfitLoss_ed20551b-0239-4691-86fd-7d8310fa89b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_da9edff1-b1d0-46c3-a5d1-c1cdb7aafdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_da9edff1-b1d0-46c3-a5d1-c1cdb7aafdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_741bc5d6-1e97-4e20-9d19-40ed21aff1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_NetIncomeLoss_741bc5d6-1e97-4e20-9d19-40ed21aff1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3234ca7b-db50-4326-b004-bd9282a37164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_EarningsPerShareAbstract_3234ca7b-db50-4326-b004-bd9282a37164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_2b2d1da5-9480-49d0-b841-beb9d5d588a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3234ca7b-db50-4326-b004-bd9282a37164" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_2b2d1da5-9480-49d0-b841-beb9d5d588a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ab749b33-1438-47a6-95f0-51adcf660d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3234ca7b-db50-4326-b004-bd9282a37164" xlink:to="loc_us-gaap_EarningsPerShareBasic_ab749b33-1438-47a6-95f0-51adcf660d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8f32d4a5-da50-4f7f-a276-0f82a941f359" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3234ca7b-db50-4326-b004-bd9282a37164" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8f32d4a5-da50-4f7f-a276-0f82a941f359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b4982c47-3115-4afe-a8c4-73452cc830f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3234ca7b-db50-4326-b004-bd9282a37164" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b4982c47-3115-4afe-a8c4-73452cc830f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5db2933a-ab43-4a47-9718-32078ab83533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5db2933a-ab43-4a47-9718-32078ab83533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_901e6d14-996f-480a-a62e-3494b1583de1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5db2933a-ab43-4a47-9718-32078ab83533" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_901e6d14-996f-480a-a62e-3494b1583de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_953bbde1-af0f-403f-9e71-05291e9d2fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5db2933a-ab43-4a47-9718-32078ab83533" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_953bbde1-af0f-403f-9e71-05291e9d2fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_66b164ff-2279-4a9f-b2ed-9d5bce185fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9fffa5b4-4278-496c-ac0d-eb374aaf5892" xlink:to="loc_us-gaap_NetIncomeLossAbstract_66b164ff-2279-4a9f-b2ed-9d5bce185fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_5931fd55-c353-447d-80f2-740f5ff17867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_66b164ff-2279-4a9f-b2ed-9d5bce185fb3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_5931fd55-c353-447d-80f2-740f5ff17867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bb2d64dc-f924-4c76-8960-d6d9a27da61d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_66b164ff-2279-4a9f-b2ed-9d5bce185fb3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bb2d64dc-f924-4c76-8960-d6d9a27da61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bb45ca70-bfdc-46ea-831c-ea9ce2b3565b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_66b164ff-2279-4a9f-b2ed-9d5bce185fb3" xlink:to="loc_us-gaap_NetIncomeLoss_bb45ca70-bfdc-46ea-831c-ea9ce2b3565b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_934b83e0-4c39-4933-9abe-44c2754f85ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f65dc073-a7c6-4230-a3fe-13dd1cd3b786" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_934b83e0-4c39-4933-9abe-44c2754f85ed" xlink:to="loc_us-gaap_ProfitLoss_f65dc073-a7c6-4230-a3fe-13dd1cd3b786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_30a685ef-85da-483f-8aeb-53e603936916" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_934b83e0-4c39-4933-9abe-44c2754f85ed" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_30a685ef-85da-483f-8aeb-53e603936916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_04c50778-62f3-40fb-9ce1-6552c4599e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_30a685ef-85da-483f-8aeb-53e603936916" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_04c50778-62f3-40fb-9ce1-6552c4599e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a248816d-a144-4fbe-b87b-9dec4eafe319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_04c50778-62f3-40fb-9ce1-6552c4599e5f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a248816d-a144-4fbe-b87b-9dec4eafe319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_ec096d3d-d40a-42c5-9b44-f31f9eb1de7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_04c50778-62f3-40fb-9ce1-6552c4599e5f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_ec096d3d-d40a-42c5-9b44-f31f9eb1de7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_ae580ef0-d408-4305-bebe-55dcfd9ff8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_30a685ef-85da-483f-8aeb-53e603936916" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_ae580ef0-d408-4305-bebe-55dcfd9ff8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cb766e66-6805-4ed3-90b0-17ff16b2c6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_30a685ef-85da-483f-8aeb-53e603936916" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cb766e66-6805-4ed3-90b0-17ff16b2c6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_4ce57147-5cf5-40ec-ba69-f38e65097bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cb766e66-6805-4ed3-90b0-17ff16b2c6ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_4ce57147-5cf5-40ec-ba69-f38e65097bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_f1a03566-cd2d-493e-a8b8-516b24194821" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cb766e66-6805-4ed3-90b0-17ff16b2c6ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_f1a03566-cd2d-493e-a8b8-516b24194821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2afac668-0d57-4d6f-95c4-95946be70dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_934b83e0-4c39-4933-9abe-44c2754f85ed" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2afac668-0d57-4d6f-95c4-95946be70dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8d053394-0dd7-47d1-85af-9094bb3343f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_934b83e0-4c39-4933-9abe-44c2754f85ed" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8d053394-0dd7-47d1-85af-9094bb3343f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_13cb31bf-80ad-46d1-8bd3-09ba71b3e3af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_934b83e0-4c39-4933-9abe-44c2754f85ed" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_13cb31bf-80ad-46d1-8bd3-09ba71b3e3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_28bd46bd-e5ab-4593-ab2d-a1035098321f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_934b83e0-4c39-4933-9abe-44c2754f85ed" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_28bd46bd-e5ab-4593-ab2d-a1035098321f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c654ce34-0304-4722-9210-8a3c2ab29f38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c654ce34-0304-4722-9210-8a3c2ab29f38" xlink:to="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80a68f27-3a8f-4bf0-8882-3515f378aea7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80a68f27-3a8f-4bf0-8882-3515f378aea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_ef6ebc0a-470c-4486-b60f-2d9b58b5834f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_ef6ebc0a-470c-4486-b60f-2d9b58b5834f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e3146536-15fb-4720-a76d-e8b04ddac52b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e3146536-15fb-4720-a76d-e8b04ddac52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5fae7d5a-e3d4-413d-86be-500ca461d191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5fae7d5a-e3d4-413d-86be-500ca461d191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_abb18e45-9de5-4f7d-9b73-17cf124b8ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_InventoryNet_abb18e45-9de5-4f7d-9b73-17cf124b8ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_5fa262f2-1f36-48a1-a552-7a01e66a26bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_5fa262f2-1f36-48a1-a552-7a01e66a26bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cdd5f05-3089-48e4-a5fa-1b6514298d46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cdd5f05-3089-48e4-a5fa-1b6514298d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_edc87f97-0646-4e1e-954b-98b12ec998ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_IncomeTaxesReceivable_edc87f97-0646-4e1e-954b-98b12ec998ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9b2613ba-20a8-4314-aac6-0b662d25bb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_AssetsCurrent_9b2613ba-20a8-4314-aac6-0b662d25bb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0fdf6a20-2bf8-447f-903c-21b00db40923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0fdf6a20-2bf8-447f-903c-21b00db40923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_79080536-38ed-4c0a-921d-ee79eb3460e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_79080536-38ed-4c0a-921d-ee79eb3460e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_87fd9317-9648-442e-95b0-d92677a47427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_87fd9317-9648-442e-95b0-d92677a47427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7d002bd6-7d06-43e3-b6d1-802717022c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7d002bd6-7d06-43e3-b6d1-802717022c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_2af24643-2004-4183-821c-3a28dbf5f228" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_2af24643-2004-4183-821c-3a28dbf5f228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cfcc4316-8795-4c96-82be-0fffc7b7a847" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cfcc4316-8795-4c96-82be-0fffc7b7a847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_40584705-52a8-4ae0-9e9a-9541ef9d8b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_Goodwill_40584705-52a8-4ae0-9e9a-9541ef9d8b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6390fcb8-bb5b-44e6-80fe-73c5f4d1f421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0558810e-d8e2-4ed2-b9c2-0a86311b35bb" xlink:to="loc_us-gaap_Assets_6390fcb8-bb5b-44e6-80fe-73c5f4d1f421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c654ce34-0304-4722-9210-8a3c2ab29f38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_56da0bff-deac-4e3e-8a10-99a23372690f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_AccountsPayableCurrent_56da0bff-deac-4e3e-8a10-99a23372690f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5c0473e6-f4dc-4686-8187-7dbb6dcf493a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5c0473e6-f4dc-4686-8187-7dbb6dcf493a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dd31ba42-880b-4406-b561-08ce3be8bb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dd31ba42-880b-4406-b561-08ce3be8bb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f9cbbd6a-1068-4ab0-a4f7-24a5b0046604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f9cbbd6a-1068-4ab0-a4f7-24a5b0046604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_52a8f35c-085b-4225-b1c1-7bdcf0c83137" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_52a8f35c-085b-4225-b1c1-7bdcf0c83137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_bf778cd3-992a-44d9-b71f-8dee9738c56d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_bf778cd3-992a-44d9-b71f-8dee9738c56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e3f4b5cb-b2d1-4a97-a209-ae4825de501f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_LiabilitiesCurrent_e3f4b5cb-b2d1-4a97-a209-ae4825de501f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_72a0051a-89de-43fc-b818-f6c14ecfe032" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_72a0051a-89de-43fc-b818-f6c14ecfe032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8a7f9c09-c979-4576-916b-8ef2522fde82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8a7f9c09-c979-4576-916b-8ef2522fde82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6ffaaf1c-75b1-48ef-acca-e67d18124528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6ffaaf1c-75b1-48ef-acca-e67d18124528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_16f064c4-a296-49c0-b5a2-a65fef23afb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_16f064c4-a296-49c0-b5a2-a65fef23afb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_79e4a702-123b-411d-b000-7e6e03f1dace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_Liabilities_79e4a702-123b-411d-b000-7e6e03f1dace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d832feee-c269-4932-b0d9-e72a70209fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d832feee-c269-4932-b0d9-e72a70209fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_96c8d064-de7c-4490-ac20-131ae51eb679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d832feee-c269-4932-b0d9-e72a70209fb1" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_96c8d064-de7c-4490-ac20-131ae51eb679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c5bf938a-8f31-437a-8afb-5a4c20fb6280" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:to="loc_us-gaap_PreferredStockValue_c5bf938a-8f31-437a-8afb-5a4c20fb6280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e5562667-16ea-4018-9c97-20f6bee7f6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:to="loc_us-gaap_CommonStockValue_e5562667-16ea-4018-9c97-20f6bee7f6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e4a21e8-af91-46c0-865c-57f71328eeee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e4a21e8-af91-46c0-865c-57f71328eeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4aeaaaf2-71be-4e55-871d-4814fdaed12a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4aeaaaf2-71be-4e55-871d-4814fdaed12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d3a6e457-e6dc-4023-a304-41f25f5f9da4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:to="loc_us-gaap_TreasuryStockValue_d3a6e457-e6dc-4023-a304-41f25f5f9da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_968affbd-314a-4a1c-a2f2-28ee8f36360f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_968affbd-314a-4a1c-a2f2-28ee8f36360f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1bb1da0-b476-4625-9779-5c3b49bfa201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:to="loc_us-gaap_StockholdersEquity_b1bb1da0-b476-4625-9779-5c3b49bfa201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f80c4687-80cc-428d-a6ec-beaf48589b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:to="loc_us-gaap_MinorityInterest_f80c4687-80cc-428d-a6ec-beaf48589b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f2056808-0dfc-4db9-b615-7a44700f938a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_72e52eaf-70b6-4d37-97f0-7647134719ef" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f2056808-0dfc-4db9-b615-7a44700f938a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_95e1bcdc-9c72-4363-b45f-6d9527c30725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67a824ec-0f3d-4628-b880-4134b316205e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_95e1bcdc-9c72-4363-b45f-6d9527c30725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5628e336-9c44-42d2-9060-01c53434db1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c654ce34-0304-4722-9210-8a3c2ab29f38" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5628e336-9c44-42d2-9060-01c53434db1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a136b13f-e45b-4c19-9526-86d12c8a33be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c654ce34-0304-4722-9210-8a3c2ab29f38" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a136b13f-e45b-4c19-9526-86d12c8a33be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a92fff32-4745-4335-b64c-8a9b3cf5a060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c654ce34-0304-4722-9210-8a3c2ab29f38" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a92fff32-4745-4335-b64c-8a9b3cf5a060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4caac5a4-f783-435f-b6b3-277ff47181aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c654ce34-0304-4722-9210-8a3c2ab29f38" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4caac5a4-f783-435f-b6b3-277ff47181aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_57e9a0b5-d045-4d7d-bf28-e38623d854da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c654ce34-0304-4722-9210-8a3c2ab29f38" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_57e9a0b5-d045-4d7d-bf28-e38623d854da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c38dcdce-da39-4847-a060-3b7fb7da3abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c654ce34-0304-4722-9210-8a3c2ab29f38" xlink:to="loc_us-gaap_CommonStockSharesIssued_c38dcdce-da39-4847-a060-3b7fb7da3abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d022f207-6740-4c1c-bcac-bb8d3b87eb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4ec444ab-05a7-4b21-9582-aa63988fa170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d022f207-6740-4c1c-bcac-bb8d3b87eb9c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4ec444ab-05a7-4b21-9582-aa63988fa170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c8d5f55c-0551-4812-994a-55ec5674da3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d022f207-6740-4c1c-bcac-bb8d3b87eb9c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c8d5f55c-0551-4812-994a-55ec5674da3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_066ea571-66a4-4fcb-805a-8012585df67b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d022f207-6740-4c1c-bcac-bb8d3b87eb9c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_066ea571-66a4-4fcb-805a-8012585df67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f50338d4-f20b-43c4-b58a-8ee2c7388eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d022f207-6740-4c1c-bcac-bb8d3b87eb9c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f50338d4-f20b-43c4-b58a-8ee2c7388eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6c99235f-4814-4940-8685-ba2a74852208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d022f207-6740-4c1c-bcac-bb8d3b87eb9c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6c99235f-4814-4940-8685-ba2a74852208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_89dbeefc-4b4c-4c41-85d8-5627f0e34648" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d022f207-6740-4c1c-bcac-bb8d3b87eb9c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_89dbeefc-4b4c-4c41-85d8-5627f0e34648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_903f8a91-2421-404d-bb29-a62b6b7b545c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d022f207-6740-4c1c-bcac-bb8d3b87eb9c" xlink:to="loc_us-gaap_TreasuryStockCommonShares_903f8a91-2421-404d-bb29-a62b6b7b545c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c234cf13-089d-4ac3-803f-632235f313cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_15b9c11f-774f-4c11-81d0-83d3e2f8fc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c234cf13-089d-4ac3-803f-632235f313cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_15b9c11f-774f-4c11-81d0-83d3e2f8fc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fa34261b-2505-4e16-bdda-e55f40d1f335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_15b9c11f-774f-4c11-81d0-83d3e2f8fc0a" xlink:to="loc_us-gaap_ProfitLoss_fa34261b-2505-4e16-bdda-e55f40d1f335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_15b9c11f-774f-4c11-81d0-83d3e2f8fc0a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_69f17a06-1127-4902-a76a-cac1ff6f4c19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_69f17a06-1127-4902-a76a-cac1ff6f4c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_4e9959d4-a1b4-4832-81f9-29fe0a917fda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_4e9959d4-a1b4-4832-81f9-29fe0a917fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtRefinancingCharges_007ff8c9-7484-484a-9690-465a114e027f" xlink:href="dva-20241231.xsd#dva_DebtRefinancingCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:to="loc_dva_DebtRefinancingCharges_007ff8c9-7484-484a-9690-465a114e027f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2ff1e952-4ba1-42d9-8da3-bd5308eac410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:to="loc_us-gaap_ShareBasedCompensation_2ff1e952-4ba1-42d9-8da3-bd5308eac410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cad61f8e-4eb6-4e06-a67c-8065d4fd8fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cad61f8e-4eb6-4e06-a67c-8065d4fd8fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_c86cace3-f2ad-488c-b5c6-a5728bea8a36" xlink:href="dva-20241231.xsd#dva_AdjustmentIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:to="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_c86cace3-f2ad-488c-b5c6-a5728bea8a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_3c836843-b9cb-443b-8785-7eee3d1beaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_3c836843-b9cb-443b-8785-7eee3d1beaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_72e6270d-0c21-409d-874b-b768dc4629e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_72e6270d-0c21-409d-874b-b768dc4629e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b312af31-2cba-409a-9633-115a03f7a883" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_208fad88-acb1-47bb-acf7-7d7912468944" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_208fad88-acb1-47bb-acf7-7d7912468944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b5b7d087-f2a9-467b-bc1a-4005e7d4c3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b5b7d087-f2a9-467b-bc1a-4005e7d4c3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_45a3c13e-c57f-49d5-9a37-de50079e2613" xlink:href="dva-20241231.xsd#dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_45a3c13e-c57f-49d5-9a37-de50079e2613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47cb2dcd-831e-4e17-91b1-2534d5a539a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47cb2dcd-831e-4e17-91b1-2534d5a539a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_64802423-0f20-4898-a701-2588bc37bd11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_64802423-0f20-4898-a701-2588bc37bd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_a061d558-2c35-4a79-a852-22387fb6c529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_a061d558-2c35-4a79-a852-22387fb6c529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_5319fabb-e7e3-443b-a82c-5873f42b6982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_5319fabb-e7e3-443b-a82c-5873f42b6982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_80ee046e-209c-4a62-8591-0639c660c794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_80ee046e-209c-4a62-8591-0639c660c794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0ff25580-e450-4a35-88fd-a6d77cb5a309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0ff25580-e450-4a35-88fd-a6d77cb5a309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a7e8590-b740-4899-acd7-2fc66ac58d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e65672a-72dd-4677-b49d-044456a85586" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a7e8590-b740-4899-acd7-2fc66ac58d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c234cf13-089d-4ac3-803f-632235f313cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5f3435fc-55d3-475a-b5b1-f9827b60d33a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5f3435fc-55d3-475a-b5b1-f9827b60d33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d1e63088-5e05-4030-b6cd-7e8becd6a3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d1e63088-5e05-4030-b6cd-7e8becd6a3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_a46c4f1e-9beb-467f-8a35-3bc8d3d70ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_a46c4f1e-9beb-467f-8a35-3bc8d3d70ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_cc75b210-957b-4b58-b624-b7468e458f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_cc75b210-957b-4b58-b624-b7468e458f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_8db3071d-4d1d-4270-a6b3-0d5cb316fbb3" xlink:href="dva-20241231.xsd#dva_PaymentsToAcquireOtherDebtAndEquityInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_8db3071d-4d1d-4270-a6b3-0d5cb316fbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_1cff17f7-4819-48cb-add3-3bf899b22c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_1cff17f7-4819-48cb-add3-3bf899b22c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_34201a86-f685-4719-b857-e4b0de1e741c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_34201a86-f685-4719-b857-e4b0de1e741c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7f8058ed-a942-4a1f-ba4d-4b20512abbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_7f8058ed-a942-4a1f-ba4d-4b20512abbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_6283ec7f-2f0c-4763-ae67-ba00fd529fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_6283ec7f-2f0c-4763-ae67-ba00fd529fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_ecf030d8-b8cb-4e27-9ec4-4ccd93fb268d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_ecf030d8-b8cb-4e27-9ec4-4ccd93fb268d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_db257a1f-bcc9-4b01-aaa9-5e8105104b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e01b4e1f-b5b3-49a8-8c82-12e92a382c93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_db257a1f-bcc9-4b01-aaa9-5e8105104b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c234cf13-089d-4ac3-803f-632235f313cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e97c126a-c1b1-4900-af59-434aa86e034a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e97c126a-c1b1-4900-af59-434aa86e034a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_3eeb8729-37de-4add-a1c6-2d1cd4bf3c89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_3eeb8729-37de-4add-a1c6-2d1cd4bf3c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtFinancingAndDebtRedemptionCosts_abb23c3a-210c-4392-9868-a649a3da4526" xlink:href="dva-20241231.xsd#dva_DebtFinancingAndDebtRedemptionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_dva_DebtFinancingAndDebtRedemptionCosts_abb23c3a-210c-4392-9868-a649a3da4526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_555bb9d4-fa1b-409c-9acc-278c0de7e853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_555bb9d4-fa1b-409c-9acc-278c0de7e853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_a1206597-7946-4baa-bb63-46548aceb4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_a1206597-7946-4baa-bb63-46548aceb4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetProceedsFromIssuanceOfStockToEmployees_a6681ef8-4920-4b0b-9169-d5ae42a05233" xlink:href="dva-20241231.xsd#dva_NetProceedsFromIssuanceOfStockToEmployees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_dva_NetProceedsFromIssuanceOfStockToEmployees_a6681ef8-4920-4b0b-9169-d5ae42a05233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a4418aeb-3f8d-4fc6-b404-6de313a23d15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a4418aeb-3f8d-4fc6-b404-6de313a23d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_afa3e668-77d9-4437-82af-474fe08bf176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_afa3e668-77d9-4437-82af-474fe08bf176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_bda882df-48b0-43dc-a90a-1e965c530b13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_bda882df-48b0-43dc-a90a-1e965c530b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_098fc6f7-6599-40bc-b76d-c3d10fb68e81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_098fc6f7-6599-40bc-b76d-c3d10fb68e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dcca4732-62ad-498c-b6cd-d09ff684bbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_04372f95-1178-459c-83d9-6e350e5108eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dcca4732-62ad-498c-b6cd-d09ff684bbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_055a5e38-aa72-4e9b-b952-b0ea99f44ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c234cf13-089d-4ac3-803f-632235f313cd" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_055a5e38-aa72-4e9b-b952-b0ea99f44ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_13a88851-3358-427c-866f-787b610a7c15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c234cf13-089d-4ac3-803f-632235f313cd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_13a88851-3358-427c-866f-787b610a7c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b570525-af4c-4758-89a1-1768b2a350d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c234cf13-089d-4ac3-803f-632235f313cd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b570525-af4c-4758-89a1-1768b2a350d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f98ed70e-6c10-4570-865d-7bdf402af008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c234cf13-089d-4ac3-803f-632235f313cd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f98ed70e-6c10-4570-865d-7bdf402af008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="dva-20241231.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7873cf90-50ab-436f-a418-3355d9b6b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7cbe968e-c751-4d5c-a610-e903130e0971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7873cf90-50ab-436f-a418-3355d9b6b3ab" xlink:to="loc_us-gaap_StatementTable_7cbe968e-c751-4d5c-a610-e903130e0971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_841623e3-4009-4a68-b550-08270153af44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7cbe968e-c751-4d5c-a610-e903130e0971" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_841623e3-4009-4a68-b550-08270153af44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_841623e3-4009-4a68-b550-08270153af44" xlink:to="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_bd828bee-dfd2-4507-80ee-1cbe62e1740e" xlink:href="dva-20241231.xsd#dva_TemporaryEquityRedeemableNoncontrollingInterestsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:to="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_bd828bee-dfd2-4507-80ee-1cbe62e1740e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:to="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86e70892-aeb7-4c1f-a909-964928964143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_CommonStockMember_86e70892-aeb7-4c1f-a909-964928964143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dcb40e22-7650-4c9c-85eb-6a36c0a6e707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dcb40e22-7650-4c9c-85eb-6a36c0a6e707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_286ab489-3dd3-44aa-b051-99de5443af09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_RetainedEarningsMember_286ab489-3dd3-44aa-b051-99de5443af09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_3d678014-fc5a-4d0b-bb1d-38af3552fead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_TreasuryStockCommonMember_3d678014-fc5a-4d0b-bb1d-38af3552fead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db7bf65c-8864-462d-82e3-db9ce5a9ea80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_580167ad-2615-45ad-b6be-fbb7367b29a2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db7bf65c-8864-462d-82e3-db9ce5a9ea80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_931dab9c-2042-4669-a681-915a243527fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_58ced667-59c3-4f06-9dd9-1e2a17df70e0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_931dab9c-2042-4669-a681-915a243527fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_37deeedf-fc69-4ba0-8e84-0b0810ca2118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7cbe968e-c751-4d5c-a610-e903130e0971" xlink:to="loc_us-gaap_StatementLineItems_37deeedf-fc69-4ba0-8e84-0b0810ca2118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_37deeedf-fc69-4ba0-8e84-0b0810ca2118" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9c2adab8-1ec9-44e0-a3cf-913d83be7edd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9c2adab8-1ec9-44e0-a3cf-913d83be7edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b7a30137-aa69-4319-a14d-12ad15f1f999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b7a30137-aa69-4319-a14d-12ad15f1f999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fc158b71-1e1d-4172-9886-09f0493410ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fc158b71-1e1d-4172-9886-09f0493410ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_0b1558ce-806f-498c-9a8d-0e0c5d3cffd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_0b1558ce-806f-498c-9a8d-0e0c5d3cffd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_1e28a025-9bc4-450a-9d4e-93b7930b345e" xlink:href="dva-20241231.xsd#dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_1e28a025-9bc4-450a-9d4e-93b7930b345e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_b4b8af51-be34-4f44-8e6e-5d9efaa2e306" xlink:href="dva-20241231.xsd#dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_b4b8af51-be34-4f44-8e6e-5d9efaa2e306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_460e53d9-3850-433c-b935-4dcdeeb86b85" xlink:href="dva-20241231.xsd#dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_460e53d9-3850-433c-b935-4dcdeeb86b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_2535f9ec-e74a-4bd5-b663-569a8c311285" xlink:href="dva-20241231.xsd#dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_2535f9ec-e74a-4bd5-b663-569a8c311285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_a152a989-d742-4bfd-80b4-5a9dde365c60" xlink:href="dva-20241231.xsd#dva_TemporaryEquityDecreasePurchaseOfInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_a152a989-d742-4bfd-80b4-5a9dde365c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_339fc744-07b1-4b39-a0ed-f8bd9173622b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_339fc744-07b1-4b39-a0ed-f8bd9173622b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_26c4a566-d2c6-4994-a766-81638e014ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_26c4a566-d2c6-4994-a766-81638e014ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_db691754-b165-4794-a6f9-78e0613b84d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bcd3d243-02f2-49cc-b008-944eb75512d6" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_db691754-b165-4794-a6f9-78e0613b84d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_b95365b2-fa67-46fd-8b93-c2bdbb02aea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_b95365b2-fa67-46fd-8b93-c2bdbb02aea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8e6563f6-e332-4683-90eb-43c623eb90cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_b95365b2-fa67-46fd-8b93-c2bdbb02aea3" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8e6563f6-e332-4683-90eb-43c623eb90cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2fc52e58-959e-4de1-ae56-83c495c1cd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_b95365b2-fa67-46fd-8b93-c2bdbb02aea3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2fc52e58-959e-4de1-ae56-83c495c1cd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2a3a6e3c-95f2-49dd-99c6-de076fc5911b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2a3a6e3c-95f2-49dd-99c6-de076fc5911b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_923727d6-cfee-4a42-8343-4be5f5714b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_923727d6-cfee-4a42-8343-4be5f5714b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_899675d5-4c08-4e0c-8ae2-893a92a97ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_899675d5-4c08-4e0c-8ae2-893a92a97ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4e0c2ab1-3a0e-43da-8b62-540a512f86e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4e0c2ab1-3a0e-43da-8b62-540a512f86e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a8452fb-d7eb-4287-a369-f9196fa8476f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3a8452fb-d7eb-4287-a369-f9196fa8476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_495476b1-ad7b-4377-88d3-491c4d6b0077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_495476b1-ad7b-4377-88d3-491c4d6b0077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseFromContributions_ea456045-3c99-4d80-afc6-986b801b33aa" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestIncreaseFromContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_dva_NoncontrollingInterestIncreaseFromContributions_ea456045-3c99-4d80-afc6-986b801b33aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_8f5fb32e-54ee-4e36-9b08-4338bbeb42bc" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_8f5fb32e-54ee-4e36-9b08-4338bbeb42bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_dd00d159-8c19-4801-adea-71f005f7fc72" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_dd00d159-8c19-4801-adea-71f005f7fc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_0a7fba1e-f351-435f-9752-8763b568c3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_0a7fba1e-f351-435f-9752-8763b568c3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_e8c43e6b-8e9b-4548-8af4-ad1057bda0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_750d844c-fa71-476f-8f06-9ce59ff3714e" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_e8c43e6b-8e9b-4548-8af4-ad1057bda0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_0c3f88a2-46d7-45cc-85b8-403336ddb90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_0c3f88a2-46d7-45cc-85b8-403336ddb90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_38689cff-51ab-474f-8c5c-fd26da61dc22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_38689cff-51ab-474f-8c5c-fd26da61dc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_ee7ce09f-09f7-4c5c-9df8-9406636df02a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_ee7ce09f-09f7-4c5c-9df8-9406636df02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_f67f094c-bee2-4a97-9c36-7dd17b516464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_f67f094c-bee2-4a97-9c36-7dd17b516464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_a28834ee-c775-4ca7-96c4-9e65a480d99a" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_a28834ee-c775-4ca7-96c4-9e65a480d99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5ea2230-0741-40bd-9b13-f407c59f0b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a5ea2230-0741-40bd-9b13-f407c59f0b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9652c167-2cf7-4ff7-889f-91a9461baa0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7379b1f1-35e1-46a6-aca9-f458ca70aa86" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9652c167-2cf7-4ff7-889f-91a9461baa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dva-20241231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a26e0463-8cd1-4b07-a0b5-151e0e0bb83f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_5f68ad35-51fe-4f2d-9eb4-b4e1e8c92f30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a26e0463-8cd1-4b07-a0b5-151e0e0bb83f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_5f68ad35-51fe-4f2d-9eb4-b4e1e8c92f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognition" xlink:type="simple" xlink:href="dva-20241231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_ad1d76ae-a2ba-41a0-99ba-cbd9de19aba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_017e7e24-95bf-43e4-90fd-88d7e1e465dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_ad1d76ae-a2ba-41a0-99ba-cbd9de19aba7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_017e7e24-95bf-43e4-90fd-88d7e1e465dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShare" xlink:type="simple" xlink:href="dva-20241231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_da2332fa-97db-434d-9eb2-982f775fb356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_65b0dfbd-ca34-430d-ad53-0cfd761109b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da2332fa-97db-434d-9eb2-982f775fb356" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_65b0dfbd-ca34-430d-ad53-0cfd761109b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Shorttermandlongterminvestments" xlink:type="simple" xlink:href="dva-20241231.xsd#Shorttermandlongterminvestments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Shorttermandlongterminvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cdbcc6f6-d83d-4459-bf7a-5156108580bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5b4a5341-1fb4-427c-9cf3-16f1567ede9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cdbcc6f6-d83d-4459-bf7a-5156108580bd" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5b4a5341-1fb4-427c-9cf3-16f1567ede9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesOtherReceivables" xlink:type="simple" xlink:href="dva-20241231.xsd#OtherReceivablesOtherReceivables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherReceivablesOtherReceivables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_f8350f26-efc6-4bd7-ad41-8fa22b60f4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_95f58637-9cd4-4b3a-9bb6-5bff9fc57d04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_f8350f26-efc6-4bd7-ad41-8fa22b60f4cd" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_95f58637-9cd4-4b3a-9bb6-5bff9fc57d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="dva-20241231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca0a4eeb-0177-475e-b7c3-5a639439b546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6246bbae-6571-4d08-9f5e-81ea2590db49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca0a4eeb-0177-475e-b7c3-5a639439b546" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6246bbae-6571-4d08-9f5e-81ea2590db49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Intangibles" xlink:type="simple" xlink:href="dva-20241231.xsd#Intangibles"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Intangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9ff137c-4b1a-4347-831c-4c3ecbff8ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_005feea8-a458-4fee-9d31-99d287c45fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9ff137c-4b1a-4347-831c-4c3ecbff8ed5" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_005feea8-a458-4fee-9d31-99d287c45fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestments" xlink:type="simple" xlink:href="dva-20241231.xsd#EquityMethodandOtherInvestments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_43ba5bb7-8a1f-4ca8-b340-cb8b14d2b79e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_db6bc106-cfcb-4601-97b6-e5f950649d47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_43ba5bb7-8a1f-4ca8-b340-cb8b14d2b79e" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_db6bc106-cfcb-4601-97b6-e5f950649d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Goodwill" xlink:type="simple" xlink:href="dva-20241231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_55949968-9ce6-4d95-aa15-1dcd3a5e64f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_93077712-be35-4008-a891-6c63a97c5305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_55949968-9ce6-4d95-aa15-1dcd3a5e64f4" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_93077712-be35-4008-a891-6c63a97c5305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilities" xlink:type="simple" xlink:href="dva-20241231.xsd#OtherLiabilities"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_80cbc628-39b0-4fa3-8c35-aa117ce33a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_4e06826d-dac6-4697-9227-eff418f914e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_80cbc628-39b0-4fa3-8c35-aa117ce33a72" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_4e06826d-dac6-4697-9227-eff418f914e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxes" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f4479fa8-cd69-4d94-b979-b4e180f1b726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c5ece08c-6a8f-47fa-9e40-aa32907e196a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f4479fa8-cd69-4d94-b979-b4e180f1b726" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c5ece08c-6a8f-47fa-9e40-aa32907e196a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebt" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ed3c2e04-7d4a-4ea9-b9ce-076b9238298b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_c4c5c714-ca46-448d-8c95-f17f7f3a393c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ed3c2e04-7d4a-4ea9-b9ce-076b9238298b" xlink:to="loc_us-gaap_LongTermDebtTextBlock_c4c5c714-ca46-448d-8c95-f17f7f3a393c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Leases" xlink:type="simple" xlink:href="dva-20241231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9cdd2ad0-77f4-4012-930f-25f92e8c10d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTextBlock_7d5c7f87-04a2-443a-bdd7-8111ae5725f8" xlink:href="dva-20241231.xsd#dva_LeasesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9cdd2ad0-77f4-4012-930f-25f92e8c10d0" xlink:to="loc_dva_LeasesDisclosureTextBlock_7d5c7f87-04a2-443a-bdd7-8111ae5725f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="dva-20241231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_91434db9-ebd0-4889-b0dc-3f787b40981a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8303d17d-2b66-4811-ad59-c6092eadc2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_91434db9-ebd0-4889-b0dc-3f787b40981a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8303d17d-2b66-4811-ad59-c6092eadc2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Contingencies" xlink:type="simple" xlink:href="dva-20241231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa912720-8757-4383-8622-90506a9fc6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_a8dc7287-ecab-4f55-a114-b227845c8a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fa912720-8757-4383-8622-90506a9fc6de" xlink:to="loc_us-gaap_LossContingencyDisclosures_a8dc7287-ecab-4f55-a114-b227845c8a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments" xlink:type="simple" xlink:href="dva-20241231.xsd#NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_24d946f1-4baa-48eb-8453-387b7bb8128e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_e01a9ef4-e73f-4453-bccc-2edd8f6f2dce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24d946f1-4baa-48eb-8453-387b7bb8128e" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_e01a9ef4-e73f-4453-bccc-2edd8f6f2dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="dva-20241231.xsd#Stockbasedcompensation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Stockbasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07b1e702-7e51-4d32-a3a2-3515c553b495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e3e89408-e5de-45cb-a110-8be260775535" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07b1e702-7e51-4d32-a3a2-3515c553b495" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e3e89408-e5de-45cb-a110-8be260775535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Stockholdersequity" xlink:type="simple" xlink:href="dva-20241231.xsd#Stockholdersequity"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Stockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_aa12ae74-41a9-4671-a096-e7cf3826b04c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_30fb0602-1e35-4718-ad25-0ae550324233" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aa12ae74-41a9-4671-a096-e7cf3826b04c" xlink:to="loc_us-gaap_TreasuryStockTextBlock_30fb0602-1e35-4718-ad25-0ae550324233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="simple" xlink:href="dva-20241231.xsd#AccumulatedOtherComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a7111590-622b-413b-8140-cbe44d0b39e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_44a70472-81b6-43ad-a40d-1bbbb3791960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a7111590-622b-413b-8140-cbe44d0b39e8" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_44a70472-81b6-43ad-a40d-1bbbb3791960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f5975164-490a-4b4c-a6b5-f8b8911441a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5a0711ac-051f-4f64-836d-0ebd56c8c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f5975164-490a-4b4c-a6b5-f8b8911441a0" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5a0711ac-051f-4f64-836d-0ebd56c8c5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperations" xlink:type="simple" xlink:href="dva-20241231.xsd#HeldforSaleandDiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/HeldforSaleandDiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ae9d7bc1-8b92-4aad-8681-545b4c985d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_f79c354a-ace7-4b4a-a87f-5811b7d7b20f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ae9d7bc1-8b92-4aad-8681-545b4c985d3c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_f79c354a-ace7-4b4a-a87f-5811b7d7b20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="dva-20241231.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8d23178-daa8-4592-a720-6efc755f600f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_b5f4fab0-da6f-4d38-affd-c57c58608d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8d23178-daa8-4592-a720-6efc755f600f" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_b5f4fab0-da6f-4d38-affd-c57c58608d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstruments" xlink:type="simple" xlink:href="dva-20241231.xsd#FairValuesofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cfdf022d-26ce-4719-a571-a0331c01195e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_42d17823-0f81-48f8-98a4-fd8f8abb81eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cfdf022d-26ce-4719-a571-a0331c01195e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_42d17823-0f81-48f8-98a4-fd8f8abb81eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReporting" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_911b851f-5e16-4c0c-b71d-8c8ac0751248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_13d088f3-7e74-441e-8085-2358718946bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_911b851f-5e16-4c0c-b71d-8c8ac0751248" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_13d088f3-7e74-441e-8085-2358718946bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_bb7f1f2a-a8a7-4587-93d1-da841e40c689" xlink:href="dva-20241231.xsd#dva_NetPropertyAndEquipmentInternationalOperationsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_911b851f-5e16-4c0c-b71d-8c8ac0751248" xlink:to="loc_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_bb7f1f2a-a8a7-4587-93d1-da841e40c689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="dva-20241231.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_bd27f24b-2dec-49cb-90b7-f048aa60ab3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_a6638011-47c6-4f31-9854-c9e9db014df6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_bd27f24b-2dec-49cb-90b7-f048aa60ab3e" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_a6638011-47c6-4f31-9854-c9e9db014df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dva-20241231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e85dafc1-e1a5-48a2-ad7d-748da246eecf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e85dafc1-e1a5-48a2-ad7d-748da246eecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_59fff6f1-5630-4349-964e-71ff6f25ef75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_UseOfEstimates_59fff6f1-5630-4349-964e-71ff6f25ef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_ef19e1b4-e227-45af-a8c3-d3d8acd7f0bf" xlink:href="dva-20241231.xsd#dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_ef19e1b4-e227-45af-a8c3-d3d8acd7f0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_d5cb9e6a-7309-45a0-b80b-fc342cf6ed18" xlink:href="dva-20241231.xsd#dva_OtherNonoperatingIncomeExpensePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_d5cb9e6a-7309-45a0-b80b-fc342cf6ed18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54a8f4c5-459b-4870-a4a0-5af26cfb1a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54a8f4c5-459b-4870-a4a0-5af26cfb1a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a9bfd674-9763-4eec-99f5-16f3aeb3a1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a9bfd674-9763-4eec-99f5-16f3aeb3a1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_7e4e74f9-82d1-4454-a365-08b52814dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_7e4e74f9-82d1-4454-a365-08b52814dc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_8774acef-977f-4976-a91b-bf65f23488e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_8774acef-977f-4976-a91b-bf65f23488e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ec5b578d-cdf1-453c-b7de-fe74e9063f87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ec5b578d-cdf1-453c-b7de-fe74e9063f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_02195c4e-16cf-4463-ad1a-9b43a5567269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_02195c4e-16cf-4463-ad1a-9b43a5567269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_22a98a2f-5485-4a58-84d6-753543c89b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_22a98a2f-5485-4a58-84d6-753543c89b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_14e17123-ba6d-49c8-aa5e-d10071654f15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_14e17123-ba6d-49c8-aa5e-d10071654f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_03974614-6249-49f4-a94b-0752adc89371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_03974614-6249-49f4-a94b-0752adc89371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_41c52d7b-7ff5-4f6f-b964-60cdc31a2a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_41c52d7b-7ff5-4f6f-b964-60cdc31a2a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock_8f3a253f-9159-4623-8de2-cc11b51a1184" xlink:href="dva-20241231.xsd#dva_InsuranceAndSelfInsurancePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock_8f3a253f-9159-4623-8de2-cc11b51a1184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2f69632d-060f-4b62-9b25-7c07cc1fab94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2f69632d-060f-4b62-9b25-7c07cc1fab94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e751731c-cf0f-40aa-ab7c-acba4d8ab962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e751731c-cf0f-40aa-ab7c-acba4d8ab962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_121f56e0-5727-4082-bd34-41f9f8361925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_121f56e0-5727-4082-bd34-41f9f8361925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_d34cbf05-e78b-4249-9937-e6f911077795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_d34cbf05-e78b-4249-9937-e6f911077795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3e297f61-d2c4-4984-b032-d2bda0c4510c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3e297f61-d2c4-4984-b032-d2bda0c4510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7b3aaa35-da39-453d-92e9-9fcdd9ed0120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7b3aaa35-da39-453d-92e9-9fcdd9ed0120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7299fd5e-d017-4868-8861-6b7f9cb61af5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7299fd5e-d017-4868-8861-6b7f9cb61af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_79ece5f1-96de-4a6b-9221-074562ba1bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_79ece5f1-96de-4a6b-9221-074562ba1bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_cf2609d6-aec8-4f33-85a3-94c65fca3320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_cf2609d6-aec8-4f33-85a3-94c65fca3320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_77754bf3-16f9-4226-bc3c-466d0ac336e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2bef9488-ad94-418e-9f26-e543d2fcd739" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_77754bf3-16f9-4226-bc3c-466d0ac336e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables" xlink:type="simple" xlink:href="dva-20241231.xsd#RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_eecfd0c1-94a2-4beb-8795-b0bfaafbdd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c628f3b5-16bf-4cac-8bb3-76ae62766d14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_eecfd0c1-94a2-4beb-8795-b0bfaafbdd7b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c628f3b5-16bf-4cac-8bb3-76ae62766d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="dva-20241231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_070f397e-5ab7-44ca-958f-e8d754dab2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0a882d7e-ce05-47f5-b4d3-0b3cc8344ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_070f397e-5ab7-44ca-958f-e8d754dab2d6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0a882d7e-ce05-47f5-b4d3-0b3cc8344ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvesmtentsTables" xlink:type="simple" xlink:href="dva-20241231.xsd#ShorttermandlongterminvesmtentsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvesmtentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0546e56f-d2d2-4f0d-b8b8-5db3558326ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_460412f4-4ff6-4339-ae8c-7ec6fc02bb08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0546e56f-d2d2-4f0d-b8b8-5db3558326ec" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_460412f4-4ff6-4339-ae8c-7ec6fc02bb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesTables" xlink:type="simple" xlink:href="dva-20241231.xsd#OtherReceivablesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherReceivablesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_11b11457-9910-48d5-9162-627b35e7ac4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherReceivablesTableTextBlock_52ba0772-1e07-479c-b1b6-987c48b92234" xlink:href="dva-20241231.xsd#dva_ScheduleOfOtherReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_11b11457-9910-48d5-9162-627b35e7ac4f" xlink:to="loc_dva_ScheduleOfOtherReceivablesTableTextBlock_52ba0772-1e07-479c-b1b6-987c48b92234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="dva-20241231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c30194cd-cd6d-4634-9211-9084d42910b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9f73d45d-3c6c-4f6a-a598-3bbf9384c521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c30194cd-cd6d-4634-9211-9084d42910b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9f73d45d-3c6c-4f6a-a598-3bbf9384c521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesTables" xlink:type="simple" xlink:href="dva-20241231.xsd#IntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f089c07f-af45-4b9a-8117-bddff30b2054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_a0446fc3-3548-4d8c-b7ed-599cbf6fcdad" xlink:href="dva-20241231.xsd#dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f089c07f-af45-4b9a-8117-bddff30b2054" xlink:to="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_a0446fc3-3548-4d8c-b7ed-599cbf6fcdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_791509b1-6845-4ef5-ab31-7234bc6d4dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f089c07f-af45-4b9a-8117-bddff30b2054" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_791509b1-6845-4ef5-ab31-7234bc6d4dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables" xlink:type="simple" xlink:href="dva-20241231.xsd#EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d2f61d79-e055-480d-844e-c0bac25bb34d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_c60b1a0e-f696-42d2-97f0-b1a0056c5939" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d2f61d79-e055-480d-844e-c0bac25bb34d" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_c60b1a0e-f696-42d2-97f0-b1a0056c5939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillTables" xlink:type="simple" xlink:href="dva-20241231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8fa5199e-aebf-44cd-bd7d-cfd5d3f662a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_b7eee62a-922b-4deb-b790-557cfcd496bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8fa5199e-aebf-44cd-bd7d-cfd5d3f662a4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_b7eee62a-922b-4deb-b790-557cfcd496bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilitiesTables" xlink:type="simple" xlink:href="dva-20241231.xsd#OtherLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_28d4e7d8-74e0-4c40-96aa-46a4f307efea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock_2f6de37b-f63a-482a-90b5-137ea782aa21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_28d4e7d8-74e0-4c40-96aa-46a4f307efea" xlink:to="loc_us-gaap_OtherLiabilitiesTableTextBlock_2f6de37b-f63a-482a-90b5-137ea782aa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6a04cc54-13bf-4fed-b4d3-0e1c5412d96c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_520e60b8-bf02-47ad-a0c0-0276d6712226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a04cc54-13bf-4fed-b4d3-0e1c5412d96c" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_520e60b8-bf02-47ad-a0c0-0276d6712226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9ed83be7-6cb8-4d07-b3aa-6ab0d3e21803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a04cc54-13bf-4fed-b4d3-0e1c5412d96c" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9ed83be7-6cb8-4d07-b3aa-6ab0d3e21803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fb784281-4629-4727-bbe5-ce7fa1e9b058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a04cc54-13bf-4fed-b4d3-0e1c5412d96c" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fb784281-4629-4727-bbe5-ce7fa1e9b058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e50d5df1-244a-4c7b-8885-46a9df61b1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a04cc54-13bf-4fed-b4d3-0e1c5412d96c" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e50d5df1-244a-4c7b-8885-46a9df61b1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_79b5f880-930a-4851-b505-173db1a8a94b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a04cc54-13bf-4fed-b4d3-0e1c5412d96c" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_79b5f880-930a-4851-b505-173db1a8a94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3a6f5548-0beb-45ad-bb16-d62591515dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7a466a4e-39be-4a3b-918f-e93712cb37e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3a6f5548-0beb-45ad-bb16-d62591515dbf" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7a466a4e-39be-4a3b-918f-e93712cb37e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_af43dc05-fa30-40db-9c99-97fa39a38942" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3a6f5548-0beb-45ad-bb16-d62591515dbf" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_af43dc05-fa30-40db-9c99-97fa39a38942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_6ddc5d12-86e8-47d3-ad90-f8c23576cdda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3a6f5548-0beb-45ad-bb16-d62591515dbf" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_6ddc5d12-86e8-47d3-ad90-f8c23576cdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e903afad-0c2d-4fb6-9880-a84111b63509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3a6f5548-0beb-45ad-bb16-d62591515dbf" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e903afad-0c2d-4fb6-9880-a84111b63509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesTables" xlink:type="simple" xlink:href="dva-20241231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1e5eddc3-7786-4a18-aad9-6fc5934c62f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_97bdb4de-9410-438c-9ff1-59c519d12bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e5eddc3-7786-4a18-aad9-6fc5934c62f4" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_97bdb4de-9410-438c-9ff1-59c519d12bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock_05fe9070-066f-4bcd-8074-6962a41d4f66" xlink:href="dva-20241231.xsd#dva_LeaseOtherInformationTableTextBlockTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e5eddc3-7786-4a18-aad9-6fc5934c62f4" xlink:to="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock_05fe9070-066f-4bcd-8074-6962a41d4f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock_f137459e-26fd-4a57-a2d0-0e503de98531" xlink:href="dva-20241231.xsd#dva_ScheduleOfMinimumLeasePaymentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e5eddc3-7786-4a18-aad9-6fc5934c62f4" xlink:to="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock_f137459e-26fd-4a57-a2d0-0e503de98531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables" xlink:type="simple" xlink:href="dva-20241231.xsd#StockbasedcompensationandShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_036b014d-e18d-4317-9bae-1c6b45f03424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_faea3103-762b-4f07-9858-8d1a3deb24d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_036b014d-e18d-4317-9bae-1c6b45f03424" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_faea3103-762b-4f07-9858-8d1a3deb24d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_d362e783-acf6-4a7e-ae3a-7ccaa3bd5c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_036b014d-e18d-4317-9bae-1c6b45f03424" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_d362e783-acf6-4a7e-ae3a-7ccaa3bd5c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d0f3abfc-a0d9-4487-a695-ca285131fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_036b014d-e18d-4317-9bae-1c6b45f03424" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d0f3abfc-a0d9-4487-a695-ca285131fa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="dva-20241231.xsd#StockholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/StockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f1bb88d3-51d2-4a84-9fb0-c1242370a49a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_79e404c6-9ce3-4d6a-8564-951e0f438501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f1bb88d3-51d2-4a84-9fb0-c1242370a49a" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_79e404c6-9ce3-4d6a-8564-951e0f438501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_33010114-01dd-42a3-861f-5ad68e6742b0" xlink:href="dva-20241231.xsd#dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f1bb88d3-51d2-4a84-9fb0-c1242370a49a" xlink:to="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_33010114-01dd-42a3-861f-5ad68e6742b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="simple" xlink:href="dva-20241231.xsd#AccumulatedOtherComprehensiveLossIncomeTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46622822-fab3-4a94-8f2e-8972e2460036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a189dc71-8b20-4c0a-97fe-97be7657910a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_46622822-fab3-4a94-8f2e-8972e2460036" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a189dc71-8b20-4c0a-97fe-97be7657910a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresTables" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsandDivestituresTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5a614dc5-61f1-4f99-85aa-331ac6f8efa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_4596e5ad-bbe4-41e4-940c-1a1e48034973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5a614dc5-61f1-4f99-85aa-331ac6f8efa0" xlink:to="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_4596e5ad-bbe4-41e4-940c-1a1e48034973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3b0b8ab5-11dc-4cc3-9a0e-40633e923cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5a614dc5-61f1-4f99-85aa-331ac6f8efa0" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3b0b8ab5-11dc-4cc3-9a0e-40633e923cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_662b4e74-382c-4d32-9aa4-00e6860e4919" xlink:href="dva-20241231.xsd#dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5a614dc5-61f1-4f99-85aa-331ac6f8efa0" xlink:to="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_662b4e74-382c-4d32-9aa4-00e6860e4919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_1447f0df-3a3a-4b19-b539-ecbaa95518d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5a614dc5-61f1-4f99-85aa-331ac6f8efa0" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_1447f0df-3a3a-4b19-b539-ecbaa95518d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsTables" xlink:type="simple" xlink:href="dva-20241231.xsd#FairValuesofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_513ca7ce-ba63-45a3-a0a5-08c49e36f9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_53c5a223-d839-4824-828c-9531d7ce7584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_513ca7ce-ba63-45a3-a0a5-08c49e36f9ce" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_53c5a223-d839-4824-828c-9531d7ce7584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1799f654-c8c2-453d-bfd6-be13c3834f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_97888174-ef7c-4515-8ff4-12243acd9258" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1799f654-c8c2-453d-bfd6-be13c3834f8a" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_97888174-ef7c-4515-8ff4-12243acd9258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_b65bd9d8-e453-493f-b166-94f0a80f3cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1799f654-c8c2-453d-bfd6-be13c3834f8a" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_b65bd9d8-e453-493f-b166-94f0a80f3cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_3ea64299-7c72-4213-8f5f-e2fb7665f4c9" xlink:href="dva-20241231.xsd#dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1799f654-c8c2-453d-bfd6-be13c3834f8a" xlink:to="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_3ea64299-7c72-4213-8f5f-e2fb7665f4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="dva-20241231.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_170ef67b-0fab-489b-8073-555794d28970" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_e32b147d-0f46-426d-aa1b-a405100fc5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_170ef67b-0fab-489b-8073-555794d28970" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_e32b147d-0f46-426d-aa1b-a405100fc5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0d4f35fb-766f-43af-ace1-5611ffab9b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_142144c9-2dfa-473c-8834-e69a75676dc4" xlink:href="dva-20241231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d4f35fb-766f-43af-ace1-5611ffab9b47" xlink:to="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_142144c9-2dfa-473c-8834-e69a75676dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4bab9a8c-fdc2-453e-b3f3-92796deaf933" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_142144c9-2dfa-473c-8834-e69a75676dc4" xlink:to="loc_srt_StatementGeographicalAxis_4bab9a8c-fdc2-453e-b3f3-92796deaf933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d924b5d2-8576-44ee-87ed-440dba501f11" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4bab9a8c-fdc2-453e-b3f3-92796deaf933" xlink:to="loc_srt_SegmentGeographicalDomain_d924b5d2-8576-44ee-87ed-440dba501f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_eb55836d-e3f7-4715-9473-b62bbab23307" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d924b5d2-8576-44ee-87ed-440dba501f11" xlink:to="loc_country_US_eb55836d-e3f7-4715-9473-b62bbab23307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InternationalOperationsMember_9b017c8e-888d-4737-b5c6-2e8180ead9b2" xlink:href="dva-20241231.xsd#dva_InternationalOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d924b5d2-8576-44ee-87ed-440dba501f11" xlink:to="loc_dva_InternationalOperationsMember_9b017c8e-888d-4737-b5c6-2e8180ead9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:href="dva-20241231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_142144c9-2dfa-473c-8834-e69a75676dc4" xlink:to="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfSites_73696e92-a2f8-4102-920f-7910341ca8f9" xlink:href="dva-20241231.xsd#dva_NumberOfSites"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_dva_NumberOfSites_73696e92-a2f8-4102-920f-7910341ca8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_9af725dd-ae6c-4950-a722-977b5ceb0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_9af725dd-ae6c-4950-a722-977b5ceb0e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfCustomers_7664178b-b3ff-4f94-a885-f2db6eb37df4" xlink:href="dva-20241231.xsd#dva_NumberOfCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_dva_NumberOfCustomers_7664178b-b3ff-4f94-a885-f2db6eb37df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_865300b5-fe46-4c44-8992-f0137ae8b6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_865300b5-fe46-4c44-8992-f0137ae8b6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_959e1b68-f12d-4cd8-80aa-729791c0868d" xlink:href="dva-20241231.xsd#dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_959e1b68-f12d-4cd8-80aa-729791c0868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_560cd326-19f7-4dc2-9115-fc98db498657" xlink:href="dva-20241231.xsd#dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_676af766-6bf1-4cba-86da-eb70f7b549e2" xlink:to="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_560cd326-19f7-4dc2-9115-fc98db498657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentRevenuebyMajorPayorAbstract_14a5f66f-c09b-4675-a8b0-303b2da725ed" xlink:href="dva-20241231.xsd#dva_SegmentRevenuebyMajorPayorAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_SegmentRevenuebyMajorPayorAbstract_14a5f66f-c09b-4675-a8b0-303b2da725ed" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b60c5b1f-ebf2-4bef-88ca-5b85fc5b0d12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b60c5b1f-ebf2-4bef-88ca-5b85fc5b0d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f83c5685-adc8-4f9b-b72f-6a3a9ff2a4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b60c5b1f-ebf2-4bef-88ca-5b85fc5b0d12" xlink:to="loc_us-gaap_SegmentDomain_f83c5685-adc8-4f9b-b72f-6a3a9ff2a4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_7fb77c8b-22e4-44da-b47e-1693dc5fe62a" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f83c5685-adc8-4f9b-b72f-6a3a9ff2a4d7" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_7fb77c8b-22e4-44da-b47e-1693dc5fe62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_680d075b-a569-458d-83b1-b36018859b27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f83c5685-adc8-4f9b-b72f-6a3a9ff2a4d7" xlink:to="loc_us-gaap_AllOtherSegmentsMember_680d075b-a569-458d-83b1-b36018859b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_0f85939d-c5a6-4498-994e-50bbe4079f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_0f85939d-c5a6-4498-994e-50bbe4079f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_0f85939d-c5a6-4498-994e-50bbe4079f63" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareandMedicareAdvantageMember_ad53b975-e17e-4b11-9b4c-feda8decfdd2" xlink:href="dva-20241231.xsd#dva_MedicareandMedicareAdvantageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_MedicareandMedicareAdvantageMember_ad53b975-e17e-4b11-9b4c-feda8decfdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicaidandManagedMedicaidMember_3752a4d7-ee53-438a-a683-4c9fcecd75cf" xlink:href="dva-20241231.xsd#dva_MedicaidandManagedMedicaidMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_MedicaidandManagedMedicaidMember_3752a4d7-ee53-438a-a683-4c9fcecd75cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherGovernmentPayorsMember_107d9f2a-c62e-4890-af75-f51621ea8d03" xlink:href="dva-20241231.xsd#dva_OtherGovernmentPayorsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_OtherGovernmentPayorsMember_107d9f2a-c62e-4890-af75-f51621ea8d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommercialPayorsMember_2b82e993-2659-4238-8bd1-b60748406e02" xlink:href="dva-20241231.xsd#dva_CommercialPayorsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_CommercialPayorsMember_2b82e993-2659-4238-8bd1-b60748406e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSourcesofRevenueMember_66d7de0a-779d-4d2e-947f-bf2d15081036" xlink:href="dva-20241231.xsd#dva_OtherSourcesofRevenueMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_8835820f-8f05-4481-8a5e-71e823618a2b" xlink:to="loc_dva_OtherSourcesofRevenueMember_66d7de0a-779d-4d2e-947f-bf2d15081036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ed48f823-7f07-4199-920f-6b1a2500df41" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:to="loc_srt_ConsolidationItemsAxis_ed48f823-7f07-4199-920f-6b1a2500df41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a769ca97-9408-432a-b3fb-6a34018c8985" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_ed48f823-7f07-4199-920f-6b1a2500df41" xlink:to="loc_srt_ConsolidationItemsDomain_a769ca97-9408-432a-b3fb-6a34018c8985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_b0b11cef-fc0b-44a2-8dbb-80fed85eaf33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a769ca97-9408-432a-b3fb-6a34018c8985" xlink:to="loc_us-gaap_IntersegmentEliminationMember_b0b11cef-fc0b-44a2-8dbb-80fed85eaf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9513b50d-1539-4fe7-a552-3905b360a46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9513b50d-1539-4fe7-a552-3905b360a46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fb9942f-f113-4435-a93a-61707455fd84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9513b50d-1539-4fe7-a552-3905b360a46f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fb9942f-f113-4435-a93a-61707455fd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_30bfe635-31f1-4aa0-bdd6-c18cbed627b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fb9942f-f113-4435-a93a-61707455fd84" xlink:to="loc_us-gaap_AccountsReceivableMember_30bfe635-31f1-4aa0-bdd6-c18cbed627b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5dd5dcef-57c7-48ec-b2dd-8372cf677137" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ffb37eaf-fb73-468c-b333-57fe2d60b0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ffb37eaf-fb73-468c-b333-57fe2d60b0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_cf23db2f-964c-482d-bb78-458001d6f37f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_us-gaap_OtherIncome_cf23db2f-964c-482d-bb78-458001d6f37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EliminationsOfIntersegmentRevenues_34ad80b6-8a93-4195-8be3-390872f2e87e" xlink:href="dva-20241231.xsd#dva_EliminationsOfIntersegmentRevenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_dva_EliminationsOfIntersegmentRevenues_34ad80b6-8a93-4195-8be3-390872f2e87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalRevenueNetOfIntersegmentRevenue_0f3eb05d-7ffa-4d06-a053-ca07179d9d19" xlink:href="dva-20241231.xsd#dva_TotalRevenueNetOfIntersegmentRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_dva_TotalRevenueNetOfIntersegmentRevenue_0f3eb05d-7ffa-4d06-a053-ca07179d9d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_e2801288-5a56-404e-ae7b-d8778d65892f" xlink:href="dva-20241231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f977cc90-45e1-4d60-8225-ec774a8b8f39" xlink:to="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_e2801288-5a56-404e-ae7b-d8778d65892f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_df8bbb5c-40ec-4ce3-8082-25b105d4a4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_df8bbb5c-40ec-4ce3-8082-25b105d4a4b1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_85c966da-5299-4b4d-9c53-6730b4e3375f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_85c966da-5299-4b4d-9c53-6730b4e3375f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4b303a54-4f2e-4e39-a4b9-15d0932acddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_85c966da-5299-4b4d-9c53-6730b4e3375f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4b303a54-4f2e-4e39-a4b9-15d0932acddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4fe713e4-49c4-42a6-a92d-a41034f63219" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4b303a54-4f2e-4e39-a4b9-15d0932acddc" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4fe713e4-49c4-42a6-a92d-a41034f63219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77e5db50-d6dd-484d-a095-0c169a3f3afc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77e5db50-d6dd-484d-a095-0c169a3f3afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9694fa71-5e44-48a8-abc8-78f79363127e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77e5db50-d6dd-484d-a095-0c169a3f3afc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9694fa71-5e44-48a8-abc8-78f79363127e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d6f11678-9187-44ba-ba88-2bb293cd5fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9694fa71-5e44-48a8-abc8-78f79363127e" xlink:to="loc_us-gaap_AccountsReceivableMember_d6f11678-9187-44ba-ba88-2bb293cd5fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2e346460-cb24-4546-b6ef-8ca952e5214e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2e346460-cb24-4546-b6ef-8ca952e5214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_77d7bced-9737-4c3a-9319-a017fd07e891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2e346460-cb24-4546-b6ef-8ca952e5214e" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_77d7bced-9737-4c3a-9319-a017fd07e891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_1b5ddd54-4ac5-4279-bad4-601ae7c14cd0" xlink:href="dva-20241231.xsd#dva_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_77d7bced-9737-4c3a-9319-a017fd07e891" xlink:to="loc_dva_MedicareMember_1b5ddd54-4ac5-4279-bad4-601ae7c14cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_1bcedd30-5841-4212-9587-dc16141223b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_77d7bced-9737-4c3a-9319-a017fd07e891" xlink:to="loc_us-gaap_ThirdPartyPayorMember_1bcedd30-5841-4212-9587-dc16141223b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f5c2699-7689-4406-957a-e506c17412cc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfConcentrationRiskCustomers_6c375855-16c4-483b-afb5-25cc0b6dd6a1" xlink:href="dva-20241231.xsd#dva_NumberOfConcentrationRiskCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_dva_NumberOfConcentrationRiskCustomers_6c375855-16c4-483b-afb5-25cc0b6dd6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_aec3a3d6-5d77-4156-b602-a429d8be5e18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_aec3a3d6-5d77-4156-b602-a429d8be5e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_42efe63d-e23f-43ce-bb0f-bae7886c0848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_42efe63d-e23f-43ce-bb0f-bae7886c0848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_4d15a11d-7bfd-4329-bc05-563297b53a26" xlink:href="dva-20241231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_4d15a11d-7bfd-4329-bc05-563297b53a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AccountsReceivablePeriodOutstanding_49639b2f-9e20-425f-8286-67e9a3badd26" xlink:href="dva-20241231.xsd#dva_AccountsReceivablePeriodOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_dva_AccountsReceivablePeriodOutstanding_49639b2f-9e20-425f-8286-67e9a3badd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_573218e6-03b8-43c5-87d9-b1203b942e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_573218e6-03b8-43c5-87d9-b1203b942e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_258974f8-dbf3-4f64-a4a7-c05a7e65fb89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4b2ff4dd-7d42-4250-a76e-20275ce4dd8f" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_258974f8-dbf3-4f64-a4a7-c05a7e65fb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84d9051b-7586-4c0d-9f8b-bd5891a8a8df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_49239846-aa36-4228-ba97-ad132bcaffb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84d9051b-7586-4c0d-9f8b-bd5891a8a8df" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_49239846-aa36-4228-ba97-ad132bcaffb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_aa9625f6-62ad-4733-845f-bb1e411d3350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_49239846-aa36-4228-ba97-ad132bcaffb0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_aa9625f6-62ad-4733-845f-bb1e411d3350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8ae0c68d-85df-4173-8a24-f73091a872e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_49239846-aa36-4228-ba97-ad132bcaffb0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8ae0c68d-85df-4173-8a24-f73091a872e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_622cdaa8-1528-484a-ac65-20d6e1cec6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_49239846-aa36-4228-ba97-ad132bcaffb0" xlink:to="loc_us-gaap_NetIncomeLoss_622cdaa8-1528-484a-ac65-20d6e1cec6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a3e9b8a2-a1be-4b21-b0ea-20c26bfffb53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84d9051b-7586-4c0d-9f8b-bd5891a8a8df" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a3e9b8a2-a1be-4b21-b0ea-20c26bfffb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_3e4a1b14-219d-443e-b123-24208c0ee6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a3e9b8a2-a1be-4b21-b0ea-20c26bfffb53" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_3e4a1b14-219d-443e-b123-24208c0ee6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d82dbfd1-ddb0-4d7b-b057-bdad09ff59ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a3e9b8a2-a1be-4b21-b0ea-20c26bfffb53" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d82dbfd1-ddb0-4d7b-b057-bdad09ff59ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7cd39ba2-df43-4e5c-b106-cfe844f6ac27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a3e9b8a2-a1be-4b21-b0ea-20c26bfffb53" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7cd39ba2-df43-4e5c-b106-cfe844f6ac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_3b2beb05-5d79-4aab-af9d-e427d5afad4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84d9051b-7586-4c0d-9f8b-bd5891a8a8df" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_3b2beb05-5d79-4aab-af9d-e427d5afad4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_4371d220-43f3-4fb8-9369-ffa0f4a9870a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3b2beb05-5d79-4aab-af9d-e427d5afad4d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_4371d220-43f3-4fb8-9369-ffa0f4a9870a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_521ba13c-1ae9-475a-92fc-11054f35b653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3b2beb05-5d79-4aab-af9d-e427d5afad4d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_521ba13c-1ae9-475a-92fc-11054f35b653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_21d1d313-6f8d-42f6-b7c9-b45c47184c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3b2beb05-5d79-4aab-af9d-e427d5afad4d" xlink:to="loc_us-gaap_EarningsPerShareBasic_21d1d313-6f8d-42f6-b7c9-b45c47184c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_0a993ba7-f04c-4946-b3ae-51edb8dbbd73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84d9051b-7586-4c0d-9f8b-bd5891a8a8df" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_0a993ba7-f04c-4946-b3ae-51edb8dbbd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_42b5e74b-6815-4288-91e4-bee320edc48e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_0a993ba7-f04c-4946-b3ae-51edb8dbbd73" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_42b5e74b-6815-4288-91e4-bee320edc48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_213fe62a-55f2-43c1-9503-334a19a67ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_0a993ba7-f04c-4946-b3ae-51edb8dbbd73" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_213fe62a-55f2-43c1-9503-334a19a67ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f0e6eb17-8c54-48c1-b312-a880c6a63746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_0a993ba7-f04c-4946-b3ae-51edb8dbbd73" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f0e6eb17-8c54-48c1-b312-a880c6a63746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e6b1dc8d-6d03-44d9-bc47-ad2aac109d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84d9051b-7586-4c0d-9f8b-bd5891a8a8df" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e6b1dc8d-6d03-44d9-bc47-ad2aac109d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ShorttermandlongterminvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_96515934-94cd-4aa0-8622-88102221e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_8572186f-337d-4d4a-b8ce-68e236adf3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_96515934-94cd-4aa0-8622-88102221e4df" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_8572186f-337d-4d4a-b8ce-68e236adf3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_2bbdb0b1-a074-4d8f-b591-ff9912b8711e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_8572186f-337d-4d4a-b8ce-68e236adf3a2" xlink:to="loc_us-gaap_InvestmentTypeAxis_2bbdb0b1-a074-4d8f-b591-ff9912b8711e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_2bbdb0b1-a074-4d8f-b591-ff9912b8711e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_4055847d-23f8-4982-8cf8-0ef10666227c" xlink:href="dva-20241231.xsd#dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:to="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_4055847d-23f8-4982-8cf8-0ef10666227c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MutualFundsAndCommonStockMember_d0a2cf7c-f60f-41dd-881a-8dea15739ebd" xlink:href="dva-20241231.xsd#dva_MutualFundsAndCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:to="loc_dva_MutualFundsAndCommonStockMember_d0a2cf7c-f60f-41dd-881a-8dea15739ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1bbbc694-4c8b-4e55-8221-e612a7f7a343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1bbbc694-4c8b-4e55-8221-e612a7f7a343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_6fcf9ed4-4386-45d5-ade1-ea2bd70b774c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0a681501-351f-406f-8a9d-3321e26373bb" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_6fcf9ed4-4386-45d5-ade1-ea2bd70b774c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_8572186f-337d-4d4a-b8ce-68e236adf3a2" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_74342330-d51e-4ecf-8e95-a1cd17ba8b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_HeldToMaturitySecurities_74342330-d51e-4ecf-8e95-a1cd17ba8b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0b2d6124-c6ff-45b6-8ab3-bceef0f8d4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0b2d6124-c6ff-45b6-8ab3-bceef0f8d4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_0fcf3f3b-6045-471a-9c04-1ea2a3f83291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_MarketableSecurities_0fcf3f3b-6045-471a-9c04-1ea2a3f83291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_4f2027ed-c389-4e58-ba4b-dd6f539c1ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_4f2027ed-c389-4e58-ba4b-dd6f539c1ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_03aa9a6b-aca5-43aa-a2b5-42094184e66d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_03aa9a6b-aca5-43aa-a2b5-42094184e66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_87a72d1b-5183-4be2-a86d-ece9b09b9ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_87a72d1b-5183-4be2-a86d-ece9b09b9ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0642a445-caf4-4f90-a1fe-0e189af0ba50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0642a445-caf4-4f90-a1fe-0e189af0ba50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5d6ff3bc-4123-4a12-a091-fe1b05be9147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5d6ff3bc-4123-4a12-a091-fe1b05be9147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_07332c9f-33d2-41d4-8fc4-bacbfe70726a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_3cf2d9cd-17e3-41c0-a91d-5a929fe47643" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_07332c9f-33d2-41d4-8fc4-bacbfe70726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#OtherReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_d0bd8ffd-0b8a-4423-9039-3da9f6f45b80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_07e92c3d-b1c2-441f-a303-29d5bafe2d54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_d0bd8ffd-0b8a-4423-9039-3da9f6f45b80" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_07e92c3d-b1c2-441f-a303-29d5bafe2d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c295f1ae-2e00-4959-9f20-d1d878086ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_07e92c3d-b1c2-441f-a303-29d5bafe2d54" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c295f1ae-2e00-4959-9f20-d1d878086ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c295f1ae-2e00-4959-9f20-d1d878086ca0" xlink:to="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_a1814962-970c-4e9f-a0a9-c6fa4f071bb7" xlink:href="dva-20241231.xsd#dva_SupplierRebatesAndOtherNonTradeReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:to="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_a1814962-970c-4e9f-a0a9-c6fa4f071bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_8cd11c67-a135-4b05-a4e0-d24ec6a52d1b" xlink:href="dva-20241231.xsd#dva_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:to="loc_dva_MedicareMember_8cd11c67-a135-4b05-a4e0-d24ec6a52d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IKCVBCArrangementsMember_05cabfd4-2966-4c7a-8acc-727adaceb39c" xlink:href="dva-20241231.xsd#dva_IKCVBCArrangementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_9262acd1-94de-44a2-939d-b954c2265c07" xlink:to="loc_dva_IKCVBCArrangementsMember_05cabfd4-2966-4c7a-8acc-727adaceb39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ca2a3b7e-1579-497d-8851-2fdfaf16bab1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_07e92c3d-b1c2-441f-a303-29d5bafe2d54" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ca2a3b7e-1579-497d-8851-2fdfaf16bab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_40f171bd-b24a-4355-85e0-510e5c3289fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ca2a3b7e-1579-497d-8851-2fdfaf16bab1" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_40f171bd-b24a-4355-85e0-510e5c3289fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c6de1d-4b5c-44fe-93b0-e20824bf1f74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_17772eea-5b2c-4bcc-a10b-f5ca014a3565" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c6de1d-4b5c-44fe-93b0-e20824bf1f74" xlink:to="loc_us-gaap_Land_17772eea-5b2c-4bcc-a10b-f5ca014a3565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_412e47d4-101c-4aee-afee-0f271d18529b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c6de1d-4b5c-44fe-93b0-e20824bf1f74" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_412e47d4-101c-4aee-afee-0f271d18529b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_3531c32c-da2b-489d-ae75-50bcab225639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c6de1d-4b5c-44fe-93b0-e20824bf1f74" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_3531c32c-da2b-489d-ae75-50bcab225639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_a5200d0e-1fbc-4151-8bfd-5a1423d80842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c6de1d-4b5c-44fe-93b0-e20824bf1f74" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_a5200d0e-1fbc-4151-8bfd-5a1423d80842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e6b92f87-6112-4188-9cd3-32e843b5140e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c6de1d-4b5c-44fe-93b0-e20824bf1f74" xlink:to="loc_us-gaap_ConstructionInProgressGross_e6b92f87-6112-4188-9cd3-32e843b5140e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_af917e31-b147-4cb1-8c6e-65fbaf102a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c6de1d-4b5c-44fe-93b0-e20824bf1f74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_af917e31-b147-4cb1-8c6e-65fbaf102a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7a823da1-e420-45eb-9aee-185343e1e895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c6de1d-4b5c-44fe-93b0-e20824bf1f74" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7a823da1-e420-45eb-9aee-185343e1e895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0f8903f6-5c3c-4f2f-962b-14490f30f041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3c6de1d-4b5c-44fe-93b0-e20824bf1f74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0f8903f6-5c3c-4f2f-962b-14490f30f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57a3a6f6-9632-47cd-a89d-55574bf655b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d9c4806c-d4bb-44e2-80e9-dcf9f1a2b15e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57a3a6f6-9632-47cd-a89d-55574bf655b2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d9c4806c-d4bb-44e2-80e9-dcf9f1a2b15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25aa514d-3380-4bb9-b331-ab03bbaccc50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d9c4806c-d4bb-44e2-80e9-dcf9f1a2b15e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25aa514d-3380-4bb9-b331-ab03bbaccc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25aa514d-3380-4bb9-b331-ab03bbaccc50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_1d125dbf-e03b-4224-bbc3-44b27367b4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:to="loc_us-gaap_BuildingMember_1d125dbf-e03b-4224-bbc3-44b27367b4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d732f6f8-ff9b-42e9-9b9f-1f32e1262d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d732f6f8-ff9b-42e9-9b9f-1f32e1262d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_9c304557-f378-44a7-9cea-bb0bea1ab7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1f654d70-3d40-4e09-95e7-8a57e07c7017" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_9c304557-f378-44a7-9cea-bb0bea1ab7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03037ed8-d5f3-4486-8732-1127979177d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d9c4806c-d4bb-44e2-80e9-dcf9f1a2b15e" xlink:to="loc_srt_RangeAxis_03037ed8-d5f3-4486-8732-1127979177d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7664d67-8118-4442-8f21-c3e6932bfb02" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_03037ed8-d5f3-4486-8732-1127979177d2" xlink:to="loc_srt_RangeMember_b7664d67-8118-4442-8f21-c3e6932bfb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b5db783a-3c77-41a1-8ee9-c69b5e893dee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7664d67-8118-4442-8f21-c3e6932bfb02" xlink:to="loc_srt_MinimumMember_b5db783a-3c77-41a1-8ee9-c69b5e893dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38bafed4-c59e-4f91-a559-851a12c23372" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7664d67-8118-4442-8f21-c3e6932bfb02" xlink:to="loc_srt_MaximumMember_38bafed4-c59e-4f91-a559-851a12c23372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d9c4806c-d4bb-44e2-80e9-dcf9f1a2b15e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_92797b50-56ba-41dd-8df7-da403137b3de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_92797b50-56ba-41dd-8df7-da403137b3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7e932bb7-a14d-4509-af8b-5e2038044c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7e932bb7-a14d-4509-af8b-5e2038044c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_68c4caa6-1fcc-47f8-a060-850af1d7cdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_74b16d04-8998-4e8a-b1f4-b3311724fcc8" xlink:to="loc_us-gaap_InterestCostsCapitalized_68c4caa6-1fcc-47f8-a060-850af1d7cdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_98bc2c92-c578-4852-afaf-cd19e48957ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_58381641-c7d7-4edd-8cac-a9849d50d5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_98bc2c92-c578-4852-afaf-cd19e48957ac" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_58381641-c7d7-4edd-8cac-a9849d50d5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7200e3c5-feef-4104-95b3-09553c511f27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_98bc2c92-c578-4852-afaf-cd19e48957ac" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7200e3c5-feef-4104-95b3-09553c511f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_269ae2ae-a076-4330-b437-2a1d36d38b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7200e3c5-feef-4104-95b3-09553c511f27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_269ae2ae-a076-4330-b437-2a1d36d38b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d204a59-d56a-4dd8-900d-fa6ac99f20af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_269ae2ae-a076-4330-b437-2a1d36d38b51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d204a59-d56a-4dd8-900d-fa6ac99f20af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_02d533a9-a629-4fce-8160-64558b3f9c83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d204a59-d56a-4dd8-900d-fa6ac99f20af" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_02d533a9-a629-4fce-8160-64558b3f9c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_11d23083-9aa4-4094-a39f-892e4fd609e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d204a59-d56a-4dd8-900d-fa6ac99f20af" xlink:to="loc_us-gaap_ServiceAgreementsMember_11d23083-9aa4-4094-a39f-892e4fd609e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7200e3c5-feef-4104-95b3-09553c511f27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_54e703d4-4aac-4422-a3f3-7d5339925496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_54e703d4-4aac-4422-a3f3-7d5339925496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_51dadc78-4396-477e-ba8b-181e73e7fb16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_51dadc78-4396-477e-ba8b-181e73e7fb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b65248fe-10d8-4a5d-82ff-1defeb394170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b65248fe-10d8-4a5d-82ff-1defeb394170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_35bcb8c6-c072-46bc-9ec8-486e9c7dd562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_35bcb8c6-c072-46bc-9ec8-486e9c7dd562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6303ee29-6082-4ef5-8413-de5f960298ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aef92152-1413-44ac-8be0-0659180e0851" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6303ee29-6082-4ef5-8413-de5f960298ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_505c59e1-6c89-468c-b188-d4128dc5e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseTable_3003eba5-6777-43d2-abaf-838fdeb444cc" xlink:href="dva-20241231.xsd#dva_ExpectedAmortizationExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_505c59e1-6c89-468c-b188-d4128dc5e4bb" xlink:to="loc_dva_ExpectedAmortizationExpenseTable_3003eba5-6777-43d2-abaf-838fdeb444cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eca66858-dcca-4ef0-959f-b8e6cc75f581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseTable_3003eba5-6777-43d2-abaf-838fdeb444cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eca66858-dcca-4ef0-959f-b8e6cc75f581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5f46d7-5340-426b-af16-ee339dc7e14e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eca66858-dcca-4ef0-959f-b8e6cc75f581" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5f46d7-5340-426b-af16-ee339dc7e14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_da84ff52-0e66-415c-aa07-f1ec968b47b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5f46d7-5340-426b-af16-ee339dc7e14e" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_da84ff52-0e66-415c-aa07-f1ec968b47b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_0467bd89-e28d-44c1-a35f-5b06c6559859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc5f46d7-5340-426b-af16-ee339dc7e14e" xlink:to="loc_us-gaap_ServiceAgreementsMember_0467bd89-e28d-44c1-a35f-5b06c6559859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:href="dva-20241231.xsd#dva_ExpectedAmortizationExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseTable_3003eba5-6777-43d2-abaf-838fdeb444cc" xlink:to="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5f4f0143-2bb2-4e01-8b9f-8f57c95f2fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5f4f0143-2bb2-4e01-8b9f-8f57c95f2fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c3536884-d248-4ef2-a2d3-8f2dc39b10a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c3536884-d248-4ef2-a2d3-8f2dc39b10a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b7c27a09-62a6-4f74-a2e5-a5117c32dcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b7c27a09-62a6-4f74-a2e5-a5117c32dcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7885dcba-600b-4f78-a55e-49bbf39f496d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7885dcba-600b-4f78-a55e-49bbf39f496d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_26d013f0-bd06-40f5-a047-8262784c4734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_26d013f0-bd06-40f5-a047-8262784c4734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fc7cec40-7e27-4a6b-9139-026acdb2a804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fc7cec40-7e27-4a6b-9139-026acdb2a804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5dc9b169-b844-4ce6-939c-0824daf8516a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_4c9c30d1-dc87-40fe-8bfa-390824547786" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5dc9b169-b844-4ce6-939c-0824daf8516a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IntangiblesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b16f2c86-5072-49d2-8c34-c2da79d885b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a554e95-a3df-4cb5-b49a-32c32a34619b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b16f2c86-5072-49d2-8c34-c2da79d885b3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a554e95-a3df-4cb5-b49a-32c32a34619b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a6225069-f11b-4a08-88e1-50cd4e2e05f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a554e95-a3df-4cb5-b49a-32c32a34619b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a6225069-f11b-4a08-88e1-50cd4e2e05f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_595994ed-0276-49c4-b11c-5bbb8b53e95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a6225069-f11b-4a08-88e1-50cd4e2e05f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_595994ed-0276-49c4-b11c-5bbb8b53e95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_d3efcbfa-9b11-46e4-ab75-3d3d236aedd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_595994ed-0276-49c4-b11c-5bbb8b53e95f" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_d3efcbfa-9b11-46e4-ab75-3d3d236aedd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3a3a63ce-ae2b-4640-9300-8445d7e96416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_595994ed-0276-49c4-b11c-5bbb8b53e95f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3a3a63ce-ae2b-4640-9300-8445d7e96416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7d0bfbf-40a8-4c1f-9ec7-03b5eaafc721" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a554e95-a3df-4cb5-b49a-32c32a34619b" xlink:to="loc_srt_RangeAxis_a7d0bfbf-40a8-4c1f-9ec7-03b5eaafc721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bfcd9fab-c79b-460c-b763-97fca803bf87" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a7d0bfbf-40a8-4c1f-9ec7-03b5eaafc721" xlink:to="loc_srt_RangeMember_bfcd9fab-c79b-460c-b763-97fca803bf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4375966d-4bc6-407f-813d-98d3a7486981" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bfcd9fab-c79b-460c-b763-97fca803bf87" xlink:to="loc_srt_MinimumMember_4375966d-4bc6-407f-813d-98d3a7486981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a079233d-c34e-48db-a20b-3dcd87cabb3f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bfcd9fab-c79b-460c-b763-97fca803bf87" xlink:to="loc_srt_MaximumMember_a079233d-c34e-48db-a20b-3dcd87cabb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a554e95-a3df-4cb5-b49a-32c32a34619b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7ad466fc-4ba7-4618-b6f3-ab7c79652f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7ad466fc-4ba7-4618-b6f3-ab7c79652f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_323f7766-508f-4bf4-94f2-3ad2fd641e96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_323f7766-508f-4bf4-94f2-3ad2fd641e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3a7ceeca-fe9b-4fbc-b1f5-30b875458992" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3a7ceeca-fe9b-4fbc-b1f5-30b875458992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_23851cae-afed-422a-b5ae-57f32327cd34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7d6c6b9c-91e8-4a2b-9766-bdd7eea5346d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_23851cae-afed-422a-b5ae-57f32327cd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3219e938-2b9a-4965-9755-159308764787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3219e938-2b9a-4965-9755-159308764787" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_0d8e37d2-feb1-467f-aff2-6989118dbf33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_0d8e37d2-feb1-467f-aff2-6989118dbf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_b607a82e-9e87-4eb1-a5ab-aca5d7f05917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_0d8e37d2-feb1-467f-aff2-6989118dbf33" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_b607a82e-9e87-4eb1-a5ab-aca5d7f05917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestMember_5e573d8a-9d4e-45ac-b4ee-0135033b6a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOwnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_b607a82e-9e87-4eb1-a5ab-aca5d7f05917" xlink:to="loc_us-gaap_OtherOwnershipInterestMember_5e573d8a-9d4e-45ac-b4ee-0135033b6a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ba8ec781-77b8-42a1-aaf8-c89dc4b2e831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:to="loc_us-gaap_InvestmentTypeAxis_ba8ec781-77b8-42a1-aaf8-c89dc4b2e831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_33cb793a-65a6-47d9-9f70-fca92cb44d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_ba8ec781-77b8-42a1-aaf8-c89dc4b2e831" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_33cb793a-65a6-47d9-9f70-fca92cb44d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d251f4ad-2839-4831-b4a7-0fa530761fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_33cb793a-65a6-47d9-9f70-fca92cb44d6c" xlink:to="loc_us-gaap_EquitySecuritiesMember_d251f4ad-2839-4831-b4a7-0fa530761fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ef8c6863-62fa-4331-af96-e8970a9d9254" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:to="loc_srt_OwnershipAxis_ef8c6863-62fa-4331-af96-e8970a9d9254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c6415dff-bff6-428b-b6bc-f50bd6e4140d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_ef8c6863-62fa-4331-af96-e8970a9d9254" xlink:to="loc_srt_OwnershipDomain_c6415dff-bff6-428b-b6bc-f50bd6e4140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember_e1d1f5f7-8bb2-4c22-9144-261f1c949f29" xlink:href="dva-20241231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_c6415dff-bff6-428b-b6bc-f50bd6e4140d" xlink:to="loc_dva_AgreementWithMedtronicMember_e1d1f5f7-8bb2-4c22-9144-261f1c949f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember_150423a3-c67b-4d07-9203-c770701f04fe" xlink:href="dva-20241231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_c6415dff-bff6-428b-b6bc-f50bd6e4140d" xlink:to="loc_dva_DeconsolidatedNoncontrollingEntityMember_150423a3-c67b-4d07-9203-c770701f04fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_24cdbfb4-b71a-4bdb-b69b-16f9f06b51d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:to="loc_us-gaap_OtherCommitmentsAxis_24cdbfb4-b71a-4bdb-b69b-16f9f06b51d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_daf47d62-e69d-4fee-a5a6-b9e7e54ff2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_24cdbfb4-b71a-4bdb-b69b-16f9f06b51d6" xlink:to="loc_us-gaap_OtherCommitmentsDomain_daf47d62-e69d-4fee-a5a6-b9e7e54ff2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember_21fe63ca-3c8c-44b6-a3e7-f88d9e39d5fb" xlink:href="dva-20241231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_daf47d62-e69d-4fee-a5a6-b9e7e54ff2e5" xlink:to="loc_dva_AgreementWithMedtronicMember_21fe63ca-3c8c-44b6-a3e7-f88d9e39d5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2f96d137-6001-4348-9a91-33255c860808" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ebf5c366-3fb7-49e0-8d85-08dd2d4b3155" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ebf5c366-3fb7-49e0-8d85-08dd2d4b3155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_49802091-181b-44ec-ab6c-da680d46f1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_49802091-181b-44ec-ab6c-da680d46f1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_2470af1f-e381-451c-8b22-79b1c07039e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_2470af1f-e381-451c-8b22-79b1c07039e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OwnershipPercentageByNoncontrollingOwners_0a53338e-d44e-464b-961c-0bec2801ec86" xlink:href="dva-20241231.xsd#dva_OwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_dva_OwnershipPercentageByNoncontrollingOwners_0a53338e-d44e-464b-961c-0bec2801ec86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAgreementEffectiveClosingDate_030e66b4-539e-4790-b053-70b3d8a44000" xlink:href="dva-20241231.xsd#dva_BusinessAgreementEffectiveClosingDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_dva_BusinessAgreementEffectiveClosingDate_030e66b4-539e-4790-b053-70b3d8a44000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FairValuePayableOfContingentConsideration_d86e8575-301e-4266-87e8-56789243101a" xlink:href="dva-20241231.xsd#dva_FairValuePayableOfContingentConsideration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_dva_FairValuePayableOfContingentConsideration_d86e8575-301e-4266-87e8-56789243101a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_682ae03b-4124-41d1-800e-d7a96134d80c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c58b0625-802d-4e1a-8132-09c0c0ef27ee" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_682ae03b-4124-41d1-800e-d7a96134d80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#EquityMethodandOtherInvestmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f081c632-84f5-4846-94d6-40da30c44ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f081c632-84f5-4846-94d6-40da30c44ec4" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4e3f1cae-967e-418a-8fbe-7fd0354a71d7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4e3f1cae-967e-418a-8fbe-7fd0354a71d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_06e00b48-4695-47b9-898e-c91de29ade4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4e3f1cae-967e-418a-8fbe-7fd0354a71d7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_06e00b48-4695-47b9-898e-c91de29ade4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_7821ae68-2d94-4d69-a167-c0c2a181ecf4" xlink:href="dva-20241231.xsd#dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_06e00b48-4695-47b9-898e-c91de29ade4a" xlink:to="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_7821ae68-2d94-4d69-a167-c0c2a181ecf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_08ef2969-898b-4844-b2df-4a68b35d3988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_08ef2969-898b-4844-b2df-4a68b35d3988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c65e48be-9574-46e7-a8bb-2d944c3edbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_08ef2969-898b-4844-b2df-4a68b35d3988" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c65e48be-9574-46e7-a8bb-2d944c3edbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1da2e15e-9343-43e9-afc2-ef27241565ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c65e48be-9574-46e7-a8bb-2d944c3edbd3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1da2e15e-9343-43e9-afc2-ef27241565ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1dfad46d-1d8c-4431-a976-3beeb1f69ba5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:to="loc_srt_RangeAxis_1dfad46d-1d8c-4431-a976-3beeb1f69ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_080dddbd-1873-497e-aa34-96c5bfbbe206" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1dfad46d-1d8c-4431-a976-3beeb1f69ba5" xlink:to="loc_srt_RangeMember_080dddbd-1873-497e-aa34-96c5bfbbe206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9398b870-2ced-4545-86b6-f1c7919d0e10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_080dddbd-1873-497e-aa34-96c5bfbbe206" xlink:to="loc_srt_MinimumMember_9398b870-2ced-4545-86b6-f1c7919d0e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60b8074d-52ad-485e-be06-a60470b83231" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_080dddbd-1873-497e-aa34-96c5bfbbe206" xlink:to="loc_srt_MaximumMember_60b8074d-52ad-485e-be06-a60470b83231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_2026df7c-c081-4ba2-9d0e-d4560c263eb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:to="loc_srt_OwnershipAxis_2026df7c-c081-4ba2-9d0e-d4560c263eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_eba945e4-30ac-4ae7-a91d-8dd07f1760c3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_2026df7c-c081-4ba2-9d0e-d4560c263eb8" xlink:to="loc_srt_OwnershipDomain_eba945e4-30ac-4ae7-a91d-8dd07f1760c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_80c49a6b-a03a-4347-bb59-3737cea05ec9" xlink:href="dva-20241231.xsd#dva_ParentCompanyAndRestrictedSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_eba945e4-30ac-4ae7-a91d-8dd07f1760c3" xlink:to="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_80c49a6b-a03a-4347-bb59-3737cea05ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_aa911305-e32b-47a3-b874-6da8d1937d83" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1a05eb5b-755c-4e66-ad2c-49dd4f449037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1a05eb5b-755c-4e66-ad2c-49dd4f449037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_23e2ee2e-d569-418c-a4a5-c0563989d3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_23e2ee2e-d569-418c-a4a5-c0563989d3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeLossFromOtherEquityMethodInvestments_2e1524fe-63f3-4938-b40a-11b9ef7675c9" xlink:href="dva-20241231.xsd#dva_IncomeLossFromOtherEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_dva_IncomeLossFromOtherEquityMethodInvestments_2e1524fe-63f3-4938-b40a-11b9ef7675c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfPartnerships_4941fd17-f3bc-4fb7-8314-f6f4565c5b55" xlink:href="dva-20241231.xsd#dva_NumberOfPartnerships"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_dva_NumberOfPartnerships_4941fd17-f3bc-4fb7-8314-f6f4565c5b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6ed67a10-13e2-4196-b12f-c3703c53d835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_148f3cdf-52fa-44ce-bb53-c0c0d7ae220c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6ed67a10-13e2-4196-b12f-c3703c53d835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bee4fcb6-8633-462d-acd8-ed79535e74cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6c3197fa-3532-438b-a357-b4d9d5b580b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bee4fcb6-8633-462d-acd8-ed79535e74cc" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6c3197fa-3532-438b-a357-b4d9d5b580b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_280b3a74-720f-4e06-9e01-76fec8224b73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c3197fa-3532-438b-a357-b4d9d5b580b3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_280b3a74-720f-4e06-9e01-76fec8224b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1318ec87-ac1c-4d34-97be-e1e534ca823d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_280b3a74-720f-4e06-9e01-76fec8224b73" xlink:to="loc_us-gaap_SegmentDomain_1318ec87-ac1c-4d34-97be-e1e534ca823d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_fc73e268-af88-4d77-b3f6-759a5fa23bd9" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1318ec87-ac1c-4d34-97be-e1e534ca823d" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_fc73e268-af88-4d77-b3f6-759a5fa23bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a6c21bd3-7193-41f9-a42a-dc0cad949858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1318ec87-ac1c-4d34-97be-e1e534ca823d" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a6c21bd3-7193-41f9-a42a-dc0cad949858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_6f335e1a-3792-4539-bd5d-7f01ddd3f902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c3197fa-3532-438b-a357-b4d9d5b580b3" xlink:to="loc_us-gaap_ReportingUnitAxis_6f335e1a-3792-4539-bd5d-7f01ddd3f902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_fc951aab-dbb5-44ba-92f8-2ab7e2b21d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_6f335e1a-3792-4539-bd5d-7f01ddd3f902" xlink:to="loc_us-gaap_ReportingUnitDomain_fc951aab-dbb5-44ba-92f8-2ab7e2b21d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember_b4abb70b-28db-488b-bdc3-ba3d8017f1dc" xlink:href="dva-20241231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_fc951aab-dbb5-44ba-92f8-2ab7e2b21d4f" xlink:to="loc_dva_TransplantSoftwareReportingUnitMember_b4abb70b-28db-488b-bdc3-ba3d8017f1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6c3197fa-3532-438b-a357-b4d9d5b580b3" xlink:to="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:to="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fa6ae642-2ca2-448b-99ae-57c783868ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_Goodwill_fa6ae642-2ca2-448b-99ae-57c783868ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1961b684-02a8-4cca-a8b8-8fcec213f002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_1961b684-02a8-4cca-a8b8-8fcec213f002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_3248a4ca-fdd0-4199-bdac-ddf123cc6722" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_3248a4ca-fdd0-4199-bdac-ddf123cc6722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_738fd0b6-ad5f-4610-b142-e5446ff31d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_738fd0b6-ad5f-4610-b142-e5446ff31d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_41b71c4b-0db2-47e6-a29c-336276e44d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_41b71c4b-0db2-47e6-a29c-336276e44d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6cefc040-dcf0-4363-8d0c-efc23e4115af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb9930aa-c88b-4f64-9d6a-fec82c52f54e" xlink:to="loc_us-gaap_Goodwill_6cefc040-dcf0-4363-8d0c-efc23e4115af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_458f88b6-ae3a-4890-81d6-ec1f3380bb87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:to="loc_us-gaap_GoodwillGross_458f88b6-ae3a-4890-81d6-ec1f3380bb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_53e8998e-ac53-4004-98ed-24e66ae04e24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8d5756c1-7411-45b4-8745-a6ad694c99a1" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_53e8998e-ac53-4004-98ed-24e66ae04e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0aa26735-d79e-4c9a-873e-9aa7b9e4c257" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5fbfca08-e232-4eca-8f15-14ffdb18f134" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0aa26735-d79e-4c9a-873e-9aa7b9e4c257" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5fbfca08-e232-4eca-8f15-14ffdb18f134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2e4c429e-d1e9-4953-98e6-1d8761f02dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5fbfca08-e232-4eca-8f15-14ffdb18f134" xlink:to="loc_us-gaap_ReportingUnitAxis_2e4c429e-d1e9-4953-98e6-1d8761f02dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_e1e1dda6-8a77-4c28-9ce5-900de8e9fb93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_2e4c429e-d1e9-4953-98e6-1d8761f02dfa" xlink:to="loc_us-gaap_ReportingUnitDomain_e1e1dda6-8a77-4c28-9ce5-900de8e9fb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember_b619165a-1949-4642-8e83-c66670a9dc6e" xlink:href="dva-20241231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_e1e1dda6-8a77-4c28-9ce5-900de8e9fb93" xlink:to="loc_dva_TransplantSoftwareReportingUnitMember_b619165a-1949-4642-8e83-c66670a9dc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_182b704a-1bf0-41ab-98b8-f77b29f33c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5fbfca08-e232-4eca-8f15-14ffdb18f134" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_182b704a-1bf0-41ab-98b8-f77b29f33c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eb5a9c97-b095-4572-b52d-50871c7ceee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_182b704a-1bf0-41ab-98b8-f77b29f33c3a" xlink:to="loc_us-gaap_SegmentDomain_eb5a9c97-b095-4572-b52d-50871c7ceee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember_57ad7ab3-9196-4eff-95d9-97196e5f691b" xlink:href="dva-20241231.xsd#dva_OtherReportingUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eb5a9c97-b095-4572-b52d-50871c7ceee6" xlink:to="loc_dva_OtherReportingUnitsMember_57ad7ab3-9196-4eff-95d9-97196e5f691b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5fbfca08-e232-4eca-8f15-14ffdb18f134" xlink:to="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0f31fcb6-d9b9-46bd-a007-db6e06fbdd29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:to="loc_us-gaap_Goodwill_0f31fcb6-d9b9-46bd-a007-db6e06fbdd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax_b58da91c-e4cc-4916-a33e-bf0d7cfdf1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:to="loc_us-gaap_GoodwillImpairmentLossNetOfTax_b58da91c-e4cc-4916-a33e-bf0d7cfdf1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6c127f7f-071a-4095-8f6e-2e7328fd479c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6c127f7f-071a-4095-8f6e-2e7328fd479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_72f3e09a-9805-42bb-990a-484d279d70f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5cf75e73-ee25-4dda-925c-393d3cf87801" xlink:to="loc_us-gaap_NumberOfOperatingSegments_72f3e09a-9805-42bb-990a-484d279d70f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#GoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c5dbc7a-ff09-4dae-b36e-373e45722b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_4265a44f-2f6a-4118-a2d4-98bcb1122426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c5dbc7a-ff09-4dae-b36e-373e45722b3c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_4265a44f-2f6a-4118-a2d4-98bcb1122426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_55d78fb2-43f0-4c3e-80e4-7d7134795bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_4265a44f-2f6a-4118-a2d4-98bcb1122426" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_55d78fb2-43f0-4c3e-80e4-7d7134795bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4c297e65-021a-4346-91a0-3d943b2e5968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_55d78fb2-43f0-4c3e-80e4-7d7134795bd8" xlink:to="loc_us-gaap_SegmentDomain_4c297e65-021a-4346-91a0-3d943b2e5968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember_59e469fa-99eb-46a3-8120-2e5df51a4e3f" xlink:href="dva-20241231.xsd#dva_OtherReportingUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4c297e65-021a-4346-91a0-3d943b2e5968" xlink:to="loc_dva_OtherReportingUnitsMember_59e469fa-99eb-46a3-8120-2e5df51a4e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_681dca0f-30fc-43af-9593-8b73abd5e2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_4265a44f-2f6a-4118-a2d4-98bcb1122426" xlink:to="loc_us-gaap_GoodwillLineItems_681dca0f-30fc-43af-9593-8b73abd5e2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ab0bfe5a-19d7-4206-a297-ea255d215a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_681dca0f-30fc-43af-9593-8b73abd5e2f8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ab0bfe5a-19d7-4206-a297-ea255d215a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#OtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3f880dfe-28ec-4829-ae24-00c763177b46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PayorRefundsAndRetractions_c4e7ffaf-ec9d-4940-8010-261c972a904d" xlink:href="dva-20241231.xsd#dva_PayorRefundsAndRetractions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3f880dfe-28ec-4829-ae24-00c763177b46" xlink:to="loc_dva_PayorRefundsAndRetractions_c4e7ffaf-ec9d-4940-8010-261c972a904d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_8e696a1d-2863-489b-8bd8-0ff9900c9d85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3f880dfe-28ec-4829-ae24-00c763177b46" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_8e696a1d-2863-489b-8bd8-0ff9900c9d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_753c0bd1-a5af-4f8e-a94f-2fb1c2203958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3f880dfe-28ec-4829-ae24-00c763177b46" xlink:to="loc_us-gaap_InterestPayableCurrent_753c0bd1-a5af-4f8e-a94f-2fb1c2203958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_6f5d745f-ba80-4003-9f09-d31c9aeea056" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3f880dfe-28ec-4829-ae24-00c763177b46" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_6f5d745f-ba80-4003-9f09-d31c9aeea056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_26fe5ba0-124f-436e-80f7-5d26338c6163" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3f880dfe-28ec-4829-ae24-00c763177b46" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_26fe5ba0-124f-436e-80f7-5d26338c6163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5ea94070-d922-40bb-b835-5ba0e19a0651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3f880dfe-28ec-4829-ae24-00c763177b46" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5ea94070-d922-40bb-b835-5ba0e19a0651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_53df6241-5964-471f-b63e-1b8f33e3349b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fded9bb5-cd23-4108-9652-071f548d340c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_53df6241-5964-471f-b63e-1b8f33e3349b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fded9bb5-cd23-4108-9652-071f548d340c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_71913a77-e703-40b3-820f-2ddbed60b6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_53df6241-5964-471f-b63e-1b8f33e3349b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_71913a77-e703-40b3-820f-2ddbed60b6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_95efcffb-0079-4732-a936-9fa3f6dc3e85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_53df6241-5964-471f-b63e-1b8f33e3349b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_95efcffb-0079-4732-a936-9fa3f6dc3e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e0997b20-c928-4c15-bca6-783ed69e6f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9df5f215-2b72-4231-b06a-a71d8a632fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0997b20-c928-4c15-bca6-783ed69e6f9e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9df5f215-2b72-4231-b06a-a71d8a632fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_47bd35ac-28dd-4afc-9bb8-8a677efb66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9df5f215-2b72-4231-b06a-a71d8a632fd0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_47bd35ac-28dd-4afc-9bb8-8a677efb66e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3eaa57d8-ada3-4e1a-a44b-1dc6fd62e1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9df5f215-2b72-4231-b06a-a71d8a632fd0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3eaa57d8-ada3-4e1a-a44b-1dc6fd62e1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a971aef5-80e8-4f75-9012-4c2f05b52301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9df5f215-2b72-4231-b06a-a71d8a632fd0" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a971aef5-80e8-4f75-9012-4c2f05b52301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_209e6e49-8924-484e-96d9-850b500974fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9df5f215-2b72-4231-b06a-a71d8a632fd0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_209e6e49-8924-484e-96d9-850b500974fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27ac0aa5-68f4-4c8b-be00-f19048e857a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0997b20-c928-4c15-bca6-783ed69e6f9e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27ac0aa5-68f4-4c8b-be00-f19048e857a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d10e061d-9b9c-4e9c-89ae-e9df4ae1aac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27ac0aa5-68f4-4c8b-be00-f19048e857a2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d10e061d-9b9c-4e9c-89ae-e9df4ae1aac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b372d14d-fd4b-42d2-b955-47e4ad49635f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27ac0aa5-68f4-4c8b-be00-f19048e857a2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b372d14d-fd4b-42d2-b955-47e4ad49635f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3adeb058-0786-429e-99b7-1d30f20200c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27ac0aa5-68f4-4c8b-be00-f19048e857a2" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3adeb058-0786-429e-99b7-1d30f20200c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_33c755c1-83f1-4b5a-80d3-47a7e65298a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27ac0aa5-68f4-4c8b-be00-f19048e857a2" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_33c755c1-83f1-4b5a-80d3-47a7e65298a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8af75070-e384-4609-baff-95fded8929b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0997b20-c928-4c15-bca6-783ed69e6f9e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8af75070-e384-4609-baff-95fded8929b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_65e884b6-128c-4b72-a6f0-c85d92cac3be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_65e884b6-128c-4b72-a6f0-c85d92cac3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c6229390-b2f7-4503-84ae-596b5fa71226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c6229390-b2f7-4503-84ae-596b5fa71226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9cc7f5b0-2570-4d75-883d-5966bdcc82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9cc7f5b0-2570-4d75-883d-5966bdcc82cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_7a9f7255-db99-4931-8bd4-359d944bf923" xlink:href="dva-20241231.xsd#dva_EffectiveIncomeTaxReconciliationInvestmentImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_7a9f7255-db99-4931-8bd4-359d944bf923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5bce0eb0-7e78-4f30-9448-99dd317b0bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5bce0eb0-7e78-4f30-9448-99dd317b0bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_c331b023-f192-4feb-b8a4-20d55229dc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_c331b023-f192-4feb-b8a4-20d55229dc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2c2c1b76-08dc-4e0b-ae27-73708df878fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2c2c1b76-08dc-4e0b-ae27-73708df878fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_838a70ba-6519-4fc3-97b1-0ce10691cfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_838a70ba-6519-4fc3-97b1-0ce10691cfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0a0125b3-54e3-4ff3-b129-1938fd8c3add" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0a0125b3-54e3-4ff3-b129-1938fd8c3add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_738adf10-f196-49af-ae4e-90af5c8f4744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_738adf10-f196-49af-ae4e-90af5c8f4744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b9ce97d8-9811-42c9-9bcc-160809511d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6ecdfd-f1b7-47bc-b16a-22497d925114" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b9ce97d8-9811-42c9-9bcc-160809511d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_abaf14b0-316c-45b5-a391-a1638cb6ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_76494627-f88c-4ab3-aa6f-bbbcbb45c401" xlink:href="dva-20241231.xsd#dva_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_abaf14b0-316c-45b5-a391-a1638cb6ed86" xlink:to="loc_dva_IncomeTaxesTable_76494627-f88c-4ab3-aa6f-bbbcbb45c401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d83e0f0d-69bd-4013-a9bb-afbc7204449c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_76494627-f88c-4ab3-aa6f-bbbcbb45c401" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d83e0f0d-69bd-4013-a9bb-afbc7204449c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e8c3f3d7-828f-458a-836f-7bcdd2e2bcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d83e0f0d-69bd-4013-a9bb-afbc7204449c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e8c3f3d7-828f-458a-836f-7bcdd2e2bcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesMember_a1bed24d-6f25-4249-bc8a-7db54ccad76d" xlink:href="dva-20241231.xsd#dva_DeferredTaxLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e8c3f3d7-828f-458a-836f-7bcdd2e2bcd6" xlink:to="loc_dva_DeferredTaxLiabilitiesMember_a1bed24d-6f25-4249-bc8a-7db54ccad76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_fb7043fb-90c3-40c1-81bc-a085dbc60854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e8c3f3d7-828f-458a-836f-7bcdd2e2bcd6" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_fb7043fb-90c3-40c1-81bc-a085dbc60854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:href="dva-20241231.xsd#dva_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_76494627-f88c-4ab3-aa6f-bbbcbb45c401" xlink:to="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables_ceb4e772-f064-41ae-b2b2-357418639542" xlink:href="dva-20241231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_dva_DeferredTaxAssetsReceivables_ceb4e772-f064-41ae-b2b2-357418639542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2bc87cd9-aafa-4e31-8350-bafdd476b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2bc87cd9-aafa-4e31-8350-bafdd476b7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_b74c59d2-3e45-4df3-8903-677d72838fc5" xlink:href="dva-20241231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_b74c59d2-3e45-4df3-8903-677d72838fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1e91978d-e760-4d28-b88f-18a490b7cd43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1e91978d-e760-4d28-b88f-18a490b7cd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_7a4bb0d4-135f-487f-90f6-316e239de791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_7a4bb0d4-135f-487f-90f6-316e239de791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_6df9650e-d740-4e7c-bcee-cab0fa8b1f38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_6df9650e-d740-4e7c-bcee-cab0fa8b1f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_13f895b7-bb68-444f-b63b-93c985278ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_13f895b7-bb68-444f-b63b-93c985278ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_07d1b0eb-8343-469f-923b-8eeb4495fa67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_07d1b0eb-8343-469f-923b-8eeb4495fa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_238bf500-8b02-45a9-a9ea-3a0ed1853be9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_238bf500-8b02-45a9-a9ea-3a0ed1853be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_38827de0-32fe-4850-986d-56d14ebf04dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_38827de0-32fe-4850-986d-56d14ebf04dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8d5f1046-f7df-49f4-a2dc-92e37d34b95a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8d5f1046-f7df-49f4-a2dc-92e37d34b95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_a0f1dfae-81d1-4095-a015-3459f1051fa0" xlink:href="dva-20241231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_a0f1dfae-81d1-4095-a015-3459f1051fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_22173adf-13ac-4805-a173-5f80b9d486b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_22173adf-13ac-4805-a173-5f80b9d486b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_e45e6dee-7880-44f7-9d96-033222043bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_e45e6dee-7880-44f7-9d96-033222043bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d6bc8b7a-a7a0-4fea-9c4a-5f98c889c13b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d6bc8b7a-a7a0-4fea-9c4a-5f98c889c13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4000a0af-21b4-478c-9f08-c0b65205c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_312e32d9-50fc-4da2-98b2-cead597dc593" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4000a0af-21b4-478c-9f08-c0b65205c06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b112ca99-91d1-4dc5-b98b-f997a558b230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_594df647-c904-441f-a6e0-fb1583e62ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b112ca99-91d1-4dc5-b98b-f997a558b230" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_594df647-c904-441f-a6e0-fb1583e62ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_aaa1a3f1-4606-4051-a6c4-d1b599d2035b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_594df647-c904-441f-a6e0-fb1583e62ea2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_aaa1a3f1-4606-4051-a6c4-d1b599d2035b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6faa0428-ca46-4509-a631-e8e8d2322bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_594df647-c904-441f-a6e0-fb1583e62ea2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6faa0428-ca46-4509-a631-e8e8d2322bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_c38dc466-5207-45ee-83df-6158e72e4afc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_594df647-c904-441f-a6e0-fb1583e62ea2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_c38dc466-5207-45ee-83df-6158e72e4afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_8a4ecf27-244a-45dd-af11-bc09f3ee8f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_594df647-c904-441f-a6e0-fb1583e62ea2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_8a4ecf27-244a-45dd-af11-bc09f3ee8f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e0f1523e-e0ee-45e2-9314-2b1ec3006735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_594df647-c904-441f-a6e0-fb1583e62ea2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e0f1523e-e0ee-45e2-9314-2b1ec3006735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1713a8a9-069f-4a13-8048-0c4568796021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_594df647-c904-441f-a6e0-fb1583e62ea2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1713a8a9-069f-4a13-8048-0c4568796021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b0b8071d-82e9-45e3-9fb1-87931b01b0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:href="dva-20241231.xsd#dva_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b0b8071d-82e9-45e3-9fb1-87931b01b0bd" xlink:to="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b87a6a4d-cc28-46d0-813b-8a412fdf1c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b87a6a4d-cc28-46d0-813b-8a412fdf1c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b87a6a4d-cc28-46d0-813b-8a412fdf1c8d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c229316c-dd89-4e1d-bdc1-ca391f937b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:to="loc_us-gaap_DomesticCountryMember_c229316c-dd89-4e1d-bdc1-ca391f937b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9bde2d7a-9e38-40c8-b537-d2edfe579145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9bde2d7a-9e38-40c8-b537-d2edfe579145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_38831b06-0bd5-4b85-b2da-2e311df59302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2cb9aae2-6e78-4964-be4c-016155b408ec" xlink:to="loc_us-gaap_ForeignCountryMember_38831b06-0bd5-4b85-b2da-2e311df59302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_16385460-cddb-4d8a-98e0-3728510250d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_TaxPeriodAxis_16385460-cddb-4d8a-98e0-3728510250d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_efc33810-30fc-4586-81a4-07068e172c10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_16385460-cddb-4d8a-98e0-3728510250d5" xlink:to="loc_us-gaap_TaxPeriodDomain_efc33810-30fc-4586-81a4-07068e172c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TaxYear2029Member_f48a3467-64da-4bfe-9cf4-33e913873f10" xlink:href="dva-20241231.xsd#dva_TaxYear2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_efc33810-30fc-4586-81a4-07068e172c10" xlink:to="loc_dva_TaxYear2029Member_f48a3467-64da-4bfe-9cf4-33e913873f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_08d33853-b366-49e7-aaa9-dba4553772cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_08d33853-b366-49e7-aaa9-dba4553772cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c8dccf78-4299-4af5-89dd-1341ee624396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_08d33853-b366-49e7-aaa9-dba4553772cf" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c8dccf78-4299-4af5-89dd-1341ee624396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_711e733f-3251-484e-9bee-3094cd329838" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_c8dccf78-4299-4af5-89dd-1341ee624396" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_711e733f-3251-484e-9bee-3094cd329838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_96808d07-4a67-4ca1-bfda-dbac0d523c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_96808d07-4a67-4ca1-bfda-dbac0d523c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_c3bdbcc4-5708-4978-b559-8a21a6260626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_96808d07-4a67-4ca1-bfda-dbac0d523c91" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_c3bdbcc4-5708-4978-b559-8a21a6260626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IndefiniteLifeNetOperatingLossesMember_04c7ab3b-04e7-4791-9115-04dfe82a1c8d" xlink:href="dva-20241231.xsd#dva_IndefiniteLifeNetOperatingLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_c3bdbcc4-5708-4978-b559-8a21a6260626" xlink:to="loc_dva_IndefiniteLifeNetOperatingLossesMember_04c7ab3b-04e7-4791-9115-04dfe82a1c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_93db957e-f1e2-4e89-bf52-982d8b748392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_93db957e-f1e2-4e89-bf52-982d8b748392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af982986-84dc-4a68-b7ed-8a2981cfc4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_93db957e-f1e2-4e89-bf52-982d8b748392" xlink:to="loc_us-gaap_EquityComponentDomain_af982986-84dc-4a68-b7ed-8a2981cfc4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8fe6bdc2-0454-4d05-a672-59a5980245fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_af982986-84dc-4a68-b7ed-8a2981cfc4d6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8fe6bdc2-0454-4d05-a672-59a5980245fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:href="dva-20241231.xsd#dva_IncomeTaxesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe1f8994-9ff4-4790-b16c-b4c1e693e102" xlink:to="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3c5e22f1-6a7d-4923-ae6d-d253b9ddd527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3c5e22f1-6a7d-4923-ae6d-d253b9ddd527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_98dcfa60-4027-4b58-a178-9b9afd018280" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_98dcfa60-4027-4b58-a178-9b9afd018280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_631adfcb-f8a7-4835-b3d2-ace9b6575e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_631adfcb-f8a7-4835-b3d2-ace9b6575e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_3f535c00-baaf-4431-b845-319f33860a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_3f535c00-baaf-4431-b845-319f33860a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9494a878-42ab-4077-bdd5-413e525af452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9494a878-42ab-4077-bdd5-413e525af452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_55279972-c9b5-4a03-87ff-585c946b731f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_55279972-c9b5-4a03-87ff-585c946b731f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_80c21e5b-48d0-4284-891d-a01fcee625e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_80c21e5b-48d0-4284-891d-a01fcee625e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7ea35fc4-811f-4a79-9d98-6b952e8b6f14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7ea35fc4-811f-4a79-9d98-6b952e8b6f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1ab73b48-e5cd-4e30-b285-4a452faabf89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1ab73b48-e5cd-4e30-b285-4a452faabf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_095a05c5-9c47-411c-88b0-ce9af0099446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_c0294da0-146b-4596-8840-4819545389fc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_095a05c5-9c47-411c-88b0-ce9af0099446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_717a11fa-8f92-48b8-8d94-61815787d229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_717a11fa-8f92-48b8-8d94-61815787d229" xlink:to="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_597d1cf6-05af-4757-a1ac-79088b38607b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_597d1cf6-05af-4757-a1ac-79088b38607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_597d1cf6-05af-4757-a1ac-79088b38607b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1AndRevolverMember_6038268d-049b-4588-a026-6ea1125867a1" xlink:href="dva-20241231.xsd#dva_TermLoanA1AndRevolverMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_TermLoanA1AndRevolverMember_6038268d-049b-4588-a026-6ea1125867a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member_f042d8a2-c9d4-45b1-b3f0-5a868042c965" xlink:href="dva-20241231.xsd#dva_TermLoanA1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_TermLoanA1Member_f042d8a2-c9d4-45b1-b3f0-5a868042c965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreasedTermLoanA1Member_7b8f5727-a2cf-4aa6-b24d-0f23175e491c" xlink:href="dva-20241231.xsd#dva_IncreasedTermLoanA1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_IncreasedTermLoanA1Member_7b8f5727-a2cf-4aa6-b24d-0f23175e491c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_9d39c6ee-9609-4599-a8bf-a311799ac059" xlink:href="dva-20241231.xsd#dva_TermLoanB1Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_TermLoanB1Member_9d39c6ee-9609-4599-a8bf-a311799ac059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExtendedTermLoanB1Member_f866f0a7-72ef-49e3-8209-928ab6657fc2" xlink:href="dva-20241231.xsd#dva_ExtendedTermLoanB1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_ExtendedTermLoanB1Member_f866f0a7-72ef-49e3-8209-928ab6657fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_2f41e429-097d-4d4c-8410-d387b6e1407c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_us-gaap_SeniorNotesMember_2f41e429-097d-4d4c-8410-d387b6e1407c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_79b35210-0ac9-4a29-ab82-12d9ead7a0d7" xlink:href="dva-20241231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c8395c1-784e-4ffa-9928-7e55900c8126" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_79b35210-0ac9-4a29-ab82-12d9ead7a0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fb137ab5-bee3-44e5-bfd6-69e3dcc8ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_CreditFacilityAxis_fb137ab5-bee3-44e5-bfd6-69e3dcc8ca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_13a227ba-310e-4371-93b3-766a6e93ea89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_fb137ab5-bee3-44e5-bfd6-69e3dcc8ca4a" xlink:to="loc_us-gaap_CreditFacilityDomain_13a227ba-310e-4371-93b3-766a6e93ea89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_415c15ad-93b4-44f8-b722-a786fdfa9303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_13a227ba-310e-4371-93b3-766a6e93ea89" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_415c15ad-93b4-44f8-b722-a786fdfa9303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_68c9b7e5-f2bc-44ab-b91e-edb194507a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_DebtInstrumentAxis_68c9b7e5-f2bc-44ab-b91e-edb194507a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_68c9b7e5-f2bc-44ab-b91e-edb194507a48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_b2716297-eee4-4b25-873e-6ebf228d1f1d" xlink:href="dva-20241231.xsd#dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_b2716297-eee4-4b25-873e-6ebf228d1f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_2662ddf8-a088-42ec-9f2f-6f674915ed06" xlink:href="dva-20241231.xsd#dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_2662ddf8-a088-42ec-9f2f-6f674915ed06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember_730c1162-7249-4354-8a99-bebae1b6abc4" xlink:href="dva-20241231.xsd#dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember_730c1162-7249-4354-8a99-bebae1b6abc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_cf8ec62e-f450-40f6-8325-ca6186f916ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_cf8ec62e-f450-40f6-8325-ca6186f916ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_08730d21-a2fb-4890-90fa-b47645e9210b" xlink:href="dva-20241231.xsd#dva_FinanceLeaseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_FinanceLeaseMember_08730d21-a2fb-4890-90fa-b47645e9210b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ChangeHealthcareTemporaryFundingAssistanceMember_1acd54c1-43dc-4e52-b2f5-1c76fec8532d" xlink:href="dva-20241231.xsd#dva_ChangeHealthcareTemporaryFundingAssistanceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5234cc3d-a4b8-4eda-8cb9-032c1ece4ab6" xlink:to="loc_dva_ChangeHealthcareTemporaryFundingAssistanceMember_1acd54c1-43dc-4e52-b2f5-1c76fec8532d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b626c697-5f4d-4d8d-9761-d48056e0b2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_VariableRateAxis_b626c697-5f4d-4d8d-9761-d48056e0b2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_b626c697-5f4d-4d8d-9761-d48056e0b2d1" xlink:to="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_57b8f581-c571-468d-8620-f5b26932c2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_57b8f581-c571-468d-8620-f5b26932c2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember_b4a944d4-452a-432b-9f31-b0e200d9c515" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_us-gaap_AdjustableRateLoansMember_b4a944d4-452a-432b-9f31-b0e200d9c515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_0d9e92d9-9cf2-4a3d-bf42-b7ecd68d8ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_0d9e92d9-9cf2-4a3d-bf42-b7ecd68d8ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A1MonthSOFRMember_17048c94-0d11-42cf-9f90-0eeb23a53b26" xlink:href="dva-20241231.xsd#dva_A1MonthSOFRMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_dva_A1MonthSOFRMember_17048c94-0d11-42cf-9f90-0eeb23a53b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_f6f09fb9-a118-43b2-bb11-14e2d1e4a538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_50de7866-d220-48d4-99ca-b499db145e8c" xlink:to="loc_us-gaap_PrimeRateMember_f6f09fb9-a118-43b2-bb11-14e2d1e4a538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_33cfc6c0-e017-4315-b536-b8b7b2a7cc51" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_srt_RangeAxis_33cfc6c0-e017-4315-b536-b8b7b2a7cc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_49a78ae7-325c-4b9f-b9b9-5414954d8d82" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_33cfc6c0-e017-4315-b536-b8b7b2a7cc51" xlink:to="loc_srt_RangeMember_49a78ae7-325c-4b9f-b9b9-5414954d8d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37afa4d5-a214-4e4d-9acc-7da04481e76f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49a78ae7-325c-4b9f-b9b9-5414954d8d82" xlink:to="loc_srt_MinimumMember_37afa4d5-a214-4e4d-9acc-7da04481e76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_277beacd-b647-41f7-8975-4cabdcc9b34f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49a78ae7-325c-4b9f-b9b9-5414954d8d82" xlink:to="loc_srt_MaximumMember_277beacd-b647-41f7-8975-4cabdcc9b34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeAxis_381c229a-e355-4325-a5b9-17639de98cba" xlink:href="dva-20241231.xsd#dva_LoansTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_dva_LoansTypeAxis_381c229a-e355-4325-a5b9-17639de98cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeDomain_42f83a2f-365a-483a-b674-973a7c166e55" xlink:href="dva-20241231.xsd#dva_LoansTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LoansTypeAxis_381c229a-e355-4325-a5b9-17639de98cba" xlink:to="loc_dva_LoansTypeDomain_42f83a2f-365a-483a-b674-973a7c166e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BaseRateLoansMember_5ecc5a01-c00d-4e00-b2ca-6874855c3d06" xlink:href="dva-20241231.xsd#dva_BaseRateLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LoansTypeDomain_42f83a2f-365a-483a-b674-973a7c166e55" xlink:to="loc_dva_BaseRateLoansMember_5ecc5a01-c00d-4e00-b2ca-6874855c3d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SOFRLoansMember_a5cca77c-5888-416d-9b67-646ff89ff1ea" xlink:href="dva-20241231.xsd#dva_SOFRLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LoansTypeDomain_42f83a2f-365a-483a-b674-973a7c166e55" xlink:to="loc_dva_SOFRLoansMember_a5cca77c-5888-416d-9b67-646ff89ff1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e1c75750-7efb-4467-b815-bff33d953520" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e1c75750-7efb-4467-b815-bff33d953520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_29f9c553-8530-4a87-a740-59fff9a69d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e1c75750-7efb-4467-b815-bff33d953520" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_29f9c553-8530-4a87-a740-59fff9a69d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b1c68891-c454-44f3-96ce-022c0db30f06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_29f9c553-8530-4a87-a740-59fff9a69d5b" xlink:to="loc_us-gaap_SubsequentEventMember_b1c68891-c454-44f3-96ce-022c0db30f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33c54ca4-9815-4203-b92e-3dd6383d656b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_56009a38-07e6-4bb1-bd50-9f2d89e3e459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_56009a38-07e6-4bb1-bd50-9f2d89e3e459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_87c8fac5-f2c8-475e-bac4-9a1f661879a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_56009a38-07e6-4bb1-bd50-9f2d89e3e459" xlink:to="loc_us-gaap_SecuredDebt_87c8fac5-f2c8-475e-bac4-9a1f661879a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableAbstract_f51fcf66-6897-4729-a199-f382f5f74a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_NotesPayableAbstract_f51fcf66-6897-4729-a199-f382f5f74a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_5817cc20-fbc9-4460-9011-051c7b5b68df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_f51fcf66-6897-4729-a199-f382f5f74a34" xlink:to="loc_us-gaap_SeniorNotes_5817cc20-fbc9-4460-9011-051c7b5b68df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_222de770-728b-4de4-92e7-a83994317377" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_222de770-728b-4de4-92e7-a83994317377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_a6b2dd11-9c9e-41bf-9e4c-1bcdf55a3263" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_a6b2dd11-9c9e-41bf-9e4c-1bcdf55a3263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_32fb4d3d-9471-45fa-b9ca-9036a71a9465" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_32fb4d3d-9471-45fa-b9ca-9036a71a9465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_11da17cd-bc89-4a00-ae44-75802da2163b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_DebtInstrumentFairValue_11da17cd-bc89-4a00-ae44-75802da2163b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayable_fba8d0bb-2d89-4de1-8c15-a0ad79c67140" xlink:href="dva-20241231.xsd#dva_AcquisitionObligationsAndOtherNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayable_fba8d0bb-2d89-4de1-8c15-a0ad79c67140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_0e6b55f1-25d0-4150-9fd8-471392be0228" xlink:href="dva-20241231.xsd#dva_AcquisitionObligationsAndOtherNotesPayableFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_0e6b55f1-25d0-4150-9fd8-471392be0228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_b906f214-df0c-42aa-a05a-acdece890e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_FinanceLeaseLiability_b906f214-df0c-42aa-a05a-acdece890e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_1a4b38cc-785a-40ca-b6cb-38288c0de31b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_1a4b38cc-785a-40ca-b6cb-38288c0de31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_8cfbc2ac-290a-48aa-914d-51845925d4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_8cfbc2ac-290a-48aa-914d-51845925d4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_38e46ff6-b3a0-4952-ab6c-8c16ab98afe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_bd18ec3e-59fe-48c4-8935-0e0f5b630537" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_38e46ff6-b3a0-4952-ab6c-8c16ab98afe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_782570d5-cae3-44ff-99a6-a5d3304bd41c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_782570d5-cae3-44ff-99a6-a5d3304bd41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountPremiumAndDeferredFinanceCosts_c29c9853-af29-4793-821f-0c09c140719e" xlink:href="dva-20241231.xsd#dva_DiscountPremiumAndDeferredFinanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_dva_DiscountPremiumAndDeferredFinanceCosts_c29c9853-af29-4793-821f-0c09c140719e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c6d69431-4fe9-4865-813e-662c99100a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c6d69431-4fe9-4865-813e-662c99100a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e4d4bd94-20e9-4a9a-932e-d343cc3d7688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e4d4bd94-20e9-4a9a-932e-d343cc3d7688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b44c8cd5-ddf4-468c-a09e-32247ab272d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_8477d22f-0761-419e-8ff3-955cf4f1ba34" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b44c8cd5-ddf4-468c-a09e-32247ab272d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6f872606-9f09-4fbc-bc3b-d4184b0f98cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6f872606-9f09-4fbc-bc3b-d4184b0f98cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_ff84ce9d-bd8c-471c-89b8-3fea770e27c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:to="loc_us-gaap_DeferredOfferingCosts_ff84ce9d-bd8c-471c-89b8-3fea770e27c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_9a3be0e8-403d-4572-bc7c-46ff9486bbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_0712587a-4266-4f29-90d1-8f1de754ffa7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_9a3be0e8-403d-4572-bc7c-46ff9486bbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CHCTemporaryFundingAssistance_85756fe4-2264-45d2-8a60-b65df7fe37eb" xlink:href="dva-20241231.xsd#dva_CHCTemporaryFundingAssistance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_CHCTemporaryFundingAssistance_85756fe4-2264-45d2-8a60-b65df7fe37eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_9be31d3b-21e4-4d76-b836-f19c26263cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_9be31d3b-21e4-4d76-b836-f19c26263cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CHCTemporaryFundingAssistanceFairValue_beb65dc8-ee7e-4f7d-8e16-4ad7d69f2709" xlink:href="dva-20241231.xsd#dva_CHCTemporaryFundingAssistanceFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_CHCTemporaryFundingAssistanceFairValue_beb65dc8-ee7e-4f7d-8e16-4ad7d69f2709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6dba3143-c7a6-41a2-8422-b951cc8dbc96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6dba3143-c7a6-41a2-8422-b951cc8dbc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_2df82ee0-ae1a-4013-a86a-dd4705e33978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_2df82ee0-ae1a-4013-a86a-dd4705e33978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_f7dce8f1-a0b6-49bb-bc2a-9d03446e27c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_f7dce8f1-a0b6-49bb-bc2a-9d03446e27c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_fd0652b1-19b6-4ea6-860d-b0e840a66e5b" xlink:href="dva-20241231.xsd#dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_fd0652b1-19b6-4ea6-860d-b0e840a66e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConstructiveFinancingCashOutflow_36ab1d99-df41-4aa7-9f7e-b18571165fc9" xlink:href="dva-20241231.xsd#dva_ConstructiveFinancingCashOutflow"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_ConstructiveFinancingCashOutflow_36ab1d99-df41-4aa7-9f7e-b18571165fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConstructiveFinancingCashInflow_801e69e7-c3ef-4736-a0ec-ec6f86b4c89a" xlink:href="dva-20241231.xsd#dva_ConstructiveFinancingCashInflow"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_ConstructiveFinancingCashInflow_801e69e7-c3ef-4736-a0ec-ec6f86b4c89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_7888cd95-fe48-42d1-9616-d725b9240013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_7888cd95-fe48-42d1-9616-d725b9240013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_b2ec483a-b1f6-4a9f-aeb8-77cedb94336f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_RepaymentsOfDebt_b2ec483a-b1f6-4a9f-aeb8-77cedb94336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescription_3644b829-4d43-4b26-8893-48d544ffc2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentDescription_3644b829-4d43-4b26-8893-48d544ffc2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_e1e5cabd-13ad-4a07-a007-256b3ba9dcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_e1e5cabd-13ad-4a07-a007-256b3ba9dcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_241321d6-5250-46dd-88f4-cd432c76db7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_241321d6-5250-46dd-88f4-cd432c76db7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSignificantNoncashFinancingActivity_b7713bc3-6a77-4360-90e4-2246d4c49a04" xlink:href="dva-20241231.xsd#dva_OtherSignificantNoncashFinancingActivity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_OtherSignificantNoncashFinancingActivity_b7713bc3-6a77-4360-90e4-2246d4c49a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_145e7bd2-288f-4316-b26c-f2360b0ea564" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_145e7bd2-288f-4316-b26c-f2360b0ea564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_d843fe08-89b6-48d3-ba4a-5371ef221da8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_d843fe08-89b6-48d3-ba4a-5371ef221da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtExtendedMaturity_ef8a827c-3496-4fdd-8ba7-493a69e4fce1" xlink:href="dva-20241231.xsd#dva_SecuredDebtExtendedMaturity"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_SecuredDebtExtendedMaturity_ef8a827c-3496-4fdd-8ba7-493a69e4fce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_14c1a5f1-f6a7-4e0f-ac21-d5e0b814b423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_14c1a5f1-f6a7-4e0f-ac21-d5e0b814b423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding_2a5e54f8-bfb4-4450-950d-84f6e0ad22a6" xlink:href="dva-20241231.xsd#dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding_2a5e54f8-bfb4-4450-950d-84f6e0ad22a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_739770f8-392c-4fab-8703-5d4f0928678e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_739770f8-392c-4fab-8703-5d4f0928678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_93dd69b2-da59-460e-93df-4c4223ffa0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_93dd69b2-da59-460e-93df-4c4223ffa0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentThroughJune302027_2d01df39-1abe-4e99-8204-f09360856422" xlink:href="dva-20241231.xsd#dva_DebtInstrumentQuarterlyPaymentThroughJune302027"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentThroughJune302027_2d01df39-1abe-4e99-8204-f09360856422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028_b22944bc-b78c-4acb-955b-eab0e5bb8377" xlink:href="dva-20241231.xsd#dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028_b22944bc-b78c-4acb-955b-eab0e5bb8377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_fd27b4ea-e84c-4288-bd8e-c274e721d46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionDescription"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_fd27b4ea-e84c-4288-bd8e-c274e721d46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1e4a576f-643f-44c1-accf-e552855e601c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1e4a576f-643f-44c1-accf-e552855e601c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e67cca5b-5e5b-4304-b06e-3eaa2038d3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e67cca5b-5e5b-4304-b06e-3eaa2038d3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_58a707d7-9756-4860-b516-1d06e75e6235" xlink:href="dva-20241231.xsd#dva_DebtPrepaymentExtinguishmentAndModificationCosts"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_58a707d7-9756-4860-b516-1d06e75e6235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027_0e436bac-fae6-4e85-bcb2-966776f7e22d" xlink:href="dva-20241231.xsd#dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027_0e436bac-fae6-4e85-bcb2-966776f7e22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentRedemptionPriceIfChangeOfControl_61a54915-4624-4787-bba0-e94833d16e1d" xlink:href="dva-20241231.xsd#dva_DebtInstrumentRedemptionPriceIfChangeOfControl"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentRedemptionPriceIfChangeOfControl_61a54915-4624-4787-bba0-e94833d16e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_3f5c4223-f7bf-4122-a02a-0a21892726cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_3f5c4223-f7bf-4122-a02a-0a21892726cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentVariableRate_bf1d8f28-9c93-4fa4-9794-f12d96a18e95" xlink:href="dva-20241231.xsd#dva_DebtInstrumentVariableRate"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4668b9d9-eb88-4c49-ba68-9717227535da" xlink:to="loc_dva_DebtInstrumentVariableRate_bf1d8f28-9c93-4fa4-9794-f12d96a18e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtScheduledMaturitiesofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d706322c-65a3-4a43-a1d4-130cccf50a27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0a4093fa-bbef-4898-a52e-286c8dae8ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d706322c-65a3-4a43-a1d4-130cccf50a27" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0a4093fa-bbef-4898-a52e-286c8dae8ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b8d25967-960a-41a5-be8a-0fcaf253a71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d706322c-65a3-4a43-a1d4-130cccf50a27" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b8d25967-960a-41a5-be8a-0fcaf253a71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f05b6ad4-7d79-4414-b7d7-3aa11673fe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d706322c-65a3-4a43-a1d4-130cccf50a27" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f05b6ad4-7d79-4414-b7d7-3aa11673fe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1d9e48fd-610f-404c-b3df-d45176fb7159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d706322c-65a3-4a43-a1d4-130cccf50a27" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1d9e48fd-610f-404c-b3df-d45176fb7159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_299463c5-1d0b-45b6-932f-5fba89c32f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d706322c-65a3-4a43-a1d4-130cccf50a27" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_299463c5-1d0b-45b6-932f-5fba89c32f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_115ba500-4a25-4707-8f59-3630824d7231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d706322c-65a3-4a43-a1d4-130cccf50a27" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_115ba500-4a25-4707-8f59-3630824d7231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bfded6b2-7133-4c98-97aa-2487f7cab388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bfded6b2-7133-4c98-97aa-2487f7cab388" xlink:to="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b389ee4d-7db9-4c11-a7ca-cd36fcbe122c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b389ee4d-7db9-4c11-a7ca-cd36fcbe122c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b389ee4d-7db9-4c11-a7ca-cd36fcbe122c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_213a0abf-5b07-4e1d-9b1b-628126e28310" xlink:href="dva-20241231.xsd#dva_A2019InterestRateCapAgreementsEffectiveJune302020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_213a0abf-5b07-4e1d-9b1b-628126e28310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_d4e2dc1f-7eb1-4f6d-b28c-9182c1cc6b02" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_d4e2dc1f-7eb1-4f6d-b28c-9182c1cc6b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_44b19f50-4511-42c3-82c4-b955b64bd09b" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_44b19f50-4511-42c3-82c4-b955b64bd09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_67a4d822-5ce4-4d3e-b08d-6ddfaad283f5" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_67a4d822-5ce4-4d3e-b08d-6ddfaad283f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_e777b5a7-fa18-4c67-b85a-6eb3d8516243" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_e777b5a7-fa18-4c67-b85a-6eb3d8516243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_c8bdf5c6-b89f-4b2c-8651-be0582cf8f18" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_c8bdf5c6-b89f-4b2c-8651-be0582cf8f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_950b75b8-edc3-4d68-954b-7cba04d3ee1f" xlink:href="dva-20241231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_950b75b8-edc3-4d68-954b-7cba04d3ee1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member_261b20ff-5dfb-4209-8b41-ad0e205b22d1" xlink:href="dva-20241231.xsd#dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member_261b20ff-5dfb-4209-8b41-ad0e205b22d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member_6719b64b-d088-41bb-8a2f-766ba7723b99" xlink:href="dva-20241231.xsd#dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member_6719b64b-d088-41bb-8a2f-766ba7723b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312024Member_3e7554f7-fd42-4ae8-958f-ad1b001f2e89" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312024Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_TotalNotionalAmountEffectiveThroughDecember312024Member_3e7554f7-fd42-4ae8-958f-ad1b001f2e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312025Member_b62c3a82-58e2-4a35-acb4-799b5c7d6340" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_TotalNotionalAmountEffectiveThroughDecember312025Member_b62c3a82-58e2-4a35-acb4-799b5c7d6340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312026Member_6469db10-8c0a-4255-b972-38c1c61ba6bc" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312026Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_TotalNotionalAmountEffectiveThroughDecember312026Member_6469db10-8c0a-4255-b972-38c1c61ba6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TotalNotionalAmountEffectiveThroughDecember312027Member_e3bca083-eeaa-4f4a-a699-2f605c1a6568" xlink:href="dva-20241231.xsd#dva_TotalNotionalAmountEffectiveThroughDecember312027Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_280c663c-5826-412a-ac97-db188d9a361c" xlink:to="loc_dva_TotalNotionalAmountEffectiveThroughDecember312027Member_e3bca083-eeaa-4f4a-a699-2f605c1a6568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b84f29fd-635b-4e94-b569-f0c440752f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_DebtInstrumentAxis_b84f29fd-635b-4e94-b569-f0c440752f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e920e97f-aa6e-4674-b023-43752aaec838" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b84f29fd-635b-4e94-b569-f0c440752f3e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e920e97f-aa6e-4674-b023-43752aaec838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember_c3530995-5552-4a37-9a91-748291d5683b" xlink:href="dva-20241231.xsd#dva_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e920e97f-aa6e-4674-b023-43752aaec838" xlink:to="loc_dva_TermLoanFacilityMember_c3530995-5552-4a37-9a91-748291d5683b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_401f9c2d-23ec-4a49-ac7a-9fa0f4a98277" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_srt_RangeAxis_401f9c2d-23ec-4a49-ac7a-9fa0f4a98277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0353f2e-afc3-4762-91ee-543681d0c4df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_401f9c2d-23ec-4a49-ac7a-9fa0f4a98277" xlink:to="loc_srt_RangeMember_c0353f2e-afc3-4762-91ee-543681d0c4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c0cab4d-f868-4b95-8831-d0889d609b1c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c0353f2e-afc3-4762-91ee-543681d0c4df" xlink:to="loc_srt_MaximumMember_5c0cab4d-f868-4b95-8831-d0889d609b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_76174bbf-e7c6-400c-b410-c6cb121774e4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c0353f2e-afc3-4762-91ee-543681d0c4df" xlink:to="loc_srt_WeightedAverageMember_76174bbf-e7c6-400c-b410-c6cb121774e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d583f251-b1b6-46a6-9d45-c3c314908b45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d583f251-b1b6-46a6-9d45-c3c314908b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_15077b86-a502-4e4e-ac12-d87ad732087a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d583f251-b1b6-46a6-9d45-c3c314908b45" xlink:to="loc_us-gaap_HedgingRelationshipDomain_15077b86-a502-4e4e-ac12-d87ad732087a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_4709fa65-d295-41eb-a9a1-c4d562b1c212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_15077b86-a502-4e4e-ac12-d87ad732087a" xlink:to="loc_us-gaap_CashFlowHedgingMember_4709fa65-d295-41eb-a9a1-c4d562b1c212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bf78dfb5-1428-4dd5-86a6-5078a52caf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bf78dfb5-1428-4dd5-86a6-5078a52caf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cae8c2e0-595f-4632-87be-c22217084c89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bf78dfb5-1428-4dd5-86a6-5078a52caf9a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cae8c2e0-595f-4632-87be-c22217084c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_d918231b-a673-4ede-93b4-85351cf4bf98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cae8c2e0-595f-4632-87be-c22217084c89" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_d918231b-a673-4ede-93b4-85351cf4bf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d391d6a1-cae3-4475-ae0f-37084d61adf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d391d6a1-cae3-4475-ae0f-37084d61adf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_69191d05-1302-404f-830b-2cd22aab1569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d391d6a1-cae3-4475-ae0f-37084d61adf7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_69191d05-1302-404f-830b-2cd22aab1569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_beb60c3a-07ca-4eec-afcc-1afd3a08397a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_69191d05-1302-404f-830b-2cd22aab1569" xlink:to="loc_us-gaap_SubsequentEventMember_beb60c3a-07ca-4eec-afcc-1afd3a08397a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e91f009d-89bf-44d0-a8d0-ecd4be8e2092" xlink:to="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_0238f121-7f3a-48af-9bfb-88536c72d31e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_0238f121-7f3a-48af-9bfb-88536c72d31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageFixedInterestRate_0bc2b956-8c08-4aa4-993a-6ecfff3266f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAverageFixedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeAverageFixedInterestRate_0bc2b956-8c08-4aa4-993a-6ecfff3266f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInceptionDates_bdf389fd-9f78-4535-89b2-9b3d9f48fe90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInceptionDates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeInceptionDates_bdf389fd-9f78-4535-89b2-9b3d9f48fe90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMaturityDates_633a61df-6b35-447f-8743-073d0b81e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeMaturityDates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeMaturityDates_633a61df-6b35-447f-8743-073d0b81e9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312024_98c174dd-03e5-4f51-9237-8dbea31ecd1c" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByDecember312024"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312024_98c174dd-03e5-4f51-9237-8dbea31ecd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312025_5aef4d95-3a2d-482d-a76c-22c5f2fc537e" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByDecember312025"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312025_5aef4d95-3a2d-482d-a76c-22c5f2fc537e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312026_da3c6606-80b1-4a4a-89b6-fd5f6e489f03" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByDecember312026"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312026_da3c6606-80b1-4a4a-89b6-fd5f6e489f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByMaturityDate_ce0eb906-de21-4a40-946f-4147737606c4" xlink:href="dva-20241231.xsd#dva_NotionalAmountAmortizableByMaturityDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_dva_NotionalAmountAmortizableByMaturityDate_ce0eb906-de21-4a40-946f-4147737606c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_e3d6bed0-0a1e-49bd-9c87-a32b60e05486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_eed5bf87-4316-4a68-88a1-b1f482ae8790" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_e3d6bed0-0a1e-49bd-9c87-a32b60e05486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9362ae10-ebf3-47a0-a354-377544dc4424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d3aa8536-2678-42ba-afea-0b5164eb8d15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9362ae10-ebf3-47a0-a354-377544dc4424" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d3aa8536-2678-42ba-afea-0b5164eb8d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_26ec4009-9555-4fd1-9748-9f4558141e24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d3aa8536-2678-42ba-afea-0b5164eb8d15" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_26ec4009-9555-4fd1-9748-9f4558141e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_71183c37-0295-4411-99a2-68dd152f15ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_26ec4009-9555-4fd1-9748-9f4558141e24" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_71183c37-0295-4411-99a2-68dd152f15ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_6d36da74-871c-4876-8977-9493c93588e9" xlink:href="dva-20241231.xsd#dva_IncomeTaxRelatedToCashFlowHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71183c37-0295-4411-99a2-68dd152f15ee" xlink:to="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_6d36da74-871c-4876-8977-9493c93588e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_c3f3f86d-1b3d-4c93-bcec-1e81e3978285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71183c37-0295-4411-99a2-68dd152f15ee" xlink:to="loc_us-gaap_InterestRateCapMember_c3f3f86d-1b3d-4c93-bcec-1e81e3978285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8641868d-18f4-4ce2-9cbf-1bac66b33455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d3aa8536-2678-42ba-afea-0b5164eb8d15" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8641868d-18f4-4ce2-9cbf-1bac66b33455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_633047b6-33a7-42ca-82fd-a50447338272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8641868d-18f4-4ce2-9cbf-1bac66b33455" xlink:to="loc_us-gaap_HedgingRelationshipDomain_633047b6-33a7-42ca-82fd-a50447338272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_7fe2e060-dab9-4ae3-b1b8-73ad73efdc34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_633047b6-33a7-42ca-82fd-a50447338272" xlink:to="loc_us-gaap_CashFlowHedgingMember_7fe2e060-dab9-4ae3-b1b8-73ad73efdc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d3aa8536-2678-42ba-afea-0b5164eb8d15" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_062600b8-aaea-4e10-8111-30ccc47c674b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_062600b8-aaea-4e10-8111-30ccc47c674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_743f3bac-5583-44b3-b972-b296fc5ed1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_743f3bac-5583-44b3-b972-b296fc5ed1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e5815168-4703-44fc-b3d8-f5fb58da76f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a6e71aff-a0b2-4f63-997b-efa3b4f1dab7" xlink:to="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e5815168-4703-44fc-b3d8-f5fb58da76f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_adb552ea-5d12-4991-87c0-50740389722b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9362ae10-ebf3-47a0-a354-377544dc4424" xlink:to="loc_us-gaap_DerivativeTable_adb552ea-5d12-4991-87c0-50740389722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_41705b1f-2b84-4614-8de5-2a99e6727fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_adb552ea-5d12-4991-87c0-50740389722b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_41705b1f-2b84-4614-8de5-2a99e6727fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7e7d47b6-00bd-47cc-9c3f-16ffb6d80b39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_41705b1f-2b84-4614-8de5-2a99e6727fb1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7e7d47b6-00bd-47cc-9c3f-16ffb6d80b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_404efe40-9846-4527-9389-3c7bdaa91470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7e7d47b6-00bd-47cc-9c3f-16ffb6d80b39" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_404efe40-9846-4527-9389-3c7bdaa91470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d1eab3c1-7cb5-4ae7-95af-05786997c151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_adb552ea-5d12-4991-87c0-50740389722b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d1eab3c1-7cb5-4ae7-95af-05786997c151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d7a8893c-f712-464a-8d95-b898d5c58a96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_c4a9d815-5095-4d7c-96d2-c07d2418bb76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateCapMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_345789c9-ce1f-4457-b6a7-e16c69510f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_adb552ea-5d12-4991-87c0-50740389722b" xlink:to="loc_us-gaap_DerivativeLineItems_345789c9-ce1f-4457-b6a7-e16c69510f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c8bd1b5e-c7e0-4f93-bcb3-34701403ddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_345789c9-ce1f-4457-b6a7-e16c69510f40" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c8bd1b5e-c7e0-4f93-bcb3-34701403ddc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="simple" xlink:href="dva-20241231.xsd#LongTermDebtAdditionalinformationDetail"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3640b137-fd17-4a76-baf7-bd87d4015f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3640b137-fd17-4a76-baf7-bd87d4015f9d" xlink:to="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_04f6b42c-2f9b-485c-82d3-4c5d3dbfd3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_04f6b42c-2f9b-485c-82d3-4c5d3dbfd3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_04f6b42c-2f9b-485c-82d3-4c5d3dbfd3ec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member_243e9509-f302-4b60-8b54-1936d6764ae6" xlink:href="dva-20241231.xsd#dva_TermLoanA1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_TermLoanA1Member_243e9509-f302-4b60-8b54-1936d6764ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_8c77f013-cb25-4f69-8257-5c967cd3aaa8" xlink:href="dva-20241231.xsd#dva_TermLoanB1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_TermLoanB1Member_8c77f013-cb25-4f69-8257-5c967cd3aaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_52c267ae-a4f5-4d14-b552-914fa8faa42f" xlink:href="dva-20241231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_52c267ae-a4f5-4d14-b552-914fa8faa42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NewCreditAgreementAmendedMember_ac876af1-1756-4c24-a08b-e64ef6bfdd6b" xlink:href="dva-20241231.xsd#dva_NewCreditAgreementAmendedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_NewCreditAgreementAmendedMember_ac876af1-1756-4c24-a08b-e64ef6bfdd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1AndRevolverMember_367a22a3-a67d-4fab-8d7e-3d9f2166dfde" xlink:href="dva-20241231.xsd#dva_TermLoanA1AndRevolverMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_780584cc-803f-496a-a8f0-c53a2447e7f2" xlink:to="loc_dva_TermLoanA1AndRevolverMember_367a22a3-a67d-4fab-8d7e-3d9f2166dfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d5236d39-fce2-4832-b9a5-1c92966e0a89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_CreditFacilityAxis_d5236d39-fce2-4832-b9a5-1c92966e0a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2599b073-c87d-4d11-9dc2-b23dc06ec939" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_d5236d39-fce2-4832-b9a5-1c92966e0a89" xlink:to="loc_us-gaap_CreditFacilityDomain_2599b073-c87d-4d11-9dc2-b23dc06ec939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_1e63e57e-d81b-44c2-a9d9-344e27453e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2599b073-c87d-4d11-9dc2-b23dc06ec939" xlink:to="loc_us-gaap_LetterOfCreditMember_1e63e57e-d81b-44c2-a9d9-344e27453e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_540630af-7bd0-4541-9035-1a53339104bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_srt_RangeAxis_540630af-7bd0-4541-9035-1a53339104bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_170b5c51-157f-4e96-a061-d606e2b7b933" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_540630af-7bd0-4541-9035-1a53339104bb" xlink:to="loc_srt_RangeMember_170b5c51-157f-4e96-a061-d606e2b7b933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8672135c-d05a-48ed-b189-480ec45e7726" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_170b5c51-157f-4e96-a061-d606e2b7b933" xlink:to="loc_srt_MinimumMember_8672135c-d05a-48ed-b189-480ec45e7726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb800573-c7aa-476b-b862-b05bd70dd7b0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_170b5c51-157f-4e96-a061-d606e2b7b933" xlink:to="loc_srt_MaximumMember_bb800573-c7aa-476b-b862-b05bd70dd7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a1f35101-4c60-475c-a172-9b9e9317a491" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_DebtInstrumentAxis_a1f35101-4c60-475c-a172-9b9e9317a491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06af9c4d-f900-4a1b-9c00-64c0b842687e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a1f35101-4c60-475c-a172-9b9e9317a491" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06af9c4d-f900-4a1b-9c00-64c0b842687e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_096ecc34-6fad-4697-9d07-65c26cf909d8" xlink:href="dva-20241231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06af9c4d-f900-4a1b-9c00-64c0b842687e" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_096ecc34-6fad-4697-9d07-65c26cf909d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember_d07447b5-19c1-4c9a-89cc-84c792536887" xlink:href="dva-20241231.xsd#dva_TermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06af9c4d-f900-4a1b-9c00-64c0b842687e" xlink:to="loc_dva_TermLoanFacilityMember_d07447b5-19c1-4c9a-89cc-84c792536887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_985babd1-c9c2-4d0f-842b-d35e538672b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_VariableRateAxis_985babd1-c9c2-4d0f-842b-d35e538672b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_985babd1-c9c2-4d0f-842b-d35e538672b7" xlink:to="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1655d63b-44a6-4ac5-808c-4faebac1db59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1655d63b-44a6-4ac5-808c-4faebac1db59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember_a52e43cc-4fbe-49ab-a432-19e19397f049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:to="loc_us-gaap_AdjustableRateLoansMember_a52e43cc-4fbe-49ab-a432-19e19397f049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_5e405608-f614-4003-9e30-f34cb0464dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ca368ad5-8194-4a78-a37a-726870fd1244" xlink:to="loc_us-gaap_PrimeRateMember_5e405608-f614-4003-9e30-f34cb0464dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7481af1b-210b-4b4b-b34b-1aea0149c225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7481af1b-210b-4b4b-b34b-1aea0149c225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0523a2a-2d64-4ae3-80a2-12987fb659a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7481af1b-210b-4b4b-b34b-1aea0149c225" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0523a2a-2d64-4ae3-80a2-12987fb659a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8f37485a-4521-4ccb-9689-754069df2e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c0523a2a-2d64-4ae3-80a2-12987fb659a7" xlink:to="loc_us-gaap_SubsequentEventMember_8f37485a-4521-4ccb-9689-754069df2e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeAxis_4169efb6-ab89-461f-8cad-89ba1f2b3bbd" xlink:href="dva-20241231.xsd#dva_LoansTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_dva_LoansTypeAxis_4169efb6-ab89-461f-8cad-89ba1f2b3bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LoansTypeDomain_ba931977-9bc3-409c-b091-9db78a8ed844" xlink:href="dva-20241231.xsd#dva_LoansTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LoansTypeAxis_4169efb6-ab89-461f-8cad-89ba1f2b3bbd" xlink:to="loc_dva_LoansTypeDomain_ba931977-9bc3-409c-b091-9db78a8ed844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BaseRateLoansMember_529af6a8-fef9-4daa-af31-b25057f4a4be" xlink:href="dva-20241231.xsd#dva_BaseRateLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LoansTypeDomain_ba931977-9bc3-409c-b091-9db78a8ed844" xlink:to="loc_dva_BaseRateLoansMember_529af6a8-fef9-4daa-af31-b25057f4a4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_559e4030-0da0-42bd-a3ea-2acc2856f30b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_88aa8105-df1a-4c8c-8a48-21dd56667b40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_88aa8105-df1a-4c8c-8a48-21dd56667b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_7d47829e-2677-4ea7-b736-21994e79c584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_7d47829e-2677-4ea7-b736-21994e79c584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_07c2f2bb-353f-4b0b-810a-6d762a11b3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_InterestExpenseDebt_07c2f2bb-353f-4b0b-810a-6d762a11b3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_cefd370e-ecfc-4399-a0ae-d4be9091b478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_cefd370e-ecfc-4399-a0ae-d4be9091b478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_eeeeff0a-0285-421d-b8c3-4ee26247499a" xlink:href="dva-20241231.xsd#dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_eeeeff0a-0285-421d-b8c3-4ee26247499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenant_5024b1fd-d04d-49a7-a85c-f266325743f4" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LeverageRatioCovenant_5024b1fd-d04d-49a7-a85c-f266325743f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantThroughJun302026_8f3033a2-6cb4-47cf-a275-d6e04e1763af" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenantThroughJun302026"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LeverageRatioCovenantThroughJun302026_8f3033a2-6cb4-47cf-a275-d6e04e1763af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantAfterJun302026_b45fedc2-c1c9-4eaf-baa4-df6d2cfc0a39" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenantAfterJun302026"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LeverageRatioCovenantAfterJun302026_b45fedc2-c1c9-4eaf-baa4-df6d2cfc0a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition_77ff314b-5d4c-4c0b-8920-41bf091b55e4" xlink:href="dva-20241231.xsd#dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition_77ff314b-5d4c-4c0b-8920-41bf091b55e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9056b490-ab53-490a-802e-020308d60122" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14eabd9b-310f-4d93-9956-e3cea0e6e7a6" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9056b490-ab53-490a-802e-020308d60122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LeasesLeaseExpenseComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_2feccae8-94c3-49fa-aa6e-67a4d0198bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_7ba37eef-ba30-4c8a-b0e5-aa59475dff1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_2feccae8-94c3-49fa-aa6e-67a4d0198bcf" xlink:to="loc_us-gaap_LeaseCostAbstract_7ba37eef-ba30-4c8a-b0e5-aa59475dff1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_faa1305c-c8f4-449f-a589-fb7441eaa892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_7ba37eef-ba30-4c8a-b0e5-aa59475dff1b" xlink:to="loc_us-gaap_OperatingLeaseExpense_faa1305c-c8f4-449f-a589-fb7441eaa892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_415e38c7-37e2-4bdb-bdd4-43da9fb20895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_7ba37eef-ba30-4c8a-b0e5-aa59475dff1b" xlink:to="loc_us-gaap_VariableLeaseCost_415e38c7-37e2-4bdb-bdd4-43da9fb20895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c4e6aab1-eb65-4eef-a140-b432a4659e29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_7ba37eef-ba30-4c8a-b0e5-aa59475dff1b" xlink:to="loc_us-gaap_OperatingLeaseCost_c4e6aab1-eb65-4eef-a140-b432a4659e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_eb745032-4970-4403-8184-54955df03270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_2feccae8-94c3-49fa-aa6e-67a4d0198bcf" xlink:to="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_eb745032-4970-4403-8184-54955df03270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_4c6e45ea-902f-4b61-9d82-c262e47f87ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_eb745032-4970-4403-8184-54955df03270" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_4c6e45ea-902f-4b61-9d82-c262e47f87ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_2de795be-7990-467b-8e30-0bdfd8229a79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_eb745032-4970-4403-8184-54955df03270" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_2de795be-7990-467b-8e30-0bdfd8229a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f4748adf-bd93-4850-af2b-a9466b2e7e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_eb745032-4970-4403-8184-54955df03270" xlink:to="loc_us-gaap_LeaseCost_f4748adf-bd93-4850-af2b-a9466b2e7e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LeasesLeasesOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_LesseeLeaseDescriptionLineItemsAbstract_4b1f2b0c-6111-4a66-8821-045ed6fb3bc6" xlink:href="dva-20241231.xsd#dva_LesseeLeaseDescriptionLineItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d166df54-512c-47ba-b12b-c7bc9f749835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LesseeLeaseDescriptionLineItemsAbstract_4b1f2b0c-6111-4a66-8821-045ed6fb3bc6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d166df54-512c-47ba-b12b-c7bc9f749835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fac1256b-6a2e-4d16-a11f-cf2d68b06a61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d166df54-512c-47ba-b12b-c7bc9f749835" xlink:to="loc_us-gaap_DebtInstrumentAxis_fac1256b-6a2e-4d16-a11f-cf2d68b06a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bb7fc9cb-4410-4b54-9947-19c5442bc51c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fac1256b-6a2e-4d16-a11f-cf2d68b06a61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bb7fc9cb-4410-4b54-9947-19c5442bc51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_173f06f5-83d0-41c2-9ad5-a47c3f0bbdeb" xlink:href="dva-20241231.xsd#dva_FinanceLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bb7fc9cb-4410-4b54-9947-19c5442bc51c" xlink:to="loc_dva_FinanceLeaseMember_173f06f5-83d0-41c2-9ad5-a47c3f0bbdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a8d4888b-8e67-4aa0-b779-866cfcf0e203" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d166df54-512c-47ba-b12b-c7bc9f749835" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a8d4888b-8e67-4aa0-b779-866cfcf0e203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a8d4888b-8e67-4aa0-b779-866cfcf0e203" xlink:to="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1bed511f-8d7c-454b-a740-cef601b09ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1bed511f-8d7c-454b-a740-cef601b09ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b45128ef-d78e-4fc7-b38f-075d9817c842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b45128ef-d78e-4fc7-b38f-075d9817c842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d2ac926c-5f6b-4531-b335-ca053df58252" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d2ac926c-5f6b-4531-b335-ca053df58252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3223d82c-3316-4089-8c89-cd03c6b9276c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_05f3e5a3-654e-49d4-b96d-3ed805e23e8e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3223d82c-3316-4089-8c89-cd03c6b9276c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:href="dva-20241231.xsd#dva_LeasesOtherInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a8d4888b-8e67-4aa0-b779-866cfcf0e203" xlink:to="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_88d73c38-5d8c-4926-aeca-821c4665fd97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_88d73c38-5d8c-4926-aeca-821c4665fd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_35696480-2087-45a8-a9ea-d95fcaae5faf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:to="loc_us-gaap_OperatingLeasePayments_35696480-2087-45a8-a9ea-d95fcaae5faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_fbf76914-6364-45aa-ace9-1a285d91a21e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_fbf76914-6364-45aa-ace9-1a285d91a21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_dba230bc-e8eb-4953-8cbe-7d53fd467791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d73c0aa4-c519-432b-bc6d-a02f9cefa885" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_dba230bc-e8eb-4953-8cbe-7d53fd467791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_edd4b316-2859-44ba-ac81-78975fa2a6e2" xlink:href="dva-20241231.xsd#dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesOtherInformationAbstract_0413ac41-9c58-4abf-851c-73b38e5cb01e" xlink:to="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_edd4b316-2859-44ba-ac81-78975fa2a6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e049f68d-c3f1-4bd5-bdc4-f9c8ee7a3e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e049f68d-c3f1-4bd5-bdc4-f9c8ee7a3e17" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9e885712-879e-4336-832e-e8e85af68a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9e885712-879e-4336-832e-e8e85af68a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0243a9b7-5b67-4bf0-8257-eb880762f85f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0243a9b7-5b67-4bf0-8257-eb880762f85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7e05c9e0-f7c6-44f8-8cf9-f044fd4be776" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7e05c9e0-f7c6-44f8-8cf9-f044fd4be776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c80cd57b-644a-4421-a9ca-2612ca2ff24a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c80cd57b-644a-4421-a9ca-2612ca2ff24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_63a7a910-2786-4112-b832-5ef9eb56f8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_63a7a910-2786-4112-b832-5ef9eb56f8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_024e01f9-1d9a-4b1a-b1b3-ee61661721a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_024e01f9-1d9a-4b1a-b1b3-ee61661721a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37169136-2d72-4d25-bb05-60685ae8fc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37169136-2d72-4d25-bb05-60685ae8fc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c0f42623-b5d9-45b1-87c1-d24930565ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c0f42623-b5d9-45b1-87c1-d24930565ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_919525f9-1766-46d0-8d30-9dfd40d7fb00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_OperatingLeaseLiability_919525f9-1766-46d0-8d30-9dfd40d7fb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_eaf9b3f8-168e-4adb-9fc3-86002deeba3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_09b16094-3987-4764-8e2b-7e6d19edbf82" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_eaf9b3f8-168e-4adb-9fc3-86002deeba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e049f68d-c3f1-4bd5-bdc4-f9c8ee7a3e17" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0e8647be-9a20-49af-b4fc-8d57686a881f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0e8647be-9a20-49af-b4fc-8d57686a881f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_606288e9-fd2e-47e2-8573-45b19d51f22f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_606288e9-fd2e-47e2-8573-45b19d51f22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9b992dd0-abf9-4265-bfd1-96def20fb137" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9b992dd0-abf9-4265-bfd1-96def20fb137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ad9e4cb1-5658-472b-b8e7-93bc2f72ed18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ad9e4cb1-5658-472b-b8e7-93bc2f72ed18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8197ed3b-02a6-4dc9-af23-daa0c5d09543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8197ed3b-02a6-4dc9-af23-daa0c5d09543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f2101c16-8ae4-46cc-be52-d425dac9eaec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f2101c16-8ae4-46cc-be52-d425dac9eaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_ef845086-c1e4-46b5-865a-9979158d03d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_ef845086-c1e4-46b5-865a-9979158d03d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1c871668-f904-482b-98ca-441dd371d4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1c871668-f904-482b-98ca-441dd371d4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_6d48254e-bfc4-46a1-a16c-1a1053dc5bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiability_6d48254e-bfc4-46a1-a16c-1a1053dc5bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_a6c2bb4b-96b2-4b3e-8e7c-1b196b9b5fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_2df38b2f-a5ab-42f1-97c7-ac08a5af5b1e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_a6c2bb4b-96b2-4b3e-8e7c-1b196b9b5fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_81b2912f-4633-4434-a78d-8e3d63245f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:href="dva-20241231.xsd#dva_LeasesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_81b2912f-4633-4434-a78d-8e3d63245f25" xlink:to="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c75d050a-1552-461e-8ef0-3b60cb105433" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:to="loc_srt_RangeAxis_c75d050a-1552-461e-8ef0-3b60cb105433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32151ec0-ffd9-481a-aae5-01e1f91a025f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c75d050a-1552-461e-8ef0-3b60cb105433" xlink:to="loc_srt_RangeMember_32151ec0-ffd9-481a-aae5-01e1f91a025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a2538fd9-16cd-4a60-ad09-734e4c96472f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32151ec0-ffd9-481a-aae5-01e1f91a025f" xlink:to="loc_srt_MinimumMember_a2538fd9-16cd-4a60-ad09-734e4c96472f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ba99e281-f59d-44d9-8298-4285cba36a8d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32151ec0-ffd9-481a-aae5-01e1f91a025f" xlink:to="loc_srt_MaximumMember_ba99e281-f59d-44d9-8298-4285cba36a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_4a42092f-0af9-4ddf-9e9e-743d31b8a386" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:to="loc_us-gaap_LeaseContractualTermAxis_4a42092f-0af9-4ddf-9e9e-743d31b8a386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_986f97b6-7c1e-4065-8924-2c0a4896978e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_4a42092f-0af9-4ddf-9e9e-743d31b8a386" xlink:to="loc_us-gaap_LeaseContractualTermDomain_986f97b6-7c1e-4065-8924-2c0a4896978e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OperatingLeaseMember_f225adb4-226c-4a97-9095-8229e610e634" xlink:href="dva-20241231.xsd#dva_OperatingLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_986f97b6-7c1e-4065-8924-2c0a4896978e" xlink:to="loc_dva_OperatingLeaseMember_f225adb4-226c-4a97-9095-8229e610e634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_90e479b1-a864-4629-8d3f-0af68c23850c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:to="loc_us-gaap_DebtInstrumentAxis_90e479b1-a864-4629-8d3f-0af68c23850c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f1a07c9c-0dce-45cb-91f9-d3eaa39c15d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_90e479b1-a864-4629-8d3f-0af68c23850c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f1a07c9c-0dce-45cb-91f9-d3eaa39c15d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_4341869d-c438-4ddd-8251-631dcd500d2c" xlink:href="dva-20241231.xsd#dva_FinanceLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f1a07c9c-0dce-45cb-91f9-d3eaa39c15d6" xlink:to="loc_dva_FinanceLeaseMember_4341869d-c438-4ddd-8251-631dcd500d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:href="dva-20241231.xsd#dva_LeasesDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_3c428f92-c1e2-4e97-ab1a-2502dbc0cb74" xlink:to="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7d87b3d4-4672-45fc-a9c9-d5a0fd477ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7d87b3d4-4672-45fc-a9c9-d5a0fd477ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d3705514-c62e-49ac-883d-8551517a8712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d3705514-c62e-49ac-883d-8551517a8712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c0bc784c-7b23-443a-9934-9ecfdae8461e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c0bc784c-7b23-443a-9934-9ecfdae8461e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6eeae28b-6fe2-4aa9-9cf9-06d9fc3d9d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6eeae28b-6fe2-4aa9-9cf9-06d9fc3d9d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseAccumulatedDepreciation_2aacd2e7-827d-4b1e-8970-50414b208c67" xlink:href="dva-20241231.xsd#dva_FinanceLeaseAccumulatedDepreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_dva_FinanceLeaseAccumulatedDepreciation_2aacd2e7-827d-4b1e-8970-50414b208c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0101b16d-76c3-4613-8497-0dc005078440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_OperatingLeaseCost_0101b16d-76c3-4613-8497-0dc005078440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionLeaseTerm_be9b322e-e95e-4b03-8ba7-56e700a27673" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionLeaseTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_us-gaap_SaleLeasebackTransactionLeaseTerm_be9b322e-e95e-4b03-8ba7-56e700a27673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SaleLeasebackTransactionRenewalLeaseTerm_c8a744eb-5e8e-4dbc-ba2a-83f761f6a90c" xlink:href="dva-20241231.xsd#dva_SaleLeasebackTransactionRenewalLeaseTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_3ae495e2-599b-4dc9-8486-309fe8594c3a" xlink:to="loc_dva_SaleLeasebackTransactionRenewalLeaseTerm_c8a744eb-5e8e-4dbc-ba2a-83f761f6a90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f89b377f-0af4-4ef1-aeb9-b1acce945166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f89b377f-0af4-4ef1-aeb9-b1acce945166" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0ac38d68-3c26-43fc-b43c-63c392606f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0ac38d68-3c26-43fc-b43c-63c392606f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3c4a8ff3-3813-4a81-9377-d8f4f14bf51a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0ac38d68-3c26-43fc-b43c-63c392606f8a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3c4a8ff3-3813-4a81-9377-d8f4f14bf51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_7488a58f-cdae-48fc-8d9f-56b4500e62c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3c4a8ff3-3813-4a81-9377-d8f4f14bf51a" xlink:to="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_7488a58f-cdae-48fc-8d9f-56b4500e62c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ba8c264b-be14-4146-9ef7-6e1ae38384cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ba8c264b-be14-4146-9ef7-6e1ae38384cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_359ad0ef-9674-403e-a7a4-14fd2083290f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_ba8c264b-be14-4146-9ef7-6e1ae38384cd" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_359ad0ef-9674-403e-a7a4-14fd2083290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AllTrustsMember_2e0cbb04-b179-490c-b612-be635d8d9747" xlink:href="dva-20241231.xsd#dva_AllTrustsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_359ad0ef-9674-403e-a7a4-14fd2083290f" xlink:to="loc_dva_AllTrustsMember_2e0cbb04-b179-490c-b612-be635d8d9747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05b158bb-ddc4-4e1b-845e-9969df86ca37" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:to="loc_srt_RangeAxis_05b158bb-ddc4-4e1b-845e-9969df86ca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92e41b11-e8d9-4288-ab4b-1d813a6e4b88" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_05b158bb-ddc4-4e1b-845e-9969df86ca37" xlink:to="loc_srt_RangeMember_92e41b11-e8d9-4288-ab4b-1d813a6e4b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c8c0c94c-767f-45c8-b4f3-9e17a426286f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92e41b11-e8d9-4288-ab4b-1d813a6e4b88" xlink:to="loc_srt_MinimumMember_c8c0c94c-767f-45c8-b4f3-9e17a426286f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_462a3dc2-e5b6-4965-b645-c21d8a34ca16" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92e41b11-e8d9-4288-ab4b-1d813a6e4b88" xlink:to="loc_srt_MaximumMember_462a3dc2-e5b6-4965-b645-c21d8a34ca16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f67b88cb-56f8-4ba7-8e2f-f205e5243df0" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_1fda8e78-c77d-4114-88c8-addb72f69c25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_1fda8e78-c77d-4114-88c8-addb72f69c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_2caa2556-e053-42fe-9297-5191f5d9bddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_2caa2556-e053-42fe-9297-5191f5d9bddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_d2f90a13-bba5-4de9-b461-39b3342c4a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_d2f90a13-bba5-4de9-b461-39b3342c4a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_bab4edc0-ebf3-4f41-ac85-763b075e20ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_bab4edc0-ebf3-4f41-ac85-763b075e20ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_6478d50b-ad27-47e4-8c51-8ee6b01d334a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_6478d50b-ad27-47e4-8c51-8ee6b01d334a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_8e82429b-fde3-442c-9b7e-f29204c14271" xlink:href="dva-20241231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_8e82429b-fde3-442c-9b7e-f29204c14271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_ab4c0a46-b96a-4893-8141-952ae142c201" xlink:href="dva-20241231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_ab4c0a46-b96a-4893-8141-952ae142c201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_fb6ad53a-80c9-4f84-a734-7649215640a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_fb6ad53a-80c9-4f84-a734-7649215640a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_edb5252a-5df1-4b63-9ac7-54940cd2de42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_15ba53e9-52eb-44c5-bfd3-ada3aa423460" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_edb5252a-5df1-4b63-9ac7-54940cd2de42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_708c3931-81b7-45f8-af08-b8b0720884ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_708c3931-81b7-45f8-af08-b8b0720884ae" xlink:to="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_83f14f60-0fe8-4603-a10d-897c7a1f761c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_83f14f60-0fe8-4603-a10d-897c7a1f761c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_965b236a-8099-4eb5-9604-6da73160a964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_83f14f60-0fe8-4603-a10d-897c7a1f761c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_965b236a-8099-4eb5-9604-6da73160a964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7ac0a79e-6af3-42ef-a45d-295a836a3495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7ac0a79e-6af3-42ef-a45d-295a836a3495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19881e87-33a1-4e50-b9c2-8ec51f06fc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7ac0a79e-6af3-42ef-a45d-295a836a3495" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19881e87-33a1-4e50-b9c2-8ec51f06fc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d119c8e6-64b7-4006-a600-6d1eacbaa88e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_srt_LitigationCaseAxis_d119c8e6-64b7-4006-a600-6d1eacbaa88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a7520c48-5757-4db2-a0b9-cf6099ff212b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d119c8e6-64b7-4006-a600-6d1eacbaa88e" xlink:to="loc_srt_LitigationCaseTypeDomain_a7520c48-5757-4db2-a0b9-cf6099ff212b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_31f91f98-72bf-4de9-b7d2-00e97b2cd824" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_us-gaap_LitigationStatusAxis_31f91f98-72bf-4de9-b7d2-00e97b2cd824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7a558ef6-8d5e-4283-8c23-e114b87c70c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_31f91f98-72bf-4de9-b7d2-00e97b2cd824" xlink:to="loc_us-gaap_LitigationStatusDomain_7a558ef6-8d5e-4283-8c23-e114b87c70c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebe8343-839c-4c0b-8e65-17955207d919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebe8343-839c-4c0b-8e65-17955207d919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_3dc62db0-9afc-40f5-b171-bc2e0e50a08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebe8343-839c-4c0b-8e65-17955207d919" xlink:to="loc_us-gaap_LossContingencyNatureDomain_3dc62db0-9afc-40f5-b171-bc2e0e50a08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2017USAttorneyColoradoInvestigationMember_4d31c128-c073-4c34-8353-aa5d9225de60" xlink:href="dva-20241231.xsd#dva_A2017USAttorneyColoradoInvestigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_3dc62db0-9afc-40f5-b171-bc2e0e50a08d" xlink:to="loc_dva_A2017USAttorneyColoradoInvestigationMember_4d31c128-c073-4c34-8353-aa5d9225de60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c7976e0-8fb6-460b-bd4d-0cab975213cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_srt_RangeAxis_7c7976e0-8fb6-460b-bd4d-0cab975213cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2e189b5d-7b5d-4175-9d68-1f3f10279df3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7c7976e0-8fb6-460b-bd4d-0cab975213cf" xlink:to="loc_srt_RangeMember_2e189b5d-7b5d-4175-9d68-1f3f10279df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c8ce7bb2-473d-4458-817c-5a0a3f1c2027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3c302a19-e7a9-4a0d-8dbe-dd0f6b25ce2c" xlink:to="loc_us-gaap_LossContingenciesLineItems_c8ce7bb2-473d-4458-817c-5a0a3f1c2027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CorporateIntegrityAgreementExpirationDate_5b35ea45-5914-41a7-a030-f77d44733f64" xlink:href="dva-20241231.xsd#dva_CorporateIntegrityAgreementExpirationDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c8ce7bb2-473d-4458-817c-5a0a3f1c2027" xlink:to="loc_dva_CorporateIntegrityAgreementExpirationDate_5b35ea45-5914-41a7-a030-f77d44733f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_03a3cd6c-8c85-4ad2-9470-eaad155c4238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c8ce7bb2-473d-4458-817c-5a0a3f1c2027" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_03a3cd6c-8c85-4ad2-9470-eaad155c4238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d859cb59-f93f-4bb0-8083-9e41bd9bd0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureTable_40fd7a83-b1ad-4aa9-9f6e-ee3705b990d6" xlink:href="dva-20241231.xsd#dva_CommitmentsAndContingenciesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d859cb59-f93f-4bb0-8083-9e41bd9bd0f5" xlink:to="loc_dva_CommitmentsAndContingenciesDisclosureTable_40fd7a83-b1ad-4aa9-9f6e-ee3705b990d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_a8fce990-6ab9-467a-bbd9-5a138041ad4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_40fd7a83-b1ad-4aa9-9f6e-ee3705b990d6" xlink:to="loc_us-gaap_OtherCommitmentsAxis_a8fce990-6ab9-467a-bbd9-5a138041ad4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_c4f0ff55-b1ab-4d8e-946c-8a22bcba6780" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_a8fce990-6ab9-467a-bbd9-5a138041ad4d" xlink:to="loc_us-gaap_OtherCommitmentsDomain_c4f0ff55-b1ab-4d8e-946c-8a22bcba6780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsToProvideOperatingCapitalMember_14de79b2-1a0d-424c-b6ef-1ddd5eb4dcee" xlink:href="dva-20241231.xsd#dva_CommitmentsToProvideOperatingCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_c4f0ff55-b1ab-4d8e-946c-8a22bcba6780" xlink:to="loc_dva_CommitmentsToProvideOperatingCapitalMember_14de79b2-1a0d-424c-b6ef-1ddd5eb4dcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3cfe7fcb-67e8-4826-92ca-5a889f8e0dc2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_40fd7a83-b1ad-4aa9-9f6e-ee3705b990d6" xlink:to="loc_srt_RangeAxis_3cfe7fcb-67e8-4826-92ca-5a889f8e0dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_730d4a28-1db8-442d-8301-7d37fef13755" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3cfe7fcb-67e8-4826-92ca-5a889f8e0dc2" xlink:to="loc_srt_RangeMember_730d4a28-1db8-442d-8301-7d37fef13755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d427e536-c8e3-4c9d-bee6-508a634bcc40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_730d4a28-1db8-442d-8301-7d37fef13755" xlink:to="loc_srt_MinimumMember_d427e536-c8e3-4c9d-bee6-508a634bcc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af363ddb-949c-4b9f-8ab6-f4cb2100844c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_730d4a28-1db8-442d-8301-7d37fef13755" xlink:to="loc_srt_MaximumMember_af363ddb-949c-4b9f-8ab6-f4cb2100844c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:href="dva-20241231.xsd#dva_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_40fd7a83-b1ad-4aa9-9f6e-ee3705b990d6" xlink:to="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DissolutionTermOfJointVentures_f17d0275-d555-42ee-890c-c0c2027c4a77" xlink:href="dva-20241231.xsd#dva_DissolutionTermOfJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_dva_DissolutionTermOfJointVentures_f17d0275-d555-42ee-890c-c0c2027c4a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_5c261fbc-2990-44a1-8ef3-0e7e1766e3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_5c261fbc-2990-44a1-8ef3-0e7e1766e3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_6f07e293-151a-4cb0-bf65-054e6a1c7f44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_6f07e293-151a-4cb0-bf65-054e6a1c7f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_c71d0db5-aad6-4de1-ba45-e48148dddc34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_c71d0db5-aad6-4de1-ba45-e48148dddc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_7a5bd231-50a2-4fd5-936e-26d9c0571819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_7a5bd231-50a2-4fd5-936e-26d9c0571819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_10ebaf58-978c-441b-8dae-91d10beb3225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_10ebaf58-978c-441b-8dae-91d10beb3225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_c98e3869-6b7b-451a-8461-b9ccad1b84db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_us-gaap_OtherCommitment_c98e3869-6b7b-451a-8461-b9ccad1b84db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OffBalanceSheetFinancingArrangements_1e8e88b3-e15b-47b0-a68e-813a4814747b" xlink:href="dva-20241231.xsd#dva_OffBalanceSheetFinancingArrangements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_5e6e62be-7469-45fc-9acc-9e176814c7ac" xlink:to="loc_dva_OffBalanceSheetFinancingArrangements_1e8e88b3-e15b-47b0-a68e-813a4814747b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e04a0fc2-c42f-4802-ab7e-6f871bafb885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_599e7b08-c7c6-40a2-a921-8d11fd83e25c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e04a0fc2-c42f-4802-ab7e-6f871bafb885" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_599e7b08-c7c6-40a2-a921-8d11fd83e25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_88e4bca8-1f58-4428-8e52-d94ddd0b6b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_599e7b08-c7c6-40a2-a921-8d11fd83e25c" xlink:to="loc_us-gaap_AwardTypeAxis_88e4bca8-1f58-4428-8e52-d94ddd0b6b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e43a334-2cc7-42c6-b786-0f30f75886d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_88e4bca8-1f58-4428-8e52-d94ddd0b6b9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e43a334-2cc7-42c6-b786-0f30f75886d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_09f8cef1-4512-4a8c-9f2f-ae8a50e51e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e43a334-2cc7-42c6-b786-0f30f75886d8" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_09f8cef1-4512-4a8c-9f2f-ae8a50e51e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember_28ce9426-01b6-4fd5-ba12-b64488735f40" xlink:href="dva-20241231.xsd#dva_StockUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e43a334-2cc7-42c6-b786-0f30f75886d8" xlink:to="loc_dva_StockUnitMember_28ce9426-01b6-4fd5-ba12-b64488735f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_599e7b08-c7c6-40a2-a921-8d11fd83e25c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f53b99ac-b4cb-4f64-a1a4-3ea256405694" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f53b99ac-b4cb-4f64-a1a4-3ea256405694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_da005f06-80f3-457b-8ce7-d1737fbe5235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_da005f06-80f3-457b-8ce7-d1737fbe5235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bce2969d-8a96-474d-8101-16819c53d7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bce2969d-8a96-474d-8101-16819c53d7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d7a12a57-e953-434a-8eee-082ab4b22fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d7a12a57-e953-434a-8eee-082ab4b22fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70802258-e40b-4cd5-9a02-61ec3a071a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c4dcec7a-4b4b-44e9-b1fe-fef0b5f7a291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70802258-e40b-4cd5-9a02-61ec3a071a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_588dbb1e-3402-4ab5-b3a9-6e36adfc3db5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_588dbb1e-3402-4ab5-b3a9-6e36adfc3db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f961adc9-7746-4e29-9cf7-53be0c6cf3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f961adc9-7746-4e29-9cf7-53be0c6cf3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d36065fb-ea5e-429a-bfdf-93e813ffe243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d36065fb-ea5e-429a-bfdf-93e813ffe243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43f7f4f8-9645-4a07-8907-15119482e17a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43f7f4f8-9645-4a07-8907-15119482e17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6f9c4a16-e95b-4bf9-b897-49a5af02a27e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6f9c4a16-e95b-4bf9-b897-49a5af02a27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_33c2d815-854c-41b4-8688-746407667fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_33c2d815-854c-41b4-8688-746407667fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d8a90cf7-3cf4-4ce9-936c-5afe95797ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b63d77d-ed9b-4721-bd92-abc18e126ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d8a90cf7-3cf4-4ce9-936c-5afe95797ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7be6c675-3070-4bf1-bb5a-1956bb0cd875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7be6c675-3070-4bf1-bb5a-1956bb0cd875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_67d97623-58c9-4cff-9314-eeca098ac13c" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_67d97623-58c9-4cff-9314-eeca098ac13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ddf119da-d02b-4a6d-aca4-b78b25f71df4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_67d97623-58c9-4cff-9314-eeca098ac13c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ddf119da-d02b-4a6d-aca4-b78b25f71df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7c8908f-6118-468c-ae67-12b749ce058b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_67d97623-58c9-4cff-9314-eeca098ac13c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7c8908f-6118-468c-ae67-12b749ce058b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2b341b67-7455-40d8-9789-970b3aedad01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2b341b67-7455-40d8-9789-970b3aedad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cc5c686c-cac2-44af-b2c2-765334008542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cc5c686c-cac2-44af-b2c2-765334008542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_b35775b9-e522-432a-8515-b226b0a4783b" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_b35775b9-e522-432a-8515-b226b0a4783b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bbe22068-ab59-4f99-b277-d1ac9695f4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bbe22068-ab59-4f99-b277-d1ac9695f4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b90a1945-738a-4890-9694-95fdcb3642f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b90a1945-738a-4890-9694-95fdcb3642f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d55127d7-f32b-42e0-a3cd-14997fbe8a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e080ab5-efbd-47d5-9daa-a37368b991d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d55127d7-f32b-42e0-a3cd-14997fbe8a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_0b07d6af-de98-41a6-aac9-ffe9458e5bc3" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_0b07d6af-de98-41a6-aac9-ffe9458e5bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b29f5d42-e9f1-4a7d-b318-28ec06e2744f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b29f5d42-e9f1-4a7d-b318-28ec06e2744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_9c5608d8-a351-4381-817f-c941dd7818f7" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42e5c29-822d-4c00-be7e-fc561633e846" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_9c5608d8-a351-4381-817f-c941dd7818f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1dd124de-26d0-42f9-ae53-283b792bb2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_9c5608d8-a351-4381-817f-c941dd7818f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1dd124de-26d0-42f9-ae53-283b792bb2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_e17aa97c-9d46-41d5-9f45-b0974b4641ad" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_9c5608d8-a351-4381-817f-c941dd7818f7" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_e17aa97c-9d46-41d5-9f45-b0974b4641ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aa435f4a-57c7-487e-b36a-72c1091dc13e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_3d0af312-faa9-4c7f-a49f-1eb2366cd24f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aa435f4a-57c7-487e-b36a-72c1091dc13e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_3d0af312-faa9-4c7f-a49f-1eb2366cd24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6c08dbfc-b003-449d-a002-0b103f8be7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_3d0af312-faa9-4c7f-a49f-1eb2366cd24f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6c08dbfc-b003-449d-a002-0b103f8be7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6c08dbfc-b003-449d-a002-0b103f8be7ae" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeOneMember_6c01ea12-b40a-4ddb-b09c-c39b31af24a5" xlink:href="dva-20241231.xsd#dva_RangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeOneMember_6c01ea12-b40a-4ddb-b09c-c39b31af24a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeTwoMember_46cd1ea8-349a-4df0-a765-5d5fcdfac7c4" xlink:href="dva-20241231.xsd#dva_RangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeTwoMember_46cd1ea8-349a-4df0-a765-5d5fcdfac7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeThreeMember_f1e8436e-8957-4683-91aa-9103bd7fc953" xlink:href="dva-20241231.xsd#dva_RangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeThreeMember_f1e8436e-8957-4683-91aa-9103bd7fc953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFourMember_27fd7bde-f4bb-4350-876c-61337e87bf50" xlink:href="dva-20241231.xsd#dva_RangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeFourMember_27fd7bde-f4bb-4350-876c-61337e87bf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFiveMember_0d2434c1-53e0-4d5d-8768-c40cf709ab83" xlink:href="dva-20241231.xsd#dva_RangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a4a8a542-87fb-4b8e-96ac-65e07d5e57a3" xlink:to="loc_dva_RangeFiveMember_0d2434c1-53e0-4d5d-8768-c40cf709ab83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_3d0af312-faa9-4c7f-a49f-1eb2366cd24f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_95861fa3-23ee-4efa-8ebf-32febc5d047a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_95861fa3-23ee-4efa-8ebf-32febc5d047a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_a1698224-f327-48f0-892a-695f590591a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_a1698224-f327-48f0-892a-695f590591a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_82f0b1f2-16eb-4071-a2d7-3496003d274a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_82f0b1f2-16eb-4071-a2d7-3496003d274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_83f0f047-af8c-4045-8e13-154cfdff6dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_83f0f047-af8c-4045-8e13-154cfdff6dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_78e08ef4-b6d2-43ed-83b0-b652ab13f373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_78e08ef4-b6d2-43ed-83b0-b652ab13f373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_7d29a8cf-a8e5-4604-ab53-f3ce5ffbbb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_065f7d63-65d9-485e-8c5f-51e4bb9856b6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_7d29a8cf-a8e5-4604-ab53-f3ce5ffbbb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb6b1061-c4fe-46a5-9c97-a8ba6e4f98b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83abb995-683c-463c-8471-46a687fdfd97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb6b1061-c4fe-46a5-9c97-a8ba6e4f98b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83abb995-683c-463c-8471-46a687fdfd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_873aa22e-60ab-4cc1-adf7-efff96001657" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83abb995-683c-463c-8471-46a687fdfd97" xlink:to="loc_us-gaap_AwardTypeAxis_873aa22e-60ab-4cc1-adf7-efff96001657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8fa5ef8-a438-43a5-8f22-a50beebab9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_873aa22e-60ab-4cc1-adf7-efff96001657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8fa5ef8-a438-43a5-8f22-a50beebab9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember_d9d9c9c6-1215-4b47-b966-87dc17fc5c3d" xlink:href="dva-20241231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8fa5ef8-a438-43a5-8f22-a50beebab9a3" xlink:to="loc_dva_StockSettledStockAppreciationRightsMember_d9d9c9c6-1215-4b47-b966-87dc17fc5c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83abb995-683c-463c-8471-46a687fdfd97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7762d74e-bf7c-4241-b2ce-d8a1b98b175c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7762d74e-bf7c-4241-b2ce-d8a1b98b175c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_58d9ce49-3f4f-4e84-bc39-e458a97d926f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_58d9ce49-3f4f-4e84-bc39-e458a97d926f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24820d2f-7164-4a8d-a0ca-dbb18dd88707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24820d2f-7164-4a8d-a0ca-dbb18dd88707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1bc07e19-b1a6-4c06-85cf-6cb351101806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_013edeaa-4da1-4c02-9253-f5c1880c5388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1bc07e19-b1a6-4c06-85cf-6cb351101806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_317db061-3210-4ca1-a975-01a1c7d03c57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_317db061-3210-4ca1-a975-01a1c7d03c57" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1614a3b1-bd0e-44e5-ae83-296a595c71fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:to="loc_us-gaap_PlanNameAxis_1614a3b1-bd0e-44e5-ae83-296a595c71fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cbc0facb-44ec-4545-93c0-adad66989492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1614a3b1-bd0e-44e5-ae83-296a595c71fd" xlink:to="loc_us-gaap_PlanNameDomain_cbc0facb-44ec-4545-93c0-adad66989492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyTwentyMember_87a9942e-2c29-425a-aae3-ec403fb84d63" xlink:href="dva-20241231.xsd#dva_StockIncentivePlanTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cbc0facb-44ec-4545-93c0-adad66989492" xlink:to="loc_dva_StockIncentivePlanTwentyTwentyMember_87a9942e-2c29-425a-aae3-ec403fb84d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98962af0-bec4-4104-b6c7-cbcf16fac54f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:to="loc_srt_RangeAxis_98962af0-bec4-4104-b6c7-cbcf16fac54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86ce1851-30bf-4c89-9b5c-56cd1b626bcd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_98962af0-bec4-4104-b6c7-cbcf16fac54f" xlink:to="loc_srt_RangeMember_86ce1851-30bf-4c89-9b5c-56cd1b626bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d78f92ca-1b69-455d-bd26-85950fe3799b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86ce1851-30bf-4c89-9b5c-56cd1b626bcd" xlink:to="loc_srt_MinimumMember_d78f92ca-1b69-455d-bd26-85950fe3799b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_157fe9ae-a816-437d-9ef9-faf2e2816c06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86ce1851-30bf-4c89-9b5c-56cd1b626bcd" xlink:to="loc_srt_MaximumMember_157fe9ae-a816-437d-9ef9-faf2e2816c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_289831cc-18b5-4c52-a0ff-cda1b16a59c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:to="loc_us-gaap_AwardTypeAxis_289831cc-18b5-4c52-a0ff-cda1b16a59c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df703902-372c-49e7-b263-513f341782ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_289831cc-18b5-4c52-a0ff-cda1b16a59c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df703902-372c-49e7-b263-513f341782ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember_e5ea723b-597a-4d81-8aac-cd15eaab4303" xlink:href="dva-20241231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df703902-372c-49e7-b263-513f341782ad" xlink:to="loc_dva_EmployeeStockPurchasePlanMember_e5ea723b-597a-4d81-8aac-cd15eaab4303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bad76c28-7ad7-489f-9649-63a08461861c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e0f7396a-9d3e-4a86-ae35-14830a11b63f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e0f7396a-9d3e-4a86-ae35-14830a11b63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_0f5a8b55-e414-4d88-a3ef-ad5da3bbb38c" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_0f5a8b55-e414-4d88-a3ef-ad5da3bbb38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_d9ccb183-5424-4982-885e-e4edbf4e7e41" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_d9ccb183-5424-4982-885e-e4edbf4e7e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_e1753b94-f4b3-42a4-a40c-043952854ba2" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_e1753b94-f4b3-42a4-a40c-043952854ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_0483252b-e082-4d17-973e-ca678b43ab28" xlink:href="dva-20241231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_0483252b-e082-4d17-973e-ca678b43ab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8f6d514f-205f-41f3-8a95-11384d722da6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8f6d514f-205f-41f3-8a95-11384d722da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1de2098d-3214-4392-b73e-e43e9353935f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1de2098d-3214-4392-b73e-e43e9353935f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98033df2-0dbf-4eaf-9aaf-3e4ec95ff568" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98033df2-0dbf-4eaf-9aaf-3e4ec95ff568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4859786b-e22d-4b7c-996e-bbc6884216ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4859786b-e22d-4b7c-996e-bbc6884216ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7aa38d1a-a52a-476b-a68b-53682753b779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7aa38d1a-a52a-476b-a68b-53682753b779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_026173b2-98b7-4b17-bf54-4af755fab293" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_026173b2-98b7-4b17-bf54-4af755fab293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_03647a7e-f1e2-4de8-b5d1-f1ea9f00e89c" xlink:href="dva-20241231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_03647a7e-f1e2-4de8-b5d1-f1ea9f00e89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1513f7b6-ed9f-4e16-8dfb-4e6f62d89aae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1513f7b6-ed9f-4e16-8dfb-4e6f62d89aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_f6404f1c-422a-4e0e-9e08-cc220d142b82" xlink:href="dva-20241231.xsd#dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_f6404f1c-422a-4e0e-9e08-cc220d142b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8499bbdb-428e-4731-a3a0-53810b54173a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8499bbdb-428e-4731-a3a0-53810b54173a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a7ebaa7f-61b3-4ed7-ad2f-8cfddcd1ae3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a7ebaa7f-61b3-4ed7-ad2f-8cfddcd1ae3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_281bf54e-14fe-4156-93d7-70d11ed839cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_281bf54e-14fe-4156-93d7-70d11ed839cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_0140d503-ec27-45d0-b077-7ef0f0244115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_0140d503-ec27-45d0-b077-7ef0f0244115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9aaf9966-d086-4f1c-bf25-5975e09bf059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9aaf9966-d086-4f1c-bf25-5975e09bf059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0384c5cb-f372-4bd4-b183-0f7a178d4cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ShareBasedCompensation_0384c5cb-f372-4bd4-b183-0f7a178d4cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_98824fbd-11c7-4573-ae6d-a6324d0f7e22" xlink:href="dva-20241231.xsd#dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_98824fbd-11c7-4573-ae6d-a6324d0f7e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c8e90491-11d0-4652-a7ca-6cdbe0cb1610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c8e90491-11d0-4652-a7ca-6cdbe0cb1610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36ce4713-04f4-44aa-ad3f-ee3653fdaf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36ce4713-04f4-44aa-ad3f-ee3653fdaf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_efa544d6-eec9-444b-833f-755f5b9d926a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_efa544d6-eec9-444b-833f-755f5b9d926a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f2e99b95-84cd-4d68-9982-2d0f381f81f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dab90d5a-e56d-4dea-96eb-7f002195d45e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f2e99b95-84cd-4d68-9982-2d0f381f81f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#StockRepurchasesTenderOfferDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract_f541c9c9-c9d7-46d5-a7bf-fa9b8c09f362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_aea80217-66e9-4f7e-a21c-2def0989391d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_f541c9c9-c9d7-46d5-a7bf-fa9b8c09f362" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_aea80217-66e9-4f7e-a21c-2def0989391d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_6e85351c-c7b2-43cf-b0b3-94548558bfed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_aea80217-66e9-4f7e-a21c-2def0989391d" xlink:to="loc_srt_ShareRepurchaseProgramAxis_6e85351c-c7b2-43cf-b0b3-94548558bfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_afeb6c58-3e4f-4a68-aae4-e44c0336a810" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_6e85351c-c7b2-43cf-b0b3-94548558bfed" xlink:to="loc_srt_ShareRepurchaseProgramDomain_afeb6c58-3e4f-4a68-aae4-e44c0336a810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_369f8db6-845c-4002-bbcd-011e79434a16" xlink:href="dva-20241231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_afeb6c58-3e4f-4a68-aae4-e44c0336a810" xlink:to="loc_dva_OpenMarketPurchasesMember_369f8db6-845c-4002-bbcd-011e79434a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_aea80217-66e9-4f7e-a21c-2def0989391d" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_34ade406-1c63-42cb-9314-e14a2ce455e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_34ade406-1c63-42cb-9314-e14a2ce455e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_980486a1-074d-4d6e-be9c-84b1faa0efed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_980486a1-074d-4d6e-be9c-84b1faa0efed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1575fb9c-8ecf-49aa-8d89-09de033e9c95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5b1ce90b-e9be-4bf9-8b28-4676e28b9554" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1575fb9c-8ecf-49aa-8d89-09de033e9c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_2e8260ec-50f1-4c4e-8c13-2d71617a9b3c" xlink:href="dva-20241231.xsd#dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_fd59372b-8d95-4a5a-9206-7ab2b9147d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_2e8260ec-50f1-4c4e-8c13-2d71617a9b3c" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_fd59372b-8d95-4a5a-9206-7ab2b9147d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4fa9ad78-0fda-44d2-9179-20f7e21f4fda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_fd59372b-8d95-4a5a-9206-7ab2b9147d67" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4fa9ad78-0fda-44d2-9179-20f7e21f4fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0c445553-55ba-478b-bdfe-3c145e5117a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4fa9ad78-0fda-44d2-9179-20f7e21f4fda" xlink:to="loc_us-gaap_EquityComponentDomain_0c445553-55ba-478b-bdfe-3c145e5117a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_aaa6ae70-53fe-4ba9-a688-3b79c355ae76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0c445553-55ba-478b-bdfe-3c145e5117a6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_aaa6ae70-53fe-4ba9-a688-3b79c355ae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_e503be50-dd9e-4ff3-99fa-d0ec02f9a1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_fd59372b-8d95-4a5a-9206-7ab2b9147d67" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_e503be50-dd9e-4ff3-99fa-d0ec02f9a1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_554d8f73-7796-4fda-8b76-a173fde1e31f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_e503be50-dd9e-4ff3-99fa-d0ec02f9a1f0" xlink:to="loc_us-gaap_NetIncomeLoss_554d8f73-7796-4fda-8b76-a173fde1e31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_e503be50-dd9e-4ff3-99fa-d0ec02f9a1f0" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8121538c-1caa-4ee0-9d0d-fed3c7541f13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8121538c-1caa-4ee0-9d0d-fed3c7541f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_95521c81-da34-474e-a63e-c925b2703266" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_95521c81-da34-474e-a63e-c925b2703266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_413a3ae4-28ea-4f6c-a95a-5e8e05ac029c" xlink:href="dva-20241231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_413a3ae4-28ea-4f6c-a95a-5e8e05ac029c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_05d32ed9-2046-4e4f-979d-dbaa5372a2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_05d32ed9-2046-4e4f-979d-dbaa5372a2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_c17452ad-5e93-4918-896a-7f64d8168100" xlink:href="dva-20241231.xsd#dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_5030bba2-e1f0-4842-9dd8-1d94e60445c3" xlink:to="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_c17452ad-5e93-4918-896a-7f64d8168100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ShareholdersequityDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_02150dc5-1984-4109-814c-0ff4acfa502f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_02150dc5-1984-4109-814c-0ff4acfa502f" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_860aa391-9ac2-4c8b-b36b-e02420f30e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_860aa391-9ac2-4c8b-b36b-e02420f30e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_24d0cf25-e37f-4c4f-a980-3bbde6f57f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_860aa391-9ac2-4c8b-b36b-e02420f30e56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_24d0cf25-e37f-4c4f-a980-3bbde6f57f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0317027c-e429-46dc-92ff-8a5418a81229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_24d0cf25-e37f-4c4f-a980-3bbde6f57f43" xlink:to="loc_us-gaap_SubsequentEventMember_0317027c-e429-46dc-92ff-8a5418a81229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6d2629e6-63ca-49ba-b0ee-aaf8f8dd6878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6d2629e6-63ca-49ba-b0ee-aaf8f8dd6878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d89d57f9-bf5d-42b4-8742-9b710259b070" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d2629e6-63ca-49ba-b0ee-aaf8f8dd6878" xlink:to="loc_us-gaap_EquityComponentDomain_d89d57f9-bf5d-42b4-8742-9b710259b070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_ee5b69cf-3632-4060-a56d-ec4f246e5fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d89d57f9-bf5d-42b4-8742-9b710259b070" xlink:to="loc_us-gaap_TreasuryStockCommonMember_ee5b69cf-3632-4060-a56d-ec4f246e5fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_38194b18-2473-49cc-935f-81e9be7e8e23" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:to="loc_srt_ShareRepurchaseProgramAxis_38194b18-2473-49cc-935f-81e9be7e8e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_3acb2669-c7f1-46ec-86bd-d02e32c1e9af" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_38194b18-2473-49cc-935f-81e9be7e8e23" xlink:to="loc_srt_ShareRepurchaseProgramDomain_3acb2669-c7f1-46ec-86bd-d02e32c1e9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_c569ee89-6fe6-4211-85e6-49fe33e495b8" xlink:href="dva-20241231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_3acb2669-c7f1-46ec-86bd-d02e32c1e9af" xlink:to="loc_dva_OpenMarketPurchasesMember_c569ee89-6fe6-4211-85e6-49fe33e495b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d43f34c3-74df-4630-b804-d2585598bd04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_91c33c09-9e14-43cc-8643-52dddb5e9816" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d43f34c3-74df-4630-b804-d2585598bd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d43f34c3-74df-4630-b804-d2585598bd04" xlink:to="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_5262f657-66c7-4338-a172-486934541160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_5262f657-66c7-4338-a172-486934541160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_79df363d-c791-422d-86b0-a3a18ba4fc24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_79df363d-c791-422d-86b0-a3a18ba4fc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7d8daa02-88ea-455f-95a7-f00f64dbf822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7d8daa02-88ea-455f-95a7-f00f64dbf822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_a6f32774-4e24-4ce6-b347-b606a20d4920" xlink:href="dva-20241231.xsd#dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_a6f32774-4e24-4ce6-b347-b606a20d4920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_965bcd89-6ce2-45cd-b4c7-a8a109963ac0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_965bcd89-6ce2-45cd-b4c7-a8a109963ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_2bff7cb2-deb2-413e-ae63-913bfaa2379b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_2bff7cb2-deb2-413e-ae63-913bfaa2379b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_19496c31-d56b-41c7-a0c4-30ca6c5c985c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_e632d349-3497-49fa-9a81-ebee85fd5c98" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_19496c31-d56b-41c7-a0c4-30ca6c5c985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:href="dva-20241231.xsd#dva_CharterdocumentsandDelawarelawAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d43f34c3-74df-4630-b804-d2585598bd04" xlink:to="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a55ee545-fc57-48ac-b864-c94c4edcea72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a55ee545-fc57-48ac-b864-c94c4edcea72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_53bfe59a-5a8c-4ad9-903d-17c458b4716f" xlink:href="dva-20241231.xsd#dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:to="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_53bfe59a-5a8c-4ad9-903d-17c458b4716f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_912b6ede-de1c-4255-b8af-eba2c14d0abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_75026ffe-292d-4e28-b4ab-0dd5da7e8fb6" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_912b6ede-de1c-4255-b8af-eba2c14d0abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8131ad9f-5f9a-42d7-9279-b51b9a93ba8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_25c2273d-7608-42f6-89ea-7b3f26fdb5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8131ad9f-5f9a-42d7-9279-b51b9a93ba8b" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_25c2273d-7608-42f6-89ea-7b3f26fdb5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f20b4194-a740-422f-90e4-e5cd0fc05ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_25c2273d-7608-42f6-89ea-7b3f26fdb5ab" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f20b4194-a740-422f-90e4-e5cd0fc05ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c74bb65b-c34c-4b95-b697-28d103d4c26e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f20b4194-a740-422f-90e4-e5cd0fc05ebd" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c74bb65b-c34c-4b95-b697-28d103d4c26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_238a7e03-fd46-4580-85b5-20545b5a8d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c74bb65b-c34c-4b95-b697-28d103d4c26e" xlink:to="loc_us-gaap_PrincipalOwnerMember_238a7e03-fd46-4580-85b5-20545b5a8d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bbe5f78e-2f51-44f4-a7ed-0b5287f284e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_25c2273d-7608-42f6-89ea-7b3f26fdb5ab" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bbe5f78e-2f51-44f4-a7ed-0b5287f284e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fed3befe-2057-4007-a5b2-57b074365f59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bbe5f78e-2f51-44f4-a7ed-0b5287f284e2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fed3befe-2057-4007-a5b2-57b074365f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_08bb1cf4-5c60-4a50-8ff4-39b406b84218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fed3befe-2057-4007-a5b2-57b074365f59" xlink:to="loc_us-gaap_SubsequentEventMember_08bb1cf4-5c60-4a50-8ff4-39b406b84218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_25c2273d-7608-42f6-89ea-7b3f26fdb5ab" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_16b1c24b-c687-45a9-82be-10eb52e292f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_16b1c24b-c687-45a9-82be-10eb52e292f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_c721e6d0-17f7-4ac6-af51-0daf9f12256d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_c721e6d0-17f7-4ac6-af51-0daf9f12256d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_f9669a30-9bc5-443b-a9b2-4bcc9a8c34a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RelatedPartyTransactionDescriptionOfTransaction1_02410e05-df17-49ca-a41b-5c8fac90f3dd" xlink:href="dva-20241231.xsd#dva_RelatedPartyTransactionDescriptionOfTransaction1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_dva_RelatedPartyTransactionDescriptionOfTransaction1_02410e05-df17-49ca-a41b-5c8fac90f3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RelatedPartyTransactionDescriptionOfTransaction2_5ba2be2f-61f6-47fd-9841-8b75abd13ef0" xlink:href="dva-20241231.xsd#dva_RelatedPartyTransactionDescriptionOfTransaction2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_dva_RelatedPartyTransactionDescriptionOfTransaction2_5ba2be2f-61f6-47fd-9841-8b75abd13ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementDate_9e57b561-afe2-4076-90cf-68fdd2288b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepurchaseAgreementDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_us-gaap_RepurchaseAgreementDate_9e57b561-afe2-4076-90cf-68fdd2288b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_19289a0c-b502-416b-a21f-21e0b5060ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_a416eff7-4636-4e62-8000-cdafa330e434" xlink:to="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_19289a0c-b502-416b-a21f-21e0b5060ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_95228925-7d53-4fd5-96c2-6ab6c270f92d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9de2cbca-cfbe-48f4-8ba3-14fdca4f5a50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_95228925-7d53-4fd5-96c2-6ab6c270f92d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9de2cbca-cfbe-48f4-8ba3-14fdca4f5a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ccb9797-c4a8-4a38-bde4-297ff4d4e4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9de2cbca-cfbe-48f4-8ba3-14fdca4f5a50" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ccb9797-c4a8-4a38-bde4-297ff4d4e4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ccb9797-c4a8-4a38-bde4-297ff4d4e4f2" xlink:to="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_04d7c127-6747-4894-a773-9c7750195b04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_04d7c127-6747-4894-a773-9c7750195b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_51e9dc38-69de-4f76-b772-b670dcfc52be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_51e9dc38-69de-4f76-b772-b670dcfc52be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8bf49747-c853-42e4-9f26-de6984e536e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8bf49747-c853-42e4-9f26-de6984e536e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f3d92b89-60bd-4533-b032-75ab7e40ac4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d7e6f7e2-51fb-4339-bc16-1e45abed3333" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f3d92b89-60bd-4533-b032-75ab7e40ac4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9de2cbca-cfbe-48f4-8ba3-14fdca4f5a50" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7c0fe23d-395e-43ee-ab65-9e7575a240a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7c0fe23d-395e-43ee-ab65-9e7575a240a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_701c1ce2-41ea-46a5-89c0-9380a89b09e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_701c1ce2-41ea-46a5-89c0-9380a89b09e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_4839a00e-7e8b-41ad-9515-d899d659b0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_4839a00e-7e8b-41ad-9515-d899d659b0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_8f5559ba-9d55-42a5-a629-005f57831790" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_8f5559ba-9d55-42a5-a629-005f57831790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_10f85615-933f-4f0c-b133-93fa01da9e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_10f85615-933f-4f0c-b133-93fa01da9e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_0633c24f-2b8a-490b-9574-c7c8146eebfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_0633c24f-2b8a-490b-9574-c7c8146eebfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_517508d1-7b2c-4459-812f-65e5fc6e21f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_517508d1-7b2c-4459-812f-65e5fc6e21f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5922aa50-9e39-47f0-b3ad-c3ea9ba70e02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b29b903c-cfc1-4817-ba9c-6a4c4a8cf074" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5922aa50-9e39-47f0-b3ad-c3ea9ba70e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsComponentsofRoutineAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e99c8c5a-6120-430b-9c9a-556dd46551b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e99c8c5a-6120-430b-9c9a-556dd46551b4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3e16a36f-850d-41ac-8f49-98662091d311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3e16a36f-850d-41ac-8f49-98662091d311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e350c7b0-54c6-4d29-b4bd-2904c58dc4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3e16a36f-850d-41ac-8f49-98662091d311" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e350c7b0-54c6-4d29-b4bd-2904c58dc4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_d6d84631-57a0-4f9f-ba7d-3e9dbea65b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e350c7b0-54c6-4d29-b4bd-2904c58dc4f5" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_d6d84631-57a0-4f9f-ba7d-3e9dbea65b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaCarePte.Ltd.Member_a7673f15-becb-453c-8c94-380438bfbf80" xlink:href="dva-20241231.xsd#dva_DaVitaCarePte.Ltd.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e350c7b0-54c6-4d29-b4bd-2904c58dc4f5" xlink:to="loc_dva_DaVitaCarePte.Ltd.Member_a7673f15-becb-453c-8c94-380438bfbf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d25681a7-a48b-42d8-aa9b-e7bdc6d3766c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d25681a7-a48b-42d8-aa9b-e7bdc6d3766c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_64e8364b-9e11-4f15-9cd1-cdd6adc9c394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d25681a7-a48b-42d8-aa9b-e7bdc6d3766c" xlink:to="loc_us-gaap_SegmentDomain_64e8364b-9e11-4f15-9cd1-cdd6adc9c394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_527ccf51-cb25-46b9-bef9-b286ad08c33c" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_64e8364b-9e11-4f15-9cd1-cdd6adc9c394" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_527ccf51-cb25-46b9-bef9-b286ad08c33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignDialysisCentersMember_c617d727-73ad-4532-87b2-8256310fccb1" xlink:href="dva-20241231.xsd#dva_ForeignDialysisCentersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_64e8364b-9e11-4f15-9cd1-cdd6adc9c394" xlink:to="loc_dva_ForeignDialysisCentersMember_c617d727-73ad-4532-87b2-8256310fccb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_4df1334d-4abc-47ea-8b06-55fd3fefe683" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_4df1334d-4abc-47ea-8b06-55fd3fefe683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_26760f34-62cd-4518-b112-70ce15c05f1d" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_4df1334d-4abc-47ea-8b06-55fd3fefe683" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_26760f34-62cd-4518-b112-70ce15c05f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NonCashGainMember_5a46cfff-d787-465f-9956-75a0973d8805" xlink:href="dva-20241231.xsd#dva_NonCashGainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_26760f34-62cd-4518-b112-70ce15c05f1d" xlink:to="loc_dva_NonCashGainMember_5a46cfff-d787-465f-9956-75a0973d8805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_934413c0-7963-4a56-9dab-dd410e4c337a" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be228cc9-e20f-43c8-8dca-a3ccfc76d409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be228cc9-e20f-43c8-8dca-a3ccfc76d409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6fc4fab9-1214-4bb8-bd0b-76dbb198aeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6fc4fab9-1214-4bb8-bd0b-76dbb198aeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_70eeefb6-e78f-4d82-9a6b-8858d708f269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_70eeefb6-e78f-4d82-9a6b-8858d708f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92e46038-a818-4b6d-876e-895bd61b819e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_92e46038-a818-4b6d-876e-895bd61b819e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_5338e20a-5ea2-43af-bb70-e543806037b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_5338e20a-5ea2-43af-bb70-e543806037b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_67aaa26a-7c46-4554-9fdf-946deecd3849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60d1efef-9f05-4e92-8e92-39622ef4cbd0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_67aaa26a-7c46-4554-9fdf-946deecd3849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsAssetsacquiredandliabilitiesassumedDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9a80ad18-add3-42f2-a35c-aeec5a955857" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c6d72b7e-9544-4323-b88c-2392f4cc59a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9a80ad18-add3-42f2-a35c-aeec5a955857" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c6d72b7e-9544-4323-b88c-2392f4cc59a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d4d1a14d-44ae-4721-93ec-8f70ed813ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c6d72b7e-9544-4323-b88c-2392f4cc59a2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d4d1a14d-44ae-4721-93ec-8f70ed813ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9ceed66-935e-4c96-8359-022065658391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4d1a14d-44ae-4721-93ec-8f70ed813ec7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9ceed66-935e-4c96-8359-022065658391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_847e4449-2250-4cee-a860-965321c899c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9ceed66-935e-4c96-8359-022065658391" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_847e4449-2250-4cee-a860-965321c899c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaCarePte.Ltd.Member_a2f09e55-feaf-4a55-9892-d139f895d205" xlink:href="dva-20241231.xsd#dva_DaVitaCarePte.Ltd.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9ceed66-935e-4c96-8359-022065658391" xlink:to="loc_dva_DaVitaCarePte.Ltd.Member_a2f09e55-feaf-4a55-9892-d139f895d205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c6d72b7e-9544-4323-b88c-2392f4cc59a2" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f21e309-099d-4ae9-984c-26650fc216d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f21e309-099d-4ae9-984c-26650fc216d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_743d0b2c-cf7c-4d94-b024-23c825a34902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_743d0b2c-cf7c-4d94-b024-23c825a34902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a3fb70cd-0adc-45db-904a-868b8d09d1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a3fb70cd-0adc-45db-904a-868b8d09d1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e269b553-746b-486f-9934-cb3b8bd00020" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e269b553-746b-486f-9934-cb3b8bd00020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d170a986-d24c-4c57-98d9-df55d528d0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d170a986-d24c-4c57-98d9-df55d528d0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2d60d880-3a4b-4eaf-a79b-2cf9d9ac45d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_Goodwill_2d60d880-3a4b-4eaf-a79b-2cf9d9ac45d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c20e5cc1-b26c-475b-affd-53b7307c39d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_c20e5cc1-b26c-475b-affd-53b7307c39d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_3135f6a2-fe1a-450b-93bc-a40546646d17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_3135f6a2-fe1a-450b-93bc-a40546646d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0948164f-8f64-4f36-9c71-f44c3a937f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_394f74f3-81bf-4a8a-9cb4-385132fcc1b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0948164f-8f64-4f36-9c71-f44c3a937f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_78e2345b-78ed-4b5a-9910-34503d6b64b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0507a69d-8a28-48a3-8665-6a4182a88462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_78e2345b-78ed-4b5a-9910-34503d6b64b1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0507a69d-8a28-48a3-8665-6a4182a88462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8bdaa82f-67a9-4f40-a625-428291a47064" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0507a69d-8a28-48a3-8665-6a4182a88462" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8bdaa82f-67a9-4f40-a625-428291a47064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_185facb0-ceac-45ff-9191-e80379bf603b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8bdaa82f-67a9-4f40-a625-428291a47064" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_185facb0-ceac-45ff-9191-e80379bf603b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_228ee6fb-54e2-4a7f-acf8-34d2bea7eb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_185facb0-ceac-45ff-9191-e80379bf603b" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_228ee6fb-54e2-4a7f-acf8-34d2bea7eb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9eaad074-9f97-4bee-8864-2da8f2e287f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0507a69d-8a28-48a3-8665-6a4182a88462" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9eaad074-9f97-4bee-8864-2da8f2e287f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ab010b6e-4774-49a6-816e-0c7d77060d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9eaad074-9f97-4bee-8864-2da8f2e287f0" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ab010b6e-4774-49a6-816e-0c7d77060d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_afb00f11-dcf2-44f1-8d17-0d8635328bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_33b967a3-2aad-4509-b377-2c5dcffc8c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_afb00f11-dcf2-44f1-8d17-0d8635328bd7" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_33b967a3-2aad-4509-b377-2c5dcffc8c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_ceeb475a-90b6-431d-ac82-1e5044747cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_afb00f11-dcf2-44f1-8d17-0d8635328bd7" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_ceeb475a-90b6-431d-ac82-1e5044747cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_31bcdd0c-e025-49a0-bdf7-1389b6e660db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_afb00f11-dcf2-44f1-8d17-0d8635328bd7" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_31bcdd0c-e025-49a0-bdf7-1389b6e660db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_c2aecc5c-f919-4d2f-9c98-2bdbdcecb40f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_afb00f11-dcf2-44f1-8d17-0d8635328bd7" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_c2aecc5c-f919-4d2f-9c98-2bdbdcecb40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_cea79cf3-1ae1-47a2-81d5-3587279f64f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93abae29-f459-4822-b2a0-c34feb14c7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_cea79cf3-1ae1-47a2-81d5-3587279f64f6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93abae29-f459-4822-b2a0-c34feb14c7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c7a2008b-c400-41b3-8a9d-eabef0046100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93abae29-f459-4822-b2a0-c34feb14c7f0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c7a2008b-c400-41b3-8a9d-eabef0046100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b1a8a1-1992-4c0a-b536-7e2e8294479a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c7a2008b-c400-41b3-8a9d-eabef0046100" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b1a8a1-1992-4c0a-b536-7e2e8294479a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_55145292-8708-4eaf-9bbd-4ba8650ed9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88b1a8a1-1992-4c0a-b536-7e2e8294479a" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_55145292-8708-4eaf-9bbd-4ba8650ed9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0729ac92-32e1-4186-8192-2a0ea30bea53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93abae29-f459-4822-b2a0-c34feb14c7f0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0729ac92-32e1-4186-8192-2a0ea30bea53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#AcquisitionsandDivestituresAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_cf73124d-2efc-4556-baef-04f6d316e204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_cf73124d-2efc-4556-baef-04f6d316e204" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5df98de6-1e13-4469-9e4b-a56c4b27959e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5df98de6-1e13-4469-9e4b-a56c4b27959e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ee4daf3b-40e0-47fd-a245-3b9f4aca4fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5df98de6-1e13-4469-9e4b-a56c4b27959e" xlink:to="loc_us-gaap_RelatedPartyDomain_ee4daf3b-40e0-47fd-a245-3b9f4aca4fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherCompaniesMember_4ffbe986-c55d-403c-9d62-bff7aff185f3" xlink:href="dva-20241231.xsd#dva_OtherCompaniesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ee4daf3b-40e0-47fd-a245-3b9f4aca4fbf" xlink:to="loc_dva_OtherCompaniesMember_4ffbe986-c55d-403c-9d62-bff7aff185f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_61de872e-f254-4bbc-80a9-539ce5d11837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_61de872e-f254-4bbc-80a9-539ce5d11837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_40e28772-6fcc-4456-95ca-8c55328461cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_61de872e-f254-4bbc-80a9-539ce5d11837" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_40e28772-6fcc-4456-95ca-8c55328461cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_55c7abf1-53c7-4ba3-ab45-baac485a4e6a" xlink:href="dva-20241231.xsd#dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_40e28772-6fcc-4456-95ca-8c55328461cb" xlink:to="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_55c7abf1-53c7-4ba3-ab45-baac485a4e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1b3272f9-2a0d-473d-a6f7-9bc46c2f4b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1b3272f9-2a0d-473d-a6f7-9bc46c2f4b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46c1ea59-f236-4468-bb7d-640a3b7fa65d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1b3272f9-2a0d-473d-a6f7-9bc46c2f4b90" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46c1ea59-f236-4468-bb7d-640a3b7fa65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_f7d48305-ec44-4314-a790-ee14d7cc2e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46c1ea59-f236-4468-bb7d-640a3b7fa65d" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_f7d48305-ec44-4314-a790-ee14d7cc2e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaCarePte.Ltd.Member_e02993a2-d0f7-4650-a114-2ee4e2b70164" xlink:href="dva-20241231.xsd#dva_DaVitaCarePte.Ltd.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46c1ea59-f236-4468-bb7d-640a3b7fa65d" xlink:to="loc_dva_DaVitaCarePte.Ltd.Member_e02993a2-d0f7-4650-a114-2ee4e2b70164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_782179af-8874-4430-ba6f-6bc54aa4a4ef" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_782179af-8874-4430-ba6f-6bc54aa4a4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_146c5744-6b9b-43f5-b8d1-f5328ee1a71a" xlink:href="dva-20241231.xsd#dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis_782179af-8874-4430-ba6f-6bc54aa4a4ef" xlink:to="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_146c5744-6b9b-43f5-b8d1-f5328ee1a71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember_7f6b1d31-7963-49a2-9189-7301ad8d844e" xlink:href="dva-20241231.xsd#dva_ForeignCurrencyGainLossTranslationAdjustmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain_146c5744-6b9b-43f5-b8d1-f5328ee1a71a" xlink:to="loc_dva_ForeignCurrencyGainLossTranslationAdjustmentsMember_7f6b1d31-7963-49a2-9189-7301ad8d844e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0f6b936-77f3-46a9-9af6-808c7ab0e9b2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_srt_RangeAxis_b0f6b936-77f3-46a9-9af6-808c7ab0e9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff2c2f93-38ea-4e69-b451-bbf8b4361885" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b0f6b936-77f3-46a9-9af6-808c7ab0e9b2" xlink:to="loc_srt_RangeMember_ff2c2f93-38ea-4e69-b451-bbf8b4361885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2fa39d97-ce4d-4152-8dd5-75279618dc86" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ff2c2f93-38ea-4e69-b451-bbf8b4361885" xlink:to="loc_srt_MinimumMember_2fa39d97-ce4d-4152-8dd5-75279618dc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1247fd40-bf6b-4d4b-aed4-9aff7f5242d6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ff2c2f93-38ea-4e69-b451-bbf8b4361885" xlink:to="loc_srt_MaximumMember_1247fd40-bf6b-4d4b-aed4-9aff7f5242d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5f336747-8b56-4923-8d52-f807a9865fe7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aa277501-d833-4a98-8bae-03de40a18ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aa277501-d833-4a98-8bae-03de40a18ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_dc8dcd7d-0a74-4fed-af1a-013c4461c501" xlink:href="dva-20241231.xsd#dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_dc8dcd7d-0a74-4fed-af1a-013c4461c501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_a36360d4-738b-4d39-a3ca-d6fe73f42719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_a36360d4-738b-4d39-a3ca-d6fe73f42719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_a25aa0d6-5f77-4e03-8701-8d8f3e50bc42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_a25aa0d6-5f77-4e03-8701-8d8f3e50bc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_e45cf259-b4f5-4350-be26-86e865bf220d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1f55c7ca-b663-4e00-94e3-33b1c56b3027" xlink:to="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_e45cf259-b4f5-4350-be26-86e865bf220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_36e40b7e-2347-46e1-af7d-4a874f2e2b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2241be05-b35e-4695-9345-fbcf3740ec78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_36e40b7e-2347-46e1-af7d-4a874f2e2b8b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2241be05-b35e-4695-9345-fbcf3740ec78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5e02d048-fd5e-48ef-8673-9396e1c86245" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2241be05-b35e-4695-9345-fbcf3740ec78" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5e02d048-fd5e-48ef-8673-9396e1c86245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6dd67cce-b453-4aa9-80eb-0959d16f7c80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5e02d048-fd5e-48ef-8673-9396e1c86245" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6dd67cce-b453-4aa9-80eb-0959d16f7c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_638c8304-a630-46da-bcb4-afe1df11a00a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6dd67cce-b453-4aa9-80eb-0959d16f7c80" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_638c8304-a630-46da-bcb4-afe1df11a00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_62293597-7311-4da1-8534-7c04b3a9ffdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2241be05-b35e-4695-9345-fbcf3740ec78" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_62293597-7311-4da1-8534-7c04b3a9ffdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4df9a4f-fcb0-495a-8505-642c8635679d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_62293597-7311-4da1-8534-7c04b3a9ffdf" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4df9a4f-fcb0-495a-8505-642c8635679d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_fb130baf-141a-4454-a3e1-99bf52c59975" xlink:href="dva-20241231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4df9a4f-fcb0-495a-8505-642c8635679d" xlink:to="loc_dva_DaVitaMedicalGroupMember_fb130baf-141a-4454-a3e1-99bf52c59975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2241be05-b35e-4695-9345-fbcf3740ec78" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_ba7eb5f1-fdbd-462c-8bed-ee601807aea4" xlink:href="dva-20241231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_ba7eb5f1-fdbd-462c-8bed-ee601807aea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_162ddbae-c845-4747-ac3d-abe9e5a43da8" xlink:href="dva-20241231.xsd#dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_162ddbae-c845-4747-ac3d-abe9e5a43da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_4c39bd55-ee90-4360-9a2e-60475b8f6086" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_4c39bd55-ee90-4360-9a2e-60475b8f6086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_23a8353c-90fe-476a-b125-f2102822c7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_23a8353c-90fe-476a-b125-f2102822c7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_4ea87dfc-bca2-4f99-b29e-82a319171383" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7f604844-977f-407d-8edf-56ccc3515130" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_4ea87dfc-bca2-4f99-b29e-82a319171383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#VariableInterestEntitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd31a15c-9b44-411b-8061-1d12b1d34e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46dac269-fd13-4c28-9b75-8f8a37fe1ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd31a15c-9b44-411b-8061-1d12b1d34e1b" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46dac269-fd13-4c28-9b75-8f8a37fe1ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6f733aa7-da72-4b93-bcc0-521588f61435" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46dac269-fd13-4c28-9b75-8f8a37fe1ff0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6f733aa7-da72-4b93-bcc0-521588f61435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8597657f-2eb9-45ca-8e95-682ffc1f7498" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6f733aa7-da72-4b93-bcc0-521588f61435" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8597657f-2eb9-45ca-8e95-682ffc1f7498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_525d09a9-0d93-4d60-a2fb-ca5d998c773e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8597657f-2eb9-45ca-8e95-682ffc1f7498" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_525d09a9-0d93-4d60-a2fb-ca5d998c773e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_64fafa83-1575-4061-bb0a-56ac6ab8463e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46dac269-fd13-4c28-9b75-8f8a37fe1ff0" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_64fafa83-1575-4061-bb0a-56ac6ab8463e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f3cb7d54-0383-4299-b7b5-76ea3ee140b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_64fafa83-1575-4061-bb0a-56ac6ab8463e" xlink:to="loc_us-gaap_Assets_f3cb7d54-0383-4299-b7b5-76ea3ee140b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_52a88fe3-751c-42bd-911c-01e66e1e09b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_64fafa83-1575-4061-bb0a-56ac6ab8463e" xlink:to="loc_us-gaap_Liabilities_52a88fe3-751c-42bd-911c-01e66e1e09b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_04d9160b-0e1d-4614-b0f4-a2caa500d922" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_04d9160b-0e1d-4614-b0f4-a2caa500d922" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_793b4240-8c5b-494c-b8db-adbace8c4657" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_793b4240-8c5b-494c-b8db-adbace8c4657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_88a9a8af-db5d-40db-81d9-b6a2f3d65416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_793b4240-8c5b-494c-b8db-adbace8c4657" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_88a9a8af-db5d-40db-81d9-b6a2f3d65416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9a0ef7c9-c5a9-4780-87ef-6086471cbbda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_88a9a8af-db5d-40db-81d9-b6a2f3d65416" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9a0ef7c9-c5a9-4780-87ef-6086471cbbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e192fac-30f3-4a4c-9eb3-b018beb79665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e192fac-30f3-4a4c-9eb3-b018beb79665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e192fac-30f3-4a4c-9eb3-b018beb79665" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7d8c0d80-425a-438c-9d35-02a88c787da4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7d8c0d80-425a-438c-9d35-02a88c787da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_50a276ea-db33-4ed9-bdef-bd4427fbe4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_50a276ea-db33-4ed9-bdef-bd4427fbe4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_77ed7bfa-42bc-47bc-a61f-0e317da4307c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_098d087f-5e51-4720-a521-63702602050a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_77ed7bfa-42bc-47bc-a61f-0e317da4307c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_433895eb-c762-43db-bf0a-3d11420b0479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_433895eb-c762-43db-bf0a-3d11420b0479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d059efb9-6375-4074-b4ab-7f36e9ac59a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_433895eb-c762-43db-bf0a-3d11420b0479" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d059efb9-6375-4074-b4ab-7f36e9ac59a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_1084bd11-cd19-4cab-ba53-6a620a323dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d059efb9-6375-4074-b4ab-7f36e9ac59a7" xlink:to="loc_us-gaap_InterestRateCapMember_1084bd11-cd19-4cab-ba53-6a620a323dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f78317d-b023-4dbf-b121-761b8877912e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d2b8716e-e2ef-43fe-8539-eb4db51bf94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d2b8716e-e2ef-43fe-8539-eb4db51bf94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_5043df74-a917-4c4e-8f76-12177f30c294" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d2b8716e-e2ef-43fe-8539-eb4db51bf94d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_5043df74-a917-4c4e-8f76-12177f30c294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_96858fe6-abe0-49a1-8f3f-e638e874722b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d2b8716e-e2ef-43fe-8539-eb4db51bf94d" xlink:to="loc_us-gaap_DerivativeAssets_96858fe6-abe0-49a1-8f3f-e638e874722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c29dcae5-12b0-4a5f-9103-f4d9454a4f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c29dcae5-12b0-4a5f-9103-f4d9454a4f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_90b89f43-45df-4f73-a1b2-18ee2a8a1344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_c29dcae5-12b0-4a5f-9103-f4d9454a4f9e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_90b89f43-45df-4f73-a1b2-18ee2a8a1344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_9c897b5d-a785-4657-bbc9-e8a6bb5ea37c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0ae70d96-1ba3-42a8-9601-f2e477690285" xlink:to="loc_us-gaap_TemporaryEquityAbstract_9c897b5d-a785-4657-bbc9-e8a6bb5ea37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_980efabc-b370-49e8-a619-8c3529f0255d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_9c897b5d-a785-4657-bbc9-e8a6bb5ea37c" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_980efabc-b370-49e8-a619-8c3529f0255d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#FairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_efe0f5c6-f147-4368-8fb3-1682f6c61259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_d00042e1-9dc0-4b3d-8fe4-6a7f7ad7f4dd" xlink:href="dva-20241231.xsd#dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_efe0f5c6-f147-4368-8fb3-1682f6c61259" xlink:to="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_d00042e1-9dc0-4b3d-8fe4-6a7f7ad7f4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a2f9fa93-0c97-4daf-99dd-af3eb8ec5800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a2f9fa93-0c97-4daf-99dd-af3eb8ec5800" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c7f816c8-fc3d-41b6-9fd5-f3df3bd3fdf8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:to="loc_srt_ConsolidationItemsAxis_c7f816c8-fc3d-41b6-9fd5-f3df3bd3fdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_33498bad-483c-45cc-9dbe-5a1726b46447" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_c7f816c8-fc3d-41b6-9fd5-f3df3bd3fdf8" xlink:to="loc_srt_ConsolidationItemsDomain_33498bad-483c-45cc-9dbe-5a1726b46447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4bec5b50-4145-449a-8eda-ab9f59c953db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_33498bad-483c-45cc-9dbe-5a1726b46447" xlink:to="loc_us-gaap_OperatingSegmentsMember_4bec5b50-4145-449a-8eda-ab9f59c953db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_68baecb0-713d-4694-ba31-eed03db04cea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_33498bad-483c-45cc-9dbe-5a1726b46447" xlink:to="loc_us-gaap_IntersegmentEliminationMember_68baecb0-713d-4694-ba31-eed03db04cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7bab60c8-88e6-4cb7-bfea-de7cdc108a01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7bab60c8-88e6-4cb7-bfea-de7cdc108a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7bab60c8-88e6-4cb7-bfea-de7cdc108a01" xlink:to="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_d9900676-13bc-494a-8370-d992839ec507" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_d9900676-13bc-494a-8370-d992839ec507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_98002beb-74c6-4922-9146-bd6e5bf8a457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:to="loc_us-gaap_AllOtherSegmentsMember_98002beb-74c6-4922-9146-bd6e5bf8a457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember_54569fb9-79fe-4f19-9609-4b0f6a1151a9" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesWithIntersegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:to="loc_dva_USDialysisAndRelatedLabServicesWithIntersegmentMember_54569fb9-79fe-4f19-9609-4b0f6a1151a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherOperatingSegmentsWithIntersegmentMember_f8dde8be-2d14-4b62-9e06-d7ee9f7ff68c" xlink:href="dva-20241231.xsd#dva_OtherOperatingSegmentsWithIntersegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3db7ff7e-51e9-49cf-b37d-833c3417e91a" xlink:to="loc_dva_OtherOperatingSegmentsWithIntersegmentMember_f8dde8be-2d14-4b62-9e06-d7ee9f7ff68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_27e3fddb-11e4-4bab-8c36-39603b1492bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_27e3fddb-11e4-4bab-8c36-39603b1492bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_e5862e4d-5644-4aac-b0e1-e9dc9c63fbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_27e3fddb-11e4-4bab-8c36-39603b1492bc" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_e5862e4d-5644-4aac-b0e1-e9dc9c63fbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExternalSourcesMember_5609a41b-cd9f-49fa-a6e1-cf2842829092" xlink:href="dva-20241231.xsd#dva_ExternalSourcesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_e5862e4d-5644-4aac-b0e1-e9dc9c63fbc4" xlink:to="loc_dva_ExternalSourcesMember_5609a41b-cd9f-49fa-a6e1-cf2842829092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersubsegmentEliminationsMember_2cd43cbd-6cee-4403-81b0-1f87e416662a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntersubsegmentEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_e5862e4d-5644-4aac-b0e1-e9dc9c63fbc4" xlink:to="loc_us-gaap_IntersubsegmentEliminationsMember_2cd43cbd-6cee-4403-81b0-1f87e416662a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ff4a3a4-069e-4bd8-b3a9-d5935f97f52e" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3d726f07-9be1-481b-b759-ed3055fe999e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3d726f07-9be1-481b-b759-ed3055fe999e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_b9fd8cb5-11e1-44d7-b8f5-10f7bb19d1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_OtherIncome_b9fd8cb5-11e1-44d7-b8f5-10f7bb19d1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0a528013-3b02-4f60-b0ac-496bff1dca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_Revenues_0a528013-3b02-4f60-b0ac-496bff1dca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_59a00326-9c6e-4f70-97c3-18aa05a75da3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_OperatingIncomeLoss_59a00326-9c6e-4f70-97c3-18aa05a75da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentReportingInformationCorporateExpenses_07e951d1-0ce2-46c4-9912-217cba816c72" xlink:href="dva-20241231.xsd#dva_SegmentReportingInformationCorporateExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_dva_SegmentReportingInformationCorporateExpenses_07e951d1-0ce2-46c4-9912-217cba816c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_76f459aa-41f4-45a1-a55c-023083fca8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_InterestAndDebtExpense_76f459aa-41f4-45a1-a55c-023083fca8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_6d8c6ef4-ce69-4a5b-bc95-bba02460f9ac" xlink:href="dva-20241231.xsd#dva_DebtPrepaymentExtinguishmentAndModificationCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_dva_DebtPrepaymentExtinguishmentAndModificationCosts_6d8c6ef4-ce69-4a5b-bc95-bba02460f9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9fd2fd0e-f780-4164-a32d-ffadafd8f533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9fd2fd0e-f780-4164-a32d-ffadafd8f533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8b79d81-75f2-4efe-90c0-518dd7ea2b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8b79d81-75f2-4efe-90c0-518dd7ea2b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1072cf80-473e-4e1b-b151-62f1d5ad5f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1072cf80-473e-4e1b-b151-62f1d5ad5f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3d62d197-7e2e-4315-bdf1-a42a7417fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_1072cf80-473e-4e1b-b151-62f1d5ad5f33" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3d62d197-7e2e-4315-bdf1-a42a7417fe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts_fe363fd1-ad1c-45a4-9e89-a275644819fa" xlink:href="dva-20241231.xsd#dva_PatientCareCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_dva_PatientCareCosts_fe363fd1-ad1c-45a4-9e89-a275644819fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_125d1ba5-60d4-4164-ae2b-11604a992dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_125d1ba5-60d4-4164-ae2b-11604a992dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_967b88f7-ffb6-4843-a7b2-5ab87bb72346" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_967b88f7-ffb6-4843-a7b2-5ab87bb72346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9b097fc1-290b-4774-a706-6a8aeab9f93e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_CostsAndExpenses_9b097fc1-290b-4774-a706-6a8aeab9f93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b44a1b59-5a95-4970-b093-ffa84e319915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30938b16-8253-4bb4-a020-96181bc90b8b" xlink:to="loc_us-gaap_DepreciationAndAmortization_b44a1b59-5a95-4970-b093-ffa84e319915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f75c77e5-4c34-4d19-b9f8-b6187a1ccf00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a2f9fa93-0c97-4daf-99dd-af3eb8ec5800" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f75c77e5-4c34-4d19-b9f8-b6187a1ccf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_340f66b3-7435-4b27-a257-0d9a7fbbd735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e65ca44-3191-4e2f-ad98-6e00e3bfc5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_340f66b3-7435-4b27-a257-0d9a7fbbd735" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e65ca44-3191-4e2f-ad98-6e00e3bfc5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f17e121a-7aaf-402a-a15c-3ae743d2b0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e65ca44-3191-4e2f-ad98-6e00e3bfc5f9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f17e121a-7aaf-402a-a15c-3ae743d2b0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2dc08ade-c372-4273-80d7-3697272a74e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f17e121a-7aaf-402a-a15c-3ae743d2b0f2" xlink:to="loc_us-gaap_SegmentDomain_2dc08ade-c372-4273-80d7-3697272a74e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_39bc5cb3-e627-46f9-b5d7-3a26dca59cb3" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2dc08ade-c372-4273-80d7-3697272a74e9" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_39bc5cb3-e627-46f9-b5d7-3a26dca59cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a5bebc7c-039a-4ba3-bb79-a0645218e86d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2dc08ade-c372-4273-80d7-3697272a74e9" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a5bebc7c-039a-4ba3-bb79-a0645218e86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c667cbb7-355f-411e-a1c7-cc03399d1896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e65ca44-3191-4e2f-ad98-6e00e3bfc5f9" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c667cbb7-355f-411e-a1c7-cc03399d1896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d12b045c-df3c-457e-988b-3154524d8268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c667cbb7-355f-411e-a1c7-cc03399d1896" xlink:to="loc_us-gaap_DepreciationAndAmortization_d12b045c-df3c-457e-988b-3154524d8268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_081e1937-f0d4-4abe-8769-277b4c44df37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f26d0467-3ccb-4d2f-826c-f0c98c561b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_081e1937-f0d4-4abe-8769-277b4c44df37" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f26d0467-3ccb-4d2f-826c-f0c98c561b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2f725a03-cce7-42c3-b77b-1822f6621daa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f26d0467-3ccb-4d2f-826c-f0c98c561b47" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2f725a03-cce7-42c3-b77b-1822f6621daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bbe67b1b-ed59-416f-8932-647860f7a610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2f725a03-cce7-42c3-b77b-1822f6621daa" xlink:to="loc_us-gaap_SegmentDomain_bbe67b1b-ed59-416f-8932-647860f7a610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_9ad93985-e9dc-453b-a2c0-05f68bd70fb7" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bbe67b1b-ed59-416f-8932-647860f7a610" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_9ad93985-e9dc-453b-a2c0-05f68bd70fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_d7ef469e-8361-469d-b7d4-2e8639783b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bbe67b1b-ed59-416f-8932-647860f7a610" xlink:to="loc_us-gaap_AllOtherSegmentsMember_d7ef469e-8361-469d-b7d4-2e8639783b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d7500c7e-5d83-49a4-89dd-a64d414b756e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f26d0467-3ccb-4d2f-826c-f0c98c561b47" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d7500c7e-5d83-49a4-89dd-a64d414b756e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_93146b4e-4e42-4f71-bb3a-5fba7291241c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d7500c7e-5d83-49a4-89dd-a64d414b756e" xlink:to="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_93146b4e-4e42-4f71-bb3a-5fba7291241c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingSummaryofAssetsbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_93bc7a95-45cc-46b6-8a59-dfbf35e18427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_83a060e4-d8dc-48de-973e-6cae332e2fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_93bc7a95-45cc-46b6-8a59-dfbf35e18427" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_83a060e4-d8dc-48de-973e-6cae332e2fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8e2cbdf1-ff24-4f6c-ae5f-334a9f97dad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_83a060e4-d8dc-48de-973e-6cae332e2fa7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8e2cbdf1-ff24-4f6c-ae5f-334a9f97dad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_228a49cf-d67d-433c-b7d3-ec2678f7cdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8e2cbdf1-ff24-4f6c-ae5f-334a9f97dad5" xlink:to="loc_us-gaap_SegmentDomain_228a49cf-d67d-433c-b7d3-ec2678f7cdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_66e1895c-3099-4319-92ce-7d7aec33eb6f" xlink:href="dva-20241231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_228a49cf-d67d-433c-b7d3-ec2678f7cdbd" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_66e1895c-3099-4319-92ce-7d7aec33eb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_fa4c8966-b613-4e35-8643-b94fd6013f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_228a49cf-d67d-433c-b7d3-ec2678f7cdbd" xlink:to="loc_us-gaap_AllOtherSegmentsMember_fa4c8966-b613-4e35-8643-b94fd6013f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e5729f65-ec2c-47c9-80b5-f9a540c71bb7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_83a060e4-d8dc-48de-973e-6cae332e2fa7" xlink:to="loc_srt_StatementGeographicalAxis_e5729f65-ec2c-47c9-80b5-f9a540c71bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_df56b135-d5bc-4e14-9b81-5b83b387871a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e5729f65-ec2c-47c9-80b5-f9a540c71bb7" xlink:to="loc_srt_SegmentGeographicalDomain_df56b135-d5bc-4e14-9b81-5b83b387871a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_d5426520-c7d2-4731-99e2-74b1868b5ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_df56b135-d5bc-4e14-9b81-5b83b387871a" xlink:to="loc_us-gaap_NonUsMember_d5426520-c7d2-4731-99e2-74b1868b5ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9dc21de6-7c34-4c1a-aa96-3eb02d1f019e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_83a060e4-d8dc-48de-973e-6cae332e2fa7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_9dc21de6-7c34-4c1a-aa96-3eb02d1f019e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9dc21de6-7c34-4c1a-aa96-3eb02d1f019e" xlink:to="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_75526cee-b6f1-4e41-95f7-e170d6eea168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:to="loc_us-gaap_Assets_75526cee-b6f1-4e41-95f7-e170d6eea168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7c811a85-13eb-4e5f-9919-bb62435919cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7c811a85-13eb-4e5f-9919-bb62435919cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e7a02409-a251-4f1a-bed2-91545cb0d17b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4f399ce-8179-4e75-a5dd-7523d8686050" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e7a02409-a251-4f1a-bed2-91545cb0d17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2369634c-d109-4fcf-b08d-509a7754da14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7440bbab-148e-4760-b9bf-5b43da7060b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2369634c-d109-4fcf-b08d-509a7754da14" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7440bbab-148e-4760-b9bf-5b43da7060b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_de8552f1-bc71-4315-b1b2-cd28cb9697f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7440bbab-148e-4760-b9bf-5b43da7060b7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_de8552f1-bc71-4315-b1b2-cd28cb9697f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00d8452b-aa14-4a7f-a921-cd211ac293e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_de8552f1-bc71-4315-b1b2-cd28cb9697f2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00d8452b-aa14-4a7f-a921-cd211ac293e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_3feca224-d083-45fe-b626-bcf878c4070c" xlink:href="dva-20241231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_00d8452b-aa14-4a7f-a921-cd211ac293e8" xlink:to="loc_dva_DaVitaMedicalGroupMember_3feca224-d083-45fe-b626-bcf878c4070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bd6b69d2-3c9f-479c-aa14-ac4eef80267b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7440bbab-148e-4760-b9bf-5b43da7060b7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_bd6b69d2-3c9f-479c-aa14-ac4eef80267b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_d6d4c099-22fb-4c56-8573-d1f9e94e8e66" xlink:href="dva-20241231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bd6b69d2-3c9f-479c-aa14-ac4eef80267b" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_d6d4c099-22fb-4c56-8573-d1f9e94e8e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="dva-20241231.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_0fa888f9-78a4-4ff2-9d62-adb538a2723c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CashPaidDuringPeriodForAbstract_535d6d13-18b0-4899-94de-808324624861" xlink:href="dva-20241231.xsd#dva_CashPaidDuringPeriodForAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0fa888f9-78a4-4ff2-9d62-adb538a2723c" xlink:to="loc_dva_CashPaidDuringPeriodForAbstract_535d6d13-18b0-4899-94de-808324624861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_6209d73e-ff26-4661-b9e4-2980d9222e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CashPaidDuringPeriodForAbstract_535d6d13-18b0-4899-94de-808324624861" xlink:to="loc_us-gaap_IncomeTaxesPaid_6209d73e-ff26-4661-b9e4-2980d9222e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_6eece38e-c640-424e-b048-7b40bb0ef162" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CashPaidDuringPeriodForAbstract_535d6d13-18b0-4899-94de-808324624861" xlink:to="loc_us-gaap_InterestPaidNet_6eece38e-c640-424e-b048-7b40bb0ef162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_37cbfd5d-cddb-4a52-81a6-280c9ab14c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0fa888f9-78a4-4ff2-9d62-adb538a2723c" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_37cbfd5d-cddb-4a52-81a6-280c9ab14c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_745e8281-f97c-4412-bd70-714115bcd245" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_37cbfd5d-cddb-4a52-81a6-280c9ab14c17" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_745e8281-f97c-4412-bd70-714115bcd245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>dva-20241231_g1.gif
<TEXT>
begin 644 dva-20241231_g1.gif
M1TE&.#EA)026 ?<         ,P  9@  F0  S   _P K   K,P K9@ KF0 K
MS  K_P!5  !5,P!59@!5F0!5S !5_P"   " ,P" 9@" F0" S " _P"J  "J
M,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5S #5_P#_  #_,P#_9@#_F0#_
MS #__S,  #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5
M,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J
MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MVCG$_QL"?PX6(?:)C28HJQRX@8\'AK]9=96'G Z; V^@"0O,9BF!>-'0;S\
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MD1Y'VIR95NU:MFW=OH4;5^Y<NG7MWL6;5V];L_MPDHRV# [&B1<A_"AH8:%
M@3C@A-K7%^W'O94MPYP\,EJT'Q,K2*08D: %AP]TC$Z<&O7J@:(=BK80NS7B
M-\M0]KV<6W=E:#E7ZILGKV?3IDJI+CV.U>A4K5>A*F?_'BQKU'7DMBJ5NBZ8
M,'TU3^K#O5O\>/+ES9]'GU[]>I+T*$?>%RK-1HP0"JL6C?%'FO#L_:?MCZ7
MX,B!,(D(.LB@A!1*+$&$&&0-P8HB6BBCA"C"" >.S%+F+)PR^R_$$*.Q29]\
MVM%N'6"PRRX[=9[*KCFC9'R.JI^:TTJYY:C3#CFF@D&&K+\^"E!$(X]$,DDE
MEV12+_!*\@@.Q&2SH# =+K3OLP=R^ $.3<Z"4K,FU3,KP  G\RB:4.!P@*($
MJL1(MM!:4TW!_%A[K4+2J#3( L0>V&^SF\ <LU"W>B-IR/?")*D[8=9AAZFO
M=*G.1^B*TS$I&EOT,3E,GUO._Z=UYDEF4$-/135555=E]:X/X=LG#2OIO"@V
MU+:LK54E2_QMT6@V26-+!$D#PKZ!<H"HSEKMK.BS'RB,LZ ^,_IA$_A U#5;
MM7#KCAUAGL(N*1\WM<Y&YSC=L47BTCU.NJU\$F:>[F#U2UM[[\4W7WW%$\FV
M4 J4Z"!C$00"0<1R> ,41O<M#]N6RMKG% (KN%):PT*K*,*")J2XH(;VS#.B
M+1V  U;W/%*48593]JTW]\YJY]M/C6.71TT]+9>XFW<L"BEWM^*9J:'6B7?>
M>E5&.FFEETZZ'H]"P>&'SX8E# *K07/@!TUL.RE-WQ9F&L!>%Z476U#4 %1D
MTC862)7"UU(+>6IF&_(82X(*_,&V\!P.^S^63\+I;\JZFT<8GE)$BL6B<K3T
MQDR-LD['H8$6UZG*U]5.&++ZYKQSSS\?<1]-'"@8-#@-&JB"8G/@J*27CS;I
M+[Y!IRFFS#;3!.#[GIWSP<_BCAONC!-C"#$<.J+]7K1P<T^?=@KO446BT(4J
MYW.OO]0Y[)<BQRJM>BHZ>?'')_^__&WW&6PB:=6W@ /4M_Q!X3--7:E(\P44
M$UNN3UJS/HC^#YFR6@/ "UD@!PJY4H(PD@,U" HG]KO?96:'$L&9!#CS.!RZ
M@E:C[$1N<5>IF;MLM"Y0B>LYPDB&=R*X0A:V4%<H.PNWQ!2-,=#'00#['1 J
MP#J%I01$*2N3"PD%JR#Z$# G>5F:XH"8.]4)0M%:30#=EIHY)<: .\0!O<"F
MJ+V!38@SD5U, O<=X$3*7***7,W4N)RA)<<Y0]D>IN#%CLS89$@0_&(>];C'
MO$S&-M#X2V!^@*PGI@XT&<H$'OF(GF44(0?#BDBQ*G2A9STR-00$'@ QAI$O
M><2.1R3_FYCHMTB73% M:!$5<S9XJ>Q!9U,:C",(M:,/]P026Z8D92YUN4N8
M1,-I&)I3P9;%I31T2)2\3,]FU- F(\SI(05:6WXJD!#49-*:PT.81_;GRR&.
M39'(A(M9]&'&HL#H<1X\IXLT>*-SJ=&-3!D&6D)2DD""TY[WS&61T (*TZ".
M-%@Z5@4<PSQ\ZL9,R_A!FT9#-]0\ZW\"G*+;AM?0+>6@A\:4ITF^65"ZE$@8
M[<Q9IA@W/7,]KJ0V6R>HN*,/1''4I2_EI6TT$:V' B&A_%')ZV#:1R@M VT_
M, Q$WA;1:#T13P6L&^H^PSK(O.>.1MRI7N;QJ9%.9X1!<U%5_]G9HIQ9;Y54
M$54R=/J=J);5K$L#$5H& ]367*1T0-@(\LXJP?P=D4!Q2I"#Y(94C6E,3QO+
MTT0HE ,X>+(E,O0++N?:DGG R%-?_: Z.6C53ZDQI":-2C#D,=:,+M:SG\V7
M1X)ED(]M3".%%2=H];(_%48#%$"U9)XPQM#9#H^V?25>P![@&*Z!1+65H<>C
MBM,I6!97G=3#5'$MY<9RTE$S(JG@;Z4[725Q)@>>44V!<# &4.POL;>A;EI
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MA'01GQ@&@OV/92"<#)J.[<@'M7S:K.7;OBW8$"R0L+68GBRJK@.LAW+4=TN
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M)G 1FLB&EH*6X_^6YG_V;-U9K9?$;)C>'L#I!BCBI(WI36EQR \<0 2:BC+
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M[,"$,%.KP?\VK_,R^L++1IW.*3TQ!5.\DT5T1,OT%4CD'<*6%61JV/=FU;@
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M:[--(]V3[+)9'1,2R(IRR"35P9*D<+:;HH'#("!Z*C'26V5UDTT"320//<>
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M8.F".!'63Z+2JHMPZ@%3C :-S(C!J[S,8$"B7<$BHQ[%^"0CF%J*1)@%2:4
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MTI"([C%2U$"%G[',=B8EQHE@P *'_CW%;U-SWJ6LR<7_$"D'IYTJ="?4))5
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M+@B%#G1<;(OD8@D+H[.V[]QJ1VLBI2!8%3S/)A163'M@;BX!DS6?4BZU%&3
M\O^B8=(: L#4(RM]9"4S+3]=\V"HT*+_0";U.%0CP^.W&I!%SW5VAJRTD(E
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M6PFIC\B$N6,QUK SI9LV?B$VH7&3_H*RZ+L4=+,(H&.,'X@LK$ T!CR>4%-
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M/YD<.-&L0..9)&0!"1E;SJV:.NYZ5.+<JI+$4]>#@RP\EE1+.J)CS+1*F)E
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M5%NO)8\+]K02WE0PJAWAX+2_^\"T'CUFO7FCT#%_[5QK."T$ 5O[;>@D#FJ
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MZ#W,HJT&C+3@_^U=E9C0 !*3\^3?#K965&27;KB.\(T-YWF:5W$=U3AAMSS
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M] 23[%')M6PA!/'E\UUH('Y5"RU529BH*_I<]*D@5V@+^B2:9.Y9B119=N"
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M6*UZL$VYJ@*]!?5(Q@]@*E6^B(E6ZQGRW$0]0+L*)_CMPR;D(P._V10;,6H
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M.?GF&TSTC%5Z=Y*N2F7XH):<8[-]2,.BM"AK+"<M'66*5EC(4L0\"ZG-MF8
M[W-E+?+P2(FA*[<FLAQ2<I>']PI3.9>Q]O1JA[XN;F]5\.Q2D]\.8=NPF=G_
M#=.S# Y/SI-HBU-*F(JFZ^UI7Q:E^,FMASDJAM-LW$$"SPRJAS-:!@?^8JOZ
M#$YE]^NV*NV9-3"%L*WW.;=7-YO/G)@AL5/#@RA):T=NK'=Y%"1\SHC[=-M1
M+CB+SE9<192X;RI<T/=O "<':Y4WAV*4EO0R\O#Z9B+ F3C0O-40HT]_/VM8
M&E \IK9.W;*+E77" &ZN[\W2?N^_%?8(-3FC3WP;87IDWF*XAQ6%Q%KHLO=
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M5X>VJ60>  $HTMMG512/JC0MQ<3\#3G_)P3KF$>E]J%[6+L[F7;J,.KV'B"
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M&&!"N<[N>"%!ED7Q!QB P2Y8-BVHFLS]F%0(@5E4"DDAL<3#83O_L6:PD*5
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*!]G,9Q9R0   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>dva-20241231_g2.jpg
<TEXT>
begin 644 dva-20241231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%,.B?%KPQ=_LM:YH3>&K><J/[8T^Y_L^(I!$2Q:"YDN&V@ RY)D35T']J?\
MX*7?$S_@KC\9_P#@GSX?^,7PWTCP_P"&OAEIFO>&_$B> IG?24NYH\R-:O=L
MU[= ,T(+3PP#_7&(X\A@#]#J*_-/]BS]HK_@J_\ M+?%#]H7]@#Q+^TKX TK
MQ9\"_&MG97'QR3X=K/=:CI]_;//91Q:,)H[5)\1NTDS2,B+MC$4K,9DL_LI?
M\%D/B1X#_P""7O[07[4G[<EOI>N^+OV9OB?XA\!Z_>^';86$'BJ_L9;6&SD2
M/YEMC<3WD,)P"JD%PO.V@#](Z*_/_P#:J^,__!3G]EG]@F#_ (*/V7QE\/\
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M2QN(X59A$LEDML^PLS+OPQ+9- 'I-%%% !1110 4444 %%%% !1110 4444
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MXQA7E&.R;_,_JC#SE4P\)2W:3_ ****R-@HHHH **** "BBB@ HHHH ****
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M $!5?_!<_P#(/]:.&?\ H.H_^#8?_)'U;17RE_P^[_X)?_\ 1SG_ )9>M?\
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MF_P/YMZ*_H'_ .'(G_!+_P#Z-C_\O36O_DVC_AR)_P $O_\ HV/_ ,O36O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !1110 5^$_P#P<"_\I#;W_L4-+_\
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MNNK^+L5_O,_5_F?W!A/]TI_X5^04445@= 4444 %%%% !1110 4444 %%%%
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M0_8_U/\ X5+XX\#2)H/B.]\21)K8L;AT6SUB723#MCL96,4@(N6N%BD61X%
M8* ?<WQ@_;T_9*^ 7[/WAG]J?XP?&*VT+P%XQFTJ'PWX@N=,NV6\?44#V8\I
M(6E3>AW'>B[%#%]@4D>OU^?OQ+_;X\#?L#?\$L_V:_&OQ0_9=UOXB:+X@\+>
M!]&@GM6T[[!INH365M]FDN/M$IF4AD+H\4$@#(H+(2I/T)^TK^W39?!C]I3X
M<_L9?#?X<-XM^)WQ-L=1U'1M.O=7_LS3-/TZQCWW%W>7@AG= 20B)%!,[-G(
M4#<0#W+Q#XB\/^$="O/%'BO7+/3-,T^W>XO]0U"Y6&"VB49:221R%10 222
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MPD\,>(+N" 0P76MZ#;W<D<8)8(K2HQ"Y9C@<9)/>K?ASX:?#GP?X:G\%^$O
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ME/\ $3X6_P#!4SXI_!W1;C3;*"U^'G@:PL)-+THPVT<3K TL88JS(6Y &6X
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M2OB-%\ +B'3=&^-MO9I:KX@M[G29;N6WNBIV?:K.+[.)LEG1I]KNY7>WA?\
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M!?P+MKVS^"/P7\)^#H=1F$NH1>%?#EKIZW4@SAY!;H@=AD\MD\FNLH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\)_\
M@X%_Y2&WO_8H:7_Z#)7[L5^$_P#P<"_\I#;W_L4-+_\ 09*_2O"K_DIW_P!>
MY?G$_,/%O_DE5_U\C^4CXCHHHK^CC^9@HHHH **** "BBB@#^H;]G_\ Y(/X
M)_[%'3?_ $ECKKJY']G_ /Y(/X)_[%'3?_26.NNK^+L5_O,_5_F?W!A/]TI_
MX5^05^<G_!SKJ'Q?\!?\$X+_ .+_ ,)OVB_''@Z;2_%>A6=WI7A;58[*WU*"
MYOT@E2XDCC%RP*R\H)EC.P90Y.?T;K\[?^#I;_E$#XI_['CPO_Z=[:L#H/T!
M\7>+/#?@+PIJGCKQEK4&FZ/HNG3W^JZC=/MBM;:&-I)97/95168GT!K\\_V*
M/VC;;_@JUXB_X:K_ &EOC:/!7PH\0ZW=:?\ L_\ P+C\7_V/<>)[&WG>W?6M
M62*6.?47GFCD2*RR;:-8R2DS,)*^@O\ @L_X9\>>,?\ @D_^T)X<^&MO<3:O
M<_"G5_*M[1299X5MV:>)0.6+PK*NT<MNP <XKXX\-?L!_L+_ !T_X-DM%U73
M?@YX0MM2A_9F@\3Q>-+31H(]0M/$EEHPN9+PW:J)=ZWD+H_S\QAX_N\4 >Y_
MMPZGJ6I?\%,_V2/V"WLI-+^#_B?2?&&KZ]X<TR1[2SUZYTO34-G82B$KO@@,
MIN#;YV.PC+JP0"HO^"/G[3FI>'/V7_VAQ\?_ (DW4G@;X _M%>.?"OAGQ;XC
MU"2YD7POIDL<L'F7$A:2X$*RR0JY+$K$B#)7%=7_ ,$X/AFW[:W_  2Q_9P\
M?_MJ>']0U;QK8^#-/UG3O$C:K=V&L6MP;=X8;Z*^M9(KF&:>S=?,=)%,JS.'
MW!B#;^'/P/\ A-\4_B;8_LO_  ,\#V>B? /X%^(%N?$%C9;F@\5>,DE%TEH\
MCEFN8K&9UO+J5V=IK]X%9RUM<HP!Z9^R%X-^)'B[4=;_ &O/CKIFH:5XF\?0
M0QZ!X0OG(/A+P[$6:SL'CR56\EWM<W;#GSI1!N9+6(U[E7Y(^,_^"J7[6&E_
ML8?%#_@K#:?$R[BT3X??M,'PG8_"9=+L_P"SKOPG!JMKI4D,K& W7]H2&X>Y
M\\3 (Z(BIY89'_6Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *_"?_ (.!?^4AM[_V*&E_^@R5^[%?A/\ \' O_*0V]_[%#2__
M $&2OTKPJ_Y*=_\ 7N7YQ/S#Q;_Y)5?]?(_E(^(Z***_HX_F8**** "BBB@
MHHHH _J&_9__ .2#^"?^Q1TW_P!)8ZZZN1_9_P#^2#^"?^Q1TW_TECKKJ_B[
M%?[S/U?YG]P83_=*?^%?D%?G;_P=+ '_ () ^*"1T\<^%\?^#>WK]$J^ _\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\)_\
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M** "BBB@ K\)_P#@X%_Y2&WO_8H:7_Z#)7[L5^$__!P+_P I#;W_ +%#2_\
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M1'\/W]E'I[ZXUW.$^VQFV:2^67[/#'*9Y'( PFW&" ?;G[<'[5GQ:_9A\0?
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MH>3[O\-^(M$\7^';#Q;X:U&.\TW5+**[T^[B^Y/!(@>-USV*L"/K0!=HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OPG_X.!?\
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MM/\ BG\4?BCI6F:%K%W:VFA7JS&X.KW-S_Q[V]G'"'DO)I1RD<*N[@$J" :
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M;\7>+?V<_P!H_P /^*;'P'D^,'LVECDTI CN))8Y41Q&5CD*R!2C>6VTG:<
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M9>'/^@VE_P"#(?YG\\_ZK\3?] -;_P %3_\ D3Y2HKZM_P"'(G_!4#_HV/\
M\O31?_DVC_AR)_P5 _Z-C_\ +TT7_P"3:/\ 67AS_H-I?^#(?YA_JOQ-_P!
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M&Q_^7IHO_P FT?\ #D3_ (*@?]&Q_P#EZ:+_ /)M?OG^LO#G_0;2_P#!D/\
M,_GG_5?B;_H!K?\ @J?_ ,B?*5%?5O\ PY$_X*@?]&Q_^7IHO_R;1_PY$_X*
M@?\ 1L?_ )>FB_\ R;1_K+PY_P!!M+_P9#_,/]5^)O\ H!K?^"I__(GRE17U
M;_PY$_X*@?\ 1L?_ )>FB_\ R;1_PY$_X*@?]&Q_^7IHO_R;1_K+PY_T&TO_
M  9#_,/]5^)O^@&M_P""I_\ R)\I45]6_P##D3_@J!_T;'_Y>FB__)M'_#D3
M_@J!_P!&Q_\ EZ:+_P#)M'^LO#G_ $&TO_!D/\P_U7XF_P"@&M_X*G_\B?NS
M^S__ ,D'\$_]BCIO_I+'73ZI_P @VX_ZX/\ ^@FL3X/Z#JOA;X2^%O#&O6OD
M7VG>'+&UO8-ZMY<L<"(Z[E)!PP(R"0>QK=OXGFL9H8ERSQ,JC/4D5_)-=IXF
M36UW^9_8>&C*.%@FM>5?D?C117L__#O?]K[_ *)%_P"5_3__ )(H_P"'>_[7
MW_1(O_*_I_\ \D5^T_VME7_01#_P./\ F?AG]CYO_P! ]3_P"7^1XQ17L_\
MP[W_ &OO^B1?^5_3_P#Y(H_X=[_M??\ 1(O_ "OZ?_\ )%']K95_T$0_\#C_
M )A_8^;_ /0/4_\  )?Y'C%%>S_\.]_VOO\ HD7_ )7]/_\ DBC_ (=[_M??
M]$B_\K^G_P#R11_:V5?]!$/_  ./^8?V/F__ $#U/_ )?Y'C%%>S_P##O?\
M:^_Z)%_Y7]/_ /DBC_AWO^U]_P!$B_\ *_I__P D4?VME7_01#_P./\ F']C
MYO\ ] ]3_P  E_D3_P#!.W_D[?PU_P!<+_\ ](YJ_2ZOAS]C']CW]HSX3_M%
M:'X[\?\ P[^P:59Q78N;K^U[.787MI47Y8YF8Y9@.!WK[CK\XXNQ&'Q.9QG1
MFI+D2NFFMY=C].X,PV(PN5SA6@XOG;LTT[6CW*>N:_I'ANS&H:U=^3"9 @?R
MV;YCD@84$]C61_PMKX??]#!_Y*2__$4WXJ:!J_B3PTFGZ+:>=,+M7*>8J_*
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MAF!Z$5V8&485[R=M#BS"$IX>T5=W/-:*Z/\ X5+\0?\ H7__ ";B_P#BZ/\
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MA_%75_ $<J^ [KXFZ]!>C07DB\EYXDM[>!9KDQ$Q_:K@37"JSA9!O?='K/\
MP3[\,+\:?'WQU^&?[2'Q6\":M\3[FUG\;V7A;7[-K*_DM[&"PC>.&]L[@6DO
MV>VB4SVWE3':#YGRKM /S?\ ^"@WQ1_9;_;._P"";G_!/#XF? CX<-I7PX\1
M?M9>!]&TWPUJ: 2:=90G4K&YTYF!Y2.2WDBRIPPC5AVKUC_@OM^SKX*\'_%+
M]BSX\_L_^!].T7XF:/\ M1^&?"WAZ;0;".VEETBX6>6>V<1 ;K=/LL?RM\B)
M+*.!(V>4_P""^_PD_9*_9S_9J_8S_8Q\)7NE>#/!NB?M6>#XUT*T\1-9W-CH
MBI?I=7OG^:)X\-,7>[WAA))O+[SFOT ^'O[%7PTE^*?AC]I#XA_&'Q=\6-?\
M*Z=/'\/M8\9ZA8S6^A0W482::TBL+6VA>:6(*ANY5EG,9*B7:[!@#Y9\8V=K
M!_P=4>$;F"W1))OV*KDRNJ@%R/$EP 3ZG%3?\$O_ /E-S_P49'?^V/AG_P"F
M.]KZ2U;_ ()S?"'6?VX[+_@H;=_$;QR/B1IV@_V!9W$>L0"QCT4S/,=-^R_9
M]A@+R.2QS+EMPD# ,(I?^"8O[+A_;7U?]O2R@\56/C/Q'%IO_"4:;IWB^[M]
M&URXT]52QNKVQC<17,L 1/+\S**R*^S>-] 'YU_&#6/ OQ<_X(A_M4>,/V /
M"&D>$O@!>S^+]4.L>*9KK6-:\:ZE]H)O;NVC>9$TNU-Q&%A>5KB5TCR88"5<
M]#_P5[GEN?\ @V,^$ES/*7>3P[\+F=V.2Q(T\DFOJ'P[_P $!O\ @GUX9\'_
M !#^%=A9^/G\!_$62^GO/AO-\0;T^'M(NKM2LEW8Z>&$,=PORM')()3$R(4V
M[5QT7Q$_X(P?LB?$[]C7PY^P9XE\0_$(_#KP]<6MP;)?&<LEYJ4]LD<=K)<W
MDJO.PA2*-(HD9(8TCC18PL42H ?6M?G/^W!9VD?_  <7_L/7T=NBS2^"?B&D
MDH4;F5=(<J">X!=B/]X^M?H-X0T"[\+>&K/P]?>*=2UJ6TA$;:IJYB-S< 'A
MI##'&A;&!D*,XR<G)/B'QC_X)R_"'XW?M=^#/VW?%/Q&\<VOCOX=VUQ;^")M
M+UB"*TTF"XB:*YC6W-NR2B9'<.9O,8[L @*@4 ^6?@;X%\&:M_P= ?'/Q#JG
MA73[F^TS]GSPY=:==7%HCO:W#2QP&:,D?)(8LQ[QAMA9<X)!YS_@GSHND67[
M4/\ P5 \(6NFP)I;>-X[EM/$0\DRW.BWCW#[.F9&)+'OWK['\(_\$XOA-X(_
M;+\2?MZ:#\4/'J_$3Q;H\>D:_>3:O;26=SIT90Q6@M6MO*C2/RXRK(JR94DN
M2[EN%OOV&?V=OV%/#GQ__:LTOXR^*+74/B;H%]J'Q'OO&'B2V:QU*[CM+A89
MF5H46W9/-=56$QK@A=I"J  ?,'_!(C]DG]F7XU?\&S>C>$?BA\-- EL?&/P]
M\1W/B75;JPC:9KB&\U!(;QIF!82VZPQ&-\YC\E=N M>:_L"^/_ 5K_P3._X)
MV>$?CU\*]1\<_'G4O$NMW/[/NAZAXDGTNRMX[.XO0NH:A.JOBRMM,>T=5$4L
MC_N5C0@OCO\ _@W^_9!^$O[3'_!%?X=^"+_]ICQW-X4U[3]4@^(WPOT'Q9:C
M3[EWU2[66WF;R&O[&.>-!YD%O<V\<HDD8H?-<M]N?M??\$M_V4OVS/#'PY\/
M^,]+U[PE=_"*_2Y^&>O_  XUM]%U#PV%2*,PVDL(Q%$4@@7:%X\E-I4J#0!\
MJ_L@:3\4="_X.3?C3;_%WQ;H>K:Y>_LRZ)<WT_AO0Y-.LQC4H4C18I;B=W*(
M-OF-)EN2%080='_P;ZA3J/[;", ?^,[/'N0?K:5[E\//^"07[&7PP_:OL/VS
MO"NF>,/^$WM/#<.D:A=7WCK4+F/7/*G\^.\U/S96?4KE9%C8/</(H:"%@H:&
M-EU/A/\ \$NOV8_@;^T;X[_:@^%%YXQT;7_B!K=UKNJZ9#XMN)-&MM;N8GBG
MU>#3I"UM]L=9)/WLJ2 >8P4*I*T ?G5^R_XE^('PR_X)L?\ !5;Q)\%6GLM<
MTC]H_P"*K:3-IN4ELU6VA#RQ;>5:.+>ZD<J4!'2O>O _["_[,G_!37_@COX"
M\.?$/]N_XC3?!6^^'VBZA+::6OA&QM]"&G0Q.T0N$T,26QM7@>*3+[E$<BN3
MEL_4_P"R%_P3?^!/[%E[\0)?A;XE\6:I9_%'7[S7?'.E>+-5BU"VU/5;HC[1
M>LK0AEDD *LJL(V5N4.%*^'?#/\ X-R/^":_PB^,%Q\2? ^D>/+;P[=:TNK3
M?"8^.KD^$9;Q6#H\FG_\MU5E4B*5WBPH4H4&V@#RKX__  _^''B?_@O?^Q-8
MW]K)XHTZ#X$^(9K'4/%5D)+N\^SVWFVMU<+)&G[\.1-\R*4E)8*C#CK_ ()V
M-GHO_!T%\:(])MDMUU?]EG1;[4UA7:+FY34X(4E?'WF$2A 3S@8KZ7^*'_!.
M;X1_%?\ ;&\+_MUZ]\2/'5KX_P#!.FSZ=X3N-.UBWCL].LYU=9X!;-;M'*L@
MD?<TH=_F&&&Q-J>&/^"<WPC\*?MM:I_P4#L/B3XZE^(VMZ$NA:K<7.L6[65Q
MI*R)(EA]E%N(TB5HT(9 LN06WEF8L ?-W_!NYQX:_;#4]1^W9X_R/^ :=7T;
M_P %</\ E%7^TI_V07Q=_P"F>ZH^!7_!,7]ES]G+]I7QG^U%\+(/%5GJ_CGQ
M)=>(M7\/2^+[N30HM9ND9+K4H=/+^2MU*KR*96#,JR.J;%8BO1OVH/V=/"/[
M6?P-\0?L\?$/Q'KNG^&_%>GRZ=XB3P]>);SWUC+&T<UJ96C=DC=6(8IM8@8W
M %@0#\F?V\?A[X%\/_\ !FGX:N]!\(Z=92V_PI^'.LPRVMHD;+J,^HZ,)KL%
M1GSG$TH9_O$2,,\U[M^TM\4=9O\ _@NU^S[\*/B#^T!X@^'^E^(?V:]5_P"%
M?:UI,&EN;GQ1<ZC ;J!?[4L[J 2265HB@JBRDLL:MB5D?Z)^(/\ P2._9V^*
M/[#NF?\ !.?QQ\1OB'>_";2K>TM8- _MZW262SM'@DL[22Y6V$SPP26Z.@+Y
MSPQ=5C5+O[7?_!)C]DC]NO\ 9Z\,?L^?M06.O^)%\%,'\)>-#JJVVOZ5( %W
MQW4,: DHD:L'1ED\I'<-(H< &+\%?^">WP$^ '_!1_7OVMK_ /:9^(?BKXM?
M$WX=2Z=K.B^(WT=+#4=+L9M/C-V]MIVF6RB6%OLD2RLW(F9<-DX^./\ @B/\
M-OA_-_P;9_$>"7P9IC#6]$^(<.L$V29O8XWU".-93C+A$X4'[O;%?>'[)7_!
M,GX#?L6?#WQ#X4^#GC?Q[<>(?%-M%;ZW\2?%7B@ZOXBGAAW"&%;FZC=(HXP\
MFR-(U13(S!=YW5E_ ;_@E%\ _P!FG]DSQ#^Q)\'/B7\0]+^'OB1+Q+S3'U^"
M>>!+L.+Q(;F6V::(3!SNPV5/S(48L2 ?!_ACP#X(C_X,X[\Q>$M.4ZA\#IM3
MOV6S0-<WL=SF.XD.,O(ODQ!7.2!$@! 4 :?Q)^+'B&U_;%_X)->#?BM=R'X>
MZMX%GU%VNV)M[[Q1_P (O#!I[R9X::*:XB,1/(:Y8C)K[:M?^"3?[/MG^PN_
M_!..W^(_Q"7X3O:-8G1/[>M_M L6D,K68NOLWG^29"6QOW8^3=L^2M7XA?\
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M?B(GP&_9]\/?#.VU=?BU=QZ0+K5=?NIRHLI3JJRQ6D,$8R\9@$C.0/-0,HH
M^MJH>%_%/ASQMX>L_%OA#6[;4M+U"!9['4+*820W$3<JZ,.&4]B.#7Y@?#?]
MN[]K?]N+_@@_^T3\:'^-UGX5^(7PI/CC1KKQYX.T-8SKD.C6+W*3P12.18R7
M$;1HTB9,?SM&$8J4S/AK\5_VY?V*_P#@VY\-_M8_!K]H?PSJ=_X?^!7AO5O#
M^D>*/A\LJ:79BUB22WBD@NHC)+ME0K+.LJY@P8SYA*@'ZPT5^6/[;_[;G_!4
M_P#9'_8?^%__  5#_P"%V^ M0\--'X5;QI\'HO XSJ5EJ201R3G56E$BW322
MA@L4,4,7F;<2B(M-WG[8W[3W_!2G]A#]I7]G_P"*?Q6^-_@3Q'\.?C-\:]*^
M'7B'X5Z+X)-N/#K:F)!;W-MJLDQN+UX?*<N[QPI(5^6&,/M0 _1*BOC#XW?M
MW>(?&_[9_CO]C/X9^/O&7@RR^%WAS1[OQ?XJ\#_"'4/%FI3ZIJD<MQ:V<:P6
M-Y;6<,=M&DLC3Q%YC<JL7E^3([>)_#__ (*&?\%2X_V#OVIO$_Q&^'1\/^-_
MV>;?4]5\&?$WX@?!;5]'TSXBZ!!:WL\=Q!87,EH8;S;:?.5+Q1>=#NA;=R ?
MIW5#7_%/ASPK':R^)-;MK%;Z_AL;(W,P3S[F5ML<29^\['H!SP3V-?E!\?\
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MX=_:*_9]\<6WB/PAXIL?M6C:M:JRB10S(Z,C@-'(CJ\;QL R.C*0""*_&?\
M9(_X*8WWP$_X(8? +]B;PS^SGXED\<_'#PMJ_@KX<^*_%KV5AX1EOKJ[NH3)
M/?-<,RA/M VPM$K2LI08&7'Z&_\ !-?]E#2/^"*O_!*.V^&_QC\>QZW_ ,*Z
M\/:SXJ\=ZQID;&W#CSKZZ6V63:QCC0%%+!2^S>50OM !]A45^6?Q;_X*&_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6'@R\5-)M=0L;:& M'(BRRN"'9XXD=T"$,H;"U^B5% 'YM^-=/\ VC?V+?\
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>dva-20241231_g3.jpg
<TEXT>
begin 644 dva-20241231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" P4$HL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>+_ +8/QDF^
M ?[-_CGQK9[AJ5E8^18L%W;+J9UAA<CT5Y%8Y[+CO7M%<M\2_A]H_P 6/A_X
M@\':]!]HT?6[*2RN57&X*ZX#J>S*<,I[%0>U 'XQ?LR_ W3_ !IIL/Q/\;74
MGBS7M6G>[B:_N&GVLLC*9)6+'S9"RD_-G'<;AQZ)XX_9)^&_C3?(NCG0+ML
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF>6PM[KP[<,!C^SYLQ9 (R8W##TSMQT]SG%\/_#7]H3X$W&[X6?%F].FQ/\
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ME=& 964Y!!Z$&I:0PHHI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD)RB)*LT:_-G@.N[IQ][L/?/B5<BKQ_AM2_ ]&&9TI?$FC]J*.M?B_H?A?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=KC.D]>HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M R%E8KC'HK*/PKCR/E^LNZUMH;YG?V*MM<]FHHHK[X^6"BBB@ HHHH ****
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH **** "BBB@ HHHH *HZMH>F^(+4VVJ:?:ZE;D$&&\@65#D8/#
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M/2H*.PHHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$DMG'/&;B%LCMT2MW3/$?[<'P9D5=*\9W/C*PC7<_P!HNH-35@/X?]+43?\
M?/->=4P.(I[P?RU.R.)HSVD?LGP:#FOR9TK_ (*T?&KX:F-/B=\'[:XA4[?/
MAANM)=^<9W2"5&Y_N@ \5[9X!_X++?!GQ%Y<7B31_$OA&X;[\DELEY;+_P "
MB;>?^_=<4HRB[-'0FGL??=%>)^ OVT?@=\3!&N@_%'P[+-)]RVO;L64[>PBG
MV.3]!7LMO<1W4*302)-%(-R21L&5@>A!'44AD]%%% !124M !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 A[U^'G[&=Q/KGC+XJ:YK/'B6ZU%'O(74[XG>2=Y/F[Y?((_P!@>HK]PO6O
MQCTO13\*?^"@7QF\(8,-IJ-S<:A!%@\>:Z740'; CN' SZ#GU]3*Y*.+@V<6
M-BY4))'T!1117Z8?&!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445X7\3OVVO@C\
M&_'$OA#Q?X^L])\10HLLUF+6XG\D,,@2/%&R(Q'.UF#8(.,$9 /=**\Q^'?[
M2WPK^+=]]A\(>/\ 0->O\;OL5K?)]H(YY$1(<CCJ!Z>M>G4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>0*\IKET9WG44444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#Y=_X*(?M'?\ #.?[.FKW6G77V?Q7X@SH^C;&
MP\<DBGS9QW'EQ[F!Z;S&#UKXM_8.^#9^'OPO/B;4(0FL^)PERN[!,=F!F!?^
M![C(<=0Z \K7+_M0>+IOVX/V[D\(6TCR>!/!3RV+A6(5HX9!]LE&""#+,%A#
M*?NB)NQK["CC2&-8XU5$4!551@ #H *^CRC#\TG6ETT1Y&85N5*FNNXVXMX[
MJWE@E7=%(I1UR1D$8(KX_P#V.OB-=_L+?M@:C\//$MT4\"^+I([5+N9QM4,[
M"RNV)  P6:*3H!N<\A!7V)7SY^V1^SS<_&[P59W6@VT<WBS2)"UJC,J?:87P
M)(2S,%!R%<%NFTCC>37J9EA7B*7-%>]$X<'7]C/EELS]6>E<7\8_BAIWP5^%
M_B3QQJMO<WNGZ'9M=S6]H%,L@& %7<0,DD=37Y8>&_VZ/VMO@%IMIIWB_P $
MQ>+=)L+=(FNK[3WE<1HH +75J^PM@#+.&)Y)R<FLS]H;_@JEJW[1WP7N_AQH
M/PZ;1=:\1NEC>2+>&_WQEAB.W01HQD=@HY!P"0,D@CXN5.<7:2LSZ-2C)73.
M9\7_ !$^,O\ P4M\63_:;G_A$/AEI]P EE"6:S@?J,CY3=7&TY). N?^68<!
MOJ?X/_ WPE\$=#;3_#6G^7--M-WJ%P?,N;I@ ,N_8<9"+A022 "3G'_9=^&N
MK?"7X*Z#X>UT1)JL9EN+B&%PZPF21G$98<%E! )&1G."1@GU>OL\#@H48*;7
MO/\  ^<Q6)E4DXI^Z%%%%>N>>%%%% !1110!Q'Q2^#/A/XRZ')IOB;2H;MA&
MR6]\BA;JU)_BBDQE>0#CE3@;@1Q7G'_!'3QQ=^"_B-\4O@[K$J1W,3'4H(0?
ME$]O)]FN@I[DAH>.N(R?6O?J^,-:UP?LT_\ !1SP1XT0BVT77KBW:\94Q&L=
MP&M+G/8D?ZX]\L#7SN;X=<BJI:K<]G+ZKNZ;9^T]%%%?*'N!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <_
MXZ\86G@#P1X@\3Z@COI^BZ=<:E<K&5#&.&)I' W$#.%/4@>]?G5K7_!:2UO_
M #D\&_![5M9V8S-?:D(MF2<%DBBDZ@?WAW].?M3]KZ^33_V5/C!(X+!O"6J1
M8'J]K(@_5A7YA_L1VL,/P36:.&-)9M0G,DBJ SXV@;CWP..:]# 87ZY5]FW;
M2YRXFO\ 5Z?/:YW&J_\ !13]J;QS!)!X?^$VBZ';393??:?.TGW>>9ID0@@]
MTP>GM7S3X-_9U^,VG>/#XOL+?1?"6IS7#W#6ZSI';+N?+1>5"'41G^X. ,8P
M0 /MVBOK:624:;4G)W7R/!GF562MRJQ4TEK^33;5M4BMX=1,8\^.TD:2(/WV
M,RJ2/J!5NBBOHEHCQPHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?+_[3?[/_ ,0/C%XO@OM-N=*.BV,'E6=K
M+<ND@)P9&8>7M!9L#ACPB]*^:?%7[,?Q)\'QR37?ABXN;9.LVGLMR,>NU"6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M14&?0X[5^R%?BM_P4/\ #ESH-UX#^)&E,+74].O!8FY4_.'4FXMB/]UDG/\
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M445ZAP!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=/L.M6TV?IM<UV5O<174*RPRI-$W*O&P93]"* )J*** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M60_\ 9PWZ4@/5Z*QM&\8:#XD .DZWINJ ]#97<<V?^^2:V,T +1110 4444
M%%)2T %%%% !1110 44E+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?-O_!1JYEM?V*?BF\3^6QL(
M8R?]EKJ%6'X@D?C7TE7RC_P5&G6+]ACXD*T@1I#IJ("V"Q_M*U) ]> 3] :
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O'OVM/C,/@%^SOXV\:1R+'J%E8M#I^[!S>2D10<=\.ZL1Z*:]AK\MO^"Q
MOQ0N_$WB'X;_  2T-O.O;ZX35KN%6^]+(S6]G&2#ZF<D'U0TTN9V0'G?_!._
MX>MH_P .]8\97B,U[X@NS%!*YW%K>$E2V>N3*90?78#7UK6#X#\(6GP_\%Z)
MX;LCOM=+LXK19"H4R;% +D#C<QRQ]R:WJ_0\+1]C1C#L?(UZGM*CF%%%%=)@
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7Q'^V5<7'P7_:&^&'Q;TN(
M^?;SQ2RK$NT226DROAFQU>.39SU5#Z5]N5X)^V]X"_X3C]G_ %J:)&DO-#D3
M5H0IQQ'E9<^PB>1OJHKS\PI>UP\EU6OW'9A*GLZT7\C]1=%U:TU_1['5-/G6
MYL+Z".YMYDZ21NH96'L00:O5\G_\$Q?BQ_PM7]D'PI'/.9M2\--)X?NMS9($
M&# /IY#PC\#7UA7P1]2%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$I\J::W3T9S5Z$J%KN]^P4445VG,%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK%'^9'[(45^.(\>?M[:6JO#XJFNCG&WS-)<_7]XF/_UU9@^.'_!0&SY?45N
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M P&-UA>*>?4&'(_&I/\ AY!^S;_T5+3_ /P"N_\ XS0!]*T5\T_\/(/V;?\
MHJ6G_P#@%=__ !FC_AY!^S;_ -%2T_\ \ KO_P",T ?2U%?-/_#R#]FW_HJ6
MG_\ @%=__&:/^'D'[-O_ $5+3_\ P"N__C- 'TM17S3_ ,/(/V;?^BI:?_X!
M7?\ \9H_X>0?LV_]%2T__P  KO\ ^,T ?2U%?-/_  \@_9M_Z*EI_P#X!7?_
M ,9H_P"'D'[-O_14M/\ _ *[_P#C- 'TM17S4O\ P4@_9O8@#XI:?SZV=V/_
M &C6K_PWW^SS_P!%8\/_ /?U_P#XF@#Z HKY_P#^&^_V>?\ HK'A_P#[^O\
M_$T?\-]_L\_]%8\/_P#?U_\ XF@#Z HKY_\ ^&^_V>?^BL>'_P#OZ_\ \31_
MPWW^SS_T5CP__P!_7_\ B: /H"OCC_@K+?1VO[%?B:-R=UQJ&GQ1X'\0N4?G
M\$->C_\ #??[//\ T5CP_P#]_7_^)KY-_P""FW[67PG^+'[,4WASP9XWTOQ+
MK%QK%I(;2RD8ND:;V9\%>@( _P"!"@"A^QI;):?LT^"8T+$-#<2?-ZM<RL?U
M)KVFO,/V8[6*S_9]\!1PH(T;289"!_><;F/XLQ/XUZ?7Z+AU:C!>2_(^0K:U
M)>K"OE[]@:^D^'W_  4J^(7A^7]TFMVVJ11Q8&,--'>1D ' Q&A_ G@$\?4-
M?&'CK6D^!O\ P4B^&OC8NT-GJEQ8O=SL"%2.7?83\].(OF(_VO>O*S>'-14N
MS._+Y6J./='[3T445\>?0!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 )Z5^=7_!4?]JWQW\-_%7@?X6_
M"[7;G1O$FN1FXOY+$(+ATED$-K$DC#,99UE)*E3PO.":_16OQ6\):\?VJO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M50!_*K==E./+!1['--\TVPHHHK0@**** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OR5_X*=6C0_P#!0#X)7K,HCDL=)B'/(*:K<$D^
MWSC\C7ZTU^3/_!9UD\._%[X/>);62/\ M**TN#M&W>!!<121D]>"TCXR,<'W
MJZ;Y9IDRU3/H^BBBOTE;'Q@4444P"BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^%_VUC_ ,))^TY\*?#+DF%Q:?*1Q^_O3&?TC'Z5
M]T5\,_%1O^$P_P""A_A#32$<:7]C &0V/+C>[Y'8C=G\C7F8_6G&/>21W8/X
MW+LF?<U%%%>F<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$5/9TVS[ HHHK] /DPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KX_P#A7K)_9K_X*?:7,V;70_&<_P!G<,_^L2_&,DG[H%ZH./1.W%?8
M%?&G_!1CPE<6^D>#/'6GMY%YIEXUE)-&I\P;QYL+[NP1HGZ]Y!7D9I2]I0<E
MO'4]' U.2M;N?M%2UPOP/^)%O\8?@_X.\:V^W;KFEV]ZZ+TCE9!YB?57W+_P
M&NZKXD^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"LL;_56!!KS:N%DZCJT9\LGOV?R.RGB$HJG4C=?B<'\,/VCOA]\70D7A[Q#
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M10 4444 %%%% !1110 4444 %%%% 'QS_P %*O$26WP_\(:%C][>ZG)>J?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^8'_!</_D5_A'_
M -?NI?\ H%O7K^GV\5I8VT$$20PQ1JB1QJ%5%    '0 =J\@_P""X?\ R*_P
MC_Z_=2_] MZ]CM_]1'_NC^5?39+O/Y'C9EM#Y_H24445].>&%%%% !1110 4
M444 %%%% !117D7[37QVM/@3\.Y]11XY?$%]F#2K1^=\N.9&']Q <GU.U?XJ
MBI4C2@YSV1<(N<E&.[.VO/BEX-T[7#HMUXNT*VUCS5A_L^;4H$N/,;&U/++;
MMQR,#&3D5T]?C1\-=2NM8^,WA:_O9Y+F\NM>M9IYI3EI':X0LQ/<DDFOV7K@
MP.,>*4FU:QUXG#K#V5[W"BBBO2.$**** "BBB@ KSO\ :&\"'XD?!;Q=X?1&
MDN9[)IK98^K3Q$2Q#\710?8FO1**SJ152#@]F7"3C)270Y?_ ((V?%;_ (2W
M]GC6?!5Q/OO/".JMY,>?N6EUF5/_ "*+G]*^_P"OQ-_9P^-&A_L&_MF^/K/Q
M*)[;P3J5O-"8[&!I3$CLEQ:%5X)VJ3&>WS-Z5]O?\/=OV>O^@EX@_P#!._\
MC7YS4BX2<7T/L(R4DFNI]JT5\5?\/>/V>O\ H)>(/_!._P#C1_P]X_9Z_P"@
MEX@_\$[_ .-04?:M%>8_ +]H3P7^TMX)E\4^![Z:\TN&[>QE6YA,,L4RJK%6
M0]/E=2/4&O3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3M7Y6_\
M!8OQ]=^-/'GPO^#.BR"6[GE&IW$!?"M<3O\ 9K0,>Q \_P#"0'Z_JC7XL^#=
M>/[3_P#P4)\<_$,M]JT'1)YGL9,!HFCB M;0?[)909AC^)2:VP]-U:L8+JS*
MI/V<'/L?7GACP]:^$O#.DZ'8*RV6FVD5E &.6\N- BY/<X YK4HHK]&BE%61
M\?*7,[L****8!1110 4444 %%%% 'QM_P4LFV^!?!L7][4I6_*+']:^@8HUA
MC2-!A5 4#V%?.7_!3!C_ ,(_X#7/!N[LG\$C_P :^CZY\%_O-;Y?D;XC^!2^
M?Z!1117MGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\Y?#BW_ .$]_;VUB_)+VWA?3&$)PV WE)"5
M.>,[[B4CM\N?>OHFYN8K.WEN)W6*&)#([L<!5 R2?PKPK_@G]IYUR3XE>.95
M9WU?5O(2:4 /QNF<$#H3Y\9/..!Z5XV/?-4I4N[O]R/1PONPJ3\K?>?7]%%%
M;&(4444 %%%% !1110 4444 %%%% !1110!F>)_#UGXN\-ZKHFHH9+#4K66S
MN%4X)CD4JV#V."<'M7Q9^P[XHN_A=\5O&/P?UR39,US-):;@RA[F'Y9-@/:2
M)0X/=8_<5]S5\(_MNZ#J'PD^-7@_XMZ%$%::2-;C@[6NH,8#GTDAPF!VB:O+
MQR=-PQ"^R]?1G=A??4J+^UMZH^[J*R?"?B:Q\9>&=)U[37,FGZE:QW<#,,-L
M=0P!'8C.".Q!K6KTXR4E='#)<KLPHHHI@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'<3+;P22N<)&I9C[
M 9KXA_X)JVLEW=?$;59ANDD:RC$G RQ,[/P.G\/YU]9_&#4WT7X2^-;^/(DM
MM%O9TP<'<L#D<]N17SQ_P3=TH6WPE\1Z@4VO=:TT08C&5C@B((]1EV_(UY=;
MWL7379-G=3TP]1]['UM1117J'"%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PS^U
M1_R?#\'_ /N$?^G*:ON:OAG]JC_D^+X/_P#<(_\ 3E-7W-7F83^+5]3OQ/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM_Q-77)]> !] !7[2^M?!8FFJ5:4%LF?5TI.=.,GU'44E+7.:A1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKI'_ *<I:^YJ^&/VIO\ D^+X0_72/_3C+7W/7F83^+5]3OQ/\*GZ!1117IG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX<LSNMM+LXK19-H4R;% +D#C<QRQ]R:WJ_1H7Y5S;GQ\K<SML%%%%62%%%%
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M%<-\*?B]X6^-'AR76O"NI1WT%M=2V-W#]V6UN8V*R12KU5@1GT((89!!KN:
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M@ZD5S0]Y>1[M14=O<PWEO'/;RI/#(-R21L&5AZ@CK4E>G>^QPA1113 ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ^:_B4G_"POVQ?A?X71/-M]'(U*;?G
M:&!,[ \?W88^^"6 ^OVU7QK^SA$_C[]K[XF>*)09;;0X6TV L/\ 5OO6)2O)
MP"L$WUW$\=*^RJ^?PS]I*=7^:3^Y:(]6O[JA3[+\]0HHHKM.4**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YY?\
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MIKO<?1117IG"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]&SITKAM:_X+:> 8%)TGX=>)+WT%[<V]MGG_ &3)V_SWI^E_LV?"S285C@\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*4?%3Q/K&A^!OC-\'/BMXE7X=^((&T>]M]!UNZMK6WO$#.HDA1U$<CQEU96
M/[GD<UXYX)_9M^,_Q4\+:#XBN_C+>/I^J6:72;]7O;J6)'7<$() W#.&&< @
MC)QS)KW_  3R\7VLVJZ5X:\=6Z^%+NX6=;*_DFC+[<^69DC!1W0,0'P,Y) 7
M.!]A_"?P%!\,?AOX=\+0>6W]FV:0RR0@A99L;I9 #TW2%V_X%7DX3+9.;5>.
MGJ=^(QB44Z4M3XN\)ZE\3O\ @FC\6K'Q3:2KXG\'ZP%MM15-T=M?#)9H9 <^
M5.N&:-^<C=C</,0?LU\&_C%X8^/7P\TGQGX1OUU#2-0C!VD@2VTF!OAE4$[9
M$)P1^()!!/R5XM\):1X[\-ZAH.NV,>HZ3?Q^5/;R]&&<@@CD," P8<@@$$$5
M\<_"_P <>(_^":O[2%E%/J-SJGPJ\2N%NXV!/F6X8*9-@P/M$&X'*_>4XXWX
M7#,,!]7?/3^'\C7"8KVWN3^+\S]MJ*I:;J-KK.G6M_8W$=W9W42SP7$3!DEC
M8!E=2.""""#[U=KQ3T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "O*_VDO@I:_'+X97VB[436;;-WI5PQV^7<*I
M5C_<<$J>N,@XRHKU2BLZE.-2+A+9EQDX24H[H\\_X)+_ +4%UXB\-WOP0\72
M2P>)/#*N^D"\RLLEHK8DMF##(>!CP#SL8# $=?HSZU^)G[77AO5_V>_C#X5^
M.W@>>/3K_P"WQK<(H('VQ48Y(S\R31*Z.H ^ZV23(:_8OX7^.(OB9\-/"7B^
M"V>S@\0:3::LEO(P9HEGA24(2.I ?'X5^?8BC+#U'!]#ZVE456"FCJJ***YS
M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5P?_ !-2_P#"L?!PZ>$]#'_<-A_^)KIJ*CV=/L5S2[G-_P#"M?"(Z>%=$_\
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M** /E/\ X*0,/^%(:&N1N/B& @=_^/:Y_P 17Z6_LG#_ (Q9^#G_ &)FC?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% ' _$?X\>!/A+>06?BS7X])N
MIXO/BA-O-*SIN*[@(T;N#^5?G5^V#\=M+^.7Q"LKK0(YQHNEVGV6&:X38T[E
MRSR!>JKRH //RYXS@?JG17G8K#5,5'DY[1]/^"=F'K0HOFY;OU_X!^<'[$_[
M2GAGX,VNNZ#XLDN+/3[^=+J"^BB:9(W"[65T4%N0%P5!Z'/:OO;X>_%#PO\
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M]2:^B*^'_P#@F3:RI9_$2Y*,(9'T^-).Q91<EA^ =?SK[@KTL!.53#PE+?\
MRT.+%14*TE$****[SD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#X5\0Z;/^RC^V)I6I:9'L\'^,W\M[6,@+
M&)9%65 ,\>7*4D7@#:P4=Z^ZJ^*/^"A;?9?&GPANL9*W5T?^^9+4_P!:^UZ\
MS"+V=6I26R:?WJYW8CWJ=.;W:_(****],X0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB+:#KLEA"Y'RVT.DP;>,9R%W^_4_2L2^\._M;^,(6;4OC-JE@)%^>W7Q'=P
M@K@J5@7:>.HZ5]$Z[XFT?PM9BYUG5;+2;9CM$U]<)"A/H"Q S[5Y#XJ_;&^&
M?AG>EOJ=SKMPC;3%IENS#Z[WV(1[JQKT9Y9@,/\ Q)OYM?Y')''8JM_#C^!P
MVD_$[]HG]BW7+'Q;+XJN/&GAV:YCEU>TN+N:ZMYB 4\N5Y1YB9#860<;MN1G
M /ZU?LU?M(^$?VHOAO;>+_"LS(P;R-0TRX(^T6%P "8I .HYRK#A@<]<@?C=
MXP_:/\:_M"Z1J7@SX>_#[4[UKY?*G:QAEO[HPDC($<:83/0D[N">AY'ZI_\
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M **** "BBB@ HHHH **** "BBB@ HHHH ^5_^"E'QF/P;_9-\5R6TWDZOXB
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M4 %>+?ME:F^D_LU^-9H\[Y(8(.#CB2XBC/Z,:]IKYH_X*#:P=+_9\>V5MO\
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M** "BBB@!*Y[QUXYT'X:>$]4\3^)]4M]&T+3(3/=7MR^%11V]2Q) "C)8D
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M:%%%8&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=*\-6&1N@TNSC@5B.[;0-Q]SDUU%%?+GN!1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+J=QDM'!R<8!$?W@0=A.50:?[-_[<I\Z+PE\59S9W\<OD0Z]-'Y8W;L>7=*
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MCLCEJ2<Y.3ZA1116A 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M445Z1PA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_[2G[3_ ((_95\%P>)/&<]RXNYOLUEIVGQK)=7<@7<0BLRC"CDLQ &0,Y8
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MR!@#FOK7X,_\$9_AYX7:"\^(OB/4?&]XI#-868-A8]LJVTF5_P#>#I]*\O\
M^"./A^?QI\:/BY\2[R(),+9;4$?=\R\N&GD"_3[.OX-[U^L72ORO$5Y5ZLI2
M=[MGW5&FJ<%%(HZ+H]CX=T:QTC3+6.QTVP@CM;6UA7:D,2*%1%'8!0 /I6A1
M17*:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$/B2VM[WXFZO"/M<^ ZZ9">?LL3>O3>X^\1@9503]D445\F>Z%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% #:_'3]N#Q<G[7'[=F@?#C39&NO"W@]CI]X\;G875O-OW##[I^1(,_W
MXQZBOT>_;&^/\'[-O[/_ (F\9!XQJZQ?8M'A?!\V^E!6+@]0OS2$=UC:OS@_
MX)__  LFTOPGJOQ$UC?/K'B.1H[>:?YI/LRN2[ECSF24$G/41H>]=V"H?6*T
M8]-WZ'-B*OL:;EU/K55"J !@#@ 4M%%??GR84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXY=S]FZ>B] /Q)]T_P"';_PS_P"@UXK_ / JV_\ D>C_ (=O?#/_ *#?BO\
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M0O/C%^V+\=_#/Q3\:Z1:Z)INER6WV8>4;:%+6&<SK%%&Q,CEC(Y\QN#G[P
MKZPK[3(\*X*56<;/97/G<SK*5J<7IU"BBBOK#P0KY0_:(\<:[\:OB%IGP0^'
ML']J7U_=);WOD'/F3AL^23T5(MN^1NQ7!V[&SZ)^U3\;)_@_X)MX=+&-?UDR
M06DS X@10/,EZ8++O0*#W8'D*0?I[_@F3^Q7_P *%\$CX@>+K''Q!\16X,<$
MR_/I=FV&$7/25^&?N/E7C#9^3SK'\J^K4WJ]_P#(][+L+S?OI_+_ #/H7]E/
M]FS0OV6?A'IO@[2-MU>G_2M5U+;AKV[8 /)[*,!57LJCODGU;4-6L=)6W-[>
M6]BMQ,EM";B58Q)*YPD:Y/+,> HY/:O)_P!IC]JKP+^RQX,.M^++SS+^X5AI
MNB6I!N[^0=D4_=4$C<YX7/<D _C]\4/'WQX_;I\02^/)/,TO0]%+SZ%I]O<-
M;V]O(C A;;O)/D<S''*XW+A5'QU.G.J^6"N_(]^4HP5Y.R/WIHK\V?V1_P#@
MJYX6_P"$'?P_\>=4F\.>*]'Q;C6/[/N)UU)1\N9(X8W:.9<8;*A3U&#E1[XO
M_!4+]F21E4?$P9)P-VA:F!^9MN*DL^JJ*XGX=?&CP'\7+(77@SQ?HWB:+;N9
M=-O8Y9(Q_MH#N0\CA@#S7;4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BDI: "BHY)%C4LS!549)8X 'K7R=^T'_P %,/@S\"XKJRM=
M:'CKQ-'D#2?#KK*BMR,2W/\ JTP1@@%G']V@#ZS!KAH?CA\.;C5KG3(OB!X7
MDU*VD,,]FFLVQFB<=59-^5(]",U^0GQ _:@_:1_;?>>QT;=X&\ SEE,.GR/:
MVKI\PQ-<X\RXY!5E0;<XR@K#F_8)T2S\+RO-XIOWUF.)W:>.W06^1R (S\V
M.#\_/7CI7?1R_$5X\\(Z'+4Q-&F^64M3]RK.\M[^$36T\=Q$W DA<,IQ[BK%
M?F!_P0[_ .17^+G_ %^Z;_Z!<5^G]<!U!1110 4444 %%%)0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBO*/VG_CE9?LZ? _Q5XZN_+>XT^U*V%O(>+B\?Y((\=2"Y4M
MCHH8]J /S=_X*.?$*]_:>_:O\+?!#P[<L=%\-R[=0FB^9?M;J'N)#V/DP@*
M>CF1>]?2FBZ/9^'='L-*TZ!;:PL8$MK>%>D<:*%51] !7R1^P%\.[[4$\2_%
MGQ%))>:SX@N)H;:ZN"2\JF3?<SDYP2\HVYQD&)^S5]B5]EE6']E2]H]Y?D?.
MXZMS5.1;(****]L\P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYE6A\6J/H7]D/]NSP+^UAI*VEE*OA_QO;Q;[WPU=R R8'WI+=\#SH_< ,O\
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MI4N?B[X%ADB^_&WB2SWCC/W?,SGVQ7Y)V?[ 7A:.%1=^)-6GFS\S0I%&IY[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAY/(&U20?M6JNGV,.EV%K96Z[+>WB6&-?15  'Y"K50:A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 )7Y,?\%2/BAJ'QW^/W@WX >%KCS(-,GCN-2*99/MLJ9!<#J(+<LYQ
M_P ]7'5:_27X]?&#2_@-\(?%/CO5MK6VBV;3) 6VF>8X6&$'U>1D7VW9K\GO
MV%?!VH^.O$WB_P",WBEGO-:U>]GB@N)D(WR2-YES,N1T+,$!7IB1:Z\)0=>M
M&'3KZ&%:K[&FYGUOX4\,6'@KPSI>@Z7%Y.G:;;1VL"'D[44 $GN3C)/<DFM6
MBBOT%)15D?(M\SNPHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444P"OB#]L?]H#5O&/B9?@[\/7DN[FYE^R:K)8G,D\I./LB
ML#A5'/F_]\D@*X;V?]KC]H:+X'^ S;:=,#XMUA'ATY%&[[.H&'N&R,?+D;0?
MO,1P0&QP?["OP#;PQX?/Q(\11>?XAUV/?8&9R[P6CX;S#G^.4_-GD[-O(WN*
M\C%5)5ZGU:D_\3[+_@GH4(JE#V\UZ+S/2/V7_P!FW3O@#X59IBE]XLU)%.HW
MR\JF.1!%GI&I/)ZN>3P%5?;***]*G3C1@H05DCCG4E4DY2W"BBBM#,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "OA?Q]IK_ !:_X*$:;X?UAUFT?0E@
M:*$CAHX[876TCH=TKD'_ &>.U?=%?"O@34!JW_!1[7IU.1&UU#^,=H(S_P"@
MUY>.U]G![-H[L+ISR71,^ZJ***]0X0HHHH **^3_ -KS]J+7OAYXHT+P5\/I
M5F\4R2QRWJQ6ZW+C?@0VPC(.7DW9( #8*8^_FL[P'_P4"M;/4/[$^*'AB\\+
M:O"XCN+FU@<QQMC.9('_ 'L8QV&\].*\^6.HQJ.G)VMUZ?>=BPM64%-+?[S[
M!HI =R@CI2UZ!QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\)_#V,^ O\ @HQXATN%V$>L27;2
M>_GVXO2#STW >O;\/NROAC]H!6\&?MY?#O5X0R_VFVG&5SPOSS/;/@^R <>_
MO7EX[W>2IVDCOPNKG#NF?<]%%%>H< 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD[6D!K]&0 N !@"N*^#GPJTKX,_#_3/#&E*CBW3?=7:Q[&N[@@>9,PR3DD<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:*D:@*JJ,  = !3J*^HPV%I86/+25OS9XE;$5*\KS84445UG.%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?,^J?\ *1_X-?\ 80TK_P!*
M7K]M/2OPT^)'BS3/AW^WA\+O$VOW'V#1=-GTR\N[IHV81PK<ON? !) P>@)X
M-?M]I6K6>N:9::CIUU#?6%W$L]O<V\@DBEC8 JZ,.&4@@@CKFOR_,/\ >I^K
M/ML+_ AZ%^BBBO/.H**:S!5))P!R:X[7OC)X \**QUOQQX;T<*-S?;]7MX,
M#.3O<=N: .SHKR7P_P#M5_"+Q9XJL?#/A_XAZ'XCUZ]D,=O9:+<B^=R.I_<[
M@% R2Q.  23@$UZU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )]:;7RO\
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M[0O&WU8U]TUYF!]U3HO[+_!ZH[L5[SC57VE^(4445Z9PA1110 4444 %%%%
M!1110 4444 %%%% !1110!X;^VQ9&]_9F\8!4#O%]DF7IQMNH=QY_P!G=7%Z
M/^S2/VI/^"8?@?7-"M?M/C_P&=36V$0S)>VHO)I)+7 '+;&1D')W+@?ZPU[!
M^T<;4? 7X@?:Y8X8?[%NMK2,%!D\MO+7)[E]H [D@5TW_!&76GO_ -EG6[*0
MMFP\474:;MQ&QK>V<8)X^\S\#Z]Z^1SB/[Y/R/H<O?[IKS/'/^"4OQ,\+:A\
M/=9\#V^G6NF>+K&9KZYGC!\W4[=FPLK$]XRPCVC@ H1RS5PG_!57PQ-X/^)W
MPW^(VE1K;WTD;V[W"IC$]K(DL+-ZDB4@=\1X["I/V[/@[K/[$?[3VB_&KP#;
M^1X8UR^:Y^SQ@K#!>$$W-H^.D<R[W7TS(% \L&N!^)7Q0^,/_!23Q%:>$O _
M@+9X=TV[^U1K$ WV=MK()+J[?:B?*S?(-N>@#D"O#OI8]#E?-='[:>"?%5IX
MZ\&:!XEL/^/+6=/M]1MR3G]W-&LB_HPK<KRG]EWX;>(O@]^S_P""?!?BJ_L]
M1US1+ 6<]Q8,[0;59O+5"X!(6/8N2!G;T%>K5!H%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4E+10 WH*_+;_@K7^T!<>-M>\._L^^"VDU'5+BZAN]:AMF'S3-_P >MJ3G
M'\7FMG@?NCG@X^VOVOOVE=,_9;^">K^+KGR[C6)!]CT;3Y#_ ,?5XX.P$==B
M@%VZ?*A Y(K\U?V)?A/JGB#5=7^,_C9IK_Q#K<\LMA<7>#(_F$^?=>Q<LR+P
M/E#XRK@UUX7#RQ%507S]#"M55&#FSZ9^%OP_L_A;\/\ 0_"UCAH=-MQ&T@&/
M-D.6DD/NSEF_&NJHHK] C%12C'9'R3DYN["BBBJ$%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<S\1OB%HOPM\'Z
MAXEU^X^SZ=9IDA1EY7/"QH.[,> /Q. ":_-[XD?M1?%+X]:]-9^'SJFG:6<B
M'1?#XD,A3/65HQOD)[]%] *X,5C(8:R>LGT1UT,-.MKLNY^H]%?B]XB\!^-_
M"6-1U[P[K^C'(/VK4+&>#GH/G=1].M>@_"7]KKXA_"N_@VZS<>(='5AYNE:M
M*TR%<\A';+1GKC:<9.2IZ5Y\<V7-RU(.)V2R_2\)7/U@HKC/A+\6-"^,W@VU
M\1:#,6AD_=SV\G$MM* -T;CU&>O0@@C@UV=>Y&2FE*+NF>5*+B[/<**I:UK5
MCX=TF]U34[F.RT^SA:>XN)#A8XU&68_0"OAK5OC]\2?VK/B1+X/^&-U-X6\-
M1AFEOT)CG\@$ S2R#YDSGY8TP3G!)ZC"OB8T+)ZM[);FU&C*K=[)=3[RHKY:
MT_\ X)]^#[R%)O%'B?Q)XBU5A^]NFN4C0GN54JS#\6-<7\3/V=_'_P"SMHUQ
MXM^%OCS6[K3--3SKK2;V42LL2\LX7'ER!1R04! !(STK&6(K4X\\Z>GD[O[C
M6-&G)\L9Z^A]LT5X!^RS^U-9?'G2Y=-U*.'3?&%C'YD]K'D17,8('FQ9)(P2
M RDG&1U!X]_KJI585H*<'=,Y:E.5.3C):A1116Q 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'[5W
MQ2;X3?!/7=2MIO)U:]4:;IY#%6$TH(+J1W1!(X]T [UY#_P3]^!L'AOPB_Q$
MU. G6-85X+ /D>19A@"VT@8:1U)SS\BK@X=@>+_:JO+O]H3]ICPO\*M)F;[!
MIA5+N2)<^7+(!)<2'G#>7"J  XPP<=Z^Y='TFTT'2;+3-/@6UL+*!+:W@C^[
M'&BA54>P  _"O(IKZSB95'\,=%Z]3T9/V-!06\M7Z%RBBBO7/."BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBF!B>,O!>B?$'PW>:#X
MBT^/5-)N@!-;RD@'!!!#*0RD$ @@@BN/\&?LV_#3X?ZQ;ZKH7A&RL]0MUVPW
M$C23O'T^93(S8;C[PYY//)KTNBLI4X2ES2BFS15)Q7*GH%%%%:&85\1_M7M]
MO_;(^#=@JLS*VG.W&1M;4'!/X!"3[5]N5\1_MW1MX%^,7PJ^($!<2P.(Y&PV
MP"VG290<?WA,_'< UYN/_@WZ)K\SNP?\6WDS[<HID,R7$22QL'C=0RLIR"#R
M"*?7HK8X0HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?&
M/_!2K5)!X;\":-'\YO+ZXN!&JDLS1HB#&/\ KMT]Z^P-#TQ-%T33]/C_ -7:
M6\=NOT10H_E7QC^W),OB;X[?"#PJ/]8TR,>><7%U'&./^V)K[<KS,/[V)JR]
M%^!W5M*%->OYA1117IG"%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>,?MC:))K_[-_C2")=TD-O%=CC.!%/'(Q_[Y5J]GK(\8^'(?&/A+6M!N"4@
MU2QFLI&7J%DC9"1[X:L:T/:4Y0[IFE*7)-2[,\8_88\11:]^SCH,"2^9/I<]
MS8S]/E82M(HX_P"F<L=>_5\0?\$W_%$^GW/CKP/?N8+FWDCU"*S8896!,-P3
M]"+<5]OUSX&I[3#Q?96^[0WQ4>6M+^MPHHHKN.0**** "BBB@ HHHH ****
M"BBB@ HHKS_XY?&#3?@C\/+_ ,1W^V6X7]S8V;-@W%PP.U![<%B>RJ:B<XTX
MN4GHBHQ<FHK=GH%%?CKX-\5:GXT^/'AS7-7NVO-2O_$%K//,YY+&X3@>@ P
M.@  '2OV*KCP>,6+4FHVL=6(P_U>R;O<***\+_:@_:<L/@-HL5E91QZEXOU!
M-UE8MDI$F<>=+CG;G("]6((Z D=56K&C!SF[)'/"G*I)1CN>Z45^7?B#X>_M
M&?&J.35]7TOQ'J%M,-ZP74@M8@IS]RW9D &/1>??->37<7C;X/:_Y$PUKPAK
M$>'"AI+64CLP((R..HX->-+-''5TWR]WI^AZ4<"I:*:N?L[17QM^Q[^V'?>.
MM6MO!'C>=9]8F!&G:MM"FX(&3%*!QOP"0W&[&#S@M]DUZV'Q$,1#G@>?5HRH
MRY9!111708A1110 4444 %%%% !1110 4444 %%%% !7C_[76JOH_P"S?XZN
M$?RR]FEMG;GB6:.(C\=^,]LU[!7@G[<]T(/V9?%*$',TMG&,?]?43<_]\US8
MI\M&3\G^1M05ZL5YHX7]C.Q%G\ =&E'6ZN+J8\>DS)_[)7M]>6_LOVZVOP%\
M'HH4 VSO\HP,M*['\<FO4J]#!1Y<-!>2.?$/FK3?FPHHHKL.8**** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M**^^HT*>'@H4U9'RE2K.M+FF[L****Z#(**** "BBB@ HHHH **** "BBB@
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M%G;C/D^6WECUQN\VO1/V[?AS<^//@?/>V,1FO- N5U+8HRS0A624#Z*V\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!\2?&P)XH_P""@/P[L(PL
MKZ?!9F1>N#&\US^8!!K[;KXET5!KG_!2K59\><FGP$K\Q(CVZ<D1Q_P)S^)]
M:^VJ\W!:NI+O)_@=V)T5./\ =04445Z1PA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!\$:#)_P *9_X*&7UJTWV;3/$5S(C,PXE%Y&)45?\
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MH!_%7Z8UXV4TI0IRG+9['I9A.,I**Z!1117O'DA1110 4444 %%%% !1110
M4444 %%%% !7SW^WE_R;9KW_ %]6G_H]*^A*\$_;FA23]F7Q4S#)CDLV7V/V
MN(?R)KEQ?^[S]#?#_P :'JC(_9H_Y(3X._Z\O_9VKTRO,_V:/^2$^#O^O+_V
M=J],KTL+_N]/T7Y')7_BR]6%%%%=9@%%%% !1110 4444 %%%% !1110 444
M4 %-DC2:-HY$5XV!5E89!!Z@BG44 ?%WB[P)XT_9C^+DNO\ P]T:\UKPWJ<;
MN]G';//"BEOFMY!'\R["59'.."!EL.#L:?\ M]K _DZSX(GMY5QO:WOLGI_<
M:,8[=^]?7-07VGVNI6[V]Y;0W4#@JT4\8=6!&""#P>*\7ZA5HM_5ZG*GK:UT
M>G]:A42]M"[[WL> Z3^W)\.-095NH]8TS)P6N;174=.?W;L<?AGBNXT?]I;X
M8:XR+;^,=/C+=/M>^UQUZF55QT_SFM+6/@/\.]<C9;GP9HP+'<SV]FD#DYSG
M=&%/ZUPNM_L6?"_58PMMI^H:,V0=]C?.S?3]]Y@_2G;,8=5+[TR?]CETDOQ/
M8-&\7:'XB_Y!.M:?J?&[_0[J.;CCGY2?4?G6K7RCKG_!/_1+AD.C>+=0L%_B
M%]:I<D_0J8\?K65<?LU?&3X=^;<>#/'3:C$GS"U%U);M*>O^KD+1$YS]YOYT
M?6\73_B4=/)I_@5]7H2^"K]ZL?8=%?'#?M#?&_X5LR^-O!W]IV4!!FO'M#&.
MG:XAS#^AKM/"?[=G@G6/)BUO3]2\/SM]^3:+F!/^!)AS_P!^ZTAF>'D^6;Y7
MV:M_P#.6"JQ5X^\O+4^DZ*Y7PI\5O!_C?:NA^)--U"5C@6\=PHF_[]G#?I75
M5Z,:D*BO!W1QRA*+M)6"BBBM" HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOF;]K+XQWT<EO\,/"
M$+:EXDUS;:W<5J#),J2X5+=$ YDEW=.H4C@[P1QXK%0PU)U)=/Q9T4*$J\U"
M)%XS_;KT#P[X@U'3]*T&77K6U<QQWT=XL4<S <E?D;Y<Y ;G(Y%<U_P\*';P
M#_Y6?_N>OTZ_8<_8MT;]F/X2PVVM6-EJGCG5PEUK=[)&LHC?'R6T9(/R1Y(R
M/O,6;H0!],V.E66FJXL[.WM W+"")4W8Z9P.:^%EG&+D[J=ODCZB.7X=+6-_
MFS\-;?\ ;NU35+=WT_X;S7&T[3)'J#RJ#Z';!Z>].D_;BU[2XXKO5?AK<6UA
M(YC$S74D8+#&0&:'!(!Z>XK]U.:K7MC;ZE:2VMW;Q75M*NV2&9 Z,/0J>"*C
M^UL9OS_@A_4</_+^9^-/AO\ ;@^'>M2"/41J>@L%R9+NV\V+/]T&(NQ_%17J
M_AKXM>"_&#P1Z/XHTJ^N)AF.UCND$Y_[9$A_TK[-^('["OP%^)0D;6OACH<4
M\G+7&DPG3Y2W]XM;E"Q^N<]\U\U_$#_@BS\,=;\V7PCXP\1>%9VY6.\6+4+=
M/HI$;_G(:[J>?5X_Q(I_@<T\LI2^%M%*BO(-:_X)@?M)?"U4;P!\1;'7["W.
M8;&+49K)C]8)08<<]"]5/^&6_P!NK_GG8_\ @7I/^%>E#/Z37OP:?E9_Y''+
M*IW]V2/4?%7C+0O!&FG4->U:TTBTR0LEU*$WL 3M0'EFP#\J@DXZ5\Z>+OVT
M)M;UJ'0/A=X8NO%&K3R>7#)-;2R><?2*WC_>/D9ZE2,?=->T?"'_ ()$^+OB
M!JB>(_CSXWGCDD.7TG2;C[3=LO4*]RX*1@'/RHKC!X9:_0[X-_LY_#C]G_23
M8> O">GZ$'7;-=QH9+N?_KI.Y,C\\X+8'8"O,Q.=5:ONTERK\3MHY;3AK/5_
M@?D)??&']ICPZV[5_@GJ5K"H9F,WA?4H<@#DABV,#UHTGXI_M'?&*X&C^!?A
M=J%I?+M2>ZBTN5Q"Y P6DG BB!SGY\\'K7[C45YO]I8JUN=G9]4H7OR(_'[1
M_P#@FY^U?XTM7UG6_B'8>&M5D^:.PN==N=T9(Y!^RQO%&.GW"1UJI<?L0_MJ
M>!=_]E:U;>)<=/+UR&?=UZ?; OKW]O2OV+^E%<BQ%:+NIN_J;^R@U9Q1^(GB
MK1?VN_A[H]\?&'POG\1:0L9%VMQI,5] 8^0V\6C8*XZYXP!]3\PV.KZSXD^)
MUCK/PJ\+:MX;\21,MQ%8^&);BY>"Y!^9[8!3+&AR,(6<C)&X@@#^ECFJ=CI-
MEILES)9V=O:274AFG:")4,KGJS$#YC[GFE4KU*UO:2;L$:<:?P*Q_/\ V/Q"
M^(?[._[66B?$KXJ^&]0TOQ'?$ZOJ-E):K:SWD%PDD$LOE<*K.1(V"%&\'A>,
M?95K_P %:_A2\6;GPQXRBDS]V*UM)!CZFX7^5?H;XX^"?P]^)M_%?>+_  )X
M;\57L4/V>*ZUK2+>[FCCR3L5Y$+*N68X!ZDFN"OOV&_@#?QJDOPD\+(%Y'V>
MP6(_FF":R3:*<5+<_/OX[?\ !4?3=<\'G1OA)IFKIXEU(_9QJ&I6R(;0-@ Q
M1JS^9*<X&> >?FZ5[U_P3!_8K\5_ F/5/B5XZNI[#Q'XDL/LR>'9$'F6L+2K
M*9+ACR)F*+\@QM!.[+'"?1O@S]B?X'_#_P :6/BOP_\ #C2=,UZP;S+6Z3S&
M$+XP'5&<H&'9MN0>0<\U[E0W<%%1V"BBBD4%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!/X?Q?ME>+KSQS\0_%%OJ*V$GEIX5L'9&@CSE5<'!6(_[.2QSE@015+XI?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5I\Q^25T(9$(Z'J))/4E5Y'3BQ-644J4/BEMY=W\CJH4U*\Y_"OZL>D?L:_
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M&N7%_P "?H_R-\/_ !8>J.?_ &8)#+\!?!S$8_T5E_*5Q_2O4:\K_9;_ .2
M^#_^O>3_ -'25ZI7IX3_ '>'HOR.2O\ Q9^K_,****ZC **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "N,\6_!GP/XY\U]:\,:;>3
M2_?NEA$4Y_[:IA_UKLZ*SG2IU%::NO,N,YQ=XNQ\Q^+/V#?">IF270-:U#0I
M7?<([A5NX$7^ZH^5_P 2YKD_^%)_M ?"[!\)^*_[:LT)6*VCO0P5?7R;D>6I
MY/W2:^R**\V668=OFIWB^Z=CMCCJJ5I>\O-7/CS2_P!L+QS\/;R&P^)'@N1=
MV0MPD+V<S '#,%<%)/\ @.T<]:]P\ _M-?#WXB-'%9ZVFG7S#/V+51]GD^@)
M.QC[*QKTK4M+L]:L9K+4+2"^LYEVRV]S&LD;CT96!!'UKQ/QU^QO\/O%WFS:
M?:3^&;YRS>9IS_NBQ'&8FRH4>B;/K6?LL;A_X<E-=GH_O+Y\-5^./*_+;[CW
M7(901R**^0?^&3?BEX$E4^"_B*6@5<F-IY[+) P!Y:F1&&/[Q%'_  L;]I+X
M=-&NK^&/^$D@(VAQ9K<G:#U+6K KQW<?AFG_ &A.G_'I2CZ:K[T+ZI&7\*HG
M^!]?45\HZ'^WI8V\QM?%'@[4--N8_ED^PRK(V[_KG($*_0L:]4\,_M4_#+Q/
MY:1^)8=-G;K%JD;6VWZNPV?^/5T4\PPU3137ST_,QG@Z\-X_J>M454TW5['6
MK87&GWMO?VY.!+;2K(GYJ2*MUWJ49*Z.3;<****H04444 %%%% !1110 444
M4 %%%% !1110 4444 %4-;\0:7X9L3>ZOJ5II=FI"FXO9UAC!/0;F(&35^OE
M#7_!,G[87[:7AOX86MU<1:!I[-;ZA=6C F".,&6\D4E2%?@0C<"-ZKP<XKS<
M?C%@J//:[>B.W"X?ZS/EO9'7>./VV/ /AE98='^U>)KQ5;;]E0PVX<'&&D<
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M\+6'B3PMJ]KKNA7\?F6U]9R;T<=QZA@<@J<$$$$ B@#HJ*** "BBB@ HHHH
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M;<T0:I\$9+K:Q;3M0M[G<N. VZ+G/;]Z.G?%?<_[,?B1?%W[._PWU57\QY=
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MY^1<G(P=O6N"\#?L#_M9_$C3T\#^(=6;PCX+TEGL!)JFI@PS0JV"L:0[I)T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M +XKV2BN:IAZ-7XX)_(VA6J4_@DT?)NI_L*RZ3?/?^#_ !S>:9,B_N5NH2)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5]#V(8JA3AR*-T?F]_PV]\:O^AS_ /*79?\ QFAOVWOC4RD'QGP1CC2[(?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KP/\ ;HOH[/\ 9H\3Q.V&NIK.%!ZD743X
M_)#^5>^5\I_\%'+UK?X):/;J^TW&NPAEP/F58)S_ #VUQXR7+AYOR.C"J]:/
MJ>J?LHZ0=$_9V\"6Y4+OL!<X48_UKM+G\=]>L5R?PDTTZ-\*O!EAA@;71;*
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M_P T+V.'?_+S\#[HHKX47]@WXG:+.6T7XHI$#U<375NQ_P"^"W\ZEF_9!_:
MM]OV/XN;^N[S-<U"+'IC"-GOZ4?6J_6B_O0?5Z72JON/N:BOA8?LI_M*1_=^
M+?\ WSXEU(?^TJ8W[,W[3EJP=/BC-,RD$ >);XCCU#)@_C2^N5?^?3*^K4_^
M?B/NRBO@ZX^"G[5UOS'XTN+G'_//73_[,!2V_P /OVO;7A-=N&Q_STU.U?\
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M=%CF/B'P[)]HB-KGS7A)&\+CG<I"R ]@K8Y-?8O['O[04/[17P7TS7)Y8_\
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M2P0Q*$2.-0JHH&  !P !VJQ7QA]$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 -K\GO^"M\O\ PDW[47P3\*"3:6MHV^7JOVB^$6?_ "#^E?K$
M:_(;]O"=O&'_  4X^'^FH68Z3;:2A"GH(YI;L_AA\UI2CS5(Q[LB;M%L^HJ*
M**_25L?&A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9Z1=31-G'[P1-LP?7=BO(?\ @E'\.=,O_A)XXU[4+*UOQJ6L)IYANH%D79!
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MS1116A 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5\5?\%);F:ZM_AQHT)P;RZNW^9N-RB!%R,?\ 35OUK[5K
MXA_;.F'B#]IOX0>&W8-$9;5BG/'GWHC)STY$0_*O.S#^!R][+\3LP?\ &3[7
M_(^VK>!+6WBAC&(XU"*/0 8%2445Z"V.-[A1113 **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC(R%SS7%4PM&C7I*"LV_R.F&(J5*4W-W5C[>HHHKWSR HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "9KP;]K#]KSP?^R;X%?5=<E6_P#$
M-XCC2/#\+XGO9!@9)YV1*2-SGH. &;"G)_;*_;2\+?LE^"WEG>'6/&]]$?[)
M\/+)\[DY GFQRD((//5B"J\Y*_FIX'^%'B[]H3XA2_%SXU7)U.ZOMLUGI$ZD
M*5!)C5XSQ' @P5B'WLY?C<'Z\+A:F*GR07_ ,:M:%&/-,H^$_"/C7]L+XA2?
M%CXP7<EUI\A']GZ9M,<3P@DI'&G\%NN?JYR2226/U1##';PQQ11K%%&H5(T
M"JH&  !T%/4!5  P!P **_1L'@Z>#I\L-^K[GR&(Q$\1*[^X****[SD"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ 8!E((R#P0:^
M8OA?XLF_8G_:NS=$VGPS\8R""4[AY<*%@5DP.GV>23'.3Y;MU)KZ=KRK]I;X
M7K\4OA;J-K!%OU>P!OK$CJ9$!W1_\#7<OIDJ>U>1FF$^LT6X_%'5?Y'H8*O[
M&I9[/1GZ% AL$'(-+7RW_P $Z/C5)\6?V>[+3]0N?M&N>%I?[)N"[9=X H-O
M(?;9\F3R3$QKZDK\^/I&K.P4444""BBB@ HHHH **** /R%\(:X?%7_!2K4;
M\+@MKNIH5]/+MIT/_H%?H57YW_L@Z1%XF_;'\4ZK=3-)<:?_ &IJ,4D;#:\C
MSB$D^HVSN>.^*_1"OJLI35%ON_\ (\G,'^\2[(****]L\T*^;?B=^W=\/_ O
MVRST@7GB?6+=VA-O!"T$*2*2"'DD X!&,J&KZ2JCJVAZ;X@M&M=4T^UU*U8$
M-#=PK*A!Z@JP(K&M&I*-J4K/TN:TG"+O-7/R1^(W[1'BGXI?$&R\5:W]CN3I
M\FZRTJ6 2V4"YSM\ILALX&2>3@>@ ^[/V9_VQ=)^-4T7A_6K:+0O%NPF.&-B
M;>]"C+&(GE6 !.PDG R"><<W\>_V#/#GBO3KK5? ,*>'M=C5I!IZL?LET0/N
M@'_5,>Q7Y?4<Y'Y[V\VI>$O$"2Q--IVK:;<AE8 K+!-&WZ,K#\Q7RW/B,OK<
MU1W4OQ/=4:.,IVAHU^!^WE%<C\(_' ^)7PS\-^)]BQR:C91S2QK]U)<8D4>P
M<,!]*ZZOK8R4HJ2V9\_*+BVF%>)_MD>!4\=?L^^)5"*UUI,8U>!F'W3#EI#^
M,1E'XU[95/6--CUC1[ZPE&8KJ"2!QC/#*5/\ZSKTU4IR@^J*I2Y*BEV/$?V(
M_'A\<?L_Z+',\DEWH<DFDS,PP,1X:(#V$3Q+]5->]5\5_P#!-/5I_P"Q?'^C
M2KL2SNK2Y"L,,'D65'!&,\>2M?:E<^!FZF'BWV_+0WQ4>2M)(****[CD.5^*
MUQ]C^%OC&?S?)\K1KQ_,W;=F('.<]L>M8'_!$RQ:+X-_$.\W96;7XX0O<%+=
M"3_Y$'Y5H?'9@OP/^(1/_0O:B/\ R6DJQ_P17L53]FSQ?>;B7F\731%>P"6=
MH0?_ !\_D*^5SGXX+R/>RWX)'Z$T445\X>N%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 444E "5^.7Q4U ^)_^"NVN2H#)!8R"'J/D\K1PA_\ (G\Z
M_8T=17XP_"V^3Q9_P4D^->I/^\%M>:P(F]H[V.!2/^ _SKLP<>;$07FC"N[4
MI/R/LBBBBOT$^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKNBBBO9/-/#OVO\ XE)X$^$UUIT+K_:7B -I\2$\B$K^_?'<!2%]C(IK[?\
M^":'P(G^!O[+>B+J4;0Z[XGE.OWL4BX:$2HBPQ'N,1)&2#T9W%?GEX$\$_\
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MLT6.V22X!42 DY*,V<D<\$#I^Y5?G%?D]H_9?#T/KX<W*N?<6BBBLBPHHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** &]Q7XF_L*2_\)9\;/B_XKWEC/.6SZ_:+F63/
M_D.OVR[U^)7_  3GB^P^*OBK9]#'+:+C_=DN1_6O2R[_ 'F']=#CQ?\  E_7
M4^WZ***^[/E@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /AG]KR:Y^-W[27@GX36%P8[>UVM=M'G,;S#S)6*]"4
MMT5E_P!]O6OMO2=+M-"TNSTW3[=+6PLX4M[>",86.-%"JH]@ !^%?%O[++?\
M+9_:V^)7Q!:1;RQL3+%9SKP-LC^5;GK_ ,\(7%?;M>7@5[1SK/[3_!:([L3[
MJC2[+\6%%%%>H<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q%?(?AC_P46MI<
M+;:?XEB!VJ,;_.MRG8][B+/Y_6OMVOB;]OV%_!GQ%^%OQ M8&:>SG*22*!C-
MO-'/$OU):7\C7U5XC^+7A3PO\/V\:WNL6[>'3")H;J%PXN,CY5C ^\Q/ 7ZY
MQ@UY.&FJ-2K"3M9W^3/0K1=2%.:ZJWW&YK_B71_"6GG4-;U6QT6Q#!#=:A<I
M!%N/0;G(&3Z5S/\ POCX:?\ 10_"G_@[MO\ XNOB>&T\<?M\?$PW$OFZ!\/M
M)EV@]8[=3SM7M)<,,9/101VP&]A_X=N_#G_H/>*/_ FV_P#C%*.*KUKNA"\>
M[=KC^KT::2JRU\CZ+\/?$SP?XLO#9Z'XKT/6KO&XV^GZE#/)CUVHQ/8_E72U
M\<>)_P#@F_H,=BLWA'Q;JVGZQ"_F1/J@CFC) )4 Q+&T9W8.\;L8^Z:YZ'XQ
M?'K]EN1+;X@Z,_C3PI$P0:L9#*0N0 1= $@DL,"==QZ#%7]:J4_X\++NM5\R
M?J\*G\&=WV>A]T45\L77_!1;X;0Z-#=PZ=KUQ?2!@=/%M&K1,.F]S)MVGL5+
M'U Z5Y_??MB?&/XKL(OAG\/);2R=_*%\MK)?,K ]Y2JPIQU# XSUJY8^A'X7
MS/LM2(X.J]U;U/N>BOB&'7_VQY^5T>$?[\>G+_-ZCGD_;2N)&=(4@4](XSH^
M!QVW$G]:GZ\NE.7W%?5?[\?O/N*BOAEOC5^TS\$P-4\>^%O^$BT+)>=C#;GR
M4&,GS;3*Q?[TBD=>*]F^%?[;7PW^)#16EW?-X4U9\+]EU@JD3MCG9.#L(SP-
MQ5CV6M*>-IS?+*\7V>A$L+4BN9:KRU/H"BF1RI-&DD;K)&X#*RG((/0@TKN(
MT9V.%49)]!7==6N<MC\\_B-X^^)/QU_:<UGX<>'/%][H>EI?W%A###/);P1I
M;HPE,AB 9\F-\!L@EE&0,$>F>$?^";_AFSF>X\5>*]4UZ9GW[+*);1#GJ'+&
M1FYYR"M>;?L(QOXX_:0\6>*KJ+S&%G=7GFLO*33W"<]P"5,HZ]SUYK]"Z\+!
MT(8F+K55S-MVOV/5Q%:=!JE3TT1\(_'O]G/4?V;=:T_XI?"5I[;3],V_;M.:
M1YC;C&#)DDM)"XX=2<J3D':?W?UC\$?BW8?&SX<Z;XHL;=[-IMT-U9R'<8)T
M.'3/\0Z$'NK#(!R!T7C?0$\6>"]?T-SM34M/N+)MOI)&R'_T*OF#_@FWK@NO
MA?XFTG+&2SUC[1R3@++"@ 'XQ,?QK>$%A<2H0TC)/3S78RE)UZ#E+>/7R9PG
M[9=J?B5^U=\-_ PG!MI_L-DZCGRY+F[*N3_P#RS7ZRU^4_P_CA^*'_!4&W=D
M:>STW4I6;G<(VLK-E!]AYT2_B:_5BOF<1+VE><O,]:G'EI0CY!1117.,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW6_#>D>)K
M;[/K&E66JV__ #ROK=)D_)@16E10!Y/X@_9/^#7B:%H[[X9>&%W=7L]-CM7/
M_ X@K?K7G'B#_@FU\!M:A*V_A>\T61O^6VGZK<EORE=U_2OI^BEH/F?<^%_$
M'_!)'X<W43?V+XO\3:;,>AO#;W2#_@*QQG_QZO/=6_X)&Z[I;"Y\.?%&VENE
M.4^U:7):E?\ @:2N?TK]*J*+%<\C\P;[]B/]JSP?$DFC?$9=7$9^6VL_$EVO
MYI.B)^IJC?:-^V]X'C26YTJ^U.WC_P"6<$.FWQ<>XBW2?R-?J916T:M6'PS:
M^9#49?%%/Y'Y2WW[6'[17@F-)/$WPJ>UM5^_->>'[ZV+?1R^W]*FT_\ X*9&
M.5(M3^'K)@XEDM]5^8?1&A_0M7ZJ5EZ]X5T7Q3;^1K6CV&KP?\\[^U2=?R8&
MNB..Q,=I_D9NC0EO _/G2_\ @HU\-KQE%YI7B&P;&2S6T,B#GIE9<_IVKNM+
M_;5^#FK,JKXO6UD(SMNK&YCQSCEC'M[^M?0OB']DGX,>*(BE]\,O#*9ZM9:>
MEHY_X%"%/ZUYOXB_X)K_  'UR$K:^&[[0I#UET[5;@G\I6D7]*Z8YIB([V9B
M\'0?=#-+^-_P\UME%EXY\/7$C#(C75(-_4#[I;/4CMWKL;>ZANXQ)!*DT;<A
MXV# _B*\)\0_\$D?AY<PG^P_&7B73)?[U\+>[3\ECC/ZUP&J?\$E?$FBM]H\
M+_%*VENNWVK3I;,CG.-\<LAZ@=JZ(YQ/[4/Q,G@8=)_@?75%?&5]^Q?^UEX,
M59='^(2:T%&%M[/Q'<X S_<N$1.U4+ZQ_;;\#(LE[HM[JL*CB."VT^^)YZGR
M,OV[^M=,<XI?:BT9/ 3^S)'VY17PM>_M;_M!>!T63Q7\*VM+8#F2\T*^M"W(
MYWLVWIGH*LZ;_P %,HED$>I_#^2+'#R6VJ!CG(S\C0CMG^*NF.:8:6\K?)F3
MP59;:GW!17ROI?\ P49^&EY(J7>F>(M/)',DEK"Z#D=UE+?^.]J[G2_VU/@Y
MJTBHGC!+:1OX;JQN8@.0.6,>WOZUTQQE"6TU]YA+#UH[Q9[?17%:9\;/A]K3
MHECXY\.W,C<B./58"_4#[N[/4CMWKL8;B.XC$D4BRH>C(P(/XBNF-2$OA=S%
MPE'=$E%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\(_LI
M[=<_;7^*.HG=-&G]J2QR') W7T:J,_[I./8>U?=DD@CC9V.%4$D^PKX-_P""
M;]J^K>.OB#KLI_?+;01MC.,S2NYZ^\5>7BM:]&/FW]R._#Z4JDO)'WI1117J
M' %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %35;?[9I=Y!C=
MYL+ICURI%?#'_!-76+/3=>^(&AW4RV^JW4=G/#:R95W6%IUEP#W4RID=>?8U
M]Y5^?W[6_@'4_P!GOXT:/\7/"*BWMM0O3-(NT^5%>[29(VQ@E)TWDC.3F7D#
M%>3CKTYT\0E=1W]'H>AA;3C.B_M;?(_0&BN"^#OQJ\-_&[PO'JV@7:M,BJ+W
M3W8?:+.1@?ED7T)#8;HVTXZ''>UZ<9QJ14HNZ9PRBX/EDM0HHHJR0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KP']H_]D?P[\;[>ZU>P6+1/&OE@1:BH(BNBHPJ7"CJ"/E\P
M#>H"_>"A*]^HK*K2A6CRU%=&E.I*G+FB[,^"O@C\6O&OPS^(UI\)/B-:2-,6
M$-C>S/NDC!4F-0XXEB;&%;J"<$X&%^KZ^7?V^+67P3\8/AMX_@,C-&@B:-1@
M9M9Q*!GU83D8)Y"_6OJ"*5)XDDC8/&X#*RG((/0BIRV<DZE";ORO2_9[%XR,
M6H58JW-OZCJ***]H\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KY$^)N/ ?[;GA+5XRRKK26ZRL<[=T@>TQ^ 5#]<&OKNO$/VF_V>Y?C5
MI=A>Z5=16?B#30RPK<<17$;$$HS $J1C*GD9)!'.Y?,S"E.I13@KRBTU\CNP
M<XPJ6F[)IK[SV^O,_P!HSXDGX7_"G5M2@E\K5+E?L-B0VUA-("-XX/**&?WV
M8[UX?\(_VIM9\!:\W@CXL17$%Q:-Y U:X!,T) &T3XSYBD8(E!).03N#;A8\
M8Z5+^V%^UIX+^%FA70N- MYPEW>VDBN@CP);R97&1\L2;%S_ !J1_%7#B<S@
M\+*4':6UNJ9TT<%+VZ4EIO?HT?<'_!(O]GT_#/X"W'CS4[<Q:[XVE6XBW?>C
MT^+*P#';>QDDR.JO'Z5]Y50T71[/P_H]AI6G6Z6>GV,$=M;6\?W8HD4*B#V"
M@#\*OU\ ?4C>*_*#_@J%^TMJ/Q<^(.G_ +//P_F:ZBANX_[>DMV)6>[!RENQ
M7/[N$?/(>@8<X\HU]D?MY_M7VW[*OP9N=0LI8W\::SOL=!M6 .)<?/<,IZI$
M&#=""Q13][(_.;]C[X.SZ+I,_P 0?$.ZY\0Z\IEMI)W+NENY#F1L]7E/S9Y.
MW;R-S"N_ X26+K*"VZ^AS8BLL/3<WOT/*?VK/A7X>^$?P[\ Z1IMG;MJ@:<7
M&IA!'-=$*AD9ADD@LPP"3L&%!Y.?WB^'5O<6OP_\,0WDC37<>EVJ322.79G$
M*AB6[DG//>OQ*_;%A/Q)^+/PW^'^D(]UK<\WD^3%@G?=RQ1QKUX;]V3SV93W
MK]UXXUC4*JA548  P /2M,R4(XF4*:LE9?<D1A'*5&,I[N_YDE%%%>8=@444
M4 %%%% !1110 445Q_Q>\=1?##X5^+_%TI7;H>DW6HA6Z,T43.J_B0!CWH _
M&3QC:Z9^U!_P4$^)NI:O'_:&@Z=>7"+$Q81SQVI2SA&5(PIVK)CO@YZFO5?C
MQ:Z!X%_9\\6VL&CV-MI@LF@ALK>!$B6:5@B.$ QN61U?.,Y7/7FO*_V"-#ED
MT/Q?XEN7\Z:^OH[3S'.7W1J9')^IF7\J=^V[XO?5HO#7PYTB*>]US4KR*Y:V
MM\Y?):*&+ ^\7=B0O8HI[BOL</"GALNE5:]Z2?XZ(\"K*=;&*FGHK?YGU3_P
M35^ K:Q^P+\0T:/R[[XC)JEI%+DKF 6[6D8_"3SSG_:KY6_8#UQI/"OBW0GB
MV&SOHKLLW!)EC*%<>WV?]:_8?X!_#4?!WX)>"/!>$$VB:1;6=PT9RKSK&/.<
M?[TA=OQK\</V9]WA_P#:;^+GA]6C6..ZO?DB3"_N;TH"O' 'F'CW'I7BY3/E
MQ<?/0]''1YL/(^LJ***_23XT**** "BBB@ HHHH **** "BBB@ HHHH ****
M *FL:3:Z]I-[IE]$)[*\@>WGC)P'C=2K#\037G7_  2=^(-W\'_V@_'?P1UN
M?]WJH>YL-P*A[NV!)*+V$MN3)D]H5KU"OGOX\?LV:GXP\60^// ^MR:%XQM0
MC_+(T/FR1X$<D<R_-'(%&,\@X7E<$GY_.,'/%4XSIJ\H_D>OE^(C1DXS=D_S
M/VA HZU^;O[!O_!0?Q5XB^(<?P:^-PCM_$__ ![:7K5P@AFN)P!MMYP/E9W7
ME)!C?P/F+ G](J^ <7%V9]0G?86BBBD,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OSQ_X+'?#CQ%KWPK\#^.=$MOM%MX/U&:2^DC4-);I/
MY027!'*!XE#>[+QC)'Z'5GZUH]AXDTB^TG4[2*_TV^@>VN;6X0-'-$ZE71@>
MH()!'O3V _,;X8_$C2OBMX/L_$&DO^YFS'-"Q!DMY1C=&X'0C(/N"IZ$5U=<
M/\4/^"7?Q-^#&N:GXC_9\\7_ &^RG+.?#NH.D5RJ DK&KR9AGVY(!DV$9[Y)
M/C'_  T1\8O!\CZ-XJ^#6L-K=H=D[+9W-MGT.SRG'(YR#@YR,"ON,+G5&4$J
MVDOP_ ^:K9;-2O2U1]/T5XI\!_VA+_XO^)-;TB_\,GP[<:7$KR1R3L\FXOM*
MLK(I4C'>O:Z^@HUZ>(@JE)W3/)J4YT9<DU9A1116YD%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7,_$SPQ?>-/ .N:#IU]%I]WJ
M-JUJ+F:,R*JMPX(!!Y7<,]LYP<8KIJ*F45.+B]F5&3@TT?*GP9^-GQ/_ &"[
M2YT/7/!=KX@\$7=Z;J6[M&*GS&5$+)< $#(4825 3MXQUK[K^"/[:GPL^.WD
M6FD:\ND:]+A1HFLXM[EF(Z1Y)67O]QB>.0*\^90ZE6 96&"",@UX=\6/V2?!
MWQ ANK[3+;_A'=>8,Z7%B L,DG)'F1].2>2NT^YZ5\AB,DE&\J$K^3_S/>I9
MA&>E56\U_D?I117Q3_P2_P#C!JWC?X;^)_"/B+4;W4-8\-7Z-$VH2L\J6LJX
M6+YOFPCQ2\'H'4<8%?:U?,'J-6=@HHHH$%%%% !7F?[36I2Z3^SO\2;R XFA
M\/WK*??R6KTRO%_VS9'C_99^)9C^]_8\H/T) /Z$TF4MSX\_X)LV9C^%/B>[
MP,2ZR8LXY^6"(_\ L]?7=?+G_!.K3Y;/X#W\TB@)=ZY<31]>5$,$?_H2-7U'
M7V^ 5L/#T/ Q;O6D%>??'Z3Q7'\'?%#>"1+_ ,),+8?9?L_^MQO7S3'_ +?E
M^9MQSNQCFO0:*[)QYXN-[7.:,N629^0O@_\ :0^)_P .]<-U;>*]5FFC?;-9
MZK.]S$Y!Y5XY"<'MD88>HKZK\$_\%)M#FTV-?%OA;4+;4%&'DT4QS12'U"R.
MA0>VYOK7U=X@^'OA7Q9(9=;\,Z/K+GJVH6$4Y/XNI]*IZ=\(? FC3>;8>"O#
MUE+D'?;Z3;QMQG'*H/4_G7CT\'B:+M"IIYH]*IB*%5>]3U/FO6_VG_B#\>+=
M]$^#?@S4M/BN04E\1ZF%C$"G@[""8T;'?<S==JY ->G_ +-/[+^E_ ?3YKZ[
MG36/%UZFVZU+:=L:D@F*+/(7(R6/+$#., #W".-88U1%"(HPJJ,  =A3J[J>
M&]]5*LN:2V[+T1RRK^[R4U9?UU"BBBNTY0HHHH **** /DW_ (*-^'5U'X2Z
M%JX/[S3=56,@G^"6-P?QW(GZU] ?!OQ0OC3X3^$-;6YCO);S2K>2>2-U<>=Y
M:B521QE7#*1Q@@C Z5>^(GP]T7XI>$;[PWX@MVN=,O I=8Y#&ZLK!E96'0@@
M'T/0@@D5\BZI^RG\5O@#J-QK'P:\63ZG9.^Z71[ADCE8=!N1_P!S,0,_-A&'
M\(KRJBJ8>O*M&/-%I7MOIY'H0E"K25-NS6U]B3]LJQ?XH?M,_!_X<"-I8KR:
MVB(3@_Z9=K"PSVPL(.>V<U^UZJ%4 # '2OPU_8OUS7OVB/\ @H?X,UOQ39Q1
MWNGM-=7%K!&\<=K]EM)!& CL64^<$)!/WF/3I7[E^M?(XJJJU:51;,]^C3]G
M3C!CJ*2EKE-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDW^AZ%/3"S?=H^KZ***]8\\**** "BBB@ HHHH **** "BBB@ HHHH ****
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MU??:Q<&1XA#()B.<[06BR>>2H[YKT'X,7EY??"7PA-J$$EO=MI=N'63&XXC
M#''3< &QVW5\R?:IOVR_VE;G4Y@__""^'\")"&V26ZR'RU((&&G8,Q! (4$9
M.P&OLWIP*X\OBZM:>(7PO1>=NIU8JU.G"B]UJ_*_0****]\\H**** "BBB@
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MU!]>?'R^7+B8/S1WXE7HS]#Z/HHHK]2/B HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOG_EI(WS$G)"[>06<5S5CJ^N?MX_M(:Q\3/%UNT?A+39%BL]-D&Z*.%23!:
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M7S-\>O"^J>-/A'XCT31K;[7J=Y"B00^8L>\B1&(W,0HX!ZFOFCPSH?[1VO\
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MEL ?P#-^=>JUXS_P37FGM/\ @HI\2XQE%N++64D##[R_;X7'7W53D5\KG_\
M#I^K/>RKXI>A^PE%%%?$GT04444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24 (*_&K2_\
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M(TU!A+.SAMU'LB!?Z5[N4+]Y*7H<6/?[N"-2BBBOJ#Q HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBBBX!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PG^U8,?MN?"CW_LG_TX
MRU]V5\*?M8<?MM?"4_[.D_\ IQFK[KKR\'_%J^IZ&)_AT_0****]0\\****
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MER3TX1>  ..E?5Y;E=:%:-:HK)'A8S'4I4W3IN[9U=%%%?:GS@4444 %%%%
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M+@L[O6M0N2D4-XK-'Y2+F1R%92<$H!S_ !>U?.'_  WQX^_Z WAO/_7M<?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$$TR01O+(ZQQH"S,QP !U)/I7\\/Q2UL?M%?'KX@_$&2YN(;'4=8EEL&C(63
MR5;; ,GD%8EC'3J?:OV6_P""@GQ:_P"%/?LF^.]4AF\G4M3M?[%L.<,9;G]T
MQ4_WEC,KC_<K\8_ >G)IGA6P48+2IYSL%VDE^>?7 P,^U?3\/8"&.Q=JJO&*
MNT>-FV*EA</S0=I-V-7P_P",/BYX%2%?#WQ%OWBC! @OW,T:#C 5)1(N/P&/
MQKTK0?VW_BIX7VIXC\):;XEMD.UIK+=!-)U^8E2Z@'_KF/UK@**_1*F04/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?$_[0$G
M_"U_VVOAWX(22.6RT7R9[FWE7*[AFZF4_P"]#%$*^V*^*_V1_P#BZG[3/Q1^
M([D7-K"SVUE*PZ++(5B*^XA@VG!Z-[U]J5YN!]Y3J_S-_<M$=V*]UQI]E^(4
M445Z1PA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD?H[1117SQZ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?CM
M_P %"V?Q7^VIJ6C+N=HDTW3U53S^\AC? SW_ 'U?HS7YO_'"\/BC_@HY='!E
M'_"7:?:L ,_+"T$1_ ",_E7Z05]%DZ]V<O-'GY@]((****^C/'"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML(SQYCQN),?@D=<F"J5</B7AJCNC?%0IU:*K15F?9U%%%?3'B!1110 4444
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MXR"IUY)?U<****]$XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***H:]KEAX7T6]U;4[A;33[.%IYYF!.Q%&2< $D^P!)Z"DY**
MNQI.3LB_7@?[,6LPR?\ !6#3/LDL5U%<?:[5Y(W#!631Y-XR#]Y7C*D=B".H
MKA[SXG?$[]KKQ8_@+X+:#?I9EE^U:C&_E2"+/^LFFX6WBR#QG<V,<[BA_0;]
MB[_@F]X5_9>O++Q=KE[_ ,)3\2(XW5=03=':6&]"CK;Q\%B59E,C\D'A4R0?
MALWS"GB4J-/5)WN?3X#"3H7J3W?0^S****^9/8"BBB@ HHHH **** "BBB@
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MSU)2[A111708A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI>'3?V@?AS=A-_D6L$H7.-VV[8XS^%?>]>5A?]XK>J_([Z_\*EZ,****]4X
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M .@"N\K@_@-_R1?P3_V";?\ ] %=Y7O8?^##T7Y'EUOXLO5A111728!1110
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MP_I8&,_;=4@AZ]/O./2@#K>U5;R]M]-LY[NZGCMK6"-I99YG")&BC+,Q/
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M6A[]1117T!Y(4444 9GB;Q!;>%?#>J:U>'%KI]M)=2<XRJ*6('N<8_&OA_\
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M=*32)GAG18"%)&/E#-CU/6OA+,^I/U5HK\^_V8_^"MWASXU?$FR\'^,?"J>
MY=280Z=J?]I&ZMY+@D!(9,Q)Y9;) ;)&< XSFOT$I %%%% !1110 45BWGC'
M0=/+BZUS3;8Q_>$UW&FWZY/%:L4J3QK)&ZO&PRK*<@CU!H EHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MP?'VK_\ "/\ @3Q'JF[;]ATVYN=WILB9L_I6]7F'[46J#1_V</B?<EMI_P"$
M;U"-6]&>W=%_5A0.)^7W_!.&U\[XV:S.5^6'09CNQP&-Q;@#/J1N_(U^D%?
MW_!,W2UF\1>.=1(^>WM+6W!]I'D8_P#HH5]\U]=E4;89/NV>-CG>L%%%%>N>
M>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!G:_X;TGQ7IS6&MZ78ZQ8LP<VNH6Z3Q%AT)5P1D?2O)O'
MG['?PK\=VDB-X9@T*Z(.R[T0"U:,GOL4>6?^!*:]JHK*=*G4TG%,TC5G#X78
M_*#]HS]ES7O@#?17+SKJ_AJ[D,=KJ4:;2&QD1RK_  M@'&"0VTX[@=O^P/\
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M2Q^I)->IA8UH04*J6BM=-G%7=.<G*FWKW7_!+M%%%=AS!1110 4444 %%%%
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M[[_@K-^SG:QAHO$>K7K'@K!HMP"/?YU45\Q?\,W_  S_ .A-TS_O@_XU=C^
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M!! (K[D_X)[_ !@N?%_@G4O!VJ3O/=:!L>SDD;)-J^0(_7$;# ]%=0.E7O\
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M)=H6;!VS*.R2A2P]"&'\-?1]?*'O!7XB_P#!0+XQ?%3QM^V#>> =9\13^!-
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MJVBM(',+$962,]6B;!P2,@J0>F3]$U_.G\)OB_XG^ 7Q$MOC-\/["32O#_\
M:1LKO3?-WVY5R9'L)&Q\RM&H96V\8!&&6OWJ^!GQJ\._M!?#'1?&_A>X\W3M
M0CR\+G]Y:S#B2"0=F1N#V/!'!!H&>A4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI'4_6O1] _;L^)?A]8E\3>!K#6TP0)-/D>WD8C'+%?,4'_@(SVZ5Y\Y5Z/\
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MOSY^$/\ P42UW1I(K'X@:>NOV6<'4[!$ANU'JT?$<GX;#[FOH@?MU?!MM/\
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M0:5::GIUPMU8W42S031GY71AD'_ZU7*^CC)25T>3\.C"BBBF2%%%% !1110
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M(8="#WJ2O).X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!T^ZD2+R,X;ZU]K5YN!]Z,ZO\S;^6R.[%>[*-/\ E04445Z1PA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>2?M9>(SX7_ &=?'-VJ[FFL?L./^OAU@)_ 2$_A7K=?+/\ P46U
MY],^!^GZ?%*$;4M8ACEC[O$D<DA_)UCKDQ<_9T)OR9T8:/-5BO,[_P#X)/\
MAG^R_P!G_7=7>+9-JFO2[9/[T44,2K^3F6OM>O!/V$O##>$_V3OA[:R)MEN;
M.34&.,%A/-),I/\ P&11^ KWNOA%L?12W84444R0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KX>_X*V:H(/@/X6T\'#W/B..7ZK';7 /ZR+7W#7Y
MV?\ !8'4C'H_PNT\'B:?4;AE_P!Q;=1_Z,-3+8N'Q(WOV#-+33_V;=$G48:^
MN[NX;W(F:/\ E&*^A:\<_8_TEM&_9M\#V[!@7M9;GYCVEGDE'Z/7L=?>X5<M
M""\E^1\Y7=ZLGYL****ZCG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K)\3^$M%\::6^FZ]I-GK%@QW&WOH
M%E3<.C ,."/4<BM:BE**DK,%)QU1XG>?L7_!F^N&EE\$PJ[=H;Z[B7_OE)0/
MTK<\._LP_"KPK-'+I_@;2C+'C8]W&;H@@8!S*6Y]_P :]0HK!8>C%W4%]R-7
M6J-6<G]XR&&.WA2**-8HD&U40 *H] !TI]%%=!D%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!\)_P#!38?Z;\.3_L:@/UMZ^[*^%?\ @IP/W_PW/MJ/\[:ONJO+
MP_\ O5;Y?D=];^!2^?YA1117J' %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<;\6OA;HWQB\"ZAX:UN%6AN!OM[C:#);3@'9,A[,,GZ@LIX8BNRHJ914
MXN,EHQQDX.ZW/S]_9G\>:K\'?B)J?P=\:L+:2.X9+!Y)24BG;#"-"?\ EG,&
M#IT^9NA,G'UY7D?[;W[/\GQ!\*KXV\/PR?\ "5:!%N=+? >ZM0=Q [[X_F=<
M')&\8)*X9^S-\:T^,'@9!>RC_A(]+"P:@N #)Q\DX XP^#G&,,&X QGFP55X
M>;PE1^<7W78ZL5356/MX?/U[GK]%%%>\>2%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 445'=745E;2W$\BQ00H9))&. J@9)/L!2V ^7/VE/'_ (E^)'CS3_@E
M\/[2>]UG4YH[>]2W4AYW<!UA#=%C"G?(W3 Y(57!_4K]CS]E/0?V3_A3;^'[
M 1WGB&\VW.N:NJ_-=W&/NJ3R(DR51?3)/S,Q/P;_ ,$C/";?$G]H;XI?%B]M
MV$=I$T%L).0DUY,TAVGU2.%E] )/I7ZU\5^6XS$2Q-:4Y/T]#[>A15&FH(=1
M117$=(4444 %%%% !1124 ?EW_P6X\.O_97PD\21!D:VN=0L7D4GJZP21]^"
M/*DZ>OL*W-'U.+6M(L=1MSN@NX([B,X(RKJ&'7V-=W_P6)\,-K?[)UGJ2I\V
MB^(K2[=\<A'CF@(Z="TJ>G0?2O$/@#K$.N?!3P7<P,&1-,AM21_>A7RF'_?2
M&OJ^'YVJ3AW5_N/#S6/N1D=_1117VI\V%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'C/[8-TEO\ L^^)(V.&GDMHT]S]IB;^2FOM
M[_@F7H9\/_L2_#>-TV2W4=Y>/U^;S+V=E.#_ +!3IZ9[U\3?M6?#W4_B-\([
MJUTA'N+[3[A-12TA!9KD(KJT8 Y)PY8 <DJ .37NG_!.']O+P#XF^'OA3X2>
M(?)\'>*M%M(M-L3<R!;755085DD.-DQ/6-OO$Y0G)5?@L\C+ZPFUI;0^IRNW
ML6EO<_0NBBH+BXCM(9)I9%BAC4N\DC!550,DDGH *^</7.)^-7QB\._ 7X::
MWXW\477V?2]+A+^6I'F7$IXCAC'=W;"CZY. "1^-_P *)?%7[5'[1&L_''Q@
MD45I'<,;6W S'O5-D,,0(^Y"FT[SR6"GDEB.B_:X^.^I_M\_M#6?@3PE>,GP
MT\.3.R7*L0EQM(2:^(_B)!V1 CHW\.]L>\>%?#&F>#/#MAHFD6J6>FV,0BAA
M0=NI)]6))8D\DDD\FOH\GP+K5/;3^&/XL\G'XKV4/9QW?Y&K1117WI\J%%%%
M !1110 5X9^Q!KP^"O\ P4FUCPV\BPZ?XJBO+->,1CS46]A ]PT8C'NQ%>YU
M\G?M1:G/\)?C]\+OB?9[O,L;F&5HXQ]YK2X67!/?>LFW!ZA:^=SRESX=3_E?
MYGKY94Y:O+W1^Y]%5;&^@U*SM[RVE6>VN(UEBE0Y#HP!5A[$$5:KX$^I"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#\H_P#@K1X!B\"?'KX4_%L6T,EA>;-/U%9(0Z%[
M:42*SC:<EXI64=2!#QR!7=V]Q'=01S0NLL,BAT=3D,I&00?3%>^_\%*OA*?B
MW^R+XQBMX%FU/P^J>(+/(R5-ODS8]S TX'N17QA^R_XT_P"$Y^"V@7,D[3WE
MDAL+HLV]@\1PNXXZF/RVYY^;J>I^KR&M:<J3ZZGA9I3O",UZ'JM%%%?:GS@4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>-?L&1_Z+\3[C<2)/$<B[<=, G/_CWZ5[+7BG_!/6%K/P;X
MZL[F9IM2@UYEN'W%@V(U&[)Y.65^3[5X^,_WBE\_R1Z&'_@5/D?6-%%%:F04
M444 %%%% !1110 445S7B3XE>$?!\ACUWQ/H^CS#_EG>WT43_P#?+,#V/Y5,
MIQBKR=BE%RT15U+X.^ =:U"XOK_P1X<O[V=S)-<7.DV\DLK'JS,R$DGU-5?^
M%$_#3_HGGA3_ ,$EM_\ $5YCXN_;P^$_A>:2&VU&_P#$,L;%6&E6A9<@XX>0
MHK#W4D8KRZ[_ &_/%?C"XGM?A[\,+G4W#,(I9O.O&('0M%"HP<8) <]>O>O.
MGB<)%ZV;\E<[(T<1);M+[CZ?_P"%%?#0=/A[X4_\$EM_\1776-C8Z#IL-K9V
M]OIVGVL8CB@@18HH4 P%51@* .PXKXMEO/VN/BE<(T=M#X*T^1 K*@@M54@_
M>.\R3@G/;CCIZH_[#'Q*^(#1M\0OBJUXBR>8(D>XU!5.>=OFM&$.">@XSTJ(
MXF7_ "YHOYV1;HK_ )>55^9]-^,OVA/AOX!\U=;\9:7;S1,%>U@F^TW"DXQF
M*(,XZCM7S!\;OVO/@YXWF6U3X>M\0;R,B*&[O8ELQM/:.3#3=3]W:O/YUVEA
M_P $Y?A[:Z;/'/JVNWU_)"R).\\21QN5(#A%CSP2#@D]*Y'_ ()RC3H6\;:+
M?:5:1>(M,NHYEN9;=/M2HP:-X]^-VU6C''0&0^M<]6IB:DXTII14K^>WX&M.
M-",95(MMQ^1X9;?L^^._C!J8NO"WPGC\'::9/,BDFEN(HRAY4EKN4^8.1S&F
M#Z 5[!X&_P"":UW)LF\8^+8;?GYK/183(2,_\]I ,''_ $S/UK[OHK:GE=&+
MO/WG]R^Y&<L=4EI'3^O,\"TO]AOX1:;X?ETU]!N+Z:6/RVU&ZOI3<9'1P5*H
MK _W5 /0@CBOG1K?QY^P#X[\Y1)XE^&^K3;21\B2-CH>ODW"@<=I%4]=IV?H
M163XI\*Z1XX\.W^A:[80ZGI-]'Y5Q:S#Y77J"".0P(!# @J0""" :WJX*%DZ
M/NR6S7ZF5/$R3:J>\GN9WPW^(VA_%;P;I_B;P]<-<:=>*<+(NV2)P<-'(O9E
M.0>H/4$@@GIZ_/G0=0UC]@_X['2-3FNK[X;:Z3(LS1ERT6<+*,8'G1$J' '*
MMG;\R8^_K"_MM5L;>]LKB*[L[F-9H;B!P\<J, 596'!!!!!'7-:87$.LG&:M
M..Z_KH17I>S:<=8O8L4445VG*%%%% !7R+^VW\&=1MYM-^,/@OS++Q-X=DBG
MO9+*/]\4B8-%= C^*$J,D@_)@D@1XKZZI" P((R*YL10CB*;IR-Z-5T9J<3A
M?A/_ ,%DOAMJ'AK3(/'^D:YHOB%(42]N+&U2XM9) H#.N'#*"<G;M..E>U^$
M?^"FW[.GC"XCMXO'RZ7.XSMU:PN+91[%V39_X]7CFI?!CP!JYS>^!_#MTV20
MTFE0,<GJ<[,\UYWKG[$/P?UR2:5?#$FFS2L69[&]G0 DY^5"Y11[!0!Z5\U+
M)ZR^&29[,<PIOXDSW;XV?\%8_@Q\,K2>#PQ<W/Q%UM5_=VVE PVN[T>X=< ?
M[BO]*^,O&'C#XY_\%%/$&F1^*K:7P/\ "RWD%Y':P0M%!(IQAD+C=<R%?NN?
MD7YB "<-[9\.OV2?AA\-9FN;'P]%JM]YBR)=ZQBZ>(J<KL##:A!YW* ??@5W
M?C7XF>%/AQ8M=^)O$&GZ-$$+JEU.!)(!_<C^\YXZ*":UHY4J?OUY:=O^"9U,
M<Y>[16I:\$>"-&^'?ABQT#0+*.PTRS3;'&G4GNS'JS$\DGDFOF3_ (*2:>DO
MPG\-7Q4>9#K:PANX#P2L1_Y#'Y5#XZ_X*+>&K7S+'P1X?U'Q#J32>5#-=H+>
MW?/1E4%I'YQ\I5"?45FW'[,_[5?[;@TYM?\ #MMX&\,VY\Z"/6%DT^V+D$>;
MY+>9.[;3@$C !.W&YL[XW&8?V+HTW?TV(PV'K>T52>A^L_P \8I\0/@?X#\2
M([2#4]$M+DNXPQ+1+G(]<YKT&O-_V=_A;<_!/X(^#? MWJ7]KW6AV"6DMXJE
M5D89)V@\A03@9YP!7I%?*'N!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'C7[7'QRA_9U_9_\ %OC4N@U*
MWMC;Z7&^#YE[+\D(P?O ,=Y']U&K\,/A_IL\.CO?WKF>_P!1D:YEFD^:1MW(
M+-DDD\MS_>-?8?\ P5L^,3_$CXQ>&/@YI=PS:9X=0:GK'EGC[5*F45N#@QP'
M(/K<$&OF15"J .@XK]"X3P/-4EBYK2.B]7O]R/E,]Q/+3C0CUU?Z?UY"T445
M^HGPX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !.!D\"N[_8$\-'
MQ7\8/&/C*7;-;Z;:_9;=FCP=\S_*RGL5BA93WQ(,^_EGC#4O[)\-W]QE@PC*
M(4X(9OE!![8)!K["_8.\#MX1^ -A>RJRW.O7<VI.LB@%4R(HP/4%(@X_ZZ&O
MB,[J>UQ-+#K:-V_R1]-ED?9T*E;O9+\V>Z:]X3T3Q5;BWUO1[#6( "!'?VJ3
MJ,C!X8&O'O%7[$OPC\5,\B^'7T:X8Y,NE74D(^@0DQC\%KW:BO)J4*=7XXIG
M;&K4A\+L?%FK?\$Z[C0;XZCX$^(=]I%Y&3Y/VR(K(.G_ "WA92/P2J?_  C/
M[6WPI5#9ZO%XTL+<AGC\^*\,@QT)G5)S_P !.?UK[?HKD> IK6#<?1G1];F]
M)I2]4?$MO^WAXZ\!S1VOQ(^%\UC*S[?.@6:Q^7G[L<RN'Z=G ->G^%?V]OA-
MXB4"]U#4/#TK$*(]2L7())Q]Z'S ![DBOHB:&.XA>*6-98G&UD< JP]"#UKS
M#Q3^S!\*_&(;^T/ ^DQNQ),FGQ&S<DG)):$H2<^N:7LL53^":EZK]1^TP\_B
MA;T9V/A;XB>%O'"LWA[Q'I6M;1EUT^\CF9/]X*21^-=#7R+XH_X)P^$;MO/\
M,^)]7T"Y#[Q]J5+N),=E \MA]2YKGY/@+^TM\+_,E\(?$/\ X2*V5=D5K/>E
MVVC.-L5TK1)QCHW?VH^L8BG_ !*=_1W_  #V-&7P5/OT/MJBOB63]J[XZ_"S
MS!X_^%_VZQM4'FWUO;RVZ_[S7">9#^0%=EX1_P""BGPYUIX8=;L-7\.RMDO+
M)"MS;I[;HSO/_?NKCCJ+=I/E?FK$O"U8JZ5UY:GU117!>#?CU\//'JPC0O&.
MDWD\W^KM6N1#<'_MC)M?_P =KO:[8U(35XNYS2C*+M)6"BBBK("BBB@ HHHH
M **** "BBB@ HHHH **** "O+/VH_&'_  A'P!\:ZDH8S26#6,7EOM97N"(
MP/JOF;N/[M>IU\>_\%'/$LS>$_!OA"UC>6ZU;4GNML;XR(E$:H1WW-.".V4K
MCQE3V=&3\OST.G#0YZL4=U^P?X._X1?]GW3KQTVW&M7<^HOD<[=PB3\"L0;_
M (%]:^B*Q?!/AJ'P;X.T/0(2'BTRQ@LE;'WA'&$S^.,_C6U6M"G[.E&/9$5I
M^TFY=PHHHK<Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *^"_^"F&O1W.N^!-#B=C<6]O=7CQ*
M?X97C2,X^L,@'XU]Z5^?W[0<*_$_]O3P=X79/,@M[W2=+F !/[MI1/(3]%G;
M\J\C-9<N':[M+]3T<#&]6_8_5#X=^&1X)^'_ (9\.K]W2-+M=/&/^F42Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>L:?K-KG;Y^GW23ID=1N0D9KKIUZ=3X))F$J52'Q*QJT445N9!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX>_X*;6\C0?#B8+F)7U!&;(X+"V('_CI_*OMJQ.;&W/_ $S7^0KXO_X*9?\
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ME+$:>SJZQ_+T,#1]6L]>TNTU+3KA+NRNXEF@FC.5=&&01^%6Z^/OV??'6M?
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M?L\7/SU^\^RP4^?#Q\CT&BBBO).X**** "BBB@ HHHH _,O_ (+-_%BY.B^
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MVX/,L@/5 > /XB#G@?-X;\+?!-W\7/B9IFC232R/J%P9;RZ8EG$8R\KDG^+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M86J[3N< @D;>^#Q4ZDJ<E*+LT=,HJ2Y9+0_1'_@FQ^Q?J&NZE#^T%\5DEO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***^3?VV_P!O30/V4].&@Z7;+XC^)6H0"2QTC#&&V5B5
M6:X(YVY!Q&IW-C^$'=32<G9 >A_M1?M9>"/V4_!3:QXHNOM.JW2L-+T&U<?:
MK^0>@_@C!QND/"^[$*?Q<\6?$+Q+^T%\7-=^*GBR*&VO-5VK:V40)2WA552-
M8]QR%"+C/5BS-WYR]3NO$WQ<\87OCKXCZC/K_B+4#N*WF"(UYPNS[J* <+&
M H[9Z;?3@5^D9#P_.,HXS$Z6U4?U?^1\?FF:QY98>AKW?Z(****_2CXP****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "HKNY2SM9KB5MD<2-(S8)P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYEQ^-;4%S5X+S7YA)VIS?D?I[1117WY\N%%%% !1110 4444 %%%% !1110
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M(>3@LQ9L#@;L#@5\!?\ !(;]GE[C3=<^/'B3-YK&MS7%EI$DO+!/,(NKC/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH3!*;L961EB;#@-'LR2H!V+CI7WYHOP_\,>&I(I-(\.:3I;QC;&UE810E!Z
MJHP*Z*FW<22CL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !117$?&CXEV7P=^$WBWQM?[3;Z%ILUZ(W.!+(JGRX_J[[5'NPH
M\Z^/O[;7PC_9PCE@\4^)XKK78P<>']'Q=7['T9 <19[&5D!]:_'7XH?%*Z_:
M,_:'\7_$^[TZXTVUU#RDTZSNAN,4"QK''ANF=D>3M[R'GUX3P7IK>)+B^\5Z
MVW]H:MJEU+=//-\V7,A9WQC[Q?<<_3WKMO8<"OTC(L@=Z>-K/S2_)MGR&:9J
MDIX:FM=F_P _\@HHHK]+/BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N>C\+O\3/C%X*\&;)'M;VZC:Z6-R"8=Q,I'NL<<A!]^U=#79?L
M*^%T\8_'CQ3XNE2.:#0[8Q6\BG.V68F-&!SWBCF'_ J^4X@J?N88=?;DON6K
M_0]_*(?O)5G]E?B]$?H  %  &!2T45XAWA1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y _P""E$.[X8^%9L?=
MU<K^<+G_ -EKZ:^&5P]W\-_"<\F-\NDVCMCIDPH37SA_P4D3=\&_#K^FNQC\
M[>?_  KZ*^%/_)+/!W_8&L__ $0E>72_WNIZ([JG^[P]6=51117J'"%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%%%P"BBBBZ ****+H HHHI706844447068444UI%CQN8
M+]3BBZ'9CJ*C^T1?\]4_[Z%1S7]M;1EYKB&)/[SN /S-'-$+2./^.ED=0^"O
MCZW5!)))H-\$7CEOL[E>OOBOEC]@G4DG^%^N6.\M+;ZLTFTG.U7AB QZ#*-^
MM?8FK:]H<FEWB76K6,5LT+B622Y155-IW$DG@ 9YKX._X)\ZDJR^-M/9\LRV
MD\<>/0RJQ_5*\]R4<=2:>Z:.Q)O"U%V:/L:BBBOI#QPHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF
M#]O+Q2]CX&T'P[ [B;5+TSNL?\<<*_=([Y>1"/=*^GZ^9=!\,M^T=_P46\&>
M%EC6?1] N8)+ME)9##:@W4P?TW.?)/N5KQ,XK>RPK766AZ>7T_:5D^VI^MO[
M-OPQ3X,_ 7P'X,$?E3Z1I$$-TH[W)7?.WXRM(?QKTNBBOSH^M"BBB@ HHHH
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M;X>7IFCJ2SR,3@2.HY" _BQ&T=R.0_9M_9]U/2]6F^)WQ'FDU3XA:L#(L=R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ]X\T;X9^$[WQ)X@N6M-*L_+$TJ1M(PWNJ+A5!)^9ATKQW_AO'X/?]!Z\_\
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ME_9_^&*]/A[X9_'28#_[)6WL\;_.ON,>?"_RO[SP+_AY1X'_ .A7\0?^0/\
MXY3)/^"E'@M8W,?A;7FDP=JL8%!/8$[S@?@:^A/^%"_#-?\ FGGA;_P36W_Q
M%+_PH?X:?]$\\*_^"6V_^(I^RQO\Z^X?/A?Y&?,7_#S32O\ H0KS_P &2?\
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M^*?^'9FE_P#0^WG_ (+4_P#CE'_#LS2_^A]O/_!:G_QROM:BJ_L_#?R_B_\
M,GZY7[_D?%/_  [-TO&/^$]O/_!:G_QRO/\ ]FKPS/\ !S]J7Q5X)OI_M$L5
MG/:13;-GG[7BECDVY.W=$"VW)QNQDXK]%J^#?VA88_AU^W-X1\0)N2/6H[1Y
MY&^Z"^^S?!]D52?KGO7)6P]+"SIU::M:2OZ,Z*=:>(C.G-WNG]Y]64445]<>
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#[IY<=Q[UFR:E^T9XV=C+JECX4MV7*QKY2#KG@HLD@/;DCI]<^Z*H50 , <
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M_P#@M4!_PRUX6..?^$SM1_Y(WU 'S;_P1+_Y+QX\_P"Q:_\ ;J&OV2K\;?\
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M5F_1117[$?G@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M13)IDMX9)9&5$C4LS,<  #))-3*2C'F927,^5%CX$^%V^)'[57ARRECD:PT#
M_B9S;6.%\H"1'Q[RM"I'<?E7Z75\4?\ !.7PC]N;QOX[N8HS/=7"Z;!(O5.D
MTZCGH2\'_?-?:]?F%";K2GB']J3?RV7X'VM=>SY:*^RDOGU"BBBNLY@HHHH
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M_M4@_:/_ &C?A:J1^-/AR=<L[==T][%9.&(&,EI[<M"O_?'\J^W:*P^H\O\
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MJNO@H['T<OB84444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q%X^L_P"V/^"C
M/A>WUX^;IT,4$M@K# 7R[:26+'//^DAC]3BOMVOB+]KRX_X0G]J[X3^+[ETA
MT[;:I+))\JJL5VQE).>R3#\J^W:\S!^[4JQZ\U_O._$:PIR\OR"BBBO3. **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KXX_P""CGA.]F\,^#_%EC#(W]CW<L$\T:;A$)=C1LW' #QX!/&7 [BOL>H[
MBWBO+>6">))X)5*212*&5U(P00>"".U<^(H_6*3A>US>C4]E-3['SO\ !OXZ
M>'?C-HJ3Z;.+75XHPUYI4Q_>P-T)']],]&'8C(4\#T:OGWXZ?L1C3[N7QG\)
M;I]!UFSW71T>.0HC,,DFW?/[MNHV'Y3G * 8.C^RE\;-3^,'A74H]<$+ZQI,
MD<<MQ"H3ST=3M=D' ;*/G& << 4\+C*GM%A\0K2Z-;.WZBK8>'*ZU%^[U75'
MN-%%%>T><%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7RGXKU:Z_9<_;0\#?$C1%\NQU6\62[MU^59 Y$-XF
M .=R2!\G/SOG' KZLKY(_P""@NFR2:1X,U  ^5#-=6[''&YUB9>?I&U>'G%-
M5,*Y/>-G^-CT\NFXUTNY^ZM%87@K71XI\&Z#K0.X:E86]X",8/F1J_;COVK=
MK\[/K0HHHH **** "BBB@ HHHH **** &^E?CI_P42^'MQ^R_P#M@:#\6M&M
M&3P[XL8W5U'"OR_:5 2\CZXW2(RR@D\N['^&OV+Z5\Y_M\_L^_\ #17[-?B3
M1+.V^T^(],7^U]&VKES<P@GRU]Y(S)']7![5=.;IR4X[HF45).+V9\TV=Y!J
M%G!=6TJSVT\:RQ2H<JZL,@CV(-35\\_L5_$L^,/AG)H%W(SZCX>=8 6R2UN^
M3$<G^[ATP.@1?6OH:OU/"UUB*,:D>I\17INC4<'T"BBBNHP"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBBET'U/+_\ @EC/%:_MQ_&:P5&#-IVHNO<!4U*!2"<]?G'Y&OUL
MK\@/^"95ZMG_ ,%#?BI"4)^TZ?K,2D?PXU*W?/Y(1^-?K_7Y-6_B2]3[R'PH
M=1116)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$>GH]UNP!QN0%1U'4COZ&O"=-_9#TV:ZDN?$/BC5-8G?'[R%%A)P ,,7,A/
MQU'%=UHO[/?@#0V1X_#T-W*HP9+UWGW>Y5R5_(5JJ>8U=H*'J[_D0YX.&\G+
MT5OS*.M?MX>'?-:W\/>&-6UFYW%8Q.4@63GJ-N]L8R?N@].!VR)OC]\<?%TC
MKH'@*WT6#&0U]"ROUSP\SHI&,#A?7\/7]+T?3]#MQ;Z=8VUA;CI%:PK$GY*
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M)P!FOF\U2I5:.(Z)V?HU_FCVL!><*E'NKKY'V?111728!1110 4444 %%%%
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M_)>/'G_8M?\ MU#7Z@?'#]I;X<?LY:/#J/C_ ,36NB"XS]FLP&FNKG'!\N%
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M?^ UZ[3(XTAC2.-0B( JJHP !T I]?'TX*G!170]^I)SDY/J%%%%:F84444
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M,_M\?";Q P6\OM3T!VX']I6+$9SCK"9 /J<"O5_#/QM\ >,8XSI'C'1;QY"
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M-%[$684444[B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P
M?'7C32OAWX1U7Q)K<XM],TZ S2MQENRHN>K,Q"@=RP%?$'[!>A:C&OB[74A%
MMH5])%!"C,2S21EFP"1R%63&>Y/L<:W[8OQ U'XS?%+1_@UX4D\RWMKE'U.:
M,DI]HQR'Q_!"A+-S]XD8R@KZ&\%^$-/\!^%=-\/Z5%Y5C8Q>7&.[')+,?]IF
M)8^Y-<-&+Q6*]HOAA?YM[_<=E1_5\/RO>?Y&W1117T)Y 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-_[>
M-J9O@_I<RJ"8=9A+-QE5,,P_GMKZ0KQO]KRU^U?L^^)SM9FB:UD 4>ES$"?R
M)KS\PCSX6:\G^&IUX67+7@_,_2#]D#7SXF_99^$VH;M[MX8T^)VSG+QP)&YZ
M#JR'CM7L5?+'_!,;7#KO[$?PZ9V)EM5O;-NO_+.]G"XS_L;:^IZ_+S[4****
M "BBB@ HHHH **** "BBB@ I*6B@#\2?$WAD?LW_ /!1?QAX8CA6UT3Q!<2R
M6@.0BPW2BYB"#OMD'DC/3#5],5QW_!9CP#<^&_%'PO\ B[I0\FZMY#H\\X7A
M)8G-S:GW/-S_ -\C\.@\.:Y;^)O#^FZQ:%OLM_:Q7<.X8.R1 RY'8X(K[;(:
MW-3E1?1W/G,TI^]&HNIHT445]4>$%%%% !1110 4444 %%%% !1110 4444
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MW*<<XZG/DWP3_P""4_P5^$>NMK&I6M]\0+R.3?:Q^)#');6X'3,"*J2-UR9
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MI;JUNG:SU3Q%8-AKT\AX+9\_+" #OFR P!P0@+/B_MO_ +>VN?M'>(;GX/\
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MZO,IQY$6#D0KM >3DL05#%RS+^S6DZ59Z'IEIIVGVD-C86D2P06MM&(XH8U
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MY:(^CRN/+2JUG_A7SW/J6BBBO,.H**** "BBB@ HHHH **** "BBB@ HHHH
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M^"??PGN6W1PZS:#^[#?Y'_CRFL6;_@F[\-V4^7KWBA&]6N;9A_Z(%?5]%9O
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M'I;W[$?^/AJ+XY=(O[Q6PKZR_ ]0A_:"^&5PN5^('AD#_;U6!/YL*TK3XP^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7+_%+Q!>>$_AGXNUO3BBW^
MFZ3=WMN9%W*)(X7=21W&5'%=17-?$S3SJWPW\5V(19#=:3=PA&&0VZ%UP1W'
M-9U;\CL7"W.KGQI^PKX4M;W1?$7C:[FFOM=NKU[%Y[@[F50J2NVXDEB[2*6)
MY^0>^?JJOE_]@6^$GP[\1V?>'5/.Z_WX4'3_ (!7U!598DL)&R_JX\=?V[N%
M%%%>J< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M96]AKW/?:***_0#Y0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9&,D,3DD[B6_UDG.2S< G@9 8^WU]OE_#KJ153%.WDM_F?.8K.%!\E!7\_\
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M^9AG8-I!"XW-D8 !+#ZO]Q@:/\J7]?-G@_O<74[MG<_$CXCZ+\+/"MUKVM7
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M&?\ P48_8A/[4W@RSU[PLD,7Q%T*-DLUD81KJ-N3N:V=ST8'+(3P"6!P&+
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M6YOXTGZH^'S^VE\8/ *%_'7PI9;=?^6ZVUS8*1C/WW$BD]>G]*ZSP]_P4?\
M 5^R)K&@ZYI,C'!DA6*XB3W)#JWY*:^M*Y3Q)\)_!7C&5IM<\):+JMPP*F>Z
ML(I)<'T<KN'X&CV&)A\%2_JOU'[6A+XJ=O1GB'Q4_:[^%_B;X,^,HM$\4I-J
M=SI5Q:6]HT$T$YEEC,:[0R#."X.1D#!.>#63_P $@_"_S?$GQ&Z=K/3X6Q_U
MUDD'_HJN%_;6_9W^&WPM^%]MK_AS0FT?5IM3AM$:&ZF>-@8Y&8%'9@.(R>-O
M(Z]C]*_\$L?#(T7]FF;4BF)-8UNYN0_<HBQP@?0&-_S-?.YA*K*LHU;72Z'J
MX:--4FZ=[-]3[%HHHKSS4**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBJVI7T>EZ;=WDO\ JK>)YG^BJ2?Y4 ?C7^SY<-XJ_;NDU3'F+-K.
ML7KMD?Q)<D'_ +Z9?SK]+:_-C_@GE;_VM^T!J=[/\\T.C7-R&_VFFA0G\I#^
M=?I/7U64QM0;[M_H>3F#_>I=D%%%%>V>:%%%% !1110 4444 %%%% !1110
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MSQ%J7C/XJZT$EU#6+N2W@DV@99G\VY<#L"S(!_NM7EXS][4IT%U=WZ([L/\
MNXSJOIHO5GV;1117J'"%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2_$;X/> [1LW#17-V8P!\S7$L4,1Y/8PR>G4UW4,*6\,<4:A(XU"JHZ  8
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MELD$0/KM4 $GN3R>]=#110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F?[27PPM_C)\!?'G@
MRX"9U;2IHX'D^['<*N^!S[+*D;?A7IE<W\1[[^R_AWXIO<[?L^E74V?3;"Q_
MI0!_/7\,-2>^\+QI)N+6[M$&9LY'##Z8#8Q[5UM<3\(XWC\+2,RL%>Y9EXQD
M809'KR"/P-=M7[UDTI2P%)SWLO\ @?@?E^9)1Q=11[A1117LGF!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %(S!5)/0<TM<_X\U%--\*W[M@M*GDHI;:27XX]<
M#)Q[5S8FM'#T9U7M%-_<;X>FZU6--=78]X_X)X^&6U;Q!X]\<RI(4D9=-M)7
MP3@MYLJGTP!;]#CGZ5]MUXG^QOX'3P+^SWX70QQI=:I&=6N&7_EH9_FC)]Q%
MY2_\!KVROSC"Q?LDY;O5^KU/K\1).HU'9:?=H%%%%=1SA1110 4444 %%%%
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M #H!3JZZ<>2"BNAA.7-)ON%%%%60%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+A%O5_!GV'?^-/#VE,BWNNZ99LXRJW%Y&A8>V6K';XS> %_YGCPY^&JVY_\
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M."YXRW4XKX7-85:>*E&LTY:;;;'TV"E3E03I7MKN>MT445XYWA1110 4444
M%%%% !1110 4444 ?CA^VOJB_$C_ (*=:/HWFJR>'(+"W!Y8#R86ORO7^]*1
M]<Y[BO<:^7_"^K1?$[_@H5\6?$LA^TQ6E]J36<^=PVI.MK$0?>+.!Z?2OJ"O
MO,CARX=R[L^8S25ZJCV04445](>,%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7B'[&+Q:+_ ,%2-1M8HCMO
M+>^'7[K-:"9FY]2#^=>WUX)^SK>-8_\ !6G11YHBCF$\3\X# Z&Y"\_[07\:
M^9SY?N(OS_0]K*W^]DO+]4?LS1117PI],%%%% !1110 4444 %%%% !1110
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M#3N  &P"J[BW#_!3X8P>*/V2;;PY<QQP2ZU;7$WF.I($K2LT$I'&=NV(_P#
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M_B?YA1117J' %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MESU92[MGU"7+",>R04445D 4444 %%%% !1110 4444 %%%% !1110 4444
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M:M)^84445V'.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO%<6\J3V\R"2.6-@RNI&0P(X(([U+7OGD!1110 4444 %%%% !1110 4444
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MHHIB"BBB@ HHHH **** "BBB@#PC]L;_ ))AIQ_ZB\7_ *)GK]COV6[J6_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDAA!4-GKGS&G'X5\C_%34$M?#)M>#)=R*H&[! 4[B<=^0!_P(5^FGP?\%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,5CZ2O-67H5"AA*CY8:L_5'X._%S2?C9X.'B31;/4+*P:XDME34HDCD8IC+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\H_M-:]K/QH^)WAGX(^"XWO-4O+Z);M5W!6G< QJQ'_ "SC1C(YY X)P4-?
M1GQ&\5_\(/X#U_7PB22:?9RW$:2'"NX4[%)]"V!^-'_!'WX$KK1\4_'?Q$ZW
M^LWMW/IFF-*N61CA[JXZ8W.7" CD 2CHU?,9WBG3IJC'>6_H>WEM#FDZKZ?F
M?H!\"_@[HOP$^$_AWP+H"?Z#H]L(C,P >XF/S2S/C^)W+,?3.!P!7H%9>N>)
MM(\,6OVC6-5L]*M^3YU]<)"G&,\L0.X_.O)/$W[:WP(\'R%-1^+'A8RJ=K1V
M6H)=LISC!$.\C\>E?#'TI[?165X=\2Z5XOT6TUG0M3M-9TF\C$MO>V,ZS0S*
M>C*ZD@CZ5JT %%%% !124M !1110 4444 %%%% !1110 44E+0 @%<-\8_C-
MX1^ W@._\7>,]6CTK2+487<09;B7!*PPIU>1L'"CT). "10^/'Q[\(_LX_#V
M^\8>,K_[)80?NX+:+#7%Y,02L,*$C<YP?0  DD $C\8?B1\2/'?_  4(^+#^
M(?$+S:)X$TN1HK+3X6S%9Q$@^5%D8DN' !>0CCC@ (AWH4*F(J*G35VS.I4A
M2@YS=DBU\5_BQXY_X*&?%1M5U9IM ^'6CRLECIL;YCMT./E'&)+AQ@LY&%!'
M&-JM[/H>AV'AO2+73-,MH[.PM4\N&&,<*.OU)))))Y)))))I-#T.P\,Z3:Z9
MI=K'96-LFR*"(< >I/4DG)).2222235^OU?*\KIY?3OO-[O]$?"X['3QD[+2
M*V04445[IY04444 %%%% !7S%X:V^%_VQ-6LH#MBU#S=_3K) MP?_'A7T[7S
M)\9&3PY^TUX,U-1Y2W(M3-(2!DF9XF)^B;:^?SCW52J_RR3^1Z^7>]*I3_FB
MSZ;HHHKWSR0HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\86Z
M7GA'7+>09CEL9T;Z&-@:V*S/%'_(MZM_UZ3?^@&L:NM.2\C2G\:/SS^'_P#R
M/WAW_L)6_P#Z-6OT?K\X/A__ ,C]X=_["-O_ .C5K]'Z^.X9^"KZH^CSKXH>
MC"J&OZHNA:'J.IN-R6=M+<D>R(6/\JOT5]K*\DTCYJ-KZGCW[//PY71-!/BK
M5$%QXBUPM=//(/FCC<[@H]"V=Q^H':O8:**Y\/AX8:FJ<.GXOJ_F;5JTJU1S
MEU(+RRM]2LYK2[ACN;:9#')#*H974C!!!ZBO@3XU>!4^'?Q"U'2K?=]A;;<6
MI8Y/E.,@?\!.Y??;FOT"KXW_ &PIDD^)M@J-N:/2HD<>A\V8X_(C\Z^;XCHP
MEAE5:]Y-?CT/9R>I*-9P6S1Z_P#LDZM/J7PI:&8[DLK^:VBYZ(523'YR-7K6
MOZHNA:'J.IN-R6=M+<L/9$+'^5>9_LN^'9-!^$MG)*I1]1N)+TJWH<(I_%8U
M/XUZW7L9=&?U*FGORK_@'G8QQ^M2:VN>/?L\?#E=%T'_ (2K5$%QXBUPFZ>>
M0?-'&YW!1Z%L[C]0.U>PT45V8?#PPM-4X=/Q?5_,YZU:5:HYRZD%Y96^I6<U
MI=PQW-M,ACDAE4,KJ1@@@]17P)\:O J?#OX@ZCI5ON^PMMN+4L<GRG&0/^ G
M<OOMS7Z!5\;_ +84R2?$VP5&W-'I42./0^;,<?D1^=?-\1T82PRJ->\FOQZ'
MLY/4E&LX+9H]?_9(U6?4?A08)CN2ROYK:+GHA5),?G(U>TUY)^R[X>DT'X2V
M<DJE'U&>2]VMZ'"*?Q6-3^->MU[>6J4<'34][(\S'-/$S<>["BBBO3.$****
M "BBB@ HHHH **** "BBB@ HHHH *^=_C)\9/&:_$(^ ?"%@(+^1HXHKF-?,
MGN#(BM\FX;4 W$%CG&TG<N#7T17SK^T=YG@/XD>!_B#;1F5K6=(IX1A0XB?S
M N<=75I%)/8#%>#G,JD<+S4Y.-FKVWMLSU<L4)5^6<;Z.U^YU7PV_8GBDNFU
MGXD:I+K>HROO:QM[A]C9!R99CAW/(^Z5P5^\P-?4]O;QVEO%!#&L4,:A$C48
M"J!@ #TQ1;SQW4$<T3K)%(H='4Y#*1D$4^N;#X:EAX_NUOUZOYFU:O4K/WV%
M%%%=ASA1110 4444 %%%% !7A?[6OQ:T?P/\.-3\/23"?7]<M6M[>SC(+)$W
MRO-)_=7&X#NS# & Q72^/_[1NE?!S39+&T,>H^+)XP;;3^2D0;($LI'11C[H
M.YN.@RP[']AG_@GGK/CWQ-!\9/CU;/>/=,MYIOAW4E#/<L0"DUTG18U&-D&.
M@&X*JA6^9S7,HTHNA2UD]_(]O X-S:JST2_$\!^#'_!/C]H/Q)\)O#OCSP#K
M"Z/#XBW,VF2:C+IUPD!)6.X;^%T9?F!SNP5*@Y!KWOP+_P $9]>\37Z:K\6/
MBD]Q<N%\ZWT2-[F9_;[5<8QCI_JFZ^W/W=\6_P!K#X5_ ?Q'HGASQ=XJL]+U
MC4Y4AAL8_P!X\"M]V295_P!5'Q@,V >W0X]BW=P>*^(YYVY;Z'T?*KWMJ?+_
M ,+?^";'[/\ \+#%-#X'A\3:A'C_ $SQ-*;\MCN8FQ"#](Q7TII.CV&@Z?%8
M:996^G6,(VQ6UI$L42#T55  _"KU%04%%%% "4M%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!')&LB%'4,K#!5AD$>E?S'?&31+;PO\7O'.C64:Q6
M>FZY?6D$:+M58X[AT4 =A@#BOZ=:_F9_:'_Y+_\ $O\ [&?4_P#TKEH _;W_
M ()B^';3P]^Q/\/3;(HEOUO+VXD P9)'NYAD^X147Z(*^J:^;/\ @G#_ ,F3
M_"S_ *\9_P#TJFKZ3H **** "BBB@ K\PO\ @M[X=MY?"/PMUTQQK=P7U[9>
M9CYV22.)\9[@&+OTR<=3G]/:_-C_ (+=?\DF^''_ &&Y_P#T0: //O\ @AU_
MR,_Q<_Z\]-_]#N*_6BOR7_X(=?\ (S_%S_KSTW_T.XK]:* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!K*&4@C(/!%?S/\ [1FA6GA7]H/XGZ+81)!8
M:;XHU2SMXHU"JD<=W*BJ .@ 4<5_3%7\UG[6/_)TWQD_['/6?_2Z:@#^A7]G
M_P#Y(/\ #?\ [%K3?_26.N^K@?V?_P#D@_PW_P"Q:TW_ -)8Z[Z@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /E?\ X*9?$*_^'G['7C:?3+MK._U0V^D)*APWESRJLRC_ 'H1
M*O\ P(U^07@W28]&\.64*HR2/&LDFY<-O89(/';ISV K]'_^"T7B#[!^SCX4
MTE7VR:AXGB<CUCBMK@D?]]/'^5?GQ&NV-0>PQ7Z%PA1C*K5JO=)+[SY//ZKC
M3A!;-_E_PXZBBBOU$^("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***"<#)X%)
MNRN-%7X?^&U^(W[2'@3P\ZQRVEM<B^N5QN&V,&9T?T#+$J\_W_<5^GM?#7_!
M/OPV=?\ B!X\\;2@O% B:=:2E,*PD?>V/0JD48Z9P_UK[EK\RIU/;U:F(_FD
M[>BT1]K4C[&$**^ROQ>K"BBBN@YPHHHH **** "BBB@ HHHH **** "BBB@
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M>?F$^3#2?R^\[,''FK1/L[_@G_X7/A?]DOP+&\/E7%[%/J$AQ@OYMQ(Z,?\
MMF8_P KZ'KEOA3X7/@?X7^$/#K#:^DZ1:6+#&/FBA1#^JUU-?$H]Y[A1113)
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\L?\ @JK,VN_M
M#>!]!B?+_P!B0@8&<--=3+T]?D%?J=7Y7?MD,?$G_!13PIIVWS5MKC1;=UR/
MN>8LK?HY--1YI*/<J+M=GW H"@ < 4M%%?H:V/E7N%%%%, HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9Y$*S7[R +&8\[L*J1R9(VG &3R*]JHK*I3C47++;_(N-1TW=!1116A!XO\
MM@?#^T\?? 3Q.)XE-WI%L^JVLS ;HFA4N^/]Z,.O_ O85^;/[/EU)9_'7X>R
M0R,C'7[&,LO7:UPBL/Q4D?C7ZB_M)ZU;^'_@%X_NKDXCDT>YM!DX^>9#"G_C
MTBU^?_[#7P]G\;?'C2[\QYT[P^C:C</CC< 5B7/J78-]$;TKYK'T^;%TU'=V
M_,]O"2Y</)RV7^1^I->:>)?A&/&_Q@T3Q3KS6]YH?AZS/]EZ<P+$7SOF2>0$
M;2%58P@Y^8$\8%>ET5]%*"FK2/'C)QU044459 V21(8VDD94C4%F9C@ #J2:
M_,WX81O^TK^V@=;E5IM,&HOJK;OX;6WP(%;/8[84/^\:^SOVO?B%_P *Y^ G
MB2ZBE\N^U*,:5:D'!WS95B#ZB,2,/]VO%?\ @FY\//L'AGQ)XTN(\37\ZZ?:
MLR\^5&-TA!]&=E'UBKQ<7^^Q-.CT6K/3P_[JC.KU>B/M"BBBO:/,"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\]^.7P5T
M;X[>")?#^K-):31OY]CJ$(R]K.%(#[<@.N"0R'J#P58*P]"HJ)PC4BX25TRX
MR<&I1W/S<T[7?%O[*7C$>#?'D4EWX7F)^PZA$I=%3/\ K(CU9>1OC/S+D$>C
M_1.FZE::QI]O?6-Q'=V=P@DBFB;<KJ>X->V_%#X6^'?C!X1NO#OB6R^U64WS
M1RIA9K:4 [98FP=KC/N""005)!^"M:\/>-?V+?%<5IJAD\0^ ;^4B.ZACVHS
M$9)4$GRI@ 3L)VN >>-RQAL94RYJG6?-3Z/JO7R-*V'AC%ST]*G;H_\ @GTE
M167X9\3:=XOT6WU72;E;JRG7*R+U![J1V([@UJ5]A&4:D5*+NF?.SBX/E:U"
MBBBM" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCK6BV
M/B32;G3-3M8[RQN4,<T,G1A]1R"#@@CD$ @@BKU%1**DG&2NF5&3@^:)X3\(
M?BWXM_X)X_&:/4[%[C7/AWK;A+[3BX'VJ%2?P6XBW95A@,"1P&8+^YVC:M:>
M(-)L=4T^9;FQOH([FWF3I)&ZAE8>Q!!K\7/VBO"'_"7_  KU5(TWW6GXU"$;
MB.8P=_3J?+,@ ]2*^[/^"5GQD'Q2_92T?2KF?S=7\'S/H<X8_,85P]LV/[HB
M=8Q[Q-7Y)G.!6!Q%H?#+5?Y'WV7XIXJCS2^):,^QZ***\(],**** "BBB@ H
MHHH _)#_ (*V:HWC?]JKX1_#ZXN7.E1V4$CQQG[CWEXT4A_WMD$?Z>M>FV]O
M%9V\4$$:PPQ*$2-!A54#  '8 5X'^T]XFT[XI?\ !44PVE[#J-AHY@M$FMY0
MZ"2WLC,Z @]4FWJ1V96!'6OH"OMLAA:G*?=V^[_ASYS-9>]&/D%%%%?5'A!1
M110 4444 %%%% !1110 4444 %%%8&L?$#PMX?E,6J^)-'TV4'!CN[^*)N_9
MF'H?RJ)5(15Y.Q2A*6R-^BO*]8_:E^%NBSM#/XOMII!_SYP37"G@'[T:,O?U
M]?2N(U3]NSX>V,TD5K9ZWJ(7[LT-K&D;?]]R!A_WSWKDGCL-3WFOO.F.%KRV
M@SZ+HKR/X$_M#6?QRO=>BM-'ETF/2Q"RM-<!WF$AD'W0HVXV#N?O>W/KE=%&
MM"O!5*;NF85*<J4N2:LPHHKD_$7Q<\%>%&F35?%6DV<\(R]N]XAF'_;,$L?P
M%5*I"FKS=A1A.3M%7.LHKP7Q!^VS\,]'\O['<ZEKA;.?L%DR;/KYQC_3-<)/
M^VYKOB22X@\'_#JZOY%;]W-++)<':,9+111\''^V<9[UPRS'#1=N:[\M?R.J
M.#KR5^6WKI^9]:T5\=S?$/\ :.\:-"]I86?ABUD;:Q2"&,+U!++,TD@'T'TJ
MDWP5^+7B6>Y7Q%\3;B.UN =\=M>7,R'/!7ROW: 8[#CVI+%UJG\&C)^JLOQ!
MX>G#^)5BO37\C[!UCQ%I7AVV-QJVIV>EV_\ SUO+A(4_-B!7"Z]^TG\,O#A4
M7?C'3I2QP/L):\[9Y\E6Q^-?/>E_L<:&N]M8\1:E?S,2Q>U6.#J>I#"3)_&N
MQTO]F3X>:?&@?1I+Z1?^6EU=2DGZA6"_I6JAF53:$8^KO^1+E@X;S<O16_,U
M]8_;D^'>GS-'9PZSJN.DMO:HB'@?\]'5N^/N]C[9Y!OVW]=\1>=#X6^&]U?2
MK]R3[1)<8X_BCCB]_P"]7I6F_#OPKH\R367AO2;6=/NS0V4:N/\ @6W-=#5K
M+\;/^)64?1?JS/ZWAH_#2;]7_D?./C#QI\=OC)X3N]&G\*6>FZ9=!5G2.$6T
MC@$,!_I$I(Y Z =,>M0>$_A7\<]'\(P^';'XBWOAKP\K._\ 8]GK5U%"&?)8
MF*(;&))Y)/>OI6BAY#0J2YZTY3?F_P#@#_M:I%<M**BO0^;8_P!CMM1O!=ZU
MXRN+Z5R#*1;$R-S_ ,]'D/;U%=%;_LA^"H8W#W>L3LRXW//&-IP1D8C'/.><
M]!7N%%=<,EP-/:FOG=_FS"698J6\SP+P;??&O]C#7I=<^&&O7&J^'7?S;O2V
MC,UO* 1Q/:YY../-CPP ;E!7Z"_LN_\ !5'X<?&U;31?&9C^'?B^3;&$O9LZ
M==N<#]U.<;"3_!)C&0 SFOG>O,?B=^S[X:^)'F7)C_L?6&Y_M"U0?.>?]:G
M?Z\-P/FQQ7SV/X<6M3"/Y/\ 1GK87.-HXA?-?JC]L8Y%D4,K!E89!4Y!'K3^
MO-?AW\*_VG/V@?V)VBTH2#QOX$7Y(;'4/,N+:(<8$4@_>6YY^X?D/.%;K7H^
ML?\ !4O]I?Q%E="^&>DZ/!)G9-_8U[/(/O?QO*$Z8_AZCWQ7Q,L)7C-TY0=U
MTL?21K4Y1YE)6/U]VT;:_%36OVJ/VU?&&<>(/[%M9<_N[*VTZWV9S_%M,HX.
M.O8'J,UQ_B+2_P!IOQE;R/K/Q@U:X5P2UDWB*\2,YSQY:*(\_,1]#CI71'+<
M7/54W]S,98NA'>:^\_=VBOS _85_X*/WFD:G:_"3XZW;V.IV[K9Z;XGOV"\@
M86&\<GJ>-L_1LC<?XS^GJL&4$'(/(->?*+B[,ZDTU=#J***0PHJO/<1VD,DT
MLBQ0QJ7>21@JJH&223T %?&_[1'_  5.^$7P76[TWP[<M\1O$\.4%IHLH%G&
M_P#TTNR"N/\ KF)#G@@4 ?9V?>@_G7XL>(/VXOVLOCE//J'ABX7P9X>F/[BV
MTVUMX5VXX(FG!E?C^)#MSV';A-;^''QR^(\I7QK\6]5O[63[T<VKW=VJC!X$
M3%4'/8'N?Q]"CEV*KI.G3;3\M/O.2IBZ%)VG-'[-_$;]HKX8?")9!XP\?:!H
M$\8R;2ZOX_M)^D()D;\%-?+'Q&_X+$_!3PIYL/AFTU[QO<C.R2UM/L=LWU><
MJX_",U\#>'_V.?#UB0VKZS?:HX.0L"+;QD>A'SM^3"O3O#_P;\$^%]IL/#=B
M)%.Y9KA/M$BGU#2%B/P->W1X<Q=36HU'\7^!YU3-\/#X+R_KS/+_ !MXJ^(G
M[?'Q('C/QI<#2/"5G(8+'3[8L(K:'.6CMP?O.2%WRMU/;"A![MHFB6/AW2;7
M3=-M8[*PM4\N*",<*/ZDG))/)))/)JX!@  8%+7VV7992R^%EK)[O^MCYK&8
MVIC)7>B6R"BBBO:/-"BBB@ HHHH **** "OFO]LRTGBC\(:I"NT6\UQ&9<=&
M/ELGM_ _Y5]*5XM^UMI<FH?"<W,>-MA?PSR9'12'BQ^<B_E7C9Q3Y\%42Z*_
MW.YZ>72Y<3%_+[]#V'3[Z/4M/MKR$YAN(EE0^JL 1^AJQ7&?!?6!KGPI\,70
M;.+*.!FSDEHQY;$GURAKLZ]'#U/:48S[I/[SBJQ]G4E#LPHHHKH,0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *S/%'_ "+>K?\ 7I-_Z :TZS/%'_(M
MZM_UZ3?^@&LJO\-FD/B1^>?P_P#^1^\._P#82M__ $:M?H_7YP?#_P#Y'[P[
M_P!A*W_]&K7Z/U\=PS\%7U1]'G7Q0]&%%%%?;'S 4444 ,FF2WA>65UCC12S
M,QP !R2:^)/[/NOVB/CE=O;^8NFRS[I)A_RQM(\*&]B0!@?WF^M>Q_M)?$B=
MHXO /A\-=:WJI6.Y6'EDC;I'[%^_HN<]<UW'P4^%,'PL\*K;N$FUFZP]]<*.
MK=HU/]U<GZDD]Z^6Q<?[3Q,</'^'!WD_/HCW</+ZC0=:7QRTCZ=SO;.S@T^S
M@M;:)8;:"-8HHT& BJ, #V %3445]/;ET1X>X44450ADTR6\+RRNL<:*69F.
M  .237Q)_9]U^T1\<KM[?S%TV6?=),/^6-I'A0WL2 ,#^\WUKV/]I+XD3M'%
MX!\/AKK6]5*QW*P\LD;=(_8OW]%SGKFNX^"GPI@^%GA5;=PDVLW6'OKA1U;M
M&I_NKD_4DGO7RV+C_:>)CAX_PX.\GY]$>[AY?4:#K2^.6D?3N=[9V<&GV<%K
M;1+#;01K%%&@P$51@ >P J:BBOITN71'A[A1115""BBB@ HHHH **** "BBB
M@ HHHH **** "O*OVG-'35O@[J[M%OFLY(;J+'\)$BJQ_P"^'>O5:J:OI-IK
MVEW6G7\(N+.ZB:&:(DC<C#!&001]0<URXJC]8H3I?S)HZ,/4]C5C4?1F3^SC
M\9_#GB3X7^&[&\\0Z?#KUI;BQFLKJY6.<F(;58*QRX*!6W#(Y/<$#V:WO(+Q
M0T$\<ZGG=&X8?I7RSJG[*7@#4%(@M;[32?XK6Z9B.?\ IIOKROXM?!'_ (4K
M::;XN\)ZKJ'F6=VFYK@HTD#=4D#*H&-PVD$<[A[U\N_KN!I7JP4HQ6K3Z>EC
MW(_5<54M3FTWT:/O^BL?P;XFM_&7A/1]=M5*0ZC:Q7*QD@E-Z@E3CN"2#[BM
MBO4A-3BI+9G!*+B^5A1115DA1110 52URUO+[1[ZWT^]&FW\T#QV]XT0E$$A
M4A7V$@-@X.#UQ5VBDUS*PUH[GYW>'_ _Q9^$/Q?77H?!D_BC7M.O&F2\OM*D
MU2RN)6Y$^YE*N<G<&8@J>3AAQ]0:A^U%^V]XVMWBAEMO#UM<?NV>WM+&W:,'
MJP+EI!]1SZ5[C17S?]A47)R<W^![/]J5+644?#'Q"_9+\8_\(7KWCSQ/XL.L
M>*8XWO[VWF#W#RJO+LURS99P@)^Z1\N,XYK]7/\ @G#^T$WQ\_9GT674;S[7
MXG\.M_8VJM(1O=HP##*1WWQ%/F[LK^E>$LH=2K ,I&"".#7S]^Q[XPN/V._V
MXAX.DD?_ (0OQHT=A&)7PH65\VLO4Y,<NZ$L>H+GC(KR,VR^.%C&I27N[/U[
MG?@<7*NY1J/7H?M!1117S9ZX4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5_,S^T/_ ,E_^)?_ &,^I_\ I7+7],U?S,_M#_\ )?\ XE_]
MC/J?_I7+0!^Z?_!.'_DR?X6?]>,__I5-7TG7S9_P3A_Y,G^%G_7C/_Z535])
MT ?$_P#P42_;?U+]G&STGP-X"CCN_B7XBC#V\C1B7^SH&<QI((R"'D=PRHIX
M^4D@X ;D_"/_  2RC^(VBVVL_'WXD>+O&7C*Z02W%M;ZD!:V;L,F-#(KEROW
M=R[5ZX7H:^(/^"G.NZOH?[?'BO4ED=9=-_LF?36D *JJ6=NXP.X\WS#]<U^N
MO[+_ .UAX(_:D\#VFK>'=4MX]=C@1M4T"20"ZL)B!N!0\M'NSMD'RL/0@@ '
MR1\7OV"OBA^SKX5O/%/[.OQ<\8@:7"TTOA34KTS>?$HR1 %41NPP<1O'R.C9
MX:G_ ,$>?B/XD^*_B_X\^*?%VKW&NZ]?'0OM%]<D;GVK?*HP   %      K]
M,:^6_P!EG]FF_P#@!^T'^T%JEOIJV?@OQ;>:7J&B2I+&0S!;I[J(1JQ9!'+/
M@;@ 5*[<X. #ZDK\V/\ @MU_R2;X<?\ 8;G_ /1!K])Z_-C_ (+=?\DF^''_
M &&Y_P#T0: //O\ @AU_R,_Q<_Z\]-_]#N*_6BOR7_X(=?\ (S_%S_KSTW_T
M.XK]:* /CK_@H)^W?#^R;H-AH7AVVM]4^(>M0M-:PW66@L+<$K]HE4$%B6#!
M%Z$HQ)PN&^9/V4?V9_'O[?'A:Z^)7QJ^*OBR?PU>74MO8Z-IE\(5N/+;;(^S
M!BBCW;DV+&"=I.1P3B?\%3_V5?BKXV_:*A\9>%_">M>,M!U73K:VC;1K1[MK
M.6,%6B=$!9%/#[B-OSGG(-?>?[!'P?\ $'P+_99\&^%/%%NMIK\/VBZN[17#
M_9S-/)*L98'!8*RAL<!LCG&: /D?]H+_ ()*Z?X \$ZKXM^"?BWQ%8>(=*MV
MNSI5]=*WVM8QN9(9HUC:-\ D;MP+ #Y<Y'AW[$'_  4F\?\ @'XC:!X4^(GB
M&Z\6^!M4N8[*2YU:0S7>G%SM299V.YD#%=RN6PH.W!'/[8U_+[\2M-MM%^(W
MBJPM(Q%:6FK7<$,:C 5%F=5 ^@ H _J"KX)_:R_;$_:$\"^&O$.H^!/@CJ&@
M>&])DDCN?%GB Q7$BHCE3-':1N=J<!A(Q=2IR0!S7W)X?N);S0-,GF.^66VB
M=V]6* D_G7/?&;38-8^$'CFPNEWVUUH5]!*O'*-;NI'/L30!^!/@WX[_ !!^
M-_[27PRO_'?BW5/$LZ^*=,:-+R<^3"?M4?\ JX5Q''U/W5'6OTQ_:>_;7\?^
M+_&6I?"7]F/0+CQ=XLL_W6L^)[.%9K;3&R08HV?]T'!!!DD.U2"H!;)7\?/A
M-H+>*OBIX.T1;VXTUM2UJSLQ>VK;9K<R3HGF(>S+NR/<"OZ0?@]\&?"/P'\"
MV'A+P7I$.DZ3:@9VJ#+<28 :69\9DD;'+'V P   #\0/C_\ L<_M0Z#I5WX^
M^(^C:MKT-LK7-YJ3:Q'J4UHO!9G"2LRJ.[*-JA>H KMO^"?W[?7B[X1_$S0_
M!_C+7[S7?A[K-S'8NNI3-.^E2.0D<T3L2RQAL;TSMVEB!N'/[=75K#>6\MO<
M1)/!*IC>*10RNI&"I!X(([5_,I\:/",/P_\ C%X[\,6R[;?1->O]-C7.<+#<
M/&!GOPM '].E%<C\)=<F\3?"OP9K%P6:XU#1;.[D+')+20(YR?7)KP;_ (*,
M?M*7/[-W[.]_=Z-<_9O%OB"7^R=)D0C? S*3+< ?[$8.#V=XZ /!?VWO^"E6
MJ^%O&Q^$_P #4CU;QDUR-/O=;CA%SY%TS;!:VL9!628,0"S!E4_* 6R59X'_
M ."6?B+XN:'#KG[0WQ6\6:KXBO1YTFDZ9J"RK9YY"-+,LBLPXR$0*""%+#!K
MP7_@C;\(;7QU\<O$WCK4HA<CPE8Q_91( V+NZ+JLG/<1Q3?BP/:OV>H _*/X
MR?L9?%[]A71[CXC_  )^)>N:GX:T=?M.I:'>-EXX5^](\(_<W$8!);**5&6'
M0D?FQ\1O&UY\2OB!XF\7:A%#;WVOZI=:K<0VX(C22>5I65<DG:"Y R2<5_3S
M>V<&H6<]I=0I<6TR-%+%( 5=&&"I!Z@@D5_,Q\</"-K\/OC5X_\ "UCG[%H?
MB#4-,@R23Y<-S)&O/T44 ?T9_L__ /)!_AO_ -BUIO\ Z2QUWU<#^S__ ,D'
M^&__ &+6F_\ I+'7?4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PGQS^'X^*7PD
M\4^&5027-[9L;4,^P?:$(DAR>P\Q$S[9KPK_ ()Y?$277OAMJWA&^D8WOAV[
MS%'(,,MO-DA>>3MD67/H&45]85\*Z1C]GK]O2YM#_H^A>+B=G("[;H[E('0
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MBBK)"BBB@ HHHH *^6/VN[ZVT7XK?!S4YP$2VU$RS2 <[$GMF_3YOSKZGKY
M_;R_Y#_PY_W[K_T.WKQLW_W.?R_-'I9?_O$?G^1^[,;B2-64Y5@"#4E4])R=
M+LR>3Y*?^@BKE?G!]<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?S,_M#_\ )?\ XE_]C/J?_I7+7],U?S,_M#_\E_\ B7_V,^I_^E<M
M '[I_P#!.'_DR?X6?]>,_P#Z535])U\V?\$X?^3)_A9_UXS_ /I5-7TG0!\-
M_P#!1C]@>?\ :<L[;QKX*>&#XA:5:_93:7#".+5+969A&7/"RJ6;:QX(.UB!
M@K^->IZ3XU^!OCMK:\@UGP1XOTF7(R9+.[MV[,K## $=&!P0<@D&OZ-?!WQL
MT#QK\6/B#\/+%+R+Q!X*^P'4?M"(L4JW<'GQ-"0Y+ +\K95<-Z@@E/C%\ /A
M_P#'S03I'CSPS8^(+=01#-,FVXMR>\4RX>,_[I&>^: /RN_9U_X+#>-_ [66
MD?%/2U\<:,I"-J]F%@U.)/4CB.; QP=A/4N:_5CX._&KP;\>O!=MXI\#ZY!K
M>E2G8[1G;+;R8!,4L9^:-QD?*PZ$$9!!/Y'?MH?\$MM=^!.E:EXV^'MY/XI\
M$6H:>\L[C'V_3(AR7. !-&O=E 91R5(!8>4?\$Z?CYJWP/\ VFO"EO;W<B^'
M_%%[!H>K66X^5(LSA(I2O3='(RL&ZA=XZ,<@'] M?FQ_P6Z_Y)-\./\ L-S_
M /H@U^D]?FQ_P6Z_Y)-\./\ L-S_ /H@T >??\$.O^1G^+G_ %YZ;_Z'<5^M
M%?DO_P $.O\ D9_BY_UYZ;_Z'<5^M% %:[NH=/M9KBYFCM[>%&DEFD8*B*!D
MLQ/   R2:^+_ (N?\%//".E^)5\%_![P_??&3QS<2&"&#1PPLE?N?-"DR@9S
M^[4K@'+KUKXM_P""H'[:NN_$OXE:Y\*?#5_)IW@?P[=/9:@MNQ5M4O(SME\T
MCK%&X9%3H2I8Y^7;^@__  3[_9?T#]GKX$^';Z/3X3XR\1:?#J&L:FZ9F)E4
M2+;ACRL<8*KM'!8%NIH \PM?V<OVGOVG&%U\9OB?_P *M\+7&&;P=X%PL[(>
ML<LX8@=?XGF''W17XV>/M%@\-^.O$6D6C2-;:?J5S:1-,P9RB2LH+$ 9. ,\
M5_4-7\POQ>_Y*SXV_P"PW??^CWH _IE\*_\ (L:1_P!></\ Z *R_BC_ ,DS
M\7?]@>\_]$O6IX5_Y%C2/^O.'_T 5E_%'_DF?B[_ + ]Y_Z)>@#^<+]GC_DO
M_P -/^QGTS_TKBK^F:OYF?V>/^2__#3_ +&?3/\ TKBK^F:@ K^:S]K'_DZ;
MXR?]CGK/_I=-7]*=?S6?M8_\G3?&3_L<]9_]+IJ /Z%?V?\ _D@_PW_[%K3?
M_26.ORV_X+:^+I[SXQ_#WPN2WV?3M DU-1_#NN;AXS^.+1?TK]2?V?\ _D@_
MPW_[%K3?_26.ORN_X+:>&;BU^.?@+Q"P_P!&O_#AL$]-]O=2NWZ724 >P_\
M!$6&%?AG\3)EQ]H;6+5'.>=HA8KQ]6;]:_2ZOR$_X(G_ !,MM)^(7Q \"W$R
MI-K-C;ZG9JP W/;,Z2*#W)6=6QZ1D\8.?U[H *_FL_:Q_P"3IOC)_P!CGK/_
M *735_2G7\UG[6/_ "=-\9/^QSUG_P!+IJ /Z%?V?_\ D@_PW_[%K3?_ $EC
MKOJX']G_ /Y(/\-_^Q:TW_TECKOJ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK@?CQ\18_A#\%_&
M_C-RJOHFD7-Y"&Z/,L9\I/\ @3[%_&@#\4/VC/'?_"X/VROBGXG619[&ROVT
MJS;J/+@Q;HZ>@80LW_ _<U@UR7PQ@D'AK[5+*TLMY/).S,><YVG)[DE2<^]=
M;7[AP_A_J^7P767O??M^%C\US>M[;%R\M/N_X(4445]&>,%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5N_LL^&U\>?M40W<JQRV?AFRDNSQN4N (U!/3<))BPZ
M?ZOV-<Y>7*6=K-<2-MCA1G9L$X &3TKZ _X)T^$Y+?P+XG\772-]JUK41 CL
MH&^.%<EE]C)+(#CNE?'Y]4YI4<.NKYGZ+_-GT65PY85*W967S_X8^N:***\D
M[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB>XS-)9Z1Y+2,/\ EI<3JV[ZD0O^9KZ$_:L\1?\ ",_L[^.KL8S+I[67.?\
MENRP?RDKD_\ @D;X9-G\+_'7B Q[3J&KQ68;'WA!"&_+-P?UKY;.)7J0AV5S
MV\#&U.4NY]Z4445X9VA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?DY^PZXU_]I?XEZ\=S^;!=L&_Z[7B/GZ_)_.OU1\2:I_8OAW5-
M1SC[):RW&?\ <0M_2ORY_P""9NGM)/\ $+4I%R<64"R$\DDSLP_1?SKMP,>;
M$P7];&59VHS9]T4445]P?.!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445YM\5/VB/
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MS!S]L69CG_II''/7T1661Z8>4/Y9-?B:9G_&4N\4PHHHKZ$\<**** "BBB@
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ML5Z<9<T4['#)<KL%%%%62%%%% !7R%^WG&5UKX;OV,EV/R:W_P :^O:^/_\
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MUZ5&HJU.-1=3BJ0]G-P?0****W,@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^*?VY3'XX^-'PC\!QEC--.))5VEDV7-Q'$K$=#
MCR9,^@SZU]K5\6:AN^(7_!1NU@F036?AJT7;M&1A+8R GTQ-/^@]:\W'>]",
M/YI)';A=)N?9-GVG1117I'$%%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2V-Z-:5%\T=S\X/^';OQ*_Z#GA7_ ,"[G_Y'I/\ AV[\2O\ H.>%?_ NY_\
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M^1[G;V\=K!'!#&L4,:A$C0855 P !V %2445]NO=5CYD****H04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% SP3X1XT#]M+Q
M%9IG%[;39RW]^..<_J.G^%?8M?&.DM)H_P"W-I\K[EBOH\#*XW*;%D&">HW)
MU'H17V=7Q^!]UUH=I,^AQ>JIR[Q1A^,O ^@_$#1GTOQ#ID&IV;'<$F7YHVQC
M<C#YD;!(RI!Y-8/A#X&^ _ LD<NC>%M/M[F)_,CNIHS//&WJLLA9E_ UW5%=
MSH4Y2YW%7[VU.55:BCRINP4445N9!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\9^/H3H/[<5K=2$I'J$,;+D\-NM#"/PW)^8KZ"
MKP7]IDG3OVJ/AW=E<1R06<9;..?M<JM^085[U7-D_NRKP_O-_>C?,-52E_=_
M(****^D/%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \6_:
MTT#^U?A:;]0@DTN[BG+,/F*.3$5!_P!Z1#_P&NL^!/B+_A)OA/X<NNDD=L+2
M1<Y.Z(F/)]R%#?\  JZ/QMH'_"5^#]:T<; ]]9RP1M(,JKLI"L?HV#^%>&_L
M:^(!/H.OZ$Q7=:W*74>3R5D7:P'L#&/^^O>OG)_[/FL9=)IKYH]F/[W 276#
MO\G_ ,$^C****^C/&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"IP4([(\V4G.3D]V%%%%:$A1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%?2'B!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&-"F[\N_J%%%%?3GB!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'SM\1IET[]KCX=3CY?-%FA/)R7N)8Q_,"OM.OB?
M]I'_ (DOQ6^&VN MN2Y3N /W4\;\>_S_ ,J^V*^2P_NXK$0\T_O1]!6]ZA2E
MY6^YA1117I'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!\B?MS;=+\7?#755/ERK+<9DSC CD@8<^VXU[C7DG[?NE^;X'\
M,:ED_P"CZDUOCM^\B9O_ &E7INAWW]J:+I][_P _%O'-_P!]*#_6N7+?=QF(
MCWL_P-\9KAJ3]5^)>HHHKZ4\4**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KY7\ R#X=?M5:WH[O'%;:G)-$H7Y402@7$2@9Z_=0>Y]Z^FM
M<URP\-Z1=:GJ=S'9V%JGF332'A1T^I))  '))  )-?#7Q$^+2^,?BI:^++*R
M_L^.QEA^S*<&5UB?<KR<XWGT'   R<9/RF=XBG1E2E?WXR3MY=3W\LHSJ1J1
MM[K5OF?>=%,AF2XB26-@\;J&5EZ$'D&GU]2GS*YX+WL%%%%4(**** "BBB@
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M$H_(5]!U\,?2A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<U\0/ >C?%#P3K7A/Q%:
M"^T36+22SNH6ZE&&,J>S X8-U! (Z5TM% '\]OC+X9ZW^S=\9/$/PK\1EI6L
MIFDTZ^*D+=V[#='(HY 5T^8@'Y6#J<FIZ_1'_@K9^S[_ ,)U\'K+XH:+:_\
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M%?-17*K(]7?4****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#(TFJ>#]!U&5CN+W>F0RDGURRGGDUQFM_LF_"/Q S-=>!=-B+#!^PF2T'7/
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M>#^XT4Z4MIH_4*BOS)M_VUOVK_#&(]4^&L6JA1EI9_#=V>,_WH9%4'BKMO\
M\%8_%OAZ18?$_P *;?S\D%8[^:R.1U^62)SQD5C*,H_$K&BC?9W/TIHKX)T/
M_@KIX)N O]L^!=>L#W^PSP77_H1CKT#0?^"H/P/U<+]KO-=T3/47^ELV/^_+
M25',@Y9=CZVHKPG0?VYO@3XBP+7XCZ;"?^G^.:T_]'(M>@:'\</AUXF;;I'C
MWPSJCG^"SUBWE;\E<FBX69VU%1PW$5U$LD,B2QMR'1@P/XBI*9(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y^?\%>M4\G
MP3\.M-S_ ,?&HW5QC_KG$B_^U?UKWCP3I;:)X+T#3F^]9Z?;VYSZI&J_TKY@
M_P""LDDFN?$#X4>'XVPYANF4=<&:6% <?]LZ^N0-J@#I7T&3KWIOT//QS]V"
M]1:***^E/'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\_?^"F'_(Z>"_\ L'S_ /HP
M5^@5?G[_ ,%,/^1T\%_]@^?_ -&"O+S3_=I?+\SOP'\=?,]'_P"";'_))_$W
M_8:/_HB*OKNOD3_@FQ_R2?Q-_P!AH_\ HB*OKNM<!_N\/0C%_P >05^=OQ^^
M-GAOXV_'FP\.>(]<;0OAIX>NF6>813.UY(AQ(P6-&8%B#&I(^5=S9RV*_1*O
M@'Q-_P $[/&>N>)-5U&+Q+H<<5Y=RW"H_G;E#N6 /R=>:PS"-:<(QI1NKZFF
M#E3C)NH[=CZ"TW]LOX%Z/I]M8V7BV.UL[:-888(M(O52-%&%4#R>   *L_\
M#;GP5_Z'3_RE7O\ \9KYA_X=K>-?^AHT'_R/_P#$4?\ #M;QK_T-&@_^1_\
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M:O\ >%%%%=QR!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5!?7UMIMI+=7EQ%:VT2EI)IW"(BCJ2QX KR3]JWXO7/P:^#]_J
M^F3_ &?7+R:.QTZ3RQ($F?+%B&!'RQI(1D8R .]?%MO\&_B1\<K6RUSQMXTG
M-M=)]I@BO))+AX@PR"L.5CC!&#A2, \@'BN2=:;J>QH0<I6OV2]6=4:4.3VE
M6?*CZY^(/[;?PK\">9##K,GB:^3 ^SZ'&)UY[^<2(R/HQ/M7S/X__P""BGC7
MQ"SVOA#1K+PU%)\JSR_Z;<YSP5W 1C/H4;ZUM>&_V3_!&CLDFH"\UN7:-RW4
MWEQ;AU(6,*?P+-7J6@^$=$\*QE-'TFRTP, &-K;K&6Q_>(&3^-:1RW,,1_%F
MH+RU?]?,S>,P='X(N3\]%_7R/DJ;P#\8_CI?)=^)+G4I8=S.DVO7#111$C^"
M(\J#_L)BO;/A3^S;HGP[N$U+4)%US6$(:.66(+% 1R"B$GY@?XCSP,!><^P4
M5ZF%R7#8>2J2O.7=_P"1Q5\RK5H\L?=CV04445] >0%%%%, HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YM_;+CEB
MA\'WL9*FWFN%W8X#$1,/_03QWK[8MYUNK>*9#E)%#K]",U\@_MC1!OAOI4G\
M2ZK&H_&&;_ 5]0_#JZ^W?#[PQ<[Q)YVEVLF]3D',2G.>]?*?#F-9=TG^%CWO
MBP=)]F_S.AHHHKT#D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^?/VX],;4/@HDZ@D66J6\[?0K)'S^,@K0^%EY_:'PU\*
MS;MQ;3+8,V,981J#^H-:_P"UC9/??L_^+$C&7C2WEYST2XB9OT!KB?V=+M;S
MX,^&V4YV1RQG/4%97']*X<+[N937\T4_N=CIK^]@HOM+]#TBBBBOJ3PPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)_>"(Y! 8')4$ X[9;/W3^SG\-_ /A7PC;:MX/GCUJ6\3$VLR8,SGNA'_+,
M_P '!Z9R>:[?K3S:*HP]U?:[^B.?V*R]^UEJ^G_!-;X _"6/X._#VVTARDNJ
M3N;J_F3D-,P VJ?[J@!1ZX)[UZ1117TM.G&C!4X+1'BSJ2J2<I;L****T("O
MAS]N7Q=-XC^(VB>$;'=/_9L(9H8^2UQ.1A<=SL$>/]\U]O7EW#86LUS<2"*"
M%&DDD;HJ@9)/T KX$^!MI+\</VHI?$-W&7MH;J769$?^!48"!/\ @+&(?137
M@YK)SC##QWD_P/5P"47*M+:*/MWX=>$HO 7@70_#\.TC3[2.%V48#R 9=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM^!]-E\?9X64_P"9V^2/2****X3<**** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^[W^1ZTJL'A%&^O_  3W2BBBO=/)"BBB@ HHHH **** "BBB@ HHHH ****
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MI/\ "H0(/0'''?Z4KIR2'-">)>\G^"T1GF4N6<:"^ROQ>K"BBBOI3Q0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#R']JG3_MGP?OILL/LES#-QWRXCY_[[KV;]GK4/[4^"/@N
M;KMTV*#_ +]CR_\ V6O+_P!HJU:\^#'B6-<Y6.)^F>$FC8_HM=A^R+?&^_9_
M\,;FW/#]IB/&,8N),#_ODBOEJWNYF_./Y,]ZEK@?27Z'L5%%%=QR!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <?\9;$ZE\
M)/&EL$\QGT:\V+ZL(6*_J!7SQ^R+??:OA;+#N)-MJ$T>T]@51^/;YC^M?65Y
M:I?6<]M*-T<R-&RGN",&OBG]C.\9;'Q7I\FY6@G@E\MN,%@ZGCU^09_"O/OR
M9C2?\R:^[4Z_BP=1=FG^A](T445]6>"%%%% !1110 4444 %%%% !1110 44
M5E^)(]7FTN2/0Y[2VU!F4+->(SQHN?F.U2,G'3MGK4R?*F[7+BKNQ+K6O:;X
M;T^2]U2]@L+6/[TUQ($7Z<]3["O+]'_:3T/Q/\0-,\-:':37\-V[(VHR'R47
M"%LJA&YAQCG;^->;_'[X*:U9>&9_%5]XJNO$=S:%?/CN8A&JJS!<Q*&(0 D9
M4>YSQ7EW[.__ "63PSC_ )ZR?^BGKX[%9MBJ>+IX?DY$VM[-M-V]$?18? 4)
M4)5>;F:3\E>Q]\4445]D?-!65XD\3Z7X0TJ74=8OHK&SCZR2'J?11U8^PR:T
MIIDMX9)97$<<:EF9C@  9)-?'^I:?XH_:C\=74]B_P!D\-V,AB@FN,B&%..=
MH^](PPQ'T!(&*\K,,9+"QC"E'FJ2V7ZOR1Z&%PZKMRF^6$=V=YKW[96BV=P4
MTC0;O4D4X\RXF6W!]P './KBF:'^V9HUW,%U;0+O3H\XWV\ZW ^I!"'\JM6/
M[&OAB.U"WFM:K/<XYDA,429_W2C']:\R^+7[,NI> M.EU?1[IM8TJ/YIE,>V
M:!?[Q X9?4C&/3&37S5>MG>'BZTK66Z23M^I[5*GEE5^SCOWU_X8^M?"_B[1
M_&NEKJ&BWT5_:L<%HSAD;^ZRGE3[$5L5^>7PS^(VJ?#'Q)#J5@[&)B%N;4GY
M)X\\J??T/8_B#^@.CZK;Z]I5GJ-G)YEK>0I/$WJK $?C@U[N4YG',*;NK3CN
MOU1Y>.P+P<E9WB]BY1117O'DA6)XH\::'X+L?M>MZG;Z="?N^<WS/[*H^9C[
M &O-OCA^T%:?#=7TG2A'?^(F7)5N8K4$<%\'ENX7\3VSY%\+?@_KGQOU:3Q/
MXPO;IM*9N)G;][=$'[D?9(P>,@8[+W(^?Q6:-5?JV%CS3_!>IZU' WI^WQ#Y
M8_B_0]3F_:FTK4;QK/PSX<UGQ)<CHL$6P'GJ,;FQ]5%=MX!\:>*/%5Y(NL^"
M9O#-DL)D2YFODE+ON ">7L5AD%CGMMQW%=+X=\,Z7X4TV/3](L(=/M(^D<*X
MS[D]2?<Y-:==M&CBDU.O5OY))+\;LPJ5*%G&G3^;;O\ Y!1117IG %%%% !1
M110 4444 %%%% !1110!\[_M@>%VET/1?$UN&2>PG-O+)'PVQ_F1L]MK+@>\
ME?:_PG\7VWQL^"FB:S<IYD>M:<T%Y&R8!D&Z&<8QTWJX'J*^7/VGH?,^"NO-
MG'EO;MTZ_OXQ_6O<?V(O^37_  7_ -OO_I;/7Q.*BJ>8S2VE%-^NQ]+1ES8.
M+>\96_4^1_V0[A]#\0>,/#5WF.]B*2>2P(VM$[QR\$ ]60<U]-U\YV]K)X!_
M;A\7Z5NRFJ75U(2<<+.@O%'_ *"*^C*]/(I?[+[-_9DU^IQ9I']_S_S),***
M*^C/'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***SM7\1:3X?16U34[/35;HU
MY<)$#^+$5$IQBKR=D6HRD[)&C17F>L_M'_#[1FE1M>6]F0?ZNSBDEW?1PNS_
M ,>KA-:_;+T2V.-*T"^O^VZZE2W'7MC><?E7F5,TP5'XJB^6OY';# XFIM!_
ME^9]#T5\P0_'+XN^.8=WA?P7(+64_N[JWT^:?'?_ %A/E]/45I6_P?\ VBO'
M#@ZGK/\ 8" <-+?I; \="ML">_<=JX7G=.7\&G*7RT^\Z5ELH_Q9QC\]3Z#U
M#5+/28/.OKN"SASCS+B18U_,FN'US]H#P#H)=9O$=M=.O1+(-<;O8% 5_6N4
MT7]@LW5U#=>)_&MQ>$C]]!96^'S_ +,TC-QG/5*].\.?L>_##P^L+2Z--K,\
M1R)M2NG?=_O(A5#]"M9O'9A5_ATU#U=_R+6%PD/BFY>BM^9X[K'[8F@Q.L>C
M:%J&J2L0N)W6W4D^F-Y/Y5Y=\8_BMXZ\76]C8ZSIEUX0T&^;,4<T$L27(!&6
M9V4&15W+D*,=#C.*_070/!^@^$UD71-$TW2%D.7%C:1P;CZG:!G\:\4_;<\'
MGQ!\'QJL2IY^B7D=P6*DL8G_ '3J/^!/&Q]DKS,=3QM3#RE4JWLMDK+[SNPL
ML+&M&,*?S;N?7O[+?[(?@[]FO04FT\)K?BJ[A O/$,R#>X/)2$<^7'TX!R<
ML3@8][KPC]B#XG#XK?LS>#-1EG2;4=/MO[(O0I)99;?]VI<G^)HQ%(?^NE>Y
M75U%8VLUS.XB@A1I))&Z*H&23^%?#+8]UWOJ?E=\3[Q?B7_P4IU1L^99:-.L
M0YSM-M: '_R/G\_6OJ"OD3]D>XG^(_QN^)?Q%N1L>]EFD*,.-]W<-,<?[HCQ
M]&KZ[K[G):?+AN;NV_T/ S&5ZO+V1RGQ,^)FC?"GPK<:YK<Q6%#LAMX^9+B4
M@E8T'J<'V !)Z5\V?#?P_KO[7'B:3Q3XU,D/@C3IBEEHT+LL4L@_ASP2 "-S
M]23@8&0/)?VN/B1/XZ^+FH:>LC?V9H+MI]O%G@2*<3/CU+@CZ(M?>/PQ\(0>
M _A]H&@01B,65I&DG&-TA&9&(]2Y8_C4PJ?VAB94W\$.G=^?D7*/U.A&:^.7
MX(^*?VBOV4K[X:FXUWPTLVI>%\[I(^7FLNN=W]Z,?W^W?U/F_P 'OC1K_P &
M=?%]IDGGV,I O--E8^5<+_[*X'1AR/<9!_4.2-)HVCD17C8%65AD$'J"*^"_
MVL/V<X?AO>#Q1X>@*>'+R79/;+R+*8] /2-NWH>.ZBO/Q^ EA']9PVB6Z[>G
MD=>$Q:Q"]C7UO^)]K> _'&E?$;PM8:_H\_G65TF<'[T;#AD8=F!X/Y]"*Z"O
MB7]@OQO<6?BC6_"DLF;*\MOMT*$\+,A56Q_O(W/_ %S%?;5?18'%?6J$:CWZ
M^IX^+H^PJN/0****] Y#QK]KCQJ?!OP3U=(GV7>K,NF1<\XDR9/_ "&KC\17
M"_L'^"/[)\"ZMXFFCQ-JUSY$#-_SQAR,CZNS@_[@K@/VY/%DWB7XAZ#X.L-T
M[6,0=X4/+7$Y 5<>H4)C_KH:^O/ASX1B\ ^!="\/0[2NGVD<+LHP'D R[_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4445J8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX52>HR(V&.HW'UKRI?N<4I=)JWS6QW1_>8=KK'\F?:5%%%>J<(4444 %%%%
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M^_$J_P#M.OE\=[N/I2[Q:^[4]S"ZX.HNS3/J.BBBNTY@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB/X&K_8?[17Q(T6-
M?*MEEO"D9XXCNPJ<?[KG\*^W*^)IE7P_^W'K%I#\L=XSEQ[R6:S'\VKRL6^2
MOAZG]ZWWG=A_>I58?W;_ ''T?1117V!\\%%%% !1110 4444 %%%% !1110
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MU[4+?39M9<W):9OG:,9$:JHY;C+8 /WS5_4/VN? UC,4BBU:^7_GI!;(%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\J_\
M!1CQ(=+^#&EZ3',$EU35XP\?=X8XW=OR?RJ^JJ^*/VUEC\>_M"?"/P&T)9&=
M)9F)!4QW-RL;#GT6W8GZBO/Q\FJ#2W=E][.S"+FJIOIJ?5WPL\-GPA\-/"NB
M-'Y<FGZ7;6TB\9WK$H8G'<MDUU-%%=T(J,5%=#ED^9W844451(4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OA3]J#S/@#^U=X.^)MI^ZT[5]K7JJ=Q?RPL-TH7W@>(
MC_:)/:ONNOBO_@IE&S>'/ C@?(MW=*3[E(\?R->9F$?W'.MXM-?>=N#?[Q1>
MSNC[4HJ"QF%Q8V\HY$D:M^8!J>O26QQ/<****8!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7PO\ MOW0U#]I#X6:2SY2-;>4K@\>
M;>%<YZ<^5^E?=%?!/[4>H0:Q^VEX,MK>>.62PM+.&=48,8W$LTNU@.AVNIP>
MS ]Z\_&>]&,>\DOQ.S"Z2E+LG^1[-1117WJV/E@HHHIB"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\._8*:33]2^(6E2E@T,EJP5EVD%3.K9'4'[O%>XUX5^RI,MI^T=\3;%3M#?:
MG5.>B787K[;Q^=?-9I[N)P\_-K[T>W@?>H58^2_ ^OZ***ZCG"BBB@ HHHH
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MDS[5/X&L5_V-?A]X$L1=>./'DT:$EE8/#9(X!&0 ^\MU ^4YY]ZHP^+OV8_
M>H01V.A3>(I-PCDNGMY;F).<%F6=@I Z_(ISVS7#6S3%K1\L/5W?X'53P.'Z
M<T_161G:E^V(MY<?9?#_ (4N;V:0[8FN9L.3V_=HK9^@:G0^)/VA?'6[^Q_"
M<FBQKT9[);;(/3!NFPW'=:^NO [^&;KPY:7GA*/31HMPNZ%M,C1(B.A&% P0
M0001D$$'!%;]-4<5B%>IB'9_RV7XDNI0I.T**OYZGQK#^RW\7_&C1_\ "3^.
M([&TD&Z2!;R:=D/IY2A8R?HU=/X=_8&\,6D?_$[\2:IJ<V[(^QQQVJ8]"&$A
M_)A7U'13668>_-.\GYML'CJUK1=EY(\L\._LO_##PU*);?PG:W4NW:6U!WN@
M??9(S*#] *]&T?0]-\/V:6FEZ?:Z;:)]V"SA6)!]%4 5=HKNIT*5+X(I>B.6
M56I4^.39X9^U]\4+GX<_#%;?2[V:QUK6)UM[>:WD*2Q1KAY'5@01QM7(_P">
ME?#O_"Z/B#_T/'B0_P#<6N/_ (NOK;Q;\,I?VF/C9J$]_</;^!_"S#3 T)PU
MW<#YID0]L,0K-Z*H'))'M6B?!/P%X=M4@LO"&CJJC;YDMFDLA'N[@L?Q-?.U
M\+B,?5E.$N6*T7G;K]Y[-*O1PM-0DKR>K/S>_P"%S_$+_H>?$G_@VN/_ (NE
M_P"%S_$'_H>?$G_@VN/_ (NOTR_X5KX1_P"A5T7_ ,%T/_Q-5-7\%>"-#TF]
MU*\\,Z)%:6<#W$S_ -G0_*B*68_=] :QED^(BN9UOS+684G_ ,N_R/SCTCXJ
M_$C6]6L]/M/&OB26ZNYDMX8QJ]Q\SNP51]_U(K]/M&L9-,T>QLYKF2\FMX(X
MGN)F+/*RJ 78GJ21DGWKX+_96\/?\+*^/\WB":TB@L["2;57ABC"Q1R,Q$4:
M@# PS[@ /^6=?H!75DL)>SG4DV[NR^1AF4H\T8)6L>&?M??%"Y^'/PQ6WTN]
MFL=:UB=;>WFMY"DL4:X>1U8$$<;5R/\ GI7P[_PNCX@_]#QXD/\ W%KC_P"+
MKZV\6_#*7]ICXV:A/?W#V_@?PLPTP-"<-=W ^:9$/;#$*S>BJ!R21[5HGP3\
M!>';5(++PAHZJHV^9+9I+(1[NX+'\345\+B<?5E.$N6*T7G;K]YI2KT<)34&
MKR>K/S>_X7/\0O\ H>?$G_@VN/\ XNE_X7/\0?\ H>?$G_@VN/\ XNOTR_X5
MKX1_Z%71?_!=#_\ $U4U?P5X(T/2;W4KSPSHD5I9P/<3/_9T/RHBEF/W?0&L
M)9/B(KF=;\RUF-)_\N_R/SCTCXJ_$C6]6L]/M/&OB26ZNYDMX8QJ]Q\SNP51
M]_U(K]/M&L9-,T>QLYKF2\FMX(XGN)F+/*RJ 78GJ21DGWKX+_96\/?\+*^/
M\WB":TB@L["2;57ABC"Q1R,Q$4:@# PS[@ /^6=?H!75DL)>SG4DV[NR^1AF
M4H\T8)6L%%9GB;Q1I7@W0[K5];OH=-TVV7=)<3' ^@'5F/0* 23P 37REXB^
M(WCW]KWQI+\/?A392V^@&,M?ZC<-Y"_9QQ+/=2](+< ].K#KDML'IXS'4L)&
M\G=]%U.'#X2>(E9;=SV+0_VGO"/B;XKP^"M*F^V"2.55U56'V=[A.1$AQ\P*
MA_GS@D*%W;LUZ]7YRS?#W3=6^+^B^%?@]>W7B"[T@J]QXLFS%!<SHX9[M(R/
MW-O&=JINW,^ >KK&/T8C#K&@D96DP-S*N 3W(&3C\ZY<KQE7&1G*HMGIV]/D
M=&.P\,.XJ#/"?VR/AT/&GPEGU2WA\S4M ?[;&54%C"<"=<]@%Q(?^N0KZ3_X
M)Y?&/_A;'[..CVMW.LNM>&#_ &+=*2-QCC4&W?'7!B*+N/5HW]ZP+FWBO+>6
MWGC6:"5#')&XRK*1@@CT(KYG_8J\52_LW?MB:U\.]0F:'0O$CFPA,C\&09EL
M9"<<LRLT>!_%-STKR,[P_+4C7771^O0[<OJ<T'2?35'ZDZEIMIK&GW-A?VT-
MY974;0SV]P@>.6-AAE93P002"#ZU^8/[4G['_B/]ESQ))\4?A+)<'PI"?,N[
M%6,DFG*3\RN#_K+8\<G)7OTW5^H]-DC66-D=0Z,,,K#((]#7S2;333LT>GY/
M8_/7X#_M!:+\;-)=(@-/\0VD8:\TR1N2. 98C_%'DX]5. 1RI;TO4M)L=:MS
M;ZA96]] ?^65S$LB_DP(KY<_;Z_9P_X9M^(&C_$+X>+/H.@ZM,RE;1R@L+[#
M,4CQ]V.1,D)R!MD'W< 9/PY_;6UG1X=-A^(>AR26%W&&M]:LH3&TJ@E&D*'Y
M)!N# F,K@J1M)&*^MP><0E'V>)T??H_4\C$9?*_/0V[=3Z:M?A/X'L[@30>#
M= AF7D21:7 K#\0E=/##';Q+'$BQ1J,*B   >@%<]X(^)/AGXCV+77AS6;75
M8T ,D<38EBSG&^,X9,X.,@9P:Z2OI:?LFN:G:S['CS]I>T]_,****V,@K+U_
MPGHGBN&&/6]&T_6(H6+1QW]K'.J,1@E0X.#]*U*YWXB>,[?X=^"-8\1W,+7,
M6GVYD$*G!D;@*N<'&6(&<'&<UE4<5!N>RW+CS.24=SQ']J/XIQ?#;PM9_#WP
M=:"UUO6(Q%%:Z7"$^S6[/MQ&BC[\AW*H49^\>#MS^@_[ /[(MM^RO\(T&IPQ
M3>.M>"7>LW(4%H?E^2T5NZQY.3W9F/3&/D?_ ()C?LUZE\8_B'>_M%^/1%<0
M17<JZ':L,B6Z7Y&GP<XCA'R(#D[AGC8-WZN]*_,\=BGBJKELEHEV1]GAZ*H4
M^7KU'4445P'4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !11368*I). .2: /Y<?!O\
MR-VA_P#7]!_Z,6OZD*_EN\*31V_B?2)976.*.\A=WD("JH<$DD]!7]2- !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KXJM5F^(/_  4>G<NMS8^&K4[1C(14M0I'U$\Y
M/UK[4)QR>!7Q5^PO'%XV^,'Q:\?QILCN[IE@# 9VW-Q).P]1@1I^?M7FXOWZ
ME*GW=_N.W#^["I/RM]Y]K4445Z1Q!1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHKF_B1XVM?AQX#UWQ-=HTL.EVCW'E+UD8#Y4SVW,0,]LYJ9244Y/9
M#BG*5D?-O[67[75_X%UJ3X?> X6G\5OMBO+[RBYMC(H*10+_ !S$.IS@A<@
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M"O"^J:[J+[;/3X&GD]6P.%'N3@#W(J9244Y/9%1BY/E1XW\<OVLK#X-^+(M
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MXQ^&KZ^MVMUUC4/&.F7;P!U*LR0B1!N )P2Q&<94]*^TJ* /P!_X=<_M._\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK"SJQV,%()VDXYSP>:]0KZW+8RCA*<9*S21X.,:EB)N+NKL****](X@HHHH
M**** "BBB@ HHKRCQEH_Q1\90WEOIM[IGA*R!9(ECF>2YF ) +2!<1@C!^7Y
MAWKEQ%9T8WC!R?9?U8Z*5)579R27F=/XY^+/A?X>PL=7U*,70&5L;<B2X;T^
M0=,^K8'O6]X;UZW\4:#I^KVB2QVU["L\:S !PK#(# $C/T)K\Y-<M;S3M9OK
M34=XO[>=XIP[;F\Q6(;)[G(/-??GP=_Y)7X4_P"P=!_Z *\#+,TJX_$3A*/+
M%+;KOU/5QV!IX6A&47=MG8T445]2>$%175U#8V\D]Q-';P1C<\LK!54>I)X
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M_04T/_O_ #__ !FOL6BN+_5W!>?WG1_;&)\ON/CS_AC?QC_T%-#Q_P!=YO\
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MN1VR !Z<"O::**[\/A:6&CRTU:^_=^K.2MB*F(E>HPHHHKK.<**** "BBB@
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M32]08H.RQ2J& _[[$A_&OI.ODK]GVT'PM_:F^(W@7RQ9V4S3-:0;LC9')YD
M_P"_,C&OK6M,KFY8=1>\;K[A8V-JS:V>OWA1117K' %%%<Q\1OB-HOPM\+7.
MN:Y<^3;1_+%"N#+<2$';'&O=CCZ  DD $U$YQIQ<I.R14(N;48K4X']IWXWQ
M?"'P68+&7_BI=51XK%5&?) &'G/8;<C /5B." V/,/!W[ .NZY\.=-\2-XHN
M/#_CRZ!O5M;B)U2$,H,<<CC$D<N>7;!V[MNS*Y-W]F_X;ZK^TI\6+GXM^,[.
M:/P[8SJ=)LY')CEDC8^6B=,QQ$98@ /(3U_>+7W;7S/)_:$W6J+W=HK]?F>U
MS?4XJG3^+K_D?#4?[-O[2^H6RV\WQ$L[2.(>4K-JLZNRCC=O2$L20,Y8[N>>
M:G;]@7QSXJMROBOXLS3L3S&8I[Y>#D<R2I]>E?;U%:_4*<M)-OU;,_K=1?"D
MOD>;_!'X"^&/@3X;&G:%!Y]_-\U[JUPH-Q=-Z$C[J#HJ#@=3EBS'TBBD)"J2
M>!7="$:<5&"LD<LI.;YI.[%HJO8ZA;:I9Q7=E<PW=K,N^.>!PZ.IZ$,."/I5
MBK("BBBF!!?6-MJEE<6=Y;Q7=I<1M#-;SH'CE1@0RLIX(()!!X(-?#OQV_9Y
MU_\ 9X\32_%+X4;DTF$M)J6D1J76VB."^4'W[<XRR]8\!A@+N3[IHKEKX>-9
M=FMGU1O1K.D^Z>Z[GSK\%?C?H?QJ\._;=//V34[<*+W3)&!D@8]P?XD)SAL<
M]P#D5Z)7P_\ M2^#;?X"_M$:+=?#5;K3=2U&"/4%TJR5C&LKS.GE1(O)CD,9
M_<\CD@84JH](\ ?MNZ'J%T=,\;:3<>%M2C<Q23HK2P!QPP=<>9&=W&,-CN14
M87,HINEB7:2TOT?^1=;!MI5**O%].J/IBBJ&A>(=+\4::FH:/J-KJEDY(6XL
MYEE0D=1E2>1W':K]>[&49*\3RY1<79E75M4M]$TJ]U&[?R[6SA>XF?\ NHBE
MF/Y U\'?LQZ9<?%S]HZ[\4ZC'OCM))]8FW#*B5F(B3/;#."/]ROHG]L?QQ_P
MB/P9O;*&39>:U*M@F#SY9^:4_3:I4_[XK#_8<\"GP[\,;K7IHMEUKER61B,'
MR(LHG_CQE/N"*\'%?[3CJ=#I'5_H>K1_<X6=3K+1'T=1117T!Y(4444 5=6U
M2WT32KW4;M_+M;.%[B9_[J(I9C^0-?!W[,>F7'Q<_:.N_%.HQ[X[22?6)MPR
MHE9B(DSVPS@C_<KZ)_;'\<?\(C\&;VRADV7FM2K8)@\^6?FE/TVJ5/\ OBL/
M]ASP*?#OPQNM>FBV76N7)9&(P?(BRB?^/&4^X(KY_%?[3CJ=#I'5_H>M1_<X
M6=3K+1'T1>7EOIMG/=7<\=K:6\;2S3S.$2-%&69F/   ))/3%?*.C^']:_X*
M$?M':5X+\-O=6W@'26\^]ORFU8K<,!+<D$???A(U;GD'"Y?'TC\0O MA\2O!
M^H^'-2>:*SOD"F2W<JZ,K!E8>N& .#P<<UX5^RK^T)KO_!._XM7_ (4\9Z>N
MH?#[Q!,DEQ?6L \U=ORI=1-C+!0</"22,Y7G[_+GDZZ@HQ7N/=^?8WRR--MR
M;][H?KSXWCN/AI\#]?C\&:>@NO#_ (=N%T73T^[O@MF^SQ#KQE$6OQJ_8%L;
M.XT_QEK$EU]IUN6YAAF63YG2+#.'W'D[V+Y_ZY"OW%T[4+;6M-MKVTD6YL[J
M%9H9%'$D;*"IY[$$5^5WCS_@D+\1O#?BO6]:^$_Q(TW3[6ZGFEMK*9KG3988
M6<NMOYD/F!MHVKD[02,X6OEL'B%A:T:K5['MUZ3K4G33M<] HKY@^ 'C+XB:
M5\=O%'PT\>:Y_:,^@07%O+"=D@%U%/$A(F"AW&"_4X.?I7T_7Z/A,5#&4O:0
M5EYGR&(HRP\^204RXMX[JWDAF19(I%*.C#(92,$&GT5UO5'.> ?\$M=8N/!'
MQP^)?P]O&C$DMIYC-NQF:SN#$0OKD7#GZ)[5^FM?DWX(O8_@_P#\%(- N5A>
M*PUR_6$(I(\PWT)A+=.1]HD+?\!K]9*_+:E/V=24.S:/L^;GC&?=!7DO[5GP
ME'QL^ GBWPQ%#YVI26INM.&.?M47[R(#TW%=A/HYKUJBLA'R#_P1?^-G]O?#
M?Q3\+K^?-YX>N?[4TZ-VY-I.<2HH]$F&X^]P*_26OQ:M=2_X8A_X*86FI,XL
M/!WB&[W2LQV1"POFVR$] $AG!;Z0#Z5^T:L&4$'([5SG8M5<=BOR(_X*Q^)O
M%'CK]IKP)\*[G49M/\'S1V<MO&@S&UQ<3-$\[#C>R#@ G@$XQN-?KOFORG_X
M+%.O@WXT?!#Q@(@QA6<MLQO?[-<02X_\B<5=.W.N;84KV=CI?"?A;3?!/AVP
MT/1[9;33K./RX8UY[DDD]R222>Y)-?.'A5;']I+_ (*$_#G3]!9K_2]&NK=K
MB\@&Z-UM))+F1P?[F[Y-W0]1D$$Q?'+]H*\^(5YI?PY^$_FZ_K'B#RX6N=/!
M+GS<;8(NF'(/SDXV#(.#NV_I5^PO^QOI?[)_PW"W*PWOCO6(HY=;U)?F"-C(
MMHF_YYH2>?XC\Q[ ?29MCJ=2"P]'X5O_ )(\C X64&ZU3=GT]1117S![(444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%0S3);Q/)*RQQH"S.QP% Y))
M["@":BOE+XU?\%,?@5\%KQ[";Q%/XPU2.0QRV/A2)+QHB#@[I6=(<@Y!42;A
MCI7U'I]XFH6-M=Q@K'<1K*H8<@, 1GWYH M4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_6JU/-+[D=M;W:=.'E?[PHHHKTCB"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J*ZN4L[6:XE.V*)&D9CV &2:EK@OCUJXT+
MX)^.KT2^2\>BW:I(.TC1,J?^/,*SJ2Y(.78N"YI)'SM_P3AT^YN_#OC[Q)=-
MYTNIZG##).Q^9Y(T:1R1TZW /'K7V-7S?^P#X?\ [%_9YM+SMJVI75[W_A80
M?^T*^D*YL%'EP\5Y?GJ=&*ES5I!1117:<@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% "-P":^'?^":HFO+[XEZC<;I)9&L=TS#[S,;E
MF_'H?Q%?;.JW L]+O)R<"*%W/X*37QQ_P31MW'ACQU-_"][;(/J$<G_T(5Y=
M?7%4EZ_D=U+^!4^1]HT445ZAPA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ7_T)A77[;$]*+^]'/[*CUJ+[C[_ *8TJ1\LZK]3BOS]?]@W5;^,1WWQ%>5
M=P1M/>0 ^O,P]:DMO^"?-NN[S_',LO3;Y6EA,>N<S'-'M,8]J/XH7L\/_P _
M?P9]XW7B#2[($W&I6< '7S9T7^9K(E^*7@R"0I)XNT*-QU5M2A!'_CU?&$/_
M  3]T53^]\77SC_8M$7^;&M.W_8%\'+CS_$&N2?]<S"G\XS3OC7_ ,NE]Z"V
M&_Y^/[CZI;X\?#1>OQ#\*_AK-L?_ &>JT_[1'POMQE_B!X</_7/4XG_DQKYM
M@_8/^'T3*7U+Q#,!U5KJ *?RA!_6KL?[#OPW0Y)UE_9KQ?Z)1RX]_8C]X_\
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M.?*F4[9$^@8''J"#WKU,KS!XI.G4^)?B<..PGL'SP^%_@=?1117OGE!1110
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MI\;_ +<EO<>%O'_@/QEI\KPZA&C)'(N1Y;V\JRQG/8YE;_OFOUN\/:[9^*-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8U>?@%^Y4GO)M_>SLQ?\7E72R"BBBO1.(**** "BBB@ HHHH **** "BBB@
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MDB)/O-7Z1U@=84444 %%%% '\XG[;/\ R=U\7O\ L9;W_P!&FOU]_P""4/\
MR9'X._Z_-1_]+):_(+]MG_D[KXO?]C+>_P#HTU^OO_!*'_DR/P=_U^:C_P"E
MDM 'U]1110 5^0?_  6E^"\&@^/O!WQ-L(!&->@?2]395 !G@"F%V]6:)BOT
M@%?KY7PI_P %BO#\>K?LE6UX57?I?B.SN58\'YHYH2!Q_P!-1Q[>PH _-G_@
MG;\8KGX-?M8^";H7#1:9KURN@:A'G"O%<LJ(6]EE\I\_[%?T(U_+)H^J7&AZ
MM9ZC:/Y=U9SI<0OS\KHP93Q[@5_4G9W4=]9P7,)W13(LB$C&5(R/T- $DDBQ
MH7=@JJ,EF. !ZU\??%S_ (*>?"WP)XGD\+>$;/6/BIXI1FB^Q^%8!+ )!U7S
MOX_K$L@ZYZ5X)_P4P_:F\3>,/B5IO[-?PSNFAOM6FM[#7+B!BKW$UR4$5D''
MW4VNK2$==X4X <-]L?LP_LM>#?V6_A_9Z#X;L(9-6>%/[5UQHQ]IU"8#YF9N
MH3=G;&#A1ZG)(!\<Z]_P6,U+P5KD5GXK_9^USPU%(2R&_P!7:&X:,'[PBDM$
MSU'&[ SUKZB_9I_;P^%/[45Q_9GAS5)]*\3A#(V@:RBPW3 #YC$0S)*!R?D8
MD#D@5ZO\6/A#X2^-W@N^\+>,]&M]:T>Z0C9.@\R%R"!+$_6.09X9<$5_.W\7
MO >M?LS_ !^\0>&K35)[?5_"NJE;+5+5C%+A2'@F4CE6*%&XZ$T ?TLT5\_?
ML._M&-^TY^SSH?BR\,:^(+9WTS68XL!1=Q!<N!V#HT<F.WF8[9KZ!H _F%^+
MW_)6?&W_ &&[[_T>]?TR^%?^18TC_KSA_P#0!7\S7Q>_Y*SXV_[#=]_Z/>OZ
M9?"O_(L:1_UYP_\ H H U:^=OVD?V[OA/^R_<'3O$VK2ZGXDVAQX?T6-;B[4
M$9!DRRI$#D$;V!(.0#7:_M0_%&\^"O[/GCWQMIL0EU/2-+DELPR;U$[82)F7
MNJNZL1Z U^'?[$UA'\8/VV?  \8[_$C:EJ\M_>F_<RM<S)#+.&D)^]\Z*2#P
M<8/% 'Z1'_@H_P#%#6-'&N^&/V3_ !QK?AUT\V+4)9YH3*G7>B)9R;EP?O*2
M.OH:S/AY_P %EOAKK6L+IGCCPCKW@2<OY4MP"M]!;L.&$FT)*,'(XC)XZ"OT
M'50J@ 8 X K\C?\ @M-\&M*T#Q3X(^(VF64-I>ZXMQIVK21)M\^6(1M!(V."
MQ1I%)/.(T'.. #]6_"OBK2/&WA^PU[0-1M=8T:^B$MK?6<HDBF0]U8<'N/8@
MBO.OVA_VC-/_ &;_  [::]JW@_Q?XJTR9I!/-X4TU+P6*HH;?<%I4$:$$X;I
MP<XXS\3_ /!$WXE:AJW@GXB>![NXDEL-%NK34;"-F+>6+@2K,J_W5W0HV!W=
MCW-?IM0!^?\ _P /JO@A_P!"M\0/_!=8_P#R97K/[/O_  4$\*?M+>*+72?!
M_P //B,;*65H9]?N]&@&F6;!"^)YX[APA(  &"26'&.:_-;_ (*I_LXV7P-^
M/D&O:!81V'ACQC ]]%;P($BAO$8"YC0 8 .^.3 Z>:0, "OM7_@C?\1K#Q'^
MS;JGA2/RX]4\-ZQ*9HU #/#<#S(Y#CDDL)5Y[1C\ #ZJ^.?QS7X':18ZC)X"
M\;>.+>X:02+X,TI;][14"G?,ID0JISP1G[K9QBOE2?\ X+0?!6VF>*7PG\08
MI8V*O&^FV096!P00;S@U]^5^-?\ P6*_9]M? _Q0T+XEZ+8K:Z?XJC>WU/RE
MPG]H1<^8>>&EC(Z#DPN3R30!]<>!?^"KOP_^)NH/I_A#X7_%?Q3>QJ&DM]'T
M"VNG12<!F$=T=H]S@5]E:'J3:UHMAJ#6EUIYN[>.X^QWR!)X-ZAO+D4$A77.
M" 3@@\FOS=_X(E^/-'G\ _$/P8(XXM?M]3CU@R8^>>VDB2( >HC>(_3SAZU^
MFE 'S[^T5^V-H_[,MT3XC^'GC_6-'2W2XE\0:!I$5QIL.YBHCDF>=-CY X(Q
M\PP37C'A7_@KQ\+O'6M0:/X;^'OQ.U[5ISB*QTW1K2XF?UPB79)KV#]O[XE6
M'PQ_9%^)-_>[)'U32Y=#M87 /F37:F 8!X.U7:3Z1GKTKS;_ ():_LWV7P=_
M9YTWQ;?:<D?C#QE&-1N+J1/WL=FQS;0J2,A2FV4CNTG.=HP ?95K-]JMXIBC
MPB1 WER##+D9P1V(KY^_:1_;N^$_[+]P=.\3:M+J?B3:''A_18UN+M01D&3+
M*D0.01O8$@Y -=K^U#\4;SX*_L^>/?&VFQ"74](TN26S#)O43MA(F9>ZJ[JQ
M'H#7X=_L36$?Q@_;9\ #QCO\2-J6KRW]Z;]S*US,D,LX:0G[WSHI(/!Q@\4
M?I$?^"C_ ,4-8T<:[X8_9/\ '&M^'73S8M0EGFA,J==Z(EG)N7!^\I(Z^AK,
M^'G_  66^&NM:PNF>./".O>!)R_E2W *WT%NPX82;0DHP<CB,GCH*_0=5"J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)W2!F^\47^$G)R<EN3\V#7K%%%=M*C3HQY::LCGG4E4?--W84445J9!1110
M4444 %%%% 'QW_P4!L_*N_ U^@*N1>1F1<C&TPLHSZ_,V/QKW2SNX[^S@N8C
MNBFC61#ZJ1D?SKS;]O;35G^%^AWPC)DM]66/<!G:KPRD_091?TKI_A=>"^^&
MOA6<-O+:9;;FQC+")0WZ@UPY=[F/KP[I/[M#KQ?O82E+LVCJ****^I/!"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[-4\0[9QN',=JN?*'_ LM)D=0Z9Z5YU:/UFO##+;>7IT1VTW["E*OUV7^9]
MQQI#&L<:JD:@*JJ,  = !3J**^CVT/'"BBBF 4444 %%%% !1110!Y1^U1J$
MFF? 'Q?-$6#-## <''RR3QQM^C&NH_8@C"?LP^#B!RWVPG_P-G']*K_'#P[)
MXK^$?BW3(8GGGETZ5X8H_O/(B[T4>Y90/QK)_8!\5P:]^S_:Z6@V3Z)?7%I(
MI8$L'<SJ^.P/G%?JAKP<1[N.BWUC^IZE/7"M+I+]#Z3HHHKK.8**X'XW?&+2
M?@;X"N/$NK0RW0$JVUK9PD*]Q.P)5 3P!A68GL%. 3@'P;X;?\%%/"7B;4H[
M+Q3HEUX5:60)%>1SB[M@#GF0[49.<#A6'.20!7+4Q5&G-4YRLV=$,/4J1YXJ
MZ/K>N&^.L/VCX)>/T.WYM U#&XA1G[/)C)/ Y[FNQL;^VU2SAN[*XAN[290\
M4\#AXY%/0JPX(]Q7F/[4_BJ'PC^SYXYNYD:3[1ILFG(BD EKC$ //IYFX^RF
MKK27LI-[69%)/VL4NY\Z?LAK?>*OV</$&CV]R;.Y^U7MA:7/WO*:2!&#@<?=
M:4G%>W?\$6?&%AH]W\4OAY?6@L?%$<T.IGS.)9(HR8)8V';RG9/QF/I7GO[&
MWAJ3P]\#=-EF3RY-4N)K_:5P0I(12?7*QJV?0BN+D\5?\,F_MU>$/B$G^B^&
M]9N VHL!MC\F;]S>9]2NX3\_Q%:\#'8>7U*C5?16^3V/7PM9?6:E/N_R/V_K
M\6_VPM4T_P"%_P#P4^U;7]5<66E3Q6MS)+L 5 ^EK 6]QO!)[DYP">O[0K(L
MBAE(96&05.01ZU^9_P"W]^P/\3?VFOVHK'7/!MGIUMX?ET&UAN]:U.Z6&&*X
M26<%"J[I7(3RSD)CY@,\5\W3J.E-3CNG?[CUY14HN+V9\/W6F?%+]I3Q7XW^
M+/@32K]M-\%10SA[=OWUK;[B$1%&=[[?-E=1D >9GC /TU^SS^T!IWQJ\/\
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MVE<2*/\ MF?I2NA\K?0\>_9QNO\ AE/_ (*B7_A5_P#1-!\27DVE(H^5/)O
ML]HJCH<2^3'_ -]?2OV6W5_.M^U)^TX?VA/B;HOCK2?#4W@O4M*MHK87$.H&
MX=GCE>2*3<(TV.I)QU/RCGBOW5_99\1/XM_9K^%FK32O/<77AG3FGDDSN:46
MT8D)SR?G#<GKUK)G6MM3U6BBBI&%%%% '\XG[;/_ "=U\7O^QEO?_1IK]??^
M"4/_ "9'X._Z_-1_]+):_(+]MG_D[KXO?]C+>_\ HTU^OO\ P2A_Y,C\'?\
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MGU^3O[)?Q"M_A1^TG\./%5[*MOI]CK5N+N9FVB.WD;RI7)R. CL?3CFOZ2J
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MS@A1(88]9F1(XU"JJBWP  .@ [4 <%_P0Z_Y&?XN?]>>F_\ H=Q7ZT5^2_\
MP0Z_Y&?XN?\ 7GIO_H=Q7ZT4 ?(?_!4'X)?\+B_93UV]M(/-UKPBXU^U*CYC
M'&I%RGKCR6=L=S&M?FW_ ,$KOC9_PJ;]J?2M)O+CR=&\80G1+A6;"B=COMG^
MOF*(Q[3&OW7O+2#4;.>UN8EFMYT:*6-AE75A@@^Q!K^;W]HKX8ZC^S/^T=XH
M\+6DLMI+H&J^?I=TK'>("1-:R@_WO+:,GT8$=J /Z2Z_.'_@KMX\NO&%CX"^
M!?A;3/[<\6Z]?KK#VT**\L44:R1Q  \J7+2G=QA86YP37V7\%OCGHWQ0_9]\
M._%"XN[>QTVZT?\ M'49F;]W:/&A^U GTC=) 3Z+7QI_P3^TF\_::_:6^)_[
M3>OVTBV7VI]%\,13?\L4V!6('8I;^4A(."TTO>@#\^/V$?CD/V?_ -IWPCXB
MN9_)T6\F_LG5B6POV6<A&=O9'\N7_MG7]$M?SS_\%!?@<?@-^U)XMTBV@,&B
MZM)_;FE8&%^SW#,Q1?9)1+&/:,5^O/[#/[1EE\4_V/\ 0O&&NZBB7/ANSET_
M7KJ9Q^[>T3+2N>Q:'RY3_OF@#YT_X*%7D_[2W[5WP?\ V<M+F9[".Z75M?\
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MS@A1(88]9F1(XU"JJBWP  .@ [4 <%_P0Z_Y&?XN?]>>F_\ H=Q7ZT5^2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'YM?\%F8LZ/\&)?[NMW2_FL)_I7P
MS7W+_P %L%>/X9_#*Y0E7BUNX"LIP03 ""#_ ,!KX:K]-X/E>%:'9I_?<^,X
MACK3EZ_H%%%%?HQ\>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*MTMW7\)I7/UKS<=[T80_F:7ZG=A=)2GV3/MBBBBO2.$**** "BBB@ HHHH
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M[37WH7L:G\K^X]#HKA5^._PU;I\0O"OXZS;#_P!GJ_#\6/!%TJ-#XR\/RK(
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MBGZW_1H^(==^ 'Q2\1:Q>ZI>>'P]W>3//*RWML 68DG \S@<]*]E^%]U\5O
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M]@7Y2_0]NHHHKZL\ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGK,D(\PA5+GRP1DA%Y!Z 5T$?PS_ &I+B3Y_B_JL/^TWB>^Q^2@U]7T5X/\
M8>&\_O\ ^ >K_:5?R^X^46^$/[3S,3_PNG4\_P#8UZD/_9:QIOV+_B!XZU*6
M]\<?$-+RY8Y^TR2W&I2M[DRE#^IK['HJUDN%3U3?S)>8UNC7W'S;X?\ V$?
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M_95UW]G?0+>[O-9\5:_;V^FO"1D6MQQ<6R^A>5(ACH1/+DCO^W?[/7P<T_\
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M*1Y4$BJEM&HR<)Y:!E'99%':OJNH((8[6&.&*-8HHU")&H 55 P  .@ J>@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU'_-34J_\%"O%D/^O^%4GX74R_SA-?<5%/ZMB/\ G\_N1/MJ/_/K\6?$:_\
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M[MB![#-OG\S4$G_!-OX=M]SQ!XF7_>N+<_\ M 5/M,9_(OO%R8;^=_<?0_\
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M **** "BBB@ HHHH **** .8^)_@Z/X@_#WQ!X=D6,M?VCQPF3[J3 ;HG/\
MNN%;\*^9/V1?%#:AX'U#09RPN-'NCM1EQLBERP'UWK+GZBOL*OC+[)_PJG]L
M'5M/;,6F^)4>>%I#A<S?O<@=/]<CH/K7FU9?5\72K]'[K^>WXG;37M</4I=M
M5\MSZ#HHHKZP^?"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%(9X)\"Q_8/[
M8GC"T8IF\MKHC:./G>*?\\#G\:^Q:^-?"=Q]D_;J*,K 7,!13C@_Z &S]/D/
MXU]E5\AE_N^UCVDT?0XO7V<N\4%%%%>J< 4444 %%%% !1110 4444 %%%%
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M;L5]?TLOC[:<\3);Z+T7^8\6_9QC0735^K_R"BBBO=/+"BBB@ HHHH ****
M"BBB@ HHHH **** /)OVJ[X:;\!?%4YLK2^/EQ0A;R(2+'YDJ1^8H[.H<E3V
M8 ]L'YN^"O[(=O\ %#X8V7B>3Q)/I&HW<\AMO)@$J1QQR%#N&Y26+(Q!#  8
MZU]'?M96LMY^S[XM2*,R.J6\A [*MS$S'\%!/X50_8YO([G]G_P_&DBNUO+=
M12*IY5C<2/@^^&!^A%?.XC#TZ^8*%577+?YW/7I59T<(Y0=GS?H</#^R/XZL
MX5L[;XR:O#8*,>6BSHH ST07&.Y_.I?#?[">A6]\]SXF\3ZCX@?*D)!&+56
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M=>=Q)<PYVI-@\EN-K_[0!.-X%?0M?+TJL:T%*/4]FI3=.3BPHHHK4S"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F[]O_ ,2#0_V>
M;NQV%SK&HVMD"/X=K&XR?;]QC\17I'[./AD>$?@1X'TT1^4ZZ7#<2)QQ)*/-
M<<?[4C5\[_\ !0JXN/$VO?#'P193*)M2O)':+&3O=XH86QGU>6OLRUMX[.VB
MMX5"11($11T"@8 _*O-I>_BIR_E27ZG=4]W#PCW;9+1117I'"%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J^H:?:ZK8W-G>6T-W
M9W$;0SV]P@>.6-@0R,IX92"00>"#5BB@#\]/C5\!O%/[*?CR'Q_\-?M-UX7E
MDV26VUIS:!B,VUPN<R0,<!7)R"%!(<([Z _;HU;C/PPNO?\ T]__ )'K[[HK
MSHX6I1;]A4Y4^ED_S.UXB%1+VL.9KK>Q\B?"?]KKPO\ $.].EZO"?"6M;]D=
MO?3!H93D@*LI"X?_ &6"\D ;C7NM>??M;?L_^"_&GP]\4>+KK3A8^)-*TZ>^
M34K'$<EPT<1*I-QB1?D49(W   $#BN,_8QU2]U7X)6IO;J:Z-O>2V\)F<N8X
ME"[4&>BCH!V'%=.%Q%95OJ]?5VNG_FC&M1ING[:EIK:Q[I1117MGFA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7RM^W%X=FTI?"/CW3U6.^TRZ%K)*$);KYL)/\ LJR2=>\@
MKZIKD/BWX C^*'PZUOPR\PMWO8AY,S#A)48/&3[;E&<=LUPXRBZ]"48[]/5:
MHZL/45*K%O;KZ'+:'J\'B#1;#4[7=]GOK>.YBW#!VNH89]\&KU?._P !?B/=
M>"]2/PP\8V[:1JUC*T%HUP<99B6$+'.#G=E&!VL" #]W=]$5[&!Q4<514UOL
MUV?4\[%8>6'J.+VZ>:"BBBO1.,**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YZU
MM?[#_;0\'W8W?Z;'$3DC'S)+#Q[8'\Z^SZ^)_BY,UA^U-\-+K"B-I+!-S=.;
MQPWY!J^V*^0PONU\1'^]?[T?15]:5%_W?R"BBBO4. **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXD\.0GPI^V=XKL,C.H
M273]>OFJMUW_ *?RK[;KXK^*4;>%OVV-,OY#A=3%L5W'C]Y ;;V[J?\ /%>3
MCGR3HU.TE^)WX3WHU8=XL^BJ***^P/G0HHHI@%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %-=UC1G=@J*,EF. !ZT
MZOG/Q/H>L?M"_M&#X<6VN2:7H5K'NG:(&2/Y(Q([M&" S[F"#<<#'X'S,?C5
M@Z:ER\S;LEYG=A</]9FXWLDKMGM7AWXA>&O%FJ7NG:-K-KJ-Y9JKS1V[[AM/
M\2MT<<@$J2 2 <$UIZ]HUMXBT:_TN]5FM;V![>7:<':RD'!['FO,/C5^Q7=_
M"71;;QK\+]5OI+W0X3/>V]TZF9U4$O-&0 I^7.Z(C#+D#/W3T/P7^)G_  M+
MP:FIRP1VU]!*;:ZBC)V>8 #N4'D*0P//3D9.,UP8/,)8F3PV)C:3^YHZL1A%
M1BJU"5X_BF<S^QW\3;SX,_%#4OA%XGG5-/OKDG3IW.%%TVT(%YX69-N!UW[1
MC+&OO.OS@^*6DQ_$K]J#P)X3LE4W,;VZWEQ#GS43S#,X/^Y$"X_WC7Z/UXF&
M7LYU*,7>,79/]/D>C6]^,*C5G)7?]>84445WG(%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"7[2T,/QD_;&\+>!Y
MC)<:5I%M$M[;%BJ9*M<S88<C?%Y*Y!Z@ $&OHS0O OAWPOM_L?0=-TQE&T-9
MVD<1Q]5&:^:/V9Y_^%H?M#?$GXA.9+BT\V1;.2<8=4FE/E <=5AB"^P/O7UE
M7+EM*-2,Z\EK*3MZ+1'5C)2BXTD]$E]X4445[IY04444 %%%% !1110 4444
M %%%% !1110 4444 9_B#0[7Q-H.I:/?*S6>H6TEK,JG!*.I5L'L<$U\8?LP
M?&#2_@;K/BKP9XTO#IENEX2DRQM+'%=1L8I5.P$_,%3!Q@>6<XS7V_7G_C3X
M _#_ .(%Q)<ZSX9LY+V1C(]U;;K>9V/\3O&5+G_>S7EXO#U:E2%:BTI1OOLT
MSNP]:$8RIU4^5]CH_#7CSPYXSCW:%KNG:L ,LMG<I(R_[R@Y7\16[7RQXA_8
M)T.22.;PYXHU'2ID8OB^B2Y&>J[2GEE<'N=QK(7P!^TA\,=G]CZ\OBBT4$>5
M]K6XPHS@%;D*P^B$^E8_7,12_C47ZK7\#3ZM1J:TZGWZ'U]17R7:_M)_&JTA
M$5[\)KJXN4.&DCTR[0-CVPWY@XITO[47Q=@3?+\)+N-/[SV%X!_Z#6G]IT.M
M_N9'U"KY?>CZRJ"^L;;4[.:TO+>*[M9E*2P3H'1U/564\$'T-?);?M9?%;;\
MOPMF!QP?L5V1_*M7PA^WAHUQ)]E\6>';S1KE3L>:S83QAAU+(VUDY[#<:2S+
M"R?+)V]4QO UXJZ5_1F'\=/V*_\ CXUOX?#UDFT.5_J3Y#'_ - ;\#T6OD*^
ML;C3;N6UNX)+6XB8K)#,I1T8=05/(/UK]4?!OQ=\&_$!4_L#Q'8ZA*W2W$GE
MS],_ZI\.._;M7-_&;]G?PS\9;5I;N/\ LS757;#J]M&#(,#A9%R/,7V)!&."
M.:\G&972KKVV$:OVZ/T['?A\=.F_9XA?YGEG["/_  4BU+]FNRM_ _C*SFU_
MX>-.6AF@;_2])WG+F,'B2(G),>006)4_PM^JOBKPG\(_VY_@O!!+=VOC+P=>
M2I<VU]I\Q26WG3G*MC?%( Q5E8!@&(8<U_.]XNT!O"?B;5=%>YAO)-/NI+5[
MBWSY;LC%25R <9!KO?V?_P!ICQ_^S/XN77O!&L&T+\76FW.9+*\7^[-%D;O9
M@0P[,*^.<7%V9] G=71^G_CK_@CG\%=/T>_U:W\7>,="MK.WDN9V:6"[CCC1
M2S,$$ =L '@$D]A7Y_\ Q:^$/P!\ V[7G@S]H+4O%=[AC%I]CX2F5UX.-UP\
M\2#/ X&<9..@/ZS_ +(O_!0;X??M36<&D22)X4\>!/WWAZ_G4BY/.3:R''G#
M R5P''.5(&X_FC\:_@KX2_99_;\AT;Q=H5OJ/PRU2^74+6WNB1#'8W190W!'
MRP2[UP<Y6'D'-*[&<G^PG\)_!_[3?[2EEX4^)6IZM>6D]C//:)%=;'O)80'$
M$CG<P3RA*WR$$;, CK7O/[>'[)-[^QKXZTGXO_"2T:T\%22);WFG O-'ITQ&
MW8^3N-O,!C).5?(W M'7,?M;>'[']D/]LKX=_$?PII=OI'A^1K345L=-A6"'
M-NZQ7,*(H"@/#LSCJ96)Y.3^Q_B#0] ^*7@>\TO4K:WUWPUKED8Y8G^:*YMY
M4Z@^X(((Y'!'-6IRC+F3U1-E*-FM#\W?AG\1M)^*G@^R\0:1*&AF&R:$ME[:
M8 ;XG]&&1]001P174U\G_$;P!X@_X)S_ +1D^D72S:E\-_$#![2^D7F>U#<-
MD#'GP%R&7'S ]!O4CZIT_4+;5;&WO;.>.ZL[B-9H9X6#)(C#*LI'4$$'-?HN
M78Y8RE9_$M_\SY'&89X>=U\+V)Z*2218HV=V"(HRS,<  =237C'Q#_:V^'_@
M$RP0Z@WB'4HP1]ETO$B!NP:7[@YZX)(]*]"KB*5%7J221RTZ52J[05SVBN#^
M+GQ@T+X3^&-0OKZ_M!JJ6[26>FO,!-<2=$ 0'=MW8RP& ,FOFR?XP?&S]H)6
M@\$:)+X<T23*M>6[;.-V#F[DV\KZ1 -P>#7G5O\ L\ZU>_M*>#/ASK6K0ZUJ
MOB'4+*.^N;6220Q+-+B0NSJ&)6,%R<="#7@8K-91IN5&#MMS/1?+N>KA\ N>
MU62OV6Y]^?\ !'_X!W5U:^)_CMXFB:XU36YIK#2)IU^9D\S==W([9>0>6",$
M>7(.C5^FU87@WP?HWP_\*Z7X;\/6$.EZ'I=NMK9V4&=D4:C &223[DDDDDDD
MFMVOAF^;5GTH4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ<UJ@HHHKJ.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /G#]IX_V?\ $3X;ZA$$^TK<
MGH/F^2:)ES[98X_&OMFOBKXE0KXD_:N^'VEJWG1VK6LDL2D':5F>5L_5%4GV
MK[5KY&A[V*Q$UMS)?<M3Z"M[M"E%]G^+"BBBO3.(**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXQ_; 8Z#^T%X UQP3 D-
ML>G4Q7;N?T<5]G5\>_\ !0>U;;X%N0G :\C9OKY!4?HU>1FE_J_.OLM/\3T<
M!_&47UNOP/>**J:3J$>K:79WT7,5U"DR?1E!'\ZMU]=3DI131\[*-I6844A(
M7))P!7 >(_CSX$\+W"P7?B"WFG)P8[(-<;><'<8P0,>A.>.E9U,12HJ]22BO
M-V-*=*I5=H1;]#T"BLKPYXJT?Q=8_;-&U*VU*W! 9K>0,4)&<,.JG'8X-:M:
M0G&HE*+NB)1<':2LPHHHK0@**** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MON',VK3Q7L,1-R4EI?75:GR^;X&FJ'M:44FGK;L=#1117ZD?#!1110 4444
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M?YGK%(S;5)ZXYX%+17Z8?%'D7Q:M574+2[5&0S1\JPP>/_UUH_!R\+?;[?'
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M^#ZHW:***W, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR"UNM35FP1@(##C\#@?A7WO7EY?JJDN\F=V+W@O[J"BBBO4.$**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYF_X*$:\^C_ +/YLTZ:
MIJMM:-_NJ'F_G"*^F:^1_P#@H]H&KZE\+] U*S4RZ3IVH%K]5!)0R)LBD/'"
M@[ESGK(HYSQQ8UM8>5NQU86SK1OW.L_9[\&6?@?X0^&;6VMHX)[JRBO;ME4!
MY)I4#L6/\1&=H]E Z"O1JYOX;^,M-\?>"-'US20L=G=6ZD0@Y,##AHC[J05_
M"NDKV,/&,:45#:RL<%9R=23EO<****Z#$**** "BBB@ HHHH **** "BBB@
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MTY*G@Y^5F]*KZG#UZ>)IJK2=TSPJU&=&;A-6:"BBBNDQ"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M***3V&MSP#X:PKXI_;:U2]B!DBTN"4G=GY"ENMN<?\#<_GFOLFOD#]C1%\2_
M%KXD^*(POENQ5>F0+BX>08/_ &R[5]?U\AEWO0G4_FDW^)]#C?=G&'\J2_ *
M***]4X HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/#EGQNEUQ)1SSA+>8'C_ (&*]#,$GAI7.3!W]O&QXC_P3K\52:1\9M0T8O\
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MIRQ]L8S<2,,=ZPM#^%/QH^)_Q<\*^(OBC$)[+298V\R:6T"B-&:4*(H" 27
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,8CKG K^?OXD^/(
M/C-^TM\4/'MJ@73[_5)([&2-0J26ZGRXV.!RQCBC8^[$G.<U^P_[=GQ<_P"%
M*_LJ^/\ 7H9O)U.XL3I>GE3A_M%R?)5E]T#M)_VS-?BA\/\ 2QI?A:UX427
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MN37(^%_$.D27#:IJEXKZA(3A&'$8]!4^K?#&^UF\>YN=25W8_P!TX'L*I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:*N:TJ;K35..[/,OVNO'FE?V#;>$XI_/UC[3'=2Q1\B",*V-Y[,VX$+UQR<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBKY.O#ZCC+KX*GX/_@GT%*7UK#6?Q0_+_@'US1117HG$%%%% !1110 4444
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MZ8UHN'LZL>9+;R/STT_X>_'S]H*Y-G<:9-X#T '9</?126088&?E;]])D$X
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M_!''_DT6Y_[&6]_]%05]TU\+?\$<?^31;G_L9;W_ -%05]TT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'X_?\ !6+Q>OBK]K+P/X36
M4M;>']&6XD5?X;B:1Y&'XI%!^=?.M=I^U]>:C>_M\?%=]5PMQ&\442]A"L%N
M(?SCVGZDUQ=?KO"=)0P4I]9-_A8^"SZ;EB(Q[(****^V/F0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J"WM%@FGEW,\DK LS$$@ 8"CC
MA1R<>I)[FIZ*EQ4FF^A<9-)I=0HHHJB HHHH CB0H7W2-(&;(# <#T& ./K4
ME%%)*RL/X@HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "N=\;^&O^$DT=
MEC'^EPY>$@#+''W,GL?KU /:NBHKEQ&'ABJ4J-174C>A6GAZBJ0W1]:?L?\
MQ\;XP^!6TO69O^*PT$+;WZR J]Q'R(Y\'J3C:_HP)( 917O]?E39^*M4^!_Q
M)TKQ]H$19(G*7UHCE([B-CAT<C/#@\'!"LJMR<5^G?@OQEI7Q \*Z9XBT2Y6
M[TO481-#(I&?0JP'1E8%6'8J1VK\[A&IAZDL+5^*/7NNC/K9N-6$:]/X9?@^
MJ-NBBBN@Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \W_:.\11^%?@/XZU"25H
M#_9,]M'(K%6669?)CP1T.^1:\S_X)]^&SHG[/L-\WS'6-3N;P9[!2L&/IF$G
M\347_!0CQ+)HOP".GQA6_M?5;>TDR<$(H>?(]?FA0?C7K?P#\-_\(E\%?!6E
ME-DD.DV[2J/^>CH'?_QYFKS/CQG^%?BW_D=WPX;U?Y'?4445Z9PA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&7@&
M&#QE_P %%/&.H+)YBZ-8.T>>0K)!!:N!Z<R/T]_4U]FU\8?L/R6GBSXT_&GQ
M; V]9[[,#*>#'<7-Q+G_ ,A+7G8KWJM*'G?[D=N']V%27E;[S[/HHHKT3B"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I" V01D&EHH \H\2_LJ_"?Q;=27&H^"-.$TC;G:S,EH6).23Y+)R
M35#3?V-_@WI,WF0>";9FR#MN+NYG7C/:21AWKV:BN?ZO1;NX*_HC;V]2UN9_
M>8_AOP?H7@VS%GH.C6&BVO\ SRL+9(5/N0H&3[FMBBBMXQ459&+;EJPHHHI@
M%<#\2O@3X'^,%U8W'B_1&U>6Q1H[?_3+B$1AB"V%CD4$G Y(SP*[ZBIE"-1<
MLU=%1DXN\79E+1M(L_#^D6.EZ= MK86,"6UO"N=L<:*%51GT  J[115;:(D*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KA_CI,UO\ !/X@R*S(Z^']0*LIP0?LTF"#7<5YA^TYJBZ3
M^S]X]G8X#:3-;_C(/+'ZO6-=VI2?DS6EK.*\SQG_ ()MV:Q_!_Q%=#[\FNO&
M?HMO 1_Z&:^M:^9/^">=J+?X RN$5?/UBYD) QN^2)<GU^[C\*^FZY\"K8>/
MH;8IWK2"BBBNXY HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFD08$DQ^:1_Q<L>>V*X*<?K.+2^S#7YO;[CLD_8X>_6?Y'54445]$>0%%%%
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M;1+]G:)661EE@D8DOY@R"!P.*^JXO^"+?PD@U2.XC\8>,)+>.17^S7$MH^\
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M&45[]7S5*K&K%3CU/7J0E3DX2W04445J0%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q
M/^W_ #?\)A\0/A7X#M[AEGO+AFEA4C/[^6*&)_S68#\:^U8XTAC2.-0B( JJ
M.@ Z"OBKQ:[?$'_@HQH-@T9:W\.V\09UQ@".W>Y!_P"_DRK7VQ7FX7WJM6IY
MV^X[L1[M.G#RO]X4445Z1PA1110 4444 %%%% !1110 4444 %%%% !1110
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MXU[+1A5:A!>2_(*[O5D_-A111748!1110 4444 %%%% !1110 4444 %%%%
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M?V[/"OQ(MXUM](\310W5Q-M^7S$ M;M0,_>\DQMGUDSZU[;7:_\ !7KX2_\
M">?LQ1^*K>/=J/@W48[S< 2QM9B()E _WFA<GL(S7YYC]I[Q9X\\#>$_A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"QW3X 09Z+)TQT#C'\1-?GN987^S\1[6/\.;^Y_Y,^MP=;ZY1Y9?'#\5_P
M^_:***S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%<]\0_$G_"&^ ?$FO;/,.EZ;<WH3.-
MQCB9P/Q(Q4S:C%ME1CS2LCY&_9#9?'_[4GQ8\;)/]NM(WGBMKC(*^7-<GR2#
M_P!<H,#VK[:KY%_X)N^&A8?"_P 1ZXR;9=2U00!L#+1PQKM/TW2R#\#7UU7!
M@(M4%)[N[^]G5BW^]LNF@4445Z)QA1110 4444 %%%% !1110 4444 %%%%
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M4TJT*\.>F[H=2G*G+EFK,****V,PHHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** /F7XY?L.^%_B%)<:WX1=/"'BC)F7R05LKB0 8+HO\
MJCD#YX_4L58FO/\ X$_'CXE?#?XT6'PB^)SKJ"3R?9X;ZZ<R7",R%H668?ZZ
M-SA?GRP+\L-A6OMJOB;_ (*&>%[KP[K7@7XEZ5^YO;*X6P>?<<K(C&XMB%]B
M)\GV6O&Q5%8=?6*6C35TMFO0]+#U'6_=5-4]O(^V:*PO WC'3OB!X0TCQ%I4
M\=Q8:E;)<1M&X;:2/F0D=&5LJPZAE(/(K=KUXR4DFCSY1<7RL****HD****
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MGB#4-1AT?3VNE+PP2R1RR&5U!&X*D,F!G[Q7.1D'XQ_8%_X*3?%#XD?'O1_
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M]YU-%%%?JA\*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>R1C5ESU'+N%%%%;&84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'QG^T9'=>+/VV/A#H$,BM#8I:ZAY9&<%;F267\X[
M=:^S*^,M"M9?%_\ P4@UFZ\\R0>'[$R(O&%7[''"5_[^7#'ZU]FUYN#]Z52?
M>3_#0[L3HH1\OS"BBBO2.$**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^)O\ @IE=!=%^']L7(:2XO) O."%6$$_AO'YU]LU\
M/?\ !2"--1\0?"W3R6R[WJMMZX=[9>/R->=F/^[2^7YH[<'_ !H_/\C[/\,V
M/]F^&]*L\8^SVD46/]U /Z5I4@XX'2EKOBK1L<<M9!1115""BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **YWQ]XR_X0/PY-JPT/6/$31LJ"PT&T-U<N2<9" C@=SVKX;_:*_;/^(=U
M#-H>F>&-2^'=E<!HVN-0A>.^E7H0I90(_P#@.6'9A7'B,5##J\MSIHX>59Z&
MA^U0U_\ M.?'[1/A]X-"ZA'X?BDCO+U3F&VDD9?/9V'&U D:GN6!4<U]E_"W
MX<Z7\)? >D^%M'#&TL(]IF<?/-(26>1O=F)/MT' %?E+\'/C_P"+O@AJTEUX
M>O(S:W#J]W872!X;G'][^('W4@U^F_P#^/6A?'SPB=5TM39:C:E8M0TV5PTE
MM(1D'/\ $C8.UL#.", @@>9@*]*K5E-_'+\O([L73J4X1BOA7Y^9Z=1117OG
MD!17.^/O&7_"!^')M6&AZQXB:-E06&@VANKER3C(0$<#N>U?#?[17[9_Q#NH
M9M#TSPQJ7P[LK@-&UQJ$+QWTJ]"%+*!'_P !RP[,*X\1BH8=7EN=-'#RK/0T
M/VJ&O_VG/C]HGP^\&A=0C\/Q21WEZIS#;22,OGL[#C:@2-3W+ J.:^R_A;\.
M=+^$O@/2?"VCAC:6$>TS./GFD)+/(WNS$GVZ#@"ORE^#GQ_\7?!#5I+KP]>1
MFUN'5[NPND#PW./[W\0/NI!K]-_@'\>M"^/GA$ZKI:FRU&U*Q:AILKAI+:0C
M(.?XD;!VM@9P1@$$#S,!7I5:LIOXY?EY'=BZ=2G",5\*_/S/3J***]\\@***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ^*OV_V7P[\0/A%XD5=KV]U-OE(P (IK>103V^\Y_.OH
M^OG'_@I@O_%.^ V]+NZ'_CD=?1<+;H8V/4J#^E<V!TQ-:/I^1T8G^!2?J/HH
MHKW#S HHHH **** "BBB@ HHHH **** "BBB@#FOB1XXM/AQX)U;Q%>8,=E
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MIX(KX3^+'[.?B_\ 9=\4S?$KX47EQ+H=MNDNK#F22T@."\<BY_?V_&23\R@
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MGKU(.G)PEN@HHHK4@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OB;]I3?\ $#]M'X7>%%=9K33Q:W$T&,[2
M9GFF!^L44=?;-?$OPI\OXA?\%!O&^N)'^ZT6.X0,RY >%(K+KV)^<CV!KS<=
MJJ=/^:2^[<[L+[KE/LF?;5%%%>D<(4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !115+6]4BT/1;_49V"06=O)<2,>@5
M%+$_D*4G:-P6Y\?_ +'UHGB3]ICXU^*EF,RQ7<]M$Q8G,<]W(ZXYZ 6Z@>U?
M9M?'O_!-?0XK?X=^+=9 _?7FK)9MP/NPPJX_6=J^PJX, OW"D^MW^)V8O^*U
MVM^04445Z!QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7PQ^V]')JW[1WPITPG=%)]G55_VI+S:?_01^5?<]?#W[3%N-2_;G
M^$T&<"./3"W&?NWT[X_$#]:\S,-:2CW:_,[L'_$OV3/N&BBBO36QPA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5#6M#TWQ)ILVG:M86VIV$PVR6UW$LL;CW5@0:OT4K*6C"[
MZ'Y[?MA?L@Z=\.M+E\;^"XI(M&64"_TLDN+3<<+)&3SLW$ J<XR,<<#R[]C#
MXA7/@3X^>'XEFV66MR?V7<Q$X#^9Q'^(DV8_$=Z_4'QEX9M_&7A'6=!O$5K?
M4K.6TDW#C#H5S]1G.>V*_)+]G'2YM6^/GP_@A&]TUNTG/^[%*LC?^.H:^5Q=
M!8?$PG2TN_QN>_AZKK4)QJ:V/V&HHHKZL\ *H:UH>F^)--FT[5K"VU.PF&V2
MVNXEEC<>ZL"#5^BE92T87?0_/;]L+]D'3OAUI<OC?P7%)%HRR@7^EDEQ:;CA
M9(R>=FX@%3G&1CC@>7?L8?$*Y\"?'SP_$LVRRUN3^R[F(G ?S.(_Q$FS'XCO
M7Z@^,O#-OXR\(ZSH-XBM;ZE9RVDFX<8="N?J,YSVQ7Y)?LXZ7-JWQ\^'\$(W
MNFMVDY_W8I5D;_QU#7RN+H+#XF$Z6EW^-SW\/5=:A.-36Q^PU%%%?5G@!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M**%'Z"KE%%?6PBH145LCY^4G*7,PHHHJR0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKQO]J?QI=>%?ATMK93+%<:M/]DD_O^1L8R;>
M>_RJ3@\,>A(-<F*Q"PU&59[11T8>BZ]2--=3@?B;XHU?]H7XAV7P]\&R>?HZ
M29N;J+_5.5/SS.V>8HQT_O-TW$I7V1\.OA_I/PP\'V'A_1HMEK:K\\K??GD/
M+R.>[,?P P!@  <-^S7\%;3X1^"(99 MQX@U2-+B^N2/N9 *PIZ*N?Q8D],
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MN;>19H)D62.13D,I&01[$&I:^@/("BBB@ HHHH **** "BBB@ HHHH ****
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M+HMS'X3\5>%+FYNKR"W;[-;ZD9X5EC9P-JM($$H!.6+2$#BOM"@#^>7]M/\
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M%#'M7Y,?\$S_ (?W?[2_[8>H^//&\\FO3:'%)XANIKK#"XOGD5(-PQT4LT@
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M?&HT^V9[W34C2(P$-Y:XCBB7(&?X?Q-?T35^%_\ P5\_Y/&OO^P)8_\ H+T
M>F_L8^!_VQ]:_9^T*\^#_P 0?#F@>!&GNA9V.H6]J\R.)W$I)DLY&Y?<1ESP
M>W2OLW]EWP9^UIH/Q)EN/C;X[\/^)/!QT^54L]+@MDE%T63RWS':1-@*)!][
M'(X/:O\ \$H?^3(_!W_7YJ/_ *62U]?4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S3_P42^$P^+W
M[(_CFQAB$NI:/ ->LCC+"2VS(X4=RT/G(/\ ?KZ6JO<VT5[;RP3QK+!*A22-
MQE64C!!'<$4 ?SO^"-6_MKPS9S%MTJ+Y3Y;<VY>,D^I&#SZUNU3\2> 9O@E\
M=OB)\-I_,\K1]2E%IY@'S6^[,3D]<O$\+?G^-ROW?)<5];P,)O>UGZK3\3\P
MS*A]7Q4XK;=?,****]P\L**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,/0_%^I? GXG:=X]T6-I;0OY.I6:?*DL+%=Z''][&X
M$@@.JDYX%?ISX3\4Z9XV\-Z;KVC7*WFEZA MQ;S+W5AT([,.00>000>17YMW
MUC!J5I):W,:RPR#:5;O_ /7]Z]"_8J^,DWPT\:S?"[Q%=9TG4I?,TBXD)"QW
M+8Q&,]%EZ  X$@P 2Y-?GV8X7^S\1[2/\.;^Y_Y,^MP=;ZY1Y9?'#\5_P#[X
MHHHK(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 07UY%I]E<74[B.""-I9&/0*HR3^0KXS_X)V6-SKM]\1_&
ME_B2[U&\BB,H7 WDR32X^I=./:OH']J+Q%'X8_9\\>7DH)672Y+(8&?FN,0+
M^LHKA?V!O#?]@_L\V%V4*2:Q?W-\V[.>&$(//;$(/XY[UYE7W\7"/\J;^_0[
MH>[AYONTCZ,HHHKTSA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^&/B2TFN?\%%O"UJ
MXRMG]E"?[JP/-_,FON>OAZ.W;4O^"FDI+;H[5 ^&)X TD#"_\";/YUYF/U]F
MN\D=V%WF_P"ZS[AHHHKTSA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_H4M?:%1E'^YP^?YEYA_O$OE^04445[)YH4444 %%%% !1110 4444 %%%%
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M%L]D98U8':RSO*<CM\NW/M^%>!G;_P!E]G_,TOQN>OEB_?\ -V3?X'VPJA5
M P!P****M;$=0HHHIB"BBB@ HHIL<J2Y*.K@'!VG.#Z4KH=F.HHKA/C%\8M%
M^"_AN/5M7CFN7N)?(MK.UV^9*^TG/)&%&.6[9'!) K.I4C2BYS=DBHQE.2C%
M7;.[K!\4>/O#?@GR/[>UVPT@S,J1K>7"QELG (!.<9ZGH,$G&*^7K7XH?'?]
MHK;'X"\.2>'-"D;8VH1X5=N[:V;J4 ':>HB4,,'@]*ZWP_\ \$Y3JUC?WGC3
MQS=7GB&ZC)233X_,CBF(/SR/+\\ZYQQB,\'GGCQY9E.I_NU-R\WHCT5@XT_X
MT[>2U9](0S)<1)+$ZR1NH970Y# \@@]Q7!_';XA7WPM^%NL>)--MX+F]M/*6
M-+D$Q@O*B9(!!.-W3(KYM;5/BG^Q7K46F>(;9O$?@*68Q6MP'+0MD;OW+\F%
M^I,3C!VO@'[]>G?&CX@:'\7OV5_$^M:#=-):,L D25-LL,J3PNT3KGA@,="1
MR""1BJ^OJK0FE[LTGH]]NG<7U5TZD'\4&UJ>>_"?]FGQC^U4MKX[^(7B6XM?
M#]PS_9(X2K3RQJVUO)3[D";E(R5))4G:00Q^W/AM\*/"OPET4:7X6T:#38&Y
MEE7+S3MDG,DC99SR<9.!G  '%>??L4W377[,_@QV;<RK=Q],<+=S #\@*]OK
MFPE"G&G&K:\I)-MZO4UQ%6<I.FM$N@51UK1-/\1Z5<Z;JEE!J&GW2>7/:W$8
M>.1?0J>#5ZBO1WT9Q'FO_#-?PK_Z$#P__P" *?X4Y?V;OA9&RL/ 'A_(.>;"
M,C\B*](HK'V%+^1?<C7VU3^9_>4](T>PT#38-/TRSM]/L+==D-K:Q+%%&N<X
M55  'TJY116VVB,@HHHH **** "BBN>\?>.M)^&O@_4_$FM3^1I]A"97QC<[
M=%11W9F(4#U(I2DHIR>PXQ<G9'DG[77Q];X0^"TTK1)#)XSUP&WL(H1ND@4_
M*T^!W!.%]6/?::L_LF_ %/@GX%\_4H@WBW6 MQJ,C'<8NI2 'T7//JQ/4 5Y
M'^S%X$U7X^_$S4/C?XWA+6RSE-!L7YC4H2H90?X(N0/5]S=1S]GUYV'B\1/Z
MQ/;[*\N_S.VK)48^RCOU_P OD?F'_P %!/\ DX:Y_P"P9:_R:OKO]A'_ )-I
M\/?]?%Y_Z4/7R)_P4$_Y.&N?^P9:_P FKZ[_ &$?^3:?#O\ U\7G_I0]>9A/
M]_J?/\T=N(_W2'R_(^@:_,K_ (*">*9-<^/LFEEV,.C:?;VPC[!G7SF/U(E7
M\A7Z:U^1_P"UQ</=?M'>.7?&X7JIQZ+$BC] *Z<WDU02[LPR]7JM]D?5W_!-
M?2Q#\./%FI8.;C55M\]OW<*MZ_\ 37]:^PJ^7O\ @G;"D/P$NW1=K2:W<.Y]
M3Y<*Y_(#\J^H:[L"N7#P7D<V*=ZT@K\:_CKI:Z)\:O'5BBA8X=<O!&J] AF<
MJ/R(K]E*_(3]J2.*/]H3QZ(#N3^TY&)SGYC@M_X\37FYPOW<'YG9EK]^2\C]
M(?V3_%#>+OV>?!-[(VZ6*R^Q/SDY@=H1GW(C!_&O6J^<_P!@65Y/V<]-5FR(
M[^Z51Z#S,X_,G\Z^C*]?"R<J$&^R/.KKEJR2[L****Z3$**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *^//VAOV3O%%OX^N?BC\*-1>T\0
M&5;N72K<K!)YI&V66%\A6W@EGC?[V9.6W!*^PZBN;F*SMY;BXE2"")#))+(P
M544#)8D\  =ZYJ]"%>-I_P##&]&K*E*\3Y,^!O[=5GJ]\/"_Q0ME\+^(H)#;
M/J#QF&W:125*SJW,#@C!S\N0V=G KZUAFCN88YH9%EBD4.DB$%64C(((Z@BO
MS5^/GB]?VO?C58:/\/\ 0+<Q62O#_;4D1BEN8\J&GG;&5@3 "!@6^8\;I @T
M?V>_C/XD_9=^)Y^'_CF65?"\T_D.KOF*S9V^2ZB9L?N23E@,<%FQN7:?(H8V
M5.7+4]Z%[*1Z%7"QFN:&DK7Y3]'**16#*"#D'D$4M?0'D!1110 4444 %%%%
M !1110!E^)_$5EX0\-ZKKFI.8M/TVUDO+AE&2(XU+-@=S@<#N:_-CX=_#?QK
M^TIXD\6_$>S\1MX;U)[\^5,DD@)<@-Y2R*0RK&AB4=>,>E?07_!0KXJ-HO@W
M2O .G2;M3\02">ZCB.7%JC#:NT<_O)0,>OE.*]!^#O@"+X8?#C0_#R!?/MH=
MURZ_QSN=TASW&XD#V %>8Z:QN)]F_@@M?5['?&;PM'G7Q2V]$?/W]E_M4_#>
MSD@TSQ,WB2V 8E_M$-Z_(/(-T@D.#T ]N"*UO@]^R;-)J9\6_%*Y;Q%K]P5E
M_L^[E^T(K8ZW#DGSFZ#;G:,?Q9&/IVBNZ&5THS4I-R2V3=TCFECJDHN*25^J
M6HBJ%4*H 4#  Z"EHHKV#S@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPQXUT.UU_1;H?-;W (9&[/&X(:-QV92"/6OAG3/^"+'PUM/&UMJ-UXTU^_\
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MJN/XI;6)I#T[R>8?Q]:_07_@C'XDGU;]EW6]-G=G&D^)[F* $<+%)!;R8'_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YOQQX;;7M.66V+)J-H?,MV5MG.02,^O'
M'N!R.:Z2BN3%8>&+HRHU%I+^OP.BA7GAJBJPW1]@?LD_'Q/C=\.T34)@?%6C
MA+;4E( ,W'R7  [. <],,K< ;<^YU^6&@>,-2^ WQ0T_QYHR/-:._DZG9H J
M2PL5WH<?WL!@3P'52<]*_3KPKXHTWQIX;TW7='NEO-+U"!;BWF7C<K#/(Z@C
MH0>000>17YY!3H5)8:M\4?Q71GUD^2I%5Z7PR_!]4:M%%%=!B%%%% !1110
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MOBAE&C>)M'U=V^Z+&_BF)[?PL:Z(UJ<OADG\SGE2G'XHM'0T445M<S"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444K(+L****8!1110 4444K(+L****8!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!\??\%*!_P 6V\)G_J+L/_(+U[-X3;=X6T8^ME"?_'!7CG_!2?\
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M&'7N <@?0'7@U\N_&;]E>ZT[5D\:?"QETC6;9C-)I,!$:/P<F$?=4GH8S\C
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MY>2W.3&PY/F1Y "@EAG%?1W[#_P=/PS^$L>K7]N8M=\2%;V<.,-'  ?(C/\
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MNV(D.[(W(FU2!TQC! Y!YKU/P[X%\.>$[?R-&T/3]-CWF3;;VZI\Q !;('7
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M"^"/BWP#>ND']L692VN) 2(+E")()#CG"R(A('4 CO7\X_BSPGX@^%GC?4=
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M]*_.;QM_P2-_:)^(_BO5?$WB7QUX&U?7=4G:YN[RXU&]WRN>^!9   8 4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC#*V?3"L3GD5T1K4I;23^9C*E./Q1:.HHHHK>YD%%%% !1110 4444 %%%%
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M>G[E8LCL2U?(YI/ZQBX4.D5=^NR/H,%'V6'G5ZRT7ZGNU%%%!(4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!^>'_  5F_9GF\6>"['XR^%X&7Q)X3C\K5?LZ_//IY)(D([F%F)/^
MQ(Y/"@5^>7A_7(?$&E07D#+AAAU!SL? RI^GZ\'O7]!^H6%MJVGW-C>V\=U9
MW430SV\JADDC8$,K \$$$@CWK\&OVBO@C<?LD?M&:UX)D$Q\*:LPO] N&RP-
MO(Q"*3G[R'=$QZDHK< BOKN&\R^IXCV4W[D_P?1GA9O@_K-'GBO>C^74QJ**
M*_9#\Z"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/>NI#!@"#D'O7RUK/_!.GX:7\TDMEJ/B'2]P^6&&ZBDC7_ON(L?^^NU<JO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXRC*C46C_J_R.G#UYX:HJL-T?8O[)OQZ3XY?#F-KZ7/BC2-EKJBD*#*V/DN
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MK&E.7PIL]$HKP36?VVOAGII(M;C5-7_Z\[(K_P"C2G^163>?M?:K>+%)X?\
MA5XBU:"9=\,LRO&'4C(8;(Y,C&#P>G>N66889:<U_37\C982O+[-O73\SZ1H
MKYQE^)7[06L:@EOI_P .-+TB&1@IFOYO,$0) W%A*O3DG"DXZ"DC\&_M&:_?
M&/4/&NC:#8,"':RMXY&3@XVCRMW7 ^^,=><5/U[F^"G)_*WYV*^JV^*<5\_\
MCZ/JGJ6LZ?HL/G:A?6UC%_STN9EC7\V(KY[MOV6_&&L2SCQ5\7->U"TD4C[-
M:221KNXP2&=EQC/ 7T.:L:/^P[X"LYI)M2N]8UIV4@K/<+&NXG.[Y%#9[<MC
MD\=,3[?%2^&E;U:#V=".]2_HO\STO6/CW\.M!S]K\9Z02I(*V]TL[ @X((CW
M$5P^M?MI_##2U)MK^_U<XSML[%U/T_>[*Z#P_P#LM_#'P['*L7A:VO#)C<^H
M.]P>,XQO)"]>V,\9Z5VVA^ /#7ANS-II>@:;86Q;>8[>U106P!N.!R< <^U.
MV-ENXQ^387PT>DG]R/"9?VT5U:W>X\+_  \\0Z] K^696'EJ&X)4F-90#@@X
M]Q2R?&KXY:];I<Z'\*(;&";B,:G(Q<<XRRL\1'0]0.QZ=?I-$6-0JJ%7T48%
M+1]6Q$OCK/Y)+_,?MJ4?AIKYML^:[C2?VF->CCD76/#^@"90[0QK&3%D9V$F
M.3D9QP3R.#3)?V<?BKKT<9UCXR7\#.@,L5B)O+#$#*@+)&& YP2!]!FOI>BC
M^SZ<OXDI2]6_TL'UN:^%)?)'SC%^P_X7N=0AN-5\2:_JT<;;C#-.GS\C(+;<
M@$#!P0?<5UVB_LE_"_0[Q;E?#OVQUSM6]N99HQD$<H6VGKW!QP1S7L%%:QP.
M&B[J"_/\S.6*KRTYF9>A>%=&\,VD-MI.E6>FP0J5CCM8%C"@G)Z#N22?4FM2
MBBNR,8Q5DCGE)RU844451(4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'BSPGI7CCP_
M>:+K5FE]I]TFV2)^H]&4]0P/((Y!K7HJ914DXR6C*BW%WB?.?P3^-GC3_@G%
M\3/[.U#[5XF^#>N7.Z6!>6B8\>;%V2X50-R\+*J]B 4_9S2]2MM:TVTU"RF6
MYL[J%)X)D^[)&RAE8>Q!!K\G?VGO#8\3? WQ5!YGEO:VWVU6QG_4L)",9'4*
M1[9S@]*^9-/_ ."C'QXT?PGX2\-:5XO72=&\,P6UM;0V=I&K3QP!1&L\A!=Q
MM0*5# ,,Y!K\XS3"1PM?EAL]?^ ?88.N\12O+=']!=%<!\"_BYI7QV^$?ACQ
MWHQ L]:LUG:'=N,$PRLL+'U2170_[M=_7D'<%%%% !1110 4444 %%%% !11
M10 4444 %%%% !117SY^UC^VCX%_9)\-I/KLIU?Q/=IOT_PW92J+BX&2!(Y.
M?*BR""Y!Z$*&(Q0!]!UQOBSXP^ O ,C)XG\;>'?#CKU75M5M[4CD#GS''<C\
MQ7Y$Z3\7/VJ/^"DGC.\T7PQJDWA/P=&X%X-+EDL=,L8R3A9YU_>3N01^[RVX
MC(10"1]0?#+_ ((T?"W0;6.;QQXBU[QGJK<S>1(MA:%B<G"+ND]LF3GK@4 ?
M8N@?M#?"OQ7=?9M$^)?A#6+C(7R=/UZTG?)Z#"2$UW\<BR('1@RL,AE.01ZU
M\9ZU_P $D?V=]5LG@M=%UO1Y6! N;+6)6D7/<"7>N1[K7B?C3]C/]H3]C>SE
M\3?L^?$G6/%OAVR!EG\'WX\R7RQR=EN<Q3G YV+')V0$T ?I+KGB32/# LFU
M?5;'2EOKN*PM&OKE(1<7,AQ'!'N(W2.>%09)/05KU^"7C3]N[XE_M*?%[X5+
MXV;3--TOP[XDL;Q-+TJ![:!IUG0&:7S'=BX7<.N%#-@#)S^]M !1110 4444
M %%%% %#5M8L/#^FW&H:G?6^G6%NN^:ZO)EBBB7U9V( 'N37S#?_ /!2OX(_
M\+8\,_#_ $+5]0\8:OKFJ6^D1W>@VJR65O--*D2&2:1T#)N<$M%YG /T/BO[
M<W["6M^,OA/XX\?ZS\7_ !7XIUCP_:76M6VE:EY,>F1P1!I7C2"-5",(@P#C
MDD#(YQ7YA_LG?\G3?!O_ +'/1O\ TNAH _I3HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OF[XY_P#!03X)? 1I[76/%2:[K4+;6T7PV%O;I3W#
M$,(XSTX=U/-3_M%?LFZE^T=J%U!J?Q;\7^&_"DEND2^&] :&WMV< [VF?:6F
M5LCY'.!CCMC\$_C!\.[KX2?%3Q9X*NYUNKC0=3N-.:X1=JS".0J) .P8 -CM
MF@#^DOX8?$+3_BO\._#GC/28+NVTO7;"'4+:&]15G2.10RAPK,H;!YPQ'O75
MUXM^Q7_R:3\(/^Q8L/\ T2M>TT %%%% !7D7[1G[3W@3]EOP?!X@\<WUQ''=
M2F"RT^QA\ZZO) ,LL:$@8 Y+,RJ,@$Y(!]=K\]?^"MG[+_CKXX>'?!?BGP3I
M=QXCE\-_:H+W2+)#)=-',8BLL48Y?!B(95RWS*0" < 'TM^S+^V-\.OVL-/U
M&7P7=7T&H:;M:\TC5K<0W42,2%?"LZ,I((RKG!'.,C/NE?EO_P $E?V2_B-\
M,?B!XC^(WC30=0\(6$NE-I%EIVJ1-;W-T\DT4CNT+8=400@?.!DN",[37ZD4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XF?MS?LT?$7X"
M?&[QS\2+;P\VL?#SQ)J<VI-J&GDR+:O*YD99\#="1([88C8=P .>!XIH/B.Q
M\26YELYMQ7&^-AAU)&<$?U''!K^A6XMXKN&2&6-9H9%*/&ZAE92,$$'J"*_
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MB.YMTDR,;XVBM$_[Z1)#^%?8^N:Q;>']%U#5;V58;.QMY+F>1SA4C12S$GL
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M/M.BOBJ/_@I&-/OA;ZW\-KS3,#+;=2W2#G'W'A3W[]JZ2W_X*1?#QE!G\/\
MB:-^XC@MW'YF<52Q^&?VOS$\)77V3ZQHKYZTO]O+X/ZA'NGUN^TT_P!RZTZ9
MB/\ OVKC]:Z;1OVNOA!KS$6WCFPB(./]-CEM?UE1:VCBJ,MIK[T9.A56\7]Q
MZ_17%Z?\;/A[JD@CM/'7ARXE(SY<>K6[-UQTWYZD?G75V>I6FH1A[6ZAN4/1
MH9 X/X@UO&I"7PNYFX3CNBS1115W("BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#P?]N.<0_LR^+4)P97LT'_ (%PM_2M/]CR
MT%E^S;X'C4;=UM+)C)/+W$KD_B6S7&?\%"+J2W_9]:-#A9]6MHW]UP[8_-17
MJ'[-UF+#X!> (@,;M%M9?^^XP_\ [-7F1UQK\E^IVO3"KU_0](HHHKTSB"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%<G\1_BIX7^$N@MJ_BG5X=
M+M<[8D;+RSMQ\L<:Y9SR,X' Y. ":^+_ !]^W)XX^*FJ-X>^%.@W.F+-D+<^
M2+G4)%XRP492$<\GYL<'>M<=;%TZ&C=WV6YTTL/.IK;3OT/L;XF?&?P=\'].
M%WXIURWTYG7=#:9\RYG[?)$N6(SQNQ@9Y(KX)^/?QCUG]L7Q#I&A^"_"%[]B
MTIY9(GD8-,_F;1OE(_=PK\N.6(R?O=JZ_P"'/[&-_KVH'Q#\4M8N-0O[AQ++
MI\=RTLLAP/\ 7W!))/4$(3T!#U]1^&O"VC^#M)BTS1--MM,L(_NP6L81<XP6
M/JQQRQR3W-8K#XC&_P 3W(/IU?\ D;>VHX5WA[TN_0THU$<:J!@*,4ZBBOI%
MHK'BA1113 ****5QA1111=!9A117 ?%WXW>&O@WHWVK6+@SW\H_T72[<@SSG
M.,X/W4'.6/'! R< YU*M.E%SF[)%QISJ2Y8J[.RUC6M.\/:;-J.J7UOIUA#C
MS+J[E6*-,D 99B ,D@#W(%<_;_%[P)<R+'%XU\/2R-T1-5@+'C/3?7R3I>B?
M$/\ ;)\2+?ZM,^A^!;:8L@0?N8\?+LB4X,TI&<R-PN6Z<(>^UW]@OPBNGSR6
M'B36+.5$9A)="&=!@9R554)_,5XWUW$U;SH4[P[MVN>C]5HT_=K3][RUL?1=
MKXV\.WJ[K?7]+G7.W,5Y&PSZ<-6C'J=G-GR[N!\==LBG^M?"G[-/[,>A?&7P
MGJFN:QJNH6RPWQLH(;$1H?EC1V9BRMG/F*  !C:>3GCUX?L$^!Q_S'/$'_?Z
M#_XU5T<5BZL%.--6?G_P!5,/AZ<G!U'=>1])-<1+&7:5 @&2Q88QZYKF;_XL
M>"M+F>*\\7Z%;3)G=%)J,*N,$@_*6SU!_*O&;/\ 81\!V]S#++JFNW42N&:%
MYXE5P#]TE8P<'V(/H175Z=^R%\+=-NDG_P"$?DNFC=75;F]F=,@YY7=AAZ@Y
M!KH]IC);0BO5M_D8\N&CO-OY%W4OVJOA7I<ICE\6P2."1_HUM/,./]I$(_'/
M-<AJ7[='P[LI"EO;:YJ [206D:KV_OR*?T[5ZCI_P1\ :7>175KX/T:*XA8/
M')]D0E&!!##(X(('-=7!I%A:R;X;*WA?INCB53^@HY,9+><8^B;_ ##FPL=H
MM_/_ (!\[WG[7'B%YA'I?PB\0W>[.#.)(VZ?W5A;/?OVJ2;XD?M":Q>K;:?\
M.])TB*1@IGO9?,$0) W%A,.F23A2?:OH^BCZK6E\=9_))!]8IQ^&FOG=GS?'
MX,_:+\07OEZCXUT?0K%L[VL8$9UX)&T>4&/.!]\<<\TEO^RQXNUN28>*OBUK
MVHVKJ0+:UED5=W&"=SLN,9X"^AS7TC13_L^E+XW*7JV+ZW47PI+T2/GO0_V(
M? &G^>^I3:KKDTI!WW-UY>TY.2/+"YSD9R3T[<UVVA_LS_#/0;,V\/A*RNE+
M;S)?;KA\X ^\Y) XZ#CD\<UZ=16L<'AZ>T%]QG+%5I;S9CZ5X.T'0K.&VT_1
MM/LK>$DQQ6]JB*A)+'  XY)/XUL*H50 , < "BBNI0C'1(P<I2W"BBBK)"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MANM5U=W:^R]$>GB*CHVI4]%9'F7[07P/TSX\?#^XT6[,=MJ<)-QIFH,#FWG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBHKFX2TMY9Y6"11(79CV
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R?_ ,%(O^2)
MZ%_V,,/_ *37-=U\&O\ DD/@;_L!V/\ Z3I7#?\ !2+_ )(CH7_8Q0_^DUS7
M<?!G_DC_ ('_ .P'8_\ HA*XL+_OT_1'96_W2'JSL:***^@/("BBB@ HHHH
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MN<;997E3J!SM=<^^<9ZUZI48.+CAX)]E^1>(=ZTWYL****[#F"BBB@ HHHH
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M2@IK%_K@4J^X.)(Y+L8(X(^3//IZTA'[%4444#"BBB@ HHHH **** "BBB@
MHHHH **** /YM_VO_$TOB[]J;XKZG,V_?XFOX8R1@^5%.T48_P"^$6OT3_X(
MA:3%#X"^*>IC'GW.IV5LWR\[8XI&7GOS,W^37YM_M/Z9-HO[27Q5L;@8E@\5
M:HI.,;A]KDPP]B,$>QK]*_\ @B'?0R?#3XG6@?-Q%J]K*ZXZ*\+!3^)1ORH
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M_P#8YZ-_Z70U_0K^T!_R0?XD?]BUJ7_I+)7\]7[)W_)TWP;_ .QST;_TNAH
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MU,15J1Y9.Z"BBBNPY@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K@?C]K0\/_  0\=WWF^0R:-=I')QQ(\3(G
MX[F6N^KP#]NK6UT?]F[7X"[))J%Q:VD97(R?/20CZ%8VKGQ$N6C.79,VHQYJ
MD5YF-_P3WT%])_9_^UL.-3U6YNU/^RH2'CVS"?UKZ8KRC]E7P_\ \(S^SOX$
MM,8\S3UO>O\ SW9I_P#VI7J]3A8\M&$?)%8B7-5D_,****ZCG"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!DD23*5D174]589%<WJOPP\':ZSMJ7
MA/0]09_O&ZTV&7=@YYW*>]=/14N$9;HI3DMF>8ZK^S'\*=87;<> M#C'_3K:
MBW/YQ[:Y:^_8>^#5]O*^%9+1V).ZWU*Z&,^@,A ^F*]WHK&6&H2W@ON1JJU1
M;2?WGRWJ'_!.OX8WC9@U#Q'9<D[8;R%ASV^>$GCZUS&I?\$UM"\X/I7C?5+
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M(KG_ *["NY_X(P_%"V\+_'3Q3X+NIUA7Q3I2RVP9L>9<VK,ZH!W/E2SM_P
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MXD?]BUJ7_I+)7\]7[)W_ "=-\&_^QST;_P!+H:_H5_: _P"2#_$C_L6M2_\
M262OYZOV3O\ DZ;X-_\ 8YZ-_P"ET- ']*=>4_M8_P#)K/QD_P"Q,UG_ -(9
MJ]6K@OCUHY\0_ SXBZ4L/VAK[PYJ-J(<XW[[61=OXYQ0!_/3^R=_R=-\&_\
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M_K\MO_2."OZ$J_GM_P""DG_)[GQ2_P"ORV_](X* /V5_8)_Y,Y^$W_8$B_\
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M?#-YS':H3R@=Q)Z#'/-;] !1110 4444 %%%% !1110 4444 %%%% !1110
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MM[?""[4&75M0LCZ3Z?*<?]\!JM8W#O[:)^K5E]EGT317A,?[<'P5;KXP9/\
M>TR\_I#6C9_MB_!R]"F/QQ:*'Z>=;7$1_$-&,?C5K%4'M-?>B/J]5?9?W'LM
M%><6O[2'PMO%!C\?^'U!_P">M_''_P"A$5<7X\_#1N1\0_"WXZU;#_V>K5>F
M]I+[R?95/Y6=W17.6GQ(\):A)Y=KXIT6Y?\ NPZA"Y_(-6U!J5I=#,-U#,/6
M.0-_(U:G![,CE:W19HI.O2EJKHFS"BBBG< HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /E+_@I%_P D-T3_ +&*#_TFNJZWX$MN^#/@D_\ 4(MA_P"0UKDO^"D7
M_)#M$_[&*#_TFNJZGX MN^"O@H_]0N ?^."N'"_[_/T1V5O]TCZL[ZBBBOH3
MR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \L_: ^!-A\:_"XB5H['Q!9@O87S+\N<<Q28&?+;U'*G#
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M1^9IA9+%)T*VKZ/JC]!:*\W_ &>/B._Q0^%.D:Q=2K+J<:FTOBK*29HS@LP
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MAL[=(4')/W5 '4D_B:OT45Z"2BK(XVV]6%%%%,04444 %%%% !1110 4444
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &8S7Y-_\%??&O\
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M/V'_ (T3>#/$,WPG\1S^7:7#O-H=Q-D#>26: <D!9.77I\^]>2X _/<PPO\
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M!M^VQ\>8_O?#BP7_ 'M$OQ_[6JR_[=?Q=C^_\,[9?]ZQO!_[-7WG11]4K_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<M3%4:4XPG*TGLC>%"I4BYQ6B/H"DDD6*-G=@B*,LS'  ]32U\Z_M8?$J_\
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M,"@#PWX _L1?"+]F^."?PKX7AN==C SX@U?%U?EL8)5V&(L]Q$$!]*][HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** $I:** /S3_X*0?L%W6K:A<?&CX5:8TGB&%_/U_0;&,EKX?Q742+
MR9,?ZQ!]\9;[V[?^?.K>,KGPV%36_#FL:1/@!X[NU,6&[@;\']*_HPIDD2S(
MR. Z,,%2,@BO7P.;8O+TXT)63[ZG!B<#0Q;3JK5'\Y=M\4M!GC+/--;'.-LD
M9)/O\N1_^JM/3?&FBZM)LM]0BWD@!'RA8GH!N R?I7[VZ_\ !'X=>*]W]M^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3PW-+',L<BG_ (^I]A9200/+7)Y!8C[M?IY"S^6ID"J^/F53D ]P#@9_*IJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS:74F.,==JOCKWKE:*'E+M[M67X?Y#^O*^M-?C_F=O:_\%"-6\PK=_"34HE
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ME\C%U:DMV11VL,/$<,:#_94"I:**TY8K9$784444[(+L****8@HHHH ****
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MHPRK ]P00:]O!XZGC87AHUNCS<1A9X:5I;=R:BBBO0.,**** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5_YOR/DN/_@FW\/E_P!9XB\2N?\ 9FMU_P#:)J=?^";_ ,->^N>*C]+NV_\
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M)96"HBCJ23P!7/\ Q"^(FA_"_P ,W.N:]=_9K2+Y8XUP9;B0CY8XUS\S'\@
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MPN?R%6***7P@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KC_BQ\2=.^$_@?4-?OWCWQJ4M+=R1]IN"I,<0P
M"><<GL 3VKL,XY/ KYW\$^!Y_P!OK]J*P\)63N_PO\*,+S5]0MI'"3Q\9 /W
M0\C QH0,[1(X) Q7E9CC%A*+:^)[?UY'=@\.\14UV6Y]'_\ !*_]G34)%UG]
MH+QO!O\ $?BDR)HL<RG-O:,W[R=0V2OF$!$](TX)$E?HO5+3=.M=&TZUL+&W
MCM+.UB6""WB4*D4:@*J*!P    /:KM?FLI.3NS[%))604444AA1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEW0JT.2I)=@HHHKH,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\ JS^W?XV_LKP#I'AJ%\3:Q=>=*%/6&'!P1[NT9'^X:]I^#?@P?#WX7^&]
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MRIJ5>I\4]7Y>1V8RLI-4X?#'0****]D\T**** "BBB@ HHHH **** "BBB@
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MR9 L+]E@N,A S *3\V 3RI(^5L$XK[9^'/\ P3[_ &?_ (9F.73?AMI6HW2
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MM;? W2X%(Q<Z] C]?NB&=OYJM>,Z7;QV>FVEO"NR**%$1<DX4* !D^U>A?\
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M8HHHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *:\:R(R,H96&"I'!%.HH>P'Q3^PO,? GQB^
M*WPYD+M]EG::$X(7;;SM"S<\_,)8B,]A7VM7Q1^SE_R?=\6_^O;4/_2RWK[7
MKSL!I2<>S:_$[<7K4OW2"BBBO1.(**** "BBB@ HHHH **** "BBB@ HHHH
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MI6F6J".WL[*%8884'1410 H]@*T:**YC8**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU&(;'3X%BB3/4X Y)/))Y/>NAHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBBD,[K]A_7E\._M"^+O#Y
ME:.#5]/,Z*W&Z9&5P,8[+)*1[#O7WS7YA^ =<;P7^TQ\.-:ROE37:6#EC]T2
MEH'8^P6;/X&OT\K\T4?8UJU+^63^YZH^SE+VE.G4[Q7WK0****V,0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK*\4>*-*\%^'[W6];O
M8M.TNRC,L]Q,<*H_J2<  <DD <U\*?%3_@HOKEYJ%Q:> M*MM,T]252_U*/S
M;B3_ &A'G8GT.[\.E<F(Q=+#KWW\CHHT*E9^XC] **_*ZU_;H^,UO=K-)XHA
MN8\Y\B32[4(>>F5C#8_&OH'X)_\ !0RUU[4K;2/B'I]OI#S,(TUFPW"W#'@>
M;&Q)0>K D<\A1DUQTLSH5)<NJ]3HG@:L%??T/M"BF13)/$DL3K)&X#*ZG(8'
MD$'N*?7KGGA165XH\4:5X+\/WNMZW>Q:=I=E&99[B8X51_4DX  Y)( YKX4^
M*G_!1?7+S4+BT\!:5;:9IZDJE_J4?FW$G^T(\[$^AW?ATKDQ&+I8=>^_D=%&
MA4K/W$?H!17Y76O[='QFM[M9I/%$-S'G/D2:7:A#STRL8;'XU] _!/\ X*&6
MNO:E;:1\0]/M](>9A&FLV&X6X8\#S8V)*#U8$CGD*,FN.EF="I+EU7J=$\#5
M@K[^A]H44R*9)XDEB=9(W 974Y# \@@]Q3Z]<\\**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXILUE\8?\%);F4.)K70;4
MGID*JV(0CKQB68_YYK[6KXK_ &/T'BK]J#XQ^*XRL]N)KB&*;_8FNRR8QQ]V
M#K[?6O-QGO3I0[N_W';A_=C4EY6^\^U****](X@HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MR)_P4B_:/^(O[,OPAT?7_ -KIZG4=0.FWFIWD!G>Q+1L\3QH3LR=CC+AE!VC
M!S7UW7FO[0WP/T7]HSX1Z[X!UV::TLM46,B[M@#+;R1R+(DB9XR&49'<$CO0
M!^$]U>>*OB3XHC\;>._%5_XH\02QC9/=3^:(T.["*>0$&\D*@502<9K7KZ:\
M8?\ !(7XJ^"X91\/?B)H_B&T7YEM-6@>QEZD[4&)DSD]2R ]?:OGOQQ^S_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJIJ.H0:787-[<R"&
MVMHFFED()"HH)8\>@!KY%\1?\%8OV<]#DVVOB?4]=(X)T[1K@ ?C,L>?PH ^
MQ:*Y7X=_$KPQ\6O"=CXG\(:U::_H=X,PWEG)N7/=6'5''0JP# \$"NJH 2EH
MHH *J_8;;[4+C[/']H&0)M@WC/7GK5JB@ HHI* /CW]OS]A>R_:>\,CQ+X8C
MATWXGZ/%_H5T,(NHQKDBVE;L<_<<_=)P?E)(_)/0->O8=4O/#GB*UFTOQ)IT
MKV]Q:W49CD#H2'5E/W7!!ROMD=\?T6BOS7_X*[?LUZ9)X+L_C=X>L!:>)M)O
M+>UUJXA4!;BV8[(II!C!=)?*0-W5\'(50/:RK-*N6UN:&L7NNZ_S/.QN#IXR
MGRRW6S['P]15?3[Q=0L;>Y0,%F174,,$ C/-6*_=H352"G'9GYA.+A)Q8444
M59 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %9?BC_D6]4_Z]G_]!-:F<<G@5SND:%XE
M^.WBK_A#_!$ E7&;S4)&*01)T)=P#A.W );H >_B9MC*6&PTHS^*2:26[;/4
MR_#SK5DX[+5OHD?=O[&MJEI^S5X)1"Q#0W$AW>K7,K']2:]HKE?A;X#@^%_P
M]T'PK;7+7D>F6RPFY9-GFOR7?;D[06+'&3C.,GK755\=1BXTHQ>Z2/>J24IR
MDNK"BBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
M+O\ @I7XPAA\+^$?"RN&GN+V34I%[JL:&-"?J9G_ .^37V/JFIVFBZ;=:A?W
M$=I96L33SW$K;4CC4$LQ/8  FOSIT?P_??MP?M+:AJ\L4T'@VP=%FD)(,=DA
M(CB![22G<V/X=SGG;SY6/FW!4(?%+0[\'%<_M9;1/=O^"??PIF\&_#.]\4W\
M)BO?$DJO K @BUCW",X[;F9V]UV&OJJH+&R@TVRM[2UA2WM;>-8HH8QA411A
M5 [   5/7;0HJA2C370YJU1U9N;ZA111708A7Q=_P4K\80P^%_"/A97#3W%[
M)J4B]U6-#&A/U,S_ /?)K['U34[31=-NM0O[B.TLK6)IY[B5MJ1QJ"68GL
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M%%%>D<04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4CW29W5-</!]KHZRBBBO2. ****!A1110 4444 %%%% !1110 4444 %%%%
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M/!_C@+KXG_$GP7\+=,9I#?7:3WPA8!D3GDD@XV1B60C!_A.#QG[N\'^#=&\
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MSA8[R$']U(,X652.O##)2OTM_9-_;>\!?M9:'C1IO[&\76\7F7_AF\D!GB'
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M^QK3I.I*R.6_:/\ B3K/Q]\<1_!?X<L;BW67_B?ZI&<PQA6&Y"P_@0XW?WF
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MUU7'_D%/\:^H*VRZ3EA8.3Z$XQ*.(DD%%%%>F<04444 %%%% !1110 4444
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MN/-[O]O+P!$S"#2]?N2.C"WA53^<N?TKG+K]ORWEN1%IG@6ZO0Q.WS-0$;G
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M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2*VY0?49I:_H.+NDS\F>CL%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L#5-'OOB%XN\/> M*8K>:U
M<QQR2!-PBBW9+D=PH5G.#G$9]:WF8*I)Z#FO4_V"? K>*/&GBCXF7D)6WASI
MNF[UZLP4R/\ [RQA%X.#YC^E?+Y]7<:4<-!ZS=GZ+?\ R/<RJDG-UY;0_/I_
MF?6WPQ^&.@?"+P?9^'/#EK]FL8/GDD?!FN92 &FE; W.V!ST  4 *H ZNBBO
MGHQ44HQ5DCU)3<W=A1115DA1110 4444 %%%% !1110 4444 %%%% !1110
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MG4+AFGN,'J [D[0?1< XKTBBBM80C37+!61E*4I.\G<****T)"BBB@ HHHH
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MQ<*FZ,L9AXT6I0V9M4445[)YH5!?WUOI=C<7MY,EM:6\;3332MM6-%!+,3V
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M**^M/GPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,_7O#^F^)M,ET[5K*'4+*4?-#.@8>Q'H1V(Y':O#Y/@7XS^%WB0ZW\)
M_%$VEF0YDL[B;'3HI!4I,@RW$@XP/O'D?0%%>;BL!0Q=G-:K9K1KYG;0Q=7#
M_ ]'T>QY"-8_:>O"AE\>Z7!Q_P ^]NN/KLMJQ?%%Y^T?H.BZAJ\GQ!CO1:HT
M\EO8N-[*.6*J8%7@9.,C@8 )P*]XHKSI9+2<6E4E?U.Q9G.]W"/W'9_LQ_':
MU^/'PXM]2D>&+Q#8XMM6LXFY27G;*%ZA) "P[ [ER=A->NU^=\&IW/[)?QPM
M/%.GP_\ %$>('%MJ%NJ,([96=6< +QN7!>,8Z;T X)K]!=)U:SU[2[/4M/N(
M[NPO(4N+>XB.4DC8!E8'T((->30E-.5"K\4='Y]F=M:,7:I3^&6W^7R+=%%%
M=9SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%%T 4444 %%
M%% !1111= %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>-/!.
MB?$+PY=Z%XATZ+5-*NAB2"7(Y'(96!!5@>C @BMNJ6M:U8>'=)N]4U.[AL-.
MM(VFGN9V"I&@&22:F5G%J>Q4;W]W<^+?$VB>+?V*=0273UNO%WPEN9EW_:"#
M=:<[9!&Y<*I9B"#MV,?E^1CN.UX@_;:^'.EV:RZ?+J&LS%E7R+>V:(@$9))D
MVC Z<9.3Z<UGP6_CO_@I%\6!X*\%"?0OA?I4JRZEJTT1"!,\2RCC=(V#Y<.>
MVXXP2OZE?!G]D_X5? C1=-LO"W@S28;ZR0*=:NK2.;49V[O)<,N\DG)P"%&<
M* .*^5EFD\-*5/#N\>E];>A[L<'&LE.LO>\OU\S\PM%^(OQ_^,V5^&?P8U1K
M26;]QJNHV[K \7.,R2>7$&/!/SD#D<]:]$T7_@GK^U%\5F9O''Q$TKP+ILTH
MF:SL)FGGBZX4+ %4J,]#,<D G)YK]6J,&O,J8[$UOCFSMIX:C3^&*/SIT7_@
MBO\ #UF,WB;XB^+-9O9&+S3V2V]J9'/);]XDQR3D\D_UKT70?^"1O[/6CX%W
MIFNZWZ_;]8D7/(_YXB/TQ^)K[3HKBNSI/G'0?^">/[.GAPI]D^%FDR[<8%_-
M<7G0YY\Z1\]>]>Y>$?".A^ ?#MGH/AO1K'0-$LE*VVGZ=;K!!$"Q9MJ* !EF
M9B>Y8D\DUN44@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P %'?B%_9/@+0O"%O+B?6+HW=RJG_EA#C (]#(RD?\ 7,UZM^QW\/O^%>?
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M_'%6HRRO5YY4)Z\O_#%8ZE#EC5AU/6Z***^A/'"BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SE_P %$O\
MDRWXJ_\ 8-C_ /2B*OHVO(?VM?AS>_%G]FOXC>%=,5I-2U#1YOLD2#)EGC'F
M1Q_\"9%7\: /P;^&?_"8? 6T\"_';PW)^YM==FLE9<A4FB1&:"4CJDT4CKQU
M"R>U?T&?!WXIZ+\;/AGX>\;^'I?,TK6K1;F-2P+0MTDB?'\:.&1O=37Y-?L#
MZ?X>^/W[-_Q*^!^N%(-0^T'5+25ER\>]45)E'K%-$N>F1(%Z$UUO_!+CX[:C
M\"?C%XC_ &?/'LG]G)?7T@TU9V.V#4TPKPJ3_!.B@J>A9%QDR4VNI*>K1^MU
M%%%(H**** "BBB@ HHHH **** "OD_\ X*F?\F-?$3_KIIG_ *<K:OK"OD__
M (*E_P#)C/Q$_P!_3/\ TXVU-;@?DAX5_P"19TO_ *]D_P#016I67X5_Y%G2
M_P#KV3_T$5J5_0V"_P!VI_X5^1^2XC^-/U?YA11178<P4444 %%%% !1110
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MBB@ HHHH **** "HKO\ X])O]QOY5+45W_QZ3?[C?RJ9_#(J/Q(]<_X)O_\
M)#];_P"QBG_])K6OJROF+_@GC_R0*?\ [#-S_P"@15].U\;@]*$3Z+%?QGZA
M11178<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M45\8?1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?)__  5+_P"3&?B)_OZ9_P"G&VIK<#\D/"O_ "+.E_\ 7LG_ *"*U*R_"O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?$_@N-?&G_!1OQ+J,+&2+1+:1OF)^4QVL5JP'_ Y&_,FOMBOBC]AWR?&'QT^
M,'C.':4FN'$?0G9=74LO!]/W(Z5YN+]ZK2I^=_N1VX?W85)>5OO/M>BBBO2.
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7QKXJLT^$O[8<8@E6'3?%,0E>)1_%.67'U-Q'NSZ-BOLJOE7]NO29].M?!/
MC"S9(+G3;YK;S,?.78"6(Y]%,+_]]5Y>87A3C66\6G^.IWX.TIND]I)H]@HJ
MII.I0:UI=GJ%JV^UNX4GB;U1E#*?R(JW7UD9*<>9'S\HN,K,****LD**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\
M(_:*%SX'\2>"?B/ID>;S1[^-)@K%&E4-YB(S#HIVRJ?7S,<]*]WJMJ&FVFKV
M<MI?6L-[:2#$EO<1B2-QG."I&#R!7!CL+];HNE>S>S[-;'7A:_U>JJEKK]#W
M#X?_ !2\+?$_1X-2\-ZS:ZG#(@9HHY!YL1PI*NG56&Y<@CC(KJ:^"?$'[,6A
M2:A'JGA/4K[P;J\3;H[BQE=D4G.2!N#*2#CY7  [5I:7\;/CY\'9-FMZ=:_$
MC1%DWM<0J?M(4@_*K( RXQDEHW SC/3'S4UB<-_'AIW6J^[='LQ]C7_A3U[/
M1_Y,^Y**\&^%/[9_P\^)EX-.FNY/"^L-)Y:6>L[8EE.0 $E!*$DD#:2&SG /
M6O>:=.K"JKP=T1.G*F[25@HHHK4@**** "BBB@ HHHH **** "BBB@#GO%'P
M[\+>-I(Y/$/AK2=<EB0QQR:C913NBGJ%9U)7\*\-^*7[!OP[\<6LTV@V[^#]
M6()26Q)>V9L<!X6.,?[A6OI.BL*F'I5E:<4S:%:I3^%V/QE^*_PIU_X,^+I_
M#WB*W2.ZC42131'=%/$<[9$;'(.".>0000"*^Y/^">_Q@N?%_@G4O!VJ3O/=
M:!L>SDD;)-J^0(_7$;# ]%=0.E7O^"AGP_M_$'P?M_$RQ 7^@W<>9=O)@F81
MLI/^^8C^!]:\-_X)N"7_ (7/X@90WD#0)=_/R[OM-OMS[XW?K7S5.F\'CE3B
M]'^3/:G-8G"N<MT?HU1117UA\^<]XH^'?A;QM)')XA\-:3KDL2&..34;**=T
M4]0K.I*_A7AOQ2_8-^'?CBUFFT&W?P?JQ!*2V)+VS-C@/"QQC_<*U])T5A4P
M]*LK3BF;0K5*?PNQ^,OQ7^%.O_!GQ=/X>\16Z1W4:B2*:([HIXCG;(C8Y!P1
MSR""" 17W)_P3W^,%SXO\$ZEX.U2=Y[K0-CV<DC9)M7R!'ZXC88'HKJ!TJ]_
MP4,^']OX@^#]OXF6("_T&[CS+MY,$S"-E)_WS$?P/K7AO_!-P2_\+G\0,H;R
M!H$N_GY=WVFWVY]\;OUKYJG3>#QRIQ>C_)GM3FL3A7.6Z/T:HHHKZP^?"BBB
M@ HHHH **** "BBB@ HHHH ^<OVZ/B6?!/P:FT2SN&CUCQ+)]@ABC 9V@X,_
M&<X*D(2 ?]8!QG(^\_V+?@.G[.O[.?A+PE+"L.L_9_M^KLO5KV;#R@GOL^6(
M'^[$M?GQ\(O"J?M9?\%%H/.62Y\(?#=/M,\<F6BDFMY<*H!  W7+#(.=R0GD
MC&/UX[5\)F%?VU=VV6A]3A:7LJ2ON]1:***\T[ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK>J_(Z,5_"I>GZA1117M'F!1110 4444 %%%% !1110 4444 %%%% !1110
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M*:>O8YJ-"5=N,3]&Z*^+/A-_P47TR\ACLOB%I,FG7( ']J:4ADA?W>(G<G_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,XYY3@Y_8MZ-G\ZEO\3_  _-&&:Y>%CU1XF)Z]]H(_(UJP^+-%FC1UU2T 8
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MA^BUO;QV=O%!"@CAB4(B*,!5 P /PJ2BBOG5L>H%%%% !1110 4444 %%%%
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M200?45:KOW.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^+?^">J^7XP^,">EY:#_P B7=?:5?&/[ 2^7X\^
M,R>E_;#_ ,BW=>9B/]YH_/\ ([:7\&I\OS/LZBBBO3.(**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!F>)/#MAXLT.]T?4X!<6-W&8Y$/Y@CT((!![$ UY=^S[\
M5[O]EWQ]=?#OQG<NW@[4YA+IFJ2$"*U9B1O.1\J-\H<9PC+NZ,S'V2N7\??#
M?0?B5I:V.MVAE$)9H;B)MDT+$8)1OR^4@J2!D' KQ<QP,L1:K1TJ1V\UV9Z6
M#Q2HWIU-8/\ #S1]:PS1W$*2Q.LL4BAD=""K C(((ZBGU^?VDZU\8?V9&#>'
M[Y_'7@B+EM-O%:1K>,;1A5!WQX&<&,E!@LR#I7UI\#_V@O"WQZT6>[T*22UO
MK4A;O3+S:L\.>C8!(9#V8?0X/%>%&L^?V=6+C+L^OH^IZ<J?N\]-\T>Z_7L>
MFT445TF 4444 %%%% !7)>.?A+X-^)2I_P )/X<T_6)(UV1S7$(\U%]%D&&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\5?'!1XT_;U^&NCPMYO]EPVLTD?]UXY)KH]/\
M8"'_ ":^U:^*/AMY'CC_ (*(^,M5AVE-'MYQG@_/%##9-CT.6;]:^UZ\W!>\
MZD^\G^!VXK3DCV2"BBBO2.(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M4CJKGGA1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVLM'N_O1QPQ[?_'GDKZSK@P":PZ;ZW?WLZL6^:LTN@4445Z)QA1110 4444
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M]7^1VT/X53Y?F?8U%%%>B<04444 %%%% !1110 4444 %%%% !1110 4444
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MD,.A'K3J^O3NKGSVP4444Q!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S/Q(\$V_Q"\%
MZEH<^U'N(\P2L/\ 53+RC>N,@9QU!([UB?LI_M+77@V\M?A1\2(VTF\L]MKI
M-_<*$0J/E2!STQQA)!D,,#/0GT&N(^*GPETCXJ:-]FO5^S:C"I^R:A&N7A;T
M/]Y">J_E@\UX.8X&=62Q%!^^E:W1KM_D>M@\5""=&K\+_!]S['HKX?\ A?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'R=_P4@N%7X-^'H,_,^OQN![+;W /_
M *$*\JMU\N"-<YVJ!^E=_P#\%%9$OK?X:Z1+(R1WNHSEE3J0HA0D'&,CS>_K
M7!UIEB?UFM+T7X?\$6._@4EZ_H%%%%?2'BA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0K?%'\5T:]3UZL8R2JT_A?X>1KT445U'.%%%% !1110 4444 %%%% !1110
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M5KYQ^,Q%U^WUX'CZ^7I2_HETW]:^CJQR[>J_[WZ(WQFU/_"%%%%>R>:%%%%
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M!K1IN3E"5[7W372_70]JG4CBJ;FHVE'>W;N?6%%%%;&(4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%6V^<Y$$:_5E611^)KV+X>^(M?\ %&AO>>(_"[>$KT3M''8O>I=%XPJD2;E
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M/;Y(^LRBK&<I04$M-^I]I_![_DEGA7_L'0_^@"NPKCO@[_R2SPK_ -@Z#_T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y+XD?"[PE\7O"]QX=\:>'['Q'HTW+6U
M]$&VMC&]&^\CC/#*0P[&NMHH _*?XZ?\$K?&GPDUR7QO^SMXDO)9(&,G_"/W
M5R(KQ%R&*13'"3ID#]W+C(7!,A.*\]^&G[<]UH.NOX1^,F@77A?7K63R)[[[
M*\0C<#_EXMV&^,]/F7();[JCFOV9Q7D/[0'[*OPU_:7T7[#XY\/17=Y'&4M=
M8M<0W]I_USF SC)SL;<A/5377A\55P[O!Z=NAA5H4ZRM-'SSI&M:?XATVWU#
M2KZWU+3[A=\-U:RK)%(OJK*2#5VODKXG?L._'K]BS5+OQ-\)M6NO'/@I7\ZX
ML[6$O.J @D7%GR'X&WS8?F W']V*W?@G^W1X/^(TEOI/B91X/\1.1&!<OFSF
M?G[LI^X>/NR8Y( 9C7U6&S.G7]V?NR_ \*M@:E/6&J/IBBD#!@"#D'H:6O8/
M."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OBCX1R+X[_ ."@OC[655E32(;F('!P7A$-GC\?F/X5]K$A5)/
MKXJ_8!D/C#X@?%?QI-$4FOKF,ITR//EFF<?AM2O-Q7O5J4/._P!R.W#^[3J2
M\K?>?:U%%%>D<04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M 7[5UZFH?M@:%"IR;/1XXF'H=L\G\G%0U6^-5T]U^V9XR4XVV]A;QKM';[/;
MMS^+']*LUU9.OW=27>3_ $1EF#]^"[17^84445[QY(4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#9(TD7#JKCKAAFG44460[L****!!7*>"_%GCS]GWQIKVN>#[&UUC2=7.Z[L;
MK+Y"G>#A2K!@7D"XW<,<@G%=717!C,'#&12DVFM4UN=>&Q,L.VTKI[IGJ_@C
M_@H3X/U&9;/QGHFI>#;X?ZR38;J!> 1DJHD!(.<>6?K7T7X.^(?ACXA69NO#
M6OZ?K<*@%_L5PLC1Y&0'4'*'V8 U\(:EHMCK,8COK*"[C!W!9HPP!'?GZG\Z
MXJ[^#=C:W<5]X?U"\T#48<-#-;S-\C9^\#G<#@XX8=O?/B3P>,H_"U-?<_\
M(]*.(PU3XDX/[U_F?J+45U=0V-M+<7$J06\*&2261@JHH&2Q)Z "OSW\-_'[
MXY_"U5C>^M?'>E1@@1ZDGFS!5.<[P5E+D>K/TZ'O#\2_VB/BM\>M+N]&T_3H
M?!'ANXC,-S#O8S7"D+NC>4J&VG/154$%E);D5RRQ$X^Y[.7/VM^NUCH5&+][
MG7+WO^ASEOXGD^,7QH\7?$"4$V4DQM]/60#<D8 5,#^$B-1GCDNW/7/9U@^"
M?"L?@WP_#IJ2K.RLTDDRQ[-[$]2,GH,#KV_"MZOHLOP\L/049_$]7ZL\C&5E
M6K.4?A6B]$<OXB^&^A>*+J6[O+9A=R)L,T,A1N!@-CH2..H/05CZ;\+;WPOF
M7POXOUK0;G=N,EO<,F>/^F90YZ<Y[=*] HHJ9;A:LG*4%=]=G^ J>-Q%-<L9
MNWW_ )F99_$CXZ^$N=+\?'6H@I8PZG''([MS\H,BM[8^<<^U>A^$OV^-9\.-
M':_$SP5-;KO\LZIHN=AR,_<=BK'UVR>O'&*X^D90RD, 0>H-<4\IY=:%1Q]=
M5]SU.J.87TJP3_!_A_D?7?P\_:,^'?Q0$2:%XGLY+V0#&GW3?9[G)XVB-\%C
MGCY<CISR*])K\S-<^%/AS6E8BQ6PE*A1+9?N\8.?N_=/Y9_2M+PSXD^+?PI
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MP=X:N[G5KN"U>Z>_AA M,(RJRJ[$,QRPY"E3ZUZM7YI?\$[O^2]77_8%N/\
MT9#7Z6U.!Q$\32]I/>X\52C1J<D0HHHKT#C"O'?B=^UI\-OA3?2Z?J6LMJ&J
MPG$FGZ3']HEC/<,<A%/^RS ^U>,_MN_M2WG@N1_ 'A&\:VU>6(-JFHP-B2U1
MAE8HR#\KLI!+=0I&.3D;7[%_[,ND>%/!FG>-_$5A%J'B75HENK5;I ZV4#<Q
ME0>DC+ABW4 @#'.?,GBIU*KHX?=;M[([HT(PI^UJ]=EW.@\+?M\?"KQ)?);7
M,^K>'R[;5EU6S41Y[9:)Y,#W. .^*^A=.U*TUBQM[VQN8;RSN$$D-Q;N'CD4
M\AE8<$'VKC?BW\&?#/QD\-7>E:[80M-)&1;ZBL8^T6KX^5T;KP<?+G!Z&O@_
MX _''7OV6_BA?>!/%D[R^&8[][.]A8EEM)-V/M,6?X#PQ ^\ISC.*F6(J8:<
M8U[.+ZK3[RHT85XMTM&NG^1^E=%,AFCN(4EB=98I%#(Z$%6!&001U%/KU3SP
MHHHH **** "BBB@ HHHH ^%-2/\ QL<UK_KW3_TV15]2U\RP1?:O^"AGB^3K
MY-BK?^2=NO\ 6OIJL<L^"I_B9MC?BA_A04445[)YP4444 %%%% !1110 5S7
MQ(\<6GPW\$ZMXBO,&*Q@+I&3CS9#PB#_ 'F('XUTM?&W[:'Q%M/$'C#0?A^-
M16QTZVGCN-5NL%UA9\!=RKDG9&S.0 <[QW%<&.Q'U:C*?79>K.O"T?;54NG7
MT///"?[,?C[XX:7)XU74-)MQJ]Q-.3J$LJ22,7.YP%B8!2V['/:MG_A@?Q]_
MT&?#?_@3<?\ QBOKSX;^-_ VJ:-I^D>%-?TZ\@L[>.""UBN%\X1JH5<H<-T'
M<5V]>51RG"U8*3?,^K3ZG=4S"O"325EZ'Q3X)_85\2:?XLTJY\0ZEHESHD-P
MLEU!;33/)*BG.P!HE&&P >1P37VLJA5  P!P ***]?"X.E@TU36YP5L14Q#3
MF]@I&8(I9B%51DD\ 4M?(W[9WQZDT_S/ &A3F.61 VKW$9P0K#*VX/N"&;V(
M'=A1BL3#"4G4E_P[%AZ,J\U")0_:$_;!N+BZNO#/P^N62,$PW&N0\O(V<%;<
M]AV\SJ?X<<,=/]G[]D.*2&+Q3\1(7O;^X/GQ:-<$D+GG?<=V<]=AX'\62<#F
MOV*_@C#X@U!O'>LVPDL["7R]-AD&5DG'WI<=PG '^UD]5K[:KR,'AYXQ_6L5
MK_*NB^1Z.(K1PR]A1T[OJ1VMK#96\<%O#'!!&-J11*%51Z #@"I***^CM8\4
M****8!1110 4444 %%%% !1110!R_P 4/#A\7?#GQ-HR1B::]TZ>*%2,_O2A
M\L_@VT_A7S9^R'KK:A\-;FPDE#OI]^Z)'W2)U5Q^;F2OKNOBKX#VX\$?'/XC
M>#UA^SVZRR20*V ?+BF(BQ]4F!^@KSI/V6.HU.DKQ?Z?B=L5[3"U8=K/_,^B
MZ***^L/GPHHHH **** "BBB@ HHHH *_/[X\?\E?\4?]?9_D*_0&OS^^/'_)
M7_%'_7V?Y"OCN)?]WA_B_0^CR7^++T_5'VA\'?\ DEGA7_L'0?\ H KL:X[X
M._\ )+/"O_8.@_\ 0!78U]-A/]VI^B_(\7$?QI>K"BBBNLY@J"^OK?3;.>[N
MYDM[:!#)+-(VU44#))/I7+>/OB%-X)6-;?PUK?B":1&<?V9:F2-,=G<?=_(U
M\C_&#XW>*/'TLFF7\#Z'IR,"=,4,I)'(,A(!;Z8 Z'&:\/,,TI8&+6\NW_!V
M/4PF J8EI[1[_P# .K\,>!9OVAOBYJWB:YBDB\+K=9>9@5,J( L<2^Y55W8^
MZ#ZD5]=QQK#&J(H1%&%51@ #L*^(OA+^T1K?PZ^S:=>?\370$.TVK "2%<\F
M-O\ V5N/IUK[-\.^(K#Q9HMGJVEW"W-C=()(Y%_4$=B#D$=B"*X<AK8:I";@
M[U).[OO\O(Z\UIUH2BI+W%HOZ[FE1117U1X 5^?WQX_Y*_XH_P"OL_R%?H#7
MY_?'C_DK_BC_ *^S_(5\=Q+_ +O#_%^A]'DO\67I^J/M#X._\DL\*_\ 8.@_
M] %=C7'?!W_DEGA7_L'0?^@"NQKZ;"?[M3]%^1XN(_C2]6%%%%=9S!1110 4
M444 %%%% !1110 4444 %%%% 'CFGZA%\&/VN?#6OCR[71O%<36%Y(^X+YC%
M5; 7_;$#$D$98DXZC[SKX3_:<\-RZQ\-VU2S,D>HZ)<1W\,L((D50=KX8<K@
M$/D?\\Q7US\&_'D7Q+^%_AKQ)&5+WUFCS*LHDV2@;9%+#N&# \#Z#I7QE2G]
M7Q52ETEJOGN?1QE[7#PJ=5H_EL=G1116ID%%%% !1110 4444 %%%% !115+
M6M:L/#NDW>J:G=PV&G6L;33W,[!4C0#))-&VK 76-8L?#^EW>I:E=PV.GVL;
M33W,[A4C0#)8D]!7Q]'XZ^*7[=?Q.;P'\'OM?ASP;:G&IZ^2T7[HL?WTT@ 9
M%(4A(5.Y_FW9'$<-M!X[_P""D'Q6/@OP5]HT+X7:7*KZEJTT9$>P'B64<;Y&
MP?+ASVW'&"5_6/X#? 3PA^SG\/;+PAX,T_[)I\/[R>XF(:YO)B &FF< ;G.!
MV       'R./S%U&Z5)^[W[_ / /H,+@U37/-:GA/[-/_!,OX3_L_2V.M7]L
MWCOQC;,LJ:MK,8$-O*IR&@M@2B$$ AF+L",AA7U]117@'JA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]M]0L+E=\-U:R"2.1?56!P:^MP^*I8B-X/Y=3Y^MAYT7:2+M%%%=9SA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ROQ9UZ7P
MO\+O&&KP'%Q8:/=W,7./G2%V7]0*^?O^"<VB_8O@OJVHL@$E]K,F&YYC2*)1
M_P"/>9^==]^VAK3Z+^S9XP>.01S7"6]JO/427$:N/^^"]2?L;:*=#_9N\&Q2
M+MDN(9KICC&?-GD=3_WRR_E7F2][&17\J;^]V.Z/NX9ONSVFBBBO3.$****
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MU_\ 0S7'C/X$_1G3A_XT?4^7_P#@G;_R7NZ_[ MQ_P"C(:_2ZOS1_P""=O\
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M.V*N$Y4Y<T79DRBI*TEH?EE\"?VP/!OQJ:WTV20^'?%#C_D%7KC;,1C/D2X
M?K]TX?@_*0,U[O6?^UG_ ,$L_ OQN^V>(? ;6_@'QI)F1UAB(TR^?K^]B4?N
MF)_CC'<DHQ.:^,+#X[?%[]CWQ0G@GXX^'=1U'3US]EU!F5YVC'\<$^=ERGLS
M!@3@L,;:^FPN;)^Y7^__ #/&KX#[5+[C[?HKF_ ?Q&\-_$[0DU?PQJUOJUDQ
MPS0M\\38SLD0_,C8[, ><UTE?11DI*\7='C.+@[,****H04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'R=_P4>UI;/X/Z%IJRA);S6D<Q\9
M>..&7=^3-'^E?1?POT%_#'PU\)Z.X*OI^DVEJP;KN2%5.??(-?)O[?$:^+_B
M?\(_!JLWF7=RXDCR0I%Q/#$A^OR/],^]?;%>;1][$U)=K([:GNT*:[W84445
MZ1Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114=Q,+>WEE8X6-2
MQ/T&:3V!;GYA_#>1M4\1^-];=OGU#5I6*$?=.]WSGW\S]*[VO,O@"N/"M^WK
M>L/RC3_&O3:]+*5;!0_K=G+F'^\R_KH%%%%>N><%%%% !1110 4444 %%%%
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M_P"$/\$JP_T@W]P4./X?+7=^I6OL^OB+_@IM=!-+^'UL0=TDU](&[858 ?\
MT,?E75F.F&G\OS1A@_X\?ZZ'D7_!/MBO[0MN 2 =-N@??A:_3JOS4_X)VZ:U
M]\>+JXP=MGHMQ,3VR9(D _\ 'S^7M7Z5UAE/^[_,UQ_\7Y!1117LGFA1110
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MW6E^* 94+-G)N#NSCL?M",H] :^AZ,GJ.6']E/XH-K[MOP%F,$JWM([35_\
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M)KH:^%E)SDY/=GU$4HI)= I:**D84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<Q\4-4_L/X9^+=2W;/L>D7=QNP3C9"[9X^E=/7EW[3^
MN)X?_9]\>74A 632Y;09..9\0C]9!65:7+3E+LF727--+S/A#X)6JVO@6&12
MQ:XGDD;=T!!"\>V%'ZUWM<O\,K/^S_ NCQ;M^Z'S<XQ]]B^/PW8_"NHKWLOA
MR86G'R1YN+ES5YOS84445WG&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$$XY(   ))/Z]*Y/X4_M4>#/BG?#34EET35F.([34BJ^=_US<':Q_P!DX/7
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M"EKZZG%0@HKH?/3ES2<GU"BBBM2 HHHH **** "BBB@ HHHH **** "BBB@
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M/_"@HHHK>R.>["BBBG9!=A11118 HHHH **** "BBB@ HHHH **** "BBB@
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M&\(6PA9_MZZY;7J,XVX0)'\PSECZ#'7FO2**RP^#CA](3=NVA=;$.MK**O\
M/_,****[SD.!^-/P7\/_ !P\(2:'KD;1NI,EI?P@>=:RXQN4GJ#T*]"/P(^5
M/ OAWXZ_LAWM]INF>&?^%A>#9I3,L6GEG.['WXU7,D3$ ;@493CC/6ONFBN.
MKA8U)JI%\LEU1TTZ\H1Y&KQ[,^,?&GC[]H#]H+3Y/#GA_P"'MU\/-)O 8KV[
MU-WBD*$8*^9(B$*>^Q"QZ9QG/K'[-_[*.A_ 6W;49YEUOQ7<1[)=09-J0*>L
M<*GH/5CR<=AQ7NU%*&%C&?M:C<I>?3T14L0W'D@K+R"BBBNTY HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^*/V];H:M\4/A5H\:[YK<S
MW;KG'[MI(<G\H'_*OM>O@;]JZ]36/VNM#MXE:3^S=%CBFV@G83Y\@)]/]:GY
MBN3$KF4*?\TDOQ.J@^7FEV3?X%6BBBOLSYH**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOQ.[":3<NR;/MBBBBO26QPA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1113 *_.?XE72ZU^V%\0[V EX((HK=G7[H=(8(RI/KE&_[Y/I7Z,5^8_A
M[44USXQ?%34HY#-%<:U,\;$YRC3SE>?3 %<_Q8FC#S;^Y&R]VA5EY6^]H[6B
MBBOKSYX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "J>M-Y>CWS?W8)#_P".FKE9GBB3R_#6K/\
MW;28_P#CAJ9_"RH[GQC^P.O_ !;+7V]=78?^08O\:^FZ^:/V"5_XM5KA_P"H
MS(/_ "!#7TO59;_ND/3]0QO^\2"BBBO3.(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO"?VTM>M-)^!>HV4^3<:I=6]M;A?[RR"4D^VV)A]2/6O=J^./VD+P_%O]HCP
MWX"1F?3=)56NU7*_,ZB6;YO^N2Q@'LQ([UYF83:H>S6\]%ZL[<)%.JI/:.K^
M1Z1\%[&ZTWX4^&(+T?OQ9H^WG(5OF4'/0A2 1V(KM:0# P!@4M?3T*?L:4:?
M9)?<>)5G[2;GW=PHHHK<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#@/C?\15^&O@&[OH9%75+C_1K('!(E8'Y\$$?( 6Y&"0 >M?5'_!)/]FAO
MAO\ ">X^)^NVA7Q+XR0&S:7.^'3 0R?]_G'F'U41'UK\_/VPHTL]8\%7]Q&]
M[9JTRRV;LPC8*T3$9'0N"02#G"CTK][?#LFGR:#IKZ2D4>E-;1M:) H6-82@
MV!0. -N, <8K\KX@Q$ZF,=*6T=OGJ?=952C##J:WE_PQJT445\P>R%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\P_M2?\$_?AC^U!%<:C>6?_  B_C-EQ'XDTF)5E=L<?:(^%G'3KA\# <"OI
MZB@#\2O%'A7]H3_@G?J:0:_9MXS^&0?RX;R)WEL<$C:%DP7M'[;&&PDM@/\
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M[$_G7Z8U\C91Q-:*[I_>D?0ZRH4F^S_!A1116QB%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^^*DD>FZCX2U@O
MLDLM3C(W':NW<KDD]L;!S]:_42ORN^/BG_A%[!NPO /_ !Q_\*_4;2;Y=3TN
MSO$;<EQ"DJMC&0R@@X_&ODZEECJJ[I?D?01UPM-^I;HHHK0R"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OGS]M[XDZ?X+^!NM:3_ &C#!K>MHEG:VF\>;)&SCSFV@YV>6'!;
MIEE'< ^U^,H=1N/".MQ:/.]MJSV,ZV<T8!9)C&WEL-P(R&QU!%? '[(_P/\
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M3?WL****^D/&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\\?MD:Q)'X=\/:)$A=[V\>X^7D_NU"A<=\F;_ ,=KZ'KQ/2_#:_&3
M]OGX8^$ CS6UI?6;7<)SM:.(M>38'O$,$^WM7SF?UO98&2_F:7Z_H>SE-/VF
M)3[:G[._!/P"OPK^$'@KP@JJ&T31[2PDVG(:2.)5=L]\L&/XUV]%%?DY]T%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 12
MPI/&T<B+(C##*PR#]17%Z]\#?AOXKW?VW\/O"VL;OO?;]%MI\_\ ?2&NYHH
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M^>'3U\$5@RA@<@C(-?J!_P %%O@__P +D_9+\:64$)FU31(AK]@,9(DM@6D
M'<M"9E '=A]*_)CX9Z]_PD'@VPG9]\\:>1,6?>VY.,L?4C#<^O?K7W'#6(M*
M=!]=5^I\UG-'W8UEZ?Y'44445]Z?*!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8V4]YG#R,"/N(5/05][5YA^SE\'H?@G\+=+T$K&=4D'VO4YDY$ERX&X ]U4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6)_P2M\.CXD?ME>/_'C;KFQT:QN7MIF.2LEQ,(X1GT\
MA9A^ JM\2/$#>%_ /B#54E\F:VL96AD(SB4J1'Q_OE:]^_X(N_#\:#\!?%OB
MZ6(I<^(=;^SHW]^WM8@$/_?R:<?A7Y_Q/6UITEYO]$?5Y+3TG4^1^AU%%%?"
M'U 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPWI&NIC&W4["*X&/^!J:\I\4?L,_ 'Q=&PO_ (2^&8L]3IMD+ _G;[#7NU%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME?[T=&,UC3GY6^X****]H\P**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD+X[R?V7^V
M#X'G7@S6$"G_ (%)<1_RKZ]KY!_:AA-K^TU\,[T%D\U;6'<<;<"[;/Z2']*\
MO,-(0EVDG^)WX/6<EWB_R/=****^N6Q\\%%%%,04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!XG^UMX@.E_"X6".N_4KR*%U/7RTS(2/HR(/QK]7/V'OA^
M?AC^R7\+]$=#'.='CU"=&&&66Z)N74^X:8K^%?CQ^VI:2R6/A.Y"_N8Y+J-F
MP>&81$#\D;\J_>7PAJ5IK'A/1;^RC6*RNK&">"->BQM&K*![ $5^4<03E+'2
M3Z))?=<^\RJ*CA8M=;FU1117S9ZX4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M45RWQ$^)7A?X2^%;OQ+XPURS\/:':_ZV\O)-JY/15'5W..%4%CV!KYS^"/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+U.K#TU4G[VRU9UW[!GPHO+C^VOBSXE#7.LZW-*EC-,!N96<M/<<=Y'RHX!
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M$L?A_P"(/"=K!X"O+KPMXALX=BW%[,]U!?-US.#RK$_Q1X _N'@#[; "X &
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M\(DK&L9<R/T$HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-US0]/\3:+
M>Z1JUC;ZEI=]"UO<V=U&)(IHV&&1E/!!!(P:_%+]L#]E'5?V(?B3_P ))X>M
M[K5/A1KLNR&0L6:PD)+"VD.>64 F-V^\NX9R&-?M]BN<\>> ]#^)W@_5O"_B
M;38=6T+4X&M[FSG7*LIZ$>C X8,.00",$5M1K3H5%4INS1G.$:D7":NF?A]I
M6JVNM6$%[93+-;S+N1U_D?0CH15JJ_[1'[/'B+]A?XM#3KN:XU3X:ZW([Z7J
MK(&+* ,HX&-LT>5#8&'7Y@.ROMKJ*\MXYH)%FAD4.DB'*L#T(-?JV69C#'TK
M[26Z_4^$QV#EA*G>+V9+1117LGG!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !117.>.]0O+714M-.5CJ.HRK9P,N?W98$LY(Y 50QR.G![5E6J*C3
M<^QK2INK-174P/&7QBT[PS>/96D!U.\C;;)M<+'&><KNP<L.,@#'/7((K@6^
M/7B-VRMK8*/01/C_ -#KTOPC\*='\+QI+-&FI:@IW?:)D^5>01L0D@8P.>3G
M/(SBNHO-%T_4H?*N[&WN8\[@LL*L <8R,CKR?SKYR6%S/$KVCJ\G:*Z>K/9C
M7P5%\L:?-YL\M\._'Y)I(X=:L%A!X:YM22 <]2AYQCK@D\<#FO6+*]M]0M8[
MBUFCN()/N2PL&5L'!P1[@C\*\/\ BE\*X_#L+:OI(VZ>NT36[.28B2 ""3DJ
M21[@GTZ2? OQ1+:ZO+HDLH^RW*M+$I7D2@#.#Z%%/7^Z,>_+@\PQ6%Q2P>-U
MOL_R]4S?$8.A6H/$8;2VZ/<Z***^R/F@HHK/U[7+;PYH]QJ%T6\F%<E5&68D
MX"CW)(%1.4:<7.3LD7&+DU&.[.5^)WQ&_P"$+AM[>T6.74;CY@LG*Q(#]Y@#
MGGH/H?3!UOA[XAN?%'A:WU&\$8GE9P1&N%&&(&!D^E>'_$;0]3MFL=:U>=7O
M-75I6A6,IY.T+A#GT5E'J,$<]:]=^#/_ "3W3_\ >E_]&-7RV"QU;$9E*%2Z
MBEHONLWYM'NXK"TJ."BX:N^K^^YV]%%9VN2W2VBV]EN6[NF,,<X7(@RK$NWL
M #@=V*CC.1]5.7)%R/"A'G=CDO&GQ>T[PO<-9VD9U._C<I+&K;$CP.06P<G/
M&!TP<D$8KAK[XT>++&<1W.G6MG(1N$<EO(AQGK@MG''Z5Z[X?\'Z7X;!>UM]
MUV^3)=RG?-(3C<2QYY(S@8&>U:E[8V^H6[V]U!%<P/\ >BF0.IP<C(/O7@5<
M'CL1>;K<KZ)+1>K/6IXC"4K15/F\V]?N/*O"_P >8KN>.#6[5+0$'==6^YD!
M[93!(&.X)Y[<\>M*P900<@\@BOG3XJ?#]/!NHQSV88Z9=%M@(),3#DH6[CTS
MS@'KC)].^">K3ZEX,$=PV_[).T$;').S:K $GTW$#T  KCRS'8E8B6"Q>LEL
M_P"M]-C?'86@Z*Q.'T3Z'?4445]:?/A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !3OV:?B%:_"W]IC5]*U:3[
M#I/BNWCC@DPHC-UD&)G.> S><F<$EG7/!)IM<Q\0/!</C30Y+?")?1C?;3L/
MNMQE3CLV,'TX.#BO)S+#SK4E*G\4'=>?E\ST,%6C2J-5/ADK/R\S]*J*^:/V
M/?VAI_'FDR>!O%<DD7C71(P@>Z;+W]NHP'R3EI%&-Q_B!5\G+8^EZ\BE5C6@
MI+_AO(]"I3=.7*PHHHK4R"BBB@#QC]H/X4ZE\8M<^'^AO:^=X/M]3DU'7)?.
M5<+%'^ZBVDAF\PNZ_*#@9)QQ7LD,,=O"D42+%%&H5$0 *H P  .@I]%9QIQC
M*4UNRW4<HJ/1!7(?%KP#:_%#X<:_X:NXED%]:ND+, ?+F S%(/=7"G\*Z^L_
MQ%K5OX:\/ZGJ]V=MKI]K+=RDG&$C0LW/T!IU$I0:EL*#:DFMS\2;.YEL;R"X
M@D:*:%UDC=>JL#D$?0U^XU?C[^SC\/9_B=\9_#&C1Q^9;"[2ZO#C(6WB(>3/
MID#:/=A7[!5X&3Q:4Y=';\/^'/7S*2O&)YM^TE9W.H? 7Q[#:@F;^R+A\+U*
MJA9A_P!\@U^;/[*/Q/M?A-\;=$U?4I/*TFXWV-[*3@1QRC <^RN$8^RFOUKG
M@CNH)(9D66*12CHPR&4C!!'IBOR;_:?_ &?]0^!?CJ:)(6E\-:@[3:9>8)79
MG)A8_P!].GN,'O@5F<)PG#$0Z"P,HRC*E+J?K-'(DT:R1LKQL RLIR"#T(-.
MK\XOV6?VTKOX;K9^%/&CRZAX63$5M? %Y]/&> >[Q#TZJ.F0 M?1?[1O[6NE
M>"_#L.D>!K^#Q#XQUB-/L(T__2$@60#;*=N=SD$;$&2202,=>ZGF%*I2=2]K
M;KJ<D\).-3DMOU/C_P#;-UP>-/VE?$$&FAKMK=K?3(UA&YGE1%5E '4B0LN.
MN17Z7?#;P]/X0^'7A;0KI@;G2]*M;&5EZ%XH40D?BIKY<_9-_8_OO#>LP>/_
M (@H7UW>;BQTN8[V@D)SY\Q[R9)(7^$\GYN%^QZQP%&<93KS5G+IY&F*JQ:C
M2AJHA1117L'G!1110 4444 %%%% 'CW[5'QJ3X)_"J]U"VD7^W]0/V+2XR>?
M-8?-+CTC7+>F=H.-U<)^PG\&V\"_#=O%VJ1EM?\ % 6Y#R?,\=GUB&>>7SYA
M.>0R C*UYIX^TN?]IK]M9/"=_(&\*^$H]\UMN.'CC\MIACUDE=(ST^4 ]17W
M,JB-0J@*JC  & !7E4;XC$2JOX8Z+UZL[ZG[FBJ:WEJ_T0M%%%>J< 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!P/Q^T4>(/@AX[L?*\]Y-%NWCCXYD2)G3KWW*M?/'[$.MMJ
MOP/2U88&FZA<6B^X.V;/YS'\J^P;BW2ZMY895#1R*493W!&"*^$?V$YKO2A\
M0/#5X-DFFWL+-'GI(?-CD[?],EKB^#&TW_,FOU.KXL--=FG^A]64445] >4%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444K@%%'3K44=Y!(Y1)HW=>"JN"12YH]QV9+7S[\>/V4X
M/B1K;^*/#>I#0O$V%9U8$03R+]V0LHW1OT^8;ONC@')KZ"HK"O0IXF'+4U1M
M1J5*,N:#/C?X0_$GQGIOQ&G^'/C>%)=1MHV(N&8&92$$BAF4E74H<@]>>2>E
M>_5X3\4+.'P[^VMH%ZY"+J5DDA/ ^9H);=?U117NU:Y/4E*G4ISDY<C:5][:
M6,\QC%3A.*MS)/3OU"BBBO?/)"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:\BQHSNP1%&2S'  ]:=
M7$?&O2;W7/A7XDM=/EDBN?LIE'EYW2*A#O'QR=ZJRX[[L=*QK5'2I2J15VDW
M;N:THJI.,6[79XIXP^)WB;XQ^./[&\$ZA<Z-H&G,?.U."5HC+R09&9"#M."$
M3.3]XX_@O?V7\7=(*Q:;XZANH,9+WT2LX;)R/FC?CIW_  JS\#9-/F^'EBUC
M;QVSAF2Y"-N9I <%F/7)&TX/0$ <8KT"O'P>7QQ5%8BK4DY2UNFTE?HEY'I8
MC&.A4=&G!*,=-4G\V>?1^,?C7H*Q[X='\0[NI950K@=\-'USVST[5+'\<OB=
MHY\S6/ ,%["6V;=.=PV?P:3C@\XQR/Q[RBNO^S)1UIUY+U:?YHYOKT7\=*+^
M37ZG'V?[3FK><%O_ (;ZQ:Q\9:%WD;'<X,2_SJ>']L#P8^T2Z?K4#'J3!$5'
MY2Y_2NIJ.2WBF^_&C_[R@T?4\;'X<1?UBO\ ,/K.%>]'[I,YOQK^T1X!\2_#
M_7[&'59$O+O39XX;>:TF!,K1,%4D*5!W$#.<>^.:^SO^"+/B:/4/V>?%^A^:
M&N=-\2O<;.ZQ36T(7MW:*7G_  KY&U+POI&L*@O=*L[L1YV>=;J^W.,XR..@
M_*O4O^"5OBR/X3_M3^-OALY:+3O%&G"ZL0ZG+2VQ:2-02>0(I;@%NYC_ "^,
MXBPF)ARUJTE);:*WGKN?193B*$E*E333WU=S]=****^*/HPHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1+^E<&*]V=*IVDOQT.S#^]&I#NG^!]/4445]$>0%%%% !1110 4444 %%%%
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MBI4OL5-8OLUNF=U6H\?AU4^U#?T[GN-%%%?1GBA1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=3(WN0P'?VHY65SQ[GT%_P % O\ @HVWA>XOOA'\';F:_P#&=Q)]AU+7=/\
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MO0#@/ ) /,#=0H^?'512&?0=%%% !1110 4444 %%%% !1110 4444 %%%%
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M_@:'L8BIS8:'/NST"BBBOH3QPHHHH **** "N5^+.J'1/A9XQU$%E:ST:\N
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M]GB*4I275)-/S/3GAZ%5\]&HDGT>Z\CZ0HKYT_X61\:K.1XSX>T6]53M$I(
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MH]JJ"6+>5*  !U)W5U2C:H'M7(?M07)76/AW;^8P$FJ&3R\G#;6B&3VR-_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;OQ&\Q0^O>%E3(W%;JY) [D#[.,_G7Z$^&/#]IX1\-Z5HE@GEV6FVL=I O\
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MZQC: ?[K*,<9)3Q-7VRIUH<MUIK<52C#V;J4Y7MN?3M%%%>F<04444 %%%%
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M1XC25!^J_7]#]@****_/3ZP**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *XCXM?!CP?\;_  S)H7C+18-6LSDPRL-L]LY&-\4@^9&^AP>A
M!&17;T4 ?EQXU_9U^-7[ OBZ?X@?"#7;[6?"T?-T88_,=80<^7>VP^66,#/[
MQ1QRW[LXK[?_ &0?^"F'@;]HS[%X=\3&#P/X_DVQK8W$O^AW[]/]&E;HQ/\
MRR?YN0%+\FO:*^+_ -J[_@G;X4^)EKJ/BOP.;?P;XJC1[F6"--MA>L 6)9%'
M[IS_ 'T&"<Y4D[JS<>QO&IT9^G%%?G%_P2!_:*\=?%C1?&O@_P 7ZU/K]CX;
M@LGTNYO#ON8DD,RM$TA^9U&Q-NXDK@C., ?H[69L%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>#_ +3O[&OPX_:LTJ)?
M%FG26NO6L)AL?$&G,([RW7)8(201)'N8G8X(&YB-I.:]XHH _!;XM?!3Q=^R
M+\=+'X::WK<'B32=0M!J&GW\:.I:W/FHHVL3Y;!H2"@+   @_-5ZOI7_ (+)
M^'!H_BSX->.$)A"2W>FW=PN<A5:&6,<#D8:?(_GDU\U5^D<.XB56A*G-WY7^
M#/C\XI*G4C.*M=?B%%%%?6GSX4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,:Y\.-#\1WSWFHP
M37,[ +N,[@ #H  < ?3U-=/16-6C"M'EJ14EYZFM.I.D^:#L_(X?_A3/A/\
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M&450K2IQV04445Z)Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5OKLW3>&;]!:ASEHK:=2R)]!(DQ'UQT K[<K=:HXVK.P4444Q!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;XF_Y%K5?^O27_P!
M-:59OB;_ )%K5?\ KTE_] - 'P?_ ,$._P#D:OBW_P!>6F_^C+BOUJK\E?\
M@AW_ ,C5\6_^O+3?_1EQ7ZU5SG:%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ J.X8I;RL.H4G]*DKD_B1XL_P"$7T$B -)J%Z3!;1K@
MMN(Y;!!R!D<8/) [USXFM"A1E4F[)&]&G*K44([L^A?^"<VF_9?@KK%V<%KK
M7)B.3]U885 /OG=^8KZJKR3]ECX7WGPE^"^BZ-J>5U6?=?WD)_Y8R2X/E_55
MVJ>O(..,5ZW7RN%BX48I[V/<Q$E.K)H****ZCG"BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH I?LZ_$9?V;_VVO"?B"1_L?AOQ7_Q
M*-4<N%C_ '[*I8XQ@)*()6)S_%SSQ^WQ]*_!WXK>#?\ A-?!]S:Q+NO8/W]M
M[NH/R]0/F&5YX&<U^E__  3>_:B/[1WP'MK;6+OS_&GA81Z;JWF-F2X3:?(N
MCW_>*I!)ZO'(>A%?CV?X)X3%N:7NRU7ZK[S]#RO$_6,.D]XZ?Y'UK124M?-G
ML!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W%
MO'=0R0RJLD4BE'1AD,I&"#4U% 'XO?\ !/=9/@Y^V)\2_AG=N1M6]TY03]^:
MSN<*??,?FG/^-?IS7YJ_&9$^%O\ P5[M9]&(G&J:M8M-;P<M$;VT2*??_P!_
M7E]@P/O7Z55K'8YJFX44459F%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9OB;_D6M5_Z])?_ $ UI5F^)O\ D6M5_P"O27_T T ?
M!_\ P0[_ .1J^+?_ %Y:;_Z,N*_6JORA_P""'%CYFJ?&.\W_ .IATF'9CKO:
M\.<^WE_K7ZO5SG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7R[_P %$/V<?^&C/V=-7M=.M?M'BOP_G6-&V#+R
M21J?-@'<^9'N4#IO$9/2OJ*B@#^?KX:>*/\ A*O"MO.[9NH?W$_'\8'7H!R,
M'CIG%=572?MF?!G_ (9?_:UOFLK;[/X*\=;M1T_RTPD,S/\ OH1@?P2MPHP
MDT?I7-U^LY/C/K>&3D_>CH_\SX/,</\ 5Z[ML]4%%%%>X>6%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (S!5))P!R2:D_97^'K_'+XQR^--0M]_A/PO)MLU;=MN+H',?!] 1(
MW3!$0(.37"_$2^O]8NM+\&Z#&MSK>O3K:K$,'"L=O/\ =R3]XC "L>,9K]"/
MA!\,=-^#_P /M)\+Z6-T=G'F:X(PUQ,QS)(WU8G'H !T KY?'5?K5=4%\,-9
M>;Z+Y'NX6'L*3JOXI:+TZL[*BBB@D**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[(/Q4^&_[0MU\?\ X+Z?)>PRE;^]M]+037=G=;"D[_9R#YL4B_,VW<<O)E0
M";/[._\ P4\\->-&M]$^)UK'X.UO_5_VI%N.GRM_MYRT!S_>W+ZL.E:1:V,*
MD6W<^Y:*@L;ZVU.SAN[.XBN[69!)%/ X=)%(R&5AP0?45/6AB%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OB;_D6M5_Z])?_0#6
ME6;XF_Y%K5?^O27_ - - 'Q+_P $,?\ FMG_ '!/_;^OU4K\J_\ @AC_ ,UL
M_P"X)_[?U^JE<YVA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?FM_P68^[\#?\ L,7G_MM7R;7UE_P68^[\
M#?\ L,7G_MM7R;7Z!PS_  ZGJCY3.OBAZ,****^U/F@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;]H3XR_\%$/$,NEV2-X1^&5O/M:Q@D;[*F/F#7$G!N9<;<(!M!*G:F2]>I>
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M@7^Q!\'?V?+6W;PWX1M;S68L$Z]K2+>7[,/XED88C^D00>U>]T45P'4%%%%
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MZR?%^VI>QEO';T_X!^K-%%%?&GT(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOXE?\DY\5?]@F[_
M /1+UTE<W\2O^2<^*O\ L$W?_HEZ /C?_@AC_P UL_[@G_M_7ZJ5^5?_  0Q
M_P":V?\ <$_]OZ_52N<[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *2EHH _-+_ (+.$V>F_!;4)4D6RM]7O/.N
M-A*I\MNP!([D(Q ZG:?2OE!6#*"#D'D$5^M/[97[/L/[2W[/WB3P>L:'653[
M?HTKX'EWT0)BY/0."T9/99&K\7?A+KTU]H<ND7\<D&IZ/)]EFAE4JZJ"0H(P
M,%<%2.OR<]:^RX;Q4:=25"7VM5\NA\[G%%RIQJKIO\SNJ***_0SY$**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.,WU'T4E+7*;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>YHT445[-SS HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK %MI+DD27U@A"#.>3)"=J,#R5*'D[\.\?>-M-^''@W5_$VKR;+#3;=IY I
M:0CA8UR0"[L5502,E@*\%_X):_!/4_C)\>O$W[0>N0?V=INGWUT-/BMB8UGO
M[A6\T#;C<D<4I!S]YI%SDAJ\#.(4XSC)?$]SU<OE-P<7LC]<:***^>/6"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 ?!_P#P4/\ V!%^
M.EA)\1?AW:1V7Q.TY1)<00GRO[8C0<#/ %PN!L?C<!M)X4K^<'P[\;W.O_:]
M*UFW:QU_36,5S#,GENQ4E6)0X*LI&&7'!QTS@?T&X]Z^ /\ @H9^P'<_%*>?
MXK_"V'[+\0[%/,O]+ME"_P!KHH^^G_3P%XP>)% 7J!N];+<PG@*O,M8O==SA
MQ>%CBJ?*]ULSXFHKD/ 7CV+Q9;R6US']CUJURMS:N"IR#@LH/.,]1U!X/8GK
MZ_5\/B*>)IJK2=TSX.M1G1FX35F@HHHKH,0HHHH **** "BBB@ HHHH ****
M "BBB@ HHJKJFIVVBZ?/>W<JPVT*[G=NW8#W). !W)J924$Y2=DBHQ<Y<L3&
M\:^-[/P381S3HUS<2L5BMXV 9C@G)ST7. 2 >HXKT'X9_L<_M$_M'>7+;Z%_
MPK?PS)@G4-?9[5W7@Y5-OG-T."$53G!;O7H7_!-#]EZZ^.WQ*?XW>-+#'A?0
M[D)H=E*"8[J\CZ. >L<)PV> TI_V6%?KS7Y?F.<U\1.4*4N6'EU/M\'EU*C%
M.:O(^&_@C_P23^$WP[ECU+QO<7GQ-U[=YC-J6;>Q#]21;HQ+Y).?,=P>.!7V
MGH/A_2O"NDP:7HNF6>D:9;KMALK"W2"&,>BH@  ^@K3HKYS<]<**** ,W7-#
MT[Q-I-YI>KV%MJ>F7D307-E>1++#-&PPR.C A@1V(KX(\??\$<_ FL>*;[5O
M!7C;6_ =M=/N&FPQ"ZB@!^\D;%U?;D @,S8Q],?H0#2TXR<7=":3T9^5^J?\
M$;?&UKSI'QT-TV!_Q]:7-;=^?NW$E<WK/_!+/]HZSRVG?$'P?J*J/N233PN>
M>,#[*5Z>K"OUSI,>]=$<5B(?#-KYF4J-.7Q13^1^,-[^P'^UCX?\T1:/H'B7
MKM\C4K9/N_W=YB^]GOZ<XKE=4_9G_:J\-N6O_A#/=QHPWK8RPW+$8R0IAG?M
MWP>?RK]Q_P#/6G5TQS3&1T51_>8RP>'EO!'\^_B#7O''@"60>-?ACXE\,Q1@
M_O+RPFB&1C_GI&HQC)R#Z5G6/QN\,W<.Z::XLFW8VRPECVY^3(Q^O'2OZ&:\
M]\8?L^_#'X@%SXD^'OAC6Y&ZS7VD022_4.4W ^X->C3S_&T]VI>J_P CCGE6
M%ELFO1_YGXEV/CCP_J/E"#5[1FFVE(VE"N2>@VGG//3K6U'(DGW'5_\ =.:_
M2GQ?_P $N?V<_%GF/'X)FT"X?K/H^IW$6/HC.T8_[YKQ'QG_ ,$8?"T=K=S^
M /B1XAT/4C$WD1ZLL5Q$S8RJ,\2Q,$+ <X8@<X8CGTZ?$\_^7E-/T..>2P^Q
M/[T?(U%<AXAM_&G[/OCR7P!\4]+DTR_M\+!J#9:.>/)"RI)TDC;H'&",$-SN
MV]<K!E!!R#R"*^OP6.HXZGSTWZKJCP,3A:F%G:2_X(M%%%>@<04444 %%%%
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M$][^SY\4/&GA_P"&_P 2O@DUWXAU2=+&SU[1=:U)!)*0>;F W0"="2\? _N
M<U\OB,TKT:C22:Z==/O/=IX&E."DV[_UY%KX[_%2Z_;(^)7@[X1?"UY=0T^^
MO(S)>-"\2SS$'+E6 810Q[W8D#)#''RJ3^R?P7^$VB? WX7>'/ WA^/9IFBV
MJVZR,H5IG^]),^.-[N6<^[&N&^#?[%GP8^ /BQ_$O@3P3'HFNO;/:&\DO[N[
M98V*E@HGE<*3M'S* <9&<$@^X;J\&M6GB)NI/=GJ4Z<:<5&(ZBBBL#0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCXC?!7P
M%\7;5;?QIX/T7Q.BKMC?4[&.:2/_ ''(W(>O*D=:[>B@#X>^(O\ P2'^!7C+
MS9="CUSP1=-RO]EWYG@W?[4=P)#CV5E]L#BOGKQ9_P $F_C'X%5I?AW\4=.\
M16J)A++5TELGVC&%13YT9(P!DE.,].E?K)^%%:PK5:+O3DT_)D2A":M-77F?
M@Y\2] ^.'[-RVLWQ4\"-9:/-,MHFK6[1R122$%@!+$[1[BB.P0[2<'I@BNMM
M;J*^M8;B"19H9D$D<B'*LI&00?0BOU5_:R^!\/[0W[/_ (P\$[5.H7EH9M-D
M8X"7L1\R Y[ NH5C_=9J_&CX&^(I=3\*-I=ZOE:AI,IM9(7P) H^[N7 (QRO
M/]SKG-??\.YK6K5GAZ\^:ZTOY'RV;X&G3I*M1C;N>CT445^@GR 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5P'Q4^'\WB:UM]6T63[%X
METUUGM;J%S'*VT[@H<$;6!PRMV([9)'?T5RXK"T\72E2JJZ9T4*\\-452F]4
M?;'_  3O_;GC_:&\/CP-XTG6R^)^BQ;7\X>7_:L*<&903_KEQ^\3_@0&,A?M
MG^5?@1\0O#&KZ'K.G^/? ]Q<:3XQTB=;F.YLFVR,%_B48^9QP,'[R[@=W K]
M2OV'_P!NSP[^U9X9BTW4'M]$^)%C#NU#1@2$N%7 -Q;9^\AR,KDLA.#D89OQ
MC,LOJ9?6=.>JZ/NC]&PF*ABZ?/'?JNQ]7T44E>6=HM%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4GNQ.26/)))/)KHZ**_-3[$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBJ>H:Q8Z1$)+Z\AM$)VAII F2>W/T/Y5,IQ@KS=D5&,I.T2Y7)>*B--\?_
M  XUAG.+'7[8F->I!EC?(.>,>7^OM6;J'QK\/6\D4=H+K4Y)&P%MX2.>,#Y\
M$DY[>E=%I_[,OQ__ &E%L4T+X7ZKINCC$RW6J*+*!\\>8)9]F\ 'H@)Z]>,?
M*YMF>%EAY4HSYI.UK:[-/?8][+\%B(UE4E&R\S[V\;?%3PA\.(0_B;Q'INC,
MRETANKA1-(H."4C^\W4?=!KYR^('_!13PAH[/:^$=&OO%%UG:EQ-_HEN<]",
M@R-]"B_6O7OA/_P1AT*&9-3^*?CO4-?O9&\Z;3]$06\9<G+!YY-[R GJ0$/O
M7VQ\)_V4_A+\#Q"_@OP'H^D7D0PNH&#S[S_P(E+2?^/5\E5S:K+2"Y?Q/=IX
M"G'XM3\KK/QI^V3\1[=-:\-_#74-/TB8?N4BT/8CKU#@W!+-D$?,/E...]:F
MFS?MO6'F>=\,[K4-V,?:=+B&S&>GENO7/?/2OV4HKS_KF(O?G?WG7]7I;<J/
MQEF\;?MFPR/&?@Y?%D8J2GAVX8<>A#X(]Q4DGQ0_;$LK4R2? N\E" 9*>&;]
MW/OM27)_ 5^RW-'-'UW$?SL/J]'^5'XN+\;_ -KE3D_ /5V^O@S5O_BZK7W[
M1G[4^ELJWGP.O+1F&56?PEJJ$CU&9*_:RBG]>Q'\[#ZO2_E/Q3M_VHOVD$4B
M?X(WDK9X:/P[J2C'I@LW\ZSIOVZ/BIX9;[7XC^%?V;2X6Q<%[:[M".P'F.&5
M3G'53Z5^W]07%O'=PR0RQK+#(I1XY%#*RD8((/4$57]H8E?:)^JT?Y3\HOAS
M^WA\,O&S0VVI75SX2U!]J[-5C_<%B.=LR94*/[TFRO?]'UK3_$&GPZAI5_;:
MG83#=%=6<RRQ./564D'\*]'^,7_!.;X$?&99YKOP=%X8U67G^U/"Y%A*">K&
M-086)ZDM&3[]:^-_&O\ P25^*GPGU"?6_@M\2A?$ ,+&ZD?3;MU!R(]Z%HIN
M>S[%.3D>OI4<XJ1TJJ_IH<=3+X2U@['T=17Q%J'[1O[0?[.%Y%9?&+X>75Q9
M*Y0ZA<V?V5I&)X$=S$#;O@9X523QEJ]?^'W[;_PL\=>5#<ZM)X7OG.WR-:3R
MDSW/G F,#_>93[5[=',*%;:5GYZ'FU,)6I[J_H>_45!8WUMJ5G#=6=Q%=VLR
MAXYH'#HZGH58<$>XJ>O1O?8X@HHHH **** $)"J2>!7P[X+TGXR?\%#/BEXM
MT?P-XG_X1OP'I+9>2::2VMTMW)2)7$2[Y9)1&[['X&'Y4 "OM?6--76-)OK!
MYIK9+J!X#-;L%DC#*5W*2" PSD<'FOB/3? _QT_8+\477BCX7:M)XC\+3%7O
M[5+<RQS(N<+=6V<_*&;$L9R!N.4S@^'FBKN"]G>W6QZN ]DI/GWZ'UG\)?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N)^.'_ "17Q_\
M]B_J'_I-)7;5Q/QP_P"2*^/_ /L7]0_])I* CN?+W_!#O_D5OBY_U^Z;_P"@
M7%?I_7Y@?\$._P#D5OBY_P!?NF_^@7%?I_7.=H4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'YZ?M6?\$M3\0O'>H^/_ (1^(;3P;K]\?.N]%NHVCL;B;(+.CQ@F/>1E
MD*,K,2>,FOA?XC>#_C#^SK=&'XH> KZUTT81-:LD$MLQP0#YR$Q$L<':2I&3
MQVK]\.U5[RTAOK66WNH8[FWF4I)#,@9'4C!!!X(/H:[L-CL1A'>E-KRZ?<<U
M;#4JZ_>1N?@=X=\?Z%XG6+['?1B>3@6TQ"2YQDC:>N/49'!YXKH:_1GXX?\
M!+OX(_&'S[S3='D^'^N29(O/#>V* MVWVQ!BQS_ $)_O5^?O[1G['_QB_8UT
MU_$=SJEKX\\ K<+%)J4.\26^Y@%,T;9:'<1M!5G0%@"<D9^OPO$B?NXF-O-?
MY'@5\FZT9?)_YF1167X;\167BG2XK^QDWQ-\K*W#1L.JL.Q&?U!Z&M2OM*=2
M-2*G!W3/FI1=-N,E9H****T("BBB@ HHHH ***1F"J23@#DDT;:@<[\0]:30
M?!^ISF1HY6B,,)4X;>X(&WD<CEN.0%)[5^I__!,+X:'X;_L<^#VFA\B^\0O-
MKUP/[WG-B%OQ@C@-?G!^R?\ L_7O[;7QU$-Y]HB^%WAIH[G4Y0"GVC^Y #_?
ME(;G@K&&/#8!_<#3=/MM(L;6PLK>.TLK6)8(+>! D<4:@*J*HX     Z 5^4
M9UCEC,1[GPQT7GW9]YEV%>&HVEN]2]1117@GJ!1110 4444 %%%% !1110 4
M444 %%%% !1110 50U;2K+Q!I=YINHVD-_I]Y"]O<6MP@>.:-@59&4\$$$@@
M^M7Z* /P\_;#_9BU/]A[XI-K&A6LU]\*?$<_^B.<NUG)\S?97<\[D!8H2?G3
M.265B.>TW4K;6+&"\LYEGMIEW)(G0C^A!X(/((P:_;?XE?#7PY\7_!&J>$?%
MNEQZQH&I1^7<6LA*YP05964@JRD A@000"*_%W]IG]D[QE^PMXN;4;4W'BCX
M5:E<;;;5 H#P,<XBG X28 </PD@'&#E4^HR?-GA'[&K\#_#_ (!XF89>L0N>
M'Q?F4Z*S]#UZP\26"WFG7*W-N6*E@""K#J"#R#]>Q!Z&M"OTJ$HU(J4'=,^-
ME%P?+)6844459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNCGFK,****H@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MB?CA_P D5\?_ /8OZA_Z325VU<3\</\ DBOC_P#[%_4/_2:2@(_$?+W_  0[
M_P"16^+G_7[IO_H%Q7Z?U^8'_!#O_D5OBY_U^Z;_ .@7%?I_7.=H4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOU''3[;AW'4Z=\-4T;=UY^1\WFV%G4M6CJDK/_,[.BBBOOSY,**** "BBB@
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M=/VD?V;_ !I_P3M^)H^(/P_:XU?X7:E.(I89BSBV#-D6ET?3D^7-USP>?O\
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M\C7_ /R6B?\ [#S?^E!KZYKY&O\ _DM,_P#V'F_]*#7Q?$G_ "X_Q'T^2_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"BBBM3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"%O#MAH5WXAO!?ZI+91!#=3A0NYO3@$X&!N9VQN=B>OHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,VY@>01TKZAK2,;&,Y<VB"BBBK,@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KS?]I7_DW/XJ_P#8J:K_ .D<M>D5YO\ M*_\FY_%
M7_L5-5_](Y:"EN>"_P#!$3_DE?Q*_P"PS;_^B#7Z55^:O_!$3_DE?Q*_[#-O
M_P"B#7Z55SG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDUV%?EN(Q%3%5'4J.[9]O2I0HP4*:LD+24M%<QL%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y/?\%:O
M'7_"POCU\-OA1;S*]II4#:KJ,>2 9)CPC8YW+#"2,?\ /?KZ>6*H50JC"@8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(8RD:JJX2"//)127.X@%BQ) P *BKD2ERH]_@@CM88X88UAAC4(D<:A550,
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M_P"3<_BK_P!BIJO_ *1RT%+<\%_X(B?\DK^)7_89M_\ T0:_2JOS5_X(B?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 %%%% !1110 5YO^TK_ ,FY_%7_ +%35?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^7?_!5C
M]E&]T75+7]H7P!'-9ZM830G7UL>'C9"!!?KCD%2%1R/1&P,.3^HE4-7TJSU[
M2[W2]1M8[W3[V%[:YMIE#1S1.I5T8'J""01Z&@#\#_COXXT3XE>&O!WQY\+Z
MS9^&/B9#>167B#2;6<0W!OH0&BU&W3.<$*NXC@':.2&)_7[]B?\ :>M_VK/@
MAI_B=HEM/$-B_P#9VMVJ#"+=HJDNG^PZLK@=MQ7)VY/QUX6_X(SV7_"^-<NM
M>U\CX3VUT)],T^U<G4+R-AN\B5_^6:H3L+C+.%R A.1^DO@CP+X?^&OA>Q\.
M>%M(M-"T*Q3R[:QLHPD:#J3[DG)+'))))))H$M#H:***!A1110 4444 %%%%
M !1110 4444 %%%% !1110!^7?\ P6\\<&'0/A?X.B<$7%U>:M<1YY'EHD41
MQ[^=-^5?1_[._P %]!^!OPMT/0='TF#3KPV<#ZG.B_O;JZ\L>9)(QY8[MV!T
M4<  <5\5_M^71^,__!2KP3X'4[[72?[)TN=%Y 5Y/M<S8]?+F'_?(K](:TB8
M5'T"BBBM#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS?]I7_ )-S^*O_
M &*FJ_\ I'+7I%>9_M.W4=I^S?\ %)Y3A3X7U.,<9^9K611^I%!2W/'O^")G
M_) _'7_8S'_TE@K]%:_.K_@B9_R0/QU_V,Q_])8*_16N<ZPHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH _&3]GVZ_X7=_P5 \=>+UQ<6>F7NK7
MT,C\@PH?L<!],[9$/MCCI7Z9U^7?A*SD_8;_ ."CFJ^%[L^3X5UZY:RAFF)(
M^Q7CK);/N/\ SSE"(S'^Y)7ZB5K'8YZFX44459D%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&5^ $-])KWQV^,6ML)&6^\2WLPD9=NYGNIW/3C/S#('3(K^@"OR)_:8_X)F_
M$+X-ZQJWC;X-WUSXRT*XD>YN]"E56U&$9+D*H&+E>N-@60;@ K<M7H9=B883
M$PJS5TNQR8NC*O1E3CNSQRBN,\+_ !0T_7)FL=04Z-K$<C126=T2IW [=H)
M^;/&TX.0>.]=G7ZY0Q-+$PYZ,KH^!K4*E"7+45F%%%%=)@%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !14=Q<16L,DT\J10QJ6>21@JJ!U))Z"N.
MM/$WB'XF>)T\'_#3P]?>*/$5R3'&UG%O5>0#(!TV#/+N55<9.17!B\=0P<.:
MK*WEU9UX?"U<3*U-%CQU\0[/P7''%Y9O=1FQY5FC8.,XW,<' ].,D_B1[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK_X(F_\ ) _'7_8S'_TE@K]%:_.K_@B;_P D#\=?]C,?_26"OT5K ZPHHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M65-] HHHKM.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVP_CFE/S.>N,G S@ #BO2*0U\/5K5*\W.K*[9]+"G&G'E@K(=11161H%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7E'[47Q4UGX)_ /QGXZT"RL]0U70[5;J*
MUO\ =Y+KYJ*^[:RG[A8C!Z@=>E>KUXE^VMIO]K?LD_%V#RO.V>&;ZXVYQCRH
MFDW=>VS/X4 ?%W@#_@MUH=PT<7C?X::A8X^_=>'[^.YW>XBE$>/IYAKZ2\ _
M\%.OV=_'7EQ?\)O_ ,([=OC_ $?7[*6UVY]9-IB'_?=?&?\ P30^%7@?XJ?
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DW[6W_)L?Q/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R
MH_X*T? &;P/XT\/_ ![\-V@\JXECTWQ#'&.LH7;#,>#@/&#"S=BL?=J^=+"^
MBU.QM[NW??!<1K+&V",J1D<5^V?Q3^&^C_%[X=>(O!FOP^=I.M6<EG/@#<FX
M?+(N>C(VUE/8J#7X1:7X;UOX)_%#Q1\)O%(6/4]$NI$MWVA1,N=P=><E9$99
M5[[2<^E?6</X[V-5X>;TEMZ_\$\'-<-[2G[6.\?R_P" =C1117Z2?&A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !6#XT\76W@O1)+^=6E=F\N*%?XW() )[#@DGV]<"MFYNHK
M.WDFGD6&&-2[R.<*H'4DU-^S'\-=$^-OC#6?BW\36&D?!3X?J)[XW&2+^<$-
M%9J,_,[DH65<D@HG5U:O!S;,%@:-H_'+;_,]7+\&\34O+X5O_D>R?LU_L_\
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M+SY8)^S:**D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%/\ V.=U_P"D-C7W_7P!_P $5?\ DUOQ3_V.=U_Z0V-??]8'6%%%% !1110
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M49)P?0/VPO%FCZAK'A3]E[X3W$</@/P7(PU/4G8!+[4U5C=WEPX_@A7S68]
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M /QQ_P""AWP-7]F;]I#3_B9H=DMKX'\:,R7L5O$%BM;OCSTP <!\+.,8+,)
M.!7,1R+)&KJ<JPR#[5^K/[47P%TW]I3X)>(O M_Y<5Q>0^;IUY(N?LEXF3#+
MZX#?*V.2K..]?B[\'=4U'2_[6\$>((9++Q#X=N9+66UG.)%"N59#DY)1P5]
M"@K[KAG,/9S>$F]):KU[?,^9SG"\\%7CNM'Z'I=%%%?I9\4%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>B?\$M=>
MC\*_MD_$?PNLACMM8T5[I%=L;IHYH9 H'?"S3$>@'?DUYW3/V=M:/@'_ (*
M_"K5RBQ6NKN^F2, /WCS0RP -CG(,D/)] .U?'<44N?!JHOLM?<_Z1]%D=3E
MQ#CW1^VU%%%?E9]R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM)[#CNCD_P#@BK_R:SXI_P"QSNO_ $AL:_0"OS__ ."*O_)K/BG_ +'.Z_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_!4;X GQ5X'T_P"*.CPM_;'AP+;:CY8^:2R9_E?CG,4C9_W9')^[7V!^P/\
MM*+^TQ^SWHVKWMQYOBG1P-)UQ6/S-<1J,3_25"KYZ;BX'W:WM;T6Q\2:-?:3
MJ=K'>Z;?0/;7-M*,I+$ZE70^Q!(_&OS)_9O^(<O_  3L_;2\0>#O%-W);_#_
M %EA:7-Y*&*_9F)>RO<*.2FXH^.@>7J5K*2ZF].70_:NBLW0M>TWQ1H]IJNC
MZA:ZKI=Y&);:]LIEFAF0]&1U)##W!K2J#8**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG;]J3]B
M7X>?M+>%-92[T#3=,\:30-]A\3V]N([F&<<H963!E3/!5]W#-C!P1]$T4 ?S
MV^$UUOX>^*=9^&OC*V;2_$>@W#6OD3$[FVDD@$\,N,,I'#(P(X&:[>O=/^"Q
M6B^&H?C%\*[K2H5L_'FH1.+V[AV_-;)+&ML[I_$P<S ,>R;3D 8\*4': 3N.
M.OK7Z;P_BZF(H.%3[.E_+_@'Q>;8>-*JIQ^UT_KN+1117U!X84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9?BK5/[#\.:C?!E
M5H8'9-_W2^,*#R.K$#\:SJ35.#G+9:EPBZDU%=3U[_@G2VE:+\9?C)\;/$2>
M3X?\ Z%*#(Q&X2OE5V9QEVBMI5"^LH'<9^.?$6L>,/VL/C_>7R6S:EXN\9:M
M^XM8SD*SL%CB!/2.- JY/1$R>E>A>(/'?_"L_P!B_P -_#[3IO+U;X@:K-XG
MUS8<.+"!_LUE WLTL$TV.O"'HPK[Q_X)+?L@'P3X7_X7-XIL3'KVMP&+0()D
M^:ULF^]<8/1INBG_ )Y\\B0U^*5:CJU)3>[;9^E4XJG!1730^POV5_V<]%_9
M?^#ND>"]($<UXB_:=5U%5PU]>,!YDI[XX"J#T15'7)KV*DI:Q+"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]7^)7[4W[/7_  3ETN\^'_@?PNMYXLMTC-SHNDILD+E \;WMY("22K C_6,
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M"W01R./(NL)@*R2X0D<GS4[+7T9^RC\<(?V@?@CH/B@NAU94^Q:K$F!Y=Y&
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MNMI#Q\ZD9. '< BOT2_9*_X*#?#O]J;[-HT+MX7\=M&6D\.7[[O-VJ69K:8
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MV592,@@U-7K1DI*\3AMRZ,****"0HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?_@M!\)M-\57MC;^%O%&J:/#+Y<6JVD< ^T*#@NL4DB$#KC<03QD+VI>-/\
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MBOOSY$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K ^("[O OB
M$9_XE\Y_\AM6_4%]_P >-Q_US;^1K'$1]I2E#NF;49<M2,NS/N__ ()*7WVO
M]C'08BFS[+JFH0@_WLSE\_\ C^/PK[+KX;_X([W<EQ^R-+'(<K;^([V./V4I
M"W\V-?<E?@+W/U4****0!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.1T^Y_>Q]=?L!_L.Z;^RGX+.KZW';W_Q)UB%?[1O%PZV4><BU@;'0<;V'WV
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O$_VT/AS=?%G]EGXE>&+"TDO]1N=)DN+2TC7<\T\#+<1(H[L7B4 >I%>V44
M ?@-\"_%":YX)@LI)/\ B8::3;RQL K! 25.!VVX7)'53]:]&KN?^"DG[,=W
M^SY\4(OCEX(L/^*7UJY*:Y80Y$=K>2?>8@=(YCEL\A91_M(*\ZT;6+3Q!I=M
MJ%A,L]K<+NCD7OV(/H0001V(K];R#,EB\.J,OC@DO5=SX+-L&Z%7VL?AE^#[
M%RBBBOJCP0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***YSQ=\0M"\%
M1$ZE>JL^W<EK%\TK\'&%'0'!&3@9[UC6K4Z,'.K))+JS6G2G5ERP5V>F?L!V
MK^)O^"AAFV(4T+0+J167<#@QI&2?4[K@CL,8[]?V(/-?E-_P2-\(>)/$7QN\
M??%2_P! NM/T"]T9M-L[Z2-U@F=KB%BD;D 2%5@&XCH?3.*_5GK7X9C:RKXF
M=1.Z;;7I?0_3L/3=*E&#W20ZBBBN,Z HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /R0_P""R'A.Z\"_&OX7?%'3%\NYGM3;>:HX6XLY
MQ-&S>Y$^![1^U?4'QY^+UQX?_96\0?$/PQ>+97,NAQW^G7;()-AG">6P!&"?
MW@QD8SC/%0?\%;_AS_PF_P"R-?ZQ%%ON_"VIVNJ*5'S>6S&WD'TQ.&/^Y[5\
M<?\ "^M"\2_\$N]1\.3^(M+'B_3H(-,.DRWD8NWA3480C+"6WE1 R\@8^0^E
M7%[F<E>QTO\ P35_8C\%_M&>%?$?Q2^*#7'BX7.H7&FPZ7/<2Q@R[4>6YEE1
MP[N?-PO(Q\S')(V\)X_^'FE?L._\%)?#%GH,4NF^#;N:TELX[B9I?+L[M#;3
M%F8DLJ2^<1G)^0=2*^X?^"1NFFQ_8UTB8QHGVS5[^<,H&6Q((\M[_N\?0"O/
M_P#@K%^R[XR^-D_PX\1_#_P[>>(-=LI+C3;N&R4;UB;;+"[,2 JJRRC).,R"
MH+\CZJKC?B)\8O!?PITF\U'Q5XET[1X;6/S'BGG7SF'8)$#O<GL%!)KX/M?V
M%_VTOC(#_P )AXSD\/VLH^>WUCQ*YCV_]<;3S$S[$#WQ7<>#?^"(OF.EQXQ^
M*KR,QW2VVC:5R?7$TLG7/K'6G,8^S[L^4_VN/VZO$?[1-U=:#HHF\.^ $?Y;
M#=B>^VG*O<$'ID B,':#C)8@&OUK^$^@_P#"+?"OP;HNW;_9NBV5GM]/+@1,
M?^.U^8_[=7PR^'/A+]HGX9_![X9V]FFF:7:VMAJ)MI5FG:_N+QED%S(.6FV"
M$G)^4,J@*!@?K'3CKJ*HDDD@HHHJS(**** "BBB@ KY3_P""@G[4&M?L[?#_
M $>S\+>3#XC\223PPWTHW&TBC5/,D1",%\R(!NX&<X-?5E?EW_P5437KKXP>
M%;R[\/ZE<>#-*TR-#>>4Z6LLTDSM+&)@"JL46)?4=<=*F6Q<%=ZGN7["W_!-
M,7DME\6/CC&->UC4"NH6/AV\E^T)\^&6XO2<B5VSN$>2H!&_))5?TX50J@ 8
M X KXS^ /_!4KX*_%N.STO5KUOAMK158UL==*K9DXQMCNE_=A1P/W@C)["OL
M2RO;?4K2&ZM9X[JVF0/%/"X='4C(96'!!'<5B=1:HHHH *^,/VL/^"EOAO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<#_MLX+_ /CU5S,EQ3/RRM_VZ/VG/C5^[^''PW9;=C\MQHVA7.H.N>[2MNC
M]RHK3M_V7_VZ_CA_R,6NW_AFPNOO?VCK<5A"P/9X+3+ ?[)C_"OV,7:J@ 8
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MG\9C::YXW^%=[<8AO(UU_38V. )4VQ7('J64P''I$U?K/7GG4%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@Y7I7%^ _P!BGXQ?M8>*4\=_'?Q)JFEVEP=PM[P@ZB\9.=D4.-EHG7@J,?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9_=K]?Z^#O\ @I#^P6GQZT6X^(O@2R$7Q(TN#-Q:P#!UFW0<)@?\MU ^1NK
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M1[=7_D?#WQ;^"^J>"_@YX?\ B-XW>6U\4^/+Y[C1=)9N8]-C3,ES(IRPWM)
ML2D\(K'G*[=[]@;X/M\?OVHO VB7,'G:%H?_ !-M04C(^SV[^;M;V>9T3Z25
M5_:>^,FL?M=?%#QM\2;P367A+1(4L]*MVZ6\!<I:P#MYDC%YG&>BRXX4"OT
M_P"",OP3/A?X2^(_B7?VVV]\3W7V'3W=?^7.W)#,I]'F+J?^N"U^8RFYR<I.
M[9]K%**LMD?HS2T45 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA -=GX?_ &"]>_9U\'P>)/!^@Z;\4?BJ.89-4N$@L-*;'$D$$A432#)PTCJ
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M&H:L:1?,KGT'1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"BL+P+XUTGXC>#]'\3Z%<_:](U6V2ZMI<8)5AG##LP.01V(([5NUL<P4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M([AIO-8>\53S,T]FC[QO/^"M?PJ2,&U\+^,9I,\K-;6D8QZY%PW/3M6+>?\
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MG@?X?^'/AGX:M/#WA30['P_HMJ,0V.GPB*,'NQ ZL>I8Y)/))-=)10 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S_ &BO@GIW[17P8\3_
M  ]U34+C2K36HHT%]:J&>&2*9)HFVGA@)(DRN1D9 *DY'Y(>&?&WQ;_X)D_%
M'_A"_'&GSZYX O96DA2%BUO<QY&ZYLG;A9!N&Z(XR2 V"5>OVZ!S7#?&+X,^
M$?CUX$OO"/C328]6T>Z^90W$MO* 0LT3]4D7)PP]2#D$@@FKZ,\G^&GQ.\-?
M&#P?9>)O">J1:KI-T/EDCX>-A]Z.13RCCNIY_ @UU5?F-^PW)=_L[_ML>//@
M_?W$IL[B2\TR$2-_KI;9S)!-CI\T"R'H/OCITK].:W3NCEE'E=@HHHIDA111
M0 4444 %%%% !7DW[4WP:B^/'P-\2^%1&K:F\/VK3';C9=Q?-%SV#'*$_P!U
MVKUFB@#XD_X)"_M/:=IOAO5O@OXMU:#2M1L[XW'AZ&_E\IIA*6,]J@;'S+(I
M<+]XF9_[M?J%^%?F+^U+_P $X=#^*U]?^*_ %W'X6\7W$C7,]K,6^PWTI8LS
MG&6A<DD[E!4G^$$EJ\T^!?\ P4,^*_[(OB:+X=_'K1=4U[1+7"1W5SAM2M8\
MX#Q3$[;J+KC+9]'P-M8--'7&2D?L-17#_";XR>#/CAX3@\2>!]?M/$&E2X#2
M6[8>%B ?+EC.&C< _=8 UW%(H**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?CS_P %*](G_9__ &Y_ WQ9LHF2UU9+/4IF QYLUJZPW$?N# (
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M]*_/#XJ?\%(/VB?B$/+NO&MQX5LYD\Q+7PY"M@0K=")5_?8(Z9?W% '[<?M
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M/ )S@*%6OF3P38>&_$WBC0]#\3_$&ZT3P-',TDTUU:7$DELI^_Y=O&)5#O@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ^"7[:O[8&)-;FU#P=X9NNJ:M,='M-A'0VT8\Z1<="R-]:7,BE3;/:/VQO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\52"^/U\K:L(/N(P:^IJ* *UG9V^G6D5M:P1VUO$H2.&%0J(HZ  < 59HHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH?\ 31869/\ QY5KTBN0^+WC"T^'_P *_%WB2^1);72]*N;EHI.DI6-BL?\
MP(X7_@5 XGS?_P $1_%0O/A-\1_#?F9.FZW!J&S^Z+B#R\_C]E/Y5^D]?EK_
M ,$0_!NH0Z5\4O%K,Z:7<S66EQ(!\LDT2R2R$G'55FCQC_GH<]J_4JN<[ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ,G&3Z[1169N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?/_[5/[%OP_\ VK] ,/B&S.E^);>/98>)+% +JWZD*_:6/)Y1
MO4[2IYK\_P ?\$F/VB/!<;1^$?BCH<5K&7,<5OJ]_8L03V5(BH)ZGYOQ-?L!
M10!^</[$?_!-?Q)\./BY??$KXU7=GK^OV,WF:3#'>->B2X/)O)I' )9>B Y.
M26."JU^CU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?XF%?7'[?G_!.&Z^)FMGXG_!RV2P\>?:$FU'2()5M5OY-PQ=0N2JQSJ<,V2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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M:XOMP,Y;:!Q$28#9!?F_CON/P_BL,/CCQU50+'<E&C^L6E>52!0LL79%?Q@
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M],.J%UB<(%KP'.(SJ T##/6&9?11NSF241,\L0S&D0G D$<L;U'%[:]JR^'
M;.51POFH/J/.C%<.0N/&UJ9#= KI()SWXNF&%"P V0LL7E#Q^7=K*]$9U(:!
MSZ_&;>90QUQ@R(@E+'-Q9 )"7H#F+:JB]%RM#4]";>55IU1[[]&<QH*'EO-C
M;3UYQM1#B*4914'F(6#QPFAEAXES01G8AL'](6XSAQ+.3?JL,@;+7!R9P+$S
M^Z)YBR-P5\,P-O-$U$Y>Q>7U^LPZ V6$Q8VKM,#2BB(AK],6NX/%#:48W[N
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M01!)@77 NZE6*?Y)1TV,^L7+7J\<A;]BZ061<AAFM"F"( B"( B"()("]C7
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MLS:MA6%)0P=6$.:('(9.F.XPP"8M<7?Z):(AY!.5MDT"-T&6\V.=NV0I.2]
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ME\5A$CD,1HD<ADZ8N-9Z4UQ>ZPV3R(3)[1C?\'CE)'Q"5:;_0O-'ZK_Z[3
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M@ZGB"72XN/POU#8IGX*7>FEC.6]1Z=SHI0>.EN5^CUGSKV,K9_?2(3HSL;G
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M\/#"-8&'IKER@,F"KP!040AYC+J/]D_ETSC<G[ _!U3:6![Z)=@I4SCYW0.
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6_P&+MB5;*=6WDP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241036144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> shares in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-14106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DAVITA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0354549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 16th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Denver,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-2100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000927066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238118144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AuditorAbstract', window );"><strong>Auditor [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Seattle, WA, USA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AuditorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AuditorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043239594592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts', window );">Dialysis patient service revenues</a></td>
<td class="nump">$ 12,260,375<span></span>
</td>
<td class="nump">$ 11,574,941<span></span>
</td>
<td class="nump">$ 11,176,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">555,175<span></span>
</td>
<td class="nump">565,206<span></span>
</td>
<td class="nump">433,430<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12,815,550<span></span>
</td>
<td class="nump">12,140,147<span></span>
</td>
<td class="nump">11,609,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PatientCareCosts', window );">Patient care costs</a></td>
<td class="nump">8,598,521<span></span>
</td>
<td class="nump">8,319,717<span></span>
</td>
<td class="nump">8,209,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,538,341<span></span>
</td>
<td class="nump">1,473,984<span></span>
</td>
<td class="nump">1,355,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">723,860<span></span>
</td>
<td class="nump">745,443<span></span>
</td>
<td class="nump">732,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income, net</a></td>
<td class="num">(26,189)<span></span>
</td>
<td class="num">(27,864)<span></span>
</td>
<td class="num">(26,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,083<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on changes in ownership interests</a></td>
<td class="num">(109,466)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,725,067<span></span>
</td>
<td class="nump">10,537,363<span></span>
</td>
<td class="nump">10,270,832<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">2,090,483<span></span>
</td>
<td class="nump">1,602,784<span></span>
</td>
<td class="nump">1,339,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Debt expense</a></td>
<td class="num">(470,469)<span></span>
</td>
<td class="num">(398,551)<span></span>
</td>
<td class="num">(357,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtPrepaymentExtinguishmentAndModificationCosts', window );">Debt prepayment, extinguishment and modification costs</a></td>
<td class="num">(19,813)<span></span>
</td>
<td class="num">(7,962)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other loss, net</a></td>
<td class="num">(69,808)<span></span>
</td>
<td class="num">(19,177)<span></span>
</td>
<td class="num">(15,765)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="nump">1,530,393<span></span>
</td>
<td class="nump">1,177,094<span></span>
</td>
<td class="nump">966,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">279,656<span></span>
</td>
<td class="nump">220,116<span></span>
</td>
<td class="nump">198,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations</a></td>
<td class="nump">1,250,737<span></span>
</td>
<td class="nump">956,978<span></span>
</td>
<td class="nump">768,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,452<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,250,737<span></span>
</td>
<td class="nump">956,978<span></span>
</td>
<td class="nump">781,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="num">(314,395)<span></span>
</td>
<td class="num">(265,443)<span></span>
</td>
<td class="num">(221,243)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to DaVita Inc.</a></td>
<td class="nump">$ 936,342<span></span>
</td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income from continuing operations</a></td>
<td class="nump">$ 11.02<span></span>
</td>
<td class="nump">$ 7.62<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income</a></td>
<td class="nump">11.02<span></span>
</td>
<td class="nump">7.62<span></span>
</td>
<td class="nump">6.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income from continuing operations</a></td>
<td class="nump">10.73<span></span>
</td>
<td class="nump">7.42<span></span>
</td>
<td class="nump">5.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income</a></td>
<td class="nump">$ 10.73<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares for earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares (in shares)</a></td>
<td class="nump">84,991,000<span></span>
</td>
<td class="nump">90,790,000<span></span>
</td>
<td class="nump">92,992,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares (in shares)</a></td>
<td class="nump">87,274,000<span></span>
</td>
<td class="nump">93,182,000<span></span>
</td>
<td class="nump">95,834,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Amounts attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">$ 936,342<span></span>
</td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 546,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to DaVita Inc.</a></td>
<td class="nump">$ 936,342<span></span>
</td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtPrepaymentExtinguishmentAndModificationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Prepayment, Extinguishment And Modification Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtPrepaymentExtinguishmentAndModificationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PatientCareCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PatientCareCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241004256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,250,737<span></span>
</td>
<td class="nump">$ 956,978<span></span>
</td>
<td class="nump">$ 781,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Unrealized gains on interest rate cap agreements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gains</a></td>
<td class="nump">7,250<span></span>
</td>
<td class="nump">6,895<span></span>
</td>
<td class="nump">108,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassification of net realized gains into net income</a></td>
<td class="num">(43,660)<span></span>
</td>
<td class="num">(77,727)<span></span>
</td>
<td class="num">(8,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gains on defined benefit plans</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Unrealized losses on foreign currency translation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized (losses) gains</a></td>
<td class="num">(207,861)<span></span>
</td>
<td class="nump">87,934<span></span>
</td>
<td class="num">(29,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of net realized gains into net income</a></td>
<td class="num">(14,487)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(258,712)<span></span>
</td>
<td class="nump">17,102<span></span>
</td>
<td class="nump">70,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income</a></td>
<td class="nump">992,025<span></span>
</td>
<td class="nump">974,080<span></span>
</td>
<td class="nump">851,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(314,395)<span></span>
</td>
<td class="num">(265,443)<span></span>
</td>
<td class="num">(221,243)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to DaVita Inc.</a></td>
<td class="nump">$ 677,630<span></span>
</td>
<td class="nump">$ 708,637<span></span>
</td>
<td class="nump">$ 630,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481724/830-30-40-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237893520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 794,933<span></span>
</td>
<td class="nump">$ 380,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and equivalents</a></td>
<td class="nump">84,892<span></span>
</td>
<td class="nump">84,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">51,064<span></span>
</td>
<td class="nump">11,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,146,975<span></span>
</td>
<td class="nump">1,986,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">134,559<span></span>
</td>
<td class="nump">143,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">383,166<span></span>
</td>
<td class="nump">422,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">122,948<span></span>
</td>
<td class="nump">102,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">27,535<span></span>
</td>
<td class="nump">6,387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,746,072<span></span>
</td>
<td class="nump">3,137,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">2,940,916<span></span>
</td>
<td class="nump">3,073,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,393,558<span></span>
</td>
<td class="nump">2,501,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">197,431<span></span>
</td>
<td class="nump">203,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">336,684<span></span>
</td>
<td class="nump">545,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">33,660<span></span>
</td>
<td class="nump">47,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">261,731<span></span>
</td>
<td class="nump">271,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,375,216<span></span>
</td>
<td class="nump">7,112,560<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets, Total</a></td>
<td class="nump">17,285,268<span></span>
</td>
<td class="nump">16,893,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">547,200<span></span>
</td>
<td class="nump">514,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">934,145<span></span>
</td>
<td class="nump">828,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">800,484<span></span>
</td>
<td class="nump">752,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">410,411<span></span>
</td>
<td class="nump">394,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">270,867<span></span>
</td>
<td class="nump">123,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">10,303<span></span>
</td>
<td class="nump">28,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,973,410<span></span>
</td>
<td class="nump">2,642,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">2,209,655<span></span>
</td>
<td class="nump">2,330,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">9,175,903<span></span>
</td>
<td class="nump">8,268,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">169,588<span></span>
</td>
<td class="nump">183,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">665,361<span></span>
</td>
<td class="nump">726,217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">15,193,917<span></span>
</td>
<td class="nump">14,150,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">1,695,483<span></span>
</td>
<td class="nump">1,499,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value, Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">286,270<span></span>
</td>
<td class="nump">509,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,534,630<span></span>
</td>
<td class="nump">598,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value</a></td>
<td class="num">(1,389,072)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(310,796)<span></span>
</td>
<td class="num">(52,084)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total DaVita Inc. shareholders' equity</a></td>
<td class="nump">121,122<span></span>
</td>
<td class="nump">1,056,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests not subject to put provisions</a></td>
<td class="nump">274,746<span></span>
</td>
<td class="nump">187,965<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">395,868<span></span>
</td>
<td class="nump">1,244,062<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 17,285,268<span></span>
</td>
<td class="nump">$ 16,893,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">90,369,000<span></span>
</td>
<td class="nump">88,824,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043244496608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">80,536,000<span></span>
</td>
<td class="nump">88,824,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="nump">9,833,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043242879008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,250,737<span></span>
</td>
<td class="nump">$ 956,978<span></span>
</td>
<td class="nump">$ 781,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">723,860<span></span>
</td>
<td class="nump">745,443<span></span>
</td>
<td class="nump">732,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,083<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtRefinancingCharges', window );">Loss on extinguishment of debt</a></td>
<td class="nump">12,527<span></span>
</td>
<td class="nump">7,132<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">102,788<span></span>
</td>
<td class="nump">112,375<span></span>
</td>
<td class="nump">95,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(57,840)<span></span>
</td>
<td class="num">(39,354)<span></span>
</td>
<td class="num">(75,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AdjustmentIncomeLossFromEquityMethodInvestments', window );">Equity investment loss, net</a></td>
<td class="nump">115,839<span></span>
</td>
<td class="nump">64,777<span></span>
</td>
<td class="nump">8,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on changes in ownership interests</a></td>
<td class="num">(109,466)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash losses and (gains), net</a></td>
<td class="nump">13,414<span></span>
</td>
<td class="num">(8,938)<span></span>
</td>
<td class="nump">21,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(29,766)<span></span>
</td>
<td class="nump">172,361<span></span>
</td>
<td class="num">(148,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">17,942<span></span>
</td>
<td class="num">(32,132)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">36,801<span></span>
</td>
<td class="num">(43,437)<span></span>
</td>
<td class="nump">27,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(67,031)<span></span>
</td>
<td class="num">(5,792)<span></span>
</td>
<td class="num">(50,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">26,890<span></span>
</td>
<td class="nump">87,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">14,687<span></span>
</td>
<td class="nump">56,209<span></span>
</td>
<td class="nump">34,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">46,733<span></span>
</td>
<td class="nump">27,082<span></span>
</td>
<td class="nump">89,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="num">(44,214)<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
<td class="num">(24,103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(6,672)<span></span>
</td>
<td class="num">(8,216)<span></span>
</td>
<td class="num">(15,601)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="nump">2,022,038<span></span>
</td>
<td class="nump">2,059,031<span></span>
</td>
<td class="nump">1,564,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions of property and equipment</a></td>
<td class="num">(555,443)<span></span>
</td>
<td class="num">(567,985)<span></span>
</td>
<td class="num">(603,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions</a></td>
<td class="nump">246,068<span></span>
</td>
<td class="nump">26,394<span></span>
</td>
<td class="nump">57,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from asset and business sales</a></td>
<td class="nump">25,862<span></span>
</td>
<td class="nump">30,610<span></span>
</td>
<td class="nump">117,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchase of debt investments held-to-maturity</a></td>
<td class="num">(15,319)<span></span>
</td>
<td class="num">(37,180)<span></span>
</td>
<td class="num">(129,803)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PaymentsToAcquireOtherDebtAndEquityInvestments', window );">Purchase of other debt and equity investments</a></td>
<td class="num">(9,140)<span></span>
</td>
<td class="num">(9,566)<span></span>
</td>
<td class="num">(3,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities', window );">Proceeds from debt investments held-to-maturity</a></td>
<td class="nump">22,638<span></span>
</td>
<td class="nump">99,639<span></span>
</td>
<td class="nump">71,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sale of other debt and equity investments</a></td>
<td class="nump">4,566<span></span>
</td>
<td class="nump">10,365<span></span>
</td>
<td class="nump">3,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of equity method investments</a></td>
<td class="num">(5,205)<span></span>
</td>
<td class="num">(276,202)<span></span>
</td>
<td class="num">(31,885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investments</a></td>
<td class="nump">6,680<span></span>
</td>
<td class="nump">4,913<span></span>
</td>
<td class="nump">3,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Payments to Acquire Other Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(782)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used in) Investing Activities, Total</a></td>
<td class="num">(771,429)<span></span>
</td>
<td class="num">(771,800)<span></span>
</td>
<td class="num">(630,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Borrowings</a></td>
<td class="nump">6,624,310<span></span>
</td>
<td class="nump">2,468,341<span></span>
</td>
<td class="nump">2,393,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on long-term debt</a></td>
<td class="num">(5,515,213)<span></span>
</td>
<td class="num">(3,020,956)<span></span>
</td>
<td class="num">(2,404,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtFinancingAndDebtRedemptionCosts', window );">Deferred and debt related financing costs</a></td>
<td class="num">(50,874)<span></span>
</td>
<td class="num">(69,791)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="num">(1,385,932)<span></span>
</td>
<td class="num">(272,219)<span></span>
</td>
<td class="num">(802,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Distributions to noncontrolling interests</a></td>
<td class="num">(337,042)<span></span>
</td>
<td class="num">(280,938)<span></span>
</td>
<td class="num">(267,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetProceedsFromIssuanceOfStockToEmployees', window );">Net proceeds from issuance of common stock under employee stock plans</a></td>
<td class="nump">20,453<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">18,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment, Tax Withholding, Share-Based Payment Arrangement</a></td>
<td class="num">(134,040)<span></span>
</td>
<td class="num">(65,012)<span></span>
</td>
<td class="num">(55,944)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Contributions from noncontrolling interests</a></td>
<td class="nump">14,499<span></span>
</td>
<td class="nump">14,773<span></span>
</td>
<td class="nump">14,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sales of additional noncontrolling interests</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">50,962<span></span>
</td>
<td class="nump">3,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Purchases of noncontrolling interests</a></td>
<td class="num">(53,958)<span></span>
</td>
<td class="num">(12,555)<span></span>
</td>
<td class="num">(20,775)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(816,937)<span></span>
</td>
<td class="num">(1,170,495)<span></span>
</td>
<td class="num">(1,121,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(18,481)<span></span>
</td>
<td class="nump">8,909<span></span>
</td>
<td class="num">(29,066)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Less: Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">415,191<span></span>
</td>
<td class="nump">125,645<span></span>
</td>
<td class="num">(215,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash of continuing operations at beginning of the year</a></td>
<td class="nump">464,634<span></span>
</td>
<td class="nump">338,989<span></span>
</td>
<td class="nump">554,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash of continuing operations at end of the year</a></td>
<td class="nump">$ 879,825<span></span>
</td>
<td class="nump">$ 464,634<span></span>
</td>
<td class="nump">$ 338,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AdjustmentIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the undistributed net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AdjustmentIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtFinancingAndDebtRedemptionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Financing And Debt Redemption Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtFinancingAndDebtRedemptionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtRefinancingCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt prepayment refinancing redemption charges related to debt modification of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtRefinancingCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in other current receivables and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetProceedsFromIssuanceOfStockToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Issuance Of Stock To Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetProceedsFromIssuanceOfStockToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PaymentsToAcquireOtherDebtAndEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Other Debt And Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PaymentsToAcquireOtherDebtAndEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043236958720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-controlling interests subject to put provisions</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury Stock, Common</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non-controlling interests not subject to put provisions</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 755,508<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 540,321<span></span>
</td>
<td class="nump">$ 354,337<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (139,247)<span></span>
</td>
<td class="nump">$ 180,640<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, beginning balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,434,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasePurchaseOfInterests', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityOtherChanges', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">$ 70,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock award payment plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock award plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,920<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">55,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-settled stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Changes in noncontrolling interest from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,095,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(787,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (787,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">47,596<span></span>
</td>
<td class="nump">740,250<span></span>
</td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,326<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">606,935<span></span>
</td>
<td class="nump">174,487<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(69,186)<span></span>
</td>
<td class="nump">163,566<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(184,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasePurchaseOfInterests', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, ending balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">17,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,213<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock award payment plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock award plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,012<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">65,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-settled stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Changes in noncontrolling interest from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,904,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (285,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">17,973<span></span>
</td>
<td class="nump">267,734<span></span>
</td>
<td class="nump">$ 285,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,244,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,056,097<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">509,804<span></span>
</td>
<td class="nump">598,288<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(52,084)<span></span>
</td>
<td class="nump">187,965<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">88,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(226,389)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasePurchaseOfInterests', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, ending balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,695,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">936,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">936,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">$ (258,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(258,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(258,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,441<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock award payment plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock award plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,040<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">134,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-settled stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Changes in noncontrolling interest from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,833,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,389,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,389,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 395,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,122<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 286,270<span></span>
</td>
<td class="nump">$ 1,534,630<span></span>
</td>
<td class="num">$ (1,389,072)<span></span>
</td>
<td class="num">$ (310,796)<span></span>
</td>
<td class="nump">$ 274,746<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">80,536,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,833,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestIncreaseFromContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest increase from contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestIncreaseFromContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interests Reclassifications And Expirations Of Put Obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Due To Acquisitions and Divestitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityDecreasePurchaseOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Purchase Of Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityDecreasePurchaseOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase Due To Acquisitions And Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in temporary equity from changes classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241086208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and summary of significant accounting policies<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are composed of its dialysis and related lab services to patients in the United States (its U.S. dialysis business), its U.S. integrated kidney care (IKC) business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support functions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s largest line of business is its U.S. dialysis business, which operates kidney dialysis centers in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease or end stage kidney disease (ESRD or ESKD). As of December&#160;31, 2024, the Company operated or provided administrative services through a network of 2,657 U.S. outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 200,800 patients. In addition, as of December&#160;31, 2024, the Company operated or provided administrative services to a total of 509 outpatient dialysis centers serving approximately 80,300 patients located in 13 countries outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#8217;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#8217;s international subsidiaries from their functional currencies into the Company&#8217;s reporting currency (the U.S. dollar, or USD).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, certain fair value estimates, accounting for income taxes and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis patient service revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized based on the Company&#8217;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's revenues are paid from government programs, principally Medicare, Medicare Advantage and Medicaid. Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare&#8217;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#8217;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#8217;s base payment rate as well as these other variable factors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues earned under government programs are subject to significant estimating risk, as they can be subject to adjustment as a result of examination by government agencies or contractors, differing interpretations of applicable regulations by different Medicare contractors or regulatory authorities, differing opinions regarding a patient's diagnosis or the medical necessity of patient services, or retroactive applications or interpretations of governmental requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to government programs, the Company also earns revenues that are paid by commercial health plans. Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#8217;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#8217;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#8217;s usual and customary rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, there are significant risks associated with estimating dialysis patient service revenue, whether paid from governmental or commercial sources, many of which take several years to resolve. These estimates are subject to examinations by or differing interpretations among government contractors or agencies or other regulatory authorities, retroactive application of interpretations, commercial insurance coverage changes, geographic coverage differences, differing interpretations of commercial contract coverage and other payor- and patient-specific issues, including determination of applicable primary and secondary coverage, changes in patient insurance coverage and coordination of benefits. As the Company's revenue estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (loss) income, net</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash and equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in debt and equity securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#8217;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes expenditures to purchase property and equipment, improvements thereon, leasehold improvements, and qualifying software costs, as well as costs to replace, extend the life of or improve the functionality of existing capital assets, where such purchases and costs have an expected benefit period of more than one year. All other expenditures related to capital assets are expensed as incurred (i.e., as repairs and maintenance expense).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortizable intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method and other investments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates multiple reporting units. The Company's annual impairment assessment is performed in the third quarter for its U.S. dialysis reporting unit and at various points throughout the year for its other reporting units. In addition to these annual impairment assessments, the Company performs impairment assessments at intervening periods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when a reporting unit is considered at risk of significant goodwill impairment.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing these assessments, the Company may first assess goodwill for impairment qualitatively as determined appropriate. If goodwill is more likely than not impaired, the Company is required to perform a quantitative assessment. When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm, which consider both discounted cash flow estimates for the subject business and observed market multiples for similar businesses, or recent good-faith offer prices received for the subject business that would be acceptable to the Company. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value after taking into account the effect of deferred taxes arising from the impairment. See Note 9 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-insurance</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#8217; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation to be settled in shares is recorded to the Company&#8217;s shareholders&#8217; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests represent third-party equity interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2024, third parties held direct or indirect noncontrolling equity interests in 728 consolidated legal entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New accounting standards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards recently adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment&#8217;s performance. The amendments in this ASU became effective for the Company beginning January 1, 2024. See Note 24 for further discussion of the Company's reportable segments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards not yet adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company intends to adopt this ASU for the fiscal year ended December 31, 2025 and is still assessing the effect this guidance may have on its consolidated financial statement disclosures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which requires disaggregated disclosure of income statement expenses, including purchases of inventory, employee compensation, depreciation, and amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this ASU are effective for fiscal years beginning after December 15, 2026. The amendments in this ASU may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043240215408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer</a></td>
<td class="text">Revenue recognition and accounts receivable<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues by segment and primary payor source were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,374,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,374,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,783,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,815,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,874,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,848,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,660,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097,120&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. IKC business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its IKC business, the Company recognized revenues for performance obligations satisfied in previous years of $116,336, $94,361, and $34,600 during the years ended December&#160;31, 2024, 2023 and 2022, respectively. The delay in recognition of these amounts resulted predominantly from measurement limitations and recognition constraints on both the Company's VBC contracts with health plans, many of which are complex and relatively new arrangements, as well as its government Comprehensive Kidney Care Contracting (CKCC) program. The Company's revenue recognition for its government CKCC program also remains heavily constrained for plan year 2024. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Other revenues"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Company's accounting for these value-based care arrangements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No single commercial payor accounted for more than 10% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively.&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $833,464 and $817,045 as of December&#160;31, 2024 and 2023, respectively. Approximately 23% and 19% of the Company&#8217;s U.S. dialysis accounts receivable balances as of December&#160;31, 2024 and 2023, respectively, were more than six months old. There were no significant balances over one year old at December&#160;31, 2024. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043242767728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings&#160;per share<div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed incremental from stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.02&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock-settled awards excluded from calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043242772944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term and long-term investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt and Equity Securities</a></td>
<td class="text">Short-term and long-term investments<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit and other time deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in mutual funds and common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,906&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,064&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,610&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. Typically, the Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2024 and 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#8217;s non-qualified deferred compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043240159280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Other Receivables</a></td>
<td class="text">Other receivables<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"><tr><td style="width:1.0%"></td><td style="width:56.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare bad debt claims</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IKC risk-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier rebates and non-trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043344282192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and equipment<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,180,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and information systems, including internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New center and capital asset projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,203,619&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,833,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,262,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,759,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073,533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, 25 years to 40 years; leasehold improvements, the shorter of ten years or the expected lease term; and equipment and information systems, including internally developed software, principally three years to 15 years. Depreciation expense on property and equipment was $716,396, $736,474 and $721,133 for 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $7,978, $9,178 and $12,677 for 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246703680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles</a></td>
<td class="text">Intangible assets<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"><tr><td style="width:1.0%"></td><td style="width:59.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,431&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompetition agreements are generally amortized over four years to 10 years and customer relationships are principally amortized over 10 years to 20 years. The weighted average renewal or extension period of customer relationships was three years and two years as of December&#160;31, 2024 and 2023, respectively. Amortization expense from amortizable intangible assets was $7,464, $8,969, and $11,469 for 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized no impairment charges on any intangible assets other than goodwill. See Note 9 for further information regarding goodwill.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2024 were as follows:&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:37.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncompetition<br/>agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Customer relationships and other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246449024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments and Joint Ventures Disclosure</a></td>
<td class="text">Equity method and other investments<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:56.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mozarc Medical Holding LLC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity method partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost method and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,684&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, 2023 and 2022, the Company recognized equity investment income of $26,189, $27,864 and $26,520, respectively, from its equity method investments in nonconsolidated dialysis partnerships.&#160;The Company also recognized equity investment losses from other equity method investments of $112,696, $59,508 and $4,703 in other loss, net during 2024, 2023 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April&#160;1, 2023, the Company formed a new, independent kidney care-focused medical device company (Mozarc Medical Holding LLC, or Mozarc) with Medtronic, Inc. (Medtronic). The Company holds a 50% voting equity interest in Mozarc and Medtronic holds the other 50% voting equity interest. The Company does not maintain a controlling financial interest in Mozarc and accounts for this investment on the equity method, with equity method income or loss recognized in other loss, net, on a one-month lag.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investment in Mozarc was recorded at a cumulative measured cost of $370,740, which includes the value of contingent consideration payable to Medtronic of $86,200. As of December&#160;31, 2024, the book value of the Company's contingent consideration payable to Medtronic approximates its estimated fair value, which is based on level 3 inputs.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also holds a 75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">voting and economic interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV) and an unrelated noncontrolling investor holds the other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25% voting and economic interest in the joint venture. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to November 1, 2024, the Company did not control or consolidate the APAC JV as a result of substantive participating rights retained by the unrelated investor over certain key operating decisions for the joint venture. Effective November 1, 2024, the third-party rights that blocked the Company's ultimate unilateral operating control of this business were removed, resulting in the Company's consolidation of this business. See Note 20 for further information.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other equity method investments include 17 legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. dialysis partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, and are often subject to blocking rights on certain key operating decisions held by outside investors, but mostly range from 30% to 65%. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant investment impairments or other valuation adjustments for the years ended December 31, 2024 and 2023. For the year ended December&#160;31, 2022, the Company recognized impairments and other valuation adjustments on the Company's adjusted cost method and other investments of $20,154 in other loss, net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043347584416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill by reportable segment were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:40.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary<br/>services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,112,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,987&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,069&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,517,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,375,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,517,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,517,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,517,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,996&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,375,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company&#8217;s operating segments described in Note 24 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied a similar aggregation to the dialysis centers within each of its international reporting units. For the Company&#8217;s other operating segments, discrete business components below the operating segment level constitute individual reporting units.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed various annual impairment assessments during the year ended December&#160;31, 2024, with no impairment indicated. None&#160;of the Company&#8217;s reporting units were considered at risk of significant goodwill impairment as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company performed its annual impairment assessment of its transplant software reporting unit and recognized a goodwill impairment charge of $26,083 in that reporting unit, or $19,575 net of tax. This charge resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate. After this impairment charge, the transplant software reporting unit had a goodwill balance of $14,424 remaining.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241208304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Liabilities</a></td>
<td class="text">Other liabilities<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"><tr><td style="width:1.0%"></td><td style="width:51.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor refunds and retractions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance and self-insurance accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241152992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income taxes<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes from continuing operations consisted of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:37.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Income tax expense for continuing operations consisted of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:46.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,790)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,332)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,656&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company&#8217;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:46.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Political advocacy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in international valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests primarily<br/>&#160;attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:60.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(757,797)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(731,024)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(464,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486,864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,035)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,352,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,452,116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619,108)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691,780)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726,217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other long-term assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 25.75pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619,108)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691,780)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the Company had federal net operating loss carryforwards of approximately $44,248 that expire through 2036, although a substantial amount expire by 2029. The Company also had state net operating loss carryforwards of $555,691, some of which have an indefinite life, while a substantial amount expire by 2044. Additionally, the Company had international net operating loss carryforwards of $410,313, some of which will begin to expire in 2026, though the majority have an indefinite life. The Company has a state capital loss carryover of $9,653, the majority of which will expire in 2025. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. A valuation allowance is recorded to account for the unrealizable balances in the table above. The net decrease of $5,285 in the valuation allowance is primarily due to unutilized state capital losses that expired in the current year.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains indefinitely reinvested in several of the foreign jurisdictions in which it operates as of December&#160;31, 2024. As a result of the passage of the Tax Cuts and Jobs Act (2017 Tax Act), the Company does not expect any significant taxes to be incurred if such earnings were remitted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized tax benefits</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:61.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to lapse of applicable statute</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,484&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,379&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company&#8217;s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $41,484. Of this balance, $27,336 would impact the Company&#8217;s effective tax rate if recognized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. We recognized a benefit of $679 and $138 related to interest and penalties net of federal tax benefit within tax expense in 2024 and 2023, respectively. At December&#160;31, 2024 and December 31, 2023, the Company had approximately $5,846 and $6,525, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are under examination in various state, local and foreign tax jurisdictions. In 2022, the Company was able to reach a settlement with the IRS for tax years 2014-2015. Subsequent to the settlement, the Company filed a 2014 refund claim with respect to a contested issue that was included in the IRS examination. During 2023 the IRS denied the refund claim and the Company has until September 2025 to appeal. Except for the 2014 refund claim, the Company is no longer subject to U.S. federal examinations prior to 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241836544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-term debt<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt comprised the following:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:39.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan A-1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,259,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,234,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4/28/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Base +1.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,256,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan B-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,603,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Extended Term Loan B-1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,636,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5/9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR + 2.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,638,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4/28/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Base +1.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6/1/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,533,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75% Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2/15/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,301,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.875% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/1/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,007,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisition obligations and other notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025-2038</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">216,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">255,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">CHC temporary funding assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">92,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">92,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total debt principal outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,511,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,445,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Discount, premium and deferred financing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(64,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(54,347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,446,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,391,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(270,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(123,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,175,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,268,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the Company's senior secured credit facilities, fair value estimates are based on bid and ask quotes, a level 2 input. For the Company's senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. For the CHC temporary funding assistance, the carrying value presented here approximates the estimated fair value based on the short-term nature of settlement.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company's senior secured credit facilities bear interest at Term SOFR, plus an interest rate margin, with certain portions also subject to a credit spread adjustment (CSA). Term SOFR plus CSA is referred to as "Base" in the table above. The Term Loan A-1 and revolving line of credit bear a CSA of 0.10%.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2024.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Change Healthcare (CHC) temporary funding assistance, as described below, is interest-free and amounts provided under this program are subject to repayment at a future date to be mutually agreed to by the parties. The balance is included in the Company's current portion of long-term debt as of December&#160;31, 2024.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2024, the carrying amount of the Company's senior secured credit facilities has been reduced by a discount of $8,084 and deferred financing costs of $28,879, and the carrying amount of the Company's senior notes has been reduced by deferred financing costs of $37,612 and increased by a debt premium of $10,239. As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $2,487 and deferred financing costs of $32,498, and the carrying amounts of the Company's senior notes was reduced by deferred financing costs of $31,491 and increased by a debt premium of $12,129.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of long-term debt at December&#160;31, 2024 were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"><tr><td style="width:1.0%"></td><td style="width:58.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">202,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2028</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,922,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2029</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,900,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9, 2024 (the Fourth Amendment Effective Date), the Company entered into the Fourth Amendment (the Fourth Amendment) to its senior secured credit agreement dated as of August 12, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the Credit Agreement). The Fourth Amendment modified the Credit Agreement to, among other things, extend the maturity date for a portion of its Term Loan B-1 in the aggregate principal amount of $911,598 and extend an additional incremental principal amount of $728,653 (together, referred to as the Extended Term Loan B-1). The Company used the incremental proceeds from the Extended Term Loan B-1 to prepay a proportionate amount of the principal balance still outstanding on its Term Loan B-1.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Extended Term Loan B-1 bears interest at the Company&#8217;s option, based on (i) the Base Rate (as defined below) plus the Applicable Margin (as defined below), or (ii) the forward-looking term rate based on the secured overnight financing rate that is published by CME Group Benchmark Administration Limited (Term SOFR) plus the Applicable Margin. The "Base Rate" is defined as the highest of (i) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 0.50%, (ii) the prime commercial lending rate of Wells Fargo as established from time to time and (iii) Term SOFR for an interest period of one month plus 1.00%; provided that if Term SOFR or the Base Rate is less than 0.00% such rate shall be deemed to be 0.00% for purposes of the Credit Agreement. The "Applicable Margin" for the Extended Term Loan B-1 is 2.00% in the case of Term SOFR loans, and 1.00% in the case of Base Rate loans. The Extended Term Loan B-1 requires quarterly principal payments beginning on December&#160;31, 2024 of 0.25% of the aggregate principal amount of the Extended Term Loan B-1 outstanding on the Fourth Amendment Effective Date, with the balance due on May&#160;9, 2031.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Fourth Amendment transaction described above, the Company recognized debt prepayment, extinguishment and modification costs of $9,732 in the second quarter of 2024 composed partially of fees incurred for this transaction and partially of deferred financing costs and original issue discount written off for the portion of debt considered extinguished and reborrowed as a result of the Fourth Amendment. For the portion of the debt that was considered extinguished and reborrowed, the Company recognized constructive financing cash outflows and financing cash inflows on the statement of cash flows of $6,302 and $728,653 for the Extended Term Loan B-1, respectively, and constructive financing cash outflows of $722,351 for the prepayment of a portion of Term Loan B-1, even though no funds were actually paid or received. Another $13,282 of the debt considered extinguished related to the Extended Term Loan B-1 represented a non-cash financing activity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;13, 2024, the Company entered into the Sixth Amendment (the Sixth Amendment) to the Credit Agreement. The Sixth Amendment modified the Credit Agreement to extend an additional incremental principal amount of $1,100,000 on its Term Loan A-1 (together with the existing Term Loan A-1 balance, referred to as the Increased Term Loan A-1). The Sixth Amendment also incorporated the provisions of the Fifth Amendment to the Credit Agreement, dated as of August&#160;7, 2024, which removed a cap on the amount of incremental term "A" loans the Company can incur under the Credit Agreement. The Company used a portion of the net proceeds from this transaction along with the net proceeds from the issuance of 6.875% Senior Notes due 2032, described below, to prepay the remainder of the balance outstanding on its Term Loan B-1 maturing 2026 in the amount of $949,819, the balance outstanding on its revolving line of credit and related accrued interest and fees. The remaining borrowings added cash to the balance sheet for general corporate purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Increased Term Loan A-1 bears interest at Term SOFR, plus a CSA of 0.10% and an interest rate margin which is subject to adjustment depending upon the Company's leverage ratio under the Credit Agreement, and which can range from </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.25% to 2.25%, provided that this adjusted rate shall never be less than 0.00%. The Increased Term Loan A-1 requires amortizing quarterly principal payments that began on September&#160;30, 2024 of $29,728 per quarter through June&#160;30, 2027, and $44,591 per quarter from September&#160;30, 2027 through March&#160;31, 2028, with the balance due on April&#160;28, 2028.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Sixth Amendment transaction described above, the Company recognized debt prepayment, extinguishment and modification costs of $10,081 in the third quarter of 2024 composed partially of fees incurred for this transaction and partially of deferred financing costs and original issue discount written off for the extinguishment of the Term Loan B-1. Additionally, $861,282 of the debt considered extinguished and reborrowed related to the Increased Term Loan A-1 represented a non-cash financing activity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company&#8217;s domestic subsidiaries' assets and rank senior to all unsecured indebtedness. Borrowings under the Term Loan A-1, Extended Term Loan B-1 and revolving line of credit rank equal in priority for that security and related subsidiary guarantees. The Credit Agreement contains certain customary affirmative and negative covenants such as various restrictions or limitations on permitted amounts of investments (including acquisitions), share repurchases, payment of dividends, and redemptions and incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company&#8217;s leverage ratio calculated in accordance with the Credit Agreement is below 4.00:1.00. In addition, the Credit Agreement requires compliance with a maximum leverage ratio covenant, tested quarterly, of 5.00:1.00 through June&#160;30, 2026 and 4.50:1.00 thereafter (subject to an increase to 5.00:1.00 during the four fiscal quarters following a material acquisition).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the prepayments described above, during 2024, the Company made regularly scheduled and other principal payments under its senior secured credit facilities totaling $75,080 on Term Loan A-1, $13,716 on Term Loan B-1 and $4,101 on Extended Term Loan B-1.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had undrawn capacity on the revolving line of credit under its senior secured credit facilities of $1,500,000. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were none as of December&#160;31, 2024. The Company also had letters of credit of approximately $161,496 outstanding under a separate bilateral secured letter of credit facility as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2019 interest rate cap agreements expired on June&#160;30, 2024 and a portion of the Company's 2023 cap agreements became effective on or prior to June&#160;30, 2024. As of December&#160;31, 2024, the effective portion of the Company's 2023 interest rate cap agreements had the economic effect of capping the Company's maximum exposure to SOFR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Extended Term Loan B-1 and a portion of Term Loan A-1. The remaining $395,445 outstanding principal balance of Term Loan A-1 is subject to SOFR-based interest rate volatility. These cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. The original premiums paid for the caps are amortized to debt expense utilizing the effective interest rate method over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit risk-contingent features.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;13, 2024, the Company issued $1,000,000 aggregate principal amount of 6.875% senior notes due 2032 (the 6.875% Senior Notes) in a private offering pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended. The 6.875% Senior Notes pay interest on March 1 and September 1 of each year beginning March&#160;1, 2025 and mature on September&#160;1, 2032. The 6.875% Senior Notes are unsecured senior obligations and rank equally in right of payment with the Company's existing and future unsecured senior indebtedness. The 6.875% Senior Notes are guaranteed by each of the Company&#8217;s domestic subsidiaries that guarantee its senior secured credit facilities. The Company may redeem up to 40% of the aggregate principal amount of the 6.875% Senior Notes at any time prior to September&#160;1, 2027 at 106.875% of the aggregate principal amount from the proceeds of one or more equity offerings, plus accrued and unpaid interest. On and after September&#160;1, 2027, the Company may at its option redeem the 6.875% Senior Notes, in whole or from time to time in part, at certain redemption prices specified in the indenture governing these notes plus accrued and unpaid interest. If the Company experiences certain change of control events, the Company must offer to repurchase all of the 6.875% Senior Notes (unless otherwise redeemed) at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest. The 6.875% Senior Notes contain restrictive covenants that limit the ability of the Company and the subsidiary guarantors of the 6.875% Senior Notes to, among other things and subject to certain exceptions and qualifications, create certain liens, enter into certain sale/leaseback transactions, or merge with or into, or convey, transfer or lease all or substantially all of their assets. The 6.875% Senior Notes and related subsidiary guarantees do not have any registration or similar rights and are not expected to be registered for exchange on public markets. As of December&#160;31, 2024, the Company incurred $11,421 in fees and other </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">professional expenses associated with this transaction that were capitalized and will amortize over the term of the 6.875% Senior Notes.</span></div><div style="margin-top:9pt;text-indent:27.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's outstanding senior notes, including the 6.875% Senior Notes (collectively, the Senior Notes), are unsecured obligations, rank equally in right of payment with the Company&#8217;s existing and future unsecured senior indebtedness and require semi-annual interest payments. The Company may redeem some or all of the Senior Notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in the indenture governing each series of Senior Notes. Interest rates on the Senior Notes are fixed by their terms.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change Healthcare</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;1, 2024, Change Healthcare (CHC), a subsidiary of UnitedHealth Group, launched a temporary assistance funding program (CHC Funding) to help bridge the gap in short-term cash flow needs for providers impacted by the disruption of CHC's services. Under the program, CHC provides funding to providers for amounts that would otherwise have been received (with certain limitations), but for the disruption in processing electronic claims as a result of the outage. Amounts provided under this program are subject to repayment at a future date to be mutually agreed to by CHC and the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHC has restored claims submission functionality and the Company has resumed claims submissions and billing processes through CHC&#8217;s information technology systems. Through a combination of CHC's platform and certain alternate billing processes, the Company is current on its primary claims submissions, but does continue to see delays in collections with some payors. As of December&#160;31, 2024, the remaining CHC Funding amount outstanding was $92,777. Subsequent to December&#160;31, 2024, the Company made a payment for a portion of the CHC Funding amount, leaving a remaining balance outstanding of $70,000 as of February&#160;13, 2025.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024 the Company entered into several forward interest rate cap agreements, described below, that have the economic effect of capping the Company's exposure to SOFR variable interest rate changes on specific portions of the Company's floating rate debt (2024 cap agreements). These 2024 cap agreements are designated as cash flow hedges and, as a result, changes in their fair values will be reported in other comprehensive income. These 2024 cap agreements do not contain credit-risk contingent features, and become effective and expire as described in the table below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s interest rate cap agreements outstanding as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount effective<br/>through December 31 unless noted</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year cap agreements executed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial notional amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SOFR maximum rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate effective date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td></tr><tr><td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional coverage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000</span></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average strike rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.58&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective January&#160;1, 2025, the maximum rate of 4.00% decreased to 3.75% for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective January&#160;1, 2025, the maximum rate of 4.75% decreased to 4.00% for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective January&#160;1, 2025, the maximum rate of 5.00% decreased to 4.50% for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective December&#160;31, 2026, the maximum rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.50%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective December&#160;31, 2026, the maximum rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increases to 4.25% for these interest rate caps.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of the Company&#8217;s interest rate cap agreements for the years ended December&#160;31, 2024, 2023 and 2022:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.536%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location in Consolidated Statements of Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification from accumulated other comprehensive income into net income</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1334">Debt expense</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,175)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1341">Related income tax</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's interest rate cap agreements, which are classified in other long-term assets on its consolidated balance sheet, were $30,062 and $79,805 for the years ended December&#160;31, 2024 and December&#160;31, 2023, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for further details on amounts recorded and reclassified from accumulated other comprehensive (loss) income and recorded as debt expense (offset) related to the Company&#8217;s interest rate cap agreements for the year ended December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the variable rate cap from the Company's 2023 interest rate cap agreements, the Company&#8217;s weighted average effective interest rate on its senior secured credit facilities at the end of December&#160;31, 2024 was 6.91%, based on the current margins in effect for its senior secured credit facilities as of December&#160;31, 2024, as detailed in the table above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was 5.07% for the year ended December&#160;31, 2024 and 5.68% as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company&#8217;s interest rates were fixed and economically fixed on approximately 59% and 96% of its total debt, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt expense</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt expense consisted of interest expense of $435,203, $373,951 and $339,247 and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs, costs for the undrawn portion of the revolving line of credit and the amortization of interest rate cap agreements of $35,266, $24,600 and $17,772 for 2024, 2023 and 2022, respectively. These interest expense amounts are net of capitalized interest.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043240627264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureTextBlock', window );">Leases Disclosure</a></td>
<td class="text">Leases<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which range in terms from five years to 15 years and which contain renewal options of five years to 10 years at the fair rental value at the time of renewal. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases. See Note 1 for further information on how the Company accounts for leases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and December&#160;31, 2023, assets recorded under <span style="-sec-ix-hidden:f-1413"><span style="-sec-ix-hidden:f-1414">finance leases</span></span> were $309,363 and $322,844, respectively, and accumulated amortization associated with finance leases was $139,071 and $122,286, respectively, included in property and equipment, net, on the Company's consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain markets, the Company acquires and develops dialysis centers. Upon completion, the Company sells the center to a third party and leases the space back with the intent of operating the center on a long-term basis. Both the sale and leaseback terms are generally market terms. Substantially all of the lease terms are consistent with the Company's other operating leases with the majority of the leases under non-cancellable operating leases ranging in terms from 10 years to 15 years and containing renewal options of five years to 15 years at the fair rental value at the time of renewal.</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes short-term lease expense and sublease income, which are immaterial. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease term and discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sale leasebacks, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the <br/>&#160;measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease assets obtained in exchange<br/>&#160;for new or modified operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2024 are as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:52.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,038,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less portion representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418,840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1481"><span style="-sec-ix-hidden:f-1482">Present value of lease liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense under all operating leases for 2024, 2023 and 2022 was $689,130, $692,834 and $679,815, respectively. Rent expense is recorded on a straight-line basis over the term of the lease, including leases that contain fixed escalation clauses or include abatement provisions. Leasehold improvement incentives reduce the carrying value of right-of-use assets and are amortized to rent expense over the term of the lease. Finance lease obligations are included in long-term debt. See Note 12 for further details on long-term debt.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases complete footnote disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241177568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee benefit plans<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) retirement savings plan for substantially all of its U.S. employees which has been established pursuant to applicable provisions of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company maintains a 401(k) matching program under which the Company matches 50% of the employee's contribution up to 6% of the employee's salary, subject to certain limitations. The matching contributions are subject to certain eligibility and vesting conditions. For the years ended December&#160;31, 2024, 2023 and 2022, the Company accrued matching contributions totaling approximately $79,006, $73,725 and $70,084, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains a voluntary compensation deferral plan, the Deferred Compensation Plan. The Deferred Compensation Plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2024, 2023 and 2022 were $2,521, $2,695 and $3,573, respectively. Deferred amounts are generally paid out in cash at the participant&#8217;s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2024, 2023 and 2022 the Company distributed $4,511, $3,899 and $3,731, respectively, to participants from its deferred compensation plans. Participants are credited with their proportional amount of annual earnings from the plans. The assets of these plans are held in rabbi trusts subject to the claims of the Company&#8217;s general creditors in the event of its bankruptcy. As of December&#160;31, 2024 and 2023, the total fair value of assets held in these plans' trusts was $39,527 and $36,936, respectively. The assets of these plans are recorded at fair value with changes in fair value recorded in other loss, net. See Note 4 for further details. Any fair value changes to the corresponding liability balance are recorded as compensation expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043242262864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to, or has the potential to be a party to, various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. Excluding amounts stated below, as of December&#160;31, 2024 and December&#160;31, 2023, the Company&#8217;s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company&#8217;s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney&#8217;s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company&#8217;s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter included an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a Civil Investigative Demand (CID) pursuant to the False Claims Act from the U.S. Attorney's Office relating to this investigation. On May 6, 2024, the Company finalized and executed a settlement agreement with the government and the relator in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matter that included a settlement amount of $34,487 for this matter. On May 7, 2024, the government notified the U.S. District Court, District of Colorado of its decision to intervene for purposes of settlement in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Kogod v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The government and the relator agreed to voluntarily dismiss all substantive claims in the matter, and, on July 18, 2024, the District Court dismissed all claims except for the relator&#8217;s statutory claim for expenses, attorney&#8217;s fees, and costs. On December 10, 2024, the parties signed an agreement to </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resolve the remaining claim for relator&#8217;s statutory claim for expenses, attorney&#8217;s fees, and costs for an immaterial amount. On December 20, 2024, the parties filed a stipulation of dismissal with the District Court on the remaining claim and the District Court ordered the relator&#8217;s claim withdrawn.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney&#8217;s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney&#8217;s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company&#8217;s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney&#8217;s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Bayne v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company&#8217;s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients&#8217; decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 District of Columbia Office of Attorney General Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company&#8217;s communications with the AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Federal Trade Commission Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2024, the Company received from the Federal Trade Commission (FTC) two CIDs in connection with an industry investigation under Section 5 of the Federal Trade Commission Act regarding the acquisition of medical director services and provision of dialysis services. The CIDs cover the period from January 1, 2016 to the present and generally seek information relating to restrictive covenants, such as non-competes, with physicians. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies. Negative findings or terms and conditions that the Company might agree to accept could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company&#8217;s reputation, required changes to the Company&#8217;s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company&#8217;s </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company. On October 27, 2024, the plaintiffs filed a Third Amended Complaint, seeking to bring an action on behalf of certain groups of individuals employed by the Company between March 2008 and January 2021, to which the Company responded on December 20, 2024. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 15, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company&#8217;s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management&#8217;s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company&#8217;s business, results of operations, financial condition, cash flows or reputation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-20/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-30/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043350415824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interests Subject to Put Provisions and Other Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Noncontrolling Interests Subject to Put Provisions and Other Commitments</a></td>
<td class="text">Noncontrolling interests subject to put provisions and other commitments<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests subject to put provisions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#8217; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#8217;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#8217; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#8217; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain consolidated dialysis partnerships are originally contractually scheduled to dissolve after terms ranging from ten years to 50 years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with various suppliers to purchase established amounts of dialysis equipment, parts, pharmaceuticals and supplies. As of December&#160;31, 2024, the remaining minimum purchase commitments under these arrangements were approximately $559,952, $547,079, $547,031, $564,134 and $414,491 for the years 2025, 2026, 2027, 2028 and 2029, respectively. If the Company fails to meet the minimum purchase commitments under these contracts during any year, it is required to pay the difference to the supplier.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately $7,131.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the letters of credit disclosed in Note 12 to these consolidated financial statements, and the arrangements as described above, the Company has no off balance sheet financing arrangements as of December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246636768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Long-term Incentive Compensation and Shareholders&#8217; Equity</a></td>
<td class="text">Stock-based compensation<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation consists primarily of stock-settled stock appreciation rights, restricted stock units and performance stock units. Stock-based compensation, which is primarily general and administrative in nature, is attributed to the Company&#8217;s U.S. dialysis business, its corporate administrative support, and its ancillary services. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization and summary of significant accounting policies" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on how the Company measures and recognizes stock-based compensation expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term incentive compensation plans</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DaVita Inc. 2020 Incentive Award Plan (the 2020 Plan) is the Company&#8217;s current omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2020 Plan provides for the grant of stock appreciation rights, nonqualified stock options, incentive stock options, restricted stock units, restricted stock, performance stock awards, dividend equivalents, stock payments, deferred stock unit awards, deferred stock awards and performance cash awards. The 2020 Plan mandates a maximum award term of 10 years for stock appreciation rights and stock options and stipulates that awards of these types be granted with a base or exercise price per share of not less than the fair market value of the Company's common stock on the date of grant. Shares available under the 2020 Plan are stated on a full value share basis. The 2020 Plan therefore provides that shares available for issuance under the plan are reduced by one share available for every four shares underlying stock appreciation rights and stock options, and are reduced by one share available for every one share underlying stock-based awards other than stock appreciation rights and stock options. At December&#160;31, 2024, there were 4,969 shares available for future grants under the 2020 Plan. The Company&#8217;s stock awards granted under the 2020 Plan generally vest over 36 months to 48 months from the date of grant.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company&#8217;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:37.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock appreciation rights</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Added by performance factor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(628)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.02&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.48&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of grants:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.61&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:28.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.438%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards Outstanding</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards exercisable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of SSARs base prices</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.01&#8211;$80.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01&#8211;$110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110.01&#8211;$120.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the aggregate intrinsic value of stock-based awards exercised was $323,681, $168,500 and $149,442, respectively. At December&#160;31, 2024, the aggregate intrinsic value of stock-based awards outstanding was $490,209 and the aggregate intrinsic value of stock awards exercisable was $3,394.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of stock-based compensation awards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant, except for portions of the Company&#8217;s performance stock unit awards for which a Monte Carlo simulation was used to estimate the grant-date fair value. The following assumptions were used in estimating these values and determining the related stock-based compensation expense attributable to the current period:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term of the awards:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company&#8217;s historical exercise and post-vesting termination patterns.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatilities expected by peer companies in near industries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No SSAR awards were granted during the years ended December&#160;31, 2024 or 2023. A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted during the year end December&#160;31, 2022 were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.181%"><tr><td style="width:1.0%"></td><td style="width:67.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $25 of the Company&#8217;s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of 100% of its fair market value on the first day of the purchase right period or 85% of its fair market value on the last day of the purchase right period. Purchase right periods begin on January&#160;1 and July&#160;1, and end on December&#160;31. Contributions used to purchase the Company&#8217;s common stock under this plan for the 2024, 2023 and 2022 purchase periods were $20,441, $18,213 and $18,061, respectively. Shares purchased pursuant to the plan&#8217;s 2024, 2023 and 2022 purchase periods were 184, 231 and 285, respectively. At December&#160;31, 2024, there were 5,286 shares remaining available for future grants under this plan.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of participants&#8217; purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2024, 2023 and 2022, respectively: expected volatility of 32.6%, 41.3% and 31.7%; risk-free interest rates of 4.8%, 4.9% and 1.3%; and no dividends. Using these assumptions, the weighted average estimated per share fair value of each purchase right was $31.78, $25.25 and $26.50 for 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense and proceeds</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized $102,788, $112,375 and $95,427 in stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock purchase plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2024, 2023 and 2022 were $16,398, $16,536 and $14,723, respectively. As of December&#160;31, 2024, there was $146,350 of total estimated but unrecognized stock-based compensation expense under the Company&#8217;s equity compensation plans. The Company expects to recognize this expense over a weighted average remaining period of 1.2 years.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the Company received $27,531, $25,629 and $24,805, respectively, in actual tax benefits upon the exercise or vesting of stock awards. Since the Company issues stock-settled stock appreciation rights rather than stock options, there were no cash proceeds from stock option exercises.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241166016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Stockholder's equity</a></td>
<td class="text">Shareholders&#8217; equity<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchases</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:38.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open market repurchases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#8217; equity.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes commissions and the excise tax described above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company repurchased 779 shares of its common stock for $124,665 at an average price paid of $158.48 per share subsequent to December&#160;31, 2024 through February&#160;13, 2025, inclusive of the shares repurchased from Berkshire Inc. as discussed below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company is authorized to make share repurchases pursuant to a September 5, 2024 Board authorized repurchase plan of $2,000,000. This authorization allows the Company to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, trading plans pursuant to Rule 10b5-1 or Rule 10b-18, or any combination of the foregoing, depending upon market conditions and other considerations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;13, 2025, the Company has a total of $1,811,069, excluding excise taxes, available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Berkshire share repurchase agreement</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;30, 2024, the Company entered into an agreement (the share repurchase agreement) with Berkshire Hathaway Inc. on behalf of itself and its affiliates (collectively, Berkshire). Under the share repurchase agreement, at any time Berkshire beneficially owns at least 45.0% of the issued and outstanding common stock of the Company in the aggregate, the Company will repurchase from Berkshire, and Berkshire will sell to the Company, on a quarterly basis, a number of shares of common stock sufficient to return Berkshire&#8217;s aggregate beneficial ownership to 45.0% of the Company's issued and outstanding common stock. The per share price the Company will pay Berkshire for any such share repurchase will be the volume-weighted average price per share paid by the Company for any shares of common stock repurchased by the Company from public stockholders pursuant to the Company&#8217;s share repurchase program during the applicable repurchase period.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, repurchases of common stock by the Company from Berkshire will occur on the date that is two business days prior to the date of the Company&#8217;s regular quarterly or annual investor call to publicly report earnings; however, if at any time the Company determines that Berkshire beneficially owns or will beneficially own shares of common stock representing more than 49.5% of the issued and outstanding common stock in the aggregate, such determination will trigger immediate share repurchases under this agreement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, Berkshire beneficially owned less than 45.0% of the issued and outstanding common stock of the Company and, as a result, no repurchase obligation existed at such date. Subsequent to December&#160;31, 2024, through February&#160;13, 2025, the Company's open market share repurchases caused Berkshire to beneficially own greater then 45.0%. As such, on February 11, 2025 the Company repurchased 203 shares of common stock from Berkshire for $32,001 at an average price paid of $156.01 per share.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Berkshire standstill agreement</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Berkshire remains subject to a standstill agreement with the Company, as amended and restated as of February 9, 2022 (the standstill agreement). The standstill agreement currently restricts Berkshire&#8217;s actions with respect to acquiring additional </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of the Company&#8217;s common stock, and for any matter presented to Company stockholders, the standstill agreement requires Berkshire to vote any shares it beneficially holds in excess of 40% of the then-outstanding voting stock of the Company in accordance with the recommendation of the Board of Directors of the Company (Board). The standstill agreement also restricts Berkshire from taking certain actions, including, among other things, actions relating to stockholder proposals and actions seeking to control or influence the Board, management or policies of the Company. The standstill agreement provisions vary depending on Berkshire&#8217;s ownership levels and in the event of certain specified leadership changes at Berkshire.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standstill agreement may be terminated by Berkshire at any time it ceases to beneficially own more than 15% of the Company's then-outstanding common stock, and terminates automatically if the Company enters into or publicly announces a plan to enter into a definitive agreement concerning a transaction involving all or a controlling portion of the Company's equity securities or all, or substantially all, of the Company's assets. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charter documents&#160;&amp; Delaware law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice for director nominations and stockholder proposals and granting the Company's Board of Directors the authority to issue up to 5,000 shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, prohibits the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. The provisions described above may discourage, delay or prevent an acquisition of the Company at a price that stockholders may find attractive.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries on the Company&#8217;s consolidated equity were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:52.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in paid-in capital for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,611)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc. net of transfers in <br/>&#160;noncontrolling interests</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,753&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired additional ownership interests in several existing majority-owned partnerships for $53,958, $12,555 and $20,775 in 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043239809888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive (Loss) Income</a></td>
<td class="text">Accumulated other comprehensive loss<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and credits to other comprehensive (loss) income have been as follows:&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"></td><td style="width:40.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">cap agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined benefit plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other<br/>comprehensive<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,069)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,554)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,802)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167,871)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,186)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,937)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,084)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,662&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207,906)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198,198)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207,861)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,175)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,252)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,660)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,487)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,147)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,557)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,285)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310,796)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income. See Note 12 for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/220/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043239822624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">Acquisitions and divestitures<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of DaVita Care Pte. Ltd.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective November&#160;1, 2024, the Company acquired control of DaVita Care Pte. Ltd. (DVC), previously referred to as the Company's APAC joint venture, through a change in control rights for no cash consideration. See Note 8 for more information.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, the Company recognized a non-cash gain of $59,067 on its previously held equity interests in the acquiree and realized a related foreign currency gain of $15,252 from foreign currency translation adjustments on this investment which were previously classified in accumulated other comprehensive loss. The Company estimated the fair value of its previously held equity interests of $114,744 using appraisals developed with an independent third party valuation firm.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in this transaction and recognized at the acquisition date at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in this transaction:</span></div><div style="margin-top:9pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.894%"><tr><td style="width:1.0%"></td><td style="width:76.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other international and routine acquisitions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, 2023 and 2022, the Company acquired other dialysis and related businesses for consideration paid in cash. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of these other international and routine transactions in 2024, the Company acquired a controlling interest in a previously nonconsolidated U.S. dialysis partnership for which it recognized a non-cash gain of $35,147 on its prior investment upon consolidation. The Company estimated the fair value of its previously held equity interest in this business using appraisals developed with independent third party valuation firms.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aggregate consideration &#8211; DVC and all other acquisitions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate consideration for both the DaVita Care Pte. Ltd. acquisition and all other international and routine acquisitions described above has been as follows:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"></td><td style="width:54.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent purchase price and liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,841&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; International</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase price allocations &#8212; DVC and all other acquisitions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company&#8217;s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2024 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"></td><td style="width:52.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use lease assets and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,081)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of goodwill related to these acquisitions recognized or adjusted in 2024, 2023 and 2022 that is deductible for local tax purposes was $54,810, $17,836 and $49,047, respectively. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro forma financial information (unaudited)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions in 2024 and 2023 had been consummated as of the beginning of 2023, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:62.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,073,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,625,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043240635856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Held for Sale and Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Held for Sale and Discontinued Operations</a></td>
<td class="text">Discontinued operations previously held for sale<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DaVita Medical Group (DMG)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;19, 2019, the Company completed the sale of its prior DMG business to Optum, a subsidiary of UnitedHealth Group Inc. At close, the Company's ultimate net proceeds from this sale remained subject to resolution of certain post-closing adjustments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shortly after December 31, 2022, Optum made an additional purchase price payment of $13,452 to the Company after resolution of one such post-closing matter, which represented a contingent gain to the Company for the fourth quarter of 2022. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no DMG operating, financing or investing cash flows for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity purchase agreement, the Company also has certain continuing indemnification obligations that could require payments to the buyer relating to the Company's previous ownership and operation of the DMG business. Potential payments under these provisions, if any, remain subject to continuing uncertainties and the amounts of such payments could be significant to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241176880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text">Variable interest entities<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, non-U.S. subsidiaries that are structurally dependent on subordinated debt, or other legal entities subject to nominee ownership arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#8217;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#8217;s economic performance, the obligation to absorb the entity&#8217;s expected losses, or the right to receive the entity&#8217;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#8217;s losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the VIEs described above, these consolidated financial statements include total assets of $577,585 and total liabilities and noncontrolling interests to third parties of $249,900 at December&#160;31, 2024. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also sponsors certain non-qualified deferred compensation plans whose trusts qualify as VIEs and the Company consolidates these plans as their primary beneficiary.&#160;The assets of these plans are recorded in short-term or long-term investments with related liabilities recorded in accrued compensation and benefits and other long-term liabilities.&#160;See Notes 4 and 14 for disclosures concerning the assets of these consolidated non-qualified deferred compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246486032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Values of Financial Instruments</a></td>
<td class="text">Fair values of financial instruments<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the FASB.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,062&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,062&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,805&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,805&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 4 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 12 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had contingent earn-out obligations associated with business acquisitions that could result in the Company paying the former owners a total of up to approximately $24,580 if certain performance targets or quality margins are met over the next one year to five years. The estimated fair value measurements of these contingent earn-out obligations are primarily based on unobservable inputs, including projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and key performance indicators. The estimated fair value of these contingent earn-out obligations is remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of December&#160;31, 2024, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $225,000. See Note 16 for a discussion of the Company&#8217;s methodology for estimating the fair values of noncontrolling interests subject to put obligations and the reconciliation of changes on the consolidated statements of equity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair value estimates for its senior secured credit facilities are based upon quoted bid and ask prices for these instruments, a level 2 input. For the Company's senior notes, fair value estimates are based on level 1 market inputs. See Note 12 for further discussion of the Company's debt. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in the consolidated financial statements at December&#160;31, 2024 and 2023 at their approximate fair values due to the short-term nature of their settlements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237848000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment reporting<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating divisions are composed of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support functions. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a summary description of the Company's businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company&#8217;s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company&#8217;s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its operations in each foreign sovereign jurisdiction, and, until its reconsolidation in the fourth quarter of 2024, the Company's equity method investment in its Asia Pacific joint venture (APAC JV). The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to assess the financial performance of and allocate resources among the Company's operating segments. For internal management reporting, segment operations include direct segment operating expenses but generally exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive compensation expenses of certain departments which provide support to more than one of the Company&#8217;s various operating lines of business. The chief operating decision maker uses segment operating margin to assess segment profitability and resource allocation. The chief operating decision maker does not review total assets by segment to make decisions regarding resources; therefore, the total assets by segment disclosure has not been included.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of segment revenues, segment operating margin, and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,294,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,823,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,366,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911,747&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,575,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,390,717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external sources</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,901,207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,236,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,701,135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,815,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant segment expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,394,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,334,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,417)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis segment expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,269,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,162,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203,664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,047)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt prepayment, extinguishment and modification costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other segment items for our U.S. dialysis segment include equity income from nonconsolidated joint ventures and a gain on changes in ownership interest.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating margin (loss) for Other - Ancillary services includes equity investment loss of $1,701, $2,103 and $1,898 in 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for property and equipment by reportable segment were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's international operations include approximately $317,488 and $240,742 in 2024 and 2023, respectively, of net property and equipment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock', window );">Net Property and Equipment International Operations</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's international operations include approximately $317,488 and $240,742 in 2024 and 2023, respectively, of net property and equipment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Property and Equipment International Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetPropertyAndEquipmentInternationalOperationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246679168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental cash flow information<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides supplemental cash flow information:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"></td><td style="width:49.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets under financing lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043240242672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to DaVita Inc.</a></td>
<td class="nump">$ 936,342<span></span>
</td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043236999008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043230525504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1C.&#160;&#160;&#160;&#160;Cybersecurity</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the increasing use of the Internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including, among others, foreign state agents. Our business and operations rely on the secure and continuous processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks, including, but not limited to, sensitive personal information, such as PHI, social security numbers, and/or credit card information of our patients, teammates, physicians, business partners and others. Our business and operations also rely on certain critical IT vendors that support such processing, transmission and storage (which have become more relevant and important given the information security issues and risks that are intensified through our increased use of remote work arrangements).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage risks to our Company, including information and security risks, our Board oversees our enterprise-wide approach to risk management with a fundamental belief that the key components of risk management are:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identifying potential risks that we face;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assessing the likelihood and potential impact of the risks;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adopting strategies and controls designed to manage the risks;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reporting on a regular basis regarding the assessment and management of the risks; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Monitoring these potential risks on a regular basis; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluating whether there are new potential risks to assess.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Enterprise Risk Management (ERM) process, the Company evaluates risks to the enterprise on short, intermediate and long-term bases. The ERM Committee, a group comprised of members of senior management, meet on a regular basis to oversee the performance of these risk management functions. We assess risks using a probability-magnitude lens, with shorter and intermediate term risks generally given greater weight. We prioritize mitigating activities on shorter and intermediate term risks, but also use risk analyses and oversight to proactively incorporate mitigating activities into our long-term strategy. The ERM process reflects a Company-wide effort designed to identify, assess, manage, report and monitor enterprise risks and risk areas. This effort includes the Company's Enterprise Risk Services (Internal Audit), Sarbanes-Oxley (SOX), Compliance Audit, legal and IT security teams, among others. The identification and evaluation of cybersecurity threats and risks is integrated into this ERM process. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ERM process is incorporated into our disclosure controls and procedures. Representatives of each of our ERM, Internal Audit, legal and compliance teams sit on the Company&#8217;s management Disclosure Committee, which is responsible for, among other things, the design and establishment of disclosure controls and procedures to help ensure the timeliness, accuracy and completeness of corporate disclosure. Our IT security and privacy teams, who are responsible for assessing cybersecurity threats and risks, in turn maintain policies and procedures designed to ensure appropriate escalation of cybersecurity incidents to meet external disclosure requirements. Our Chief Information Officer (CIO) and Chief Information Security Officer (CISO) regularly meet and coordinate with our Chief Privacy Officer (CPO). Each of the CIO, CISO and CPO also advise members of the Disclosure Committee, including our Chief Legal and Public Affairs Officer (CLO), on disclosure matters on an as-needed basis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to assessing privacy, data and cybersecurity risks, the Company adopts a hybrid approach that primarily aligns with the National Institute of Standards and Technology (NIST) Cybersecurity Framework, including the guidance set </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forth in the NIST HIPAA Security Rule Cybersecurity Guide, while also evaluating against certain elements of the ISO 27001 and 27005 standards that management believes provide additional levels of guidance or structure. We regularly evaluate the Company&#8217;s cybersecurity and privacy processes and procedures, both through regular audits by our Internal Audit and IT security teams, as well as regular retention of outside advisors under direction of our IT security team. Among other things, the IT security team oversees an external third party review at least every two years that evaluates the readiness of the entire Company against the NIST Cybersecurity Framework and provides an assessment that measures Capability Maturity Model Integration levels. Additionally, our CISO engages in regular consultations, typically monthly, with third-party cybersecurity advisors. Among other things, these sessions provide the Company with a broader review of the external cybersecurity environment, helping us to stay current on emerging or developing security approaches and risks. Among other initiatives, our CISO and the Company&#8217;s IT security team actively participate in industry conferences and maintain memberships to resources such as the Health Information Sharing and Analysis Center (Health-ISAC), a trusted community of critical infrastructure owners and operators within the Health Care and Public Health sector which, among other things, allows the Company to monitor email updates and alerts coordinated with the U.S. Department of Homeland Security&#8217;s Cybersecurity and Infrastructure Security Agency. In order to maintain awareness of privacy, data and cybersecurity risks, the Company incorporates these topics into its annual compliance training materials that are mandatory for all teammates and new hires, and among other things cover HIPAA privacy and security requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and have established processes involving our IT security, privacy and legal teams that assess potential cybersecurity risks associated with our retention and use of third-party service providers. These policies and procedures are generally aligned with the NIST Cybersecurity Framework. Prior to retaining or renewing a third-party vendor, the Company policy requires a risk assessment of such potential new vendor or new engagement through a collaborative process among the Company&#8217;s IT security, privacy, insurance and legal teams, among others. Potential vendor engagements also are reviewed to assess a range of other considerations and contractual terms and conditions, including, among other things, a potential vendor&#8217;s liability insurance limits, scope and coverage of cyber insurance and privacy data protections. Our IT SOX team also conducts annual SOX reviews for those vendors that are considered in scope for SOX controls. All finalized vendor engagements are considered by Internal Audit as part of our ordinary course risk assessment and audit planning.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage risks to our Company, including information and security risks, our Board oversees our enterprise-wide approach to risk management with a fundamental belief that the key components of risk management are:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identifying potential risks that we face;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assessing the likelihood and potential impact of the risks;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adopting strategies and controls designed to manage the risks;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reporting on a regular basis regarding the assessment and management of the risks; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Monitoring these potential risks on a regular basis; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluating whether there are new potential risks to assess.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Enterprise Risk Management (ERM) process, the Company evaluates risks to the enterprise on short, intermediate and long-term bases. The ERM Committee, a group comprised of members of senior management, meet on a regular basis to oversee the performance of these risk management functions. We assess risks using a probability-magnitude lens, with shorter and intermediate term risks generally given greater weight. We prioritize mitigating activities on shorter and intermediate term risks, but also use risk analyses and oversight to proactively incorporate mitigating activities into our long-term strategy. The ERM process reflects a Company-wide effort designed to identify, assess, manage, report and monitor enterprise risks and risk areas. This effort includes the Company's Enterprise Risk Services (Internal Audit), Sarbanes-Oxley (SOX), Compliance Audit, legal and IT security teams, among others. The identification and evaluation of cybersecurity threats and risks is integrated into this ERM process. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ERM process is incorporated into our disclosure controls and procedures. Representatives of each of our ERM, Internal Audit, legal and compliance teams sit on the Company&#8217;s management Disclosure Committee, which is responsible for, among other things, the design and establishment of disclosure controls and procedures to help ensure the timeliness, accuracy and completeness of corporate disclosure. Our IT security and privacy teams, who are responsible for assessing cybersecurity threats and risks, in turn maintain policies and procedures designed to ensure appropriate escalation of cybersecurity incidents to meet external disclosure requirements. Our Chief Information Officer (CIO) and Chief Information Security Officer (CISO) regularly meet and coordinate with our Chief Privacy Officer (CPO). Each of the CIO, CISO and CPO also advise members of the Disclosure Committee, including our Chief Legal and Public Affairs Officer (CLO), on disclosure matters on an as-needed basis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to assessing privacy, data and cybersecurity risks, the Company adopts a hybrid approach that primarily aligns with the National Institute of Standards and Technology (NIST) Cybersecurity Framework, including the guidance set </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forth in the NIST HIPAA Security Rule Cybersecurity Guide, while also evaluating against certain elements of the ISO 27001 and 27005 standards that management believes provide additional levels of guidance or structure. We regularly evaluate the Company&#8217;s cybersecurity and privacy processes and procedures, both through regular audits by our Internal Audit and IT security teams, as well as regular retention of outside advisors under direction of our IT security team. Among other things, the IT security team oversees an external third party review at least every two years that evaluates the readiness of the entire Company against the NIST Cybersecurity Framework and provides an assessment that measures Capability Maturity Model Integration levels. Additionally, our CISO engages in regular consultations, typically monthly, with third-party cybersecurity advisors. Among other things, these sessions provide the Company with a broader review of the external cybersecurity environment, helping us to stay current on emerging or developing security approaches and risks. Among other initiatives, our CISO and the Company&#8217;s IT security team actively participate in industry conferences and maintain memberships to resources such as the Health Information Sharing and Analysis Center (Health-ISAC), a trusted community of critical infrastructure owners and operators within the Health Care and Public Health sector which, among other things, allows the Company to monitor email updates and alerts coordinated with the U.S. Department of Homeland Security&#8217;s Cybersecurity and Infrastructure Security Agency. In order to maintain awareness of privacy, data and cybersecurity risks, the Company incorporates these topics into its annual compliance training materials that are mandatory for all teammates and new hires, and among other things cover HIPAA privacy and security requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and have established processes involving our IT security, privacy and legal teams that assess potential cybersecurity risks associated with our retention and use of third-party service providers. These policies and procedures are generally aligned with the NIST Cybersecurity Framework. Prior to retaining or renewing a third-party vendor, the Company policy requires a risk assessment of such potential new vendor or new engagement through a collaborative process among the Company&#8217;s IT security, privacy, insurance and legal teams, among others. Potential vendor engagements also are reviewed to assess a range of other considerations and contractual terms and conditions, including, among other things, a potential vendor&#8217;s liability insurance limits, scope and coverage of cyber insurance and privacy data protections. Our IT SOX team also conducts annual SOX reviews for those vendors that are considered in scope for SOX controls. All finalized vendor engagements are considered by Internal Audit as part of our ordinary course risk assessment and audit planning.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity Risks and the Impact on our Company</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the continuously evolving series of laws and regulations related to cybersecurity, data protection and privacy that are applicable to our business, as well as the associated risks from cybersecurity threats, we have expended significant resources in order to protect our information systems and data. We regularly review, monitor and implement multiple layers of security measures through technology, processes and our people. We utilize security technologies designed to protect and maintain the integrity of our information systems and data, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses and other malicious code; coordinated attacks by a variety of actors, including, among others, activist entities or state sponsored cyberattacks; emerging cybersecurity risks; cyber risk related to connected devices; misplaced or lost data; programming and/or human errors; or other similar events that could impact the security, reliability and availability of our systems. Internal or external parties have attempted to, and will continue to attempt to, circumvent our security systems, and we have in the past, and expect that we will in the future, defend against, experience, and respond to attacks on our network including, without limitation, reconnaissance probes, denial of service attempts, malicious software attacks including ransomware or other attacks intended to render our internal operating systems or data unavailable, and phishing attacks or business email compromise. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have experienced cybersecurity incidents in the past, to date none have had a material impact on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity requires ongoing investment and diligence against evolving threats and in the context of new or developing technologies. For further information regarding the risks we face from cybersecurity threats and how our business strategy, results of operations, and financial condition could be materially affected by such risks, see Part I Item IA. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and information security laws are complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8230;".</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board Oversight</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its oversight responsibilities, the Audit Committee monitors privacy, data and cybersecurity as specific risk areas. The Audit Committee also works with the Compliance and Quality Committee to oversee enterprise risks with healthcare and anti-corruption requirements, and those requirements include certain privacy, data and cybersecurity aspects. Both Mr. Schechter, a member of the Audit Committee, and Ms. Schoppert, a member of the Audit Committee, hold a CERT Certificate in Cybersecurity Oversight. The Audit Committee engages in regular discussions with management on privacy, data, and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cybersecurity risk exposures, receiving quarterly reports from the ERM team and the CIO. On a periodic basis, the full Board of Directors also receives these reports from the ERM team and the CIO. The CPO and/or CLO periodically reports to the Audit Committee about the Company&#8217;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, the Company&#8217;s privacy team actively develops and implements policies designed to comply with the requirements of privacy laws in the countries where the Company operates. Working with Internal Audit and the CIO, the privacy team assesses the nature and potential severity of privacy risks within DaVita and guides the organization in taking steps to help mitigate such risks. The Audit Committee also oversees the Company's negotiation of any cybersecurity insurance. Currently, the Company maintains a cybersecurity risk insurance policy providing coverage for certain cybersecurity breaches among other specified risks.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The ERM Committee, a group comprised of members of senior management, meet on a regular basis to oversee the performance of these risk management functions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee engages in regular discussions with management on privacy, data, and <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cybersecurity risk exposures, receiving quarterly reports from the ERM team and the CIO. On a periodic basis, the full Board of Directors also receives these reports from the ERM team and the CIO. The CPO and/or CLO periodically reports to the Audit Committee about the Company&#8217;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, our IT security team, in consultation with our privacy team, is primarily responsible for frontline assessments and management of day-to-day risks from cybersecurity threats, including the monitoring and detection of cybersecurity incidents and the execution of DaVita's cybersecurity and privacy incident response plans, as needed. Pursuant to the plan, the teams are responsible for assessing and classifying cybersecurity incidents and coordinating the response to such incidents, including managing both internal and external reporting obligations and remediation efforts. Our key personnel responsible for privacy and cybersecurity expertise include our CIO, CISO and CPO. Their qualifications include expertise in international privacy laws, compliance, global IT strategy, and security responsibilities, helping to ensure a comprehensive approach to risk management. Our CISO has more than two decades of experience in information technology risk and compliance and holds a Certified Chief Information Security Officer certification from EC-Council, a Certified Information Security Manager certification from ISACA and a certification from the Massachusetts Institute of Technology on AI management in healthcare. Our CPO is a Certified Information Privacy Professional and a Certified Compliance and Ethics Professional, and has more than two decades of experience in creating and implementing privacy and data protection programs that enable multinational organizations to respect and protect personal data and execute mission critical business strategies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IT security team also operates a 24x7 security operations center through a managed service provider. This dedicated center, alongside active monitoring of the dark web for DaVita-related data, and our use of both internal and external tools, is designed to ensure proactive detection, prevention and remediation of cybersecurity incidents. We inform and develop this integrated approach through our ongoing internal and external evaluations and risk assessments of our IT security program as described above.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The Audit Committee engages in regular discussions with management on privacy, data, and <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cybersecurity risk exposures, receiving quarterly reports from the ERM team and the CIO. On a periodic basis, the full Board of Directors also receives these reports from the ERM team and the CIO. The CPO and/or CLO periodically reports to the Audit Committee about the Company&#8217;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our key personnel responsible for privacy and cybersecurity expertise include our CIO, CISO and CPO. Their qualifications include expertise in international privacy laws, compliance, global IT strategy, and security responsibilities, helping to ensure a comprehensive approach to risk management. Our CISO has more than two decades of experience in information technology risk and compliance and holds a Certified Chief Information Security Officer certification from EC-Council, a Certified Information Security Manager certification from ISACA and a certification from the Massachusetts Institute of Technology on AI management in healthcare. Our CPO is a Certified Information Privacy Professional and a Certified Compliance and Ethics Professional, and has more than two decades of experience in creating and implementing privacy and data protection programs that enable multinational organizations to respect and protect personal data and execute mission critical business strategies.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The CPO and/or CLO periodically reports to the Audit Committee about the Company&#8217;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237191440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#8217;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#8217;s international subsidiaries from their functional currencies into the Company&#8217;s reporting currency (the U.S. dollar, or USD).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, certain fair value estimates, accounting for income taxes and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock', window );">Patient service net revenues and accounts receivable</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis patient service revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized based on the Company&#8217;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's revenues are paid from government programs, principally Medicare, Medicare Advantage and Medicaid. Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare&#8217;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#8217;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#8217;s base payment rate as well as these other variable factors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues earned under government programs are subject to significant estimating risk, as they can be subject to adjustment as a result of examination by government agencies or contractors, differing interpretations of applicable regulations by different Medicare contractors or regulatory authorities, differing opinions regarding a patient's diagnosis or the medical necessity of patient services, or retroactive applications or interpretations of governmental requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to government programs, the Company also earns revenues that are paid by commercial health plans. Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#8217;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#8217;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#8217;s usual and customary rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, there are significant risks associated with estimating dialysis patient service revenue, whether paid from governmental or commercial sources, many of which take several years to resolve. These estimates are subject to examinations by or differing interpretations among government contractors or agencies or other regulatory authorities, retroactive application of interpretations, commercial insurance coverage changes, geographic coverage differences, differing interpretations of commercial contract coverage and other payor- and patient-specific issues, including determination of applicable primary and secondary coverage, changes in patient insurance coverage and coordination of benefits. As the Company's revenue estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OtherNonoperatingIncomeExpensePolicyTextBlock', window );">Other income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (loss) income, net</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash and equivalents</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash and equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in debt and equity securities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in debt and equity securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#8217;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes expenditures to purchase property and equipment, improvements thereon, leasehold improvements, and qualifying software costs, as well as costs to replace, extend the life of or improve the functionality of existing capital assets, where such purchases and costs have an expected benefit period of more than one year. All other expenditures related to capital assets are expensed as incurred (i.e., as repairs and maintenance expense).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Amortizable intangibles</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortizable intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Indefinite-lived intangibles</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity investments and other investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method and other investments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates multiple reporting units. The Company's annual impairment assessment is performed in the third quarter for its U.S. dialysis reporting unit and at various points throughout the year for its other reporting units. In addition to these annual impairment assessments, the Company performs impairment assessments at intervening periods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when a reporting unit is considered at risk of significant goodwill impairment.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing these assessments, the Company may first assess goodwill for impairment qualitatively as determined appropriate. If goodwill is more likely than not impaired, the Company is required to perform a quantitative assessment. When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm, which consider both discounted cash flow estimates for the subject business and observed market multiples for similar businesses, or recent good-faith offer prices received for the subject business that would be acceptable to the Company. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value after taking into account the effect of deferred taxes arising from the impairment. See Note 9 for further details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_InsuranceAndSelfInsurancePolicyTextBlock', window );">Self insurance</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-insurance</span></div>The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#8217; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation to be settled in shares is recorded to the Company&#8217;s shareholders&#8217; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Interest rate swap and cap agreements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling interests</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests represent third-party equity interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2024, third parties held direct or indirect noncontrolling equity interests in 728 consolidated legal entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests subject to put provisions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#8217; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#8217;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#8217; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#8217; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting standards</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New accounting standards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards recently adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment&#8217;s performance. The amendments in this ASU became effective for the Company beginning January 1, 2024. See Note 24 for further discussion of the Company's reportable segments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards not yet adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company intends to adopt this ASU for the fiscal year ended December 31, 2025 and is still assessing the effect this guidance may have on its consolidated financial statement disclosures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which requires disaggregated disclosure of income statement expenses, including purchases of inventory, employee compensation, depreciation, and amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this ASU are effective for fiscal years beginning after December 15, 2026. The amendments in this ASU may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term and long-term investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. Typically, the Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2024 and 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#8217;s non-qualified deferred compensation plans.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive (Loss) Income</a></td>
<td class="text">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, non-U.S. subsidiaries that are structurally dependent on subordinated debt, or other legal entities subject to nominee ownership arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#8217;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#8217;s economic performance, the obligation to absorb the entity&#8217;s expected losses, or the right to receive the entity&#8217;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#8217;s losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_InsuranceAndSelfInsurancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance and self insurance policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_InsuranceAndSelfInsurancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OtherNonoperatingIncomeExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income (expense), policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OtherNonoperatingIncomeExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition and accounts receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043239820784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues by segment and primary payor source were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,374,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,374,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,783,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,815,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,874,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,848,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,660,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097,120&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246663472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed incremental from stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.02&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock-settled awards excluded from calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246674208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term and long-term invesmtents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit and other time deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in mutual funds and common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,906&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,064&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,610&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246680400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfOtherReceivablesTableTextBlock', window );">Schedule of Other Receivables</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"><tr><td style="width:1.0%"></td><td style="width:56.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare bad debt claims</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IKC risk-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier rebates and non-trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfOtherReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of claims held for amounts due to an entity. Examples include non-trade receivables and Medicare bad debt claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfOtherReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241171184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,180,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and information systems, including internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New center and capital asset projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,203,619&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,833,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,262,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,759,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073,533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246636768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets other than Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"><tr><td style="width:1.0%"></td><td style="width:59.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,431&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Scheduled Amortization Charges from Intangible Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2024 were as follows:&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:37.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncompetition<br/>agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Customer relationships and other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Finite And Indefinite Intangible Assets Table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043242768496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investmetns Equity Method and Other Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:56.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mozarc Medical Holding LLC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity method partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost method and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,684&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246647424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Changes in Carrying Value of Goodwill by Reportable Segments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill by reportable segment were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:40.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary<br/>services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,112,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,987&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,069&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,517,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,375,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,517,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,517,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,517,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,996&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,375,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043240449760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Schedule of Other Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"><tr><td style="width:1.0%"></td><td style="width:51.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor refunds and retractions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance and self-insurance accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043244519568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes from continuing operations consisted of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:37.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Expense (Benefit)</a></td>
<td class="text">Income tax expense for continuing operations consisted of the following:<div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:46.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,790)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,332)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,656&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between U.S. Federal Income Tax Rate and Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company&#8217;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:46.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Political advocacy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in international valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests primarily<br/>&#160;attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities Arising from Temporary Differences</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:60.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(757,797)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(731,024)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(464,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486,864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,035)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,352,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,452,116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619,108)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691,780)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726,217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other long-term assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 25.75pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619,108)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691,780)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:61.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to lapse of applicable statute</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,484&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,379&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241776672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt comprised the following:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:39.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan A-1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,259,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,234,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4/28/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Base +1.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,256,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan B-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,603,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Extended Term Loan B-1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,636,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5/9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR + 2.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,638,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4/28/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Base +1.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6/1/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,533,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75% Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2/15/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,301,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.875% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/1/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,007,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisition obligations and other notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025-2038</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">216,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">255,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">CHC temporary funding assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">92,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">92,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total debt principal outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,511,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,445,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Discount, premium and deferred financing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(64,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(54,347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,446,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,391,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(270,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(123,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,175,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,268,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the Company's senior secured credit facilities, fair value estimates are based on bid and ask quotes, a level 2 input. For the Company's senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. For the CHC temporary funding assistance, the carrying value presented here approximates the estimated fair value based on the short-term nature of settlement.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company's senior secured credit facilities bear interest at Term SOFR, plus an interest rate margin, with certain portions also subject to a credit spread adjustment (CSA). Term SOFR plus CSA is referred to as "Base" in the table above. The Term Loan A-1 and revolving line of credit bear a CSA of 0.10%.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2024.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Change Healthcare (CHC) temporary funding assistance, as described below, is interest-free and amounts provided under this program are subject to repayment at a future date to be mutually agreed to by the parties. The balance is included in the Company's current portion of long-term debt as of December&#160;31, 2024.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2024, the carrying amount of the Company's senior secured credit facilities has been reduced by a discount of $8,084 and deferred financing costs of $28,879, and the carrying amount of the Company's senior notes has been reduced by deferred financing costs of $37,612 and increased by a debt premium of $10,239. As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $2,487 and deferred financing costs of $32,498, and the carrying amounts of the Company's senior notes was reduced by deferred financing costs of $31,491 and increased by a debt premium of $12,129.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Scheduled Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of long-term debt at December&#160;31, 2024 were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"><tr><td style="width:1.0%"></td><td style="width:58.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">202,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2028</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,922,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2029</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,900,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s interest rate cap agreements outstanding as of December&#160;31, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount effective<br/>through December 31 unless noted</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year cap agreements executed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial notional amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SOFR maximum rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate effective date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td></tr><tr><td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional coverage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000</span></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average strike rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.58&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective January&#160;1, 2025, the maximum rate of 4.00% decreased to 3.75% for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective January&#160;1, 2025, the maximum rate of 4.75% decreased to 4.00% for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective January&#160;1, 2025, the maximum rate of 5.00% decreased to 4.50% for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective December&#160;31, 2026, the maximum rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.50%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for these interest rate caps.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Effective December&#160;31, 2026, the maximum rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increases to 4.25% for these interest rate caps.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Effects of Interest Rate Swap and Cap Agreements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of the Company&#8217;s interest rate cap agreements for the years ended December&#160;31, 2024, 2023 and 2022:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.536%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location in Consolidated Statements of Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification from accumulated other comprehensive income into net income</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1334">Debt expense</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,175)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1341">Related income tax</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043240237888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Expense Components</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span>Includes short-term lease expense and sublease income, which are immaterial.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeaseOtherInformationTableTextBlockTableTextBlock', window );">Lease Other Information</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease term and discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sale leasebacks, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the <br/>&#160;measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease assets obtained in exchange<br/>&#160;for new or modified operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfMinimumLeasePaymentsTextBlock', window );">Schedule Of Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2024 are as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:52.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,038,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less portion representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418,840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1481"><span style="-sec-ix-hidden:f-1482">Present value of lease liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeaseOtherInformationTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Other Information in tabular disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeaseOtherInformationTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfMinimumLeasePaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of minimum lease payments under non-cancelable operating leases and capital leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfMinimumLeasePaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237490256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation and Shareholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company&#8217;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:37.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock appreciation rights</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Added by performance factor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(628)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.02&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.48&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of grants:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.61&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Range of Exercise Prices</a></td>
<td class="text"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:28.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.438%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards Outstanding</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards exercisable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of SSARs base prices</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.01&#8211;$80.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01&#8211;$110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110.01&#8211;$120.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Valuation Inputs</a></td>
<td class="text">A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted during the year end December&#160;31, 2022 were as follows:<div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.181%"><tr><td style="width:1.0%"></td><td style="width:67.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241176880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Shares repurchases summary table</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:38.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open market repurchases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#8217; equity.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes commissions and the excise tax described above.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock', window );">Net effect of transfers from to noncontrolling interests on stock holders equity disclosure</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries on the Company&#8217;s consolidated equity were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:52.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in paid-in capital for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,611)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc. net of transfers in <br/>&#160;noncontrolling interests</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,753&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246699728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in Other Comprehensive (Loss) Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and credits to other comprehensive (loss) income have been as follows:&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"></td><td style="width:40.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">cap agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined benefit plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other<br/>comprehensive<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,069)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,554)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,802)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,867&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167,871)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,186)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,937)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,084)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,662&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207,906)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198,198)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207,861)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,175)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,252)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,660)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,487)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,147)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,557)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,285)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310,796)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241183312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock', window );">Schedule of Components of Routine Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, 2023 and 2022, the Company acquired other dialysis and related businesses for consideration paid in cash. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of these other international and routine transactions in 2024, the Company acquired a controlling interest in a previously nonconsolidated U.S. dialysis partnership for which it recognized a non-cash gain of $35,147 on its prior investment upon consolidation. The Company estimated the fair value of its previously held equity interest in this business using appraisals developed with independent third party valuation firms.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aggregate consideration &#8211; DVC and all other acquisitions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate consideration for both the DaVita Care Pte. Ltd. acquisition and all other international and routine acquisitions described above has been as follows:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"></td><td style="width:54.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent purchase price and liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,841&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; International</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Aggregate Purchase Cost Allocations for Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"></td><td style="width:52.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use lease assets and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,081)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock', window );">Schedule of other information related to acquired intangibles and goodwill</a></td>
<td class="text">The amount of goodwill related to these acquisitions recognized or adjusted in 2024, 2023 and 2022 that is deductible for local tax purposes was $54,810, $17,836 and $49,047, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Pro Forma Summary of Results of Operations</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions in 2024 and 2023 had been consummated as of the beginning of 2023, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:62.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,073,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,625,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other information related to acquisitions, including weighted-average estimated useful lives of intangible assets acquired, and goodwill deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043242686432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,062&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,062&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,805&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,805&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043240453520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of segment revenues, segment operating margin, and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,294,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,823,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,366,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911,747&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,575,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,390,717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external sources</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,901,207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,236,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,701,135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,815,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant segment expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,394,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,334,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,417)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis segment expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,269,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,162,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203,664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,047)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt prepayment, extinguishment and modification costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other segment items for our U.S. dialysis segment include equity income from nonconsolidated joint ventures and a gain on changes in ownership interest.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating margin (loss) for Other - Ancillary services includes equity investment loss of $1,701, $2,103 and $1,898 in 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Summary of Depreciation and Amortization Expense by Segment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723,860&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock', window );">Summary of Expenditures for Property and Equipment by Segment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for property and equipment by reportable segment were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of capital expenditures for property and equipment from segment to consolidated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241170432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides supplemental cash flow information:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"></td><td style="width:49.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets under financing lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238498224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>patient </div>
<div>entity </div>
<div>country </div>
<div>clinic </div>
<div>state</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor', window );">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests', window );">Number of legal entities that third parties held noncontrolling equity interests | entity</a></td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfSites', window );">Number of dialysis centers that the company operated or provided administrative services | clinic</a></td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states where dialysis centers are located | state</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfCustomers', window );">Number of patients served | patient</a></td>
<td class="nump">200,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=dva_InternationalOperationsMember', window );">International Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfSites', window );">Number of dialysis centers that the company operated or provided administrative services | clinic</a></td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfCustomers', window );">Number of patients served | patient</a></td>
<td class="nump">80,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which dialysis centers located | country</a></td>
<td class="nump">13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entities that third parties held non controlling equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfSites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of sites.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfSites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=dva_InternationalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=dva_InternationalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043247209888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">$ 555,175<span></span>
</td>
<td class="nump">$ 565,206<span></span>
</td>
<td class="nump">$ 433,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TotalRevenueNetOfIntersegmentRevenue', window );">Total revenue net of intersegment revenue</a></td>
<td class="nump">$ 12,815,550<span></span>
</td>
<td class="nump">$ 12,140,147<span></span>
</td>
<td class="nump">11,609,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue', window );">Percentage Of Accounts Receivable Six Months Or More Past Due</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EliminationsOfIntersegmentRevenues', window );">Eliminations of intersegment revenues</a></td>
<td class="num">$ (85,657)<span></span>
</td>
<td class="num">$ (96,074)<span></span>
</td>
<td class="num">(91,241)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareandMedicareAdvantageMember', window );">Medicare and Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">6,374,882<span></span>
</td>
<td class="nump">6,100,183<span></span>
</td>
<td class="nump">6,041,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">463,731<span></span>
</td>
<td class="nump">460,991<span></span>
</td>
<td class="nump">345,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicaidandManagedMedicaidMember', window );">Medicaid and Managed Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">863,947<span></span>
</td>
<td class="nump">833,744<span></span>
</td>
<td class="nump">759,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherGovernmentPayorsMember', window );">Other Government Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">1,061,440<span></span>
</td>
<td class="nump">854,441<span></span>
</td>
<td class="nump">801,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_CommercialPayorsMember', window );">Commercial Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">4,031,853<span></span>
</td>
<td class="nump">3,874,795<span></span>
</td>
<td class="nump">3,660,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">21,396<span></span>
</td>
<td class="nump">32,329<span></span>
</td>
<td class="nump">22,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherSourcesofRevenueMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">83,218<span></span>
</td>
<td class="nump">78,005<span></span>
</td>
<td class="nump">68,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TotalRevenueNetOfIntersegmentRevenue', window );">Total revenue net of intersegment revenue</a></td>
<td class="nump">11,318,970<span></span>
</td>
<td class="nump">10,848,776<span></span>
</td>
<td class="nump">10,512,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EliminationsOfIntersegmentRevenues', window );">Eliminations of intersegment revenues</a></td>
<td class="num">(71,747)<span></span>
</td>
<td class="num">(88,222)<span></span>
</td>
<td class="num">(87,035)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Medicare and Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">6,374,882<span></span>
</td>
<td class="nump">6,100,183<span></span>
</td>
<td class="nump">6,041,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Medicaid and Managed Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">863,947<span></span>
</td>
<td class="nump">833,744<span></span>
</td>
<td class="nump">759,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Other Government Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">343,705<span></span>
</td>
<td class="nump">354,304<span></span>
</td>
<td class="nump">336,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Commercial Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">3,783,827<span></span>
</td>
<td class="nump">3,623,516<span></span>
</td>
<td class="nump">3,437,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">24,356<span></span>
</td>
<td class="nump">25,251<span></span>
</td>
<td class="nump">24,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TotalRevenueNetOfIntersegmentRevenue', window );">Total revenue net of intersegment revenue</a></td>
<td class="nump">1,496,580<span></span>
</td>
<td class="nump">1,291,371<span></span>
</td>
<td class="nump">1,097,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EliminationsOfIntersegmentRevenues', window );">Eliminations of intersegment revenues</a></td>
<td class="num">(13,910)<span></span>
</td>
<td class="num">(7,852)<span></span>
</td>
<td class="num">(4,206)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Medicare and Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">463,731<span></span>
</td>
<td class="nump">460,991<span></span>
</td>
<td class="nump">345,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Medicaid and Managed Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Other Government Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">717,735<span></span>
</td>
<td class="nump">500,137<span></span>
</td>
<td class="nump">464,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Commercial Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">248,026<span></span>
</td>
<td class="nump">251,279<span></span>
</td>
<td class="nump">223,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">21,396<span></span>
</td>
<td class="nump">32,329<span></span>
</td>
<td class="nump">22,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">$ 58,862<span></span>
</td>
<td class="nump">$ 52,754<span></span>
</td>
<td class="nump">$ 44,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EliminationsOfIntersegmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Eliminations of intersegment revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EliminationsOfIntersegmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Accounts Receivable , 6 months or More Past Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TotalRevenueNetOfIntersegmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total revenue net of intersegment revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TotalRevenueNetOfIntersegmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareandMedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareandMedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicaidandManagedMedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicaidandManagedMedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherGovernmentPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherGovernmentPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_CommercialPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_CommercialPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherSourcesofRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherSourcesofRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043247201376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Accounts Receivable - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 2,146,975<span></span>
</td>
<td class="nump">$ 1,986,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Contract with Customer, Performance Obligation Satisfied in Previous Period</a></td>
<td class="nump">116,336<span></span>
</td>
<td class="nump">94,361<span></span>
</td>
<td class="nump">$ 34,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareMember', window );">Medicare bad debt claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">833,464<span></span>
</td>
<td class="nump">$ 817,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue', window );">Percentage Of Accounts Receivable Six Months Or More Past Due</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AccountsReceivablePeriodOutstanding', window );">Accounts Receivable Period Outstanding</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue', window );">Accounts Receivable, Noncurrent, Threshold Period Past Due</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfConcentrationRiskCustomers', window );">Number of concentration risk customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AccountsReceivablePeriodOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patient accounts receivable months outstanding to be reserved per company policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AccountsReceivablePeriodOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfConcentrationRiskCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Concentration Risk Customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfConcentrationRiskCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Accounts Receivable , 6 months or More Past Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period for when accounts receivable, classified as noncurrent, is considered past due, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes threshold period past due to write off as uncollectible.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237475008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net income attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">$ 936,342<span></span>
</td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 546,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,452<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to DaVita Inc.</a></td>
<td class="nump">$ 936,342<span></span>
</td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average shares outstanding during the period (in shares)</a></td>
<td class="nump">84,991,000<span></span>
</td>
<td class="nump">90,790,000<span></span>
</td>
<td class="nump">92,992,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Assumed incremental shares from stock plans (in shares)</a></td>
<td class="nump">2,283,000<span></span>
</td>
<td class="nump">2,392,000<span></span>
</td>
<td class="nump">2,842,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares - diluted (in shares)</a></td>
<td class="nump">87,274,000<span></span>
</td>
<td class="nump">93,182,000<span></span>
</td>
<td class="nump">95,834,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net income attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income from continuing operations</a></td>
<td class="nump">$ 11.02<span></span>
</td>
<td class="nump">$ 7.62<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic net income from discontinued operations per share attributable to DaVita Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share attributable to DaVita Inc.</a></td>
<td class="nump">11.02<span></span>
</td>
<td class="nump">7.62<span></span>
</td>
<td class="nump">6.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net income attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income from continuing operations per share attributable to DaVita Inc.</a></td>
<td class="nump">10.73<span></span>
</td>
<td class="nump">7.42<span></span>
</td>
<td class="nump">5.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Diluted net income from discontinued operations per share attributable to DaVita Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share attributable to DaVita Inc.</a></td>
<td class="nump">$ 10.73<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock-settled awards excluded from calculation (in shares)</a></td>
<td class="nump">103,000<span></span>
</td>
<td class="nump">531,000<span></span>
</td>
<td class="nump">1,058,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043239406256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term and long-term investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities</a></td>
<td class="nump">$ 44,158<span></span>
</td>
<td class="nump">$ 22,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">40,566<span></span>
</td>
<td class="nump">37,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">84,724<span></span>
</td>
<td class="nump">59,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Debt securities, short-term investments</a></td>
<td class="nump">44,158<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total Short-term investments</a></td>
<td class="nump">51,064<span></span>
</td>
<td class="nump">11,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Debt securities, long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Total Long-term investments</a></td>
<td class="nump">33,660<span></span>
</td>
<td class="nump">47,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity Securities, FV-NI</a></td>
<td class="nump">40,566<span></span>
</td>
<td class="nump">37,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember', window );">Certificates of deposit and other time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities</a></td>
<td class="nump">44,158<span></span>
</td>
<td class="nump">22,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">44,158<span></span>
</td>
<td class="nump">22,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dva_MutualFundsAndCommonStockMember', window );">Investments in mutual funds and common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">40,566<span></span>
</td>
<td class="nump">37,391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">40,566<span></span>
</td>
<td class="nump">37,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">6,906<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Other long-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity Securities, FV-NI, Noncurrent</a></td>
<td class="nump">$ 33,660<span></span>
</td>
<td class="nump">$ 32,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478297/946-220-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dva_MutualFundsAndCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dva_MutualFundsAndCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043242832928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">$ 383,166<span></span>
</td>
<td class="nump">$ 422,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_SupplierRebatesAndOtherNonTradeReceivablesMember', window );">Supplier rebates and non-trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">132,095<span></span>
</td>
<td class="nump">187,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_MedicareMember', window );">Medicare bad debt claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">107,129<span></span>
</td>
<td class="nump">107,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_IKCVBCArrangementsMember', window );">IKC VBC arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">$ 143,942<span></span>
</td>
<td class="nump">$ 127,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_SupplierRebatesAndOtherNonTradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_SupplierRebatesAndOtherNonTradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_IKCVBCArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_IKCVBCArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238045120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 50,172<span></span>
</td>
<td class="nump">$ 35,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">428,994<span></span>
</td>
<td class="nump">436,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">4,180,747<span></span>
</td>
<td class="nump">4,058,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Equipment and information systems, including internally developed software</a></td>
<td class="nump">4,410,395<span></span>
</td>
<td class="nump">4,125,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">New center and capital asset projects in progress</a></td>
<td class="nump">133,311<span></span>
</td>
<td class="nump">177,149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross, total</a></td>
<td class="nump">9,203,619<span></span>
</td>
<td class="nump">8,833,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(6,262,703)<span></span>
</td>
<td class="num">(5,759,514)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 2,940,916<span></span>
</td>
<td class="nump">$ 3,073,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237127120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense on property and equipment</a></td>
<td class="nump">$ 716,396<span></span>
</td>
<td class="nump">$ 736,474<span></span>
</td>
<td class="nump">$ 721,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Capitalized interest</a></td>
<td class="nump">$ 7,978<span></span>
</td>
<td class="nump">$ 9,178<span></span>
</td>
<td class="nump">$ 12,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment and Information Systems | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment and Information Systems | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043236999296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived licenses</a></td>
<td class="nump">$ 146,025<span></span>
</td>
<td class="nump">$ 153,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedNoncompeteAgreementsGross', window );">Noncompetition agreements</a></td>
<td class="nump">22,234<span></span>
</td>
<td class="nump">31,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Customer relationships and other</a></td>
<td class="nump">61,580<span></span>
</td>
<td class="nump">56,596<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross (excluding goodwill)</a></td>
<td class="nump">229,839<span></span>
</td>
<td class="nump">241,669<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets Net</a></td>
<td class="nump">197,431<span></span>
</td>
<td class="nump">203,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(13,982)<span></span>
</td>
<td class="num">(23,680)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember', window );">Customer relationships and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (18,426)<span></span>
</td>
<td class="num">$ (14,765)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedNoncompeteAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedNoncompeteAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238521840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ExpectedAmortizationExpenseLineItems', window );"><strong>Expected Amortization Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">8,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember', window );">Customer relationships and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ExpectedAmortizationExpenseLineItems', window );"><strong>Expected Amortization Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">4,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">4,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">3,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">3,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">3,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">23,641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 43,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ExpectedAmortizationExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Amortization Expense [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ExpectedAmortizationExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238176336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense from amortizable intangible assets, other than lease agreements</a></td>
<td class="nump">$ 7,464<span></span>
</td>
<td class="nump">$ 8,969<span></span>
</td>
<td class="nump">$ 11,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension', window );">Acquired Finite-lived Intangible Asset, Weighted-Average Period before Renewal or Extension</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period before the next renewal or extension for intangible assets with renewal or extension terms, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043245710096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Method and Other Investmetns Equity Method and Other Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,684<span></span>
</td>
<td class="nump">$ 545,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dva_AgreementWithMedtronicMember', window );">Mozarc Medical Holding LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessAgreementEffectiveClosingDate', window );">Transaction Agreement Effective Closing Date</a></td>
<td class="text">Apr.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_FairValuePayableOfContingentConsideration', window );">Fair value of Contingent Consideration payable to Medtronic</a></td>
<td class="nump">$ 86,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Cumulative measured cost</a></td>
<td class="nump">$ 370,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dva_AgreementWithMedtronicMember', window );">Mozarc Medical Holding LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,706<span></span>
</td>
<td class="nump">324,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Voting Equity Interest by the Company</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Voting Equity Interest in Mozarc, Owned by Medtronic</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember', window );">APAC joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">98,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Voting Equity Interest by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OwnershipPercentageByNoncontrollingOwners', window );">Current economic interest in the APAC JV, Owned by Other Noncontrolling Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Adjusted cost method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,732<span></span>
</td>
<td class="nump">14,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_OtherOwnershipInterestMember', window );">Other equity method partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,246<span></span>
</td>
<td class="nump">$ 107,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessAgreementEffectiveClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Agreement Effective Closing Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessAgreementEffectiveClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_FairValuePayableOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Payable Of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_FairValuePayableOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership Percentage By Noncontrolling Owners</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dva_AgreementWithMedtronicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dva_AgreementWithMedtronicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dva_AgreementWithMedtronicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dva_AgreementWithMedtronicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_OtherOwnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_OtherOwnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241026352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investments - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="nump">$ 26,189<span></span>
</td>
<td class="nump">$ 27,864<span></span>
</td>
<td class="nump">$ 26,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Company and Restricted Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by the Company</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Company and Restricted Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by the Company</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, significant impairments and other valuation adjustments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeLossFromOtherEquityMethodInvestments', window );">Equity investment income (loss) from other equity method investments</a></td>
<td class="num">(112,696)<span></span>
</td>
<td class="num">(59,508)<span></span>
</td>
<td class="num">(4,703)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember', window );">Equity Method Investments In Nonconsolidated Dialysis Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="nump">$ 26,189<span></span>
</td>
<td class="nump">$ 27,864<span></span>
</td>
<td class="nump">$ 26,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfPartnerships', window );">Number of equity method investments</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncomeLossFromOtherEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Loss From Other Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncomeLossFromOtherEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Partnerships that are included in the Equity Investments category.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dva_ParentCompanyAndRestrictedSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dva_ParentCompanyAndRestrictedSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043242860832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 7,112,560<span></span>
</td>
<td class="nump">$ 7,076,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">349,069<span></span>
</td>
<td class="nump">25,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, Written off Related to Sale of Business Unit</a></td>
<td class="num">(3,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26,083)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency and other adjustments</a></td>
<td class="num">(83,220)<span></span>
</td>
<td class="nump">36,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">7,375,216<span></span>
</td>
<td class="nump">7,112,560<span></span>
</td>
<td class="nump">7,076,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">7,517,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment charges</a></td>
<td class="num">(141,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember', window );">Transplant Software Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">14,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">6,416,825<span></span>
</td>
<td class="nump">6,416,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">102,082<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, Written off Related to Sale of Business Unit</a></td>
<td class="num">(1,687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency and other adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">6,517,220<span></span>
</td>
<td class="nump">6,416,825<span></span>
</td>
<td class="nump">6,416,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">6,517,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">695,735<span></span>
</td>
<td class="nump">659,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">246,987<span></span>
</td>
<td class="nump">25,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, Written off Related to Sale of Business Unit</a></td>
<td class="num">(1,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency and other adjustments</a></td>
<td class="num">(83,220)<span></span>
</td>
<td class="nump">36,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">857,996<span></span>
</td>
<td class="nump">$ 695,735<span></span>
</td>
<td class="nump">$ 659,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">999,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment charges</a></td>
<td class="num">$ (141,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238241936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Schedule of Reporting Units Goodwill Balances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segments</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 7,375,216<span></span>
</td>
<td class="nump">$ 7,112,560<span></span>
</td>
<td class="nump">$ 7,076,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(26,083)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember', window );">Other reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments that were considered at risk of significant goodwill impairment | Segments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember', window );">Transplant Software Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLossNetOfTax', window );">Goodwill, Impairment Loss, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246457104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segments</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember', window );">Other reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments that were considered at risk of significant goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241181376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PayorRefundsAndRetractions', window );">Payor refunds and retractions</a></td>
<td class="nump">$ 484,459<span></span>
</td>
<td class="nump">$ 448,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Insurance and self-insurance accruals</a></td>
<td class="nump">83,038<span></span>
</td>
<td class="nump">74,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">60,541<span></span>
</td>
<td class="nump">35,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued non-income tax liabilities</a></td>
<td class="nump">59,007<span></span>
</td>
<td class="nump">47,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">247,100<span></span>
</td>
<td class="nump">222,647<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">$ 934,145<span></span>
</td>
<td class="nump">$ 828,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PayorRefundsAndRetractions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payor Refunds And Retractions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PayorRefundsAndRetractions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246571120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 1,374,571<span></span>
</td>
<td class="nump">$ 1,100,420<span></span>
</td>
<td class="nump">$ 926,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">155,822<span></span>
</td>
<td class="nump">76,674<span></span>
</td>
<td class="nump">39,674<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="nump">$ 1,530,393<span></span>
</td>
<td class="nump">$ 1,177,094<span></span>
</td>
<td class="nump">$ 966,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241081408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 253,504<span></span>
</td>
<td class="nump">$ 200,070<span></span>
</td>
<td class="nump">$ 201,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">52,410<span></span>
</td>
<td class="nump">38,370<span></span>
</td>
<td class="nump">55,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International</a></td>
<td class="nump">31,532<span></span>
</td>
<td class="nump">21,008<span></span>
</td>
<td class="nump">16,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax</a></td>
<td class="nump">337,446<span></span>
</td>
<td class="nump">259,448<span></span>
</td>
<td class="nump">273,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(47,715)<span></span>
</td>
<td class="num">(40,234)<span></span>
</td>
<td class="num">(66,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2,855)<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="num">(12,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International</a></td>
<td class="num">(7,220)<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Total deferred income tax</a></td>
<td class="num">(57,790)<span></span>
</td>
<td class="num">(39,332)<span></span>
</td>
<td class="num">(75,691)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 279,656<span></span>
</td>
<td class="nump">$ 220,116<span></span>
</td>
<td class="nump">$ 198,087<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237497808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity compensation</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment', window );">Nondeductible executive compensation</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Political advocacy costs</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Unrecognized tax benefits</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in international valuation allowance</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Impact of noncontrolling interests primarily attributable to non-tax paying entities</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(5.60%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">18.30%<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Investment Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EffectiveIncomeTaxReconciliationInvestmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043236906960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DeferredTaxAssetsReceivables', window );">Receivables</a></td>
<td class="nump">$ 37,630<span></span>
</td>
<td class="nump">$ 23,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">74,419<span></span>
</td>
<td class="nump">81,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">508,729<span></span>
</td>
<td class="nump">533,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">161,371<span></span>
</td>
<td class="nump">183,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investments in partnerships</a></td>
<td class="nump">4,108<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">54,600<span></span>
</td>
<td class="nump">52,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">840,857<span></span>
</td>
<td class="nump">873,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(107,952)<span></span>
</td>
<td class="num">(113,237)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">732,905<span></span>
</td>
<td class="nump">760,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(757,797)<span></span>
</td>
<td class="num">(731,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(63,726)<span></span>
</td>
<td class="num">(127,191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DeferredTaxLiabilitiesOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="num">(464,455)<span></span>
</td>
<td class="num">(486,864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Investments in partnerships</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(66,035)<span></span>
</td>
<td class="num">(87,918)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(1,352,013)<span></span>
</td>
<td class="num">(1,452,116)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(619,108)<span></span>
</td>
<td class="num">(691,780)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=dva_DeferredTaxLiabilitiesMember', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(665,361)<span></span>
</td>
<td class="num">(726,217)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 46,253<span></span>
</td>
<td class="nump">$ 34,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DeferredTaxAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DeferredTaxAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DeferredTaxLiabilitiesOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DeferredTaxLiabilitiesOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=dva_DeferredTaxLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=dva_DeferredTaxLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043247694208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 47,379<span></span>
</td>
<td class="nump">$ 63,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to current year</a></td>
<td class="nump">3,866<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Adjustments for tax positions related to prior years</a></td>
<td class="num">(1,452)<span></span>
</td>
<td class="num">(7,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions related to lapse of applicable statute</a></td>
<td class="num">(8,309)<span></span>
</td>
<td class="num">(5,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Reductions related to settlements with taxing authorities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 41,484<span></span>
</td>
<td class="nump">$ 47,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043239428352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 279,656<span></span>
</td>
<td class="nump">$ 220,116<span></span>
</td>
<td class="nump">$ 198,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Liability for unrecognized tax benefits</a></td>
<td class="nump">41,484<span></span>
</td>
<td class="nump">47,379<span></span>
</td>
<td class="nump">$ 63,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">27,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax expense (benefit), income tax penalties and interest expense, net of federal tax benefits</a></td>
<td class="num">(679)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits</a></td>
<td class="nump">5,846<span></span>
</td>
<td class="nump">$ 6,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_IndefiniteLifeNetOperatingLossesMember', window );">Indefinite Life Net Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance related to changes in the estimated tax benefit</a></td>
<td class="num">(5,285)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember', window );">Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">State capital loss carryforward, amount</a></td>
<td class="nump">$ 9,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">State capital loss carryforward, expiration date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction | Tax Year 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 555,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 410,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_IndefiniteLifeNetOperatingLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_IndefiniteLifeNetOperatingLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=dva_TaxYear2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=dva_TaxYear2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043229412976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 13, 2024</div></th>
<th class="th"><div>Aug. 07, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Long-term debt totals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,511,106<span></span>
</td>
<td class="nump">$ 8,445,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DiscountPremiumAndDeferredFinanceCosts', window );">Discount, premium and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,336)<span></span>
</td>
<td class="num">(54,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Carrying amount of long-term debt, net of unamortized discounts, premiums and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,446,770<span></span>
</td>
<td class="nump">8,391,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270,867)<span></span>
</td>
<td class="num">(123,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,175,903<span></span>
</td>
<td class="nump">8,268,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtPrepaymentExtinguishmentAndModificationCosts', window );">Debt prepayment, extinguishment and modification costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,081<span></span>
</td>
<td class="nump">$ 9,732<span></span>
</td>
<td class="nump">$ 19,813<span></span>
</td>
<td class="nump">7,962<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, Weighted Average Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember', window );">Senior Notes 4.625% due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750,000<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt, interest rate at a point in time.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,533,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember', window );">Senior Notes 3.75% due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt, interest rate at a point in time.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,301,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember', window );">Senior Notes 6.875% due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior Notes</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Sep.  01,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  01,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt, interest rate at a point in time.</a></td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,007,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt Instrument, Payment Terms</a></td>
<td class="text">The 6.875% Senior Notes pay interest on March 1 and September 1 of each year beginning March&#160;1, 2025 and mature on September&#160;1, 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Debt Instrument, Date of First Required Payment</a></td>
<td class="text">Mar.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Debt Instrument, Redemption, Description</a></td>
<td class="text">The Company may redeem up to 40% of the aggregate principal amount of the 6.875% Senior Notes at any time prior to September&#160;1, 2027 at 106.875% of the aggregate principal amount from the proceeds of one or more equity offerings, plus accrued and unpaid interest.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="nump">$ 11,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027', window );">Debt Instrument, Redemption Price, Percentage Any time Prior to September 1, 2027</a></td>
<td class="nump">106.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentRedemptionPriceIfChangeOfControl', window );">Debt Instrument, Redemption Price, if change of control</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Acquisition obligations and other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AcquisitionObligationsAndOtherNotesPayable', window );">Acquisition obligations and other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,483<span></span>
</td>
<td class="nump">102,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AcquisitionObligationsAndOtherNotesPayableFairValue', window );">Acquisition obligations and other notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument, maturity date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember', window );">Financing lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,401<span></span>
</td>
<td class="nump">$ 255,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.58%<span></span>
</td>
<td class="nump">4.58%<span></span>
</td>
<td class="nump">4.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument, maturity date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_ChangeHealthcareTemporaryFundingAssistanceMember', window );">Change Healthcare Temporary Funding Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt, interest rate at a point in time.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CHCTemporaryFundingAssistance', window );">CHC Temporary Funding Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CHCTemporaryFundingAssistanceFairValue', window );">CHC Temporary Funding Assistance, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_ChangeHealthcareTemporaryFundingAssistanceMember', window );">Change Healthcare Temporary Funding Assistance | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CHCTemporaryFundingAssistance', window );">CHC Temporary Funding Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 28,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Line of Credit Facility, Fair Value of Amount Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity on revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1AndRevolverMember', window );">Term Loan A-1 and Revolver | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Base + 1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1AndRevolverMember', window );">Term Loan A-1 and Revolver | Adjusted Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,259,295<span></span>
</td>
<td class="nump">1,234,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 28,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,256,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR', window );">Secured Debt Outstanding Principal Balance Subject To SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_IncreasedTermLoanA1Member', window );">Increased Term Loan A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Apr. 28,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt Instrument, Payment Terms</a></td>
<td class="text">The Increased Term Loan A-1 requires amortizing quarterly principal payments that began on September&#160;30, 2024 of $29,728 per quarter through June&#160;30, 2027, and $44,591 per quarter from September&#160;30, 2027 through March&#160;31, 2028, with the balance due on April&#160;28, 2028.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Debt Instrument, Maturity Date Range, Start</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Effective Date</a></td>
<td class="text">Aug. 13,  2024<span></span>
</td>
<td class="text">Aug.  07,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Sixth Amendment also incorporated the provisions of the Fifth Amendment to the Credit Agreement, dated as of August&#160;7, 2024, which removed a cap on the amount of incremental term "A" loans the Company can incur under the Credit Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Debt Instrument, Date of First Required Payment</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Debt Instrument, Maturity Date Range, End</a></td>
<td class="text">Apr. 28,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OtherSignificantNoncashFinancingActivity', window );">Other Significant Noncash Financing Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 861,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,828,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt Instrument, Frequency of Periodic Payment</a></td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentQuarterlyPaymentThroughJune302027', window );">Debt Instrument, Quarterly Payment Through June 30, 2027</a></td>
<td class="nump">29,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028', window );">Debt Instrument, Quarterly Payment From September 30, 2027 Through March 31, 2028</a></td>
<td class="nump">$ 44,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_IncreasedTermLoanA1Member', window );">Increased Term Loan A-1 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentVariableRate', window );">Debt Instrument, Variable Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_IncreasedTermLoanA1Member', window );">Increased Term Loan A-1 | SOFR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_IncreasedTermLoanA1Member', window );">Increased Term Loan A-1 | SOFR | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_IncreasedTermLoanA1Member', window );">Increased Term Loan A-1 | Adjusted Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member', window );">Term Loan B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,603,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ConstructiveFinancingCashOutflow', window );">Constructive Financing Cash Outflow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="nump">$ 949,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member', window );">Extended Term Loan B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,636,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  09,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  09,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,638,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt Instrument, Payment Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Extended Term Loan B-1 requires quarterly principal payments beginning on December&#160;31, 2024 of 0.25% of the aggregate principal amount of the Extended Term Loan B-1 outstanding on the Fourth Amendment Effective Date, with the balance due on May&#160;9, 2031.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Debt Instrument, Maturity Date Range, Start</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ConstructiveFinancingCashOutflow', window );">Constructive Financing Cash Outflow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ConstructiveFinancingCashInflow', window );">Constructive Financing Cash Inflow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Effective Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  09,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Debt Instrument, Date of First Required Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Debt Instrument, Maturity Date Range, End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  09,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OtherSignificantNoncashFinancingActivity', window );">Other Significant Noncash Financing Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt Instrument, Frequency of Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SecuredDebtExtendedMaturity', window );">Secured Debt, Extended Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 911,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Debt Instrument, Increase (Decrease), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 728,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding', window );">Debt Instrument, Quarterly Payment, % of Beginning Balance Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member', window );">Extended Term Loan B-1 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentVariableRate', window );">Debt Instrument, Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member', window );">Extended Term Loan B-1 | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">SOFR + 2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member', window );">Extended Term Loan B-1 | SOFR | SOFR Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member', window );">Extended Term Loan B-1 | Adjusted Rate | Base Rate Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member', window );">Extended Term Loan B-1 | Fed Funds Effective Rate Overnight Index Swap Rate | Maximum | Base Rate Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member', window );">Extended Term Loan B-1 | 1-Month SOFR | Maximum | Base Rate Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member', window );">Extended Term Loan B-1 | Prime Rate | Maximum | Base Rate Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">prime commercial lending rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,612<span></span>
</td>
<td class="nump">31,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt Instrument, Unamortized Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,239<span></span>
</td>
<td class="nump">12,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,084<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,879<span></span>
</td>
<td class="nump">$ 32,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AcquisitionObligationsAndOtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents deferred purchase price obligations associated with acquisitions as well as other notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AcquisitionObligationsAndOtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AcquisitionObligationsAndOtherNotesPayableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Obligations And Other Notes Payable, Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AcquisitionObligationsAndOtherNotesPayableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CHCTemporaryFundingAssistance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CHC Temporary Funding Assistance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CHCTemporaryFundingAssistance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CHCTemporaryFundingAssistanceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CHC Temporary Funding Assistance, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CHCTemporaryFundingAssistanceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ConstructiveFinancingCashInflow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Constructive Financing Cash Inflow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ConstructiveFinancingCashInflow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ConstructiveFinancingCashOutflow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Constructive Financing Cash Outflow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ConstructiveFinancingCashOutflow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Quarterly Payment From September 30, 2027 Through March 31, 2028</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Quarterly Payment, % of Beginning Balance Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentQuarterlyPaymentThroughJune302027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Quarterly Payment Through June 30, 2027</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentQuarterlyPaymentThroughJune302027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentRedemptionPriceIfChangeOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, if change of control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentRedemptionPriceIfChangeOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage Any time Prior to September 1, 2027</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtPrepaymentExtinguishmentAndModificationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Prepayment, Extinguishment And Modification Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtPrepaymentExtinguishmentAndModificationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DiscountPremiumAndDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount, premium and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DiscountPremiumAndDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OtherSignificantNoncashFinancingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Significant Noncash Financing Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OtherSignificantNoncashFinancingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SecuredDebtExtendedMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Secured Debt, Extended Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SecuredDebtExtendedMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Secured Debt Outstanding Principal Balance Subject To SOFR</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDateOfFirstRequiredPayment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeEnd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_ChangeHealthcareTemporaryFundingAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_ChangeHealthcareTemporaryFundingAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1AndRevolverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1AndRevolverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_AdjustableRateLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_AdjustableRateLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_IncreasedTermLoanA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_IncreasedTermLoanA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_ExtendedTermLoanB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LoansTypeAxis=dva_SOFRLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LoansTypeAxis=dva_SOFRLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LoansTypeAxis=dva_BaseRateLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LoansTypeAxis=dva_BaseRateLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=dva_A1MonthSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=dva_A1MonthSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043239540496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 270,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">174,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">202,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2028</a></td>
<td class="nump">1,922,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2029</a></td>
<td class="nump">39,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 6,900,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237018288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Derivative Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2026</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member', window );">2019 Interest Rate Cap Agreements Effective June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312024', window );">Notional Amount Amortizable By December 31, 2024</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312024', window );">Notional Amount Amortizable By December 31, 2024</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024 | Term Loan Facility | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312024', window );">Notional Amount Amortizable By December 31, 2024</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024 | Term Loan Facility | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024 | Term Loan Facility | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member', window );">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member', window );">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312025', window );">Notional Amount Amortizable By December 31, 2025</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member', window );">2024 Interest Rate Cap Agreements 4.50% Effective December 31 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">Dec. 31,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312026', window );">Notional Amount Amortizable By December 31, 2026</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member', window );">2024 Interest Rate Cap Agreements 4.50% Effective December 31 2025 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member', window );">2024 Interest Rate Cap Agreements 4.50% Effective December 31 2025 | Term Loan Facility | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member', window );">2024 Interest Rate Cap Agreements 4.00% Effective December 31 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">Dec. 31,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312026', window );">Notional Amount Amortizable By December 31, 2026</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member', window );">2024 Interest Rate Cap Agreements 4.00% Effective December 31 2025 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member', window );">2024 Interest Rate Cap Agreements 4.00% Effective December 31 2025 | Term Loan Facility | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312024Member', window );">Total Notional Amount Effective Through December 31, 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312024Member', window );">Total Notional Amount Effective Through December 31, 2024 | Term Loan Facility | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageFixedInterestRate', window );">Derivative, Average Fixed Interest Rate</a></td>
<td class="nump">4.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312025Member', window );">Total Notional Amount Effective Through December 31, 2025 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312025Member', window );">Total Notional Amount Effective Through December 31, 2025 | Term Loan Facility | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageFixedInterestRate', window );">Derivative, Average Fixed Interest Rate</a></td>
<td class="nump">4.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312026Member', window );">Total Notional Amount Effective Through December 31, 2026 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312026Member', window );">Total Notional Amount Effective Through December 31, 2026 | Term Loan Facility | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageFixedInterestRate', window );">Derivative, Average Fixed Interest Rate</a></td>
<td class="nump">4.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312027Member', window );">Total Notional Amount Effective Through December 31, 2027 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312027Member', window );">Total Notional Amount Effective Through December 31, 2027 | Term Loan Facility | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageFixedInterestRate', window );">Derivative, Average Fixed Interest Rate</a></td>
<td class="nump">4.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NotionalAmountAmortizableByDecember312024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notional Amount Amortizable By December 31, 2024</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NotionalAmountAmortizableByDecember312024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NotionalAmountAmortizableByDecember312025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notional Amount Amortizable By December 31, 2025</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NotionalAmountAmortizableByDecember312025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NotionalAmountAmortizableByDecember312026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notional Amount Amortizable By December 31, 2026</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NotionalAmountAmortizableByDecember312026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NotionalAmountAmortizableByMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notional Amount Amortizable By Maturity Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NotionalAmountAmortizableByMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average fixed interest rate related to the group of interest rate derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInceptionDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the entity entered into the derivative contract, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInceptionDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeMaturityDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date derivative contract ends, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeMaturityDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_TotalNotionalAmountEffectiveThroughDecember312027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246681136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="nump">$ 6,895<span></span>
</td>
<td class="nump">$ 108,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="nump">7,250<span></span>
</td>
<td class="nump">6,895<span></span>
</td>
<td class="nump">108,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Reclassification from accumulated other comprehensive income into net income</a></td>
<td class="num">(43,660)<span></span>
</td>
<td class="num">(77,727)<span></span>
</td>
<td class="num">(8,806)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_IncomeTaxRelatedToCashFlowHedgesMember', window );">Income Tax Related To Cash Flow Hedges | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="num">(2,412)<span></span>
</td>
<td class="num">(2,291)<span></span>
</td>
<td class="num">(36,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Reclassification from accumulated other comprehensive income into net income</a></td>
<td class="nump">$ 14,515<span></span>
</td>
<td class="nump">25,840<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Income tax expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember', window );">Interest Rate Cap | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="nump">$ 9,662<span></span>
</td>
<td class="nump">9,186<span></span>
</td>
<td class="nump">144,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Reclassification from accumulated other comprehensive income into net income</a></td>
<td class="num">$ (58,175)<span></span>
</td>
<td class="num">(103,567)<span></span>
</td>
<td class="num">$ (11,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Interest and Debt Expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative Asset, Fair Value, Gross Asset</a></td>
<td class="nump">$ 30,062<span></span>
</td>
<td class="nump">$ 79,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_IncomeTaxRelatedToCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_IncomeTaxRelatedToCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043229257200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit Outstanding, Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="nump">$ 435,203<span></span>
</td>
<td class="nump">$ 373,951<span></span>
</td>
<td class="nump">$ 339,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Discounts, Premiums and Deferred Financing Costs</a></td>
<td class="nump">$ 35,266<span></span>
</td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="nump">$ 17,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate', window );">Long Term Debt Percentage Bearing Economically Fixed Interest Rate</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Secured Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit Outstanding, Amount</a></td>
<td class="nump">$ 161,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_NewCreditAgreementAmendedMember', window );">New Credit Agreement - Amended | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeverageRatioCovenant', window );">Leverage Ratio Covenant</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeverageRatioCovenantThroughJun302026', window );">Leverage Ratio Covenant Through Jun 30, 2026</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeverageRatioCovenantAfterJun302026', window );">Leverage Ratio Covenant after Jun 30, 2026</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition', window );">Leverage Ratio Covenant after Jun 30, 2026 - Subject to Increase during four fiscal quarters following a material acquisition</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1AndRevolverMember', window );">Term Loan A-1 and Revolver | Adjusted Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">SOFR Plus Interest Rate Margin</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeverageRatioCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leverage Ratio Covenant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeverageRatioCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeverageRatioCovenantAfterJun302026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leverage Ratio Covenant after Jun 30, 2026</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeverageRatioCovenantAfterJun302026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leverage Ratio Covenant after Jun 30, 2026 - Subject to Increase during four fiscal quarters following a material acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeverageRatioCovenantThroughJun302026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leverage Ratio Covenant Through Jun 30, 2026</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeverageRatioCovenantThroughJun302026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt Percentage Bearing Economically Fixed Interest Rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_NewCreditAgreementAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_NewCreditAgreementAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1AndRevolverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1AndRevolverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_AdjustableRateLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_AdjustableRateLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238105984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Lease Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Fixed lease expense</a></td>
<td class="nump">$ 557,591<span></span>
</td>
<td class="nump">$ 556,844<span></span>
</td>
<td class="nump">$ 552,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">131,539<span></span>
</td>
<td class="nump">135,990<span></span>
</td>
<td class="nump">127,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">689,130<span></span>
</td>
<td class="nump">692,834<span></span>
</td>
<td class="nump">679,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">28,262<span></span>
</td>
<td class="nump">26,964<span></span>
</td>
<td class="nump">27,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">10,885<span></span>
</td>
<td class="nump">11,724<span></span>
</td>
<td class="nump">12,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">$ 728,277<span></span>
</td>
<td class="nump">$ 731,522<span></span>
</td>
<td class="nump">$ 719,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237193248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases term and discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesOtherInformationAbstract', window );"><strong>Leases Other Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">Sale and Leaseback Transaction, Gain (Loss), Net</a></td>
<td class="nump">$ 2,260<span></span>
</td>
<td class="nump">$ 3,387<span></span>
</td>
<td class="nump">$ 28,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">719,339<span></span>
</td>
<td class="nump">708,162<span></span>
</td>
<td class="nump">696,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Finance Lease, Interest Payment on Liability</a></td>
<td class="nump">18,599<span></span>
</td>
<td class="nump">19,246<span></span>
</td>
<td class="nump">20,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance Lease, Principal Payments</a></td>
<td class="nump">29,592<span></span>
</td>
<td class="nump">26,455<span></span>
</td>
<td class="nump">24,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities', window );">Net Operating Lease Assets Obtained In Exchange For Lease Liabilities</a></td>
<td class="nump">$ 286,022<span></span>
</td>
<td class="nump">$ 269,564<span></span>
</td>
<td class="nump">$ 278,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember', window );">Finance Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases term and discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate, percent</a></td>
<td class="nump">4.58%<span></span>
</td>
<td class="nump">4.58%<span></span>
</td>
<td class="nump">4.51%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeasesOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases Other Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeasesOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Lease Assets Obtained In Exchange For New or Modified Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238523184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 508,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">517,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">453,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">385,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">310,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">863,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments due under operating leases</a></td>
<td class="nump">3,038,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less portion representing interest, operating lease liabilities</a></td>
<td class="num">(418,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities, operating leases</a></td>
<td class="nump">$ 2,620,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current portion of operating lease liabilities, Long-term operating lease liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 36,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">38,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">37,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">33,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">24,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">82,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum payments due under finance leases</a></td>
<td class="nump">253,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less portion representing interest, financing lease liabilities</a></td>
<td class="num">(37,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="nump">$ 216,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-term debt, Current portion of long-term debt<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043245626560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 309,363<span></span>
</td>
<td class="nump">$ 309,363<span></span>
</td>
<td class="nump">$ 322,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net of accumulated depreciation<span></span>
</td>
<td class="text">Property and equipment, net of accumulated depreciation<span></span>
</td>
<td class="text">Property and equipment, net of accumulated depreciation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_FinanceLeaseAccumulatedDepreciation', window );">Finance Lease Accumulated Depreciation</a></td>
<td class="nump">$ 139,071<span></span>
</td>
<td class="nump">$ 139,071<span></span>
</td>
<td class="nump">$ 122,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent Expense, Operating Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689,130<span></span>
</td>
<td class="nump">692,834<span></span>
</td>
<td class="nump">$ 679,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dva_OperatingLeaseMember', window );">Operating Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent Expense, Operating Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689,130<span></span>
</td>
<td class="nump">$ 692,834<span></span>
</td>
<td class="nump">$ 679,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionLeaseTerm', window );">Sale Leaseback Transaction, Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SaleLeasebackTransactionRenewalLeaseTerm', window );">Sale Leaseback Transaction, Renewal Lease Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionLeaseTerm', window );">Sale Leaseback Transaction, Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SaleLeasebackTransactionRenewalLeaseTerm', window );">Sale Leaseback Transaction, Renewal Lease Term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_FinanceLeaseAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Accumulated Depreciation, contra asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_FinanceLeaseAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeasesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeasesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SaleLeasebackTransactionRenewalLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback Transaction, Renewal Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SaleLeasebackTransactionRenewalLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease term for sale and leaseback transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dva_OperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dva_OperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237947008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Defined Benefit Plan, Benefit Obligation, Benefits Paid</a></td>
<td class="nump">$ 79,006<span></span>
</td>
<td class="nump">$ 73,725<span></span>
</td>
<td class="nump">$ 70,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross wages</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember', window );">Deferred Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of employees' base salary to be maintained into deferral account</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer', window );">Non-qualified deferred compensation plan, contributions</a></td>
<td class="nump">$ 2,521<span></span>
</td>
<td class="nump">2,695<span></span>
</td>
<td class="nump">3,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid', window );">Deferred compensation plan, distributions</a></td>
<td class="nump">4,511<span></span>
</td>
<td class="nump">3,899<span></span>
</td>
<td class="nump">$ 3,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember', window );">Deferred Compensation Plan | Rabbi trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total fair value of assets held in trust</a></td>
<td class="nump">$ 39,527<span></span>
</td>
<td class="nump">$ 36,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election Effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution made to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=dva_AllTrustsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=dva_AllTrustsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043344322432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 22, 2019</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CorporateIntegrityAgreementExpirationDate', window );">Corporate Integrity Agreement Expiration Date</a></td>
<td class="text">Oct. 22,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=dva_A2017USAttorneyColoradoInvestigationMember', window );">2017 U S Attorney Colorado Investigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CorporateIntegrityAgreementExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Integrity Agreement Expiration Date, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CorporateIntegrityAgreementExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=dva_A2017USAttorneyColoradoInvestigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=dva_A2017USAttorneyColoradoInvestigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238131504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase Obligation, Due in Next Twelve Months</a></td>
<td class="nump">$ 559,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase Obligation, Due in Second Year</a></td>
<td class="nump">547,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">Purchase Obligation, Due in Third Year</a></td>
<td class="nump">547,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">Purchase Obligation, to be Paid, Year Four</a></td>
<td class="nump">564,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">Purchase Obligation, to be Paid, Year Five</a></td>
<td class="nump">414,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OffBalanceSheetFinancingArrangements', window );">Off -Balance Sheet Financing Arrangements</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DissolutionTermOfJointVentures', window );">Scheduled dissolution term of joint ventures</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DissolutionTermOfJointVentures', window );">Scheduled dissolution term of joint ventures</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dva_CommitmentsToProvideOperatingCapitalMember', window );">Commitments to Provide Operating Capital</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other potential commitments to provide operating capital to nonconsolidated dialysis centers</a></td>
<td class="nump">$ 7,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DissolutionTermOfJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dissolution term of joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DissolutionTermOfJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OffBalanceSheetFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off -Balance Sheet Financing Arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OffBalanceSheetFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dva_CommitmentsToProvideOperatingCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dva_CommitmentsToProvideOperatingCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043247583888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">3,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised/ Vested (in shares)</a></td>
<td class="num">(3,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">268,000<span></span>
</td>
<td class="nump">3,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 35.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (USD per share)</a></td>
<td class="nump">67.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (USD per share)</a></td>
<td class="nump">63.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (USD per share)</a></td>
<td class="nump">75.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (USD per share)</a></td>
<td class="nump">108.02<span></span>
</td>
<td class="nump">$ 67.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (USD per share)</a></td>
<td class="nump">$ 102.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual&#160;life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
<td class="text">1 year 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dva_StockUnitMember', window );">Stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">3,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod', window );">Added by performance factor (in shares)</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Exercised/ Vested (in shares)</a></td>
<td class="num">(628,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(292,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">3,146,000<span></span>
</td>
<td class="nump">3,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of grants (USD per share)</a></td>
<td class="nump">$ 142.36<span></span>
</td>
<td class="nump">$ 77.61<span></span>
</td>
<td class="nump">$ 107.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual&#160;life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding at end of period</a></td>
<td class="text">1 year 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Exercisable at end of period</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement by Share based Payment Award, Other than Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dva_StockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dva_StockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241804896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Range of Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">268,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 108.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 102.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">50.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">60.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">60.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeThreeMember', window );">$70.01&#8211;$80.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 75.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 75.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">70.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFourMember', window );">$100.01&#8211;$110.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">124,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 108.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 108.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">100.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 110.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFiveMember', window );">$110.01&#8211;$120.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 110.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">110.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238048544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details) - Stock-settled Stock Appreciation Rights<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">34.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dva_StockSettledStockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dva_StockSettledStockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043227688704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders&#8217; Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jul. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock awards exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,681,000<span></span>
</td>
<td class="nump">$ 168,500,000<span></span>
</td>
<td class="nump">$ 149,442,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock awards outstanding</a></td>
<td class="nump">$ 490,209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of stock awards exercisable</a></td>
<td class="nump">3,394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Payments of ordinary dividends, common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,788,000<span></span>
</td>
<td class="nump">112,375,000<span></span>
</td>
<td class="nump">95,427,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense', window );">Estimated tax benefits recorded for stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,398,000<span></span>
</td>
<td class="nump">16,536,000<span></span>
</td>
<td class="nump">14,723,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans</a></td>
<td class="nump">$ 146,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share-based Payment Arrangement, Expense, Tax Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,531,000<span></span>
</td>
<td class="nump">25,629,000<span></span>
</td>
<td class="nump">24,805,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dva_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">5,286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase', window );">Employee entitlement for purchase of the Company's common stock during each calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Stock purchase price as percentage of fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares', window );">Contributions used to purchase shares, employee-related current liabilities</a></td>
<td class="nump">$ 20,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,441,000<span></span>
</td>
<td class="nump">$ 18,213,000<span></span>
</td>
<td class="nump">$ 18,061,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued for employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">231,000<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.60%<span></span>
</td>
<td class="nump">41.30%<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Share-based awards, fair value assumptions, expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.78<span></span>
</td>
<td class="nump">$ 25.25<span></span>
</td>
<td class="nump">$ 26.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember', window );">Stock Incentive 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions', window );">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance', window );">Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward', window );">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance', window );">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">4,969,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,969,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember', window );">Stock Incentive 2020 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember', window );">Stock Incentive 2020 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms of award (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share-based compensation estimated tax benefit from compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum share value authorized for purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dva_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dva_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043247212880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Repurchases Tender Offer (Details) - Open Market Purchases - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">9,833<span></span>
</td>
<td class="nump">2,904<span></span>
</td>
<td class="nump">8,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="nump">$ 1,389,072<span></span>
</td>
<td class="nump">$ 285,710<span></span>
</td>
<td class="nump">$ 787,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share</a></td>
<td class="nump">$ 140.06<span></span>
</td>
<td class="nump">$ 97.82<span></span>
</td>
<td class="nump">$ 97.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043240539136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to DaVita Inc.</a></td>
<td class="nump">$ 936,342<span></span>
</td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interests</a></td>
<td class="num">(3,102)<span></span>
</td>
<td class="num">(5,375)<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Sale of noncontrolling interest</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures', window );">Sale of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Noncontrolling Interest, Period Increase (Decrease)</a></td>
<td class="num">(2,611)<span></span>
</td>
<td class="nump">7,702<span></span>
</td>
<td class="num">(5,647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests', window );">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</a></td>
<td class="nump">$ 933,731<span></span>
</td>
<td class="nump">$ 699,237<span></span>
</td>
<td class="nump">$ 554,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043247220976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 05, 2024</div></th>
<th class="th"><div>Dec. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount', window );">Terminated Remaining Prior Share Repurchases Authorized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share Repurchase Program, Authorized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CharterdocumentsandDelawarelawAbstract', window );"><strong>Charter documents and Delaware law:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation', window );">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,958<span></span>
</td>
<td class="nump">$ 12,555<span></span>
</td>
<td class="nump">$ 20,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember', window );">Open Market Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,833,000<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,389,072<span></span>
</td>
<td class="nump">$ 285,710<span></span>
</td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140.06<span></span>
</td>
<td class="nump">$ 97.82<span></span>
</td>
<td class="nump">$ 97.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,833,000<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,389,072<span></span>
</td>
<td class="nump">$ 285,710<span></span>
</td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="nump">$ 124,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share</a></td>
<td class="nump">$ 158.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Share Repurchase Program, Remaining Authorized, Amount</a></td>
<td class="nump">$ 1,811,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CharterdocumentsandDelawarelawAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Charter documents and Delaware law [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CharterdocumentsandDelawarelawAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law limitation. The Company is subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period three years following the date on which that stockholder became an interested stockholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terminated Remaining Prior Share Repurchases Authorized, Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238259952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Berkshire<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Berkshire Share Repurchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Berkshire share repurchase agreement</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;30, 2024, the Company entered into an agreement (the share repurchase agreement) with Berkshire Hathaway Inc. on behalf of itself and its affiliates (collectively, Berkshire). Under the share repurchase agreement, at any time Berkshire beneficially owns at least 45.0% of the issued and outstanding common stock of the Company in the aggregate, the Company will repurchase from Berkshire, and Berkshire will sell to the Company, on a quarterly basis, a number of shares of common stock sufficient to return Berkshire&#8217;s aggregate beneficial ownership to 45.0% of the Company's issued and outstanding common stock. The per share price the Company will pay Berkshire for any such share repurchase will be the volume-weighted average price per share paid by the Company for any shares of common stock repurchased by the Company from public stockholders pursuant to the Company&#8217;s share repurchase program during the applicable repurchase period.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, repurchases of common stock by the Company from Berkshire will occur on the date that is two business days prior to the date of the Company&#8217;s regular quarterly or annual investor call to publicly report earnings; however, if at any time the Company determines that Berkshire beneficially owns or will beneficially own shares of common stock representing more than 49.5% of the issued and outstanding common stock in the aggregate, such determination will trigger immediate share repurchases under this agreement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, Berkshire beneficially owned less than 45.0% of the issued and outstanding common stock of the Company and, as a result, no repurchase obligation existed at such date. Subsequent to December&#160;31, 2024, through February&#160;13, 2025, the Company's open market share repurchases caused Berkshire to beneficially own greater then 45.0%. As such, on February 11, 2025 the Company repurchased 203 shares of common stock from Berkshire for $32,001 at an average price paid of $156.01 per share.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Berkshire standstill agreement</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Berkshire remains subject to a standstill agreement with the Company, as amended and restated as of February 9, 2022 (the standstill agreement). The standstill agreement currently restricts Berkshire&#8217;s actions with respect to acquiring additional </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of the Company&#8217;s common stock, and for any matter presented to Company stockholders, the standstill agreement requires Berkshire to vote any shares it beneficially holds in excess of 40% of the then-outstanding voting stock of the Company in accordance with the recommendation of the Board of Directors of the Company (Board). The standstill agreement also restricts Berkshire from taking certain actions, including, among other things, actions relating to stockholder proposals and actions seeking to control or influence the Board, management or policies of the Company. The standstill agreement provisions vary depending on Berkshire&#8217;s ownership levels and in the event of certain specified leadership changes at Berkshire.</span></div>The standstill agreement may be terminated by Berkshire at any time it ceases to beneficially own more than 15% of the Company's then-outstanding common stock, and terminates automatically if the Company enters into or publicly announces a plan to enter into a definitive agreement concerning a transaction involving all or a controlling portion of the Company's equity securities or all, or substantially all, of the Company's assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related Party Transaction, Description of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Berkshire beneficially owns at least 45.0%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_RelatedPartyTransactionDescriptionOfTransaction1', window );">Related Party Transaction, Description of Transaction 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Berkshire beneficially owns or will beneficially own shares of common stock representing more than 49.5% of the issued and outstanding common stock in the aggregate, such determination will trigger immediate share repurchases under this agreement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_RelatedPartyTransactionDescriptionOfTransaction2', window );">Related Party Transaction, Description of Transaction 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As of December&#160;31, 2024, Berkshire beneficially owned less than 45.0% of the issued and outstanding common stock of the Company and, as a result, no repurchase obligation existed at such date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepurchaseAgreementDate', window );">Repurchase Agreement, Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Related Party Transaction, Terms and Manner of Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">two business days prior to the date of the Company&#8217;s regular quarterly or annual investor call to publicly report earnings<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_PrincipalOwnerMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_RelatedPartyTransactionDescriptionOfTransaction2', window );">Related Party Transaction, Description of Transaction 2</a></td>
<td class="text">Subsequent to December&#160;31, 2024, through February&#160;13, 2025, the Company's open market share repurchases caused Berkshire to beneficially own greater then 45.0%. As such, on February 11, 2025 the Company repurchased 203 shares of common stock from Berkshire for $32,001 at an average price paid of $156.01 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_RelatedPartyTransactionDescriptionOfTransaction1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Description of Transaction 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_RelatedPartyTransactionDescriptionOfTransaction1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_RelatedPartyTransactionDescriptionOfTransaction2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Description of Transaction 2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_RelatedPartyTransactionDescriptionOfTransaction2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepurchaseAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of repurchase agreement, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepurchaseAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043227874256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">$ (52,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">(310,796)<span></span>
</td>
<td class="num">$ (52,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Interest rate cap agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="nump">27,853<span></span>
</td>
<td class="nump">98,685<span></span>
</td>
<td class="num">$ (1,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="nump">9,662<span></span>
</td>
<td class="nump">9,186<span></span>
</td>
<td class="nump">144,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="num">(2,412)<span></span>
</td>
<td class="num">(2,291)<span></span>
</td>
<td class="num">(36,124)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="nump">7,250<span></span>
</td>
<td class="nump">6,895<span></span>
</td>
<td class="nump">108,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (losses) into net income</a></td>
<td class="num">(58,175)<span></span>
</td>
<td class="num">(103,567)<span></span>
</td>
<td class="num">(11,732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">14,515<span></span>
</td>
<td class="nump">25,840<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="num">(43,660)<span></span>
</td>
<td class="num">(77,727)<span></span>
</td>
<td class="num">(8,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">(8,557)<span></span>
</td>
<td class="nump">27,853<span></span>
</td>
<td class="nump">98,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">(79,937)<span></span>
</td>
<td class="num">(167,871)<span></span>
</td>
<td class="num">(138,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="num">(207,906)<span></span>
</td>
<td class="nump">89,055<span></span>
</td>
<td class="num">(30,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
<td class="nump">752<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="num">(207,861)<span></span>
</td>
<td class="nump">87,934<span></span>
</td>
<td class="num">(29,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (losses) into net income</a></td>
<td class="num">(15,252)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="num">(14,487)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">(302,285)<span></span>
</td>
<td class="num">(79,937)<span></span>
</td>
<td class="num">(167,871)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">(52,084)<span></span>
</td>
<td class="num">(69,186)<span></span>
</td>
<td class="num">(139,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="num">(198,198)<span></span>
</td>
<td class="nump">98,241<span></span>
</td>
<td class="nump">114,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="num">(2,367)<span></span>
</td>
<td class="num">(3,412)<span></span>
</td>
<td class="num">(35,372)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="num">(200,565)<span></span>
</td>
<td class="nump">94,829<span></span>
</td>
<td class="nump">78,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (losses) into net income</a></td>
<td class="num">(73,427)<span></span>
</td>
<td class="num">(103,567)<span></span>
</td>
<td class="num">(11,732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">15,280<span></span>
</td>
<td class="nump">25,840<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="num">(58,147)<span></span>
</td>
<td class="num">(77,727)<span></span>
</td>
<td class="num">(8,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">(310,796)<span></span>
</td>
<td class="num">(52,084)<span></span>
</td>
<td class="num">(69,186)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (losses) into net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241220080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Components of Routine Acquisitions (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on changes in ownership interest</a></td>
<td class="nump">$ 109,466<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="nump">329,187<span></span>
</td>
<td class="nump">27,648<span></span>
</td>
<td class="nump">59,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent purchase price and liabilities assumed</a></td>
<td class="nump">50,384<span></span>
</td>
<td class="nump">19,801<span></span>
</td>
<td class="nump">19,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair Value of Previously Held Equity Interests</a></td>
<td class="nump">182,270<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Aggregate purchase cost recognized</a></td>
<td class="nump">561,841<span></span>
</td>
<td class="nump">$ 47,449<span></span>
</td>
<td class="nump">$ 78,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions | Non-Cash Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on changes in ownership interest</a></td>
<td class="nump">$ 35,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions | U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | Clinic</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions | Foreign Dialysis Centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | Clinic</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member', window );">DaVita Care Pte. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair Value of Previously Held Equity Interests</a></td>
<td class="nump">$ 114,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Aggregate purchase cost recognized</a></td>
<td class="nump">114,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member', window );">DaVita Care Pte. Ltd. | Non-Cash Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on changes in ownership interest</a></td>
<td class="nump">$ 59,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis=dva_NonCashGainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis=dva_NonCashGainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_ForeignDialysisCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_ForeignDialysisCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043236847488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Assets acquired and liabilities assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 7,375,216<span></span>
</td>
<td class="nump">$ 7,112,560<span></span>
</td>
<td class="nump">$ 7,076,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="nump">83,119<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Other current assets</a></td>
<td class="nump">249,738<span></span>
</td>
<td class="nump">6,128<span></span>
</td>
<td class="nump">6,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">94,951<span></span>
</td>
<td class="nump">4,130<span></span>
</td>
<td class="nump">7,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other long-term assets</a></td>
<td class="nump">97,591<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite-lived licenses</a></td>
<td class="nump">22,725<span></span>
</td>
<td class="nump">15,789<span></span>
</td>
<td class="nump">19,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">349,069<span></span>
</td>
<td class="nump">25,723<span></span>
</td>
<td class="nump">49,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities Assumed</a></td>
<td class="num">(201,704)<span></span>
</td>
<td class="num">(6,179)<span></span>
</td>
<td class="num">(6,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interests assumed</a></td>
<td class="num">(133,648)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="num">(867)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Aggregate purchase price</a></td>
<td class="nump">561,841<span></span>
</td>
<td class="nump">$ 47,449<span></span>
</td>
<td class="nump">$ 78,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member', window );">DaVita Care Pte. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="nump">34,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Other current assets</a></td>
<td class="nump">44,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">22,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other long-term assets</a></td>
<td class="nump">37,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite-lived licenses</a></td>
<td class="nump">15,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">127,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities Assumed</a></td>
<td class="num">(54,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interests assumed</a></td>
<td class="num">(112,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Aggregate purchase price</a></td>
<td class="nump">$ 114,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043242366768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes associated with acquisitions</a></td>
<td class="nump">$ 54,810<span></span>
</td>
<td class="nump">$ 17,836<span></span>
</td>
<td class="nump">$ 49,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043247171904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Pro forma total revenues</a></td>
<td class="nump">$ 13,073,083<span></span>
</td>
<td class="nump">$ 12,625,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Pro forma net income attributable to DaVita Inc.</a></td>
<td class="nump">$ 952,836<span></span>
</td>
<td class="nump">$ 732,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Pro forma basic net income per share attributable to DaVita Inc.</a></td>
<td class="nump">$ 11.21<span></span>
</td>
<td class="nump">$ 8.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Pro forma diluted net income per share attributable to DaVita Inc.</a></td>
<td class="nump">$ 10.92<span></span>
</td>
<td class="nump">$ 7.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043237195936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on changes in ownership interest</a></td>
<td class="nump">$ 109,466<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="nump">$ 24,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member', window );">DaVita Care Pte. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Business Acquisition, Name of Acquired Entity</a></td>
<td class="text">DaVita Care Pte. Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Business Acquisition, Effective Date of Acquisition</a></td>
<td class="text">Nov.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member', window );">DaVita Care Pte. Ltd. | Foreign Currency Gain (Loss) Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on changes in ownership interest</a></td>
<td class="nump">$ 15,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember', window );">Other companies | Performance Targets or Quality Margins | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod', window );">Earn-out consideration payment period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember', window );">Other companies | Performance Targets or Quality Margins | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod', window );">Earn-out consideration payment period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration revenue earn-out period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 7<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the acquired entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionNameOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dva_DaVitaCarePte.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis=dva_ForeignCurrencyGainLossTranslationAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis=dva_ForeignCurrencyGainLossTranslationAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246614896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Held for Sale and Discontinued Operations - Additional Information (Details) - DMG - discontinued operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 19, 2019</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash Provided by (Used in) Operating Activities, Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Cash Provided by (Used in) Financing Activities, Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash Provided by (Used in) Investing Activities, Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessSaleEffectiveDateOfSale', window );">Business Sale, Effective Date Of Sale</a></td>
<td class="text">Jun. 19,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment', window );">Gain on disposition of business, additional purchase price payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessSaleEffectiveDateOfSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Sale, Effective Date Of Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessSaleEffectiveDateOfSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on disposition of business, additional purchase price payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043241195840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 17,285,268<span></span>
</td>
<td class="nump">$ 16,893,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">15,193,917<span></span>
</td>
<td class="nump">$ 14,150,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">577,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">$ 249,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043239117856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">$ 40,566<span></span>
</td>
<td class="nump">$ 37,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">40,566<span></span>
</td>
<td class="nump">37,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="nump">13,542<span></span>
</td>
<td class="nump">23,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">1,695,483<span></span>
</td>
<td class="nump">1,499,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="nump">30,062<span></span>
</td>
<td class="nump">79,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;prices&#160;in active&#160;markets&#160;for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">40,566<span></span>
</td>
<td class="nump">37,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;prices&#160;in active&#160;markets&#160;for identical assets (Level 1) | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;other observable&#160;inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;other observable&#160;inputs (Level 2) | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="nump">30,062<span></span>
</td>
<td class="nump">79,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="nump">13,542<span></span>
</td>
<td class="nump">23,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">1,695,483<span></span>
</td>
<td class="nump">1,499,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043236991568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Values of Financial Instruments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple', window );">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</a></td>
<td class="nump">$ 225,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043244672512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555,175<span></span>
</td>
<td class="nump">$ 565,206<span></span>
</td>
<td class="nump">$ 433,430<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,815,550<span></span>
</td>
<td class="nump">12,140,147<span></span>
</td>
<td class="nump">11,609,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090,483<span></span>
</td>
<td class="nump">1,602,784<span></span>
</td>
<td class="nump">1,339,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SegmentReportingInformationCorporateExpenses', window );">Corporate administrative support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,181)<span></span>
</td>
<td class="num">(163,047)<span></span>
</td>
<td class="num">(129,669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(470,469)<span></span>
</td>
<td class="num">(398,551)<span></span>
</td>
<td class="num">(357,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtPrepaymentExtinguishmentAndModificationCosts', window );">Debt prepayment, extinguishment and modification costs</a></td>
<td class="num">$ (10,081)<span></span>
</td>
<td class="num">$ (9,732)<span></span>
</td>
<td class="num">(19,813)<span></span>
</td>
<td class="num">(7,962)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other loss, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,808)<span></span>
</td>
<td class="num">(19,177)<span></span>
</td>
<td class="num">(15,765)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530,393<span></span>
</td>
<td class="nump">1,177,094<span></span>
</td>
<td class="nump">966,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment Reporting Information footnote:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,189<span></span>
</td>
<td class="nump">27,864<span></span>
</td>
<td class="nump">26,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PatientCareCosts', window );">Patient care costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,598,521<span></span>
</td>
<td class="nump">8,319,717<span></span>
</td>
<td class="nump">8,209,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,538,341<span></span>
</td>
<td class="nump">1,473,984<span></span>
</td>
<td class="nump">1,355,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses and charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,725,067<span></span>
</td>
<td class="nump">10,537,363<span></span>
</td>
<td class="nump">10,270,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,860<span></span>
</td>
<td class="nump">745,443<span></span>
</td>
<td class="nump">732,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,940,916<span></span>
</td>
<td class="nump">3,073,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment Reporting Information footnote:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,679<span></span>
</td>
<td class="nump">49,769<span></span>
</td>
<td class="nump">41,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,901,207<span></span>
</td>
<td class="nump">12,236,221<span></span>
</td>
<td class="nump">11,701,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,203,664<span></span>
</td>
<td class="nump">1,765,831<span></span>
</td>
<td class="nump">1,468,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,121,007<span></span>
</td>
<td class="nump">1,774,578<span></span>
</td>
<td class="nump">1,565,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment Reporting Information footnote:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PatientCareCosts', window );">Patient care costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,497,576<span></span>
</td>
<td class="nump">7,394,640<span></span>
</td>
<td class="nump">7,334,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,173,990<span></span>
</td>
<td class="nump">1,102,072<span></span>
</td>
<td class="nump">1,037,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Segment Reporting, Other Segment Item, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,037)<span></span>
</td>
<td class="num">(29,966)<span></span>
</td>
<td class="num">(28,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses and charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,269,710<span></span>
</td>
<td class="nump">9,162,420<span></span>
</td>
<td class="nump">9,034,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661,181<span></span>
</td>
<td class="nump">695,674<span></span>
</td>
<td class="nump">690,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,657<span></span>
</td>
<td class="num">(8,747)<span></span>
</td>
<td class="num">(96,579)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment Reporting Information footnote:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,701)<span></span>
</td>
<td class="num">(2,103)<span></span>
</td>
<td class="num">(1,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses and charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,427,833<span></span>
</td>
<td class="nump">1,307,970<span></span>
</td>
<td class="nump">1,197,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U S Dialysis And Related Lab Services with Intersegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,366,361<span></span>
</td>
<td class="nump">10,911,747<span></span>
</td>
<td class="nump">10,575,372<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,390,717<span></span>
</td>
<td class="nump">10,936,998<span></span>
</td>
<td class="nump">10,599,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U S Dialysis And Related Lab Services with Intersegment | External Sources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,294,614<span></span>
</td>
<td class="nump">10,823,525<span></span>
</td>
<td class="nump">10,488,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,356<span></span>
</td>
<td class="nump">25,251<span></span>
</td>
<td class="nump">24,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U S Dialysis And Related Lab Services with Intersegment | Intersubsegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,747<span></span>
</td>
<td class="nump">88,222<span></span>
</td>
<td class="nump">87,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operating Segments with Intersegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965,761<span></span>
</td>
<td class="nump">751,416<span></span>
</td>
<td class="nump">688,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,819<span></span>
</td>
<td class="nump">539,955<span></span>
</td>
<td class="nump">408,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,510,490<span></span>
</td>
<td class="nump">1,299,223<span></span>
</td>
<td class="nump">1,101,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operating Segments with Intersegment | Intersubsegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,910<span></span>
</td>
<td class="nump">7,852<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (85,657)<span></span>
</td>
<td class="num">$ (96,074)<span></span>
</td>
<td class="num">$ (91,241)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtPrepaymentExtinguishmentAndModificationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Prepayment, Extinguishment And Modification Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtPrepaymentExtinguishmentAndModificationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PatientCareCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PatientCareCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SegmentReportingInformationCorporateExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative support costs, such as labor, benefits and stock-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SegmentReportingInformationCorporateExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesWithIntersegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesWithIntersegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=dva_ExternalSourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=dva_ExternalSourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=us-gaap_IntersubsegmentEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=us-gaap_IntersubsegmentEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_OtherOperatingSegmentsWithIntersegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_OtherOperatingSegmentsWithIntersegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043247943376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 723,860<span></span>
</td>
<td class="nump">$ 745,443<span></span>
</td>
<td class="nump">$ 732,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 62,679<span></span>
</td>
<td class="nump">$ 49,769<span></span>
</td>
<td class="nump">$ 41,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043246417680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Segment, Expenditure, Addition to Long-Lived Assets</a></td>
<td class="nump">$ 555,443<span></span>
</td>
<td class="nump">$ 567,985<span></span>
</td>
<td class="nump">$ 603,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Segment, Expenditure, Addition to Long-Lived Assets</a></td>
<td class="nump">469,799<span></span>
</td>
<td class="nump">501,149<span></span>
</td>
<td class="nump">533,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Segment, Expenditure, Addition to Long-Lived Assets</a></td>
<td class="nump">$ 85,644<span></span>
</td>
<td class="nump">$ 66,836<span></span>
</td>
<td class="nump">$ 69,829<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentExpenditureAdditionToLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043238523552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Summary of Assets by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 17,285,268<span></span>
</td>
<td class="nump">$ 16,893,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">336,684<span></span>
</td>
<td class="nump">545,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">2,940,916<span></span>
</td>
<td class="nump">3,073,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">$ 317,488<span></span>
</td>
<td class="nump">$ 240,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45043239065536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes, net</a></td>
<td class="nump">$ 387,940<span></span>
</td>
<td class="nump">$ 268,091<span></span>
</td>
<td class="nump">$ 344,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest, net</a></td>
<td class="nump">423,360<span></span>
</td>
<td class="nump">387,661<span></span>
</td>
<td class="nump">350,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Fixed assets under financing lease obligations</a></td>
<td class="nump">$ 11,327<span></span>
</td>
<td class="nump">$ 13,269<span></span>
</td>
<td class="nump">$ 1,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid during period for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>134
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2][\7G-/L:^-K-WT\U9BWDA$5R3""*T%UZ5"7W@!Q?\"ON'IH*(3U#SJ55Q
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M53TV#[T86'I0W.V3#]MOMP_6G#>/DPR^OV#':?MX3!^F?5KG<U8]YJ4AA7J
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M:1HT OW]JJK:QS?F!_8/Q9S_#U!+ P04    "  SBTU:U$Y[,5,3   &  $
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MD*=MTIP@:4MJ*'3W&93&H32!HJG6E$%D]KV[IKH%O'T+K2G,S,PS"DMBW%5
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MZ18^@3(NS]#<$DKC4)I T51SRMRRF-'R])NZZKD%O)T++30LS(BT+,-2[W(
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M49'/^MN,J/F3*3#5WZ"D91NC!']W>JZG+(U4>@>[5\/F @GX4LH&%EB*._=
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MYYINU*BL :TOI32[@0W0W='G_P!02P,$%     @ ,XM-6@\XI0='!   B0H
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MPXO1P /=+93.L:INAWBM+*V$UBQH!Z-V!93?*&4/COM O]7G_P!02P,$%
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M^\Q>!5>2_[)6*F34WIY(@J9&O+H[U+*9(;<\NSESC? &DE6_E0"C.@=,;8R
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MY*H#CC5;4J%D9\[+S^$66<R&*.5R1F0990PN+"ZK<6!L/K^D9R#(-4^:B]J
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M$.F<&LSICBS\BOU" ]3OSWS]WU!+ P04    "  SBTU:D@F#$E,'  "S$0
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M\(O$M?\0?UCN?\[XD>L5$7,KEA -YT4V\P$;'ZS:N,_R6V7QD>^&:\&!35J
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M:_S[1Z=%*VL1?U_:M7*&[(4)M5DKW^JEI @.]I-=B??$(VV*"A_-<H*(:5?
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M.AY%Z60OU\P[)L"A>1*XXZ&< Z/5G4'6",X:\@R^A%.%.>&$SHJ&>6/NH>K
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M:T_]>](==-ER(]ZK[ ^95H>WD_6$I6+'ZZSZI![^(9P^"Z27J,S0_^S!KEW
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MJM;)@2IQ['G1/LT"V\1]] NH*<8)&M0VAMDQ&\T#.@JKEEY=XNU%O#A5M_3
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MB><\Y9+]9.',F.EBRR7O&4;BH<-Y!P4+P!J[V%D XI &DM;<5M%I Z5*T[<
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M1U372743([>N>UE)@[V0&Y;8?(*R&W!]+='Y?F(-#.WL\C]02P,$%     @
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M>#I(PV--?RYHV8"^EX9RV"^88/@76GT#4$L#!!0    ( #.+35J_>!57=0<
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ML6:G%'W0 @:WBO3M-WD89&^W2Z5=436;<_@S%:(A\<'BRJH2BM98VUHLN8T
M]RADY$4V3KREG<(-0V%:,5LA&?6&+5M5K4H8< 5^A.Z1S<VVIX,_Y5R*AVT
MB=("")+T&:62=K!] WF?XBQ@O*Y5Z=: ,VK54AF-LIMRBE_3+=KRV6_L8AUO
M2K&7N<&?1]Y*M=K.$Y%!T_0^M2ZQ7W&<2K9EGS)$>+BUJ]X_B7)E8?#QX0'
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M^_G%?3%J:7_RF"ICU,(.YX)7HJ4)";VA5:;_0AL,OX%=_QM02P,$%     @
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M#$Z-X\G6$]N)%K5SB;G0QG/<L#2_$90VP.POA-";B4W0_YC2OU!+ P04
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MN##\-Q>)YP&V^Y2E))RPWQT"P:"W65MO&<PC6I48Q@Z"PHS %-/##&B^[3O
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M,26-Y!JSSP]%3QYQ?Y-D 35E"JRL&X+<3'EOXO[\WM*F?)%8$AV*$9*$>"4
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MXM4'5Y-?SE.-['I@7J0+1(TR"[E*17FC!_R/D3R)FZCT3'?60QY/LI96'&B
M^K"2:^O+QAP/&@%PB!";=P<)H=ME+:4+&XK^/L^:%26%U "W\CU)9/,;WXG<
M0/1:31$%AX;@F=>SK4@V%BC/L_30N:+T-C3M-2>*YY33L23O"%X#S[:*HZV>
MN?-T@1 IZA#%QSBB+0@]TB7&$JG[^2AO"0N!207FI;N*+)F"<J9==RRE[T)U
M"QBO-(!Z?^&2R\$L'C82O\1YRHFW .9S#TPX.N>V;;I.W!JR:.J!G*NVMHC4
MI7BZQF +I"KGQ/LYT&WK<U"ZRK@86BJ_T&U2#"3,R0RQ0$A4A4!>SG5A<@I
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M[_5-]I>ZZ@YM]F-5N"(=X"EL(NSD1G?R^F9QQ+=NN\Z^O%YE-\]NOEH8[\L
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M-LXD0KLVB'1RC:\+0 @/AUYXV$$3,!TV'7:\@I> 81D(  (5L*,2=-."=++
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MYH5;[]>K[/FS_T,#A7TH$EW2CBXVEZ-Y@/4E0S-JGT=3K(PXD3-3"0_$2S_
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MD4=3LCD0=+PC)T*%?)S&86H3)<FCG@@F!/HL"LDR.8%5?P!:70+JGP)0__1
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M6T0IT4M2<?+W.Z1DQ4D=(]C=%UYGSIP9#H><[Z3ZJ2M$ W>U:/3"JXS9SH)
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M-ZSHEX7*"M#^6DJSGU@#P[]M^0]02P,$%     @ ,XM-6CJ^BF!> P  M@<
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MU6P:$-V]$MW&JL9/YJVR..?];XVE#=HIX'FEE.TWSL'P5*__ U!+ P04
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MTI$7._"Z91<1[[&Y@30)@<4LNX"7'G6F'B]] ^]GI=J=D!+XT,*+:%@8@];
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M7"N)%HHFX/VJ;>W^AA0,!U'G_P902P,$%     @ ,XM-6E=JL\D<"@  YQP
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MS<J/V!>-%WAM]Q.X0]ZVBW;%_P?YW+Y6MX]B'D[0VX5?8+EN5SHZU^<K';!
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M-#BO=8L5])971I)<<M9M6KB$*#KA&=O+Z*:#_OAA&OC)YWY&C&P$KY].!&E
M%$U2)39TW$8^PNA$F\2'-HE/%O7O6#>0Y]"%!UNYUCFR9+F2%3.2U;).<1(I
MK'NJ5U%CY$%C_1PJN=>U'WJ9T&DI,4I'.^PDF>,3P2;+,K0YP'C76Z#XLBO^
M31A.)3;JHXH6NQK)%*(94$53U*!E*3)N,'BZW6B1">Q;L#H&G7O >>702]LA
M'N6X&P)ZSO[&SGVO<0<]2C'&<I 5>AN#"6R[X8'A'4B@M@DG;AA1 TUFOAN'
M,:[BB>=&GL<N7W13#_Y"HGB#SB7R47-V.QPW[V;M+'1]#RON+';#),;GQ(VG
MDW-VS\N3GBR:^<P/<4@DR')F);T4"W)Y_\3 G?@X"!(W\0(Z=Q(EYS\:DAK>
ME"6>1&$*W23T;9AF;A F%*8X<I,X9,=:8CSX7Z] ;>WMA5*,@[#[BS^\/5R0
MUMV]X,6\NUU]X6HKL#E+R-'5&R58T*J[L70;(QM[2]A(@W<.NRSPD@>*#/![
M+J79;^B P[5Q]3]02P,$%     @ ,XM-6FN.S*TH!   !0H  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3(N>&ULE59M;]LV$/XKA%H4-D!$$D7J);4-Y&5#
M"ZQ8D*S;AV$?:(FVA$JD1])QNE^_(R4K3JNXZ(?$Y/'NN;OGCB<N#DI_,;40
M%CUUK33+H+9V=QF&IJQ%Q\V%V@D))QNE.VYAJ[>AV6G!*V_4M2&)HC3L>".#
MU<++[O1JH?:V;:2XT\CLNX[KK]>B58=E$ ='P7VSK:T3A*O%CF_%@["?=W<:
M=N&(4C6=D*91$FFQ6097\>4U=?I>X<]&',S)&KE,UDI]<9N/U3*(7$"B%:5U
M"!Q^'L6-:%L'!&'\.V &HTMG>+H^HO_J<X=<UMR(&]7^U52V7@9Y@"JQX?O6
MWJO#!S'DPQQ>J5KC_Z-#K\M8@,J]L:H;C"&"KI']+W\:>#@QR*-7#,A@0'S<
MO2,?Y2VW?+70ZH"TTP8TM_"I>FL(KI&N* ]6PVD#=G9U59;[;M]R*RKTNZV%
M1C>J@_+6CO='@6:_*6/FZ*,L50>[/_BZ%6:^""WX=@AA.?BY[OV05_S$!'U2
MTM8&_2(K4;T$""'H,7)RC/R:G$6\%>4%2F*,2$3H&;QD9"+Q>,DK> \62(!V
MLTAMOB%AR/[OJ[6Q&OKHGZG\>W0ZC>[NUJ79\5(L P V0C^*8/7N39Q&[\_$
M3L?8Z3GTU4W-Y588U,@?%W$J]A^B:X?.985*+:K&&F054MY3^=)3ZSTU/6$U
M!]%:"+A\!FU4"Q/ 7$(85@ %%FD@')5\A_A6"T^]0;-XCF[%!B*HP%+"RJ)=
MRZ5!< GABDFX%%H+67Y%IZW;QW+-0;,4B%O *$6W!MG0(3%Z"]@XSO(YK-Z]
MR4E,WGM9DN,H+>;]NL"$9G/T6<* :YO_ 'D+@\WT>4'CHYA2G!7)B#!+(LP8
MA8.88I(4Z%[T$0T46/X$.BF.">@<C3)&0,APDA$PC'*<IL4S(BEP'L%!EN,\
MS0"P;+DQS:8IN1]DT)X#>".A#!(F]["?Q3'.$O+L:,0\'DQ$1W!!TN\L>ND,
M0HC2";Q!?H9P H06D%G.ON$[S7">Q9[OM,!QGD[0[>6C55[@B#&'1F@\23#!
MI(CG)^D"W["?)9C&D'6*\X(]PV6X2"@J*,Y)\7/T1@EF:3;%[_%DBF"&<QI]
MSW OGF49SL@4YO'@#,D)L$B 3Y:\)#DK(,7,<\P(CG)ZKJ4+:#^"*%2;1$"-
MJ^LL!K+A;S(?8-NS>O1'F1,E+OL,$Q:-4'GJ:@#/ Z"&S7^*:0;N,W9:40;0
MX'2604W)--%P UG\7.<L9<B9Y4 R32#)Z!2/8IH#C/=$S[-,'8\Y7'//*&3W
MUEU[Z+F<>8J3.(*9D,ZG!GEX\FGN!(Q1]P Q,#7WTO9?Z5$ZOG&N^D_[LWK_
M0/H$4]@5KA4;,(TN,GA2Z/[1T6^LVOD/_5I9>#;X90WO-*&= IQOE++'C7,P
MOOQ6_P-02P,$%     @ ,XM-6@O]HAH?!P  B!$  !D   !X;"]W;W)K<VAE
M971S+W-H965T-3,N>&ULG5AI;^.V%OTKA!L4":#8VBS),TF +%T&Z!),VBD>
M'MX'6J)MMA*IDE0\Z:_ON92\M8[3O@^)-MYS]\-+7ZVU^<VNA'#L<U,K>SU:
M.=>^FTQLN1(-MV/="H4O"VT:[O!HEA/;&L$K+]34DS@,LTG#I1K=7/EWC^;F
M2G>NEDH\&F:[IN'FY4[4>GT]BD:;%Q_E<N7HQ>3FJN5+\23<S^VCP=-DBU+)
M1B@KM6)&+*Y'M]&[NYS6^P6?I%C;O7M&GLRU_HT>/E37HY ,$K4H'2%P7)[%
MO:AK H(9OP^8HZU*$MR_WZ!_[7V'+W-NQ;VN?Y&56UV/BA&KQ()WM?NHU]^*
MP9\IX96ZMOX_6_=K\^F(E9UUNAF$84$C57_EGX<X[ D4X2L"\2 0>[M[1=[*
M!^[XS971:V9H-=#HQKOJI6&<5)24)V?P54+.W=R6OW?22HJ095Q5[ %!LDZZ
MS@C+SG_B\UK8BZN)@RZ2F)0#[EV/&[^"&\7L>ZW<RK*O5"6J0X )C-Q:&F\L
MO8M/(CZ(<LR2*&!Q&*<G\)*MYXG'2U[!N^LLWEC+[G4SEXKW(?CO[=PZ@UKY
MWS&?>\3T."+USSO;\E)<C] @5IAG,;KY\HLH"]^?L#?=VIN>0K]Y0C]672V8
M7I#)K59".4M/']%L6,SV<WG,^M/X#YV1:NFCZV.<^'+ 31PPMQ)>)U<OZ"-H
M,:)B&F\-JR2O7ZSLB\>(FCM\F@^Q10F!-U@)@V0EC(\Q:[FLF%2LY'8U9K<6
M+XPC/X!GQ0 KE1.F3PJO>^S!2V1'65[VZ0),;_!1"SEI=D;7-7GF(5';),09
M,O0L=6?K%Z:T(@MU+2MO_<_CI_'.+[)."6-7LO7.K%>R7#'IX&RIETK^X14!
MXY(<8DL0(3ESEDR#*,T9')9(4VND)J^HN<!ICG5((-NIA3=C]M.>$]2$C3>'
M7%MP:=@SKSN?_AYP:_]*U!43\-F]'#CI5C!_DPI&UR7C;6NXM+RVX*YG<'(+
M#6OIX!'Z%%1?D7&0-)7W_,5K[1.WD*:QR-AR:<02IOTEKU]^4<11])X]?+KW
M">-U/223[Y/,:^(4VSG6>W\?^"?I.+OG1K!')\;L.U>-]W'^HN'U<CG070E;
M&CFGC,WULV KC@ ) 30JU!H[E'W'_B.X810(D*$H13,'_H9W^L:@IH!MR+:O
MY3.6Q+,@*G+<Q7F0I05NIK,@SB.D4\&,)06U[4P)A8)JH13>R%KRN:QA'!J%
M6VR,T#D-@Z1(630+BC"B2Y+D[.N#_+^1>\NB(H;VL$])_'Y[?2WV,#>+@B*-
M<)?F09K.<),70186[(?.1P!JMRU1"M)D=XVVP?>= ^K?/$__E?2'@R1&LX*@
MHN@$=TZWW#D]R6T[OQ\W2;C7:));I+P<F)_J[RT&/:GE./]33_>E1>WG:#\=
M)B PA_7%CLP+MQ>/URK#MS11Y $%]KR[HR+J7B$/FHX1KUGZM&.5':/8@,I_
MC<&(KF30L564PIXH_T:H;UCX[SKJC!5)$$54@%$03U-_G64)^]$W>MD90\TT
MQ"Q.9T&>%"P+HIC^)\6,/1J0&C$7189:H_6$.TN#V31B:1 E(4.-%Q'S(^BE
M7EQV,+D65!:;7*C-_E9KM;R$G\WFTRP/IK,(W3&%86&6H6PQ!4HEG;BL,3Q1
M[E#BM/=AZ\QC+)L&.>Q"*V=1R+[1NEI+!#N![6$V8S$^(P3TA/WBNR.)/X_#
M*,C#](*=P]%\YJ]A$5VP'][*R'F4),1($(E(X+S(\HN3_7ZBW;)MNV7_>%39
M\'-_?NA'^7Y(<'I7\C"<JZ6D8=/'?CD$Z5@3GM9-_<8;W2D_4FQP]I7V%7JP
M+^SU#UB 5[]B\.[+^<@X! !TDJ3=I.I0XM311!Y$)34Z_#,Q?:NI -9HJ+-I
M&A11&+"S* ^*)/,X9WVV VBVK? GD_IE?"+T^3;T^4GW4?S,'U?84W_,\@.B
ML#BD^%GQQW;@_*/\=A+[G_#;<+8+:(O"^$#Q[(<MS7P!T E*@G!*/W,/_&=V
MYNFM><1%<N&W^(-4#3G99"/!'E[U>SAM::2>,L?M,%#BTU(J1;;A!0D$@"CK
MKO)TC 42\U;IBZ4$:]#TUN>_\>.U[3#L 0TE99S\HZ]@&L%V!1OLAB[QN:7.
M]T[OT2_8@:O2CU^*J@K>"U\H8K% \C%3O<V0YYWB,!K.71###>%TVG$J[F>A
M0.3$E4D0YO@K$GJ(@PSL$D-\)Z*$VYC G<,TU/6;$CICF+H^*)RTSMAL&OMZ
M!3,D&">RZ1X(I;'<AT+>F%W1N'8:-(K&,;%.,0[S/;Q*UAWE[?]!#,>SF(P<
M%]E1\IKLG8X;89;^-P",(<01_4%Y^W;[,\-M?[K>+>]_H_B>&U23Q5ZQ@&@X
MIE.]Z<_]_8/3K3]K8Y#%R=W?K@3'G$4+\'VAM=L\D(+MCR\W?P)02P,$%
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M]38IWO8PG3\/<=G7$AY5MK^;/L[%^D5MZSMZ>G,9P?"8(ZVV;S/?W['MDM]
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M)A ;K- TNACA\LI?\WW#R-)=K9?2X$7=O>;X:03*3L#QE93FN6$7:#ZV9E\
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MW@%+S8^J8W>.4N_ 43$=54UCJ?D1/"@3QJMWX,/J!,:9ZJ^)7$)V@K-XD&R
M'9.'E02^4XZ<>9B<^\EVU&9%6'-R)\%4TUAJ?CP=IW.)DF:H+(ZJIK'4_ @Z
M%N?AQ?!):::&::$2EM#!I 882LH$&13G X8V<5D\0I+<$3(/$S(XK8%.H2Y9
MHZII+#4_AH[&>8J27:C,C:JFL=3\0R*.N<4QI1ZAG-H)>)M<G(G^EAED)JCH
M[ZJ#:C:A1@Z[./(58?+=^G$2713+?+W.JI?7\0+V"77]&E5-8ZGY@72T+2A&
M2@E4LD95TUAJ?@0=68OPJOC[3EZQX6H]3Z5(!B>O $.:$J8&&0<8QJDB=.R
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M!@A3+FA\3)8,8I(4_X,?1R%J"=#I2$#'!'1I@GU,L/-""V9Y67>!"&831@^
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M'9Y/[?E"LC0;?.=,JC$Z.UVI+QW@.D#=7S"UL\5"S]+EMU/P#U!+ P04
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M)Z.";4&AK"5-'51B5MXR?)JK?K\7A;Q+I9^8S HYA KQ!'">@,\_2KJ6G2K
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MP0HN+Q=X3 1E#?#Y3$JS6=B#2'/P''X'4$L#!!0    ( #.+35J59FX[7P,
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M ,S(O>>IU:K*%JTI9UU7^8.#9@"KQ9556FB+UOQB79=7@;'(L)\!7FDO,&0
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M3I#HL113]6;%>(*DNN5K6Z0<HS!72F+;=1S/3A"AUGR:/WOB\RG+9$PH?N)
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MELHTO8 =E&8L"C/<,V9 %SPR*B,!'FB(PR: K7RJ''/WCBW<3D0?!SW0AQ^
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M([7O\&*X7MQ(EN;CYB63DB7Y9811B+D64.]7C,G]C5Z@^HMC_C=02P,$%
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MNJ!QJ1>QE%=_P::.=08@6G/!LGJPS"!+\NU_\J,V8F< =%\8@.H!J#]@],(
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MR@#Y^9PQ\7Q03M#LE)S^!U!+ P04    "  SBTU:X5;11]@#  !#$0  &0
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MQ; B1:KN^>8WJ!,:&U[$4UG^HDUMZU@H*J3B6>VL(\@HJ_[):RW$GH/GON&
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MSJYL<X:9\C5G( 4'I85#T=H:[I6^[O_>^/M=SY;-/9KG[FB$1P?[ZE"=MO7
M.SWP27I<H+UZXC.7\@)]U2=0O=@]D-=.L7JY9XN%C\6Z&@?C0[$&ZK0MUJ[F
M=GMKTA-+KG[(V<IX1X579WTV5*^5-/;>Z3(#G:DYI4N]'19,56>RIK7Y$O"I
M//\>M"_,%X+RU+K#5)\7OF@!*9,HA95&.I>!KC!%=6*O;A3/RS/L$U?Z1%Q>
M)D#T9FP,]/,5YVI[8SIHOIO,OP-02P,$%     @ ,XM-6M24..EC @  B04
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M8C9L$[_@];@_:FF>%H:GTWN^$!6@)[8'A3ZBN:@V@@/7"HDE.CQ$G_?FGZ8
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M&B%93*;%C18;-ZLMA#:3G[M<FVD>I#4P[Y="Z-<;^P75[P/3_P%02P,$%
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M%>WX(Z,1/A1<\#/#*:)G?V=<*-IQYHV0HC.%],2PHZY*ZCX0X;B] +49:H5
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M\>TO4#KD:;R0QUG^%VW+MJ,!"C>9Y$EIK$:0L+3X3Q]*(G8,\/B  2D-2-O
M/6#@E ;.4PW<TL#-F2E<R7D(J*2S<\&W2.C6"DU?Y&3FULI]ENIYOY5"O67*
M3LZNTY G@#[3!\C0&W0914S/!XW1=5JL*CT[KP.0E,79B6KRY39 KU^=H%>(
MI>CSBF\RFD;9^5"JT6C,85CV?%7T3 [TC EZSU.YRM#/:011$V"HW*A\(8^^
M7!$C8@#A6^3@4T1&Q.T8T/SIYDZ'>?!T<V+PQJEFQLGQG*?,S%\WZBVZEI!D
M?W=174"YW5 Z=YQE:QK"Q4 EAPS$/0QF/_Z QZ.?NFBR"198 FM0Z%84NB;T
M1PHE?4#PH#)E!EW<%1B3'$.GR?L9F4S'WOA\>+_+2D<S,L*XU2S8;X:G_LB?
M5,T:GGB5)Y[1DQM&[UC,Y#>D@A)M4@$A7Z;L7XAR[^X@A063G5%8 (]W!N1B
MUW=;WG6TFCB3:<LY;\^YL3/UO6[?QI5O8Z-O7PYY@^2*2K5O;.((L42M$HE@
ML8!\I\@;"BH[9W2\YPR9.$Y[0HVCZKO,+8$U")Q4!$[Z$5@N=O2Z9/+D5.7J
M*A34.QI+IK**2MSJA00U)/EH=(I256WP!5I !$+M \?6UV2/[#?C]L*9=S3"
MCM]:748OG\FA7W'H&SF\#$.Q@1TZ-#<U4P)BM=84N_QP\/5FSM\CQ?/=]BKU
M]T/.(UZ+.:-OSV1N6C$W/9)D59G%4B8!W; %H-\4"1_6B@#)TB6ZX5D&G=X;
M4?MN63;! DM@#3;QJ"[(1O;V_1++$HM6T0);:$T>=PI;?&SS5T)(9\$(BJL3
M7;'>TWA3%+4T5J*'IB'L1G>XHNE2$:]:RA4@E0E84KRK@[ES(O!^AO.(WPK4
MN7G,O1FVA-9DF-0,$R/#<[IF4N4Y'>-H3H7XIHJ3+151)T%&K-XKU29:8 NM
MR6-=Z&.+E3ZV6NI;10MLH35YK*M];"[W;Z6*5!26JS+6JS+<696GB"9\DW:'
M[W[9KB2 TXY>8_^]V;*$UF2K5A38+"F.LJ4*0B:*5!D=*+2/=%%)8JV)O<[U
M9P3HS:@EM":CM8[!9B$3J"A6^T6H(QG]NA$LBUC^=:N3.IOR8VX5+;"%UN2Q
MEC-X8C$?6E(-)8\VT0);:$T>:TF#S9I&5^*\JL3W(KS[F]V^WG!=XOKM3&A)
M<90\O81^P;6 P68%\\' T=/2H!E_-PWJKQ =R\ZJ?K&%UOP(6PL88BSL#Z=!
M]%_^Z$^@0F\(TRXJS=A]P]DJ6F +K<EK+6@(MI<6B4VA,;>*%MA":_)8RQ9B
MEBW?'>Y'\!M53]<BGYL!>M/Y$NJ%U.J%&*OZHH[LI,FJ4K&*%MA":W)6*Q7B
M6@QEFZIC;A4ML(76Y+'6,,0L,)Y3X9#]'S$\SQM/<:O$,7?=FZB7D":DEB;$
M+$V^/^<=D3X[.<_M_NW5JD*QA=:DLU8HQ/R+RSLN@"W3)PD],U3O\+4J4&RA
M-6FL!0KQ+:9!FY)C;A4ML(76Y+$6,,0L,)Z5!J?[0@^/'-S^YF7NNC=1+R%-
MG%J:.&9I\MUI\ A^H_3K5'IF@-Z'*ZPJDN'.,:($Q#(_CJ58TA]-BU,XU=/J
MR-=E?M"I]?P*GP7%P:T:ICA']IZ*)4LS%,-"08[>3M2V*(JC6<6-Y.O\L-(=
MEY(G^>4*: 1"-U#O%YS+QQO=075 ;O8_4$L#!!0    ( #.+35K"9;UDHR0
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M170D ZH)5).HIE M0C6-:H;2["*IQSO,>XYWZ+R2$IME9WFX[>LW[]U [_)
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M-3 9/EVWC!TD@'(ARPF6DRRG6"YB.<UR!N-:1=,8)#!Q)JK8XP'NW?0O(';
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M6".=NZPLL]7VV[E(9R*O/U#]_3[+RMT/]0J>L_SKMGC7_P=02P,$%     @
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M+W=O<FMS:&5E=',O<VAE970X-"YX;6RUF5MOVS84Q[\*H15#"R2Q+K[$F6W
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M"=FX5PP.N]MS^_T]VP]+N=V^O>> _F$I9S 8N,V67Y:67[[J#*3:'QM\X6/
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MD+X515]&]AW%.UM8W7.ERS3[NM6E-Q$&H+^O.5=/'3/!6,P7/P%02P,$%
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MMDS-HUQ_Q:V>KN4+9:K=$]:%;;?M0;C41F9;,$60<5&\V>LV#WL XJD&!%M
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M/I6C*KIG,3$R=PWH6=(]R=PPH1\.5-: ]A=2FMW$.BA_849_ %!+ P04
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M?"Z@W?FP<3Z\Z/R!FTUGI1&!2RH'&@N:66QS/FR+/DKB_P2$9U.F1+WVL]1
MIK;2U@.G.6W&]:2>4O_,ZUE_S_2:2P,"5P2-ND,J@*[G9[VQJO(S:ZDL34"_
M+.B7@]H9T/>54O:T<0Z:GUCZ%U!+ P04    "  SBTU:YQV5$S4*  #(40
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;.U::V_;R!7]*P/M=IL
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M&'%%M"MRI$1Q&E55LD[BJ'G-6)=%IMXU-/,6#?/&O9EK7] N#TDNBSH-^P_
M;!"S+B['OCO,!Z###G4]?Y@22(A]2D92HFD23Z+5J:.6 C>-BPT[IHRXG#E#
M,X L(-Z(%8UQ>)KC_G]UC=HVAVJ.'4L+,ZO"J.<9PQ[0^;Y/C"H#.LZ=L<QH
MAL.V( X#%,==UQ\:,F7 PR4$9/VG2]^/QC,\S6?J%5^]P.?JA;@L11Y_1K*,
M\BIMJQZM_E3OR:.L-AWZ2]'":K305K1^6C6OX:\';-@JL5F-%MJ*UD^KAC9L
MD=JP"61G?A!0XPX$=-CSN6\@ B2D:E(9>YIJ?,,6^0V;V'5&U-NA,WP]!(0\
M<%R#$8!X5,E&R(=HC",V,(Z8X,6&3T- HY[99%@@0.:[(\]UH@&.6 8X8D)7
M72#NX:$M4\@5/@_?W\%X 7?&G&F((\\$X@C$7"YQAZP.Z(;$,RGIYT&3&[%!
M;L1D+=\S1JHI,AQ,2?H.-+"1YP9L!  L]?;'A[,KH#,2,B7I)T1S&K'%:01:
M;7,(&;ZY+R$A\#P)(=W@>=(WI6&-3,/:U9%Z=H4<O0^M$IO5:*&M:/W<:F(C
M7X_8B%5BLQHMM!6MGU9-;,0BL1$ L*"?!""=!ZQ/03I, \+\D3M1 QNQ"&P$
M "P<</5OZ M8=>.$&9@#K+MA1N@(AE(-;-0&L%%H08T.UUF6D(P:RW,A*'.I
M/P(W5&,;M8QM%,0VQS6>\8 P8)P$0V? .A[GWLC8HYK:Z#.A-@I0FT_9<*UE
M">G I3=0.+[T1@]^R+4!<!18>G,)'RXQ 3)HZ0V2C2Z]44UR]+F1' 5(SN68
M&64^<>D-THTOO5&-=-06TM%3?T"%A- OJ)"N_\#I>])$1T\GNE"LU:<K="UR
M=231K?)9H:MN#:Z&DG37Y."V*)NQ<25EF=SM9'27JE%?H)\+5?!<ED6:UK*G
M'U_!'%E%0:O10EO1^D71*$B_'@I2JRAH-5IH*UH_K1H%J444I":Z&?/T44DX
M*>G;T.A'+:(?-5&-&9.0J3%\3$GZ.W4T[#$;L,=,/!O6X;@DG)3T^Z_YCEGF
M.V;RF%$+0&-XF9+TO6BD8\\$Z=C1!;;E<4DX*>FG0",<LX%P[.CRVO*X))R4
M]/M_L//MN7$;.[JRMCPN"2<E_5QH4F.V2(V96]C,>]+4&":F)*V)^<%.WDR4
MFV9'=*7*L<MENP&VN]KMNKYJ]AH/KE_C\[#=.ZW#M%NYWT;EIIY_4K%6(9W7
MONI5V>Z.;D]D<=_L%[XKI"RRYG KHI4H:X'Z?%T4\NFD_H)NC_KB7U!+ P04
M    "  SBTU:QM30#7P%  #T(   &@   'AL+W=O<FMS:&5E=',O<VAE970Q
M,#$N>&ULM5IA;]HX&/XK%C>=-ND&L0DA]"A2(>M6:9NJ]MK[<+H/;F+ 6A(S
MV\!ZNA]_=A(2$H)7>N8+).'U8[^/_;Y^GYCQEO%O8DF(!#^2.!67G:64JXM>
M3X1+DF#192N2JE_FC"=8JEN^Z(D5)SC*&B5Q#SF.UTLP33N3<?;LED_&;"UC
MFI);#L0Z23!_GI*8;2\[L+-[<$<72ZD?]";C%5Z0>R(?5K=<W?5*E(@F)!64
MI8"3^67G"EX$R-,-,HM'2K9B[QIH5YX8^Z9O;J++CJ-'1&(22@V!U=>&S$@<
M:R0UCN\%:*?L4S?<O]ZA7V?.*V>>L" S%O])([F\[/@=$)$Y7L?RCFT_D<*A
M@<8+62RR3[ M;)T."-="LJ1HK$:0T#3_QC\*(O8:H-&1!JAH@%[:H%\TZ+^T
M@5LT<#-F<E<R'@(L\63,V19P;:W0]$5&9M9:N4]3/>_WDJM?J6HG)U?A]S45
M5,^! ._!C"4KEI)4"L#FX$XM%&4/:D9O R(QC<4[\ ;0%/RQ9&N!TTB,>U*-
M1Z/VPJ+O:=XW.M(W1. +2^52@ ]I1*(Z0$\Y4GJ#=MY,D1$Q(&$7].%O #G(
M!0_W 7C[YAV8*3,:MHQO]G*T_L_1@I>C(2-:S?5^.9']#+Y_!'ZZ%NJ)$/N3
M!?[ZK*?O1I)$_-TV/SFDVPZI4\Z%6.&07'943A&$;TAG\NLOT'-^;R/3)EA@
M":Q&I5M2Z9K0)Q]5N@2*O7")TP41>I6S;4JX6-*5NI%$=2G;Z,QAAQFL3KB;
M"71&KN>->YM]H@[-G+I%8+*HN30H71H87;HGG)(LIFD:T0V-UCB.GP%5R5ZY
M0W$,GG;K!^\%>YN3QHY.73,VP0)+8#6"O9)@SW[X>3:IM D66 *K43DLJ1P:
MU^H,BR5881H!R?+5R$FY/-MHS.&\O6CIHQ'TAXVP.S1#0\_U&Z%W:#48H2%L
M#S^_=,DWNZ2V.:IR22K!:LU57A$$K#@-"5 [)X@I?J*Q6C(J0K%0%5AS+\S=
M] ]'YO1]M^'EH14<^0YL>-EFU>\/V[T<E5Z.C%Y>8\K!(X[71">:6TXV5-4&
M*LU\(G$$/JB)E,_@ILB?K3,Y.AR6C]"PD1YGAV;-!&JRJ/D&G:I0<HS>72T6
MG"Q4NJRF,&1"JN(W9(N4_M,^:05H;=8\Z+N-"9D5=OLIWQVZ[JCA5XO9T/<<
M_XAS>U4@/,?^ /X%7UGZ/HM8O6NV,F#L^=0L9Q4ML(569QU5K"/[FT:!:8M/
MFVB!+;0ZGU4)#(UEX>L+MP)W/ZSZ ^@V=Q!S]R>3=8X:%U9%+C17N:\/^8?N
M?1=$RN)9T';99^SYY"5J$RVPA59GO:K#X> ,(6^UYK:*%MA"J_-9E=W06(I.
MOJZ3)\+U*MZM5B)V16.DUNI1M3XM@&O%!FH&_*%-L])H,1D<V8VK AB:*^#7
MA^8UXX0N4A 4T0EF1*>]]B@U#N+D5643+;"%5I^ JER'_AFBU*@!3N;3)EI@
M"ZW.9R4,H%D9_(\H;9$$([\9IBU&J!FG+39'5!VJ- $R:X( /U*)P0PKA7HK
M21=\EE&WS0TSSJEKPRI:8 NMSF$E/1"T'VO(JJBPBA;80JOS68D*9"RR+:CP
MHH/:>TRHU6@C[,P#.9FV<V@'5&D'9-8.KY/W!:CW4ZJL*@=;:'6J*N6 S,JA
M->N]Y%6 &??DJ+6J"VRAU3FM= $Z@RY 5G6!5;3 %EJ=STH7(+,N>/6K@ )W
M/_D-1H[7?!5@[OYDLJR^;^_M'0<GA"^R8W6ATMDZE?E9:OFT/+J_R@ZL&\^G
M\"+(#^ KF/S_ %\P7U"E.&(R5Y!.=ZAFF^='[/F-9*OLT/F)2<F2['))<$2X
M-E"_SQF3NQO=0?E'A\E_4$L#!!0    ( #.+35K:G"+Q604  (X<   :
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M&JJ]33.CYQ25-:#YF91FV;$%N'^@H[]02P,$%     @ ,XM-6I[,]J(- P
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M&_>![?SGCO5).^=046W1ZJKN;,3]GU#U<CJEN34"W-Y7^A:/&[5M;^6=6'8
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M J@Z:@:,RA93(&.5/.)BH#H %*$=P0YJ. #D=IBKPQ'570Y,3TV"=XE"M0W
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M,N Z0'U?,"8W%=U!^\J;_@502P,$%     @ ,XM-6L) X.?Q @  +@D  !H
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MP%2 _#ZG5*PGZLSLKDCA;U!+ P04    "  SBTU:TU5:-@8#  "!"0  &@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,30N>&ULK59=;]HP%/TK5E9-G=0VGR3
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MP) HJM^#.^^C</6>"M?_PQP^ U!+ P04    "  SBTU:EXJ[',     3 @
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MO?ACQ?V!6Y*]J?-\"MN6Q54IL\/SE@[/BOK\)U!+ P04    "  SBTU:GO@
MH2X#  #M0@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=M+3N-
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MJG<%Z%U5[PK0NZK>%:!W5;TK0.^J>E> WE7UK@"]J^I= 7K7[K W0.^J>E>
MWDWU;@"]F^K= 'HWU;L!]&ZJ=P/HW53O!M"[J=X-H'=3O1M [Z9Z-X#>3?5N
M +U;5]8!Z&VNK^L _#;7%78<0'!S767' 0PWUY5V'$!Q<UUMQP$<-]<5=QQ
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MX_X?QR_/N*_:X34_6?Y'X.8G4$L! A0#%     @ ,XM-6@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  SBTU:F*-V8>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  SBTU:F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #.+35J7
MU)!6+ <  &XN   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  SBTU:.SN#G3("  "B!0  &
M    @(%O#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M,XM-6AL)X)+(!P  DB0  !@              ("!UQ$  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #.+35K8SKTUD@0  #D1   8
M          " @=49  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  SBTU: Y8+4Y (   0)P  &               @(&='@  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ,XM-6H/"0[;X @  ?@D
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M965T,3 N>&UL4$L! A0#%     @ ,XM-6OKNYP"3!   KPL  !D
M     ("!D7<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #.+35I@=/MRU 8  $81   9              "
M@7Z,  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ,XM-
M6H%9=J I!@  Y@X  !D              ("!B9,  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  SBTU:6=R]PJ4"  #A!0  &0
M        @('IF0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( #.+35IJ6M\.^ H  +P;   9              " @<6<  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ ,XM-6@APO2O+&0  2U,
M !D              ("!]*<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  SBTU:D@F#$E,'  "S$0  &0              @('VP0
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #.+35KL7YPL
MV04  *D-   9              " @8#)  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ ,XM-6E;A[)DV$0  U#(  !D
M ("!D,\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  S
MBTU:'0,^'_T'  ! %0  &0              @(']X   >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( #.+35HXAQI;X0P  'PF   9
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M970R.2YX;6Q02P$"% ,4    "  SBTU:OW@55W4'  "2$P  &0
M    @($@%0$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M #.+35I)X:A"$ D  ,$8   9              " @<P< 0!X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ ,XM-6M.^GU_&"0  #QL  !D
M             ("!$R8! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  SBTU:VO?"@KP"   V!@  &0              @($0, $ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #.+35H$P/U-> (
M *0&   9              " @0,S 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ ,XM-6@8"ZLM$ @  BP8  !D              ("!
MLC4! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  SBTU:
MBMG*0H06  "+90  &0              @($M. $ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( #.+35K[:]6I9"T  #Z@   9
M      " @>A. 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ ,XM-6J20P*O$!   E0P  !D              ("!@WP! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  SBTU:9N;T1.<#  ##"0
M&0              @(%^@0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( #.+35HZOHI@7@,  +8'   9              " @9R% 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ ,XM-6A02Z\:C
M @  LP4  !D              ("!,8D! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  SBTU:46']D1(#  !G!@  &0
M@($+C $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( #.+
M35IZ0=*RA ,  $0(   9              " @52/ 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ ,XM-6JJ:_[_] @  C08  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( #.+35I#4W E_ 0  /X+   9
M  " @=^N 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M,XM-6D1*K:JL!   8PL  !D              ("!$K0! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  SBTU:QGHX<WH$  !""@  &0
M            @('UN $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( #.+35IKCLRM* 0   4*   9              " @::] 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ ,XM-6@O]HAH?!P
MB!$  !D              ("!!<(! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    "  SBTU:SM?9BV8#   Q"   &0              @(%;
MR0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( #.+35IP
M&S[*YP8  /P1   9              " @?C, 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ ,XM-6HH^?W'" @  ' 8  !D
M     ("!%M0! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #.+35H;#\']6P0  -\6   9              "
M@1_O 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ ,XM-
M6HAZ-(HF P  1PT  !D              ("!L?,! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    "  SBTU:N7J='W$#   #"@  &0
M        @($.]P$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( #.+35H7SI=80 0   4;   9              " @;;Z 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ ,XM-6K.\>.2^ P  A X
M !D              ("!+?\! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    "  SBTU:E69N.U\#   8#   &0              @($B P(
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( #.+35H6\S'V
MD00  ,<;   9              " @;@& @!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ ,XM-6O,RF!$R!0  <"   !D
M ("!@ L" 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  S
MBTU:[ 5!!84$  #N&   &0              @('I$ ( >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( #.+35IG#G8;- 8  #4I   9
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M970W-"YX;6Q02P$"% ,4    "  SBTU:FJ8FFKP#  #\#0  &0
M    @('R* ( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (
M #.+35J]%O9E3P0  "L0   9              " @>4L @!X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL4$L! A0#%     @ ,XM-6@H#1_2W!   3!0  !D
M             ("!:S$" 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"
M% ,4    "  SBTU:AU(*>GX#  #+"0  &0              @(%9-@( >&PO
M=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( #.+35IP#$^/"08
M "PG   9              " @0XZ @!X;"]W;W)K<VAE971S+W-H965T-SDN
M>&UL4$L! A0#%     @ ,XM-6L)EO62C)   :QX" !D              ("!
M3D " 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    "  SBTU:
M)45#ZWD"  !:!@  &0              @($H90( >&PO=V]R:W-H965T<R]S
M:&5E=#@Q+GAM;%!+ 0(4 Q0    ( #.+35JO.JTXV0P  '>A   9
M      " @=AG @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%
M  @ ,XM-6ID9DJ13!0  6AP  !D              ("!Z'0" 'AL+W=O<FMS
M:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    "  SBTU:F,MOJ# %  !Z&@
M&0              @(%R>@( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+
M 0(4 Q0    ( #.+35I-9I'8<@,  -@+   9              " @=E_ @!X
M;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ ,XM-6C8R=./
M!   %Q0  !D              ("!@H," 'AL+W=O<FMS:&5E=',O<VAE970X
M-BYX;6Q02P$"% ,4    "  SBTU:>WIAHS4$  "C#P  &0
M@(%YB ( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( #.+
M35KR$NH#(04  .DB   9              " @>6, @!X;"]W;W)K<VAE971S
M+W-H965T.#@N>&UL4$L! A0#%     @ ,XM-6K-1!:DU!0  HQT  !D
M         ("!/9(" 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4
M    "  SBTU:IS371]4"  #."   &0              @(&IEP( >&PO=V]R
M:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( #.+35H;C/K"_@,  &<.
M   9              " @;6: @!X;"]W;W)K<VAE971S+W-H965T.3$N>&UL
M4$L! A0#%     @ ,XM-6@"",^9(!@  OBH  !D              ("!ZIX"
M 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4    "  SBTU:ODSH
MS_4$   &'   &0              @(%II0( >&PO=V]R:W-H965T<R]S:&5E
M=#DS+GAM;%!+ 0(4 Q0    ( #.+35HR%I23TP(  - &   9
M  " @96J @!X;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @
M,XM-6N<=E1,U"@  R%$  !D              ("!GZT" 'AL+W=O<FMS:&5E
M=',O<VAE970Y-2YX;6Q02P$"% ,4    "  SBTU:YTS19AX#  "\"   &0
M            @($+N ( >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4
M Q0    ( #.+35I:V8<T"P0  .P.   9              " @6"[ @!X;"]W
M;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ ,XM-6AJ!XEB^!@
M5S4  !D              ("!HK\" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX
M;6Q02P$"% ,4    "  SBTU:XCB\.;X'  #)(   &0              @(&7
MQ@( >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0    ( #.+35KR
M;C*G,0<  *\N   :              " @8S. @!X;"]W;W)K<VAE971S+W-H
M965T,3 P+GAM;%!+ 0(4 Q0    ( #.+35K&U- -? 4  /0@   :
M      " @?75 @!X;"]W;W)K<VAE971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0
M   ( #.+35K:G"+Q604  (X<   :              " @:G; @!X;"]W;W)K
M<VAE971S+W-H965T,3 R+GAM;%!+ 0(4 Q0    ( #.+35HUI*.%KP(  *P'
M   :              " @3KA @!X;"]W;W)K<VAE971S+W-H965T,3 S+GAM
M;%!+ 0(4 Q0    ( #.+35J>S/:B#0,  %P(   :              " @2'D
M @!X;"]W;W)K<VAE971S+W-H965T,3 T+GAM;%!+ 0(4 Q0    ( #.+35H8
M.T.2S 0  ,@;   :              " @6;G @!X;"]W;W)K<VAE971S+W-H
M965T,3 U+GAM;%!+ 0(4 Q0    ( #.+35JG_C/9[P,  )X1   :
M      " @6KL @!X;"]W;W)K<VAE971S+W-H965T,3 V+GAM;%!+ 0(4 Q0
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M965T,3$P+GAM;%!+ 0(4 Q0    ( #.+35HC5)F$[0(  $<*   :
M      " @<<( P!X;"]W;W)K<VAE971S+W-H965T,3$Q+GAM;%!+ 0(4 Q0
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M96QS+RYR96QS4$L! A0#%     @ ,XM-6B(U>9-Q"   KTH   \
M     ( !21H# 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #.+35J>^ "A
M+@,  .U"   :              "  ><B P!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( #.+35KFVQ*!A@(  $]    3
M  "  4TF P!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !Z 'H G"$   0I
$ P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>466</ContextCount>
  <ElementCount>665</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>138</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Short-term and long-term investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Shorttermandlongterminvestments</Role>
      <ShortName>Short-term and long-term investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Other Receivables Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherReceivablesOtherReceivables</Role>
      <ShortName>Other Receivables Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Intangibles</Role>
      <ShortName>Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Equity Method and Other Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestments</Role>
      <ShortName>Equity Method and Other Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherLiabilities</Role>
      <ShortName>Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments</Role>
      <ShortName>Noncontrolling Interests Subject to Put Provisions and Other Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Stockbasedcompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Stockholder's equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Stockholdersequity</Role>
      <ShortName>Stockholder's equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Accumulated Other Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Held for Sale and Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/HeldforSaleandDiscontinuedOperations</Role>
      <ShortName>Held for Sale and Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9952179 - Disclosure - Fair Values of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstruments</Role>
      <ShortName>Fair Values of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9952180 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9952181 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables</Role>
      <ShortName>Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/EarningsPerShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Short-term and long-term invesmtents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShorttermandlongterminvesmtentsTables</Role>
      <ShortName>Short-term and long-term invesmtents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Shorttermandlongterminvestments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherReceivablesTables</Role>
      <ShortName>Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherReceivablesOtherReceivables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/PropertyandEquipment</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesTables</Role>
      <ShortName>Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Intangibles</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables</Role>
      <ShortName>Equity Method and Other Investmetns Equity Method and Other Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Goodwill</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherLiabilitiesTables</Role>
      <ShortName>Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherLiabilities</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/IncomeTaxes</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/LongTermDebt</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Leases</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Stock-based compensation and Shareholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables</Role>
      <ShortName>Stock-based compensation and Shareholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Stockholder's equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/StockholdersequityTables</Role>
      <ShortName>Stockholder's equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Stockholdersequity</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Acquisitions and Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresTables</Role>
      <ShortName>Acquisitions and Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/AcquisitionsandDivestitures</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Fair Values of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstrumentsTables</Role>
      <ShortName>Fair Values of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/FairValuesofFinancialInstruments</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/SegmentReporting</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails</Role>
      <ShortName>Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Revenue Recognition and Accounts Receivable - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition and Accounts Receivable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Short-term and long-term investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShorttermandlongterminvestmentsDetails</Role>
      <ShortName>Short-term and long-term investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/ShorttermandlongterminvesmtentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherReceivablesDetails</Role>
      <ShortName>Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherReceivablesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails</Role>
      <ShortName>Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails</Role>
      <ShortName>Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Intangibles - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesAdditionalInformationDetails</Role>
      <ShortName>Intangibles - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails</Role>
      <ShortName>Equity Method and Other Investmetns Equity Method and Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Equity Method and Other Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Equity Method and Other Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails</Role>
      <ShortName>Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Goodwill - Schedule of Reporting Units Goodwill Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails</Role>
      <ShortName>Goodwill - Schedule of Reporting Units Goodwill Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillAdditionalInformationDetails</Role>
      <ShortName>Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherLiabilitiesDetails</Role>
      <ShortName>Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherLiabilitiesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails</Role>
      <ShortName>Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Long-Term Debt - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails</Role>
      <ShortName>Long-Term Debt - Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails</Role>
      <ShortName>Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Long-Term Debt - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtAdditionalinformationDetail</Role>
      <ShortName>Long-Term Debt - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Leases Lease Expense Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails</Role>
      <ShortName>Leases Lease Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Leases Leases Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesLeasesOtherInformationDetails</Role>
      <ShortName>Leases Leases Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/Contingencies</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Long-term Incentive Compensation and Shareholders??? Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders??? Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Long-term Incentive Compensation and Shareholders??? Equity - Summary of Range of Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders??? Equity - Summary of Range of Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Long-term Incentive Compensation and Shareholders??? Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders??? Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Stock Repurchases Tender Offer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/StockRepurchasesTenderOfferDetails</Role>
      <ShortName>Stock Repurchases Tender Offer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails</Role>
      <ShortName>Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Shareholder's equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShareholdersequityDetails</Role>
      <ShortName>Shareholder's equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Acquisitions - Components of Routine Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails</Role>
      <ShortName>Acquisitions - Components of Routine Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Acquisitions - Assets acquired and liabilities assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails</Role>
      <ShortName>Acquisitions - Assets acquired and liabilities assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails</Role>
      <ShortName>Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails</Role>
      <ShortName>Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Acquisitions and Divestitures - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails</Role>
      <ShortName>Acquisitions and Divestitures - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Held for Sale and Discontinued Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>Held for Sale and Discontinued Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Variable Interest Entities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails</Role>
      <ShortName>Variable Interest Entities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/FairValuesofFinancialInstrumentsTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails</Role>
      <ShortName>Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9955586 - Disclosure - Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9955587 - Disclosure - Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9955588 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Assets by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="dva-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9955590 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="dva-20241231.htm">dva-20241231.htm</File>
    <File>dva-20241231.xsd</File>
    <File>dva-20241231_cal.xml</File>
    <File>dva-20241231_def.xml</File>
    <File>dva-20241231_lab.xml</File>
    <File>dva-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dva-20241231_g1.gif</File>
    <File>dva-20241231_g2.jpg</File>
    <File>dva-20241231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1753">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>141
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dva-20241231.htm": {
   "nsprefix": "dva",
   "nsuri": "http://www.davita.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "dva-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "dva-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "dva-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dva-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dva-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dva-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 563,
   "keyCustom": 102,
   "axisStandard": 48,
   "axisCustom": 2,
   "memberStandard": 60,
   "memberCustom": 76,
   "hidden": {
    "total": 149,
    "http://fasb.org/us-gaap/2024": 118,
    "http://www.davita.com/20241231": 26,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 466,
   "entityCount": 1,
   "segmentCount": 138,
   "elementCount": 1156,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1753,
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/cyd/2024": 16,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.davita.com/role/DocumentandEntityInformation",
     "longName": "0000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.davita.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "longName": "9952151 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "longName": "9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952153 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
     "longName": "9952156 - Statement - CONSOLIDATED STATEMENTS OF EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.davita.com/role/RevenueRecognition",
     "longName": "9952158 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.davita.com/role/EarningsPerShare",
     "longName": "9952159 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.davita.com/role/Shorttermandlongterminvestments",
     "longName": "9952160 - Disclosure - Short-term and long-term investments",
     "shortName": "Short-term and long-term investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.davita.com/role/OtherReceivablesOtherReceivables",
     "longName": "9952161 - Disclosure - Other Receivables Other Receivables",
     "shortName": "Other Receivables Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.davita.com/role/PropertyandEquipment",
     "longName": "9952162 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.davita.com/role/Intangibles",
     "longName": "9952163 - Disclosure - Intangibles",
     "shortName": "Intangibles",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestments",
     "longName": "9952164 - Disclosure - Equity Method and Other Investments",
     "shortName": "Equity Method and Other Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.davita.com/role/Goodwill",
     "longName": "9952165 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.davita.com/role/OtherLiabilities",
     "longName": "9952166 - Disclosure - Other Liabilities",
     "shortName": "Other Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.davita.com/role/IncomeTaxes",
     "longName": "9952167 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.davita.com/role/LongTermDebt",
     "longName": "9952168 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.davita.com/role/Leases",
     "longName": "9952169 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dva:LeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:LeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.davita.com/role/EmployeeBenefitPlans",
     "longName": "9952170 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.davita.com/role/Contingencies",
     "longName": "9952171 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments",
     "longName": "9952172 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments",
     "shortName": "Noncontrolling Interests Subject to Put Provisions and Other Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.davita.com/role/Stockbasedcompensation",
     "longName": "9952173 - Disclosure - Stock-based compensation",
     "shortName": "Stock-based compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.davita.com/role/Stockholdersequity",
     "longName": "9952174 - Disclosure - Stockholder's equity",
     "shortName": "Stockholder's equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome",
     "longName": "9952175 - Disclosure - Accumulated Other Comprehensive (Loss) Income",
     "shortName": "Accumulated Other Comprehensive (Loss) Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.davita.com/role/AcquisitionsandDivestitures",
     "longName": "9952176 - Disclosure - Acquisitions and Divestitures",
     "shortName": "Acquisitions and Divestitures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.davita.com/role/HeldforSaleandDiscontinuedOperations",
     "longName": "9952177 - Disclosure - Held for Sale and Discontinued Operations",
     "shortName": "Held for Sale and Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.davita.com/role/VariableInterestEntities",
     "longName": "9952178 - Disclosure - Variable Interest Entities",
     "shortName": "Variable Interest Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.davita.com/role/FairValuesofFinancialInstruments",
     "longName": "9952179 - Disclosure - Fair Values of Financial Instruments",
     "shortName": "Fair Values of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.davita.com/role/SegmentReporting",
     "longName": "9952180 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.davita.com/role/SupplementalCashFlowInformation",
     "longName": "9952181 - Disclosure - Supplemental Cash Flow Information",
     "shortName": "Supplemental Cash Flow Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables",
     "longName": "9955512 - Disclosure - Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)",
     "shortName": "Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.davita.com/role/EarningsPerShareTables",
     "longName": "9955513 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.davita.com/role/ShorttermandlongterminvesmtentsTables",
     "longName": "9955514 - Disclosure - Short-term and long-term invesmtents (Tables)",
     "shortName": "Short-term and long-term invesmtents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.davita.com/role/OtherReceivablesTables",
     "longName": "9955515 - Disclosure - Other Receivables (Tables)",
     "shortName": "Other Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dva:ScheduleOfOtherReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:ScheduleOfOtherReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.davita.com/role/PropertyandEquipmentTables",
     "longName": "9955516 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.davita.com/role/IntangiblesTables",
     "longName": "9955517 - Disclosure - Intangibles (Tables)",
     "shortName": "Intangibles (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables",
     "longName": "9955518 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Tables)",
     "shortName": "Equity Method and Other Investmetns Equity Method and Other Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.davita.com/role/GoodwillTables",
     "longName": "9955519 - Disclosure - Goodwill (Tables)",
     "shortName": "Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.davita.com/role/OtherLiabilitiesTables",
     "longName": "9955520 - Disclosure - Other Liabilities (Tables)",
     "shortName": "Other Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.davita.com/role/IncomeTaxesTables",
     "longName": "9955521 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.davita.com/role/LongTermDebtTables",
     "longName": "9955522 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.davita.com/role/LeasesTables",
     "longName": "9955523 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables",
     "longName": "9955524 - Disclosure - Stock-based compensation and Shareholders\u2019 Equity (Tables)",
     "shortName": "Stock-based compensation and Shareholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.davita.com/role/StockholdersequityTables",
     "longName": "9955525 - Disclosure - Stockholder's equity (Tables)",
     "shortName": "Stockholder's equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables",
     "longName": "9955526 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)",
     "shortName": "Accumulated Other Comprehensive (Loss) Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresTables",
     "longName": "9955527 - Disclosure - Acquisitions and Divestitures (Tables)",
     "shortName": "Acquisitions and Divestitures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.davita.com/role/FairValuesofFinancialInstrumentsTables",
     "longName": "9955528 - Disclosure - Fair Values of Financial Instruments (Tables)",
     "shortName": "Fair Values of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.davita.com/role/SegmentReportingTables",
     "longName": "9955529 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.davita.com/role/SupplementalCashFlowInformationTables",
     "longName": "9955530 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9955531 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
     "longName": "9955532 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)",
     "shortName": "Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:TotalRevenueNetOfIntersegmentRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
     "longName": "9955533 - Disclosure - Revenue Recognition and Accounts Receivable - Additional Information (Details)",
     "shortName": "Revenue Recognition and Accounts Receivable - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails",
     "longName": "9955534 - Disclosure - Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)",
     "shortName": "Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails",
     "longName": "9955535 - Disclosure - Short-term and long-term investments (Details)",
     "shortName": "Short-term and long-term investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:HeldToMaturitySecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:HeldToMaturitySecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.davita.com/role/OtherReceivablesDetails",
     "longName": "9955536 - Disclosure - Other Receivables (Details)",
     "shortName": "Other Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-150",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "dva:ScheduleOfOtherReceivablesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.davita.com/role/PropertyandEquipmentDetails",
     "longName": "9955537 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Land",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Land",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails",
     "longName": "9955538 - Disclosure - Property and Equipment - Additional Information (Details)",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
     "longName": "9955539 - Disclosure - Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)",
     "shortName": "Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails",
     "longName": "9955540 - Disclosure - Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)",
     "shortName": "Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-157",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-157",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
     "longName": "9955541 - Disclosure - Intangibles - Additional Information (Details)",
     "shortName": "Intangibles - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
     "longName": "9955542 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Details)",
     "shortName": "Equity Method and Other Investmetns Equity Method and Other Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-181",
      "name": "dva:BusinessAgreementEffectiveClosingDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
     "longName": "9955543 - Disclosure - Equity Method and Other Investments - Additional Information (Details)",
     "shortName": "Equity Method and Other Investments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-185",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
     "longName": "9955544 - Disclosure - Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)",
     "shortName": "Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails",
     "longName": "9955545 - Disclosure - Goodwill - Schedule of Reporting Units Goodwill Balances (Details)",
     "shortName": "Goodwill - Schedule of Reporting Units Goodwill Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-194",
      "name": "us-gaap:GoodwillImpairmentLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
     "longName": "9955546 - Disclosure - Goodwill - Additional Information (Details)",
     "shortName": "Goodwill - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segments",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://www.davita.com/role/OtherLiabilitiesDetails",
     "longName": "9955547 - Disclosure - Other Liabilities (Details)",
     "shortName": "Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "dva:PayorRefundsAndRetractions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "dva:PayorRefundsAndRetractions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails",
     "longName": "9955548 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Income Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails",
     "longName": "9955549 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)",
     "shortName": "Income Taxes - Components of Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails",
     "longName": "9955550 - Disclosure - Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)",
     "shortName": "Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
     "longName": "9955551 - Disclosure - Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)",
     "shortName": "Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "dva:DeferredTaxAssetsReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "dva:DeferredTaxAssetsReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails",
     "longName": "9955552 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9955553 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
     "longName": "9955554 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)",
     "shortName": "Long-Term Debt - Schedule of Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LongtermDebtWeightedAverageInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LongtermDebtWeightedAverageInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails",
     "longName": "9955555 - Disclosure - Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)",
     "shortName": "Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
     "longName": "9955556 - Disclosure - Long-Term Debt - Derivative Instruments (Details)",
     "shortName": "Long-Term Debt - Derivative Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-266",
      "name": "us-gaap:DerivativeMaturityDates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-266",
      "name": "us-gaap:DerivativeMaturityDates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails",
     "longName": "9955557 - Disclosure - Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)",
     "shortName": "Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-304",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
     "longName": "9955558 - Disclosure - Long-Term Debt - Additional information (Detail)",
     "shortName": "Long-Term Debt - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails",
     "longName": "9955559 - Disclosure - Leases Lease Expense Components (Details)",
     "shortName": "Leases Lease Expense Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
     "longName": "9955560 - Disclosure - Leases Leases Other Information (Details)",
     "shortName": "Leases Leases Other Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:LeaseOtherInformationTableTextBlockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:LeaseOtherInformationTableTextBlockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails",
     "longName": "9955561 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)",
     "shortName": "Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfMinimumLeasePaymentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfMinimumLeasePaymentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.davita.com/role/LeasesAdditionalInformationDetails",
     "longName": "9955562 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "9955563 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.davita.com/role/ContingenciesDetails",
     "longName": "9955564 - Disclosure - Contingencies (Details)",
     "shortName": "Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-328",
      "name": "dva:CorporateIntegrityAgreementExpirationDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-328",
      "name": "dva:CorporateIntegrityAgreementExpirationDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
     "longName": "9955565 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)",
     "shortName": "Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
     "longName": "9955566 - Disclosure - Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)",
     "shortName": "Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-334",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-336",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails",
     "longName": "9955567 - Disclosure - Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Range of Exercise Prices (Details)",
     "shortName": "Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Range of Exercise Prices (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails",
     "longName": "9955568 - Disclosure - Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)",
     "shortName": "Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
     "longName": "9955569 - Disclosure - Long-term Incentive Compensation and Shareholders\u2019 Equity - Additional Information (Details)",
     "shortName": "Long-term Incentive Compensation and Shareholders\u2019 Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.davita.com/role/StockRepurchasesTenderOfferDetails",
     "longName": "9955570 - Disclosure - Stock Repurchases Tender Offer (Details)",
     "shortName": "Stock Repurchases Tender Offer (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-362",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R97": {
     "role": "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails",
     "longName": "9955571 - Disclosure - Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)",
     "shortName": "Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:MinorityInterestPeriodIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.davita.com/role/ShareholdersequityDetails",
     "longName": "9955572 - Disclosure - Shareholder's equity (Details)",
     "shortName": "Shareholder's equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-366",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-366",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.davita.com/role/RelatedPartyTransactionsDetails",
     "longName": "9955573 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-368",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-368",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
     "longName": "9955574 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)",
     "shortName": "Accumulated Other Comprehensive (Loss) Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-372",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
     "longName": "9955575 - Disclosure - Acquisitions - Components of Routine Acquisitions (Details)",
     "shortName": "Acquisitions - Components of Routine Acquisitions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-405",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
     "longName": "9955576 - Disclosure - Acquisitions - Assets acquired and liabilities assumed (Details)",
     "shortName": "Acquisitions - Assets acquired and liabilities assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-408",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails",
     "longName": "9955577 - Disclosure - Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)",
     "shortName": "Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-408",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-408",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails",
     "longName": "9955578 - Disclosure - Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)",
     "shortName": "Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
     "longName": "9955580 - Disclosure - Acquisitions and Divestitures - Additional Information (Details)",
     "shortName": "Acquisitions and Divestitures - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-408",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
     "longName": "9955581 - Disclosure - Held for Sale and Discontinued Operations - Additional Information (Details)",
     "shortName": "Held for Sale and Discontinued Operations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-419",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-419",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails",
     "longName": "9955582 - Disclosure - Variable Interest Entities - Additional Information (Details)",
     "shortName": "Variable Interest Entities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-422",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9955583 - Disclosure - Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-423",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails",
     "longName": "9955584 - Disclosure - Fair Values of Financial Instruments (Details)",
     "shortName": "Fair Values of Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails",
     "longName": "9955585 - Disclosure - Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)",
     "shortName": "Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:SegmentReportingInformationCorporateExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
     "longName": "9955586 - Disclosure - Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)",
     "shortName": "Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R112": {
     "role": "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
     "longName": "9955587 - Disclosure - Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)",
     "shortName": "Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
     "longName": "9955588 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)",
     "shortName": "Segment Reporting - Summary of Assets by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-465",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "dva:NetPropertyAndEquipmentInternationalOperationsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.davita.com/role/SupplementalCashFlowInformationDetails",
     "longName": "9955590 - Disclosure - Supplemental Cash Flow Information (Details)",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxesPaid",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxesPaid",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dva_A1MonthSOFRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A1MonthSOFRMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1-Month SOFR",
        "label": "1-Month SOFR [Member]",
        "documentation": "1-Month SOFR"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2017USAttorneyColoradoInvestigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2017USAttorneyColoradoInvestigationMember",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 U S Attorney Colorado Investigation",
        "label": "2017 U S Attorney Colorado Investigation [Member]",
        "documentation": "2017 U S Attorney Colorado Investigation"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2019InterestRateCapAgreementsEffectiveJune302020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2019InterestRateCapAgreementsEffectiveJune302020Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Interest Rate Cap Agreements Effective June 30, 2020",
        "label": "2019 Interest Rate Cap Agreements Effective June 30, 2020 [Member]",
        "documentation": "2019 Interest Rate Cap Agreements Effective June 30, 2020."
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2023InterestRateCapAgreements3.75EffectiveJune302024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024",
        "label": "2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2023InterestRateCapAgreements4.00EffectiveDecember312024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024",
        "label": "2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2023InterestRateCapAgreements4.00EffectiveJune302024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024",
        "label": "2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2023InterestRateCapAgreements4.50EffectiveDecember312024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024",
        "label": "2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2023InterestRateCapAgreements4.75EffectiveJune302024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024",
        "label": "2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2023InterestRateCapAgreements5.00EffectiveJune302024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024",
        "label": "2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2024InterestRateCapAgreements4.00EffectiveDecember312025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2024InterestRateCapAgreements4.00EffectiveDecember312025Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Interest Rate Cap Agreements 4.00% Effective December 31 2025",
        "label": "2024 Interest Rate Cap Agreements 4.00% Effective December 31 2025 [Member]",
        "documentation": "2024 Interest Rate Cap Agreements 4.00% Effective December 31 2025"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2024InterestRateCapAgreements4.50EffectiveDecember312025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "A2024InterestRateCapAgreements4.50EffectiveDecember312025Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Interest Rate Cap Agreements 4.50% Effective December 31 2025",
        "label": "2024 Interest Rate Cap Agreements 4.50% Effective December 31 2025 [Member]",
        "documentation": "2024 Interest Rate Cap Agreements 4.50% Effective December 31 2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r1360"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable Type",
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r196"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r1171"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1359"
     ]
    },
    "us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNoncurrentThresholdPeriodPastDue",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Noncurrent, Threshold Period Past Due",
        "label": "Accounts Receivable, Noncurrent, Threshold Period Past Due",
        "documentation": "Threshold period for when accounts receivable, classified as noncurrent, is considered past due, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes threshold period past due to write off as uncollectible."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "dva_AccountsReceivablePeriodOutstanding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "AccountsReceivablePeriodOutstanding",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable Period Outstanding",
        "label": "Accounts Receivable Period Outstanding",
        "documentation": "Patient accounts receivable months outstanding to be reserved per company policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued non-income tax liabilities",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r1112",
      "r1435"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r258"
     ]
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedInsuranceCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance and self-insurance accruals",
        "label": "Accrued Insurance, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r25",
      "r42",
      "r201",
      "r932",
      "r1332",
      "r1333",
      "r1334"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r333",
      "r924"
     ]
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r42",
      "r199",
      "r200",
      "r358",
      "r932",
      "r1333",
      "r1334"
     ]
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate cap agreements",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r25",
      "r42"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r808",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "periodStartLabel": "Beginning Balance of AOCI",
        "periodEndLabel": "Ending Balance of AOCI",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r202",
      "r341",
      "r918",
      "r959",
      "r960"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r808",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25",
      "r42",
      "r767",
      "r770",
      "r845",
      "r955",
      "r956",
      "r1332",
      "r1333",
      "r1334",
      "r1347",
      "r1348",
      "r1349",
      "r1350"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-lived Intangible Asset, Weighted-Average Period before Renewal or Extension",
        "label": "Acquired Finite-Lived Intangible Asset, Weighted-Average Period before Renewal or Extension",
        "documentation": "Weighted average period before the next renewal or extension for intangible assets with renewal or extension terms, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r1105"
     ]
    },
    "dva_AcquisitionObligationsAndOtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "AcquisitionObligationsAndOtherNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition obligations and other notes payable",
        "label": "Acquisition Obligations And Other Notes Payable",
        "documentation": "This represents deferred purchase price obligations associated with acquisitions as well as other notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "dva_AcquisitionObligationsAndOtherNotesPayableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "AcquisitionObligationsAndOtherNotesPayableFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition obligations and other notes payable, fair value",
        "label": "Acquisition Obligations And Other Notes Payable, Fair Value",
        "documentation": "Acquisition Obligations And Other Notes Payable, Fair Value."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1249"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1457",
      "r1533"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "us-gaap_AdjustableRateLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustableRateLoansMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted Rate",
        "label": "Adjustable Rate Loans [Member]",
        "documentation": "Loan where the rate is adjusted, moving higher or lower according to changes in a specified reference rate."
       }
      }
     },
     "auth_ref": []
    },
    "dva_AdjustmentIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "AdjustmentIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity investment loss, net",
        "label": "Adjustment Income Loss From Equity Method Investments",
        "documentation": "This item represents the entity's proportionate share for the period of the undistributed net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-settled stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r655"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1307"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1220",
      "r1231",
      "r1241",
      "r1274"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1223",
      "r1234",
      "r1244",
      "r1277"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1308"
     ]
    },
    "dva_AgreementWithMedtronicMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "AgreementWithMedtronicMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mozarc Medical Holding LLC",
        "label": "Agreement with Medtronic [Member]",
        "documentation": "Agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (NewCo)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1269"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1235",
      "r1245",
      "r1269",
      "r1278",
      "r1282",
      "r1290"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other - Ancillary services",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r1123",
      "r1124"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "dva_AllTrustsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "AllTrustsMember",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rabbi trusts",
        "label": "All Trusts [Member]",
        "documentation": "All trusts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of Debt Discounts, Premiums and Deferred Financing Costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r549",
      "r1340",
      "r1479"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense from amortizable intangible assets, other than lease agreements",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r488",
      "r495",
      "r1130"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive stock-settled awards excluded from calculation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25",
      "r42",
      "r1332",
      "r1333",
      "r1334"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Total",
        "terseLabel": "Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r273",
      "r337",
      "r377",
      "r413",
      "r419",
      "r437",
      "r441",
      "r462",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r757",
      "r762",
      "r803",
      "r911",
      "r1015",
      "r1123",
      "r1124",
      "r1171",
      "r1199",
      "r1400",
      "r1401",
      "r1486"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r344",
      "r377",
      "r462",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r757",
      "r762",
      "r803",
      "r1171",
      "r1400",
      "r1401",
      "r1486"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_AuditorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "AuditorAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor [Abstract]",
        "label": "Auditor [Abstract]",
        "documentation": "Auditor information."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.davita.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1203",
      "r1204",
      "r1227"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.davita.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1203",
      "r1204",
      "r1227"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.davita.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1203",
      "r1204",
      "r1227"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1285"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1283"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r1499",
      "r1500"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r136",
      "r507",
      "r1499",
      "r1500"
     ]
    },
    "dva_BaseRateLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "BaseRateLoansMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate Loans",
        "label": "Base Rate Loans [Member]",
        "documentation": "Base Rate Loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingsAndImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Buildings and Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r750",
      "r1149",
      "r1152"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r101",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r750",
      "r1149",
      "r1152"
     ]
    },
    "dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earn-out consideration payment period",
        "label": "Business Acquisition Contingent Consideration Revenue Earnout Period",
        "documentation": "Business acquisition contingent consideration revenue earn-out period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Effective Date of Acquisition",
        "label": "Business Acquisition, Effective Date of Acquisition",
        "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r29"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_BusinessAcquisitionNameOfAcquiredEntity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionNameOfAcquiredEntity",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Name of Acquired Entity",
        "label": "Business Acquisition, Name of Acquired Entity",
        "documentation": "Name of the acquired entity."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma basic net income per share attributable to DaVita Inc.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r1317",
      "r1318"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma diluted net income per share attributable to DaVita Inc.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r1317",
      "r1318"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro Forma Summary of Results of Operations",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r1317",
      "r1318"
     ]
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill deductible for tax purposes associated with acquisitions",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma net income attributable to DaVita Inc.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma total revenues",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749"
     ]
    },
    "dva_BusinessAgreementEffectiveClosingDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "BusinessAgreementEffectiveClosingDate",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction Agreement Effective Closing Date",
        "label": "Business Agreement Effective Closing Date",
        "documentation": "Business Agreement Effective Closing Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Noncontrolling interests assumed",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent purchase price and liabilities assumed",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r108",
      "r752"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent earn-out obligations for acquisitions",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r244",
      "r753",
      "r780",
      "r781",
      "r782"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived licenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liabilities Assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate purchase cost recognized",
        "totalLabel": "Aggregate purchase price",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Previously Held Equity Interests",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on changes in ownership interests",
        "terseLabel": "Gain on changes in ownership interest",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Abstract]",
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_BusinessSaleEffectiveDateOfSale": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "BusinessSaleEffectiveDateOfSale",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Sale, Effective Date Of Sale",
        "label": "Business Sale, Effective Date Of Sale",
        "documentation": "Business Sale, Effective Date Of Sale"
       }
      }
     },
     "auth_ref": []
    },
    "dva_CHCTemporaryFundingAssistance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CHCTemporaryFundingAssistance",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CHC Temporary Funding Assistance",
        "label": "CHC Temporary Funding Assistance",
        "documentation": "CHC Temporary Funding Assistance"
       }
      }
     },
     "auth_ref": []
    },
    "dva_CHCTemporaryFundingAssistanceFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CHCTemporaryFundingAssistanceFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CHC Temporary Funding Assistance, Fair Value",
        "label": "CHC Temporary Funding Assistance, Fair Value",
        "documentation": "CHC Temporary Funding Assistance, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Capital Leases, Future Minimum Payments, Net Minimum Payments, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalLossCarryforwardMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Loss Carryforward",
        "label": "Capital Loss Carryforward [Member]",
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r331",
      "r1109"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash and equivalents",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r254"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash of continuing operations at beginning of the year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash of continuing operations at end of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r216",
      "r375"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Less: Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r216"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedging",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "dva_CashPaidDuringPeriodForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CashPaidDuringPeriodForAbstract",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid:",
        "label": "Cash Paid During Period For [Abstract]",
        "documentation": "Cash paid during period for."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r216"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r216"
     ]
    },
    "dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit and other time deposits",
        "label": "Certificates Of Deposit Commercial Paper And Money Market Funds [Member]",
        "documentation": "Certificates of deposit, commercial paper, and money market funds."
       }
      }
     },
     "auth_ref": []
    },
    "dva_ChangeHealthcareTemporaryFundingAssistanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ChangeHealthcareTemporaryFundingAssistanceMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change Healthcare Temporary Funding Assistance",
        "label": "Change Healthcare Temporary Funding Assistance [Member]",
        "documentation": "Change Healthcare Temporary Funding Assistance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "dva_CharterdocumentsandDelawarelawAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CharterdocumentsandDelawarelawAbstract",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charter documents and Delaware law:",
        "label": "Charter documents and Delaware law [Abstract]",
        "documentation": "Charter documents and Delaware law [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1255"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Treasury Stock [Table]",
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "dva_CommercialPayorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CommercialPayorsMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Payors",
        "label": "Commercial Payors [Member]",
        "documentation": "Commercial Payors in healthcare industry."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "documentation": "Commitments and contingencies disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dva_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies Disclosure [Table]",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "documentation": "Commitments and contingencies disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests Subject to Put Provisions and Other Commitments",
        "label": "Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "dva_CommitmentsToProvideOperatingCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CommitmentsToProvideOperatingCapitalMember",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments to Provide Operating Capital",
        "label": "Commitments To Provide Operating Capital [Member]",
        "documentation": "Commitments to provide operating capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1186",
      "r1187",
      "r1188",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1347",
      "r1348",
      "r1350",
      "r1457",
      "r1531",
      "r1533"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r1003"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r189",
      "r1003",
      "r1021",
      "r1533",
      "r1534"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Value, Issued",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r917",
      "r1171"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1266"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1267"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1264"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income attributable to DaVita Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r354",
      "r356",
      "r365",
      "r905",
      "r933",
      "r935"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Comprehensive income attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r115",
      "r126",
      "r354",
      "r356",
      "r364",
      "r904",
      "r933",
      "r934"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r246",
      "r354",
      "r356",
      "r363",
      "r903",
      "r933"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income:",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive (Loss) Income",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r362",
      "r902",
      "r932"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive (Loss) Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r448",
      "r1091"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r448",
      "r962",
      "r1091"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r448",
      "r1091",
      "r1316"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r448"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r448",
      "r1091"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r305",
      "r381",
      "r757",
      "r758",
      "r762",
      "r763",
      "r852",
      "r1096",
      "r1321",
      "r1324",
      "r1325",
      "r1399",
      "r1402",
      "r1403"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r305",
      "r381",
      "r757",
      "r758",
      "r762",
      "r763",
      "r852",
      "r1096",
      "r1321",
      "r1324",
      "r1325",
      "r1399",
      "r1402",
      "r1403"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r291",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r381",
      "r413",
      "r421",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r1123",
      "r1124",
      "r1322",
      "r1323",
      "r1400",
      "r1401"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r291",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r381",
      "r413",
      "r421",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r1123",
      "r1124",
      "r1322",
      "r1323",
      "r1400",
      "r1401"
     ]
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]",
        "label": "Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]",
        "documentation": "Disclosure of information about effect of change in parent's ownership interest in subsidiary on equity attributable to parent. Excludes change from deconsolidation of subsidiary."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r127"
     ]
    },
    "dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]",
        "documentation": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r119",
      "r121"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New center and capital asset projects in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "dva_ConstructiveFinancingCashInflow": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ConstructiveFinancingCashInflow",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Constructive Financing Cash Inflow",
        "label": "Constructive Financing Cash Inflow",
        "documentation": "Constructive Financing Cash Inflow"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ConstructiveFinancingCashOutflow": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ConstructiveFinancingCashOutflow",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Constructive Financing Cash Outflow",
        "label": "Constructive Financing Cash Outflow",
        "documentation": "Constructive Financing Cash Outflow"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dva_CorporateIntegrityAgreementExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "CorporateIntegrityAgreementExpirationDate",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Integrity Agreement Expiration Date",
        "label": "Corporate Integrity Agreement Expiration Date",
        "documentation": "Corporate Integrity Agreement Expiration Date, in CCYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "terseLabel": "Operating expenses and charges",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r1397"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r1397",
      "r1398"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1320",
      "r1344",
      "r1448"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1320",
      "r1344"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r1344"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1320",
      "r1344",
      "r1448"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r448"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1387",
      "r1388"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1212",
      "r1301"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1212",
      "r1301"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1303"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1303"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1216",
      "r1305"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1303"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1207",
      "r1296"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1208",
      "r1297"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1208",
      "r1297"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1295"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1295"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1295"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1209",
      "r1298"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1211",
      "r1300"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1211",
      "r1300"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1212",
      "r1301"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1215",
      "r1304"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1213",
      "r1302"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1210",
      "r1299"
     ]
    },
    "dva_DaVitaCarePte.Ltd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DaVitaCarePte.Ltd.Member",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DaVita Care Pte. Ltd.",
        "label": "DaVita Care Pte. Ltd. [Member]",
        "documentation": "DaVita Care Pte. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "dva_DaVitaMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DaVitaMedicalGroupMember",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "DMG - discontinued operations",
        "label": "Da Vita Medical Group [Member]",
        "documentation": "DaVita medical group."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtFinancingAndDebtRedemptionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DebtFinancingAndDebtRedemptionCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred and debt related financing costs",
        "label": "Debt Financing And Debt Redemption Costs",
        "documentation": "Debt Financing And Debt Redemption Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r173",
      "r174",
      "r257",
      "r260",
      "r381",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1169",
      "r1342",
      "r1390",
      "r1391",
      "r1392",
      "r1478",
      "r1480"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate",
        "verboseLabel": "SOFR Plus Interest Rate Margin",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total debt principal outstanding",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r260",
      "r551"
     ]
    },
    "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDateOfFirstRequiredPayment1",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Date of First Required Payment",
        "label": "Debt Instrument, Date of First Required Payment",
        "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r150"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Description",
        "label": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r79",
      "r149",
      "r173",
      "r257",
      "r260",
      "r817"
     ]
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Description of Variable Rate Basis",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "documentation": "Description of reference rate used for variable rate of debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Fair Value Disclosure",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r802",
      "r1133",
      "r1134",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1469"
     ]
    },
    "us-gaap_DebtInstrumentFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValueDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, footnotes to the table",
        "label": "Debt Instrument, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Fee Amount",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Frequency of Periodic Payment",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r150"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Increase (Decrease), Net",
        "label": "Debt Instrument, Increase (Decrease), Net",
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r1342"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt, interest rate at a point in time.",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r546",
      "r1478"
     ]
    },
    "us-gaap_DebtInstrumentIssuanceDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuanceDate1",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Effective Date",
        "label": "Debt Instrument, Issuance Date",
        "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r1404"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1169",
      "r1342",
      "r1478",
      "r1480"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Maturity Date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r1132",
      "r1461",
      "r1462"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, maturity date, description",
        "label": "Debt Instrument, Maturity Date, Description",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeEnd1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateRangeEnd1",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Maturity Date Range, End",
        "label": "Debt Instrument, Maturity Date Range, End",
        "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeStart1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateRangeStart1",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Maturity Date Range, Start",
        "label": "Debt Instrument, Maturity Date Range, Start",
        "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r381",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1169",
      "r1342",
      "r1390",
      "r1391",
      "r1392",
      "r1478",
      "r1480"
     ]
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPaymentTerms",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Payment Terms",
        "label": "Debt Instrument, Payment Terms",
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r178"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Periodic Payment, Principal",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Quarterly Payment From September 30, 2027 Through March 31, 2028",
        "label": "Debt Instrument, Quarterly Payment From September 30, 2027 Through March 31, 2028",
        "documentation": "Debt Instrument, Quarterly Payment From September 30, 2027 Through March 31, 2028"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Quarterly Payment, % of Beginning Balance Outstanding",
        "label": "Debt Instrument, Quarterly Payment, % of Beginning Balance Outstanding",
        "documentation": "Debt Instrument, Quarterly Payment, % of Beginning Balance Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentQuarterlyPaymentThroughJune302027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DebtInstrumentQuarterlyPaymentThroughJune302027",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Quarterly Payment Through June 30, 2027",
        "label": "Debt Instrument, Quarterly Payment Through June 30, 2027",
        "documentation": "Debt Instrument, Quarterly Payment Through June 30, 2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionDescription",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Description",
        "label": "Debt Instrument, Redemption, Description",
        "documentation": "Description of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "dva_DebtInstrumentRedemptionPriceIfChangeOfControl": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DebtInstrumentRedemptionPriceIfChangeOfControl",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption Price, if change of control",
        "label": "Debt Instrument, Redemption Price, if change of control",
        "documentation": "Debt Instrument, Redemption Price, if change of control"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption Price, Percentage Any time Prior to September 1, 2027",
        "label": "Debt Instrument, Redemption Price, Percentage Any time Prior to September 1, 2027",
        "documentation": "Debt Instrument, Redemption Price, Percentage Any time Prior to September 1, 2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r79",
      "r80",
      "r148",
      "r232",
      "r233",
      "r381",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1169",
      "r1342",
      "r1478",
      "r1480"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Unamortized Discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1405",
      "r1477",
      "r1478",
      "r1480"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Unamortized Premium",
        "label": "Debt Instrument, Unamortized Premium",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r1405",
      "r1477",
      "r1478",
      "r1480"
     ]
    },
    "dva_DebtInstrumentVariableRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DebtInstrumentVariableRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Variable Rate",
        "label": "Debt Instrument, Variable Rate",
        "documentation": "Debt Instrument, Variable Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentsAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Secured Credit Facilities:",
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtPrepaymentExtinguishmentAndModificationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DebtPrepaymentExtinguishmentAndModificationCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt prepayment, extinguishment and modification costs",
        "terseLabel": "Debt prepayment, extinguishment and modification costs",
        "label": "Debt Prepayment, Extinguishment And Modification Costs",
        "documentation": "Debt Prepayment, Extinguishment And Modification Costs"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtRefinancingCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DebtRefinancingCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of debt",
        "label": "Debt Refinancing Charges",
        "documentation": "Debt prepayment refinancing redemption charges related to debt modification of long-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, Weighted Average Interest Rate",
        "label": "Debt, Weighted Average Interest Rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "dva_DeconsolidatedNoncontrollingEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DeconsolidatedNoncontrollingEntityMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APAC joint venture",
        "label": "Deconsolidated Noncontrolling Entity [Member]",
        "documentation": "Deconsolidated Noncontrolling Entity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-qualified deferred compensation plan, contributions",
        "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer",
        "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualDistributionPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation plan, distributions",
        "label": "Deferred Compensation Arrangement with Individual, Distribution Paid",
        "documentation": "Amount of distribution made to individual in accordance with deferred compensation arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1344",
      "r1447",
      "r1448"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1344",
      "r1447"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r286",
      "r1344"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r259",
      "r724"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r912"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Financing Costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1366"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1344",
      "r1447",
      "r1448"
     ]
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetDomain",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Asset [Domain]",
        "label": "Deferred Tax Asset [Domain]",
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists."
       }
      }
     },
     "auth_ref": [
      "r1441"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in partnerships",
        "label": "Deferred Tax Assets, Investments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1440"
     ]
    },
    "dva_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "dva_DeferredTaxAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DeferredTaxAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Deferred Tax Assets Receivables",
        "documentation": "Deferred tax assets, receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1440"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments in partnerships",
        "label": "Deferred Tax Liabilities, Investments",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "dva_DeferredTaxLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DeferredTaxLiabilitiesMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities [Member]",
        "documentation": "Deferred Tax Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DeferredTaxLiabilitiesOperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease assets",
        "label": "Deferred Tax Liabilities Operating Lease Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r647"
     ]
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Asset Categories",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "documentation": "Information by defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r628",
      "r1145",
      "r1146",
      "r1147"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of assets held in trust",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r603",
      "r605",
      "r606",
      "r1145",
      "r1146",
      "r1147"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer matching contribution, percent of employees' gross wages",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer matching contribution, percent of match",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAmortizationAndAccretionNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Amortization and Accretion, Net",
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r73"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense on property and equipment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r413",
      "r424",
      "r441",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetNotionalAmount",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amounts of interest rate agreements",
        "label": "Derivative Asset, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1068",
      "r1070",
      "r1075",
      "r1453",
      "r1454",
      "r1455"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate cap agreements",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r778",
      "r779",
      "r792",
      "r802",
      "r980",
      "r981",
      "r982",
      "r984",
      "r985",
      "r987",
      "r988",
      "r990",
      "r992",
      "r993",
      "r1009",
      "r1010",
      "r1064",
      "r1069",
      "r1072",
      "r1073",
      "r1076",
      "r1077",
      "r1113",
      "r1162",
      "r1165",
      "r1188",
      "r1460",
      "r1461",
      "r1462",
      "r1532"
     ]
    },
    "us-gaap_DerivativeAverageFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAverageFixedInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Average Fixed Interest Rate",
        "label": "Derivative, Average Fixed Interest Rate",
        "documentation": "Average fixed interest rate related to the group of interest rate derivatives."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r993",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1064",
      "r1066",
      "r1072",
      "r1076",
      "r1186",
      "r1188",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1470",
      "r1471"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Fair Value, Gross Asset",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r197",
      "r250",
      "r251",
      "r345",
      "r1113"
     ]
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFixedInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Fixed Interest Rate",
        "label": "Derivative, Fixed Interest Rate",
        "documentation": "Fixed interest rate related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInceptionDates": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInceptionDates",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, effective date",
        "label": "Derivative, Inception Date",
        "documentation": "Date the entity entered into the derivative contract, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r137",
      "r138",
      "r252",
      "r990",
      "r993",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1064",
      "r1066",
      "r1072",
      "r1076",
      "r1113",
      "r1186",
      "r1188",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1470",
      "r1471"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r134",
      "r137"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r134",
      "r137",
      "r138",
      "r142",
      "r143",
      "r765"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from accumulated other comprehensive income into net income",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r253"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_DerivativeMaturityDates": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeMaturityDates",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative, contractual maturity date",
        "label": "Derivative, Contract End Date",
        "documentation": "Date derivative contract ends, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r993",
      "r1064",
      "r1065",
      "r1067",
      "r1071",
      "r1074",
      "r1188"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r128",
      "r129",
      "r130",
      "r132",
      "r135",
      "r137",
      "r139",
      "r141",
      "r143",
      "r772"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate swap and cap agreements",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r128",
      "r129",
      "r132",
      "r140",
      "r380",
      "r395"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net income from discontinued operations per share attributable to DaVita Inc.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]",
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations, Held-for-sale",
        "label": "Discontinued Operations, Held-for-Sale [Member]",
        "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r326"
     ]
    },
    "dva_DiscountPremiumAndDeferredFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DiscountPremiumAndDeferredFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Discount, premium and deferred financing costs",
        "label": "Discount, Premium and Deferred Finance Costs",
        "documentation": "Discount, premium and deferred financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held for Sale and Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r224"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1152"
     ]
    },
    "dva_DissolutionTermOfJointVentures": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "DissolutionTermOfJointVentures",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheduled dissolution term of joint ventures",
        "label": "Dissolution Term Of Joint Ventures",
        "documentation": "Dissolution term of joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1203",
      "r1204",
      "r1227"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1203",
      "r1204",
      "r1227",
      "r1270"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1248"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Jurisdiction",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1259"
     ]
    },
    "dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Targets or Quality Margins",
        "label": "E B I T D A Operating Income Performance Targets Or Quality Margins [Member]",
        "documentation": "EBITDA operating income performance targets or quality margins."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share attributable to DaVita Inc.:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net income",
        "totalLabel": "Basic net income per share attributable to DaVita Inc.",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r397",
      "r399",
      "r405",
      "r406",
      "r407",
      "r412",
      "r746",
      "r755",
      "r775",
      "r776",
      "r906",
      "r936",
      "r1116"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net income attributable to DaVita Inc.:",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net income",
        "totalLabel": "Diluted net income per share attributable to DaVita Inc.",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r399",
      "r405",
      "r406",
      "r407",
      "r412",
      "r746",
      "r755",
      "r775",
      "r776",
      "r906",
      "r936",
      "r1116"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net income attributable to DaVita Inc.:",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r409"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income attributable to DaVita Inc.:",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r408",
      "r410",
      "r411"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1474"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r1159"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r702",
      "r735",
      "r1159"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in international valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r1159",
      "r1345",
      "r1436"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impact of noncontrolling interests primarily attributable to non-tax paying entities",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r1345",
      "r1436",
      "r1437"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Political advocacy costs",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1345",
      "r1436",
      "r1438"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1345",
      "r1436",
      "r1438"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1345",
      "r1436",
      "r1437"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r1159",
      "r1345",
      "r1436"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r1159",
      "r1345",
      "r1436"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r709",
      "r1345",
      "r1436"
     ]
    },
    "dva_EffectiveIncomeTaxReconciliationInvestmentImpairment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "EffectiveIncomeTaxReconciliationInvestmentImpairment",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nondeductible executive compensation",
        "label": "Effective Income Tax Reconciliation, Investment Impairment",
        "documentation": "Effective Income Tax Reconciliation, Investment Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "dva_EliminationsOfIntersegmentRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "EliminationsOfIntersegmentRevenues",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eliminations of intersegment revenues",
        "label": "Eliminations of intersegment revenues",
        "documentation": "Eliminations of intersegment revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated tax benefits recorded for stock-based compensation",
        "label": "Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense",
        "documentation": "Employee service share-based compensation estimated tax benefit from compensation expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dva_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions used to purchase shares, employee-related current liabilities",
        "label": "Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares",
        "documentation": "Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filer",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1306"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1306"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1306"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityClassOfTreasuryStockLineItems",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r323",
      "r358",
      "r359",
      "r360",
      "r382",
      "r383",
      "r384",
      "r386",
      "r391",
      "r393",
      "r395",
      "r414",
      "r464",
      "r465",
      "r504",
      "r566",
      "r733",
      "r734",
      "r743",
      "r744",
      "r745",
      "r747",
      "r754",
      "r755",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r774",
      "r808",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r818",
      "r820",
      "r845",
      "r932",
      "r955",
      "r956",
      "r957",
      "r977",
      "r1045"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r461",
      "r742",
      "r1312",
      "r1313",
      "r1314",
      "r1449",
      "r1450",
      "r1451",
      "r1452"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Cumulative measured cost",
        "label": "Equity Method Investment, Aggregate Cost",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment, significant impairments and other valuation adjustments",
        "label": "Equity Method Investment, Other-than-Temporary Impairment",
        "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r1363"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]",
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures Disclosure",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r460",
      "r463",
      "r1314"
     ]
    },
    "dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments In Nonconsolidated Dialysis Partnerships",
        "label": "Equity Method Investments In Nonconsolidated Dialysis Partnerships [Member]",
        "documentation": "Equity Method Investments In Nonconsolidated Dialysis Partnerships."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments and other investments",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r146",
      "r459"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFVNINoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, FV-NI, Noncurrent",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, FV-NI",
        "verboseLabel": "Investments in equity securities",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r801",
      "r1111"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, FV-NI",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r778",
      "r801",
      "r909",
      "r910",
      "r1162",
      "r1184",
      "r1185",
      "r1460",
      "r1461",
      "r1462"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted cost method and other investments",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r1172",
      "r1194",
      "r1195",
      "r1196",
      "r1536"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1263"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1220",
      "r1231",
      "r1241",
      "r1274"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1228",
      "r1238",
      "r1271"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1269"
     ]
    },
    "dva_ExpectedAmortizationExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ExpectedAmortizationExpenseLineItems",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Amortization Expense [Line Items]",
        "label": "Expected Amortization Expense [Line Items]",
        "documentation": "Expected Amortization Expense [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ExpectedAmortizationExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ExpectedAmortizationExpenseTable",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Amortization Expense [Table]",
        "label": "Expected Amortization Expense [Table]",
        "documentation": "Expected Amortization Expense [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ExtendedTermLoanB1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ExtendedTermLoanB1Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extended Term Loan B-1",
        "label": "Extended Term Loan B-1 [Member]",
        "documentation": "Extended Term Loan B-1"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ExternalSourcesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ExternalSourcesMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External Sources",
        "label": "External Sources [Member]",
        "documentation": "External sources."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Hierarchy",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r791",
      "r792",
      "r794",
      "r854",
      "r855",
      "r856",
      "r1133",
      "r1134",
      "r1145",
      "r1146",
      "r1147",
      "r1162",
      "r1165"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r780",
      "r782",
      "r1162",
      "r1461",
      "r1472"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values of Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r789",
      "r790",
      "r791",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r900",
      "r1162",
      "r1166"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted\u00a0prices\u00a0in active\u00a0markets\u00a0for identical assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r605",
      "r610",
      "r779",
      "r792",
      "r854",
      "r1145",
      "r1146",
      "r1147",
      "r1162"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant\u00a0other observable\u00a0inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r605",
      "r610",
      "r779",
      "r780",
      "r792",
      "r855",
      "r1133",
      "r1134",
      "r1145",
      "r1146",
      "r1147",
      "r1162"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r779",
      "r780",
      "r781",
      "r782",
      "r792",
      "r856",
      "r1133",
      "r1134",
      "r1145",
      "r1146",
      "r1147",
      "r1162",
      "r1165"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r780",
      "r782",
      "r1162",
      "r1461",
      "r1472"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r791",
      "r792",
      "r794",
      "r854",
      "r855",
      "r856",
      "r1133",
      "r1134",
      "r1145",
      "r1146",
      "r1147",
      "r1162",
      "r1165"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1472"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784",
      "r786",
      "r787",
      "r788",
      "r793"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r793"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value estimates",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "dva_FairValuePayableOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "FairValuePayableOfContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Contingent Consideration payable to Medtronic",
        "label": "Fair Value Payable Of Contingent Consideration",
        "documentation": "Fair Value Payable Of Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalFundsEffectiveSwapRateMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r1456"
     ]
    },
    "dva_FinanceLeaseAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "FinanceLeaseAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease Accumulated Depreciation",
        "label": "Finance Lease Accumulated Depreciation",
        "documentation": "Finance Lease Accumulated Depreciation, contra asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r831",
      "r1170"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Interest Payment on Liability",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r835"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease obligations",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r838"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum payments due under finance leases",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less portion representing interest, financing lease liabilities",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dva_FinanceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "FinanceLeaseMember",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease obligations",
        "verboseLabel": "Finance Lease",
        "label": "Finance Lease [Member]",
        "documentation": "Finance Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Principal Payments",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r835"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Right-of-Use Asset",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of leased assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r831",
      "r1170"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, weighted average discount rate, percent",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r1170"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r1170"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r470",
      "r494",
      "r1130"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1385",
      "r1540"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1105",
      "r1130"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1105",
      "r1130"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1105",
      "r1130"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1105",
      "r1130"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1105",
      "r1130"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r498",
      "r499",
      "r868",
      "r869",
      "r1105"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r494",
      "r498",
      "r499",
      "r502",
      "r868",
      "r1105",
      "r1130"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r498",
      "r499",
      "r1105"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r1384"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_FiniteLivedNoncompeteAgreementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedNoncompeteAgreementsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncompetition agreements",
        "label": "Finite-Lived Noncompete Agreements, Gross",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1327",
      "r1384"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Jurisdiction",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703"
     ]
    },
    "dva_ForeignCurrencyGainLossTranslationAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ForeignCurrencyGainLossTranslationAdjustmentsMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Gain (Loss) Translation Adjustments",
        "label": "Foreign Currency Gain (Loss) Translation Adjustments [Member]",
        "documentation": "Foreign Currency Gain (Loss) Translation Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ForeignDialysisCentersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ForeignDialysisCentersMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Dialysis Centers",
        "label": "Foreign Dialysis Centers [Member]",
        "documentation": "Foreign dialysis and other medical businesses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1235",
      "r1245",
      "r1278"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1235",
      "r1245",
      "r1278"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1235",
      "r1245",
      "r1278"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1235",
      "r1245",
      "r1278"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1235",
      "r1245",
      "r1278"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1258"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on changes in ownership interests",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r1340"
     ]
    },
    "dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "GainOnDispositionOfBusinessAdditionalPurchasePricePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on disposition of business, additional purchase price payment",
        "label": "Gain on disposition of business, additional purchase price payment",
        "documentation": "Gain on disposition of business, additional purchase price payment."
       }
      }
     },
     "auth_ref": []
    },
    "dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain Recognized on its Previously Held Equity Interest in Acquiree [Axis]",
        "label": "Gain Recognized on its Previously Held Equity Interest in Acquiree [Axis]",
        "documentation": "Gain Recognized on its Previously Held Equity Interest in Acquiree"
       }
      }
     },
     "auth_ref": []
    },
    "dva_GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain Recognized on its Previously Held Equity Interest in Acquiree [Domain]",
        "label": "Gain Recognized on its Previously Held Equity Interest in Acquiree [Domain]",
        "documentation": "Gain Recognized on its Previously Held Equity Interest in Acquiree [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r1027"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r472",
      "r901",
      "r1124",
      "r1129",
      "r1163",
      "r1171",
      "r1368",
      "r1375"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r1129"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r485",
      "r1129"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangibles",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r1378"
     ]
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Goodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r474",
      "r484",
      "r1129"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency and other adjustments",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_GoodwillGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillGross",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill, Gross",
        "documentation": "Amount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r482",
      "r1129"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated impairment charges",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r482",
      "r1129"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment charges",
        "negatedTerseLabel": "Impairment charges",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r473",
      "r479",
      "r485",
      "r1129",
      "r1163"
     ]
    },
    "us-gaap_GoodwillImpairmentLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLossNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, Impairment Loss, Net of Tax",
        "label": "Goodwill, Impairment Loss, Net of Tax",
        "documentation": "Amount, after tax, of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r1129"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Goodwill, Written off Related to Sale of Business Unit",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "documentation": "Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r1129"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "documentation": "Information by major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_HeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r455",
      "r466",
      "r1365"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, short-term investments",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r1362",
      "r1365"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, long-term investments",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r1362",
      "r1365"
     ]
    },
    "dva_IKCVBCArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "IKCVBCArrangementsMember",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IKC VBC arrangements",
        "label": "IKC VBC arrangements [Member]",
        "documentation": "IKC VBC arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1203",
      "r1204",
      "r1227"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r488",
      "r501"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r205",
      "r219",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r404",
      "r407",
      "r755"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r701"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from continuing operations before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r265",
      "r272",
      "r907",
      "r927",
      "r1118",
      "r1123",
      "r1352",
      "r1354",
      "r1355",
      "r1356",
      "r1357"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r701"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r272",
      "r377",
      "r385",
      "r391",
      "r462",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r746",
      "r755",
      "r776",
      "r803",
      "r927",
      "r1118",
      "r1352",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1400"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic net income from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r266",
      "r366",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r399",
      "r405",
      "r406",
      "r746",
      "r755",
      "r776",
      "r906",
      "r1497"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted net income from continuing operations",
        "terseLabel": "Diluted net income from continuing operations per share attributable to DaVita Inc.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r366",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r399",
      "r405",
      "r406",
      "r407",
      "r755",
      "r776",
      "r906",
      "r1497"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from discontinued operations, net of tax",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r167",
      "r327",
      "r739",
      "r928"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from discontinued operations",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r164",
      "r167",
      "r246"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net income from discontinued operations per share attributable to DaVita Inc.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r366",
      "r403",
      "r405",
      "r406",
      "r1495",
      "r1497"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity investment income, net",
        "terseLabel": "Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r204",
      "r264",
      "r413",
      "r426",
      "r441",
      "r456",
      "r926"
     ]
    },
    "dva_IncomeLossFromOtherEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "IncomeLossFromOtherEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment income (loss) from other equity method investments",
        "label": "Income Loss From Other Equity Method Investments",
        "documentation": "Income Loss From Other Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1152"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r34",
      "r40",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r166",
      "r168",
      "r169",
      "r226"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r507",
      "r508",
      "r784",
      "r788",
      "r793",
      "r952",
      "r954",
      "r1030",
      "r1105",
      "r1164",
      "r1501"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r508",
      "r784",
      "r788",
      "r793",
      "r952",
      "r954",
      "r1030",
      "r1105",
      "r1164",
      "r1501"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r702",
      "r703",
      "r714",
      "r729",
      "r1159",
      "r1444"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r702",
      "r703",
      "r714",
      "r729",
      "r1159",
      "r1444"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r694",
      "r702",
      "r710",
      "r711",
      "r712",
      "r721",
      "r728",
      "r736",
      "r738",
      "r740",
      "r741",
      "r970",
      "r1159"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax expense",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r287",
      "r394",
      "r395",
      "r413",
      "r427",
      "r441",
      "r700",
      "r702",
      "r737",
      "r939",
      "r1159"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r696",
      "r697",
      "r721",
      "r722",
      "r727",
      "r731",
      "r967"
     ]
    },
    "dva_IncomeTaxRelatedToCashFlowHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "IncomeTaxRelatedToCashFlowHedgesMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Related To Cash Flow Hedges",
        "label": "Income Tax Related To Cash Flow Hedges [Member]",
        "documentation": "Income Tax Related To Cash Flow Hedges"
       }
      }
     },
     "auth_ref": []
    },
    "dva_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes, net",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r218",
      "r1341",
      "r1442",
      "r1443"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r1330"
     ]
    },
    "dva_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase Decrease In Other Current Receivables And Other Current Assets",
        "documentation": "The net change during the reporting period in other current receivables and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dva_IncreasedTermLoanA1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "IncreasedTermLoanA1Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increased Term Loan A-1",
        "label": "Increased Term Loan A-1 [Member]",
        "documentation": "Increased Term Loan A-1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumed incremental shares from stock plans (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r407",
      "r657"
     ]
    },
    "dva_IndefiniteLifeNetOperatingLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "IndefiniteLifeNetOperatingLossesMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite Life Net Operating Losses",
        "label": "Indefinite Life Net Operating Losses [Member]",
        "documentation": "Indefinite Life Net Operating Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived licenses",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r497",
      "r1130"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1235",
      "r1245",
      "r1269",
      "r1278",
      "r1282",
      "r1290"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1205",
      "r1294"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1205",
      "r1294"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1205",
      "r1294"
     ]
    },
    "dva_InsuranceAndSelfInsurancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "InsuranceAndSelfInsurancePolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Self insurance",
        "label": "Insurance And Self Insurance Policy [Text Block]",
        "documentation": "Insurance and self insurance policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Intangibles"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r500",
      "r503",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortizable intangibles",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r865",
      "r866",
      "r868",
      "r1114",
      "r1378"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible assets, gross (excluding goodwill)",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net of accumulated amortization",
        "totalLabel": "Total intangible assets Net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r1384",
      "r1386"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt expense",
        "label": "Interest and Debt Expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "us-gaap_InterestCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized interest",
        "label": "Interest Costs Capitalized",
        "documentation": "Amount of interest capitalized during the period."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Expense, Debt",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r547",
      "r552",
      "r1135",
      "r1136"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest, net",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r372",
      "r373"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_InterestRateCapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestRateCapMember",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Cap",
        "label": "Interest Rate Cap [Member]",
        "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "dva_InternationalOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "InternationalOperationsMember",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International Operations",
        "label": "International Operations [Member]",
        "documentation": "International operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntersegmentEliminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntersegmentEliminationMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersegment Elimination",
        "label": "Intersegment Eliminations [Member]",
        "documentation": "Eliminating entries used in operating segment consolidation."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r413",
      "r421",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r1123"
     ]
    },
    "us-gaap_IntersubsegmentEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntersubsegmentEliminationsMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersubsegment Eliminations",
        "label": "Intersubsegment Eliminations [Member]",
        "documentation": "Eliminating entries used in subsegment consolidation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r1110",
      "r1171"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r330",
      "r342",
      "r467",
      "r468",
      "r469",
      "r863",
      "r1115"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in debt and equity securities",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r963",
      "r964",
      "r965",
      "r966",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r981",
      "r983",
      "r984",
      "r987",
      "r991",
      "r1053",
      "r1055",
      "r1059",
      "r1062",
      "r1063",
      "r1078",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1188"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r981",
      "r983",
      "r984",
      "r987",
      "r991",
      "r1053",
      "r1055",
      "r1059",
      "r1062",
      "r1063",
      "r1078",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1188"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method and other investments",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r1328"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Shorttermandlongterminvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Debt and Equity Securities",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r290",
      "r451",
      "r454",
      "r799",
      "r800",
      "r1494"
     ]
    },
    "us-gaap_Land": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Land",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land",
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale."
       }
      }
     },
     "auth_ref": [
      "r1326"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r1319"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r1319"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r1170"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost:",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Expense Components",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1483"
     ]
    },
    "dva_LeaseOtherInformationTableTextBlockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LeaseOtherInformationTableTextBlockTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Other Information",
        "label": "Lease Other Information Table Text Block [Table Text Block]",
        "documentation": "Lease Other Information in tabular disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r840"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "verboseLabel": "Leases term and discount rate",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeasesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LeasesDisclosureLineItems",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases Disclosure [Line Items]",
        "label": "Leases Disclosure [Line Items]",
        "documentation": "Leases Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeasesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LeasesDisclosureTable",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases Disclosure [Table]",
        "label": "Leases Disclosure [Table]",
        "documentation": "Leases Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeasesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LeasesDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases Disclosure",
        "label": "Leases Disclosure [Text Block]",
        "documentation": "Leases complete footnote disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeasesOtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LeasesOtherInformationAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases Other Information [Abstract]",
        "label": "Leases Other Information [Abstract]",
        "documentation": "Leases Other Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Disclosure [Abstract]",
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease cost:",
        "label": "Lessee, Finance Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r841"
     ]
    },
    "dva_LesseeLeaseDescriptionLineItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LesseeLeaseDescriptionLineItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items] [Abstract]",
        "label": "Lessee, Lease, Description [Line Items] [Abstract]",
        "documentation": "Lessee, Lease, Description [Line Items] [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r841"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments due under operating leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less portion representing interest, operating lease liabilities",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Renewal Term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1482"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Term of Contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1482"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of Credit Outstanding, Amount",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeverageRatioCovenant": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LeverageRatioCovenant",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage Ratio Covenant",
        "label": "Leverage Ratio Covenant",
        "documentation": "Leverage Ratio Covenant"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeverageRatioCovenantAfterJun302026": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LeverageRatioCovenantAfterJun302026",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage Ratio Covenant after Jun 30, 2026",
        "label": "Leverage Ratio Covenant after Jun 30, 2026",
        "documentation": "Leverage Ratio Covenant after Jun 30, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage Ratio Covenant after Jun 30, 2026 - Subject to Increase during four fiscal quarters following a material acquisition",
        "label": "Leverage Ratio Covenant after Jun 30, 2026 - Subject to Increase during four fiscal quarters following a material acquisition",
        "documentation": "Leverage Ratio Covenant after Jun 30, 2026 - Subject to Increase during four fiscal quarters following a material acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeverageRatioCovenantThroughJun302026": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LeverageRatioCovenantThroughJun302026",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage Ratio Covenant Through Jun 30, 2026",
        "label": "Leverage Ratio Covenant Through Jun 30, 2026",
        "documentation": "Leverage Ratio Covenant Through Jun 30, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r173",
      "r174",
      "r175",
      "r181",
      "r182",
      "r183",
      "r186",
      "r377",
      "r462",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r758",
      "r762",
      "r763",
      "r803",
      "r1002",
      "r1117",
      "r1199",
      "r1400",
      "r1486",
      "r1487"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r262",
      "r921",
      "r1171",
      "r1343",
      "r1364",
      "r1473"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r329",
      "r377",
      "r462",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r758",
      "r762",
      "r763",
      "r803",
      "r1171",
      "r1400",
      "r1486",
      "r1487"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "documentation": "Fair value of the amount outstanding under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity on revolving credit facilities",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r180"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Settlement, Amount Awarded to Other Party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Axis]",
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1390",
      "r1391",
      "r1392",
      "r1394"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Domain]",
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1390",
      "r1391",
      "r1392",
      "r1394"
     ]
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesOtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Receivables",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r1358"
     ]
    },
    "dva_LoansTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LoansTypeAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans Type [Axis]",
        "label": "Loans Type [Axis]",
        "documentation": "Loans Type"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LoansTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LoansTypeDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans Type [Domain]",
        "label": "Loans Type [Domain]",
        "documentation": "Loans Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "verboseLabel": "Total long-term debt",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r913"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term debt",
        "negatedLabel": "Less current portion",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Carrying amount of long-term debt, net of unamortized discounts, premiums and deferred financing costs",
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities",
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r381",
      "r1406"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r381",
      "r545"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r381",
      "r545"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r381",
      "r545"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r381",
      "r545"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r381",
      "r545"
     ]
    },
    "us-gaap_LongTermDebtOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtOtherDisclosuresAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt disclosure",
        "label": "Long-Term Debt, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "LongTermDebtPercentageBearingEconomicallyFixedInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long Term Debt Percentage Bearing Economically Fixed Interest Rate",
        "label": "Long Term Debt Percentage Bearing Economically Fixed Interest Rate",
        "documentation": "Long Term Debt Percentage Bearing Economically Fixed Interest Rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r1390",
      "r1391",
      "r1392"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r76",
      "r1390",
      "r1391",
      "r1392"
     ]
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, weighted average interest rate, at point in time",
        "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Nature [Axis]",
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r514",
      "r516",
      "r521",
      "r693",
      "r961",
      "r1131",
      "r1395",
      "r1396"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r514",
      "r516",
      "r521",
      "r693",
      "r1131",
      "r1395",
      "r1396"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r514",
      "r516",
      "r521",
      "r693",
      "r1131",
      "r1395",
      "r1396"
     ]
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.davita.com/role/Contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r693"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.davita.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Nature [Domain]",
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r514",
      "r516",
      "r521",
      "r693",
      "r961",
      "r1131",
      "r1395",
      "r1396"
     ]
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment and information systems, including internally developed software",
        "label": "Machinery and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment and Information Systems",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r1329"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "verboseLabel": "Total Short-term investments",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1329"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "verboseLabel": "Total Long-term investments",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1329"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term and long-term investments",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvesmtentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297",
      "r299",
      "r321",
      "r322",
      "r514",
      "r516",
      "r517",
      "r518",
      "r651",
      "r693",
      "r782",
      "r862",
      "r951",
      "r953",
      "r961",
      "r992",
      "r993",
      "r1054",
      "r1058",
      "r1060",
      "r1061",
      "r1079",
      "r1102",
      "r1103",
      "r1128",
      "r1137",
      "r1155",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1181",
      "r1404",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "dva_MedicaidandManagedMedicaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "MedicaidandManagedMedicaidMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicaid and Managed Medicaid",
        "label": "Medicaid and Managed Medicaid [Member]",
        "documentation": "Medicaid and Managed Medicaid Member."
       }
      }
     },
     "auth_ref": []
    },
    "dva_MedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "MedicareMember",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare bad debt claims",
        "label": "Medicare [Member]",
        "documentation": "Medicare governmental agency."
       }
      }
     },
     "auth_ref": []
    },
    "dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor",
        "label": "Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor",
        "documentation": "Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor"
       }
      }
     },
     "auth_ref": []
    },
    "dva_MedicareandMedicareAdvantageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "MedicareandMedicareAdvantageMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare and Medicare Advantage",
        "label": "Medicare and Medicare Advantage [Member]",
        "documentation": "Medicare and Medicare Advantage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestitures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and Divestitures",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r242"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297",
      "r299",
      "r321",
      "r322",
      "r514",
      "r516",
      "r517",
      "r518",
      "r651",
      "r693",
      "r782",
      "r862",
      "r951",
      "r953",
      "r961",
      "r992",
      "r993",
      "r1054",
      "r1058",
      "r1060",
      "r1061",
      "r1079",
      "r1102",
      "r1103",
      "r1128",
      "r1137",
      "r1155",
      "r1165",
      "r1166",
      "r1167",
      "r1181",
      "r1404",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests not subject to put provisions",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r261",
      "r377",
      "r462",
      "r523",
      "r526",
      "r527",
      "r528",
      "r532",
      "r533",
      "r803",
      "r920",
      "r1005"
     ]
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestChangeInRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurements",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r81",
      "r229",
      "r230"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distributions",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partial purchases",
        "verboseLabel": "Purchase of noncontrolling interests",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r234",
      "r247"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting Equity Interest in Mozarc, Owned by Medtronic",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting Equity Interest by the Company",
        "verboseLabel": "Ownership percentage by the Company",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest, Period Increase (Decrease)",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1281"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "dva_MutualFundsAndCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "MutualFundsAndCommonStockMember",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in mutual funds and common stock",
        "label": "Mutual Funds And Common Stock [Member]",
        "documentation": "Mutual Funds And Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by (Used in) Investing Activities, Total",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by (Used in) Operating Activities, Total",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r219"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net effect of transfers from to noncontrolling interests on stock holders equity disclosure",
        "label": "Net Effect Of Transfers From To Noncontrolling Interests On Stock Holders Equity Disclosure [Text Block]",
        "documentation": "Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.",
        "label": "Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.",
        "documentation": "Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income attributable to DaVita Inc.",
        "terseLabel": "Net (loss) income attributable to DaVita Inc.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r219",
      "r267",
      "r327",
      "r352",
      "r355",
      "r360",
      "r377",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r404",
      "r462",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r746",
      "r755",
      "r776",
      "r803",
      "r931",
      "r1023",
      "r1043",
      "r1044",
      "r1197",
      "r1400"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts attributable to DaVita Inc.:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Net income attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r248",
      "r352",
      "r355",
      "r391",
      "r394",
      "r395",
      "r930",
      "r1334"
     ]
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r248",
      "r249"
     ]
    },
    "dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Operating Lease Assets Obtained In Exchange For Lease Liabilities",
        "label": "Net Operating Lease Assets Obtained In Exchange For Lease Liabilities",
        "documentation": "Net Operating Lease Assets Obtained In Exchange For New or Modified Lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NetProceedsFromIssuanceOfStockToEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NetProceedsFromIssuanceOfStockToEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock under employee stock plans",
        "label": "Net Proceeds From Issuance Of Stock To Employees",
        "documentation": "Net Proceeds From Issuance Of Stock To Employees"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NetPropertyAndEquipmentInternationalOperationsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NetPropertyAndEquipmentInternationalOperationsTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Property and Equipment International Operations",
        "label": "Net Property and Equipment International Operations [Text Block]",
        "documentation": "Net Property and Equipment International Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NewCreditAgreementAmendedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NewCreditAgreementAmendedMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Credit Agreement - Amended",
        "label": "New Credit Agreement - Amended [Member]",
        "documentation": "New Credit Agreement - Amended"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NonCashGainMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NonCashGainMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Cash Gain",
        "label": "Non-Cash Gain [Member]",
        "documentation": "Non-Cash Gain"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1235",
      "r1245",
      "r1269",
      "r1278"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1252"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1269"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1535",
      "r1537",
      "r1538",
      "r1539"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets under financing lease obligations",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncompeteAgreementsMember",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncompete Agreements [Member]",
        "label": "Noncompete Agreements [Member]",
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1387",
      "r1388"
     ]
    },
    "dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and divestitures",
        "verboseLabel": "Sale of noncontrolling interest",
        "label": "Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures",
        "documentation": "Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and divestitures",
        "verboseLabel": "Sale of noncontrolling interest",
        "label": "Noncontrolling Interest, Increase Due To Acquisitions and Divestitures",
        "documentation": "Noncontrolling Interest, Increase Due To Acquisitions and Divestitures."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NoncontrollingInterestIncreaseFromContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NoncontrollingInterestIncreaseFromContributions",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions",
        "label": "Noncontrolling Interest Increase From Contributions",
        "documentation": "Noncontrolling interest increase from contributions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestItemsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in noncontrolling interest from:",
        "label": "Noncontrolling Interest Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests not subject to put provisions",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r566",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1533"
     ]
    },
    "dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Noncontrolling Interests Reclassifications And Expirations Of Put Obligations",
        "documentation": "Noncontrolling Interests Reclassifications And Expirations Of Put Obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes:",
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableOtherPayablesMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition obligations and other notes payable",
        "label": "Notes Payable, Other Payables [Member]",
        "documentation": "A written promise to pay a note to a third party."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NotionalAmountAmortizableByDecember312024": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NotionalAmountAmortizableByDecember312024",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Amount Amortizable By December 31, 2024",
        "label": "Notional Amount Amortizable By December 31, 2024",
        "documentation": "Notional Amount Amortizable By December 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NotionalAmountAmortizableByDecember312025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NotionalAmountAmortizableByDecember312025",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Amount Amortizable By December 31, 2025",
        "label": "Notional Amount Amortizable By December 31, 2025",
        "documentation": "Notional Amount Amortizable By December 31, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NotionalAmountAmortizableByDecember312026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NotionalAmountAmortizableByDecember312026",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Amount Amortizable By December 31, 2026",
        "label": "Notional Amount Amortizable By December 31, 2026",
        "documentation": "Notional Amount Amortizable By December 31, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NotionalAmountAmortizableByMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NotionalAmountAmortizableByMaturityDate",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Amount Amortizable By Maturity Date",
        "label": "Notional Amount Amortizable By Maturity Date",
        "documentation": "Notional Amount Amortizable By Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfBusinessesAcquired",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of businesses acquired",
        "label": "Number of Businesses Acquired",
        "documentation": "The number of businesses acquired by the entity during the period."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NumberOfConcentrationRiskCustomers": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NumberOfConcentrationRiskCustomers",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of concentration risk customers",
        "label": "Number Of Concentration Risk Customers",
        "documentation": "Number Of Concentration Risk Customers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of countries in which dialysis centers located",
        "label": "Number of Countries in which Entity Operates",
        "documentation": "The number of countries in which the entity operates as of balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NumberOfCustomers",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of patients served",
        "label": "Number Of Customers",
        "documentation": "Number of customers."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of legal entities that third parties held noncontrolling equity interests",
        "label": "Number Of Entities That Third Parties Held Non Controlling Equity Interests",
        "documentation": "Number of entities that third parties held non controlling equity interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments that were considered at risk of significant goodwill impairment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1124",
      "r1353"
     ]
    },
    "dva_NumberOfPartnerships": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NumberOfPartnerships",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of equity method investments",
        "label": "Number Of Partnerships",
        "documentation": "Number Of Partnerships that are included in the Equity Investments category."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NumberOfSites": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "NumberOfSites",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of dialysis centers that the company operated or provided administrative services",
        "label": "Number Of Sites",
        "documentation": "Number of sites."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfStatesInWhichEntityOperates",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of states where dialysis centers are located",
        "label": "Number of States in which Entity Operates",
        "documentation": "The number of states the entity operates in as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses)",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrealized (losses) gains net",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r42"
     ]
    },
    "dva_OffBalanceSheetFinancingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OffBalanceSheetFinancingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off -Balance Sheet Financing Arrangements",
        "label": "Off -Balance Sheet Financing Arrangements",
        "documentation": "Off -Balance Sheet Financing Arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OpenMarketPurchasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OpenMarketPurchasesMember",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Market Purchases",
        "label": "Open Market Purchases [Member]",
        "documentation": "Open Market Purchases Member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "terseLabel": "Operating Income (Loss)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r1118",
      "r1352",
      "r1354",
      "r1355",
      "r1356",
      "r1357"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Cost",
        "verboseLabel": "Rent Expense, Operating Leases",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r1170"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1481"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities, operating leases",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "dva_OperatingLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OperatingLeaseMember",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease",
        "label": "Operating Lease [Member]",
        "documentation": "Operating Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r835"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r1170"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r1170"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, expiration date",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r220",
      "r221",
      "r245"
     ]
    },
    "dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "documentation": "Organization consolidation and presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "documentation": "Organization consolidation and presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other potential commitments to provide operating capital to nonconsolidated dialysis centers",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OtherCompaniesMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other companies",
        "label": "Other Companies [Member]",
        "documentation": "Other companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains on defined benefit plans",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax",
        "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r622"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains on interest rate cap agreements:",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses on foreign currency translation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (losses) gains",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r199",
      "r200",
      "r202",
      "r804",
      "r805",
      "r807"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Related income tax",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r358",
      "r932"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains",
        "verboseLabel": "Amount of unrealized gains (losses) in OCI on interest rate cap agreements",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification of net realized gains into net income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification of net realized gains into net income",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r202",
      "r351",
      "r806"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive loss",
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r37",
      "r353",
      "r356",
      "r362",
      "r391",
      "r808",
      "r809",
      "r814",
      "r902",
      "r932",
      "r1332",
      "r1333"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss, net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherGovernmentPayorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OtherGovernmentPayorsMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Government Payors",
        "label": "Other Government Payors [Member]",
        "documentation": "Other government payors in healthcare industry."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1025",
      "r1080",
      "r1081",
      "r1082"
     ]
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships and other",
        "label": "Other Indefinite-Lived Intangible Assets",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r1327",
      "r1386"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "totalLabel": "Other liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r1171"
     ]
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities Disclosure [Abstract]",
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities",
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r182",
      "r1389"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Liabilities",
        "label": "Other Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLongTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermInvestmentsMember",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term Investments",
        "label": "Other Long-Term Investments [Member]",
        "documentation": "Long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1528"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-cash losses and (gains), net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other loss, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Nonoperating Income (Expense)",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherNonoperatingIncomeExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OtherNonoperatingIncomeExpensePolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income Expense Policy [Text Block]",
        "documentation": "Other nonoperating income (expense), policy."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherOperatingSegmentsWithIntersegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OtherOperatingSegmentsWithIntersegmentMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Segments with Intersegment",
        "label": "Other Operating Segments with Intersegment [Member]",
        "documentation": "Other Operating Segments with Intersegment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOwnershipInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOwnershipInterestMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other equity method partnerships",
        "label": "Other Ownership Interest [Member]",
        "documentation": "Holder of an ownership interest in a partnership who is not classified as a general partner, preferred partner, or limited partner."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPensionPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPensionPlansDefinedBenefitMember",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Compensation Plan",
        "label": "Other Pension Plan [Member]",
        "documentation": "Plan designed to provide retirement benefits, classified as other. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherReportingUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OtherReportingUnitsMember",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other reporting units",
        "label": "Other Reporting Units [Member]",
        "documentation": "Other Reporting Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherSignificantNoncashFinancingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OtherSignificantNoncashFinancingActivity",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Significant Noncash Financing Activity",
        "label": "Other Significant Noncash Financing Activity",
        "documentation": "Other Significant Noncash Financing Activity"
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherSourcesofRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OtherSourcesofRevenueMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sources of Revenue [Member]",
        "documentation": "Other sources of revenue (management fees and revenue from the Company's ancillary services and strategic initiatives)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r174"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1233",
      "r1243",
      "r1276"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1225",
      "r1236",
      "r1246",
      "r1279"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1225",
      "r1236",
      "r1246",
      "r1279"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "OwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current economic interest in the APAC JV, Owned by Other Noncontrolling Investors",
        "label": "Ownership Percentage By Noncontrolling Owners",
        "documentation": "Ownership Percentage By Noncontrolling Owners"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ParentCompanyAndRestrictedSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ParentCompanyAndRestrictedSubsidiariesMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company and Restricted Subsidiaries",
        "label": "Parent Company And Restricted Subsidiaries [Member]",
        "documentation": "Parent company and restricted subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PartnerTypeOfPartnersCapitalAccountAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner Type [Axis]",
        "label": "Partner Type [Axis]",
        "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r978"
     ]
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner Type of Partners' Capital Account, Name [Domain]",
        "label": "Partner Type of Partners' Capital Account, Name [Domain]",
        "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r978"
     ]
    },
    "dva_PatientCareCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "PatientCareCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patient care costs",
        "label": "Patient Care Costs",
        "documentation": "Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1250"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_PaymentsOfDistributionsToAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDistributionsToAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distributions to noncontrolling interests",
        "label": "Payments of Distributions to Affiliates",
        "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of ordinary dividends, common stock",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid to acquire business",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r751"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equity method investments",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of debt investments held-to-maturity",
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r452"
     ]
    },
    "dva_PaymentsToAcquireOtherDebtAndEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "PaymentsToAcquireOtherDebtAndEquityInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of other debt and equity investments",
        "label": "Payments To Acquire Other Debt And Equity Investments",
        "documentation": "Payments To Acquire Other Debt And Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments to Acquire Other Investments",
        "label": "Payments to Acquire Other Investments",
        "documentation": "Amount of cash outflow to acquire investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToMinorityShareholders",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of noncontrolling interests",
        "terseLabel": "Payments to Noncontrolling Interests",
        "label": "Payments to Noncontrolling Interests",
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "dva_PayorRefundsAndRetractions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "PayorRefundsAndRetractions",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payor refunds and retractions",
        "label": "Payor Refunds And Retractions",
        "documentation": "Payor Refunds And Retractions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r602",
      "r604",
      "r610",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r645",
      "r646",
      "r648",
      "r1147"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1252"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1269"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "PercentageOfAccountsReceivableSixMonthsOrMorePastDue",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Accounts Receivable Six Months Or More Past Due",
        "label": "Percentage Of Accounts Receivable Six Months Or More Past Due",
        "documentation": "Percentage of Accounts Receivable , 6 months or More Past Due"
       }
      }
     },
     "auth_ref": []
    },
    "dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation",
        "label": "Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation",
        "documentation": "Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law limitation. The Company is subject to Section\u00a0203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period three years following the date on which that stockholder became an interested stockholder."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanAssetCategoriesDomain",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Asset Categories",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "documentation": "Defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r628",
      "r1145",
      "r1146",
      "r1147"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1309"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1252"
     ]
    },
    "dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple",
        "label": "Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple",
        "documentation": "Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r554"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r1003"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r554"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Value, Issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r916",
      "r1171"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime Rate",
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrincipalOwnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrincipalOwnerMember",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Berkshire",
        "label": "Principal Owner [Member]",
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromContributionsFromAffiliates",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions from noncontrolling interests",
        "label": "Proceeds from Contributions from Affiliates",
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributions from equity method investments",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r1336"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance of Debt",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r968"
     ]
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMinorityShareholders",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of additional noncontrolling interests",
        "label": "Proceeds from Noncontrolling Interests",
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt investments held-to-maturity",
        "label": "Proceeds from Sale and Maturity of Held-to-Maturity Securities",
        "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r1361"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of other debt and equity investments",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from asset and business sales",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r1315"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from stock option exercises",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r33"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r352",
      "r355",
      "r369",
      "r377",
      "r385",
      "r391",
      "r394",
      "r395",
      "r462",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r746",
      "r755",
      "r756",
      "r759",
      "r760",
      "r776",
      "r803",
      "r907",
      "r929",
      "r976",
      "r1023",
      "r1043",
      "r1044",
      "r1160",
      "r1161",
      "r1198",
      "r1334",
      "r1400"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r840"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r281",
      "r284",
      "r285"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant and equipment, gross, total",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r332",
      "r925"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/PropertyandEquipmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r840",
      "r908",
      "r925",
      "r1171"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r281",
      "r284",
      "r923"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r840"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, and equipment useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInFifthYear",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, to be Paid, Year Five",
        "label": "Purchase Obligation, to be Paid, Year Five",
        "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInFourthYear",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, to be Paid, Year Four",
        "label": "Purchase Obligation, to be Paid, Year Four",
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, Due in Next Twelve Months",
        "label": "Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, Due in Second Year",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, Due in Third Year",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1250"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1250"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/ContingenciesDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297",
      "r299",
      "r321",
      "r322",
      "r514",
      "r516",
      "r517",
      "r518",
      "r602",
      "r651",
      "r683",
      "r684",
      "r685",
      "r693",
      "r782",
      "r857",
      "r861",
      "r862",
      "r951",
      "r953",
      "r961",
      "r992",
      "r993",
      "r1054",
      "r1058",
      "r1060",
      "r1061",
      "r1079",
      "r1102",
      "r1103",
      "r1128",
      "r1137",
      "r1155",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1181",
      "r1188",
      "r1393",
      "r1404",
      "r1461",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493"
     ]
    },
    "dva_RangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "RangeFiveMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$110.01\u2013$120.00",
        "label": "Range Five [Member]",
        "documentation": "Range Five"
       }
      }
     },
     "auth_ref": []
    },
    "dva_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "RangeFourMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$100.01\u2013$110.00",
        "label": "Range Four [Member]",
        "documentation": "Range Four."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/ContingenciesDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297",
      "r299",
      "r321",
      "r322",
      "r514",
      "r516",
      "r517",
      "r518",
      "r602",
      "r651",
      "r683",
      "r684",
      "r685",
      "r693",
      "r782",
      "r857",
      "r861",
      "r862",
      "r951",
      "r953",
      "r961",
      "r992",
      "r993",
      "r1054",
      "r1058",
      "r1060",
      "r1061",
      "r1079",
      "r1102",
      "r1103",
      "r1128",
      "r1137",
      "r1155",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1181",
      "r1188",
      "r1393",
      "r1404",
      "r1461",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493"
     ]
    },
    "dva_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "RangeOneMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range One [Member]",
        "label": "Range One [Member]",
        "documentation": "Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$70.01\u2013$80.00",
        "label": "Range Three [Member]",
        "documentation": "Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range Two [Member]",
        "label": "Range Two [Member]",
        "documentation": "Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable",
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r196"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables [Abstract]",
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from accumulated other comprehensive income (losses) into net income",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Reclassification from accumulated other comprehensive income (loss) into net income net of tax",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r42"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Related income tax",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r351",
      "r358",
      "r932"
     ]
    },
    "dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Expenditures for Property and Equipment by Segment",
        "label": "Reconciliation Of Capital Expenditures For Property And Equipment From Segment To Consolidated Table [Text Block]",
        "documentation": "Reconciliation of capital expenditures for property and equipment from segment to consolidated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r71"
     ]
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Depreciation and Amortization Expense by Segment",
        "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1228",
      "r1238",
      "r1271"
     ]
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests subject to put provisions",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r229",
      "r230"
     ]
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests subject to put provisions",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r229",
      "r230"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r628",
      "r849",
      "r850",
      "r914",
      "r922",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1020",
      "r1022",
      "r1052"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r1485"
     ]
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction, Description of Transaction",
        "label": "Related Party Transaction, Description of Transaction",
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r340",
      "r839",
      "r842",
      "r843",
      "r848"
     ]
    },
    "dva_RelatedPartyTransactionDescriptionOfTransaction1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction1",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction, Description of Transaction 1",
        "label": "Related Party Transaction, Description of Transaction 1",
        "documentation": "Related Party Transaction, Description of Transaction 1"
       }
      }
     },
     "auth_ref": []
    },
    "dva_RelatedPartyTransactionDescriptionOfTransaction2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction2",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction, Description of Transaction 2",
        "label": "Related Party Transaction, Description of Transaction 2",
        "documentation": "Related Party Transaction, Description of Transaction 2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionTermsAndMannerOfSettlement",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction, Terms and Manner of Settlement",
        "label": "Related Party Transaction, Terms and Manner of Settlement",
        "documentation": "Description of the terms and manner of settlement of the related party transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r628",
      "r849",
      "r850",
      "r914",
      "r922",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1020",
      "r1022",
      "r1052",
      "r1485"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Berkshire Share Repurchase Agreement",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r847",
      "r848",
      "r850",
      "r851",
      "r971",
      "r972",
      "r973",
      "r1028",
      "r1029",
      "r1030",
      "r1049",
      "r1051"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of Debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on long-term debt",
        "label": "Repayments of Debt and Lease Obligation",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReportingUnitAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReportingUnitAxis",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Axis]",
        "label": "Reporting Unit [Axis]",
        "documentation": "Information by reporting unit."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r485",
      "r1129"
     ]
    },
    "us-gaap_ReportingUnitDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReportingUnitDomain",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Domain]",
        "label": "Reporting Unit [Domain]",
        "documentation": "Level of reporting at which goodwill is tested for impairment."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r485",
      "r1129"
     ]
    },
    "us-gaap_RepurchaseAgreementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepurchaseAgreementDate",
     "presentation": [
      "http://www.davita.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase Agreement, Date",
        "label": "Repurchase Agreement, Date",
        "documentation": "Date of repurchase agreement, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1058",
      "r1061",
      "r1079"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1229",
      "r1239",
      "r1272"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1230",
      "r1240",
      "r1273"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1226",
      "r1237",
      "r1247",
      "r1280"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash and equivalents",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r254",
      "r331",
      "r375",
      "r915"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r234",
      "r919",
      "r958",
      "r960",
      "r969",
      "r1004",
      "r1171"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r382",
      "r383",
      "r384",
      "r386",
      "r391",
      "r393",
      "r395",
      "r464",
      "r465",
      "r504",
      "r733",
      "r734",
      "r743",
      "r744",
      "r745",
      "r747",
      "r754",
      "r755",
      "r766",
      "r768",
      "r769",
      "r771",
      "r774",
      "r818",
      "r820",
      "r955",
      "r957",
      "r977",
      "r1533"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r650",
      "r652",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r648",
      "r649",
      "r650",
      "r652",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Patient service revenues",
        "terseLabel": "Dialysis patient service revenues",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r413",
      "r420",
      "r421",
      "r435",
      "r441",
      "r444",
      "r446",
      "r448",
      "r576",
      "r577",
      "r867"
     ]
    },
    "dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dialysis patient service revenues",
        "label": "Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts",
        "documentation": "Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r575",
      "r578"
     ]
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition [Abstract]",
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "RevenueRecognitionAndAccountsReceivablePolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patient service net revenues and accounts receivable",
        "label": "Revenue Recognition And Accounts Receivable Policy [Text Block]",
        "documentation": "Revenue recognition and accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r361",
      "r377",
      "r413",
      "r420",
      "r421",
      "r435",
      "r441",
      "r444",
      "r446",
      "r448",
      "r462",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r803",
      "r907",
      "r1123",
      "r1400"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving line of credit",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "dva_SOFRLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SOFRLoansMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR Loans",
        "label": "SOFR Loans [Member]",
        "documentation": "SOFR Loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleAndLeasebackTransactionGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleAndLeasebackTransactionGainLossNet",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "label": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r844",
      "r1170"
     ]
    },
    "us-gaap_SaleLeasebackTransactionLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleLeasebackTransactionLeaseTerm",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Leaseback Transaction, Lease Term",
        "label": "Sale Leaseback Transaction, Lease Term",
        "documentation": "Lease term for sale and leaseback transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1484"
     ]
    },
    "dva_SaleLeasebackTransactionRenewalLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SaleLeasebackTransactionRenewalLeaseTerm",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Leaseback Transaction, Renewal Lease Term",
        "label": "Sale Leaseback Transaction, Renewal Lease Term",
        "documentation": "Sale Leaseback Transaction, Renewal Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts and Financing Receivables [Table]",
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r196",
      "r450",
      "r1360"
     ]
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Other Comprehensive (Loss) Income",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r1475",
      "r1476"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r101",
      "r750"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r79",
      "r80",
      "r148",
      "r232",
      "r233",
      "r1133",
      "r1135",
      "r1346",
      "r1478"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets and Liabilities Arising from Temporary Differences",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1440"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan [Table]",
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r86",
      "r87",
      "r88",
      "r89"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of Interest Rate Swap and Cap Agreements",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r137",
      "r765"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation between U.S. Federal Income Tax Rate and Effective Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r1159",
      "r1436"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r461",
      "r742",
      "r1312",
      "r1313",
      "r1314",
      "r1449",
      "r1450",
      "r1451",
      "r1452"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "verboseLabel": "Equity Method Investment income from equity method investments",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r458",
      "r459",
      "r461",
      "r462",
      "r803"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment [Table]",
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r377",
      "r458",
      "r459",
      "r461",
      "r462",
      "r803"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1458",
      "r1459"
     ]
    },
    "dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IntangiblesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets other than Goodwill",
        "label": "Schedule Of Finite And Indefinite Intangible Assets Table [Text Block]",
        "documentation": "Schedule Of Finite And Indefinite Intangible Assets Table"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r494",
      "r498",
      "r499",
      "r502",
      "r868",
      "r1105",
      "r1130"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r1129"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.davita.com/role/GoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Carrying Value of Goodwill by Reportable Segments",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheduled Maturities of Long-term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "dva_ScheduleOfMinimumLeasePaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ScheduleOfMinimumLeasePaymentsTextBlock",
     "presentation": [
      "http://www.davita.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Minimum Lease Payments",
        "label": "Schedule Of Minimum Lease Payments [Text Block]",
        "documentation": "Schedule of minimum lease payments under non-cancelable operating leases and capital leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Routine Acquisitions",
        "label": "Schedule of Noncash or Part Noncash Acquisitions [Table Text Block]",
        "documentation": "Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of other information related to acquired intangibles and goodwill",
        "label": "Schedule of other information related to acquisitions [Table Text Block]",
        "documentation": "Schedule of other information related to acquisitions, including weighted-average estimated useful lives of intangible assets acquired, and goodwill deductible for tax purposes."
       }
      }
     },
     "auth_ref": []
    },
    "dva_ScheduleOfOtherReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ScheduleOfOtherReceivablesTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Receivables",
        "label": "Schedule Of Other Receivables [Table Text Block]",
        "documentation": "Tabular disclosure of claims held for amounts due to an entity. Examples include non-trade receivables and Medicare bad debt claims."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r840"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Purchase Cost Allocations for Acquisitions",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r239"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r656",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Range of Exercise Prices",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Weighted Average Valuation Inputs",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchases summary table",
        "label": "Class of Treasury Stock [Table Text Block]",
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r1158"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity [Table]",
        "label": "Variable Interest Entity [Table]",
        "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r120",
      "r122",
      "r123",
      "r757",
      "r758",
      "r762",
      "r763",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IntangiblesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheduled Amortization Charges from Intangible Assets and Liabilities",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1130",
      "r1385"
     ]
    },
    "us-gaap_SecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt",
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r260",
      "r1496"
     ]
    },
    "dva_SecuredDebtExtendedMaturity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SecuredDebtExtendedMaturity",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt, Extended Maturity",
        "label": "Secured Debt, Extended Maturity",
        "documentation": "Secured Debt, Extended Maturity"
       }
      }
     },
     "auth_ref": []
    },
    "dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt Outstanding Principal Balance Subject To SOFR",
        "label": "Secured Debt Outstanding Principal Balance Subject To SOFR",
        "documentation": "Secured Debt Outstanding Principal Balance Subject To SOFR"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredLongtermDebtCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt totals:",
        "label": "Secured Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r1456"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1200"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r413",
      "r416",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r448",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r502",
      "r509",
      "r510",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r1120",
      "r1123",
      "r1124",
      "r1129",
      "r1183",
      "r1498",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1521",
      "r1522",
      "r1523",
      "r1524",
      "r1525",
      "r1526",
      "r1527",
      "r1529",
      "r1530"
     ]
    },
    "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentExpenditureAdditionToLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Expenditure, Addition to Long-Lived Assets",
        "label": "Segment, Expenditure, Addition to Long-Lived Assets",
        "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r430",
      "r441",
      "r1123",
      "r1124"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r295",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r446",
      "r447",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r982",
      "r986",
      "r988",
      "r1055",
      "r1059",
      "r1063",
      "r1083",
      "r1090",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1107",
      "r1139",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1182",
      "r1188",
      "r1408",
      "r1498",
      "r1502",
      "r1503",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1521",
      "r1522",
      "r1523",
      "r1524",
      "r1525",
      "r1526",
      "r1527",
      "r1529",
      "r1530"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r413",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r431",
      "r433",
      "r434",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r1119",
      "r1121",
      "r1122",
      "r1123",
      "r1125",
      "r1126",
      "r1127"
     ]
    },
    "dva_SegmentReportingInformationCorporateExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SegmentReportingInformationCorporateExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Corporate administrative support",
        "label": "Segment Reporting Information Corporate Expenses",
        "documentation": "Amount of general and administrative support costs, such as labor, benefits and stock-based compensation costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationOperatingIncomeLossAbstract",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information footnote:",
        "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Other Segment Item, Amount",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r433",
      "r434",
      "r441",
      "r1123"
     ]
    },
    "dva_SegmentRevenuebyMajorPayorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SegmentRevenuebyMajorPayorAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Revenue by Major Payor [Abstract]",
        "label": "Segment Revenue by Major Payor [Abstract]",
        "documentation": "Segment Revenue by Major Payor [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r1496"
     ]
    },
    "dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes 4.625% due 2030",
        "label": "Senior Notes Four Point Six Two Five Percent Due Twenty Thirty [Member]",
        "documentation": "Senior Notes Four Point Six Two Five Percent Due Twenty Thirty."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "dva_SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes 6.875% due 2032",
        "label": "Senior Notes Six Point Eight Seven Five Percent Due Twenty Thirty Two [Member]",
        "documentation": "Senior Notes Six Point Eight Seven Five Percent Due Twenty Thirty Two"
       }
      }
     },
     "auth_ref": []
    },
    "dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes 3.75% due 2031",
        "label": "Senior Notes Three Point Seven Five Percent Due Twenty Thirty One [Member]",
        "documentation": "Senior Notes Three Point Seven Five Percent Due Twenty Thirty One"
       }
      }
     },
     "auth_ref": []
    },
    "dva_SeniorSecuredCreditFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Secured Credit Facilities",
        "label": "Senior Secured Credit Facilities [Member]",
        "documentation": "Senior secured credit facilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series of individually immaterial business acquisitions",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ServiceAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceAgreementsMember",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships and other",
        "label": "Service Agreements [Member]",
        "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1387",
      "r1388"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average fair value of grants (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised/ Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "verboseLabel": "Expected volatility Rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based awards, fair value assumptions, expected dividend",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r656",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of employees' base salary to be maintained into deferral account",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee entitlement for purchase of the Company's common stock during each calendar year",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Share Value Authorized For Purchase",
        "documentation": "Share based compensation arrangement by share based payment award maximum share value authorized for purchase."
       }
      }
     },
     "auth_ref": []
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock awards exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average fair value of grants",
        "terseLabel": "Weighted average fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock awards outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r663"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (USD per share)",
        "periodEndLabel": "Outstanding at end of period (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r663"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual\u00a0life",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual\u00a0life",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share based Compensation Arrangement by Share based Payment Award, Other than Options, Weighted Average Remaining Contractual Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Added by performance factor (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r661",
      "r680",
      "r681",
      "r682",
      "r683",
      "r686",
      "r689",
      "r690",
      "r691",
      "r692"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range",
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range",
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of exercise prices, lower range (USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards exercisable (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards outstanding (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of exercise prices, upper range (USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1407"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1407"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms of award (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock awards exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase price as percentage of fair market value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Investments",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087",
      "r1108"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r325",
      "r413",
      "r416",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r448",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r502",
      "r506",
      "r509",
      "r510",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r1120",
      "r1123",
      "r1124",
      "r1129",
      "r1183",
      "r1498",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1521",
      "r1522",
      "r1523",
      "r1524",
      "r1525",
      "r1526",
      "r1527",
      "r1529",
      "r1530"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r189",
      "r193",
      "r194",
      "r323",
      "r358",
      "r359",
      "r360",
      "r382",
      "r383",
      "r384",
      "r386",
      "r391",
      "r393",
      "r395",
      "r414",
      "r464",
      "r465",
      "r504",
      "r566",
      "r733",
      "r734",
      "r743",
      "r744",
      "r745",
      "r747",
      "r754",
      "r755",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r774",
      "r808",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r818",
      "r820",
      "r845",
      "r932",
      "r955",
      "r956",
      "r957",
      "r977",
      "r1045"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r295",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r446",
      "r447",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r982",
      "r986",
      "r988",
      "r1055",
      "r1059",
      "r1063",
      "r1083",
      "r1090",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1107",
      "r1139",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1182",
      "r1188",
      "r1408",
      "r1498",
      "r1502",
      "r1503",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1521",
      "r1522",
      "r1523",
      "r1524",
      "r1525",
      "r1526",
      "r1527",
      "r1529",
      "r1530"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r414",
      "r820",
      "r867",
      "r963",
      "r979",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1003",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1022",
      "r1026",
      "r1027",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1045",
      "r1189"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r414",
      "r449",
      "r820",
      "r867",
      "r963",
      "r979",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1003",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1022",
      "r1026",
      "r1027",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1045",
      "r1189"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1221",
      "r1232",
      "r1242",
      "r1275"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options",
        "label": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options",
        "documentation": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award",
        "label": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award",
        "documentation": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award"
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance",
        "label": "Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance",
        "documentation": "Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance",
        "label": "Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance",
        "documentation": "Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockIncentivePlanTwentyTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "StockIncentivePlanTwentyTwentyMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Incentive 2020 Plan",
        "label": "Stock Incentive Plan Twenty Twenty [Member]",
        "documentation": "Stock Incentive Plan Twenty Twenty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase shares issued (in shares)",
        "verboseLabel": "Stock issued for employee stock purchase plans",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r188",
      "r189",
      "r234"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock award payment plan (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r188",
      "r189",
      "r234"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised/ Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r188",
      "r189",
      "r234",
      "r667"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r188",
      "r189",
      "r234"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock award plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r188",
      "r189",
      "r234"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program, Authorized, Amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1407"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program, Remaining Authorized, Amount",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockSettledStockAppreciationRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "StockSettledStockAppreciationRightsMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-settled Stock Appreciation Rights",
        "label": "Stock-Settled Stock Appreciation Rights [Member]",
        "documentation": "Stock-Settled Stock Appreciation Rights."
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "StockUnitMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock units",
        "label": "Stock Unit [Member]",
        "documentation": "Stock Unit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total DaVita Inc. shareholders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r193",
      "r194",
      "r223",
      "r1005",
      "r1021",
      "r1046",
      "r1047",
      "r1171",
      "r1199",
      "r1343",
      "r1364",
      "r1473",
      "r1533"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r124",
      "r323",
      "r324",
      "r359",
      "r382",
      "r383",
      "r384",
      "r386",
      "r391",
      "r393",
      "r464",
      "r465",
      "r504",
      "r566",
      "r733",
      "r734",
      "r743",
      "r744",
      "r745",
      "r747",
      "r754",
      "r755",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r774",
      "r808",
      "r810",
      "r814",
      "r819",
      "r845",
      "r956",
      "r957",
      "r975",
      "r1005",
      "r1021",
      "r1046",
      "r1047",
      "r1088",
      "r1198",
      "r1343",
      "r1364",
      "r1473",
      "r1533"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Stockbasedcompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Incentive Compensation and Shareholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r376",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r773",
      "r1048",
      "r1050",
      "r1089"
     ]
    },
    "us-gaap_SubsegmentsConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsConsolidationItemsAxis",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments Consolidation Items",
        "label": "Subsegments Consolidation Items [Axis]",
        "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsConsolidationItemsDomain",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments Consolidation Items",
        "label": "Subsegments Consolidation Items [Domain]",
        "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/RelatedPartyTransactionsDetails",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r853"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/RelatedPartyTransactionsDetails",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r853"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/RelatedPartyTransactionsDetails",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r853"
     ]
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Holdings [Line Items]",
        "label": "Summary of Investment Holdings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r974",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r994",
      "r995",
      "r1024",
      "r1188"
     ]
    },
    "us-gaap_SummaryOfInvestmentHoldingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfInvestmentHoldingsTable",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Holdings [Table]",
        "label": "Investment Holdings [Table]",
        "documentation": "Disclosure of information about summary of investment holding, including, but not limited to, investment with value exceeding one percent of net asset value of registrant."
       }
      }
     },
     "auth_ref": [
      "r974",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r994",
      "r995",
      "r1024",
      "r1188"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_SupplierRebatesAndOtherNonTradeReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "SupplierRebatesAndOtherNonTradeReceivablesMember",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier rebates and non-trade receivables",
        "label": "Supplier Rebates And Other Non Trade Receivables [Member]",
        "documentation": "Supplier Rebates And Other Non Trade Receivables [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1268"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State capital loss carryforward, amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardExpirationDate",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State capital loss carryforward, expiration date",
        "label": "Tax Credit Carryforward, Expiration Date",
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1439"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1439"
     ]
    },
    "dva_TaxYear2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TaxYear2029Member",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2029",
        "label": "Tax Year 2029 [Member]",
        "documentation": "Tax Year 2029"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity",
        "label": "Temporary Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurements",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Temporary equity, beginning balance",
        "periodEndLabel": "Temporary equity, ending balance",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r377",
      "r462",
      "r803"
     ]
    },
    "dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions and divestitures",
        "label": "Temporary Equity, Decrease Due To Acquisitions and Divestitures",
        "documentation": "Temporary Equity, Decrease Due To Acquisitions and Divestitures."
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityDecreasePurchaseOfInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TemporaryEquityDecreasePurchaseOfInterests",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Partial purchases",
        "label": "Temporary Equity, Decrease Purchase Of Interests",
        "documentation": "Temporary Equity, Decrease Purchase Of Interests"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distributions",
        "label": "Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders",
        "documentation": "Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and divestitures",
        "label": "Temporary Equity, Increase Due To Acquisitions And Divestitures",
        "documentation": "Temporary Equity, Increase Due To Acquisitions And Divestitures"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contributions",
        "label": "Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders",
        "documentation": "Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityNetIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income",
        "label": "Temporary Equity, Net Income",
        "documentation": "The portion of net income or loss attributable to temporary equity interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityOtherChanges",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Temporary Equity, Other Changes",
        "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityRedeemableNoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TemporaryEquityRedeemableNoncontrollingInterestsMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests subject to put provisions",
        "label": "Temporary Equity Redeemable Noncontrolling Interests [Member]",
        "documentation": "Redeemable Noncontrolling Interests Temporary Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TermLoanA1AndRevolverMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TermLoanA1AndRevolverMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan A-1 and Revolver",
        "label": "Term Loan A-1 and Revolver [Member]",
        "documentation": "Term Loan A-1 and Revolver"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TermLoanA1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TermLoanA1Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan A-1",
        "label": "Term Loan A-1 [Member]",
        "documentation": "Term Loan A-1 Member"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TermLoanB1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TermLoanB1Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan B-1",
        "label": "Term Loan B-1 [Member]",
        "documentation": "Term Loan B-1 member"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TermLoanFacilityMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "documentation": "Term Loan Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TerminatedRemainingPriorShareRepurchasesAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terminated Remaining Prior Share Repurchases Authorized, Amount",
        "label": "Terminated Remaining Prior Share Repurchases Authorized, Amount",
        "documentation": "Terminated Remaining Prior Share Repurchases Authorized, Amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Text Block [Abstract]",
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ThirdPartyPayorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ThirdPartyPayorMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third-Party Payor",
        "label": "Third-Party Payor [Member]",
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services."
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "dva_TotalNotionalAmountEffectiveThroughDecember312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TotalNotionalAmountEffectiveThroughDecember312024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Notional Amount Effective Through December 31, 2024",
        "label": "Total Notional Amount Effective Through December 31, 2024 [Member]",
        "documentation": "Total Notional Amount Effective Through December 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TotalNotionalAmountEffectiveThroughDecember312025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TotalNotionalAmountEffectiveThroughDecember312025Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Notional Amount Effective Through December 31, 2025",
        "label": "Total Notional Amount Effective Through December 31, 2025 [Member]",
        "documentation": "Total Notional Amount Effective Through December 31, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TotalNotionalAmountEffectiveThroughDecember312026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TotalNotionalAmountEffectiveThroughDecember312026Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Notional Amount Effective Through December 31, 2026",
        "label": "Total Notional Amount Effective Through December 31, 2026 [Member]",
        "documentation": "Total Notional Amount Effective Through December 31, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TotalNotionalAmountEffectiveThroughDecember312027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TotalNotionalAmountEffectiveThroughDecember312027Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Notional Amount Effective Through December 31, 2027",
        "label": "Total Notional Amount Effective Through December 31, 2027 [Member]",
        "documentation": "Total Notional Amount Effective Through December 31, 2027"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TotalRevenueNetOfIntersegmentRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TotalRevenueNetOfIntersegmentRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue net of intersegment revenue",
        "label": "Total revenue net of intersegment revenue",
        "documentation": "Total revenue net of intersegment revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1267"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dva_TransplantSoftwareReportingUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "TransplantSoftwareReportingUnitMember",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transplant Software Reporting Unit",
        "label": "Transplant Software Reporting Unit [Member]",
        "documentation": "Transplant Software Reporting Unit"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1293"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock acquired, average cost per share",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock, Common",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock, Common, Shares",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement of treasury stock",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r81",
      "r189"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of treasury stock (in shares)",
        "verboseLabel": "Repurchase of common stock (in shares)",
        "terseLabel": "Repurchase of common stock (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r189",
      "r234"
     ]
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockSharesRetired",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement of treasury stock (in shares)",
        "label": "Treasury Stock, Shares, Retired",
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r189",
      "r234"
     ]
    },
    "us-gaap_TreasuryStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockTextBlock",
     "presentation": [
      "http://www.davita.com/role/Stockholdersequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholder's equity",
        "label": "Treasury Stock [Text Block]",
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury Stock, Value",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r85",
      "r189",
      "r193"
     ]
    },
    "us-gaap_TreasuryStockValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValueAbstract",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchases",
        "label": "Treasury Stock, Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury stock",
        "terseLabel": "Value of treasury stock acquired",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r82",
      "r234"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "dva_USDialysisAndRelatedLabServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "USDialysisAndRelatedLabServicesMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. dialysis",
        "label": "U S Dialysis And Related Lab Services [Member]",
        "documentation": "US dialysis \u200band \u200brelated \u200blab\u200b services\u200b."
       }
      }
     },
     "auth_ref": []
    },
    "dva_USDialysisAndRelatedLabServicesWithIntersegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "USDialysisAndRelatedLabServicesWithIntersegmentMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U S Dialysis And Related Lab Services with Intersegment",
        "label": "U S Dialysis And Related Lab Services with Intersegment [Member]",
        "documentation": "U S Dialysis And Related Lab Services with Intersegment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Liability for unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r715",
      "r1158"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Adjustments for tax positions related to prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r1158"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reductions related to settlements with taxing authorities",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r1158"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r1158"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrecognized tax expense (benefit), income tax penalties and interest expense, net of federal tax benefits",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r1158"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions related to current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r1158"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reductions related to lapse of applicable statute",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r1158"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r279",
      "r280",
      "r282",
      "r283"
     ]
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences."
       }
      }
     },
     "auth_ref": [
      "r1441"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in valuation allowance related to changes in the estimated tax benefit",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity",
        "label": "Variable Interest Entity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758",
      "r762",
      "r763",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Primary Beneficiary",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r757",
      "r758",
      "r762",
      "r763"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r1170"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election",
        "label": "Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election",
        "documentation": "Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election Effective date."
       }
      }
     },
     "auth_ref": []
    },
    "dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20241231",
     "localname": "VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date",
        "label": "Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date",
        "documentation": "Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1256"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r861",
      "r1102",
      "r1103",
      "r1165",
      "r1488",
      "r1490",
      "r1493"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted shares (in shares)",
        "totalLabel": "Weighted average shares - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r407"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding during the period (in shares)",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares for earnings per share:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r407"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1254"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-6"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "7",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-16"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(3)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-24"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4M"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/220/tableOfContent"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/230/tableOfContent"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505-30/tableOfContent"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r243": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r244": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r245": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r246": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r247": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r248": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r249": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r250": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r251": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r252": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r253": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r254": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r255": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r256": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r257": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r258": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r259": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r260": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r261": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r262": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r263": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r264": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r265": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r266": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r267": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r268": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r269": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r270": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r271": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r272": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r273": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r274": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r275": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-20/tableOfContent"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-30/tableOfContent"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481724/830-30-40-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-9"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>142
<FILENAME>0000927066-25-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000927066-25-000012-xbrl.zip
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M&[W^[<M?YE_?^(>?;;PD$V;F4"MMIQJ_^_;>X[M/']R[TYOVP]U??X3'CU_
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MA?BJL9RP(P$/Y W%NY>4)G <X+%6?Y7NO%7G(O+A(_<,UZ%X1_;I4, STR2
M:*]LR,QNQP%^.#;'_5WW6]$,1FS#)Z[3IL3I='$<X%[[9=578W.H*W5AV18(
MQ#YX[)O$F1D0;^O*UV,"'!!Q)RGUZE!$CH,\)/;J2,"#ZY?4R1N*=Z]U3^9
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MP)-R>@;#^Z*TH;U]Q(7$!T_<^\!%5B#><=YP"(<"SF+A4+P[ZF(#T=XX#M]
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M_S>BEE;",ZGFP^_N9 :6_0@S=JLSGG_7M#RW+0M&)J&CE9\!=4+U_.,LJ#Q
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M?!4V@1Q3O$+(8PL4M):H"U:8 =:XYF2!A/[T3/WBL!N_).P&;KZ9<E5Z J/
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M%0  %P   &1V82TQ,C,Q,C1E>#,R,3$P>&LN:'1MY5AM;]LV$/Z^7W%SL+X
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M$N,I6)K=)KM0O/.36_V_^@"X[SX\_@-02P,$%     @ ,XM-6L88!YAR,P0
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MR6?!B.9&Z-KR%:%OP4AO)DQ$,AN_&W21Q4U["GSX]>#BV^=H*&HU'5\)/N+
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M4KNL\?6NK8H.O"E[F/U:)D@'7I4^/"_"4]:!<66/ZW>*9>G H++'_Z\&?.G
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MO>-^@#<E$DLE0US@HTV8LG\Y.N,SS[>#=!T1S/_$M;YZ+I]_!;[RX'/H6CL
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MJR'PQ 4!P0X5:E(-U:D7NH&8GT((MAP ^7C%3'AW^)P$:A@@U."P>R;XOL1
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M!VV%"XRGEGZBQNQDQ[EJ^QB"PH*!#V%Y#I$OW)(, RT6D"*!59M:IB09KA?
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M,7Q#VL*!Y>K0I=FY-+#" ZQ'BQYA^_0^;*0AUZA2'?/HKE'H4K05W=:3MZF
M5;768)&- ML'+CP:J=@^6@P4C8XKX%$!.8EGI(Q%%%^DJ8"3C3A,="#+#Z0,
M#!=M#5@"D(.(@LK/$/*J$<.8!10YJ&N7Z F:!!3PWY)'XB4UJ6=(52IFN8M#
MXN@'T+# JP45&POM^<WUV?N:#&9^N-X]!5;)U8LR?GY#0OZ)FPQ\J$4!P+>#
M:*&EA'>@7P(Z]\Z^D_9**7H_+7#I.UWTY7&=V +M"!@TB.9J!KXR\6\$_W=H
M"QZI8YA?;"L#B <#"1=X:!G4*U*6&8&!T*>-"NC(-8RSZ%XEXX)//1PM+C'O
MP<:="K3NI!?@@]0;Y"7$ZP^OC,<V1+,>V&H_UY3#>QO&5?2K'XY&T@S3(VA:
MB6Z(Y@7F*T1D!L=75X/%>Y)9PAIGLWE\ZI[ -2E5@HVWW7&:/E8L.]+5$-SD
MU#1_F2*-$BKEA,_&V%-B=IH6D9FP/8*SHG5H$WXTI4UUDI'@;D3&62I#D$"E
M5B-1)U4IS\Y:%%9:I<N+ )8BN@SXMOD,W7@'_20*-4 R//"C8%CD)YGHK QM
M2^(-?FA.<-7=SF?<N* !RC\OD.O@WW 0PPE\ ZZBZY,S,_.<N3GW@R4KA+B3
M.ZXCKF>P,/#LZ31T$9((F/F#(IZ4Q<&X07AX PP1?5/LZ!T@D@+1,_B!H2E=
M)R17Y.>F*99(K^W>>0Y*'AHQO)24CLMG$WP^'@LI5Y!E\P!7A^M+,^+,:"'#
M16HY(<FQ75,-".7:N#E(?C]V0A/A/WQ(A+G$9@B?JBPE%R:"I>"B!X@#@V*;
M8M C'3WP=MVQ3_HT(4/,\$BC^&DK*74KR9F4(N6S&WPTDCBD)Y:7E8S6)':1
MH(8T=FXIR6 S> >(*D.P4,9Y]"[9@&KQ6:0>(;0 [2FU(@R%' 8B-#%&V2)\
M%,8=:$1@SFD>T/C9B#MJK+8*:)*;%1BVK%+EX#TK#H2ENMD7UQ4]_Z%*'?"<
MDP<[CUO_(;W4!/2(V1=#'DJVOL.2HGW$Z);)>.=[XZ:1W(!<%FK#'@BMX:M]
M+L:[S'7O8V))"?$3Y4ORN. A*\TH37EMY6#4$I"AEH.H.H@K3A5E+7J9'+'P
MX#,L!1@E(C?I:# -M\1#)]<FB<)]3+9*Z#=>&Q)HF;$Y+!J1WL&8MWW<N2Q
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M9.+ZY)ZT%V[42MNN9VS:H@Z,$9#BI]IUQ5V&6#PX3F>DU!-4;\1Y7 B1G!@
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M%50T0"H_+']_V&X<-8]6_M1LM%9^O^Y1H/H&1ZMO23T*YHT$_?6@$X--$07
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MR9IZ<7C-)34^M;>_I+;02!TCF^]?S$8]?[(S4;<UMN_KTO#J_44,U+47U,Y
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M5@N ,!RH79G:EJF?;$>9^HZ&)VQX:6"(^#=RO]AOF^7+]M8DEHOMS]AHTP.
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MFX"*J/.V2FQ^/.0YZ>@CB<0-(]B+94P7'F=58>#F=2.+W*^5*$@Z#G=+UTJ
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M;16;'<;Q<)DR<#J%1G5;-!MXO/P%=N$B$-G^Y%U%)4Z.#2$&Q"R^M$=C9;>
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M'W94FUCP(<<-?>&\LADF!$Z0BZ;H)LHQK=QB08$HYN'C&U$TR&&?.29S;&A
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M2A-1F-P@5FM55]Y0Z8F(&#.F_MRRQ?0+0A ;B9&G.E!8$%R+,#V[+>Q;H.>
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M2>-S;5[6TS2PK 7\IF%$@I?W+&_8@,JT];I;QYY[VQ;NQ9D0&7F3B2#V7NH
MHL4QF[SXZN\0.<(:H'%[!C\MV<<E2@IX"8@)+[R'O?B+)W[Q<- FAN[YH?]]
MC)8(=V8&8;''HO92HPH]_K%$=[BGX(I??W9H'_[PQ<C#AW"_B%_\Z>/HNX]'
MOOLG<)H_\=GW7LM&^*[8G .[X%7(!VS9HO\!O)S8&- BD<7#W1*40B&(NE-
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M"R)?28^R@'8QV.E,,]T^9S%%5 !F<21,I[(DRUSXD)QR+H?)4PL;@YG@?$U
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MHD;RM"\5?[W%%%;-R)+RTK&M5Z075MQ6E8)U48ONM[X(_"=F@(M9P00ZF"#
MR+EQ#/$C#(-F1A@#2SD@>$$DP&2"AJ7@&F8^L!H;"DF"Y+YEQX=:8AO@&^NZ
MF[0G-%QR4)AG7=5S1\!UJ8BC3=S\.%O7/D"S%Z^HD5%DSQK&8A3+?]5(_]XX
M(Q]HL7P(X0*N('^.:E[C6]DE-T('/'F^=37'V>P/K3GRZ.00H?&P_X.<)?PF
MC%)ZKY]O<@(6ZG\>_.WRL_+YTP??N#\L=C67'=NHB>T:H#,"S;2*8GM5>D1,
MX,B*]MA0*9N(V3[^^&I$(AO66/K-;L/L-LR--\R+!]](;9'H?H72;XX%?N7K
MQ] N$0$([]S*2A?A3R/]+NN[BS9=:.+.3M**@')8C%G5=OW>Q<J[&5O);O/L
M-@]LGA>/'WRCZQG\7<V*4,D&4P"3$LD/2O%R&KN%=H9[M_9^V]I[PH9;I330
M2'=44\X=%BB))P.UI9/)%6SL;QV!:P4$?_C\_%Y/=[W9@8-QLD**A%L?_?LT
MUG_$R$YDI4=>"C,$(P[%NRB*A?#>"MCCH&[EDX>2/&D[XNO@)DM4FB&(=$W_
MWKDINZ/BGCW?-;;,<SXJM 62V,&PQLE<Q(&@@U)N3$N]MV2I&1*0:BA+Z='
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MQ2%VX![F<W>P=YF&K+5%CEJ_QZ4\XP]96F5T(Z24-T\;[T2'I1GB704[M0;
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MJ<3RR(W.P[[$>D:-A9-@DD;:GG56JG$A8_5.\TX>]W%RB=\='1_%'%V>VHL
M2OW)1:V8A6HR\3G*7^&8<Q\E^!C/'TE-VOU3R[<*0P*7_W8==RQ%;<!7X&2;
MTFI#S'E&CPX'$@'A*$Y(L!R4QIUQB-LNES9&?JB]B\1I5P9\C?,HE,36]F#
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MQGCHYQSHSGB5$)U\>,WPCX[2B:D+"P'*I>P-&4F#&^T^@H$7T?2>*#0)O_"
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M&V6DF1WO'3TB#I?*'@O9*<;+):_3F#79G*(2B$T5IB$7Y)3"&X71&(MAM3I
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M@>7^@9U<?3FOD)Q#"QRR4\[1N*[A_("*4_FKXF!,'L&M&-.KOTY!_*X&SET
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M=Q4,9A*(G51-M:R5 #NS1@C[',G<I+<SU>[,;-I$?D)G%/VO"*\E1'F47<(
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M185%+,WFD45LY!!N.>:V8Z&U,^*+(<]D2>DNU(O!3S?1\8A]+X:EVWNA679
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M:=-BDV>$0S)FZPQ;YUG"(C^U@Y./N5K,)J/:-FL[8.[YAMXSOW/7$[<&&'R
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M/X_E89^H&*D%75U-<BQC)5[=:?1%6!>\@M:9PT4?.8G& WZ8=-UQ'F6_3$4
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MH"N,+W+TJ3 ^KIOMU^*N V/.0YNW<&D]NM(T>(>S($8-?%VA3S?BON"D2_"
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M.0<3JW&#&9;I7KL%0J3M-\%M0BFTGROA#./H:EY[N _3Y(M*YY[6T!\+-;H
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M&$5Z,/2%Q3[@7,Q =^\P]):[YU!_)'2JQ#C4+?RP>\4HQ3BAN&F"U[6-=@C
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MRDHRK$#BSB18;T^6_RC,M'U G7@17* IUG_D.-,=4VZ]%[]*&.1Q4H$K;D^
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ML'*"+$@[0($KEBR&K0AV#SPJNA;NORJ7:G=\UN[)]+I5)TMB. L>"*V=>?(
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M/CJ&S:;X_JX)LMA_.,2Z,^K:16_DL;!'U_H=H!*(:.LMR :XWK@[+E"1C%W
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MT.[=AG+ER$TO/J@<K5[^")L!QZ3)_D=>W%4_$NMC>^LFIO#?9>9SKMF"W\X
M 5]NV1PV^YX%#VPCT'4LTC40]18,MX\O#_GW?Y_%Z'7NOKAU7+)GU%M&KR#A
M^L-^)O(T[^RRS&<@!7_NNRQ$;SV-74X*FB2>E\:X/!FKL.THLT6E 0N0X60]
M:K,5_"EX C@$1;84TW?I(@7I!^\:X3M_9!OX=]\F+F?6.HJ+YLQO/%Y9_XP
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M,N<1DRCV%C%?]M$_%>_ ZC3P.K6BZ47/6)W26IVWOS]Q\:A6)LU&*\;7GNO
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MS]&?J3X=7 M@G]RER8#V)7LU&>B:CDVF8Y/IV'3NT*CIV'2!-;1V9SP>FJX
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M;U>"[<T+;_O@)N>1Y-6W_:$>"DF0?#L>Z+\[N.LU=_'2-MATK=^6((Z4"'H
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M+GX.^$U =A(5S"0P?(%4(L6'>F90^4S; /,IS,BBDTG1+8W3GV8*!P0B_PK
M("66F=4^D.D*Y W[:@4^F^GA1V@AI&',W6@1PI8\^L&,AWSN)^7^LYJBD0T
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M: 5/B$!8P0XW" 8:_DB6S#I&M2S)"'\2>U3\0OKX?T(?E_R<$)B U="3!YT
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M+2@KYC^4U2%YEWA2N:#@!2*4T1L=Q18J#Z:X?46A7B<C98&!!SA_[H25EJ2
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M*\.3U!+Z;)GAH$(619M9Q>VS6#Z&\NA"7JC$%>WAR$B#BRDTRHR.=?W@]GV
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M\?""<;)]KD@FU30AU9HMU0@&+"'5A%1KC52SM>U&G1N_2%_&X8]8F')=%7H
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MK(!AW@]#),X<Q/@Y"".JO;ZFZ$C+*0P6N3#-1MK^1LM!D*;U^JII(#VGA9I
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M589L4AG99N6VAL+LY1!;.T3O8;$%N0*JAM3JDEB8P/MT']YP6BDLDQ+'>Q#
M66H?NR\KJ-"(&VDR+UVPA(%[W!.QFF"D$6UM(T,6/8AYZ$%<-9102W)FLSEG
ME^U;.0ZGTF&:CJ4AO;;ILKQG POPU6,<5P>? > S=16I2EW'"DU+EN5.AB_Z
M3HC0\/%"P_L7O*JT([$J.\@T1 Y$&Q&U7WRX J(LVG15(PZ9+8+$IY"\(B)\
M^(AP::ZP>WT'*9:!G.IA"A$,YA!6M02#2\/*Z?5M*,4D I>7U)HNF+GO&P )
MX_8 2;W[VR :E"F;#C)L7C(RA4U[PKS>"D""4S8;IFR(1L/'@\(5'F&R79[D
MSX_;J@6!6\X..^1J1L[Y$<DR:Y2>@Z!J:J]OF@;23-%GK8UHVB%<ZT:3UNM;
MJHE4A9<<F9KLUX8=N]5DP7;YQ*/X<5MI)M&)&6(@Q=&04YU/RFY5 ^S=+L.N
M^$%;:=@9!'8Z4@P9J6I=GA1?1VP-M(XOP\G$9PW=:;T;H(&L'0?#;;*[JEUT
MBNOKU,36N<6[(@8WE7PH"L=C.#;UH0\2CLDNQ[.G/_$PD9)0FLX2:1J%KWX,
MX4(1:]I7&=]C#^,))'"N4OTF)3J;=7/I1M$;>74P@:8+I<6G2<0G,AT#Z;9(
M36PCR':HWJ. S *0Z8Z#5&Z"G5W0PFSO+NK0MXU@BPJ-WFHV#YI*KF.?BWG^
M:W;O]!9G\/D+1:$QB9/-K\^"NW$2#O^2/OQMF\"]P]'#BQOAK=K]YON7]3G;
MZ;<\P)?<N=%M])! [?D?[GB&%W=-Q:F\$*=VKR^?R_)Z:%.:NI'T"I<C:>.2
M8[AM7&VU=&GQ8):\A!$AK%=:(SB]OH'DG'9G$EN>Y,[O_>D8CW(3Q[/WCS'R
M?V+O[+\X"G.>0)=[?;(FO/X /KW5QSE?$8SS8OVF-^;#,-EA_:[N$N6),MNC
M@'RS547]Q(G!T7BKEBOP[+!J*X)'Y0T\Q[96^=3+$%4*@X,J9?85936RKIU
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MUX'W1>"ALJ'"]N-V=)WNQCW9C-L >!'^NU[0_WY.>GAC$'BK+RQ]\B88CF=
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M"%8 ./WS;O)%,N;[F"]_<D+;];'-%?SZ'B[(F8"(\J(KV\8,1I+@KF,[+'R
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M^$',C("<='&I<5 3;C$2(2J>T"MR312]/L2E^6.X<J).),LJAH"/20$+0*!
M!%>3%_ISQZ/U$OEE237CK^3.>_1\2ASCRM^,WB2S#82?*N,:#77^[BCP+1)G
M\@SB3$'1,1,X49B6=(@-E9[5Q$0E?QD1I= ]I[JJB4D@UBH>OE@V24-C!4M=
MX[%;Q82+774QXB!OX%QGDE;W10A0+,:U1%J0WE:<RD5""120QX QP3O!]+J0
M[X(WJR9'S$CY^YT)KY#0E>VJ5HE4$F'1*:C!@-NVXD%&33..#:=^(>/$F(LP
M6>!?*=Y+]F[,%94,FG>(R"+U#2M^/(;,W(D3G@JC%2OT6<  )!MYP\A6!..
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M'#>Y+J3HQ?;QKL-;5XS(T:,(94=B5JQ.9@B=2BF$$X_<S%3H)7.2U=3$B<R
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ME:U*^-G %=9F:VR'OT4AWK(7.<>\$;/.&ZGS1NJ\D>WS1KJ%>2.]QHZZ#R\
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MGOPQF6N22$$Q20Z]7@0?P$ \@4]#$,G"C!NFCE>_F>R3YWC*D(W.-TNTSE*
M2M;(2L-#-!?AM.K%'7:I+#K*4>]?\Z:&D\)!JG"U&?+[*'6)HJ6C]4,,8O&E
MQLM?1UU\D0N 3<*H6#FR?K),0)^4@X0A)+U$AJ_52P0[0=[(;DN@J]XS=Q+_
M>T6=2Z_5RCDCX;-3:52 (+B(.U"MAW'EF?0*CS*_KI1F!$KOV$<W&]G'80P$
MD7ZVN>F6OJ+C%FDWB\B?^? [WJQ5Y+A8ZGA[*A.8S5U_*9JQREY>(K,_?E+H
M1?3 MMW#1/=SI-Q0-#(J&#I$AJG0GS"[@Z<>8%N0V VF"A$:R;82;.-<YV]^
M.I9TDDZ\8Z)W=3SA*/\^6128;#N;V\E3LK>^)5'2E+HK7;DH/=EO>G>\X4IR
M<5M<&N?DF-/.HKB[9B)Z*+TQ?I2?Q0_ELS('*9%V5!H3T$@KR[7CT:IQFVF>
M9$*3NM41DTF?83Y>,G8?V#+0SYDL-9GAOV[F8\@97]&.V7[H:WBP?J[DK.T"
MSMH^%<XJW%8D^(Y,V?W"QDA'NFALJ#:1=913Q0VX%[(G!R]/Q4IACT\WA-^)
M2>8\1 +_Y,DFH9)MQ].QU QNZ2AK:I^R"H02.R!%CQN);)8.#24[(5<NO1=P
MG@( MLA[D6Q$%/-2XG.LN%#%6N)33LXA5!>?VMW$E=&+4!8=R$&2JN:C%C.I
M>>5 &SR%)B2"E+DZLD5J3.+):>;6DJ>6*7LK>E,V'5XLY83HU[&QZI#<,[$G
M6QFQEW+\ -.B&KL)5RDYH*FHH= EJ:B@29F'D_+(<,>/1"+LK(,5Z6'J1#PW
M,6DVCEO%WXK<CS"NFLX\DQ@&E+_$Y9VU$ XB2_P<?_WG8OS(;9>1=#G(IF..
MJU3$QIVS\C &1;SPA0YE@<(M.>%4JN)\$#4"FA*!L.U,X;6A'BTN/^/>E_VA
M]TD".L?4FVZ=>E.GWM2I-]NGWO0*4V_Z:XPKTM@*]+BUDZBJHNJH5@?5F5HI
MR8,-R$/J42?:N5UPKQN/!%-0@DP[M8+4BJ+ &6$J/Y<+&=F%DWZIP4>&P_//
MJ9R)M TJA*4 7C#F-4VCHMFLB8PE94VT+[M#2905H\EAT(7(Q%0>=7?X132E
MX1NB8CBETY"RQBOUDQDYTE BR28+NM=MKM1.)?=('K^B"72MF'9WE'M#T4@D
M"!!OV)<RD_C5:YU(Z^G["*PJ.8]3@<*161T**<8=2,(51TO-\>(_ @4J<M$.
M>;;(=1#FRMX+NS6CKL^?$(DZ<K; 8QP33$_@L%2#86TI,<;XR<:AKA:R4(A>
MIJM)8[1_N8M4<UGLUL"=T (&ZMB<>#P0$)MP@6/1I%+9E$J"HLHE.40HF7 D
MY$\VFP2G8(^5@G_1$(KR^!-E7@Z$7H6!J6M"/WS!+:E%,JERZU02WW8;23Q)
MV3EO*B(E[U9N5N22Q7" !R>,-^<\MEC5RMO@=RNO ),%A?*A9"VEHPT)(>(O
M47:DG&F>D'1CV;24@C$N6TVWN2U0=$;=  WQBQT!@%MRCX21Y.=B/W'(.]JP
M@2YB'4K5E20[1&Z%LG2>-,.7(2M>S++'V\=\@H4GON10*3,_YA/\Z(DXQJIV
M6KW6R;0O%^7N5 D.YU'*'8^,CE*I%& 7>B)A%A$4D'JD-***&[-1U@+B6U+W
M+P%!$D:XDD,9!, T"(KRT:]X9_^0*Y3\1U,V?J0@&_<)^"C1J$MPXOJXQP$'
M@+=W.#T2]Z\E[6%^PV7?W=]]^>U]>D?$4]'#+'="<0$,[*;V3>%\902\&+ZP
ME V\"DXI*[1HJ@A)GL :QX,\F2UEIW3]Q#W5QPR3!F3UK-(".HG@(C30<Q;'
M"MO&:P\>N(YS#.'>[A>CT!D[V+<]O MH))E26'"MI"-^QIBYPW(Z9[XE)GQV
M*C[O6TK)Q'&BK@@,\WS((R/\5<=(LN4T=;9CG",J?X9YH^+ZE>;_Z;SOU%C/
MC+<T-I94#4=0"\U5!9+]Q&R:.LE5GDY;UXR68>I*Z C?3C0HQKK2_%'Q=R]]
MPJ(3""KY$HA)<9@P0#1"1ULV,G33:P#QV:"ZN>'_-&YNOZ@Q]UO2-N\FDB8>
MIE;T@/O\SK?YO[!+@/EULB.>-"YE2=C0L&D>K-9*"*G;N.P; TG;<IN7:3"[
M[!&;I(GWELD6OH!V^@<JIW>3+_+B;G!BYJ*@QJC7.I%^%E\2PRF.:!X9<2M'
MH&27"<^V"D5(V;%9)A4G3MW!KH T>4"VJJ5N@&)".<Y4Q'P?17<E9X[PW[CI
ML8LRQB(RC(A<<:B)R#N,IDS+-B43QHVR?>47H1"@<>9.JO5 ,I\;VP]3.UL@
M2R\"H8XIF&(3TDC$( ]L$/F"M*"QI ;;4G+(C!9+)KV7  \6R)9#<;H69B!P
MSD*R768Q"0#P? @<!^BB..=:.T_ZLBEE00P.5UNY\3X7('<Q3RYNZX8F#,TL
M5X&KYX>TT.[G2N"\".[\PA>DU,1C5R1 =)Z!K*P3ES4)BREAU9Q!\MQ:&R=/
MV?&P"4N\<H$99),\,67,KVRU4)$_30R5";EI1.W]^ Q%NA]J6CE9?:]*=AC\
M;.&)GJ>\)YGWY+M/2G*WLO#,0J\B1BNIPP<-Z$).FP10%5#A S+BEJ0C-K5K
MT6"U !"8F>;)':222=-[5"<ZJ[^* WS*7&58%^@##,&0YK=.XL1!0>A*J]:X
M"RRFQ(>Q!7-LGH!T3@U.0*(N=*M82"I/A?H[2!6=B$;"6?J5J:<W3;*-$T!Y
MC^YD.+5L%YG.,N33/V5W7=&>2PE7<PKV5FEARCW-%Y$:07^'(]O8C.XMI].D
M2_>2V#?_X7MIT<1GY@@H)]0SF>%(^8MJ QC5%%384/AQ56(Y/BWS:/6X8C#3
M!H(@*;K&9GN9?43P"XLS8$D0F@+S6XXAU(49\LC$!#J<P*6VR-/SMEVJI]/+
MKNACS$PRX-RFE))/_ROV+&6:[^3[YRK7[T1A$=KQK67P@F>W9DI;I@[8RH$]
M7<K96U*-$&I]K!%B*TAYRGNXX3%Y'G_UT4'P[LO5_:_OX0(G6!\LA V\@N=B
M4%,5AO .TYQYJ5B_1N>UK5]@1,D1O@>^YR]$_U2AXJ[T9_4+#-W^R1BZL+""
MP*&\VNK)AQ<<+#Z-2&I'E6OLSU$!J=[Y-E5MW.)@,8QU@'G<X?H.TIUT!!?2
MY^]S"@*]N[K__3T]=]'JZQ7K%'G/N'[S6ZQVOGOPYT#0QJ#U_H-VDQJYYHN?
MD6"43WYR0MLE?^(;%345'T36;["?<TQ^$'HT[304.QW'.TT-5M112Q<V@<R3
M9MX4@V-CY9E0)'FIZJ%<.1Z?0>+B<0%Z-N7*8K*S>%6HOE[J,R  U ZPZ/E
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M5^]V3X.TR:#XA3KV'J:M\<H.V-N-7*E[%&^Q5-VCN.Y1G##8-3V*.W6/XC6
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M1_ [QQ_O;!5TT2KHZ9U./NJD[W:V#4D*!S@;#E@T]4XO'_W@5+/3\39T^3G
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M_*X$2<Q\N)AH"@#=[X1& :-/GPVX-WX 6ED[/@5HKO$Q<+17GD7_!9'-5D:
M),H([#[UA3@8\@^;.4_DQ1+8B$H+B YT)Y"NQY44CJ:I-2;(C+E^")R7HRJ^
MR(KPUTX@%KI@I/*G!$#&,W@<:/U)^DABMT41%!.?2/)A1BO7 :"BD4J!<BY%
M3J*ZHT:>/#'+:.OR]\\,V<8<F/Q/P+,(A=%N>F1G@R9Y)4[[6WRN6Q9=+X(
M[F5716/8:EP..AW=[.7=QKOK4>W.AASZ4K?>AJVW^WK+S*?IH9 '&BS6B:0V
MU,EJ0U>I2]N9MW36<,^$D=Q-\D"X=WY^@\6FX5WP#7C;=RN,/F$4(,]QAF V
M&YT"CH-GVGG'YEOL&*..^0SDOV0$\G_]Q\!H]S]FW:!%E#VR7%2[PY=<LB#/
MG 01;LP<A+HJ2/)@X-K]W2("SNLA5T@A,3 X^P.HZ\]^, 8.GH#$C&7SJO?V
M7N6]8!"&SD\X/=Y<SH.;^;?FNV/2<@%4!+3=.,&&DHCM.<%:16((=J!7J$B
M$CX!O@PZ=XPOJ(9ONO!M-@I: M_HPQ1P:PIPXO<14\$V=P$6GN]Q$ZX(\BB]
MBS$[:WD4"C^XKCF8B;8SMUS@96.P3%8YI%!R<8,DS/J;P"Y9!.0T(=FV,2:
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M8Q,$Z"CPK3'\"  3 :8#$,?I>YA:L-CC8\ >"<T%YHNSXW)C!LA.7\RRMX&
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ME+2: =W5FC/EQ/X ^(6=$PA,&B/VL&8COD-5$#=E]LBJI\NN@3$8)Z"(.R;
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MHJV^W[3; T;<6(M&-K4U(_TK.7>K5B++FT#W1[J-W^I&7^XW.&._P3I-KJY
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MVV::$BSX7Y7*RM5.E6+$W^%+E'[_(4Y:S% ]U$ K$CMF,<RPLOYJ'T=C;WH
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MIRUJR%A/.T/(LB<(U8>I^0OKZFW3T'X3DBR,>UJ?CE8Q6'^R6.SM-0O2X4(
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M/=79@=YF0$R\U(4X(5(? "G*H#4 NPX0 )ZUAT,7J0A3%7!Y'Y, \8\!<'3
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MJBE"M@S0&6 I2)*HRN59W#0K>Y;8PBNP5U9@F[P"FU=@\PKL"A78:GD%MM;
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MK*BM_+/$1D4+%GXG1('G.@)>UL>3NGW6*&#MI:\_[<6 2^/@J@(NO086>W9
M,<KTVJ7'M@<_GT%-]IVK9(># 0$Q]K'Q\%COGDP!HFQ"5,O@4(8^]<"N(Y1
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M &8D,G,R)FB-A/ ,OP@IE0'-_8GN&#@MLUZ107F,TPP\>XI/!&%V=ZC!XZ9
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M\XJF"5S;WJO]%J%PR4L.$!O)IC2SC:!O#M0*_0HHU#[W_KA[Z@EW]S<+R-7
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M5[8>;F%3?^">'H;X)VN&7QVSL&S  ME>S-W;AFK6A.KW=@J3=D.TE#*#=%[
MK4;'+/X'LB5WZY0*V' !BEZYK[(GX.. RCDOB")1\$D^W*661;L $T&LY-9*
MWY#B?1#BWM%#@2'%-+4!<-FCX;?Y#4?SE)W$\3:*GVT8)<)IYDWUE&LU><J_
MPN7=4  !7QF\S7SBT0S;)*7H"X</B[[PV4(TEW(+%WBR;-G;Y%/SC+.T#49
MMC""7X%"&9+GJ6?'E'X<X)TA<\^Y:!:C($,S5T1-$!W@5*H .5&G.5))G\S]
M[,4&O1 ,7,]^C:; ]46@M#&+'3$9(@HIU/<$#+KBM8L>OL$&X/EK"C+/'N]Y
M4RNW("20>L: OX^Z"X#6]:E_-(OJ8[; U$$Y^B[+<1 I5T1;8.::%1>?A(MC
M3)%Q8\Q4B*8>];QFFLDL?P"O-"+>\"HDJ&G UBCG!N1X<0,O77*(]_N>;BIA
MN.09/3UA@/X4U$%RF1CENXRIA\8AZ%OHH\%/P/J8CSTPQAHQ;RYZ;)"!9\[H
MQ3?2W22X'(0T^@#F1\;)@1A1%Z'I(',F!<%$![@37 !$Z]!^"4(:PX$= SNG
M.2GPFC[]#-^!3\]T+YJ3 1P+;#$?B2$$<PC4LSX0%MX"NI:=MO#E5YJ6DAIU
M44Q)CAY;7#/MQ%_B!%?$4G6,:4PSL92"CXK01!0C6#8%(96D3,]D*BIN/!ZY
MH9,0/KX*4!<XK,@<+NX8SQT"BV@+_QJY'DFD?+:5D R9WZQD^WV 6P:[%,39
M#5!8#VF8 !$HO64[4TX=RN#H'T'NE0Q4,Z DUS"VT:H<HNLNW3+<7*9  \U,
MYU3M]+I)R29$1J7H(UT+*/HT_C2:#D;IBK@9C,TA>28QB3Y)'\+3@[KBL%@)
M;A-I3(@010>8Z@37%!3A!BN[&=S@G=0^HA2,'[!!EEB8AM>;^AM8] 26QRN'
MUR2H/;8=C"D/,&4J7=_UL8>%'\-6I_X$]?\!FZ7CV]1/0$L:-D4S%D),',ST
M["Z@!N4^_;=,M SADR#<A,,P4G^CBP%7#+P7W'!*\0BEQ*X9TI&=@.7HG73L
ML?W,<L+R#Z+:#"\%E<[V8I=]CR[I[#ETF3CPQ4<A*>V#KT'A3<X/&PG"Y#'V
MR=1/>%E,'TK?@T.&J(,#SPF?9Y6"Z(89N4/J^,E!;Q* H'O[F.1],5YGAW ?
M4<R.D1%0"O^/Z=&8)&#* %-\\=?]:81'1:Z'(@.PHRW<,K69$A'6N[/;R80]
MV'D>?=.?<!\#EW*?%Q>DH_T"6C;%AX0-IVP7G5>![Z?>(.1,&37,MGJ*<9*9
M'XUJ4$S"3=)80":^,OTH58LVE/XK9"["N!B%=S-C?BMH2@IFE.T/GDO5M7(K
MXR:!WS_RT+KS08NCQ(70^4&8-OM]!IF30B.V"P<E%;W^:YI?@;_"[FZ2P;)3
M>C%0OP_,[08W93L!0"&',\?49Z]A*V!SOU"%1< M,^$[M^],W#\,A\!C1(%Y
MZ 94RF9G<GUT0Q!G#J.I)C)/(J#%4H\/NK.G@[2H.IB)OR%QJ(MJ1(![CP8V
M%4U#-,^CA//B,Y_M/P 3A?_K.A2R\"NJFKT2SV,1P!>ZR!(WV.L(2/_M*GC%
M !;F%KF.2Q-QV@@0.Y'<2*5E[XE'J2(Q2]\M'M.?/?WCEYC^\ZO=1V1!<?!(
MPA?DV2*\<] 6WLU^$;UG"LJ/;X_"5W=(:$8U^U'ZYWNZ4V(#"X$S]J;/8 [B
M!9JB\ U8/OS+8FO\]]3#/V5I/N\"5!7BON#&A1OWQ?7R./F"\5TT!85W-W>?
MW\]E3N$:MR#W824FD'N !YD2-H<W?TLQ1F!IQ7!K:1QP#E1MX<&GF];3?)'\
M1D&8)X%AW!#Y1094Y-H8Y(T]%ONPGT/"_I5Z8',\.K,$Z"[2, DW;1=-VP2C
MJ2XV0^LY,&>Z=45'YYHZD:]NB@J/V<M8=36-<A/G*6"9F*B95W9W2FJKJZBB
M6E)PG1@&;I0</L-$(X^).50"E9_%UC)DSWCA30"*UQ+>F+C5<9-1PE=H(XD7
MXA.Z!Z PX'],!<P!/%$2DYN![YJ%M2SW\A<25EOXO\%SX @O[931(;L2!;!&
M;>^8:,W\%"NX >4=M*(CS8Z!3:!J/W9!L<8DD2SW]"6S0N8NAO)9$5,X*:]%
M%CQ#GGG\2-=%RH*5D]625.UADE&7["P35NA_F%*)07_/4DZ9PQH-V44I/20D
ML6\'011'%*=3GX0@=?*;H\$O@'7D/OM,ALTX*2:Z\&J25=4D\O)J$EX7TJ2]
M\KJ00]:%K C.R.7!&655<.9(] V HSX>QI QW8TF)V<,N%XFG?@8<][81-F:
MY]YR*?<>NA[3U&)W,DVJ)4%72$0-+)4IQ0O"*/!+CY=*R,5?8_TU<4I%%'L0
MW^.$]JM_6LZ@U5:\W%FPXO&=_TW""/[9+#O^FQV"-8@[KFK$YXX4H58Z;\0S
MEQ^J09. ^#9S<0E@&<[9=04#N$_2DH%IZA>FMD7 ;,(4RU;O\HL=83'.W&Z_
M$]^/WKP7VW=MIM[-;8UM[*\IQB:84R(A"3_S"@#ZN8.\6SIS]BWQ%_P9N-CZ
M!] 4/>7V+'4I"=5,1F\1>E,3!V#VIX"]#B;P)O0W@V4"1 F&=Z9VTA52-C">
M>"[-5* KHKTP!-WIBF;\W01@'V \F!8G/8>8V-!+5Q#G*H^96Q%8CXO$NC*>
MK\AF:HHY+_9U]I+L'=DKON!R%(R?:5YQW@3#* ZZUN,1+G7EV&]TSU?$S]E@
M6JO[_]E[]^>TE:Q1]%]1<6?.)+=D!H1X)5-4.7&RC[^3;>?&WOO4]]-7,FJ,
M=H3$Z&&'^>OO6JM;4@N)AT & 9JI[=B@1_?J]7[>P[Z)B6DJN2>60_S-)5_4
M<J6(C4E3A)I&0-KV]1Q4=87'U[3-*!_KURLP?Y-MM^G^92,O*MV*LLX3B^^4
MS+H;ERT9=6^]VK5K0U*)Y-U#6M[=1/*.9*9 CDX&.XH=:F*O\78!/HL#6'./
M40R%T?LB[&YKA?%Q$X_;PNNPZ1%J >RD4)SE*X$U.RU4_60LG&5D%1Z(YE$]
M:X^4GH;8!K!$7YG/#%O8VS->.4?L'P.,26C59A@33.=R1+YQTNXQ+2'CBP5Q
M H*6=#6*KYL)9O)\;8W0->:S SD] 6CF!1\:A<"YAR2B-\P71TU@><GI!VK#
MG(2'^!DS-W*L1QX6RG)?]>3STB,_8T44L (@Z1N&,)Z)G-M;QP\]DOW5TB@Y
M$TTTRBTV\.[SS>U[Q><)/%(IFK,48'B(5+8]=,BF B]3 (E";O^$<V3:I,_%
M&B$PL >P=V.EHB4R/^(@CV&OOKB-ZB6FC417^*LT2V#25/Q%"F1&NWP*R77,
M<QZXLS%/RP2\GX4.Z(F<WKEF"7^0GFD\\4J2"- B#9?D(3:8(9O1]RUT5:)P
MB4(RUZ1=P89%".MKB'&=Z__SE6),AKWPI<R#.%V09W/@Y]$"Q"IC"<*+W7DJ
M@K0JK*8WXPP;TQV'7$V6C]D$J,<9;SF%8K#H__,UG6!F^9'G0#QC[(H,20XF
M0@0G+[AT3BRDLQQ> )P#6A3Z!,8!(R/U-Y'G7RU^\E^&$V+^32(?DJ73L2\O
M/T\[B[<=$SY:?-LDK5"R%Q4=Y,5JTW@'CZ1<+I%'RVNHB*BB39#AT>Y%;Q:I
M/\GM@E/X!V,58@/J1JI+-AO;GBOYCKI,TD3K"!>//1L>K7DUQ2;-Y_("L^=/
ML+KR56ALCQZFY %P4.E!3*@69<:27E^1)A#+DY4;>O?U\?-[)7AU$?O]%108
MYZVG"9#W)7D0%W<C?K#R79ATD,8_8_SOT.)!)+P[XV_Q1;(%]\]$/5^XGQ2%
M(.9>B4MB$O8Y"RC( >@-21&HS]C/% N0:1)'"2!?H] BO,LQB.0HM\[@=?14
MIQ)0OF[:TW0,<JM X.W_5>#_)\4C&J-K&UT&S^EL/]#)D-&+3%PP^QCE"KK8
MGP>L1#E;<(;/HB1;!S"<K+KH,IZM'>56BVQ/$;P /8_G'X+.[" ^B:^35'Y0
M*E\8*()6H(AF0Z$3^J&0O%:<K!<A)'^;Z'*$81P>N, _?901O*,2)Q6D870A
M!%,OWGN4ACJ?&D+MC&0540U@+:6SQJ*34BB=9Q=1&OOOA[Z?B*@XLY9?1XT=
M7ICMSI-VC&AUBPQH6$HFN8NG1<L9B3+4127UF,C80AP2_2P0:$OF+:V8<JNM
M5$4FAW_RCJ>%L-O1KA;<34Y.$.5/3< \82B!=L^7@ZH0\V:^$-E1)YYLG03'
M%G(PDU$UIH ?@,(VDSQB%0-, -4(07@EB-1F2S(K4HG4!J;DP"*>L:=(ZL7I
MVZ/16B(7?9&^<FIXLU6ZC<?F8909CG E1_92M5^F$B&3":WR>!HW8QSYIG_X
M,1YR7@Q0G%IS NP_(XL$,[KYUQDE[!_)ZRB<:H<D2D@T1#7W48FP4"_I]M])
M)F$"(?_-,J44X736HT)ICZ)KE\_S2ZR) E2+V?#I5&)>QA$SAMR#F9%)Z\?U
MO2Z<(9=]7#R*%'K'>!81A3@;,WEEA 2J(C([N:.*X]74>,'JLB1Z::+NS$3C
M@*4#J*"*5S"WF=+1SC1M66LKU[&=A&7YXR!FT-^),%_(X>B3OQ'Q^R&T@N-J
ML/=1[A7W<;95H6M&:W\ESPV0IFA88RA 6+"?OT)210NF\^60&#>->"!_!J@Q
MGEIL(K)5$5[<816W]:BT/[V"'G3RAG-5'X0=94MZG-E%452%=%*JC,52UX78
MPC\VGH@(A& _^3&H0:#!6ZYW174R4I<J[H:'QT<V2CNR41Z $\ &D1;DP%,W
M"@,9',EB[#,4X(RD\5E.KBBKL^[69MUUZJR[.NNNSKHKD'57Q?0ZJMU6N=<F
M((\%'.MT%XGJ.CR5F@IB)0XL<N5$()Z'7R,9\5=H/G.I@05*? TBJHH-+*1H
M/W\@KZX91KJ%G RQY2I)20?3D_<>P?9"CDG]@WA%)U@@.,^$),P\TK'&I&.)
M HLX)EIU%>(6/5S*?1@(#[(P=FSE,T%?B5M>)TIF4O]Q5"5CG1YXYU)5;3K#
MXM:&I[@6>>(L?]5Y8?\<+Y#L=.GTMU(K.%=A["=9OT_4?@W].>,HHO#$IH8]
MD6M6>=H9F7MQ7RT_4F>R+1NE_!4M5?K"MV!-)DF6Z2,5R5^+4/WG)&\!5RC<
MFN6O$>X/7K&C=Y3DV!KPZK8DHM16\ZMJ15<@/J8DDTJ;]J**BFX>]"&E4\1$
M!&[D'W&J\I#NI"//=.)8.M<HGA( */VH+REE15KQ.[#?)CFY3Z\3;;K_ 8\?
MD#_0C?R">97/B=-L35^: @78.:772(>&9V%/DS"N=D^:()"#)/;O;.A<$/F*
M0HHU<.1)_/<BDK:@'@A^B$WGF2<5AJ-B(-CA5>1KBMMD<&_DA)'+4TBGJ'U;
MTMZ*@Z2I?%V&[U*;;>S4$#F)?,6..6[2=":G^0/U%8I8 ,$,Z1IA@'0<N\GB
M1XBUUS&% ZSY?@O/?AH'E@(.^%74OB3JH!.SJ:1?Q/:]>W(;&HC^%4])G_D,
M)Y##W\N]AJ*8%1^#U*7F5I3MC%[)YZ1G,44\P@BA4UL3'5LPGA$GM8A  =<!
MN:8N-X?9V;,I^;!I= 02>-3JD;1+[ ([P<$14J,.GMR\#&>J,<F .2F 3_EW
MH^ 1YOK ]71TU/0$A8S'.+A1RPQGQ,J( X%A[$0.=LGY&^\!7^EP*>1(D0.J
M%J2XB!.(=8M"%_[<=+L24G@L!)D(M\IWBW@EL3<\P= CQSWU<N%G]39N^YAC
MO:(4X+&(-4$%5>R'J"->,WR<A$CB>(PJG3$_PRB846ISP4%UFPOV2FHN2.%^
M<M^N';8#(,FK*NME&PS>N0[AB&O;HNL$\]A2!]5Y* ^3D^(SXV0U._8F[.7W
M)NQ1;\+\NWJM(C-]CM;_)5] %0?WB4E@V7# AHM)]J0\Y(]V"38+E@X@DT%^
M&RPD<%!K7+)VHNYC%G<?S42<S:(@ZE\N5N2(EB5QS@I>#BIAS @%MCH$^\2G
M@.L*+)': @MQBI,"/@\>@G.-0(%@H))C>#"SFVA6(BZ#35Q/V$PB<@[@ (77
M]<1LAVB^#(YAM'@?V;@37ZJ/\'+\-FKJZD\9.[$L\<;H0<HK4$5*178LI$B,
MYT5=2V<A3!ALE<B\L>7SAH=<6A(:7?$,?D06+\G<!2Z*#>-%.A9*\KA7/,_9
M\%$/M&FJ@R6:RT1)$.DE-)7;N!UP>FGDZ!++PL9TLCKX2@H5Y:>(J/XR<:Q>
M_#*BJ5**E=@YC@@R\*T<=>#P?[(@Z42=2WR\'4SDDJ#F?/@X@[3DJ-\DZ#2H
M3<YM>DZLT*'.D<AZT)8HC5ENH99Y'0(KK96HP@' @2%-.9+P7XQP A7/-0%'
MG].>$9J*&DC]! EQXIM):=F!WH%HPYGPA&#[6>YK%-,)#+ @86\F%U8QB+'Y
M9-0NFNJ9#:RW?&:Y\%-IT AY94##1ZUU+'5&5Z,,5&5F_9(X&R JI=(A]5.
MER< \=FQ^$:NEHL\#*&WI1PT(M^"MR;DH,UC.CO##1V]F#9!DZ:C@2EXMW1
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MP['^D_BN_7 VP\4OY1Q*WFJ:QV:A&_^8=2=\HAWE?*3Z1$V%LSI6V[@O/LK
M';NPI_]@_'@5PN</-:X" 1<\VV^N\WQ%_8TM!_UJO%O.\F#VZFUSHZD@%Y)1
M;\+;>'\T^4;!*=_*.\0"^AK_?(\L8%WDW9TYP!W\2%_/ "KI@&2*X998"\^]
M5#(NB48?F%D2E4&K4L.()"5#+M_ASZ4.C%'#I>5\%^%3C>8,B?URONG.D]"[
MZ_"4!(// $HMA(>,8YBDMX-OHRW%.\KGZ"#T>03-BGFZ>+^Z:F&KQ$#V<S5'
M*G"((A!QL3C-"H[H!312WO2)KHG:IJA4#>1YJ?<D3TA_%_5D69)%E)W$OUL&
M&(_ (3.!7W^1;4\7QFW$UP=).ZV,ZH;N<4*<SQ+"25KYIT5RR7>^2<+QI+7X
M=\I!VR*FJO5!YUP14R4,6'GHHG&NC&K\$]Y).K*6!3SCD&*PF&/O'H%6E M"
M+?%Q,PH->N#Y;BC-QTP*%U V V;)4Z-;896MS$Y+\AO108#]ZOE*11:]F!5+
M:P!)S.,5R=C.V TC'3/%>/GX8NH\. EMD2(D%@@[L#+(D>1NQG1%8/&77TE-
MHGR<#3>6WS^/7@T8&HZY0V"E^<<?FK'Y.VW9!KR]^RH;@:17?5I&MCMJJW@_
MX9"YCE;YU?5NQ1I_\/5\6MP[C*Z2+_KRPKP%.A?Y_7]03Q2, C]<_WBX=DQZ
MZ3W'FBR2.N$LSD005F9+PMA!8^0Z+&MF\E-(0Q2'%!P!8&LW#/ !F'T%],G
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MU9R?#!M[;;=S'76]<MO05IV6:P%4=0$DU9"N$T#]6@#5 J@60(<50%G:7">
M\@7.X(0$SB74 ?\-_I',OG9[9[NOI#Z ER!9NQ4V[;!<1]M;M*XI JE8/^%S
M%I!Y6SQ14EHK [LG;83U1>O@X=ZY>]6ANIKC5X#C;V=+]=N-4;>L[O(50+V:
MX=<,OUI&3U^K&(._A"ZVW)1)#!OMV &M2Q!SO>H:-GW,2>V4E9!Z F[!<Y9S
M%]+W0]]BD&&5#1L=2 ZX<*^LHJ0*4%W-\2O \?,,FPV=1F5)T"V[TVB5\/)
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M-DY1DOY''X?_$@DX8Y;S1GS"Z]0:3Q5#^1U)5OEL>+:K^-8LM/GRD=A#1(S
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MBDTN^&?&@IR PDSG3KH$]63O!]#:F)&]DF>>),Z#=C?'QYDAO2SSB-= ,7$
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M=S+6F=:>=-N]P43_GPZJC.*N:<QFYL8SNWH"!/EY94Q@DQ\,^]58^,@M9-8
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M%N<;..( ^49=K7PX7/KN@6F)QB/:1VAOS]'^O[!I2)4EJ.ATOML&D!47RW1
MQ8D+9SMH:J^;[9=\G!DB&XAKMYS<RY'GMNL\7X%=-ULAT>M&',>AV%LG,)QG
M"R[>00 .0''NJ[U!6?.$:P&X&9-N'9--+$ ?=F5;+YB]9(TQ*VDWBJIEX!M0
M5'1 W_!\$@+;5<WD37':[:SSO9*2\"R$UF^N:[Y:MEV+J=V)*H)A88P?M@#C
MM;ZJM;*!UTH*E@,I?R<HK;YEHUT7)J<*E58<5%!)GQ0GT79CU-75?FN?0=&U
M/-H:B^XV1&DO3$Z].5%)"17WDV_PW>/4<.#=WYF'\<GT<43)%G&*17%RPAY
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M$X.#^ELA70#4T*/''MJMQ@@ W1VT,LJ 8DV4,8AD X S9QX]V!D#T0 >(2L
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M@3ZX2DXAL1K)&8")*=R1GLH)']?Y*A:N!!Z<+1<4?*_Q]B*1RY !!*^,(>L
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M0ET+CN"NA<E&8^\CX[92"JJ*8E2HUX$?J3&E/O?'K7ZZ9EH')XY,3$>V-B\
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M'?).7]-JC9SWT,S1DT8 RB!A+AH.X.Z1IJ^4ALL!'MQ0#.C- 6-5'<"Z"[.
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MGTL)FQ\;)XR9M^\;6QHVV!<_3IE,P="C]E*>!X&@;)$O:2E_T2+?4,<%K&,
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M4]MFJ)7:? ^;*Q+8KA]$%+,/V7[X'C?NR?*G5J8O*^W,DKVU2-$/^!%[$7[
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M&BE$I,K3^]JHEDSB71-M%,&42BA)#$EPM%'R=7E[H1<HTOH:N0.[Z$FIWT+
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MU02#,4Y6ANBQ?T]]-D/AQ)F*7R=4OPZBB\&$54)+34HOK2F6EZYS18* 3<*
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M$$\=XOO32CDU1_3"UM20X+-=<7[VXIQ?H6_, 'O,/N]#_.8F=-XHWO6K;&]
MQA_;YF R\^2;PST,RYG"&:N',<$?^X6U@N<N9QXL/D,&$=Q3_$C\*'!77[";
M'/V)M7O@\8M+%->^<K E4F->1=B8C_I7%+9&:\!HN!.YR<"*XOIOL:$!Y/.H
MG%A=E<](E;<U8?#V+P?CJVZ24RH<\TQNT!C1&5S=HG^/$*^AP3X3U2L36R(U
M02[QM"LB+O8*; _>,.1KHRLB7L[O4?R"N-8,W@R5 09^&05L8QH$F7NF22YN
M"/M@XF!!P@,\\13A/J)><LV@T@79%NV+NZ'"Q;AE.R0;N1RKCDM2UMX$0Y?J
M@'M4:;$PYB0.I_"54HV5<"]ZXP &V9 Y3<'2C]]!F29V%^<X(C>)E_(JQB)2
M7<GO%AA-#57<^R$<\",WN7N.Q7\'7O)@QG!:$8&!9]Q\$<,:>&L)6V+^OXW<
MD"QK3.B[]6]H(.3K2'KU_#U9OC.[09,X(!W\2L(Y9S? ,X"KGV4V1&; .L.=
MH\19& GZ&G+?#(<!3,.;#93-&".?31DJ][&BL0G+1RSJ![R$JDLP/I,:!\GM
MM/B$I":=I!$20\\'Q3U+$H??A+?"7#]E/%,%]MT",#\=,ZX">XX7Z.<?_A]0
M2P,$%     @ ,XM-6A9_[F*0-0  NB4" !0   !D=F$M,C R-#$R,S%?8V%L
M+GAM;.5]5Y,;29+F^_X*7M_KQ71H,;:S:]5%<H9G5$:R=_:>8"$\2.R@@-H$
MBF)__7E L'01PA.5[.D'=A4(9GJ$?^$J7/SKOW\]FSSY#-U\/)O^Y1?Q)_[+
M$YCF61E//_[EE]\_/&?^EW__MW_YEW_]7XS]YV_O7CYY.LL79S!=/#GM("Z@
M//DR7GQZLO@$3_X^Z_XQ_AR?O)W$19UU9XS]V_*?G<[.OW7CCY\63R279O.U
MS=]V?]:..UZU8-JKP'0MEB5(FG&I@/M200GY?S[^N20)1MK*LA><Z>@X2RE+
M%A(78*4IP=7E0R?CZ3_^W/Y(<0Y/<'G3^?+7O_SR:;$X__.OOW[Y\N5/7U,W
M^=.L^_BKY%S]NOGV+^NO?[WU_2]J^6T10OAU^;??OSH?W_5%?*SX]3]?O7R?
M/\%99./I?!&GN;U@/O[S?/GARUF.B^6N_Y"N)_=^H_W&-E]C[2,F)%/B3U_G
MY9=_^Y<G3U;;T<TF\ [JD_;_W]^]N/;*$C^/%_%/>7;V:_OK7T_?O'[_YN6+
MIR<?GCU]_P'_?/7L]8?W;YZ_>'WZYM4S7,'RB8MOY_"77^;CL_,);#[[U$']
MRR\%F8N<UD*NR/C?/WC@KY=DYCC)%Y/EKKS$W]>/;52140Q?%S ML-J<S7LG
MLWSM2Y/&FEFW^9>3F&"R_'1T,6<?8SP?O3F'#NF<?GR!A^4,7L[F\U$!)5VN
MP(R5BFFI.(LA.U94E%Q8JV2NU[>JK6F.BUKRM,9Y6C)V_8Y?VR;^"I/%?//)
M<EN76_H &:O]W']E[^ S3"]@/M*\<,ZCQK.F)=/"2):4B*R6[%)-3D65B9>S
M>??U-5Q!Q4F7G\RZ AV*JE^>?($F5M92:T5([/(MN%P_,>MO_#J_.#M;/I.-
M%W"V^?>UFYW1<GHQ(]C?%?.0]$.Y>SJ;+^8GT_+LZSE,YTA%-<[7Y(&AK$7I
MRU' )HG2U^180RS>5SPKM%R^2<,VW):7W&8_%;L/VG RMK_M9G6\6"Z& T\Z
MJ<1,")9I0'7K4RJ,@TO2:BYT!&*&7[[]T'5<,N4Y<NYT-D5.72"SUER;3>?X
MC<E%LU[>SKHEAA:+;IPN%C%-X,/L]0P?,%T@(B9+%B^@@_EB9*H.R2M@.4?D
M24J2Q69J(#="CM:66C7QGO2SDB$)SCTQ=_, #8#E9,?P^EJ>CN=YM1PHEZMY
M#8LW]4/\.@*1-<H:0#$3*M-(%8LV!R:4M28'@**I)?,N].THM7\^J!&RAPQ
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M4%\#]1H=W7U'KS1 <+QP4W6SFD$R74 PGV)@%:V% -X%?C.9XP_:7N(Q4?9
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MFY(AQ:UZPLRMI/7#64*I95I/2W@*J_^_F&X,YK9*R0&,B@Y%74+)9]!HCMP
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M'[[,1E %V@H.F'!:XMX$M!O:G5H0&:*4*OE,/6YE+T*'9/,-!GC[,/$Q\88
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M#!OS!V1O@UC_SX=82F8?%:57+AJ\S9!+&ST2:[N7XL"\XZV%:0!MA9/"U4<
MY&Y70>%8+><'!+X]>7A4G+T:3V=M6O6FBF+UU;7[-9+!6>-P7Y1,*,2M+BRD
M*!@7,0A;90^-L@\F>JL .?\GA",=JX]SG7G%RKC>Z/>D&\]QZ]IF?X"S\UD7
MNV]/Q[@#':#E07-;>>C+22\C27>BK]*8*V2-O 1C0T;C#UH+19$T2\D;5I4I
M*86:M:*NCWN('JK\C.M/W?0O;\-\;_2^NM6!/ <998R6Y9KQ;*N6LZ6L9"'S
M!-X)&R)U-X"#B1[232,9VNY+\S@.:\DSAJZ3??_XN S@JG**\6!:#R8!+%4>
M66O!%DUQ)O260+0EB4.Z7CPRVFC81A+DOIO M9$R_;@<3[W&?8K&!U7\NDUN
MB(FA6V^9,,G)JD+D=IO0]O9O'-*M'SE">MS\GH7.96!]/G(6G6G.#8-D#--M
MIEL*,C.AC*W.YR)37T6A]Q(UI.NV(PN6?5G3,V)6=])6YL*%QT7F-O7% CH<
MQK2)ILXI5VL;:GH4K&R=4G"LV[(CHV1W=O2!CRL3@D915[ U9N9D:PL7G$!K
MJJ+R<+QD%X4&V2,TKE!"I$I73T1O',:?6_N[^4AJA0Z[T2PLXT':HIL?9>LV
MKY"#VK;TX=V4YZUW#-%\/X#/]RC*P[:V/R#C#YO/UA&6=S"'[O,RBWS=V6Z^
M;I%Y]7@;'8330K$@)(IIN>R(&!SCQ;:%18Y&7]_0WY/V(5KP!(![5!93&_7K
M:=773,JKM&7%JY0F,.4$'AZG*_.B!,937*;;&'>SG\EV<NG>-P[1J.]+2M%L
M>W\RZY(^7/9I[+IO==9]B5V9CX(1$46G9-6BTZ$S C=X5U@"[DHLUJ9$/=QF
M!_*&:.+W*7F(&-4CDI8FI50YUPJ(ZEI;)O2R*ZMPK&0=74+[-1K7.VB&:MSW
MBH^=M[\_*%SU06W0LO7X9J'JUOJ[E2]76= 'E586&6S2O0-BQ\C L9+3C@&+
M?5G1<SA@5' AB,S$C$._5G-A66PWY"$8-"NL@BB.<SE"#OXV7H5+4X2-BKG4
MQA\XY%Z$K)D1)49A51+D^41WT;&C.]COK3@!$'Z(]EWWOK]J[JM+3")['4M%
MIFD4RE44%L +IJ+.QBJE,U!W$-[^9G0P/ALU* YF17_ZL<%4)%&M+X))ZS/3
MFFN6?/(L<8/<!%Y\;Z"X7T201?-LR1:LJLRDT.XJG&;!HOMK/>?."*X-[UWK
MWQ'-&UA$;%<<_%#^[;[Y_8'\COQ@I51%\Y0SJR2*9M"6)2-]"S\[XVOR//;5
MH^_ Q&_Y"%JR)XP<R)<>\\!>SJ8?/T!W]A32XG*<P-5/]T_SVO[9AV=Q[;D.
MHB2MJ^\YF9;3>([$39;AIS=I,OZXRCQ$[3BY*./IQW5OG%=Q<=&M=*2KRO.
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M@N%?3=X-# 3D9=G0X!7,__MV;L->C ;X^9.%OXK WXS&O_IQZAEA7&"9$:&
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MG,Z^_9#?]'$)L>\'U\TF)Z_ZDS)7ZFH,[Z[[3FJC?2[WPG3 K53&X(E%@YQ
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M78N2A->#_F5_?N=G<? $BCYAV=1RI $/,\^)32$02]%%M I\[G8%>HL(SD9
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M ,'[)9PG&;??2N6/Q^UW$OTA8J\%V+)@I0.T0T7K;V ]F4#];BI\C!I[RO_
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M(W&60W%@&RD?TJ;C+(,6T1,1;9E0&33Q @S)UB8'PB65P[.QZ6KJH*MYMXT
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M[\O^%?Q@>A']&+[ Y=?1V(^_O[D:IO[P_&PRZ4^F!? "*_,QH6_.<.\IK6-
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MK<<?7L?[ZV-]W[6MA-E K[=G-,PN5;WJ3TKO>MQM;G:ND)B%**"8(T"D+7.
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ME-+;?M-A;J)YBJS86]L]Y+IL3\B9]V+\/ N3&1_0?I:0?&<(+!)9?8Q0$W3
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MXS[-TL..M!T@U\S:Z P$S2CX0T5;<.("LK,A6RD8_?-Q\V6/\J&3T647:_1
MDSK[[]W%^*\EP%5\8AFYPT9#%N0=*8X1@@\<Z$S61I!_)'CKDN6-0(Y_ ]/(
M4./66F[HB*Y K6:Y?D.<_3Y>-&]:W!T6ZW*)&K@2Y"#G3 YR93LIP 4M4BCK
MPS0/MOXV+$_![VBBYX:)KO?A6EWX=T#6DVNQ'=5I?(LVUNM B0-4W\.Y< _"
M%- E@0RTU[06C!3@;*SM004%6LS5(;&/G!0/.!#'YL0N&N^!"_,Y7W6XU^5D
M4M^7IE.<35>%BK4B47(ZN8RE*!YS[5D>%3@M-4]%Q>);/[W= ^?X_D(KJXW[
M47D/;L/GRSB=SU2:O?U96Y;3?[9PCZ7GV53W)2#!4E9#J"-49!4U&QYR:3V3
M<PN4I^ TM-!RPZ*&>V"MPMX.P'IR&;:".HW'T,1T#]/A +WW<$9L!V@\)X2,
MSD19XR:F"CC)(HA4!^.$R+5I[2X<F1 /> O'Y<,NZNZ?!ZO49(R&)1F U4XL
M"C'56_\$/)0L:T:A;W[EM!'(\?V#1H:ZW_Q[:+D'Q^#Z^)N[*[?S2P=,2%>X
MX& +(50N%*!3,8(CM\4D*[+D[1,U[P%TRE3>WQMWQSM4W_V28?%.]V[X-^9;
MG5I93")Z;6KZ.05+H3;U]++6BZ=2BA3&E/ZZ/6Y#]:1HT4+S/3^6)ER,'R%8
M%#[G(EU-6O041X.B>*:ZSH*(*[,GR0OVV/_S-I:GQ(,#M-Q+6O<*U\U9\=.!
MD3(8G@N82(C(':+ST"I)AYG,=?PF^M3:1]@"Y2G9?G\=-V[O<OMXHE\GL^%_
MUS#Y]:_;U8\#[Q*W*F=@$@EDT1R\D!9<CACHU$IY/:=I8TYOYR]\O.;N3Z^-
M^[-T!:D'.F!1V6N0061R6^B78$T"(9(NHB0M[4,-M'?ZPN=A_-WTVKBI2E>0
M9I"#3,8P\DM8[7I7A['/9[.7K(M!18<6Z]+&J?,7/@_C[Z;7QIU0[@%Y\V@:
M)&08/4',*.80&7AEZ@ '9:VT!#ZIPTQ_\^N>K.'WUFG#QB5W1;X;@:#,)F)F
MP )'4#Z2-YI($T&*:!@RK5SKP<+WP'F\=&BMZZU]1WJ:G;$H.YZ.RTW$G_\*
M/\(HWVJOTF:>QLY?UW3&QF'"-I^[L2'Y[9J,P:#EH10(C$)#58P$[VT$+$%&
M57@.L?5K7C=DQ\_4?OV+ NCQ=_P\(W/-1]TLWWGK.;NY$?GB_2_+$.IM&PA3
M VT1 X2" 5B=A*<PNLQ/G]V]KW3'GRG2C*^')X8?A1*/8H*),)@48[Y.D:Y!
M9::@TBH'OBBM'5<<1:?:E0,Y?CX33,Z+0KL,1]G%E$>?>M$!V\MPE)VMN-/X
MBSU,<&R:6,Z=3-("FV=4*TX8?1!@7*95(0K7V-\CXV,8CM(;.W;1?./6$(M]
M]$OX>[Z]8OXROIENCZNT.9.ER<$J<)8G4,X:<-Y:"HF]3%YJY[!++\-NWW9F
MC:)VLLZX5]7V\-:\UI/SJL=%D<69##S*#*H.CHP)$W!T'*6W3KC6WO=&($^
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M2XL!%#.ZEFDJ$(D%Y;SQMI]4U2.2XH'\\F-S8A>--\XSOWT!MSRZBA ZY$@
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M,8/"*E4>S1;T4BAZJAO_/FEW=_VYT^1!K<F\Z_NF)PLQERE0D)IDEHZ#X[9
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M%-5NP/]"ZF,9_RZ1S<F(?'LR/4[?+^^VOHQGM1QH-AF.IL,TKPP;>,>DS$4
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M17_<O.CO'D GN\0\#\[<J?MK9;L>_-PU3,M[@2Z@>AH>M1'0::8_-33<>A)
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MH-L!J)W*IK9> E-:D<P%*!;*?DP->$H9:!(2E8'(3+OTVSM)PNVP5I\OW_J
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MII>AB[LV'7X;CR[74;G-:#5<;2HS,#0M3%=6@'><0DJ1H%Q$A%0[J_Y1@<Z
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M85ENDC,3I=5( )=D!LZ%L]GJZ&+MY,ZSB97T8D.O6$D?5)H[S%V$^55C);V
M>M1SWD?+[<-DS+AET^:H= 3!>2@6/X<4F-(FZQ!][0OJ4X^5U$.\CW*/$BM1
M*E%C2VH-L;94)EJP+"304;L4.!ZR][M[/=]822\P>L=*^FARN%A)=B(8JQ1X
M1='?2UR"48*#MR)'12C/]_O1GVFL9!_P*^JV\F3*F_WKCS3].G/?OXV"&R_W
MKB31O<Y*EH6AP:*#!4.\A&R=%.CY4W\_^+G7:,J= IR[<5=/^Q6[^BV%6JWL
MKD@W_6Z?%JKBJ-J=@@P_J[824--66JZ]*^P4+F:I/,4-*LHR2RE1 =8;"M(;
M[KG11G>;279:T#\RL79(Y/LHMX$Y_V$Z^>=-^%X*IB0C$'1DI9\%!6L3 RT\
M-<IX&5+M'C-W'C_L5-)*@$SK:+.%2;>,X]ZT*0DB<VO1HC14HX&9M 0G8P0M
M&8\HCB*R]J7VSQ*<Z)7&(0'" U3<#/ ++25;-H]'CZ&4/ FDG<P:$M4DJI0<
MK9X[?*P[JT/TOQ7*7LIKL!G?Z?KS;O(JY]%XA ?1O(PE&,61FXW2' 6=AN5/
MT9W\]REJ[E_XUTO6ZX4.AE)G)% D+PHO<^G^:L%[Q027^&6H'8LY2.!G39CA
MH&K0OWN3'?UI[);=06]2I#^DQ472I0$H*<V))"W#\ASX%,LP12ED\"127;LY
MXF/R/&N65%/TSB;>#6^Y-_?S;GSGY*QWQ?WHQU>_W^Z^F"$OMWU47EG$G(<R
M%TC;@-8'&IPNB)2R(4Q5?]=.]7);"T%\F:1%A4FHBC+2P/J,9K?@L;2Z(=U"
M3[_0Y78?]M2XW.X#T:E<;J]:+-[>V#C<B4/Z_"VEQ;(1VV97>#N:%['*Z?SZ
M&K_Y/IV[\1^SZ=7W^<T@G?)W5JUH4[SM1+N,"\1DT'1$F]$'3=<]&JEG$"(S
MP5ME=?4F#<.L[#E%9'OQ<VLKSI/B28NBTSX"?W"7:1,3Z2!VHQO^/44^3B[
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M@O3TR_1X5_CUC\L?'C_W__RO_P]02P,$%     @ ,XM-6B&G\9GRR   ]<@
M !,   !D=F$M,C R-#$R,S%?9S$N9VEF1'=E5!3N$^Z22W=W-P@L7=+=2(?D
MTMT(N'1W+MVQA'2+="X(R)(B)0T* H* [OW][_UPY]N<.6>>F>>9=\Z\:AJJ
M$I)V[.CY* ^ _V<@   , $ ! #@ @ 3P @"\(  O&, +!?#" ;Q(@#$ 8 P"
M&(,!QE" ,1Q@C 1    ("  ! R!0  0.@" !,   !@+ P  8% "# V!(  (
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MPK-8#W*-!%)N0G^M;!KV7VMLJSUXKGONO3@HK-P9Q@/)C*<PTV387H./XWK
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MO\VXJI"1R^V*-WX%Y-"2FDR"(N:B('5LKV3Z:H=/),I%P.14%_48QB44( 1
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M-239%2KN\J6'+-&UIBYSUZ9X\Y"8U*P4"-:)RU.,SJF]>VEZ15X6\D[K?D
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M"I R"G4<I$,4&TU/XZ$&F=G'H(5=W(K=5*<-=)V*6Z(+-6*T0DOG3*RZPMX
M)6],+%PB'KS8ZY&Q42 VL; V5B7S1#01J8F^F<%^3 KE>]OP:U;\$J?GJBM>
M\^QOZCGS=XB8'KWRV0(AYY5FUUN.Q1*IX%^79[><2Q6*_MDBU/SX!.E ?#F
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MD5L6\<V71U4WNJR2/-W<+(_7$W8_%RA__WG24O]2\_[WWY,[S(0&=+X*6>S
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MJ;BU3BO,'-&ST\Y^\SL6_:SGDY( ZV9J@6]BN*^WT]"YPMKOKV<]QVJL),?
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MPOI'Y#JPF<-^XNQ55=3R+0*QKGV\?2])TK&CZ8&3SD1^0KM&BYO_/7$#/RL
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M'MV9'CTRD"UG3K?!'%>RPS$QHY_9)'X^]F7F=4=#E,)OO.%17W#'KAIQ@C=
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M(BF[WLA=C7"[,&G6N8Q3<.$/$LDDLE#;EG>N3N%)1,$-;_<IV146$G&-@JK
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M!N@R7Y;9<I-(&+C(I9$/P %FTH!G\E7GP$0[RS+@4(0_D\0DBWOT0H#@F,.
MF]M+I#2;P8P=X)3XK0X];(=EC.XS[L.60GRKO0-URZ-94"5VHS9GN =I-MZ$
M0F^(=K5!;$LGENJ&-11<_TZ(B#(Y3RD-/_)W==F2.D<'=YXLE:NM'"#ED:G-
MCUQ!C=A0M$:,@><'ZX*9F)F"N%XV.;$"MTH%0&YLFY*UT0]7'W1R_=W4L:I(
M'V)V;XH>1?K=>L4?FF*'+2/JF#0K&DF9IFSC6:#;3AH'/]#$*40KLFTJ!S,
M]"* 6:2Q9LYM=H?.;;RMHP\]87F-',^I6.>9@TR\W5#:28HF;@NVR\G5[C<?
M::*M\P-/+4AU9+OB_#P,A]!FD#,6C^8"U2O%WIQFK(W>N%?2V"<W;DB$YSZO
M3*)RTHNLTN."9OU<;ELGO"4Z]?T#X'U64UMW(TAP#DF#,*5YDBW+.KBWB0W\
M%/\8-':E/H=9=KWN5Y5 S-#/!\#Q0;--YNR)./M#V?\-UWG\FT@B]#?  <YJ
M<8"#D ^).&KY9B-9[^4$AK>3$C:C4S2Q6HFGK\R!1UIY\/(Q^+5W2P$<;]$S
M&N=IG@<Q8 %O SAU[K5[=H=JL_9P0 !O6E5ZQA$*3<=?O4,14P- :W);/)1G
MR!4-TW0P@.4[%_(0BJ<RY&1-#V$4%Z0K!V9UKG$P-Q-PKX4D$?$S=;,6E8<<
M0@(-W():4%4S/J%AJ799%P($("> ?1%S2T-H_4<1$(A;@J4E7O51$ 12\55W
M6V%P![=GDT<R9YA6]6=&1H-ENG,30_$;=P$<:: ,Y"/_A'>"?P[1-=)R+EM1
M;VW4<$T8%C]XAPZ801A5&A[5>*PDB%ZF?H98'(?7$DWG8('H(C0W'B1HAMEA
M5&HP&5=1,ZV"(;=5 =!F>O$&"N\S)G$1)7;W6/R7&U.3)073&5)W%A8V+7-1
M&M34>O'47THF$9'5=X^3>F'";BG2>L[Q%JX$%G6%@>4S;SAF/,>X2]*Q%?L6
M=B_D*,ZU?WE$A;039P4&B8;B539R$17"$^T!3RL4A7@3=S6A<ZZ39 ,!&A9C
M3IY6( EQ%S\ (2$RCIP!15@VC1?C$[#C$'+TC]G1%W?Q+^'D?#&X<[]Q<7F#
M':&0400!;DO#BJD%2)"8*!\R_VQ/DA V1HTLAE-K4HLDE'B[)QBOPHA+%C<5
M$!=%=SHSH86'8G6_YG,;Y5'=*!*QIR4U(CL!9"2=9U5056(\Y'9V@CI/96;Y
M^#WLE)#-8A,FEQ"@:!N_\09?AX:6IWSJ@7_]HC4,9V8*&!9?IAV2.)4J85"E
MXI3%0C:@UHHB&8C%MI;06!8U$5MPTTRB1X6@!B^_T8XS(V;1@%TC@3Z> P2W
MQ7*#24>)XHE9PY/&<G=Q>4T[,Q 9B5L'%S(SXD!6MWE.\B68N6[((X'!UVS-
M(V_+@CJ(M65I1RR%]1:N@2$-R!EJ,1-MH6GXV#E3]46+L6HF@7PBHXU75&)>
MB&8=A_]3-W09CWB7_\::>\(T9G43BYE$75>"?Z&6-)5?B3(A;.*&I,DIDU-F
MXTF%GM65S\E ZG9[#5>%C0@2MJF>?T$<$A*/.L)_.).?Y2(1]S4TV5D<2=&4
MJ*$8^S@1OC<<D,@27!)>%M*%((6)/ <F=H%SZ7%L#8:95?@YWY@@J0,'3B%F
MA6@=0@,*;1,P\ >#BW@9_!%>VS0D0HD3)#DORJEQ%0- X$54[$(55X@D];4Z
MP/FA\WD<(D(<TR0L%+&8X.4S,N:8AZ(V(J()17!(YX([/>F0$1A$PE(7CK,2
M2SF?&%41?DAW3/B0XY)^0DHBC-9N1TESN%6#UT$<)\@>C[3_?4$Z;:JIFO'6
M/(G"1(D!/C\*CCT#E(8C(JI)1IX8FN]BDH%G%THV26OQ<E\9#9ZH1(&2)!]!
M'A[6F3255W]XF0%'0;H7HPF$C5.W# 9X6!'D;@'S(7J!IC05#6V2/'CQ!KY2
M-WE:975#,HNB:0(YF?>F; >8=&@Q2*\Z$X<TICY':Q,#32)JK ^2@O/R06 X
MH<Z9'L1A6>&G+L\J$VIP2+4B(( )-D9I&YMY'<MP&2PX-J@6K)"", U1H2*7
M-P,*3B$9H3TZ'PF1%U,&IS(1<P(AB M(HV%2-8K1D8="%9;16EC7?SE1%_+)
MK:1V:?M0(XSR ^%5J_7GK+:()Y%JHUW;L5^NJ:HGA" XX*I-.H#>=)$PE"-Z
M9&\]@541>Q1JB5&+.K+B\4RGB!UYZA0622$B ;$O49\..",GE6\WY(*B 8N(
M\1"? 7?)5U-4$JXER:9AA"Y$L68Q<9-#LJ>!D4@\\6!D*A<(8CL?8BAM$6S&
M,US+J81K0E[$B17OVGQ,R(@/(%(,)+,?^Y_YAR5D,6U49C>X*C)"V(G[LZ@J
M!W%19*W_ZDD<F.%_@?.4J%*EYY&WQC&ITJJ?56MF4#AEPS@DDY5^*$M2(V03
M!W,A\%.U-TLJX*4,6YN7?7$'[G4AD8NYRCHK?0)+_CAC,G&TKLAY8,2'*A:D
MLO2B\;BFZ11#=HL2(S,A$:BZ;\,F% &QE?NZ>HM1=-)"&[N[*LF!TTJ[JV*N
MHHMNFO)_JVJ[5MAUU,MF_6@T3+8^WTNP/12GG&D=R_!C$"*)VLMW)*02^H)$
M#!NP2?(ARE)MWK(9[F>W-PI1&..[6.80B[M;WP1N*$&U5TJ7,BD4CH0##8(<
MQ<0E.':I2RNN"#0WYG8HVCBC"NN[',=SLPK!ZLM FB!YQMJ/_R?H-8OX@LD:
M*5E+D33,6SHWM1((E8JZ8:I1%.*KH$RQ7[-&IKCG<$5Y%4"))X2*ILJU#X$1
M+/]WO%\X1%&GD \22E-"1:#CD"(L)1GA/IN)Q#/S+.3$L,AI38_E,VOANNA5
M1_4X>);(2^9";#JK)0F+C M,A<,G8M,+PS-+-&HYM!YI.MV3:C:+CT%15Y6+
M45EQ19QWB:0Y&Y;(:GIWR'YA$P!&7Y.#H@PG$CC@Q]WTR25R,"\E3O;TFW_Y
MQ%<[*5),GT2BBDH(EV<FQ!>\$.#EJNRB#VJ!76(159:9(;@A$HDTBW>BFY^8
M7;R\;L&EPSWC \R;4>#A7U;*GS)G3O_":0>K;%>8HK]J55T69Q,($GPW!E<X
M?'5 89"84<="JAQ:[)>QV;+%LHK2N\9[1ZRDY:^@5YF:L\TL>TJ4TA*J6<X3
M>3?;R= .:!8AFYC@<XSK(X>Z6[W0F3H9N<XBG+:PI<SZ**A.(;AWXD[&Y\XN
M*1ET2RP.T#SL1R+XIQ6B_*L[R%P6\3,+O27?Q"^KF*5<ME%]V49*Z:7BK)TZ
M#6:Q:FCW^+PB!F%&\8S<JK*^^KQOPA\J]L(P7**P^;M-7,I.:\78P1)Y&M5K
M^:8DXU6;UGR1J[3FNHD)VA*OUCNEF;1;C&:F5!?]S,9V88^>:IHP*3AK!!RI
M7#Y3Z-<5S)__S$$UES'/%6E/83NM[@%!ER&.,*PKU1$5@K4]>HNW)&4Z^X M
MT9&B"PQ3D6$V(Z77)(6L*?R:0+US7%1BALRMDOA-(-A@U.R["-ALT\;9 <JQ
M?L$LLY34BO8@11"WC@JL+\G.IE&JOVU=FQT;:CW:2]O$LF$AIZV&.)F5!CW*
MX#-L#]',A&T<N)B8EUG&"@/ #H$#RH#42]&4\-O:@P$[LJV^0ILWP6V(B^QO
M0J.F2 B1B_B0+:@0%$6]-8L0#5E6*RP>K*.OGFS4+E$=I]IS%CSA/<IRQL8K
M?M'>PLP4:F O,Z3;KZ$B;MT7N'G?H.D5$[Y& 3YZ0A3%Q MV9>% _\?Q(P_$
M6G8-H4XIF*73PR4$)2UKEA1(9V=5TGK6WX%&3NZ[.L 1S@\^SI'JT%]\-QO+
M+8=7M#S-@HR:PQ'AQ7F+1CSAR[U<NRV%C'^4VN-H%DGA7EX-WX,XP^DI,PX]
M9%*7%'6.-T*S";"F$777DW_-?/3];Q+%0;J-V/F9+6?ST$-B2%##1ZP=P$"!
M1#VC30T=T]#<L(YU<F;3V-<!R._EDWQN0V)%V4[NI&^7:,\8#49#RC,$B'_]
M&6BA55&>WW+GEO AY,I(T!IQID:-ORKQ?)LL>,$.V"CA*POJ@&>NG3">T7B;
MUN@"YBH,K(AK&A,1S)D2RB-)X82,(G\X<,_'I<KF0XG#\JE^N=;TH3_5ONR6
MFYOK7*,5?MY40N)WXBXJ3<3).*Z1U6:DCFX;3FJ&N2>U0BV?.NQ,/1?U^($F
M++,%2-5L&E:%X6" _LF6U=KD45;O;/%7P<$)B=_*CK?965[#9.</0G**4=[
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M2ZJ!=WWFM9M=[>R>ZD;(_Q<",;MH,'UFD>]YO7( \S1B;W&@AZSG,$P8%#F
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M2) :H>,X!.GY\@W;;4DPYB@KJ5CO<)P=LW"RZB4:IJMI(G".;15YU$-UHTF
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M-T:P)98*+)(76E68WI(N:[JCP9+\X'Z NTUH>,>R9UT-"**\3(^$]H.V+L_
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MX IP'RC2QW07-2'@-,"R)"ARL!0G>J=7>JMWL-IO;2,%5']&@U!%.D5P.2R
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M*KBBJ(=,Q#:"[40PYZWB$ LZNU9 [3M?QJ.)79HY0>NKM0Q,-XP87XNPI._
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M,PU[>C61?9+1%" @5!#XX(&R:/L2*ES(L*'#APFC1<M1X8$%" \J0K!@L>/
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MV[%XDFVP296H=#$^^N*'U*&Z&4</X$ BH+Q1)!]'\BV[W*D7\HBCM],]1V:
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MB=5G$45*0Z*%OH=4>H)9K%8IAU=[<;AN/L-9,($2\TA31F%0G:@^<I,2/^"
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M*PGO[&RC30]#3K"_:"*TU1'3V&V?92S=!Q0U,L8M#:C_B7LCC32 J-O;N]\
M(@TCU"A"#6]_ %P-O/LV8F_$%>?;;\4+'QP.P@-/_'#'+?];;[PAA\/NS?56
M PX0-=$$E&5"8;+FXL#-R;QQ<X8=]BHW>6/$44L[6K7XK'M*HDYOPRV'-S1A
M&D!*<4Z,4!&) @(T+Q=D2"N-'NV3^*9CSY!8->R&0_ TWA"\\>X[[YO\--0
M'^WS T>;</ 'A[SPP]6H_+&Z7\0^_]49BR:434#LW/8JUS[)H:UP?A.<X<#W
MAO[H;R=NB@:&RM*8_CT&-UT1F.^LQ1H(M00^&<D8>/H$!V4DRB91&QOL4,@_
MIY''2E?R5WLT,QJBE>@CS7% __7ZPCK6):<Q/1L1?E;C'M]MI2+1:TM"8)(#
M3330-QPZ#H<$<QN?-80YS'+4@7"S,)OT\"\82I38&--%,H[1C,42XZ^>ICHV
M%D<?46O2I/:Q0@?642>OXTECEG&'NUV&.6:K4X+<0IL]L6I$.-#4;O#7M,5
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M(L5)IJ%6B Q>IXHP39L<53%O56M5H^39T)86LC2U92]Y!8K_TH$(%.(1SR9
M@3K'#C.R,0)M&2FXC%,L QI5,B%125G513$RK0NUHZ3V 1S3-A0YPNPLE(PE
M7 >.R[J2S6B53@>*3=A!$][UKNAB&@K4F36IPV63:-,[+.8RE'_ +2GI8NI:
M3_(&N,5Y:VZ'1=J*]K)73*-E1HN[5LD:M76A;&>5@L+:F (X.-1M;H31"$D)
M=Y2_-7WPQRZL(:E6V,,?!G&(/PSA-8I8PE&=*7*/==0-\]7$+X9QC&4\8QK7
MV,8WQG&.=;QC'O?8QS\&<I"%/&0B%]G(1T9RDI6\9"8WV<E/AG*4I3QE*E?9
MRE?&<I:UO&4N=]G+7P9SF,4\9C*7!]G,9Q9R0   .U!+ P04    "  SBTU:
MJ4.+/'&   "6H0  $P   &1V82TR,#(T,3(S,5]G,BYJ<&?LO =44^_:)QI
M.H)T:4:ITD2DJ2!!D29J0)30HR!=B I"T) H2!<0$!#X2Q0$5$J0+F!"1T1%
M1%HH(4%%!"01#%O39GMF[KWGSCEK??-],]^:>V>=S7K"SLK>[_L\[]-^O^P7
M>%.\!<B.$_9.]A ^?C[(>? 'POL.D3QZ$>4?" F$@ <?;P9B"^'G^W/\>>7_
M<VP3^/,JN&V;P#8A02&AOXFPJ @HPD)"(N(BHF)_#O!,0EQ,XL^;/X/\UUOY
M!04$!,6$A83%_MT'KPLB+<+GMXTFP*<.X9?F$Y#FX_5!H*".@G]3CP_RWPX^
M?H%M@D+"H!KBX 7-.T#U!01 I05!C<%/X\'/(=ND!67V&!\5DG6](*Q^1>[
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MYAW2H-0;-JLL7?^W"_<\["AL86;DE[61/&YZ+Y$'&2LM0K;( W@>1&@>-\1
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M69$)81BMZ2]LU^_'\[/#@P.O,(:LU6JVO++PN$L;TPX*=[2SQG7Z(C^<_'!
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MAI#D!KO>(IG-0'S$8H!. 7$'OM^]^IE)A.&M,.1;G1"=I*^BRWXD9"Z^>7T
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M)U.C*;=V:7XTN% X\!Q(%S5[H/SA9WZ$F?B<JL/]AW<[@\-\G Z+REGI:@=
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M1]P_75.V>@=\T)ICUZ'88=X@48C]!T5#?6*3(+K88,A47C<XM0V+;MB&C;8
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M9 ;(*DG:O4E9=+-5F36*-'=:3^O]!>U@N2(]@F:Z<T]&JAJ\S[A  @,[<M3
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MC1R9]PJ$] KO&Q!L8C"9ESP$I.-%MGXG='GO,YPQ[,2NFV!NT@#,N\5"U+5
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MVQ<"H4(P?HVHAMRG:].119!Q)0:KI'EWEJB\4J[M_?(O!/0^'_X+\0%!M]
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MQV_4A5( 2O?<@.&0*H+6_@?"X\7-< PZE,PU]@OQP=P!Q]?$>^ $#$7Y*U
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MNMZ'@'JM?4LQN1!FJ3OX^)>?_6)/%U+-? FIN>B<[Q55YIQ]WL"AW1<W*D,
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MAGZN%3D*[RBE]1)&]]=%97TO4)2BUOJBO^9KDMPT'BQT*,@>@?X4%M>S*IM
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M-EDM'V@DK@>(I$W;;HYUWJ]@ZAI1Q8DTLT0-Y1IKR2E_?)$4\SY5+95\,>[
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MS9P;YKCJZ^/7\36H.:6 D!66"[V?W[&6P4RN4%J'3EB]TAPUZAPMJZP$>Y!
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M?-Z3^QOM+,RG[FW%&+GIRP6Q0QWUKU.AN'_4&>^:R D;P>5-?R-R5=B<-=4
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M5ULTY=E+7=Y$;:'5R2XVTXGN:]<&;-O<^N;?]O/I?*7/M0F1D\'HIV(,<-'
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M>V;T;^SV_VFCQG?&*8@3&M&9:I^V9S$Q'VU+,2I#Z7N#>M'/W[,-4;SU'>X
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MI+/BY1P.6;NXEDJ8*EI/M,/\04-F==&,,[>W'(L51/]K=VXZR.PMEVBP8AJ
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M>+/67',^SURS'"XS$<9'1KL"8L4XA'^U-[X<^E-'U'__'PQ,4BY"P^?8QLD
MI]@I$0/L=C3&V)NS><\_9FD?]J/4CC'1(EI$HC2FV8IZ@G1M 3TINP@)]/A5
M:(D-#D'Q12F-5=#,:5\_Q<W1!)UNO-TVIVZ&OL.3 =0P5@^;QM,Q='5=ZC$9
MH'_'1]13,4;S=5T:NWG^8>QLT7']L9SQIGY>??JIA;K-(Y4AYMD,='XZ+<X
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MTSAZ9"MA.'_;(TQ/U0>\38%#:Q!,%SZ;/Q\5-6UG5%DQF1#HMC,!7K<1EGB
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MT!6'/>:$CK@Z#+BFN/:#9^><<1C)\>9HMBXFWJ)@2&H-'&R&[Q:))D!Q[JU
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MFC&\>5BK\.MDY);Z(-+K7Y=8;@(2P=G&G8&'^<W: ^(SVS@K8)J;YUV%IW8
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M[V)=FWUC(XB6^2H9]C*TM8ZYX<L)P:IZ/74\YW($4HDX0OZ?,LZ(G>WRV'=
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MUKE'<P%*$$2T(*Z4,VTF'Z]%N%@U>^^(,<[-AI$!+Z2OQ+Y8;8S&@IN (63
M%1,![$"@E!+?HAS;$^-.?&R'/BVR/S_Q_898:&LI?&R^$K4MR#5V>@6[E7YM
M^(9!^'Z#O%.RPR_5T6'/3@_+_3P9,/8Q,AK)_ED<+D+43Y5_3->SV760,OX3
MMG<KAL3^%IJU;_@Z@UL-YOGGHU MXE<Z:3>'-GENUYJQG>B,3RY8;<59!N#%
M''^1 >>)# 0$=K['E98@KO)S-?I-9*3"Q:'72BL=>*)FT51$/K_LC<,SF/'Q
M3_X2?3=J<DS# ST]O]10FD^5[OQ"ZLH$J59V[?1(^E 4IO)U@Q5T!F@"D[T[
MANQ/>UASO3S/JQ;GKVHS]M*#YVQXK7+_4+O1%;%]CJW)94SR+M/?6JYD]BE"
M\6B"+X@/1HGCKE5O/-2./;$8CWJ/#>P'[#Q2,^39-@&7T+<!"8\;*=9EAK57
MH?;Z,HDRF/ZV5I7.+^%Q\!S'N95PH7!,'*O&#(N-Y7OEC8NH4+1U6A#6#I^.
M.VS93-HKV'VF\D)PQF2*<4@E]K!P^8U0XV"?3R+:/3SX<?S@J?U.]DDW8Z@A
MZ@CY^HQBK7_ZSRYMJ9O_C!5RV T',C0*J6.S6U@E8.#Z6K3.G<8L3Y:*F7@%
M0%WV;"FSPH<@3L96*K.0YE^G8$2SZ %Z\C?>%7BU@*@I&Z9HES$CN%KB^OVK
MMJ.C1?!V__FH0="8G0+<['-^\=H@V'%WL@@<-<=V;S7\\BO"@&94/7W@E>5;
MUZ)K>+&3\FKRS9B ]M &,J#Y#MH^6AV?3*!? M)XKVI4;!NTZO"DN(M.2"@=
MO,/=B1V8_;SUYM&[,RJ@]^E3 N[:.\<'5;O<PQ/',('<;F1UX<SOV,ELS&TP
MYRGS^M1P;?2+>1+MT[#+SC6JURR;CLQ8W*+>UKF\_MY@U'@9)\"&P#X&3K6V
M@[@:*AH:L:R%;%-.8WR%M_%.YH7?]-LN>*?U!I>J(;S=NL?]L0-X?"7A,\Y1
M&5O P\X!2LXU4P2ZU-;_%A3JL6)GR -D?>(CK6Y:[##=R;KE%JWI-\UC#N/"
MR,N)>[GWHET'6!Q3L]MUZ;P=VUC':X4""J?D,QJJ>+RF99V9^G,3C;R#F(TG
MEE^_/I_1.$_*!\G^0E @%I#'S(AS*E!OJ-%;*5$%BV%)@6?^=?D^I=T8*B'W
M!M!S=FU^IA S#@1+(Q?!=2DYT'4?S&)ZJ;S20/93ME-ET9<E^S1JQQRA=.7S
MN52:U"M0P@U0*$:<&V:(LPOP^)Q^@\#MR=RSY*CD,MO8)26:&/@P2G:GZ%.&
ME:,UU0O-B8LX=RW&;-,I64_^H69#@^SNQ (_:B)C]N):L,=\R+W.J-L'G.;:
M[<?1K<^@ZM= +FGGN#II*7_,J7\T?C4OO!%2CEC(F6>O( -"P9<5Y1>W*9\F
M:R&8S,Q4?01K:&\G#?*Y1LG./7GVM'\N,_"5!H@?AUE Q" 64L!<MQ6]%GQV
M/!&AS[[U,=N^:.>0\)(.GJ3D+(F/]YJNOIQ/LT<&3+7B/R"F(1WP<T/UHHL-
M#SHV)K^55I6D*BL,N+D)/'>Z")[0&Y9>GM?FAJ%2U]9UB4P#^&O8@2W20@-G
M9^T7<\<EUJIL]=>N F;JWUNE+*.NWOPUX:08FO"#\^E[^&A>K7_4/?/@PL3:
MK:JJ<,MH?Y;[ /B#PJ=__U;^+Y1+T 0@]FEL!$=H)R)V[@J!8M$Q5N**A/>.
M-%^*]8E3[GLSN@S:U_UN9("2F><SDB#A !>D3;B"#6T'*8Q65E1&V@X+4%6F
MK,H96U*/+EM#G2=17;L3D.:IV)AZG24R(&KNIEW]6(7?Y%+@DC4_+%XVQ5UB
MV>-V,X7%QSA'U"7E\4)VC\U?EL]0)=]7_5T7=2\;>XNTWK,(RFI?7I]R+G]3
M?'UY6Q7P;\T(XAV-(D3VF3\8QNV)_E8HSHBX&?!71_+.I$EDB7X:B \8K;=:
MLB$H8 ^6ZVIJDK=2"Y*$)'1ORIWP%<L9<AVA#[MX14+PB"D,/B1R 1'05_GY
M#DATC&%Q.$YMMRR'W2_D1V=/7#FPONW5?:=7B&)4DPRV,W2@+99!=8T0:A[K
M_S:EIYXU-N0W'2+&X+==0IDKOU_$WEU#08OLT5PP#M1S>NG7DX@L>E?I7_4#
M&J3D,U8]J[! 'VSR_:;_4I\F\X9L3_=W^:NJZ7&YBNE%/HI4AOAN89369[G!
MP'<L\7)K^H8"*Z(M$<*%EUO^7JROD0V'3R4#6-$+7SE<0P]"3<K]+SVW_\H?
M$J-@Z5D>$^I1= 84[&)&#U5A(@LZ]U_.8_6V?3WE&2I&P%%O O^6M94<,S[9
MO#6E4%SKWN7QZ"0O0ACUY-\RTD26SX[G;WS&>"./=^8#+*1UW<B5N>OVZ[D"
MH\W7&/AYF18).@N=25[ Q,U8=&H_%DADIAD;>'+:1OBZ&#E ^Q);';.T.D9]
MMV.BW_HM&>#'WFE9O[]4?V25TY&9+>3HN7[X.9+6Z(F!-J+^Y$+$?2]A_BQ1
M7VKV_P8Z]%\5BI0E?Q,I^BL;4]^0&UN%-VJ<+F/#C,F 6T="IY>ROBN"J'!)
M&8C1F9=ZIK$%;B[@8RG(S_ERU3T',H#BE+?G^E3AU[D'(!0M+\D8<L9!FA7W
M6ZVP5-F35=NU#;TG-4?%)9U(8FAL2WUW.EZ,MM1U7^'K=P[7.O6_S7JS^Y?6
MQOS=>'D+@MX*=.X,6$5YAVH'3Z@7:+X9\CO"+^T'#>@T^>*)H"U4"-B>RO4"
M? Y*=^"M(HY/<^B *(H/2$Z#Z$LI.M$-/MZ[7O'9#OQHVOQ/"M_]!U29(3FO
M_M<:4T@DS)^45R^(Y0&6S+J.P;3Y7$+5*YY?4SZ?W[L6-K) %QRC3*.FT9VE
MH1>K.!N7):>5N1)1I^1E-';;@UL&HS>R*[I_0NLAH>/IR1LC-^)E*P3P=\20
M >'0RJ0J')-%4#/PW+[IMM>S1L0M)66G5$UHU.K<.8F[(_4! (HCM]\7B-*D
M5/@]1+.*M)_N5<+W=2(#MDWC1F6JMXFE];+MV.4@A>=Q:_+3/9;H0+0>P@XQ
M"5U<VVI=G-]"G[>/O-*;7_G;I+ZMZO S_:Y@$X87%L%"_>3+:J,I2^KC[!IM
MU?G<G2=-'<@&)9.CKBQ$\VTRP($^K);K$B8V(BG)R$OO6_RZUU3[3J: >L@D
MG_->I C525$K/R\.F@DL)0.VNA:ADU:+GY'!BO+ *9=YII>I;27!2+WJG=V8
M"(D'-S0,#P0_GK#>=&SYD"7T9D!/H))&:P\</5\!;1F87.KZAAN(+/#H^5F7
M.61II;1?<XWS^:-&>J DH'Y/%0XC&O]I70>[3\CR=_O3&QU$73V<V*B7O\&Z
MM$>X*4=WW:R=7FZE-VA]4DTBH?3^E-8621$WWJ9[&2:.)4ZM1=8K9Q/<-2-#
MZD9<6)F%SF^;=ZY:!05?$^*B(5#B \[>W>[MKA6!>4B0_VKFC7H65_^QXK,6
M:TB?\:<+$3R"']>^6 +UQK-@*/HM-(X68U&OJ(-+ZS@./MA/$749![^L,917
MH*RT>D<9R$(I)L>.0IP1#D0+D'8;[^WWL*HL)80']UNP]7A5K<>*]/[^/LNN
MY6O?@PID;?WA2:Q$I:56>MPA\F $"Z2##\S)D[XH&L]?!<EM3@4?S(YUL;8X
MR,S46A='-U$X8]9(^@"U56 =/S*G7)3R,;8_P35K74;F^,UG%YEV9U?VAV;Q
MNI0U O&^\9J*HQLB6Z^J;\EI3-%:D'3341&Y85X)PR4&1J.%4MQBN_KHSZ).
MSGP.:ZDJ>QG"@N''%%!1&!-!" ,FW*3NJ,O/[TG9!X?47OYB9I9#N?6S1/!Y
M\&,5LQ]LMSNONR4T/90X'6F4& ,)>8\_((@L?$S3&SW0KK:J#Q''I'QDMQ3]
M1&4A\%KMPM5E9TMHX7P9L(F;#6]'D/[JS:DQ+3F5_3D'FK?M.-U)V?>1I$'S
M9>UB3HT<*JG?;6X,WD(_:WJ$)E#7)%LV?/+_EH1R52DE>&+76M&7B->R"+HM
MOD_OR01];^.KJJCBHEOYF&[R<;F,*TD@7E-Z9% 5UKSU;T ,TDT&5(02F?D7
M![8:KG0D#<>R>B_?W",J?.^59'HC*[$0IEY)FWZG>C5 T?641N?$T;MS$1$N
MM1L$O;SMX@0S+WK6ZB;30/OVMEX/?X:*DX)&.YVUW!0]U^<>7.]\F6L'-.(J
M/U&%D)LS*[#>L+WK*5*H^?,]2 WB^2A&>:KMU1V-7"F'QIOP<210"A65?K>\
M;+#\1-[R1*+@ GM?O76]V_U04=X>Y)Q\\\RK3I?!@V!_(TCB,$JGOQZ:K-+6
M@;%1TV)&YNZM1IY0$)ZQN^5[)T :DD_&_@=S[QG59-BLC4810:KT)J "HA3I
M'1(5:2($4'J)B$@' 9$6"*" = 0!I2O22^A=(KV#TCLAH=<$, 13.+C/C[/V
M.>^[OW?O<\YZOQ^3K*RLE>=^\LQ<<\W<<\\X\58?\WY^<9!-ZO;] ]J-Q-1H
MF^GZ><+78\@62S:/"0FEMU]%DD^[ X78CBL',;5D3HELQ&>T+I>-Y7#F.=\F
M\^$M.[RCCB$,3A;&/8L1+BJ*J,2$!P.Y.5W3]S78ECDUTVN-/PS>&7 _M-5@
M-6;^9Z=<[?Q&.^J#%3$%I;G. %*R07V@KSV@VOV:\JJ=5Z;DR<4F"%X0T>-R
MCMFL4 B&L9M%3-S'6WP_K2F^W?_JO*I3HK1@'+L&DNXAV(1MT^?(84^- -I.
M)Q=S=($NZ7BZH195!E,=Q6:^C?N;W9$50TA^!G "UL(J%J1#EI4RG^7;I)?J
MV1@2$4B^'LC[I]]6%/*(H_/<YS0-+YRS=V)/T'*4]!/M24N<A1J,HZ[+H&2G
MGAL.5<6'&5"-<A[?S>,)"T) +@7=,]20^R22I ]830?XL*V3+Y*^ GF(8&Q$
MRXH'C=_HHVD?$EO8TJSY<%/:Q)>MZU01M\WN()%8FP__9\G>:[@D*1?DF$!)
M'@92-&'!<7(2U?.'J6\D5RK@!3T/#0J"[;;]C*]54:2C02[\\RKM_-6P=]^:
M)BOL)HFFROR[!_1S0PBGK#X5F_M3MVLF^W &O='$XC&HRKE'F(]!/40P!XO:
M+&BM3+J:SVHUWTY77;6<^P)J>0=CS3+;H/Q4(Z%!PR;%\G2KM-[>J.QV]X#'
M P]./_3?5$\@RG,*JB&6S8_W_?;89*YCL88R/?/E[2B*X4;;L#')CK<_Z=\'
MIV @G6< 1J+JF-TX$?1MWJE21*2EDY-9+S1D#"B]MZ]3[B:L4_WS];R;BGY=
M]$#/[*57\S^^&+*^!M T0'*17G_\M'?*FA&'0#!;;/:-K:^[YWH1L/&?O+JQ
MFSY'X[@[*M8]2=OZJ0.7D#;;RV@CJX%NK<6)4U\<%:FR%C8#,\<B(MIN^)E:
MGCO"[]VE.D+1-](GOYI?YK[#Y2MZ1?TR_<]7#!K!64094EO;1:*I&7HL6,#)
M(F@'&11C95?XB/,,0'W449IS0FO:WR:$,8TDVM-H5&RF!U=\"!,@^%0_LANU
MS@\5"4Y!VXB1HLB\^%#SX\V#5C4@ WU6>Y+:4K[]8F]U"CRR/'$JQCTS&>(-
M3,UVT(=P5_WI1'O$\S,&\\SFCT9#/59(%[E8AF.WN3]*UI9HWM<03^O;JKTV
M/01C1B#+ER^T7JWNSH,X+RFVVEQTQ-%?L_R^EC/(>6(PB?&-A#T3OSCU?&XC
M6HY>1[GLC?R6"YZYYS&9$VZ%:=@=Q8RW'UYQ)8H[^0!_TC5'N=0D>G&*A:>
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MP4F-_T<OZ!S*'G^GYXV9F78J^_:V?ZZ":% @Y%>+O!DB577#8]2194/X:>_
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M@2U&N/4-0;TRG0V*[!Y)=FE@<4[ 9OO:;\^T52>AA8$V$<Y ;_>^8.F_X\F
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MG[PL9B2$*=ZRN-^55AKIQ%'MGGL\RA!,ZI?<.<<S %>91ZL**O#E885<#*V
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MOKCTG-$&;Y''Y;Z-M\Y_4TUM_!R_E5&@M=BG=)<^2.F:$YW+-<=B[I"2$DD
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MB'4SM.C>:C1QDA05S+*=?7W2!Q9+EG>"$]7+1\7J.3C\I$&?P#D^NU8U-S%
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M*Z7</W$?UQBVTHW2!"=:9'I M@E,&O#@$66Z*Q*?@6EJP[$DH ES;;3B&:#
MJ]>&!+D*:U<@&@)SO-%PBN6FL/4E[=_493.V*:&2"RS'-Q=,YW^/AA;O26*#
M4MKVZ+&&:^42.Z_.+:1Q]1_S13@(OX9]JX<7P!R> ;I\"?:-D(69V9IG"U:2
M*@:!K\RR!PJ^>L<I-NEL1L=:I4<O9H=J!"OC%;HM<N* JG[>5I/[<T=&""QE
MV='01E+/BB)?"!U &0#@%<6)-&+\NF.,G.6K)M]WDFSZ6Q9N?VV5P.62"L6
M%(Y5YN9:?/DHTGT%<[/Z1P\_]V;=59K/#/EN%J9\4<O8HNH_IKYY=V26Z&BJ
M9&]I!%OCWZX<['%A2Y3D@B"Z6+XO;I)+E=;:XL]IO$_$9Q,O)&AL+,NM3GOZ
MS2-QB-7'<G!J%Z:5CHBD*2,5R>NQ\<KQ]'YCP]=\7B]+^!9N!AC^*'8LJ @>
M^07A">Y%U/.>Q->Y>%SR6_+),?O$5.@\_R C[/)CH] >XD5USQ9.563#K-R.
M+?9JEWHV58Y);-%@ZOUS?GK__3^MZT\@3UN4;IXC/RR^@HE8C7-RRVI"F>>]
M3^@-EIF7VV5#YC2H_7R+L\<^NNHM6^\9"YN>T!LE'5G-% YJ@OO)FA-LV]W^
M>>&DV%V-G!^\W(93VZAMN]YO0SD$H< @?X]=A'L]X@*4+YJ5PO7@,):NMJ(7
MVP\W@JM3\EG)<B0I81G3:Y?_3MEL8?A/I_OSX)>C;U,D8D8[^"_[R5@U3<E"
MZ&><YN+:!\%T]UC1G+&O8YDFK@-.*MJB116?Q*E=+XOYN";LKQ+N'3#:":'&
M1Z_LRX%I'>?"N]ZEIN^ HW6NJ.FCFD8I$,Y;MPMO]SB/F;*^7"DS7P7QM@&V
M8"QMO)W?G$SJ_YCD?RM.UCE\;H;65WH7HJCU8ROV:OD(M2K_;A2V VU>E[RR
M$<V[UZKU;3]Z=._9MYJ'F;)B/#G2JGS*>[Q 3>&MDE,[7!U>):C0IA/[I(->
MKKZFH%JW2*CZQ1ZXQ>NR<M$/Z"H;()/2%8\OD>X<?EXDWB:T"$M7NZ:F80'L
MR%MVF#T#M ,+O[8>(3UZ:/ECEZ@B3<.-EHU"3KG#DW)^RUS(C#VJBA0)SE-Z
M8A-I4Z?\H9S2B&$KDZ50Q,LS=?,\V)H8^E_WY_M_+RM 22+O+Z",WXNM]))3
MCL3]0%Y-N<N6YM1< H2^5Q0W5D)XJ4T@TJ0DF"N8@]P)!,(B8*S 21AFVUR&
MY8M3?"97_%VWP%8Z+QNI/I7W%SI%@YBLTKH.(I2%NW-H1K^ZO'*/:_.[:\ H
M/_?XU68@O_N[5R[M0](SJ&E5V71B$-B4*C:%:E#<[I2_H(T+*Y^"EF#<^K,>
M"?,HV>)^)^KI$NARW:\@+D+]#J]&< "LW1;D>'"5J/ +2HM,H/9+,,3LEQ;K
M $N+P'G+.BZ>N!>06[=G\YX]]I)-2BH,L^5+.1)N!\W9H7J)+'#K1LQZ>8%"
M;##/PO"ZNH= ZZO+SW4"G>IS1!Y0N$>%7@KS[/,^/HEJY2*HP=I-/2L<@V]/
M0H6QZN#QU/G=AL>J^"\F+PUP9=VWHBRT5+[X*'DVQH9"*(PRBW4ZG(?YGW#=
MN>O8DK=A"<+?@O=(1+&G3I/%\%\*%K5\N(>;+7>^:V!>=0I-WE?-?A=[+*Q4
M4:IQ'LW<F^VMJX-%C8^.2\TZ#O(I;ZP[9:@AWOF6'>!OP6)\$)%G )[@ZU#^
MZ3K:"%WM#2;S85'.W.;:1JG'55\4'[3/9/H<1@30D(0+DEY*?TRN&QWP""'+
M3)[SP\^@.GM<&MI:6DVW([WUP9B;C>C]]>^?H;T^[C-B\CF_/U",C#$\^@*?
M0]#A,QYATR*/2=X/$0V3LG$/V!KKOM<EJC[1[+SQ,?YKFRDI#^0 H@L>"Z9,
MNS^-(J@=JWP;]W%,Y-I]*7 @<9*(O/S@U8\W-\S\J(A,'JB"<OD,+-5*1+&G
M6/V<2G?QUD^5?7;"(KI)8R-\Z:8K@X),=OF0CMF4]+K6UAZKH9'9_P:'P/Z!
M: @67W+='WB?6R-S#4!EI <PFJHK9:3;4DBO* WT*-A*]90]44A+*C-HYXZM
M::FZ\/1"D@Y\T&,N@4RC@LJ)3R?U=IS'[>L\?6(O;XDNLVN67SO22BS[F5V/
M.901M1VYQP.*H<#-D$KDX/,"*'4H.]X4RO$CE?E@LLYQF6E;CR=DC)EQV(/'
M;8YJ&:H@8,OK<?YSX<W"'1#:SCS'G\]>32OH@P*];TE:CQ[R I"F=6EKU3U
M)R?*:422*M'FKJ*/?5D\+=)WM_,K5+S.DF3M1E1'%;]/LMS*6TI4NE:F$A&0
M?)0I$R#QZ.^AQ;:\!]E\-*R3'PY31$9JFPKV.Z)O5[R]_H^(+#P3R.WR%N=&
M^EZ6[X4C<V-_R-?()"3*#<9>]4Y(7;N:B7960G,*;_XYG<=-8T1W$ Q[JGJ.
MM[@3(@N9J2)5WDFSF:I>U9QBJM?T?/OS10*'_)>]RGU=OQTR+'3KF7.@<K%:
M=N06B6T=40/K=B3+09DQ"3&=I=;+YB)+)2$7%S4?>\<ZA*Z+,I'[J;X'&$.O
M'/_C0_5L46@PEQ,_(U2X!)]LTVI)+_"XP27C\S+>4/,5E5< 0$DP1/DG57KP
M)*+6/84@3[S;.BWL5SB]GU)^["8W3^\)HO#D7[BG+G4,<! 31?'/]"*SR]&,
MS M$%^S\8&#Q\JC8'\=F):<7T,@6VZU!$8K]'\]N5!AUJ+F0::X0-)V!0E/!
MXW9(>MZP;F<SE,JSY99Z*SZACQ='!L?7-_:C">LC(_3 ,5I+1Z.EN4MF7R/D
M:(I*)%DO_ 0 N@/]W5GF=.?U'.M_[WNB2@,5"8K[)[?.>=1V MU?L#[-(--0
M( U1":$;%M',)\'\K?&;TJLYM]37M*6V4C6!H3([-LD$&3RI30C*@,FNDXT3
M0M:RI[GNTM;^3&9IL?OR/(,<+]J 38MP(SJM\+K<:SD#)+@9#;@H,2B+O7_Z
M85\FIZ--YQR9_/'I&^K-V.E.:\/6<G7=%H4/EHDZ=.6K5@G/RBK)=UT&T_8]
M/=-T2J&_%OF7;.=V.&#)P-'S=4[\%SWS\ 04QYX;5OX(S=> .0.L1(8*8.7V
M,V34JWEX,G;29D,%3CVE]PRZZ#)#8Y-'V6O/=1[4X-!]E6P3(Q%>=O<"U1Z]
MK>U:A'#N<P=.JJ+59[X[Z,GAV^/NRO4)FIS<R3J;\1ZX(FQ!'4$="L&<_/"(
M7(7HB?_1"!(T8D[P&3$<.(ZGI#OH[Z1(I//YLXCA0+9%$H!$8<Q)*%3U[:Z%
MU07!QF<4B_K+LC4(@OYJSK-[UP"BZQYXX=%=GI+@8>6T]U G[.7M3G,LN>3Q
M53TGE07Q\J8;W^P$OB:+)9PDJ-YN/_UD.I]==V@6/=;UU$=HXJ3XR=/<W'@0
MJK C@0;JC+&??D=TRNNL<.0PTA*KKZX1'HKG?=1\=<!+N9CJ4OR[J<)W4*Y<
M(@A#*HA<^<XW^.#7'L<+=F4H+9VV6HK6DX7?:GH>AE;K[?\;1%;_5(SA=W.K
MZM+7UQWW]E#J@LG:[8:L=*G/_0 7,M-K(%G\&!/&N1)T1QMW+5X V9_?A#6-
M^@"JZ_XD(2;O_B:_.GQC**MQ3FF&ND>0]<*15H_'>^Y((JL=KEY7A4LX9@42
MKJOE/L I:DG%]V*Q2GSP-NVBP9WVF5F""GA\[W46<*JC9TE45]0LE5I\Y=Z'
M;NZ0DNB\$   H"8Z^+=:*$P><9',;>$D9/A[L-7:N4%TY'0@(9%___JIEEW8
M#&5<0'?0""3\SW=11-0!66OH^0[!:=8U[/\Z3OW?G;2G0\I7E2LF_^+G)<IA
MZ@>V=?4HM.K(TU/N=JM:K7N&"0=[/R!_=O6I+[<E81@[<QB@4ABBLD)$;6G0
MW0&Y"ZW?>-:>2;5I;>_MZ\C9Z6),8K[B,ZRP;"GO(\VGNFZ2=X;>R% _>6%W
M*3%7PIY"31\LUV156W1[Q%BH+&?M%R]+V1H;936QK\+M2VM#$NW[)#]!HP36
M:"YS\*6K?C<12B WQ&QVYXK^%S?4&8#NAWBK4HD5IW#5_4/SA:MFEX[C.NJI
M,"G77]WC_\;VMR<3?>N3X*'@N_XLWAU37IJPYF77<.]3&<:>)NR$G4ELAD6^
MSZ%\Q\1'D6_U ?RW8.UJQ"#?E>4X^A6$7 882_^MZ.<9@#&+1K;H#&!0*G(&
M^-&6\L<4DKI<^3(*6$[0=O0UA)6.B[OOKZ-!-T*_\../!R'%<A%&JYLNB^GK
M5T2:WP!-SS$IRJ]^1QTO4[B)&_E5454LZ'N)_SNK\Y@;T4H3AI0;@K7+VHV?
MPPH3MD:SE%2*VV1_@P:"4Y?,?O<<R']GP>WAO;W1HZ%'2S-=+UM_WC4UFLD3
M^QG^XB/CU_JC,X#5S@IX%H'.7_X!>B^Y0\NSN,7Q2/RWJ*QJ/[MWDW_/;]58
M0KQ,^FK7!(YS<Z1@2B&/W^7=JXB-G3II1[O&".U\C:0[K*5Y=!&7GKTU:[N"
M;8O$,G;6-Q]$^G#ZB$LCH<D/ OBV.TLJ]PLOF3(2M*&NX^0K4(4)N3ON+ 3W
M;>&&L7(%^L,130HTH3AQ*"AD6R-PK)A2;\)#O3].2>E0J/BT%\-CF-&^7+L<
MKIDL=5OU/E^FH!41,ZB0N)RNM .ID#L=)UR&4K5AM>)OX$.+YU4#&.*'7-/O
MA_KZAN7"2WJ3NLX ?K<WZ!-^.1\>EGC%"=]Q78H,!AJF/$Q[R&JH$:CUZ;^?
M?S"T6NAV\!#O[BJ^Q'0C2>?%LY+HR[K,?@"&XPOBT%*"=O!<.N3MGONY7N-6
MY XXA\X ]@3[YM,IG)CG0":3;&M(29/![&)2/L^PJC]6M!=4[]#ELGR)J/0]
M0P<C5))3MZQM0;TOL/:X)E$A!9J8> ;@H!N0?!3$A 'A=#'@=K.] [MZZ\"N
MJH0,,T0LN^:^;8*@QO*'U/;K56RK W563UY]^1;X=YI-3Y8R>XHUQ.-(B7^6
M$><\$<R=,7H-W^-4H>I4_K!]Y?-0@FN2I*^TE&#MR ]VM2:NU>GQUX8VX=Q2
M7R@Y=SV?%HM4>R4::K!5_;>'69D.@S &8-HX;QPLP_"2Z&9SRO<5M8$F23;B
M^I,SP 5X?FD\OG,%A-=O8_-KN&>6:@X_[D>%FKWPG[\22V9@);.-1D76YBF>
M:$X(]1M)'TDA7BZSP3KL,<+MW!F@SZ).598#LU2O$\EK_;U>OY+QT_FF _P8
M?0@;KR62#/_:+Z#:K%_4S5'=*2)Z^PS0UE6(A9=NOTI1VNP^96CU%QD VFJP
MFAJ&_/OI]K^6&L8*]_S(/K^1L!"B2F6L&+RP_>4+FT:IUFG0ITO<!/<VH5\&
M+CD8HW(3J']_X8]'Q*[WN*U^IE[BE5%4D,M>R=$KB^:D V$\[TP6F^(9X.]
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MX^'X%/N"TA@5E<!["Y5A0GHS6YD,+BOVF<]7]PL]DH!?E8)YQ>U@&2!ZMS.
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M9--&JBZI,\AZ?$(A]V[,-)]CA&YJ"GM><V^_O'>HDAFOK\OR/D[LI'=;ABI
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M-22=0)10[FWB+8Q(>_BCX=WXO2]:F_ "S^M!S8TF CLWNZ'WB#^;F%KQQI!
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M"NS]OOW)4.Y)KGX$D;JP4\&?I:!*98 ]EIN?R>0--Y7 ,AQ,%2"SW)!( KR
M<]Y=A$?+ZE4$<"ZF%L_?/PQ\R)O18#?&V F1]&HTE(/#]V3H<?DZF*)PY_(_
M01'(TD+K(IQ[18Z\[$\:K& 8C1H9Y+):VF+D*GS&"QH>C'_>=&D*OFGZ-U/T
MX3\[^_V_E:(V$L ][L\.">"0Q-:U&]F4]9-=H,#Z 8[PCFBRGWX )[!['5<0
M:9VP6WB]GF8:^[;3].<Y)(!Z76]\AK2 Q_<_'6432:5;\.K$=S[ZT[-M[]?N
M[7_E4C9(.JX<V< LV%0]@W?H*?Q9H&OAMHV\-*E9'1JY?= 6#H=*E%>4:+]/
MLYL64DG*\H+^37'W_"/%;?#,LMVGV2'R=@:^6LSV;*S6L)J^)J\9Y[^D=[?!
M.L!.N]'#HOR:]UG%"QO(19P+Y-G@(I#QYFV13)\2CAAUG:LWL_;%RG^+J2\G
M"!FZ. 2*;.SDHA-/&W06]>3TS^466 CI$2^LB5V@2]*94P&:'QV$4YD*_>3@
M=^S;SEZTSL0.+I7H!L@TLI>96.F<;PSZP]'Z"V\G)1^_=N$,'^$]T":J%56Y
MHQ9S0$PB\\\G"'H4+QX:>;MO(1>V;B;U("L_UP3PJ>+%ZF++D:,:\BUDU7/"
M!6F!7F(J2^G.])SYHHXD+ Y@[;?VRFU,1Y#7]5XADI)K.PH6_>US''.P^V#W
M80L2P'$)E8&!K8,G)4X(2=&VYS%(Z3_B0L,:,GH>E]%?,C+>+T)I>L@XEF$
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MZ331"[A:(#MS81U9*&>.8>!.$D"%:UR"!+AQ',%QD$%0BR/#?0HU\IL.?;]
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MS) 21'=*O7*RVR*YG_06RM:CIHEX_%C4O#YIEU5KX_/L1^J?T&)_,5E9H*B
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M)032;MSG?N?[[GWV.7?O;^]S]OTQ\B?/2M:::\XQWO>=8XY! >B8'R(K'='
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M/Z;73^)O=459YK7BP FNE=B.3W]Z.I\PN(/D/D#-"^U/6J56'IY\C;3K B0
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M(HL4SA?,0#X]X[EO6'W3L>%V@O/5V:.L871WX\UI'RZAS@TD,,=W^8F,)?]
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MA>=;YP.Y5W+18.HJH !<RE++$1<W+L98%)S6:D=>>XYPUCBO\\&V05/Y)@7
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M_GGNHJ1VVY]JAPI?>F97G2_]=U<F?]V!:^GNS,WKLA/;-<Q!9R%G.<W,ZV3
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M8S$LN2-BRD4K+"@KO3 =C;&-A)[;_Y<:*,TR(EZR?Y7(;G4L=^3.80"?'-*
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MF9U].9LGLG2L[J&VMZML:C)WHK)R4E@I,S50PXX?FL5L!-N9=2S0DRWCW-E
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MZND(/W9[+I+LXA5[PYZ=+9\]C]?-8$M\%3GMWPW$)1#%XK2B].NLMMO:3/B
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M8); R#2TEOR^/)3EU-S%',P&?L$/;LOT/HY[_G@HE]]\X.TK/R)],?)DU<[
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MVHO3MO\]TXZNR^E1"&-J]=\W$N@_I_N8$JHD^DW-97'\5:-"2DG 0/N)!=?
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M 9JQ^T%[B,ENTGU@*'B+UH4,R.L,4@MF T<"[P6.PE]+_UE7XBV8]PW)0WR
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M8!R\4/<[LV!HC0R@I9YR[FF;L][V^3@D&N"H&1HI8K_,,'&@YH*1&"@"F[Y
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MH+WIF^!]'BD6(.L=.]P^SZ1D4FBFR5]:B_S4(GS@0>7P;OL!>AGR-9./E![
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M_,/4ZY%\JJ\S%GEN^KY[[E0Y,G.:NZV[<J3Q4VZ;,P']ZM\<OX7$0RK#B5_
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M61+B#J&O%*J A9%%D=5>L4OCFO5I<C$]DF6MVU>LN^0Y_<"?8"V*%( U-W7
MV!SG>-,MXL.QRL)""T[KBMV?YGV\<H:B][31HOVUZ--5%LN\IIW1#7C%Y>PT
M_180V\#ZM2G;7QYH28ED$)AQ%X+5R& GB!RI^66DPRH:U/R\,K+?M*K1^%,
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M[GEAU O0V)3EX];=B"._AE[VO^P<EKE]BL69GM//^W974^6;G\SLI:APZI]
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MC?25ZE3%JN% S>:+F(ZU ?S,*^Z).NE9DBSOC?!B#*/61D Y$8"+A#[ <R^
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M M)+<PCC@8L[M:/KI #*QM74&?<$2OZ[BJK_KMPX\:( +KT?;=B-4 $,[5,
M7%-/CA7]E;JKUBF 6^2DTPA(/!QK$O/4B;NB*N,UD.B-?S]V7KEOG XFP)":
M _I($%A01TR0K^#/TV5:B =9UYJ]")/=T.0=YQOW?-;$/C3\"+N3E/=8MM/>
MD;$N[L%'!ICP$.)7@;BYXWN-7MU]W9_?(T4>_E\Y#/J_.SZ'(A?R0'Z+!13
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M@]4O[FB^\51]5B/:W:=YWL=OQ@\4[<)#Q80'T&5@E8CO3?+XF 781V0Y8T,
M/Q8>Y5J)N-[.4]R>^?5),$#S@B]]18' F]4I5=XMJV.LP')8"JX<)>;U)AAM
M5C&5<L1>OEHZP*KO\9J#:^+6P;KV_7:%IHYL'[O)PP-_S8*P=^&5(6MQA[6_
M/0S4?058#-2]]3O^-'C^XV]EFZX]- A579)9Q"PGWK3@/G5:QB,GK+Q7$(RA
M3@=8W'K^=DS!4(:C6XME)D8=ZK]X@VK9'D/+YI2&C+#'>H4)L']G<G@A^8T"
MR'Q70-.C@=.<4"ZWBL\F=W !@CY,M:55?]R)DY YW!)?_@(_]-,#T8\7OS-J
M-RVI+3 Z]JMV1;E_]_;UJ/ARN >F 'CG'/XXW_S-J 5Q []($,+#EMJ&-JOH
M;EQH"]5R_LOF,GMNEWPJE>FF7 %5IM>+<SO&IHSY1FUJ"3_J9//,/>SZJ5Y!
MC['#1U.D[T@;[Q>#4-=L.!=>?)98DS.2X\A*SR<8=NAFS/$V4>3FW?/%3@&#
M% #68)>#/)9V XUR#>6B:?QUD&%Z*<ZXUN=12OGC=TUBFX_>/M3OZ=,2O<^O
M*NQ?YV!3$[J4Q&26;5@2*UD$O$@[8^H:WB#T':\W9N%"KUDZ)+;B+M)N\_I3
MX3TR#P/UEQ?^ ,9]R2X;C 2K'S)B6W1T;XL3=N$#"1Y /0UEP2J9 E?0)58O
M7;3W9 A[[E5W]?EOTE$5S$RP?T3H?X\\]97^]OC:%\8$)?,D?D,]MS_;>!:L
M_Z/V[BV *5Z,P\P'>S%OOA./][NQ?CVAIZT5]9OPJY,T=5R'PJ'#F3NXJ,>E
MY5Z$&)2FC2A2;XN'J@5<#,&#[PBG5'V[[_7X0&![\[%_ZF'>]@4<+YDI93L<
M.VV<H'O\WO?MT!LWMU8=4]D3U_=FH\@%DP.9  =8"T, +PG1#+M)YK;4*5O7
M&OD^6KR8&#ZIX&,8J+!H?A']+7$.J;.U5[[S\!^S1/A\SLA@&%/IHK+6L<=0
M6UX;\2V-];+IHQ=J0IPM%R.)AJ1,CWI$,(P[0)#(-<)YY#A>UICZ*5JA_4[S
M<JWD(QQH4!&,:7+>LR=?<UQHA"W,8RP67:.YF =+*J_K.NN;'=)>U.OFP[YD
MUF)5G6*['"BN8=PU<,^R1I@" +<]SIIT_3VRWF9T-))SJ?:W,;B/"52=%\;7
M<',.[VY29CFMLQ-S]&5AAY7JPI=E@=BD@Q7Z3D]J]X=;HH:"'O$T)I^C@X'O
M(DD\8<*Q=\@]X%+<H:!QEJM#\;L# W7/+_],/??O#BMZ C=$;1$=!V%K$-P+
MDC[.,JBLCI9+YGF63:W!<O'Z1U5.@NVU8Z>3XV9WQZ;+I :9^ROO*RB #W&/
M1&XF_G_$O6=84U&W+AH5!40ITFM0JA11>H^($$ %D5X#@E0!$9 6$A4!J:$(
M2)$H13I(EQIZ0*3W#@E%>D()@02X^-V[S]GG//>T;^^S]X^Q_N1Y5N::<\PQ
MQSO*.[>U%79G0N3_P/K0)YLQ"R:(SX'EN0:5Q8>%/*&,<T9\RT=2FQ&BZ7A@
M.Y*:J%"]T20TN.^[F3P^^ !=>O\W]9^  )-(OP0"D:CQK:-N^-E(U9H40D)O
M>%9O52X)9![Q.<+P5(%??C!?(E0<J:D/8>CYRU^)EX@LO2,&I<9U!FENK- ?
MQ??XWN3:<@AE:^%9YSH)'/5;/2F!W7[$JW]N>6%IGI^4XN>Z-":P-TLHK;.&
M^5*7C\D"9/G: #YX@3;4#3R*?-4K_09?&5^'YHA*>@T 1OOKA<-==CXT,=O4
M-,D/.[Y^LS7<,^>ULU2(S0TXFNL_I3[$]+-9YQPB3@6T@UZKXD)>-+RF6J)V
M>#'=3Q+*"2@-@=L@/LQQ/_4HD@'2=_U4JA)=T8_U.K3=;>%!2S>6W,EMN0PT
M!CF&A77(GK >I8=%H!:RYAC+?SHIRRVZ64 ^:2]GS6@EQ?7T7;"DYLQHSE-M
MK?UTDHURZH]XK=-TE1A0I_%A'K_C3;BC\U[Q:*^\%:U\,C@=L0)3@0UQT+59
M/=]H.0-<D>8&/D@=C6Y<_?BRZ/E>JEH;F,9ME:TE=BGA,. *"+1A34DLPVI-
MFXSN ]DV]&OZ/$K%2E8A)81G2L>'I2S5(C5285*)->4UF !OW/Z1?^VS@W&<
M:AZ"X'62K<H_QXE@A8+=KE)RVK_G?J";LLY;0\/J-<.3.$B$G%*C%DY4QO3H
M_9*-Q])M/E5K;?'9Q;Q6?=,9Q&;2-G>#F(.%A :\=:-LY\B(E)8(K8EQ8%CB
M,<)X)-9RL_$D'IX!-G-)-FKX\.$V52%Z4[_&IY_Y/[B%/7TJJ8-8C+T0WTC'
M[WO)4@Q7]3WKF41:[TQ?@R<3UD_&0\!N""I.$B/?Q@5JCJE2#PLF>H;[4,A%
MQWK5'W;\\)IYWJ@ZUD?#Z?U^BFUK0>U#!/_5 A4 U]74B&-Y@Q"5FTP(%B,A
M4/B,<&D2R&5GZNB4Q1I)Z7?/K@G_X9U&1QMX)2=F039/%W&;@I[V?E>70H>M
MGQQ! 0]N[Y55<<12QOAL1$YWW/C",?3G^;4S $W%E?N>H_KWN192EY)$#K@5
M[ZVXPL*A?1\7MRXKQG1OS9!N- %QMX%49X"%KW.\0[1_BI1U!>V=:9FC_M3<
MCX&O%DC;;41L5<$G.#6&W.QK<<"H!HW%(%N3>UWC%A@'X-P$0V> O1S7JT R
M'-O/Z7?8 N>L#"SEGM$.PL"I9BTZ!9,OKX3>ABY=#E7NL%D*54Z$,@[0@=C-
M/5]YA10--VXW#$Z'YES)_B8Z&P L-C24]8U=9XFULM"IF.Z+%'OV[5?=CR[>
M8WH7EV,*O[\FB/(2OGZ!$(>O;Y9KXAX%A!I?L1!MKD\=6KAXX[ZDI )OB3]%
M5$S6\AE@DA5#R,<%HUF1%,I!RQ,RC6W@G"=\-F"E<ZC!)]_&7W^8Y=EC]V6=
M=6O]"$7X=9*&[I2@CH:KUP!QGYT&&6]D+I<6=YI]Q1+?"224*D"P77N>AB_8
M1?:;!(@E:+>K<<Z#^3A4"U)+'Z((ZT !TS"';7O9KJPPWXA] 5,'9WZ'I.UY
M /C5(Q_W@IF$Q&N>#5>/[]0+CQKEYZ,=O$:^KW6W6ETL5S;!7F=LGA([KD85
M6*PI>O.M_JR+O;7Z@R>;<(F?4*).>$NL\,!!%JTK,').O<=H0I B:\N>>SH#
MVY36#.6=9JXMS0X_Y&8;Z8)?/V%@>%/U-M0&'WV2&[IC>1+11Z\ZZ7LUG26*
M>7<+\YQ6-K^/>DJ2[8@XTRIOTI6XY+/X(P;5,!OW"VK^]_X<=5<I,ZC2X-A.
MSZ?"]=21E[?B-,';B\;7@UNN+6MQ,75C-R A37?@0*@L#OTQV]#LX(DB37X2
MJ*Y<\N*Z2K [,"0 T=$_$;R8@2 )$5>;8==P(3$IHFL('P_O./^:!*OFII>Z
M>[)6G\NQ"5'W  !/"!N\18EL/;7:8K'%XOIQ*4UC9"E&V# :WR)2%*%U&-L?
MO EVV=LE^^@0PS@0WCX8W$"NMKPX(K\PBIB(CSRW+%3[Q!UEHQ*+M?>61W>Y
MNI4G-LH%+G^^%I5N8V\?L0N9&B>D)B^RI%&&*HM<WHFILF&Y'$V!>AX=0Q&B
M,,O'^.&Q37I"[$64"4GB' ((%Q],6X'0<)Z= VZ[=M;YM6=$YU7;&I"W57_\
M-K%%),=S("'8RF^FVW9>0,8?1M5V/=C'1'DV#@/$#9U_B<MU3_(]G&B+W!A^
MY_:=@O5XG3S/][N@;3=BW^O? 6XVKG.JU\__A6?+AZ8#3]>YPP[Q2S/YV9[,
MX9 F]0YU*=P]/3EA>)EFTW7_44L3U0",AP@;5\?U(1R_.;-DT4^LX<3TA9H
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MREQU_R')^^D<LJI<XC$DV0-[MEA-4;B21L?\B2<"WW-R9_AQOQJD7_-=I%L
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M16$^?48#E>"-!ZC#41FX$VI*:A&2#(P^Y8*[3]X/66VLJ;3I +_)F&D0/0-
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MSOB(3W8%UVMC*J-WQPZ+80NNETZO<F.HI9%O!R;:)TY'1HNWEBP/HHVUO<X
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M8L?0ZM$"3S#]ZQU'\=[Z;866O=GF,T"3E6LDG8O?D0 A"Y[J^.)1#U7:GS.
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M::KPR0.C)_=WWI $#[EI9^5;E.A LA_6C<+]-P",(630!!&#F@0TC<4%0XJ
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M$5-<>OVFDLX< ]VHT\6:-4HXTH&I>0Z8J1VFBWP_P9?Y<Y7/[$#MHL"B0'$
MD3FEEYJZF]-_6+?*:$4G@\U8;EUAG>ALW$($Z^8:6,LDO<"(+WV[E%G+\1I]
MEIJ#<4P37^!X_UVJ. N7LA0YL3S?7!!W;&@GEE\L1NW921$6T7'K^3":($FW
MG6]P;I7&,^C=4SUP)TDP$<7>&LE_X=VI%3WK,F&O+JV*Z)<C'P6_KO4YJEZ6
M5/*"ZTBV&_'I;ITQ$D$XA=??'Q+0WALM-Q>UXGI3<L',=$K5FO/CD2CS #K
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M41Q%E.LX^;!Y'@=2=*;3N)'KAS:VQU86,U))IE:F=OPS==]7KFZ?#G @-F/
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M5_:$7'G&?.-<#3OK%FU4C)I%!U[.AWR+)0UCN\9EUL>]]DL>JSX[H6@9X#&
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M8H^ND=X))OZIUKI.S2U'LEN6"2Q4E Q5YG?NO(C-/L;Y4-*HTSP^V2B)8SQ
M?.!'1W(1&90[7[H?0@>P[-0TN+"CA(\!;XBS3$%,G#Y_; =U=]TVZX'%9,O?
MT\BM<I/<W 3;!#FQIL"1 ];TQAO$_^FL+\X>3I+T^_Q%V!."61J*M#^0C'?+
M_>Q^?I$.G(,G[(%_3.M\)TDO\(OXZ(L&/Q'QX!!:6TY//T"'_RU48ID_@G&2
M+W, /QE8EVW\[,B0T5,5LR\QWSDCKP6P^9:2:OR^VO@9U H9Z!MS?5?\UJ-Z
M@2-H742=(V'%?BB?I?L1MF^G)$9*(4$UO[MC:L2\+0E2:M018+.:"W.NC[UQ
M3G/6EB:<_F-=]LW!< :)B_QP6<:^BI1EYT4'9N--THT/]-TB]ALK3&&/4 M^
M"//@J4RMP<S&R]4#=.!5H(I'4]'D_/%C2)GE#M_O.^+"U)?!K:A*N9B,C6ML
MU[5-;YR_F5OB!M,64],:H37,I39B \W+\?LH9\: -B3?A(]86CP%-]<91 ?%
MV0W)V?^\KEES0+E\CHIN5'/, )F1KGK_/G[0[6@^\'Q?[/LKSI\H(H.B)1\H
M'*;=CP9_)K;Q;%U#$8S9$89FM &2@3>;#IN:BXY>$%.^1M%/*4,-&NO3[$Z3
M=1I38Z7P!EDK,]XN_<JG8<W 2[2!%H3*WX)\$),B"B9":S2S\1Z#T;V-I6C:
MB_J&4@R%_'6/UW&./;4\1%#.JF!M_O2KR_KW^$+*+3*F^P/C5):3*Z);,.7A
M4,N>M;+E;NDF63K@ZA9\]9(\[G-1__[S83G&Q^NP4RIX2K:#"8^X_X;.C2I.
M(X9D7<\MTICY\?,Y3B6/1(<A_E</&TR)D)D )9[%2DRY2@M;VRG4:4W5+W2@
MW^8^?_^O7FFS'AP=>*,D(V0D2/)9<ITF1ULR'S2HPNM'OXW,#4'\M+HS9T5<
M>!X.FY5@'HQ55>Y+^?/;FX$R"KS1UVQ;_Q8BNX_[[XBG::*([ZAI7O)3;"V5
M8[51.XY3C>D7U'UR6&1_)4U77_,[,K)V+^9DQ['GB[\WCU*<2*%D$5+$>!.(
M6\9^E'*^Q25A[=X0?Y8U^]B0LDK[EZC6'XJ_W:NR G<LM%0)6F^V^%I\+4%A
MNQ/>AG+N.RT*Y&P.$0N/*,77/]Y>=^Y'A_R!3\7_3EJ@WN]6.K!;6Y'NV-Z5
M(""C=B$@*'S<BD#,.E&08R.WM"$[C?1^XF<F,AHD1KBA5 9A^5M9P:L2$88Z
M+>_EO'Z;QB5DT=;0T-";N_]5/_R]_EG@JVG,>1; SF^)/7#2$NNLJ:VD7.A@
MFYQEW*;P']B+_,_N__#&&TICY]]Y0\XX>T8&7KT?U"?MGKB65[/2VWI)I.<(
MY#2\R9\W2Y!49Z.G71D2>.'!K:C6,GV!%S\N>/ \;P^(7W,O(C^CW!B!7X4]
M'*2Q0Q\:*<Y-_0:9)"O>#<P2#NT@W'I7YKD?SM_->BC4!#\]3&'&,H3'X2-;
MT^@H6VN[.N&X7L34"PEDC5*+CCQ/!#$2&T)SV=P720"-$BAH/YK.[%ECR"V_
M?RH3'Z)"FU/^ZA9\:-W]Y9/W)P,5 5.%7G#ZU.&M>C=B?079?(V,\ZSXG.G\
M&#!>]CPMN7VQGM*L27J,EB0Y>6/M>VPY>ZEBU ]*.SBW20>L<D9=0-7[:Z2T
MLM3ZUQ=<_3D*0V-&UTRW.RC<0M;JFVNZA.6T\,11MU?3:$I90ZK<55K[U&$Z
M1EYKY!_MU+A\^>47SE84-_0YO(\.$(P1_-!GJF;C=[:.MY9:,GV(9!^*_/26
M@_Q<5*__GE+@%6M?"J_=#Q4MH2W=O\5^:Q]LNQ;]4M?<"<%*A/?UY>]KSM"!
M>7'"DJ9:L14II>70M>2EU5H5L<2FI?K)6BR3G*[=6^GU4L&9D=_:N[Y:GM=R
M-W4R5UX.:O/LZ;[[9PDGS\[\.FK+B'8:'<K40C1Y-0J[6<L[Y1<S8M<')LB\
M:UH1V-IW7E*)M=/Q?1*6)?%IX<@J1 W>#>:<)DY2*U-:DP:$4$>@JAW^/>=A
M<=K<J-);'LR'D[YW34-GSZ"?VO*Z1QPV<.AA_"UAM>E?(;>G1O\$Z![J<N9
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M<O71=Y_W#>8VEMF/#)\EAK5(^,OW[ LH44=M^W"EZ=^Q+&L4G@G1VI^A[PY
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M-7\Y;BVT[[2/H$@>R*(G?6H!=J!@ERU>B=?J[.AYTD_DW&$_$'RN.L@,*6$
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M!GXE9QHQZ+G/F<#XTZG^:E3NGU/^JWCT8'\N5F)E_M+?\X.IZ<..NSKF1Q2
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M,5W@"VM0>_PK(_EET0^#V,\KH1C0!:@XH8I\<1&7J*37OB,S$.P[]:5Q.#P
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MO8(_7F36#YS%.A]UH"9:;1*L"+9(JS>-/%[[+@>5$7VNPK3OE8I\Y!;[X)<
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M 7YYD)?W;W>Z"R^'!>LEQ8I*.L+,?T0!:&)T(9JG" _B8XA;G1],ZL.DPXQ
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M/K$JV$/;^W!B7GU4^J+ V8V6%^?GG^X-[O1/TG6W_OD$H.L"LJ.>(\. 9<A
M5T4CHCS)"A?"924NW<@Z@M29A6C=?7S&6'WKSGONSM]KDYA<"J"9%\I/B%U
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MOL_>9KU;&_TI@_<"?P7L+H)+D9^1"G0B;!2P[:7;58,RFZ?W9?K?%4\K/G=
M,3P$#F>R_28)CM_"R;:@SCNQGTM<?#KX=F=)S$U;\^R#KL,NY'FJ:D5 AQ)
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M&ZD((0'KU>P>N_G+4.;/2E&VBS'B4*2^ZF=&%?""2PK!L52/X9L>A>Y5P"7
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MP&(&?][Z>!W=XS8F'!FM[/K0/$(1 )=&TA.'AT3%72YOU^Y;E]I):D^9SKR
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M//-D&PL'O$Z.LF1S?HXXV!BV#U0GZCNBAN +W^:I:L* CHD=,D "?#.H@@2
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M>1#'UZR*Q=(A;E2+:$BSW""B$\'/  1"29X$\6_,Y\:]IS][[(SET/68"0P
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MP*BJ"9NMZ7T7*[^@ S8,0CCJI?WT#!LB;^*R?FJW4V[V#)">AC2_.<I)1&#
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M$K M'U;U6=MN7'6PUSP01BGG[N^JH.;8?K.B\B;6QE^D9E@+)\&\F"'LWOD
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MCKDA9WY;R=4S_U('R4]PMA=!WO6VF5VZN>$YE!IUF*#H#Z4W__D@X4$B<>I
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M3(^"0#P$VT7YSV;>;D958Y9/KL6V328*K;$M/;8:H!6[_,$A&Y&3NY6RFNL
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M],MQRX4XX2/T,A"+/3NNG]*1]:&GZ<AD@L62X& X)]4P\9E/]IF+"\H IG'
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M^W].R?!_[VC*=C#V)6I2!S@MVUJ\!+[<S)'4?IV3O:7GN:5^B/2MG=FW"A2
MT.S1L>%"$#S!G EW<:(7E%R@R)N(>KU]:26GS4::*2$R-7_YAA*S2W Z%1.)
MT2W6(MT"JR,R*0D-5W?#03$)6<I+GZ\0YTS4*[6^OXJ@.ID<]4C3>XT@5FK#
M&@!0+_[^^]8)Q^-E?HB)T7V72?ZE_+U&GFK;IJ_Z=,'$E^G\(W(=-$RC%CQ#
M:ZBCCYO!N[/T ^(F8Z=.0'HM)C6)_/H.$V#*>)8,$X=TX=]4CONW?Z^B7$MA
MWKGKG:,8QW?)B/D?4JD?I*_(!Z@FBP@$AN,M9J)Y_FZR__<(;Q._^"J=I[X
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M* "/3(?;$)G?Q=..]P^)_4K,$]^-8$8?P(&#//CW:WF=P:F8#;6'""UO"L!
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MOS<KEJG_ENL%OO4Q-ZGGA _?B>LD<H$O.[_/B+=>K;H_>8\.9'2< ]8HT*,
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M*8#7(0,%V#<SE,1Z'WX:816<O7P]R%X%6JT%EWTT-B9K0.[._?T:+AW@%R
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M GAD[Q)C.JBPL5'-4+0;[ICW6^]=X%6[*S<.O2 VAQ_0NT*-#QM:#S]3*:#
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M=&X:"Q(57L+';A.&DIX1)HS:U9!Z#\1<MT=$)"(AQJPF/53P#H;J1/:S,#/
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MF0T)*:G5RJW)M1#/8[EADOA;<Q"&3F_=C-4DK\L*ED.:YPH1[6_EIDV6<R=
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MBO90!9N[Y3AWPX/TD--CEFVB ZV).Z6A,F6_^.%/C!6[\+(>+$J*#@4T/,/
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MO*AW9'(;JN*H-9;!-^KPA"]F;/LR7BC=^#I\)]5!^]")Y"8.>8< J0D@HBA
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M!R0-OI[@!%/#FPU/F%LJ1'C6[*)LAJ;-9*TGM9O6]YH9:\..H/</#?%;A;!
M;'I]D5,5NY][Y4C*T RW%%%S*3-ZL\=;WG3W5*S3DFG!T_S-!='.50\G$7^-
M"M6Z?YK=4G!T]/O$,KIW::3P3%&#LVQ9]0/UT^6@YS3(\&+P7,Y =ELD<VMN
M_,4V@:;*RL_V[S0G^BXHOR1!4ZJ$DOAF!B>7]U='B@+5_4%N@Y#S\-:^,-)E
M PH0O$->SB3S>8%74Q!$/@IP)/>: CA:PU.Q\$77@[]#,_&9VWZB& 3>EXIH
M!^7!>%4*L.UTXC_'W-Y%5H0IA[4_777^IJG:4]+JXM(TV/@D5(+[!9P=$P5G
M<M6\<J^A]L:OG<$OAJU&6;4Y/V*UOD>(EBS_KV4A):=2374E#YUQK!IZ$CIK
M1>*9*V=B)UFHF*K)QK55;J=R%T1D33"-#N3&Z]R'I._NF2I(:V2*=;-*1+^=
M_3*\5RSF4>NV&PA)#WO,I3+ZO:'_%>FS+"MV=I,TI_R _T>*A4D:H(2XE9Z^
MRW5PK@^[' L*@ZEFKTG%#XQ/MCN%QF@;WLG<9\NT9,WL8D"7R>1+.-9Z4[]9
MY:W_[%"G!(J<C%RE &>)4#A#3U4=[_Y&<(PQO74_!D*]/)OEB^[!KN)X^Y02
M+'SZB70SERE ^5A]X( !0^ 9XAV;#@_N)>*<.PG:"9[[6M5-_U,Y_]1<;]$?
M+;1PO$#HFV,14*BOIUS'_:Y;35S6V>NQN:O?(PXN_.<(TH: H;',?XAG\20,
M*N)$19R$*-!B/^'$,\F(/#/(H4_]:PR.EH7;)W@4^1PDG[-!>"Z2Z=?IH^K+
M6_W"W=$<BONDE771/O3:?<2/5V-%?7] .%8_U2O[[*EYYNLGGD4'6>G.12/:
M*D^?1W?^E$GCTSQM%)'Y;6U!>V!_@PWC[)P9 O]I*+E?.+HO51]1N]@]__?W
MI[)[_S=:M?^R"M93;',J<RT=CW[CIB>F'PSTG@X6O2;5_%250<XI0O>&J#11
MN/W0Y/;LI@(N=6O@QR2R=<N]JIL''H Y_3%,F ]F'OY4Z\+9)6_YF=G#!E(!
M$;2P$W;$=PKKF]PVEH*>L$0Z#\:+2 N^+A"Q_;/+F_$P2'Z;_^O/(C-2G<HS
MYRRB>-E CUNW[P^K_-@>BPKW]KWZC,W7-I#,RI<P1CPH&P8>?"4'+;2KP8FW
M,0J66XCTYGLN*Z*Q'R\,3>OU=M+3+BT$%QJPJ CQ&;_?)DD.^J4OEK)B'BJF
M=,^LK;CD:F)U-$>(8&SUG>$#J%TYZITP,^/%9X:_EFZ]<_-*5-Q*<Q^J3Q%!
M-F7JZN=R:4^K7S\""3]UR?HS:^+V5^1 ZE_-(5$ /(X"7 ]NFSTXA']$EI,O
M4( N,2R2%/R- @R<@5GC%L@Z].&HC4T*<!5B3^2E /'/,! "_5T*\.T<_E$"
M68,S%K$<\-B6O*:S=,S[MS?5!Y9G\CEP&+3[ *:]7TT!ACX7#F_T@!UCCZ^I
M_<O$[)5ET'8BO(4"")33DW%Z1)T]-2=2$GBQ; URT$*]==3E KH@3.1NT.XS
M#^0)YI_:2!>1S.\IP)\ELO"QP% ??(;C.]5UFTJP]_ZV=^?;\8M<$=QG??\&
M<DD%ZHJE>JU?4J6R!/[%-88ILMDC'W4B#O%<S^FX\- 2[ZH0T6 B&>7YP/'5
M#UMQ1NU^A(?O]$ZU<CEIONE])<P]SPE<D=OV ::<H2P9*IL[K;H>U:&GD:QZ
M5N!F,$HX0_'$H+4)5((M#K//6OO(Z,^MU>;> 7ZJ]_JQMFJ7W!Y++BDWT@B"
M7=M:/D$]\(^!/&FM@[OX'PL\C!!!YJG\=W<?DI]44$'ED#"^IE0QM:XWI_]X
M=W\XIL;CC;&-7K@#P;L.+SIO^-A44.;-:GD'>I^N8;-%9?QA81=9TX5I=_X&
M2NXX/9>@N@Z:A)]NX% X\NBTI@ HFVX*, $=@**IE"QUISJPG\PN[++:WO:
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MPM2?LS^&'JBPN8JG*0KP+P+033]1'@W(?18)7TG_QDFY[,A"]=?MJS!QJIG
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MH.:^SYY6.YV::M[/*ADA-_X:-4[FFO(5>>YFM'A:_0I]GCW36'#$""D&#"5
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M+"T,F+H/G*C$0=<'L% 1%\RYLJI7G8IL4X]ZU47KPQ<>OGTIWK'_7#_]ZN-
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MAC^J701<6E-;.0 "%NRZ]!1!C/,?9=YB64#(7RP*/LU<?S9Z*=_(@B=+&6@
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MYZ5X+;L0Q9D6_J6KMW?; N-X5NPEJ?9I.3UX>+YW=)RQDZ*JA.<1\!0=T*(
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M*K>G1]D:0[>T.WN SF(G0LP\X'W+-3,HG(=(O^4@U&-/]@:)IZJBKNR='O=
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M$2AP8..#S>L[U07ES;V<:VN5G[$H_S-S[,;_F?DY@FCJ[Z 0M//-!#IL($>
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M[WB&O-*8;DLJKBK9O]<*F]ZZE-V;>UJ)!:T0GB*'*;:&PY;O7Y8_%O"3!U\
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M]1&[3_Q6MRO^$9Z6;@;8?>%%ID@TJ*6L]="84:[U=9*<!*]$W'FR3 FCDK)
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MU"""8S@+VS[D&]L-ZS/I5RF6'6TBV884*6RNYYQU3A=M7H."M<*B;C9J&YS
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M>\N.SH('YDO:K1< >AP'QFTA2,[J^QS6QZ2B)79X0UD]/;*0U$ Q($CW%2I
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M3*D?OG3Q?&L(NX^FS/WD*U$(2=HKZ].J3-R'FH8$1BFB@"\;K:X"V =?Y4O
M)^W%O-^+20X'(26),X"E^A T;Q:,6TIIT-!<0$ R6WJ(92BX(B78M1G^]A)
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MLJ35QQ&EEX"N3FS;HM[P27+3\H_?CV<6BCX4SJIW1_ER9*U SD5Y/S"KOK^
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M\O7"CUO]T2,+HQ-3E>C@71!?;KB2)-X6;4_98-/83Y$;P-XQT%YS">C6-/,
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MTF\@QGLJ-3VDZJ6>!6,B#+P$A37948?//UA85W=V]^T(V'"N;A G'N2_,-S
M0W8$SG@PNI4U6#!Z9=FS;<!M?WRI.HZI.F;OB+<R_0]?X@FO)*\NJWN-5<@A
M<6,_'>,Z_&!\/W1O#O_)^F;VEZO,F!=UW2L83U?5*H)3A\VF\V"3W8),R5OS
M3A-W>Q\=L4DUQ(EO!*P5Q<$;F!IL"6-*"AS$6(FB>D?5]3Q0N1"*VE"WZBNF
MW?PQ=1[#21*>MFHQ'ZN-$[3UZ5CE>%Z^PAQ5I;1T1.Y!Y*"OV!+Z1P"AC@5]
MM*NZQD*>@SR6/ZS5BRAH4ME-N9_1^.Q4.Q$.&<3R'WP V:7*GNB%>%ET%3+.
MP&]/<5V@B<F2=(Z3?2AG90!O?SQ$=""F63%OL!]Q8MC2"FV6S3TH181J(M*>
M19-UC00_I/DQ_F-<!'&)VFM+_>-DDZ9VD:#Y.]C2)?DF2J\ZE7+TC6#W *&T
M94>3J(C<@A^[O<KL(=^H-^(QT(O"QKNPOO1[A%&48Y%>JXU>T^_]0XQT,P7L
M4"'BH9Q<3-L$,RFF'*-Y40_C((S5^NH9^5X")CEDHD3$#]JD!Y/52/M1&A_*
M.V57WWY@MC*)('C!)B\!J*=(.CPWSC.,P%B\$.'+?,=V7[*3J%)(5DVC-<(O
M0^QBE;59(9_,K)%L^$1S@.Y%5=-(26YI8V6LM?_VN%J40=:K!#<KKL)KXC=7
M7Y">2*O"= B=5[^J=UJ)H_X$D^D^4CUL<U@A]RKK!C0SQ2*%1B[L*(Z.'JSM
MG$BHCA\?T-H^K,V)A3L4V";IA#H<V*\;?D^F5E-_J4*\30EX]T\W^RQSXAE!
M[1YRIWMOWT*L7-G;I[6#A 0=QZ4IUYXY"EM/3FYZ:#&W;,2""T#,(&L/; \2
M_JZJ(SH41A:PN^7H-DBZT_/6;D:3?<TWT:'+@WK G]X9+ .&MS W4MKIN\[-
M>W4MLX^-]ELFVE;*\WO?^9IH_=";-WW] ]?5^13SRNC2N4C&JV3RHBDUGZ%Y
M#X2J8YA)7K8013UN"!#OSASMA!S?:&1%!>.OHEA5V]Z+;25&; +Z59M/J%;0
MT9,)AV+KF1CG1OE'SC$R@W;G54O:;=XP1BP8QZC-Y)7:&;E1<0F8-A-LT*QK
MOG/_\+3HW4/*&F+F'H7?I-!_)?+_;Q;2%1$\?5U;Y!)H)EMD6.H0K[6$,ZYA
M93=D?")W'EV6NPAI*SPF)9 -X.1VYB51Z1_1D-;-"?UYBC#=,<%8#<]2:RKK
M.[+<XJPNEP 7-5FBYW YO"Q295GQ'FMWX\LI_6@G/@-WTK-H<^ )%6VG\G Z
M0Y.W/%*+.GSPQ^%&I%M%9:-U&KT.^#N"Z[^K;O%_%67XVQO9MGS%_3![6LJB
MW*9+ 'B^#CK9M2+Y9\L3ER9JI)WIV3E'J:B<_:YHC*GHF7/ZX[[614M2\J@B
M2$R)35<Z(P?O\.GC.F3QX6_?25*9V=QM4HY%U_%&&[GFW@:IT(P&K,-Z;>9T
MG_/3KVDLR-FDQ7/0$4CO'9+H(AK^C@B=NX0M&W,DQE;]H1N$XPIP9NZ.6K3)
M?R,ZJ2#*3\:L^O[$=TR@M)!!YD31)R9!5D;3[4_0\U_MIR1"@_8N =+X>YRW
ME1BP5/-+B>_[@FS?OI3 G9D'\>/'WX!8<'HRPW>&94:YN<@*Y !R9-C"CI*%
MV_#%3!;* #6CA;:?Z!ONG8"HN7WE2T!3O,#$#,/ZDM]VI9WWS+Y\*<>>G--A
MT_R__FVMR!4M&(@,*V\VOD[2D3.I[8-EEK>(_$H(!XO!6Z3=O/8(M-CHEX>8
M0??BBGN/Q1IX_+FK3XBRX.,-[S'%:"8\]R6@O"D*^9#I2/+(ZN/$Q=UQ"@*'
M(YRLY2*D KF+G"IL#?Q^F%T+*4PZ<9@0OVYQ\@B1[3UR6NID&@]_7SK#Z4G)
M/Y?UOO(_42STKQ6&9=#/A!E#0G^ZE!N98=PX*'6H9.G5.9W9'%B),#?M/T48
M@'$%1E'.=60!]U5;08<J)M6Y]@H+\?A(U/E8= $GCFR*7'LJL\TEJDK"["F<
M/)GN$F")A"-9+J*%5!&[$XM>8Q[[/U.>T6J+. /CL8F#*V9]:@Q&GYCB\/YU
M#8:@/VL'W._\0S#VSP@# ND5KHEJ3+J76;2MEZ+["0[;QEB%26$$VRDFXN9A
M4X@;%;B?54F=OR7#G&M9@?FOD*?#W$W%5G(56_B7FF-)+*Z(UE3%@K U7QJT
M9BN(]JVM@L2R$,AP4EK!XXA8@%HO M^'_6BJ:\O\ -@Q1[N\O'N50.9P992?
M'-#8PIB&5T?=TYZ.//T1?3!GUE^JUMCQY6/*H?'@C,3B.,)C_! [?2/VN;2*
ME;N .^'\#_V3HER]-%"8AD_9RG-7["N;2AT3I+_2 R_UY6="_$&^JKD[\C<V
MHN;?6"EO#R&2X;>!!<4\?'Q>=1DF)J9?KNSWK]M,CX5AAM>LH_IU X[%D<WO
MN^2NBX.32FHC*VA,R.Y,$?*-O?C>ZEG><XF6B\GN<_VQRL.J9D8YD3TK=( J
MKE33V=NI('=MNBK@W?E>ZMG$F!2S\27 >FUW&J\EMM"Y?F"#_7."6VGS?Z-M
M N_.)<MU?7(3N>U<L)GBD2.J?FZ5Y8+RB?["LNH>/;6PE%/#T8>X82L687%!
M=86N?G'G--"&=;Y^\!J[C.@>EK)37XI7[^>D@9O72<5*08.FL^99QA:YNB!2
M_4$BCU\Z6D:6IF=_W#J,@D1AQ="Y'4GS2E B;$$O,.WQM'$(?[V^;AS3IX=K
M3LD:2E8S"5TFJZ>X1U\ITJ_[\N-$Z^=%L)4K8,;:@JP^8&V5[OM0?$MTJS1G
MI/?+W!,3J_M+J=$28T(I1@U4)Z]FEK;E>O&%ZN,'_>=A5^"C2NG-?XKD7(-/
M&[^ 4N-=4-8_F/5W?QCUD[.]Z7+G6<6Y +=9=W;\Q#N7#_=U_:?G'Z88WEG2
MH:?M]_M ,M';1.4+\L2]PGL@7H^:0[%J;N.&-I$M1 YCT?%7B#B+*W$5WO>8
M&J#?MU%)G]]&S6YSK_AP^WVRB;>5P##VY<2ZWZDJO;[YY,;_OF03N'$0N5#I
MD;H(R4&=?OH>W=X(C-,NWPL75W:X*S/M<<2;^D.A\N!KC-K(()A&FYK*+JI[
M/I)Y/$F0IL?7*;+^%<[<%SAT5QNT.SRE+6XC ZZ4C*.P('AW(3H;CY$Q(&OP
M%+)3P@O3M[S17OQ\2>HB3@.2U9OYBW5%+"BUX@W/S[LO;O*YZ-NJG%QX5>L^
MD$O(*N[?;Y#C"+K;*2"Y?-#;= 7V@/4K?XEQQ\JKC]*I7B5_G\%^147D[I(Q
MA<]F #8_KLN="'I\D-]G.(WT]<;Y^O(UOI,$AYFQA+VK3&/\(XH >>';$6KL
M*\WN=?CU]A.2I=&O)$@)=F87M2SW-=NT:KV:6<YI/:6VC'K0(M.>Z1)UI)Q?
M8/R">A:V)D-'*<$=5R[X$69!Q$\KK'*;:!:P2E6YSS#SO BHGBZ\N9[__/6"
M8,*7/P=;?OEG8]]KIHGQ<X>$CK79'B@$RJHI.,PFP.UO&+H+(!D].;P$[)VB
MWV$YEYZ9,9=][BKP2IZ^(?#DP;LO$FS1![2A 6.F%T"RDP06%X2%G>2<85Y)
M;BB>#J>]QX#3\@I?UOM.'Z QPG<DQ/V9^G.,165(1&Q"I&9<[D$>J -LH9\(
M&^"DG%E*:M6ZU[DN(O*J@1/:P.K4J@&X2UW[355I&S*ZXUL;D*GZ%$Q?"2N*
M,%5]F;DV]:Y1^<KZ<IP"_X'39^800ELG+<*IS79\!H:GML9M&S6,XR>('NVW
MQP#8-9#QQZ;&[?"?-E'"0B5F*RI8:'9WF1:$_&VN;"^P2BVV%/$'NVR+PNG>
M )ICQ0#=@0SXEA"O/<RCL1'A]CZ4R8E_PMZ^^A+@5[@E,@5M%?4"+48',\JT
M#N:U763+KUR?!B=KG-_K.!?RW2VH]WBP--'"CE^ JDQ&2@6V%2S8&7MS@F"_
M+P&E."Q,%J^Z*,-;/1(#K1Z:<(MK!34PNICZO3X4ZU0GWD &PVDK#P+G><(-
M?@O7AP?*Q#'VA+GMQPG#WIY'?0L8@)7H=W%6;NRN0'-GYKR.VAC][[=!Q^S?
M<M[ON028?7#;."#:J<.-=7RQ*HG&J;%JV@WCAT8".M]KSTZ,7P+&<X<N :1*
M@EOP._6L-ZIRE\D#E737DNTK*YHM\T](\QQ7%K@\&<XV<'>PRW!RO'GEL&^_
MP4ZL8E&W-NN8X0HTCPN)IYC8M'KO[?A@>?.!IGNF0K_5]>!"J_+)LSY,[D7*
M&C;Y#EH]:.75LJ;7)]=IR_L-D3YOTDG"Y&SRFG>!JX-!<+JK@PW"]BY["655
M?5X&7MP[8Q$3"(AAUA9HXZ<<M3PA"3C_:"AW>N7@Z;ES*C.VSFOOMQ9?%+E^
M_.4U2^VSUF%EEZT-?6Q2)OT]:BVXK)#C'4+6D#!O)/P=2J\W3SV6.Y;=FOU5
MG*=0EG"[;1UTVK5D0KK'OA(=2N#&PJ]? D(%%U'08.1^XDTW!E=,W=<'?D>6
M-G9[;.SU";W'4ABSX,4+TM9MM<@,V]HGBJJ164Z7@$TN_5;03\_VR7HH6LP-
M(OMIVN-#I$/-<Q43L1L66(?7Y]]+!'V0ZE1S/DG0/^*J%L;29+1M7A9@7I09
MS6V[<)8S!2QT@EE]I1QOUS/J$[_XNL(E")(9+'4*OP1<0XX\/2O'\&.?$FA0
M]@3@*-?AB:(]D?T=WZ%IJM<X*#1U,P^R)7?0@]H/8I>%"L&[U_J! I5%/XW^
MC*M+:W]W#L27;^Y_BV..M0Q3O;_9=O=SQ&TXF1\]T6%T!,@&S.1+C;Z/_8A2
M,1IU*U9K9[Z!@ !9/YD5E<8C9&\2BU;SE48C[D+VP),( IFM#;JMG07>A@B9
MUD&=MFLD%Q>7%)N_M<U[$J8)O'OV+8D,]BJ!EXV!E\^5X3"I'<QD"[IQ"7 \
M"$J7')TUV/(8GERPDQ9K-OUD;LL=VTTL_(>=G.7BG_E_T8QPKAK'='K*=G16
MLP6_GEFOSQFBQDW/,;#$EG!OR-[=[QYFX>7PP5OC<$B?(4FL%BM%82'53:Z
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MD J^U@Z7S8%H(/B;C-GS>HU2W#S5WR+Y/,K:*1,@S^6>TDQ4_>] C UZ3JQ
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M)N7IW9P*J!2:7HH=XJ$]Z;,FO7&:]TUN8J O=%@K9"CI]XZMQ=C?S)*(ALV
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M$3!J\F]0U?=(]J@F7VR.?IAL[<::!1Z.2KV<)CO\8T%+(%E$;<"O:0"EO"-
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M+5,YX*51(7E'M^_7>J+Z\R5]_&AM\GB6EIJTU:/DCBU!]^P/0\NWE4,9O:R
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MA^%,XT#]XJTRX3RW"6OS:?7-V:8UZ:);\0)JLD>SE+\M @[--*16S&8HNH)
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MH)G$FZAA-:FX"Q$1_ID9UMM3!VHN2V)ZZU+S=:N0"GC;0\@B=ZL 7^N/97R
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M6$Z9JT=%G0*P)LCIM44-1B_J\^-_ *-D../B-,'M=IG^*S$]5RZ[?DL.U07
MJJP$;*S+?RG,).A8--:,E,B,]*5O[%C%2KSS>^8O1+-C @M";<T083*HJ:ZN
M0<;C$"-/9?8T*A;P(JK[A^ZGK_R=T'JVAK"-RUI2(A3@R'X&[X^BT<.'EW(T
MGG9Q)+#+P5[!&@ 6Y ;T0B&O'SZN$*I!D/M:-3(K9>\&DXV2C./YV6 =OF?,
MRCP+ %\Q9$;SP[HAY< $M#OPXLWGVZM#T(MG/[MIB=9&'QM])@VU( ^_8PCZ
M3&_OOXZG9$(%J(9>'\I%\/&A.XKNS,4Q6<3OS!1W"U>P; @A> 0'!C2+MUE
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MU3W'T#..<S?V"EJY_*?V'+0VUZ6;WZ-':^$ ->#%!V\1@;L@HRE28U"3)8A
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M/*3^TGS8"7<+F&Z&$'(K^AM]?UW#.Z#2ZI-K3Z&AU^AO @0/\DTPY1<*O5Z
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M0 \C,)WB?H"6$_PUF%?#W:N^ \0),7ZF;C=O:,UP#]0NLJ>M*GKAC0J]>/5
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M/5*4J =2Z0(S[Y1B]WY-2;]\&YM')5QACCX4EO3X>[K91Z( [NI(LT:Y2WG
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M!J1D:@>D.Y<Z7XYZ"GJGHOL3%Q+Z.>&>;=)X5Q!S6LA^Y^O40O+Y]@7W7-G
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M/D<#K"O]]@73/UOZ2!2D_K $'1LG=8;2 $%9.1J2\,;ND0RZN0'?]/]GA]T
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M%[EX@4,HZ]DMTQ FV9_S;YF51EKSK&U[D(*2?N""M44+T-?<1'ZI5;[C*S2
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MQLX[02-PTV\[Q^8F.\^P+"N#F*KF?&HG,0)OW@8\HWAA%.J\:*_2;NM^U^9
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MHS**AD@6P=[(+E-SICR(1=<?% QW\3A-''GZ=@-#8C1S9^7]Q?0,DY% &=2
M3AEL28[$C^I:6O[W=$CL@T[3CN[43XF:D]773:$U8L^?^F':E)'JN/+<' =
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M0OP755>]37NT/ODBUE=07[(F@50C&J #1>(_ %$DDX-!N7.A<[OWR&(TP.-
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M9U?4?%Q<- R=99;6%(MCT7O4_4H'<&XV1  !)]^!CBNQXZ%VP]Z,DNVG\]3
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MN>CF]<X1()'^'07P],B-]DD%9C3:.F\#&\!Z5TJPDFFY>D25/E<H^?6#+.V
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MZ$_3IZ)EAED/J-)/)NR/EO;JQ=7/GOOSMKIDOJ3?I,O^7]G<OQ<"JO*MPE
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M,BBKZ2:9/Z6-S EOOYL$BB(J]KNX"+CQTMCSQ?ZZJ!A] Y$30RI&K%W'W:(
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M(*>H#1VLPQH15,78Z5+F1F;N$]ZI>-;DL7+F4B-#2=G?P&D+SU 8X!5G6@K
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MU$A,036;N;]0C4-ZYAD +NL@'GP1B-H?V*[$EZHX,E1YLO<L (!*XY32V]5
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M<U#BQ.O8*328T8VO8H"HZN-F?<77M(O5T9!5[)$Z-4.R9N>#]-/K"^B=>0K
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M"P  J";+QE9_IJ0T*'4(I+[_JT#_HQ+E6%9 58G$]/Y.'<)U.3B)+[W)K+$
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MPC%"7$;=7Z-YTK+P5KZ@T$@:"F!2V%2QJ; 72P%(G!9!]G!PT'+@*-O2/GP
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MCE\U)W?Q2=+>/G9PO[/'OBH(+?*9 QQC&RTMIS05/I19;HP_##"IN&Y5.I2
MSD O $&&)MY-FCR6!F_V+LUR=W-XTO)^6?JA LRS0 X7_I*U+=*8E5[,HZ95
MT/7^WY*G_GMAZAA&]/##RB]V1BXU\,=;7G.OV$@:K)5N;5NU,> O"C5LOG(]
MP<(';#S\?+3JS]::]>#C]P: N'7-H+?=I^"$SPODAM!7D55)Y<&IY)) #FZM
MT>([JIFQ@Q0 &/2X*L-HV&IHZU!4[:_;)6[^=;O$+U/MV0<BC+8TH&A+9!)B
M(0NEU#BNQK')RSXBL"\&DT6L:):HW[GPI>*K*NY6_]L_KQ78#F5A>G298ZF)
MI2278!ZG(,4?[UD-+3G_2<U0C\^C9,XF>;S+?@]F_AS>]X*4W-=O!IZL=DGA
MS+*< XBJZP0QU!U2T74(&WP"2 .3,3: 4EE8-;Y8?KXS\5,R=N<>Z'1T=8D"
M"/E97X5FJ:4E/B189]D[G;HJB278%TR730=I,\_)'A@_^0*_7V:H$7A9PRY\
MY^_2^OXC2DC O]QV76A]</(8TR2NXX]5"7'K_*ELU!3 3>#/NI\-A!>/:^>K
M_=Z)IAV73Z^7 T7K3!!2*\=VY80"M;:A0M/)1XW%!H0Q0KR@A&^TT ED]PSI
M@ =Y)?[>LF8_3+M1%WA^4PSSP8G>SFE-[#YCVUV13?1$3<?!&59-:_'H!OC%
MK+Z4'MS)MR?1(*/49!['X2_AK$<M=/B,Z5^9[5)3C2RPX*\3" L,F3+S(2A
M+5/*A).I?G?;!>G[49.\=;=1EAPSY>0XXN0.YJ UL'=/*UB#]2G_/[.K$5]P
MY$4!).S@:RD FZDP<I+E^-0HSF!KC0(0G,5!R4W5C*2[M<CJXKYF&/,95B7^
MVH)T 1_^U?3K2/./KB:;^I9C^@7;)4Z4RI+M"SO23_R2_@B3'U]Q&M3IE!J,
M.9K8U[,[<L:#R[169O#4ZM%>Z9.3 N7$Q2GHAQ'0<^#;Y'C-WWCX1KO()1'W
M0JNK2[]W?15.GXW_-C9E;GN2W''Q^'K1J%U5UES 7SCFQ1G)S&2;<R5>R=>W
M+!QY, ^_[_L*1&_JN/VXWC$$[8#@$LO(-[>PE,VV*&V\MOZ!?IC?\LWK2YJD
MR2U-Z#1T&8D7JHU.T\6[?<4;S90WC+L3QTTX9^D!S.BG?!VQUOEUY1(%FN_J
M;),R&M(,$Q]59^?N%C)N69^!]2U(B*^\X,U#R][(L2N9_<NQ??<9EVPVK0;:
M0'19%XBJV)UW/XMEHZ.>]-=^_22T3W-:;H<?U[/Y=2VKXBN-6C@W1SCA447P
MQ!GI'/-Z_W>N+TS66OQCE5JLF8]+H@IO<$YI+Y#93BR7KC!V0.AA'E[7OHU/
M.32Y2S^JC>0K[O9$!,;[/)LA-I\2QC>:C$:K5)5M:@EJ!053&W(G XE^=#_K
M3B5N-9; +RX9!]@[LJ!I(TXK_<"/\07-B-JP#S*6'-LJ!MD/%B^I5]FHRT_F
MJ_AX5"?&_A;UC21H$O7Q XP3:MSX.U4I>6J6F_)& 3WLA0P_RPMYLQ07%AQ0
MH57XIPL92L]ED6\;06X2?_B5K&CFFNX'@9]\*,_.%C(Q?%TD 3@H"S13,:D3
M'O/=LR 14@>8PM R=S;7:F<"&)OG)^?:,#II9B-E,4V+A*9^KR*]A.^U=\MW
MUA)&8_OFVB(.3X60-M$<3]Z\8XM;&RD4CE]-:U! 1$'8JLZ(&IPV#8(.U:UQ
MUJ@N+8%QKMH[F(B^K7IN%A\("$RG.FG"75YT:,*)="3XOP4W.#2($MY]2-2U
MIQ:.B\50[0LF]/3#2P9M'.2IGG(,':676XM2 !=V6A>_AH&7&W81>.H5,%',
M_0/D0,4_F0*X- [\RY6K#G43\1NW""%R62%P/J?%&@'S$Z.(M7T">B$C:^K5
MO]R-3 &\AAM9$TUQO_+8$WT62?!5:2*+B]>/M8FF8$G"13Q]8^8-7.+(BTR9
M::WG,YC5EXCME($&.@)#Q'K;BEBTTVB&/C0 T2)1FA+TZ&7Z<R@%8/TF0@B9
MK?+Z/\9?:XT!2\'2S;R<([)NCXZF!MVVEY/X?WQ^TK>1^^Z>05][%$"1?T3?
MA<DSJ?O'?:/$N 50I6O/XNX4]>):^$QI;QMHHG2'+?8T]/,H@+/EISH0M(4;
M&1\^W,_:$L\;<,,F&Z)_/,UX8))D')?EX6T<+<_K?](6$["D*@G1!%^R9C_T
M$6PL(Q_YV %W4ZUE"!__@\*+)TH-GX=Q#Y6[M=D>V('*^N&@0"NNTABRIUGG
ML!SU44+ZETB'*%R$""9]O2V'IB/*S?'\YJP!A?N\9@W:YI=Z0V-_\T*)%&.O
ME2SNTS>4Y9QU$O+T4*D04V#H)<KN5[X-_]?'F_[KX],Y'(3^S>/=X"(P,])7
M!RCD/?RZ.P,^.,T.GV9^3LO&-YY3_8)4HKH(_=N]\3R8).D#4033L+L]P#5G
M@+O<7G%USZ H?JSE===I#7]/YZ47=QG.T54?N$ITN=-IL$)9#;\91P/HOM #
M .LB Y_*.6*C][HJYE=/>70G!O%@Z9TC KKOI!>3O*6%,;@RCWCI/[>WM,@>
M_N+F2I:)0.E;.^!&2H(@M\/]YH6KQ6>$!XIINMT*D1O7K:A)YIB_4G_G<(/Z
M>^EUD4?>SD.F4:Z.2I7?=F^?K?CN=C?^O4F1>T/B1M3;$:/!>T >^&#6N46\
MR#<-' +3*)Z'2E-Q*UXW=>&K21VI")4L0G:CYZW86N;D/ITTH=OJ#[,BO'F4
MS8;S]DO<O^BF0"[8<YR78KRQ_WL\#WI=+[\I=\XY]7V]M=G<_:/]EAL_>[@*
M38U4:?C!/:!*PBQ1!%<;@6+8V&NH29"&. UK@Y86?SYH>,-Z7MW>;F#.CVH'
M+,OU'+I7R@=JH0!:M#1TQ_/\<%I[9YD3M,(:M7D]R8%.5:?#RV*\@Y$:[^DN
M;HS3C'TN(IAR*_-(P+,QZKUHO!0-460B45O=1K\K\^L=I[AA0QOE;^1QX&69
MD_Q(,O,#+_['3TB9/_V,U%NFIN6^'U-3UT#/40!N0%J(B[3Y^G7&#T0=&>=5
MA\YN-OL3SPGQ1H EI[#BZ5NKBDY,3N/X/*)[]CFT=TMZ_;K(6B]B2KZ+? LM
M@7=?*/B %)V!;VSL]X7HLR;\.%%F_]@,(RZ-+);*AR.<10-WY@GBF-"$' O4
MJ-^H.--/GG9V$/H^*_VKJYFTG-ULR4?1[%CK4T&R9M;3PJ.2)@O5U0C<-;P[
M0<\_ NJ3UHYBPW;4HVX'&>];?TH\^3ZHILW93%^W)O@UKYZ4@+J+#XGS<8^1
M3QKLRD!/UL3R;AW.,)OM_[93[#30W\,-(2XJ@NK@=J=%!!/VQ0&WNZPOTNE^
M->)N)Q10 %USA?;0_1($ZL?#DY3W)LN'_*^I/34"\L:WV+*A@R<V-W 40)3L
M-Y46H1AH^PTYFMG]G*B]@"ZO3<MKD.]:K<J6/C'6\D9-'NQ)#EF&'R5=SS5N
M3<G[_8D)-"9!F8_RDXO/P"#AND@ NH%,N^[2\HGMQMO?$1:X3>1$K3DV>L0/
M>(4L"%7CJHW1<CIH.)27^UGB526VD'O^%_R%ZS+W\HM]I?%8E#R,T4D,%HRQ
M%&?UMY6][%7B#V/A?_9J""5!_3,/=88UGLF+WP"/GX"BJ8&JXYAOP> TO*<!
M%C'>=\H;L=)(A5-N [%4C35AYTH9LN.6?KVS=PCC#T%)AUIM*_ _6UB2'1G/
MNQY7R":DG._Q2(SA7TMN'_^FDMHB@AOM;"V-:=7[XJ0PKN(AJ7UC^$MT[M4&
M;!Y6\65*%$][X@)5:AN^%E?; ;^#6P;2D1G-=$O]?RY";D'39,P?WU7T'P8)
M"9^;V][[0J]P(Y'@>"1XAJO]UR&5L<E+C)PZC)%P(:NW=U/??8Z_(ILFD#3_
MJE?;T^_QO.3Z5W6W>9&4U8TT[V\P:XC[@[F6!<52H[+9V%ND6,1"VFE^7<D4
MS)CTM2]U#BT2<*3&AG*7O,%YM]0;[?=&Q]+GA-7.SQLRY#1H]Z3HJXGF^6_-
M5$/I\*JFIN+%/$%YWT.U]_R)'ZL,-6[^O8CE;PF.3#%LV><E)+U+)G"L-+=^
MR$?$K[H^5''Y?:8\QS->.?#3MZ/:?.7(]!W00@JB4F]F5[:K+2S34=&9'W?I
M6U_72()/?["!!@!62 $PU)%2*(#USQ3 "L*8 EA.78>=Y?8%,OX*MJ'# O&A
M470AH"K#SB!#S&V';]Q'\/Q#1:/NXXO<5),AO*,')O^7YOT-,8CT@7P5/B0?
M9HA#O/\-G;Z/</OCR679"FB>ZVU/X:#J,^U4Z @:93V''7]' 2S$0LZIR!<+
MK&QE"N-4A!\$1YJ.\IGY*[805"05J4D;!)86^,6_5.](!HMU-8Y!UX,KUT=L
MN7C4+D;P#SQ]K<B_I[-\7!;ZS[='^4>&"$O''-M0HP<FXVG;U$I48&9<X;2.
MLX^SQ(E ^$CQG8.%0^Z8[)KU+XQK[XG<%,!ELA#L(?;.S&\\PNI'182.&J'H
M$:Z8Y?>*(=>730N?#33VB3@M\C4%X&[ K+LBXTL6'':K5C@?(S5X]R4\5#?
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M@1(7?,O 8R,+H@3^#^YS#J_ :"G\NO]+![$CBZ?L:*?C*,T^VI:I@M49-0I
MR-,$=K)4F+]D, >'%"LMO<M @GP"*("D-0\<U9+C&Q0'F\'5S9JC9#&I&H]+
MJ9X,KQX[T5*M\'DT=W=">Q(6_3KF8\% 6[P=QKQ1\NL/HSF^L=^"/YLE[/G9
MEE\\OU! 7[""=,%#"$"B'-Z.E;DL!G5CU,X^@:!E?EDYS$A;*&4B13"*'EO'
M_QHZS79?R.2<,3W@$J!,1T4#$6-57#&_J\1>GH,M<YS=/@;*$Z5)'QI%,+V8
M4OS_+!<M9QD+E+X]%WOHJI,01=]MQGV>#;J^_CQFBC6"8TPHYTGA=2&Z+]X
MAC=9&L[ZT4JZLZ;2&3HC?@EGT*1&ZC_%+CA(++!2K[8SELG?RZ8:=V7\W6&I
MH+<!HJ#C\VJM7=9=!7LA30CT1<BJG/%J4U'$KSR%T=B[HX-YBC_35L/WK4#?
M:T-E&47(S! ._X9V'-]GO>J=;)50F 2]YM#DN?I0'@*SR#?L\98S-JRMQ%KE
M=NJ[O$><LI<_O[Q$2[U3Z48=TFU%V(-."Y687H_P6X%DK3KAV&S2^Y:K&-^A
M:+ EXM?B,#SL!N;GP^FO,8FHS2QYN?7:"2(+#\LRQ\8N"YF*^-N]$>"@97YO
MV*E$EQHQ)_'..Z(\,CVOX>S=2OYOE\U\/7J_JXU&V;VL$2:#S<+-?W5ZWCEX
M0MT/847;045*'_LG8QQRU7CQV:I]=I5S27X0[W="!4QBQB^$$U56&"TP1&6"
M)A3!"%.G?J<FL9[@I)2_>TO\JA;OW5VYY8""U^>SDN]^MJJ])<&@UE\B?MT?
M>!\?AIDN96P/=%4J2_:4Y&=YX:UXT>SJ3_5UXS>JT(2)G^EUZVK@Z9P3[T.E
MX(K4E9*RAD,MGH(-T]2.*/8:>8FYR5]OM,M$EQFY(P*EOB_$>IB*-*MH$.2(
M#_&T"(\B(L<(NJ:*-FV@'HLJON$KWMT7,,5QL>MF(EF#,W"=S$(>YN7 9_C+
M!(Q!&/!?Y?E3];_()?ET'D:?2E+S.4]1 '>47UWQ->SL-#+>%#.',PZF&+?)
MU/U!.9%%1GGKSE;,7(__D./[[VZ+XBI [U LELIL21#F3<D>ALSOA^\6J"07
M2$.](;$IN-_,JNQ=<.EA,A"O:S1^J'C>PJQUR'6&+>^9FMFXX,64LV2'4I%I
MAPER&X@J]G8">@JXR).CDSTU*T_D4PH>Z(M_''7OXWF Y#VXB<))[L7ZKP,A
M:7;D4H/)%L(>D=UKM!D37'6R@LWY8X 7!&WY"6YM8D_=V?PKKB4OND<\,2C4
M>>778T>K/#;ML18@" MK6/"\RG(D*R *AP7_TWKM__\4X.XLK)'X%&A1?*L7
M&Z8U3J2"%A2.^%#ES[GX?>2<:Z]RQ:DXZ?=EQ$AA/O'D4,L>S@8@MZ]@01JD
M'#6F3=2Y<8?4H5YCL^Z&&D"O.[_GW?!;CE&AAG$SS,J_J3&JHVL1*'Y\-HC+
M?[<#3!;"72B/3I@U6/WP>Z?USO(%KAZZ$&-FC]1Q9'[C<PK@PGM\\<(/>R C
M_)83^685Y+.;K!-OITWNMGIX@J*J[@W5X.(U-#=\@ *HDF]57>L T55#&[23
MKP3GMAUU_R#+Q<]T%S'^L&FJ!_^ITP].?K9>I!*C>EI\7(?[041R?OBVH7C'
M]T_!X>J+0:M?7Y=T9-))#6U3HYE*I.R^?)"T^5$64Q[NRL%U2)B,+LG.O!XA
M//6+YG&LR,=7;"Q>BK_4#,?'4*GF1]:L*]O@);)6)'<!I^#+!Y6I3MN8 'N?
M&/Z+GR<6 $KQT//C7?6JJ]]E\&7RRK!B,8GW^]%?C@7+UX.AF\#7".RCK ^@
M:_G5XVI2&T-X:75;?KWS[3GSW8T?N4I>O0JL.=XR!@]3 $#$0C+H,M$-:Z*B
MB-U_4([UBY3Y./PGM<9\;N>^FE/9BF( $ZZ-.V5 6++.<MG#RA+DA"IE]/&;
MI0#B=G]W/^\F557O32(^G^1H>$U90N>8<;<+%[(XS?IS\5E:*=-Z4&]),? W
MU32J"Q+\4A\UM02_(E'-2\YVZYK5@N@%@O2*AYDS1KC^Z1_\>U9#FY#.?X"F
MD4HA-F)01<DZ-._\]Q^5=?05WP2?\2GR%<R9;&YO0@K)M#@39(P*3[9_:$]B
MJ8^N0MFP\Z_9=2[GXPL?M6ROP-WG)RPWDCPMK=HKVFZT\2$R&9M>PEA)7QK5
M"5)Z8G'?IO0600 ]\=2XKR12),L^1\^)I@ZG9FOYRJ/X$[S5-*.*V&VS!AMF
M'65O:/'>OEK..5/9]2+VX^S9QN$M>.R@U7$;!<#K=(:<&V_FX]/4,W6CQ4CF
MV0&V3C-LGC%Y!O=+2E!AG!>BKJ]#(Z2,'NDZN Y'5I[M1BEO_C/7DTBTRT.<
MX#8;KE8/KXX):(P6UPIW]XG,Y^]@C3IWY08PR%;IHN%H+E_4BR#VMJR))8Q?
M&TE.* ][B X7?\WK=E03Z6E%T-3LX&V!YQZ6=6'0K4&(L+D;N/R:X_FIU(+P
M:C Z"?-EKT_B('1^EZ=5PG)U2;F>;K=X(.]]9'K1*#B!R/Z@PC\TNW#85Q>G
MXMXU7R'?NLOK[&4)>N_JK9P$F;59_UZ:&R<GP>4"B#ZPOX66)2O .,=0E_"K
M2VVG/\R71-;,YS5I8E:9M1FH[5HN!C'-/,N:^'E"1:8SQ! L8T-MV,<FJ:?=
M9!'EFA-KO4F</&%KY\'7[-[EK]>7FSK]:5D4W&;EWTF9QPLF=UX>8/&W,\&J
M%2I;Z64763GO\MFC^KJ@6@>:T['.DK_I")?0BNB%--^*VD[0U1EA%OI ^KB&
M(_IQN16M12:T,(FS++T^MR#,:E9&HK-#L[(<Y[>MG<E/RD;)_4'3J(C+Q^6M
MXT1WRKW;4[+C7M_,I=IU/>/)2E7O/*)B;?%>!&Z8&!Z1W\&*XJW%"6"I^E%C
M@R]ULYRZ)W(FQ$<RJR>(\G@#=RRAG5=F;(Y >&J,DRLZWIN1X34/Y?TX35KZ
MH7D9-N/HIVY]Z*Q[F5W1I @IB!=[-W!UQ/A.@P ^4WYI=Y(+XQ<K4U>:U5JC
MQ-,KOH/T-C,=TD[CN%(-T#R5BH.D4@#<:O2;$"J8EP>&9'47E[A?LIMS0<N+
MEI^:JGSA3=.''0F#+7M8" 5P40A+*NUJ$[^\Z?IVNR85/9'CZK722Q_3MA\B
M$BG9^M3;VJQ8QGL!QW(4P>SWV)W(TKMT<2V\4;((#S3.*+L]:"(F<QQ7,>]@
M5YUSRN?6596R?C'X+21]'JO78&ZY!/SPDHTV5/62]BSA$C3-,P=',Y\(CQK7
MMU0T8.1]F<IAEYUC_I=KRR'#U;^UK*/<;M$.Y\62"XOZLVYWCED6-/=,?3 C
MOT'I4@!O7-=W4-2XS 8^]Z!M(V6C_EX65LL>P4(* $+<G$&X&#")AR(<D;PV
M"@+VP_P5'#P[-*_A%1%+%,!SGLL$X)''H*/RVPTP&!Q5(AD[5_4 >^L&XOJ^
M2]#$#_$5/=(I3_GQJZ'@*4CA@<#9<A77_M]E;_6?!/VUM56QI')K6! >Z7_I
M!7FZT=@UJ_[8*![$4WP"=K=YCDU^HC00J>+QK?)NZ,;!8VM]]7G^TH_!(L.;
ME;<I "^CG?G5YY\1C;)3\_%_=8>U]?Z]@B_%R]Y*7=MWL UZ&BVUHZ(O(QG3
M;NB7:2I[L%L='ZT=_$0KP2]K\983'/TU6(ZS?\TYI-6TBCH\'T>*9:@&1\,C
MP9W#,'S$,/D0M1QWX,,N*FRX1VR-$"K+2?^OE!OO<+ZYXW#3F#X^D&Y@7$4C
MS]_.()X 'G'S;E!H$?<(D.JX'K+1=P\93@&XN$_#NTP'W1OYL#O.@I9Y3N[5
M_7GLO7Q7N %[.IP7NSDXI]-#N5.B]%14W 7WE(0&,YS-^=I@BMC5I:./I'R8
MNGNN""H<46:]P0X>)$W<G<*DH((??;^\T:?L@#9QW<(,;RU4UT9IN%^ LGH@
M-<YX<#  ^0GQ?#<\BVX1.V-S#7NJFXVO6#I.]MAX_WCJW>L7*2L<]$72[Q9"
M$JKVNC8?+?<ZMTKXL#0D40#+WG8NCYX^<>FYZ!^[[8;K)K+@(3)C4N]PMTOZ
M'?-C:*.6I/1B'QI)DH=O^]]NJD>+40 O!SX8+!G$C)]Z&^T.$T',SM@R.$2:
M:]4U<->M@%P7,2S1KL1J&;/[4),YOM1$L&)D">0(>2\-\\)WY*\?N_'7"$P1
MC-/+Q9=O7MR;]5-F>WR*@AYV_OQU1>[795TSH[FQ.=D((;LG11]RZ+XPO 9<
MA+N1NQ'L,NYOIQB:O!RS(?ZU7?6SK19F3O6PQ[]N1ON]= 1LF_KR :3A6]SG
M^@.[HE2""18;1Q4;2HYO%[#;H?+\<I(6,U87-]_$-]2Y!M[8_ W^_+K0@%$W
M]9=1T*1-EZ]8^J;^N([83M>4,7BU-A3A#HE 71Z+KHVPK1XWO4-G-3D_69K7
M^FSO2V=Q>1A!&YYX#&[)BL[DPF,PL=L(QAF)>.;" #NU"T<53!EEJ@P,'*]>
M!=/PU@"Y=*^>V&X1I =*WQ=J6&_Y'1AJ^*6'_,V5LB1I TPL_H[LLG:#Z&'#
M_8)O/RD QY)W!VO''WTI@$WPE _.<9M/A<Q!JE5CAE[]9MR@*Z+Y\O.LSUTC
M7_)R#@50"OF76Q'LC7ARSZ! +4M1@;AX]]E4/HCY=]49__O1ADN./A /J[_8
M6;VH:C2O/7P3*#-^960AHRA'8&(!8\P<1/=9YVPD%#IZI@0SR>/7]_%^1QZX
M_B'/(7/1+/WAGQ^SAA[8F!.XG47RB1<&!>A,=AU_U#UK ^Y-?@1V/ $GPEQ)
M.2HZ!!,]4-M\&)PG'0_7B=L1OVW5^^K; Q%M^!;3+N=RDEMQ=\^#@]I6]*7>
M!<8P-2#V8)>[5BDX6T.Z5>>!(%A8^T)T^]*-8)%(:@$(QT:761[TH.E7/<[[
MU48ZZO:NNPB/":LAY&' /ZDUW*B>)\70?"HK7":#S<]%*2_QS4'_:*LF"+<H
MDEJ/G\<>_9+:\Y^^9P_<[S6,>' BPF+^J%H(9J2[:I%G9,E7D]T8L7]4A7]J
M.VW9$<YGIQ#Z<U7]Y /N=%RZ"#Z#8) YH6M._94M'3U6X_*%0,;]I@!.-S/-
MMF3\4@G]IM<::R()L;[CLOR#5=8/GGQ<5+8,$+3;*C*C (1/T$?4M3YXZ"+G
M*=_&"O7H\Z@L$@U8&<=WM/ ;IK&P[:XU"%,MXJSFNE/2T;%<WK9\$E?A?N[R
M<O1D%V>7H15B:Q]GN2@8 F/QRL$'-;=95O[X7"8J_B+DJSJ?&*T?!W.9">(#
M4]3+SM\HC<?VPBD_'K''1P3=/E;E>%Y K[(DX# UF^4W"+G[X.P+PT?*XBS;
M4+Q#B^Z+<9^R]V=H9]'ZHQ:JC$ODKS(.QXNW,Z! +W?FEYR=<,/S;[O0^_V!
MQ2Q&D(N<H$2TW"L"C=9B(1!UQB4.WZM[?;.8W/?PHJ=2("V'(#)@R< M"F"1
M4,AT"(J$WVB@*BK6RYQLD^D:'A[*H #HXS"*.S:+^R;CXB_Y'0)L=#]0 /[M
M\699XOS+:XJ;%LBR7A>Y0^@!'RE5>12=[?A[*KDS]IS3,;.ZWQ(/\YTE+^ZX
MX'HY[V?:-U_SOZ&YL?J#I'M4CS?/M]*AQ7%9-;XT1 TX*I>IW_@X+?=]Z1L_
M-\Y*#[DUC%T==Z8 W@7UVY/OB NZDC2)\,1A"Z((UBTUNPMCS>'60C\F*4WO
M-P.618#[!,9$=E\07&^1'8_Y@,:D>A5:-_^C4WA6Z4:*,+/3]M+#C^FOY!5>
MXE<"8_6A:IM']3C-W$GL<6NP[='@T0D8?$F]X8:GB:TPM6#&6A2O$CC?TJ+%
M_FK$',="N.9YS:_WMG\;5T,F\84PD]+UY(V>TY6+V"'"Y+(7T06_7WHM30?+
MD%!@(4&:\8MG5/1OZ0E(4%DFM4PCGUY<Z=IF6;P73P&T:GSU]_!UD_O>V>0)
MMYTS#N.WR[$KX.P/XF&#WC%8*A;<KUW6&I_".W? D*>9 C[8A$5$^+U@Z.)8
MSDN""EJXY859Q/*A2;R$@6!\W7:F2"K^/4'> !CB(_KHN&,*_<''6FY*-^4:
MKB>2CDK[O*3#A:+,Z''WO.!SB^+,SBB6P1T?:YMMURK"*_H$!4'.&^=>T_+'
M7P+T^U>/=QDPP9XVUIV-Q@"=#12L7\HU;W6?[F&N!+UQ1@0#[253JO*G0S\D
M?U@U7*&^GNP)U?"=G_6JO SAM'AD."32(W \<7KYB-'MVM+"I0RU-#M'*+P6
M?-6%V9*^L5)D6>9=_'24@_3;D.YF*K8#/7_&+3^L5CN:"L96\@<ED-I?@$(1
MC W-?PU]:+X7YFL,T!\<5K'[8T.R\G^XI'FG6";:@UF_)-WZ]_^6>/??1(!C
M)W*RMB6+NT1[["ZYH[AL7L3L^T/=O"D&MI3"N?2L1#0]+W3D?[#WWE%-_E^Z
M:% 1+( (2"<H5:H*2"<*TA4$!*1&14"D]Q8(B!2I @**0*2#E(CTEM [TGL/
MTEM""8&TBW/FK'/OW)DSW]_WSMQ9L];Y8_^1-V_6RJ?M_>S]>?;>ZP7I,J-_
M0JBNG[Z=9&T/1#M[.D<NE(LN5F,LTCO;@.'CF"4IHM)L0.G<(RNN5[L]H=-N
MKQ?7E&S1$S]]Z%#2X0C^-]F&Z-U<KDS[FHYE.TV>EV,F+.?RXT?=J'EN-6:\
ML:H)127=>)ZC7QI+873AQ3LZ/; 409\8XU!:R8<1;^G7@"A@'IE][K1K%-FM
MNQ;Z#,77$QVJGY^6N?6\PQ"-I$)R#7BNGWX] Q:H8^N%_'ZN;%6?&R%XM;>(
M2Q@>G#&*= ;#J$MSBO473")EE5K]P\^[H5UJK.6;A2>\?B7MU@5FVQ4];_:W
M<J?925OGC43-/\!TY6<+TU(?,VT,M1FTB;MN5EL8?Y?Y_C1=8$]\7^1L$89?
M_+]!LJ%4C/Z"RK"S)WOM=78S#4O?U_'OOG\OY$WP.7^^L/!3K>&4]KR7PO6M
MI8Y,O,V9O0.UO-G-^X'.#W_EJ&Y2\T&K)IJZK[CAX_.]2-Y72@8\'/036/E6
M);9A OO2G+S*D$/FB$?,_3E11Y%%B[+6ZX*&3Q4!YY *T,58I7,P_<% ?HC)
M*.H<&=#F5SW)[4 ?&B>ATYN@:93@P9'8!S(EWKJ(%&HW\MS2RMX<J,E^HI_W
MK8XV*U+X\^1_-6OGOYU\3XW-O)CRTMW?G3ML>IH_U82:5TB0+XXKB.V$N0V,
M-A*?&E!)=(1_.%+TB+TT4F$?1+5\KQ/6$J34GE4+#H=>;[B+L6_Q4A) AU7:
MP=>]0^[,FW37NL\]]U3GO/SC*MV%RYL%%+??G'D[15AVY\HK<>6=V."/_)/2
MT4=K):9_G*"<;W1Q4.>!2<M>; :Z"R,>QA/^! ?+;B>%>MR)*NBHO35MM.U^
MS$$<=@G4UR D#DIM37IJ#]#Z1(X[BK>E>L"=7>T]66,?K&MX6H,\FZF$=^(7
M@$-OX/U0G'#U]D2>YF(]*&:>Z\>-#/YA9]$=SZ*(9Y0U558_;^>P-'ND]#R8
M&T.[,3W _BP>+C4S2V5KWZV''RAL.]%FW(.)5)LI=;:.&@8H83ROL/M_NGKC
MM?'3U@OG)/J?P^<RI?0ONT[!/NN(77?]R]S&_RWO,045=W+C2/<4"R5>&,]S
M[5XTEL]Y8\F'VT'!<2H$>D"2Z]=^9;7;%S0'4UQH&:H!R>L4>RB;R9[G#I+9
MH$C-G.2=\M%>]$&)B<QVI7.6^ARRK.2[:6"_Y:5'(BHJKC?G-B?NE1$UX6]*
MC9><@Q9Q8/3Q0W1)9:^E>IZ9"/]*HFTJ(26@5O[AJTY6F5_W_"8,P9QJ8I+9
MS'4:Q]\UM=P2-EO^$*I:_@IA W'F2KU+PK6P0,27@%>$PS)0V"=:JKM%;"R#
ML,(O9,!>(MAJ,S4]+RIO[BWS,?VTB6G;R("KL*/&\E/MNXI!@%3"QA !%(!W
M"1R>#H.+&#Q<G*%23576N#MU\Y9,\ YOOKL5SEMVS5G)2,FQ^6EXNR@M@<,8
M5)D\I#A#NG2,SG.^2)!HQ#PA\ LO7->"G_O!'?7\F/J7O).-U[%%&.)[@8C#
MMQ&'DAW1E]K^9C[C@IG1+_487SZC;0)0ZEI4"'YGS'[B(5OTS--F]?3,.%E<
MO EFAC9K$5Y>56)&QX4FM>JZ^O/GWCHVC+GZ1G>TCPPX[H:7'3W1&5$=<:J\
M@H_8$2EY9;=6DU25XUK ]SFC"? DT&.=!$00:T!VCBK&R;>_H1U#LOIO\K)L
M?XSG>(!-,*@M(\BG'53#A('W%PM44,GA@;3"L.G>-QD[9, %/,Y .B20=1Z7
M1V)@VOO 9QS\_)IJL?][6\YJ"7G_TE:PX;,;]Y_:51EADW_D-I8TV#,^[;A3
M$'GG.]4+P+G\TFE&P\MZ>74<8]_ERMT#E",%2T/^<J1H%883E(X JQ%A?.6J
M UA$H:/-?+.W+NP7Q<G$]\ !4S:<\Z)ML,@Y7X<ZQ8J?XAR:O*_4-T@CE9 5
M,H 2."H&=T!PXM[.7)42WOI0]9L,*'[(Z(JF(DK[X6]U_!*]WS$_3#E%>?:'
MW\H+!0$(H;X5C=OF*U-\I^GEQRYHBQEHIN+?CA*Y 9D#N6<(PCA'%!WC[ 7W
M?-.*C^TW6WKOGKQ2&5!SRXXSQ<G\Z;B'X+,E/;!D(@.:M&$D#?A;8F7.!.FV
M3W@+C!K"1S5=>07EZ:BR.L-QI_ VN];DR=/KVP$M+ZX_^#Y_[6R+._LH_VKA
M08&O;4ZGDT ^D@><#8#EC^=Y[G:6J@\WB#PND_I>\W+NDW>@;8GJTUS=U)_U
MT/CE!?2^[@?PX3DTG'3.G S85P7^RP<!5&0 +09G2 8H5I(!!%I=DK0Z0;YS
MR9AP/$$&H&5!N#GW /!=$K1M8F:1#/AT<D#B4L4(DX+^US@:E.AP7TTQL%8@
MS1:)NZJJ8JQ27K(^F5W*^H,*H3NHKPT2ZG9)(1'\A9D,N.P!ND8:64##&_B=
M<H8NEM9Y?U5HT?12#W;G7P1P.WR*I@WRA(_+^_OL.*+>,3Y?BE&^)=AD>!Y
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M4\0LYV HW6.9*6+P*]J+2LXWI:'+4Z6DQ@:%9W:J8ET'PIH].5]W(0%G2@Z
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MU2IK)J1NY^QG556HO=KY>.?.)8>#F&]K3-Y-"$J,P([4LBY.74&VKO-!I76
MNF'\I5B6?9=MF=E.JM<FE!&\B\+W C\0A''LBP,A?N9>"+:AI7?+O?3]A8\O
MI'AS7$WY%+VOYE7*R- 2B4O3<073RZI065/F2QC7[YM!!O*R4X8SF41T?D)M
M"0.Q! H\&T$#EW:K$9.<I\"4W1V"I0[#IR@KO;"B">TBX:_?"[0<PX:W(-_/
M<^"DEWPJ@#13)S=Z#YZXWJ91[/N\JFE.41LW2#$(D"GMB-S/5KV-UZR^[>VT
M1Z*8DBOI3+@MB#V;6*/5OP;KF0ZH=N@Q,V83#;IDP.7PI;>5:U'PX'"]T:R
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MB[3Q(IL*^U6OP?:Q5@*=^M"V+_4XR&ZK)0S,M>'B2@8H8;?B2GO?MF-4UW:
MW];KPN ";2Q[JM\E]\TF:^9[9%]]?V&X^'J9)SCH4A/<)ZMAXW5%FJDA']2@
MS,:]<9;GF!.VW8F9GECN;(T*T%(/$[\VB9HQ*O]0J^D[(VB9R0OXL4V[TCWY
MQ&\GT+NY<);4#>4053#(;R4#&-4C.,S>WMB,YJDR\K0%B+.G4"ZS;#0"%E.)
ME,.>]HK^VN6C%?B(W7_N3ABKKS%YT8AJ\!V-KR2?Y(HRO)T3"+/Q&H^V^&Z
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M^'H%* 1)=P1C]4FP<SP4O054VM2X=:]&OUF-T4WG^5,J,U6(U-("3J@S)%
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MK_"Z:N/E-Z1AE70[=TL(3\=+%O!4JE]L?E9_33*Y:#1\\]>]2(25(PAR3GT
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M[\^LGE>^R,:OFJ,+*XWM@/>I7C4MFQI$.SYY2P84E9MJB5F2.KN4>#$IG63
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MI/L$8#%GT$.BZK#D9;ON]GI] SO!4AWVY>Q[;WPYK%Q)[//SE1DXD7GN4"K
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MLQ=[WA4YS</PW--%'^KYP<WQA,[^>(BQ?GQ)0A,5H'$$U.*+X&:% L/\M?=
M7VD>^<M?+^U(?,:C6OJ8_6]6:=7I8 3 :NQBC@-K<R9:@/52T X,,-H&+G?
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MK!-\?P7-0.F;:,=*%JH5K5\*$)J;RLR\2/P*^9K,A<!W.*S4Y2]L"DV2N*D
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MV%J"S(..:CG9\0OV>[=L]9%J=!4!_'F/FO.=#DR\V I++._][.0__<Z$_FQ
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M &XV-W]D?D>Y8G'JNZ20E[W*#[/^\EMGCD]A=XF.V'0G/O5';7(M"U3 ZUT
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M64Y2.$Q'N)V\>72A"G^_S"J[=%7/@Z6I)G.!T]]&6U\DZ<N7E/03^5&,' '
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M<(OV+RQUO&W.-N(L)J>V+B,G/W@[<WE9-R16['(5\ L]$A;7RHGI0\^CNC#
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M(0MES8-"MM(2<7U4A_.U=PJ,T_'/LO64OY &\*GQP'-JXNB(P.K5O[:VK@0
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M[8YBD6^!VFXETR,1'03 C"MVJ>9S*R,&[EC@H#O9#>TO,2I(L1]_F6PD(7S
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M-_T<^-<7,#R7*21VCUSW&^QJ^ V>9H8]:,!]Q'L<)T-6L%!8?^," 3#Y!$$
M/!7KB\9?OF :#<.+^FNE$@"+&6V'YOMMNU1$F)AS%SZRC1LF^DZ>!$"_'Q'L
ME@OTX:-#V]2+HW@) *^S#$D"8!D7V$   #&MB"7B+XH-W9R+^6WOZ3K'>,[
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M'_UBP Z77R-O?>C'O.-XZ*P^WOP4">^]+O=Y=/,<_>G=L*3NC\9:)D9WB_A
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M_D;O9[0&>C;':LZ&=!V;%)\KZ?S9X'F3[ZZC&&C/"/::F5TP]03D'1RHKA5
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MYQV?>%EOY,V>W9N?;F0KMASYF#HUH9F>ICP8&>W+%BE:%//WU!'_$__]<?:
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MBPJ@ Y$$#CRH &DNUKV1"5C<EBPC<:X.D_)(H X\#(_KDCC/Z9:QQ,=-B,.
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M*G5",GL0(2U!)WFGX.7S@:">+H<.C)W''..QIMU8+7(GBH3OQS#XD6GV/TP
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M30GV!]!MMB+":!X!8NDL]$KE&1@TW099AOZQQ?XS&.AD7EI6_8IL[_. 5--
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MKC*V]0TSLXMY/F(N8\6NJ,<(.]#-;TW6>-+5J?,T??3(JA/)\+@P*<- VBY
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M.6-NZ)J.Q 0SN'\>W6/T4EFC#/@$+5V*E<1I5*-3(U\=@96\G\K_3*.Q\1L
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MG+!N?E$*W!2Y!'3T_P9@_H1&Y%8+!>X=Q@&M-O^;:U2*677C<RM3..A^B,]
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MC[H-Z?2='E%QL"-Y%\I26EI $J,X6L0W;P4Y=_?5I!6S<>D!?^X/;Z>18N2
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M?J.VGI.MV#B<6?X+>Y)DOHX1=S;9NSZP&;(10C'](XG+<M%2)M7% 2@JF0$
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M'OL &"E4!>0"EE;74@' @FD*LS;VD #56'QX$#$#Q[AH-D=2G@(?E9+RQWW
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MAD]W*7=YAMED<K<:2[4]](_EF+SF=]%@X&[>Y_5Q2Z&<:7/+;M?3%+X)P7A
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M$T( 9*VD;Y'R5.57D[]AW[9_ID+IB^Y'/-60X_U4*N"F8IY%RV4J(-'5E I
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M*D#^;@VBJM2_8I0,(6>V<+5C00OPT";VT_>GI#]R\;(!9X-#E0:6R!N6.E3
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M%8\A5 ##'+D@ 2.$%9Z:-F_<(SFC[833BP/C/DJ?<]Z53H#/77VKOXGK">*
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M0E!#^RP\<@;JK>T-XJ3P0KW)[RX]([Q!!_K^9M%95,!=3NL*#FD"W/WVS'N
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MS'-1$C".4E"Q2YK;G+L5?_H=WZ2>"EC7K3425:/9]*<8NRIA<4[?"(%;U?=
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MJ]CYG WQZ_M6AOGOYPX>KB;:@Z_U2I^Z+PHPP$SOG0#IKG])M_P$.MG"23B
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M:HP7!]OG+H[:W"?W_*C)R='[)I[3[=&7#]KK(;ON+[;\V2G?8#]RNR!G?*B
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MOPA^,S4*=(P.]>?*18Y<Q$^%9@/./LYB@UJ,149JW.\80.QX*ZR&3/[EAK\
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M=,,4Z$K&B"^A]T5[+P!S&R^TVY4LVMIHIA#8IM)@G!IT\MSL[A*$MJ7&CLT
MWFE:S*"D9E,^-RA$"*+'[RF7:YYI]RC YF(P'U1OPT)ED^K\'2ZC!<&^;]2R
M1]^W$:X)T5EL;K78!"1XMJ;!C.7J?MD^Q1[Y1V3J"X\I[7SH\B0+,WJQBT^B
MMZKK=HK_NL[@H!H%SPF9 <SAM=&<P$X-+ 6?@_7"^4,DT-6/78HLS+&:.L$E
MU08)IU??;[T92*4"M?(/GA* IA-XE8*N0D<CS-R7=UW>1H9>(I5R)X9Z*GCA
M,:(XK$.^C0QB9[+9C/*V9)VRW<+I=ZX;/Z/<Z96^QBQ0=(]-F>"\!F._E!AW
MH'<A I,"TT1JR#.6;D!G[X[ZA.NB2G]"('.T:Y!RC[P\=ULJYVJ>=W'Y=G:?
MONB[VK#*8Q\F-',V3HWX$U8=OFX(9FWCMC W$4YY$#X,GS55$WC+]>/A?-LU
M?P,^=%HY&!N,<\.+H&=2KX^4"H0?9N[_D<[[DZPTFDD92W?Z2;LVR-N+BJDN
M%9X5^5F?TC1KAQB)T-4Q7C9S,G1?-%E0]7.6B(QWX'SP("O<V%V]H6AWK!7S
M?XU )N.[F^3/A#H,/8;'PE$ZH]&6]\;PUU=A6#4\>5Z=I<:WI+G%>PLI4>9/
MFC>2=#G:^E9>G>D RFM/XJ1]XOC/.S8S9N]_]:>9WF-^VB5D,?B41VQ$G3P#
MFZ"% O5I_Q+M8;$4Q%J4:*R"J)\;'.[K+0QQ]C=V+IK9@P3MNBLSWS9L2(8A
M-Z.;0S%^]6;<9:2S0LK!YT 3_%_%_1)X"10BU6MMF=Z96Z[9G+FV#C0[;3_U
M]-$XO# 1FI55C480*4M0SJL)7=*HI;?(4E![8.E'^XG:4NY?(@.WN 0.W2-)
M;XT<*!N:;L'L0-B[]IV'<74>VTMBS?58Y]6\! G5$O/B[:,5R##3T"NC;[X:
M-4<A8+*9X+4$K.#IWOZ*3))P>10S>VGG<>3C".=+#M"XK99P] K,&4QR]LD9
MM86IP4JN!HV&/N!/+W9*UQ<+HMXU;L$R+US_INE<!'B:S5/V.+'B;4BL&>@)
MY-[E"TGUE3FDFQ;T+ .=DK!5V(!O2E>>>+\=Y1N2^CVL$+C"0YXK:WJJ30KK
MN-2D]A< -O^WQR6EVJ:HIH-9YNPRQXY[M@)C.0%4= %7$@+/)SJS)'\J^N4^
M+O%W,YLX(=QW._'+L!TT?[2L_DC5\6YRDFYRTQ,U\1B7>Z,_@#=@':QX$Z0S
M9I+("0''<ZR/)A*R'>_%)H;-C[Y=(-XB'V_QZ\X8[7/[9;^:$'Z<$!/XH^DT
M7%K=D7W%@@/[+<9=PU0^3UM*T2P5WR9!%?NJ&EP/,D5ISQMA;*L)1="K.T16
M:DXH;\TP,=R/GSS5/]HWVW6 AU]FC_1:Q]V[13-%&D6JO_0+V*/'U1-,EE0*
M355\G*7\F"=RAFZ.B=EXOTJUY0VEX-G\5IX$L[H Q/B=9KB6H*J[$[7)WRM*
M;DHWF0L'Q+A6D26QC*I%JU&1@'Q"2"G!9D;+KW;56N_(G2@;ULJJN=((YD1O
M_S\7T9Q]QIQAOT+H4&ZX:],P47VTR+)-9Z4A<U'$EX@'8;B&?J4G!>-MG\I'
MX7/"O1EFT'ENUN152WCA/);T<6,U'=5\NJQO--$FZ2X#:6Z_"6O1R&3?DKE1
M^B=#[T(%UV.%"F]"OBTT _X"<N=O+7)D>T%7%>^4^!=T6_+_A+@5.F[[P:[7
MI.V[4&ND&^,OE];&4-5MR<?P9&T"9@?&WH'"<;+XH#'BK8($<#>FR=SH]K(V
M7(/Y(&F _KW\A^<=%>4"J'@/L(,_W2HP@BCH;]C5W<8X72J]3X5U#<6,:/4O
M%0>5D'88 L(Z #.:8)K@OR_#Z3\8$0A6A!LB[+QOKQ&GZ02FER)(:!"YL4LK
M"XH?,K_+)APM/%F\TF^N6)1%U0R &O;M;7@L,RLS8;W6M+L(UAUM(A46ZJI3
MM\6?99+'-7U/K*.=4>L2]N4QG!36IM.3=FS68)LL8*]PSVBR7VN#PZX5O7(+
M<A;XXN+!/L090M]H;,/)K<X59US&V >G5=3%,>-M&[ !JV=Q,^'E; 7CT@5Z
M'X8I!=Z4S#B.,#\]^E,YXC'D]ZPC1>*#"AN97_GLGY;>+.O'7QSO-.U= /KQ
MNUQA6;3EHNK5S-&"Y59'C_ZN;)RM'C"=]'6!;AWL<GM3^&@D_I6U8%.$&1LD
M9YQF(R6A:8].<=]5!2@N_7O2B%:47)U+8Z*X#"$JY8.LE!:KWOJV%]R%H[QD
M'Q6I\KD'(Z+7L&-?+QU4C[#4+\P?^INF=6-'&E<R75*LTB,+-]+O4FA7U^&,
M5L#=;A'Z3J<5_LE=7@-YV.*>Z57JF  :+=[LJQ3N:@,DI,[G(72O$=DPE/;R
M_-SAFNT6_NYRE'@MO)N@S,8N/![%&5CC$6*\STHM9UY))5-5Y!'_$!\F,21L
M.R5O4\Y2_?M27<._(L53T!\VXQ.*E?=SHH7[%/Z^,^O_?4'FA-=&S<1)B89>
M % OM=_/P:/<2KVYV+7L38[*#C[N:2M BCTEA\3!N-U:Z*^9?B S:"4=00Z5
M@#R9@3B6FV,S[EF;-N"TQF>=Z//,,"&^)4^Z:96TK@26L(%1<W#2"\#O_-_P
M4S0"F_$',;>%44"=[ILA2[2YL-=.7VBS*%+>:<NE^3KGA++>,.'RE"4YM=GZ
M-KUV-8@+3*280#W;U6R*[C)&^\3M]@Y=_9'^<[!26=E0:#VNG3N75SFW%.+U
M;7?Y4LNNI%\ &$8C\+IV1!YL0.&+4;JTOKWT0HH?TV6PJ><D'+E*_OV\SE-'
M8*_[+RQ>>\^!>\#SY9@WM1'CFS,&:+5(:_;>2O/9KE+5C<)V?N-J,0#M@=+N
M/,(>B!4.PU;WU64Q8%N1<0H=23\,@?O.\O?IF9%?Z'F=[=5MR!I?#_-0W4S.
M$MZ&A5\ &*6 L=RDXQ PLB2M::Q6;JAS_):ZWG?=L9EJ86&A_<0.WFMM*I>N
M^3N$^P+P[C,2&H.^-@AP:Y'UP)A-&VQ\W[+ZFCRYEVY%6I^Q&<EU/U32KQKT
M4K <CG@%C@>B?H*K@6%X=0^/K5W#"IBM4W>=V;X[(';X8+<*C',0_LT>9O7?
MI@P6GS*/69H-D:%%4(/YW/(W)9H20RD4;Z@[5:H"H ^A"\!*:#..%[LZOY;>
M8>UABVP.JO0(*)@+7?[U1WQ])7A7?4"O('RQ!O]=_(1E+QMGB(5AOJ#\YERZ
M ^VC]^C52G*9!^(2N-^8;.18_SS1[]C3GC.:ECG/_]+S9;'%S]>/OD;2;.3M
M6BKKC<%!?YY0%?+0ZU 0]!>\RBT&\6HY:@SO@)6R"^NP<Y\PZVI2R:O^P+[D
M,SKJ? NI@<L+Y[L1._GE?4I PO@SX54WZDMG8TAD6?(/TOX,'KL,G9WOW<!9
ME'[Y[M7%">^F_Q%M$A0;XAY0%@W$WJ5K/[NM[MSJR_\JF6/;7GC/O1NJ5MLD
M?V;[ZWPI^LP3A!4R:G?D57-C6%;[02(XIS5B] M),?ISIA(B@"5<NK&U\+!%
M?^%N3.!8K)V9P3VF'X^_6;)0[4@NQ')WCWG?-TQ0R8D6>O^_NL&J<!06>0'@
M,[I4I1C1'>"YUAW?J6Z\^P4@27CM H!C.:$C\">%Q&\-+?_ODO+Q+P!FP6OM
M\0R3^$?HI=S+U7@'O56#<D5 (+NMS#LR\;VK;T)'$ECYE=9M/^0*BPO$9F#!
MJ[)A1#'B2+T:,)K[2EOMA!J]= D?P[QX!^"L__F3RHZY9XG)?4X$U+[!X;U;
M;;5I2SNL!RZ;>DF/):ZI_ZU;)%UVV9Z, OT[OWR9EJ;@/NDWTG=W3Q,;L5S(
M9>!O2P'CMKY@UJP75VNZ^1I[G\X%KDW:N >L-K$3V/[ZC&3-6%YTY&C+A'>
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MSCG@X7:Z+2=A[NCSZ%S]FML>+H Y&9V ;!UB_*,>X.$Z!TG.S*P:+/XY"+@
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MTR1^F=<S9.5/OQS@2WWM!=8CCL*J87MOT11S]^KC:ND8G<931Q++G8"S5=7
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MZ<0N /.2:QLE*JO[EO.=[*K]PI="NTC5->E)5ZK#FZDA&H\ZE9.3<C5"X07
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MBOP:>3I3= 1M;,G+0-Y<ND?^T=$ILO:/5Q.BLKA1F9MS?TY_M'7T?*GZ9"L
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MA6A^!C0=4F4ZUIT$BI_08,\!BUVU9R<=G.9V0M?OILXR-J.808EQ#S2$XUZ
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MY^@?-!,'@-W>NL"MD:(H[ ;)@/ABH8MK*098F^)9+)EA;[R0G;!O?H4GNWO
M1-TNV[LE:K H-E&'I,PLCT'H%/M]['1K\D[H:/E9S/<XU[[+21V#RZ[-K@!K
M"_K'9WYL]5.5$"=\'',I>#P--U#%#T]78B;.SM,U!OPPV9+H1>V\>,C8_CUC
MO#,6LM/"_C#:\R.?\9G ^";[EGVI\+?8Q3D#>HZR>]:>"D%4J,B3@A?Y1N;I
MI;[/\^7>C+RXDQTIZ'$3SDO( MGWTQ_[#[W=*M'^N?2\>31C>/CG6)(6.:!!
M0GI6MT[M 9^0S)9Y!9@5:]7.?4RRHT$1&S<N1.V87T-_2H,GA5HY^4O/\EL,
M1HBPJL:/&>DX'DC0:K7K-4+XRJ:#LXOT*ZM5%26.\[ X3)=:U()=6UIR5>(*
MB]>QQ/RI^NCOAP\1Z#OP)U@QDO0&L/F8]D5]<S%"KHMU^3!*XR!/Q9<VQ3LR
M-^F=+WFW"XO>-)6ET0\R,8NS5@Y-<L?PPO"O H71 ,H'ES3![(8,QC48GLE#
M_?61/+1:]R?\(\(7(A=>$RMW#KCB@A?+-\':LELQPYQ=WI3%R#W-Y?GAW*JN
MI]FCL!S\L1N4!$;KF-F>M-6?=(!"ZUOW)3FEMG8>CG#DEM75U/<>"P(VML _
ME!2Q:0NB(?6:8PH6BV:B[<8^E R;W@X 2WF1Q<M FU[9#7#DV4"7RT726D#K
MFAEV*5$A5=?>-ZI__Y2)?G#<,^!Q/4*+VD!#^6U VP0'[6')#X/ &)_>':+U
MXJV=NX_YYI,P]#N<B["KQ%$81R7HW3S]EY4(E\:,AS8WV^^T13?4F<($9E62
M-Y*O[">$.PV? QSCIMI5L ZH?A5-='6='73)!'[HDU/I!IJXL+#RL:"M/GI'
MSZ.V0$#_QADED=H-!XQ[C[BB'H?7LEO!+G5Z;6*Z!18."0H+.5&<F4^$XC8^
MF-.DXV0SQ4PF1B"(9=_/'/(Z4T_]H%^.1%OBWA/9")G$&^M$6G13NJOQR[8B
MQ<%H(62%U5JFGM)!6>_:UQ96 ,VA,3_\LV+97?OL=S0%@5;.!4;]3MXN3+/%
M/_4T[!ZL;_J%/F_EZBH9>@"D@0R1I*0)"P4Q0\8*L8SG@+9J#,>'YCZ9QGYQ
MVT.G@#A!18EKS^2V'4\OH^ =+NS$_G, YQ$P",Q\1%W*9&-BIG2V^ES(K8XM
M)">IQ3;(1H %]':;%0P#5A[M&^Y,XZ@F(,@I2!CTFZ/7'#LF.:&+<4SDIL/U
MQ:%R8[:+'R$OY#\=1-=V_])8SPK/Y')\)E[P6#)[B3LCN]F.I#PE\"0'+[LA
M[QPPGP;'E,HOIN 9H$O=V[-?NTE,D0K;@:T_T?BH(UD:SLNBJR97&['/J_WK
MLZR>>W%#V:'8[YQ "VRF^K'3AFC+F=-B3><5!M1)D"3]]:T*\NH:=HL0C>MF
M3Y0G::T:Q"C7R<06-+F I/6/(:0?#4RE+=U!DG99A"Y;):?(H6:><3ECZ/Z^
MQ#[5:$) 5( H]$M;D,GK=]B!]FE0.!"M!X\Q9T<W_12)6C"[S5@WMEQV9=FX
MZQXO3#B][]9/M7QY9<X'\0,[>^\;67("9-&A\0MQ]"^[OZVG/BTWGC+NDM$8
M?>4QDYF;J<F3^=3W2ZCTEMY*7%OLM@C[A-H^]LN?LXCEC-9_ $?KWR/>\M\'
M6+923V^< XA:3TB> 9<+@5\2$Z!)\O5!'8%*6N< T4#Z4OOL2)QDN9+-+M/^
M0'<<)>P*]J?6>JA0E3B2*I!G8(^E0%'C3?M:RP;X^0N[\$;);]@*+:<K>I-O
M2KX$A_ $%<N)_UCF:I*_+L=@+N6<4MP5=MLK80P$PO+EI2P2\TV^;&9&[P],
M[G4/SCF T;'FC[D;J^^4>'/XQB<FY(P6#'"%32 K# =2:[9G"R=F(RH5S>\^
MK+,^:'^$0<74VI S[.T?;@QPBB2B@!$2JL>!*EV:#LXU%Q9^E:]M&N@\.6B0
M7%F92/=B3FTWS.)=RG8<KTGSXPH5#V6_)FV<I)\X*Y&-'5HT$69IJ<^H1(KE
MK<RH\=\4/FC6('^_3N&[ 98-$!U9'B7>M+_:I;;@E<BQMILU-Y^=>C@?G7EM
M4($)=?BL'+QE>"*@-.\KZ]MC]JO_</DN@+XQ=_F]/L(6<26MR>/9>&Z<V&3G
M\J-^+N7XLZ0W'?RMW78G:QW= A/;XTEW<TN<&9J2=_?J-BP",UDNR'V:]FZ&
M%TWOUAT^]3T'=,)O]&=-J&1M !$8NB)<^.V8\(3[KX/YNU4R+_2L\6&?>C;S
M8B[!0][*][\XK)DL2?2@0@IU?"S,F4F@S%= &4;XT"_2AZYB.,\!D8TZA1_&
M5FUCAR>SDI6=Z&4 A58R,DO5FBLQ@>8V42'2' *I4<D[#<:*X*)U'QD.A?P
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MZG33G]YN!IT#RJ#/S@'##H+5<! ARX5=!WL)([["*-&Z$*-M\&+]\=1C5ZC
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MQ93*E2*#+!>;W\-[$5@>:%<?B6!=;[1!LW0.0^U,9\RT//)-9J04&K!0;P_
M@-<C6DJ"V)N\HJ.$C_]G'K%,)#$N-+QUC\H<F]-E/%OZ/LLH;L[,3&PEUC4\
M1VC7U37R,E<;@I>H1)P%,T&=!QAG L2QW#F;QJ(AI>Z)C4+<34UA.8J_ON[4
MO%N[1.:1+B&U4WGA$/XOG30?HY&M%= %8*C:2!>7C-Y@_W=!WU2O5 +5'9V]
M/,J82*_@DUAEE7T2[8-.>"_2[T@N?L,F84Z,QBR"\!$A&>T[HZ(LA:&LG97F
MX8P<KDP45P(OX01([P;A[Z(Y7^.5%W6X.R%R3S1J]'B=A=B'9UG=VXE^]P8
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M^J/N[8-%$ M>%I.JR96ST+>QLV2?_?/7SPX+'TKZ]B*QUA>;,@/KHOAKB(6
M>I>V 5:\UF@.GR[F1<&QDR_;@_ZF9BTYE.L-!QMR.M!;P1V/@"G61B9^9=R
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MW)_DCFOC VK1T,A&99P2-A6=R)&PJ<21\&*KZQ2EF_BN#W=D/M\\P(L07%1
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M=>23'?3V6)ZF:_IX*D0O"O50U"- 9LQ0P^Z?R=?\?P5,/L#&H*SRB! X".^
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MR*A+]7Z>LJ/CB 9KP="?<N1[=;&Z!I\&[OBC3,$^Y,BPS*Q,B%""7)TB"I-
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M4=J'_-<<0SJZG775*!YH,LG3N=/:+KE%0B_]@LD$W6J>1)9[#9[A#KLXM1G
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M#F[BAWW?VIE2$G0X1+/^4H"%9[L3ID<"M9H2Q9T7F9IO^(DM04+EN4/UOI%
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M^I:]=YI8I[+=/<)  _H<@#$%QB>M@",_@:.\G.;"5K.6EL2/[S:N._KN?F0
M/KEN_@G6:=!N#Z0C_PPU2\+JK.2U_I*2;O"O:QX7^)AH]E1>+668*AS?9R_$
M)<#:$GB$S"?3$%5_P5RM8;'G %XUB\%5/BN^RU/3AG4?@ZQGYG6^VOQ\M@$I
M@2DP0/\^[)B7YX8,=/D:!VDXDA)ARSGR'H,.:$3"74.OXA<N7S!#,^9?KP_T
M^ZN4^PMJ5!$M@!*BNVX$;0]8/3RY_AP0 :*NLCH'Z*8&U*37=[ $< G]M']
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M]>C$,34_;=GG/.9$D/L27G2_>XDMF+FG301C%OW/Z"&ATG/]>^2T[@N^*K2
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M!S#%_OUME3N;*+H63N$-U$?X* \L#TX=[Q% O6KI/WS'W_H-6:RH@?3CZ3D
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M>%-_;8P>%!*._X P9F#Z!2M\W4I0@G]O.O*F?I*:/MV>X*.U9(N+Z(IKPA^
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M<U6T1X8!.M+&S!SFGWGWQ*KH[N[026VBU1SPQ)38G:L@SD]GCH3\8Y_00Y3
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MT"G]78EB(U1IS])_O/_VV $7](^Q!T0$W^%UNYWCT1)CJZXT6TF%F)>&SCG
M?AL@0VJ@576<GFUL>K)DC5)O+5-C%7/,$&&H+,VG?JD%#8?X4[X?2)3&=S29
MGYEF$@46A3*E<+O\LE)K/I92M5</4_4\[4/3P-*S>!]<)>6SX0OZ?BOJ#V"L
MP1RB\OV,Y7?(G\R5':3JH ?S1_.;3>,A^;UY)@8D9$$[".:"Q$M0&N9;A,M8
MF]#O?LRAU:MKNQT-/S]*\"NT,F(=<0'B-.;(UMOJ8898C32OLK^SZ255)3;5
M>!E)%\O\]'#3B7?=\]RIP^+_ W>,*RW%@_\999=V-".BB"^*JY$KI(=BN9,Y
MA<IF#(G51?*UM9&TZM\E#CW0("(KJ#>7/G7#',^'OB639S+&S+@]5FF2G>B5
M_%RM[,I?ZO@(@/Q:/,F4+5Q\<R)=<9C&9<V@H*CJIC],8U$$RQE/OKJ]A($3
MC3'0TA5U:R6S3PL9RL_D+C_L[\Y#_TG*YO?=M.5(J;;PF++?,&J.W[I&-&X2
M?\E$N\5$NWP(_MJFA(>M(./L@(B'6+NH4GS"HZS,VHFJU. 3ID0JJAB^MVN!
MR$BH$JP3V*I:INM;">'!JD^_/M:F3A)]\DEW!_%5ZP-0Y<8[90V7QY%MA5=Z
M[OPE-&3*$XVNL;P?JZA2'* (9_26!'#5*!(J"QTVK_+ ZG0&)93$S'!\=ZZ0
MJOSN&Y=VXIC]F2Y0=D_A2; /RDHF/G_)(33WN>T(-<HQ;ESYZ03#ZY24W&/<
M!YMQ^L3:-Y4$=:[#!@P[A76Q^>\U*E($ZW%UR/\M#MC]<Z)]'):W#4@JT)#&
MJ^@&B127ZE2(1S[Z/]A[K["FPFY=-(@"@O1> ])4FG20$AM=Q$97(@+2!*0)
M2$@0I#<!!04A@BA*BW20$GHOTGL-@I1 0@D34CAQK;W/L]8Z^V)?[+W^_SQK
M78S<9&9^^69&>=^1\8VA:]IT)T2Y"N>\CK5C>A2PI8F2#CL!+>; N:Z)Q8+9
M70\M?-.T'6<,N^CH ZKC?6<GNKV%=9^I.$]17([/9;PHOG!H,(3 _>V)T[T,
MCFCD!3XX<Y"K6ZL14]7]30KNS_5;0EX8?P)!UNH$<"A W* #"N@UJKI3T<SV
M-N,44-(V.VW0#'Y6=0X0^?"Z[S9D+8,"#CH!-9NJ(+!)DU'+#]TR5\)DM/(\
M,F./ L:WVU["<B*#3[GORE#.3A0C6B!$5YCLSX7?1QFOJSYTG8#2QH=;$T-@
M?7#5HUH"_;[R/X$C_*\J])IXUF;" EL][3*4R>ZCC7N&QT"FXKY1KDLW*0--
MKPN:?3CE\K,SRI]F94- 9Z]=LD[^W-44QM1$N']J+212YIC6LQ)PQ13+0Q@H
MTQ A/[.+N:X'A7' J#R71"J_]X!B>PN&EH^DO/\08CW<)_K3>)-J#,I=_:Y[
M2Y*_G8%,O[MZ\ [X"ZZ[US"I3;F$67L]_4-V?:7=W"2+QY>*M^OR7:M0WOXA
M7J?9,7XIQJ?BW]#=#C$L^FWQT7RVR";_HDNN78G#,F]2$1S\!^W^DWS05VOK
M[J3A:H60Y.?7*=-Z(T-K"D0L0V(%=@'?)<O7_@I\[@IA-DR6?O$<ND_O'EJF
M,&F:GW9.AEK F/Z.P-L0$1G# ,5$H\ XL]3;0Z)7$CJC[L0LW8PQ6=ZXJMT0
M$]:AT2H3X&D( 7_P9A:XXX=#980<*^SI1IU)'?WX=K/0H-J28M"ZP$-AVLAF
M C273D#1\^I!'K#[F-ZUFB&_-$^'$8=;W;[G/_Z8'[Y:>E'[?.F:3'4P@0[0
M70"CW11H7=(O!TWS1)V .#VN&781=>J.ZFRG5OW,\MY9$K*![B+X!)1+VP,O
MA3-U6I+CX"H?+I[Y4G^FQZ9)*RA%,>BC<VYO(A<C^>_L2B42IRXO8+(,B0D@
MS'C!S/P)PCISB-\#LV_Z\H=6Y?,I-7)PAXNUW3VWL4AWKMRB*H,__7)<#\[]
MHY-+__^43S4UB</\4FEZL7RC==WB9\SO*!E)?SH5"M&"+'Y!5CFW02(A'/4R
MN,]+\@4_$=&J6DYIQ^XNYS-6NK5SM5S$Y1D2$L>EXY=OBL;B((Q4QZK2* VS
M&>=M@_ WBIIRC]:X.J@K%+B=T_I\"UO*<'!?E%"T,S6\:C:]1V$47DZ*.8P>
M_I-AWC==69/L<\H@+IAA\/,9AA.050(<.9Z<</!4.?5V%^[OB/8?:\V#X91;
MQP$18N.5AL=N+X]X4QW]'A=I5WCYZ:GNB)YIH@7=&[+A>]3PK]1%)@5XAX>V
M@!E4Z,;K[5%4$HP0$UBG!%F=>Y= 9Z-_ G*ZID(S/I%)>DK.J:?%L1KQSBM-
M+(ZL)/O2(<$[GMN0S8\F>^S)"9V,6LE0-M@#JF(F!&YB>*-YFZ$T,(5O<F/K
ME]MAXTC7T:<'+CF/>CDP6?TUKP:[8[&44]3'( $SP/1;!?82PO"JF+FYR]D>
M+ -[6-YR=:&'<UE-?LU6AT(BPH;??+;<!;R^KV9?)E?JJE+&LZ40ITGG<%5?
M\J9-=[7'03I'\1^]TC#1V/NS[.$G(#D6;SLL49UZ>_!^EMJR @?)<QS<?J6^
M> T2M7\TY_&NNWMO6TGB_7'$M'+V0P'B"6AIL 7-0!+#S>J"<<Y11=J:>7I=
M53]>2Q$ZU.M"UASFWJ<$9ZR7R#\IKTX+^FTE%F-2GW+97(]6(B40Q'*0M>V9
M8LL%4U_*$F_^*?DUZ=.ZQ4NUU*?9CQH27C.=NXS*S0T%'3/N0:>9"-\ ;Z(R
M -O0U9APJ*Q+9K)Q(=2D47")0VTLWMGJ5:.GXW]TH6(@;FC@TM?\H&7;I"AT
M^>_H"55K"34D+M6 ?KHO99=QLHF&PZ&BB#'[>9Y]4B:,BMG#O('/RP'1K(F-
M$/?#ZH#J(NET(W4/56PSEI 9GQ4N].SZ[<OJ4HK736.Z#7PYEP.P07@B@8)G
M7@N'\[I,P+EQ1E[RRS+\L3S1^)^$O5 :?MU[C]D,VU[3/D)2/=7CAF""/PXF
M(H&#AW\EW04*-"--[RV)_AC.%#(ZS<'-::CT?/A*Z-7'GW.(^<WSC+_@(@!\
MY@9N/-DYUY6GE=W&^J;XM8W;5TJW.R6RC52K;2Z\_YF I*HJ1ST$#V[]VP8!
M;]:QP  D62WXE-F=@-Q5JH;FOT$V4GX_*)!^+/Y'XZ%WD@6^,Q'BB(C/8.Y?
M@3/C YK-N#MI_!Z=[BQT':FQ8^N42/Z8#9H^+]R]"47MW1!N4^#Z5M9^_IV?
M][O'^@SB-2A>_,X6%&>[K/TUQ+9)X"'OK9EIC GSXRW?%*NF^]X0+.UX^D7C
M?#^XV(VEN7M[!HUCBS]^U@QM68MEGX!Z=!_<6F,HFJ,5>5X[2/]#E?CW9'H8
MX$X? 7&RJC<<3R[)6?:PV=[!ZE^6O*S?ZQE3]_W.+\,FO]Y4* 31;%:O3-^Z
M,'781.'#?7W%D[1TX>"SQ&9^DWC811Y>=AE,W<Z;E8.+J0,RVUZ3,C:X^5+B
M>9*B"$^]2:^,J8B@;7&]BF4!>OU"[V2,"?+Y-?[3 I%%KKQ])2'T>ES_YXLK
M@1$"%;V%>0#2A+>V"^Q_1 S"X>>OI%.&8[5M-EA'F;Z-^DLGJ>I3@EA#9986
M(D] %1/M@Y-F'=XD%: _%[JA*Q@5YZL<E-K*\ERR_&-6^0U*L[8#*.>,.^&'
MP-X)*'Z!%L9-O!IX!=,JHCDD.EXQ<93[],BY,E7(Z%SX:D+G-^U$!M$WC[:D
M4H>RS[@3+6#G:W AR)C!-KE3"T9UIGC!N-%$'X,'ETOW:!,WJ\6'Z[TZP;@'
MK.$BO XBJ6J5RQ,#ZJYI4A<Z2VQ\^4FO!D<RCHB$7.I^_ .9"#=PIA.)VN88
M,S:@4/_G&*_)L,JC\P-,6FG)RVD/..>Z',UI[)];VVN_BEAC6D27[VP]PB"G
MS>Y1AH?W=P ]&-]PBG_"5<TD3_@6(]QUTD?I<BV];,.EVLS)WJEVM\$)]&N(
MH+8@?J3U; F@;AWUH'+I:=2VV;,U0#*>U 6O%_F4W!]@CD&7#VX5+II-51NG
M*#!;JW:4^_(E[CUL%-O.YS]=<K5%ZJH6%TW3@&%_,+?;$VS(W\30M;\PSEI7
M%M?X >-U;B,;/.YAL6<\6IQ74?NJDU7P^SV=)&V13KK*;Y]8^Z!3"LMT7ZC*
M>0(BE_M[15(NU3OB+*.=$SML:QNM"*52/40=D&"LY@"7]H>!9FB%^1'R!'3F
M$CD+L>1"DH4*NO(T>D63+@J:7.JH#8ZC[2O<=H#4B[1<U70C[ !225BC$Q S
M.TZ*6=JJ;H_DOB29='O4YL;>;'.8W/;+E33S2YW? R<_>G+'O_LPQN\KOD4E
MN7G_;)5HM'OI%"8C7.<]O'J+PFF@HZ7#O49;^=O#&\&R-\[/"WZ)#XJ'U*W>
M$%@KM=]\5+WE0+SF A9N9/G3:__<$OIK"[NE&LP?S=%Y29^W7Z2T<;AGX4X0
M7>/86$6FCJ])W4@EDZ%7D?RRB[Q<B0.'GLHS!D=_;:4WAJ('_7!)RAB2V1.]
M^!%=J9N$(JE,.+@SV]"/>E183Y8W>PYSI8S[TZ]%1&L)[L#0\TE!W^K8+^R)
M'WC&=N.RBP-0@;8&HP?,:J8"Q[L#@G$)5YZ>(Y1=H7-YG_C%2 ;I-EZ<>'\-
MG0C]@6ZAOKHT_!SJC-*^(:HQKG+UAV'_ID3@E/2S-,'2)GLH> X^@*Z8V+I6
M^' 3P:BM%[RLP%)X-"*5J%[TR9N2G%_[N)/_-^T;S=G*XQ@]DUBG#@^P"&7P
M!(2SPM+:9,CQ8L!1CKBO>:C?1L5_\-KC]J^:E9J,TF3]CF #P8QD.ARDC949
M=@M'$EA[?8"%M-EH=YX-^CI0;I"]89S-%W _3"OVR $3L)6*Z\7L*QLM>[$:
M\/S8K/3OU^(Y_-Y!(T\GT6DO^EA'9CF) TX-#$)4]('B,%W>>34O7S_V.'I[
M=_](=Q!V1V@K;:Z<NR518\V;2C6?E'N[3)DJ$V)C2>WD#"II+N&8V;RXN)-T
MK!48;!YI5JX>[>$A(B84'B:/]?ZIG%T4S@_QOMH/3P40;5><XU3<3:$W1SW\
M/2[M*LI58M_VRBJ+_>G9,!1?O^?B.O2?6)MK=F<$ZV_+O[7CL5Q?^>&<S\S
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MB$0J%, OEQ9'O/48]K.M=71OJ@$-^I\OC!!U< --BJ_=4X3F9=,#B*7!2+A
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M!)$85,<L5]6WU"47MG:(SP+W%LGDMJ\#RR;]2NSBB)*TJ;XWIHE(%2:Q/[K
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M6R^^)-/J#Q58Z['WS-T"QNUA:Q(KWH.5\$)$LS9<JQN_1X#B!O*_V>GL1%?
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MF#<D3K%HG=I2>OE<QWT5R8YH?H!V-F/==#"%\LZ[Y=R6J!^IJ(N1^[7&-_N
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M%QAL"K 3 YR7!FGM @4[U<HKOXP7?K^53L?7U=/KEO.\0T\L37_QXNF+$AY
M72>4 2X+[Z'N?2'>3N(MDMU-(&>,)OMIMHNG@_\[B_6]WAXF#J7 <V<']$Y!
M<HQET@!G#%EA&=6ZPQK8JH=0-IZ0M4=7RQV^>W3#PTO_GG'R9/@CT_]TP"'0
MPV\H+HK3"^QL T_V+D:U@Q7K#7"=K1.<W8?;15AX^_,%Z\<7UBC'*-?<4 @O
MQ&-PRA,Z2=U&F.Y%V 7>%Q0>]P@FX=%^C8J&1VU-VT&*ICR+-!)99?'[J%^H
MUQ NE:3X$Q"+B@+?GZ1,X7NS)K]YSOTRU$B1.@&Y\BDAO[J/PS5AX"%='=A%
M/.LK?^!PTHVP*G:9WSWHVAQ7+V58PT*DIGDQ@Y1#CH)+N"/*=K!GELU"LW4A
M3ZKK1P6F616C$X6O@L0=!TGE-::99KZ_V4?'VC_<5K>$&!^XJXVJ%,X\>(S2
M5N H]SOS-AXY@.9 .T-G3)9YM]:]SV0C8:J#C#M]/^GRVI=H:R,:]^4FMDEY
MN^:%AZ?0V::(5DN>X_R8OKNY!GGS%?=OYL&QMXI"DQXW6R;M,/I(95??HKS>
M4O@T)NN!DLOCF'FH7ZYW?M_I,8/X!D,A]\H)J Q!Y3)+*N1,72&W(HIC0J[M
M3 ]V+"\"E@Z)TQ_;Y,Z)_I\-(MXMHY@G WM;KU2]*FA?6\_XDE=EJ7@">JG)
M]IFUY"RJ!QF.Y&^40S0KP[R7&Y3^-F\L#'0PK[/Z<B7^7O.9M3<#XAGC2]?,
M94M\6Y];BK+)')1\:BRM&BU:K:ROCMT>=[HHP?G)SU_GQL7%I&(32WFEW]KN
MBQ,D[M3%I+;QV!&[^@8@N*"1MW?B_)Q;'Z+.6^0!:]!I?P)]%,D@#R@W"G_P
MZ\!$Q_G6QZ<R_;I+TI'7-DI>AP," &2YFL19O3C1-JBV/',SM7DZ=86<WUHD
MFJ03%!HN IDSUSW88\DATI'@Y(\'1I6#X79:F7?-Q:9UY+$5,]]?K+R2D.VX
M^. EKR8%Z]S3/SH"<?F&ZD+14+=GT:@$XQRWQ^UT*IQ2*W%8VA;XM?XR3>.(
M@-UU$NX8N^I[^--R[@1TBDH5(6$+%?13Q3#(,N"']7E&D[/99&WGJ<-^0SBE
MNN+6@23RQC_#=#Y@CQKO98:ER<@3D">"%F9=%I,R86&B8_R45N39>,F/68/M
M<Z= WH,[K*.4^.FY&R'NS/WU<:KU764&YX4*+_*?!E]GANU0[Q$+V&C;$U4F
M ZOXJNT  _-$YU3^\^,8-D,(/S,U3(0BOPV3(W7/(V.@951_AI),[V\<*4Y,
M]DU-8_:$579OWWJB-D@TS[OE)I_?,*3'G1/Z'[^M)3?>87$AG*(>^-24J<-&
MLA'EZ/,DB$ZJRD>Q\2)]7\(VJPZ+ ??T1"A\#%PE'0%Y&G*N55F^$B/X[=#J
MC[<A+>BEB1:B5^,$9/'G\_<'I Y4".O@8)PN$SY]BX:HM\Z#8(1Y!\MM%WL)
MMQ?__,9A)-B'_W_:N\^@)K=W4> !1*2&#H(0E*94:8*41&0CL!%1JM2HB)0(
M2$<("46E"@@"(DI0Z46D]UXBTJ1W"+UC@A("*1S<Y[8S<V?NEW./_S.3#[]O
MF4S6F]6>M=;[K.S&7N3F*GWR%_VM?NX0V(&W 9]ASI0LZ94AXDMF30#-W2FC
M3YZWGP+>881'#[F(@I0^%#?D,3 N4!X]$.6E@GK^:_:Z(/%&;803/N;:PF+8
ME.C0K"U+[5>U>ZH*7I![K45LE?^Y*;VI_CLA0/"X?W(7AN.-":%NF&*Z5M[
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M:O9=TW)5J^$@0RI. 4^KIG'/PFV(+@-$H[]BDPT(GB3^11EI!B(?@5B. ;"
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MV;"6IO\?+RHSL"X9AR%.$:(646R$U(XF[F&5ET'MP\&?;H[(9;+*UF.64(N
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M6 G+X!XE8: LFPB1<0^'X8J75T[7UM6^)N5%*R)RO] EZM,E71,.)AHB!@5
MV^/8.227:YY\23:R?*/N[V^<AMU?^[\_\2N(L_KR1,L 0.);F <@AI!8DT8[
M#[EEL #!8\WQ49K]M$'L[SM\/Q$/3&B!O?[WEGFU.W4Q2&9"+H7I)='"P#^P
MVMJR7>M4/LJEI:QTQJ\C-W=*4LKK*;KWZ=V6DBECM@"D$38BXM<.\$99A-&0
MSU; CIO,SOCC)QW1/!QZF0"F+I/:8?X]E":B]Z3D\\^;RV78[2<W"A>1?/07
MC#FV.*2_9>VSZWUK4X]/76T5*6>*7UPC<2$QJEVR7K).M['Q>-[LU<-J3H*?
MPX/J8 ,KASM?EM^EF%M"YDKR+N8K:_8LJ&[/8M$8\P)=#/34ACI+=#WK\N6G
MJ>X*L5KMN\G-O%I&@6Y_>E6:BHKJOQ;/-])-W&Q).RAB3A3GNY.]0LZ(N'_E
M@\IG%%^:9I0 [[V85_T,7H#-@$S@ )(@/;[]$[L*HD?C[F[Z-9TEA SK.:>4
MEH!%SM[6UAY(XX3/>1@5\-3ES,H3)$%=T$@0+YC;#KVDP?BYR">*<]@()][.
M?A06HG-CDK@C#%#T_\JPRF+\K8FI% <E<?_$OQG1U%[2,E">9UK?+)%(]WA"
M9VW%YR$U-:O?H\3NWQ-7*WGJX_@T"HA071< [B@4DDX/RQ97-$I>QY+3AMPP
M *G>Z(=O10*3EGN868X! Y*2B:Y+,]]RZD Z_PP6/&UP9\+@0GQ($WT#SC*Z
M!#S@!.QF;0A0FNW5EF8Q1*7%@4-H#0!<=K,(%V2K5=,Y0IA64!M"W::^\ >+
M,L/-(-4']TMKNT]BFPS7@ZTW3R$^)NY?\PKKE3:!D^7X52QPA_W\L.8 09=D
M/R,$O/V:2^$8D,.)843.MB" /:%OCZXTL>#X3F8F+:"*M58(,]R4C)+G:U//
MGGO/79QI;Z<Y5F9[H_YA3+]8@U)AX25W\^CPY]VN/Y&G*%/S9X\!#P?8;0B@
MI=3GOK(60\*<,-S*)C.[VCSWVH&__M56L67<JF<HDUV?N''ID;_N4W0K:@K4
M A'^E12$V4&P7K\[HM*%DGA07WT,0$@<A@P(OC##2S0*5R@P_41.&;8CL:F_
M4V-S^"349]5\]]#\<'PR*^=]> Q )\.&I!,(C4O,QA'' ":2W:+ALH&;3Z/4
MZLK'I*QLAP>EQX"6.#X*_;5%^/S)?$4/=[N!8(0#M2,>W4HO;LU[3%FO">\9
M6,*;'EIN:"&L3^8+["3!/)ULN D.II23ZJV2DLI)L]>M;"A6QNDY:N&,BS]<
M]YYJ-BE\M_TG(RSP@V- V&OG,ABJ5+)CRSG10,PPR#"A](-?AV75GD++SK.K
M6B^,X*]^9PLEX!8N47BFX2KU8[S#G2FI_ERM#OZ1G1TF5XX!,Z4+7\6CH(TC
MF#C8/E@_,6!2R'PP]-^3*T>3ULBES9CD0/]8.7>X-U9?9P'%>V-U$\KV*5)F
M-XOA">P1/^_>\I.&&[<@HYC$X5+%>,72_6*>PQZBQLECU"9I8\?M/2(@H,<_
M'GL4.1(OC<ME.M97W6^QJ<&E@'Y]9UDZ]:)_DPP<\H7)!AE5C?A,?U5A9L[K
M^&)G_54LVDST?')H*\.(1??,ZFM;?]GQ5=6=*%Q]!Z@2W24KBC%NRW8S-K)9
MH._XHK!7LON:U-^K%!-P[9'L]X2^KV8J6U#L'>#4E =@PPA;W6I:3VBW?FEZ
MNZ9"K-O10Y)6#'W!1;MEM\#KJJ/H+!+S#E0J@RRW#-&+AM]YU(PM:] ^HRJ%
MX<JQ.:<XE4\Y;'$Y0Y&1/Z\X*/E]Z%U@^2SR$7!RO/T84'8,:+.3;PUD*AK2
MH[S*=]6]THWT:V&4\-!N,;?W*\CK[C+^/*C[KY.1B(J*ZK\.#_<K,5R9>N$G
MVJ(BQ3-:VCRRW#2$+>(=1#>4$_( &?L3;D.0=/%]BIF.LK>H+ W-I?19GL^J
MK(G2ZWN,WOU"S+PH;F6>OE(XP LWQ8(Z7S(L'416".G=2K(8%V^LJJL)W5EH
MN/2E[U10D\?%SHNQPL\- .^+X]>;FKS)#<U.3R$N'I,#]EA\.E/?H@UM756T
M(*!RY!IEF^L8H"7J(BITVLY C9NI*^(Y2>_^$HAE0WTW675*>=9D3'K:"MG,
M'2EDO*SKC+Y@)-#@_CE6\>PM;1)L 400/P;LT)-K%S3FG]4MI0?#KOV44QY-
M7WGJ9I@D=E=S]^4$;AP6]Q7VK4F!\AW)#GD0/U7>.>7^$H+/#=N'?2C.C=CG
ME9@<6SM(K) LDA%7DK-<$??Z-M'IUI?=[VX9!,H;[2 Y$RRS23""PR+P].8Q
M0/9SOKN#0=A*YFOVP;^;-A=LYOE_V*IN;Q&A 73X^%+]7X;'@.T!3BGW&BPE
M\UNJ0>A/Y>!L;?+*ND*-G*?]O+&7[TT2Z62L-"4]&FUB(3GC]+8/EGA@5YKJ
M,FS.+$L>",1*$]?'(>TR=W89/BC(*34U&R/$X-+8B,X?K-V9A.'V.F24<KXB
M8B#X3/#+6/<;Q*_S.Y=.!8XODSLB=$^^]ZL+)]JC\M&H3%C89<'>H4\W[F_U
M*!R%0TMC[@K!S+UQ _BYW[?05&^79!K@/!8@D?O.RN_5]R 5$PU9=AMA-Z;*
M=9\\4Q+Q,VL5?($Q5%4CTN%U"2M\.S18U>LX[L1"V&UY/**$?[/:,T2H=$)-
M6D3H68A?26&#/Z91>E$RW+>9>:MJ\<>-,5GQTOIG^\[+)L7A$R%>P <T.]!X
M:&E58R&B&U)Y$$UA#,CQ%GJ1&S %][IY1=HVQWK(]QS&6!# X"WV=,.<[]%?
M2SZ(C'$T!&L6'QG>ABRO  M%&U4C)$8^5CWL9PSC6M/7([&>9R ?'?TT&Y55
MMKNR=;NY-JZ_:TPB(RCJC92N0)C5FXP0P"W8'KHK=4[BI,SO$*/6EL\;+K&D
M@!D'=0J@^N^L)SV@X#UC_+)4*->4 KIW-"OCQ6U+IPU)$E?X@@=)JF22KJ5J
MJ'W%56"$M<0.%];GY8]^-1$)3SX&A(P/)QL;#1=7!(/'VOIYJLLKH^Z%\7?Q
MJHW0FPNW *16'OC\R>W(?_(F0BBCD-+?^X13S=<N$U[T;B#$J^,=(Z)D;C,7
M(K*D\2F:&7<:;PWEOCVICR"L0?R4:*MG!8*#\.E#)^RL]SF+HT9R#+NQHWYT
M6" J':="I-$%()Y0.I!8(R0G7(U0&XR37C*?S6@NF>A;=;F,#AC_:!C>W?!6
M#Y!B'\EVR\ AK!#Z:>3//@,J*JH_#Q3?C+V#"IM";W\BZCI#0)HTH$GE8H?;
M/W<M5#HLCE(84U316%O)-QW^8/];TLP4)IJL:<1WU!D$B!2(#:ZM&UJL@ G9
M7F*5?5L1WF.)=EY5$@59<<>QP?:3EBS;[!B6<MM9D2T4T?"^8948OV=?"YBG
MN\>N)FD)G9,&^J[%CB]%A)&L%@<(DA$=*$Z2#*%D8;)R/L+Z(&VM)5)8HT9?
M(:;^7E]E>"83+A$(X&3"#&W_E6IF%X&_/8AT+@G#D5S)&3FU@PVP#V7-D9H,
M;DIG9>6^N[L\!FF,7-'\NB1>IEC0FN08#"2R4V;OP!_>A3,O37[X@MNF<ZP<
MOABM979QV>%C_V6O3S2U4@PB\-&3*/A@K,$JBS*EV(F]U44TQ6JMC$3E3V^Z
MK72]U7OCU_.D_8GE-6V='MY#9-3S8$\B MFJYMXD 7-:1+;V//R"6YOB=-/3
M#S.OM#E49;&[OER 5G^G]#"$,)N ^6$PX16O"$82:D#Z)X->10#M\HS,A2W+
MP2M5.PV7]:M0?B*Q_K/1Y%?6I![R&PCF-4(,>PSH\ #";Q*JEUZ@.M0?9;L5
MH7-<$@73Q&I>Z":#AWTO'C8]I$DV6W8"SC4;Y3E82]/##8@!)S&U!GK'^+-5
MP'C;V_WF"$UO!V=9*_D+'N70 @7G@Z\H9??ZR#F>O2NQ+'10MT%])\Q\IQ8$
M7S:XXS,?DJ%4,5XB.BZ_6#E,&N$#>;1J/# <_9HH%]?Z[O499C= -/DA.?88
MX"C$AS<B&+MEVKSQ:# *KEJS'?UD2DGRC*_)^KFBEUB@MMM!V]6XDZ AS<YH
MFJ"_[AD;WX+JS_[C6XQ45%14_TL-- 9"#^? #;3+9Q+6VOW %X;C?LC828B'
M1K8&9-MJ&K4<)H3;C7+3K*#*3P+(!0QT,K5U8&& SL7-R4VS*ZBP_L5/]\\H
MR=-6EU7=&%SC $*G#21'UO\%CM9045%145%145%145%145%145%145%145%1
M45%145']-P,YGOPW4$L#!!0    ( #2+35JP:<+6*Q0" -!R%  4    9'9A
M+3(P,C0Q,C,Q7VQA8BYX;6SLO7F3W#B2)_K_?@J\GCVJS0)5/,"K=V?64E>/
MQE1*K935O6-ES\)P9K(G,IA-,B3E?/H'\(A@7 P  3+59F]L6I492<+=?PAW
M.  __M?__OZX E]Y6>7%^I__X/_L_0'P-2U8OK[_YS_\=O<.IG_XW__R7_[+
M__I_(/R_KSY_ &\*NGGDZQJ\+CFN.0/?\OH!U \<_+4H_R/_BL&G%:Y%43Y"
M^"_-:Z^+I^<ROW^H0> %4?]8_]?R3RCQ$D\@'Z(TS" 2+(:$$P2](.1>R@0/
M_6!Q_R=& AX%L8 T]3V(<.)!0F@ ,^+Y/ XBEB6B&725K__C3^H?@BL.I'CK
MJOGUG__P4-=/?_KEEV_?OOW\G92KGXOR_I? \\)?^J?_T#W^_>CY;V'SM)]E
MV2_-7[>/5OFI!^6P_B__]]</7^@#?\0P7U<U7E-%H,K_5#4??B@HKAO4+_(%
MSCZA?H/]8U!]!/T AO[/WROVAW_Y+P"T<)3%BG_F JC__O;Y_5F2V2_JB5_6
M_%[-[2=>Y@7[4N.R_H )7TGNF]'JYR?^SW^H\L>G%>\_>RBY.#WLJBSW1E5<
M9HI+/U9<_M,Y8K]<P;XC?NMC7ATPUXC[T16/8YA^=,;NG;00?'J&!V2N9KG]
M0KU=L[F^NUM25[,^/<>NOA9%C5<S?"UV9 8LK]0''^1/'1DUT(@Q;>ATIGO
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M5CE]_MG-_L, FY$-B,XHL^U #$0:;D%,7C,/';HKL1KAR_,C*59+S+.4>D3
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M$QO'GIB9O=/'3<^D38*&F=7JZ32GZ3LFVMU();=HW=\7H.4$_-[]=Y(BHL:
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M)CEWC5YM$$[4Z]5_US(O#9>J*;GJ/])<0Q[&Z(1$1#X6!&9A)!=YYB40LUA
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MZ\,MY&\[R'MV0<OO FPY!AW+8,BS.DC:YWJ;N.4P@'$Z2!UY=1,P.*OG-QW
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MEG:)*&$T2%*8>JHY3Y!FD!#YC\\#GD2816EF5D_6B/S$VMV7<5BU_O*WCA^
MNP8<?=8_4*U,%^"I9<J^"H8&WGIF83H4S6S%01V,GA70\0)Z9E0K$_GW3Q<
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MF&%/0+GH!X&(&>))8%18;+9F8,8MK4Z)K[?0SQ*SJ2./>:VNR<(R7RP64R,
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M6VRCPV=@%99H(-Q 0.'0V[.% AJ(T _B,WE\C$)JOZ^4$BYM)PK3*!(0H3"
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MI&IVNPZZ19CC/,:0TB2'"$<YS+,LAG$B,A00@DB*K*):A^E-K'PT=<L0U@L
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M?X7N]P(_];?EX<K@Y_^LO-Q2O-DT3GB!,;],;WZW\6;3:'+M\7;,N1D(;8K
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M1!&B,,^)^A$'..$Q$M@JQM&0[L3+^2,N:_!=$0(U?^987;BZ)-(8@FBV#4\
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M".9!1"!*.(>8Y0CR,!&(A'D8!,RX'(@5Z8GU1K^P[O5@85WKDXD#S)>-E.G
MLU,M/Q=N%L5')L//L1K)4/EKU4JR9<E3T).;^$-U2NP&G*]PB9.@>Y5,W$9P
M,]_^RO%B_?0>U_Q+_8B7Y?_JK^@K_\Z7&_Y-?SPK738L2$26XIS#,(QSB(J4
MPEQ:;9#F*4%%(,^2S.HJTY3PQ&JX84/U.N"@S\@5:%D!+2].==B,T34S[*;
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MJYKOJO[[?_+R\6G-V;5<Q_B1?_@A#VSEBM_5I3SI)HRF),(IS'!!5'P:AB3
MRA$91EF:1F'$LP<I9EFQ;VM<KPVUT#S<VZS00QF,%VN/%X#7@/#'<KE4/U0"
MO')<@U]^^W8#Y/!@I43ZDZ5NFVF>22XXR4D!<QZI>ZLLAX0D%-(@083FA&/Y
M4(/1AR7[!Y_E3@+7.>92'\O9;0;[QYA?PZWOYYLQNYU3<P<U>P<EI'8R /(*
M^L^U<@ MR!5H19'_L1/F"G3B@%8>T D$M$0>-^-YI\#77CX3U_.: O-.Q9$E
M,3-Y^R"UK?N.]\I)IGE,&,E4 ?J$28LAY3 /,8*8H"@D!<Z16;.Y<P0F/O3O
M/.#<I>;I65B&%; /8>TTY51RFH=ZC977+:#+7FZK *XAH0;"M$Z^-ELPUA#3
M_9"KP>?<SC%?7G3[R^7C)U66ZJM24U_$;RNN??T/$2^R M$,\D!=AP9)!G,F
M0HCB&$<$XX2AV.8Z=)#:Q(IE2QLL="FU6E&'E8 ;^0/65QMVIN,P=&8&GS=
M[)3/#@M-]PI\[<"0M)O;1'\6E9&,GNR@85JS6B]&8A_:'&8O.5?A55=\T@1Y
MM?+VGWIWXK6ZK4.[>&V.!8?'B8X9ZSJ\^PA<OA$8*[S=NC26V^]-P9"08PKP
M[@\X=_'=D^*<*+Q[^CF/G5ZZ5M8[(PT)DN P$E#:Y (B+C?7@H0)C/,X%E$L
M<F26=6I'=N)%>[JOR!50?(!?%"=_&E6PS0A9LVW7/UYVZ]P;5'[ZK9R5?,K6
M*L=$W[Z+RED@C!JFG'_[S>\8/F]T,G3(14$*$<!8B RB-$ 0\SR#+ A8@C.$
M,<=O>IO0\/F3W!O(M:A=RJNW\RFW\R90&J:QH# 7B$%$8@9SRN3DT2#%:1 &
M$4_>\'; ==8\WP/\//,UN[???@9^$K]^P_A/Z;[?Q_3G<]2W_/VCNN3WX9W0
M^7Y R-[-KKH_?U6E6INB0N\EW4>^>A X"J4A'\$<XT*E!Q%8A'$(,\IQR*.<
MIK%QSO=I$A,;[,I6 7(-\Q_*X[ I5T]ZO4J-RB0[YG[H,_A<]KB/E]K6["9K
MT",(6HJC135WNH\7V<WMKD5_J?E+JY3K'@KUKE$M;?B1OUJHEBI@7>EO 3Q7
MK!0E;72^_$ 6JBV]"D#5?_:4?#V,S8#W_LR+L_GOAQGO>_ O/.GSG*!_N[K>
MK)^JNOQ?SGY;RA%UK8Q&1:JPJ-7>3:2NN-.V0%"5KZ(L)%"$!86(ISG$ 1*0
MDSA(@QC1&$=6S1;]\SBQ=FQ,&7)D\EPU1LX*[-@&&\5W6SFYX5Q'#DIC9S],
M 6CV?5BGXV9WC'TZVYQ9NDY/ #U!#XP),9G4PAS'X4]@8WJ!V,S*]$/*U8%,
MUOT>O%U)K:A@.$BD*J8BRZ6Q23*(8X%A&A8D"$+$$+-J?GN&SM0ZE2_+2BI*
M3C<J=?&]_$>Y!A\Q;:LY_9NM3_@T6*9.X-$0.)B?_9;;TS34'I3*FT?W-)69
M7;B#HA[[;(<?=VRUU1C4J[:=5\W/]%)]*)*P8"G*8"8*!%$0!S!/@A"B), D
M$"),F.AZ*YJM85/21E_T?B]%NV5])W__I&(JY,G 4_]D8UC-UKI7J%P3OYI%
MOV[;]]7\? ]ECSV[+ 7WU<++E.R\';TLP3AJ\&7[OJ-*.9>XLMW@"D:RC!(.
MTRAD$(E$P#S($IBR*$@CE/(\L;(&+E*<V"ZXD'!U>9MTQ-%0>?A$QU)KC 7&
M7F&8"NM+4URD-Z^*,!7_2#<8O^A6C%2=-O!":J"J7K6EK0G/BR3(""R"O(#R
M !#!G',! XPREJ=IE"&KHJ/')"9>]CNBH*%J5P#S!"27?<[C!;5;P4<R.M0T
M/R.L757/<4*[5^_<%[Y<@B==U8VJVGSEDFWDZGCU6+WSO)@7JG2>>''6:ISG
M&3^LNCGPI&-Q=!5L^GY7%^Z>U\^ZWF/*&8ZS+(=Y',00Y32$.<D)C%DF0I+&
M!0ZQ53'T,X2FONC2 =\]ND 1=BJ5>18J,U/"!P!V^L=-=OOZYA<$\U7/_!R9
M>>N77Q#VJ%[YI>==4K^8ND8JU_Q3*?AGOMY%CE>K%>^V")ZF* DI@CR1_T!9
M%$ <(=7].\IX$D4XR8RZ&9B3G'@I[Y@ B@L@V0"]; ;-B$T&E1&*EZT*_]C8
MK7(36!P,#T-\;'+.?./DFH4VXC.R3$BSD7@P1<UHH!F3UFP$VT]CLWK3L3(H
MKE4TY^J.U_H^YY[_6+^3O/_](4H2EHLDA90&&"*1)K 0(8612((B+4A*D%4K
MN;.4)E:%'5U53*JYD[8LRGD6(3-;QHO<=FKN6&3PNR(+-%V?C8HOR>:K6N59
M.O/6G;PD[E$%R8LON*W:^Z>R9G=8^5'4\:;=7^(P3N-$'SX2H;JK9)!@=9."
M8YIF&6%Y;%74_R25B5>KI@DUT>8L;+=83P-CME!'BVNW2(\DO6QX6*_/09$\
MK<W3-&9=EX-B'J[)X8?=UN-'7-:JX*O:I7<Y+SH;M6O"]/JK;D3.V9?E5W6O
M7TN]\ ZORM5ORXJL>*U;-]XN7S;K_0*SG[8Y6V&!<! 1#I,$RT-*S#)8,%1
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M)8\#!5MWN<TS&I$D@W&>"XC"3!H3199"%G(L,AS%)#'RLX_D8V(UIA@#'6=
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ME7+"VGHK3F-EZK<8C8"M!T,3[(>P3%"X8U@J;UZ-TU1F]F\,BGKLZ1A^W+6
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M?9<$U*Y/IC\81WA#SH#8]%?Y$U#KYGP-4E67<JDC\%;5HF1J#@$K\>)U5:[
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M *>4'1LZLZ7S. C?3_5Q>7ULH;EWFU6YY*M57S.]>^W]U!1*XQG" >,QS)(
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M^,MNMQTM-,T=]!GVMS?*YWYOOA6N-K00&'Z14*HT"Q[X!'D))&$DCE,:BMU
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M3H(\]:$79<+%Y5D.LS253:^YG^<Y#BF-YZ^LS%<7-'T;XL)DTW1Y,;F2:!@
M#)=+N-JL][H#R$07O*ON-71\;7#7TSDC8VFF@$YW:>M N\?0;.NTGI]KZ*+_
MFBX>XW58&^3@O7NHZ4*DT25->RG+&%YW[/GU E=5P8LZ.MC,FXMYZH<LS&&>
M4Z&O6);"G'$$D4=(D*8T8KEO%)P;HCBR%=32!XH!L,^!Y02_810U(VPNL3$,
MG5T&BWDL3%=45T&N07K31J]TQ3\*2VD_:-X8\:96, ]EW2=)&$UWY8I\6ZVO
MZ.I%!6T,1^YI+SCRGF_X &T[PI8;%?R5+#&Z$8_+3C"@84V_^:(^:OU*8#3
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MYC1-M+,G1^1S9!6]1Q]L*CF7:K7MPUA?1%<SP!K^82/A=BBW<8/;L5_K\"7
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M+(^\"&9Q2B!B40:QQQ'T8R\,,?,P"HU*7,[0&7D+2ZI@1W8&!.$A(\T()MT
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M;-E)V)C,%)X2U*XE/2E=RT8]DMK5RTO)2*&X4PV7*\E+DQF(&.:)'Z0PH)Q
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M0%_.S@0!J/4;J#D$'1;%W\$!DZ#E$G39U-=@#M[-\#$P+>)FA\/E8 \'R,=
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M)(B%6>"E$"&/0NQ1"JD7L(A&D?#%8I,-?)K,R)M7$7M:+00:_[M21[YN.<0
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M4M?:=I=4'#=-.(HM2; 0',W DAET$#.%M%]?C063G8>S9:2] I&L ,D+.-O
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MOEBEE+<('UG]WZV+S%F6I<B/(?7C&*)4_)&%009I2F*4,Y3EJ=$4\:D%F,Y
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M<"VGE(H%FMF8&8XQBE(9BJ091)02F*5"PW*:H2Q#%)%8JTEF'Y&1->B.K+2
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M9F32(SIM\1V?Q0W3?95#-VTXKIVNZ3_ /%AZTA*RG0#M17Z(4P*C%!$HO:
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M6Y7+=&%M7$X?!4J/GEQ7L^ZHC&LB0'OBBZXISA:?G BJ;GQS*A+V.5?J?^H
M[3M>J13TK_(K+7(JB:M?W*S9\3]TKESBF.#(YQ32-.'2T%5Y6*'/(0VIQT02
M^A2'R^?:$-_B8JMG[H[BR62YGW)FE%^T %5/ 'X@774%*/:,U;_?"-"T,%;V
MY6;?Q!C@K50 S;11=97*['KAN#!/WK)_?](?89D@ 20QH1!Y40 SA$.(2>1+
MCX5D<1@W[^_CFKW)M]?R-?>[X_+Z5WIK>C[4;._!S+2IX:\2]#KT%N# "J@O
M42_DY!^[=[A-V!L-E,,D/GM>9D_L&PW;I62_\0^UG>!%MB<I3[=-=OU7N14O
M8Q+%&28AS%@80,1\ 3'.*$QQ0!+!TC2.,K,97KWT)O;Q%/4+P^1;#H!BP71Z
M5S]^>FK+(2IFBFD4(!9#O+3$=#;&JY_:S(.\M$0_'^6E=YME"\(J@>P;I[NB
M2BW^]/WW?,DSC@F+I#W+0FD>13R1YI$?0HK2D"9>G)+ *(Y[B<C4H9PZ,:[<
MTUR 3W_"WV\-NPI>0H>F 4&A1Z ?^4P:_R&"),A\*!@)0I4Z'5%D=E8W%A^K
M@[ANV]%\7=F$1X Y0$I/\XV5WC#$5,OY[?3#D+;9KBBXRQ+,/L%<=5:\1&+>
M=HH]0I[U4.R[UO(@2CHBA0H/%/R1K\O\.Z_'01\&();_SPZO<O&B*BC*?W#V
MP,O?^?9.W..?]5%96X[;%N,>JJVD.Y@*-;</8>GELQ1#@CU?>?E<^"GA?JC5
M,&8&7B?6IG^L);65ZL\#'G N'<'-^F3T*<7/G?&GAI584[Y$S8.WM_%J#(_O
M%-/@B.OCD?:-OZFJB$#%\@)TZDFEJRGD*Y3.)EWALLQ%3IN& .LZJCY%E=@,
M0+LZ5IR0TWD/)Z>'_.R(<P:2EO:N3A3Z]TUE&TE[NYH44@V([?Y>3;/\?;/]
M+[Z5:V?SL%:*<1D)XH4QE59RF,80^;& 61C%4& />6$2T"@TFBHY&:<S[!4M
MJ>/3';I1N\6AQ\BZ9?[JH2K AWD,)=BMY7MN#=7CR];,0?K8=-^&IB'\%MZX
MV19T<5[+X9U5+82;=]R,<5'\J1GAX(5OP8%%]PU0)D?3E0D_&9_S^@%3PWWF
M3$Q.T/)DL78C/VT*GC^LY7[6'%@VQYE+X7D<BRR%@@<,JCH,F$:A#X,P\:+(
MCP2.(Z,>#OWT)M;V52AJC>OQ\H:'00- :1[WN!/?\$"G)@P:RI7%W- &OS34
MKV>/FY_6Z,GIZCQF@-J\)RYZHI^=J6C>9IYQ)RW5+\6&<LY*E9V@LF]5[Z<[
M4>79WF]:U50N!8I8RD@( XI]:11Z(22Q_(D%610%G 0,:76U-*(Z\9*7?(#G
MAI$ZAR=O6*D/CI^>I$566V.-Q7:2X:]OF9F!W:\P)H/03&TH]%H>ZGRUE@MP
M)YHL_?O-/F]_$J#T<](F <PNV\P9<$8Y9,8 ]&2'Z3]KMKPO8_&Z&5WF-YMW
MJ'F_69>;5<ZJ;Z6JBJL:5@N/Q0GV"/1BD4*4AA%,?89AAB**J?#C2&@94==)
M3*Q$CXC6I9C&_;RO8-.O!MU(;&@JF0MKU+"F7YX1'6NN/'BVEC7]@G5[U@Q<
M:>?*J%XC5:N1.]$,=,&KVW6Y+2KU77Z1!.G+,DX]$OA,=:$C&41>DM;]<Z5#
M$]*,)BP,C*;4:5&=>'E675;JL<%M[K)A,$D/.ST?QSDB9LOWN.7,G@/086$!
M:B; 7\U_[_G/+7@GO^-_.3P\,,+!D2>D1W-6?\@(AE.OR.QFN\E,JHW%.[]I
M2$(I2H*,A3 B*8:(!QRFA 8P2807)O*OH:?=9N;TX1-K 46N:E@"WD'?;(+/
M$03#CLD8P<P6\Y%,%OUFSH0S&SMD*Z3].*&#L$\557<C@B[),C#ZY^B664?Z
M7&+V=%3/Q6MLQUBK\SYUSES7;[39Y'?[9/)EX/$T"W@*A2_\^L ,^VD HR"@
M G,/^Z%6G:$^R1D"(\U@VZ:TZ4(.O>F ZT$8]4P(M^"8J9RCG(0:F@,#X,#!
M B@$I8EQCW\NP,W);. OV&UVECXBS@9C#Q*<>3"V+@#G@[&U[[33'O=%U>KY
MI0HDO*\BBG5#@R7FF,6$AY"0.(8H\E*8<C^4UD00<A8'G*5&IR=7*4UM6C1T
MZ\"5.A95I-N^'69*XCI:>KK!"0:&5HB=^,:+?% T1VO[.IU9E_2@N*<K>?@&
MR]Y3*L>3L\^;]8-<'$\JA[TYCKE9,S4OMOE+FZ7'H]@G?HPA)@RK7I2JC#C)
M8!)3(J*4BX"&1CVGS.A/O-@5&U#Q 9AD1&YF6[PRS9$T151OZ4^(DYE":!@!
MBH-)$@\M)775F<B0^KP=B>R@.>M$9/D8\X;:GZ2DFS57*1O?>?'R8<?O-Q_R
M\K^KE,(FB[5*)6R.>LN;IZUN9VV;9T\=C*Q9 BU/@.TJB_B4K<9T!BUG9K.'
MK8'MUS1S8&H8SIP*3J-^V6,PL6J<;45PM@[:8^#HMM(>]1P[6^=+D3]Q58K7
M!CRQ\"E/&(Q\-3Y#VB_266$^3#&+N(@1"BDVL65.GC^QLJFH653!GJ*@9W^,
MD,ULT1_$<MCW?D *1[;#Z=-GM0VNB':Z]U^[S&Y%W=#_WN72E/B4K_,M_YQ_
MY^QVO96O,R<K7HW5.RF(K4L&WG&Q46/%U_P'7MT5'W]N5>W!9KT,DXQD(8E@
M2/T8(B^F$/L!@9CY*(Z3&%.J=00Q$7\3K^B66U"S"U>*7W!@N!U+V?(,VQ+P
MFFM *K9!P[=\D6#/N9F*</U:]53,*[XL,Q5U^IX^S_">C%7=1&@Z4I6NN9M5
MU4X$[:FJGHJ,Y4C3S8;]R%>KKYN5FG6BLO27. JQEWH4DB@)(,J\ !),"/0\
M'/M))O^/&#4<N4!C8I7;4@1_*9J@(6HX?^ 2-'HJ;Z3 9FK+5%;SD:37I7$U
MC?0"A7D'D5X7\6P&:<^E([.\I)]$5QLU8K,\U, +A)'G^5#$(8>(RV5(B)_"
MA#(>R+48(2:LDKLN$)LCIZM.8^H0UPDVFL.FMTY=@6$8_[#&P3YAJT= UWE:
METB]3GI6C]!7L[+Z[K%M[U5/).^6O75*-/\SWS[>KEG^/6<[O)+DZU-W>=$7
MG+,EBV*>)AZ!$1.1W(LY@5E*,(R#+&9>C-,,&P4S1G$SL8)H>3NN+5;E*@O
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M26_J,_6*^@+LZ=?-QA:@80$H'@Q/UP< U#QH=P>+X9G[*$3,3]_UY'1U$#]
M;=XS>3W1SX[G-6^S6_[=(>EJ''*5D:GR0X((^P$),8PCSB!"#*GL1P%Q%C+N
M95E(P]1DW5\C-+GS@;=5P%6%XILI\/*C_K*I2W= R\JBS2<S6_Q7X=-;]2Y
M,;6^#?%PGG\S)+.CI7^5S*QK?DC8T\4^>+W=*F^K__?31(XGGB]]WY-[?""@
MB#(.498D,%4[O1H9ZF,O\$AD-#1H@-[$:W[?KR*WGA@T!)C>\G8(@]DJWR-P
MF 4$&MK@EX;Z];IDXR6M*:>CE3U$;=8%KBGZZ3K7O<VR1O=:.Z'#F>/AB#VB
MG/J17.P^94'32Y5B#_K2\&<^H81Z1AN]"?&)%4'+BF9+KO%8ZJF%J1 RTQ$G
M?<N.,3J:*#I)6H(-"*[*=4U(SUNN:P'*6;FNS3,LG8>F$+A3"R^I?U(I0IU,
MH</R"")?VA>,02&0!U$<(ICR)(+,\S(<1B$G9KE3AO2GUS:@H@V^[9Z>U)FB
M-+&_\G*WJON;-RZ<<;\ 4Y0U78_IL#/30RTCH,-)U56Q ;/#S:1Y4I: N')7
M#*G/Z\7807/FW%@^QOP ^+3;6?F54YY7Z:3EDH0!3:1G S-!,41)BB%)I<&#
M$B]"./)3G&H9/$.$)E8W'4KZAUF]P P?0[H2U]*;V?<?+(%[Z?5/W5RA8'=
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M1&F^4B)0D'IR+]'*2-2@-;&Q*JFWLS'W] $$#0L&2?\#B V?L#G$P= D[87
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M\Y#WWB*29I):''="92%+[2,_??E3F;.FR^S28PE*(XR@'XE(VBB92LV+I<I
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M *)ODHL)<JX-)7=56Z%)==X*"S,HSNHL#&]W47REE)BRB576J;_TI.M$$IS
M,*891(G*TJ;<AY@ARC"*49(9E5'VT)K#=>J6%GT4@M.M"E+H)VWK0*:I'MP
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ML/3[TJ4<#^O'1U]RGHF<Q"G,0XD@RD0,\RP0,,<\CBCFB<32ZM3]:E-$8=L
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MD:RP-O:5ID+0VF>R F^"JT='+/RY45;4YW:G7* YXE8Y+>-XW5FN[G7D7!>
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M<Z%A&!5W$MMPG.(KFH=1",8MQ/BKWK)&OPA6WJ^T'?K(%=5"-L.\NAGR;7L
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M4B((3%)$19@@*I%Q^YTSM*:^M>BH=^WIMK.*]6P6\]O!<WB-:[5G%"QO,WH
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M[244$(LH@RQ(XH2G7(3<*/!_(1\3J_#>/)0KL&6N[RQ[!?ZWONS;L@@Z'L&
M27/GX9(O<MXOFPEG.^/QWPEB<Q]M)JC=_+2)(;=RVCP ->*X7;+Z;,Z;!PB&
M#IR/Y5Q'%>IJUI4.4(H5*T3]YOFSGD@F;N3NCULG1G N.4<!3!B*(,+*K\L#
MF< L3:,81UBY=U9%7N:D)]XQ-"-@0!*T;#@Y?Q9XFCF%TZ!D9^\= 7(81V@K
MJ[<1A,:$9QX[: O(X:A!ZQ5<VX=^449*)[VLUI_)HUA@09*0AJ$Z_!$.D<PY
M)"R.H'([)8\YD0$S,A>G"$R=(]*VRMS1!)JH;8?0/4S.^'L>)+53;$LA'9J
M'I?D@MZ?>PO.W/+SN#B'G3Y//.>V1_?=ON[*KJ%$WX9"U'^ME'XO4H(S&@D)
M \*(.MBQ!!)*<ICA) T3E$<I-JJM,B4X=1!&WTD]D8+K_E2DY0#0C@6[[?@L
M=&:;L$] [#2TIZRAZ&B#'7$]%*4<P<1Z!S85U-.^>Y;<K+NMJ?#[>ZSQ>_;A
MGK</.HGI;X(LUP],)_>+QZ>R(M7SATWC_5_7=:%/ DQT5Q*,9@&*!($!2I0I
M()Q!0H(,DBA.TS#,>9H956B[$)_:+#3L@!T_8,L0Z#@".Y;,HPO6&)^/VDR)
MG&6<UPHTA[LS:_3, S)3HN@6A?'T$[2*MKBB,!)BL5YRMKB*J[##8(KS&EXS
MKK9Y7[NLB_; M=$56^U?EJM=O4V*HS"0*(!1' 3*APN0#LX+*$68IS+/4X:M
M^G+Y86L.3T\NRS]KH'\'H-SF1.X2M>R;L_KX'&9^X?P@VUG_,QE>NQ34':-7
M8,<JV/$Z58-8C_!-FQ]FR]2/D#OF"*1A7IGKZG9F5C"^N.;_]Z[\7*YN1?E9
ME+HNX,-J-\#!P"B>761B.Z=H;]H63?H<IYB M^]OP&?U_U^4RW\HR_6J7!OZ
MKN>1&3=B7D&QLTN6>'B>>&$L^$B82JW1&1/&=S;D_,JSF 5C 7M--W_!S4=Z
M)YXJP8KFJZI_7XJNC/+ZL:S678GE@B1Q3B2.(4_TQ+> J:,KCP@DF @2A R)
MW*I0W(3HY+D(.Q: ^*Y_V0*H?WVJM*>S?FZ*D,4_-L73HW6!C!&F9FZ,;Z3L
MC,&0^A78TF^P&7+@S^^PD=>35V%$<E:?P0:$?8_ ZEW7J5;JB'9?;'LI'QO=
M%"1Y1KC$,*&8Z3,3A50G-*D#$Q<I25"86+4C-* YL<'8<6 ]XNH\7&;&P#,(
M=K9@1[QOYC[#W"MC>;V-OSI/<>8I6,80' [#,G_5U7>0HJH$;WHKZ$[JZHLN
MMPV.W[>;ZANQ$K)8+WB$DSQ*)4Q$*"&B,H=Y+@0D:2!RSE&$(ZO>!C;$)S8-
M#0NV+H(%=*:NPC2 V+H,+1=MFY9VSH-F9-#"''2\@)\Z;D[W<G7P'^Q!\.9'
M6)">V9^P!^70KW!8PR&>H)MC_57?SK]3=#Z0HOJ-+#?".))P_/6)]5_3 0TA
M0&J=Z=EP -X96X4QR0TB!9<+;1DCT 0'0H(= )Y" .,2N1W^3ZPYW[%_7*@7
M!_XSCSI6!6WJM5+7ZJWF=;5N@X!?BOJ/[OH/19(2FN60())"1/(<XB"24# I
M\CA&.$BL!M*>H3?U!49'';P@#S1]RZ*A,["9[<X>P;!3UA$<)I@68"BFKTJC
M,]3F+3LR$_V@!LGP-3>=W]J.CZNGS;K^)+Z)9=3]<#%%C"8XAW% *$1I)F".
M<01CE&5$1#$3D=49?836U YX<;\J9,&4P?S7?PG3X-_+IN]L26M1?=,=.ML_
M+1J^P$\-9R"R'"$P!J69#? $D)W^[_;F*]#2O0(= !/HOX&(GG1_C-*L>F\@
M\K[.F[SBJ._%JEB+3\4W?0WX\OS_13R20E>J#$.!MZ(J2AXN1)KDH2 YI"15
MMB 6(<0L26&":4"XC"*6!%:VP(V/J1WUABO8L 4. EIZL$;'VHOH-FB9L[06
MCA_"T)),#Z^EE9D$67OS<QDNODR3(Q?SFJW+H#HP:1<NY]B$5?<9?"B7ZHWZ
M_3\VQ?KYXXHM-SJ7[%;3*E?#H<K-):J"9ZUP4HO>*T:%^DVOMZE%DL<TY81!
M'H4!1!@',.=Q"'D>LC ($_S_M?=M36[C2IKO\ROXLK%](H0)7L +]F$BW+;[
MC"?<+J]=W1,G'!L*7*LXHY(J2)7M.K]^ 9"4J))$ B!(NS?VQ2Z716;F!R&1
M2"2^Y+F5%_2KWLS.L5'0LJ;+\P"8>;\?!ZN=4VQT4V%7JUW0JG?6ZOM4PZ!3
M<9;2KGG0\\7'ZE>Y9:E89P'VC(5U'BEV_K>N]NO/_$Z51OR=[^XJ_'@O=U^;
M-SOEZ=<P#0DD@@ NJ'2C.66*OA"#-(*)"#G'(LQ-W.B@E)F]85]@\*41:5A[
M/PS.L(OS9K*=I[*SUMCE&%DSY#GD"WI>0_[KZ#&&W[W(Q#<RKYN_9A]V/(@M
M:WQW5_&[EO7^D]Q0;I_XK?8 AR*#B-"4QC "$4$,0)HDH$@0!VF"BR+AA MN
ME=\UDCIW&=>)#NKLI=7"\CC6"$##<UC?L%@>P%Y#)/BB50AF*=6P,MK7@:N1
MS&5/6FU@.#MBM7K8_FSUDUSWVR88ZEA),UT8GJM>>'3FB=V3&+SAJMMSN6V^
MT4H!PUW*-:O'SU0G&FPW98=M]<;E,6*7TZGJI?<M=J(Z8$S_-'7H8_:,&I\Y
M?:IDU!W%Y+;<;_@Z1@7E$2) !KMR64VS'* XC>3:FE(:YEF*0S/NM@LOGWF2
M:1EJB8CB7\C?@DZZ.97&&1C#,VNJB7;3RM8Z*PZ-:V8X\6><O6PQ[HQK9O1Y
M,ZY^QK$,X>5!YZ_/JC%>PU)**8-YD0+.99P*,Y6 $Y #420T#J,\89%5D>"
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M.Q5X=U?IZWIRH[FM]2Z5_==3%P!_YM77DO) =>VS2 Q>@\(@+^@!!<NTH#$
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M#ZW<X/ 4&UD*7S0><@/F90SD^!;'X^_V1/UVUU+KZ\1N_PB!A 5*B@0"RI@
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M[C,$J]DDGP$LNUE_VNKG FI')>;I]V-@]0QM?X:D_K#N/P90##4!,GG<9Y,
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M],MO7.P ?="@_@'Z\ >OS:4^ZN_E3__V+]UOY!\$U_S?_N7_ E!+ P04
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M%#X6R$BGQ$4*?[J<??T%'_Q+$5GYHI-=)[=[KUL)ZSBZ-T*ZP,^.B&(&]:.
M.I)!L.3!.%P\QD81G1$D*GX2V=MONTOUMI)?S<-/LWE,<S0[F]>Y>;BG\+N
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MPVR.)JP3_#G*/[V>74^7\^^O9S&-0E"1:EJR-LZ"B-&",S%"CD))3C@AU%<
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M(-HF(-)9O]=NF2YG\^\C[[G.)"/"B?<@5$ CF),!QEC263/TG6J43]QYZ6&
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MY>]533\0#%>^@B4TJ=CUEE1E,"=!-A5+P(45GDK#8ZI=D/\L H<- _K%RI'
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M!3-UT*X^,DZC?XD+)M@R?$IJ!98J#R9E)AG+,9G:<#N,LF$+-1MRO)ZEH@:
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ME^6.PR@[+IBB'I@DLDRY5N!C=)"DS()$FCFO74QX^_9A036$[N^/"CY&$0U
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M*7>,1]K72>9S:6WR['T(*]FKDAMR+K=6:I'IS;90OK&],63'$RY7T!H%*5#
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M6AF(IO;C2,%K@5IPU5I;-:T)'R?Y_)@+<1#1O!+(;4^HM=G&A.3RU/D**LD
M7G(R5QFW)3.+SK<.T_WE:L+W0L?A->'[B*J+PM[%E<;F4>><JSL4DB:7Q7K2
MV%F!83R@35RE?&\@Z;/UWSU<?4/)[9%:[P.8V($.NF[4N6FL>+T)8D26#+13
MO XO%J2MZ1;/9%]RDK:0]R?D'*UN'B7DU51\'P*>=B+H $<OOJ.J*$I1Y*W8
MK.H\[/5$ H,5"%8GI+]QK4/F3=(]QZEW.,9<:BJ*3AI%/W!A;L87F"2M=EH#
M-S70YF2$4*(&H5-BD?QC$_@.M];+*W7YS'*@5!\;"-&&Q1WHH@<[N<G%X).
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MY=(!U*[>/JY:QF4N=(X%D+@!2@@%,:;:ASX**XV-*@SU[-1#%F=S 3_QTG0
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M&TFZ2DV2*5HO QA=J[5M]N"+95!2\")%I;)I/ZCT):K&'L5YG-R?A='10N@
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MI2;9;RK^5A.'QIO ,W'&R%JQ$TF=9@>L%.^)/3Z[UO?-$Z2,:Z8,!**6[.\
M15?]Y.E<5"/N:A=6R\1BYA T'0A5:DV.7YMVD2<AF/3-FSL^3LFX+TX#8Z@!
M\SN T/HDA%J1^C7\B<OK03R;82KKSZYV9HK.5ND",3A6"[PD^!K.S))4;, Z
M):_U';T[=>.^3IU"7;474@?PV_1,I?M\\?,6^ZXV(PQY C$PX().D*H1<\>*
M!?(#C)0N&6Y:5R \2]"X30<&!ED[4?2"JT>VH9&4,;,,LA>"CD>,$)W44+>&
MW =F=.MDP"=(&;<;P2FP="3[#T?1?!7.AW+N;ZG<F_K9S8=OL<P7>.L7#G?\
M#UFE05#@Z,TU"AA<+_,(++7,Q1"K0'NC0%E.5YV1"#RZ(B5*J7QL;MP^24[;
M&:KOYK/5='8YG9UMXV+DV3YD//UAN9JF22%&^]HU-F51>XLS!]YH47.?BE8N
M2]5\LN\1Y(X;E&B%J.<'K XGOPZNU .VNFUG-+'<<UGKX="RVAHB2G!U7(?(
M.6(V+)K=IML/B]0MM>,&/CH"ZB'2>YTX??\G,9@D.YW5R;/U<>/W.?WM;$6D
MT3)G5Z[^Q&LLJ91(1I#U) $IR+F7AERL((O)26+S\-R VQDW/-,1T@>1?_?V
MZ[OYQ??YK#ZZ71EY]/'[/[_C;(E-3-==%FAKM>Z]I1,8K,B\MU$P2%[4WK9<
M0TS!@'62M*='4WSKKIP#&JQ;3^X^<]_B#,MT]=AINV:$ST470=L7T9+S1X"!
MR$R 8'EVP4A1,FO,B,.I[==<W0=/]W7CB:37@16PW>FO2((*YP^V.E$V9JE#
MJI,Q,JA0$I M[H"V8BV6: RVKJQX@:1Q$7<J9#P.R"9BZ@=UZY3,-[/\D?Z#
M1S8E,01MLX.0 QG4=3A04"H"S\F4; 1R;-WX8B?"QO5\QD5@0Y'U@\.M!_=P
M.\%;'K#HF@M,=TBQM4$-%[5?36$Z:B&;U\2_0-*XOLC(VJ^%F/I!W1-<G A&
MQ@DJ#\X+50OJ$+S)]*-F43/FK2JMQ]@^3]&X;\;C8JZ%D)IYN(=#[I?MLH=P
M4=B0&*EU,*[05E,=CH:,0>&>*4>>O VMYW(<06Z_8<EC'))3R:\#[7BUU:VM
M^]0!S)PA,SR3G>L361KT#U?'*B$=>A7(\ BI]=6\&V7C^B<G \H3 &THM8ZP
M>,?J?6IO45J1N<I0,EF\2F0!T6M=9T^HD)4W4K<>V; /?>,JQK%QV5R"':%S
M:Q<_M2L9,D:F'3#K#*Q[LGH?+?EDDA6"%&.I=3QQ-\K&]67&1F1#J76$Q5N/
M#'3:Z-_OZ,/I:CF1,EFM$P<G"P<5=2!O+4LZ6Z$67PKO0NOV82_1-*Y?,S;^
MFDBJ ]?FJ0/D0K&ZYM"A=,0CPSS$L.[*6!-*R&WSL7UV?X=Z;BB7I 7?NW_[
M_8QI/DO3\^GZ*]_BZM^(LW]\N6_E?B;C(LSR'Y>+]Z5@6DU_7'WZU-MZDX?C
MP:EK^^I\6F:>X,FZ9(,I%[(7.=W,RL8$D1N2EU#>9B\TYZWGC0SX9'W-[3N2
MN"NT-U=/4-6>OJ3O^WGGER=&HW,J&N#"D7]7PV[!%-(O3A,_4D@RMG[$;T!V
MOX_8^R#LOH(^M3P[L$)WV?+CGB N)\D(X:5G$$4A7FLFP:DZJ-N;J$NP7#1O
MV74,O?T&.H<&;1,)OA*T_CZO=]@E_5H\QZVE]>4;B>AM6&*N>5STR?HWW\UK
MXEU*MNC(0&BRP%2V&IR3N7+ Q)SJN,S6N>[M=]&OO3PTL@>4]LBMIA[9_9V=
M?YC]P.6JMC:Y:54[L<$7*[2&''V=(21Y+3-7(+7/7JE8O) O6,N'KCUN;* U
M!D\B@5>L4==U>!,=$S*DXV31UC0"R8#VZ,#[G"6WD<74.H!_%,'CEMGVIB?W
ME^$K 6P-S:V=WC.D#ZN9(R6/3,@:[A.T1ZS5H4$1NK+69 'E]@.A#J%SW,K=
M,>%YE,1>"2K??0NTO0^SJW R_=*FK>\_P_GE1LKGY_-_UZXQ$Y%$(DX;8"[7
M5U\6:XFT!2LM?5);D#<?IMEX"SMAV?X5L3R4G%\)S&^]BSCI@F4Q@-&<;*&2
M)'@;.;"$G!G/4XFMJS/WHW GD+J_(D@/E%(_HRUVV>3:P'F3_^-R8Z4O)RPP
M+G24H!5*VFJ1Q%7A@7OI2G9TI^36B:*'T+D3+/U?$99'2>R5*,C?IK/Y8KKZ
M>57[N?G5K4T^L70:<^'KEVE#_F,H="/47%D6BDZN**M:OY <3?1NKP'LKPC8
M=L+L7;4^]HPXB3ZAK]4KWG$.2B0//J8$W##'/#$W^],HU,>HVPV6?Y%7JJ/%
MTWUFP2U[.LSRK1Y0;Q;3)>V[2N K7GR?+\+BYR]3XA))*35JEG3LXFWS IJR
MX@3/_B&&PE5D(+DA-T='#4%Z#H$;Z5(TF%WKA\(!GOUK3/B6$#;M[:U17AER
MV8JK[[UUGFT(ID",,<6H=%+W"]X>C;C?_]Y^']CWD>7M:/I1G.O M'L;SJO+
M_N4;XJJ^HZYE40>A9">1%9;!^)B!B*9]^$B.?(G)"J:4:CZ&\2E:QD'-\=*=
M#\#J3B%S-4Z;7)<BLP4G7*%3Y (X2>PA2R!G@8+^U5HC/DW-N,JFC;1W@- !
MK!_Y#?C6/7_KDM_.S D\8A:*V%/JF$JR'"$FVHS-4:N40K9FEV[_SZW1'S .
MD>%\ (9VH%W6L9+:3FI3=[N),6^W4J)E2I9(GF:JG=5J;CHG)R,P5^<%DOFO
M6T<1GB%GW,2KQC!JS?Z15<RMB_OC]0 >R05*D3WH]0">'$0=UR0@8<B:',JD
M_2YI)(]]]SA8:&:B-&%9/[?*!K6?,>'T1^7)<I(P*K160&&U01ZO T4%[4-J
MJ[@STFLE]KM5'JS1A95ZH.0>OTN.8V,'=\F#O53?;_O9-ICYF<2T^+$N?=I.
M#5ANAYW<NDDGI#*=3<3,$$H A37]26I6"UIR5M9$V[P51RO:N]!,Q\%R5''V
MIM6N)\!]Q$#??VM7T2KB7J;3B*H.>"\2G&<2C+79"B==2?H0'??DBN/DYPZO
M\=JPN$?]=[.S^7+Y+BP6/\M\\>^PR,L)1\^]=1G0FII#+!Q$1^8C=T%Y%NFX
MJ-99#7N0-TX:[FFT6".A](BWFUSBY<0&%2/+"KC4Y)4X6\B/**8&7%%(G]'Z
MH1JU/$;/.$FSIT'4H6SO$4*;=%Z3BS>:(62KZ""@31 3(J0060DN\B);%W$_
M3LDXR:PG4D1[L[I'P/QM06ITPF5Q7D=+;J]QH.JDYFAD!"^3=UJ03FV>$_4X
M)>-DC)X&,/NSNH,^$;LDL#*;>608R2U0$NH,=_""MN20'&#E=0FF=;?C5LG'
MS?,Z3P.E(X5P;)K1,,CZ'5<3(5TLFC%PD0E0.I#7Z3& # PS=UI&'*K?S6TZ
MQDF^/ UV]F5S7TKHEG]Y-3/^S2Q_(.G,SFI9TY5)=_?GB71.V(P,I"A(=IUF
MQ$&309O,%<;"5&[]/G\TT2-E5 Z-PA-(L#?]=FO+GQ9S<F!7/S^=A]F*]OW^
MORZGW]=%HR[KPIDR4&PFU\,7!4'D1%H<I<U21:];E_OL2>)(N90G!&0;Z8P*
MOZ=?N.\&ZK;'*K#"<PD(CF<.BGD-@7$-4FE/&]:\A'MM#O=(('ALQ=U U'>(
M?4 >]Y,!_O@&;P=+A.!6!CH.7(8ZPY71ON@3T,6QZ+-RIGFON!>)V@U>?8?9
MAY% QY?B)I2"2J/)B&!='2ZNB@6?O0$FI1""*3)*A^H$_ @YNP'IU071C^)Z
M5Q"ZYM+M)Z=L8G+1UF$%@=62\0 ^J4 'PKODG$]<MI[?^QP]NX'H=<7-C^;[
MT5?<P'[E1#'& @L%!(]U/J0C,Z\P!XE%HP73B9G6[?@>IV0W^+RZ^/FAO&X-
MG-.T/YV7MW@VG<W(* SD4<QRM0ZW'*AOE_^8+>CWSV;3_[=FSK8A['+U+:Q^
MF?\^7_V&N/IMOL"/T__$\Y]?OX49??B5<+?\-C_/ W1$/0W!0S9)'8'E)RB@
MBIR+%+P'OW8CZ+1!I.,'Q7L;M*:#*%MWI!^P;^J]FN_RA$S>_YG.+ZO\WES,
M+\GD_43N>9A6R7Z=O_\S7)!NJK_^&5>7B]GR\_S\_-=-.L!$>Y6+41:29Z19
M%"\0##(HD6LGT0AL/H!GZ#WU6Q"V#S;OWPQ=(:&#-]HG]C\)(?"P;BYOF '%
M-*=M) 691^U]%DSJUK;M$Z2,B\.^\#)O+[R#,?@=%]-Y'=JR6 V)1%($BQK>
MHEMW>7E>HUWK%N.;&HA/:QKHMS_-E]--!;HI(3 ER*@+RM0&LY[V+CF@0Y<%
MN9DQMM;$;2@?MV;E->)\2&CTJYI_P<=V_8EVNWADSTFZG)0Q0/Y-[;>,"$[F
M H:XCE9@G4-\FN.P%]WC]A=^C8=A.%CT\TKPQ-8_;_J,TK[N[/UC^+[$/\J;
M[]_/IZD6R6P:Z--''Z<7T]6V8XD+"E,1%H12@3B1,X3".<3$?)&(KKC6\9<!
MMC%N+^37>%Y.!IHNXMA[*8TON%J=X_K1YU_3U3?Z_2JSR]6WVGBJQM&0%:Z%
M1$!&BH.TAP ON0(1.2;)F+%2CWFIO+2!<;LRO\;3<@*@]'Q.)MQR&5SPP&JN
MHPI<@F/* 4M*&V>]8:)UA<0Q[O!@+9M?(W;W$MZ1[O#[63Y!S/]-SFL[KHY6
M*?/%Q:;#0(O@_+/?W#:*OOLF3A'N9M$QRS,X@;XJ*@F>( >$CMH6G/X76]<D
MG*I?6$%>G/>*-E0'4=HZ>Z<VTHHJ<31>(F>[U->_GGYA^\CRV7YA^W"N@WC!
M-?U7-_#/=5.CZ&PP065(J0Z0-)F!XS57/Y" 2RX\N<&@?8>2+KHP'"#9IX9J
M'L[F+L&R[5 C4O0AD*%FUM,YO%$0425@W'"MHV(.6P>,GJ*E$Q5SA)Q?A,X!
M3.\ /$0U+E?3]*X:=XN?VQY$J4YVJZ<H9T=Z%TD#QYPXI-JML7AIHV]>F?48
M(;W!YA 9W\]G.9KA':#FSDS _WVYF"[S=!V!V6['QXPBVP >I:L]K!Q$+2UD
M@;F@MIZKUE&%%TCJ9'YC2R2U%$('F"*W$:=GL[OG0CI7#3T#9.AI4-%IB"*3
M38N2\URTE_<MWJ.!]!@=G<Q(;(F>H]G= 63J.\C:5U]?Y[6'L%:&0<HY@LJ.
MD.]JX9<53I,5J%ENK73N$-!%#ZCCC>+#F=H3(JZ:-)8DI>-$[SKS5#M#)EY0
MP"PS#KD5B;?.?;M'PK@FS!'"? H6!W!VY.Y>1/K_Q; @2?FK'IO*!:F,!:-(
MNZE8$'RBDR(E>BZ=E>4^+!X-I#SXXDZ$?8B(YJWXU8<6V RHNMWG:7T"F,O$
M$BTA2E.'JJ"%$(*''(/29!P13UK7"CU)3!>-W9K<%PV8W2MJ?@\7N#U.R>64
M2C6T1)W.&XH&YW,&+A5'-$))W[KM^@LDC:YN6@A^%S@=*(4.0/4N?)_6ZI%[
M3>>V>M5RCE;* E)H#LK5\4X1D12V5RE+X5WSAEO/$M0AH X5_7PH.70 JH=M
M?-[^O-^O97T0O7%T%FM:6*#+6Z7 (1:ZP>D@)K+UA$S-NP'N2EL7O2:/O_T&
M$44'$+N_AZLC*&..*2G0EM6(@ZTQ)>W!!<&#$8;1_UL'AA^E9%Q--8S47^C
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M[S*SM9"*D^G5(5<6ZB""4@O2A(!@G2FY!"^9;(R:)PGJ"3Z'Z/O!',Y6PN\
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M;EO9<51!6U/ *$D'/P71%#:G JBU<%JC82,W&+PF91B.3O@2_S"A=X>=>S?
MU]G2,S0VI4 FEH+B"$K2P1^909 8@F#299G&A=)CE U#U@G?SS=120<.V?O5
M5>[:KW^=4[1[,5]_J7][M<A_(_[JPVS5VF6S".V"939;DI>N+P^U3%MS SP3
MAY8VD9!ZH/>US[K#P'0R]_BCBKT#2.TZQFE_I*NV_>$SOEK\^#3_BO33Y>K3
M\MJSY)N0AJ&2)H8$)=2)SN@TQ$01LS?&D@6W*$3>V\<_B)1AP#N)Z_TIE-,S
M%G\K;[[4U*1WY<UR<4ZKS@P/6GFN01FA0%EG(<;  +UR4F9ND!\-NP>K#D/8
MB=[L-Q5Y)T[9DZ,%B][<XD&QD7Q,+@0$)@*P(+CSP@J3Q@@6CY[Y>%)7]BV5
MT)6!NEWZ/XN%9U>$J_-197UK4"0<KZ!PD;T)W*$?ZFGM7F$8,D[BUKVA*)L!
MXO_[/P_D2DS^]^97F]_4_^H#EO^G_OGW#[_=^?P<OL_/P[^DY=?+#[_=[_1C
M^H+YXNPZ]6..ZV6YW77U%SP/\[/U78[6\Z_?SI[K)G_0,O_GAJ7[S&Y7>X";
M]NSA-AWF_SW>ON_HBY8M,U*(!$8' E!0$@+/"KAD*:6BR;*,4;'P7&?5 QZC
M;PGZ1KZWBY>NP]C?%G^04#_]B6??\6]T6G]9SUA0S,LZ+C?6$DKG'00M$(0S
MR>6 #E/K9E9'$3Q]F] CL?14V^-QU=>!K[47L_^)8?7IS^4LNBRT-Q0HFSJ=
MB[Q+B.CH["\I%*%EG>\\)42W=$[?;71*9!ZBK),$)"$,9X7I: +)T6;K02FN
M(-:K'!D"Y\;*@NUS>@ZB=/HNI9.#<F^%G2(LWRXO5C.>/2I7,AC.Z#!@*D&L
M62A9:6Y-B99K/S4J*Z'33U:;&I1[J^LD,3G_CC/AO3(RZ7JM'4'1+JP#0PKH
M.AS=)_I6M'[+.HC0Z><;3([)?=5U6IA\56C9:SXYUS%HQDBH0H.RS((KVH,T
MDCFALA5RS'DO^] Z?=OHZ9!YN-+ZO_/Y!5?S[Z&V-KJYXEJWN>=Y\J,;W^T,
M9Z/9?<Z.!5\M\K]A_GQ37DR(V@';6&A]$P58+@FVR=<[R$"25,X6FT*4S<>.
M'4'N\2\;5TM_JO>F,_2\,.9S+3&LV3*907#T!5-6%*2A8+Y]X_([)$Q]>_,R
MR'GXN'&X'CHX9'>)[<-\_=^O_IJO9\2W1U29 JM(@57B' *) U*6IJ2(7#3W
M[YZBIQ> ':#H1T%SI-2[0M#FC9CVTR?Z+W]9?@WSQ4PXE@SYG*"=J.VP18"0
MO(4<N7/9!VE&2)Q\G)Y>$'2LUA^%TY$JF/AU]95@W-]^&GX3OKWZO$+<&/-?
M2\%-M\CK6@KVMTV:RTQP&5B@7:@CJU6M/(.//((1C@N#PDG.GO&PCEB^%U =
MJ_OERRIB>JP)^2B+\E^L?LBFVK*9%8J<> &+L8[P-1FB< D\=R+QE$QD0\JF
MCB!AZO>(<3#W(@KI&G?J7QA[G$VE(O>EMN+2=#PHD>H4]*3J< D=C8J9^2$M
MS8\@8>HGAQ?'73N%=(Z[I[:7L4%E)P3HM!F[)!$B<QE,SB6$3&:]#$EM.H*$
MJ5\5)L!=*X5TC3O]Y/9":VW4P4()O*:6&0O1Z0 &H\Q.<R.4/!IW3Y(P]<O!
MB^.NG4*ZQIWZ%WW#YB^8+JMD^2U6DXNYZ%0'S/E2N_DF<$9SB,A(X*FXPET#
MF_<,&5._#TQ@]UHJIG,,LF=8]9I%JZ,#S.19J%RS:K6*8%,,K%I]Y*6MOW<P
M!D=,.Y[6YSM:,1U@4!VPW?152&]X%*Q02)]+)!>7>7!1<0B9H6 Z"I&']/P[
MDHRI)U>.A,&74DSG&'QLN^EK=[>.D:+]E5DM,> Q@@N"HGUC8K!6R.B'3& Z
MDHRIIUI.@,&6BID8@Y^6Y^'LCV555SB[[#!PS=NV,<I.4R_1:JT*N;Q9"5 !
MJZEWA;89CXSQ(M -P=Z!RT\^]W($T+V$)DX,;%?[*1J19' 4USNL+$I-(HT*
MK/=1)YN-5$,>,@Y<?O))F!V [1!-G!C8S)7Q5L:3^!BX5+/YA=80O14@7>*)
MG(M@8AH!;&8?L)W6$\9+:.+$P&:O;HYD3($Y"8B!6"R*1&J\!U$,TXD'H\V0
MZY0#EY]\MF8'8#M$$UVDE]PN$[Y,E7"J"%]SZV7MUX->0=3&0V%)*6:U*+)U
M@<Y#*GIY@6V1C'24A+O#R!_AZ]7>0B\8>DL^8C (RMC:V4E(4))X" &3D^..
MP[BA9>HLD>-T_"1D#A3XU"<9KK[^O@R+ZR;2V^MEJ27S7H/6>N/X6?#!<[#*
M"<\S&4<YY(U]]Z?W!()#M;9L*L()0;!>G<\VL\XVVT%1!.F3R" DUDZHRM,Q
M; /X$AB=D=Z)^VUJ=YL*^M1;9H+^=F,B[BS82R;%X>?'X?+K0>E76&4$UB(0
M0JDW^=8(\!P1M)+&\4RV, ^:KCM$[5/:@".4=5_=!TAN8H5OYP-L"=>)I1!5
MAN*, Q7)4#DG^>8.TV?#?!R6D_R,RN\L.K'2#U'9LH7\)E;\O:Y36P:LX59%
MLG-H$T5<C"6(BJ+O9%+D@ENK<-#,OF< L'/Q:<*&5D X7IY=1 L[*H7^E?R@
MWY?K]>L?VX*A#WBV4<OZR_S;QF9F[4AD-=& UQEN)ACP66E(,DFN/'-1Z2&H
M.;:\[%E*>\F5&Z=,IK&F.L#C#C:V?CG7S-KH# 3-R)%&11LV<0'9V9"M%(S^
M; RY1XF9.G09'PG+,=32 ;[>U &]9\L_MPQ=I2Y;1MZ>T9 %'>"*8X3@ P<R
M_=H(.L(%%XVQM9.0:7'52,G+UA+O #;;26X?OR">_[Z\;&Y]>7%4K,LE:N!*
MD/^7,_E_=6>1P%S0(H7B6UNEQVCI)3WW^*.NB;0[1<UV1Z6 +@EDH+TF\1@I
MP-E89X$(<A*94^E^)L4HN.GA.&NC[0$0.D#T'8!H,V6^CI:_6%5IOEJO\7Q]
M5>I5:[HD)]MI+(4NF.LTMJC ::EY*BH6W_I*_PER^H/1(1I?CB/^#I#T\2*N
M-U.YSW_]3E_JL^NE8R@]SZ8>O@&)#64UA#H,5U;19,-#+JT;Q#Y"2B\9_L<?
M82UDW2=DMGO*>$Z<,%T;(8G:TZV DRR"2'6&;8A<F]8'V*/$3&MXFJCZ>?@<
M(/?^ '254(;1L"0#L-K502&F>OF6@(>29<W'\,UC^9V$= ><0Y3\-'0.D'@'
ML+DQQ;]?]]9'S#H69T%);D#5MOK.A7J=4903=,1;SQJ#9@<9O10 M;Q0/$S&
M7<%DXY?=30";,2%=X8*#+01\Y4(!DE(DCK0TR8HL>?O4J"<(ZN76\$!U/PJ?
M8V7?%Y N7W/>SO_"?&<P"XM)1*]-S4NE:#34.1Q>UG+?5$J1PI@RGOEYC*I>
M$N^:0ZJ%%KK"U6\4FUY.A"4VUK.8BW0UX<P72WQ0P%A-N*!-(K,G214<\3"[
M2TLOR3>M,72$Q+M"SK9S[(]+-HR4P?!<P$3B@*(*<@VMDN37R<RBX^A3:]?Y
M$5)Z>5IMC9O#Y7TP;,C:Q66#-,Z[AS!]79W/_Z<ZBJ]_W*TBFWF7N%4Y Y-(
M;!7-P0MIP>6(@<[FE._G_>S,[!R\8"^/$\>!93P93YS_.Y0I/=,!B\I>@PPB
MDV-'7X(U"81(NHB2M+3/-7#>:\%>K@1?#CC[R?A$@&-F.<AD#"//C=6V=$&%
M>OX:*%D7@XJ.9C:D?]'@!7L)U%\../O)N%_@W#Z 9PD91D\L910;EAAX9>ID
M3&6MM,1L4L?!YO9RO;36&!4T!\NW*[?X86R(,IN(F0$+'$'Y2+Y^(LD%*:)A
MR+1R9C37^+#0_ 4Z9+1VCX^3>__3*B[K1M?+<IO'CW^&;V&1[W0$:3/!8N_E
M&D^U.([=#B9=>&D(NYP!QE+3MP,CX&D%TEJM5$Y*B4$)[,>F(K_TI(NAN9^O
M?_RV(,WC1\+)1I-7R1'5>]C=@_WR;2'+$.IM+0A3+TQ$#! *!F!1<Z,PNLRG
MS_$^E+M>[N+'Q?OQ.>0O@IZN_(H=XPB$P:08\^"UKH%\ID#>*@>^**T=5QQ?
MQ,3T-OJC+PSM,U5D'X5V!<X=+3,LYTXF:8%M,JD5)UY\$&!<)O&(PC6.]\IY
M4E-%]M+Z/E-%]E'!Q&'WY4[\%/[:;%#,GY:W\_/Q*K/19&ERL J<Y0F4LP:<
MMY9"0R^3E]HY'-+H;=AJO4#F6,TN1Q5S!W;H7G/$ZPX'119G,O H<QT8)B$F
M3,#1<93>.N%:^XD[">GE+;P1C-H)O0/D'%BRYHSBCH0$W!5%7*( GV(AID,R
M)DI)AGOR$*2G!D@GYY(U!D$'4'^\BLY(R92-!J0,M@Y(">!$R;6H3BDKI1.V
M=97ASU7!NA<2!E>P[J.6#O"UNY[2%A3(#(,<ZL2\FG$>>71@92W0Q)*3;!VB
MGE0%ZUY*'E3!NH_$.X#-DUONYHT@&+0\E *!15&'ATGR5&P$+$%&53@QV[H6
M:!AEO62IG>X)>YB2.X#NI@3OS?(KK?\%%^O+U#X2;67J3EAUK1 LRQ5^P'06
MUNMYF6]K2NN(=0K)9LP(PQAMU1"PUD+47K.<7/+-1'=ED[$J-L9X8Q8Z/KT/
M1-FNJLN)5#YI%M\@&=^PB?DMJ>=52A=?+S87#>_>_$8!X_)26M<M<-_7U__E
MX@\\GUE%D2/Y2Z"UJU5I45ZV5X["FY(T9E[D2QKX(WCI..AJLPNZ $$'!\ N
M.3PJAF6:/\[\]6G\KES^@W>[K,RO]55[/:?3^-<%+;;:8&J&VG$Z@NE,MJP*
MK22H@]Z@Z!*UR\&:PE]@Y[PXXQU[7N-ML[[AU=6>O'1;0XY:"SI<=>:D .\Y
M.)M8;=:AF'1D741KI^H>"1T>!R_ZI+^_'CJ T:/-7Q2W3$=>0$2G0!FNP&74
M((+W:*RP);:VMD<U5GH!;_L !0]MK+2/M#M%S=53"]J\N>@A=S_37DH)?)(%
MN"DEFNQ8E/_K&ROMI>WAC97V$7T'('JJLX]BBHBJN=!.&5!:6/"TMT F&W,(
MGM,A/<85P8DU5MI+XWLT5MI'_!T@Z<FLD\PQ1)EXG8>JZSTQ\:)# ::M,^2C
M)O+Z>DL>>[%1+<<<9LVDWA6"=F0/9!N<\S)!L55(IE;UU.JPZ+S+.FD7_'AU
M#<]E>#7+(E'!9XJ 2/4U12);,B4F"TC,9J&XB]&V9G) %LDQFKP)3J4BU/GD
M(2&O75JTA6B"!>0F&:\Y*_<G&4[6N>;%AFRTV?F'R;BK#?\VS%?_"&<7^*[<
M:ZFRF>[.HT9(%AFHLDGRB1(D'7^<I)1S:NW+#J&KEWCH0.4_7MG41A/]ESB]
MRGE^61TX7Y3EZNNE2[>I[SFRFNFI3VY<N#28B68U2O%\Q]V--(I%+NL@7F[)
MT; &8BB$O^S(-V9<%Y^;[]%=E+2=&W=II+7VY(5+!BP'5M^B,P1)-EN$E(33
MIDC6_E+O 1E3VYNC]?[TQ+C]1=W!^55WXOEV)UYWO&2JF*A$ E%\!.5T B>R
M!)5TECF6+''0,*$]X+*+CNGQ<I1REXTEW2%:KJX/'--.):*=23JVO0D07&&0
MM Q"*8NVM$Z(W$W)M(@Y7L//0.8 <7<RC_(5WX:'0DGT%!I"V71$C8:!BUH!
M]])D8RDF1O.,G[+K<_M2_"%ZVC&!\B"A=:+PUU>TNV1M85Q"BJ(6:QE/^">_
M7B=O;*I)<F'0C.Q[GSOM]==("C](:!,K_",NYLO51TSD5.4W]/_Y^79RZORZ
M/$J+)(P-"$&5>B?$ZU1>7<>SJ4(""D&),@ # Y::]FZD,2Q:BW;J3D'XYR43
MU[TH7GW=!'1;5D)RUH3"@5MMZ'P4"@)S$= HI#.TY&R&#"E^9IEINQTV1DA+
MD79R<+SBKQ;Y WY?GGW'U98-20@7(L@ZGR.3.0P17+8(M>&GX,;DDH?TJGMB
MB6G;&H[F/QPGR@X"CCM6[\=V_)T@KT>2,U3KAI23 J(/&GCRPAN#+#2?N/20
MBJE?W]J&ID=*N3N<;/>/T-Y'9LF+<A7KN5;KYE2S8V5.S&#RS5-(=M$Q;6QR
MK&Z?A,H!@NX ++_C.7W8NW+)R]8P<C02-5G"[#C%Z7160O#9@U0*A55:(A\T
M,WV?.XP==/0$ED.T>_\&XUA13PB7N]/EM6)&LE# QDSV52N2 I.T:8*64GK.
M5!QTA?[,?.WK!:=^Y6USPAPNPQX4?X57RZ).FKQH;<D/0V_(BS8<LB'TBVBC
MEX-*;8:H?DHK<(2R[JO[ ,E-K/"_S1?SKQ=?KRY@C!5<Z@29Z3KV!#-$[CQ]
MQS IC=:*05DLSZC\SJ(3*_T0E2U;R&]JQ8>_;A$>HV-,U\/.!B+<F@C1&3KL
MF([9LIQM')3B\YSB;R\Z33#13/$'RZ\#5_#N.;>Q>X$7J3GCH)(ANV<)Q(';
M.E_$HY?<!N7;YWG>IV+JF1QMX\LCI=P=3OX(7Z_N:)@)Q2>5H7A&? 1R:'VB
M[XQ*+#HEC+L_1J$Q6FYHZ>FY?'\=/PF9 P5^ D\CS%, E:0"4P(%5\9;"JZ8
M!:.3,(EX]'G(\UBKIY$7@L>A^MSS<60?X79R_7T5>U]-IF96*5M'I_M4]Y&O
M@R#JC;!*U@LMC7-V #QV?WI/EY@-$-% A!V<-/\(JWD]<&LR^\:*>J=CB)E#
M\DF RJP0Z2)"EAJUK(YV\TX^]VF8>NA36V_D* EWAI#MEDF!8!RR!L>]JDF,
MCL1A ]BZ65C)7*C67<,>4C'M 7.<5I^ R $B[@ DVX/QW7=<+>:?OYR_G2_"
M(M7>5G4LQ+*LKG_SVR+C7W501/W-52QHM,Y&ULO94">,)&*;N53?"S&&Q'/4
MS8?"'T-P/] [!"WW!W^_F.HZP.FK_%\7Z_,KZ=7C^\IY"UJ@DJE2'NLTFA A
M*"GH&$?NI;>%J=88?)28:3VEQOAJ(_(.L/-^-?^*MZ"OR270ACDHM1)>T8K@
MD7R$(E6*3!F54^O2PWLD3/MHTQ@GQXBW W1\O(AK_.<%R>W7[]5OO$K(MLKQ
M4"BH$)R1E8PJ0I3TA0<,C"MR%D3K7M2/D#+U2,RV;G4+>?<)FZN]Q+2009 T
MLE&7C6(="V0=A7>V1*-]:!V(/4K,M Y/$U4_#Y\#Y-X?@*X>Q(HDZ=2W,%W'
M,Z84P1OGP=9G5I^+0-'ZGG@G(=T!YQ E/PV= R0^\>7?Q@>[WD6*&X_$,H18
M7TP-I\ UA5PGP 9>1)0QWJM$W7GG=^=#IQZBV^:H.4Y6O2AYB_@8O.2;(3$Q
M27*G?(+(?,VMBM8%A]G=O[-Y6LU3'@Q'*F:7>@^0TL0*?AW6#R(J+7PH)I#/
MC(7$D$-M BXY1*&9MD4%%8=DKN_XZ X4?8B*ENWDU<%9?]>P_7[=QX(K##'[
M")*S0FSXVL54&T"9R!-"@S:T[_2SDY2I!V&/F4APF+P[@,UE5NSZ*BWVW<7Y
M^CPL<FTONIGR/7,N!,>9AEPX.3#))7!!.?*K<];&&!N;-QIZCJ:>GH\/5/S.
MW.1&6N@!5;>:JKS'5:KZ^8RO,:R(I8?3OFO'/R<\UOD4%DB.%J*MXRJX]PJM
M3]JU?C/:C\*>GJ<;(6X\#76 ORO:?_WK&R[66)F<,9L$>7LD+5U+V"*+0#LJ
M@,G6B,#KT+O6E_@[R.@IE[X-DHZ5=0=P(2.[.I__ST8-[\KU(]>;Y?I\/4M8
MLK0, 5-)H*3W$%A R.3_>7(N(^V,UH\_3]#34SIF&P UD_[D4?43)O77M%PL
MO\Y3.#O[\="\(OVO%-H@C-Q.<D1YANAJ!(,HC%!6>1\&!>"'4M!36LUQJ'I!
M34R--_R.*^+K0]73F^5WI(US/M,$BLA+ALQ4K@^G%D+M]%.$,5+H.J9ET%W.
MK@_OZ96H 4J.EE^/ /CT9;6\^/SEWR\6DI%63;U\9E+6R< IJMI0NT 0EB()
M@TPAMT:&(1U/!BW6T]WN2  Y2KX] F8ST.R&G:ATP5I3FWCRU=,O$$-0%'B:
M+.@,9N%^I?IPN-Q=JJ?[H)' <H1L^X?*QXOX7YC./]7!12L,Y/I?;(+'Y<7J
M[7Q-Y^O_O0BK2LW;Y=G9\L]ZF?$W.F)7\W#V*OWS8K[>]%J=65N*Y"J"SHH\
MO%1C!2\8*!Y+=?"TQH,/K#$('@1;_Q/!=@(]=Q 3WA7TZ[">KS\2+2&_6]Q.
M;N(SS[2)RC,(49.?Z,EW=$P@.9!,,I<-XZ)UQ\FAM V[*&6G@-51U7(PW!Z.
MYVS;8+ONMO7FZ_9VI8Y^6R[HD]>7;:G7=UD8UEQ[P*>V:*R]+_&-FFK_CNLU
MXH[VRJ)@2@$=>%4#.E\"A& 0C TJ,^Y=3.W;JNRFY?A7FU#%N3Z_9L[&("V%
MKN102%8?" )$AIHXU%Y9G4OAK=MJ/R!BXLZG+?3^\&'F&$%W<(R]^[89!KGX
M?'LCSDH(7#**:I,K%+.03"!HYZ%$JQ3'$.AD;HR6G81,C9BCE'M_^-31DNX
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MOJ3,9#+1"VM:WQWL1^'$$WQ?Q.8=JYC)"UEVO2_<"$UQ&5(=*):T(_<WDOM
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M6W6G LGZ=N"XMYAE!":" 963K^UP)>006-*9>:U:M]L:2MNTSY-]0W)?U9T
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ML<PEZ27%'CS:VNS'02C,070460OFG JM&YKL1>#1W8&6Z_6=):[Z<4DF O>
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M:&Q$DXS5()EEU8,@]44=@'MM8F0I.]OQH]]/N!/[N$0= SY3E[T=*9)[<OB
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M!#+27LK E?>U@Y$+ZG3.Q4/N5_I[;O^9]N(Q<)LX6>PH;YWXOI3  PD][ /
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M"I:=?IJM9V3E/YPR;7N0@%&2M.U94D=*EA$57$YO,4HPP!8T"ZPF@3"QQ*N
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M"R,KL%G:O)8.G"7&/4.*!W Q)</(:<Q1H$(+8;0+N-:>+,,E8P?QI$I+HP*
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M=046['QBI_L4=%O@$F307#*"A+)P R23P$Q6 ;%H@HM6"B>+WZ@]::T/AD=
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MV^S#VT\7[]]L"UYSZX9<B'4>YVM/?.;CA9U_B\O%V?S_6]GI9'G]!_QY<B?
MYY5UB0#??"[5M@Q9!U>!L]9S+2R/TK:X]HXBHDJH]05#,X9D*CCEGLJC$,>H
MHLGD>!Z8!XJ!K2&30L9Y+CU-W)F:\IF#%<6=] XM(8Q*,74_*0)4DVB%@5N
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M$Y4JP*?9NG=^&VV/5JN0/'+>4L23,<A1$Y&FEA%#%&&Z],B*HP@>M[3N)2O
M,)BHLW#O3SN?9$]]5YN]+HN=%!^6T>LS!0KTCM]>H:*\L_DW.YO\G]T;HT4S
MG82-,L["^9W-G:7M\6NG-\IS6]CD B.6"#AP76Z918A#&DN"2" T=V'@D90N
MU2M">+G!&T\)=!-NRME<3Z4!GSKW4?=4 Z>40#IIRU2*) TX(O(@:>/&2TZ/
MOJ?G<923X,C/R6\9N7U-D,^5=<XI*<:L52A8!;>",PSN!X^1H$1H< L(9R6Z
M2#SU_5I&:A04=%.8ZQ4B9S=93A@E!9@Q-#J#^+JU<30"24U3\B0I;EJ5$/?
MSIA9X7*2?08J/=A<@>>R5Y6NS^>3*SN_?AMG,4W@S)Y?[]I54Q&PL0;A +SB
M06)D:7+(6Q&,T5XI5GKB3S<*ZP)9'TPT)Q-0M?"[=< D3S99S1 1<(+S;!,X
MARTX8-9+ZS27)\);M^SJ"69TE+\#AY!)!1![LUC$Y>(R,>]4$!QA\)P1I]FA
M5DX@):-EN3$P=J4'!FZ^/*[15%28S=&<K0 /NX8;H"MP6EJXYB-#2A /I+N
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M@)96L1@OI?*P"\2$@".7D A'KE?(>\P8^-)$FZ'#Z;T?-U;5KN\H<Z>TI"I
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MP\;D-]T&&>HC4D'9Z!F+[F$_S-<1PNHDR,XAK"Y<K> D>2*TDBSWVDB9GY*
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MWMP<?!^G8;VW=\TL+-[/X3>ED%.(A-$>EI;!45E!C(RJ]S]#6)S-SY;?YQ^
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M$%9 1#=+C??*O(]P'G*@"K%\C7XUGRPG<?'FV[<W/^UD>O3[A@/KCO=.O(_
M#O+F9:2#SYOIQ,,&SN>-'S =?.\S Z2#G]Y&\73PW4\]PDB!O/#^]8]*FFR7
M#W>7+N5[/[]Z):GC@W*[GVEIR:_1DV'[Z/S<++>DEHGWM_]*)>'_(^5\@'_#
MG^C;O\B_.+N(_\__]?\#4$L#!!0    ( #2+35JA.YV9EA@  /L, 0 >
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M%H[V!,S-'':$)^39^WWUWSD>V>O1(??&9__H\"$+2(,]D9884O\?A8#ZP5[
M)._I$P/^-SLKE>#FZN.3H0;&\;C/8NI*923)_C;@71Z2TG[QXZ</>'X\I_F9
M4=F'R75%&(HA7 [C)R;Q5Q2$O#?67W'?!?XJ!OSR>1UFSNNR=MFY)M:-W:C"
MOPYQE<#0@(@>L:(^$$N."R@AAV0G'/" _/'^I%S>/X]Y\/HT:\ZYS!&2AESX
M9Q$P4>)9[SY;(*ZN%MEUD??NL^)0Z7RW0$)!P@$C%<E<$!VK+QE3>KD#_'59
M#ZYT29=YXFF7T*$ %:W2+SRDI.8[Q0(NPH604CPQB;QGF\WZF-0-X3RP2\ /
M2>J"^N26RI##?4;P>TS@:Q:* F'4&9 ZPSFDCA#JN^2>>5Y +D&7!;F@_D.!
M--2<J4>L(! .5Y_4*EDN&#,>A,B41P;K#&M<3!N)I<V# ]<RN19C\-SJMNQ*
MK6/5VR^<U889/:M(0)E*'_?/YW]V0')B6=9RI"4D%I[0R$A/BB$)@2JEY? [
M*70C(V_ASQ.H+3 !661OACFH",\#QR:1UXJ9N"#M)T!%>)5986"]9/$JH^6F
M@*"8#"GWYTUXAI\LE=%1EDZ5>:?HB9A;($$T&GGJ&CA?2"T@3SQ@9"A<WN/P
M[9PHD9'D<*IQ'W@K99E$3\O81@O!+*<V00!>:HPWS&Q=%)<Q6H L B[1^ @M
MA=D81/CJ>U"*84 "%I*>D.% R1GWWPC#*@L9UF8."BXIE8HE5.%,%HVD>.2N
M,N-@"C)/&=(Q(+A8V\D3!Q;BB8[P \5E/72+_3N"-7%C7_)&^%M=S-^H^Q>P
M&&4P-J' $N =,#TH9/)$6=\G[GD8JZ+L(I/QCR "F$9C9/]BWFTHLK*N6K:-
MH=<;P58UM=(!Z(V>:ZP"8%Y87^#:HN_MQ9Z0](5PU5>/U(MHUV/IR[6L2.8P
M/M)N.XAZ/>YPYCMC'/MIP%$\I':1W3&ASH,OGCSF]M']AM^!<PF A@<SD5<\
ML!)(\.T]0!/B*?CC_=')^?RB+9<3.<S,B6RD *N4C-7JU"IUF]2*:W+H0,7Y
MB+HN2-">QWKPS<?BX9$2\ZY4_^:"_U77Y'CU-=D<Y5.KU+8KG5JS04K%_=+&
M+-1^\>0HYEJV#:R:7$@'P<CZR'[W&>+""AWQ$!;W;Z!'@Z,H@#\U+B([W'>\
M".=&N!^;)CP_,)9D5YD27X0)H!^G>LP8P8!Z'AE0L"\XP)!1'\8#_Q<$(%)X
M6^/S].W-?6:A!Y"*J$]&'E-!"%K-4$8:U@0CH$K%%G"UP3K:,9>*!POQ#LP"
M+"&$*R;^X1")QCJ5X7673/[NOR6M*F^15DW6#A=\0\(RHV5VKX="^<A,!(WB
M>,E[ )ZG1$_/J4( 7(C%F)2+Y<.=[NX.WUTHR'P2?Z,@2S841M<4H@<AG\8[
M*OWZ0YZ\=+"*@!MI/OBX-H"6D.:#=4ES.5N:3<2^J:D-$P^ZZTQI3&-1V@=Y
M[V-N:"3!*_$1];"*$&E]1Q=3\QVI% *.H&LEELJ&!\8#H9-BWQP&6K)C[9+_
M.C[:+P#Q^(^,O"@@.Q?HS>)!(5R#<4Q."J\+()#C<"=_7, [[GS;U71-:.A(
MZCL(JO=*^O[Z[B(*@Q"\)#I1DX7H#+AT%^H^ 1<'U(QGQU_A!NC5N*/""\45
M"FXY?1.P :?G)F'T8E/P\06F8#,<V^%6.K;)$OH@(6L&CIT47C(ZUH4)#$%=
M)J)FY%'E='<4RG.5=UM_7G?_>>/WO'M>)^_C+._4-&9&\0G8K=()CV#WV#?F
M1)B81^1-PTCE__LL!O,Z,Q\G#!3"YF$4J@151@8KG6U0@8 J,<X4(L>+,UC)
MAHB1"%2Z[$PR3\UC88N$L2S[TTMH-Q >3&R9KHI46D$'T[/D+3PVVP&QI)D\
MG9C)@8PI0K[O=<$R/^S1'A!T1KTG.@[>;7C3B!KQ3$6,SE)M)"AP"&._@,#
M[Q_J)=F,C- &I83*Q>/39$KHA@<.\SSJ,Q$%+_7JY?*;B6#+VY47:K&19%A'
M44<"74:G$E ?5M?7ZN]?+$Q'6R],.W1W4T2H?% \03YT! &^1 [+Z,$PKAS^
M5]823IQ+;L6M0!,/#0C!2)X6NB<M=*JFJEUZ+UE+*#Q?/T!<4E@ZTZ'&4BZ0
M]/DC8@V-'N/0"\;V ^I,-6):&L-3A.-$,H:9W\NII-D X"@ Q,I\XD;>F- H
M' B)B=#"%"CA#5WFP1 (?+KC.<[A"1.DQ!*LF<W2*([$:1I38EF2;*P2)FX"
M82C,W8-@V"M@&8EK,KO<A(!=T")33&)^3TB'J4"0]BF'(=(+FNP6XQ#[.F"7
M7(@RF:[MXHU46A8;.R8ESD1TV:7^@XQ&H0-!,8PNO$<L5!5 H(3L4Y__;0@9
MHKD#[D;#25,(\>@3<$3/%>AV%,.$#!#@EH[/B8(R 0&9PDX6;VS*81,RS($X
M'V 2PPA20T5!GTI7A=*J;,;4/>-BFTX54\R084; )+CUM4@A(&L@[^5F[V3[
MS5YWD\Q>2=L]58"8=Y)/$R>I)&!&1:?93U-;4,?B;F]5B"\LMD IBX&UAD00
M*R-F#("4> &*%*CJ$'NO.$@F$#J"[P.R@PFDD3:-F$&:F45R$F-]$MP6$U"Z
MJD&5J3/Q<CPZ2*H)!5%@S<&;^-:6"R9KDO6)3XRC](6DQQ3O$D/5TF9\T@L2
MT$D&0!$^$%%_ #QQ67K,!"-C[L3)ME %L'C\.ZO-ON'AP$.&8L>;LDZ@QQ00
M%;8&J;0#3$U7S1U,@RTS+(2SBUDTO[J)^23OG-6'M9SY.,C>0K!5YL/9)/.A
MK(>UE(K'_CN%.\!MA&PX\E07Y&K.VQ>DRGHT\D)44_O1%*CB[Q"#* PC#=K@
M^F[<CQ+YW.=O\G(Y>T%;QH;)62+4VZ9BI5Y U4T;+ZK*R),6 T3$Y5!=L>84
M+T0^<WE>^("%%(@J)@5'!<LF)98I3@5XY8O'5%?4?%NF5.[0'$YD#B?N&>BP
MM7N@27L_V\(Y!^ZQ8#JE"O25#Q5JU>0D&Y,]/N0 S^$XY;*0GL 31>A/L!4Y
M=0TUY@,!B8:IR 4L/[D:A132 1-^J 6!TNDXP8HMSP,3- 5$"<?S3)KGC@XW
M=GAJKM0+L?E+]5L#$-9-L4(J_P7#/-%Q3'Z"]0;E)[L6IX&$.@"62\6$2$U,
MFK955+5[+&C<>(;ZXI(KJP"=2B_#6HP5J0E*"ZF()Z93 XT)$3]")LJ\L?FH
MR!J1J=7>T[IJ@@DO"0DF.F&,.<-3>A%\H2(R/1VU"BC@,XC5W&W*DT237Y#H
M8U9K-^>]8K#Y+%=W@59-?9",U5/-]ZA"NKLW7OL44V<6?PJ[)XP#XZ"1E\)&
MB0EBQX+N2,2PT;08%2:C(% KZ(L6WINJ@-6X<3Y$Q0/:D5<_U\U/%2P]!Q.E
M0GP:4<2-C,4\;$[U)J'55Y/3ICU*N+UR83^V3AA,0NV""7^SB= [*/J2)J:F
M4@,JGNV1.F<&Y@8,P 9^BR8<A ,UVJC$=-<(MF3A>3K!U%9_NJF)C2(91-2?
M@/9V/&PBKM*I$25C)O(!\=<S>(Z<[VK,$N1-^3X;["TC':"2]QP#EU [A[@"
M9C(.AJ>I-M_"<US ><>K/&6RRP)'\BYS];XIF*TKL@Q'>K8C.HZ;G/"LK,EG
M)7<6,225ENJ."\^DXV9=;'&1W3*[ 8(%:C<O$^*%Q$\-S-PEV"%M3$P&/Q-=
M?UF*-^UZC"-6Q9!EX/Y<D@]DJ0%.!0=+-41VL5$2\8)*L@8AZ#@/!BHEQ1R&
ML%IUC8.>C42@$QM*1>#P1!YU?U>2;5EN#7[A?G;EWA*+A6R8;-S U44/: !/
M89IE-4!B%CD19T#]/E-(9\TP B\)0$T]*O$L(+8'C$:GSR6<@;TQ#@L6M2Q,
M1$'E4-.]"W! I36,6X\%9@FVQS8X"]'&[:J.2FI*!M1*+0;?VXVTS?7RGUSZ
M_LX]MS6<W<2L*VFN9@0UAE-RS;"2L$BCIRE-[23B R9968B/HE8H#Y!U0/2R
MON5^(C7Z)*2K--7C#PS#/(#!A6F[RI30A?Y@0N8B2L)L4L*E:(D#L\SX;M99
MT&7H?6&E:9&)3$7$9FHI,N,)HL/""Y).:V7S^.)LUN';:;TOOUZS\ESCS@NR
M65?@U:6O<AOT:7UDZ[[$ZUJ;3'89$JM1A:]LTJI=77?:ZF/SHEZ[LI#/;=*\
M5$=OL;O';I.[1M5NS0[1OK;J=7)ADZOF%[O5L*ODXFM!C52!(3JM._@&/]4:
M';MUV[([-OY-K$JEV:I:C8I-[FN=ZX*Z4=VZC^_9[E@=&S\T['ORM=GZD^S4
M&I7Z7;76N"JH2YIW'5*OW=0ZBM@",=+1)D=[I</]DKJI^K,<CSD9ZLINV"VK
MGIHKW+M +F#,)IS:NJ^U[<E=6O:5U0)&-7%*E_5:I:-8 U>TR6T+R*K=UH$]
M>)W=O%RCBS*MIXS\!7%6X'(G43XSF3J=D%/&495IP/K!R>,D:DM&X*5BJ;S8
M3DET7R#R(Y3ZZ9ZF[CAAAH<1EI$"]1M@[P\8L)6V5FRZ =NF%NL*]MA#; 6!
MT8;U59L=]Y.&%(,5_&C8U=+N)$C7,<PX$0+-= 5AI,3@.T1IR0L+DZX0'4X_
M#1B<*1;UP<R!$HP+.4@I=J1THT2B)T5=*/JZ"V,.5N UPF<37*!JR%SM\#/Y
M& LF/>U:GD\L&#ZE>G5ZU%%Q(83EQ9$+@2KS0.NE\+D#YW,OCBD37T]OX8@A
M!(;HTR:5[;MBNTAZS%79&[M=NP(CKXLX9=Q$8O+Y* I?A7P@]G38]F18G&$+
M91!@H+HXCJ=5(G+( [109 A\$JY)QOCC)!MQ61:O! :1V/*=:&O2>\VY"W]/
MKS/![K1[:!KVSH$X S,Q%<>P?TB7YT<0Z?,PU)Q.= 1AVXPVT9G-8;A.4C>2
M3[LA="M *F4V68C@V36=\B^YM@RWQ719G&DR-,*]_4C%W&;C:2RS9 +?L0*W
MF?L1UKP9:S^]&:L'VF/T$!<3Q0(S+WJAIAH\K4FI-*KN[DCN85%93!" >.UQ
ME*D*OFSA7^Y^5]K.M.GN]VB+W.\UHWCZ^ETOUKXT*5FU-<GF4K)3%*BRA>E2
MN!;Z175CLQ'>5-L6)_UF>'F*N3_SE4*ZYKL-V">A=VS^\?ZT]*LW=2W<AK)@
M#_#,=B?]1)/U/JKK]"!CW^4;R/.N8&]_V;ZH'T\.;\"#A1H8G3?L=IO<Z["[
M8.I_*42OT)Y#U4,[9NP5'$5@B"!P<3\[#,DQCNAQ1SV4*MT) .@)7#OMX@,%
MGB3"O1<\*VW]O%STV*Z?]3-F2:@0\$0=)3BX/0<+OJ. G<5_G+L\&'ET?,9]
M1:FZZ#S-//27L$0AUHB,?BI6ZL-&WH]*Q8_[913Y$.0\=.,;&VTH*FWX$+KS
MQTZ+I<.3A4?WBZ6%QYX;M70$0?_I3Q_VN%P\VC]8:M@/BA&:&<#N8$3]?[X[
M?3?C2<_*HV^DE':9Z%QG.:Z9_=-%MKQ4)K-J?:EU+%)K5*8*EYCBC*?0C]=X
M?M;[..=G.76PX9S*!FX7X_3S3(R03&;U<2MG]<?[P^/S0/TD#0YW!<O\9Y'8
M'J=!8AOM"FN96O_L4XW)"L7H#,XE !ZX2^*Y;A/W&A!]/B\5;W'2KR4F*S(%
M.+LFCG2P[V5%.8CARYPH_$PY61]+KJ2(1N0+H#UR*QGNA<."L7D*'+FA\H&%
M^-:#@Y-S4O,?61!"_-I2H8?P@WF!^J#@RR;&,#^-LZ?+1G2E\^H72Q7(2Z7S
M1,[W%F(:1.,SU?>,&' C&F;2SQ@XV7\%V)[]](BK.ZME-3K-5GO!$\N^1W!V
M&+O&>2YXKG#-JG]MU]KDNEG'ZF^[D,9]FTLXB'NB@+U-9%_;5KUS7;%:J@1_
M8[7;5N7ZKFUW.EO%_<0T6G;#JA/\<YLFH*F>3F-;:*^UJZ06*RRI-&]NK<;7
MK2)^JZE78K,M!-]>@W6OU*Q&FTQ,O57YG[M:NZ8Z<[9E'EI7Z[5+&WXTML;<
M:[([+=OJJ'ZNBHV-6EO&]3GR)SBS8L&*-%N-FO569E2K@W@U:V]FA6YJU3VK
M4P<H6ZN\E3DUFJT.>.UVYZU,Z-[>GKETFAV8R_8!OB3==>NBV;(@N*O96Z/H
MG59E93DI[Q\7#R;]#Z86ME?67ZX>I[[R<'E%:P,K6GF=9G-FE:S3W-)0<N>!
M_*M(;IP_N>_GA9J\4),QZ=>3DZTI2^25FCF65 :<]<@E]ZGOX#Z6IN[16:$$
MLT4X9!,C@SW2;M[%04[]=DF^E#XN[GO:$H883[VHVZG%L&>^(QD-59]9157=
M@H)^C_?F3V_1O/CT8:.JR\Y/*-NO+CF]X+(<FN?0/(?F.33/H7D.S7-HOLW0
M_)?CA[P7*^_%^LDE!]*Q_]=JZ\=3V%7U (T&!$W7M27CI"ULTS(HB70$MDKJ
M**BB'AZO A^2QP]Y_)#'#WG\D,</>?R0QP]Y_/!VXH>-@6!?:O6Z=67K=F%2
MO2F0>KWR9F>[#."$F] ^/D9BR/")4#G@S %G#CASP)D#SAQPYH S!YSK!IQY
MYCG///\@"OZS4:O\:;<NFOASLH%J6UK&S7-<?L(NV=>-[%:]+-T'MI_WC^>8
M/\?\*V+^>D1]GU2+$.KWF1]T(]G/,7^.^><F_7IRLC4 -\?\<RQ)/^-'/?D1
M>W8#P*(_!OP7N/JWGWVNUR[L5N<K:;UX%V^.X7(,EV.XMXSA*E0*/(/<<B8=
MEN.W'+_-9^->14:V!JCDV&T^JQ_#MJT":GFR]TTD>]46QASW;2;NV_2GF6?;
MLWN[7F^32ZMUU207%CXZK*%>2FC5B=5N-RLU\X9#&F2^-2I_ OIOCJJK5'*?
MW$2>QS.>09Q#ZM\>4K^"@&P3.S864J^5*S=QKV252^:$8I4T:(YM?Q#;NDN_
M%^JH_&[M@#@-8,N',)CY2JF!DH(<,^>8^9?B']# NJW>2-ZP;FRE7P5B!822
M.L.7)^:P^"?#XI=P(H>6/S#I7\3P;>+IZT.U>:8O1#T9K_3[OAM,LEN]H71-
MY=I:CP3,$<F721,>$)\Y+ BH'#__4I$< ;PA!+"=IB%W8+D#VWR>;I$#R[+B
M:W).^*[QZ:MZP2U1+Q#3]_3J-_.:%U5CRL)3B#\@.U-?IM]E+8;X6EZ7]*08
MDAZ'._5W?]2SO;H;.SPM'I5.7^3&3HJG^XL/K^ 9S"1US3,E>[%4ZM>M9Q^;
ME]CG#*/.[+R2&G]7(+6SH?X#OOL9A%("3072*%J9KY[-^?<L_RKCD8P"<AMU
M/>Z0BA@"F\:D'KHY+U?F94,\4M)V1,AISKU5N.<S29").=>6YEI%_O&^?'
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MR3U^9L8M?VK6JR?8/G2%.X9?@W#H??Y_4$L#!!0    ( #2+35JK2^8SUSD
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M:\<?<7KR[OCPWO0/SUX-G]]/+=G=P3M7=.2!(K#"?=30ZX8[>K@6;W[8<K=
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M5Y8RP>4ME94Q3<I4B9CA@9"]PD=6FA)ER!53P[F$/-^<G_IK$4Y_&3_U;:5
M-&RBQU$%:D4^5TK"2*?:L8I7K=AZ7%2A0U/:6&^<5L!(I[#9?LU@ZYFJDH(C
MI^?A%<&EL:OL%GJC"VW@72ICL4R_._*]3*"[&->6\9S1>+I4%I:+I,5%:PJ:
M>;-ABZ7)K#1;K?0L20A8SQ*^VRLZB7Y'I\C)F<3@60Q4T82#PQF+"QHW%%UF
MV?#CQW466P>_I8;L6V$\VJ&WPK"-9:V+)=F)DGG".C[$.((?B7>)2P<8/$';
M";P1-@AYK0MSQZF >>="CMUZ*WE-,=VK0JD:+_!,VWYT<D'?1K$3!/_,K^'
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MK3%IVB(JK3?"+U3=3-M6DEM 6'_R")NJALQTKF+C#^S7#XF'L0>NL*S*UP[
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M2J7S@=Z+;_'!O]*##^AF_?(!RXT\ H6A[!49DIK0W+ANHI#3=^R<=<&U7KU
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MZRF/:1:98E)DJ;3.G3,]\JNM4)TG+!I9)HS2,"865;S!T6EJ5HR$[AM13-S
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M=5=',L:/R\]2IA_V.; ^"-6[G@,7R6RV?O(?A;NH@B:KQ1.8F!C))"2HGVV
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MJ05M=W;I4M3S]9RB]KD9]A8*8O!6?3O)KU?H-D6GY;DDZ^TDDX65Q#/M9=3
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M              "  5H@  !D=F$M,3(S,3(T97@R,S$N:'1M4$L! A0#%
M  @ ,XM-6KBCL;*A!P  &R0  !<              ( !7",  &1V82TQ,C,Q
M,C1E>#,Q,3$P>&LN:'1M4$L! A0#%     @ ,XM-6K I\8%\!P  ?R(  !<
M             ( !,BL  &1V82TQ,C,Q,C1E>#,Q,C$P>&LN:'1M4$L! A0#
M%     @ ,XM-6K;P56<(!0  YA4  !<              ( !XS(  &1V82TQ
M,C,Q,C1E>#,R,3$P>&LN:'1M4$L! A0#%     @ ,XM-6A*;RQGN!   ?Q0
M !<              ( !(#@  &1V82TQ,C,Q,C1E>#,R,C$P>&LN:'1M4$L!
M A0#%     @ ,XM-6L88!YAR,P0 GBLP !               ( !0ST  &1V
M82TR,#(T,3(S,2YH=&U02P$"% ,4    "  SBTU:1[O"1ODD   WI@$ $
M            @ 'C< 0 9'9A+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( #.+
M35H6?^YBD#4  +HE @ 4              "  0J6! !D=F$M,C R-#$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( #.+35I:4MW86LP  '$H"0 4
M  "  <S+! !D=F$M,C R-#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( #.+35HA
MI_&9\L@  /7(   3              "  5B8!0!D=F$M,C R-#$R,S%?9S$N
M9VEF4$L! A0#%     @ ,XM-6JE#BSQQ@   EJ$  !,              ( !
M>V$& &1V82TR,#(T,3(S,5]G,BYJ<&=02P$"% ,4    "  SBTU:4FG._/&=
M"0!5GPP $P              @ $=X@8 9'9A+3(P,C0Q,C,Q7V<S+FIP9U!+
M 0(4 Q0    ( #2+35JP:<+6*Q0" -!R%  4              "  3^ $ !D
M=F$M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( #2+35J=26:OM3T! ,R9
M#@ 4              "  9R4$@!D=F$M,C R-#$R,S%?<')E+GAM;%!+ 0(4
M Q0    ( #2+35JA.YV9EA@  /L, 0 >              "  8/2$P!E>#$P
M-BUF:69T:&%M96YD;65N='1O8W)E9"YH=&U02P$"% ,4    "  TBTU:JTOF
M,]<Y  !R90$ '@              @ %5ZQ, 97@Q.3$M9'9A:6YS:61E<G1R
B861I;F=P;VPN:'1M4$L%!@     1 !$ =00  &@E%     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>dva-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:dva="http://www.davita.com/20241231"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dva-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:IKCVBCArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:IKCVBCArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherReportingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">dva:TransplantSoftwareReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">dva:TransplantSoftwareReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:IndefiniteLifeNetOperatingLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">dva:TaxYear2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:ChangeHealthcareTemporaryFundingAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:ChangeHealthcareTemporaryFundingAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1AndRevolverMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:BaseRateLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:BaseRateLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dva:A1MonthSOFRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:BaseRateLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:SOFRLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dva:LoansTypeAxis">dva:BaseRateLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:ExtendedTermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-07</startDate>
            <endDate>2024-08-07</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:NewCreditAgreementAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-13</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:ChangeHealthcareTemporaryFundingAssistanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.50EffectiveDecember312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.50EffectiveDecember312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.00EffectiveDecember312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.00EffectiveDecember312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:TotalNotionalAmountEffectiveThroughDecember312027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.50EffectiveDecember312025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2024InterestRateCapAgreements4.00EffectiveDecember312025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1AndRevolverMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:IncreasedTermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">dva:A2017USAttorneyColoradoInvestigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2019-10-22</startDate>
            <endDate>2019-10-22</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:CommitmentsToProvideOperatingCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-02-13</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2024-09-05</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-13</startDate>
            <endDate>2025-02-13</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dva:DaVitaCarePte.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dva:DaVitaCarePte.Ltd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dva:GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis">dva:NonCashGainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dva:DaVitaCarePte.Ltd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dva:GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis">dva:ForeignCurrencyGainLossTranslationAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dva:DaVitaCarePte.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dva:GainRecognizedOnItsPreviouslyHeldEquityInterestInAcquireeAxis">dva:NonCashGainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-19</startDate>
            <endDate>2019-06-19</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesWithIntersegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherOperatingSegmentsWithIntersegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="clinic">
        <measure>dva:clinic</measure>
    </unit>
    <unit id="state">
        <measure>dva:state</measure>
    </unit>
    <unit id="patient">
        <measure>dva:patient</measure>
    </unit>
    <unit id="country">
        <measure>dva:country</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="entity">
        <measure>dva:entity</measure>
    </unit>
    <unit id="segments">
        <measure>dva:Segments</measure>
    </unit>
    <unit id="clinic2">
        <measure>dva:Clinic</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-31">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-32">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-34">0000927066</dei:EntityCentralIndexKey>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-267"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-268" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-269" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-270"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-271" unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-272" unitRef="shares">80536000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-273" unitRef="shares">88824000</us-gaap:CommonStockSharesOutstanding>
    <dva:NumberOfConcentrationRiskCustomers
      contextRef="c-137"
      decimals="INF"
      id="f-698"
      unitRef="number">0</dva:NumberOfConcentrationRiskCustomers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-137" decimals="2" id="f-699" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <dva:AccountsReceivablePeriodOutstanding contextRef="c-135" id="f-700">P6M</dva:AccountsReceivablePeriodOutstanding>
    <dva:AccountsReceivablePeriodOutstanding contextRef="c-136" id="f-701">P6M</dva:AccountsReceivablePeriodOutstanding>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-863" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-3" id="f-864" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-3" id="f-865" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c-205" id="f-1089">2036-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c-206" id="f-1090">2029-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c-207" id="f-1091">2044-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c-208" id="f-1092">2026-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="c-209" id="f-1093">2025-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-1"
      decimals="INF"
      id="f-1094"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-4"
      decimals="INF"
      id="f-1095"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-5"
      decimals="INF"
      id="f-1096"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1097" unitRef="number">0.0340</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-4" decimals="3" id="f-1098" unitRef="number">0.0260</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-5" decimals="3" id="f-1099" unitRef="number">0.0380</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1100" unitRef="number">-0.0110</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-4" decimals="3" id="f-1101" unitRef="number">-0.0110</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-5" decimals="3" id="f-1102" unitRef="number">-0.0160</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment contextRef="c-1" decimals="3" id="f-1103" unitRef="number">0.0070</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment contextRef="c-4" decimals="3" id="f-1104" unitRef="number">0.0120</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment contextRef="c-5" decimals="3" id="f-1105" unitRef="number">0.0110</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-1106" unitRef="number">0.0030</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-4" decimals="3" id="f-1107" unitRef="number">0.0020</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-5" decimals="3" id="f-1108" unitRef="number">0.0220</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-1" decimals="3" id="f-1109" unitRef="number">-0.0050</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-4" decimals="3" id="f-1110" unitRef="number">-0.0110</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-5" decimals="3" id="f-1111" unitRef="number">-0.0110</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-1112" unitRef="number">0.0010</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="3" id="f-1113" unitRef="number">0.0080</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="3" id="f-1114" unitRef="number">0.0120</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1115" unitRef="number">0.0120</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-4" decimals="3" id="f-1116" unitRef="number">0.0120</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-5" decimals="3" id="f-1117" unitRef="number">0.0120</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1118" unitRef="number">0.0030</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-4" decimals="3" id="f-1119" unitRef="number">0.0190</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-5" decimals="3" id="f-1120" unitRef="number">0.0110</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-1" decimals="3" id="f-1121" unitRef="number">0.0470</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-4" decimals="3" id="f-1122" unitRef="number">0.0560</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-5" decimals="3" id="f-1123" unitRef="number">0.0600</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1124" unitRef="number">0.1830</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-4" decimals="3" id="f-1125" unitRef="number">0.1870</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="3" id="f-1126" unitRef="number">0.2050</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-298" id="f-1334">http://fasb.org/us-gaap/2024#InterestAndDebtExpense</us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-301" id="f-1341">http://fasb.org/us-gaap/2024#IncomeTaxExpenseBenefit</us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="c-309" id="f-1364">Base + 1.75%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c-216" decimals="-3" id="f-1365" unitRef="usd">1533635000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c-310" decimals="-3" id="f-1366" unitRef="usd">1828245000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-269" decimals="-3" id="f-1367" unitRef="usd">1000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-269"
      decimals="INF"
      id="f-1368"
      unitRef="number">0.0375</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeInceptionDates contextRef="c-270" id="f-1369">2024-06-30</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-270" id="f-1370">2025-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByDecember312024 contextRef="c-270" decimals="-3" id="f-1371" unitRef="usd">500000000</dva:NotionalAmountAmortizableByDecember312024>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-270" decimals="-3" id="f-1372" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-271" decimals="-3" id="f-1373" unitRef="usd">1000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-272" id="f-1374">2024-06-30</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-272" id="f-1375">2025-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByDecember312024 contextRef="c-272" decimals="-3" id="f-1376" unitRef="usd">250000000</dva:NotionalAmountAmortizableByDecember312024>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-272" decimals="-3" id="f-1377" unitRef="usd">750000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-273" decimals="-3" id="f-1378" unitRef="usd">1000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-274" id="f-1379">2024-06-30</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-274" id="f-1380">2025-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByDecember312024 contextRef="c-274" decimals="-3" id="f-1381" unitRef="usd">250000000</dva:NotionalAmountAmortizableByDecember312024>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-274" decimals="-3" id="f-1382" unitRef="usd">750000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-275" decimals="-3" id="f-1383" unitRef="usd">500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-276" id="f-1384">2024-06-30</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-276" id="f-1385">2026-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-276" decimals="-3" id="f-1386" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-277" decimals="-3" id="f-1387" unitRef="usd">250000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-277"
      decimals="INF"
      id="f-1388"
      unitRef="number">0.0450</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeInceptionDates contextRef="c-278" id="f-1389">2024-12-31</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-278" id="f-1390">2025-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-278" decimals="-3" id="f-1391" unitRef="usd">250000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-279" decimals="-3" id="f-1392" unitRef="usd">750000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-279"
      decimals="INF"
      id="f-1393"
      unitRef="number">0.0400</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeInceptionDates contextRef="c-280" id="f-1394">2024-12-31</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-280" id="f-1395">2026-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByDecember312025 contextRef="c-280" decimals="-3" id="f-1396" unitRef="usd">250000000</dva:NotionalAmountAmortizableByDecember312025>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-280" decimals="-3" id="f-1397" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-281" decimals="-3" id="f-1398" unitRef="usd">1750000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-282" id="f-1399">2025-12-31</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-282" id="f-1400">2027-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByDecember312026 contextRef="c-282" decimals="-3" id="f-1401" unitRef="usd">750000000</dva:NotionalAmountAmortizableByDecember312026>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-282" decimals="-3" id="f-1402" unitRef="usd">1000000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-283" decimals="-3" id="f-1403" unitRef="usd">750000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-284" id="f-1404">2025-12-31</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-284" id="f-1405">2027-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByDecember312026 contextRef="c-284" decimals="-3" id="f-1406" unitRef="usd">250000000</dva:NotionalAmountAmortizableByDecember312026>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-284" decimals="-3" id="f-1407" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-7" id="f-1413">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-1414">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-1481">http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-1482">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-1488" unitRef="usd">689130000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-4" decimals="-3" id="f-1489" unitRef="usd">692834000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-3" id="f-1490" unitRef="usd">679815000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="c-234"
      decimals="INF"
      id="f-1491"
      unitRef="number">0.0458</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="c-235"
      decimals="INF"
      id="f-1492"
      unitRef="number">0.0458</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="c-320"
      decimals="INF"
      id="f-1493"
      unitRef="number">0.0451</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate contextRef="c-313" id="f-1509">P1Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate contextRef="c-314" id="f-1510">P2Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection contextRef="c-313" id="f-1511">P3Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection contextRef="c-314" id="f-1512">P4Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms contextRef="c-337" id="f-1623">P0Y</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-356"
      decimals="INF"
      id="f-1624"
      unitRef="usdPerShare">50.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-356"
      decimals="INF"
      id="f-1625"
      unitRef="usdPerShare">60.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-357"
      decimals="INF"
      id="f-1626"
      unitRef="usdPerShare">60.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-357"
      decimals="INF"
      id="f-1627"
      unitRef="usdPerShare">70.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-358"
      decimals="INF"
      id="f-1628"
      unitRef="usdPerShare">70.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-358"
      decimals="INF"
      id="f-1629"
      unitRef="usdPerShare">80.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-359"
      decimals="INF"
      id="f-1630"
      unitRef="usdPerShare">100.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-359"
      decimals="INF"
      id="f-1631"
      unitRef="usdPerShare">110.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-360"
      decimals="INF"
      id="f-1632"
      unitRef="usdPerShare">110.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-360"
      decimals="INF"
      id="f-1633"
      unitRef="usdPerShare">120.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-361"
      decimals="INF"
      id="f-1634"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-4" decimals="INF" id="f-1635" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-5" decimals="INF" id="f-1636" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="INF" id="f-1637" unitRef="usd">0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-4" decimals="INF" id="f-1638" unitRef="usd">0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-5" decimals="INF" id="f-1639" unitRef="usd">0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-354" decimals="INF" id="f-1640" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-355" decimals="INF" id="f-1641" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount contextRef="c-371" decimals="-3" id="f-1686" unitRef="usd">329302000</dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="c-41"
      decimals="-3"
      id="f-1687"
      unitRef="shares">2904000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-419" decimals="-3" id="f-1861" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-420" decimals="-3" id="f-1862" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-421" decimals="-3" id="f-1863" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-421" decimals="-3" id="f-1864" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-419" decimals="-3" id="f-1865" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-420" decimals="-3" id="f-1866" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-421" decimals="-3" id="f-1867" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-419" decimals="-3" id="f-1868" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-420" decimals="-3" id="f-1869" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-421" decimals="-3" id="f-1870" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-419" decimals="-3" id="f-1871" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">1-14106</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">DAVITA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">51-0354549</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">2000 16th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Denver,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">80202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">631-2100</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">DVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-27">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-28" unitRef="usd">11800000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="-5" id="f-29" unitRef="shares">80000000.0</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-35">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Item&#160;1C.&#160;&#160;&#160;&#160;Cybersecurity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the increasing use of the Internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including, among others, foreign state agents. Our business and operations rely on the secure and continuous processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks, including, but not limited to, sensitive personal information, such as PHI, social security numbers, and/or credit card information of our patients, teammates, physicians, business partners and others. Our business and operations also rely on certain critical IT vendors that support such processing, transmission and storage (which have become more relevant and important given the information security issues and risks that are intensified through our increased use of remote work arrangements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To manage risks to our Company, including information and security risks, our Board oversees our enterprise-wide approach to risk management with a fundamental belief that the key components of risk management are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identifying potential risks that we face;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Assessing the likelihood and potential impact of the risks;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Adopting strategies and controls designed to manage the risks;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Reporting on a regular basis regarding the assessment and management of the risks; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Monitoring these potential risks on a regular basis; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Evaluating whether there are new potential risks to assess.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our Enterprise Risk Management (ERM) process, the Company evaluates risks to the enterprise on short, intermediate and long-term bases. The ERM Committee, a group comprised of members of senior management, meet on a regular basis to oversee the performance of these risk management functions. We assess risks using a probability-magnitude lens, with shorter and intermediate term risks generally given greater weight. We prioritize mitigating activities on shorter and intermediate term risks, but also use risk analyses and oversight to proactively incorporate mitigating activities into our long-term strategy. The ERM process reflects a Company-wide effort designed to identify, assess, manage, report and monitor enterprise risks and risk areas. This effort includes the Company's Enterprise Risk Services (Internal Audit), Sarbanes-Oxley (SOX), Compliance Audit, legal and IT security teams, among others. The identification and evaluation of cybersecurity threats and risks is integrated into this ERM process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ERM process is incorporated into our disclosure controls and procedures. Representatives of each of our ERM, Internal Audit, legal and compliance teams sit on the Company&#x2019;s management Disclosure Committee, which is responsible for, among other things, the design and establishment of disclosure controls and procedures to help ensure the timeliness, accuracy and completeness of corporate disclosure. Our IT security and privacy teams, who are responsible for assessing cybersecurity threats and risks, in turn maintain policies and procedures designed to ensure appropriate escalation of cybersecurity incidents to meet external disclosure requirements. Our Chief Information Officer (CIO) and Chief Information Security Officer (CISO) regularly meet and coordinate with our Chief Privacy Officer (CPO). Each of the CIO, CISO and CPO also advise members of the Disclosure Committee, including our Chief Legal and Public Affairs Officer (CLO), on disclosure matters on an as-needed basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to assessing privacy, data and cybersecurity risks, the Company adopts a hybrid approach that primarily aligns with the National Institute of Standards and Technology (NIST) Cybersecurity Framework, including the guidance set &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forth in the NIST HIPAA Security Rule Cybersecurity Guide, while also evaluating against certain elements of the ISO 27001 and 27005 standards that management believes provide additional levels of guidance or structure. We regularly evaluate the Company&#x2019;s cybersecurity and privacy processes and procedures, both through regular audits by our Internal Audit and IT security teams, as well as regular retention of outside advisors under direction of our IT security team. Among other things, the IT security team oversees an external third party review at least every two years that evaluates the readiness of the entire Company against the NIST Cybersecurity Framework and provides an assessment that measures Capability Maturity Model Integration levels. Additionally, our CISO engages in regular consultations, typically monthly, with third-party cybersecurity advisors. Among other things, these sessions provide the Company with a broader review of the external cybersecurity environment, helping us to stay current on emerging or developing security approaches and risks. Among other initiatives, our CISO and the Company&#x2019;s IT security team actively participate in industry conferences and maintain memberships to resources such as the Health Information Sharing and Analysis Center (Health-ISAC), a trusted community of critical infrastructure owners and operators within the Health Care and Public Health sector which, among other things, allows the Company to monitor email updates and alerts coordinated with the U.S. Department of Homeland Security&#x2019;s Cybersecurity and Infrastructure Security Agency. In order to maintain awareness of privacy, data and cybersecurity risks, the Company incorporates these topics into its annual compliance training materials that are mandatory for all teammates and new hires, and among other things cover HIPAA privacy and security requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and have established processes involving our IT security, privacy and legal teams that assess potential cybersecurity risks associated with our retention and use of third-party service providers. These policies and procedures are generally aligned with the NIST Cybersecurity Framework. Prior to retaining or renewing a third-party vendor, the Company policy requires a risk assessment of such potential new vendor or new engagement through a collaborative process among the Company&#x2019;s IT security, privacy, insurance and legal teams, among others. Potential vendor engagements also are reviewed to assess a range of other considerations and contractual terms and conditions, including, among other things, a potential vendor&#x2019;s liability insurance limits, scope and coverage of cyber insurance and privacy data protections. Our IT SOX team also conducts annual SOX reviews for those vendors that are considered in scope for SOX controls. All finalized vendor engagements are considered by Internal Audit as part of our ordinary course risk assessment and audit planning.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-36">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To manage risks to our Company, including information and security risks, our Board oversees our enterprise-wide approach to risk management with a fundamental belief that the key components of risk management are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identifying potential risks that we face;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Assessing the likelihood and potential impact of the risks;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Adopting strategies and controls designed to manage the risks;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Reporting on a regular basis regarding the assessment and management of the risks; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Monitoring these potential risks on a regular basis; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Evaluating whether there are new potential risks to assess.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our Enterprise Risk Management (ERM) process, the Company evaluates risks to the enterprise on short, intermediate and long-term bases. The ERM Committee, a group comprised of members of senior management, meet on a regular basis to oversee the performance of these risk management functions. We assess risks using a probability-magnitude lens, with shorter and intermediate term risks generally given greater weight. We prioritize mitigating activities on shorter and intermediate term risks, but also use risk analyses and oversight to proactively incorporate mitigating activities into our long-term strategy. The ERM process reflects a Company-wide effort designed to identify, assess, manage, report and monitor enterprise risks and risk areas. This effort includes the Company's Enterprise Risk Services (Internal Audit), Sarbanes-Oxley (SOX), Compliance Audit, legal and IT security teams, among others. The identification and evaluation of cybersecurity threats and risks is integrated into this ERM process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ERM process is incorporated into our disclosure controls and procedures. Representatives of each of our ERM, Internal Audit, legal and compliance teams sit on the Company&#x2019;s management Disclosure Committee, which is responsible for, among other things, the design and establishment of disclosure controls and procedures to help ensure the timeliness, accuracy and completeness of corporate disclosure. Our IT security and privacy teams, who are responsible for assessing cybersecurity threats and risks, in turn maintain policies and procedures designed to ensure appropriate escalation of cybersecurity incidents to meet external disclosure requirements. Our Chief Information Officer (CIO) and Chief Information Security Officer (CISO) regularly meet and coordinate with our Chief Privacy Officer (CPO). Each of the CIO, CISO and CPO also advise members of the Disclosure Committee, including our Chief Legal and Public Affairs Officer (CLO), on disclosure matters on an as-needed basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to assessing privacy, data and cybersecurity risks, the Company adopts a hybrid approach that primarily aligns with the National Institute of Standards and Technology (NIST) Cybersecurity Framework, including the guidance set &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forth in the NIST HIPAA Security Rule Cybersecurity Guide, while also evaluating against certain elements of the ISO 27001 and 27005 standards that management believes provide additional levels of guidance or structure. We regularly evaluate the Company&#x2019;s cybersecurity and privacy processes and procedures, both through regular audits by our Internal Audit and IT security teams, as well as regular retention of outside advisors under direction of our IT security team. Among other things, the IT security team oversees an external third party review at least every two years that evaluates the readiness of the entire Company against the NIST Cybersecurity Framework and provides an assessment that measures Capability Maturity Model Integration levels. Additionally, our CISO engages in regular consultations, typically monthly, with third-party cybersecurity advisors. Among other things, these sessions provide the Company with a broader review of the external cybersecurity environment, helping us to stay current on emerging or developing security approaches and risks. Among other initiatives, our CISO and the Company&#x2019;s IT security team actively participate in industry conferences and maintain memberships to resources such as the Health Information Sharing and Analysis Center (Health-ISAC), a trusted community of critical infrastructure owners and operators within the Health Care and Public Health sector which, among other things, allows the Company to monitor email updates and alerts coordinated with the U.S. Department of Homeland Security&#x2019;s Cybersecurity and Infrastructure Security Agency. In order to maintain awareness of privacy, data and cybersecurity risks, the Company incorporates these topics into its annual compliance training materials that are mandatory for all teammates and new hires, and among other things cover HIPAA privacy and security requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and have established processes involving our IT security, privacy and legal teams that assess potential cybersecurity risks associated with our retention and use of third-party service providers. These policies and procedures are generally aligned with the NIST Cybersecurity Framework. Prior to retaining or renewing a third-party vendor, the Company policy requires a risk assessment of such potential new vendor or new engagement through a collaborative process among the Company&#x2019;s IT security, privacy, insurance and legal teams, among others. Potential vendor engagements also are reviewed to assess a range of other considerations and contractual terms and conditions, including, among other things, a potential vendor&#x2019;s liability insurance limits, scope and coverage of cyber insurance and privacy data protections. Our IT SOX team also conducts annual SOX reviews for those vendors that are considered in scope for SOX controls. All finalized vendor engagements are considered by Internal Audit as part of our ordinary course risk assessment and audit planning.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-37">The ERM Committee, a group comprised of members of senior management, meet on a regular basis to oversee the performance of these risk management functions.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c-1" id="f-40">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cybersecurity Risks and the Impact on our Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the continuously evolving series of laws and regulations related to cybersecurity, data protection and privacy that are applicable to our business, as well as the associated risks from cybersecurity threats, we have expended significant resources in order to protect our information systems and data. We regularly review, monitor and implement multiple layers of security measures through technology, processes and our people. We utilize security technologies designed to protect and maintain the integrity of our information systems and data, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses and other malicious code; coordinated attacks by a variety of actors, including, among others, activist entities or state sponsored cyberattacks; emerging cybersecurity risks; cyber risk related to connected devices; misplaced or lost data; programming and/or human errors; or other similar events that could impact the security, reliability and availability of our systems. Internal or external parties have attempted to, and will continue to attempt to, circumvent our security systems, and we have in the past, and expect that we will in the future, defend against, experience, and respond to attacks on our network including, without limitation, reconnaissance probes, denial of service attempts, malicious software attacks including ransomware or other attacks intended to render our internal operating systems or data unavailable, and phishing attacks or business email compromise. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we have experienced cybersecurity incidents in the past, to date none have had a material impact on our business, results of operations, financial condition and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity requires ongoing investment and diligence against evolving threats and in the context of new or developing technologies. For further information regarding the risks we face from cybersecurity threats and how our business strategy, results of operations, and financial condition could be materially affected by such risks, see Part I Item IA. "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Factors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;" under the heading, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Privacy and information security laws are complex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2026;".&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-42">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-43">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Board Oversight&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its oversight responsibilities, the Audit Committee monitors privacy, data and cybersecurity as specific risk areas. The Audit Committee also works with the Compliance and Quality Committee to oversee enterprise risks with healthcare and anti-corruption requirements, and those requirements include certain privacy, data and cybersecurity aspects. Both Mr. Schechter, a member of the Audit Committee, and Ms. Schoppert, a member of the Audit Committee, hold a CERT Certificate in Cybersecurity Oversight. The Audit Committee engages in regular discussions with management on privacy, data, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cybersecurity risk exposures, receiving quarterly reports from the ERM team and the CIO. On a periodic basis, the full Board of Directors also receives these reports from the ERM team and the CIO. The CPO and/or CLO periodically reports to the Audit Committee about the Company&#x2019;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Among other things, the Company&#x2019;s privacy team actively develops and implements policies designed to comply with the requirements of privacy laws in the countries where the Company operates. Working with Internal Audit and the CIO, the privacy team assesses the nature and potential severity of privacy risks within DaVita and guides the organization in taking steps to help mitigate such risks. The Audit Committee also oversees the Company's negotiation of any cybersecurity insurance. Currently, the Company maintains a cybersecurity risk insurance policy providing coverage for certain cybersecurity breaches among other specified risks.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-46">The Audit Committee engages in regular discussions with management on privacy, data, and &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cybersecurity risk exposures, receiving quarterly reports from the ERM team and the CIO. On a periodic basis, the full Board of Directors also receives these reports from the ERM team and the CIO. The CPO and/or CLO periodically reports to the Audit Committee about the Company&#x2019;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-45">The Audit Committee engages in regular discussions with management on privacy, data, and &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cybersecurity risk exposures, receiving quarterly reports from the ERM team and the CIO. On a periodic basis, the full Board of Directors also receives these reports from the ERM team and the CIO. The CPO and/or CLO periodically reports to the Audit Committee about the Company&#x2019;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-44">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-47">false</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-48">The CPO and/or CLO periodically reports to the Audit Committee about the Company&#x2019;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-49">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, our IT security team, in consultation with our privacy team, is primarily responsible for frontline assessments and management of day-to-day risks from cybersecurity threats, including the monitoring and detection of cybersecurity incidents and the execution of DaVita's cybersecurity and privacy incident response plans, as needed. Pursuant to the plan, the teams are responsible for assessing and classifying cybersecurity incidents and coordinating the response to such incidents, including managing both internal and external reporting obligations and remediation efforts. Our key personnel responsible for privacy and cybersecurity expertise include our CIO, CISO and CPO. Their qualifications include expertise in international privacy laws, compliance, global IT strategy, and security responsibilities, helping to ensure a comprehensive approach to risk management. Our CISO has more than two decades of experience in information technology risk and compliance and holds a Certified Chief Information Security Officer certification from EC-Council, a Certified Information Security Manager certification from ISACA and a certification from the Massachusetts Institute of Technology on AI management in healthcare. Our CPO is a Certified Information Privacy Professional and a Certified Compliance and Ethics Professional, and has more than two decades of experience in creating and implementing privacy and data protection programs that enable multinational organizations to respect and protect personal data and execute mission critical business strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our IT security team also operates a 24x7 security operations center through a managed service provider. This dedicated center, alongside active monitoring of the dark web for DaVita-related data, and our use of both internal and external tools, is designed to ensure proactive detection, prevention and remediation of cybersecurity incidents. We inform and develop this integrated approach through our ongoing internal and external evaluations and risk assessments of our IT security program as described above.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-50">Our key personnel responsible for privacy and cybersecurity expertise include our CIO, CISO and CPO. Their qualifications include expertise in international privacy laws, compliance, global IT strategy, and security responsibilities, helping to ensure a comprehensive approach to risk management. Our CISO has more than two decades of experience in information technology risk and compliance and holds a Certified Chief Information Security Officer certification from EC-Council, a Certified Information Security Manager certification from ISACA and a certification from the Massachusetts Institute of Technology on AI management in healthcare. Our CPO is a Certified Information Privacy Professional and a Certified Compliance and Ethics Professional, and has more than two decades of experience in creating and implementing privacy and data protection programs that enable multinational organizations to respect and protect personal data and execute mission critical business strategies.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-51">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-52">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-53">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-54">false</ecd:NonRule10b51ArrAdoptedFlag>
    <dei:AuditorName contextRef="c-1" id="f-55">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-56">Seattle, WA, USA</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-57">185</dei:AuditorFirmId>
    <dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts contextRef="c-1" decimals="-3" id="f-58" unitRef="usd">12260375000</dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts>
    <dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">11574941000</dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts>
    <dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">11176464000</dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts>
    <us-gaap:OtherIncome contextRef="c-1" decimals="-3" id="f-61" unitRef="usd">555175000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">565206000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">433430000</us-gaap:OtherIncome>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-64" unitRef="usd">12815550000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">12140147000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">11609894000</us-gaap:Revenues>
    <dva:PatientCareCosts contextRef="c-1" decimals="-3" id="f-67" unitRef="usd">8598521000</dva:PatientCareCosts>
    <dva:PatientCareCosts contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">8319717000</dva:PatientCareCosts>
    <dva:PatientCareCosts contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">8209553000</dva:PatientCareCosts>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-70" unitRef="usd">1538341000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">1473984000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">1355197000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-73" unitRef="usd">723860000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">745443000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">732602000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-76" unitRef="usd">26189000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">27864000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">26520000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-79" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">26083000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-3" id="f-82" unitRef="usd">109466000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-85" unitRef="usd">10725067000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">10537363000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">10270832000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-88" unitRef="usd">2090483000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">1602784000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">1339062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndDebtExpense contextRef="c-1" decimals="-3" id="f-91" unitRef="usd">470469000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">398551000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">357019000</us-gaap:InterestAndDebtExpense>
    <dva:DebtPrepaymentExtinguishmentAndModificationCosts contextRef="c-1" decimals="-3" id="f-94" unitRef="usd">19813000</dva:DebtPrepaymentExtinguishmentAndModificationCosts>
    <dva:DebtPrepaymentExtinguishmentAndModificationCosts contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">7962000</dva:DebtPrepaymentExtinguishmentAndModificationCosts>
    <dva:DebtPrepaymentExtinguishmentAndModificationCosts contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">0</dva:DebtPrepaymentExtinguishmentAndModificationCosts>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-97" unitRef="usd">-69808000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">-19177000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">-15765000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">1530393000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-101" unitRef="usd">1177094000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">966278000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">279656000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-104" unitRef="usd">220116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">198087000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">1250737000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">956978000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">768191000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-4" decimals="-3" id="f-110" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">13452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">1250737000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">956978000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">781643000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">314395000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">265443000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">221243000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">936342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-119" unitRef="usd">691535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-121"
      unitRef="usdPerShare">11.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-4"
      decimals="2"
      id="f-122"
      unitRef="usdPerShare">7.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-5"
      decimals="2"
      id="f-123"
      unitRef="usdPerShare">5.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-124"
      unitRef="usdPerShare">11.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-125"
      unitRef="usdPerShare">7.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-126"
      unitRef="usdPerShare">6.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-127"
      unitRef="usdPerShare">10.73</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-4"
      decimals="2"
      id="f-128"
      unitRef="usdPerShare">7.42</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-5"
      decimals="2"
      id="f-129"
      unitRef="usdPerShare">5.71</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-130"
      unitRef="usdPerShare">10.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-131"
      unitRef="usdPerShare">7.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-132"
      unitRef="usdPerShare">5.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-133" unitRef="shares">84991000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-4" decimals="0" id="f-134" unitRef="shares">90790000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-135" unitRef="shares">92992000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-136" unitRef="shares">87274000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-4" decimals="0" id="f-137" unitRef="shares">93182000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-138" unitRef="shares">95834000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">936342000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-4" decimals="-3" id="f-140" unitRef="usd">691535000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-5" decimals="-3" id="f-141" unitRef="usd">546948000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-4" decimals="-3" id="f-143" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-5" decimals="-3" id="f-144" unitRef="usd">13452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">936342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-146" unitRef="usd">691535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-147" unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">1250737000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-4" decimals="-3" id="f-149" unitRef="usd">956978000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-150" unitRef="usd">781643000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">7250000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-4" decimals="-3" id="f-152" unitRef="usd">6895000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-5" decimals="-3" id="f-153" unitRef="usd">108669000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">43660000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-4" decimals="-3" id="f-155" unitRef="usd">77727000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-5" decimals="-3" id="f-156" unitRef="usd">8806000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">46000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax contextRef="c-4" decimals="-3" id="f-158" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-159" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">-207861000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-4" decimals="-3" id="f-161" unitRef="usd">87934000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-162" unitRef="usd">-29802000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">14487000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-4" decimals="-3" id="f-164" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-5" decimals="-3" id="f-165" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-258712000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-167" unitRef="usd">17102000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-168" unitRef="usd">70061000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">992025000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-170" unitRef="usd">974080000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-171" unitRef="usd">851704000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">314395000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-173" unitRef="usd">265443000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-174" unitRef="usd">221243000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">677630000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-4" decimals="-3" id="f-176" unitRef="usd">708637000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-177" unitRef="usd">630461000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-178" unitRef="usd">794933000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-179" unitRef="usd">380063000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-6" decimals="-3" id="f-180" unitRef="usd">84892000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-181" unitRef="usd">84571000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-182" unitRef="usd">51064000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-7" decimals="-3" id="f-183" unitRef="usd">11610000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-3" id="f-184" unitRef="usd">2146975000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="-3" id="f-185" unitRef="usd">1986856000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-6" decimals="-3" id="f-186" unitRef="usd">134559000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-187" unitRef="usd">143105000</us-gaap:InventoryNet>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-6" decimals="-3" id="f-188" unitRef="usd">383166000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-7" decimals="-3" id="f-189" unitRef="usd">422669000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-190" unitRef="usd">122948000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-191" unitRef="usd">102645000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-6" decimals="-3" id="f-192" unitRef="usd">27535000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-7" decimals="-3" id="f-193" unitRef="usd">6387000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-194" unitRef="usd">3746072000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-195" unitRef="usd">3137906000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-196" unitRef="usd">2940916000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-197" unitRef="usd">3073533000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-198" unitRef="usd">2393558000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-199" unitRef="usd">2501364000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-200" unitRef="usd">197431000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-201" unitRef="usd">203224000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-6" decimals="-3" id="f-202" unitRef="usd">336684000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-7" decimals="-3" id="f-203" unitRef="usd">545848000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-6" decimals="-3" id="f-204" unitRef="usd">33660000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-7" decimals="-3" id="f-205" unitRef="usd">47890000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-206" unitRef="usd">261731000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-207" unitRef="usd">271253000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-208" unitRef="usd">7375216000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-209" unitRef="usd">7112560000</us-gaap:Goodwill>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-210" unitRef="usd">17285268000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-211" unitRef="usd">16893578000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-212" unitRef="usd">547200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-213" unitRef="usd">514533000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-214" unitRef="usd">934145000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-215" unitRef="usd">828878000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-216" unitRef="usd">800484000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-217" unitRef="usd">752598000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-218" unitRef="usd">410411000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-219" unitRef="usd">394399000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-6" decimals="-3" id="f-220" unitRef="usd">270867000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-7" decimals="-3" id="f-221" unitRef="usd">123299000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-6" decimals="-3" id="f-222" unitRef="usd">10303000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-7" decimals="-3" id="f-223" unitRef="usd">28507000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-224" unitRef="usd">2973410000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-225" unitRef="usd">2642214000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-226" unitRef="usd">2209655000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-227" unitRef="usd">2330389000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-6" decimals="-3" id="f-228" unitRef="usd">9175903000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-7" decimals="-3" id="f-229" unitRef="usd">8268334000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-230" unitRef="usd">169588000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-231" unitRef="usd">183074000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-6" decimals="-3" id="f-232" unitRef="usd">665361000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-7" decimals="-3" id="f-233" unitRef="usd">726217000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-234" unitRef="usd">15193917000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-235" unitRef="usd">14150228000</us-gaap:Liabilities>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-6" decimals="-3" id="f-236" unitRef="usd">1695483000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-7" decimals="-3" id="f-237" unitRef="usd">1499288000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-238"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-239" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-240" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-242" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-243"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-244" unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-245" unitRef="shares">90369000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-246" unitRef="shares">88824000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-247" unitRef="usd">90000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-248" unitRef="usd">89000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-6" decimals="-3" id="f-249" unitRef="usd">286270000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-7" decimals="-3" id="f-250" unitRef="usd">509804000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-251" unitRef="usd">1534630000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-252" unitRef="usd">598288000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares contextRef="c-6" decimals="-3" id="f-253" unitRef="shares">9833000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-7" decimals="-3" id="f-254" unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-6" decimals="-3" id="f-255" unitRef="usd">1389072000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-7" decimals="-3" id="f-256" unitRef="usd">0</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-257" unitRef="usd">-310796000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-258" unitRef="usd">-52084000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-259" unitRef="usd">121122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-260" unitRef="usd">1056097000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-6" decimals="-3" id="f-261" unitRef="usd">274746000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">187965000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-263" unitRef="usd">395868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-264" unitRef="usd">1244062000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-265" unitRef="usd">17285268000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">16893578000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">1250737000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-4" decimals="-3" id="f-275" unitRef="usd">956978000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-276" unitRef="usd">781643000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">723860000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="c-4" decimals="-3" id="f-278" unitRef="usd">745443000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="c-5" decimals="-3" id="f-279" unitRef="usd">732602000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-4" decimals="-3" id="f-281" unitRef="usd">26083000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-5" decimals="-3" id="f-282" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <dva:DebtRefinancingCharges contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">12527000</dva:DebtRefinancingCharges>
    <dva:DebtRefinancingCharges contextRef="c-4" decimals="-3" id="f-284" unitRef="usd">7132000</dva:DebtRefinancingCharges>
    <dva:DebtRefinancingCharges contextRef="c-5" decimals="-3" id="f-285" unitRef="usd">0</dva:DebtRefinancingCharges>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">102788000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-4" decimals="-3" id="f-287" unitRef="usd">112375000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-288" unitRef="usd">95427000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">-57840000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-290" unitRef="usd">-39354000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-291" unitRef="usd">-75669000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <dva:AdjustmentIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">-115839000</dva:AdjustmentIncomeLossFromEquityMethodInvestments>
    <dva:AdjustmentIncomeLossFromEquityMethodInvestments contextRef="c-4" decimals="-3" id="f-293" unitRef="usd">-64777000</dva:AdjustmentIncomeLossFromEquityMethodInvestments>
    <dva:AdjustmentIncomeLossFromEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-294" unitRef="usd">-8773000</dva:AdjustmentIncomeLossFromEquityMethodInvestments>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">109466000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain contextRef="c-4" decimals="-3" id="f-296" unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain contextRef="c-5" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">-13414000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-4" decimals="-3" id="f-299" unitRef="usd">8938000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-5" decimals="-3" id="f-300" unitRef="usd">-21693000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">29766000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-4" decimals="-3" id="f-302" unitRef="usd">-172361000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="-3" id="f-303" unitRef="usd">148394000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">-17942000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-4" decimals="-3" id="f-305" unitRef="usd">32132000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-5" decimals="-3" id="f-306" unitRef="usd">757000</us-gaap:IncreaseDecreaseInInventories>
    <dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">-36801000</dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets>
    <dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets contextRef="c-4" decimals="-3" id="f-308" unitRef="usd">43437000</dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets>
    <dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets contextRef="c-5" decimals="-3" id="f-309" unitRef="usd">-27533000</dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">67031000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-4" decimals="-3" id="f-311" unitRef="usd">5792000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-5" decimals="-3" id="f-312" unitRef="usd">50549000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">1699000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-4" decimals="-3" id="f-314" unitRef="usd">26890000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-315" unitRef="usd">87481000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">14687000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-4" decimals="-3" id="f-317" unitRef="usd">56209000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-5" decimals="-3" id="f-318" unitRef="usd">34536000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">46733000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-320" unitRef="usd">27082000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-5" decimals="-3" id="f-321" unitRef="usd">89955000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">-44214000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-4" decimals="-3" id="f-323" unitRef="usd">1570000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-5" decimals="-3" id="f-324" unitRef="usd">-24103000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">-6672000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-4" decimals="-3" id="f-326" unitRef="usd">-8216000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-5" decimals="-3" id="f-327" unitRef="usd">-15601000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">2022038000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-4" decimals="-3" id="f-329" unitRef="usd">2059031000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-330" unitRef="usd">1564570000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">555443000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-332" unitRef="usd">567985000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-333" unitRef="usd">603429000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">246068000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-4" decimals="-3" id="f-335" unitRef="usd">26394000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-5" decimals="-3" id="f-336" unitRef="usd">57308000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">25862000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets contextRef="c-4" decimals="-3" id="f-338" unitRef="usd">30610000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets contextRef="c-5" decimals="-3" id="f-339" unitRef="usd">117582000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">15319000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="c-4" decimals="-3" id="f-341" unitRef="usd">37180000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="c-5" decimals="-3" id="f-342" unitRef="usd">129803000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <dva:PaymentsToAcquireOtherDebtAndEquityInvestments contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">9140000</dva:PaymentsToAcquireOtherDebtAndEquityInvestments>
    <dva:PaymentsToAcquireOtherDebtAndEquityInvestments contextRef="c-4" decimals="-3" id="f-344" unitRef="usd">9566000</dva:PaymentsToAcquireOtherDebtAndEquityInvestments>
    <dva:PaymentsToAcquireOtherDebtAndEquityInvestments contextRef="c-5" decimals="-3" id="f-345" unitRef="usd">3590000</dva:PaymentsToAcquireOtherDebtAndEquityInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">22638000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-4" decimals="-3" id="f-347" unitRef="usd">99639000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-5" decimals="-3" id="f-348" unitRef="usd">71125000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">4566000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-4" decimals="-3" id="f-350" unitRef="usd">10365000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-5" decimals="-3" id="f-351" unitRef="usd">3781000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">5205000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-4" decimals="-3" id="f-353" unitRef="usd">276202000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-354" unitRef="usd">31885000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">6680000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="c-4" decimals="-3" id="f-356" unitRef="usd">4913000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="c-5" decimals="-3" id="f-357" unitRef="usd">3962000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-4" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-5" decimals="-3" id="f-360" unitRef="usd">782000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-361" unitRef="usd">-771429000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-4" decimals="-3" id="f-362" unitRef="usd">-771800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-363" unitRef="usd">-630347000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">6624310000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-4" decimals="-3" id="f-365" unitRef="usd">2468341000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-5" decimals="-3" id="f-366" unitRef="usd">2393116000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="c-1" decimals="-3" id="f-367" unitRef="usd">5515213000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="c-4" decimals="-3" id="f-368" unitRef="usd">3020956000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="c-5" decimals="-3" id="f-369" unitRef="usd">2404395000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <dva:DebtFinancingAndDebtRedemptionCosts contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">50874000</dva:DebtFinancingAndDebtRedemptionCosts>
    <dva:DebtFinancingAndDebtRedemptionCosts contextRef="c-4" decimals="-3" id="f-371" unitRef="usd">69791000</dva:DebtFinancingAndDebtRedemptionCosts>
    <dva:DebtFinancingAndDebtRedemptionCosts contextRef="c-5" decimals="-3" id="f-372" unitRef="usd">3000</dva:DebtFinancingAndDebtRedemptionCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-373" unitRef="usd">1385932000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-4" decimals="-3" id="f-374" unitRef="usd">272219000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-5" decimals="-3" id="f-375" unitRef="usd">802228000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDistributionsToAffiliates contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">337042000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates contextRef="c-4" decimals="-3" id="f-377" unitRef="usd">280938000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates contextRef="c-5" decimals="-3" id="f-378" unitRef="usd">267946000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <dva:NetProceedsFromIssuanceOfStockToEmployees contextRef="c-1" decimals="-3" id="f-379" unitRef="usd">20453000</dva:NetProceedsFromIssuanceOfStockToEmployees>
    <dva:NetProceedsFromIssuanceOfStockToEmployees contextRef="c-4" decimals="-3" id="f-380" unitRef="usd">16900000</dva:NetProceedsFromIssuanceOfStockToEmployees>
    <dva:NetProceedsFromIssuanceOfStockToEmployees contextRef="c-5" decimals="-3" id="f-381" unitRef="usd">18577000</dva:NetProceedsFromIssuanceOfStockToEmployees>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-382" unitRef="usd">134040000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">65012000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-384" unitRef="usd">55944000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-1" decimals="-3" id="f-385" unitRef="usd">14499000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-4" decimals="-3" id="f-386" unitRef="usd">14773000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-5" decimals="-3" id="f-387" unitRef="usd">14797000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="c-1" decimals="-3" id="f-388" unitRef="usd">860000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="c-4" decimals="-3" id="f-389" unitRef="usd">50962000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="c-5" decimals="-3" id="f-390" unitRef="usd">3673000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-1" decimals="-3" id="f-391" unitRef="usd">53958000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-4" decimals="-3" id="f-392" unitRef="usd">12555000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-5" decimals="-3" id="f-393" unitRef="usd">20775000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-394" unitRef="usd">-816937000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-4" decimals="-3" id="f-395" unitRef="usd">-1170495000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-396" unitRef="usd">-1121128000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-397" unitRef="usd">-18481000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-398" unitRef="usd">8909000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-399" unitRef="usd">-29066000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-400" unitRef="usd">415191000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-4" decimals="-3" id="f-401" unitRef="usd">125645000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-402" unitRef="usd">-215971000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-403" unitRef="usd">464634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-404" unitRef="usd">338989000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-405" unitRef="usd">554960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-406" unitRef="usd">879825000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-407" unitRef="usd">464634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-408" unitRef="usd">338989000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-10" decimals="-3" id="f-409" unitRef="usd">1434832000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-11" decimals="-3" id="f-410" unitRef="shares">97289000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-411" unitRef="usd">97000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-412" unitRef="usd">540321000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-413" unitRef="usd">354337000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="-3" id="f-414" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-415" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-416" unitRef="usd">-139247000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-417" unitRef="usd">755508000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-418" unitRef="usd">180640000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-18" decimals="-3" id="f-419" unitRef="usd">151379000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-420" unitRef="usd">560400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-421" unitRef="usd">560400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-422" unitRef="usd">69864000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-22" decimals="-3" id="f-423" unitRef="usd">70061000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-20" decimals="-3" id="f-424" unitRef="usd">70061000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-23" decimals="-3" id="f-425" unitRef="shares">285000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-23" decimals="-3" id="f-426" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-24" decimals="-3" id="f-427" unitRef="usd">18061000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-20" decimals="-3" id="f-428" unitRef="usd">18061000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-23" decimals="-3" id="f-429" unitRef="shares">932000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-23" decimals="-3" id="f-430" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-24" decimals="-3" id="f-431" unitRef="usd">55921000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-20" decimals="-3" id="f-432" unitRef="usd">55920000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-433" unitRef="usd">95230000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-434" unitRef="usd">95230000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders contextRef="c-18" decimals="-3" id="f-435" unitRef="usd">176957000</dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-21" decimals="-3" id="f-436" unitRef="usd">90989000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders contextRef="c-18" decimals="-3" id="f-437" unitRef="usd">10962000</dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders>
    <dva:NoncontrollingInterestIncreaseFromContributions contextRef="c-21" decimals="-3" id="f-438" unitRef="usd">3835000</dva:NoncontrollingInterestIncreaseFromContributions>
    <dva:TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures contextRef="c-18" decimals="-3" id="f-439" unitRef="usd">-2392000</dva:TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures contextRef="c-24" decimals="-3" id="f-440" unitRef="usd">939000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures contextRef="c-20" decimals="-3" id="f-441" unitRef="usd">939000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-21" decimals="-3" id="f-442" unitRef="usd">866000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:TemporaryEquityDecreasePurchaseOfInterests contextRef="c-18" decimals="-3" id="f-443" unitRef="usd">11670000</dva:TemporaryEquityDecreasePurchaseOfInterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-24" decimals="-3" id="f-444" unitRef="usd">-6586000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-20" decimals="-3" id="f-445" unitRef="usd">-6586000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-21" decimals="-3" id="f-446" unitRef="usd">193000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="c-18" decimals="-3" id="f-447" unitRef="usd">-62487000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-24" decimals="-3" id="f-448" unitRef="usd">62487000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-20" decimals="-3" id="f-449" unitRef="usd">62487000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:TemporaryEquityOtherChanges contextRef="c-18" decimals="-3" id="f-450" unitRef="usd">457000</us-gaap:TemporaryEquityOtherChanges>
    <dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations contextRef="c-20" decimals="-3" id="f-451" unitRef="usd">0</dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations>
    <dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations contextRef="c-21" decimals="-3" id="f-452" unitRef="usd">457000</dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-25" decimals="-3" id="f-453" unitRef="shares">8095000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-25" decimals="-3" id="f-454" unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-20" decimals="-3" id="f-455" unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-23" decimals="-3" id="f-456" unitRef="shares">8095000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-23" decimals="-3" id="f-457" unitRef="usd">8000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-24" decimals="-3" id="f-458" unitRef="usd">47596000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-19" decimals="-3" id="f-459" unitRef="usd">740250000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-25" decimals="-3" id="f-460" unitRef="shares">8095000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-25" decimals="-3" id="f-461" unitRef="usd">787854000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-20" decimals="-3" id="f-462" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-26" decimals="-3" id="f-463" unitRef="usd">1348908000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-464" unitRef="shares">90411000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-465" unitRef="usd">90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-466" unitRef="usd">606935000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-467" unitRef="usd">174487000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="-3" id="f-468" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-470" unitRef="usd">-69186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-471" unitRef="usd">712326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-472" unitRef="usd">163566000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-34" decimals="-3" id="f-473" unitRef="usd">176789000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-474" unitRef="usd">691535000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-475" unitRef="usd">691535000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-37" decimals="-3" id="f-476" unitRef="usd">88654000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-3" id="f-477" unitRef="usd">17102000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-36" decimals="-3" id="f-478" unitRef="usd">17102000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-39" decimals="-3" id="f-479" unitRef="shares">231000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-39" decimals="-3" id="f-480" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-40" decimals="-3" id="f-481" unitRef="usd">18213000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-36" decimals="-3" id="f-482" unitRef="usd">18213000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-39" decimals="-3" id="f-483" unitRef="shares">1086000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-39" decimals="-3" id="f-484" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-40" decimals="-3" id="f-485" unitRef="usd">65014000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-36" decimals="-3" id="f-486" unitRef="usd">65012000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-40" decimals="-3" id="f-487" unitRef="usd">109813000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="-3" id="f-488" unitRef="usd">109813000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders contextRef="c-34" decimals="-3" id="f-489" unitRef="usd">184044000</dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-37" decimals="-3" id="f-490" unitRef="usd">96894000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders contextRef="c-34" decimals="-3" id="f-491" unitRef="usd">12878000</dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders>
    <dva:NoncontrollingInterestIncreaseFromContributions contextRef="c-37" decimals="-3" id="f-492" unitRef="usd">1895000</dva:NoncontrollingInterestIncreaseFromContributions>
    <dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures contextRef="c-34" decimals="-3" id="f-493" unitRef="usd">181000</dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-40" decimals="-3" id="f-494" unitRef="usd">13077000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-36" decimals="-3" id="f-495" unitRef="usd">13077000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-37" decimals="-3" id="f-496" unitRef="usd">30776000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:TemporaryEquityDecreasePurchaseOfInterests contextRef="c-34" decimals="-3" id="f-497" unitRef="usd">5296000</dva:TemporaryEquityDecreasePurchaseOfInterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-40" decimals="-3" id="f-498" unitRef="usd">-5375000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-36" decimals="-3" id="f-499" unitRef="usd">-5375000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-37" decimals="-3" id="f-500" unitRef="usd">-32000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="c-34" decimals="-3" id="f-501" unitRef="usd">149872000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-40" decimals="-3" id="f-502" unitRef="usd">-149872000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-36" decimals="-3" id="f-503" unitRef="usd">-149872000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-41" decimals="-3" id="f-504" unitRef="shares">2904000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-41" decimals="-3" id="f-505" unitRef="usd">285710000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-36" decimals="-3" id="f-506" unitRef="usd">285710000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-39" decimals="-3" id="f-507" unitRef="shares">2904000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-39" decimals="-3" id="f-508" unitRef="usd">3000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-40" decimals="-3" id="f-509" unitRef="usd">17973000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-35" decimals="-3" id="f-510" unitRef="usd">267734000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-41" decimals="-3" id="f-511" unitRef="shares">2904000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-41" decimals="-3" id="f-512" unitRef="usd">285710000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-36" decimals="-3" id="f-513" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-42" decimals="-3" id="f-514" unitRef="usd">1499288000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-43" decimals="-3" id="f-515" unitRef="shares">88824000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-516" unitRef="usd">89000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-517" unitRef="usd">509804000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-518" unitRef="usd">598288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-3" id="f-519" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-520" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-521" unitRef="usd">-52084000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-522" unitRef="usd">1056097000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-523" unitRef="usd">187965000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-42" decimals="-3" id="f-524" unitRef="usd">1499288000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-43" decimals="-3" id="f-525" unitRef="shares">88824000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-526" unitRef="usd">89000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-527" unitRef="usd">509804000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-528" unitRef="usd">598288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-3" id="f-529" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-530" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-531" unitRef="usd">-52084000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-532" unitRef="usd">1056097000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-533" unitRef="usd">187965000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-50" decimals="-3" id="f-534" unitRef="usd">214986000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-51" decimals="-3" id="f-535" unitRef="usd">936342000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-536" unitRef="usd">936342000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-53" decimals="-3" id="f-537" unitRef="usd">99409000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-54" decimals="-3" id="f-538" unitRef="usd">-258712000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-52" decimals="-3" id="f-539" unitRef="usd">-258712000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-55" decimals="-3" id="f-540" unitRef="shares">184000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-55" id="f-541" unitRef="usd" xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-56" decimals="-3" id="f-542" unitRef="usd">20441000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-52" decimals="-3" id="f-543" unitRef="usd">20441000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-55" decimals="-3" id="f-544" unitRef="shares">1361000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-55" decimals="-3" id="f-545" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-56" decimals="-3" id="f-546" unitRef="usd">134041000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-52" decimals="-3" id="f-547" unitRef="usd">134040000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-56" decimals="-3" id="f-548" unitRef="usd">99095000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-52" decimals="-3" id="f-549" unitRef="usd">99095000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders contextRef="c-50" decimals="-3" id="f-550" unitRef="usd">226389000</dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-53" decimals="-3" id="f-551" unitRef="usd">110653000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders contextRef="c-50" decimals="-3" id="f-552" unitRef="usd">11639000</dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders>
    <dva:NoncontrollingInterestIncreaseFromContributions contextRef="c-53" decimals="-3" id="f-553" unitRef="usd">2860000</dva:NoncontrollingInterestIncreaseFromContributions>
    <dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures contextRef="c-50" decimals="-3" id="f-554" unitRef="usd">38806000</dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-56" decimals="-3" id="f-555" unitRef="usd">491000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-52" decimals="-3" id="f-556" unitRef="usd">491000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-53" decimals="-3" id="f-557" unitRef="usd">95024000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:TemporaryEquityDecreasePurchaseOfInterests contextRef="c-50" decimals="-3" id="f-558" unitRef="usd">49265000</dva:TemporaryEquityDecreasePurchaseOfInterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-56" decimals="-3" id="f-559" unitRef="usd">-3102000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-52" decimals="-3" id="f-560" unitRef="usd">3102000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-53" decimals="-3" id="f-561" unitRef="usd">141000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="c-50" decimals="-3" id="f-562" unitRef="usd">206418000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-56" decimals="-3" id="f-563" unitRef="usd">-206418000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-52" decimals="-3" id="f-564" unitRef="usd">-206418000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-57" decimals="-3" id="f-565" unitRef="shares">9833000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-57" decimals="-3" id="f-566" unitRef="usd">1389072000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-52" decimals="-3" id="f-567" unitRef="usd">1389072000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-58" decimals="-3" id="f-568" unitRef="usd">1695483000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-59" decimals="-3" id="f-569" unitRef="shares">90369000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-570" unitRef="usd">90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-571" unitRef="usd">286270000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-572" unitRef="usd">1534630000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-62" decimals="-3" id="f-573" unitRef="shares">-9833000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-3" id="f-574" unitRef="usd">-1389072000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-3" id="f-575" unitRef="usd">-310796000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-576" unitRef="usd">121122000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-3" id="f-577" unitRef="usd">274746000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-578">Organization and summary of significant accounting policies&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operations are composed of its dialysis and related lab services to patients in the United States (its U.S. dialysis business), its U.S. integrated kidney care (IKC) business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s largest line of business is its U.S. dialysis business, which operates kidney dialysis centers in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease or end stage kidney disease (ESRD or ESKD). As of December&#160;31, 2024, the Company operated or provided administrative services through a network of 2,657 U.S. outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 200,800 patients. In addition, as of December&#160;31, 2024, the Company operated or provided administrative services to a total of 509 outpatient dialysis centers serving approximately 80,300 patients located in 13 countries outside of the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#x2019;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#x2019;s international subsidiaries from their functional currencies into the Company&#x2019;s reporting currency (the U.S. dollar, or USD).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#x2019;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, certain fair value estimates, accounting for income taxes and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dialysis patient service revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized based on the Company&#x2019;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company's revenues are paid from government programs, principally Medicare, Medicare Advantage and Medicaid. Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#x2019;s commercial health plan secondary coverage, or the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Medicare&#x2019;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#x2019;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#x2019;s base payment rate as well as these other variable factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues earned under government programs are subject to significant estimating risk, as they can be subject to adjustment as a result of examination by government agencies or contractors, differing interpretations of applicable regulations by different Medicare contractors or regulatory authorities, differing opinions regarding a patient's diagnosis or the medical necessity of patient services, or retroactive applications or interpretations of governmental requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to government programs, the Company also earns revenues that are paid by commercial health plans. Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#x2019;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#x2019;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#x2019;s usual and customary rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described above, there are significant risks associated with estimating dialysis patient service revenue, whether paid from governmental or commercial sources, many of which take several years to resolve. These estimates are subject to examinations by or differing interpretations among government contractors or agencies or other regulatory authorities, retroactive application of interpretations, commercial insurance coverage changes, geographic coverage differences, differing interpretations of commercial contract coverage and other payor- and patient-specific issues, including determination of applicable primary and secondary coverage, changes in patient insurance coverage and coordination of benefits. As the Company's revenue estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (loss) income, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash and equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in debt and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#x2019;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes expenditures to purchase property and equipment, improvements thereon, leasehold improvements, and qualifying software costs, as well as costs to replace, extend the life of or improve the functionality of existing capital assets, where such purchases and costs have an expected benefit period of more than one year. All other expenditures related to capital assets are expensed as incurred (i.e., as repairs and maintenance expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases substantially all of its dialysis facilities. The majority of the Company&#x2019;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method and other investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates multiple reporting units. The Company's annual impairment assessment is performed in the third quarter for its U.S. dialysis reporting unit and at various points throughout the year for its other reporting units. In addition to these annual impairment assessments, the Company performs impairment assessments at intervening periods&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when a reporting unit is considered at risk of significant goodwill impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing these assessments, the Company may first assess goodwill for impairment qualitatively as determined appropriate. If goodwill is more likely than not impaired, the Company is required to perform a quantitative assessment. When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm, which consider both discounted cash flow estimates for the subject business and observed market multiples for similar businesses, or recent good-faith offer prices received for the subject business that would be acceptable to the Company. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value after taking into account the effect of deferred taxes arising from the impairment. See Note 9 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Self-insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#x2019; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation to be settled in shares is recorded to the Company&#x2019;s shareholders&#x2019; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interests represent third-party equity interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2024, third parties held direct or indirect noncontrolling equity interests in 728 consolidated legal entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards recently adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;segment&#x2019;s performance. The amendments in this ASU became effective for the Company beginning January 1, 2024. See Note 24 for further discussion of the Company's reportable segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards not yet adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company intends to adopt this ASU for the fiscal year ended December 31, 2025 and is still assessing the effect this guidance may have on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the Financial Accounting Standards Board issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which requires disaggregated disclosure of income statement expenses, including purchases of inventory, employee compensation, depreciation, and amortization.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendments in this ASU are effective for fiscal years beginning after December 15, 2026. The amendments in this ASU may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <dva:NumberOfSites
      contextRef="c-66"
      decimals="INF"
      id="f-579"
      unitRef="clinic">2657</dva:NumberOfSites>
    <us-gaap:NumberOfStatesInWhichEntityOperates contextRef="c-66" decimals="INF" id="f-580" unitRef="state">46</us-gaap:NumberOfStatesInWhichEntityOperates>
    <dva:NumberOfCustomers contextRef="c-67" decimals="0" id="f-581" unitRef="patient">200800</dva:NumberOfCustomers>
    <dva:NumberOfSites
      contextRef="c-68"
      decimals="INF"
      id="f-582"
      unitRef="clinic">509</dva:NumberOfSites>
    <dva:NumberOfCustomers contextRef="c-69" decimals="0" id="f-583" unitRef="patient">80300</dva:NumberOfCustomers>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="c-68"
      decimals="INF"
      id="f-584"
      unitRef="country">13</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-585">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#x2019;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#x2019;s international subsidiaries from their functional currencies into the Company&#x2019;s reporting currency (the U.S. dollar, or USD).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-586">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#x2019;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, certain fair value estimates, accounting for income taxes and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock contextRef="c-1" id="f-587">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dialysis patient service revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized based on the Company&#x2019;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company's revenues are paid from government programs, principally Medicare, Medicare Advantage and Medicaid. Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#x2019;s commercial health plan secondary coverage, or the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Medicare&#x2019;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#x2019;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#x2019;s base payment rate as well as these other variable factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues earned under government programs are subject to significant estimating risk, as they can be subject to adjustment as a result of examination by government agencies or contractors, differing interpretations of applicable regulations by different Medicare contractors or regulatory authorities, differing opinions regarding a patient's diagnosis or the medical necessity of patient services, or retroactive applications or interpretations of governmental requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to government programs, the Company also earns revenues that are paid by commercial health plans. Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#x2019;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#x2019;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#x2019;s usual and customary rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described above, there are significant risks associated with estimating dialysis patient service revenue, whether paid from governmental or commercial sources, many of which take several years to resolve. These estimates are subject to examinations by or differing interpretations among government contractors or agencies or other regulatory authorities, retroactive application of interpretations, commercial insurance coverage changes, geographic coverage differences, differing interpretations of commercial contract coverage and other payor- and patient-specific issues, including determination of applicable primary and secondary coverage, changes in patient insurance coverage and coordination of benefits. As the Company's revenue estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.&lt;/span&gt;&lt;/div&gt;</dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock>
    <dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor contextRef="c-6" decimals="INF" id="f-588" unitRef="number">0.80</dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor>
    <dva:OtherNonoperatingIncomeExpensePolicyTextBlock contextRef="c-1" id="f-589">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (loss) income, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.&lt;/span&gt;&lt;/div&gt;</dva:OtherNonoperatingIncomeExpensePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-590">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-591">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash and equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-592">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in debt and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#x2019;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-593">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-594">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes expenditures to purchase property and equipment, improvements thereon, leasehold improvements, and qualifying software costs, as well as costs to replace, extend the life of or improve the functionality of existing capital assets, where such purchases and costs have an expected benefit period of more than one year. All other expenditures related to capital assets are expensed as incurred (i.e., as repairs and maintenance expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-595">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases substantially all of its dialysis facilities. The majority of the Company&#x2019;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-596">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy contextRef="c-1" id="f-597">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-598">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method and other investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-599">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates multiple reporting units. The Company's annual impairment assessment is performed in the third quarter for its U.S. dialysis reporting unit and at various points throughout the year for its other reporting units. In addition to these annual impairment assessments, the Company performs impairment assessments at intervening periods&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when a reporting unit is considered at risk of significant goodwill impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing these assessments, the Company may first assess goodwill for impairment qualitatively as determined appropriate. If goodwill is more likely than not impaired, the Company is required to perform a quantitative assessment. When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm, which consider both discounted cash flow estimates for the subject business and observed market multiples for similar businesses, or recent good-faith offer prices received for the subject business that would be acceptable to the Company. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value after taking into account the effect of deferred taxes arising from the impairment. See Note 9 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <dva:InsuranceAndSelfInsurancePolicyTextBlock contextRef="c-1" id="f-600">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Self-insurance&lt;/span&gt;&lt;/div&gt;The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#x2019; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims.</dva:InsuranceAndSelfInsurancePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-601">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-602">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation to be settled in shares is recorded to the Company&#x2019;s shareholders&#x2019; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-603">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="c-1" id="f-604">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interests represent third-party equity interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2024, third parties held direct or indirect noncontrolling equity interests in 728 consolidated legal entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#x2019; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#x2019; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#x2019;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#x2019; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#x2019; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <dva:NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests contextRef="c-6" decimals="INF" id="f-605" unitRef="entity">728</dva:NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-606">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-607">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards recently adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;segment&#x2019;s performance. The amendments in this ASU became effective for the Company beginning January 1, 2024. See Note 24 for further discussion of the Company's reportable segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards not yet adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company intends to adopt this ASU for the fiscal year ended December 31, 2025 and is still assessing the effect this guidance may have on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the Financial Accounting Standards Board issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which requires disaggregated disclosure of income statement expenses, including purchases of inventory, employee compensation, depreciation, and amortization.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendments in this ASU are effective for fiscal years beginning after December 15, 2026. The amendments in this ASU may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-608">Revenue recognition and accounts receivable&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues by segment and primary payor source were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,374,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,374,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,783,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,031,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,318,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,815,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,623,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,874,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,848,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,512,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. IKC business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its IKC business, the Company recognized revenues for performance obligations satisfied in previous years of $116,336, $94,361, and $34,600 during the years ended December&#160;31, 2024, 2023 and 2022, respectively. The delay in recognition of these amounts resulted predominantly from measurement limitations and recognition constraints on both the Company's VBC contracts with health plans, many of which are complex and relatively new arrangements, as well as its government Comprehensive Kidney Care Contracting (CKCC) program. The Company's revenue recognition for its government CKCC program also remains heavily constrained for plan year 2024. See Note 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Other revenues"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the Company's accounting for these value-based care arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No single commercial payor accounted for more than 10% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $833,464 and $817,045 as of December&#160;31, 2024 and 2023, respectively. Approximately 23% and 19% of the Company&#x2019;s U.S. dialysis accounts receivable balances as of December&#160;31, 2024 and 2023, respectively, were more than six months old. There were no significant balances over one year old at December&#160;31, 2024. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-609">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues by segment and primary payor source were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,374,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,374,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,783,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,031,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,318,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,815,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,623,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,874,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,848,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,512,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-70" decimals="-3" id="f-610" unitRef="usd">6374882000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-71" decimals="-3" id="f-611" unitRef="usd">6374882000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-72" decimals="-3" id="f-612" unitRef="usd">863947000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-73" decimals="-3" id="f-613" unitRef="usd">863947000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-74" decimals="-3" id="f-614" unitRef="usd">343705000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-75" decimals="-3" id="f-615" unitRef="usd">717735000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-76" decimals="-3" id="f-616" unitRef="usd">1061440000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-77" decimals="-3" id="f-617" unitRef="usd">3783827000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-78" decimals="-3" id="f-618" unitRef="usd">248026000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-79" decimals="-3" id="f-619" unitRef="usd">4031853000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-80" decimals="-3" id="f-620" unitRef="usd">463731000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-71" decimals="-3" id="f-621" unitRef="usd">463731000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-81" decimals="-3" id="f-622" unitRef="usd">740000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-73" decimals="-3" id="f-623" unitRef="usd">740000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-78" decimals="-3" id="f-624" unitRef="usd">21396000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-79" decimals="-3" id="f-625" unitRef="usd">21396000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-82" decimals="-3" id="f-626" unitRef="usd">24356000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-83" decimals="-3" id="f-627" unitRef="usd">58862000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-84" decimals="-3" id="f-628" unitRef="usd">83218000</us-gaap:OtherIncome>
    <dva:EliminationsOfIntersegmentRevenues contextRef="c-85" decimals="-3" id="f-629" unitRef="usd">-71747000</dva:EliminationsOfIntersegmentRevenues>
    <dva:EliminationsOfIntersegmentRevenues contextRef="c-86" decimals="-3" id="f-630" unitRef="usd">-13910000</dva:EliminationsOfIntersegmentRevenues>
    <dva:EliminationsOfIntersegmentRevenues contextRef="c-87" decimals="-3" id="f-631" unitRef="usd">-85657000</dva:EliminationsOfIntersegmentRevenues>
    <dva:TotalRevenueNetOfIntersegmentRevenue contextRef="c-88" decimals="-3" id="f-632" unitRef="usd">11318970000</dva:TotalRevenueNetOfIntersegmentRevenue>
    <dva:TotalRevenueNetOfIntersegmentRevenue contextRef="c-89" decimals="-3" id="f-633" unitRef="usd">1496580000</dva:TotalRevenueNetOfIntersegmentRevenue>
    <dva:TotalRevenueNetOfIntersegmentRevenue contextRef="c-1" decimals="-3" id="f-634" unitRef="usd">12815550000</dva:TotalRevenueNetOfIntersegmentRevenue>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-90" decimals="-3" id="f-635" unitRef="usd">6100183000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-91" decimals="-3" id="f-636" unitRef="usd">6100183000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-92" decimals="-3" id="f-637" unitRef="usd">833744000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-93" decimals="-3" id="f-638" unitRef="usd">833744000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-94" decimals="-3" id="f-639" unitRef="usd">354304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-95" decimals="-3" id="f-640" unitRef="usd">500137000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-96" decimals="-3" id="f-641" unitRef="usd">854441000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-97" decimals="-3" id="f-642" unitRef="usd">3623516000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-98" decimals="-3" id="f-643" unitRef="usd">251279000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-99" decimals="-3" id="f-644" unitRef="usd">3874795000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-100" decimals="-3" id="f-645" unitRef="usd">460991000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-91" decimals="-3" id="f-646" unitRef="usd">460991000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-101" decimals="-3" id="f-647" unitRef="usd">1733000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-93" decimals="-3" id="f-648" unitRef="usd">1733000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-98" decimals="-3" id="f-649" unitRef="usd">32329000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-99" decimals="-3" id="f-650" unitRef="usd">32329000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-102" decimals="-3" id="f-651" unitRef="usd">25251000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-103" decimals="-3" id="f-652" unitRef="usd">52754000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-104" decimals="-3" id="f-653" unitRef="usd">78005000</us-gaap:OtherIncome>
    <dva:EliminationsOfIntersegmentRevenues contextRef="c-105" decimals="-3" id="f-654" unitRef="usd">-88222000</dva:EliminationsOfIntersegmentRevenues>
    <dva:EliminationsOfIntersegmentRevenues contextRef="c-106" decimals="-3" id="f-655" unitRef="usd">-7852000</dva:EliminationsOfIntersegmentRevenues>
    <dva:EliminationsOfIntersegmentRevenues contextRef="c-107" decimals="-3" id="f-656" unitRef="usd">-96074000</dva:EliminationsOfIntersegmentRevenues>
    <dva:TotalRevenueNetOfIntersegmentRevenue contextRef="c-108" decimals="-3" id="f-657" unitRef="usd">10848776000</dva:TotalRevenueNetOfIntersegmentRevenue>
    <dva:TotalRevenueNetOfIntersegmentRevenue contextRef="c-109" decimals="-3" id="f-658" unitRef="usd">1291371000</dva:TotalRevenueNetOfIntersegmentRevenue>
    <dva:TotalRevenueNetOfIntersegmentRevenue contextRef="c-4" decimals="-3" id="f-659" unitRef="usd">12140147000</dva:TotalRevenueNetOfIntersegmentRevenue>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-110" decimals="-3" id="f-660" unitRef="usd">6041496000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-111" decimals="-3" id="f-661" unitRef="usd">6041496000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-112" decimals="-3" id="f-662" unitRef="usd">759579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-113" decimals="-3" id="f-663" unitRef="usd">759579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-114" decimals="-3" id="f-664" unitRef="usd">336991000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-115" decimals="-3" id="f-665" unitRef="usd">464921000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-116" decimals="-3" id="f-666" unitRef="usd">801912000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-117" decimals="-3" id="f-667" unitRef="usd">3437306000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-118" decimals="-3" id="f-668" unitRef="usd">223216000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-119" decimals="-3" id="f-669" unitRef="usd">3660522000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-120" decimals="-3" id="f-670" unitRef="usd">345340000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-111" decimals="-3" id="f-671" unitRef="usd">345340000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-121" decimals="-3" id="f-672" unitRef="usd">1546000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-113" decimals="-3" id="f-673" unitRef="usd">1546000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-118" decimals="-3" id="f-674" unitRef="usd">22211000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-119" decimals="-3" id="f-675" unitRef="usd">22211000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-122" decimals="-3" id="f-676" unitRef="usd">24437000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-123" decimals="-3" id="f-677" unitRef="usd">44092000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-124" decimals="-3" id="f-678" unitRef="usd">68529000</us-gaap:OtherIncome>
    <dva:EliminationsOfIntersegmentRevenues contextRef="c-125" decimals="-3" id="f-679" unitRef="usd">-87035000</dva:EliminationsOfIntersegmentRevenues>
    <dva:EliminationsOfIntersegmentRevenues contextRef="c-126" decimals="-3" id="f-680" unitRef="usd">-4206000</dva:EliminationsOfIntersegmentRevenues>
    <dva:EliminationsOfIntersegmentRevenues contextRef="c-127" decimals="-3" id="f-681" unitRef="usd">-91241000</dva:EliminationsOfIntersegmentRevenues>
    <dva:TotalRevenueNetOfIntersegmentRevenue contextRef="c-128" decimals="-3" id="f-682" unitRef="usd">10512774000</dva:TotalRevenueNetOfIntersegmentRevenue>
    <dva:TotalRevenueNetOfIntersegmentRevenue contextRef="c-129" decimals="-3" id="f-683" unitRef="usd">1097120000</dva:TotalRevenueNetOfIntersegmentRevenue>
    <dva:TotalRevenueNetOfIntersegmentRevenue contextRef="c-5" decimals="-3" id="f-684" unitRef="usd">11609894000</dva:TotalRevenueNetOfIntersegmentRevenue>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-1" decimals="-3" id="f-685" unitRef="usd">116336000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-4" decimals="-3" id="f-686" unitRef="usd">94361000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-5" decimals="-3" id="f-687" unitRef="usd">34600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <dva:NumberOfConcentrationRiskCustomers
      contextRef="c-130"
      decimals="INF"
      id="f-688"
      unitRef="number">0</dva:NumberOfConcentrationRiskCustomers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-130" decimals="2" id="f-689" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-131" decimals="-3" id="f-690" unitRef="usd">833464000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-132" decimals="-3" id="f-691" unitRef="usd">817045000</us-gaap:AccountsReceivableNetCurrent>
    <dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue
      contextRef="c-133"
      decimals="INF"
      id="f-692"
      unitRef="number">0.23</dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue>
    <dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue
      contextRef="c-134"
      decimals="INF"
      id="f-693"
      unitRef="number">0.19</dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue>
    <dva:AccountsReceivablePeriodOutstanding contextRef="c-135" id="f-694">P6M</dva:AccountsReceivablePeriodOutstanding>
    <dva:AccountsReceivablePeriodOutstanding contextRef="c-136" id="f-695">P6M</dva:AccountsReceivablePeriodOutstanding>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-133" decimals="-3" id="f-696" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNoncurrentThresholdPeriodPastDue contextRef="c-133" id="f-697">P1Y</us-gaap:AccountsReceivableNoncurrentThresholdPeriodPastDue>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-702">Earnings&#160;per share&lt;div style="margin-top:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed incremental from stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock-settled awards excluded from calculation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-703">&lt;div style="margin-top:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-704">&lt;div style="margin-top:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed incremental from stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock-settled awards excluded from calculation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-705" unitRef="usd">936342000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-4" decimals="-3" id="f-706" unitRef="usd">691535000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-5" decimals="-3" id="f-707" unitRef="usd">546948000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-708" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-4" decimals="-3" id="f-709" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-5" decimals="-3" id="f-710" unitRef="usd">13452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-711" unitRef="usd">936342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-712" unitRef="usd">691535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-713" unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-1" decimals="-3" id="f-714" unitRef="shares">84991000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-4" decimals="-3" id="f-715" unitRef="shares">90790000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-5" decimals="-3" id="f-716" unitRef="shares">92992000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-717" unitRef="shares">2283000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-4" decimals="-3" id="f-718" unitRef="shares">2392000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-5" decimals="-3" id="f-719" unitRef="shares">2842000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-720" unitRef="shares">87274000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-4" decimals="-3" id="f-721" unitRef="shares">93182000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-722" unitRef="shares">95834000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-723"
      unitRef="usdPerShare">11.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-4"
      decimals="2"
      id="f-724"
      unitRef="usdPerShare">7.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-5"
      decimals="2"
      id="f-725"
      unitRef="usdPerShare">5.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-726"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-4"
      decimals="2"
      id="f-727"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-5"
      decimals="2"
      id="f-728"
      unitRef="usdPerShare">0.15</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-729"
      unitRef="usdPerShare">11.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-730"
      unitRef="usdPerShare">7.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-731"
      unitRef="usdPerShare">6.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-732"
      unitRef="usdPerShare">10.73</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-4"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">7.42</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-5"
      decimals="2"
      id="f-734"
      unitRef="usdPerShare">5.71</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-735"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-4"
      decimals="2"
      id="f-736"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-5"
      decimals="2"
      id="f-737"
      unitRef="usdPerShare">0.14</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-738"
      unitRef="usdPerShare">10.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-739"
      unitRef="usdPerShare">7.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-740"
      unitRef="usdPerShare">5.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-741" unitRef="shares">103000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-4" decimals="-3" id="f-742" unitRef="shares">531000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-3" id="f-743" unitRef="shares">1058000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-744">Short-term and long-term investments&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit and other time deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds and common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. Typically, the Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#x2019;s non-qualified deferred compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-745">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit and other time deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds and common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:HeldToMaturitySecurities contextRef="c-138" decimals="-3" id="f-746" unitRef="usd">44158000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-138" decimals="-3" id="f-747" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-138" decimals="-3" id="f-748" unitRef="usd">44158000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-139" decimals="-3" id="f-749" unitRef="usd">22109000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-139" decimals="-3" id="f-750" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-139" decimals="-3" id="f-751" unitRef="usd">22109000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-140" decimals="-3" id="f-752" unitRef="usd">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-140" decimals="-3" id="f-753" unitRef="usd">40566000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-140" decimals="-3" id="f-754" unitRef="usd">40566000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-141" decimals="-3" id="f-755" unitRef="usd">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-141" decimals="-3" id="f-756" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-141" decimals="-3" id="f-757" unitRef="usd">37391000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-6" decimals="-3" id="f-758" unitRef="usd">44158000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-6" decimals="-3" id="f-759" unitRef="usd">40566000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-6" decimals="-3" id="f-760" unitRef="usd">84724000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-7" decimals="-3" id="f-761" unitRef="usd">22109000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-7" decimals="-3" id="f-762" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-7" decimals="-3" id="f-763" unitRef="usd">59500000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecuritiesCurrent contextRef="c-6" decimals="-3" id="f-764" unitRef="usd">44158000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-142" decimals="-3" id="f-765" unitRef="usd">6906000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-766" unitRef="usd">51064000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent contextRef="c-7" decimals="-3" id="f-767" unitRef="usd">7110000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-143" decimals="-3" id="f-768" unitRef="usd">4500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-7" decimals="-3" id="f-769" unitRef="usd">11610000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent contextRef="c-6" decimals="-3" id="f-770" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent contextRef="c-144" decimals="-3" id="f-771" unitRef="usd">33660000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-6" decimals="-3" id="f-772" unitRef="usd">33660000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent contextRef="c-7" decimals="-3" id="f-773" unitRef="usd">14999000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent contextRef="c-145" decimals="-3" id="f-774" unitRef="usd">32891000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-7" decimals="-3" id="f-775" unitRef="usd">47890000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-6" decimals="-3" id="f-776" unitRef="usd">44158000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-6" decimals="-3" id="f-777" unitRef="usd">40566000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:MarketableSecurities contextRef="c-6" decimals="-3" id="f-778" unitRef="usd">84724000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-7" decimals="-3" id="f-779" unitRef="usd">22109000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-7" decimals="-3" id="f-780" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:MarketableSecurities contextRef="c-7" decimals="-3" id="f-781" unitRef="usd">59500000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-782">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. Typically, the Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#x2019;s non-qualified deferred compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c-1" id="f-783">Other receivables&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.523%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contract assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare bad debt claims&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IKC risk-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier rebates and non-trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <dva:ScheduleOfOtherReceivablesTableTextBlock contextRef="c-1" id="f-784">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.523%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contract assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare bad debt claims&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IKC risk-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier rebates and non-trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfOtherReceivablesTableTextBlock>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-146" decimals="-3" id="f-785" unitRef="usd">107129000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-147" decimals="-3" id="f-786" unitRef="usd">107444000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-148" decimals="-3" id="f-787" unitRef="usd">143942000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-149" decimals="-3" id="f-788" unitRef="usd">127442000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-150" decimals="-3" id="f-789" unitRef="usd">132095000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-151" decimals="-3" id="f-790" unitRef="usd">187783000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-6" decimals="-3" id="f-791" unitRef="usd">383166000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-7" decimals="-3" id="f-792" unitRef="usd">422669000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-793">Property and equipment&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.586%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,180,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and information systems, including internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New center and capital asset projects in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,203,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,833,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,262,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,759,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, 25 years to 40 years; leasehold improvements, the shorter of ten years or the expected lease term; and equipment and information systems, including internally developed software, principally three years to 15 years. Depreciation expense on property and equipment was $716,396, $736,474 and $721,133 for 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $7,978, $9,178 and $12,677 for 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-794">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.586%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,180,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and information systems, including internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New center and capital asset projects in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,203,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,833,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,262,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,759,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land contextRef="c-6" decimals="-3" id="f-795" unitRef="usd">50172000</us-gaap:Land>
    <us-gaap:Land contextRef="c-7" decimals="-3" id="f-796" unitRef="usd">35216000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross contextRef="c-6" decimals="-3" id="f-797" unitRef="usd">428994000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross contextRef="c-7" decimals="-3" id="f-798" unitRef="usd">436460000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-6" decimals="-3" id="f-799" unitRef="usd">4180747000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-7" decimals="-3" id="f-800" unitRef="usd">4058987000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="c-6" decimals="-3" id="f-801" unitRef="usd">4410395000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="c-7" decimals="-3" id="f-802" unitRef="usd">4125235000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-6" decimals="-3" id="f-803" unitRef="usd">133311000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-7" decimals="-3" id="f-804" unitRef="usd">177149000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="-3" id="f-805" unitRef="usd">9203619000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-806" unitRef="usd">8833047000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-807" unitRef="usd">6262703000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-808" unitRef="usd">5759514000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-809" unitRef="usd">2940916000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-810" unitRef="usd">3073533000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-152" id="f-811">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-153" id="f-812">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-154" id="f-813">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-155" id="f-814">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-156" id="f-815">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-816" unitRef="usd">716396000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-4" decimals="-3" id="f-817" unitRef="usd">736474000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-818" unitRef="usd">721133000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestCostsCapitalized contextRef="c-1" decimals="-3" id="f-819" unitRef="usd">7978000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-4" decimals="-3" id="f-820" unitRef="usd">9178000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-5" decimals="-3" id="f-821" unitRef="usd">12677000</us-gaap:InterestCostsCapitalized>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-822">Intangible assets&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets other than goodwill comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncompetition agreements are generally amortized over four years to 10 years and customer relationships are principally amortized over 10 years to 20 years. The weighted average renewal or extension period of customer relationships was three years and two years as of December&#160;31, 2024 and 2023, respectively. Amortization expense from amortizable intangible assets was $7,464, $8,969, and $11,469 for 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized no impairment charges on any intangible assets other than goodwill. See Note 9 for further information regarding goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2024 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.341%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.032%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Noncompetition&lt;br/&gt;agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock contextRef="c-1" id="f-823">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets other than goodwill comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-6" decimals="-3" id="f-824" unitRef="usd">146025000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-7" decimals="-3" id="f-825" unitRef="usd">153983000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedNoncompeteAgreementsGross contextRef="c-6" decimals="-3" id="f-826" unitRef="usd">22234000</us-gaap:FiniteLivedNoncompeteAgreementsGross>
    <us-gaap:FiniteLivedNoncompeteAgreementsGross contextRef="c-7" decimals="-3" id="f-827" unitRef="usd">31090000</us-gaap:FiniteLivedNoncompeteAgreementsGross>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets contextRef="c-6" decimals="-3" id="f-828" unitRef="usd">61580000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets contextRef="c-7" decimals="-3" id="f-829" unitRef="usd">56596000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-6" decimals="-3" id="f-830" unitRef="usd">229839000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-7" decimals="-3" id="f-831" unitRef="usd">241669000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-157" decimals="-3" id="f-832" unitRef="usd">13982000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-158" decimals="-3" id="f-833" unitRef="usd">23680000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-159" decimals="-3" id="f-834" unitRef="usd">18426000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-160" decimals="-3" id="f-835" unitRef="usd">14765000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-836" unitRef="usd">197431000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-837" unitRef="usd">203224000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-161" id="f-838">P4Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-162" id="f-839">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-163" id="f-840">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-164" id="f-841">P20Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension contextRef="c-165" id="f-842">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension contextRef="c-166" id="f-843">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-844" unitRef="usd">7464000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-4" decimals="-3" id="f-845" unitRef="usd">8969000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-3" id="f-846" unitRef="usd">11469000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-847" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-848">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2024 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.341%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.032%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Noncompetition&lt;br/&gt;agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-157" decimals="-3" id="f-849" unitRef="usd">2301000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-159" decimals="-3" id="f-850" unitRef="usd">4031000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-157" decimals="-3" id="f-851" unitRef="usd">1598000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-159" decimals="-3" id="f-852" unitRef="usd">4047000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-157" decimals="-3" id="f-853" unitRef="usd">1157000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-159" decimals="-3" id="f-854" unitRef="usd">3871000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-157" decimals="-3" id="f-855" unitRef="usd">956000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-159" decimals="-3" id="f-856" unitRef="usd">3784000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-157" decimals="-3" id="f-857" unitRef="usd">427000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-159" decimals="-3" id="f-858" unitRef="usd">3780000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-157" decimals="-3" id="f-859" unitRef="usd">1813000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-159" decimals="-3" id="f-860" unitRef="usd">23641000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-157" decimals="-3" id="f-861" unitRef="usd">8252000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-159" decimals="-3" id="f-862" unitRef="usd">43154000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c-1" id="f-866">Equity method and other investments&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.612%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mozarc Medical Holding LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equity method partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted cost method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2024, 2023 and 2022, the Company recognized equity investment income of $26,189, $27,864 and $26,520, respectively, from its equity method investments in nonconsolidated dialysis partnerships.&#160;The Company also recognized equity investment losses from other equity method investments of $112,696, $59,508 and $4,703 in other loss, net during 2024, 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April&#160;1, 2023, the Company formed a new, independent kidney care-focused medical device company (Mozarc Medical Holding LLC, or Mozarc) with Medtronic, Inc. (Medtronic). The Company holds a 50% voting equity interest in Mozarc and Medtronic holds the other 50% voting equity interest. The Company does not maintain a controlling financial interest in Mozarc and accounts for this investment on the equity method, with equity method income or loss recognized in other loss, net, on a one-month lag.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's investment in Mozarc was recorded at a cumulative measured cost of $370,740, which includes the value of contingent consideration payable to Medtronic of $86,200. As of December&#160;31, 2024, the book value of the Company's contingent consideration payable to Medtronic approximates its estimated fair value, which is based on level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also holds a 75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;voting and economic interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV) and an unrelated noncontrolling investor holds the other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25% voting and economic interest in the joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to November 1, 2024, the Company did not control or consolidate the APAC JV as a result of substantive participating rights retained by the unrelated investor over certain key operating decisions for the joint venture. Effective November 1, 2024, the third-party rights that blocked the Company's ultimate unilateral operating control of this business were removed, resulting in the Company's consolidation of this business. See Note 20 for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's other equity method investments include 17 legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. dialysis partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, and are often subject to blocking rights on certain key operating decisions held by outside investors, but mostly range from 30% to 65%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no significant investment impairments or other valuation adjustments for the years ended December 31, 2024 and 2023. For the year ended December&#160;31, 2022, the Company recognized impairments and other valuation adjustments on the Company's adjusted cost method and other investments of $20,154 in other loss, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c-1" id="f-867">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.612%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mozarc Medical Holding LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equity method partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted cost method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-167" decimals="-3" id="f-868" unitRef="usd">215706000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-168" decimals="-3" id="f-869" unitRef="usd">324711000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-169" decimals="-3" id="f-870" unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-170" decimals="-3" id="f-871" unitRef="usd">98865000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-171" decimals="-3" id="f-872" unitRef="usd">99246000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-172" decimals="-3" id="f-873" unitRef="usd">107282000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-173" decimals="-3" id="f-874" unitRef="usd">21732000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-174" decimals="-3" id="f-875" unitRef="usd">14990000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-6" decimals="-3" id="f-876" unitRef="usd">336684000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-7" decimals="-3" id="f-877" unitRef="usd">545848000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-175" decimals="-3" id="f-878" unitRef="usd">26189000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-176" decimals="-3" id="f-879" unitRef="usd">27864000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-177" decimals="-3" id="f-880" unitRef="usd">26520000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <dva:IncomeLossFromOtherEquityMethodInvestments contextRef="c-178" decimals="-3" id="f-881" unitRef="usd">-112696000</dva:IncomeLossFromOtherEquityMethodInvestments>
    <dva:IncomeLossFromOtherEquityMethodInvestments contextRef="c-179" decimals="-3" id="f-882" unitRef="usd">-59508000</dva:IncomeLossFromOtherEquityMethodInvestments>
    <dva:IncomeLossFromOtherEquityMethodInvestments contextRef="c-180" decimals="-3" id="f-883" unitRef="usd">-4703000</dva:IncomeLossFromOtherEquityMethodInvestments>
    <dva:BusinessAgreementEffectiveClosingDate contextRef="c-181" id="f-884">2023-04-01</dva:BusinessAgreementEffectiveClosingDate>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-182" decimals="2" id="f-885" unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-182" decimals="2" id="f-886" unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:EquityMethodInvestmentAggregateCost contextRef="c-183" decimals="-3" id="f-887" unitRef="usd">370740000</us-gaap:EquityMethodInvestmentAggregateCost>
    <dva:FairValuePayableOfContingentConsideration contextRef="c-183" decimals="-3" id="f-888" unitRef="usd">86200000</dva:FairValuePayableOfContingentConsideration>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-169" decimals="2" id="f-889" unitRef="number">0.75</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <dva:OwnershipPercentageByNoncontrollingOwners contextRef="c-169" decimals="2" id="f-890" unitRef="number">0.25</dva:OwnershipPercentageByNoncontrollingOwners>
    <dva:NumberOfPartnerships
      contextRef="c-184"
      decimals="INF"
      id="f-891"
      unitRef="number">17</dva:NumberOfPartnerships>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-185" decimals="2" id="f-892" unitRef="number">0.30</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-186" decimals="2" id="f-893" unitRef="number">0.65</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-178" decimals="-3" id="f-894" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-179" decimals="-3" id="f-895" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-180" decimals="-3" id="f-896" unitRef="usd">20154000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="c-1" id="f-897">Goodwill&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of goodwill by reportable segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary&lt;br/&gt;services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,112,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,517,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,375,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,517,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,517,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,517,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,375,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company&#x2019;s operating segments described in Note 24 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has applied a similar aggregation to the dialysis centers within each of its international reporting units. For the Company&#x2019;s other operating segments, discrete business components below the operating segment level constitute individual reporting units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed various annual impairment assessments during the year ended December&#160;31, 2024, with no impairment indicated. None&#160;of the Company&#x2019;s reporting units were considered at risk of significant goodwill impairment as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the Company performed its annual impairment assessment of its transplant software reporting unit and recognized a goodwill impairment charge of $26,083 in that reporting unit, or $19,575 net of tax. This charge resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate. After this impairment charge, the transplant software reporting unit had a goodwill balance of $14,424 remaining.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-898">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of goodwill by reportable segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary&lt;br/&gt;services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,112,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,517,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,375,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,517,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,517,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,517,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,375,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-187" decimals="-3" id="f-899" unitRef="usd">6416825000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-188" decimals="-3" id="f-900" unitRef="usd">659785000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-3" id="f-901" unitRef="usd">7076610000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-108" decimals="-3" id="f-902" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-109" decimals="-3" id="f-903" unitRef="usd">25723000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-4" decimals="-3" id="f-904" unitRef="usd">25723000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-108" decimals="-3" id="f-905" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-109" decimals="-3" id="f-906" unitRef="usd">26083000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-4" decimals="-3" id="f-907" unitRef="usd">26083000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-108" decimals="-3" id="f-908" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-109" decimals="-3" id="f-909" unitRef="usd">-36310000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-4" decimals="-3" id="f-910" unitRef="usd">-36310000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-189" decimals="-3" id="f-911" unitRef="usd">6416825000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-190" decimals="-3" id="f-912" unitRef="usd">695735000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-913" unitRef="usd">7112560000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-88" decimals="-3" id="f-914" unitRef="usd">102082000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-89" decimals="-3" id="f-915" unitRef="usd">246987000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-3" id="f-916" unitRef="usd">349069000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-88" decimals="-3" id="f-917" unitRef="usd">1687000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-89" decimals="-3" id="f-918" unitRef="usd">1506000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-1" decimals="-3" id="f-919" unitRef="usd">3193000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-88" decimals="-3" id="f-920" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-89" decimals="-3" id="f-921" unitRef="usd">83220000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-3" id="f-922" unitRef="usd">83220000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-191" decimals="-3" id="f-923" unitRef="usd">6517220000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-192" decimals="-3" id="f-924" unitRef="usd">857996000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-925" unitRef="usd">7375216000</us-gaap:Goodwill>
    <us-gaap:GoodwillGross contextRef="c-191" decimals="-3" id="f-926" unitRef="usd">6517220000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-192" decimals="-3" id="f-927" unitRef="usd">999817000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-6" decimals="-3" id="f-928" unitRef="usd">7517037000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-191" decimals="-3" id="f-929" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-192" decimals="-3" id="f-930" unitRef="usd">141821000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-6" decimals="-3" id="f-931" unitRef="usd">141821000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-191" decimals="-3" id="f-932" unitRef="usd">6517220000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-192" decimals="-3" id="f-933" unitRef="usd">857996000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-934" unitRef="usd">7375216000</us-gaap:Goodwill>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-193"
      decimals="0"
      id="f-935"
      unitRef="segments">0</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-194" decimals="-3" id="f-936" unitRef="usd">26083000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLossNetOfTax contextRef="c-194" decimals="-3" id="f-937" unitRef="usd">19575000</us-gaap:GoodwillImpairmentLossNetOfTax>
    <us-gaap:Goodwill contextRef="c-195" decimals="-3" id="f-938" unitRef="usd">14424000</us-gaap:Goodwill>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-939">Other liabilities&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor refunds and retractions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance and self-insurance accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued non-income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesTableTextBlock contextRef="c-1" id="f-940">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor refunds and retractions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance and self-insurance accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued non-income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
    <dva:PayorRefundsAndRetractions contextRef="c-6" decimals="-3" id="f-941" unitRef="usd">484459000</dva:PayorRefundsAndRetractions>
    <dva:PayorRefundsAndRetractions contextRef="c-7" decimals="-3" id="f-942" unitRef="usd">448589000</dva:PayorRefundsAndRetractions>
    <us-gaap:AccruedInsuranceCurrent contextRef="c-6" decimals="-3" id="f-943" unitRef="usd">83038000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent contextRef="c-7" decimals="-3" id="f-944" unitRef="usd">74337000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-6" decimals="-3" id="f-945" unitRef="usd">60541000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-7" decimals="-3" id="f-946" unitRef="usd">35914000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-6" decimals="-3" id="f-947" unitRef="usd">59007000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-7" decimals="-3" id="f-948" unitRef="usd">47391000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-949" unitRef="usd">247100000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-950" unitRef="usd">222647000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-951" unitRef="usd">934145000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-952" unitRef="usd">828878000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-953">Income taxes&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes from continuing operations consisted of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.219%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,374,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Income tax expense for continuing operations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company&#x2019;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Political advocacy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in international valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of noncontrolling interests primarily&lt;br/&gt;&#160;attributable to non-tax paying entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.439%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(757,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(731,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(464,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(486,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,352,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,452,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(691,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(726,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (included in Other long-term assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 25.75pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(691,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, the Company had federal net operating loss carryforwards of approximately $44,248 that expire through 2036, although a substantial amount expire by 2029. The Company also had state net operating loss carryforwards of $555,691, some of which have an indefinite life, while a substantial amount expire by 2044. Additionally, the Company had international net operating loss carryforwards of $410,313, some of which will begin to expire in 2026, though the majority have an indefinite life. The Company has a state capital loss carryover of $9,653, the majority of which will expire in 2025. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. A valuation allowance is recorded to account for the unrealizable balances in the table above. The net decrease of $5,285 in the valuation allowance is primarily due to unutilized state capital losses that expired in the current year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains indefinitely reinvested in several of the foreign jurisdictions in which it operates as of December&#160;31, 2024. As a result of the passage of the Tax Cuts and Jobs Act (2017 Tax Act), the Company does not expect any significant taxes to be incurred if such earnings were remitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to lapse of applicable statute&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company&#x2019;s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $41,484. Of this balance, $27,336 would impact the Company&#x2019;s effective tax rate if recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. We recognized a benefit of $679 and $138 related to interest and penalties net of federal tax benefit within tax expense in 2024 and 2023, respectively. At December&#160;31, 2024 and December 31, 2023, the Company had approximately $5,846 and $6,525, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries are under examination in various state, local and foreign tax jurisdictions. In 2022, the Company was able to reach a settlement with the IRS for tax years 2014-2015. Subsequent to the settlement, the Company filed a 2014 refund claim with respect to a contested issue that was included in the IRS examination. During 2023 the IRS denied the refund claim and the Company has until September 2025 to appeal. Except for the 2014 refund claim, the Company is no longer subject to U.S. federal examinations prior to 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-954">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes from continuing operations consisted of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.219%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,374,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-955" unitRef="usd">1374571000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-4" decimals="-3" id="f-956" unitRef="usd">1100420000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-5" decimals="-3" id="f-957" unitRef="usd">926604000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-958" unitRef="usd">155822000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-4" decimals="-3" id="f-959" unitRef="usd">76674000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-5" decimals="-3" id="f-960" unitRef="usd">39674000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-961" unitRef="usd">1530393000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-962" unitRef="usd">1177094000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-963" unitRef="usd">966278000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-964">Income tax expense for continuing operations consisted of the following:&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-965" unitRef="usd">253504000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-966" unitRef="usd">200070000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-967" unitRef="usd">201932000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-968" unitRef="usd">52410000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-969" unitRef="usd">38370000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-970" unitRef="usd">55593000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-971" unitRef="usd">31532000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-972" unitRef="usd">21008000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-973" unitRef="usd">16253000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-974" unitRef="usd">337446000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-975" unitRef="usd">259448000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-976" unitRef="usd">273778000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-977" unitRef="usd">-47715000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-978" unitRef="usd">-40234000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-979" unitRef="usd">-66400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-980" unitRef="usd">-2855000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-981" unitRef="usd">367000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-982" unitRef="usd">-12289000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-983" unitRef="usd">-7220000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-984" unitRef="usd">535000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-985" unitRef="usd">2998000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-986" unitRef="usd">-57790000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-4" decimals="-3" id="f-987" unitRef="usd">-39332000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-5" decimals="-3" id="f-988" unitRef="usd">-75691000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-989" unitRef="usd">279656000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-990" unitRef="usd">220116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-991" unitRef="usd">198087000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-992">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company&#x2019;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Political advocacy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in international valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of noncontrolling interests primarily&lt;br/&gt;&#160;attributable to non-tax paying entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-993" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-4" decimals="INF" id="f-994" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-5" decimals="INF" id="f-995" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-996" unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-4" decimals="3" id="f-997" unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-5" decimals="3" id="f-998" unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-999" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-4" decimals="3" id="f-1000" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-5" decimals="3" id="f-1001" unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment contextRef="c-1" decimals="3" id="f-1002" unitRef="number">0.007</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment contextRef="c-4" decimals="3" id="f-1003" unitRef="number">0.012</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment contextRef="c-5" decimals="3" id="f-1004" unitRef="number">0.011</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-1005" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-4" decimals="3" id="f-1006" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-5" decimals="3" id="f-1007" unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-1" decimals="3" id="f-1008" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-4" decimals="3" id="f-1009" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-5" decimals="3" id="f-1010" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-1011" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="3" id="f-1012" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="3" id="f-1013" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1014" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-4" decimals="3" id="f-1015" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-5" decimals="3" id="f-1016" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1017" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-4" decimals="3" id="f-1018" unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-5" decimals="3" id="f-1019" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-1" decimals="3" id="f-1020" unitRef="number">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-4" decimals="3" id="f-1021" unitRef="number">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-5" decimals="3" id="f-1022" unitRef="number">0.060</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1023" unitRef="number">0.183</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-4" decimals="3" id="f-1024" unitRef="number">0.187</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="3" id="f-1025" unitRef="number">0.205</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1026">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.439%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(757,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(731,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(464,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(486,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,352,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,452,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(691,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(726,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (included in Other long-term assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 25.75pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(691,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <dva:DeferredTaxAssetsReceivables contextRef="c-6" decimals="-3" id="f-1027" unitRef="usd">37630000</dva:DeferredTaxAssetsReceivables>
    <dva:DeferredTaxAssetsReceivables contextRef="c-7" decimals="-3" id="f-1028" unitRef="usd">23075000</dva:DeferredTaxAssetsReceivables>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-6" decimals="-3" id="f-1029" unitRef="usd">74419000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-7" decimals="-3" id="f-1030" unitRef="usd">81281000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <dva:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-6" decimals="-3" id="f-1031" unitRef="usd">508729000</dva:DeferredTaxAssetsOperatingLeaseLiabilities>
    <dva:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-7" decimals="-3" id="f-1032" unitRef="usd">533859000</dva:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-1033" unitRef="usd">161371000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-1034" unitRef="usd">183216000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-6" decimals="-3" id="f-1035" unitRef="usd">4108000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-7" decimals="-3" id="f-1036" unitRef="usd">0</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-1037" unitRef="usd">54600000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-7" decimals="-3" id="f-1038" unitRef="usd">52142000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-1039" unitRef="usd">840857000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-1040" unitRef="usd">873573000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-1041" unitRef="usd">107952000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-1042" unitRef="usd">113237000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-1043" unitRef="usd">732905000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-7" decimals="-3" id="f-1044" unitRef="usd">760336000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-6" decimals="-3" id="f-1045" unitRef="usd">757797000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-7" decimals="-3" id="f-1046" unitRef="usd">731024000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-1047" unitRef="usd">63726000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-1048" unitRef="usd">127191000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <dva:DeferredTaxLiabilitiesOperatingLeaseAssets contextRef="c-6" decimals="-3" id="f-1049" unitRef="usd">464455000</dva:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <dva:DeferredTaxLiabilitiesOperatingLeaseAssets contextRef="c-7" decimals="-3" id="f-1050" unitRef="usd">486864000</dva:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <us-gaap:DeferredTaxLiabilitiesInvestments contextRef="c-6" decimals="-3" id="f-1051" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments contextRef="c-7" decimals="-3" id="f-1052" unitRef="usd">19119000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-6" decimals="-3" id="f-1053" unitRef="usd">66035000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-7" decimals="-3" id="f-1054" unitRef="usd">87918000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-1055" unitRef="usd">1352013000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-1056" unitRef="usd">1452116000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-3" id="f-1057" unitRef="usd">619108000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-1058" unitRef="usd">691780000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-196" decimals="-3" id="f-1059" unitRef="usd">665361000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-197" decimals="-3" id="f-1060" unitRef="usd">726217000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-198" decimals="-3" id="f-1061" unitRef="usd">46253000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-199" decimals="-3" id="f-1062" unitRef="usd">34437000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-3" id="f-1063" unitRef="usd">619108000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-1064" unitRef="usd">691780000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards contextRef="c-200" decimals="-3" id="f-1065" unitRef="usd">44248000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-201" decimals="-3" id="f-1066" unitRef="usd">555691000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-202" decimals="-3" id="f-1067" unitRef="usd">410313000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-203" decimals="-3" id="f-1068" unitRef="usd">9653000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-204" decimals="-3" id="f-1069" unitRef="usd">-5285000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1070">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to lapse of applicable statute&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-1071" unitRef="usd">47379000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-8" decimals="-3" id="f-1072" unitRef="usd">63985000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1073" unitRef="usd">3866000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-4" decimals="-3" id="f-1074" unitRef="usd">4088000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1075" unitRef="usd">1452000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-4" decimals="-3" id="f-1076" unitRef="usd">7273000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-3" id="f-1077" unitRef="usd">8309000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-4" decimals="-3" id="f-1078" unitRef="usd">5428000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-3" id="f-1079" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-4" decimals="-3" id="f-1080" unitRef="usd">7993000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-1081" unitRef="usd">41484000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-1082" unitRef="usd">47379000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-1083" unitRef="usd">41484000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-6" decimals="-3" id="f-1084" unitRef="usd">27336000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="-3" id="f-1085" unitRef="usd">679000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-4" decimals="-3" id="f-1086" unitRef="usd">138000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-6" decimals="-3" id="f-1087" unitRef="usd">5846000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-7" decimals="-3" id="f-1088" unitRef="usd">6525000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:LongTermDebtTextBlock contextRef="c-1" id="f-1127">Long-term debt&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt comprised the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term Loan A-1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,259,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,234,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4/28/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Base +1.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,256,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term Loan B-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,603,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Extended Term Loan B-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,636,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5/9/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR + 2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,638,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revolving line of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4/28/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Base +1.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Senior Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6/1/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,533,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2/15/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,301,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.875% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9/1/2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,007,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Acquisition obligations and other notes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;102,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025-2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Financing lease obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;216,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;255,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;CHC temporary funding assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;92,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;92,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total debt principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,511,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,445,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Discount, premium and deferred financing costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(64,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(54,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,446,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,391,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(270,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(123,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,175,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,268,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;For the Company's senior secured credit facilities, fair value estimates are based on bid and ask quotes, a level 2 input. For the Company's senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. For the CHC temporary funding assistance, the carrying value presented here approximates the estimated fair value based on the short-term nature of settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company's senior secured credit facilities bear interest at Term SOFR, plus an interest rate margin, with certain portions also subject to a credit spread adjustment (CSA). Term SOFR plus CSA is referred to as "Base" in the table above. The Term Loan A-1 and revolving line of credit bear a CSA of 0.10%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Change Healthcare (CHC) temporary funding assistance, as described below, is interest-free and amounts provided under this program are subject to repayment at a future date to be mutually agreed to by the parties. The balance is included in the Company's current portion of long-term debt as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of December&#160;31, 2024, the carrying amount of the Company's senior secured credit facilities has been reduced by a discount of $8,084 and deferred financing costs of $28,879, and the carrying amount of the Company's senior notes has been reduced by deferred financing costs of $37,612 and increased by a debt premium of $10,239. As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $2,487 and deferred financing costs of $32,498, and the carrying amounts of the Company's senior notes was reduced by deferred financing costs of $31,491 and increased by a debt premium of $12,129.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled maturities of long-term debt at December&#160;31, 2024 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.359%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;202,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,922,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;39,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,900,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;9, 2024 (the Fourth Amendment Effective Date), the Company entered into the Fourth Amendment (the Fourth Amendment) to its senior secured credit agreement dated as of August 12, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the Credit Agreement). The Fourth Amendment modified the Credit Agreement to, among other things, extend the maturity date for a portion of its Term Loan B-1 in the aggregate principal amount of $911,598 and extend an additional incremental principal amount of $728,653 (together, referred to as the Extended Term Loan B-1). The Company used the incremental proceeds from the Extended Term Loan B-1 to prepay a proportionate amount of the principal balance still outstanding on its Term Loan B-1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Extended Term Loan B-1 bears interest at the Company&#x2019;s option, based on (i) the Base Rate (as defined below) plus the Applicable Margin (as defined below), or (ii) the forward-looking term rate based on the secured overnight financing rate that is published by CME Group Benchmark Administration Limited (Term SOFR) plus the Applicable Margin. The "Base Rate" is defined as the highest of (i) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 0.50%, (ii) the prime commercial lending rate of Wells Fargo as established from time to time and (iii) Term SOFR for an interest period of one month plus 1.00%; provided that if Term SOFR or the Base Rate is less than 0.00% such rate shall be deemed to be 0.00% for purposes of the Credit Agreement. The "Applicable Margin" for the Extended Term Loan B-1 is 2.00% in the case of Term SOFR loans, and 1.00% in the case of Base Rate loans. The Extended Term Loan B-1 requires quarterly principal payments beginning on December&#160;31, 2024 of 0.25% of the aggregate principal amount of the Extended Term Loan B-1 outstanding on the Fourth Amendment Effective Date, with the balance due on May&#160;9, 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Fourth Amendment transaction described above, the Company recognized debt prepayment, extinguishment and modification costs of $9,732 in the second quarter of 2024 composed partially of fees incurred for this transaction and partially of deferred financing costs and original issue discount written off for the portion of debt considered extinguished and reborrowed as a result of the Fourth Amendment. For the portion of the debt that was considered extinguished and reborrowed, the Company recognized constructive financing cash outflows and financing cash inflows on the statement of cash flows of $6,302 and $728,653 for the Extended Term Loan B-1, respectively, and constructive financing cash outflows of $722,351 for the prepayment of a portion of Term Loan B-1, even though no funds were actually paid or received. Another $13,282 of the debt considered extinguished related to the Extended Term Loan B-1 represented a non-cash financing activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;13, 2024, the Company entered into the Sixth Amendment (the Sixth Amendment) to the Credit Agreement. The Sixth Amendment modified the Credit Agreement to extend an additional incremental principal amount of $1,100,000 on its Term Loan A-1 (together with the existing Term Loan A-1 balance, referred to as the Increased Term Loan A-1). The Sixth Amendment also incorporated the provisions of the Fifth Amendment to the Credit Agreement, dated as of August&#160;7, 2024, which removed a cap on the amount of incremental term "A" loans the Company can incur under the Credit Agreement. The Company used a portion of the net proceeds from this transaction along with the net proceeds from the issuance of 6.875% Senior Notes due 2032, described below, to prepay the remainder of the balance outstanding on its Term Loan B-1 maturing 2026 in the amount of $949,819, the balance outstanding on its revolving line of credit and related accrued interest and fees. The remaining borrowings added cash to the balance sheet for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Increased Term Loan A-1 bears interest at Term SOFR, plus a CSA of 0.10% and an interest rate margin which is subject to adjustment depending upon the Company's leverage ratio under the Credit Agreement, and which can range from &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.25% to 2.25%, provided that this adjusted rate shall never be less than 0.00%. The Increased Term Loan A-1 requires amortizing quarterly principal payments that began on September&#160;30, 2024 of $29,728 per quarter through June&#160;30, 2027, and $44,591 per quarter from September&#160;30, 2027 through March&#160;31, 2028, with the balance due on April&#160;28, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Sixth Amendment transaction described above, the Company recognized debt prepayment, extinguishment and modification costs of $10,081 in the third quarter of 2024 composed partially of fees incurred for this transaction and partially of deferred financing costs and original issue discount written off for the extinguishment of the Term Loan B-1. Additionally, $861,282 of the debt considered extinguished and reborrowed related to the Increased Term Loan A-1 represented a non-cash financing activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company&#x2019;s domestic subsidiaries' assets and rank senior to all unsecured indebtedness. Borrowings under the Term Loan A-1, Extended Term Loan B-1 and revolving line of credit rank equal in priority for that security and related subsidiary guarantees. The Credit Agreement contains certain customary affirmative and negative covenants such as various restrictions or limitations on permitted amounts of investments (including acquisitions), share repurchases, payment of dividends, and redemptions and incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company&#x2019;s leverage ratio calculated in accordance with the Credit Agreement is below 4.00:1.00. In addition, the Credit Agreement requires compliance with a maximum leverage ratio covenant, tested quarterly, of 5.00:1.00 through June&#160;30, 2026 and 4.50:1.00 thereafter (subject to an increase to 5.00:1.00 during the four fiscal quarters following a material acquisition).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the prepayments described above, during 2024, the Company made regularly scheduled and other principal payments under its senior secured credit facilities totaling $75,080 on Term Loan A-1, $13,716 on Term Loan B-1 and $4,101 on Extended Term Loan B-1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had undrawn capacity on the revolving line of credit under its senior secured credit facilities of $1,500,000. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were none as of December&#160;31, 2024. The Company also had letters of credit of approximately $161,496 outstanding under a separate bilateral secured letter of credit facility as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2019 interest rate cap agreements expired on June&#160;30, 2024 and a portion of the Company's 2023 cap agreements became effective on or prior to June&#160;30, 2024. As of December&#160;31, 2024, the effective portion of the Company's 2023 interest rate cap agreements had the economic effect of capping the Company's maximum exposure to SOFR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Extended Term Loan B-1 and a portion of Term Loan A-1. The remaining $395,445 outstanding principal balance of Term Loan A-1 is subject to SOFR-based interest rate volatility. These cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. The original premiums paid for the caps are amortized to debt expense utilizing the effective interest rate method over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit risk-contingent features.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;13, 2024, the Company issued $1,000,000 aggregate principal amount of 6.875% senior notes due 2032 (the 6.875% Senior Notes) in a private offering pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended. The 6.875% Senior Notes pay interest on March 1 and September 1 of each year beginning March&#160;1, 2025 and mature on September&#160;1, 2032. The 6.875% Senior Notes are unsecured senior obligations and rank equally in right of payment with the Company's existing and future unsecured senior indebtedness. The 6.875% Senior Notes are guaranteed by each of the Company&#x2019;s domestic subsidiaries that guarantee its senior secured credit facilities. The Company may redeem up to 40% of the aggregate principal amount of the 6.875% Senior Notes at any time prior to September&#160;1, 2027 at 106.875% of the aggregate principal amount from the proceeds of one or more equity offerings, plus accrued and unpaid interest. On and after September&#160;1, 2027, the Company may at its option redeem the 6.875% Senior Notes, in whole or from time to time in part, at certain redemption prices specified in the indenture governing these notes plus accrued and unpaid interest. If the Company experiences certain change of control events, the Company must offer to repurchase all of the 6.875% Senior Notes (unless otherwise redeemed) at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest. The 6.875% Senior Notes contain restrictive covenants that limit the ability of the Company and the subsidiary guarantors of the 6.875% Senior Notes to, among other things and subject to certain exceptions and qualifications, create certain liens, enter into certain sale/leaseback transactions, or merge with or into, or convey, transfer or lease all or substantially all of their assets. The 6.875% Senior Notes and related subsidiary guarantees do not have any registration or similar rights and are not expected to be registered for exchange on public markets. As of December&#160;31, 2024, the Company incurred $11,421 in fees and other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;professional expenses associated with this transaction that were capitalized and will amortize over the term of the 6.875% Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's outstanding senior notes, including the 6.875% Senior Notes (collectively, the Senior Notes), are unsecured obligations, rank equally in right of payment with the Company&#x2019;s existing and future unsecured senior indebtedness and require semi-annual interest payments. The Company may redeem some or all of the Senior Notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in the indenture governing each series of Senior Notes. Interest rates on the Senior Notes are fixed by their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Change Healthcare&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;1, 2024, Change Healthcare (CHC), a subsidiary of UnitedHealth Group, launched a temporary assistance funding program (CHC Funding) to help bridge the gap in short-term cash flow needs for providers impacted by the disruption of CHC's services. Under the program, CHC provides funding to providers for amounts that would otherwise have been received (with certain limitations), but for the disruption in processing electronic claims as a result of the outage. Amounts provided under this program are subject to repayment at a future date to be mutually agreed to by CHC and the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CHC has restored claims submission functionality and the Company has resumed claims submissions and billing processes through CHC&#x2019;s information technology systems. Through a combination of CHC's platform and certain alternate billing processes, the Company is current on its primary claims submissions, but does continue to see delays in collections with some payors. As of December&#160;31, 2024, the remaining CHC Funding amount outstanding was $92,777. Subsequent to December&#160;31, 2024, the Company made a payment for a portion of the CHC Funding amount, leaving a remaining balance outstanding of $70,000 as of February&#160;13, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2024 the Company entered into several forward interest rate cap agreements, described below, that have the economic effect of capping the Company's exposure to SOFR variable interest rate changes on specific portions of the Company's floating rate debt (2024 cap agreements). These 2024 cap agreements are designated as cash flow hedges and, as a result, changes in their fair values will be reported in other comprehensive income. These 2024 cap agreements do not contain credit-risk contingent features, and become effective and expire as described in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s interest rate cap agreements outstanding as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount effective&lt;br/&gt;through December 31 unless noted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year cap agreements executed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Initial notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;SOFR maximum rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Approximate effective date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional coverage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average strike rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 4.00% decreased to 3.75% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 4.75% decreased to 4.00% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 5.00% decreased to 4.50% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective December&#160;31, 2026, the maximum rate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.50%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; increases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective December&#160;31, 2026, the maximum rate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; increases to 4.25% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of the Company&#x2019;s interest rate cap agreements for the years ended December&#160;31, 2024, 2023 and 2022:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount of unrealized gains (losses) in OCI on interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Location in Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification from accumulated other comprehensive income into net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1334"&gt;Debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1341"&gt;Related income tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's interest rate cap agreements, which are classified in other long-term assets on its consolidated balance sheet, were $30,062 and $79,805 for the years ended December&#160;31, 2024 and December&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 19 for further details on amounts recorded and reclassified from accumulated other comprehensive (loss) income and recorded as debt expense (offset) related to the Company&#x2019;s interest rate cap agreements for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the variable rate cap from the Company's 2023 interest rate cap agreements, the Company&#x2019;s weighted average effective interest rate on its senior secured credit facilities at the end of December&#160;31, 2024 was 6.91%, based on the current margins in effect for its senior secured credit facilities as of December&#160;31, 2024, as detailed in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was 5.07% for the year ended December&#160;31, 2024 and 5.68% as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company&#x2019;s interest rates were fixed and economically fixed on approximately 59% and 96% of its total debt, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt expense consisted of interest expense of $435,203, $373,951 and $339,247 and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs, costs for the undrawn portion of the revolving line of credit and the amortization of interest rate cap agreements of $35,266, $24,600 and $17,772 for 2024, 2023 and 2022, respectively. These interest expense amounts are net of capitalized interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-1128">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt comprised the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term Loan A-1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,259,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,234,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4/28/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Base +1.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,256,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term Loan B-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,603,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Extended Term Loan B-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,636,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5/9/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR + 2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,638,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revolving line of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4/28/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Base +1.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Senior Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6/1/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,533,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2/15/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,301,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.875% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9/1/2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,007,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Acquisition obligations and other notes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;102,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025-2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;56,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Financing lease obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;216,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;255,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;CHC temporary funding assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;92,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;92,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total debt principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,511,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,445,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Discount, premium and deferred financing costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(64,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(54,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,446,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,391,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(270,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(123,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,175,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,268,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;For the Company's senior secured credit facilities, fair value estimates are based on bid and ask quotes, a level 2 input. For the Company's senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. For the CHC temporary funding assistance, the carrying value presented here approximates the estimated fair value based on the short-term nature of settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company's senior secured credit facilities bear interest at Term SOFR, plus an interest rate margin, with certain portions also subject to a credit spread adjustment (CSA). Term SOFR plus CSA is referred to as "Base" in the table above. The Term Loan A-1 and revolving line of credit bear a CSA of 0.10%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Change Healthcare (CHC) temporary funding assistance, as described below, is interest-free and amounts provided under this program are subject to repayment at a future date to be mutually agreed to by the parties. The balance is included in the Company's current portion of long-term debt as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of December&#160;31, 2024, the carrying amount of the Company's senior secured credit facilities has been reduced by a discount of $8,084 and deferred financing costs of $28,879, and the carrying amount of the Company's senior notes has been reduced by deferred financing costs of $37,612 and increased by a debt premium of $10,239. As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $2,487 and deferred financing costs of $32,498, and the carrying amounts of the Company's senior notes was reduced by deferred financing costs of $31,491 and increased by a debt premium of $12,129.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:SecuredDebt contextRef="c-210" decimals="-3" id="f-1129" unitRef="usd">2259295000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt contextRef="c-211" decimals="-3" id="f-1130" unitRef="usd">1234375000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-212" id="f-1131">2028-04-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-213" id="f-1132">2028-04-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1 contextRef="c-213" id="f-1133">2028-04-28</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:DebtInstrumentFairValue contextRef="c-210" decimals="-3" id="f-1134" unitRef="usd">2256471000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SecuredDebt contextRef="c-214" decimals="-3" id="f-1135" unitRef="usd">0</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt contextRef="c-215" decimals="-3" id="f-1136" unitRef="usd">2603786000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentFairValue contextRef="c-214" decimals="-3" id="f-1137" unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SecuredDebt contextRef="c-216" decimals="-3" id="f-1138" unitRef="usd">1636150000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-217" id="f-1139">2031-05-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="c-218" id="f-1140">SOFR + 2.00%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentFairValue contextRef="c-216" decimals="-3" id="f-1141" unitRef="usd">1638195000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SecuredDebt contextRef="c-219" decimals="-3" id="f-1142" unitRef="usd">0</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt contextRef="c-220" decimals="-3" id="f-1143" unitRef="usd">0</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-221" id="f-1144">2028-04-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="c-219" decimals="-3" id="f-1145" unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:SeniorNotes contextRef="c-222" decimals="-3" id="f-1146" unitRef="usd">2750000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes contextRef="c-223" decimals="-3" id="f-1147" unitRef="usd">2750000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-224" id="f-1148">2030-06-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-224"
      decimals="5"
      id="f-1149"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFairValue contextRef="c-222" decimals="-3" id="f-1150" unitRef="usd">2533438000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SeniorNotes contextRef="c-225" decimals="-3" id="f-1151" unitRef="usd">1500000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes contextRef="c-226" decimals="-3" id="f-1152" unitRef="usd">1500000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-227" id="f-1153">2031-02-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-227"
      decimals="5"
      id="f-1154"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFairValue contextRef="c-225" decimals="-3" id="f-1155" unitRef="usd">1301250000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SeniorNotes contextRef="c-228" decimals="-3" id="f-1156" unitRef="usd">1000000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-229" id="f-1157">2032-09-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-230" id="f-1158">2032-09-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-230"
      decimals="5"
      id="f-1159"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFairValue contextRef="c-228" decimals="-3" id="f-1160" unitRef="usd">1007500000</us-gaap:DebtInstrumentFairValue>
    <dva:AcquisitionObligationsAndOtherNotesPayable contextRef="c-231" decimals="-3" id="f-1161" unitRef="usd">56483000</dva:AcquisitionObligationsAndOtherNotesPayable>
    <dva:AcquisitionObligationsAndOtherNotesPayable contextRef="c-232" decimals="-3" id="f-1162" unitRef="usd">102328000</dva:AcquisitionObligationsAndOtherNotesPayable>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c-233" id="f-1163">2025-2038</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="c-231"
      decimals="4"
      id="f-1164"
      unitRef="number">0.0558</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <dva:AcquisitionObligationsAndOtherNotesPayableFairValue contextRef="c-231" decimals="-3" id="f-1165" unitRef="usd">56483000</dva:AcquisitionObligationsAndOtherNotesPayableFairValue>
    <us-gaap:FinanceLeaseLiability contextRef="c-234" decimals="-3" id="f-1166" unitRef="usd">216401000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-235" decimals="-3" id="f-1167" unitRef="usd">255491000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c-236" id="f-1168">2025-2039</us-gaap:DebtInstrumentMaturityDateDescription>
    <dva:CHCTemporaryFundingAssistance contextRef="c-237" decimals="-3" id="f-1169" unitRef="usd">92777000</dva:CHCTemporaryFundingAssistance>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-238"
      decimals="5"
      id="f-1170"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <dva:CHCTemporaryFundingAssistanceFairValue contextRef="c-237" decimals="-3" id="f-1171" unitRef="usd">92777000</dva:CHCTemporaryFundingAssistanceFairValue>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-6" decimals="-3" id="f-1172" unitRef="usd">9511106000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-7" decimals="-3" id="f-1173" unitRef="usd">8445980000</us-gaap:DebtInstrumentCarryingAmount>
    <dva:DiscountPremiumAndDeferredFinanceCosts contextRef="c-6" decimals="-3" id="f-1174" unitRef="usd">64336000</dva:DiscountPremiumAndDeferredFinanceCosts>
    <dva:DiscountPremiumAndDeferredFinanceCosts contextRef="c-7" decimals="-3" id="f-1175" unitRef="usd">54347000</dva:DiscountPremiumAndDeferredFinanceCosts>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities contextRef="c-6" decimals="-3" id="f-1176" unitRef="usd">9446770000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities contextRef="c-7" decimals="-3" id="f-1177" unitRef="usd">8391633000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-6" decimals="-3" id="f-1178" unitRef="usd">270867000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-7" decimals="-3" id="f-1179" unitRef="usd">123299000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-6" decimals="-3" id="f-1180" unitRef="usd">9175903000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-7" decimals="-3" id="f-1181" unitRef="usd">8268334000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-239"
      decimals="3"
      id="f-1182"
      unitRef="number">0.0010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-240" decimals="-3" id="f-1183" unitRef="usd">8084000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts contextRef="c-240" decimals="-3" id="f-1184" unitRef="usd">28879000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c-241" decimals="-3" id="f-1185" unitRef="usd">37612000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-241" decimals="-3" id="f-1186" unitRef="usd">10239000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-242" decimals="-3" id="f-1187" unitRef="usd">2487000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts contextRef="c-242" decimals="-3" id="f-1188" unitRef="usd">32498000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c-243" decimals="-3" id="f-1189" unitRef="usd">31491000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-243" decimals="-3" id="f-1190" unitRef="usd">12129000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-1191">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled maturities of long-term debt at December&#160;31, 2024 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.359%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;202,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,922,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;39,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,900,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-6" decimals="-3" id="f-1192" unitRef="usd">270867000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-6" decimals="-3" id="f-1193" unitRef="usd">174693000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-6" decimals="-3" id="f-1194" unitRef="usd">202674000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-6" decimals="-3" id="f-1195" unitRef="usd">1922275000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-6" decimals="-3" id="f-1196" unitRef="usd">39993000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-6" decimals="-3" id="f-1197" unitRef="usd">6900604000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c-244" id="f-1198">2024-05-09</us-gaap:DebtInstrumentIssuanceDate1>
    <dva:SecuredDebtExtendedMaturity contextRef="c-244" decimals="-3" id="f-1199" unitRef="usd">911598000</dva:SecuredDebtExtendedMaturity>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet contextRef="c-245" decimals="-3" id="f-1200" unitRef="usd">728653000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:RepaymentsOfDebt contextRef="c-246" decimals="-3" id="f-1201" unitRef="usd">728653000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-247"
      decimals="3"
      id="f-1202"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="c-248" id="f-1203">prime commercial lending rate</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-249"
      decimals="2"
      id="f-1204"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <dva:DebtInstrumentVariableRate
      contextRef="c-250"
      decimals="2"
      id="f-1205"
      unitRef="number">0.0000</dva:DebtInstrumentVariableRate>
    <dva:DebtInstrumentVariableRate
      contextRef="c-250"
      decimals="2"
      id="f-1206"
      unitRef="number">0.0000</dva:DebtInstrumentVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-251"
      decimals="2"
      id="f-1207"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-252"
      decimals="2"
      id="f-1208"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentPaymentTerms contextRef="c-244" id="f-1209">The Extended Term Loan B-1 requires quarterly principal payments beginning on December&#160;31, 2024 of 0.25% of the aggregate principal amount of the Extended Term Loan B-1 outstanding on the Fourth Amendment Effective Date, with the balance due on May&#160;9, 2031.</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="c-244" id="f-1210">quarterly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1 contextRef="c-244" id="f-1211">2024-12-31</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="c-244" id="f-1212">2024-12-31</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
    <dva:DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding
      contextRef="c-253"
      decimals="4"
      id="f-1213"
      unitRef="number">0.0025</dva:DebtInstrumentQuarterlyPaymentOfBeginningBalanceOutstanding>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1 contextRef="c-244" id="f-1214">2031-05-09</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-244" id="f-1215">2031-05-09</us-gaap:DebtInstrumentMaturityDate>
    <dva:DebtPrepaymentExtinguishmentAndModificationCosts contextRef="c-254" decimals="-3" id="f-1216" unitRef="usd">9732000</dva:DebtPrepaymentExtinguishmentAndModificationCosts>
    <dva:ConstructiveFinancingCashOutflow contextRef="c-245" decimals="-3" id="f-1217" unitRef="usd">6302000</dva:ConstructiveFinancingCashOutflow>
    <dva:ConstructiveFinancingCashInflow contextRef="c-245" decimals="-3" id="f-1218" unitRef="usd">728653000</dva:ConstructiveFinancingCashInflow>
    <dva:ConstructiveFinancingCashOutflow contextRef="c-246" decimals="-3" id="f-1219" unitRef="usd">722351000</dva:ConstructiveFinancingCashOutflow>
    <dva:OtherSignificantNoncashFinancingActivity contextRef="c-245" decimals="-3" id="f-1220" unitRef="usd">13282000</dva:OtherSignificantNoncashFinancingActivity>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c-213" id="f-1221">2024-08-13</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-213" decimals="-3" id="f-1222" unitRef="usd">1100000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentDescription contextRef="c-255" id="f-1223">The Sixth Amendment also incorporated the provisions of the Fifth Amendment to the Credit Agreement, dated as of August&#160;7, 2024, which removed a cap on the amount of incremental term "A" loans the Company can incur under the Credit Agreement.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c-255" id="f-1224">2024-08-07</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:RepaymentsOfDebt contextRef="c-256" decimals="-3" id="f-1225" unitRef="usd">949819000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-257"
      decimals="3"
      id="f-1226"
      unitRef="number">0.0010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-258"
      decimals="4"
      id="f-1227"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-259"
      decimals="4"
      id="f-1228"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <dva:DebtInstrumentVariableRate
      contextRef="c-260"
      decimals="2"
      id="f-1229"
      unitRef="number">0.0000</dva:DebtInstrumentVariableRate>
    <us-gaap:DebtInstrumentPaymentTerms contextRef="c-213" id="f-1230">The Increased Term Loan A-1 requires amortizing quarterly principal payments that began on September&#160;30, 2024 of $29,728 per quarter through June&#160;30, 2027, and $44,591 per quarter from September&#160;30, 2027 through March&#160;31, 2028, with the balance due on April&#160;28, 2028.</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="c-213" id="f-1231">quarterly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1 contextRef="c-213" id="f-1232">2024-09-30</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="c-213" id="f-1233">2024-09-30</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
    <dva:DebtInstrumentQuarterlyPaymentThroughJune302027 contextRef="c-213" decimals="-3" id="f-1234" unitRef="usd">29728000</dva:DebtInstrumentQuarterlyPaymentThroughJune302027>
    <dva:DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028 contextRef="c-213" decimals="-3" id="f-1235" unitRef="usd">44591000</dva:DebtInstrumentQuarterlyPaymentFromSeptember302027ThroughMarch312028>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-212" id="f-1236">2028-04-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-213" id="f-1237">2028-04-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1 contextRef="c-213" id="f-1238">2028-04-28</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <dva:DebtPrepaymentExtinguishmentAndModificationCosts contextRef="c-261" decimals="-3" id="f-1239" unitRef="usd">10081000</dva:DebtPrepaymentExtinguishmentAndModificationCosts>
    <dva:OtherSignificantNoncashFinancingActivity contextRef="c-262" decimals="-3" id="f-1240" unitRef="usd">861282000</dva:OtherSignificantNoncashFinancingActivity>
    <dva:LeverageRatioCovenant
      contextRef="c-263"
      decimals="2"
      id="f-1241"
      unitRef="number">4.00</dva:LeverageRatioCovenant>
    <dva:LeverageRatioCovenantThroughJun302026
      contextRef="c-263"
      decimals="2"
      id="f-1242"
      unitRef="number">5.00</dva:LeverageRatioCovenantThroughJun302026>
    <dva:LeverageRatioCovenantAfterJun302026
      contextRef="c-263"
      decimals="3"
      id="f-1243"
      unitRef="number">4.50</dva:LeverageRatioCovenantAfterJun302026>
    <dva:LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition
      contextRef="c-263"
      decimals="3"
      id="f-1244"
      unitRef="number">5.00</dva:LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-212" decimals="-3" id="f-1245" unitRef="usd">75080000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-264" decimals="-3" id="f-1246" unitRef="usd">13716000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-217" decimals="-3" id="f-1247" unitRef="usd">4101000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-219" decimals="-3" id="f-1248" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-6" decimals="-3" id="f-1249" unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-265" decimals="-3" id="f-1250" unitRef="usd">161496000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:DerivativeMaturityDates contextRef="c-266" id="f-1251">2024-06-30</us-gaap:DerivativeMaturityDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-266" id="f-1252">2024-06-30</us-gaap:DerivativeMaturityDates>
    <dva:SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR contextRef="c-210" decimals="-3" id="f-1253" unitRef="usd">395445000</dva:SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR>
    <us-gaap:SeniorNotes contextRef="c-267" decimals="-3" id="f-1254" unitRef="usd">1000000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1255"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1256"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentPaymentTerms contextRef="c-229" id="f-1257">The 6.875% Senior Notes pay interest on March 1 and September 1 of each year beginning March&#160;1, 2025 and mature on September&#160;1, 2032</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1258"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="c-229" id="f-1259">2025-03-01</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1260"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1261"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentRedemptionDescription contextRef="c-229" id="f-1262">The Company may redeem up to 40% of the aggregate principal amount of the 6.875% Senior Notes at any time prior to September&#160;1, 2027 at 106.875% of the aggregate principal amount from the proceeds of one or more equity offerings, plus accrued and unpaid interest.</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1263"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <dva:DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027
      contextRef="c-229"
      decimals="INF"
      id="f-1264"
      unitRef="number">1.06875</dva:DebtInstrumentRedemptionPricePercentageAnyTimePriorToSeptember12027>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1265"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1266"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <dva:DebtInstrumentRedemptionPriceIfChangeOfControl
      contextRef="c-229"
      decimals="INF"
      id="f-1267"
      unitRef="number">1.01</dva:DebtInstrumentRedemptionPriceIfChangeOfControl>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1268"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1269"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1270"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-267" decimals="-3" id="f-1271" unitRef="usd">11421000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1272"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-229"
      decimals="5"
      id="f-1273"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <dva:CHCTemporaryFundingAssistance contextRef="c-237" decimals="-3" id="f-1274" unitRef="usd">92777000</dva:CHCTemporaryFundingAssistance>
    <dva:CHCTemporaryFundingAssistance contextRef="c-268" decimals="-3" id="f-1275" unitRef="usd">70000000</dva:CHCTemporaryFundingAssistance>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-1276">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s interest rate cap agreements outstanding as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount effective&lt;br/&gt;through December 31 unless noted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year cap agreements executed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Initial notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;SOFR maximum rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Approximate effective date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional coverage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average strike rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 4.00% decreased to 3.75% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 4.75% decreased to 4.00% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 5.00% decreased to 4.50% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective December&#160;31, 2026, the maximum rate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.50%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; increases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"&gt;Effective December&#160;31, 2026, the maximum rate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; increases to 4.25% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-269" decimals="-3" id="f-1277" unitRef="usd">1000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-269"
      decimals="INF"
      id="f-1278"
      unitRef="number">0.0375</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeInceptionDates contextRef="c-270" id="f-1279">2024-06-30</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-270" id="f-1280">2025-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-270" decimals="-3" id="f-1281" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-271" decimals="-3" id="f-1282" unitRef="usd">1000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-272" id="f-1283">2024-06-30</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-272" id="f-1284">2025-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-272" decimals="-3" id="f-1285" unitRef="usd">750000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-273" decimals="-3" id="f-1286" unitRef="usd">1000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-274" id="f-1287">2024-06-30</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-274" id="f-1288">2025-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-274" decimals="-3" id="f-1289" unitRef="usd">750000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-275" decimals="-3" id="f-1290" unitRef="usd">500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-276" id="f-1291">2024-06-30</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-276" id="f-1292">2026-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-276" decimals="-3" id="f-1293" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-277" decimals="-3" id="f-1294" unitRef="usd">250000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-277"
      decimals="INF"
      id="f-1295"
      unitRef="number">0.0450</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeInceptionDates contextRef="c-278" id="f-1296">2024-12-31</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-278" id="f-1297">2025-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-278" decimals="-3" id="f-1298" unitRef="usd">250000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-279" decimals="-3" id="f-1299" unitRef="usd">750000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-279"
      decimals="INF"
      id="f-1300"
      unitRef="number">0.0400</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeInceptionDates contextRef="c-280" id="f-1301">2024-12-31</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-280" id="f-1302">2026-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-280" decimals="-3" id="f-1303" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-281" decimals="-3" id="f-1304" unitRef="usd">1750000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-282" id="f-1305">2025-12-31</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-282" id="f-1306">2027-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-282" decimals="-3" id="f-1307" unitRef="usd">1000000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-283" decimals="-3" id="f-1308" unitRef="usd">750000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-284" id="f-1309">2025-12-31</us-gaap:DerivativeInceptionDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-284" id="f-1310">2027-12-31</us-gaap:DerivativeMaturityDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-284" decimals="-3" id="f-1311" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-285" decimals="-3" id="f-1312" unitRef="usd">3500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-286" decimals="-3" id="f-1313" unitRef="usd">3500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-287" decimals="-3" id="f-1314" unitRef="usd">3500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-288" decimals="-3" id="f-1315" unitRef="usd">1500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAverageFixedInterestRate
      contextRef="c-289"
      decimals="INF"
      id="f-1316"
      unitRef="number">0.0429</us-gaap:DerivativeAverageFixedInterestRate>
    <us-gaap:DerivativeAverageFixedInterestRate
      contextRef="c-290"
      decimals="INF"
      id="f-1317"
      unitRef="number">0.0402</us-gaap:DerivativeAverageFixedInterestRate>
    <us-gaap:DerivativeAverageFixedInterestRate
      contextRef="c-291"
      decimals="INF"
      id="f-1318"
      unitRef="number">0.0432</us-gaap:DerivativeAverageFixedInterestRate>
    <us-gaap:DerivativeAverageFixedInterestRate
      contextRef="c-292"
      decimals="INF"
      id="f-1319"
      unitRef="number">0.0458</us-gaap:DerivativeAverageFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-271"
      decimals="INF"
      id="f-1320"
      unitRef="number">0.0400</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-293"
      decimals="INF"
      id="f-1321"
      unitRef="number">0.0375</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-273"
      decimals="INF"
      id="f-1322"
      unitRef="number">0.0475</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-294"
      decimals="INF"
      id="f-1323"
      unitRef="number">0.0400</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-275"
      decimals="INF"
      id="f-1324"
      unitRef="number">0.0500</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-295"
      decimals="INF"
      id="f-1325"
      unitRef="number">0.0450</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-281"
      decimals="INF"
      id="f-1326"
      unitRef="number">0.0450</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-296"
      decimals="INF"
      id="f-1327"
      unitRef="number">0.0475</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-283"
      decimals="INF"
      id="f-1328"
      unitRef="number">0.0400</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c-297"
      decimals="INF"
      id="f-1329"
      unitRef="number">0.0425</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-1330">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of the Company&#x2019;s interest rate cap agreements for the years ended December&#160;31, 2024, 2023 and 2022:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount of unrealized gains (losses) in OCI on interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Location in Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification from accumulated other comprehensive income into net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1334"&gt;Debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1341"&gt;Related income tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-298" decimals="-3" id="f-1331" unitRef="usd">9662000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-299" decimals="-3" id="f-1332" unitRef="usd">9186000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-300" decimals="-3" id="f-1333" unitRef="usd">144793000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-298" decimals="-3" id="f-1335" unitRef="usd">-58175000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-299" decimals="-3" id="f-1336" unitRef="usd">-103567000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-300" decimals="-3" id="f-1337" unitRef="usd">-11732000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-301" decimals="-3" id="f-1338" unitRef="usd">-2412000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-302" decimals="-3" id="f-1339" unitRef="usd">-2291000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-303" decimals="-3" id="f-1340" unitRef="usd">-36124000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-301" decimals="-3" id="f-1342" unitRef="usd">14515000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-302" decimals="-3" id="f-1343" unitRef="usd">25840000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-303" decimals="-3" id="f-1344" unitRef="usd">2926000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-304" decimals="-3" id="f-1345" unitRef="usd">7250000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-305" decimals="-3" id="f-1346" unitRef="usd">6895000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-306" decimals="-3" id="f-1347" unitRef="usd">108669000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-304" decimals="-3" id="f-1348" unitRef="usd">-43660000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-305" decimals="-3" id="f-1349" unitRef="usd">-77727000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-306" decimals="-3" id="f-1350" unitRef="usd">-8806000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-307" decimals="-3" id="f-1351" unitRef="usd">30062000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-308" decimals="-3" id="f-1352" unitRef="usd">79805000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="c-240"
      decimals="4"
      id="f-1353"
      unitRef="number">0.0691</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c-6" decimals="4" id="f-1354" unitRef="number">0.0507</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LongtermDebtWeightedAverageInterestRate contextRef="c-6" decimals="4" id="f-1355" unitRef="number">0.0568</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c-6" decimals="4" id="f-1356" unitRef="number">0.59</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <dva:LongTermDebtPercentageBearingEconomicallyFixedInterestRate contextRef="c-6" decimals="4" id="f-1357" unitRef="number">0.96</dva:LongTermDebtPercentageBearingEconomicallyFixedInterestRate>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-1358" unitRef="usd">435203000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-4" decimals="-3" id="f-1359" unitRef="usd">373951000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-5" decimals="-3" id="f-1360" unitRef="usd">339247000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-1361" unitRef="usd">35266000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-4" decimals="-3" id="f-1362" unitRef="usd">24600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-5" decimals="-3" id="f-1363" unitRef="usd">17772000</us-gaap:AmortizationOfFinancingCosts>
    <dva:LeasesDisclosureTextBlock contextRef="c-1" id="f-1408">Leases&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases substantially all of its dialysis facilities. The majority of the Company&#x2019;s facilities are leased under non-cancellable operating leases which range in terms from five years to 15 years and which contain renewal options of five years to 10 years at the fair rental value at the time of renewal. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases. See Note 1 for further information on how the Company accounts for leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and December&#160;31, 2023, assets recorded under &lt;span style="-sec-ix-hidden:f-1413"&gt;&lt;span style="-sec-ix-hidden:f-1414"&gt;finance leases&lt;/span&gt;&lt;/span&gt; were $309,363 and $322,844, respectively, and accumulated amortization associated with finance leases was $139,071 and $122,286, respectively, included in property and equipment, net, on the Company's consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain markets, the Company acquires and develops dialysis centers. Upon completion, the Company sells the center to a third party and leases the space back with the intent of operating the center on a long-term basis. Both the sale and leaseback terms are generally market terms. Substantially all of the lease terms are consistent with the Company's other operating leases with the majority of the leases under non-cancellable operating leases ranging in terms from 10 years to 15 years and containing renewal options of five years to 15 years at the fair rental value at the time of renewal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes short-term lease expense and sublease income, which are immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on sale leasebacks, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the &lt;br/&gt;&#160;measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease assets obtained in exchange&lt;br/&gt;&#160;for new or modified operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2024 are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,038,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less portion representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1481"&gt;&lt;span style="-sec-ix-hidden:f-1482"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense under all operating leases for 2024, 2023 and 2022 was $689,130, $692,834 and $679,815, respectively. Rent expense is recorded on a straight-line basis over the term of the lease, including leases that contain fixed escalation clauses or include abatement provisions. Leasehold improvement incentives reduce the carrying value of right-of-use assets and are amortized to rent expense over the term of the lease. Finance lease obligations are included in long-term debt. See Note 12 for further details on long-term debt.&lt;/span&gt;&lt;/div&gt;</dva:LeasesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-311" id="f-1409">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-312" id="f-1410">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-311" id="f-1411">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-312" id="f-1412">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-1415" unitRef="usd">309363000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-1416" unitRef="usd">322844000</us-gaap:FinanceLeaseRightOfUseAsset>
    <dva:FinanceLeaseAccumulatedDepreciation contextRef="c-6" decimals="-3" id="f-1417" unitRef="usd">139071000</dva:FinanceLeaseAccumulatedDepreciation>
    <dva:FinanceLeaseAccumulatedDepreciation contextRef="c-7" decimals="-3" id="f-1418" unitRef="usd">122286000</dva:FinanceLeaseAccumulatedDepreciation>
    <us-gaap:SaleLeasebackTransactionLeaseTerm contextRef="c-313" id="f-1419">P10Y</us-gaap:SaleLeasebackTransactionLeaseTerm>
    <us-gaap:SaleLeasebackTransactionLeaseTerm contextRef="c-314" id="f-1420">P15Y</us-gaap:SaleLeasebackTransactionLeaseTerm>
    <dva:SaleLeasebackTransactionRenewalLeaseTerm contextRef="c-315" id="f-1421">P5Y</dva:SaleLeasebackTransactionRenewalLeaseTerm>
    <dva:SaleLeasebackTransactionRenewalLeaseTerm contextRef="c-316" id="f-1422">P15Y</dva:SaleLeasebackTransactionRenewalLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1423">&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Includes short-term lease expense and sublease income, which are immaterial.</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-3" id="f-1424" unitRef="usd">557591000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-4" decimals="-3" id="f-1425" unitRef="usd">556844000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-5" decimals="-3" id="f-1426" unitRef="usd">552194000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-1427" unitRef="usd">131539000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-4" decimals="-3" id="f-1428" unitRef="usd">135990000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-5" decimals="-3" id="f-1429" unitRef="usd">127621000</us-gaap:VariableLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-1430" unitRef="usd">28262000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-4" decimals="-3" id="f-1431" unitRef="usd">26964000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-5" decimals="-3" id="f-1432" unitRef="usd">27079000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-1433" unitRef="usd">10885000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-4" decimals="-3" id="f-1434" unitRef="usd">11724000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-5" decimals="-3" id="f-1435" unitRef="usd">12776000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-1436" unitRef="usd">728277000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-4" decimals="-3" id="f-1437" unitRef="usd">731522000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-5" decimals="-3" id="f-1438" unitRef="usd">719670000</us-gaap:LeaseCost>
    <dva:LeaseOtherInformationTableTextBlockTableTextBlock contextRef="c-1" id="f-1439">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on sale leasebacks, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the &lt;br/&gt;&#160;measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease assets obtained in exchange&lt;br/&gt;&#160;for new or modified operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:LeaseOtherInformationTableTextBlockTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-1440">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-1441">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-8" id="f-1442">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-1443">P7Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-1444">P8Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-8" id="f-1445">P9Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-1446" unitRef="number">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-1447" unitRef="number">0.040</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-8" decimals="3" id="f-1448" unitRef="number">0.036</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c-1" decimals="-3" id="f-1449" unitRef="usd">2260000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c-4" decimals="-3" id="f-1450" unitRef="usd">3387000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c-5" decimals="-3" id="f-1451" unitRef="usd">28005000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-1452" unitRef="usd">719339000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-4" decimals="-3" id="f-1453" unitRef="usd">708162000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-5" decimals="-3" id="f-1454" unitRef="usd">696291000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-1455" unitRef="usd">18599000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-4" decimals="-3" id="f-1456" unitRef="usd">19246000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-5" decimals="-3" id="f-1457" unitRef="usd">20103000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-1458" unitRef="usd">29592000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-4" decimals="-3" id="f-1459" unitRef="usd">26455000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-5" decimals="-3" id="f-1460" unitRef="usd">24329000</us-gaap:FinanceLeasePrincipalPayments>
    <dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities contextRef="c-1" decimals="-3" id="f-1461" unitRef="usd">286022000</dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities>
    <dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities contextRef="c-4" decimals="-3" id="f-1462" unitRef="usd">269564000</dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities>
    <dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities contextRef="c-5" decimals="-3" id="f-1463" unitRef="usd">278108000</dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities>
    <dva:ScheduleOfMinimumLeasePaymentsTextBlock contextRef="c-1" id="f-1464">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2024 are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,038,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less portion representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1481"&gt;&lt;span style="-sec-ix-hidden:f-1482"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfMinimumLeasePaymentsTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-1465" unitRef="usd">508420000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-1466" unitRef="usd">36557000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-1467" unitRef="usd">517309000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-1468" unitRef="usd">38694000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-1469" unitRef="usd">453895000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-1470" unitRef="usd">37421000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="-3" id="f-1471" unitRef="usd">385211000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="-3" id="f-1472" unitRef="usd">33854000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-6" decimals="-3" id="f-1473" unitRef="usd">310332000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-6" decimals="-3" id="f-1474" unitRef="usd">24862000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-6" decimals="-3" id="f-1475" unitRef="usd">863739000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-6" decimals="-3" id="f-1476" unitRef="usd">82400000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-1477" unitRef="usd">3038906000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-1478" unitRef="usd">253788000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-1479" unitRef="usd">418840000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-1480" unitRef="usd">37387000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-1483" unitRef="usd">2620066000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-6" decimals="-3" id="f-1484" unitRef="usd">216401000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-317" decimals="-3" id="f-1485" unitRef="usd">689130000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-318" decimals="-3" id="f-1486" unitRef="usd">692834000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-319" decimals="-3" id="f-1487" unitRef="usd">679815000</us-gaap:OperatingLeaseCost>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1494">Employee benefit plans&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a 401(k) retirement savings plan for substantially all of its U.S. employees which has been established pursuant to applicable provisions of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company maintains a 401(k) matching program under which the Company matches 50% of the employee's contribution up to 6% of the employee's salary, subject to certain limitations. The matching contributions are subject to certain eligibility and vesting conditions. For the years ended December&#160;31, 2024, 2023 and 2022, the Company accrued matching contributions totaling approximately $79,006, $73,725 and $70,084, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also maintains a voluntary compensation deferral plan, the Deferred Compensation Plan. The Deferred Compensation Plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2024, 2023 and 2022 were $2,521, $2,695 and $3,573, respectively. Deferred amounts are generally paid out in cash at the participant&#x2019;s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2024, 2023 and 2022 the Company distributed $4,511, $3,899 and $3,731, respectively, to participants from its deferred compensation plans. Participants are credited with their proportional amount of annual earnings from the plans. The assets of these plans are held in rabbi trusts subject to the claims of the Company&#x2019;s general creditors in the event of its bankruptcy. As of December&#160;31, 2024 and 2023, the total fair value of assets held in these plans' trusts was $39,527 and $36,936, respectively. The assets of these plans are recorded at fair value with changes in fair value recorded in other loss, net. See Note 4 for further details. Any fair value changes to the corresponding liability balance are recorded as compensation expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-1"
      decimals="INF"
      id="f-1495"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-314"
      decimals="INF"
      id="f-1496"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-1" decimals="-3" id="f-1497" unitRef="usd">79006000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-4" decimals="-3" id="f-1498" unitRef="usd">73725000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-5" decimals="-3" id="f-1499" unitRef="usd">70084000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-321"
      decimals="INF"
      id="f-1500"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer contextRef="c-322" decimals="-3" id="f-1501" unitRef="usd">2521000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer contextRef="c-323" decimals="-3" id="f-1502" unitRef="usd">2695000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer contextRef="c-324" decimals="-3" id="f-1503" unitRef="usd">3573000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid contextRef="c-322" decimals="-3" id="f-1504" unitRef="usd">4511000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid contextRef="c-323" decimals="-3" id="f-1505" unitRef="usd">3899000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid contextRef="c-324" decimals="-3" id="f-1506" unitRef="usd">3731000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-325" decimals="-3" id="f-1507" unitRef="usd">39527000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-326" decimals="-3" id="f-1508" unitRef="usd">36936000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:LossContingencyDisclosures contextRef="c-1" id="f-1513">Contingencies&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in a highly regulated industry and is a party to, or has the potential to be a party to, various lawsuits, demands, claims, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. Excluding amounts stated below, as of December&#160;31, 2024 and December&#160;31, 2023, the Company&#x2019;s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company&#x2019;s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Certain Governmental Inquiries and Related Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2017 U.S. Attorney Colorado Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In November 2017, the U.S. Attorney&#x2019;s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company&#x2019;s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter included an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a Civil Investigative Demand (CID) pursuant to the False Claims Act from the U.S. Attorney's Office relating to this investigation. On May 6, 2024, the Company finalized and executed a settlement agreement with the government and the relator in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; matter that included a settlement amount of $34,487 for this matter. On May 7, 2024, the government notified the U.S. District Court, District of Colorado of its decision to intervene for purposes of settlement in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Kogod v. DaVita Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The government and the relator agreed to voluntarily dismiss all substantive claims in the matter, and, on July 18, 2024, the District Court dismissed all claims except for the relator&#x2019;s statutory claim for expenses, attorney&#x2019;s fees, and costs. On December 10, 2024, the parties signed an agreement to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;resolve the remaining claim for relator&#x2019;s statutory claim for expenses, attorney&#x2019;s fees, and costs for an immaterial amount. On December 20, 2024, the parties filed a stipulation of dismissal with the District Court on the remaining claim and the District Court ordered the relator&#x2019;s claim withdrawn.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020 U.S. Attorney New Jersey Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In March 2020, the U.S. Attorney&#x2019;s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney&#x2019;s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company&#x2019;s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney&#x2019;s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Doe v. DaVita Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney&#x2019;s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Bayne v. DaVita Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020 California Department of Insurance Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company&#x2019;s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients&#x2019; decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2023 District of Columbia Office of Attorney General Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company&#x2019;s communications with the AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2024 Federal Trade Commission Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In April 2024, the Company received from the Federal Trade Commission (FTC) two CIDs in connection with an industry investigation under Section 5 of the Federal Trade Commission Act regarding the acquisition of medical director services and provision of dialysis services. The CIDs cover the period from January 1, 2016 to the present and generally seek information relating to restrictive covenants, such as non-competes, with physicians. The Company is cooperating with the government in this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* * *&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies. Negative findings or terms and conditions that the Company might agree to accept could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company&#x2019;s reputation, required changes to the Company&#x2019;s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Antitrust Indictment and Putative Class Action Suit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. v. DaVita Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Outpatient Medical Center Employee Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company. On October 27, 2024, the plaintiffs filed a Third Amended Complaint, seeking to bring an action on behalf of certain groups of individuals employed by the Company between March 2008 and January 2021, to which the Company responded on December 20, 2024. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* * *&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 15, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company&#x2019;s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management&#x2019;s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company&#x2019;s business, results of operations, financial condition, cash flows or reputation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-327" decimals="-3" id="f-1514" unitRef="usd">34487000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <dva:CorporateIntegrityAgreementExpirationDate contextRef="c-328" id="f-1515">2019-10-22</dva:CorporateIntegrityAgreementExpirationDate>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="c-1" id="f-1516">Noncontrolling interests subject to put provisions and other commitments&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#x2019; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#x2019; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#x2019;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#x2019; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#x2019; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain consolidated dialysis partnerships are originally contractually scheduled to dissolve after terms ranging from ten years to 50 years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with various suppliers to purchase established amounts of dialysis equipment, parts, pharmaceuticals and supplies. As of December&#160;31, 2024, the remaining minimum purchase commitments under these arrangements were approximately $559,952, $547,079, $547,031, $564,134 and $414,491 for the years 2025, 2026, 2027, 2028 and 2029, respectively. If the Company fails to meet the minimum purchase commitments under these contracts during any year, it is required to pay the difference to the supplier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately $7,131.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the letters of credit disclosed in Note 12 to these consolidated financial statements, and the arrangements as described above, the Company has no off balance sheet financing arrangements as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <dva:DissolutionTermOfJointVentures contextRef="c-313" id="f-1517">P10Y</dva:DissolutionTermOfJointVentures>
    <dva:DissolutionTermOfJointVentures contextRef="c-314" id="f-1518">P50Y</dva:DissolutionTermOfJointVentures>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-6" decimals="-3" id="f-1519" unitRef="usd">559952000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="c-6" decimals="-3" id="f-1520" unitRef="usd">547079000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear contextRef="c-6" decimals="-3" id="f-1521" unitRef="usd">547031000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear contextRef="c-6" decimals="-3" id="f-1522" unitRef="usd">564134000</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:PurchaseObligationDueInFifthYear contextRef="c-6" decimals="-3" id="f-1523" unitRef="usd">414491000</us-gaap:PurchaseObligationDueInFifthYear>
    <us-gaap:OtherCommitment contextRef="c-329" decimals="-3" id="f-1524" unitRef="usd">7131000</us-gaap:OtherCommitment>
    <dva:OffBalanceSheetFinancingArrangements contextRef="c-6" decimals="-3" id="f-1525" unitRef="usd">0</dva:OffBalanceSheetFinancingArrangements>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1526">Stock-based compensation&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation consists primarily of stock-settled stock appreciation rights, restricted stock units and performance stock units. Stock-based compensation, which is primarily general and administrative in nature, is attributed to the Company&#x2019;s U.S. dialysis business, its corporate administrative support, and its ancillary services. See Note 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Organization and summary of significant accounting policies" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for more information on how the Company measures and recognizes stock-based compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term incentive compensation plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The DaVita Inc. 2020 Incentive Award Plan (the 2020 Plan) is the Company&#x2019;s current omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2020 Plan provides for the grant of stock appreciation rights, nonqualified stock options, incentive stock options, restricted stock units, restricted stock, performance stock awards, dividend equivalents, stock payments, deferred stock unit awards, deferred stock awards and performance cash awards. The 2020 Plan mandates a maximum award term of 10 years for stock appreciation rights and stock options and stipulates that awards of these types be granted with a base or exercise price per share of not less than the fair market value of the Company's common stock on the date of grant. Shares available under the 2020 Plan are stated on a full value share basis. The 2020 Plan therefore provides that shares available for issuance under the plan are reduced by one share available for every four shares underlying stock appreciation rights and stock options, and are reduced by one share available for every one share underlying stock-based awards other than stock appreciation rights and stock options. At December&#160;31, 2024, there were 4,969 shares available for future grants under the 2020 Plan. The Company&#x2019;s stock awards granted under the 2020 Plan generally vest over 36 months to 48 months from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the status of the Company&#x2019;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.819%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock appreciation rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Added by performance factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised/Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of grants:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of SSARs base prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.01&#x2013;$80.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.01&#x2013;$110.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$110.01&#x2013;$120.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, 2023 and 2022, the aggregate intrinsic value of stock-based awards exercised was $323,681, $168,500 and $149,442, respectively. At December&#160;31, 2024, the aggregate intrinsic value of stock-based awards outstanding was $490,209 and the aggregate intrinsic value of stock awards exercisable was $3,394.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated fair value of stock-based compensation awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant, except for portions of the Company&#x2019;s performance stock unit awards for which a Monte Carlo simulation was used to estimate the grant-date fair value. The following assumptions were used in estimating these values and determining the related stock-based compensation expense attributable to the current period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term of the awards:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company&#x2019;s historical exercise and post-vesting termination patterns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatilities expected by peer companies in near industries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend yield:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No SSAR awards were granted during the years ended December&#160;31, 2024 or 2023. A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted during the year end December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $25 of the Company&#x2019;s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of 100% of its fair market value on the first day of the purchase right period or 85% of its fair market value on the last day of the purchase right period. Purchase right periods begin on January&#160;1 and July&#160;1, and end on December&#160;31. Contributions used to purchase the Company&#x2019;s common stock under this plan for the 2024, 2023 and 2022 purchase periods were $20,441, $18,213 and $18,061, respectively. Shares purchased pursuant to the plan&#x2019;s 2024, 2023 and 2022 purchase periods were 184, 231 and 285, respectively. At December&#160;31, 2024, there were 5,286 shares remaining available for future grants under this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of participants&#x2019; purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2024, 2023 and 2022, respectively: expected volatility of 32.6%, 41.3% and 31.7%; risk-free interest rates of 4.8%, 4.9% and 1.3%; and no dividends. Using these assumptions, the weighted average estimated per share fair value of each purchase right was $31.78, $25.25 and $26.50 for 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation expense and proceeds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized $102,788, $112,375 and $95,427 in stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock purchase plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2024, 2023 and 2022 were $16,398, $16,536 and $14,723, respectively. As of December&#160;31, 2024, there was $146,350 of total estimated but unrecognized stock-based compensation expense under the Company&#x2019;s equity compensation plans. The Company expects to recognize this expense over a weighted average remaining period of 1.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, 2023 and 2022, the Company received $27,531, $25,629 and $24,805, respectively, in actual tax benefits upon the exercise or vesting of stock awards. Since the Company issues stock-settled stock appreciation rights rather than stock options, there were no cash proceeds from stock option exercises.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-330" id="f-1527">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions
      contextRef="c-331"
      decimals="INF"
      id="f-1528"
      unitRef="shares">1</dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions>
    <dva:StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance
      contextRef="c-331"
      decimals="INF"
      id="f-1529"
      unitRef="shares">4</dva:StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance>
    <dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward
      contextRef="c-331"
      decimals="INF"
      id="f-1530"
      unitRef="shares">1</dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward>
    <dva:StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance
      contextRef="c-331"
      decimals="INF"
      id="f-1531"
      unitRef="shares">1</dva:StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-332"
      decimals="-3"
      id="f-1532"
      unitRef="shares">4969000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-333" id="f-1533">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-330" id="f-1534">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-1535">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the status of the Company&#x2019;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.819%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock appreciation rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Added by performance factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised/Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of grants:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-334"
      decimals="INF"
      id="f-1536"
      unitRef="shares">3471000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-334"
      decimals="2"
      id="f-1537"
      unitRef="usdPerShare">67.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-335"
      decimals="INF"
      id="f-1538"
      unitRef="shares">3223000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-336"
      decimals="INF"
      id="f-1539"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-336"
      id="f-1540"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-337"
      decimals="INF"
      id="f-1541"
      unitRef="shares">827000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod
      contextRef="c-337"
      decimals="-3"
      id="f-1542"
      unitRef="shares">16000</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-336"
      decimals="-3"
      id="f-1543"
      unitRef="shares">3200000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-336"
      decimals="2"
      id="f-1544"
      unitRef="usdPerShare">63.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-337"
      decimals="INF"
      id="f-1545"
      unitRef="shares">628000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-336"
      decimals="-3"
      id="f-1546"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-336"
      decimals="2"
      id="f-1547"
      unitRef="usdPerShare">75.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-337"
      decimals="INF"
      id="f-1548"
      unitRef="shares">292000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-338"
      decimals="INF"
      id="f-1549"
      unitRef="shares">268000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-338"
      decimals="2"
      id="f-1550"
      unitRef="usdPerShare">108.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-336" id="f-1551">P1Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-339"
      decimals="INF"
      id="f-1552"
      unitRef="shares">3146000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-337" id="f-1553">P1Y11M15D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-338"
      decimals="-3"
      id="f-1554"
      unitRef="shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-338"
      decimals="2"
      id="f-1555"
      unitRef="usdPerShare">102.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-336" id="f-1556">P1Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="c-339"
      decimals="INF"
      id="f-1557"
      unitRef="shares">0</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-336"
      id="f-1558"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-337"
      decimals="2"
      id="f-1559"
      unitRef="usdPerShare">142.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-340"
      id="f-1560"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-341"
      decimals="2"
      id="f-1561"
      unitRef="usdPerShare">77.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-342"
      decimals="2"
      id="f-1562"
      unitRef="usdPerShare">35.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-343"
      decimals="2"
      id="f-1563"
      unitRef="usdPerShare">107.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c-1" id="f-1564">&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of SSARs base prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.01&#x2013;$80.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.01&#x2013;$110.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$110.01&#x2013;$120.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-344"
      decimals="INF"
      id="f-1565"
      unitRef="shares">14000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-344"
      decimals="2"
      id="f-1566"
      unitRef="usdPerShare">75.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-344"
      decimals="INF"
      id="f-1567"
      unitRef="shares">14000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-344"
      decimals="2"
      id="f-1568"
      unitRef="usdPerShare">75.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-345"
      decimals="INF"
      id="f-1569"
      unitRef="shares">124000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-345"
      decimals="2"
      id="f-1570"
      unitRef="usdPerShare">108.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-345"
      decimals="INF"
      id="f-1571"
      unitRef="shares">58000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-345"
      decimals="2"
      id="f-1572"
      unitRef="usdPerShare">108.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-346"
      decimals="INF"
      id="f-1573"
      unitRef="shares">130000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-346"
      decimals="2"
      id="f-1574"
      unitRef="usdPerShare">110.63</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-346"
      decimals="INF"
      id="f-1575"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-346"
      id="f-1576"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-6"
      decimals="INF"
      id="f-1577"
      unitRef="shares">268000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-6"
      decimals="2"
      id="f-1578"
      unitRef="usdPerShare">108.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-6"
      decimals="INF"
      id="f-1579"
      unitRef="shares">72000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-6"
      decimals="2"
      id="f-1580"
      unitRef="usdPerShare">102.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-1581" unitRef="usd">323681000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-4" decimals="-3" id="f-1582" unitRef="usd">168500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-5" decimals="-3" id="f-1583" unitRef="usd">149442000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-1584" unitRef="usd">490209000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-6" decimals="-3" id="f-1585" unitRef="usd">3394000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1586">A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted during the year end December&#160;31, 2022 were as follows:&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-347" id="f-1587">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-347"
      decimals="3"
      id="f-1588"
      unitRef="number">0.343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-347"
      decimals="INF"
      id="f-1589"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-347"
      decimals="3"
      id="f-1590"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase contextRef="c-348" decimals="INF" id="f-1591" unitRef="usd">25000</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-349"
      decimals="INF"
      id="f-1592"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-350"
      decimals="2"
      id="f-1593"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares contextRef="c-351" decimals="-3" id="f-1594" unitRef="usd">20441000</dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares>
    <dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares contextRef="c-352" decimals="-3" id="f-1595" unitRef="usd">18213000</dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares>
    <dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares contextRef="c-353" decimals="-3" id="f-1596" unitRef="usd">18061000</dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-348"
      decimals="INF"
      id="f-1597"
      unitRef="shares">184000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-354"
      decimals="INF"
      id="f-1598"
      unitRef="shares">231000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-355"
      decimals="INF"
      id="f-1599"
      unitRef="shares">285000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-351"
      decimals="INF"
      id="f-1600"
      unitRef="shares">5286000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-348"
      decimals="3"
      id="f-1601"
      unitRef="number">0.326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-354"
      decimals="3"
      id="f-1602"
      unitRef="number">0.413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-355"
      decimals="3"
      id="f-1603"
      unitRef="number">0.317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-348"
      decimals="3"
      id="f-1604"
      unitRef="number">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-354"
      decimals="3"
      id="f-1605"
      unitRef="number">0.049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-355"
      decimals="3"
      id="f-1606"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-348" decimals="INF" id="f-1607" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-348"
      decimals="2"
      id="f-1608"
      unitRef="usdPerShare">31.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-354"
      decimals="2"
      id="f-1609"
      unitRef="usdPerShare">25.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-355"
      decimals="2"
      id="f-1610"
      unitRef="usdPerShare">26.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-1611" unitRef="usd">102788000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-4" decimals="-3" id="f-1612" unitRef="usd">112375000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-1613" unitRef="usd">95427000</us-gaap:ShareBasedCompensation>
    <dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-3" id="f-1614" unitRef="usd">16398000</dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense>
    <dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense contextRef="c-4" decimals="-3" id="f-1615" unitRef="usd">16536000</dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense>
    <dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense contextRef="c-5" decimals="-3" id="f-1616" unitRef="usd">14723000</dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-6" decimals="-3" id="f-1617" unitRef="usd">146350000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-1618">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-3" id="f-1619" unitRef="usd">27531000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-4" decimals="-3" id="f-1620" unitRef="usd">25629000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-5" decimals="-3" id="f-1621" unitRef="usd">24805000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="INF" id="f-1622" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:TreasuryStockTextBlock contextRef="c-1" id="f-1642">Shareholders&#x2019; equity&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.801%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open market repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price paid per share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Excludes commissions and the excise tax described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company repurchased 779 shares of its common stock for $124,665 at an average price paid of $158.48 per share subsequent to December&#160;31, 2024 through February&#160;13, 2025, inclusive of the shares repurchased from Berkshire Inc. as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company is authorized to make share repurchases pursuant to a September 5, 2024 Board authorized repurchase plan of $2,000,000. This authorization allows the Company to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, trading plans pursuant to Rule 10b5-1 or Rule 10b-18, or any combination of the foregoing, depending upon market conditions and other considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of February&#160;13, 2025, the Company has a total of $1,811,069, excluding excise taxes, available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Berkshire share repurchase agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;30, 2024, the Company entered into an agreement (the share repurchase agreement) with Berkshire Hathaway Inc. on behalf of itself and its affiliates (collectively, Berkshire). Under the share repurchase agreement, at any time Berkshire beneficially owns at least 45.0% of the issued and outstanding common stock of the Company in the aggregate, the Company will repurchase from Berkshire, and Berkshire will sell to the Company, on a quarterly basis, a number of shares of common stock sufficient to return Berkshire&#x2019;s aggregate beneficial ownership to 45.0% of the Company's issued and outstanding common stock. The per share price the Company will pay Berkshire for any such share repurchase will be the volume-weighted average price per share paid by the Company for any shares of common stock repurchased by the Company from public stockholders pursuant to the Company&#x2019;s share repurchase program during the applicable repurchase period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, repurchases of common stock by the Company from Berkshire will occur on the date that is two business days prior to the date of the Company&#x2019;s regular quarterly or annual investor call to publicly report earnings; however, if at any time the Company determines that Berkshire beneficially owns or will beneficially own shares of common stock representing more than 49.5% of the issued and outstanding common stock in the aggregate, such determination will trigger immediate share repurchases under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, Berkshire beneficially owned less than 45.0% of the issued and outstanding common stock of the Company and, as a result, no repurchase obligation existed at such date. Subsequent to December&#160;31, 2024, through February&#160;13, 2025, the Company's open market share repurchases caused Berkshire to beneficially own greater then 45.0%. As such, on February 11, 2025 the Company repurchased 203 shares of common stock from Berkshire for $32,001 at an average price paid of $156.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Berkshire standstill agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Berkshire remains subject to a standstill agreement with the Company, as amended and restated as of February 9, 2022 (the standstill agreement). The standstill agreement currently restricts Berkshire&#x2019;s actions with respect to acquiring additional &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of the Company&#x2019;s common stock, and for any matter presented to Company stockholders, the standstill agreement requires Berkshire to vote any shares it beneficially holds in excess of 40% of the then-outstanding voting stock of the Company in accordance with the recommendation of the Board of Directors of the Company (Board). The standstill agreement also restricts Berkshire from taking certain actions, including, among other things, actions relating to stockholder proposals and actions seeking to control or influence the Board, management or policies of the Company. The standstill agreement provisions vary depending on Berkshire&#x2019;s ownership levels and in the event of certain specified leadership changes at Berkshire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The standstill agreement may be terminated by Berkshire at any time it ceases to beneficially own more than 15% of the Company's then-outstanding common stock, and terminates automatically if the Company enters into or publicly announces a plan to enter into a definitive agreement concerning a transaction involving all or a controlling portion of the Company's equity securities or all, or substantially all, of the Company's assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Charter documents&#160;&amp;amp; Delaware law&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice for director nominations and stockholder proposals and granting the Company's Board of Directors the authority to issue up to 5,000 shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, prohibits the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. The provisions described above may discourage, delay or prevent an acquisition of the Company at a price that stockholders may find attractive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in DaVita Inc.&#x2019;s ownership interests in consolidated subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of changes in DaVita Inc.&#x2019;s ownership interests in consolidated subsidiaries on the Company&#x2019;s consolidated equity were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in paid-in capital for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net transfers in noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc. net of transfers in &lt;br/&gt;&#160;noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquired additional ownership interests in several existing majority-owned partnerships for $53,958, $12,555 and $20,775 in 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock contextRef="c-1" id="f-1643">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.801%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open market repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price paid per share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Excludes commissions and the excise tax described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-362"
      decimals="-3"
      id="f-1644"
      unitRef="shares">9833000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-363"
      decimals="-3"
      id="f-1645"
      unitRef="shares">2904000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-364"
      decimals="-3"
      id="f-1646"
      unitRef="shares">8095000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-362" decimals="-3" id="f-1647" unitRef="usd">1389072000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-363" decimals="-3" id="f-1648" unitRef="usd">285710000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-364" decimals="-3" id="f-1649" unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-362"
      decimals="2"
      id="f-1650"
      unitRef="usdPerShare">140.06</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-363"
      decimals="2"
      id="f-1651"
      unitRef="usdPerShare">97.82</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-364"
      decimals="2"
      id="f-1652"
      unitRef="usdPerShare">97.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-365"
      decimals="-3"
      id="f-1653"
      unitRef="shares">779000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-365" decimals="-3" id="f-1654" unitRef="usd">124665000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-365"
      decimals="2"
      id="f-1655"
      unitRef="usdPerShare">158.48</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-366" decimals="-3" id="f-1656" unitRef="usd">2000000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-367" decimals="-3" id="f-1657" unitRef="usd">1811069000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-368" id="f-1658">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Berkshire share repurchase agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;30, 2024, the Company entered into an agreement (the share repurchase agreement) with Berkshire Hathaway Inc. on behalf of itself and its affiliates (collectively, Berkshire). Under the share repurchase agreement, at any time Berkshire beneficially owns at least 45.0% of the issued and outstanding common stock of the Company in the aggregate, the Company will repurchase from Berkshire, and Berkshire will sell to the Company, on a quarterly basis, a number of shares of common stock sufficient to return Berkshire&#x2019;s aggregate beneficial ownership to 45.0% of the Company's issued and outstanding common stock. The per share price the Company will pay Berkshire for any such share repurchase will be the volume-weighted average price per share paid by the Company for any shares of common stock repurchased by the Company from public stockholders pursuant to the Company&#x2019;s share repurchase program during the applicable repurchase period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, repurchases of common stock by the Company from Berkshire will occur on the date that is two business days prior to the date of the Company&#x2019;s regular quarterly or annual investor call to publicly report earnings; however, if at any time the Company determines that Berkshire beneficially owns or will beneficially own shares of common stock representing more than 49.5% of the issued and outstanding common stock in the aggregate, such determination will trigger immediate share repurchases under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, Berkshire beneficially owned less than 45.0% of the issued and outstanding common stock of the Company and, as a result, no repurchase obligation existed at such date. Subsequent to December&#160;31, 2024, through February&#160;13, 2025, the Company's open market share repurchases caused Berkshire to beneficially own greater then 45.0%. As such, on February 11, 2025 the Company repurchased 203 shares of common stock from Berkshire for $32,001 at an average price paid of $156.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Berkshire standstill agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Berkshire remains subject to a standstill agreement with the Company, as amended and restated as of February 9, 2022 (the standstill agreement). The standstill agreement currently restricts Berkshire&#x2019;s actions with respect to acquiring additional &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of the Company&#x2019;s common stock, and for any matter presented to Company stockholders, the standstill agreement requires Berkshire to vote any shares it beneficially holds in excess of 40% of the then-outstanding voting stock of the Company in accordance with the recommendation of the Board of Directors of the Company (Board). The standstill agreement also restricts Berkshire from taking certain actions, including, among other things, actions relating to stockholder proposals and actions seeking to control or influence the Board, management or policies of the Company. The standstill agreement provisions vary depending on Berkshire&#x2019;s ownership levels and in the event of certain specified leadership changes at Berkshire.&lt;/span&gt;&lt;/div&gt;The standstill agreement may be terminated by Berkshire at any time it ceases to beneficially own more than 15% of the Company's then-outstanding common stock, and terminates automatically if the Company enters into or publicly announces a plan to enter into a definitive agreement concerning a transaction involving all or a controlling portion of the Company's equity securities or all, or substantially all, of the Company's assets.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RepurchaseAgreementDate contextRef="c-368" id="f-1659">2024-04-30</us-gaap:RepurchaseAgreementDate>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c-368" id="f-1660">Berkshire beneficially owns at least 45.0%</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c-368" id="f-1661">two business days prior to the date of the Company&#x2019;s regular quarterly or annual investor call to publicly report earnings</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <dva:RelatedPartyTransactionDescriptionOfTransaction1 contextRef="c-368" id="f-1662">Berkshire beneficially owns or will beneficially own shares of common stock representing more than 49.5% of the issued and outstanding common stock in the aggregate, such determination will trigger immediate share repurchases under this agreement.</dva:RelatedPartyTransactionDescriptionOfTransaction1>
    <dva:RelatedPartyTransactionDescriptionOfTransaction2 contextRef="c-369" id="f-1663">As of December&#160;31, 2024, Berkshire beneficially owned less than 45.0% of the issued and outstanding common stock of the Company and, as a result, no repurchase obligation existed at such date.</dva:RelatedPartyTransactionDescriptionOfTransaction2>
    <dva:RelatedPartyTransactionDescriptionOfTransaction2 contextRef="c-370" id="f-1664">Subsequent to December&#160;31, 2024, through February&#160;13, 2025, the Company's open market share repurchases caused Berkshire to beneficially own greater then 45.0%. As such, on February 11, 2025 the Company repurchased 203 shares of common stock from Berkshire for $32,001 at an average price paid of $156.01 per share.</dva:RelatedPartyTransactionDescriptionOfTransaction2>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="-3" id="f-1665" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <dva:PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation contextRef="c-1" id="f-1666">P3Y</dva:PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation>
    <dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock contextRef="c-1" id="f-1667">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of changes in DaVita Inc.&#x2019;s ownership interests in consolidated subsidiaries on the Company&#x2019;s consolidated equity were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in paid-in capital for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net transfers in noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc. net of transfers in &lt;br/&gt;&#160;noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-1668" unitRef="usd">936342000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-1669" unitRef="usd">691535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-1670" unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-56" decimals="-3" id="f-1671" unitRef="usd">-3102000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-40" decimals="-3" id="f-1672" unitRef="usd">-5375000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-24" decimals="-3" id="f-1673" unitRef="usd">-6586000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-56" decimals="-3" id="f-1674" unitRef="usd">491000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-40" decimals="-3" id="f-1675" unitRef="usd">13077000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures contextRef="c-24" decimals="-3" id="f-1676" unitRef="usd">939000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-56" decimals="-3" id="f-1677" unitRef="usd">-2611000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-40" decimals="-3" id="f-1678" unitRef="usd">7702000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-24" decimals="-3" id="f-1679" unitRef="usd">-5647000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests contextRef="c-56" decimals="-3" id="f-1680" unitRef="usd">933731000</dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests>
    <dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests contextRef="c-40" decimals="-3" id="f-1681" unitRef="usd">699237000</dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests>
    <dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests contextRef="c-24" decimals="-3" id="f-1682" unitRef="usd">554753000</dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-1" decimals="-3" id="f-1683" unitRef="usd">53958000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-4" decimals="-3" id="f-1684" unitRef="usd">12555000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-5" decimals="-3" id="f-1685" unitRef="usd">20775000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c-1" id="f-1688">Accumulated other comprehensive loss&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and credits to other comprehensive (loss) income have been as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.920%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;cap agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;br/&gt;translation&lt;br/&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated other&lt;br/&gt;comprehensive&lt;br/&gt;(loss) income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income. See Note 12 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1689">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and credits to other comprehensive (loss) income have been as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.920%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;cap agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;br/&gt;translation&lt;br/&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated other&lt;br/&gt;comprehensive&lt;br/&gt;(loss) income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-372" decimals="-3" id="f-1690" unitRef="usd">-1178000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-373" decimals="-3" id="f-1691" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-374" decimals="-3" id="f-1692" unitRef="usd">-138069000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-375" decimals="-3" id="f-1693" unitRef="usd">-139247000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-376" decimals="-3" id="f-1694" unitRef="usd">144793000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-377" decimals="-3" id="f-1695" unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-378" decimals="-3" id="f-1696" unitRef="usd">-30554000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-379" decimals="-3" id="f-1697" unitRef="usd">114239000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-376" decimals="-3" id="f-1698" unitRef="usd">36124000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-377" decimals="-3" id="f-1699" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-378" decimals="-3" id="f-1700" unitRef="usd">-752000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-379" decimals="-3" id="f-1701" unitRef="usd">35372000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-376" decimals="-3" id="f-1702" unitRef="usd">108669000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-377" decimals="-3" id="f-1703" unitRef="usd">0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-378" decimals="-3" id="f-1704" unitRef="usd">-29802000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-379" decimals="-3" id="f-1705" unitRef="usd">78867000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-376" decimals="-3" id="f-1706" unitRef="usd">-11732000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-377" decimals="-3" id="f-1707" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-378" decimals="-3" id="f-1708" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-379" decimals="-3" id="f-1709" unitRef="usd">-11732000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-376" decimals="-3" id="f-1710" unitRef="usd">-2926000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-377" decimals="-3" id="f-1711" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-378" decimals="-3" id="f-1712" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-379" decimals="-3" id="f-1713" unitRef="usd">-2926000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-376" decimals="-3" id="f-1714" unitRef="usd">-8806000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-377" decimals="-3" id="f-1715" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-378" decimals="-3" id="f-1716" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-379" decimals="-3" id="f-1717" unitRef="usd">-8806000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-380" decimals="-3" id="f-1718" unitRef="usd">98685000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-381" decimals="-3" id="f-1719" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-382" decimals="-3" id="f-1720" unitRef="usd">-167871000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-383" decimals="-3" id="f-1721" unitRef="usd">-69186000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-384" decimals="-3" id="f-1722" unitRef="usd">9186000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-385" decimals="-3" id="f-1723" unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-386" decimals="-3" id="f-1724" unitRef="usd">89055000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-387" decimals="-3" id="f-1725" unitRef="usd">98241000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-384" decimals="-3" id="f-1726" unitRef="usd">2291000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-385" decimals="-3" id="f-1727" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-386" decimals="-3" id="f-1728" unitRef="usd">1121000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-387" decimals="-3" id="f-1729" unitRef="usd">3412000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-384" decimals="-3" id="f-1730" unitRef="usd">6895000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-385" decimals="-3" id="f-1731" unitRef="usd">0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-386" decimals="-3" id="f-1732" unitRef="usd">87934000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-387" decimals="-3" id="f-1733" unitRef="usd">94829000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-384" decimals="-3" id="f-1734" unitRef="usd">-103567000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-385" decimals="-3" id="f-1735" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-386" decimals="-3" id="f-1736" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-387" decimals="-3" id="f-1737" unitRef="usd">-103567000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-384" decimals="-3" id="f-1738" unitRef="usd">-25840000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-385" decimals="-3" id="f-1739" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-386" decimals="-3" id="f-1740" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-387" decimals="-3" id="f-1741" unitRef="usd">-25840000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-384" decimals="-3" id="f-1742" unitRef="usd">-77727000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-385" decimals="-3" id="f-1743" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-386" decimals="-3" id="f-1744" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-387" decimals="-3" id="f-1745" unitRef="usd">-77727000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-388" decimals="-3" id="f-1746" unitRef="usd">27853000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-389" decimals="-3" id="f-1747" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-390" decimals="-3" id="f-1748" unitRef="usd">-79937000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-391" decimals="-3" id="f-1749" unitRef="usd">-52084000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-392" decimals="-3" id="f-1750" unitRef="usd">9662000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-393" decimals="-3" id="f-1751" unitRef="usd">46000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-394" decimals="-3" id="f-1752" unitRef="usd">-207906000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-395" decimals="-3" id="f-1753" unitRef="usd">-198198000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-392" decimals="-3" id="f-1754" unitRef="usd">2412000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-393" decimals="-3" id="f-1755" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-394" decimals="-3" id="f-1756" unitRef="usd">-45000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-395" decimals="-3" id="f-1757" unitRef="usd">2367000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-392" decimals="-3" id="f-1758" unitRef="usd">7250000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-393" decimals="-3" id="f-1759" unitRef="usd">46000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-394" decimals="-3" id="f-1760" unitRef="usd">-207861000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-395" decimals="-3" id="f-1761" unitRef="usd">-200565000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-392" decimals="-3" id="f-1762" unitRef="usd">-58175000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-393" decimals="-3" id="f-1763" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-394" decimals="-3" id="f-1764" unitRef="usd">-15252000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-395" decimals="-3" id="f-1765" unitRef="usd">-73427000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-392" decimals="-3" id="f-1766" unitRef="usd">-14515000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-393" decimals="-3" id="f-1767" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-394" decimals="-3" id="f-1768" unitRef="usd">-765000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-395" decimals="-3" id="f-1769" unitRef="usd">-15280000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-392" decimals="-3" id="f-1770" unitRef="usd">-43660000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-393" decimals="-3" id="f-1771" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-394" decimals="-3" id="f-1772" unitRef="usd">-14487000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-395" decimals="-3" id="f-1773" unitRef="usd">-58147000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-396" decimals="-3" id="f-1774" unitRef="usd">-8557000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-397" decimals="-3" id="f-1775" unitRef="usd">46000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-398" decimals="-3" id="f-1776" unitRef="usd">-302285000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-399" decimals="-3" id="f-1777" unitRef="usd">-310796000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-1778">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c-1" id="f-1779">Acquisitions and divestitures&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of DaVita Care Pte. Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective November&#160;1, 2024, the Company acquired control of DaVita Care Pte. Ltd. (DVC), previously referred to as the Company's APAC joint venture, through a change in control rights for no cash consideration. See Note 8 for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this acquisition, the Company recognized a non-cash gain of $59,067 on its previously held equity interests in the acquiree and realized a related foreign currency gain of $15,252 from foreign currency translation adjustments on this investment which were previously classified in accumulated other comprehensive loss. The Company estimated the fair value of its previously held equity interests of $114,744 using appraisals developed with an independent third party valuation firm.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets acquired and liabilities assumed in this transaction and recognized at the acquisition date at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in this transaction:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other international and routine acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2024, 2023 and 2022, the Company acquired other dialysis and related businesses for consideration paid in cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of these other international and routine transactions in 2024, the Company acquired a controlling interest in a previously nonconsolidated U.S. dialysis partnership for which it recognized a non-cash gain of $35,147 on its prior investment upon consolidation. The Company estimated the fair value of its previously held equity interest in this business using appraisals developed with independent third party valuation firms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aggregate consideration &#x2013; DVC and all other acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate consideration for both the DaVita Care Pte. Ltd. acquisition and all other international and routine acquisitions described above has been as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent purchase price and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of previously held equity interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Purchase price allocations &#x2014; DVC and all other acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company&#x2019;s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2024 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use lease assets and other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of goodwill related to these acquisitions recognized or adjusted in 2024, 2023 and 2022 that is deductible for local tax purposes was $54,810, $17,836 and $49,047, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pro forma financial information (unaudited)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions in 2024 and 2023 had been consummated as of the beginning of 2023, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,073,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,625,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma basic net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma diluted net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1 contextRef="c-400" id="f-1780">2024-11-01</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity contextRef="c-400" id="f-1781">DaVita Care Pte. Ltd.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain contextRef="c-401" decimals="-3" id="f-1782" unitRef="usd">59067000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain contextRef="c-402" decimals="-3" id="f-1783" unitRef="usd">15252000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="c-400" decimals="-3" id="f-1784" unitRef="usd">114744000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-403" decimals="-3" id="f-1785" unitRef="usd">34818000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets contextRef="c-403" decimals="-3" id="f-1786" unitRef="usd">44810000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-403" decimals="-3" id="f-1787" unitRef="usd">22651000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-403" decimals="-3" id="f-1788" unitRef="usd">37682000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-403" decimals="-3" id="f-1789" unitRef="usd">15114000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill contextRef="c-403" decimals="-3" id="f-1790" unitRef="usd">127207000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-403" decimals="-3" id="f-1791" unitRef="usd">54708000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-403" decimals="-3" id="f-1792" unitRef="usd">112830000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-403" decimals="-3" id="f-1793" unitRef="usd">114744000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock contextRef="c-1" id="f-1794">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2024, 2023 and 2022, the Company acquired other dialysis and related businesses for consideration paid in cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of these other international and routine transactions in 2024, the Company acquired a controlling interest in a previously nonconsolidated U.S. dialysis partnership for which it recognized a non-cash gain of $35,147 on its prior investment upon consolidation. The Company estimated the fair value of its previously held equity interest in this business using appraisals developed with independent third party valuation firms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aggregate consideration &#x2013; DVC and all other acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate consideration for both the DaVita Care Pte. Ltd. acquisition and all other international and routine acquisitions described above has been as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent purchase price and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of previously held equity interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain contextRef="c-404" decimals="-3" id="f-1795" unitRef="usd">35147000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-405" decimals="-3" id="f-1796" unitRef="usd">329187000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-406" decimals="-3" id="f-1797" unitRef="usd">27648000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-407" decimals="-3" id="f-1798" unitRef="usd">59271000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-405" decimals="-3" id="f-1799" unitRef="usd">50384000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-406" decimals="-3" id="f-1800" unitRef="usd">19801000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-407" decimals="-3" id="f-1801" unitRef="usd">19337000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="c-405" decimals="-3" id="f-1802" unitRef="usd">182270000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="c-406" decimals="-3" id="f-1803" unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="c-407" decimals="-3" id="f-1804" unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-408" decimals="-3" id="f-1805" unitRef="usd">561841000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-409" decimals="-3" id="f-1806" unitRef="usd">47449000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-410" decimals="-3" id="f-1807" unitRef="usd">78608000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-411"
      decimals="0"
      id="f-1808"
      unitRef="clinic2">12</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-412"
      decimals="0"
      id="f-1809"
      unitRef="clinic2">0</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-413"
      decimals="0"
      id="f-1810"
      unitRef="clinic2">5</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-414"
      decimals="0"
      id="f-1811"
      unitRef="clinic2">198</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-415"
      decimals="0"
      id="f-1812"
      unitRef="clinic2">12</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-416"
      decimals="0"
      id="f-1813"
      unitRef="clinic2">11</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-1814">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use lease assets and other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-408" decimals="-3" id="f-1815" unitRef="usd">83119000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-409" decimals="-3" id="f-1816" unitRef="usd">1254000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-410" decimals="-3" id="f-1817" unitRef="usd">1963000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets contextRef="c-408" decimals="-3" id="f-1818" unitRef="usd">249738000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets contextRef="c-409" decimals="-3" id="f-1819" unitRef="usd">6128000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets contextRef="c-410" decimals="-3" id="f-1820" unitRef="usd">6389000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-408" decimals="-3" id="f-1821" unitRef="usd">94951000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-409" decimals="-3" id="f-1822" unitRef="usd">4130000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-410" decimals="-3" id="f-1823" unitRef="usd">7481000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-408" decimals="-3" id="f-1824" unitRef="usd">97591000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-409" decimals="-3" id="f-1825" unitRef="usd">785000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-410" decimals="-3" id="f-1826" unitRef="usd">1066000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-408" decimals="-3" id="f-1827" unitRef="usd">22725000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-409" decimals="-3" id="f-1828" unitRef="usd">15789000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-410" decimals="-3" id="f-1829" unitRef="usd">19610000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill contextRef="c-408" decimals="-3" id="f-1830" unitRef="usd">349069000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-409" decimals="-3" id="f-1831" unitRef="usd">25723000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-410" decimals="-3" id="f-1832" unitRef="usd">49047000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-408" decimals="-3" id="f-1833" unitRef="usd">201704000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-409" decimals="-3" id="f-1834" unitRef="usd">6179000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-410" decimals="-3" id="f-1835" unitRef="usd">6081000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-408" decimals="-3" id="f-1836" unitRef="usd">133648000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-409" decimals="-3" id="f-1837" unitRef="usd">181000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-410" decimals="-3" id="f-1838" unitRef="usd">867000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-408" decimals="-3" id="f-1839" unitRef="usd">561841000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-409" decimals="-3" id="f-1840" unitRef="usd">47449000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-410" decimals="-3" id="f-1841" unitRef="usd">78608000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock contextRef="c-1" id="f-1842">The amount of goodwill related to these acquisitions recognized or adjusted in 2024, 2023 and 2022 that is deductible for local tax purposes was $54,810, $17,836 and $49,047, respectively.</dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount contextRef="c-408" decimals="-3" id="f-1843" unitRef="usd">54810000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount contextRef="c-409" decimals="-3" id="f-1844" unitRef="usd">17836000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount contextRef="c-410" decimals="-3" id="f-1845" unitRef="usd">49047000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c-1" id="f-1846">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions in 2024 and 2023 had been consummated as of the beginning of 2023, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,073,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,625,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma basic net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma diluted net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-1" decimals="-3" id="f-1847" unitRef="usd">13073083000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-4" decimals="-3" id="f-1848" unitRef="usd">12625223000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-1" decimals="-3" id="f-1849" unitRef="usd">952836000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-4" decimals="-3" id="f-1850" unitRef="usd">732265000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1851"
      unitRef="usdPerShare">11.21</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-1852"
      unitRef="usdPerShare">8.07</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1853"
      unitRef="usdPerShare">10.92</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-1854"
      unitRef="usdPerShare">7.86</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-1855">Discontinued operations previously held for sale&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DaVita Medical Group (DMG)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;19, 2019, the Company completed the sale of its prior DMG business to Optum, a subsidiary of UnitedHealth Group Inc. At close, the Company's ultimate net proceeds from this sale remained subject to resolution of certain post-closing adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shortly after December 31, 2022, Optum made an additional purchase price payment of $13,452 to the Company after resolution of one such post-closing matter, which represented a contingent gain to the Company for the fourth quarter of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized no DMG operating, financing or investing cash flows for the years ended December&#160;31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the equity purchase agreement, the Company also has certain continuing indemnification obligations that could require payments to the buyer relating to the Company's previous ownership and operation of the DMG business. Potential payments under these provisions, if any, remain subject to continuing uncertainties and the amounts of such payments could be significant to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <dva:BusinessSaleEffectiveDateOfSale contextRef="c-417" id="f-1856">2019-06-19</dva:BusinessSaleEffectiveDateOfSale>
    <dva:GainOnDispositionOfBusinessAdditionalPurchasePricePayment contextRef="c-418" decimals="-3" id="f-1857" unitRef="usd">13452000</dva:GainOnDispositionOfBusinessAdditionalPurchasePricePayment>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-419" decimals="-3" id="f-1858" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-420" decimals="-3" id="f-1859" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-421" decimals="-3" id="f-1860" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-1872">Variable interest entities&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, non-U.S. subsidiaries that are structurally dependent on subordinated debt, or other legal entities subject to nominee ownership arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#x2019;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#x2019;s economic performance, the obligation to absorb the entity&#x2019;s expected losses, or the right to receive the entity&#x2019;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the VIEs described above, these consolidated financial statements include total assets of $577,585 and total liabilities and noncontrolling interests to third parties of $249,900 at December&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also sponsors certain non-qualified deferred compensation plans whose trusts qualify as VIEs and the Company consolidates these plans as their primary beneficiary.&#160;The assets of these plans are recorded in short-term or long-term investments with related liabilities recorded in accrued compensation and benefits and other long-term liabilities.&#160;See Notes 4 and 14 for disclosures concerning the assets of these consolidated non-qualified deferred compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c-1" id="f-1873">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, non-U.S. subsidiaries that are structurally dependent on subordinated debt, or other legal entities subject to nominee ownership arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#x2019;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#x2019;s economic performance, the obligation to absorb the entity&#x2019;s expected losses, or the right to receive the entity&#x2019;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:Assets contextRef="c-422" decimals="-3" id="f-1874" unitRef="usd">577585000</us-gaap:Assets>
    <us-gaap:Liabilities contextRef="c-422" decimals="-3" id="f-1875" unitRef="usd">249900000</us-gaap:Liabilities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-1876">Fair values of financial instruments&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the FASB.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&#160;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 4 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 12 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had contingent earn-out obligations associated with business acquisitions that could result in the Company paying the former owners a total of up to approximately $24,580 if certain performance targets or quality margins are met over the next one year to five years. The estimated fair value measurements of these contingent earn-out obligations are primarily based on unobservable inputs, including projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and key performance indicators. The estimated fair value of these contingent earn-out obligations is remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of December&#160;31, 2024, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $225,000. See Note 16 for a discussion of the Company&#x2019;s methodology for estimating the fair values of noncontrolling interests subject to put obligations and the reconciliation of changes on the consolidated statements of equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's fair value estimates for its senior secured credit facilities are based upon quoted bid and ask prices for these instruments, a level 2 input. For the Company's senior notes, fair value estimates are based on level 1 market inputs. See Note 12 for further discussion of the Company's debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in the consolidated financial statements at December&#160;31, 2024 and 2023 at their approximate fair values due to the short-term nature of their settlements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-1877">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&#160;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-423" decimals="-3" id="f-1878" unitRef="usd">40566000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-424" decimals="-3" id="f-1879" unitRef="usd">40566000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-425" id="f-1880" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-426" id="f-1881" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeAssets contextRef="c-427" decimals="-3" id="f-1882" unitRef="usd">30062000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-428" id="f-1883" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeAssets contextRef="c-429" decimals="-3" id="f-1884" unitRef="usd">30062000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-430" id="f-1885" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-423" decimals="-3" id="f-1886" unitRef="usd">13542000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-424" id="f-1887" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-425" id="f-1888" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-426" decimals="-3" id="f-1889" unitRef="usd">13542000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-423" decimals="-3" id="f-1890" unitRef="usd">1695483000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-424" id="f-1891" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-425" id="f-1892" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-426" decimals="-3" id="f-1893" unitRef="usd">1695483000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-431" decimals="-3" id="f-1894" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-432" decimals="-3" id="f-1895" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-433" id="f-1896" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-434" id="f-1897" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeAssets contextRef="c-435" decimals="-3" id="f-1898" unitRef="usd">79805000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-436" id="f-1899" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeAssets contextRef="c-437" decimals="-3" id="f-1900" unitRef="usd">79805000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-438" id="f-1901" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-431" decimals="-3" id="f-1902" unitRef="usd">23088000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-432" id="f-1903" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-433" id="f-1904" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-434" decimals="-3" id="f-1905" unitRef="usd">23088000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-431" decimals="-3" id="f-1906" unitRef="usd">1499288000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-432" id="f-1907" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-433" id="f-1908" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-434" decimals="-3" id="f-1909" unitRef="usd">1499288000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-408" decimals="-3" id="f-1910" unitRef="usd">24580000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod contextRef="c-439" id="f-1911">P1Y</dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod>
    <dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod contextRef="c-440" id="f-1912">P5Y</dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod>
    <dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple contextRef="c-6" decimals="-3" id="f-1913" unitRef="usd">225000000</dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1914">Segment reporting&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operating divisions are composed of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support functions. See Note 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Organization" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for a summary description of the Company's businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company&#x2019;s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company&#x2019;s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its operations in each foreign sovereign jurisdiction, and, until its reconsolidation in the fourth quarter of 2024, the Company's equity method investment in its Asia Pacific joint venture (APAC JV). The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to assess the financial performance of and allocate resources among the Company's operating segments. For internal management reporting, segment operations include direct segment operating expenses but generally exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive compensation expenses of certain departments which provide support to more than one of the Company&#x2019;s various operating lines of business. The chief operating decision maker uses segment operating margin to assess segment profitability and resource allocation. The chief operating decision maker does not review total assets by segment to make decisions regarding resources; therefore, the total assets by segment disclosure has not been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of segment revenues, segment operating margin, and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,294,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,823,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,366,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,911,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,575,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. dialysis revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,390,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,599,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,901,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,236,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,701,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,815,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant segment expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient care costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,497,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,394,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,334,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis segment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,269,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,162,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment operating margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,203,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate administrative support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,047)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,090,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt prepayment, extinguishment and modification costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other segment items for our U.S. dialysis segment include equity income from nonconsolidated joint ventures and a gain on changes in ownership interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Segment operating margin (loss) for Other - Ancillary services includes equity investment loss of $1,701, $2,103 and $1,898 in 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for property and equipment by reportable segment were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's international operations include approximately $317,488 and $240,742 in 2024 and 2023, respectively, of net property and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-1915">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of segment revenues, segment operating margin, and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,294,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,823,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,366,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,911,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,575,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. dialysis revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,390,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,599,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,901,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,236,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,701,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,815,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant segment expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient care costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,497,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,394,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,334,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis segment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,269,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,162,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment operating margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,203,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate administrative support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,047)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,090,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt prepayment, extinguishment and modification costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other segment items for our U.S. dialysis segment include equity income from nonconsolidated joint ventures and a gain on changes in ownership interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Segment operating margin (loss) for Other - Ancillary services includes equity investment loss of $1,701, $2,103 and $1,898 in 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-441" decimals="-3" id="f-1916" unitRef="usd">11294614000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-442" decimals="-3" id="f-1917" unitRef="usd">10823525000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-443" decimals="-3" id="f-1918" unitRef="usd">10488327000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-444" decimals="-3" id="f-1919" unitRef="usd">71747000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-445" decimals="-3" id="f-1920" unitRef="usd">88222000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-446" decimals="-3" id="f-1921" unitRef="usd">87045000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-447" decimals="-3" id="f-1922" unitRef="usd">11366361000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-448" decimals="-3" id="f-1923" unitRef="usd">10911747000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-449" decimals="-3" id="f-1924" unitRef="usd">10575372000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-441" decimals="-3" id="f-1925" unitRef="usd">24356000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-442" decimals="-3" id="f-1926" unitRef="usd">25251000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-443" decimals="-3" id="f-1927" unitRef="usd">24447000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-444" decimals="-3" id="f-1928" unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-445" decimals="-3" id="f-1929" unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-446" decimals="-3" id="f-1930" unitRef="usd">-10000</us-gaap:OtherIncome>
    <us-gaap:Revenues contextRef="c-447" decimals="-3" id="f-1931" unitRef="usd">11390717000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-448" decimals="-3" id="f-1932" unitRef="usd">10936998000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-449" decimals="-3" id="f-1933" unitRef="usd">10599809000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-450" decimals="-3" id="f-1934" unitRef="usd">965761000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-451" decimals="-3" id="f-1935" unitRef="usd">751416000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-452" decimals="-3" id="f-1936" unitRef="usd">688137000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-450" decimals="-3" id="f-1937" unitRef="usd">530819000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-451" decimals="-3" id="f-1938" unitRef="usd">539955000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-452" decimals="-3" id="f-1939" unitRef="usd">408983000</us-gaap:OtherIncome>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-453" decimals="-3" id="f-1940" unitRef="usd">13910000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-454" decimals="-3" id="f-1941" unitRef="usd">7852000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-455" decimals="-3" id="f-1942" unitRef="usd">4206000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues contextRef="c-450" decimals="-3" id="f-1943" unitRef="usd">1510490000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-451" decimals="-3" id="f-1944" unitRef="usd">1299223000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-452" decimals="-3" id="f-1945" unitRef="usd">1101326000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-456" decimals="-3" id="f-1946" unitRef="usd">12901207000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-457" decimals="-3" id="f-1947" unitRef="usd">12236221000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-458" decimals="-3" id="f-1948" unitRef="usd">11701135000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-87" decimals="-3" id="f-1949" unitRef="usd">-85657000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-107" decimals="-3" id="f-1950" unitRef="usd">-96074000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-127" decimals="-3" id="f-1951" unitRef="usd">-91241000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-1952" unitRef="usd">12815550000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-3" id="f-1953" unitRef="usd">12140147000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-1954" unitRef="usd">11609894000</us-gaap:Revenues>
    <dva:PatientCareCosts contextRef="c-459" decimals="-3" id="f-1955" unitRef="usd">7497576000</dva:PatientCareCosts>
    <dva:PatientCareCosts contextRef="c-460" decimals="-3" id="f-1956" unitRef="usd">7394640000</dva:PatientCareCosts>
    <dva:PatientCareCosts contextRef="c-461" decimals="-3" id="f-1957" unitRef="usd">7334415000</dva:PatientCareCosts>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-459" decimals="-3" id="f-1958" unitRef="usd">1173990000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-460" decimals="-3" id="f-1959" unitRef="usd">1102072000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-461" decimals="-3" id="f-1960" unitRef="usd">1037552000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c-459" decimals="-3" id="f-1961" unitRef="usd">661181000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-460" decimals="-3" id="f-1962" unitRef="usd">695674000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-461" decimals="-3" id="f-1963" unitRef="usd">690949000</us-gaap:DepreciationAndAmortization>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-459" decimals="-3" id="f-1964" unitRef="usd">-63037000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-460" decimals="-3" id="f-1965" unitRef="usd">-29966000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-461" decimals="-3" id="f-1966" unitRef="usd">-28417000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:CostsAndExpenses contextRef="c-459" decimals="-3" id="f-1967" unitRef="usd">9269710000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-460" decimals="-3" id="f-1968" unitRef="usd">9162420000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-461" decimals="-3" id="f-1969" unitRef="usd">9034499000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-462" decimals="-3" id="f-1970" unitRef="usd">1427833000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-463" decimals="-3" id="f-1971" unitRef="usd">1307970000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-464" decimals="-3" id="f-1972" unitRef="usd">1197905000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-459" decimals="-3" id="f-1973" unitRef="usd">2121007000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-460" decimals="-3" id="f-1974" unitRef="usd">1774578000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-461" decimals="-3" id="f-1975" unitRef="usd">1565310000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-462" decimals="-3" id="f-1976" unitRef="usd">82657000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-463" decimals="-3" id="f-1977" unitRef="usd">-8747000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-464" decimals="-3" id="f-1978" unitRef="usd">-96579000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-456" decimals="-3" id="f-1979" unitRef="usd">2203664000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-457" decimals="-3" id="f-1980" unitRef="usd">1765831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-458" decimals="-3" id="f-1981" unitRef="usd">1468731000</us-gaap:OperatingIncomeLoss>
    <dva:SegmentReportingInformationCorporateExpenses contextRef="c-1" decimals="-3" id="f-1982" unitRef="usd">113181000</dva:SegmentReportingInformationCorporateExpenses>
    <dva:SegmentReportingInformationCorporateExpenses contextRef="c-4" decimals="-3" id="f-1983" unitRef="usd">163047000</dva:SegmentReportingInformationCorporateExpenses>
    <dva:SegmentReportingInformationCorporateExpenses contextRef="c-5" decimals="-3" id="f-1984" unitRef="usd">129669000</dva:SegmentReportingInformationCorporateExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-1985" unitRef="usd">2090483000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-4" decimals="-3" id="f-1986" unitRef="usd">1602784000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-1987" unitRef="usd">1339062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndDebtExpense contextRef="c-1" decimals="-3" id="f-1988" unitRef="usd">470469000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c-4" decimals="-3" id="f-1989" unitRef="usd">398551000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c-5" decimals="-3" id="f-1990" unitRef="usd">357019000</us-gaap:InterestAndDebtExpense>
    <dva:DebtPrepaymentExtinguishmentAndModificationCosts contextRef="c-1" decimals="-3" id="f-1991" unitRef="usd">19813000</dva:DebtPrepaymentExtinguishmentAndModificationCosts>
    <dva:DebtPrepaymentExtinguishmentAndModificationCosts contextRef="c-4" decimals="-3" id="f-1992" unitRef="usd">7962000</dva:DebtPrepaymentExtinguishmentAndModificationCosts>
    <dva:DebtPrepaymentExtinguishmentAndModificationCosts contextRef="c-5" decimals="-3" id="f-1993" unitRef="usd">0</dva:DebtPrepaymentExtinguishmentAndModificationCosts>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-1994" unitRef="usd">-69808000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-4" decimals="-3" id="f-1995" unitRef="usd">-19177000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-1996" unitRef="usd">-15765000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-1997" unitRef="usd">1530393000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-1998" unitRef="usd">1177094000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-1999" unitRef="usd">966278000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-462" decimals="-3" id="f-2000" unitRef="usd">-1701000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-463" decimals="-3" id="f-2001" unitRef="usd">-2103000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-464" decimals="-3" id="f-2002" unitRef="usd">-1898000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-2003">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <us-gaap:DepreciationAndAmortization contextRef="c-459" decimals="-3" id="f-2004" unitRef="usd">661181000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-460" decimals="-3" id="f-2005" unitRef="usd">695674000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-461" decimals="-3" id="f-2006" unitRef="usd">690949000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-89" decimals="-3" id="f-2007" unitRef="usd">62679000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-109" decimals="-3" id="f-2008" unitRef="usd">49769000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-129" decimals="-3" id="f-2009" unitRef="usd">41653000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-2010" unitRef="usd">723860000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-2011" unitRef="usd">745443000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-2012" unitRef="usd">732602000</us-gaap:DepreciationAndAmortization>
    <dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock contextRef="c-1" id="f-2013">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for property and equipment by reportable segment were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-88" decimals="-3" id="f-2014" unitRef="usd">469799000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-108" decimals="-3" id="f-2015" unitRef="usd">501149000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-128" decimals="-3" id="f-2016" unitRef="usd">533600000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-89" decimals="-3" id="f-2017" unitRef="usd">85644000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-109" decimals="-3" id="f-2018" unitRef="usd">66836000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-129" decimals="-3" id="f-2019" unitRef="usd">69829000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-1" decimals="-3" id="f-2020" unitRef="usd">555443000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-4" decimals="-3" id="f-2021" unitRef="usd">567985000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-5" decimals="-3" id="f-2022" unitRef="usd">603429000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <dva:NetPropertyAndEquipmentInternationalOperationsTextBlock contextRef="c-1" id="f-2023">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's international operations include approximately $317,488 and $240,742 in 2024 and 2023, respectively, of net property and equipment.&lt;/span&gt;&lt;/div&gt;</dva:NetPropertyAndEquipmentInternationalOperationsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-465" decimals="-3" id="f-2024" unitRef="usd">317488000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-466" decimals="-3" id="f-2025" unitRef="usd">240742000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="c-1" id="f-2026">Supplemental cash flow information&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides supplemental cash flow information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets under financing lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c-1" id="f-2027">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides supplemental cash flow information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets under financing lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-2028" unitRef="usd">387940000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-4" decimals="-3" id="f-2029" unitRef="usd">268091000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-5" decimals="-3" id="f-2030" unitRef="usd">344430000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-2031" unitRef="usd">423360000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-4" decimals="-3" id="f-2032" unitRef="usd">387661000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-5" decimals="-3" id="f-2033" unitRef="usd">350999000</us-gaap:InterestPaidNet>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-1" decimals="-3" id="f-2034" unitRef="usd">11327000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-4" decimals="-3" id="f-2035" unitRef="usd">13269000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-5" decimals="-3" id="f-2036" unitRef="usd">1928000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
